no,DT,O
drug,NN,D
",",",",O
nutritional,JJ,O
supplement,NN,O
",",",",O
food,NN,O
or,CC,O
herb,NN,O
interactions,NNS,O
have,VBP,O
yet,RB,O
been,VBN,O
reported,VBN,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug/drug,NN,O
interaction,NN,O
studies,NNS,O
with,IN,O
plenaxis,NNPS,B
were,VBD,O
performed,VBN,O
.,.,.
,,
cytochrome,NN,O
p-450,NN,O
is,VBZ,O
not,RB,O
known,VBN,O
to,TO,O
be,VB,O
involved,VBN,O
in,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
plenaxis,NNP,B
.,.,.
,,
plenaxis,NNP,B
is,VBZ,O
highly,RB,O
bound,VBN,O
to,TO,O
plasma,NN,O
proteins,NNS,O
-lrb-,-LRB-,O
96,CD,O
to,TO,O
99,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
laboratory,NN,O
tests,NNS,O
response,NN,O
to,TO,O
plenaxis,NNP,B
should,MD,O
be,VB,O
monitored,VBN,O
by,IN,O
measuring,VBG,O
serum,NN,O
total,JJ,O
testosterone,NN,D
concentrations,NNS,O
just,RB,O
prior,RB,O
to,TO,O
administration,NN,O
on,IN,O
day,NN,O
29,CD,O
and,CC,O
every,DT,O
8,CD,O
weeks,NNS,O
thereafter,RB,O
.,.,.
,,
serum,NN,O
transaminase,NN,O
levels,NNS,O
should,MD,O
be,VB,O
obtained,VBN,O
before,IN,O
starting,VBG,O
treatment,NN,O
with,IN,O
plenaxis,NNPS,B
and,CC,O
periodically,RB,O
during,IN,O
treatment,NN,O
.,.,.
,,
periodic,JJ,O
measurement,NN,O
of,IN,O
serum,NN,O
psa,NN,O
levels,NNS,O
may,MD,O
also,RB,O
be,VB,O
considered,VBN,O
.,.,.
,,
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
with,IN,O
orencia,NN,B
.,.,.
,,
population,NNP,O
pharmacokinetic,JJ,O
analyses,NNS,O
revealed,VBD,O
that,IN,O
mtx,NNP,D
",",",",O
nsaids,NNS,G
",",",",O
corticosteroids,NNS,G
",",",",O
and,CC,O
tnf,NN,O
blocking,VBG,O
agents,NNS,O
did,VBD,O
not,RB,O
influence,VB,O
abatacept,JJ,D
clearance,NN,O
.,.,.
,,
the,DT,O
majority,NN,O
of,IN,O
patients,NNS,O
in,IN,O
ra,NN,O
clinical,JJ,O
studies,NNS,O
received,VBD,O
one,CD,O
or,CC,O
more,JJR,O
of,IN,O
the,DT,O
following,VBG,O
concomitant,JJ,O
medications,NNS,O
with,IN,O
orencia,NNP,B
:,:,O
mtx,NNP,D
",",",",O
nsaids,NNS,G
",",",",O
corticosteroids,NNS,G
",",",",O
tnf,NN,O
blocking,VBG,O
agents,NNS,O
",",",",O
azathioprine,NN,D
",",",",O
chloroquine,NN,D
",",",",O
gold,NN,D
",",",",O
hydroxychloroquine,NN,D
",",",",O
leflunomide,NN,D
",",",",O
sulfasalazine,NN,D
",",",",O
and,CC,O
anakinra,NN,D
.,.,.
,,
concurrent,JJ,O
administration,NN,O
of,IN,O
a,DT,O
tnf,NN,O
antagonist,NN,O
with,IN,O
orencia,NNP,B
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
serious,JJ,O
infections,NNS,O
and,CC,O
no,DT,O
significant,JJ,O
additional,JJ,O
efficacy,NN,O
over,IN,O
use,NN,O
of,IN,O
the,DT,O
tnf,NN,O
antagonists,NNS,O
alone,RB,O
.,.,.
,,
concurrent,JJ,O
therapy,NN,O
with,IN,O
orencia,NN,B
and,CC,O
tnf,NN,O
antagonists,NNS,O
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
there,EX,O
is,VBZ,O
insufficient,JJ,O
experience,NN,O
to,TO,O
assess,VB,O
the,DT,O
safety,NN,O
and,CC,O
efficacy,NN,O
of,IN,O
orencia,NNP,B
administered,VBN,O
concurrently,RB,O
with,IN,O
anakinra,NN,D
",",",",O
and,CC,O
therefore,RB,O
such,JJ,O
use,NN,O
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
with,IN,O
abciximab,NNP,D
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
abciximab,NNP,D
has,VBZ,O
been,VBN,O
administered,VBN,O
to,TO,O
patients,NNS,O
with,IN,O
ischemic,JJ,O
heart,NN,O
disease,NN,O
treated,VBN,O
concomitantly,RB,O
with,IN,O
a,DT,O
broad,JJ,O
range,NN,O
of,IN,O
medications,NNS,O
used,VBN,O
in,IN,O
the,DT,O
treatment,NN,O
of,IN,O
angina,NN,O
myocardial,JJ,O
infarction,NN,O
and,CC,O
hypertension,NN,O
.,.,.
,,
these,DT,O
medications,NNS,O
have,VBP,O
included,VBN,O
heparin,NN,D
",",",",O
warfarin,NN,D
",",",",O
beta-adrenergic,JJ,O
receptor,NN,D
blockers,NNS,O
",",",",O
calcium,NN,D
channel,NN,O
antagonists,NNS,O
",",",",O
angiotensin,NN,O
converting,VBG,O
enzyme,NN,O
inhibitors,NNS,O
",",",",O
intravenous,JJ,O
and,CC,O
oral,JJ,O
nitrates,NNS,G
",",",",O
ticlopidine,NN,D
",",",",O
and,CC,O
aspirin,NN,B
.,.,.
,,
heparin,NN,D
",",",",O
other,JJ,O
anticoagulants,NNS,G
",",",",O
thrombolytics,NNS,G
",",",",O
and,CC,O
anti,JJ,O
platelet,NN,O
agents,NNS,O
are,VBP,O
associated,VBN,O
with,IN,O
an,DT,O
increase,NN,O
in,IN,O
bleeding,NN,O
.,.,.
,,
patients,NNS,O
with,IN,O
haca,NN,O
titers,NNS,O
may,MD,O
have,VB,O
allergic,JJ,O
or,CC,O
hypersensitivity,NN,O
reactions,NNS,O
when,WRB,O
treated,VBN,O
with,IN,O
other,JJ,O
diagnostic,JJ,O
or,CC,O
therapeutic,JJ,O
monoclonal,JJ,O
antibodies,NNS,G
.,.,.
,,
the,DT,O
concomitant,JJ,O
intake,NN,O
of,IN,O
alcohol,NN,D
and,CC,O
acamprosate,NN,D
does,VBZ,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
alcohol,NN,D
or,CC,O
acamprosate,NN,D
.,.,.
,,
pharmacokinetic,JJ,O
studies,NNS,O
indicate,VBP,O
that,IN,O
administration,NN,O
of,IN,O
disulfiram,NN,D
or,CC,O
diazepam,NN,D
does,VBZ,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
acamprosate,NN,D
.,.,.
,,
co-administration,NN,O
of,IN,O
naltrexone,NN,D
with,IN,O
acamprosate,NNP,D
produced,VBD,O
a,DT,O
25,CD,O
%,NN,O
increase,NN,O
in,IN,O
auc,NN,O
and,CC,O
a,DT,O
33,CD,O
%,NN,O
increase,NN,O
in,IN,O
the,DT,O
cmax,NN,O
of,IN,O
acamprosate,NN,D
.,.,.
,,
no,DT,O
adjustment,NN,O
of,IN,O
dosage,NN,O
is,VBZ,O
recommended,VBN,O
in,IN,O
such,JJ,O
patients,NNS,O
.,.,.
,,
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
naltrexone,NN,D
and,CC,O
its,PRP$,O
major,JJ,O
metabolite,NN,O
6-beta-naltrexol,NN,D_n
were,VBD,O
unaffected,JJ,O
following,VBG,O
co-administration,NN,O
with,IN,O
acamprosate,NNP,D
.,.,.
,,
other,JJ,O
concomitant,JJ,O
therapies,NNS,O
:,:,O
in,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
the,DT,O
safety,NN,O
profile,NN,O
in,IN,O
subjects,NNS,O
treated,VBN,O
with,IN,O
acamprosate,NNP,D
concomitantly,RB,O
with,IN,O
anxiolytics,NNS,G
",",",",O
hypnotics,NNS,G
and,CC,O
sedatives,NNS,G
-lrb-,-LRB-,O
including,VBG,O
benzodiazepines,NNS,G
-rrb-,-RRB-,O
",",",",O
or,CC,O
non-opioid,JJ,O
analgesics,NNS,G
was,VBD,O
similar,JJ,O
to,TO,O
that,DT,O
of,IN,O
subjects,NNS,O
taking,VBG,O
placebo,NN,O
with,IN,O
these,DT,O
concomitant,JJ,O
medications,NNS,O
.,.,.
,,
patients,NNS,O
taking,VBG,O
acamprosate,NNP,D
concomitantly,RB,O
with,IN,O
antidepressants,NNS,G
more,RBR,O
commonly,RB,O
reported,VBD,O
both,CC,O
weight,NN,O
gain,NN,O
and,CC,O
weight,NN,O
loss,NN,O
",",",",O
compared,VBN,O
with,IN,O
patients,NNS,O
taking,VBG,O
either,CC,O
medication,NN,O
alone,RB,O
.,.,.
,,
certain,JJ,O
drugs,NNS,D
tend,VBP,O
to,TO,O
produce,VB,O
hyperglycemia,NN,O
and,CC,O
may,MD,O
lead,VB,O
to,TO,O
loss,NN,O
of,IN,O
blood,NN,O
glucose,NN,O
control,NN,O
.,.,.
,,
these,DT,O
drugs,NNS,D
include,VBP,O
the,DT,O
thiazides,NNS,G
and,CC,O
other,JJ,O
diuretics,NNS,G
",",",",O
corticosteroids,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
thyroid,NN,G
products,NNS,O
",",",",O
estrogens,NNS,G
",",",",O
oral,JJ,O
contraceptives,NNS,G
",",",",O
phenytoin,NN,D
",",",",O
nicotinic,JJ,O
acid,NN,O
",",",",O
sympathomimetics,NNS,G
",",",",O
calcium,NN,D
channel-blocking,NN,O
drugs,NNS,D
",",",",O
and,CC,O
isoniazid,NN,D
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
to,TO,O
a,DT,O
patient,NN,O
receiving,VBG,O
acarbose,NNP,D
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
closely,RB,O
observed,VBN,O
for,IN,O
loss,NN,O
of,IN,O
blood,NN,O
glucose,NN,O
control,NN,O
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
withdrawn,VBN,O
from,IN,O
patients,NNS,O
receiving,VBG,O
acarbose,NNP,D
in,IN,O
combination,NN,O
with,IN,O
sulfonylureas,NNS,G
or,CC,O
insulin,NN,D
",",",",O
patients,NNS,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
any,DT,O
evidence,NN,O
of,IN,O
hypoglycemia,NN,O
.,.,.
,,
intestinal,JJ,O
adsorbents,NNS,O
-lrb-,-LRB-,O
e.,FW,O
g.,FW,O
",",",",O
charcoal,NN,D
-rrb-,-RRB-,O
and,CC,O
digestive,JJ,O
enzyme,NN,O
preparations,NNS,O
containing,VBG,O
carbohydrate-splitting,JJ,O
enzymes,NNS,O
-lrb-,-LRB-,O
e.,FW,O
g.,FW,O
",",",",O
amylase,NN,D
",",",",O
pancreatin,NN,D
-rrb-,-RRB-,O
may,MD,O
reduce,VB,O
the,DT,O
effect,NN,O
of,IN,O
acarbose,NNP,D
and,CC,O
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
concomitantly,RB,O
.,.,.
,,
acarbose,NNP,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
change,VB,O
the,DT,O
bioavailabillty,NN,O
digoxin,NN,D
when,WRB,O
they,PRP,O
are,VBP,O
co-administered,JJ,O
",",",",O
which,WDT,O
may,MD,O
require,VB,O
digoxin,NN,D
dose,NN,O
adjustment,NN,O
.,.,.
,,
studies,NNS,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
acarbose,NNP,D
has,VBZ,O
no,DT,O
effect,NN,O
on,IN,O
either,CC,O
the,DT,O
pharmacokinetics,NNS,O
or,CC,O
pharmacodynamics,NNS,O
of,IN,O
digoxin,NN,D
",",",",O
nifedipine,NN,D
",",",",O
propranolol,NN,D
",",",",O
or,CC,O
ranitidine,NN,D
.,.,.
,,
acarbose,NNP,D
did,VBD,O
not,RB,O
interfere,VB,O
with,IN,O
the,DT,O
absorption,NN,O
or,CC,O
disposition,NN,O
of,IN,O
the,DT,O
sulfonylurea,NN,G
glyburide,NN,D
in,IN,O
diabetic,JJ,O
patients,NNS,O
.,.,.
,,
acarbose,NNP,D
may,MD,O
affect,VB,O
digoxin,NN,D
bioavailabillty,NN,O
and,CC,O
may,MD,O
require,VB,O
dose,NN,O
adjustment,NN,O
of,IN,O
digoxin,NN,D
by,IN,O
16,CD,O
%,NN,O
-lrb-,-LRB-,O
90,CD,O
%,NN,O
confidence,NN,O
interval,NN,O
:,:,O
23-Aug,CD,O
%,NN,O
-rrb-,-RRB-,O
",",",",O
decrease,NN,O
mean,NN,O
c,NN,O
max,NN,O
digoxin,NN,D
by,IN,O
26,CD,O
%,NN,O
-lrb-,-LRB-,O
90,CD,O
%,NN,O
confidence,NN,O
interval,NN,O
:,:,O
16-34,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
decrease,VB,O
mean,JJ,O
trough,NN,O
concentrations,NNS,O
of,IN,O
digoxin,NN,D
by,IN,O
9,CD,O
%,NN,O
-lrb-,-LRB-,O
90,CD,O
%,NN,O
confidence,NN,O
limit,NN,O
:,:,O
19,CD,O
%,NN,O
decrease,NN,O
to,TO,O
2,CD,O
%,NN,O
increase,NN,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
amount,NN,O
of,IN,O
metformin,NN,D
absorbed,VBN,O
while,IN,O
taking,VBG,O
acarbose,NNP,D
was,VBD,O
bioequivalent,JJ,O
to,TO,O
the,DT,O
amount,NN,O
absorbed,VBN,O
when,WRB,O
taking,VBG,O
placebo,NN,O
",",",",O
as,IN,O
indicated,VBN,O
by,IN,O
the,DT,O
plasma,NN,O
auc,NN,O
values,NNS,O
.,.,.
,,
however,RB,O
",",",",O
the,DT,O
peak,NN,O
plasma,NN,O
level,NN,O
of,IN,O
metformin,NN,D
was,VBD,O
reduced,VBN,O
by,IN,O
approximately,RB,O
20,CD,O
%,NN,O
when,WRB,O
taking,VBG,O
acarbose,NNP,D
due,JJ,O
to,TO,O
a,DT,O
slight,JJ,O
delay,NN,O
in,IN,O
the,DT,O
absorption,NN,O
of,IN,O
metformin,NN,D
.,.,.
,,
there,EX,O
is,VBZ,O
little,JJ,O
if,IN,O
any,DT,O
clinically,RB,O
significant,JJ,O
interaction,NN,O
between,IN,O
acarbose,NNP,D
and,CC,O
metformin,NN,D
.,.,.
,,
catecholamine-depleting,JJ,O
drugs,NNS,D
",",",",O
such,JJ,O
as,IN,O
reserpine,NN,D
",",",",O
may,MD,O
have,VB,O
an,DT,O
additive,JJ,O
effect,NN,O
when,WRB,O
given,VBN,O
with,IN,O
beta-blocking,JJ,D
agents,NNS,O
.,.,.
,,
patients,NNS,O
treated,VBN,O
with,IN,O
acebutolol,NN,D
plus,CC,O
catecholamine,NN,O
depletors,NNS,O
should,MD,O
",",",",O
therefore,RB,O
",",",",O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
evidence,NN,O
of,IN,O
marked,JJ,O
bradycardia,NN,O
or,CC,O
hypotension,NN,O
which,WDT,O
may,MD,O
present,VB,O
as,IN,O
vertigo,NN,O
",",",",O
syncope/presyncope,NN,O
",",",",O
or,CC,O
orthostatic,JJ,O
changes,NNS,O
in,IN,O
blood,NN,O
pressure,NN,O
without,IN,O
compensatory,JJ,O
tachycardia,NN,O
.,.,.
,,
exaggerated,JJ,O
hypertensive,JJ,O
responses,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
from,IN,O
the,DT,O
combined,VBN,O
use,NN,O
of,IN,O
beta-adrenergic,JJ,O
antagonists,NNS,O
and,CC,O
alpha-adrenergic,JJ,O
stimulants,NNS,O
",",",",O
including,VBG,O
those,DT,O
contained,VBN,O
in,IN,O
proprietary,JJ,O
cold,JJ,O
remedies,NNS,O
and,CC,O
vasoconstrictive,JJ,O
nasal,JJ,O
drops,NNS,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
beta-blockers,NNS,G
should,MD,O
be,VB,O
warned,VBN,O
of,IN,O
this,DT,O
potential,JJ,O
hazard,NN,O
.,.,.
,,
blunting,VBG,O
of,IN,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
beta-adrenoceptor,NN,O
blocking,VBG,O
agents,NNS,O
by,IN,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
has,VBZ,O
been,VBN,O
reported,VBN,O
.,.,.
,,
no,DT,O
significant,JJ,O
interactions,NNS,O
with,IN,O
digoxin,NN,D
",",",",O
hydrochlorothiazide,NN,D
",",",",O
hydralazine,NN,D
",",",",O
sulfinpyrazone,NN,D
",",",",O
oral,JJ,O
contraceptives,NNS,G
",",",",O
tolbutamide,NN,D
",",",",O
or,CC,O
warfarin,NN,D
have,VBP,O
been,VBN,O
observed,VBN,O
.,.,.
,,
diamox,NNP,B
modifies,VBZ,O
phenytoin,NN,D
metabolism,NN,O
with,IN,O
increased,VBN,O
serum,NN,O
levels,NNS,O
of,IN,O
phenytoin,NN,D
.,.,.
,,
this,DT,O
may,MD,O
increase,VB,O
or,CC,O
enhance,VB,O
the,DT,O
occurrence,NN,O
of,IN,O
osteomalacia,NN,O
in,IN,O
some,DT,O
patients,NNS,O
receiving,VBG,O
chronic,JJ,O
phenytoin,NN,D
therapy,NN,O
.,.,.
,,
caution,NN,O
is,VBZ,O
advised,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
chronic,JJ,O
concomitant,JJ,O
therapy,NN,O
.,.,.
,,
by,IN,O
decreasing,VBG,O
the,DT,O
gastrointestinal,JJ,O
absorption,NN,O
of,IN,O
primidone,NN,D
",",",",O
diamox,NNP,B
may,MD,O
decrease,VB,O
serum,NN,O
concentrations,NNS,O
of,IN,O
primidone,NN,D
and,CC,O
its,PRP$,O
metabolites,NNS,O
",",",",O
with,IN,O
a,DT,O
consequent,JJ,O
possible,JJ,O
decrease,NN,O
in,IN,O
anticonvulsant,JJ,G
effect,NN,O
.,.,.
,,
caution,NN,O
is,VBZ,O
advised,VBN,O
when,WRB,O
beginning,VBG,O
",",",",O
discontinuing,VBG,O
",",",",O
or,CC,O
changing,VBG,O
the,DT,O
dose,NN,O
of,IN,O
diamox,NNP,B
in,IN,O
patients,NNS,O
receiving,VBG,O
primidone,NN,D
.,.,.
,,
because,IN,O
of,IN,O
possible,JJ,O
additive,JJ,O
effects,NNS,O
with,IN,O
other,JJ,O
carbonic,JJ,O
anhydrase,NN,O
inhibitors,NNS,O
",",",",O
concomitant,JJ,O
use,NN,O
is,VBZ,O
not,RB,O
advisable,JJ,O
.,.,.
,,
acetazolamide,NNP,D
may,MD,O
increase,VB,O
the,DT,O
effects,NNS,O
of,IN,O
other,JJ,O
folic,JJ,O
acid,NN,O
antagonists,NNS,O
.,.,.
,,
acetazolamide,NNP,D
may,MD,O
increase,VB,O
or,CC,O
decrease,VB,O
blood,NN,O
glucose,NN,O
levels,NNS,O
.,.,.
,,
consideration,NN,O
should,MD,O
be,VB,O
taken,VBN,O
in,IN,O
patients,NNS,O
being,VBG,O
treated,VBN,O
with,IN,O
antidiabetic,JJ,D
agents,NNS,O
.,.,.
,,
acetazolamide,NN,D
decreases,VBZ,O
urinary,JJ,O
excretion,NN,O
of,IN,O
amphetamine,NN,D
and,CC,O
may,MD,O
enhance,VB,O
the,DT,O
magnitude,NN,O
and,CC,O
duration,NN,O
of,IN,O
their,PRP$,O
effect,NN,O
.,.,.
,,
acetazolamide,NNP,D
reduces,VBZ,O
urinary,JJ,O
excretion,NN,O
of,IN,O
quinidine,NN,D
and,CC,O
may,MD,O
enhance,VB,O
its,PRP$,O
effect,NN,O
.,.,.
,,
acetazolamide,NNP,D
may,MD,O
prevent,VB,O
the,DT,O
urinary,JJ,O
antiseptic,JJ,O
effect,NN,O
of,IN,O
methenamine,NN,D
.,.,.
,,
acetazolamide,NNP,D
increases,VBZ,O
lithium,NN,D
excretion,NN,O
and,CC,O
the,DT,O
lithium,NN,D
may,MD,O
be,VB,O
decreased,VBN,O
.,.,.
,,
acetazolamide,NNP,D
and,CC,O
sodium,NN,O
bicarbonate,NN,O
used,VBN,O
concurrently,RB,O
increases,VBZ,O
the,DT,O
risk,NN,O
of,IN,O
renal,JJ,O
calculus,NN,O
formation,NN,O
.,.,.
,,
acetazolamide,NNP,D
may,MD,O
elevate,VB,O
cyclosporine,NN,D
levels,NNS,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
with,IN,O
iron,NN,D
supplements,NNS,O
may,MD,O
result,VB,O
in,IN,O
the,DT,O
reduced,VBN,O
absorption,NN,O
of,IN,O
iron,NN,D
.,.,.
,,
co-administration,NN,O
of,IN,O
probenecid,NN,D
with,IN,O
acyclovir,NN,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
increase,VB,O
the,DT,O
mean,NN,O
half-life,NN,O
and,CC,O
the,DT,O
area,NN,O
under,IN,O
the,DT,O
concentration-time,JJ,O
curve,NN,O
.,.,.
,,
urinary,JJ,O
excretion,NN,O
and,CC,O
renal,JJ,O
clearance,NN,O
were,VBD,O
correspondingly,RB,O
reduced,VBN,O
.,.,.
,,
the,DT,O
clinical,JJ,O
effects,NNS,O
of,IN,O
this,DT,O
combination,NN,O
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
ethanol,NN,D
:,:,O
clinical,JJ,O
evidence,NN,O
has,VBZ,O
shown,VBN,O
that,IN,O
etretinate,NN,D
can,MD,O
be,VB,O
formed,VBN,O
with,IN,O
concurrent,JJ,O
ingestion,NN,O
of,IN,O
acitretin,NN,D
and,CC,O
ethanol,NN,D
.,.,.
,,
glibenclamide,NNP,D
:,:,O
in,IN,O
a,DT,O
study,NN,O
of,IN,O
7,CD,O
healthy,JJ,O
male,JJ,O
volunteers,NNS,O
",",",",O
acitretin,NN,D
treatment,NN,O
potentiated,VBD,O
the,DT,O
blood,NN,O
glucose,NN,O
lowering,VBG,O
effect,NN,O
of,IN,O
glibenclamide,NN,D
-lrb-,-LRB-,O
a,DT,O
sulfonylurea,NN,G
similar,JJ,O
to,TO,O
chlorpropamide,NN,D
-rrb-,-RRB-,O
in,IN,O
3,CD,O
of,IN,O
the,DT,O
7,CD,O
subjects,NNS,O
.,.,.
,,
repeating,VBG,O
the,DT,O
study,NN,O
with,IN,O
6,CD,O
healthy,JJ,O
male,JJ,O
volunteers,NNS,O
in,IN,O
the,DT,O
absence,NN,O
of,IN,O
glibenclamide,NN,D
did,VBD,O
not,RB,O
detect,VB,O
an,DT,O
effect,NN,O
of,IN,O
acitretin,NN,D
on,IN,O
glucose,NN,O
tolerance,NN,O
.,.,.
,,
careful,JJ,O
supervision,NN,O
of,IN,O
diabetic,JJ,O
patients,NNS,O
under,IN,O
treatment,NN,O
with,IN,O
soriatane,NN,B
is,VBZ,O
recommended,VBN,O
.,.,.
,,
hormonal,JJ,O
contraceptives,NNS,G
:,:,O
it,PRP,O
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
if,IN,O
there,EX,O
is,VBZ,O
a,DT,O
pharmacokinetic,JJ,O
interaction,NN,O
between,IN,O
acitretin,NN,D
and,CC,O
combined,VBN,O
oral,JJ,O
contraceptives,NNS,G
.,.,.
,,
however,RB,O
",",",",O
it,PRP,O
has,VBZ,O
been,VBN,O
established,VBN,O
that,IN,O
acitretin,NN,D
interferes,VBZ,O
with,IN,O
the,DT,O
contraceptive,JJ,G
effect,NN,O
of,IN,O
microdosed,JJ,O
progestin,NN,G
minipill,NN,O
preparations,NNS,O
.,.,.
,,
microdosed,JJ,O
minipill,NN,O
progestin,NN,G
preparations,NNS,O
are,VBP,O
not,RB,O
recommended,VBN,O
for,IN,O
use,NN,O
with,IN,O
soriatane,NN,B
.,.,.
,,
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
whether,IN,O
other,JJ,O
progestational,JJ,O
contraceptives,NNS,G
",",",",O
such,JJ,O
as,IN,O
implants,NNS,O
and,CC,O
injectables,NNS,O
",",",",O
are,VBP,O
adequate,JJ,O
methods,NNS,O
of,IN,O
contraception,NN,O
during,IN,O
acitretin,NN,D
therapy,NN,O
.,.,.
,,
methotrexate,NNP,D
:,:,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
hepatitis,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
result,VB,O
from,IN,O
combined,VBN,O
use,NN,O
of,IN,O
methotrexate,NN,D
and,CC,O
etretinate,NN,D
.,.,.
,,
consequently,RB,O
",",",",O
the,DT,O
combination,NN,O
of,IN,O
methotrexate,NN,D
with,IN,O
acitretin,NN,D
is,VBZ,O
also,RB,O
contraindicated,VBN,O
.,.,.
,,
phenytoin,NNP,D
:,:,O
if,IN,O
acitretin,NN,D
is,VBZ,O
given,VBN,O
concurrently,RB,O
with,IN,O
phenytoin,NN,D
",",",",O
the,DT,O
protein,NN,O
binding,NN,O
of,IN,O
phenytoin,NN,D
may,MD,O
be,VB,O
reduced,VBN,O
.,.,.
,,
tetracyclines,NNS,G
:,:,O
since,IN,O
both,DT,O
acitretin,NN,D
and,CC,O
tetracyclines,NNS,G
can,MD,O
cause,VB,O
increased,VBN,O
intracranial,JJ,O
pressure,NN,O
",",",",O
their,PRP$,O
combined,VBN,O
use,NN,O
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
vitamin,NN,O
a,NN,O
and,CC,O
oral,JJ,O
retinoids,NNS,G
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
vitamin,NN,G
a,NN,O
and/or,CC,O
other,JJ,O
oral,JJ,O
retinoids,NNS,G
with,IN,O
acitretin,NN,D
must,MD,O
be,VB,O
avoided,VBN,O
because,IN,O
of,IN,O
the,DT,O
risk,NN,O
of,IN,O
hypervitaminosis,NN,O
a.,NN,O
other,JJ,O
:,:,O
there,EX,O
appears,VBZ,O
to,TO,O
be,VB,O
no,DT,O
pharmacokinetic,JJ,O
interaction,NN,O
between,IN,O
acitretin,NN,D
and,CC,O
cimetidine,NN,D
",",",",O
digoxin,NN,D
",",",",O
or,CC,O
glyburide,NN,D
.,.,.
,,
investigations,NNS,O
into,IN,O
the,DT,O
effect,NN,O
of,IN,O
acitretin,NN,D
on,IN,O
the,DT,O
protein,NN,O
binding,NN,O
of,IN,O
anticoagulants,NNS,G
of,IN,O
the,DT,O
coumarin,NN,G
type,NN,O
-lrb-,-LRB-,O
warfarin,NN,D
-rrb-,-RRB-,O
revealed,VBD,O
no,DT,O
interaction,NN,O
.,.,.
,,
laboratory,NN,O
tests,NNS,O
if,IN,O
significant,JJ,O
abnormal,JJ,O
laboratory,NN,O
results,NNS,O
are,VBP,O
obtained,VBN,O
",",",",O
either,CC,O
dosage,NN,O
reduction,NN,O
with,IN,O
careful,JJ,O
monitoring,NN,O
or,CC,O
treatment,NN,O
discontinuation,NN,O
is,VBZ,O
recommended,VBN,O
",",",",O
depending,VBG,O
on,IN,O
clinical,JJ,O
judgement,NN,O
.,.,.
,,
blood,NN,O
sugar,NNP,O
:,:,O
some,DT,O
patients,NNS,O
receiving,VBG,O
retinoids,NNS,G
have,VBP,O
experienced,VBN,O
problems,NNS,O
with,IN,O
blood,NN,O
sugar,NN,O
control,NN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
new,JJ,O
cases,NNS,O
of,IN,O
diabetes,NNS,O
have,VBP,O
been,VBN,O
diagnosed,VBN,O
during,IN,O
retinoid,NN,G
therapy,NN,O
",",",",O
including,VBG,O
diabetic,JJ,O
ketoacidosis,NN,O
.,.,.
,,
in,IN,O
diabetics,NNS,O
",",",",O
blood-sugar,JJ,O
levels,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
very,RB,O
carefully,RB,O
.,.,.
,,
lipids,NNS,O
:,:,O
in,IN,O
clinical,JJ,O
studies,NNS,O
",",",",O
the,DT,O
incidence,NN,O
of,IN,O
hypertriglyceridemia,NN,O
was,VBD,O
66,CD,O
%,NN,O
",",",",O
hypercholesterolemia,NN,O
was,VBD,O
33,CD,O
%,NN,O
and,CC,O
that,IN,O
of,IN,O
decreased,VBN,O
hdl,NN,O
was,VBD,O
40,CD,O
%,NN,O
.,.,.
,,
pretreatment,NN,O
and,CC,O
follow-up,NN,O
measurements,NNS,O
should,MD,O
be,VB,O
obtained,VBN,O
under,IN,O
fasting,NN,O
conditions,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
these,DT,O
tests,NNS,O
be,VB,O
performed,VBN,O
weekly,JJ,O
or,CC,O
every,DT,O
other,JJ,O
week,NN,O
until,IN,O
the,DT,O
lipid,NN,O
response,NN,O
to,TO,O
soriatane,NNP,B
has,VBZ,O
stabilized,VBN,O
.,.,.
,,
liver,NN,O
function,NN,O
tests,NNS,O
:,:,O
elevations,NNS,O
of,IN,O
ast,NNP,O
-lrb-,-LRB-,O
sgot,NNP,O
-rrb-,-RRB-,O
",",",",O
alt,NN,O
-lrb-,-LRB-,O
sgpt,NN,O
-rrb-,-RRB-,O
or,CC,O
ldh,NN,O
were,VBD,O
experienced,VBN,O
by,IN,O
approximately,RB,O
1,CD,O
in,IN,O
3,CD,O
patients,NNS,O
treated,VBN,O
with,IN,O
soriatane,NN,B
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
these,DT,O
tests,NNS,O
be,VB,O
performed,VBN,O
prior,RB,O
to,TO,O
initiation,NN,O
of,IN,O
soriatane,NN,B
therapy,NN,O
",",",",O
at,IN,O
1,LS,O
-,:,O
to,TO,O
2-week,JJ,O
intervals,NNS,O
until,IN,O
stable,JJ,O
and,CC,O
thereafter,RB,O
at,IN,O
intervals,NNS,O
as,IN,O
clinically,RB,O
indicated,VBN,O
.,.,.
,,
methotrexate,NNP,D
:,:,O
humira,NNP,B
has,VBZ,O
been,VBN,O
studied,VBN,O
in,IN,O
rheumatoid,JJ,O
arthritis,NN,O
patients,NNS,O
taking,VBG,O
concomitant,JJ,O
mtx,NN,D
.,.,.
,,
the,DT,O
data,NNS,O
do,VBP,O
not,RB,O
suggest,VB,O
the,DT,O
need,NN,O
for,IN,O
dose,NN,O
adjustment,NN,O
of,IN,O
either,CC,O
humira,NN,B
or,CC,O
mtx,NN,D
.,.,.
,,
anakinra,NNP,D
:,:,O
concurrent,JJ,O
administration,NN,O
of,IN,O
anakinra,NN,D
-lrb-,-LRB-,O
an,DT,O
interleukin-1,NN,O
antagonist,NN,O
-rrb-,-RRB-,O
and,CC,O
another,DT,O
tnf-blocking,JJ,O
agent,NN,O
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
serious,JJ,O
infections,NNS,O
",",",",O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
neutropenia,NN,O
and,CC,O
no,DT,O
additional,JJ,O
benefit,NN,O
compared,VBN,O
to,TO,O
these,DT,O
medicinal,JJ,O
products,NNS,O
alone,RB,O
.,.,.
,,
the,DT,O
safety,NN,O
and,CC,O
efficacy,NN,O
of,IN,O
anakinra,NN,D
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
humira,NNP,B
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
therefore,RB,O
the,DT,O
",",",",O
combination,NN,O
of,IN,O
anakinra,NN,D
with,IN,O
other,JJ,O
tnf-blocking,JJ,O
agents,NNS,O
",",",",O
including,VBG,O
humira,NNP,B
",",",",O
may,MD,O
also,RB,O
result,VB,O
i,FW,O
n,NN,O
similar,JJ,O
toxicities,NNS,O
.,.,.
,,
as,IN,O
differin,NNP,B
gel,NN,O
has,VBZ,O
the,DT,O
potential,JJ,O
to,TO,O
produce,VB,O
local,JJ,O
irritation,NN,O
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
concomitant,JJ,O
use,NN,O
of,IN,O
other,JJ,O
potentially,RB,O
irritating,JJ,O
topical,JJ,O
products,NNS,O
-lrb-,-LRB-,O
medicated,VBN,O
or,CC,O
abrasive,JJ,O
soaps,NNS,O
and,CC,O
cleansers,NNS,O
",",",",O
soaps,NNS,O
and,CC,O
cosmetics,NNS,O
that,WDT,O
have,VBP,O
a,DT,O
strong,JJ,O
drying,VBG,O
effect,NN,O
",",",",O
and,CC,O
products,NNS,O
with,IN,O
high,JJ,O
concentrations,NNS,O
of,IN,O
alcohol,NN,D
",",",",O
astringents,NNS,O
",",",",O
spices,NNS,O
or,CC,O
lime,NN,O
-rrb-,-RRB-,O
should,MD,O
be,VB,O
approached,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
particular,JJ,O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
in,IN,O
using,VBG,O
preparations,NNS,O
containing,VBG,O
sulfur,NN,D
",",",",O
resorcinol,NN,D
",",",",O
or,CC,O
salicylic,JJ,O
acid,NN,O
in,IN,O
combination,NN,O
with,IN,O
differin,NNP,B
gel,NN,O
.,.,.
,,
if,IN,O
these,DT,O
preparations,NNS,O
have,VBP,O
been,VBN,O
used,VBN,O
it,PRP,O
is,VBZ,O
advisable,JJ,O
not,RB,O
to,TO,O
start,VB,O
therapy,NN,O
with,IN,O
differin,NNP,B
gel,NN,O
until,IN,O
the,DT,O
effects,NNS,O
of,IN,O
such,JJ,O
preparations,NNS,O
in,IN,O
the,DT,O
skin,NN,O
have,VBP,O
subsided,VBN,O
.,.,.
,,
before,IN,O
using,VBG,O
this,DT,O
medication,NN,O
",",",",O
tell,VB,O
your,PRP$,O
doctor,NN,O
or,CC,O
pharmacist,NN,O
of,IN,O
all,DT,O
prescription,NN,O
and,CC,O
nonprescription,NN,O
products,NNS,O
you,PRP,O
may,MD,O
use,VB,O
",",",",O
especially,RB,O
of,IN,O
:,:,O
aminoglycosides,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
gentamicin,NN,D
",",",",O
amikacin,NN,D
-rrb-,-RRB-,O
",",",",O
amphotericin,NN,D
b,NN,O
",",",",O
cyclosporine,NN,D
",",",",O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
ibuprofen,NN,D
-rrb-,-RRB-,O
",",",",O
tacrolimus,NN,D
",",",",O
vancomycin,NN,D
.,.,.
,,
do,VB,O
not,RB,O
start,VB,O
or,CC,O
stop,VB,O
any,DT,O
medicine,NN,O
without,IN,O
doctor,NN,O
or,CC,O
pharmacist,NN,O
approval,NN,O
.,.,.
,,
intravenous,JJ,O
adenocard,NN,B
-lrb-,-LRB-,O
adenosine,NN,D
-rrb-,-RRB-,O
has,VBZ,O
been,VBN,O
effectively,RB,O
administered,VBN,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
other,JJ,O
cardioactive,JJ,O
drugs,NNS,D
",",",",O
such,JJ,O
as,IN,O
quinidine,NN,D
",",",",O
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
",",",",O
calcium,NN,D
channel,NN,O
blocking,VBG,O
agents,NNS,O
",",",",O
and,CC,O
angiotensin,NN,O
converting,NN,O
enzyme,NN,O
inhibitors,NNS,O
",",",",O
without,IN,O
any,DT,O
change,NN,O
in,IN,O
the,DT,O
adverse,JJ,O
reaction,NN,O
profile,NN,O
.,.,.
,,
digoxin,NN,D
and,CC,O
verapamil,NN,D
use,NN,O
may,MD,O
be,VB,O
rarely,RB,O
associated,VBN,O
with,IN,O
ventricular,JJ,O
fibrillation,NN,O
when,WRB,O
combined,VBN,O
with,IN,O
adenocard,NNP,B
.,.,.
,,
because,IN,O
of,IN,O
the,DT,O
potential,NN,O
for,IN,O
additive,JJ,O
or,CC,O
synergistic,JJ,O
depressant,NN,O
effects,NNS,O
on,IN,O
the,DT,O
sa,NNP,O
and,CC,O
av,NNP,O
nodes,NNS,O
",",",",O
however,RB,O
",",",",O
adenocard,NNP,B
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
these,DT,O
agents,NNS,O
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
adenocard,NNP,B
in,IN,O
patients,NNS,O
receiving,VBG,O
digitalis,NN,G
may,MD,O
be,VB,O
rarely,RB,O
associated,VBN,O
with,IN,O
ventricular,JJ,O
fibrillation,NN,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
adenosine,NN,D
are,VBP,O
antagonized,VBN,O
by,IN,O
methylxanthines,NNS,G
such,JJ,O
as,IN,O
caffeine,NN,D
and,CC,O
theophylline,NN,D
.,.,.
,,
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
these,DT,O
methylxanthines,NNS,G
",",",",O
larger,JJR,O
doses,NNS,O
of,IN,O
adenosine,NN,D
may,MD,O
be,VB,O
required,VBN,O
or,CC,O
adenosine,NN,D
may,MD,O
not,RB,O
be,VB,O
effective,JJ,O
.,.,.
,,
adenosine,NN,D
effects,NNS,O
are,VBP,O
potentiated,VBN,O
by,IN,O
dipyridamole,NN,D
.,.,.
,,
thus,RB,O
",",",",O
smaller,JJR,O
doses,NNS,O
of,IN,O
adenosine,NN,D
may,MD,O
be,VB,O
effective,JJ,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
dipyridamole,NN,D
.,.,.
,,
carbamazepine,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
increase,VB,O
the,DT,O
degree,NN,O
of,IN,O
heart,NN,O
block,NN,O
produced,VBN,O
by,IN,O
other,JJ,O
agents,NNS,O
.,.,.
,,
as,IN,O
the,DT,O
primary,JJ,O
effect,NN,O
of,IN,O
adenosine,NN,D
is,VBZ,O
to,TO,O
decrease,VB,O
conduction,NN,O
through,IN,O
the,DT,O
a-v,NN,O
node,NN,O
",",",",O
higher,JJR,O
degrees,NNS,O
of,IN,O
heart,NN,O
block,NN,O
may,MD,O
be,VB,O
produced,VBN,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
carbamazepine,NN,D
.,.,.
,,
co-administration,NN,O
with,IN,O
antifungal,JJ,O
agents,NNS,O
such,JJ,O
as,IN,O
ketoconazole,NN,D
or,CC,O
itraconazole,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
nafazodone,NNP,D
",",",",O
fluvoxamine,NN,D
",",",",O
cimetidine,NN,D
-lrb-,-LRB-,O
consider,VB,O
xanax,NNP,B
dose,NN,O
reduction,NN,O
-rrb-,-RRB-,O
.,.,.
,,
fluoxetine,NNP,D
",",",",O
ocs,NNP,G
",",",",O
sertraline,NN,D
",",",",O
diltiazem,NN,D
",",",",O
macrolide,NN,O
antibiotics,NNS,G
-lrb-,-LRB-,O
exercise,NN,O
caution,NN,O
-rrb-,-RRB-,O
.,.,.
,,
no,DT,O
drug,NN,D
interaction,NN,O
studies,NNS,O
were,VBD,O
performed,VBN,O
.,.,.
,,
no,DT,O
in,FW,O
vitro,FW,O
metabolism,NN,O
studies,NNS,O
were,VBD,O
performed,VBN,O
.,.,.
,,
dexamethasone,NN,D
:,:,O
steady-state,JJ,O
trough,NN,O
concentrations,NNS,O
of,IN,O
albendazole,NN,D
sulfoxide,NN,O
were,VBD,O
about,IN,O
56,CD,O
%,NN,O
higher,JJR,O
when,WRB,O
8,CD,O
mg,NN,O
dexamethasone,NN,D
was,VBD,O
coadministered,VBN,O
with,IN,O
each,DT,O
dose,NN,O
of,IN,O
albendazole,NN,D
-lrb-,-LRB-,O
15,CD,O
mg/kg/day,NN,O
-rrb-,-RRB-,O
in,IN,O
eight,CD,O
neurocysticercosis,NN,O
patients,NNS,O
.,.,.
,,
praziquantel,NNP,D
:,:,O
in,IN,O
the,DT,O
fed,NN,O
state,NN,O
",",",",O
praziquantel,NN,D
-lrb-,-LRB-,O
40,CD,O
mg/kg,NN,O
-rrb-,-RRB-,O
increased,VBD,O
mean,JJ,O
maximum,NN,O
plasma,NN,O
concentration,NN,O
and,CC,O
area,NN,O
under,IN,O
the,DT,O
curve,NN,O
of,IN,O
albendazole,NN,D
sulfoxide,NN,O
by,IN,O
about,IN,O
50,CD,O
%,NN,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
10,CD,O
-rrb-,-RRB-,O
compared,VBN,O
with,IN,O
a,DT,O
separate,JJ,O
group,NN,O
of,IN,O
subjects,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
6,CD,O
-rrb-,-RRB-,O
given,VBN,O
albendazole,NN,D
alone,RB,O
.,.,.
,,
mean,NN,O
t,NN,O
max,NN,O
and,CC,O
mean,VB,O
plasma,NN,O
elimination,NN,O
half-life,NN,O
of,IN,O
albendazole,NN,D
sulfoxide,NN,O
were,VBD,O
unchanged,JJ,O
.,.,.
,,
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
praziquantel,NN,D
were,VBD,O
unchanged,JJ,O
following,VBG,O
coadministration,NN,O
with,IN,O
albendazole,NN,D
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
-rrb-,-RRB-,O
.,.,.
,,
cimetidine,NNP,D
:,:,O
albendazole,NNP,O
sulfoxide,NN,O
concentrations,NNS,O
in,IN,O
bile,NN,O
and,CC,O
cystic,JJ,O
fluid,NN,O
were,VBD,O
increased,VBN,O
-lrb-,-LRB-,O
about,IN,O
2-fold,JJ,O
-rrb-,-RRB-,O
in,IN,O
hydatid,NN,O
cyst,NN,O
patients,NNS,O
treated,VBN,O
with,IN,O
cimetidine,NN,D
-lrb-,-LRB-,O
10,CD,O
mg/kg/day,NN,O
-rrb-,-RRB-,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
7,CD,O
-rrb-,-RRB-,O
compared,VBN,O
with,IN,O
albendazole,NN,D
-lrb-,-LRB-,O
20,CD,O
mg/kg/day,NN,O
-rrb-,-RRB-,O
alone,RB,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
12,CD,O
-rrb-,-RRB-,O
.,.,.
,,
albendazole,NNP,O
sulfoxide,NN,O
plasma,NN,O
concentrations,NNS,O
were,VBD,O
unchanged,JJ,O
4,CD,O
hours,NNS,O
after,IN,O
dosing,NN,O
.,.,.
,,
theophylline,NNP,D
:,:,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
theophylline,NN,D
-lrb-,-LRB-,O
aminophylline,NN,D
5.8,CD,O
mg/kg,NN,O
infused,VBD,O
over,IN,O
20,CD,O
minutes,NNS,O
-rrb-,-RRB-,O
were,VBD,O
unchanged,JJ,O
following,VBG,O
a,DT,O
single,JJ,O
oral,JJ,O
dose,NN,O
of,IN,O
albendazole,NN,D
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
-rrb-,-RRB-,O
in,IN,O
6,CD,O
healthy,JJ,O
subjects,NNS,O
.,.,.
,,
no,DT,O
information,NN,O
provided,VBN,O
.,.,.
,,
proleukin,NNP,B
may,MD,O
affect,VB,O
central,JJ,O
nervous,JJ,O
function,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
interactions,NNS,O
could,MD,O
occur,VB,O
following,VBG,O
concomitant,JJ,O
administration,NN,O
of,IN,O
psychotropic,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
narcotics,NNS,G
",",",",O
analgesics,NNS,G
",",",",O
antiemetics,NNS,G
",",",",O
sedatives,NNS,G
",",",",O
tranquilizers,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
concurrent,JJ,O
administration,NN,O
of,IN,O
drugs,NNS,D
possessing,VBG,O
nephrotoxic,JJ,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
aminoglycosides,NNS,G
",",",",O
indomethacin,NN,D
-rrb-,-RRB-,O
",",",",O
myelotoxic,JJ,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
cytotoxic,JJ,G
chemotherapy,NN,O
-rrb-,-RRB-,O
",",",",O
cardiotoxic,JJ,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
doxorubicin,NN,D
-rrb-,-RRB-,O
or,CC,O
hepatotoxic,JJ,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
methotrexate,NN,D
",",",",O
asparaginase,NN,D
-rrb-,-RRB-,O
effects,NNS,O
with,IN,O
proleukin,NN,B
may,MD,O
increase,VB,O
toxicity,NN,O
in,IN,O
these,DT,O
organ,NN,O
systems,NNS,O
.,.,.
,,
the,DT,O
safety,NN,O
and,CC,O
efficacy,NN,O
of,IN,O
proleukin,NNP,B
in,IN,O
combination,NN,O
with,IN,O
any,DT,O
antineoplastic,JJ,O
agents,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
reduced,VBD,O
kidney,NN,O
and,CC,O
liver,NN,O
function,NN,O
secondary,JJ,O
to,TO,O
proleukin,NN,B
treatment,NN,O
may,MD,O
delay,VB,O
elimination,NN,O
of,IN,O
concomitant,JJ,O
medications,NNS,O
and,CC,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
adverse,JJ,O
events,NNS,O
from,IN,O
those,DT,O
drugs,NNS,D
.,.,.
,,
hypersensitivity,NN,O
reactions,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
combination,NN,O
regimens,NNS,O
containing,VBG,O
sequential,JJ,O
high,JJ,O
dose,NN,O
proleukin,NN,B
and,CC,O
antineoplastic,JJ,O
agents,NNS,O
",",",",O
specifically,RB,O
",",",",O
dacarbazine,NN,D
",",",",O
cis-platinum,NN,D
",",",",O
tamoxifen,NN,D
and,CC,O
interferon-alfa,NN,D
.,.,.
,,
these,DT,O
reactions,NNS,O
consisted,VBD,O
of,IN,O
erythema,NN,O
",",",",O
pruritus,NN,O
",",",",O
and,CC,O
hypotension,NN,O
and,CC,O
occurred,VBD,O
within,IN,O
hours,NNS,O
of,IN,O
administration,NN,O
of,IN,O
chemotherapy,NN,O
.,.,.
,,
these,DT,O
events,NNS,O
required,VBN,O
medical,JJ,O
intervention,NN,O
in,IN,O
some,DT,O
patients,NNS,O
.,.,.
,,
myocardial,JJ,O
injury,NN,O
",",",",O
including,VBG,O
myocardial,JJ,O
infarction,NN,O
",",",",O
myocarditis,NN,O
",",",",O
ventricular,JJ,O
hypokinesia,NN,O
",",",",O
and,CC,O
severe,JJ,O
rhabdomyolysis,NN,O
appear,VBP,O
to,TO,O
be,VB,O
increased,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
proleukin,NNP,B
and,CC,O
interferon-alfa,JJ,D
concurrently,RB,O
.,.,.
,,
exacerbation,NN,O
or,CC,O
the,DT,O
initial,JJ,O
presentation,NN,O
of,IN,O
a,DT,O
number,NN,O
of,IN,O
autoimmune,JJ,O
and,CC,O
inflammatory,JJ,O
disorders,NNS,O
has,VBZ,O
been,VBN,O
observed,VBN,O
following,VBG,O
concurrent,JJ,O
use,NN,O
of,IN,O
interferon-alfa,NN,D
and,CC,O
proleukin,NN,B
",",",",O
including,VBG,O
crescentic,JJ,O
iga,NN,O
glomerulonephritis,NN,O
",",",",O
oculo-bulbar,JJ,O
myasthenia,NN,O
gravis,NN,O
",",",",O
inflammatory,JJ,O
arthritis,NN,O
",",",",O
thyroiditis,NN,O
",",",",O
bullous,JJ,O
pemphigoid,NN,O
",",",",O
and,CC,O
stevens-johnson,NN,O
syndrome,NN,O
.,.,.
,,
although,IN,O
glucocorticoids,NNS,G
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
reduce,VB,O
proleukin-induced,JJ,O
side,JJ,O
effects,NNS,O
including,VBG,O
fever,NN,O
",",",",O
renal,JJ,O
insufficiency,NN,O
",",",",O
hyperbilirubinemia,NN,O
",",",",O
confusion,NN,O
",",",",O
and,CC,O
dyspnea,NN,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
these,DT,O
agents,NNS,O
with,IN,O
proleukin,NN,B
may,MD,O
reduce,VB,O
the,DT,O
antitumor,NN,O
effectiveness,NN,O
of,IN,O
proleukin,NNP,B
and,CC,O
thus,RB,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
12,CD,O
beta-blockers,NNS,G
and,CC,O
other,JJ,O
antihypertensives,NNS,D
may,MD,O
potentiate,VB,O
the,DT,O
hypotension,NN,O
seen,VBN,O
with,IN,O
proleukin,NN,B
.,.,.
,,
delayed,VBN,O
adverse,JJ,O
reactions,NNS,O
to,TO,O
iodinated,NNP,O
contrast,NNP,O
media,NNP,O
:,:,O
a,NNP,O
review,NN,O
of,IN,O
the,DT,O
literature,NN,O
revealed,VBD,O
that,IN,O
12.6,CD,O
%,NN,O
-lrb-,-LRB-,O
range,NN,O
28-Nov,CD,O
%,NN,O
-rrb-,-RRB-,O
of,IN,O
501,CD,O
patients,NNS,O
treated,VBN,O
with,IN,O
various,JJ,O
interleukin-2,NN,D
containing,VBG,O
regimens,NNS,O
who,WP,O
were,VBD,O
subsequently,RB,O
administered,VBN,O
radiographic,JJ,O
iodinated,VBN,O
contrast,NN,O
media,NNS,O
experienced,VBD,O
acute,JJ,O
",",",",O
atypical,JJ,O
adverse,JJ,O
reactions,NNS,O
.,.,.
,,
the,DT,O
onset,NN,O
of,IN,O
symptoms,NNS,O
usually,RB,O
occurred,VBD,O
within,IN,O
hours,NNS,O
-lrb-,-LRB-,O
most,RBS,O
commonly,RB,O
1,CD,O
to,TO,O
4,CD,O
hours,NNS,O
-rrb-,-RRB-,O
following,VBG,O
the,DT,O
administration,NN,O
of,IN,O
contrast,NN,O
media,NNS,O
.,.,.
,,
these,DT,O
reactions,NNS,O
include,VBP,O
fever,NN,O
",",",",O
chills,NNS,O
",",",",O
nausea,NN,O
",",",",O
vomiting,VBG,O
",",",",O
pruritus,NN,O
",",",",O
rash,NN,O
",",",",O
diarrhea,NN,O
",",",",O
hypotension,NN,O
",",",",O
edema,NN,O
",",",",O
and,CC,O
oliguria,NN,O
.,.,.
,,
some,DT,O
clinicians,NNS,O
have,VBP,O
noted,VBN,O
that,IN,O
these,DT,O
reactions,NNS,O
resemble,VBP,O
the,DT,O
immediate,JJ,O
side,JJ,O
effects,NNS,O
caused,VBN,O
by,IN,O
interleukin-2,NN,D
administration,NN,O
",",",",O
however,RB,O
the,DT,O
cause,NN,O
of,IN,O
contrast,NN,O
reactions,NNS,O
after,IN,O
interleukin-2,NN,D
therapy,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
most,JJS,O
events,NNS,O
were,VBD,O
reported,VBN,O
to,TO,O
occur,VB,O
when,WRB,O
contrast,NN,O
media,NNS,O
was,VBD,O
given,VBN,O
within,IN,O
4,CD,O
weeks,NNS,O
after,IN,O
the,DT,O
last,JJ,O
dose,NN,O
of,IN,O
interleukin-2,NN,D
.,.,.
,,
these,DT,O
events,NNS,O
were,VBD,O
also,RB,O
reported,VBN,O
to,TO,O
occur,VB,O
when,WRB,O
contrast,NN,O
media,NNS,O
was,VBD,O
given,VBN,O
several,JJ,O
months,NNS,O
after,IN,O
interleukin-2,NN,D
treatment,NN,O
.,.,.
,,
no,DT,O
formal,JJ,O
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
.,.,.
,,
the,DT,O
duration,NN,O
of,IN,O
the,DT,O
period,NN,O
following,VBG,O
treatment,NN,O
with,IN,O
amevive,NN,B
before,IN,O
one,CD,O
should,MD,O
consider,VB,O
starting,VBG,O
other,JJ,O
immunosuppressive,JJ,G
therapy,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
evaluated,VBN,O
.,.,.
,,
carcinogenesis,NN,O
",",",",O
mutagenesis,NN,O
",",",",O
and,CC,O
fertility,NN,O
.,.,.
,,
in,IN,O
a,DT,O
chronic,JJ,O
toxicity,NN,O
study,NN,O
",",",",O
cynomolgus,NN,O
monkeys,NNS,O
were,VBD,O
dosed,VBN,O
weekly,RB,O
for,IN,O
52,CD,O
weeks,NNS,O
with,IN,O
intravenous,JJ,O
alefacept,NN,D
at,IN,O
1,CD,O
mg/kg/dose,NN,O
or,CC,O
20,CD,O
mg/kg/dose,NN,O
.,.,.
,,
one,CD,O
animal,NN,O
in,IN,O
the,DT,O
high,JJ,O
dose,NN,O
group,NN,O
developed,VBD,O
a,DT,O
b-cell,NN,O
lymphoma,NN,O
that,WDT,O
was,VBD,O
detected,VBN,O
after,IN,O
28,CD,O
weeks,NNS,O
of,IN,O
dosing,NN,O
.,.,.
,,
additional,JJ,O
animals,NNS,O
in,IN,O
both,DT,O
dose,NN,O
groups,NNS,O
developed,VBD,O
b-cell,NN,O
hyperplasia,NN,O
of,IN,O
the,DT,O
spleen,NN,O
and,CC,O
lymph,NN,O
nodes,NNS,O
.,.,.
,,
all,DT,O
animals,NNS,O
in,IN,O
the,DT,O
study,NN,O
were,VBD,O
positive,JJ,O
for,IN,O
an,DT,O
endemic,JJ,O
primate,JJ,O
gammaherpes,NNS,O
virus,NN,O
also,RB,O
known,VBN,O
as,IN,O
lymphocryptovirus,NN,O
-lrb-,-LRB-,O
lcv,NN,O
-rrb-,-RRB-,O
.,.,.
,,
latent,JJ,O
lcv,NN,O
infection,NN,O
is,VBZ,O
generally,RB,O
asymptomatic,JJ,O
",",",",O
but,CC,O
can,MD,O
lead,VB,O
to,TO,O
b-cell,NN,O
lymphomas,NNS,O
when,WRB,O
animals,NNS,O
are,VBP,O
immune,JJ,O
suppressed,VBN,O
.,.,.
,,
in,IN,O
a,DT,O
separate,JJ,O
study,NN,O
",",",",O
baboons,NNS,O
given,VBN,O
3,CD,O
doses,NNS,O
of,IN,O
alefacept,NN,D
at,IN,O
1,CD,O
mg/kg,NN,O
every,DT,O
8,CD,O
weeks,NNS,O
were,VBD,O
found,VBN,O
to,TO,O
have,VB,O
centroblast,NN,O
proliferation,NN,O
in,IN,O
b-cell,NN,O
dependent,JJ,O
areas,NNS,O
in,IN,O
the,DT,O
germinal,JJ,O
centers,NNS,O
of,IN,O
the,DT,O
spleen,NN,O
following,VBG,O
a,DT,O
116-day,JJ,O
washout,NN,O
period,NN,O
.,.,.
,,
the,DT,O
role,NN,O
of,IN,O
amevive,NNP,B
in,IN,O
the,DT,O
development,NN,O
of,IN,O
the,DT,O
lymphoid,JJ,O
malignancy,NN,O
and,CC,O
the,DT,O
hyperplasia,NN,O
observed,VBN,O
in,IN,O
non-human,JJ,O
primates,NNS,O
and,CC,O
the,DT,O
relevance,NN,O
to,TO,O
humans,NNS,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
immunodeficiency-associated,JJ,O
lymphocyte,NN,O
disorders,NNS,O
-lrb-,-LRB-,O
plasmacytic,JJ,O
hyperplasia,NN,O
",",",",O
polymorphic,JJ,O
proliferation,NN,O
",",",",O
and,CC,O
b-cell,NN,O
lymphomas,NNS,O
-rrb-,-RRB-,O
occur,VBP,O
in,IN,O
patients,NNS,O
who,WP,O
have,VBP,O
congenital,JJ,O
or,CC,O
acquired,VBN,O
immunodeficiencies,NNS,O
including,VBG,O
those,DT,O
resulting,VBG,O
from,IN,O
immunosuppressive,JJ,G
therapy,NN,O
.,.,.
,,
no,DT,O
carcinogenicity,NN,O
or,CC,O
fertility,NN,O
studies,NNS,O
were,VBD,O
conducted,VBN,O
.,.,.
,,
mutagenicity,NN,O
studies,NNS,O
were,VBD,O
conducted,VBN,O
in,FW,O
vitro,FW,O
and,CC,O
in,FW,O
vivo,FW,O
;,:,O
.,.,.
,,
no,DT,O
evidence,NN,O
of,IN,O
mutagenicity,NN,O
was,VBD,O
observed,VBN,O
.,.,.
,,
pregnancy,NN,O
-lrb-,-LRB-,O
category,NN,O
b,NN,O
-rrb-,-RRB-,O
.,.,.
,,
women,NNS,O
of,IN,O
childbearing,JJ,O
potential,JJ,O
make,VB,O
up,RP,O
a,DT,O
considerable,JJ,O
segment,NN,O
of,IN,O
the,DT,O
patient,NN,O
population,NN,O
affected,VBN,O
by,IN,O
psoriasis,NN,O
.,.,.
,,
since,IN,O
the,DT,O
effect,NN,O
of,IN,O
amevive,NNP,B
on,IN,O
pregnancy,NN,O
and,CC,O
fetal,JJ,O
development,NN,O
",",",",O
including,VBG,O
immune,JJ,O
system,NN,O
development,NN,O
",",",",O
is,VBZ,O
not,RB,O
known,VBN,O
",",",",O
health,NN,O
care,NN,O
providers,NNS,O
are,VBP,O
encouraged,VBN,O
to,TO,O
enroll,VB,O
patients,NNS,O
currently,RB,O
taking,VBG,O
amevive,NNP,B
who,WP,O
become,VBP,O
pregnant,JJ,O
into,IN,O
the,DT,O
biogen,NNP,O
pregnancy,NNP,O
registry,NNP,O
by,IN,O
calling,VBG,O
1-866-amevive,NN,O
-lrb-,-LRB-,O
1-866-263-8483,CD,O
-rrb-,-RRB-,O
.,.,.
,,
reproductive,NNP,O
toxicology,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
in,IN,O
cynomolgus,NN,O
monkeys,NNS,O
at,IN,O
doses,NNS,O
up,RB,O
to,TO,O
5,CD,O
mg/kg/week,NN,O
-lrb-,-LRB-,O
about,IN,O
62,CD,O
times,NNS,O
the,DT,O
human,JJ,O
dose,NN,O
based,VBN,O
on,IN,O
body,NN,O
weight,NN,O
-rrb-,-RRB-,O
and,CC,O
have,VBP,O
revealed,VBN,O
no,DT,O
evidence,NN,O
of,IN,O
impaired,JJ,O
fertility,NN,O
or,CC,O
harm,NN,O
to,TO,O
the,DT,O
fetus,NN,O
due,JJ,O
to,TO,O
amevive,NNP,B
.,.,.
,,
no,DT,O
abortifacient,NN,O
or,CC,O
teratogenic,JJ,O
effects,NNS,O
were,VBD,O
observed,VBN,O
in,IN,O
cynomolgus,NN,O
monkeys,NNS,O
following,VBG,O
intravenous,JJ,O
bolus,NN,O
injections,NNS,O
of,IN,O
amevive,NNP,B
administered,VBN,O
weekly,RB,O
during,IN,O
the,DT,O
period,NN,O
of,IN,O
organogenesis,NN,O
to,TO,O
gestation,NN,O
.,.,.
,,
amevive,NNP,B
underwent,VBD,O
trans-placental,JJ,O
passage,NN,O
and,CC,O
produced,VBN,O
in,IN,O
utero,NN,O
exposure,NN,O
in,IN,O
the,DT,O
developing,VBG,O
monkeys,NNS,O
.,.,.
,,
in,IN,O
utero,NN,O
",",",",O
serum,NN,O
levels,NNS,O
of,IN,O
exposure,NN,O
in,IN,O
these,DT,O
monkeys,NNS,O
were,VBD,O
23,CD,O
%,NN,O
of,IN,O
maternal,JJ,O
serum,NN,O
levels,NNS,O
.,.,.
,,
no,DT,O
evidence,NN,O
of,IN,O
fetal,JJ,O
toxicity,NN,O
including,VBG,O
adverse,JJ,O
effects,NNS,O
on,IN,O
immune,JJ,O
system,NN,O
development,NN,O
was,VBD,O
observed,VBN,O
in,IN,O
any,DT,O
of,IN,O
these,DT,O
animals,NNS,O
.,.,.
,,
animal,NN,O
reproduction,NN,O
studies,NNS,O
",",",",O
however,RB,O
",",",",O
are,VBP,O
not,RB,O
always,RB,O
predictive,JJ,O
of,IN,O
human,JJ,O
response,NN,O
and,CC,O
there,EX,O
are,VBP,O
no,DT,O
adequate,JJ,O
and,CC,O
well-controlled,JJ,O
studies,NNS,O
in,IN,O
pregnant,JJ,O
women,NNS,O
.,.,.
,,
because,IN,O
the,DT,O
risk,NN,O
to,TO,O
the,DT,O
development,NN,O
of,IN,O
the,DT,O
fetal,JJ,O
immune,JJ,O
system,NN,O
and,CC,O
postnatal,JJ,O
immune,JJ,O
function,NN,O
in,IN,O
humans,NNS,O
is,VBZ,O
unknown,JJ,O
",",",",O
amevive,NNP,B
should,MD,O
be,VB,O
used,VBN,O
during,IN,O
pregnancy,NN,O
only,RB,O
if,IN,O
clearly,RB,O
needed,VBN,O
.,.,.
,,
if,IN,O
pregnancy,NN,O
occurs,VBZ,O
while,IN,O
taking,VBG,O
amevive,NNP,B
",",",",O
continued,VBD,O
use,NN,O
of,IN,O
the,DT,O
drug,NN,D
should,MD,O
be,VB,O
assessed,VBN,O
.,.,.
,,
nursing,NNP,O
mothers,NNP,O
.,.,.
,,
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
whether,IN,O
amevive,NNP,B
is,VBZ,O
excreted,VBN,O
in,IN,O
human,JJ,O
milk,NN,O
.,.,.
,,
because,IN,O
many,JJ,O
drugs,NNS,D
are,VBP,O
excreted,VBN,O
in,IN,O
human,JJ,O
milk,NN,O
",",",",O
and,CC,O
because,IN,O
there,EX,O
exists,VBZ,O
the,DT,O
potential,NN,O
for,IN,O
serious,JJ,O
adverse,JJ,O
reactions,NNS,O
in,IN,O
nursing,NN,O
infants,NNS,O
from,IN,O
amevive,NNP,B
",",",",O
a,DT,O
decision,NN,O
should,MD,O
be,VB,O
made,VBN,O
whether,IN,O
to,TO,O
discontinue,VB,O
nursing,NN,O
while,IN,O
taking,VBG,O
the,DT,O
drug,NN,D
or,CC,O
to,TO,O
discontinue,VB,O
the,DT,O
use,NN,O
of,IN,O
the,DT,O
drug,NN,D
",",",",O
taking,VBG,O
into,IN,O
account,NN,O
the,DT,O
importance,NN,O
of,IN,O
the,DT,O
drug,NN,D
to,TO,O
the,DT,O
mother,NN,O
.,.,.
,,
geriatric,NNP,O
use,NNP,O
.,.,.
,,
of,IN,O
the,DT,O
1357,CD,O
patients,NNS,O
who,WP,O
received,VBD,O
amevive,NNP,B
in,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
a,DT,O
total,NN,O
of,IN,O
100,CD,O
patients,NNS,O
wer,NN,O
.,.,.
,,
65,CD,O
years,NNS,O
of,IN,O
age,NN,O
and,CC,O
13,CD,O
patients,NNS,O
were,VBD,O
.,.,.
,,
75,CD,O
years,NNS,O
of,IN,O
age,NN,O
.,.,.
,,
no,DT,O
differences,NNS,O
in,IN,O
safety,NN,O
or,CC,O
efficacy,NN,O
were,VBD,O
observed,VBN,O
between,IN,O
older,JJR,O
and,CC,O
younger,JJR,O
patients,NNS,O
",",",",O
but,CC,O
there,EX,O
were,VBD,O
not,RB,O
sufficient,JJ,O
data,NNS,O
to,TO,O
exclude,VB,O
important,JJ,O
differences,NNS,O
.,.,.
,,
because,IN,O
the,DT,O
incidence,NN,O
of,IN,O
infections,NNS,O
and,CC,O
certain,JJ,O
malignancies,NNS,O
is,VBZ,O
higher,JJR,O
in,IN,O
the,DT,O
elderly,JJ,O
population,NN,O
",",",",O
in,IN,O
general,JJ,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
in,IN,O
treating,VBG,O
the,DT,O
elderly,JJ,O
.,.,.
,,
pediatric,NNP,O
use,NNP,O
.,.,.
,,
the,DT,O
safety,NN,O
and,CC,O
efficacy,NN,O
of,IN,O
amevive,NNP,B
in,IN,O
pediatric,JJ,O
patients,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
amevive,NNP,B
is,VBZ,O
not,RB,O
indicated,VBN,O
for,IN,O
pediatric,JJ,O
patients,NNS,O
.,.,.
,,
drug/laboratory,NNP,O
interactions,NNS,O
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
with,IN,O
campath,NNP,B
.,.,.
,,
an,DT,O
immune,JJ,O
response,NN,O
to,TO,O
campath,NNP,B
may,MD,O
interfere,VB,O
with,IN,O
subsequent,JJ,O
diagnostic,JJ,O
serum,NN,O
tests,NNS,O
that,WDT,O
utilize,VBP,O
antibodie,NN,O
.,.,.
,,
intravenous,JJ,O
ranitidine,NN,D
was,VBD,O
shown,VBN,O
to,TO,O
double,VB,O
the,DT,O
bioavailability,NN,O
of,IN,O
oral,JJ,O
alendronate,NN,D
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
increased,VBN,O
bioavailability,NN,O
and,CC,O
whether,IN,O
similar,JJ,O
increases,NNS,O
will,MD,O
occur,VB,O
in,IN,O
patients,NNS,O
given,VBN,O
oral,JJ,O
h2-antagonists,NNS,G
is,VBZ,O
unknown,JJ,O
.,.,.
,,
no,DT,O
other,JJ,O
specific,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
were,VBD,O
performed,VBN,O
.,.,.
,,
products,NNPS,O
containing,VBG,O
calcium,NN,D
and,CC,O
other,JJ,O
multivalent,JJ,O
cations,NNS,O
likely,RB,O
will,MD,O
interfere,VB,O
with,IN,O
absorption,NN,O
of,IN,O
alendronate,NN,D
.,.,.
,,
both,CC,O
the,DT,O
magnitude,NN,O
and,CC,O
duration,NN,O
of,IN,O
central,JJ,O
nervous,JJ,O
system,NN,O
and,CC,O
cardiovascular,JJ,O
effects,NNS,O
may,MD,O
be,VB,O
enhanced,VBN,O
when,WRB,O
alfenta,NNP,B
is,VBZ,O
administered,VBN,O
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
cns,NN,O
depressants,NNS,O
such,JJ,O
as,IN,O
barbiturates,NNS,G
",",",",O
tranquilizers,NNS,G
",",",",O
opioids,NNS,G
",",",",O
or,CC,O
inhalation,NN,O
general,JJ,O
anesthetics,NNS,G
.,.,.
,,
postoperative,JJ,O
respiratory,JJ,O
depression,NN,O
may,MD,O
be,VB,O
enhanced,VBN,O
or,CC,O
prolonged,VBN,O
by,IN,O
these,DT,O
agents,NNS,O
.,.,.
,,
in,IN,O
such,JJ,O
cases,NNS,O
of,IN,O
combined,JJ,O
treatment,NN,O
",",",",O
the,DT,O
dose,NN,O
of,IN,O
one,CD,O
or,CC,O
both,DT,O
agents,NNS,O
should,MD,O
be,VB,O
reduced,VBN,O
.,.,.
,,
limited,JJ,O
clinical,JJ,O
experience,NN,O
indicates,VBZ,O
that,IN,O
requirements,NNS,O
for,IN,O
volatile,JJ,O
inhalation,NN,O
anesthetics,NNS,G
are,VBP,O
reduced,VBN,O
by,IN,O
30,CD,O
to,TO,O
50,CD,O
%,NN,O
for,IN,O
the,DT,O
first,JJ,O
sixty,NN,O
-lrb-,-LRB-,O
60,CD,O
-rrb-,-RRB-,O
minutes,NNS,O
following,VBG,O
alfenta,NNP,B
induction,NN,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
erythromycin,NN,D
with,IN,O
alfenta,NN,B
can,MD,O
significantly,RB,O
inhibit,VB,O
alfenta,NN,B
clearance,NN,O
and,CC,O
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
prolonged,JJ,O
or,CC,O
delayed,VBN,O
respiratory,JJ,O
depression,NN,O
.,.,.
,,
cimetidine,NNP,D
reduces,VBZ,O
the,DT,O
clearance,NN,O
of,IN,O
alfenta,NNP,B
.,.,.
,,
therefore,RB,O
smaller,JJR,O
alfenta,NN,B
doses,NNS,O
will,MD,O
be,VB,O
required,VBN,O
with,IN,O
prolonged,JJ,O
administration,NN,O
and,CC,O
the,DT,O
duration,NN,O
of,IN,O
action,NN,O
of,IN,O
alfenta,NNP,B
my,PRP$,O
be,VB,O
extended,VBN,O
.,.,.
,,
perioperative,NNP,O
administration,NN,O
of,IN,O
drugs,NNS,D
affecting,VBG,O
hepatic,JJ,O
blood,NN,O
flow,NN,O
or,CC,O
enzyme,NN,O
function,NN,O
may,MD,O
reduce,VB,O
plasma,NN,O
clearance,NN,O
and,CC,O
prolong,VB,O
recovery,NN,O
.,.,.
,,
drug-drug,NNP,O
interactions,NNS,O
:,:,O
the,DT,O
pharmacokinetic,JJ,O
and,CC,O
pharmacodynamic,JJ,O
interactions,NNS,O
between,IN,O
uroxatral,NNP,B
and,CC,O
other,JJ,O
alpha-blockers,NNS,G
have,VBP,O
not,RB,O
been,VBN,O
determined,VBN,O
.,.,.
,,
however,RB,O
",",",",O
interactions,NNS,O
may,MD,O
be,VB,O
expected,VBN,O
",",",",O
and,CC,O
uroxatral,NNP,B
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
alpha-blockers,NNS,G
.,.,.
,,
no,DT,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
.,.,.
,,
effects,NNS,O
of,IN,O
other,JJ,O
drugs,NNS,O
on,IN,O
aliskiren,NNP,D
based,VBD,O
on,IN,O
in-vitro,FW,O
studies,NNS,O
",",",",O
aliskiren,NN,D
is,VBZ,O
metabolized,VBN,O
by,IN,O
cyp,NN,O
3a4,NN,O
.,.,.
,,
co-administration,NN,O
of,IN,O
lovastatin,NN,D
",",",",O
atenolol,NN,D
",",",",O
warfarin,NN,D
",",",",O
furosemide,NN,D
",",",",O
digoxin,NN,D
",",",",O
celecoxib,NN,D
",",",",O
hydrochlorothiazide,NN,D
",",",",O
ramipril,NN,D
",",",",O
valsartan,NN,D
",",",",O
metformin,NN,D
and,CC,O
amlodipine,NN,D
did,VBD,O
not,RB,O
result,VB,O
in,IN,O
clinically,RB,O
significant,JJ,O
increases,NNS,O
in,IN,O
aliskiren,JJ,D
exposure,NN,O
.,.,.
,,
co-administration,NN,O
of,IN,O
irbesartan,NN,D
reduced,VBD,O
aliskiren,JJ,D
cmax,NN,O
up,IN,O
to,TO,O
50,CD,O
%,NN,O
after,IN,O
multiple,JJ,O
dosing,NN,O
.,.,.
,,
co-administration,NN,O
of,IN,O
atorvastatin,NN,D
resulted,VBD,O
in,IN,O
about,IN,O
a,DT,O
50,CD,O
%,NN,O
increase,NN,O
in,IN,O
aliskiren,NN,D
cmax,NN,O
and,CC,O
auc,NN,O
after,IN,O
multiple,JJ,O
dosing,NN,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
co-administration,NN,O
of,IN,O
200,CD,O
mg,NN,O
twice-daily,JJ,O
ketoconazole,NN,D
with,IN,O
aliskiren,NN,D
resulted,VBD,O
in,IN,O
an,DT,O
approximate,JJ,O
80,CD,O
%,NN,O
increase,NN,O
in,IN,O
plasma,NN,O
levels,NNS,O
of,IN,O
aliskiren,NN,D
.,.,.
,,
a,DT,O
400,CD,O
mg,NN,O
once-daily,JJ,O
dose,NN,O
was,VBD,O
not,RB,O
studied,VBN,O
but,CC,O
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
increase,VB,O
aliskiren,JJ,D
blood,NN,O
levels,NNS,O
further,RB,O
.,.,.
,,
effects,NNS,O
of,IN,O
aliskiren,NN,D
on,IN,O
other,JJ,O
drugs,NNS,O
aliskiren,NN,D
does,VBZ,O
not,RB,O
inhibit,VB,O
the,DT,O
cyp450,NN,O
isoenzymes,NNS,O
-lrb-,-LRB-,O
cyp1a2,NN,D
",",",",O
2c8,NN,O
",",",",O
2c9,NN,O
",",",",O
2c19,NN,O
",",",",O
2d6,NN,O
",",",",O
2.00E+01,NN,O
",",",",O
and,CC,O
cyp,NN,O
3a,NN,O
-rrb-,-RRB-,O
or,CC,O
induce,VB,O
cyp,NN,O
3a4,NN,O
.,.,.
,,
co-administration,NN,O
of,IN,O
aliskiren,NN,D
did,VBD,O
not,RB,O
significantly,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
lovastatin,NN,D
",",",",O
digoxin,NN,D
",",",",O
valsartan,NN,D
",",",",O
amlodipine,NN,D
",",",",O
metformin,NN,D
",",",",O
celecoxib,NN,D
",",",",O
atenolol,NN,D
",",",",O
atorvastatin,NN,D
",",",",O
ramipril,NN,D
or,CC,O
hydrochlorothiazide,NN,D
.,.,.
,,
warfarin,NNP,D
:,:,O
the,DT,O
effects,NNS,O
of,IN,O
aliskiren,NN,D
on,IN,O
warfarin,NN,D
pharmacokinetics,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
evaluated,VBN,O
in,IN,O
a,DT,O
well-controlled,JJ,O
clinical,JJ,O
trial,NN,O
.,.,.
,,
furosemide,NNP,D
:,:,O
when,WRB,O
aliskiren,NN,D
was,VBD,O
co-administered,VBN,O
with,IN,O
furosemide,NN,D
",",",",O
the,DT,O
auc,NN,O
and,CC,O
cmax,NN,O
of,IN,O
furosemide,NN,D
were,VBD,O
reduced,VBN,O
by,IN,O
about,IN,O
30,CD,O
%,NN,O
and,CC,O
50,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
patients,NNS,O
who,WP,O
are,VBP,O
applying,VBG,O
panretin,NNP,B
gel,NN,O
should,MD,O
not,RB,O
concurrently,RB,O
use,VB,O
products,NNS,O
that,WDT,O
contain,VBP,O
deet,NN,D
-lrb-,-LRB-,O
n,NN,O
",",",",O
n-diethyl-m-toluamide,NN,D
-rrb-,-RRB-,O
",",",",O
a,DT,O
common,JJ,O
component,NN,O
of,IN,O
insect,JJ,O
repellent,NN,O
products,NNS,O
.,.,.
,,
animal,NN,O
toxicology,NN,O
studies,NNS,O
showed,VBD,O
increased,VBN,O
deet,NNP,D
toxicity,NN,O
when,WRB,O
deet,NNP,D
was,VBD,O
included,VBN,O
as,IN,O
proof,NN,O
of,IN,O
the,DT,O
formulation,NN,O
.,.,.
,,
although,IN,O
there,EX,O
was,VBD,O
no,DT,O
clinical,JJ,O
evidence,NN,O
in,IN,O
the,DT,O
vehicle-controlled,JJ,O
studies,NNS,O
of,IN,O
drug,NN,D
interactions,NNS,O
with,IN,O
systemic,JJ,O
antiretroviral,JJ,G
agents,NNS,O
",",",",O
including,VBG,O
protease,NN,O
inhibitors,NNS,O
",",",",O
macrolide,NN,O
antibiotics,NNS,G
",",",",O
and,CC,O
azole,NN,O
antifungals,NNS,G
",",",",O
the,DT,O
effect,NN,O
of,IN,O
panretin,NNP,B
gel,NN,O
on,IN,O
the,DT,O
steady-state,JJ,O
concentrations,NNS,O
of,IN,O
these,DT,O
drugs,NNS,D
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
no,DT,O
drug,NN,D
interaction,NN,O
data,NNS,O
are,VBP,O
available,JJ,O
on,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
panretin,NNP,B
gel,NN,O
and,CC,O
systemic,JJ,O
anti-ks,JJ,O
agents,NNS,O
.,.,.
,,
the,DT,O
following,VBG,O
drug,NN,D
interactions,NNS,O
were,VBD,O
observed,VBN,O
in,IN,O
some,DT,O
patients,NNS,O
undergoing,VBG,O
treatment,NN,O
with,IN,O
oral,JJ,O
allopurinol,NN,D
.,.,.
,,
although,IN,O
the,DT,O
pattern,NN,O
of,IN,O
use,NN,O
for,IN,O
oral,JJ,O
allopurinol,NN,D
includes,VBZ,O
longer,JJR,O
term,NN,O
therapy,NN,O
",",",",O
particularly,RB,O
for,IN,O
gout,NN,O
and,CC,O
renal,JJ,O
calculi,NNS,O
",",",",O
the,DT,O
experience,NN,O
gained,VBD,O
may,MD,O
be,VB,O
relevant,JJ,O
.,.,.
,,
mercaptopurine/azathioprine,NNP,O
:,:,O
allopurinol,NN,D
inhibits,VBZ,O
the,DT,O
enzymatic,JJ,O
oxidation,NN,O
of,IN,O
mercaptopurine,NN,D
and,CC,O
azathioprine,NN,D
to,TO,O
6-thiouric,JJ,O
acid,NN,O
.,.,.
,,
this,DT,O
oxidation,NN,O
",",",",O
which,WDT,O
is,VBZ,O
catalyzed,VBN,O
by,IN,O
xanthine,NN,O
oxidase,NN,O
",",",",O
inactivates,VBZ,O
mercaptopurine,NN,D
.,.,.
,,
in,IN,O
patients,NNS,O
receiving,VBG,O
mercaptopurine,NN,D
-lrb-,-LRB-,O
purinethol,NN,B
-rrb-,-RRB-,O
or,CC,O
azathioprine,NN,D
-lrb-,-LRB-,O
imuran,NN,B
-rrb-,-RRB-,O
",",",",O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
300-600,CD,O
mg,NN,O
of,IN,O
allopurinol,NN,D
per,IN,O
day,NN,O
will,MD,O
require,VB,O
a,DT,O
reduction,NN,O
in,IN,O
dose,NN,O
to,TO,O
approximately,RB,O
one-third,JJ,O
to,TO,O
one-fourth,NN,O
of,IN,O
the,DT,O
usual,JJ,O
dose,NN,O
of,IN,O
mercaptopurine,NN,D
or,CC,O
azathioprine,NN,D
.,.,.
,,
subsequent,JJ,O
adjustment,NN,O
of,IN,O
doses,NNS,O
of,IN,O
mercaptopurine,NN,D
or,CC,O
azathioprine,NN,D
should,MD,O
be,VB,O
made,VBN,O
on,IN,O
the,DT,O
basis,NN,O
of,IN,O
therapeutic,JJ,O
response,NN,O
and,CC,O
the,DT,O
appearance,NN,O
of,IN,O
toxic,JJ,O
effects,NNS,O
.,.,.
,,
dicumarol,NNP,D
:,:,O
it,PRP,O
has,VBZ,O
been,VBN,O
reported,VBN,O
that,IN,O
allopurinol,NN,D
prolongs,VBZ,O
the,DT,O
half-life,NN,O
of,IN,O
the,DT,O
anticoagulant,NN,G
",",",",O
dicumarol,NN,D
.,.,.
,,
the,DT,O
clinical,JJ,O
basis,NN,O
of,IN,O
this,DT,O
drug,NN,D
interaction,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
but,CC,O
should,MD,O
be,VB,O
noted,VBN,O
when,WRB,O
allopurinol,NN,D
is,VBZ,O
given,VBN,O
to,TO,O
patients,NNS,O
already,RB,O
on,IN,O
dicumarol,NN,D
therapy,NN,O
.,.,.
,,
consequently,RB,O
",",",",O
prothrombin,NN,O
time,NN,O
should,MD,O
be,VB,O
reassessed,VBN,O
periodically,RB,O
in,IN,O
patients,NNS,O
receiving,VBG,O
both,CC,O
drugs,NNS,D
.,.,.
,,
uricosuric,NNP,O
agents,NNPS,O
:,:,O
since,IN,O
the,DT,O
excretion,NN,O
of,IN,O
oxipurinol,NN,D
is,VBZ,O
similar,JJ,O
to,TO,O
that,DT,O
of,IN,O
urate,NN,O
",",",",O
uricosuric,JJ,O
agents,NNS,O
",",",",O
which,WDT,O
increase,VBP,O
the,DT,O
excretion,NN,O
of,IN,O
urate,NN,O
",",",",O
are,VBP,O
also,RB,O
likely,JJ,O
to,TO,O
increase,VB,O
the,DT,O
excretion,NN,O
of,IN,O
oxipurinol,NN,D
and,CC,O
thus,RB,O
lower,JJR,O
the,DT,O
degree,NN,O
of,IN,O
inhibition,NN,O
of,IN,O
xanthine,NN,O
oxidase,NN,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
uricosuric,JJ,O
agents,NNS,O
and,CC,O
allopurinol,NN,D
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
a,DT,O
decrease,NN,O
in,IN,O
the,DT,O
excretion,NN,O
of,IN,O
oxypurines,NNS,O
-lrb-,-LRB-,O
hypoxanthine,NN,O
and,CC,O
xanthine,NN,O
-rrb-,-RRB-,O
and,CC,O
an,DT,O
increase,NN,O
in,IN,O
urinary,JJ,O
uric,JJ,O
acid,NN,O
excretion,NN,O
compared,VBN,O
with,IN,O
that,DT,O
observed,VBN,O
with,IN,O
allopurinol,NN,D
alone,RB,O
.,.,.
,,
although,IN,O
clinical,JJ,O
evidence,NN,O
to,TO,O
date,NN,O
has,VBZ,O
not,RB,O
demonstrated,VBN,O
renal,JJ,O
precipitation,NN,O
of,IN,O
oxypurines,NNS,O
in,IN,O
patients,NNS,O
either,CC,O
on,IN,O
allopurinol,NN,D
alone,RB,O
or,CC,O
in,IN,O
combination,NN,O
with,IN,O
uricosuric,JJ,O
agents,NNS,O
",",",",O
the,DT,O
possibility,NN,O
should,MD,O
be,VB,O
kept,VBN,O
in,IN,O
mind,NN,O
.,.,.
,,
thiazide,NNP,O
diuretics,NNPS,G
:,:,O
the,DT,O
reports,NNS,O
that,IN,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
allopurinol,NN,D
and,CC,O
thiazide,JJ,G
diuretics,NNS,G
may,MD,O
contribute,VB,O
to,TO,O
the,DT,O
enhancement,NN,O
of,IN,O
allopurinol,NN,D
toxicity,NN,O
in,IN,O
some,DT,O
patients,NNS,O
have,VBP,O
been,VBN,O
reviewed,VBN,O
in,IN,O
an,DT,O
attempt,NN,O
to,TO,O
establish,VB,O
a,DT,O
cause-and-effect,JJ,O
relationship,NN,O
and,CC,O
a,DT,O
mechanism,NN,O
of,IN,O
causation,NN,O
.,.,.
,,
review,NN,O
of,IN,O
these,DT,O
case,NN,O
reports,VBZ,O
indicates,VBZ,O
that,IN,O
the,DT,O
patients,NNS,O
were,VBD,O
mainly,RB,O
receiving,VBG,O
thiazide,JJ,G
diuretics,NNS,G
for,IN,O
hypertension,NN,O
and,CC,O
that,IN,O
tests,NNS,O
to,TO,O
rule,VB,O
out,RP,O
decreased,VBN,O
renal,JJ,O
function,NN,O
secondary,JJ,O
to,TO,O
hypertensive,JJ,O
nephropathy,NN,O
were,VBD,O
not,RB,O
often,RB,O
performed,VBN,O
.,.,.
,,
in,IN,O
those,DT,O
patients,NNS,O
in,IN,O
whom,WP,O
renal,JJ,O
insufficiency,NN,O
was,VBD,O
documented,VBN,O
",",",",O
however,RB,O
",",",",O
the,DT,O
recommendation,NN,O
to,TO,O
lower,VB,O
the,DT,O
dose,NN,O
of,IN,O
allopurinol,NN,D
was,VBD,O
not,RB,O
followed,VBN,O
.,.,.
,,
although,IN,O
a,DT,O
causal,JJ,O
mechanism,NN,O
and,CC,O
a,DT,O
cause-and-effect,JJ,O
relationship,NN,O
have,VBP,O
not,RB,O
been,VBN,O
established,VBN,O
",",",",O
current,JJ,O
evidence,NN,O
suggests,VBZ,O
that,IN,O
renal,JJ,O
function,NN,O
should,MD,O
be,VB,O
monitored,VBN,O
in,IN,O
patients,NNS,O
on,IN,O
thiazide,JJ,G
diuretics,NNS,G
and,CC,O
allopurinol,NN,D
even,RB,O
in,IN,O
the,DT,O
absence,NN,O
of,IN,O
renal,JJ,O
failure,NN,O
",",",",O
and,CC,O
dosage,NN,O
levels,NNS,O
should,MD,O
be,VB,O
even,RB,O
more,RBR,O
conservatively,RB,O
adjusted,VBN,O
in,IN,O
those,DT,O
patients,NNS,O
on,IN,O
such,JJ,O
combined,JJ,O
therapy,NN,O
if,IN,O
diminished,VBN,O
renal,JJ,O
function,NN,O
is,VBZ,O
detected,VBN,O
.,.,.
,,
ampicillin/amoxicillin,NNP,O
:,:,O
an,DT,O
increase,NN,O
in,IN,O
the,DT,O
frequency,NN,O
of,IN,O
skin,NN,O
rash,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
among,IN,O
patients,NNS,O
receiving,VBG,O
ampicillin,NN,D
or,CC,O
amoxicillin,NNP,D
concurrently,RB,O
with,IN,O
allopurinol,NN,D
compared,VBN,O
to,TO,O
patients,NNS,O
who,WP,O
are,VBP,O
not,RB,O
receiving,VBG,O
both,CC,O
drugs,NNS,D
.,.,.
,,
the,DT,O
cause,NN,O
of,IN,O
the,DT,O
reported,VBN,O
association,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
cytotoxic,JJ,O
agents,NNS,O
:,:,O
enhanced,VBN,O
bone,NN,O
marrow,NN,O
suppression,NN,O
by,IN,O
cyclophosphamide,NN,D
and,CC,O
other,JJ,O
cytotoxic,JJ,G
agents,NNS,O
has,VBZ,O
been,VBN,O
reported,VBN,O
among,IN,O
patients,NNS,O
with,IN,O
neoplastic,JJ,O
disease,NN,O
",",",",O
except,IN,O
leukemia,NN,O
",",",",O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
allopurinol,NN,D
.,.,.
,,
however,RB,O
",",",",O
in,IN,O
a,DT,O
well-controlled,JJ,O
study,NN,O
of,IN,O
patients,NNS,O
with,IN,O
lymphoma,NN,O
on,IN,O
combination,NN,O
therapy,NN,O
",",",",O
allopurinol,NN,D
did,VBD,O
not,RB,O
increase,VB,O
the,DT,O
marrow,NN,O
toxicity,NN,O
of,IN,O
patients,NNS,O
treated,VBN,O
with,IN,O
cyclophosphamide,NN,D
",",",",O
doxorubicin,NN,D
",",",",O
bleomycin,NN,D
",",",",O
procarbazine,NN,D
and/or,CC,O
mechlorethamine,NN,D
.,.,.
,,
chlorpropamide,NNP,D
:,:,O
chlorpropamides,NNP,O
plasma,NN,O
half-life,NN,O
may,MD,O
be,VB,O
prolonged,VBN,O
by,IN,O
allopurinol,NN,D
",",",",O
since,IN,O
allopurinol,NN,D
and,CC,O
chlorpropamide,NN,D
may,MD,O
compete,VB,O
for,IN,O
excretion,NN,O
in,IN,O
the,DT,O
renal,JJ,O
tubule,NN,O
.,.,.
,,
the,DT,O
risk,NN,O
of,IN,O
hypoglycemia,NN,O
secondary,JJ,O
to,TO,O
this,DT,O
mechanism,NN,O
may,MD,O
be,VB,O
increased,VBN,O
if,IN,O
allopurinol,NN,D
and,CC,O
chlorpropamide,NN,D
are,VBP,O
given,VBN,O
concomitantly,RB,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
renal,JJ,O
insufficiency,NN,O
.,.,.
,,
cyclosporin,NN,D
:,:,O
reports,NNS,O
indicate,VBP,O
that,IN,O
cyclosporine,NN,D
levels,NNS,O
may,MD,O
be,VB,O
increased,VBN,O
during,IN,O
concomitant,JJ,O
treatment,NN,O
with,IN,O
allopurinol,NN,D
sodium,NN,O
for,IN,O
injection,NN,O
.,.,.
,,
monitoring,NN,O
of,IN,O
cyclosporine,NN,D
levels,NNS,O
and,CC,O
possible,JJ,O
adjustment,NN,O
of,IN,O
cyclosporine,NN,D
dosage,NN,O
should,MD,O
be,VB,O
considered,VBN,O
when,WRB,O
these,DT,O
drugs,NNS,D
are,VBP,O
co-administered,JJ,O
.,.,.
,,
tolbutamides,NNS,O
conversion,NN,O
to,TO,O
inactive,JJ,O
metabolites,NNS,O
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
be,VB,O
catalyzed,VBN,O
by,IN,O
xanthine,NN,O
oxidase,NN,O
from,IN,O
rat,NN,O
liver,NN,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
",",",",O
if,IN,O
any,DT,O
",",",",O
of,IN,O
these,DT,O
observations,NNS,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
ergot-containing,JJ,O
drugs,NNS,O
:,:,O
these,DT,O
drugs,NNS,D
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
cause,VB,O
prolonged,JJ,O
vasospastic,JJ,O
reactions,NNS,O
.,.,.
,,
because,IN,O
there,EX,O
is,VBZ,O
a,DT,O
theoretical,JJ,O
basis,NN,O
that,IN,O
these,DT,O
effects,NNS,O
may,MD,O
be,VB,O
additive,JJ,O
",",",",O
use,NN,O
of,IN,O
ergotamine-containing,JJ,O
or,CC,O
ergot-type,JJ,O
medications,NNS,O
-lrb-,-LRB-,O
like,IN,O
dihydroergotamine,NN,D
or,CC,O
methysergide,NN,D
-rrb-,-RRB-,O
and,CC,O
axert,NN,B
within,IN,O
24,CD,O
hours,NNS,O
of,IN,O
each,DT,O
other,JJ,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
monoamine,NNP,O
oxidase,NNP,O
inhibitors,NNS,O
:,:,O
coadministration,NN,O
of,IN,O
moclobemide,NN,D
resulted,VBD,O
in,IN,O
a,DT,O
27,CD,O
%,NN,O
decrease,NN,O
in,IN,O
almotriptan,NN,D
clearance,NN,O
and,CC,O
an,DT,O
increase,NN,O
in,IN,O
cmax,NN,O
of,IN,O
approximately,RB,O
6,CD,O
%,NN,O
.,.,.
,,
no,DT,O
dose,NN,O
adjustment,NN,O
is,VBZ,O
necessary,JJ,O
.,.,.
,,
other,JJ,O
5-ht1b,NN,O
/,:,O
1d,NN,O
agonists,NNS,O
concomitant,JJ,O
use,NN,O
of,IN,O
other,JJ,O
5-ht1b,NN,O
/,:,O
1d,NN,O
agonists,NNS,O
within,IN,O
24,CD,O
hours,NNS,O
of,IN,O
treatment,NN,O
with,IN,O
axert,NN,B
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
propanolol,NNP,D
:,:,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
almotriptan,NN,D
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
coadministration,NN,O
of,IN,O
propranolol,NN,D
.,.,.
,,
selective,JJ,O
serotonin,NN,O
reuptake,NNP,O
inhibitors,NNS,O
-lrb-,-LRB-,O
ssris,NNS,G
-rrb-,-RRB-,O
:,:,O
ssris,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
fluoxetine,NN,D
",",",",O
fluvoxamine,NN,D
",",",",O
paroxetine,NN,D
",",",",O
sertraline,NN,D
-rrb-,-RRB-,O
have,VBP,O
been,VBN,O
rarely,RB,O
reported,VBN,O
to,TO,O
cause,VB,O
weakness,NN,O
",",",",O
hyperreflexia,NN,O
",",",",O
and,CC,O
incoordination,NN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
5-ht1,NN,O
agonists,NNS,O
.,.,.
,,
if,IN,O
concomitant,JJ,O
treatment,NN,O
with,IN,O
axert,NN,B
and,CC,O
an,DT,O
ssri,NNP,G
is,VBZ,O
clinically,RB,O
warranted,VBN,O
",",",",O
appropriate,JJ,O
observation,NN,O
of,IN,O
the,DT,O
patient,NN,O
is,VBZ,O
advised,VBN,O
.,.,.
,,
verapamil,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
almotriptan,NN,D
and,CC,O
verapamil,NN,D
resulted,VBD,O
in,IN,O
a,DT,O
24,CD,O
%,NN,O
increase,NN,O
in,IN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
almotriptan,NN,D
.,.,.
,,
no,DT,O
dose,NN,O
adjustment,NN,O
is,VBZ,O
necessary,JJ,O
.,.,.
,,
coadministration,NN,O
of,IN,O
almotriptan,NN,D
and,CC,O
the,DT,O
potent,JJ,O
cyp3a4,NN,D
inhibitor,NN,O
ketoconazole,NN,D
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
q.d.,NN,O
for,IN,O
3,CD,O
days,NNS,O
-rrb-,-RRB-,O
resulted,VBD,O
in,IN,O
an,DT,O
approximately,RB,O
60,CD,O
%,NN,O
increase,NN,O
in,IN,O
the,DT,O
area,NN,O
under,IN,O
the,DT,O
plasma,NN,O
concentration-time,NN,O
curve,NN,O
and,CC,O
maximal,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
almotriptan,NN,D
.,.,.
,,
although,IN,O
the,DT,O
interaction,NN,O
between,IN,O
almotriptan,NN,D
and,CC,O
other,JJ,O
potent,JJ,O
cyp3a4,NN,D
inhibitors,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
itraconazole,NN,D
",",",",O
ritonavir,NN,D
",",",",O
and,CC,O
erythromycin,NN,D
-rrb-,-RRB-,O
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
",",",",O
increased,VBD,O
exposures,NNS,O
to,TO,O
almotriptan,NN,D
may,MD,O
be,VB,O
expected,VBN,O
when,WRB,O
almotriptan,NN,D
is,VBZ,O
used,VBN,O
concomitantly,RB,O
with,IN,O
these,DT,O
medications,NNS,O
.,.,.
,,
axert,NNP,B
is,VBZ,O
not,RB,O
known,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
commonly,RB,O
employed,VBN,O
clinical,JJ,O
laboratory,NN,O
tests,NNS,O
.,.,.
,,
because,IN,O
alosetron,NN,D
is,VBZ,O
metabolized,VBN,O
by,IN,O
a,DT,O
variety,NN,O
of,IN,O
hepatic,JJ,O
cyp,NN,O
drug-metabolizing,JJ,O
enzymes,NNS,O
",",",",O
inducers,NNS,O
or,CC,O
inhibitors,NNS,O
of,IN,O
these,DT,O
enzymes,NNS,O
may,MD,O
change,VB,O
the,DT,O
clearance,NN,O
of,IN,O
alosetron,NN,D
.,.,.
,,
fluvoxamine,NN,D
is,VBZ,O
a,DT,O
known,JJ,O
strong,JJ,O
inhibitor,NN,O
of,IN,O
cyp1a2,NN,D
and,CC,O
also,RB,O
inhibits,VBZ,O
cyp3a4,NN,D
",",",",O
cyp2c9,NN,D
",",",",O
and,CC,O
cyp2c19,NN,O
.,.,.
,,
in,IN,O
a,DT,O
pharmacokinetic,JJ,O
study,NN,O
",",",",O
40,CD,O
healthy,JJ,O
female,JJ,O
subjects,NNS,O
received,VBD,O
fluvoxamine,NN,D
in,IN,O
escalating,VBG,O
doses,NNS,O
from,IN,O
50,CD,O
to,TO,O
200,CD,O
mg,NN,O
per,IN,O
day,NN,O
for,IN,O
16,CD,O
days,NNS,O
",",",",O
with,IN,O
coadministration,NN,O
of,IN,O
alosetron,NN,D
1,CD,O
mg,NN,O
on,IN,O
the,DT,O
last,JJ,O
day,NN,O
.,.,.
,,
fluvoxamine,NN,D
increased,VBD,O
mean,JJ,O
alosetron,NN,D
plasma,NN,O
concentrations,NNS,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
approximately,RB,O
6-fold,RB,O
and,CC,O
prolonged,VBD,O
the,DT,O
half-life,NN,O
by,IN,O
approximately,RB,O
3-fold,RB,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
alosetron,NN,D
and,CC,O
fluvoxamine,NN,D
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
alosetron,NN,D
and,CC,O
moderate,JJ,O
cyp1a2,NN,D
inhibitors,NNS,O
",",",",O
including,VBG,O
quinolone,JJ,G
antibiotics,NNS,G
and,CC,O
cimetidine,NN,D
",",",",O
has,VBZ,O
not,RB,O
been,VBN,O
evaluated,VBN,O
",",",",O
but,CC,O
should,MD,O
be,VB,O
avoided,VBN,O
unless,IN,O
clinically,RB,O
necessary,JJ,O
because,IN,O
of,IN,O
similar,JJ,O
potential,JJ,O
drug,NN,D
interactions,NNS,O
.,.,.
,,
ketoconazole,NN,D
is,VBZ,O
a,DT,O
known,JJ,O
strong,JJ,O
inhibitor,NN,O
of,IN,O
cyp3a4,NN,D
.,.,.
,,
in,IN,O
a,DT,O
pharmacokinetic,JJ,O
study,NN,O
",",",",O
38,CD,O
healthy,JJ,O
female,JJ,O
subjects,NNS,O
received,VBD,O
ketoconazole,NN,D
200,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
for,IN,O
7,CD,O
days,NNS,O
",",",",O
with,IN,O
coadministration,NN,O
of,IN,O
alosetron,NN,D
1,CD,O
mg,NN,O
on,IN,O
the,DT,O
last,JJ,O
day,NN,O
.,.,.
,,
ketoconazole,NN,D
increased,VBD,O
mean,JJ,O
alosetron,NN,D
plasma,NN,O
concentrations,NNS,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
by,IN,O
29,CD,O
%,NN,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
when,WRB,O
alosetron,NN,D
and,CC,O
ketoconazole,NN,D
are,VBP,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
coadministration,NN,O
of,IN,O
alosetron,NN,D
and,CC,O
strong,JJ,O
cyp3a4,NN,D
inhibitors,NNS,O
",",",",O
such,JJ,O
as,IN,O
clarithromycin,NN,D
",",",",O
telithromycin,NN,D
",",",",O
protease,NN,O
inhibitors,NNS,O
",",",",O
voriconazole,NN,D
",",",",O
and,CC,O
itraconazole,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
evaluated,VBN,O
but,CC,O
should,MD,O
be,VB,O
undertaken,VBN,O
with,IN,O
caution,NN,O
because,IN,O
of,IN,O
similar,JJ,O
potential,JJ,O
drug,NN,D
interactions,NNS,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
induction,NN,O
or,CC,O
inhibition,NN,O
of,IN,O
other,JJ,O
pathways,NNS,O
on,IN,O
exposure,NN,O
to,TO,O
alosetron,NN,D
and,CC,O
its,PRP$,O
metabolites,NNS,O
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
in,FW,O
vitro,FW,O
human,JJ,O
liver,NN,O
microsome,NN,O
studies,NNS,O
and,CC,O
an,DT,O
in,FW,O
vivo,FW,O
metabolic,JJ,O
probe,NN,O
study,NN,O
demonstrated,VBD,O
that,IN,O
alosetron,NN,D
did,VBD,O
not,RB,O
inhibit,VB,O
cyp,NN,O
enzymes,NNS,O
2d6,NN,O
",",",",O
3a4,NN,O
",",",",O
2c9,NN,O
",",",",O
or,CC,O
2c19,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
",",",",O
at,IN,O
total,JJ,O
drug,NN,D
concentrations,NNS,O
27-fold,RB,O
higher,JJR,O
than,IN,O
peak,JJ,O
plasma,NN,O
concentrations,NNS,O
observed,VBN,O
with,IN,O
the,DT,O
1-mg,JJ,O
dosage,NN,O
",",",",O
alosetron,NN,D
inhibited,VBD,O
cyp,NN,O
enzymes,NNS,O
1a2,NN,O
-lrb-,-LRB-,O
60,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
2.00E+01,NN,O
-lrb-,-LRB-,O
50,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
an,DT,O
in,FW,O
vivo,FW,O
metabolic,JJ,O
probe,NN,O
study,NN,O
",",",",O
alosetron,NN,D
did,VBD,O
not,RB,O
inhibit,VB,O
cyp2e1,NN,O
but,CC,O
did,VBD,O
produce,VB,O
30,CD,O
%,NN,O
inhibition,NN,O
of,IN,O
both,CC,O
cyp1a2,NN,D
and,CC,O
n-acetyltransferase,NN,O
.,.,.
,,
although,IN,O
not,RB,O
studied,VBN,O
with,IN,O
alosetron,NN,D
",",",",O
inhibition,NN,O
of,IN,O
n-acetyltransferase,NN,O
may,MD,O
have,VB,O
clinically,RB,O
relevant,JJ,O
consequences,NNS,O
for,IN,O
drugs,NNS,D
such,JJ,O
as,IN,O
isoniazid,NN,D
",",",",O
procainamide,NN,D
",",",",O
and,CC,O
hydralazine,NN,D
.,.,.
,,
the,DT,O
effect,NN,O
on,IN,O
cyp1a2,NN,D
was,VBD,O
explored,VBN,O
further,RB,O
in,IN,O
a,DT,O
clinical,JJ,O
interaction,NN,O
study,NN,O
with,IN,O
theophylline,NN,D
and,CC,O
no,DT,O
effect,NN,O
on,IN,O
metabolism,NN,O
was,VBD,O
observed,VBN,O
.,.,.
,,
another,DT,O
study,NN,O
showed,VBD,O
that,IN,O
alosetron,NN,D
had,VBD,O
no,DT,O
clinically,RB,O
significant,JJ,O
effect,NN,O
on,IN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
the,DT,O
oral,JJ,O
contraceptive,JJ,G
agents,NNS,O
ethinyl,NN,O
estradiol,NN,O
and,CC,O
levonorgestrel,NN,D
-lrb-,-LRB-,O
cyp3a4,NN,D
substrates,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
a,DT,O
clinical,JJ,O
interaction,NN,O
study,NN,O
was,VBD,O
also,RB,O
conducted,VBN,O
with,IN,O
alosetron,NN,D
and,CC,O
the,DT,O
cyp3a4,NN,D
substrate,NN,O
cisapride,NN,D
.,.,.
,,
no,DT,O
significant,JJ,O
effects,NNS,O
on,IN,O
cisapride,NN,D
metabolism,NN,O
or,CC,O
qt,NN,O
interval,NN,O
were,VBD,O
noted,VBN,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
alosetron,NN,D
on,IN,O
monoamine,NN,O
oxidases,NNS,O
and,CC,O
on,IN,O
intestinal,JJ,O
first,JJ,O
pass,NN,O
secondary,JJ,O
to,TO,O
high,JJ,O
intraluminal,JJ,O
concentrations,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
examined,VBN,O
.,.,.
,,
based,VBN,O
on,IN,O
the,DT,O
above,JJ,O
data,NNS,O
from,IN,O
in,FW,O
vitro,FW,O
and,CC,O
in,FW,O
vivo,FW,O
studies,NNS,O
",",",",O
it,PRP,O
is,VBZ,O
unlikely,JJ,O
that,IN,O
alosetron,NN,D
will,MD,O
inhibit,VB,O
the,DT,O
hepatic,JJ,O
metabolic,JJ,O
clearance,NN,O
of,IN,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
the,DT,O
major,JJ,O
cyp,NN,O
enzyme,NN,O
3a4,NN,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
the,DT,O
cyp,NN,O
enzymes,NNS,O
2d6,NN,O
",",",",O
2c9,NN,O
",",",",O
2c19,NN,O
",",",",O
2.00E+01,NN,O
",",",",O
or,CC,O
1a2,NN,O
.,.,.
,,
alosetron,NNP,D
does,VBZ,O
not,RB,O
appear,VB,O
to,TO,O
induce,VB,O
the,DT,O
major,JJ,O
cytochrome,NN,O
p450,NN,O
-lrb-,-LRB-,O
cyp,NN,O
-rrb-,-RRB-,O
drug,NN,D
metabolizing,VBG,O
enzyme,NN,O
3a,NN,O
.,.,.
,,
alosetron,NNP,D
also,RB,O
does,VBZ,O
not,RB,O
appear,VB,O
to,TO,O
induce,VB,O
cyp,NN,O
enzymes,NNS,O
2.00E+01,NN,O
or,CC,O
2c19,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
whether,IN,O
alosetron,NN,D
might,MD,O
induce,VB,O
other,JJ,O
enzymes,NNS,O
.,.,.
,,
the,DT,O
benzodiazepines,NNS,G
",",",",O
including,VBG,O
alprazolam,NN,D
",",",",O
produce,VBP,O
additive,JJ,O
cns,NNS,O
depressant,NN,O
effects,NNS,O
when,WRB,O
co-administered,VBN,O
with,IN,O
other,JJ,O
psychotropic,JJ,O
medications,NNS,O
",",",",O
anticonvulsants,NNS,G
",",",",O
antihistaminics,NNS,G
",",",",O
ethanol,NN,D
",",",",O
and,CC,O
other,JJ,O
drugs,NNS,D
which,WDT,O
themselves,PRP,O
produce,VBP,O
cns,NN,O
depression,NN,O
.,.,.
,,
the,DT,O
steady,JJ,O
state,NN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
imipramine,NN,D
and,CC,O
desipramine,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
be,VB,O
increased,VBN,O
an,DT,O
average,NN,O
of,IN,O
31,CD,O
%,NN,O
and,CC,O
20,CD,O
%,NN,O
",",",",O
respectively,RB,O
",",",",O
by,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
alprazolam,NN,D
tablets,NNS,O
in,IN,O
doses,NNS,O
up,RB,O
to,TO,O
4,CD,O
mg/day,NN,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
these,DT,O
changes,NNS,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
inhibit,VBP,O
alprazolam,NNP,D
metabolism,NNP,O
via,NNP,O
cytochrome,NNP,O
p450,NN,O
3a,NN,O
:,:,O
the,DT,O
initial,JJ,O
step,NN,O
in,IN,O
alprazolam,NN,D
metabolism,NN,O
is,VBZ,O
hydroxylation,NN,O
catalyzed,VBN,O
by,IN,O
cytochrome,NN,O
p450,NN,O
3a,NN,O
-lrb-,-LRB-,O
cyp,NN,O
3a,NN,O
-rrb-,-RRB-,O
.,.,.
,,
drugs,NNS,O
which,WDT,O
inhibit,VBP,O
this,DT,O
metabolic,JJ,O
pathway,NN,O
may,MD,O
have,VB,O
a,DT,O
profound,JJ,O
effect,NN,O
on,IN,O
the,DT,O
clearance,NN,O
of,IN,O
alprazolam,NN,D
.,.,.
,,
drugs,NNS,O
demonstrated,VBN,O
to,TO,O
be,VB,O
cyp,NN,O
3a,NN,O
inhibitors,NNS,O
of,IN,O
possible,JJ,O
clinical,JJ,O
significance,NN,O
on,IN,O
the,DT,O
basis,NN,O
of,IN,O
clinical,JJ,O
studies,NNS,O
involving,VBG,O
alprazolam,NN,D
-lrb-,-LRB-,O
caution,NN,O
is,VBZ,O
recommended,VBN,O
during,IN,O
coadministration,NN,O
with,IN,O
alprazolam,NN,D
-rrb-,-RRB-,O
:,:,O
coadministration,NN,O
of,IN,O
fluoxetine,NN,D
with,IN,O
alprazolam,NN,D
increased,VBD,O
the,DT,O
maximum,NN,O
plasma,NN,O
concentration,NN,O
of,IN,O
alprazolam,NN,D
by,IN,O
46,CD,O
%,NN,O
",",",",O
decreased,VBD,O
clearance,NN,O
by,IN,O
21,CD,O
%,NN,O
",",",",O
increased,VBD,O
half-life,NN,O
by,IN,O
17,CD,O
%,NN,O
",",",",O
and,CC,O
decreased,VBD,O
measured,VBN,O
psychomotor,NN,O
performance,NN,O
.,.,.
,,
coadministration,NN,O
of,IN,O
propoxyphene,NN,D
decreased,VBD,O
the,DT,O
maximum,NN,O
plasma,NN,O
concentration,NN,O
of,IN,O
alprazolam,NN,D
by,IN,O
6,CD,O
%,NN,O
",",",",O
decreased,VBD,O
clearance,NN,O
by,IN,O
38,CD,O
%,NN,O
",",",",O
and,CC,O
increased,VBD,O
half-life,NN,O
by,IN,O
58,CD,O
%,NN,O
.,.,.
,,
coadministration,NN,O
of,IN,O
oral,JJ,O
contraceptives,NNS,G
increased,VBD,O
the,DT,O
maximum,NN,O
plasma,NN,O
concentration,NN,O
of,IN,O
alprazolam,NN,D
by,IN,O
18,CD,O
%,NN,O
",",",",O
decreased,VBD,O
clearance,NN,O
by,IN,O
22,CD,O
%,NN,O
",",",",O
and,CC,O
increased,VBD,O
half-life,NN,O
by,IN,O
29,CD,O
%,NN,O
.,.,.
,,
drugs,NNS,O
and,CC,O
other,JJ,O
substances,NNS,O
demonstrated,VBD,O
to,TO,O
be,VB,O
cyp,NN,O
3a,NN,O
inhibitors,NNS,O
on,IN,O
the,DT,O
basis,NN,O
of,IN,O
clinical,JJ,O
studies,NNS,O
involving,VBG,O
benzodiazepines,NNS,G
metabolized,VBN,O
similarly,RB,O
to,TO,O
alprazolam,NN,D
or,CC,O
on,IN,O
the,DT,O
basis,NN,O
of,IN,O
in,FW,O
vitro,FW,O
studies,NNS,O
with,IN,O
alprazolam,NN,D
or,CC,O
other,JJ,O
benzodiazepines,NNS,G
-lrb-,-LRB-,O
caution,NN,O
is,VBZ,O
recommended,VBN,O
during,IN,O
coadministration,NN,O
with,IN,O
alprazolam,NN,D
-rrb-,-RRB-,O
:,:,O
available,JJ,O
data,NNS,O
from,IN,O
clinical,JJ,O
studies,NNS,O
of,IN,O
benzodiazepines,NNS,G
other,JJ,O
than,IN,O
alprazolam,NN,D
suggest,VBP,O
a,DT,O
possible,JJ,O
drug,NN,D
interaction,NN,O
with,IN,O
alprazolam,NN,D
for,IN,O
the,DT,O
following,NN,O
:,:,O
diltiazem,NN,D
",",",",O
isoniazid,NN,D
",",",",O
macrolide,NN,O
antibiotics,NNS,G
such,JJ,O
as,IN,O
erythromycin,NN,D
and,CC,O
clarithromycin,NN,D
",",",",O
and,CC,O
grapefruit,NN,O
juice,NN,O
.,.,.
,,
data,NNS,O
from,IN,O
in,FW,O
vitro,FW,O
studies,NNS,O
of,IN,O
alprazolam,NN,D
suggest,VBP,O
a,DT,O
possible,JJ,O
drug,NN,D
interaction,NN,O
with,IN,O
alprazolam,NN,D
for,IN,O
the,DT,O
following,NN,O
:,:,O
sertraline,NN,D
and,CC,O
paroxetine,NN,D
.,.,.
,,
data,NNS,O
from,IN,O
in,FW,O
vitro,FW,O
studies,NNS,O
of,IN,O
benzodiazepines,NNS,G
other,JJ,O
than,IN,O
alprazolam,NN,D
suggest,VBP,O
a,DT,O
possible,JJ,O
drug,NN,D
interaction,NN,O
for,IN,O
the,DT,O
following,NN,O
:,:,O
ergotamine,NN,D
",",",",O
cyclosporine,NN,D
",",",",O
amiodarone,NN,D
",",",",O
nicardipine,NN,D
",",",",O
and,CC,O
nifedipine,NN,D
.,.,.
,,
caution,NN,O
is,VBZ,O
recommended,VBN,O
during,IN,O
the,DT,O
coadministration,NN,O
of,IN,O
any,DT,O
of,IN,O
these,DT,O
with,IN,O
alprazolam,NN,D
.,.,.
,,
no,DT,O
drug,NN,D
interactions,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
between,IN,O
prostin,NNP,O
vr,NN,O
pediatric,NNP,O
and,CC,O
the,DT,O
therapy,NN,O
standard,NN,O
in,IN,O
neonates,NNS,O
with,IN,O
restricted,JJ,O
pulmonary,JJ,O
or,CC,O
systemic,JJ,O
blood,NN,O
flow,NN,O
.,.,.
,,
standard,JJ,O
therapy,NN,O
includes,VBZ,O
antibiotics,NNS,G
",",",",O
such,JJ,O
as,IN,O
penicillin,NN,D
and,CC,O
gentamicin,NN,D
.,.,.
,,
vasopressors,NNS,G
",",",",O
such,JJ,O
as,IN,O
dopamine,NN,D
and,CC,O
isoproterenol,NN,D
.,.,.
,,
cardiac,JJ,O
glycosides,NNS,G
.,.,.
,,
and,CC,O
diuretics,NNS,G
",",",",O
such,JJ,O
as,IN,O
furosemide,NN,D
.,.,.
,,
caverject,NNP,B
:,:,O
the,DT,O
potential,NN,O
for,IN,O
pharmacokinetic,JJ,O
drug-drug,NN,O
interactions,NNS,O
between,IN,O
alprostadil,NN,D
and,CC,O
other,JJ,O
agents,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
formally,RB,O
studied,VBN,O
.,.,.
,,
the,DT,O
interaction,NN,O
of,IN,O
activase,NN,B
with,IN,O
other,JJ,O
cardioactive,JJ,O
or,CC,O
cerebroactive,JJ,O
drugs,NNS,D
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
in,IN,O
addition,NN,O
to,TO,O
bleeding,NN,O
associated,VBN,O
with,IN,O
heparin,NN,D
and,CC,O
vitamin,NN,G
k,NN,O
antagonists,NNS,O
",",",",O
drugs,NNS,D
that,WDT,O
alter,VBP,O
platelet,NN,O
function,NN,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
acetylsalicylic,JJ,O
acid,NN,O
",",",",O
dipyridamole,NN,D
and,CC,O
abciximab,NNP,D
-rrb-,-RRB-,O
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
bleeding,VBG,O
if,IN,O
administered,VBN,O
prior,RB,O
to,TO,O
",",",",O
during,IN,O
",",",",O
or,CC,O
after,IN,O
activase,NN,B
therapy,NN,O
.,.,.
,,
use,NN,O
of,IN,O
antithrombotics,NNP,G
aspirin,NNP,B
and,CC,O
heparin,NN,D
have,VBP,O
been,VBN,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
and,CC,O
following,VBG,O
infusions,NNS,O
of,IN,O
activase,NNP,B
in,IN,O
the,DT,O
management,NN,O
of,IN,O
acute,JJ,O
myocardial,JJ,O
infarction,NN,O
or,CC,O
pulmonary,JJ,O
embolism,NN,O
.,.,.
,,
because,IN,O
heparin,NN,D
",",",",O
aspirin,NN,B
",",",",O
or,CC,O
activase,NNP,B
may,MD,O
cause,VB,O
bleeding,JJ,O
complications,NNS,O
",",",",O
careful,JJ,O
monitoring,NN,O
for,IN,O
bleeding,NN,O
is,VBZ,O
advised,VBN,O
",",",",O
especially,RB,O
at,IN,O
arterial,JJ,O
puncture,NN,O
sites,NNS,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
heparin,NN,D
or,CC,O
aspirin,NN,B
during,IN,O
the,DT,O
first,JJ,O
24,CD,O
hours,NNS,O
following,VBG,O
symptom,NN,O
onset,NN,O
were,VBD,O
prohibited,VBN,O
in,IN,O
the,DT,O
ninds,NN,O
t-pa,NN,O
stroke,NNP,O
trial,NNP,O
.,.,.
,,
the,DT,O
safety,NN,O
of,IN,O
such,JJ,O
concomitant,JJ,O
use,NN,O
with,IN,O
activase,NN,B
for,IN,O
the,DT,O
management,NN,O
of,IN,O
acute,JJ,O
ischemic,JJ,O
stroke,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
concurrent,JJ,O
administration,NN,O
of,IN,O
hexalen,NN,B
and,CC,O
antidepressants,NNS,G
of,IN,O
the,DT,O
mao,NNP,O
inhibitor,NN,O
class,NN,O
may,MD,O
cause,VB,O
severe,JJ,O
orthostatic,JJ,O
hypotension.cimetidine,NN,O
",",",",O
an,DT,O
inhibitor,NN,O
of,IN,O
microsomal,JJ,O
drug,NN,D
metabolism,NN,O
",",",",O
increased,VBD,O
altretamines,NNS,O
half-life,NN,O
and,CC,O
toxicity,NN,O
in,IN,O
a,DT,O
rat,NN,O
model,NN,O
.,.,.
,,
data,NNS,O
from,IN,O
a,DT,O
randomized,JJ,O
trial,NN,O
of,IN,O
hexalen,NN,B
and,CC,O
cisplatin,NN,D
plus,CC,O
or,CC,O
minus,CC,O
pyridoxine,NN,D
in,IN,O
ovarian,JJ,O
cancer,NN,O
indicated,VBD,O
that,IN,O
pyridoxine,NN,D
significantly,RB,O
reduced,VBD,O
neurotoxicity,NN,O
.,.,.
,,
however,RB,O
",",",",O
it,PRP,O
adversely,RB,O
affected,VBD,O
response,NN,O
duration,NN,O
suggesting,VBG,O
that,IN,O
pyridoxine,NN,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
with,IN,O
hexalen,NN,B
and/or,CC,O
cisplatin,NN,D
.,.,.
,,
careful,JJ,O
observation,NN,O
is,VBZ,O
required,VBN,O
when,WRB,O
amantadine,NN,D
is,VBZ,O
administered,VBN,O
concurrently,RB,O
with,IN,O
central,JJ,O
nervous,JJ,O
system,NN,O
stimulants,NNS,O
.,.,.
,,
coadministration,NN,O
of,IN,O
thioridazine,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
worsen,VB,O
the,DT,O
tremor,NN,O
in,IN,O
elderly,JJ,O
patients,NNS,O
with,IN,O
parkinsons,NNPS,O
disease,NN,O
.,.,.
,,
however,RB,O
",",",",O
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
if,IN,O
other,JJ,O
phenothiazines,NNS,G
produce,VBP,O
a,DT,O
similar,JJ,O
response,NN,O
.,.,.
,,
special,JJ,O
consideration,NN,O
should,MD,O
be,VB,O
given,VBN,O
to,TO,O
the,DT,O
administration,NN,O
of,IN,O
ethyol,NNP,B
in,IN,O
patients,NNS,O
receiving,VBG,O
antihypertensive,JJ,G
medications,NNS,O
or,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
could,MD,O
cause,VB,O
or,CC,O
potentiate,VB,O
hypotension,NN,O
.,.,.
,,
when,WRB,O
amiloride,NN,D
hcl,NN,O
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
an,DT,O
angiotensin-converting,JJ,O
enzyme,NN,O
inhibitor,NN,O
",",",",O
the,DT,O
risk,NN,O
of,IN,O
hyperkalemia,NN,O
may,MD,O
be,VB,O
increased,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
if,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
these,DT,O
agents,NNS,O
is,VBZ,O
indicated,VBN,O
because,IN,O
of,IN,O
demonstrated,VBN,O
hypokalemia,NN,O
",",",",O
they,PRP,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
and,CC,O
with,IN,O
frequent,JJ,O
monitoring,NN,O
of,IN,O
serum,NN,O
potassium,NN,D
.,.,.
,,
lithium,NN,D
generally,RB,O
should,MD,O
not,RB,O
be,VB,O
given,VBN,O
with,IN,O
diuretics,NNS,G
because,IN,O
they,PRP,O
reduce,VBP,O
its,PRP$,O
renal,JJ,O
clearance,NN,O
and,CC,O
add,VB,O
a,DT,O
high,JJ,O
risk,NN,O
of,IN,O
lithium,NN,D
toxicity,NN,O
.,.,.
,,
read,VB,O
circulars,NNS,O
for,IN,O
lithium,NN,D
preparations,NNS,O
before,IN,O
use,NN,O
of,IN,O
such,JJ,O
concomitant,JJ,O
therapy,NN,O
.,.,.
,,
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
the,DT,O
administration,NN,O
of,IN,O
a,DT,O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
agent,NN,O
can,MD,O
reduce,VB,O
the,DT,O
diuretic,JJ,G
",",",",O
natriuretic,JJ,O
",",",",O
and,CC,O
antihypertensive,JJ,G
effects,NNS,O
of,IN,O
loop,NN,O
",",",",O
potassium-sparing,NN,O
and,CC,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
when,WRB,O
midamor,NN,B
and,CC,O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
are,VBP,O
used,VBN,O
concomitantly,RB,O
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
to,TO,O
determine,VB,O
if,IN,O
the,DT,O
desired,VBN,O
effect,NN,O
of,IN,O
the,DT,O
diuretic,JJ,G
is,VBZ,O
obtained,VBN,O
.,.,.
,,
since,IN,O
indomethacin,NN,D
and,CC,O
potassium-sparing,JJ,O
diuretics,NNS,G
",",",",O
including,VBG,O
midamor,NNP,B
",",",",O
may,MD,O
each,DT,O
be,VB,O
associated,VBN,O
with,IN,O
increased,VBN,O
serum,NN,O
potassium,NN,D
levels,NNS,O
",",",",O
the,DT,O
potential,JJ,O
effects,NNS,O
on,IN,O
potassium,NN,D
kinetics,NNS,O
and,CC,O
renal,JJ,O
function,NN,O
should,MD,O
be,VB,O
considered,VBN,O
when,WRB,O
these,DT,O
agents,NNS,O
are,VBP,O
administered,VBN,O
concurrently,RB,O
.,.,.
,,
drug,NNP,O
laboratory,NNP,O
test,NNP,O
interactions,NNS,O
:,:,O
prolongation,NN,O
of,IN,O
the,DT,O
template,NN,O
bleeding,NN,O
time,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
during,IN,O
continuous,JJ,O
intravenous,JJ,O
infusion,NN,O
of,IN,O
amicar,NN,B
at,IN,O
dosages,NNS,O
exceeding,VBG,O
24,CD,O
g/day,NN,O
.,.,.
,,
platelet,NN,O
function,NN,O
studies,NNS,O
in,IN,O
these,DT,O
patients,NNS,O
have,VBP,O
not,RB,O
demonstrated,VBN,O
any,DT,O
significant,JJ,O
platelet,NN,O
dysfunction,NN,O
.,.,.
,,
however,RB,O
",",",",O
in,FW,O
vitro,FW,O
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
at,IN,O
high,JJ,O
concentrations,NNS,O
-lrb-,-LRB-,O
7.4,CD,O
mmol/l,NN,O
or,CC,O
0.97,CD,O
mg/ml,NN,O
and,CC,O
greater,JJR,O
-rrb-,-RRB-,O
eaca,NN,D
inhibits,VBZ,O
adp,NN,O
and,CC,O
collagen-induced,JJ,O
platelet,NN,O
aggregation,NN,O
",",",",O
the,DT,O
release,NN,O
of,IN,O
atp,NN,O
and,CC,O
serotonin,NN,O
",",",",O
and,CC,O
the,DT,O
binding,NN,O
of,IN,O
fibrinogen,NN,D
to,TO,O
the,DT,O
platelets,NNS,O
in,IN,O
a,DT,O
concentration-response,JJ,O
manner,NN,O
.,.,.
,,
following,VBG,O
a,DT,O
10,CD,O
g,NN,O
bolus,NN,O
of,IN,O
amicar,NNP,B
",",",",O
transient,JJ,O
peak,NN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
4.6,CD,O
mmol/l,NN,O
or,CC,O
0.6,CD,O
mg/ml,NN,O
have,VBP,O
been,VBN,O
obtained,VBN,O
.,.,.
,,
the,DT,O
concentration,NN,O
of,IN,O
amicar,NNP,B
necessary,JJ,O
to,TO,O
maintain,VB,O
inhibition,NN,O
of,IN,O
fibrinolysis,NN,O
is,VBZ,O
0.99,CD,O
mmol/l,NN,O
or,CC,O
0.13,CD,O
mg/ml,NN,O
.,.,.
,,
administration,NN,O
of,IN,O
a,DT,O
5,CD,O
g,NN,O
bolus,NN,O
followed,VBN,O
by,IN,O
1,CD,O
to,TO,O
1.25,CD,O
g/hr,NN,O
should,MD,O
achieve,VB,O
and,CC,O
sustain,VB,O
plasma,NN,O
levels,NNS,O
of,IN,O
0.13,CD,O
mg/ml,NN,O
.,.,.
,,
thus,RB,O
",",",",O
concentrations,NNS,O
which,WDT,O
have,VBP,O
been,VBN,O
obtained,VBN,O
in,FW,O
vivo,FW,O
clinically,RB,O
in,IN,O
patients,NNS,O
with,IN,O
normal,JJ,O
renal,JJ,O
function,NN,O
are,VBP,O
considerably,RB,O
lower,JJR,O
than,IN,O
the,DT,O
in,FW,O
vitro,FW,O
concentrations,NNS,O
found,VBN,O
to,TO,O
induce,VB,O
abnormalities,NNS,O
in,IN,O
platelet,NN,O
function,NN,O
tests,NNS,O
.,.,.
,,
however,RB,O
",",",",O
higher,JJR,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
amicar,NN,B
may,MD,O
occur,VB,O
in,IN,O
patients,NNS,O
with,IN,O
severe,JJ,O
renal,JJ,O
failure,NN,O
.,.,.
,,
cytadren,NN,B
accelerates,VBZ,O
the,DT,O
metabolism,NN,O
of,IN,O
dexamethasone,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
if,IN,O
glucocorticoid,NN,G
replacement,NN,O
is,VBZ,O
needed,VBN,O
",",",",O
hydrocortisone,NN,D
should,MD,O
be,VB,O
prescribed,VBN,O
.,.,.
,,
aminoglutethimide,NNP,D
diminishes,VBZ,O
the,DT,O
effect,NN,O
of,IN,O
coumarin,NN,G
and,CC,O
warfarin,NN,D
.,.,.
,,
renal,JJ,O
clearance,NN,O
measurements,NNS,O
of,IN,O
pah,NN,D
can,MD,O
not,RB,O
be,VB,O
made,VBN,O
with,IN,O
any,DT,O
significant,JJ,O
accuracy,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
sulfonamides,NNS,G
",",",",O
procaine,NN,D
",",",",O
or,CC,O
thiazolesulfone,NN,D
.,.,.
,,
these,DT,O
compounds,NNS,O
interfere,VBP,O
with,IN,O
chemical,NN,O
color,NN,O
development,NN,O
essential,JJ,O
to,TO,O
the,DT,O
analytical,JJ,O
procedures,NNS,O
.,.,.
,,
probenecid,NNP,D
depresses,VBZ,O
tubular,JJ,O
secretion,NN,O
of,IN,O
certain,JJ,O
weak,JJ,O
acids,NNS,O
such,JJ,O
as,IN,O
pah,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
patients,NNS,O
receiving,VBG,O
probenecid,NN,D
will,MD,O
have,VB,O
erroneously,RB,O
low,JJ,O
erpf,NN,O
and,CC,O
tm,NN,O
pah,NN,D
values,NNS,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
no,DT,O
formal,JJ,O
studies,NNS,O
of,IN,O
the,DT,O
interaction,NN,O
of,IN,O
levulan,NNP,O
kerastick,NNP,O
for,IN,O
topical,NNP,O
solution,NN,O
with,IN,O
any,DT,O
other,JJ,O
drugs,NNS,D
",",",",O
and,CC,O
no,DT,O
drug-specific,JJ,O
interactions,NNS,O
were,VBD,O
noted,VBN,O
during,IN,O
any,DT,O
of,IN,O
the,DT,O
controlled,JJ,O
clinical,JJ,O
trials,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
",",",",O
however,RB,O
",",",",O
possible,JJ,O
that,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
other,JJ,O
known,JJ,O
photosensitizing,JJ,O
agents,NNS,O
such,JJ,O
as,IN,O
griseofulvin,NN,D
",",",",O
thiazide,JJ,G
diuretics,NNS,G
",",",",O
sulfonylureas,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
sulfonamides,NNS,G
and,CC,O
tetracyclines,NNS,G
might,MD,O
increase,VB,O
the,DT,O
photosensitivity,NN,O
reaction,NN,O
of,IN,O
actinic,JJ,O
keratoses,NNS,O
treated,VBN,O
with,IN,O
the,DT,O
levulan,NNP,O
kerastick,NNP,O
for,IN,O
topical,NNP,O
solution,NN,O
.,.,.
,,
aminosalicylic,JJ,O
acid,NN,O
may,MD,O
decrease,VB,O
the,DT,O
amount,NN,O
of,IN,O
digoxin,NN,D
-lrb-,-LRB-,O
lanoxin,NN,B
",",",",O
lanoxicaps,NN,D
-rrb-,-RRB-,O
that,WDT,O
gets,VBZ,O
absorbed,VBN,O
into,IN,O
your,PRP$,O
body,NN,O
.,.,.
,,
in,IN,O
the,DT,O
case,NN,O
that,IN,O
you,PRP,O
are,VBP,O
taking,VBG,O
digoxin,NN,D
while,IN,O
taking,VBG,O
aminosalicylic,JJ,O
acid,NN,O
",",",",O
higher,JJR,O
doses,NNS,O
of,IN,O
digoxin,NN,D
may,MD,O
be,VB,O
needed,VBN,O
.,.,.
,,
aminosalicylic,JJ,O
acid,NN,O
may,MD,O
also,RB,O
decrease,VB,O
the,DT,O
absorption,NN,O
of,IN,O
vitamin,NN,G
b12,NN,O
",",",",O
which,WDT,O
can,MD,O
lead,VB,O
to,TO,O
a,DT,O
deficiency,NN,O
.,.,.
,,
therefore,RB,O
you,PRP,O
may,MD,O
need,VB,O
to,TO,O
take,VB,O
a,DT,O
vitamin,NN,G
b12,NN,O
supplement,NN,O
while,IN,O
taking,VBG,O
aminosalicylic,JJ,O
acid,NN,O
.,.,.
,,
amiodarone,NNP,D
is,VBZ,O
metabolized,VBN,O
to,TO,O
desethylamiodarone,VBN,D
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
-lrb-,-LRB-,O
cyp450,NN,O
-rrb-,-RRB-,O
enzyme,NN,O
group,NN,O
",",",",O
specifically,RB,O
cytochromes,VBZ,O
p450,NN,O
3a4,NN,O
-lrb-,-LRB-,O
cyp3a4,NN,D
-rrb-,-RRB-,O
and,CC,O
cyp2c8,NN,O
.,.,.
,,
the,DT,O
cyp3a4,NN,D
isoenzyme,NN,O
is,VBZ,O
present,JJ,O
in,IN,O
both,CC,O
the,DT,O
liver,NN,O
and,CC,O
intestines,NNS,O
.,.,.
,,
amiodarone,NNP,D
is,VBZ,O
also,RB,O
known,VBN,O
to,TO,O
be,VB,O
an,DT,O
inhibitor,NN,O
of,IN,O
cyp3a4,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
amiodarone,NN,D
has,VBZ,O
the,DT,O
potential,NN,O
for,IN,O
interactions,NNS,O
with,IN,O
drugs,NNS,D
or,CC,O
substances,NNS,O
that,WDT,O
may,MD,O
be,VB,O
substrates,NNS,O
",",",",O
inhibitors,NNS,O
or,CC,O
inducers,NNS,O
of,IN,O
cyp3a4,NN,D
.,.,.
,,
while,IN,O
only,RB,O
a,DT,O
limited,JJ,O
number,NN,O
of,IN,O
in,FW,O
vivo,FW,O
drug-drug,JJ,O
interactions,NNS,O
with,IN,O
amiodarone,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
",",",",O
chiefly,RB,O
with,IN,O
the,DT,O
oral,JJ,O
formulation,NN,O
",",",",O
the,DT,O
potential,NN,O
for,IN,O
other,JJ,O
interactions,NNS,O
should,MD,O
be,VB,O
anticipated,VBN,O
.,.,.
,,
this,DT,O
is,VBZ,O
especially,RB,O
important,JJ,O
for,IN,O
drugs,NNS,D
associated,VBN,O
with,IN,O
serious,JJ,O
toxicity,NN,O
",",",",O
such,JJ,O
as,IN,O
other,JJ,O
antiarrhythmics,NNS,G
.,.,.
,,
if,IN,O
such,JJ,O
drugs,NNS,D
are,VBP,O
needed,VBN,O
",",",",O
their,PRP$,O
dose,NN,O
should,MD,O
be,VB,O
reassessed,VBN,O
and,CC,O
",",",",O
where,WRB,O
appropriate,JJ,O
",",",",O
plasma,NN,O
concentration,NN,O
measured,VBN,O
.,.,.
,,
in,IN,O
view,NN,O
of,IN,O
the,DT,O
long,JJ,O
and,CC,O
variable,JJ,O
half-life,NN,O
of,IN,O
amiodarone,NN,D
",",",",O
potential,NN,O
for,IN,O
drug,NN,D
interactions,NNS,O
exists,VBZ,O
not,RB,O
only,RB,O
with,IN,O
concomitant,JJ,O
medication,NN,O
but,CC,O
also,RB,O
with,IN,O
drugs,NNS,D
administered,VBN,O
after,IN,O
discontinuation,NN,O
of,IN,O
amiodarone,NN,D
.,.,.
,,
since,IN,O
amiodarone,NN,D
is,VBZ,O
a,DT,O
substrate,NN,O
for,IN,O
cyp3a4,NN,D
and,CC,O
cyp2c8,NN,O
",",",",O
drugs/substances,NNS,O
that,WDT,O
inhibit,VBP,O
these,DT,O
isoenzymes,NNS,O
may,MD,O
decrease,VB,O
the,DT,O
metabolism,NN,O
and,CC,O
increase,NN,O
serum,NN,O
concentration,NN,O
of,IN,O
amiodarone,NN,D
.,.,.
,,
reported,VBN,O
examples,NNS,O
include,VBP,O
the,DT,O
following,NN,O
:,:,O
protease,NN,O
inhibitors,NNS,O
:,:,O
protease,NN,O
inhibitors,NNS,O
are,VBP,O
known,VBN,O
to,TO,O
inhibit,VB,O
cyp3a4,NN,D
to,TO,O
varying,VBG,O
degrees,NNS,O
.,.,.
,,
a,DT,O
case,NN,O
report,NN,O
of,IN,O
one,CD,O
patient,NN,O
taking,VBG,O
amiodarone,NN,D
200,CD,O
mg,NN,O
and,CC,O
indinavir,NN,D
800,CD,O
mg,NN,O
three,CD,O
times,NNS,O
a,DT,O
day,NN,O
resulted,VBD,O
in,IN,O
increases,NNS,O
in,IN,O
amiodarone,NN,D
concentrations,NNS,O
from,IN,O
0.9,CD,O
mg/l,NN,O
to,TO,O
1.3,CD,O
mg/l,NN,O
.,.,.
,,
dea,NNP,O
concentrations,NNS,O
were,VBD,O
not,RB,O
affected,VBN,O
.,.,.
,,
there,EX,O
was,VBD,O
no,DT,O
evidence,NN,O
of,IN,O
toxicity,NN,O
.,.,.
,,
monitoring,VBG,O
for,IN,O
amiodarone,NN,D
toxicity,NN,O
and,CC,O
serial,NN,O
measurement,NN,O
of,IN,O
amiodarone,NN,D
serum,NN,O
concentration,NN,O
during,IN,O
concomitant,JJ,O
protease,NN,O
inhibitor,NN,O
therapy,NN,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
histamine,NN,O
h2,NN,O
antagonists,NNS,O
:,:,O
cimetidine,NN,D
inhibits,VBZ,O
cyp3a4,NN,D
and,CC,O
can,MD,O
increase,VB,O
serum,NN,O
amiodarone,NN,D
levels,NNS,O
.,.,.
,,
other,JJ,O
substances,NNS,O
:,:,O
grapefruit,NN,O
juice,NN,O
given,VBN,O
to,TO,O
healthy,JJ,O
volunteers,NNS,O
increased,VBD,O
amiodarone,NN,D
auc,NN,O
by,IN,O
50,CD,O
%,NN,O
and,CC,O
cmax,NN,O
by,IN,O
84,CD,O
%,NN,O
",",",",O
resulting,VBG,O
in,IN,O
increased,VBN,O
plasma,NN,O
levels,NNS,O
of,IN,O
amiodarone,NN,D
.,.,.
,,
grapefruit,NN,O
juice,NN,O
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
during,IN,O
treatment,NN,O
with,IN,O
oral,JJ,O
amiodarone,NN,D
.,.,.
,,
this,DT,O
information,NN,O
should,MD,O
be,VB,O
considered,VBN,O
when,WRB,O
changing,VBG,O
from,IN,O
intravenous,JJ,O
amiodarone,NN,D
to,TO,O
oral,JJ,O
amiodarone,NN,D
.,.,.
,,
amiodarone,NNP,D
may,MD,O
suppress,VB,O
certain,JJ,O
cyp450,NN,O
enzymes,NNS,O
",",",",O
including,VBG,O
cyp1a2,NN,D
",",",",O
cyp2c9,NN,D
",",",",O
cyp2d6,NN,D
",",",",O
and,CC,O
cyp3a4,NN,D
.,.,.
,,
this,DT,O
inhibition,NN,O
can,MD,O
result,VB,O
in,IN,O
unexpectedly,RB,O
high,JJ,O
plasma,NN,O
levels,NNS,O
of,IN,O
other,JJ,O
drugs,NNS,D
which,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
those,DT,O
cyp450,NN,O
enzymes,NNS,O
.,.,.
,,
reported,VBN,O
examples,NNS,O
of,IN,O
this,DT,O
interaction,NN,O
include,VBP,O
the,DT,O
following,NN,O
:,:,O
immunosuppressives,NNS,O
:,:,O
cyclosporine,NN,D
-lrb-,-LRB-,O
cyp3a4,NN,D
substrate,NN,O
-rrb-,-RRB-,O
administered,VBN,O
in,IN,O
combination,NN,O
with,IN,O
oral,JJ,O
amiodarone,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
produce,VB,O
persistently,RB,O
elevated,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
cyclosporine,NN,D
resulting,VBG,O
in,IN,O
elevated,JJ,O
creatinine,NN,O
",",",",O
despite,IN,O
reduction,NN,O
in,IN,O
dose,NN,O
of,IN,O
cyclosporine,NN,D
.,.,.
,,
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
:,:,O
simvastatin,NN,D
-lrb-,-LRB-,O
cyp3a4,NN,D
substrate,NN,O
-rrb-,-RRB-,O
in,IN,O
combination,NN,O
with,IN,O
amiodarone,NN,D
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
reports,NNS,O
of,IN,O
myopathy/rhabdomyolysis,NN,O
.,.,.
,,
cardiovasculars,NNP,O
:,:,O
cardiac,JJ,O
glycosides,NNS,G
:,:,O
in,IN,O
patients,NNS,O
receiving,VBG,O
digoxin,NN,D
therapy,NN,O
",",",",O
administration,NN,O
of,IN,O
oral,JJ,O
amiodarone,NN,D
regularly,RB,O
results,VBZ,O
in,IN,O
an,DT,O
increase,NN,O
in,IN,O
serum,NN,O
digoxin,NN,D
concentration,NN,O
that,WDT,O
may,MD,O
reach,VB,O
toxic,JJ,O
levels,NNS,O
with,IN,O
resultant,JJ,O
clinical,JJ,O
toxicity,NN,O
.,.,.
,,
amiodarone,NNP,D
taken,VBN,O
concomitantly,RB,O
with,IN,O
digoxin,NN,D
increases,VBZ,O
the,DT,O
serum,NN,O
digoxin,NN,D
concentration,NN,O
by,IN,O
70,CD,O
%,NN,O
after,IN,O
one,CD,O
day,NN,O
.,.,.
,,
on,IN,O
administration,NN,O
of,IN,O
oral,JJ,O
amiodarone,NN,D
",",",",O
the,DT,O
need,NN,O
for,IN,O
digitalis,NN,G
therapy,NN,O
should,MD,O
be,VB,O
reviewed,VBN,O
and,CC,O
the,DT,O
dose,NN,O
reduced,VBN,O
by,IN,O
approximately,RB,O
50,CD,O
%,NN,O
or,CC,O
discontinued,VBN,O
.,.,.
,,
if,IN,O
digitalis,NN,G
treatment,NN,O
is,VBZ,O
continued,VBN,O
",",",",O
serum,NN,O
levels,NNS,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
and,CC,O
patients,NNS,O
observed,VBN,O
for,IN,O
clinical,JJ,O
evidence,NN,O
of,IN,O
toxicity,NN,O
.,.,.
,,
these,DT,O
precautions,NNS,O
probably,RB,O
should,MD,O
apply,VB,O
to,TO,O
digitoxin,NN,D
administration,NN,O
as,RB,O
well,RB,O
.,.,.
,,
antiarrhythmics,NNS,G
:,:,O
other,JJ,O
antiarrhythmic,JJ,D
drugs,NNS,D
",",",",O
such,JJ,O
as,IN,O
quinidine,NN,D
",",",",O
procainamide,NN,D
",",",",O
disopyramide,NN,D
",",",",O
and,CC,O
phenytoin,NN,D
",",",",O
have,VBP,O
been,VBN,O
used,VBN,O
concurrently,RB,O
with,IN,O
amiodarone,NN,D
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
case,NN,O
reports,NNS,O
of,IN,O
increased,VBN,O
steady-state,JJ,O
levels,NNS,O
of,IN,O
quinidine,NN,D
",",",",O
procainamide,NN,D
",",",",O
and,CC,O
phenytoin,NN,D
during,IN,O
concomitant,JJ,O
therapy,NN,O
with,IN,O
amiodarone,NN,D
.,.,.
,,
phenytoin,NN,D
decreases,VBZ,O
serum,NN,O
amiodarone,NN,D
levels,NNS,O
.,.,.
,,
amiodarone,NNP,D
taken,VBN,O
concomitantly,RB,O
with,IN,O
quinidine,NN,D
increases,VBZ,O
quinidine,NN,D
serum,NN,O
concentration,NN,O
by,IN,O
33,CD,O
%,NN,O
after,IN,O
two,CD,O
days,NNS,O
.,.,.
,,
amiodarone,NNP,D
taken,VBN,O
concomitantly,RB,O
with,IN,O
procainamide,NN,D
for,IN,O
less,JJR,O
than,IN,O
seven,CD,O
days,NNS,O
increases,VBZ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
procainamide,NN,D
and,CC,O
n-acetyl,NN,O
procainamide,NN,D
by,IN,O
55,CD,O
%,NN,O
and,CC,O
33,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
quinidine,NN,D
and,CC,O
procainamide,NN,D
doses,NNS,O
should,MD,O
be,VB,O
reduced,VBN,O
by,IN,O
one-third,NN,O
when,WRB,O
either,CC,O
is,VBZ,O
administered,VBN,O
with,IN,O
amiodarone,NN,D
.,.,.
,,
plasma,NN,O
levels,NNS,O
of,IN,O
flecainide,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
increase,VB,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
oral,JJ,O
amiodarone,NN,D
.,.,.
,,
because,IN,O
of,IN,O
this,DT,O
",",",",O
the,DT,O
dosage,NN,O
of,IN,O
flecainide,NN,D
should,MD,O
be,VB,O
adjusted,VBN,O
when,WRB,O
these,DT,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
in,IN,O
general,JJ,O
",",",",O
any,DT,O
added,VBD,O
antiarrhythmic,JJ,D
drug,NN,D
should,MD,O
be,VB,O
initiated,VBN,O
at,IN,O
a,DT,O
lower,JJR,O
than,IN,O
usual,JJ,O
dose,NN,O
with,IN,O
careful,JJ,O
monitoring,NN,O
.,.,.
,,
combination,NN,O
of,IN,O
amiodarone,NN,D
with,IN,O
other,JJ,O
antiarrhythmic,JJ,D
therapy,NN,O
should,MD,O
be,VB,O
reserved,VBN,O
for,IN,O
patients,NNS,O
with,IN,O
life-threatening,JJ,O
ventricular,JJ,O
arrhythmias,NNS,O
who,WP,O
are,VBP,O
incompletely,RB,O
responsive,JJ,O
to,TO,O
a,DT,O
single,JJ,O
agent,NN,O
or,CC,O
incompletely,RB,O
responsive,JJ,O
to,TO,O
amiodarone,NN,D
.,.,.
,,
during,IN,O
transfer,NN,O
to,TO,O
oral,JJ,O
amiodarone,NN,D
",",",",O
the,DT,O
dose,NN,O
levels,NNS,O
of,IN,O
previously,RB,O
administered,VBN,O
agents,NNS,O
should,MD,O
be,VB,O
reduced,VBN,O
by,IN,O
30,CD,O
to,TO,O
50,CD,O
%,NN,O
several,JJ,O
days,NNS,O
after,IN,O
the,DT,O
addition,NN,O
of,IN,O
oral,JJ,O
amiodarone,NN,D
.,.,.
,,
the,DT,O
continued,JJ,O
need,NN,O
for,IN,O
the,DT,O
other,JJ,O
antiarrhythmic,JJ,D
agent,NN,O
should,MD,O
be,VB,O
reviewed,VBN,O
after,IN,O
the,DT,O
effects,NNS,O
of,IN,O
amiodarone,NN,D
have,VBP,O
been,VBN,O
established,VBN,O
",",",",O
and,CC,O
discontinuation,NN,O
ordinarily,RB,O
should,MD,O
be,VB,O
attempted,VBN,O
.,.,.
,,
if,IN,O
the,DT,O
treatment,NN,O
is,VBZ,O
continued,VBN,O
",",",",O
these,DT,O
patients,NNS,O
should,MD,O
be,VB,O
particularly,RB,O
carefully,RB,O
monitored,VBN,O
for,IN,O
adverse,JJ,O
effects,NNS,O
",",",",O
especially,RB,O
conduction,NN,O
disturbances,NNS,O
and,CC,O
exacerbation,NN,O
of,IN,O
tachyarrhythmias,NNS,O
",",",",O
as,IN,O
amiodarone,NN,D
is,VBZ,O
continued,VBN,O
.,.,.
,,
in,IN,O
amiodarone-treated,JJ,O
patients,NNS,O
who,WP,O
require,VBP,O
additional,JJ,O
antiarrhythmic,JJ,D
therapy,NN,O
",",",",O
the,DT,O
initial,JJ,O
dose,NN,O
of,IN,O
such,JJ,O
agents,NNS,O
should,MD,O
be,VB,O
approximately,RB,O
half,NN,O
of,IN,O
the,DT,O
usual,JJ,O
recommended,VBN,O
dose,NN,O
.,.,.
,,
antihypertensives,NNS,G
:,:,O
amiodarone,NN,D
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
-,:,O
receptor,NN,D
blocking,VBG,O
agents,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
propranolol,NN,D
",",",",O
a,DT,O
cyp3a4,NN,D
inhibitor,NN,O
-rrb-,-RRB-,O
or,CC,O
calcium,NN,D
channel,NN,O
antagonists,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
verapamil,NN,D
",",",",O
a,DT,O
cyp3a4,NN,D
substrate,NN,O
",",",",O
and,CC,O
diltiazem,NN,D
",",",",O
a,DT,O
cyp3a4,NN,D
inhibitor,NN,O
-rrb-,-RRB-,O
because,IN,O
of,IN,O
the,DT,O
possible,JJ,O
potentiation,NN,O
of,IN,O
bradycardia,NN,O
",",",",O
sinus,NN,O
arrest,NN,O
",",",",O
and,CC,O
av,NN,O
block,NN,O
.,.,.
,,
if,IN,O
necessary,JJ,O
",",",",O
amiodarone,NN,D
can,MD,O
continue,VB,O
to,TO,O
be,VB,O
used,VBN,O
after,IN,O
insertion,NN,O
of,IN,O
a,DT,O
pacemaker,NN,O
in,IN,O
patients,NNS,O
with,IN,O
severe,JJ,O
bradycardia,NN,O
or,CC,O
sinus,NN,O
arrest,NN,O
.,.,.
,,
anticoagulants,NNPS,G
:,:,O
potentiation,NN,O
of,IN,O
warfarin-type,JJ,O
-lrb-,-LRB-,O
cyp2c9,NN,D
and,CC,O
cyp3a4,NN,D
substrate,NN,O
-rrb-,-RRB-,O
anticoagulant,JJ,G
response,NN,O
is,VBZ,O
almost,RB,O
always,RB,O
seen,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
amiodarone,NN,D
and,CC,O
can,MD,O
result,VB,O
in,IN,O
serious,JJ,O
or,CC,O
fatal,JJ,O
bleeding,NN,O
.,.,.
,,
since,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
warfarin,NN,D
with,IN,O
amiodarone,NN,D
increases,VBZ,O
the,DT,O
prothrombin,NN,O
time,NN,O
by,IN,O
100,CD,O
%,NN,O
after,IN,O
3,CD,O
to,TO,O
4,CD,O
days,NNS,O
",",",",O
the,DT,O
dose,NN,O
of,IN,O
the,DT,O
anticoagulant,NN,G
should,MD,O
be,VB,O
reduced,VBN,O
by,IN,O
one-third,NN,O
to,TO,O
one-half,NN,O
",",",",O
and,CC,O
prothrombin,NN,O
times,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
.,.,.
,,
some,DT,O
drugs/substances,NNS,O
are,VBP,O
known,VBN,O
to,TO,O
accelerate,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
amiodarone,NN,D
by,IN,O
stimulating,VBG,O
the,DT,O
synthesis,NN,O
of,IN,O
cyp3a4,NN,D
-lrb-,-LRB-,O
enzyme,NN,O
induction,NN,O
-rrb-,-RRB-,O
.,.,.
,,
this,DT,O
may,MD,O
lead,VB,O
to,TO,O
low,JJ,O
amiodarone,NN,D
serum,NN,O
levels,NNS,O
and,CC,O
potential,JJ,O
decrease,NN,O
in,IN,O
efficacy,NN,O
.,.,.
,,
reported,VBN,O
examples,NNS,O
of,IN,O
this,DT,O
interaction,NN,O
include,VBP,O
the,DT,O
following,NN,O
:,:,O
antibiotics,NNS,G
:,:,O
rifampin,NNP,D
is,VBZ,O
a,DT,O
potent,JJ,O
inducer,NN,O
of,IN,O
cyp3a4,NN,D
.,.,.
,,
administration,NN,O
of,IN,O
rifampin,NN,D
concomitantly,RB,O
with,IN,O
oral,JJ,O
amiodarone,NN,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
result,VB,O
in,IN,O
decreases,NNS,O
in,IN,O
serum,NN,O
concentrations,NNS,O
of,IN,O
amiodarone,NN,D
and,CC,O
desethylamiodarone,NN,D
.,.,.
,,
other,JJ,O
substances,NNS,O
",",",",O
including,VBG,O
herbal,JJ,O
preparations,NNS,O
:,:,O
st.,NNP,O
john,NNP,O
s,VBZ,O
wort,NNP,O
-lrb-,-LRB-,O
hypericum,NNP,O
perforatum,NN,O
-rrb-,-RRB-,O
induces,VBZ,O
cyp3a4,NN,D
.,.,.
,,
since,IN,O
amiodarone,NN,D
is,VBZ,O
a,DT,O
substrate,NN,O
for,IN,O
cyp3a4,NN,D
",",",",O
there,EX,O
is,VBZ,O
the,DT,O
potential,NN,O
that,IN,O
the,DT,O
use,NN,O
of,IN,O
st.,NNP,O
john,NNP,O
s,VBZ,O
wort,NNP,O
in,IN,O
patients,NNS,O
receiving,VBG,O
amiodarone,NN,D
could,MD,O
result,VB,O
in,IN,O
reduced,VBN,O
amiodarone,NN,D
levels,NNS,O
.,.,.
,,
other,JJ,O
reported,VBN,O
interactions,NNS,O
with,IN,O
amiodarone,NN,D
:,:,O
fentanyl,NN,D
-lrb-,-LRB-,O
cyp3a4,NN,D
substrate,NN,O
-rrb-,-RRB-,O
in,IN,O
combination,NN,O
with,IN,O
amiodarone,NN,D
may,MD,O
cause,VB,O
hypotension,NN,O
",",",",O
bradycardia,NN,O
",",",",O
and,CC,O
decreased,VBD,O
cardiac,JJ,O
output,NN,O
.,.,.
,,
sinus,NN,O
bradycardia,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
with,IN,O
oral,JJ,O
amiodarone,NN,D
in,IN,O
combination,NN,O
with,IN,O
lidocaine,NN,D
-lrb-,-LRB-,O
cyp3a4,NN,D
substrate,NN,O
-rrb-,-RRB-,O
given,VBN,O
for,IN,O
local,JJ,O
anesthesia,NN,D
.,.,.
,,
seizure,NN,O
",",",",O
associated,VBN,O
with,IN,O
increased,VBN,O
lidocaine,NN,D
concentrations,NNS,O
",",",",O
has,VBZ,O
been,VBN,O
reported,VBN,O
with,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
intravenous,JJ,O
amiodarone,NN,D
.,.,.
,,
dextromethorphan,NNP,D
is,VBZ,O
a,DT,O
substrate,NN,O
for,IN,O
both,DT,O
cyp2d6,NN,D
and,CC,O
cyp3a4,NN,D
.,.,.
,,
amiodarone,NN,D
inhibits,VBZ,O
cyp2d6,NN,D
.,.,.
,,
cholestyramine,NNP,D
increases,VBZ,O
enterohepatic,JJ,O
elimination,NN,O
of,IN,O
amiodarone,NN,D
and,CC,O
may,MD,O
reduce,VB,O
its,PRP$,O
serum,NN,O
levels,NNS,O
and,CC,O
t1/2,NN,O
.,.,.
,,
disopyramide,NNP,D
increases,VBZ,O
qt,NNP,O
prolongation,NN,O
which,WDT,O
could,MD,O
cause,VB,O
arrhythmia,NN,O
.,.,.
,,
fluoroquinolones,NNP,D
",",",",O
macrolide,NN,O
antibiotics,NNS,G
",",",",O
and,CC,O
azoles,NNS,G
are,VBP,O
known,VBN,O
to,TO,O
cause,VB,O
qtc,NN,O
prolongation,NN,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
qtc,NN,O
prolongation,NN,O
",",",",O
with,IN,O
or,CC,O
without,IN,O
tdp,NN,O
",",",",O
in,IN,O
patients,NNS,O
taking,VBG,O
amiodarone,NN,D
when,WRB,O
fluoroquinolones,NNS,D
",",",",O
macrolide,NN,O
antibiotics,NNS,G
",",",",O
or,CC,O
azoles,NNS,G
were,VBD,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
hemodynamic,JJ,O
and,CC,O
electrophysiologic,JJ,O
interactions,NNS,O
have,VBP,O
also,RB,O
been,VBN,O
observed,VBN,O
after,IN,O
concomitant,JJ,O
administration,NN,O
with,IN,O
propranolol,NN,D
",",",",O
diltiazem,NN,D
",",",",O
and,CC,O
verapamil,NN,D
.,.,.
,,
volatile,JJ,O
anesthetic,NNP,D
agents,NNPS,O
:,:,O
.,.,.
,,
in,IN,O
addition,NN,O
to,TO,O
the,DT,O
interactions,NNS,O
noted,VBD,O
above,RB,O
",",",",O
chronic,JJ,O
-lrb-,-LRB-,O
2,CD,O
weeks,NNS,O
-rrb-,-RRB-,O
oral,JJ,O
cordarone,NNP,B
administration,NN,O
impairs,VBZ,O
metabolism,NN,O
of,IN,O
phenytoin,NN,D
",",",",O
dextromethorphan,NN,D
",",",",O
and,CC,O
methotrexate,NN,D
.,.,.
,,
electrolyte,NNP,O
disturbances,NNPS,O
patients,NNPS,O
with,IN,O
hypokalemia,NN,O
or,CC,O
hypomagnesemia,NN,O
should,MD,O
have,VB,O
the,DT,O
condition,NN,O
corrected,VBN,O
whenever,WRB,O
possible,JJ,O
before,IN,O
being,VBG,O
treated,VBN,O
with,IN,O
cordarone,JJ,B
i.v.,NNP,O
",",",",O
as,IN,O
these,DT,O
disorders,NNS,O
can,MD,O
exaggerate,VB,O
the,DT,O
degree,NN,O
of,IN,O
qtc,NN,O
prolongation,NN,O
and,CC,O
increase,VB,O
the,DT,O
potential,NN,O
for,IN,O
tdp,NN,O
.,.,.
,,
special,JJ,O
attention,NN,O
should,MD,O
be,VB,O
given,VBN,O
to,TO,O
electrolyte,NN,O
and,CC,O
acid-base,NN,O
balance,NN,O
in,IN,O
patients,NNS,O
experiencing,VBG,O
severe,JJ,O
or,CC,O
prolonged,JJ,O
diarrhea,NN,O
or,CC,O
in,IN,O
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
diuretics,NNS,G
.,.,.
,,
drugs,NNS,O
metabolized,VBN,O
by,IN,O
p450,NN,O
2d6,NN,O
-,:,O
the,DT,O
biochemical,JJ,O
activity,NN,O
of,IN,O
the,DT,O
drug,NN,D
metabolizing,VBG,O
isozyme,NN,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
-lrb-,-LRB-,O
debrisoquin,NN,D
hydroxylase,NN,O
-rrb-,-RRB-,O
is,VBZ,O
reduced,VBN,O
in,IN,O
a,DT,O
subset,NN,O
of,IN,O
the,DT,O
caucasian,JJ,O
population,NN,O
-lrb-,-LRB-,O
about,IN,O
10-Jul,CD,O
%,NN,O
of,IN,O
caucasians,NNS,O
are,VBP,O
so,RB,O
called,VBN,O
poor,JJ,O
metabolizers,NNS,O
-rrb-,-RRB-,O
;,:,O
.,.,.
,,
reliable,JJ,O
estimates,NNS,O
of,IN,O
the,DT,O
prevalence,NN,O
of,IN,O
reduced,VBN,O
p450,NN,O
2d6,NN,O
isozyme,NN,O
activity,NN,O
among,IN,O
asian,JJ,O
",",",",O
african,JJ,O
and,CC,O
other,JJ,O
populations,NNS,O
are,VBP,O
not,RB,O
yet,RB,O
available,JJ,O
.,.,.
,,
poor,NNP,O
metabolizers,NNS,O
have,VBP,O
higher,JJR,O
than,IN,O
expected,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
-lrb-,-LRB-,O
tcas,NNS,G
-rrb-,-RRB-,O
when,WRB,O
given,VBN,O
usual,JJ,O
doses,NNS,O
.,.,.
,,
depending,VBG,O
on,IN,O
the,DT,O
fraction,NN,O
of,IN,O
drug,NN,D
metabolized,VBN,O
by,IN,O
p450,NN,O
2d6,NN,O
",",",",O
the,DT,O
increase,NN,O
in,IN,O
plasma,NN,O
concentration,NN,O
may,MD,O
be,VB,O
small,JJ,O
",",",",O
or,CC,O
quite,RB,O
large,JJ,O
-lrb-,-LRB-,O
8-fold,JJ,O
increase,NN,O
in,IN,O
plasma,NN,O
auc,NN,O
of,IN,O
the,DT,O
tca,NNP,G
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
certain,JJ,O
drugs,NNS,D
inhibit,VBP,O
the,DT,O
activity,NN,O
of,IN,O
this,DT,O
isozyme,NN,O
and,CC,O
make,VB,O
normal,JJ,O
metabolizers,NNS,O
resemble,VBP,O
poor,JJ,O
metabolizers,NNS,O
.,.,.
,,
an,DT,O
individual,NN,O
who,WP,O
is,VBZ,O
stable,JJ,O
on,IN,O
a,DT,O
given,VBN,O
dose,NN,O
of,IN,O
tca,NNP,G
may,MD,O
become,VB,O
abruptly,RB,O
toxic,JJ,O
when,WRB,O
given,VBN,O
one,CD,O
of,IN,O
these,DT,O
inhibiting,VBG,O
drugs,NNS,D
as,IN,O
concomitant,JJ,O
therapy,NN,O
.,.,.
,,
the,DT,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
include,VBP,O
some,DT,O
that,WDT,O
are,VBP,O
not,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
enzyme,NN,O
-lrb-,-LRB-,O
quinidine,NN,D
.,.,.
,,
cimetidine,NN,D
-rrb-,-RRB-,O
and,CC,O
many,JJ,O
that,WDT,O
are,VBP,O
substrates,NNS,O
for,IN,O
p450,NN,O
2d6,NN,O
-lrb-,-LRB-,O
many,JJ,O
other,JJ,O
antidepressants,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
and,CC,O
the,DT,O
type,NN,O
1c,NN,O
antiarrhythmics,NNS,G
propafenone,NN,D
and,CC,O
flecainide,NN,D
-rrb-,-RRB-,O
.,.,.
,,
while,IN,O
all,PDT,O
the,DT,O
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
ssris,NNS,G
-rrb-,-RRB-,O
",",",",O
e.g.,FW,O
",",",",O
fluoxetine,NN,D
",",",",O
sertraline,NN,D
",",",",O
and,CC,O
paroxetine,NN,D
",",",",O
inhibit,VBP,O
p450,NN,O
2d6,NN,O
",",",",O
they,PRP,O
may,MD,O
vary,VB,O
in,IN,O
the,DT,O
extent,NN,O
of,IN,O
inhibition,NN,O
.,.,.
,,
the,DT,O
extent,NN,O
to,TO,O
which,WDT,O
ssri-tca,NNP,O
interactions,NNS,O
may,MD,O
pose,VB,O
clinical,JJ,O
problems,NNS,O
will,MD,O
depend,VB,O
on,IN,O
the,DT,O
degree,NN,O
of,IN,O
inhibition,NN,O
and,CC,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
the,DT,O
ssri,NNP,G
involved,VBN,O
.,.,.
,,
nevertheless,RB,O
",",",",O
caution,NN,O
is,VBZ,O
indicated,VBN,O
in,IN,O
the,DT,O
coadministration,NN,O
of,IN,O
tcas,NNS,G
with,IN,O
any,DT,O
of,IN,O
the,DT,O
ssris,NNS,G
and,CC,O
also,RB,O
in,IN,O
switching,NN,O
from,IN,O
one,CD,O
class,NN,O
to,TO,O
the,DT,O
other,JJ,O
.,.,.
,,
of,IN,O
particular,JJ,O
importance,NN,O
",",",",O
sufficient,JJ,O
time,NN,O
must,MD,O
elapse,VB,O
before,IN,O
initiating,VBG,O
tca,NNP,G
treatment,NN,O
in,IN,O
a,DT,O
patient,NN,O
being,VBG,O
withdrawn,VBN,O
from,IN,O
fluoxetine,NN,D
",",",",O
given,VBN,O
the,DT,O
long,JJ,O
half-life,NN,O
of,IN,O
the,DT,O
parent,NN,O
and,CC,O
active,JJ,O
metabolite,NN,O
-lrb-,-LRB-,O
at,IN,O
least,JJS,O
5,CD,O
weeks,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
-rrb-,-RRB-,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
with,IN,O
drugs,NNS,D
that,WDT,O
can,MD,O
inhibit,VB,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
may,MD,O
require,VB,O
lower,JJR,O
doses,NNS,O
than,IN,O
usually,RB,O
prescribed,VBN,O
for,IN,O
either,CC,O
the,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
or,CC,O
the,DT,O
other,JJ,O
drug,NN,D
.,.,.
,,
furthermore,RB,O
",",",",O
whenever,WRB,O
one,CD,O
of,IN,O
these,DT,O
other,JJ,O
drugs,NNS,D
is,VBZ,O
withdrawn,VBN,O
from,IN,O
co-therapy,JJ,O
",",",",O
an,DT,O
increased,VBN,O
dose,NN,O
of,IN,O
tricyclic,JJ,G
antidepressant,JJ,G
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
desirable,JJ,O
to,TO,O
monitor,VB,O
tca,NNP,G
plasma,NN,O
levels,NNS,O
whenever,WRB,O
a,DT,O
tca,NNP,G
is,VBZ,O
going,VBG,O
to,TO,O
be,VB,O
coadministered,VBN,O
with,IN,O
another,DT,O
drug,NN,D
known,VBN,O
to,TO,O
be,VB,O
an,DT,O
inhibitor,NN,O
of,IN,O
p450,NN,O
2d6,NN,O
.,.,.
,,
monoamine,NNP,O
oxidase,NNP,O
inhibitors,NNS,O
:,:,O
guanethidine,NN,D
or,CC,O
similarly,RB,O
acting,VBG,O
compounds,NNS,O
.,.,.
,,
thyroid,NN,G
medication,NN,O
.,.,.
,,
alcohol,NN,D
",",",",O
barbiturates,NNS,G
and,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
.,.,.
,,
and,CC,O
disulfiram,NN,D
when,WRB,O
amitriptyline,NNP,D
hcl,NN,O
is,VBZ,O
given,VBN,O
with,IN,O
anticholinergic,JJ,G
agents,NNS,O
or,CC,O
sympathomimetic,JJ,G
drugs,NNS,D
",",",",O
including,VBG,O
epinephrine,NN,D
combined,VBN,O
with,IN,O
local,JJ,O
anesthetics,NNS,G
",",",",O
close,JJ,O
supervision,NN,O
and,CC,O
careful,JJ,O
adjustment,NN,O
of,IN,O
dosages,NNS,O
are,VBP,O
required,VBN,O
.,.,.
,,
hyperpyrexia,NNP,O
has,VBZ,O
been,VBN,O
reported,VBN,O
when,WRB,O
amitriptyline,NNP,D
hcl,NN,O
is,VBZ,O
administered,VBN,O
with,IN,O
anticholinergic,JJ,G
agents,NNS,O
or,CC,O
with,IN,O
neuroleptic,JJ,G
drugs,NNS,D
",",",",O
particularly,RB,O
during,IN,O
hot,JJ,O
weather,NN,O
.,.,.
,,
paralytic,JJ,O
ileus,NN,O
may,MD,O
occur,VB,O
in,IN,O
patients,NNS,O
taking,VBG,O
tricyclic,JJ,G
antidepressants,NNS,G
in,IN,O
combination,NN,O
with,IN,O
anticholinergic-type,JJ,O
drugs,NNS,D
.,.,.
,,
cimetidine,NNP,D
is,VBZ,O
reported,VBN,O
to,TO,O
reduce,VB,O
hepatic,JJ,O
metabolism,NN,O
of,IN,O
certain,JJ,O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
thereby,RB,O
delaying,VBG,O
elimination,NN,O
and,CC,O
increasing,VBG,O
steady-state,JJ,O
concentrations,NNS,O
of,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
clinically,RB,O
significant,JJ,O
effects,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
the,DT,O
tricyclic,JJ,G
antidepressants,NNS,G
when,WRB,O
used,VBN,O
concomitantly,RB,O
with,IN,O
cimetidine,NN,D
.,.,.
,,
increases,NNS,O
in,IN,O
plasma,NN,O
levels,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
and,CC,O
in,IN,O
the,DT,O
frequency,NN,O
and,CC,O
severity,NN,O
of,IN,O
side,JJ,O
effects,NNS,O
",",",",O
particularly,RB,O
anticholinergic,JJ,G
",",",",O
have,VBP,O
been,VBN,O
reported,VBN,O
when,WRB,O
cimetidine,NN,D
was,VBD,O
added,VBN,O
to,TO,O
the,DT,O
drug,NN,D
regimen,NN,O
.,.,.
,,
discontinuation,NN,O
of,IN,O
cimetidine,NN,D
in,IN,O
well-controlled,JJ,O
patients,NNS,O
receiving,VBG,O
tricyclic,JJ,G
antidepressants,NNS,G
and,CC,O
cimetidine,NN,D
may,MD,O
decrease,VB,O
the,DT,O
plasma,NN,O
levels,NNS,O
and,CC,O
efficacy,NN,O
of,IN,O
the,DT,O
antidepressants,NNS,G
.,.,.
,,
caution,NN,O
is,VBZ,O
advised,VBN,O
if,IN,O
patients,NNS,O
receive,VBP,O
large,JJ,O
doses,NNS,O
of,IN,O
ethchlorvynol,NN,D
concurrently,RB,O
.,.,.
,,
transient,JJ,O
delirium,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
who,WP,O
were,VBD,O
treated,VBN,O
with,IN,O
one,CD,O
gram,NN,O
of,IN,O
ethchlorvynol,NN,D
and,CC,O
75,CD,O
-,:,O
150,CD,O
mg,NN,O
of,IN,O
amitriptyline,NNP,D
hcl,NN,O
.,.,.
,,
when,WRB,O
administered,VBN,O
concurrently,RB,O
",",",",O
the,DT,O
following,VBG,O
drugs,NNS,D
may,MD,O
interact,VB,O
with,IN,O
amphotericin,NN,D
b,NN,O
:,:,O
antineoplastic,JJ,O
agents,NNS,O
:,:,O
may,MD,O
enhance,VB,O
the,DT,O
potential,NN,O
for,IN,O
renal,JJ,O
toxicity,NN,O
",",",",O
bronchospasm,NN,O
and,CC,O
hypotension,NN,O
.,.,.
,,
antineoplastic,JJ,O
agents,NNS,O
-lrb-,-LRB-,O
e.,FW,O
g.,FW,O
",",",",O
nitrogen,NN,O
mustard,NN,O
",",",",O
etc.,FW,O
-rrb-,-RRB-,O
should,MD,O
be,VB,O
given,VBN,O
concomitantly,RB,O
only,RB,O
with,IN,O
great,JJ,O
caution,NN,O
.,.,.
,,
corticosteroids,NNS,G
and,CC,O
corticotropin,NN,D
-lrb-,-LRB-,O
acth,NN,D
-rrb-,-RRB-,O
:,:,O
may,MD,O
potentiate,VB,O
amphotericin,NN,D
b,NN,O
-,:,O
induced,VBN,O
hypokalemia,NN,O
which,WDT,O
may,MD,O
predispose,VB,O
the,DT,O
patient,NN,O
to,TO,O
cardiac,JJ,O
dysfunction,NN,O
.,.,.
,,
avoid,VB,O
concomitant,JJ,O
use,NN,O
unless,IN,O
necessary,JJ,O
to,TO,O
control,VB,O
side,JJ,O
effects,NNS,O
of,IN,O
amphotericin,NN,D
b,NN,O
.,.,.
,,
if,IN,O
used,VBN,O
concomitantly,RB,O
",",",",O
closely,RB,O
monitor,VB,O
serum,NN,O
electrolytes,NNS,O
and,CC,O
cardiac,JJ,O
function,NN,O
.,.,.
,,
digitalis,NN,G
glycosides,NNS,G
:,:,O
amphotericin,NN,D
b-induced,JJ,O
hypokalemia,NN,O
may,MD,O
potentiate,VB,O
digitalis,NN,G
toxicity,NN,O
.,.,.
,,
serum,NN,O
potassium,NN,D
levels,NNS,O
and,CC,O
cardiac,JJ,O
function,NN,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
and,CC,O
any,DT,O
deficit,NN,O
promptly,RB,O
corrected,VBN,O
.,.,.
,,
flucytosine,NNP,D
:,:,O
while,IN,O
a,DT,O
synergistic,JJ,O
relationship,NN,O
with,IN,O
amphotericin,NN,D
b,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
",",",",O
concomitant,JJ,O
use,NN,O
may,MD,O
increase,VB,O
the,DT,O
toxicity,NN,O
of,IN,O
flucytosine,NN,D
by,IN,O
possibly,RB,O
increasing,VBG,O
its,PRP$,O
cellular,JJ,O
uptake,NN,O
and/or,CC,O
impairing,VBG,O
its,PRP$,O
renal,JJ,O
excretion,NN,O
.,.,.
,,
imidazoles,NNS,G
-lrb-,-LRB-,O
e.,FW,O
g.,FW,O
",",",",O
ketoconazole,NN,D
",",",",O
miconazole,NN,D
",",",",O
clotrimazole,NN,D
",",",",O
fluconazole,NN,D
",",",",O
etc.,FW,O
-rrb-,-RRB-,O
:,:,O
in,FW,O
vitro,FW,O
and,CC,O
animal,JJ,O
studies,NNS,O
with,IN,O
the,DT,O
combination,NN,O
of,IN,O
amphotericin,NN,D
b,NN,O
and,CC,O
imidazoles,NNS,G
suggest,VBP,O
that,IN,O
imidazoles,NNS,G
may,MD,O
induce,VB,O
fungal,JJ,O
resistance,NN,O
to,TO,O
amphotericin,NN,D
b.,NNP,O
combination,NNP,O
therapy,NN,O
should,MD,O
be,VB,O
administered,VBN,O
with,IN,O
caution,NN,O
",",",",O
especially,RB,O
in,IN,O
immunocompromised,JJ,O
patients,NNS,O
.,.,.
,,
other,JJ,O
nephrotoxic,JJ,O
medications,NNS,O
:,:,O
agents,NNS,O
such,JJ,O
as,IN,O
aminoglycosides,NNS,G
",",",",O
cyclosporine,NN,D
",",",",O
and,CC,O
pentamidine,NN,D
may,MD,O
enhance,VB,O
the,DT,O
potential,NN,O
for,IN,O
drug-induced,JJ,O
renal,JJ,O
toxicity,NN,O
",",",",O
and,CC,O
should,MD,O
be,VB,O
used,VBN,O
concomitantly,RB,O
only,RB,O
with,IN,O
great,JJ,O
caution,NN,O
.,.,.
,,
intensive,JJ,O
monitoring,NN,O
of,IN,O
renal,JJ,O
function,NN,O
is,VBZ,O
recommended,VBN,O
in,IN,O
patients,NNS,O
requiring,VBG,O
any,DT,O
combination,NN,O
of,IN,O
nephrotoxic,JJ,O
medications,NNS,O
.,.,.
,,
skeletal,JJ,O
muscle,NN,O
relaxants,NNS,O
:,:,O
amphotericin,NN,D
b-induced,JJ,O
hypokalemia,NN,O
may,MD,O
enhance,VB,O
the,DT,O
curariform,NN,O
effect,NN,O
of,IN,O
skeletal,JJ,O
muscle,NN,O
relaxants,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
tubocurarine,NN,D
-rrb-,-RRB-,O
.,.,.
,,
serum,NN,O
potassium,NN,D
levels,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
and,CC,O
deficiencies,NNS,O
corrected,VBN,O
.,.,.
,,
leukocyte,NN,O
transfusions,NNS,O
:,:,O
acute,JJ,O
pulmonary,JJ,O
toxicity,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
intravenous,JJ,O
amphotericin,NN,D
b,NN,O
and,CC,O
leukocyte,NN,O
transfusions,NNS,O
.,.,.
,,
when,WRB,O
administered,VBN,O
concurrently,RB,O
",",",",O
the,DT,O
following,VBG,O
drugs,NNS,D
may,MD,O
interact,VB,O
with,IN,O
ampicillin,NN,D
.,.,.
,,
allopurinol,NNP,D
:,:,O
increased,VBN,O
possibility,NN,O
of,IN,O
skin,NN,O
rash,NN,O
",",",",O
particularly,RB,O
in,IN,O
hyperuricemic,JJ,O
patients,NNS,O
may,MD,O
occur,VB,O
.,.,.
,,
bacteriostatic,JJ,O
antibiotics,NNS,G
:,:,O
chloramphenicol,NN,D
",",",",O
erythromycins,NNS,D
",",",",O
sulfonamides,NNS,G
",",",",O
or,CC,O
tetracyclines,NNS,G
may,MD,O
interfere,VB,O
with,IN,O
the,DT,O
bactericidal,JJ,O
effect,NN,O
of,IN,O
penicillins,NNS,D
.,.,.
,,
this,DT,O
has,VBZ,O
been,VBN,O
demonstrated,VBN,O
in,IN,O
view,NN,O
",",",",O
however,RB,O
",",",",O
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
interaction,NN,O
is,VBZ,O
not,RB,O
well,RB,O
documented,VBN,O
.,.,.
,,
oral,JJ,O
contraceptives,NNS,G
:,:,O
may,MD,O
be,VB,O
less,RBR,O
effective,JJ,O
and,CC,O
increased,VBD,O
breakthrough,NN,O
bleeding,NN,O
may,MD,O
occur,VB,O
.,.,.
,,
probenecid,NNP,D
:,:,O
may,NNP,O
decrease,VB,O
renal,JJ,O
tubular,JJ,O
secretion,NN,O
of,IN,O
ampicillin,NN,D
resulting,VBG,O
in,IN,O
increased,VBN,O
blood,NN,O
levels,NNS,O
and/or,CC,O
ampicillin,NN,D
toxicity,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interaction,NN,O
after,IN,O
treatment,NN,O
with,IN,O
ampicillin,NN,D
",",",",O
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
the,DT,O
urine,NN,O
may,MD,O
occur,VB,O
with,IN,O
copper,NN,O
sulfate,NN,O
tests,NNS,O
-lrb-,-LRB-,O
benedicts,NNS,O
solution,NN,O
",",",",O
fehlings,NNP,O
solution,NN,O
",",",",O
or,CC,O
clinitest,NNP,O
tablets,NNS,O
-rrb-,-RRB-,O
but,CC,O
not,RB,O
with,IN,O
enzyme,NN,O
based,VBN,O
tests,NNS,O
such,JJ,O
as,IN,O
clinistix,NNP,O
and,CC,O
glucose,NNP,O
enzymatic,JJ,O
test,NN,O
strip,NNP,O
usp,NNP,O
.,.,.
,,
amprenavir,NNP,D
is,VBZ,O
metabolized,VBN,O
in,IN,O
the,DT,O
liver,NN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
enzyme,NN,O
system,NN,O
.,.,.
,,
amprenavir,NN,D
inhibits,VBZ,O
cyp3a4,NN,D
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
when,WRB,O
coadministering,VBG,O
medications,NNS,O
that,WDT,O
are,VBP,O
substrates,NNS,O
",",",",O
inhibitors,NNS,O
",",",",O
or,CC,O
inducers,NNS,O
of,IN,O
cyp3a4,NN,D
",",",",O
or,CC,O
potentially,RB,O
toxic,JJ,O
medications,NNS,O
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
cyp3a4,NN,D
.,.,.
,,
amprenavir,NNP,D
does,VBZ,O
not,RB,O
inhibit,VB,O
cyp2d6,NN,D
",",",",O
cyp1a2,NN,D
",",",",O
cyp2c9,NN,D
",",",",O
cyp2c19,NN,O
",",",",O
cyp2e1,NN,O
",",",",O
or,CC,O
uridine,NN,O
glucuronosyltransferase,NN,O
-lrb-,-LRB-,O
udpgt,NN,O
-rrb-,-RRB-,O
.,.,.
,,
hiv,NN,O
protease,NN,O
inhibitors,NNS,O
:,:,O
the,DT,O
effect,NN,O
of,IN,O
amprenavir,NN,D
on,IN,O
total,JJ,O
drug,NN,D
concentrations,NNS,O
of,IN,O
other,JJ,O
hiv,NN,O
protease,NN,O
inhibitors,NNS,O
in,IN,O
subjects,NNS,O
receiving,VBG,O
both,CC,O
agents,NNS,O
was,VBD,O
evaluated,VBN,O
using,VBG,O
comparisons,NNS,O
to,TO,O
historical,JJ,O
data,NNS,O
.,.,.
,,
indinavir,NNP,D
steady-state,JJ,O
cmax,NNP,O
",",",",O
a.c.,NNP,O
and,CC,O
cmin,NNP,O
were,VBD,O
decreased,VBN,O
by,IN,O
22,CD,O
%,NN,O
",",",",O
38,CD,O
%,NN,O
",",",",O
and,CC,O
27,CD,O
%,NN,O
",",",",O
respectively,RB,O
",",",",O
by,IN,O
concomitant,JJ,O
amprenavir,NN,D
.,.,.
,,
similar,JJ,O
decreases,NNS,O
in,IN,O
cmax,NN,O
and,CC,O
auc,NN,O
were,VBD,O
seen,VBN,O
after,IN,O
the,DT,O
first,JJ,O
dose,NN,O
.,.,.
,,
saquinavir,NNP,D
steady-state,JJ,O
cmax,NNP,O
",",",",O
a.c.,NNP,O
and,CC,O
cmin,NNP,O
were,VBD,O
increased,VBN,O
21,CD,O
%,NN,O
",",",",O
decreased,VBD,O
19,CD,O
%,NN,O
",",",",O
and,CC,O
decreased,VBD,O
48,CD,O
%,NN,O
",",",",O
respectively,RB,O
",",",",O
by,IN,O
concomitant,JJ,O
amprenavir,NN,D
.,.,.
,,
nelfinavir,NNP,D
steady-state,JJ,O
cmax,NNP,O
",",",",O
a.c.,NNP,O
and,CC,O
cmin,NNP,O
were,VBD,O
increased,VBN,O
by,IN,O
12,CD,O
%,NN,O
",",",",O
15,CD,O
%,NN,O
",",",",O
and,CC,O
14,CD,O
%,NN,O
",",",",O
respectively,RB,O
",",",",O
by,IN,O
concomitant,JJ,O
amprenavir,NN,D
.,.,.
,,
methadone,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
amprenavir,NN,D
and,CC,O
methadone,NN,D
can,MD,O
decrease,VB,O
plasma,NN,O
levels,NNS,O
of,IN,O
methadone,NN,D
.,.,.
,,
coadministration,NN,O
of,IN,O
amprenavir,NN,D
and,CC,O
methadone,NN,D
as,IN,O
compared,VBN,O
to,TO,O
a,DT,O
non-matched,JJ,O
historicalcontrol,NN,O
group,NN,O
resulted,VBD,O
in,IN,O
a,DT,O
30,CD,O
%,NN,O
",",",",O
27,CD,O
%,NN,O
",",",",O
and,CC,O
25,CD,O
%,NN,O
decrease,NN,O
in,IN,O
serum,NN,O
amprenavir,NN,D
auc,NN,O
",",",",O
cmax,NN,O
",",",",O
andcmin,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
amprenavir,NNP,D
is,VBZ,O
an,DT,O
inhibitor,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
c.p.a.,NN,O
metabolism,NN,O
and,CC,O
therefore,RB,O
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
concurrently,RB,O
with,IN,O
medications,NNS,O
with,IN,O
narrow,JJ,O
therapeutic,JJ,O
windows,NNS,O
that,WDT,O
are,VBP,O
substrates,NNS,O
of,IN,O
cyp3a4,NN,D
.,.,.
,,
there,EX,O
are,VBP,O
other,JJ,O
agents,NNS,O
that,WDT,O
may,MD,O
result,VB,O
in,IN,O
serious,JJ,O
and/or,CC,O
life-threatening,JJ,O
drug,NN,D
interactions,NNS,O
.,.,.
,,
laboratory,NN,O
tests,NNS,O
:,:,O
the,DT,O
combination,NN,O
of,IN,O
amprenavir,NNP,D
and,CC,O
low-dose,JJ,O
ritonavir,NN,D
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
elevations,NNS,O
of,IN,O
cholesterol,NN,O
and,CC,O
triglycerides,NNS,O
",",",",O
sgot,NN,O
-lrb-,-LRB-,O
ast,NNP,O
-rrb-,-RRB-,O
",",",",O
and,CC,O
sgpt,NN,O
-lrb-,-LRB-,O
alt,NN,O
-rrb-,-RRB-,O
in,IN,O
some,DT,O
patients,NNS,O
.,.,.
,,
appropriate,JJ,O
laboratory,NN,O
testing,NN,O
should,MD,O
be,VB,O
considered,VBN,O
prior,RB,O
to,TO,O
initiating,VBG,O
combination,NN,O
therapy,NN,O
with,IN,O
amprenavir,NN,D
and,CC,O
ritonavir,NN,D
and,CC,O
at,IN,O
periodic,JJ,O
intervals,NNS,O
or,CC,O
if,IN,O
any,DT,O
clinical,JJ,O
signs,NNS,O
or,CC,O
symptoms,NNS,O
of,IN,O
hyperlipidemia,NN,O
or,CC,O
elevated,JJ,O
liver,NN,O
function,NN,O
tests,NNS,O
occur,VBP,O
during,IN,O
therapy,NN,O
.,.,.
,,
for,IN,O
comprehensive,JJ,O
information,NN,O
concerning,VBG,O
laboratory,NN,O
test,NN,O
alterations,NNS,O
associated,VBN,O
with,IN,O
ritonavir,NN,D
",",",",O
physicians,NNS,O
should,MD,O
refer,VB,O
to,TO,O
the,DT,O
complete,JJ,O
prescribing,VBG,O
information,NN,O
for,IN,O
norvir,NN,B
-lrb-,-LRB-,O
ritonavir,NN,D
-rrb-,-RRB-,O
.,.,.
,,
taking,VBG,O
amyl,NN,O
nitrite,NN,D
after,IN,O
drinking,VBG,O
alcohol,NN,D
may,MD,O
worsen,VB,O
side,JJ,O
effects,NNS,O
and,CC,O
may,MD,O
cause,VB,O
severe,JJ,O
hypotension,NN,O
and,CC,O
cardiovascular,JJ,O
collapse,NN,O
.,.,.
,,
limited,JJ,O
pk,NN,O
and/or,CC,O
pd,NN,O
studies,NNS,O
investigating,VBG,O
possible,JJ,O
interactions,NNS,O
between,IN,O
anagrelide,NN,D
and,CC,O
other,JJ,O
medicinal,JJ,O
products,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
in,FW,O
vivo,FW,O
interaction,NN,O
studies,NNS,O
in,IN,O
humans,NNS,O
have,VBP,O
demonstrated,VBN,O
that,IN,O
digoxin,NN,D
and,CC,O
warfarin,NN,D
do,VBP,O
not,RB,O
affect,VB,O
the,DT,O
pk,NN,O
properties,NNS,O
of,IN,O
anagrelide,NN,D
",",",",O
nor,CC,O
does,VBZ,O
anagrelide,NN,D
affect,VB,O
the,DT,O
pk,NN,O
properties,NNS,O
of,IN,O
digoxin,NN,D
or,CC,O
warfarin,NN,D
.,.,.
,,
although,IN,O
additional,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
",",",",O
the,DT,O
most,RBS,O
common,JJ,O
medications,NNS,O
used,VBN,O
concomitantly,RB,O
with,IN,O
anagrelide,NN,D
in,IN,O
clinical,JJ,O
trials,NNS,O
were,VBD,O
aspirin,NN,B
",",",",O
acetaminophen,NN,D
",",",",O
furosemide,NN,D
",",",",O
iron,NN,D
",",",",O
ranitidine,NN,D
",",",",O
hydroxyurea,NN,D
",",",",O
and,CC,O
allopurinol,NN,D
.,.,.
,,
there,EX,O
is,VBZ,O
no,DT,O
clinical,JJ,O
evidence,NN,O
to,TO,O
suggest,VB,O
that,IN,O
anagrelide,NN,D
interacts,VBZ,O
with,IN,O
any,DT,O
of,IN,O
these,DT,O
compounds,NNS,O
.,.,.
,,
an,DT,O
in,FW,O
vivo,FW,O
interaction,NN,O
study,NN,O
in,IN,O
humans,NNS,O
demonstrated,VBD,O
that,IN,O
a,DT,O
single,JJ,O
1mg,JJ,O
dose,NN,O
of,IN,O
anagrelide,NN,D
administered,VBN,O
concomitantly,RB,O
with,IN,O
a,DT,O
single,JJ,O
900,CD,O
mg,NN,O
dose,NN,O
of,IN,O
aspirin,NN,B
was,VBD,O
generally,RB,O
well,RB,O
tolerated,VBN,O
.,.,.
,,
there,EX,O
was,VBD,O
no,DT,O
effect,NN,O
on,IN,O
bleeding,JJ,O
time,NN,O
",",",",O
pt,NN,O
or,CC,O
aptt,NN,O
.,.,.
,,
no,DT,O
clinically,RB,O
relevant,JJ,O
pharmacokinetic,JJ,O
interactions,NNS,O
between,IN,O
anagrelide,NN,D
and,CC,O
acetylsalicylic,JJ,O
acid,NN,O
were,VBD,O
observed,VBN,O
.,.,.
,,
in,IN,O
that,DT,O
same,JJ,O
study,NN,O
",",",",O
aspirin,NN,B
alone,RB,O
produced,VBD,O
a,DT,O
marked,JJ,O
inhibition,NN,O
in,IN,O
platelet,NN,O
aggregation,NN,O
ex,FW,O
vivo,FW,O
.,.,.
,,
anagrelide,NN,D
alone,RB,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
platelet,NN,O
aggregation,NN,O
",",",",O
but,CC,O
did,VBD,O
slightly,RB,O
enhance,VB,O
the,DT,O
inhibition,NN,O
of,IN,O
platelet,NN,O
aggregation,NN,O
by,IN,O
aspirin,NN,B
.,.,.
,,
anagrelide,NNP,D
is,VBZ,O
metabolized,VBN,O
at,IN,O
least,JJS,O
in,IN,O
part,NN,O
by,IN,O
cyp1a2,NN,D
.,.,.
,,
it,PRP,O
is,VBZ,O
known,VBN,O
that,IN,O
cyp1a2,NN,D
is,VBZ,O
inhibited,VBN,O
by,IN,O
several,JJ,O
medicinal,JJ,O
products,NNS,O
",",",",O
including,VBG,O
fluvoxamine,NN,D
",",",",O
and,CC,O
such,JJ,O
medicinal,JJ,O
products,NNS,O
could,MD,O
theoretically,RB,O
adversely,RB,O
influence,VB,O
the,DT,O
clearance,NN,O
of,IN,O
anagrelide,NN,D
.,.,.
,,
anagrelide,NNP,D
demonstrates,VBZ,O
some,DT,O
limited,JJ,O
inhibitory,JJ,O
activity,NN,O
towards,IN,O
cyp1a2,NN,D
which,WDT,O
may,MD,O
present,VB,O
a,DT,O
theoretical,JJ,O
potential,NN,O
for,IN,O
interaction,NN,O
with,IN,O
other,JJ,O
coadministered,JJ,O
medicinal,JJ,O
products,NNS,O
sharing,VBG,O
that,IN,O
clearance,NN,O
mechanism,NN,O
e.g.,FW,O
anagrelide,FW,D
demonstrates,VBZ,O
some,DT,O
limited,JJ,O
inhibitory,JJ,O
activity,NN,O
towards,IN,O
cyp1a2,NN,D
which,WDT,O
may,MD,O
present,VB,O
a,DT,O
theoretical,JJ,O
potential,NN,O
for,IN,O
interaction,NN,O
with,IN,O
other,JJ,O
coadministered,JJ,O
medicinal,JJ,O
products,NNS,O
sharing,VBG,O
that,IN,O
clearance,NN,O
mechanism,NN,O
e.g.,FW,O
theophylline,FW,D
.,.,.
,,
anagrelide,NNP,D
is,VBZ,O
an,DT,O
inhibitor,NN,O
of,IN,O
cyclic,JJ,O
amp,NN,O
pde,NN,O
iii,CD,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
medicinal,JJ,O
products,NNS,O
with,IN,O
similar,JJ,O
properties,NNS,O
such,JJ,O
as,IN,O
inotropes,NNS,O
milrinone,NN,D
",",",",O
enoximone,NN,D
",",",",O
amrinone,NN,D
",",",",O
olprinone,NN,D_n
and,CC,O
cilostazol,NN,D
may,MD,O
be,VB,O
exacerbated,VBN,O
by,IN,O
anagrelide,NN,D
.,.,.
,,
there,EX,O
is,VBZ,O
a,DT,O
single,JJ,O
case,NN,O
report,NN,O
",",",",O
which,WDT,O
suggests,VBZ,O
that,IN,O
sucralfate,NN,D
may,MD,O
interfere,VB,O
with,IN,O
anagrelide,NN,D
absorption,NN,O
.,.,.
,,
food,NNP,O
has,VBZ,O
no,DT,O
clinically,RB,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
bioavailability,NN,O
of,IN,O
anagrelide,NN,D
.,.,.
,,
no,DT,O
drug-drug,NN,O
interaction,NN,O
studies,NNS,O
in,IN,O
human,JJ,O
subjects,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
toxicologic,JJ,O
and,CC,O
toxicokinetic,JJ,O
studies,NNS,O
in,IN,O
rats,NNS,O
did,VBD,O
not,RB,O
demonstrate,VB,O
any,DT,O
alterations,NNS,O
in,IN,O
the,DT,O
clearance,NN,O
or,CC,O
toxicologic,JJ,O
profile,NN,O
of,IN,O
either,CC,O
methotrexate,NN,D
or,CC,O
kineret,NN,B
when,WRB,O
the,DT,O
two,CD,O
agents,NNS,O
were,VBD,O
administered,VBN,O
together,RB,O
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
in,IN,O
which,WDT,O
patients,NNS,O
with,IN,O
active,JJ,O
ra,NN,O
were,VBD,O
treated,VBN,O
for,IN,O
up,RB,O
to,TO,O
24,CD,O
weeks,NNS,O
with,IN,O
concurrent,JJ,O
kineret,NN,B
and,CC,O
etanercept,NN,D
therapy,NN,O
",",",",O
a,DT,O
7,CD,O
%,NN,O
rate,NN,O
of,IN,O
serious,JJ,O
infections,NNS,O
was,VBD,O
observed,VBN,O
",",",",O
which,WDT,O
was,VBD,O
higher,JJR,O
than,IN,O
that,DT,O
observed,VBN,O
with,IN,O
etanercept,NN,D
alone,RB,O
-lrb-,-LRB-,O
0,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
two,CD,O
percent,NN,O
of,IN,O
patients,NNS,O
treated,VBN,O
concurrently,RB,O
with,IN,O
kineret,NN,B
and,CC,O
etanercept,NN,D
developed,VBD,O
neutropenia,NN,O
-lrb-,-LRB-,O
anc,NNP,O
1,CD,O
x,CC,O
109/l,CD,O
-rrb-,-RRB-,O
.,.,.
,,
anastrozole,NNP,D
inhibited,VBD,O
in,FW,O
vitro,FW,O
metabolic,JJ,O
reactions,NNS,O
catalyzed,VBN,O
by,IN,O
cytochromes,NNS,O
p450,NN,O
1a2,NN,O
",",",",O
2c8/9,NN,O
",",",",O
and,CC,O
3a4,NN,O
but,CC,O
only,RB,O
at,IN,O
relatively,RB,O
high,JJ,O
concentrations,NNS,O
.,.,.
,,
anastrozole,NNP,D
did,VBD,O
not,RB,O
inhibit,VB,O
p450,NN,O
2a6,NN,O
or,CC,O
the,DT,O
polymorphic,JJ,O
p450,NN,O
2d6,NN,O
in,IN,O
human,JJ,O
liver,NN,O
microsomes,NNS,O
.,.,.
,,
anastrozole,NNP,D
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
antipyrine,NN,D
.,.,.
,,
although,IN,O
there,EX,O
have,VBP,O
been,VBN,O
no,DT,O
formal,JJ,O
interaction,NN,O
studies,NNS,O
other,JJ,O
than,IN,O
with,IN,O
antipyrine,NN,D
",",",",O
based,VBN,O
on,IN,O
these,DT,O
in,FW,O
vivo,FW,O
and,CC,O
in,FW,O
vitro,FW,O
studies,NNS,O
",",",",O
it,PRP,O
is,VBZ,O
unlikely,JJ,O
that,IN,O
co-administration,NN,O
of,IN,O
a,DT,O
1,CD,O
mg,NN,O
dose,NN,O
of,IN,O
arimidex,NN,B
with,IN,O
other,JJ,O
drugs,NNS,D
will,MD,O
result,VB,O
in,IN,O
clinically,RB,O
significant,JJ,O
drug,NN,D
inhibition,NN,O
of,IN,O
cytochrome,NN,O
p450-mediated,JJ,O
metabolism,NN,O
of,IN,O
the,DT,O
other,JJ,O
drugs,NNS,D
.,.,.
,,
an,DT,O
interaction,NN,O
study,NN,O
with,IN,O
warfarin,NN,D
showed,VBD,O
no,DT,O
clinically,RB,O
significant,JJ,O
effect,NN,O
of,IN,O
anastrozole,NN,D
on,IN,O
warfarin,NN,D
pharmacokinetics,NNS,O
or,CC,O
anticoagulant,JJ,G
activity,NN,O
.,.,.
,,
at,IN,O
a,DT,O
median,JJ,O
follow-up,NN,O
of,IN,O
33,CD,O
months,NNS,O
",",",",O
the,DT,O
combination,NN,O
of,IN,O
arimidex,NNP,B
and,CC,O
tamoxifen,NN,D
did,VBD,O
not,RB,O
demonstrate,VB,O
any,DT,O
efficacy,NN,O
benefit,NN,O
when,WRB,O
compared,VBN,O
with,IN,O
tamoxifen,NN,D
in,IN,O
all,DT,O
patients,NNS,O
as,RB,O
well,RB,O
as,IN,O
in,IN,O
the,DT,O
hormone,NN,O
receptor-positive,JJ,O
subpopulation,NN,O
.,.,.
,,
this,DT,O
treatment,NN,O
arm,NN,O
was,VBD,O
discontinued,VBN,O
from,IN,O
the,DT,O
trial,NN,O
.,.,.
,,
based,VBN,O
on,IN,O
clinical,JJ,O
and,CC,O
pharmacokinetic,JJ,O
results,NNS,O
from,IN,O
the,DT,O
atac,NN,O
trial,NN,O
",",",",O
tamoxifen,NN,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
with,IN,O
anastrozole,NN,D
-lrb-,-LRB-,O
see,VB,O
clinical,NNP,O
pharmacology,NNP,O
drug,NNP,O
interactions,NNS,O
and,CC,O
clinical,JJ,O
pharmacology,NN,O
-,:,O
clinical,JJ,O
studies,NNS,O
-,:,O
adjuvant,JJ,O
treatment,NN,O
of,IN,O
breast,NN,O
cancer,NN,O
in,IN,O
postmenopausal,NNP,O
women,NNP,O
subsections,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
co-administration,NN,O
of,IN,O
anastrozole,NN,D
and,CC,O
tamoxifen,NN,D
resulted,VBD,O
in,IN,O
a,DT,O
reduction,NN,O
of,IN,O
anastrozole,NN,D
plasma,NN,O
levels,NNS,O
by,IN,O
27,CD,O
%,NN,O
compared,VBN,O
with,IN,O
those,DT,O
achieved,VBN,O
with,IN,O
anastrozole,NN,D
alone,RB,O
.,.,.
,,
estrogen-containing,JJ,O
therapies,NNS,O
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
with,IN,O
arimidex,NN,B
as,IN,O
they,PRP,O
may,MD,O
diminish,VB,O
its,PRP$,O
pharmacologic,JJ,O
action,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
no,DT,O
clinically,RB,O
significant,JJ,O
changes,NNS,O
in,IN,O
the,DT,O
results,NNS,O
of,IN,O
clinical,JJ,O
laboratory,NN,O
tests,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
.,.,.
,,
no,DT,O
clinically,RB,O
relevant,JJ,O
drug-drug,JJ,O
interactions,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
with,IN,O
drugs,NNS,D
likely,JJ,O
to,TO,O
be,VB,O
co-administered,VBN,O
with,IN,O
anidulafungin,NN,D
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
observed,VBN,O
when,WRB,O
anileridine,NN,D
is,VBZ,O
coadministered,VBN,O
with,IN,O
other,JJ,O
opioids,NNS,G
",",",",O
sedatives,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
or,CC,O
anesthetics,NNS,G
",",",",O
as,IN,O
these,DT,O
agents,NNS,O
may,MD,O
increase,VB,O
respiratory,JJ,O
and,CC,O
circulatory,JJ,O
depression,NN,O
.,.,.
,,
addition,NN,O
or,CC,O
deletion,NN,O
of,IN,O
any,DT,O
drug,NN,D
from,IN,O
the,DT,O
therapeutic,JJ,O
regimen,NN,O
of,IN,O
patients,NNS,O
receiving,VBG,O
oral,JJ,O
anticoagulants,NNS,G
may,MD,O
affect,VB,O
patient,NN,O
response,NN,O
to,TO,O
the,DT,O
anticoagulant,NN,G
.,.,.
,,
frequent,JJ,O
determination,NN,O
of,IN,O
prothrombin,NN,O
time,NN,O
and,CC,O
close,JJ,O
monitoring,NN,O
of,IN,O
the,DT,O
patient,NN,O
is,VBZ,O
essential,JJ,O
to,TO,O
ascertain,VB,O
when,WRB,O
adjustment,NN,O
of,IN,O
dosage,NN,O
of,IN,O
anticoagulant,NN,G
may,MD,O
be,VB,O
needed,VBN,O
.,.,.
,,
because,IN,O
of,IN,O
the,DT,O
variability,NN,O
of,IN,O
individual,JJ,O
patient,NN,O
response,NN,O
",",",",O
multiple,JJ,O
interacting,VBG,O
mechanisms,NNS,O
with,IN,O
some,DT,O
drugs,NNS,D
",",",",O
the,DT,O
dependency,NN,O
of,IN,O
the,DT,O
extent,NN,O
of,IN,O
the,DT,O
interaction,NN,O
on,IN,O
the,DT,O
dosage,NN,O
and,CC,O
duration,NN,O
of,IN,O
therapy,NN,O
",",",",O
and,CC,O
the,DT,O
possible,JJ,O
administration,NN,O
of,IN,O
several,JJ,O
interacting,VBG,O
drugs,NNS,D
simultaneously,RB,O
",",",",O
it,PRP,O
is,VBZ,O
difficult,JJ,O
to,TO,O
predict,VB,O
the,DT,O
direction,NN,O
and,CC,O
degree,NN,O
of,IN,O
the,DT,O
ultimate,JJ,O
effect,NN,O
of,IN,O
concomitant,JJ,O
medications,NNS,O
on,IN,O
anticoagulant,JJ,G
response,NN,O
.,.,.
,,
for,IN,O
example,NN,O
",",",",O
since,IN,O
cholestyramine,NN,D
may,MD,O
reduce,VB,O
the,DT,O
gastrointestinal,JJ,O
absorption,NN,O
of,IN,O
both,CC,O
the,DT,O
oral,JJ,O
anticoagulants,NNS,G
and,CC,O
vitamin,NN,G
k,NN,O
",",",",O
the,DT,O
net,JJ,O
effects,NNS,O
are,VBP,O
unpredictable,JJ,O
.,.,.
,,
chloral,JJ,O
hydrate,NN,O
may,MD,O
cause,VB,O
an,DT,O
increased,VBN,O
prothrombin,NN,O
response,NN,O
by,IN,O
displacing,VBG,O
the,DT,O
anticoagulant,NN,G
from,IN,O
protein,NN,O
binding,NN,O
sites,NNS,O
or,CC,O
a,DT,O
diminished,VBN,O
prothrombin,NN,O
response,NN,O
through,IN,O
increased,VBN,O
metabolism,NN,O
of,IN,O
the,DT,O
unbound,JJ,O
drug,NN,D
by,IN,O
hepatic,JJ,O
enzyme,NN,O
induction,NN,O
",",",",O
thus,RB,O
leading,VBG,O
to,TO,O
inter-patient,JJ,O
variation,NN,O
in,IN,O
ultimate,JJ,O
prothrombin,NN,O
effect,NN,O
.,.,.
,,
an,DT,O
interacting,VBG,O
drug,NN,D
which,WDT,O
leads,VBZ,O
to,TO,O
a,DT,O
decrease,NN,O
in,IN,O
prothrombin,NN,O
time,NN,O
necessitating,VBG,O
an,DT,O
increased,VBN,O
dose,NN,O
of,IN,O
oral,JJ,O
anticoagulant,NN,G
to,TO,O
maintain,VB,O
an,DT,O
adequate,JJ,O
degree,NN,O
of,IN,O
anticoagulation,NN,O
may,MD,O
",",",",O
if,IN,O
abruptly,RB,O
discontinued,VBN,O
",",",",O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
subsequent,JJ,O
bleeding,NN,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
diminish,VB,O
oral,JJ,O
anticoagulant,JJ,G
response,NN,O
",",",",O
ie,FW,O
",",",",O
decreased,VBD,O
prothrom-bin,NN,O
time,NN,O
response,NN,O
",",",",O
in,IN,O
man,NN,O
significantly,RB,O
include,VBP,O
:,:,O
adrenocortical,JJ,O
steroids,NNS,G
.,.,.
,,
alcohol,NN,D
*,SYM,O
.,.,.
,,
antacids,NNS,G
.,.,.
,,
antihistamines,NNS,G
.,.,.
,,
barbiturates,NNS,G
.,.,.
,,
carbamazepine,NN,D
.,.,.
,,
chloral,JJ,O
hydrate,NN,O
*,NN,O
.,.,.
,,
chlordiazepoxide,NN,D
.,.,.
,,
cholestyramine,NN,D
.,.,.
,,
diet,NN,O
high,JJ,O
in,IN,O
vitamin,NN,G
k.,NNP,O
diuretics,NNS,G
*,SYM,O
.,.,.
,,
ethchlorvynol,NN,D
.,.,.
,,
glutethimide,NN,D
.,.,.
,,
griseofulvin,NN,D
.,.,.
,,
haloperidol,NN,D
.,.,.
,,
meprobamate,NN,D
.,.,.
,,
oral,JJ,O
contraceptives,NNS,G
.,.,.
,,
paraldehyde,NN,D
.,.,.
,,
primidone,NN,D
.,.,.
,,
ranitidine,NN,D
*,SYM,O
.,.,.
,,
rifampin,NN,D
.,.,.
,,
unreliable,JJ,O
prothrombin,NN,O
time,NN,O
determinations,NNS,O
;,:,O
.,.,.
,,
vitamin,NN,G
c.,NN,O
drugs,NNS,O
that,WDT,O
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
diminish,VB,O
oral,JJ,O
anticoagulant,JJ,G
response,NN,O
",",",",O
ie,FW,O
",",",",O
decreased,VBD,O
prothrom-bin,NN,O
time,NN,O
response,NN,O
",",",",O
in,IN,O
man,NN,O
significantly,RB,O
include,VBP,O
:,:,O
adrenocortical,JJ,O
steroids,NNS,G
;,:,O
alcohol,NN,D
*,SYM,O
;,:,O
antacids,NNS,G
;,:,O
antihistamines,NNS,G
;,:,O
barbiturates,NNS,G
;,:,O
carbamazepine,NN,D
;,:,O
chloral,JJ,O
hydrate,NN,O
*,NN,O
;,:,O
chlordiazepoxide,NN,D
;,:,O
cholestyramine,NN,D
;,:,O
diet,NN,O
high,JJ,O
in,IN,O
vitamin,NN,G
k,NN,O
;,:,O
diuretics,NNS,G
*,SYM,O
;,:,O
ethchlorvynol,NN,D
;,:,O
glutethimide,NN,D
;,:,O
griseofulvin,NN,D
;,:,O
haloperidol,NN,D
;,:,O
meprobamate,NN,D
;,:,O
oral,JJ,O
contraceptives,NNS,G
;,:,O
paraldehyde,NN,D
;,:,O
primidone,NN,D
;,:,O
ranitidine,NN,D
*,SYM,O
;,:,O
rifampin,NN,D
;,:,O
unreliable,JJ,O
prothrombin,NN,O
time,NN,O
determinations,NNS,O
;,:,O
vitamin,NN,G
c,NN,O
;,:,O
warfarin,NN,D
sodium,NN,O
under-dosage,NN,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
reportedly,RB,O
may,MD,O
increase,VB,O
oral,JJ,O
anticoagulant,JJ,G
response,NN,O
",",",",O
ie,FW,O
",",",",O
increased,VBD,O
prothrombin,NN,O
response,NN,O
",",",",O
in,IN,O
man,NN,O
include,VBP,O
:,:,O
alcohol,NN,D
*,NN,O
.,.,.
,,
allopurinol,NN,D
.,.,.
,,
aminosalicylic,JJ,O
acid,NN,O
.,.,.
,,
amiodarone,NN,D
.,.,.
,,
anabolic,JJ,O
steroids,NNS,G
.,.,.
,,
antibiotics,NNS,G
.,.,.
,,
bromelains,NNS,D
.,.,.
,,
chloral,JJ,O
hydrate,NN,O
*,NN,O
.,.,.
,,
chlorpropamide,NN,D
.,.,.
,,
chymotrypsin,NN,D
.,.,.
,,
cimetidine,NN,D
.,.,.
,,
cinchophen,NN,D
.,.,.
,,
clofibrate,NN,D
.,.,.
,,
dextran,NN,D
.,.,.
,,
dextrothyroxine,NN,D
.,.,.
,,
diazoxide,NN,D
.,.,.
,,
dietary,JJ,O
deficiencies,NNS,O
;,:,O
.,.,.
,,
diflunisal,NN,D
.,.,.
,,
diuretics,NNS,G
*,SYM,O
.,.,.
,,
disulfiram,NN,D
.,.,.
,,
drugs,NNS,D
affecting,VBG,O
blood,NN,O
elements,NNS,O
;,:,O
.,.,.
,,
ethacrynic,JJ,O
acid,NN,O
.,.,.
,,
fenoprofen,NN,D
.,.,.
,,
glucagon,NN,D
.,.,.
,,
hepatotoxic,JJ,O
drugs,NNS,D
;,:,O
.,.,.
,,
ibuprofen,NN,D
.,.,.
,,
indomethacin,NN,D
.,.,.
,,
influenza,NN,O
virus,NN,O
vaccine,NN,O
.,.,.
,,
inhalation,NN,O
anesthetics,NNS,G
.,.,.
,,
mefenamic,JJ,O
acid,NN,O
.,.,.
,,
methyldopa,NN,D
.,.,.
,,
methylphenidate,NN,D
.,.,.
,,
metronidazole,NN,D
.,.,.
,,
miconazole,NN,D
.,.,.
,,
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
.,.,.
,,
nalidixic,JJ,O
acid,NN,O
.,.,.
,,
naproxen,NN,D
.,.,.
,,
oxolinic,JJ,O
acid,NN,O
.,.,.
,,
oxyphenbutazone,NN,D
.,.,.
,,
pentoxifylline,NN,D
.,.,.
,,
phenylbutazone,NN,D
.,.,.
,,
phenyramidol,NN,D_n
.,.,.
,,
phenytoin,NN,D
.,.,.
,,
prolonged,JJ,O
hot,JJ,O
weather,NN,O
;,:,O
.,.,.
,,
prolonged,JJ,O
narcotics,NNS,G
.,.,.
,,
pyrazolones,NNS,G
.,.,.
,,
quinidine,NN,D
.,.,.
,,
quinine,NN,D
.,.,.
,,
ranitidine,NN,D
*,SYM,O
.,.,.
,,
salicylates,NNS,G
;,:,O
sulfinpyrazone,NN,D
.,.,.
,,
sulfonamides,NNS,G
",",",",O
long,RB,O
acting,VBG,O
.,.,.
,,
sulindac,NN,D
.,.,.
,,
thyroid,NN,G
drugs,NNS,D
.,.,.
,,
tolbutamide,NN,D
.,.,.
,,
triclofos,NNS,O
sodium,NN,O
.,.,.
,,
trimethoprim/sulfamethoxazole,NN,O
.,.,.
,,
unreliable,JJ,O
prothrombin,NN,O
time,NN,O
determinations,NNS,O
;,:,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
reportedly,RB,O
may,MD,O
increase,VB,O
oral,JJ,O
anticoagulant,JJ,G
response,NN,O
",",",",O
ie,FW,O
",",",",O
increased,VBD,O
prothrombin,NN,O
response,NN,O
",",",",O
in,IN,O
man,NN,O
include,VBP,O
:,:,O
alcohol,NN,D
*,SYM,O
;,:,O
allopurinol,NN,D
;,:,O
aminosalicylic,JJ,O
acid,NN,O
;,:,O
amiodarone,NN,D
;,:,O
anabolic,JJ,O
steroids,NNS,G
;,:,O
antibiotics,NNS,G
;,:,O
bromelains,NNS,D
;,:,O
chloral,JJ,O
hydrate,NN,O
*,NN,O
;,:,O
chlorpropamide,NN,D
;,:,O
chymotrypsin,NN,D
;,:,O
cimetidine,NN,D
;,:,O
cinchophen,NN,D
;,:,O
clofibrate,NN,D
;,:,O
dextran,NN,D
;,:,O
dextrothyroxine,NN,D
;,:,O
diazoxide,NN,D
;,:,O
dietary,JJ,O
deficiencies,NNS,O
;,:,O
diflunisal,NN,D
;,:,O
disulfiram,NN,D
;,:,O
drugs,NNS,D
affecting,VBG,O
blood,NN,O
elements,NNS,O
;,:,O
ethacrynic,JJ,O
acid,NN,O
;,:,O
fenoprofen,NN,D
;,:,O
glucagon,NN,D
;,:,O
hepatotoxic,JJ,O
drugs,NNS,D
;,:,O
ibuprofen,NN,D
;,:,O
indomethacin,NN,D
;,:,O
influenza,NN,O
virus,NN,O
vaccine,NN,O
;,:,O
inhalation,NN,O
anesthetics,NNS,G
;,:,O
mefenamic,JJ,O
acid,NN,O
;,:,O
methyldopa,NN,D
;,:,O
methylphenidate,NN,D
;,:,O
metronidazole,NN,D
;,:,O
miconazole,NN,D
;,:,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
;,:,O
nalidixic,JJ,O
acid,NN,O
;,:,O
naproxen,NN,D
;,:,O
oxolinic,JJ,O
acid,NN,O
;,:,O
oxyphenbutazone,NN,D
;,:,O
pentoxifylline,NN,D
;,:,O
phenylbutazone,NN,D
;,:,O
phenyramidol,NN,D_n
;,:,O
phenytoin,NN,D
;,:,O
prolonged,JJ,O
hot,JJ,O
weather,NN,O
;,:,O
prolonged,JJ,O
narcotics,NNS,G
;,:,O
pyrazolones,NNS,G
;,:,O
quinidine,NN,D
;,:,O
quinine,NN,D
;,:,O
ranitidine,NN,D
*,SYM,O
;,:,O
salicylates,NNS,G
;,:,O
sulfinpyrazone,NN,D
;,:,O
sulfonamides,NNS,G
",",",",O
long,RB,O
acting,VBG,O
;,:,O
sulindac,NN,D
;,:,O
thyroid,NN,G
drugs,NNS,D
;,:,O
tolbutamide,NN,D
;,:,O
triclofos,NNS,O
sodium,NN,O
;,:,O
trimethoprim/sulfamethoxazole,NN,O
;,:,O
unreliable,JJ,O
prothrombin,NN,O
time,NN,O
determinations,NNS,O
;,:,O
warfarin,NN,D
sodium,NN,O
overdosage,NN,O
.,.,.
,,
oral,JJ,O
anticoagulants,NNS,G
may,MD,O
potentiate,VB,O
the,DT,O
hypoglycemic,JJ,G
action,NN,O
of,IN,O
hypoglycemic,JJ,G
agents,NNS,O
",",",",O
eg,FW,O
",",",",O
tolbutamide,NN,D
and,CC,O
chlorpropamide,NN,D
",",",",O
by,IN,O
inhibiting,VBG,O
their,PRP$,O
metabolism,NN,O
in,IN,O
the,DT,O
liver,NN,O
.,.,.
,,
because,IN,O
oral,JJ,O
anticoagulants,NNS,G
may,MD,O
interfere,VB,O
with,IN,O
the,DT,O
hepatic,JJ,O
metabolism,NN,O
of,IN,O
phenytoin,NN,D
",",",",O
toxic,JJ,O
levels,NNS,O
of,IN,O
the,DT,O
anticonvulsant,NN,G
may,MD,O
occur,VB,O
when,WRB,O
an,DT,O
oral,JJ,O
anticoagulant,NN,G
and,CC,O
phenytoin,NN,D
are,VBP,O
administered,VBN,O
concurrently,RB,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
reduce,VBP,O
the,DT,O
number,NN,O
of,IN,O
blood,NN,O
platelets,NNS,O
by,IN,O
causing,VBG,O
bone,NN,O
marrow,NN,O
depression,NN,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
antineoplastic,JJ,O
agents,NNS,O
-rrb-,-RRB-,O
or,CC,O
drugs,NNS,D
which,WDT,O
inhibit,VBP,O
platelet,NN,O
function,NN,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
aspirin,NN,B
and,CC,O
other,JJ,O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
",",",",O
dipyridamole,NN,D
",",",",O
hydrochloroquine,NN,D
",",",",O
clofibrate,NN,D
",",",",O
dextran,NN,D
-rrb-,-RRB-,O
may,MD,O
increase,VB,O
the,DT,O
bleeding,NN,O
tendency,NN,O
produced,VBN,O
by,IN,O
anticoagulants,NNS,G
without,IN,O
altering,VBG,O
prothrombin,NN,O
time,NN,O
determinations,NNS,O
.,.,.
,,
the,DT,O
beneficial,JJ,O
effects,NNS,O
on,IN,O
arterial,JJ,O
thrombus,NN,O
formation,NN,O
from,IN,O
combined,JJ,O
therapy,NN,O
with,IN,O
antiplatelet,JJ,O
and,CC,O
anticoagulant,JJ,G
medication,NN,O
must,MD,O
be,VB,O
weighed,VBN,O
against,IN,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
inducing,VBG,O
hemorrhage,NN,O
.,.,.
,,
*,SYM,O
increased,VBN,O
and,CC,O
decreased,VBN,O
prothrombin,NN,O
time,NN,O
responses,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interferences,NNS,O
:,:,O
dicumarol,NN,D
and,CC,O
indanedione,NN,O
anticoagulants,NNS,G
",",",",O
including,VBG,O
anisindione,NN,D
",",",",O
or,CC,O
their,PRP$,O
metabolites,NNS,O
may,MD,O
color,VB,O
alkaline,NN,O
urine,NN,O
red-orange,NN,O
",",",",O
which,WDT,O
may,MD,O
interfere,VB,O
with,IN,O
spectrophotometrically,RB,O
determined,VBN,O
urinary,JJ,O
laboratory,NN,O
tests,NNS,O
.,.,.
,,
the,DT,O
color,NN,O
reverses,VBZ,O
when,WRB,O
the,DT,O
test,NN,O
sample,NN,O
is,VBZ,O
acidified,VBN,O
in,FW,O
vitro,FW,O
to,TO,O
a,DT,O
ph,NN,O
below,IN,O
4,CD,O
.,.,.
,,
5ht3,NN,O
antagonists,NNS,O
:,:,O
based,VBN,O
on,IN,O
reports,NNS,O
of,IN,O
profound,JJ,O
hypotension,NN,O
and,CC,O
loss,NN,O
of,IN,O
consciousness,NN,O
when,WRB,O
apomorphine,NN,D
was,VBD,O
administered,VBN,O
with,IN,O
ondansetron,NN,D
",",",",O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
apomorphine,NN,D
with,IN,O
drugs,NNS,D
of,IN,O
the,DT,O
5ht3,NN,O
antagonist,NN,O
class,NN,O
-lrb-,-LRB-,O
including,VBG,O
",",",",O
for,IN,O
example,NN,O
",",",",O
ondansetron,NN,D
",",",",O
granisetron,NN,D
",",",",O
dolasetron,NN,D
",",",",O
palonosetron,NN,D
",",",",O
and,CC,O
alosetron,NN,D
-rrb-,-RRB-,O
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
antihypertensive,JJ,G
medications,NNS,O
and,CC,O
vasodilators,NNS,G
:,:,O
the,DT,O
following,VBG,O
adverse,JJ,O
events,NNS,O
were,VBD,O
experienced,VBN,O
more,RBR,O
commonly,RB,O
in,IN,O
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
antihypertensive,JJ,G
medications,NNS,O
or,CC,O
vasodilators,NNS,G
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
94,CD,O
-rrb-,-RRB-,O
compared,VBN,O
to,TO,O
patients,NNS,O
not,RB,O
receiving,VBG,O
these,DT,O
concomitant,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
456,CD,O
-rrb-,-RRB-,O
:,:,O
hypotension,NN,O
10,CD,O
%,NN,O
vs,CC,O
4,CD,O
%,NN,O
",",",",O
myocardial,JJ,O
infarction,NN,O
3,CD,O
%,NN,O
vs,CC,O
1,CD,O
%,NN,O
",",",",O
serious,JJ,O
pneumonia,NN,O
5,CD,O
%,NN,O
vs,CC,O
3,CD,O
%,NN,O
",",",",O
serious,JJ,O
falls,VBZ,O
9,CD,O
%,NN,O
vs,CC,O
3,CD,O
%,NN,O
",",",",O
and,CC,O
bone,NN,O
and,CC,O
joint,JJ,O
injuries,NNS,O
6,CD,O
%,NN,O
vs,CC,O
2,CD,O
%,NN,O
.,.,.
,,
the,DT,O
mechanism,NN,O
underlying,VBG,O
many,JJ,O
of,IN,O
these,DT,O
events,NNS,O
is,VBZ,O
unknown,JJ,O
",",",",O
but,CC,O
may,MD,O
represent,VB,O
increased,VBN,O
hypotension,NN,O
.,.,.
,,
dopamine,NN,D
antagonists,NNS,O
:,:,O
since,IN,O
apomorphine,NN,D
is,VBZ,O
a,DT,O
dopamine,NN,D
agonist,NN,O
",",",",O
it,PRP,O
is,VBZ,O
possible,JJ,O
that,IN,O
dopamine,NN,D
antagonists,NNS,O
",",",",O
such,JJ,O
as,IN,O
the,DT,O
neuroleptics,NNS,G
-lrb-,-LRB-,O
phenothiazines,NNS,G
",",",",O
butyrophenones,NNS,G
",",",",O
thioxanthenes,NNS,G
-rrb-,-RRB-,O
or,CC,O
metoclopramide,NN,D
",",",",O
may,MD,O
diminish,VB,O
the,DT,O
effectiveness,NN,O
of,IN,O
apokyn,NNP,B
.,.,.
,,
patients,NNS,O
with,IN,O
major,JJ,O
psychotic,JJ,O
disorders,NNS,O
",",",",O
treated,VBN,O
with,IN,O
neuroleptics,NNS,G
",",",",O
should,MD,O
be,VB,O
treated,VBN,O
with,IN,O
dopamine,NN,D
agonists,NNS,O
only,RB,O
if,IN,O
the,DT,O
potential,JJ,O
benefits,NNS,O
outweigh,VBP,O
the,DT,O
risks,NNS,O
.,.,.
,,
drugs,NNS,O
prolonging,VBG,O
the,DT,O
qt/qtc,NNP,O
interval,NNP,O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
prescribing,VBG,O
apomorphine,NN,D
concomitantly,RB,O
with,IN,O
drugs,NNS,D
that,WDT,O
prolong,VBP,O
the,DT,O
qt/qtc,JJ,O
interval,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
there,EX,O
are,VBP,O
no,DT,O
known,JJ,O
interactions,NNS,O
between,IN,O
apokyn,NNP,B
and,CC,O
laboratory,NN,O
tests,NNS,O
.,.,.
,,
apraclonidine,NN,D
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
mao,NNP,O
inhibitors,NNS,O
.,.,.
,,
although,IN,O
no,DT,O
specific,JJ,O
drug,NN,D
interactions,NNS,O
with,IN,O
topical,JJ,O
glaucoma,NN,O
drugs,NNS,D
or,CC,O
systemic,JJ,O
medications,NNS,O
were,VBD,O
identified,VBN,O
in,IN,O
clinical,JJ,O
studies,NNS,O
of,IN,O
iopidine,NNP,B
0.5,CD,O
%,NN,O
ophthalmic,JJ,O
solution,NN,O
",",",",O
the,DT,O
possibility,NN,O
of,IN,O
an,DT,O
additive,JJ,O
or,CC,O
potentiating,NN,O
effect,NN,O
with,IN,O
cns,NN,O
depressants,NNS,O
-lrb-,-LRB-,O
alcohol,NN,D
",",",",O
barbiturates,NNS,G
",",",",O
opiates,NNS,G
",",",",O
sedatives,NNS,G
",",",",O
anesthetics,NNS,G
-rrb-,-RRB-,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
tricyclic,JJ,O
antidepressants,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
blunt,VB,O
the,DT,O
hypotensive,JJ,O
effect,NN,O
of,IN,O
systemic,JJ,O
clonidine,NN,D
.,.,.
,,
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
whether,IN,O
the,DT,O
concurrent,JJ,O
use,NN,O
of,IN,O
these,DT,O
agents,NNS,O
with,IN,O
apraclonidine,NN,D
can,MD,O
lead,VB,O
to,TO,O
a,DT,O
reduction,NN,O
in,IN,O
iop,NNP,O
lowering,VBG,O
effect,NN,O
.,.,.
,,
no,DT,O
data,NNS,O
on,IN,O
the,DT,O
level,NN,O
of,IN,O
circulating,VBG,O
catecholamines,NNS,G
after,IN,O
apraclonidine,NN,D
withdrawal,NN,O
are,VBP,O
available,JJ,O
.,.,.
,,
caution,NN,O
",",",",O
however,RB,O
",",",",O
is,VBZ,O
advised,VBN,O
in,IN,O
patients,NNS,O
taking,VBG,O
tricyclic,JJ,G
antidepressants,NNS,G
which,WDT,O
can,MD,O
affect,VB,O
the,DT,O
metabolism,NN,O
and,CC,O
uptake,NN,O
of,IN,O
circulating,VBG,O
amines,NNS,O
.,.,.
,,
an,DT,O
additive,JJ,O
hypotensive,JJ,O
effect,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
with,IN,O
the,DT,O
combination,NN,O
of,IN,O
systemic,JJ,O
clonidine,NN,D
and,CC,O
neuroleptic,JJ,G
therapy,NN,O
.,.,.
,,
systemic,JJ,O
clonidine,NN,D
may,MD,O
inhibit,VB,O
the,DT,O
production,NN,O
of,IN,O
catecholamines,NNS,G
in,IN,O
response,NN,O
to,TO,O
insulin-induced,JJ,O
hypoglycemia,NN,O
and,CC,O
mask,NN,O
the,DT,O
signs,NNS,O
and,CC,O
symptoms,NNS,O
of,IN,O
hypoglycemia,NN,O
.,.,.
,,
since,IN,O
apraclonidine,NN,D
may,MD,O
reduce,VB,O
pulse,NN,O
and,CC,O
blood,NN,O
pressure,NN,O
",",",",O
caution,NN,O
in,IN,O
using,VBG,O
drugs,NNS,D
such,JJ,O
as,IN,O
beta-blockers,NNS,G
-lrb-,-LRB-,O
ophthalmic,JJ,O
and,CC,O
systemic,JJ,O
-rrb-,-RRB-,O
",",",",O
antihypertensives,NNS,D
",",",",O
and,CC,O
cardiac,JJ,O
glycosides,NNS,G
is,VBZ,O
advised,VBN,O
.,.,.
,,
patients,NNS,O
using,VBG,O
cardiovascular,JJ,O
drugs,NNS,D
concurrently,RB,O
with,IN,O
iopidine,NN,B
0.5,CD,O
%,NN,O
ophthalmic,JJ,O
solution,NN,O
should,MD,O
have,VB,O
pulse,NN,O
and,CC,O
blood,NN,O
pressures,NNS,O
frequently,RB,O
monitored,VBD,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
with,IN,O
simultaneous,JJ,O
use,NN,O
of,IN,O
clonidine,NN,D
and,CC,O
other,JJ,O
similar,JJ,O
pharmacologic,JJ,O
agent,NN,O
.,.,.
,,
aprepitant,NN,D
is,VBZ,O
a,DT,O
substrate,NN,O
",",",",O
a,DT,O
moderate,JJ,O
inhibitor,NN,O
",",",",O
and,CC,O
an,DT,O
inducer,NN,O
of,IN,O
cyp3a4,NN,D
.,.,.
,,
aprepitant,NN,D
is,VBZ,O
also,RB,O
an,DT,O
inducer,NN,O
of,IN,O
cyp2c9,NN,D
.,.,.
,,
effect,NN,O
of,IN,O
aprepitant,NN,D
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
other,JJ,O
agent,NN,O
.,.,.
,,
as,IN,O
a,DT,O
moderate,JJ,O
inhibitor,NN,O
of,IN,O
cyp3a4,NN,D
",",",",O
aprepitant,NN,D
can,MD,O
increase,VB,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
coadministered,JJ,O
medicinal,JJ,O
products,NNS,O
that,WDT,O
are,VBP,O
metabolized,VBN,O
through,IN,O
cyp3a4,NN,D
.,.,.
,,
aprepitant,NN,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
induce,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
s,NN,O
-lrb-,-LRB-,O
-,:,O
-rrb-,-RRB-,O
warfarin,NN,D
and,CC,O
tolbutamide,NN,D
",",",",O
which,WDT,O
are,VBP,O
metabolized,VBN,O
through,IN,O
cyp2c9,NN,D
.,.,.
,,
coadministration,NN,O
of,IN,O
aprepitant,JJ,D
with,IN,O
these,DT,O
drugs,NNS,D
or,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
known,VBN,O
to,TO,O
be,VB,O
metabolized,VBN,O
by,IN,O
cyp2c9,NN,D
",",",",O
such,JJ,O
as,IN,O
phenytoin,NN,D
",",",",O
may,MD,O
result,VB,O
in,IN,O
lower,JJR,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
aprepitant,NN,D
is,VBZ,O
unlikely,JJ,O
to,TO,O
interact,VB,O
with,IN,O
drugs,NNS,D
that,WDT,O
are,VBP,O
substrates,NNS,O
for,IN,O
the,DT,O
p-glycoprotein,NN,O
transporter,NN,O
",",",",O
as,IN,O
demonstrated,VBN,O
by,IN,O
the,DT,O
lack,NN,O
of,IN,O
interaction,NN,O
of,IN,O
aprepitant,JJ,D
with,IN,O
digoxin,NN,D
in,IN,O
a,DT,O
clinical,JJ,O
drug,NN,D
interaction,NN,O
study,NN,O
.,.,.
,,
5-ht3,NN,O
antagonists,NNS,O
:,:,O
in,IN,O
clinical,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
",",",",O
aprepitant,NN,D
did,VBD,O
not,RB,O
have,VB,O
clinically,RB,O
important,JJ,O
effects,NNS,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
ondansetron,NN,D
or,CC,O
granisetron,NN,D
.,.,.
,,
no,DT,O
clinical,JJ,O
or,CC,O
drug,NN,D
interaction,NN,O
study,NN,O
was,VBD,O
conducted,VBN,O
with,IN,O
dolasetron,NN,D
.,.,.
,,
corticosteroids,NNS,G
:,:,O
dexamethasone,NN,D
:,:,O
aprepitant,NN,D
",",",",O
when,WRB,O
given,VBN,O
as,IN,O
a,DT,O
regimen,NN,O
of,IN,O
125mg,NN,O
with,IN,O
dexamethasone,NN,D
coadministered,VBN,O
orally,RB,O
as,IN,O
20,CD,O
mg,NN,O
on,IN,O
day,NN,O
1,CD,O
",",",",O
and,CC,O
aprepitant,NN,D
when,WRB,O
given,VBN,O
as,IN,O
80,CD,O
mg/day,NN,O
with,IN,O
dexamethasone,NN,D
coadministered,VBN,O
orally,RB,O
as,IN,O
8,CD,O
mg,NN,O
on,IN,O
days,NNS,O
2,CD,O
through,IN,O
5,CD,O
",",",",O
increased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
dexamethasone,NN,D
",",",",O
a,DT,O
cyp3a4,NN,D
substrate,NN,O
by,IN,O
2.2-fold,JJ,O
",",",",O
on,IN,O
days,NNS,O
1,CD,O
and,CC,O
5,CD,O
.,.,.
,,
the,DT,O
oral,JJ,O
dexamethasone,NN,D
doses,NNS,O
should,MD,O
be,VB,O
reduced,VBN,O
by,IN,O
approximately,RB,O
50,CD,O
%,NN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
aprepitant,NN,D
",",",",O
to,TO,O
achieve,VB,O
exposures,NNS,O
of,IN,O
dexamethasone,NN,D
similar,JJ,O
to,TO,O
those,DT,O
obtained,VBN,O
when,WRB,O
it,PRP,O
is,VBZ,O
given,VBN,O
without,IN,O
aprepitant,NN,D
.,.,.
,,
the,DT,O
daily,JJ,O
dose,NN,O
of,IN,O
dexamethasone,NN,D
administered,VBN,O
in,IN,O
clinical,JJ,O
studies,NNS,O
with,IN,O
aprepitant,NN,D
reflects,VBZ,O
an,DT,O
approximate,JJ,O
50,CD,O
%,NN,O
reduction,NN,O
of,IN,O
the,DT,O
dose,NN,O
of,IN,O
dexamethasone,NN,D
.,.,.
,,
methylprednisolon,NNP,O
.,.,.
,,
aprepitant,NNP,D
",",",",O
when,WRB,O
given,VBN,O
as,IN,O
a,DT,O
regimen,NN,O
of,IN,O
125,CD,O
mg,NN,O
on,IN,O
day,NN,O
1,CD,O
and,CC,O
80,CD,O
mg/day,NN,O
on,IN,O
days,NNS,O
2,CD,O
and,CC,O
3,CD,O
",",",",O
increased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
methylprednisolone,NN,D
",",",",O
a,DT,O
cyp3a4,NN,D
substrate,NN,O
",",",",O
by,IN,O
1.34-fold,JJ,O
on,IN,O
day,NN,O
1,CD,O
and,CC,O
by,IN,O
2.5-fold,RB,O
on,IN,O
day,NN,O
3,CD,O
",",",",O
when,WRB,O
methylprednisolone,NN,D
was,VBD,O
coadministered,VBN,O
intravenously,RB,O
as,IN,O
125,CD,O
mg,NN,O
on,IN,O
day,NN,O
1,CD,O
and,CC,O
orally,RB,O
as,IN,O
40,CD,O
mg,NN,O
on,IN,O
days,NNS,O
2,CD,O
and,CC,O
3,CD,O
.,.,.
,,
the,DT,O
iv,CD,O
methylprednisolone,NN,D
dose,NN,O
should,MD,O
be,VB,O
reduced,VBN,O
by,IN,O
approximately,RB,O
25,CD,O
%,NN,O
",",",",O
and,CC,O
the,DT,O
oral,JJ,O
methylprednisolone,NN,D
dose,NN,O
should,MD,O
be,VB,O
reduced,VBN,O
by,IN,O
approximately,RB,O
50,CD,O
%,NN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
aprepitant,NN,D
to,TO,O
achieve,VB,O
exposures,NNS,O
of,IN,O
methylprednisolone,NN,D
similar,JJ,O
to,TO,O
those,DT,O
obtained,VBN,O
when,WRB,O
it,PRP,O
is,VBZ,O
given,VBN,O
without,IN,O
aprepitant,NN,D
.,.,.
,,
warfarin,NNP,D
:,:,O
a,NNP,O
single,JJ,O
125-mg,JJ,O
dose,NN,O
of,IN,O
aprepitant,NN,D
was,VBD,O
administered,VBN,O
on,IN,O
day,NN,O
1,CD,O
and,CC,O
80,CD,O
mg/day,NN,O
on,IN,O
days,NNS,O
2,CD,O
and,CC,O
3,CD,O
to,TO,O
healthy,JJ,O
subjects,NNS,O
who,WP,O
were,VBD,O
stabilized,VBN,O
on,IN,O
chronic,JJ,O
warfarin,NN,D
therapy,NN,O
.,.,.
,,
although,IN,O
there,EX,O
was,VBD,O
no,DT,O
effect,NN,O
of,IN,O
aprepitant,NN,D
on,IN,O
the,DT,O
plasma,NN,O
auc,NN,O
of,IN,O
r,NN,O
-lrb-,-LRB-,O
+,CC,O
-rrb-,-RRB-,O
or,CC,O
s,NN,O
-lrb-,-LRB-,O
-,:,O
-rrb-,-RRB-,O
warfarin,NN,D
determined,VBN,O
on,IN,O
day,NN,O
3,CD,O
",",",",O
there,EX,O
was,VBD,O
a,DT,O
34,CD,O
%,NN,O
decrease,NN,O
in,IN,O
s,NN,O
-lrb-,-LRB-,O
-,:,O
-rrb-,-RRB-,O
warfarin,NN,D
-lrb-,-LRB-,O
a,DT,O
cyp2c9,NN,D
substrate,NN,O
-rrb-,-RRB-,O
trough,NN,O
concentration,NN,O
accompanied,VBN,O
by,IN,O
a,DT,O
14,CD,O
%,NN,O
decrease,NN,O
in,IN,O
the,DT,O
prothrombin,NN,O
time,NN,O
-lrb-,-LRB-,O
reported,VBN,O
as,IN,O
international,NNP,O
normalized,NNP,O
ratio,NNP,O
or,CC,O
inr,NNP,O
-rrb-,-RRB-,O
5,CD,O
days,NNS,O
after,IN,O
completion,NN,O
of,IN,O
dosing,NN,O
with,IN,O
aprepitant,NN,D
.,.,.
,,
in,IN,O
patients,NNS,O
on,IN,O
chronic,JJ,O
warfarin,NN,D
therapy,NN,O
",",",",O
the,DT,O
prothrombin,NN,O
time,NN,O
-lrb-,-LRB-,O
inr,NN,O
-rrb-,-RRB-,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
in,IN,O
the,DT,O
2-week,JJ,O
period,NN,O
",",",",O
particularly,RB,O
at,IN,O
7,CD,O
to,TO,O
10,CD,O
days,NNS,O
",",",",O
following,VBG,O
initiation,NN,O
of,IN,O
the,DT,O
3-day,JJ,O
regimen,NN,O
of,IN,O
aprepitant,JJ,D
with,IN,O
each,DT,O
chemotherapy,NN,O
cycle,NN,O
.,.,.
,,
tolbutamide,NNP,D
:,:,O
aprepitant,NN,D
",",",",O
when,WRB,O
given,VBN,O
as,IN,O
125,CD,O
mg,NN,O
on,IN,O
day,NN,O
1,CD,O
and,CC,O
80,CD,O
mg/day,NN,O
on,IN,O
days,NNS,O
2,CD,O
and,CC,O
3,CD,O
",",",",O
decreased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
tolbutamide,NN,D
-lrb-,-LRB-,O
a,DT,O
cyp2c9,NN,D
substrate,NN,O
-rrb-,-RRB-,O
by,IN,O
23,CD,O
%,NN,O
on,IN,O
day,NN,O
4,CD,O
",",",",O
28,CD,O
%,NN,O
on,IN,O
day,NN,O
8,CD,O
",",",",O
and,CC,O
15,CD,O
%,NN,O
on,IN,O
day,NN,O
15,CD,O
",",",",O
when,WRB,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
tolbutamide,NN,D
500,CD,O
mg,NN,O
was,VBD,O
admini,JJ,O
",",",",O
stered,JJ,O
orally,RB,O
prior,RB,O
to,TO,O
the,DT,O
administration,NN,O
of,IN,O
the,DT,O
3-day,JJ,O
regimen,NN,O
of,IN,O
aprepitant,NN,D
and,CC,O
on,IN,O
days,NNS,O
"4,8",CD,O
",",",",O
and,CC,O
15,CD,O
.,.,.
,,
oral,JJ,O
contraceptives,NNS,G
:,:,O
aprepitant,JJ,D
",",",",O
when,WRB,O
given,VBN,O
once,RB,O
daily,RB,O
for,IN,O
14,CD,O
days,NNS,O
as,IN,O
a,DT,O
100-mg,JJ,O
capsule,NN,O
with,IN,O
an,DT,O
oral,JJ,O
contraceptive,NN,G
containing,VBG,O
35,CD,O
mcg,NN,O
of,IN,O
ethinyl,NN,O
estradiol,NN,O
and,CC,O
1,CD,O
mg,NN,O
of,IN,O
norethindrone,NN,D
",",",",O
decreased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
ethinyl,NN,O
estradiol,NN,O
by,IN,O
43,CD,O
%,NN,O
",",",",O
and,CC,O
decreased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
norethindrone,NN,D
by,IN,O
8,CD,O
%,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
efficacy,NN,O
of,IN,O
oral,JJ,O
contraceptives,NNS,G
during,IN,O
administration,NN,O
of,IN,O
aprepitant,NN,D
may,MD,O
be,VB,O
reduced,VBN,O
.,.,.
,,
although,IN,O
a,DT,O
3-day,JJ,O
regimen,NN,O
of,IN,O
aprepitant,JJ,D
given,VBN,O
concomitantly,RB,O
with,IN,O
oral,JJ,O
contraceptives,NNS,G
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
",",",",O
alternative,JJ,O
or,CC,O
back-up,JJ,O
methods,NNS,O
of,IN,O
contraception,NN,O
should,MD,O
be,VB,O
used,VBN,O
.,.,.
,,
midazolam,NNP,D
:,:,O
aprepitant,NN,D
increased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
midazolam,NN,D
",",",",O
a,DT,O
sensitive,JJ,O
cyp3a4,NN,D
substrate,NN,O
",",",",O
by,IN,O
2.3-fold,JJ,O
on,IN,O
day,NN,O
1,CD,O
and,CC,O
3.3-fold,RB,O
on,IN,O
day,NN,O
5,CD,O
",",",",O
when,WRB,O
a,DT,O
single,JJ,O
oral,JJ,O
dose,NN,O
of,IN,O
midazolam,NN,D
2,CD,O
mg,NN,O
was,VBD,O
coadministered,VBN,O
on,IN,O
day,NN,O
1,CD,O
and,CC,O
day,NNP,O
5,CD,O
of,IN,O
a,DT,O
regimen,NN,O
of,IN,O
aprepitant,JJ,D
125,CD,O
mg,NN,O
on,IN,O
day,NN,O
1,CD,O
and,CC,O
80,CD,O
mg/day,NN,O
on,IN,O
days,NNS,O
2,CD,O
through,IN,O
5,CD,O
.,.,.
,,
the,DT,O
potential,JJ,O
effects,NNS,O
of,IN,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
midazolam,NN,D
or,CC,O
other,JJ,O
benzodiazepines,NNS,G
metabolized,VBN,O
via,IN,O
cyp3a4,NN,D
-lrb-,-LRB-,O
alprazolam,NN,D
",",",",O
triazolam,NN,D
-rrb-,-RRB-,O
should,MD,O
be,VB,O
considered,VBN,O
when,WRB,O
coadministering,VBG,O
these,DT,O
agents,NNS,O
with,IN,O
aprepitant,NN,D
.,.,.
,,
in,IN,O
another,DT,O
study,NN,O
with,IN,O
intravenous,JJ,O
administration,NN,O
of,IN,O
midazolam,NN,D
",",",",O
aprepitant,NN,D
was,VBD,O
given,VBN,O
as,IN,O
125,CD,O
mg,NN,O
on,IN,O
day,NN,O
1,CD,O
and,CC,O
80,CD,O
mg/day,NN,O
on,IN,O
days,NNS,O
2,CD,O
and,CC,O
3,CD,O
",",",",O
and,CC,O
midazolam,NN,D
2,CD,O
mg,NN,O
iv,CD,O
was,VBD,O
given,VBN,O
prior,RB,O
to,TO,O
the,DT,O
administration,NN,O
of,IN,O
the,DT,O
3-day,JJ,O
regimen,NN,O
of,IN,O
aprepitant,NN,D
and,CC,O
on,IN,O
days,NNS,O
4,CD,O
",",",",O
8,CD,O
",",",",O
and,CC,O
15,CD,O
.,.,.
,,
aprepitant,NN,D
increased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
midazolam,NN,D
by,IN,O
25,CD,O
%,NN,O
on,IN,O
day,NN,O
4,CD,O
and,CC,O
decreased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
midazolam,NN,D
by,IN,O
19,CD,O
%,NN,O
on,IN,O
day,NN,O
8,CD,O
relative,JJ,O
to,TO,O
the,DT,O
dosing,NN,O
of,IN,O
aprepitant,NN,D
on,IN,O
days,NNS,O
1,CD,O
through,IN,O
3,CD,O
.,.,.
,,
these,DT,O
effects,NNS,O
were,VBD,O
not,RB,O
considered,VBN,O
clinically,RB,O
important,JJ,O
.,.,.
,,
the,DT,O
auc,NN,O
of,IN,O
midazolam,NN,D
on,IN,O
day,NN,O
15,CD,O
was,VBD,O
similar,JJ,O
to,TO,O
that,DT,O
observed,VBN,O
at,IN,O
baseline,NN,O
.,.,.
,,
effect,NN,O
of,IN,O
other,JJ,O
agents,NNS,O
on,IN,O
the,DT,O
pharmacokinefics,NNS,O
of,IN,O
aprepitan,NN,O
.,.,.
,,
aprepitant,NN,D
is,VBZ,O
a,DT,O
substrate,NN,O
for,IN,O
cyp3a4,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
coadministration,NN,O
of,IN,O
aprepitant,JJ,D
with,IN,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
cyp3a4,NN,D
activity,NN,O
may,MD,O
result,VB,O
in,IN,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
aprepitant,NN,D
.,.,.
,,
consequently,RB,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
aprepitant,JJ,D
with,IN,O
strong,JJ,O
cyp3a4,NN,D
inhibitors,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
ketoconazole,NN,D
",",",",O
itraconazole,NN,D
",",",",O
nefazodone,NN,D
",",",",O
troleandomycin,NN,D
",",",",O
clarithromycin,NN,D
",",",",O
ritonavir,NN,D
",",",",O
nelfinavir,NN,D
-rrb-,-RRB-,O
should,MD,O
be,VB,O
approached,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
because,IN,O
moderate,JJ,O
cyp3a4,NN,D
inhibitors,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
diltiazem,NN,D
-rrb-,-RRB-,O
result,VBP,O
in,IN,O
2-fold,JJ,O
increase,NN,O
in,IN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
aprepitant,NN,D
",",",",O
concomitant,JJ,O
administration,NN,O
should,MD,O
also,RB,O
be,VB,O
approached,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
aprepitant,NN,D
is,VBZ,O
a,DT,O
substrate,NN,O
for,IN,O
cyp3a4,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
coadministration,NN,O
of,IN,O
aprepitant,JJ,D
with,IN,O
drugs,NNS,D
that,WDT,O
strongly,RB,O
induce,VBP,O
cyp3a4,NN,D
activity,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
rifampin,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
phenytoin,NN,D
-rrb-,-RRB-,O
may,MD,O
result,VB,O
in,IN,O
reduced,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
aprepitant,NN,D
that,WDT,O
may,MD,O
result,VB,O
in,IN,O
decreased,VBN,O
efficacy,NN,O
of,IN,O
aprepitant,NN,D
.,.,.
,,
ketoconazole,NN,D
:,:,O
when,WRB,O
a,DT,O
single,JJ,O
125-mg,JJ,O
dose,NN,O
of,IN,O
aprepitant,NN,D
was,VBD,O
administered,VBN,O
on,IN,O
day5,NN,O
of,IN,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
when,WRB,O
a,DT,O
single,JJ,O
125-mg,JJ,O
dose,NN,O
of,IN,O
aprepitant,NN,D
was,VBD,O
administered,VBN,O
on,IN,O
day5,NN,O
of,IN,O
a,DT,O
10-day,JJ,O
regimen,NN,O
of,IN,O
400,CD,O
mg/day,NN,O
of,IN,O
ketoconazole,NN,D
",",",",O
a,DT,O
strong,JJ,O
cyp3a4,NN,D
inhibitor,NN,O
",",",",O
the,DT,O
auc,NN,O
of,IN,O
aprepitant,NN,D
increased,VBD,O
approximately,RB,O
5-fold,RB,O
and,CC,O
the,DT,O
mean,JJ,O
terminal,JJ,O
half-life,NN,O
of,IN,O
aprepitant,NN,D
increased,VBD,O
approximately,RB,O
3-fold,RB,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
aprepitant,JJ,D
with,IN,O
strong,JJ,O
cyp3a4,NN,D
inhibitors,NNS,O
should,MD,O
be,VB,O
approached,VBN,O
cautiously,RB,O
.,.,.
,,
rifampin,NNP,D
:,:,O
when,WRB,O
a,DT,O
single,JJ,O
375-mg,JJ,O
dose,NN,O
of,IN,O
aprepitant,NN,D
was,VBD,O
administered,VBN,O
on,IN,O
day9,NN,O
of,IN,O
a,DT,O
14-day,JJ,O
regimen,NN,O
of,IN,O
600,CD,O
mg/day,NN,O
of,IN,O
rifampin,NN,D
",",",",O
a,DT,O
strong,JJ,O
cyp3a4,NN,D
inducer,NN,O
",",",",O
the,DT,O
auc,NN,O
of,IN,O
aprepitant,NN,D
decreased,VBD,O
approximately,RB,O
11-fold,JJ,O
and,CC,O
the,DT,O
mean,JJ,O
terminal,JJ,O
half-life,NN,O
decreased,VBD,O
approximately,RB,O
3-fold,RB,O
.,.,.
,,
coadministration,NN,O
of,IN,O
aprepitant,JJ,D
with,IN,O
drugs,NNS,D
that,WDT,O
induce,VBP,O
cyp3a4,NN,D
activity,NN,O
may,MD,O
result,VB,O
in,IN,O
reduced,VBN,O
plasma,NN,O
concentrations,NNS,O
and,CC,O
decreased,VBD,O
efficacy,NN,O
of,IN,O
aprepitant,NN,D
.,.,.
,,
additional,JJ,O
interactions,NNS,O
.,.,.
,,
diltiazem,NNP,D
:,:,O
in,IN,O
patients,NNS,O
with,IN,O
mild,JJ,O
to,TO,O
moderate,JJ,O
hypertension,NN,O
",",",",O
administration,NN,O
of,IN,O
aprepitant,NN,D
once,RB,O
daily,RB,O
",",",",O
as,IN,O
a,DT,O
tablet,JJ,O
formulation,NN,O
comparable,JJ,O
to,TO,O
230,CD,O
mg,NN,O
of,IN,O
the,DT,O
capsule,NN,O
formulation,NN,O
",",",",O
with,IN,O
diltiazem,NN,D
120,CD,O
mg,NN,O
3,CD,O
times,NNS,O
daily,RB,O
for,IN,O
5,CD,O
days,NNS,O
",",",",O
resulted,VBD,O
in,IN,O
a,DT,O
2-fold,JJ,O
increase,NN,O
of,IN,O
aprepitant,JJ,D
auc,NN,O
and,CC,O
a,DT,O
simultaneous,JJ,O
1.7-fold,JJ,O
increase,NN,O
of,IN,O
diltiazem,NN,D
auc,NN,O
.,.,.
,,
these,DT,O
pharmacokinetic,JJ,O
effects,NNS,O
did,VBD,O
not,RB,O
result,VB,O
in,IN,O
clinically,RB,O
meaningful,JJ,O
changes,NNS,O
in,IN,O
ecg,NN,O
",",",",O
heart,NN,O
rate,NN,O
or,CC,O
blood,NN,O
pressure,NN,O
beyond,IN,O
those,DT,O
changes,NNS,O
induced,VBN,O
by,IN,O
diltiazem,NN,D
alone,RB,O
.,.,.
,,
paroxetine,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
once,RB,O
daily,JJ,O
doses,NNS,O
of,IN,O
aprepitant,NN,D
",",",",O
as,IN,O
a,DT,O
tablet,JJ,O
formulation,NN,O
comparable,JJ,O
to,TO,O
85,CD,O
mg,NN,O
or,CC,O
170,CD,O
mg,NN,O
of,IN,O
the,DT,O
capsule,NN,O
formulation,NN,O
",",",",O
with,IN,O
paroxetine,NN,D
20,CD,O
mg,NN,O
once,RB,O
daily,RB,O
",",",",O
resulted,VBD,O
in,IN,O
a,DT,O
decrease,NN,O
in,IN,O
auc,NN,O
by,IN,O
approximately,RB,O
25,CD,O
%,NN,O
and,CC,O
cmax,NN,O
",",",",O
by,IN,O
approximately,RB,O
20,CD,O
%,NN,O
of,IN,O
both,CC,O
aprepitant,JJ,D
and,CC,O
paroxetine,NN,D
.,.,.
,,
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
:,:,O
concurrent,JJ,O
use,NN,O
may,MD,O
blunt,VB,O
the,DT,O
response,NN,O
to,TO,O
arbutamine,NN,D
.,.,.
,,
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
should,MD,O
be,VB,O
withdrawn,VBN,O
at,IN,O
least,JJS,O
48,CD,O
hours,NNS,O
before,IN,O
conducting,VBG,O
an,DT,O
arbutamine-mediated,JJ,O
stress,NN,O
test,NN,O
.,.,.
,,
antiarrhythmic,JJ,O
agents,NNS,O
",",",",O
class,NN,O
i,CD,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
flecainide,NN,D
",",",",O
lidocaine,NN,D
",",",",O
or,CC,O
quinidine,NN,D
-rrb-,-RRB-,O
:,:,O
concurrent,JJ,O
use,NN,O
with,IN,O
arbutamine,NN,D
may,MD,O
have,VB,O
a,DT,O
proarrhythmic,JJ,O
effect,NN,O
.,.,.
,,
antidepressants,NNS,G
-lrb-,-LRB-,O
tricyclic,JJ,G
-rrb-,-RRB-,O
",",",",O
atropine,NN,D
or,CC,O
other,JJ,O
anticholinergic,JJ,G
agents,NNS,O
",",",",O
or,CC,O
digitalis,NN,G
glycosides,NNS,G
:,:,O
concurrent,JJ,O
use,NN,O
with,IN,O
arbutamine,NN,D
may,MD,O
produce,VB,O
additive,JJ,O
inotropic,JJ,O
and/or,CC,O
chronotropic,JJ,O
effects,NNS,O
.,.,.
,,
anticoagulants,NNS,G
including,VBG,O
coumarin,NN,G
derivatives,NNS,O
",",",",O
indandione,NN,O
derivatives,NNS,O
",",",",O
and,CC,O
platelet,NN,O
aggregation,NN,O
inhibitors,NNS,O
such,JJ,O
as,IN,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
-lrb-,-LRB-,O
nsaids,NNS,G
-rrb-,-RRB-,O
",",",",O
and,CC,O
aspirin,NN,B
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
bleeding,VBG,O
when,WRB,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
ardeparin,NN,D
.,.,.
,,
if,IN,O
additional,JJ,O
adrenergic,JJ,G
drugs,NNS,D
are,VBP,O
to,TO,O
be,VB,O
administered,VBN,O
by,IN,O
any,DT,O
route,NN,O
",",",",O
they,PRP,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
because,IN,O
the,DT,O
pharmacologically,RB,O
predictable,JJ,O
sympathetic,JJ,O
effects,NNS,O
of,IN,O
brovana,NN,B
may,MD,O
be,VB,O
potentiated,VBN,O
.,.,.
,,
when,WRB,O
paroxetine,NN,D
",",",",O
a,DT,O
potent,JJ,O
inhibitor,NN,O
of,IN,O
cyp2d6,NN,D
",",",",O
was,VBD,O
co-administered,VBN,O
with,IN,O
brovana,NN,B
at,IN,O
steady-state,JJ,O
",",",",O
exposure,NN,O
to,TO,O
either,CC,O
drug,NN,D
was,VBD,O
not,RB,O
altered,VBN,O
.,.,.
,,
dosage,NN,O
adjustments,NNS,O
of,IN,O
brovana,NNP,B
are,VBP,O
not,RB,O
necessary,JJ,O
when,WRB,O
the,DT,O
drug,NN,D
is,VBZ,O
given,VBN,O
concomitantly,RB,O
with,IN,O
potent,JJ,O
cyp2d6,NN,D
inhibitors,NNS,O
.,.,.
,,
concomitant,JJ,O
treatment,NN,O
with,IN,O
methylxanthines,NNS,G
-lrb-,-LRB-,O
aminophylline,NN,D
",",",",O
theophylline,NN,D
-rrb-,-RRB-,O
",",",",O
steroids,NNS,G
",",",",O
or,CC,O
diuretics,NNS,G
may,MD,O
potentiate,VB,O
any,DT,O
hypokalemic,JJ,O
effect,NN,O
of,IN,O
adrenergic,JJ,G
agonists,NNS,O
.,.,.
,,
the,DT,O
ecg,NN,O
changes,NNS,O
and/or,CC,O
hypokalemia,NN,O
that,WDT,O
may,MD,O
result,VB,O
from,IN,O
the,DT,O
administration,NN,O
of,IN,O
non-potassium,JJ,O
sparing,NN,O
diuretics,NNS,G
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
loop,NN,O
or,CC,O
thiazide,JJ,G
diuretics,NNS,G
-rrb-,-RRB-,O
can,MD,O
be,VB,O
acutely,RB,O
worsened,VBN,O
by,IN,O
beta-agonists,NNS,G
",",",",O
especially,RB,O
when,WRB,O
the,DT,O
recommended,VBN,O
dose,NN,O
of,IN,O
the,DT,O
beta-agonist,NN,G
is,VBZ,O
exceeded,VBN,O
.,.,.
,,
although,IN,O
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
these,DT,O
effects,NNS,O
is,VBZ,O
not,RB,O
known,VBN,O
",",",",O
caution,NN,O
is,VBZ,O
advised,VBN,O
in,IN,O
the,DT,O
co-administration,NN,O
of,IN,O
beta-agonists,NNS,G
with,IN,O
non-potassium,JJ,O
sparing,NN,O
diuretics,NNS,G
.,.,.
,,
brovana,NNP,B
",",",",O
as,IN,O
with,IN,O
other,JJ,O
beta2-agonists,NNS,G
",",",",O
should,MD,O
be,VB,O
administered,VBN,O
with,IN,O
extreme,JJ,O
caution,NN,O
to,TO,O
patients,NNS,O
being,VBG,O
treated,VBN,O
with,IN,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
",",",",O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
or,CC,O
drugs,NNS,D
known,VBN,O
to,TO,O
prolong,VB,O
the,DT,O
qtc,NN,O
interval,NN,O
because,IN,O
the,DT,O
action,NN,O
of,IN,O
adrenergic,JJ,G
agonists,NNS,O
on,IN,O
the,DT,O
cardiovascular,JJ,O
system,NN,O
may,MD,O
be,VB,O
potentiated,VBN,O
by,IN,O
these,DT,O
agents,NNS,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
are,VBP,O
known,VBN,O
to,TO,O
prolong,VB,O
the,DT,O
qtc,NN,O
interval,NN,O
have,VBP,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
ventricular,JJ,O
arrhythmias,NNS,O
.,.,.
,,
the,DT,O
concurrent,JJ,O
use,NN,O
of,IN,O
intravenously,RB,O
or,CC,O
orally,RB,O
administered,VBN,O
methylxanthines,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
aminophylline,NN,D
",",",",O
theophylline,NN,D
-rrb-,-RRB-,O
by,IN,O
patients,NNS,O
receiving,VBG,O
brovana,NNP,B
has,VBZ,O
not,RB,O
been,VBN,O
completely,RB,O
evaluated,VBN,O
.,.,.
,,
in,IN,O
two,CD,O
combined,JJ,O
12-week,JJ,O
placebo,NN,O
controlled,VBN,O
trials,NNS,O
that,WDT,O
included,VBD,O
brovana,NN,B
doses,NNS,O
of,IN,O
15,CD,O
mcg,NN,O
twice,RB,O
daily,RB,O
",",",",O
25,CD,O
mcg,NN,O
twice,RB,O
daily,RB,O
",",",",O
and,CC,O
50,CD,O
mcg,NN,O
once,RB,O
daily,RB,O
",",",",O
54,CD,O
of,IN,O
873,CD,O
brovana,NN,B
-,:,O
treated,JJ,O
subjects,NNS,O
received,VBD,O
concomitant,JJ,O
theophylline,NN,D
at,IN,O
study,NN,O
entry,NN,O
.,.,.
,,
in,IN,O
a,DT,O
12-month,JJ,O
controlled,JJ,O
trial,NN,O
that,WDT,O
included,VBD,O
a,DT,O
50,CD,O
mcg,NN,O
once,RB,O
daily,JJ,O
brovana,NNP,B
dose,NN,O
",",",",O
30,CD,O
of,IN,O
the,DT,O
528,CD,O
brovana,NN,B
-,:,O
treated,JJ,O
subjects,NNS,O
received,VBD,O
concomitant,JJ,O
theophylline,NN,D
at,IN,O
study,NN,O
entry,NN,O
.,.,.
,,
in,IN,O
these,DT,O
trials,NNS,O
",",",",O
heart,NN,O
rate,NN,O
and,CC,O
systolic,JJ,O
blood,NN,O
pressure,NN,O
were,VBD,O
approximately,RB,O
3-Feb,CD,O
bpm,NN,O
and,CC,O
8-Jun,CD,O
mm,NN,O
hg,NN,O
higher,JJR,O
",",",",O
respectively,RB,O
",",",",O
in,IN,O
subjects,NNS,O
on,IN,O
concomitant,JJ,O
theophylline,NN,D
compared,VBN,O
with,IN,O
the,DT,O
overall,JJ,O
population,NN,O
.,.,.
,,
beta-adrenergic,JJ,O
receptor,NN,D
antagonists,NNS,O
-lrb-,-LRB-,O
beta-blockers,NNS,G
-rrb-,-RRB-,O
and,CC,O
brovana,NN,B
may,MD,O
interfere,VB,O
with,IN,O
the,DT,O
effect,NN,O
of,IN,O
each,DT,O
other,JJ,O
when,WRB,O
administered,VBN,O
concurrently,RB,O
.,.,.
,,
beta-blockers,NNS,G
not,RB,O
only,RB,O
block,VB,O
the,DT,O
therapeutic,JJ,O
effects,NNS,O
of,IN,O
beta-agonists,NNS,G
",",",",O
but,CC,O
may,MD,O
produce,VB,O
severe,JJ,O
bronchospasm,NN,O
in,IN,O
copd,NN,O
patients,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
patients,NNS,O
with,IN,O
copd,NN,O
should,MD,O
not,RB,O
normally,RB,O
be,VB,O
treated,VBN,O
with,IN,O
beta-blockers,NNS,G
.,.,.
,,
however,RB,O
",",",",O
under,IN,O
certain,JJ,O
circumstances,NNS,O
",",",",O
e.g.,FW,O
",",",",O
as,IN,O
prophylaxis,NN,O
after,IN,O
myocardial,JJ,O
infarction,NN,O
",",",",O
there,EX,O
may,MD,O
be,VB,O
no,DT,O
acceptable,JJ,O
alternatives,NNS,O
to,TO,O
the,DT,O
use,NN,O
of,IN,O
beta-blockers,NNS,G
in,IN,O
patients,NNS,O
with,IN,O
copd,NN,O
.,.,.
,,
in,IN,O
this,DT,O
setting,NN,O
",",",",O
cardioselective,JJ,O
beta-blockers,NNS,G
could,MD,O
be,VB,O
considered,VBN,O
",",",",O
although,IN,O
they,PRP,O
should,MD,O
be,VB,O
administered,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
heparin,NN,D
:,:,O
since,IN,O
heparin,NN,D
is,VBZ,O
contraindicated,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
heparin-induced,JJ,O
thrombocytopenia,NN,O
",",",",O
the,DT,O
co-administration,NN,O
of,IN,O
argatroban,NN,D
and,CC,O
heparin,NN,D
is,VBZ,O
unlikely,JJ,O
for,IN,O
this,DT,O
indication,NN,O
.,.,.
,,
however,RB,O
",",",",O
if,IN,O
argatroban,NN,D
is,VBZ,O
to,TO,O
be,VB,O
initiated,VBN,O
after,IN,O
cessation,NN,O
of,IN,O
heparin,NN,D
therapy,NN,O
",",",",O
allow,VBP,O
sufficient,JJ,O
time,NN,O
for,IN,O
heparins,NNS,O
effect,NN,O
on,IN,O
the,DT,O
aptt,NN,O
to,TO,O
decrease,VB,O
prior,RB,O
to,TO,O
initiation,NN,O
of,IN,O
argatroban,NN,D
therapy,NN,O
.,.,.
,,
aspirin/acetaminophen,NNP,O
:,:,O
pharmacokinetic,JJ,O
or,CC,O
pharmacodynamic,JJ,O
drug-drug,NN,O
interactions,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
demonstrated,VBN,O
between,IN,O
argatroban,NN,D
and,CC,O
concomitantly,RB,O
administered,VBN,O
aspirin,NN,B
-lrb-,-LRB-,O
162.5,CD,O
mg,NN,O
orally,RB,O
given,VBN,O
26,CD,O
and,CC,O
2,CD,O
hours,NNS,O
prior,RB,O
to,TO,O
initiation,NN,O
of,IN,O
argatroban,NN,D
1,CD,O
g/kg/min,NN,O
.,.,.
,,
over,IN,O
4,CD,O
hours,NNS,O
-rrb-,-RRB-,O
or,CC,O
acetaminophen,NN,D
-lrb-,-LRB-,O
1000,CD,O
mg,NN,O
orally,RB,O
given,VBN,O
12,CD,O
",",",",O
6,CD,O
and,CC,O
0,CD,O
hours,NNS,O
prior,RB,O
to,TO,O
",",",",O
and,CC,O
6,CD,O
and,CC,O
12,CD,O
hours,NNS,O
subsequent,JJ,O
to,TO,O
",",",",O
initiation,NN,O
of,IN,O
argatroban,JJ,D
1.5,CD,O
g/kg/min,NN,O
.,.,.
,,
over,IN,O
18,CD,O
hours,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
oral,JJ,O
anticoagulant,JJ,G
agents,NNS,O
:,:,O
pharmacokinetic,JJ,O
drug-drug,JJ,O
interactions,NNS,O
between,IN,O
argatroban,NN,D
and,CC,O
warfarin,NN,D
-lrb-,-LRB-,O
7.5,CD,O
mg,NN,O
single,JJ,O
oral,JJ,O
dose,NN,O
-rrb-,-RRB-,O
have,VBP,O
not,RB,O
been,VBN,O
demonstrated,VBN,O
.,.,.
,,
however,RB,O
",",",",O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
argatroban,NN,D
and,CC,O
warfarin,NN,D
-lrb-,-LRB-,O
7-May,CD,O
0.5,CD,O
mg,NN,O
initial,JJ,O
oral,JJ,O
dose,NN,O
followed,VBN,O
by,IN,O
2.5-6,CD,O
mg/day,NN,O
orally,RB,O
for,IN,O
10-Jun,CD,O
days,NNS,O
-rrb-,-RRB-,O
results,VBZ,O
in,IN,O
prolongation,NN,O
of,IN,O
the,DT,O
prothrombin,NN,O
time,NN,O
-lrb-,-LRB-,O
pt,NN,O
-rrb-,-RRB-,O
and,CC,O
international,NNP,O
normalized,NNP,O
ratio,NNP,O
-lrb-,-LRB-,O
inr,NNP,O
-rrb-,-RRB-,O
.,.,.
,,
thrombolytic,JJ,O
agents,NNS,O
:,:,O
the,DT,O
safety,NN,O
and,CC,O
effectiveness,NN,O
of,IN,O
argatroban,NN,D
with,IN,O
thrombolytic,JJ,O
agents,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
co-administration,NN,O
:,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
argatroban,NN,D
with,IN,O
antiplatelet,JJ,O
agents,NNS,O
",",",",O
thrombolytics,NNS,G
",",",",O
and,CC,O
other,JJ,O
anticoagulants,NNS,G
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
bleeding,NN,O
.,.,.
,,
drug-drug,JJ,O
interactions,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
observed,VBN,O
between,IN,O
argatroban,NN,D
and,CC,O
digoxin,NN,D
or,CC,O
erythromycin,NN,D
.,.,.
,,
drug-drug,NNP,O
interactions,NNS,O
given,VBN,O
the,DT,O
primary,JJ,O
cns,NN,O
effects,NNS,O
of,IN,O
aripiprazole,NN,D
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
when,WRB,O
abilify,NNP,B
is,VBZ,O
taken,VBN,O
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
centrally,RB,O
acting,VBG,O
drugs,NNS,D
and,CC,O
alcohol,NN,D
.,.,.
,,
due,JJ,O
to,TO,O
its,PRP$,O
.,.,.
,,
1,LS,O
-,:,O
adrenergic,JJ,G
receptor,NN,D
antagonism,NN,O
",",",",O
aripiprazole,NN,D
has,VBZ,O
the,DT,O
potential,JJ,O
to,TO,O
enhance,VB,O
the,DT,O
effect,NN,O
of,IN,O
certain,JJ,O
antihypertensive,JJ,G
agents,NNS,O
.,.,.
,,
potential,JJ,O
for,IN,O
other,JJ,O
drugs,NNS,O
to,TO,O
affect,VB,O
abilify,NNP,B
aripiprazole,NNP,D
is,VBZ,O
not,RB,O
a,DT,O
substrate,NN,O
of,IN,O
cyp1a1,NN,O
",",",",O
cyp1a2,NN,D
",",",",O
cyp2a6,NN,O
",",",",O
cyp2b6,NN,O
",",",",O
cyp2c8,NN,O
",",",",O
cyp2c9,NN,D
",",",",O
cyp2c19,NN,O
",",",",O
or,CC,O
cyp2e1,NN,O
enzymes,NNS,O
.,.,.
,,
aripiprazole,NNP,D
also,RB,O
does,VBZ,O
not,RB,O
undergo,VB,O
direct,JJ,O
glucuronidation,NN,O
.,.,.
,,
this,DT,O
suggests,VBZ,O
that,IN,O
an,DT,O
interaction,NN,O
of,IN,O
aripiprazole,NN,D
with,IN,O
inhibitors,NNS,O
or,CC,O
inducers,NNS,O
of,IN,O
these,DT,O
enzymes,NNS,O
",",",",O
or,CC,O
other,JJ,O
factors,NNS,O
",",",",O
like,IN,O
smoking,NN,O
",",",",O
is,VBZ,O
unlikely,JJ,O
.,.,.
,,
both,DT,O
cyp3a4,NN,D
and,CC,O
cyp2d6,NN,D
are,VBP,O
responsible,JJ,O
for,IN,O
aripiprazole,NN,D
metabolism,NN,O
.,.,.
,,
agents,NNS,O
that,WDT,O
induce,VBP,O
cyp3a4,NN,D
-lrb-,-LRB-,O
eg,FW,O
",",",",O
carbamazepine,NN,D
-rrb-,-RRB-,O
could,MD,O
cause,VB,O
an,DT,O
increase,NN,O
in,IN,O
aripiprazole,JJ,D
clearance,NN,O
and,CC,O
lower,JJR,O
blood,NN,O
levels,NNS,O
.,.,.
,,
inhibitors,NNS,O
of,IN,O
cyp3a4,NN,D
-lrb-,-LRB-,O
eg,FW,O
",",",",O
ketoconazole,NN,D
-rrb-,-RRB-,O
or,CC,O
cyp2d6,NN,D
-lrb-,-LRB-,O
eg,FW,O
",",",",O
quinidine,NN,D
",",",",O
fluoxetine,NN,D
",",",",O
or,CC,O
paroxetine,NN,D
-rrb-,-RRB-,O
can,MD,O
inhibit,VB,O
aripiprazole,NN,D
elimination,NN,O
and,CC,O
cause,VB,O
increased,VBN,O
blood,NN,O
levels,NNS,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
coadministration,NN,O
of,IN,O
ketoconazole,NN,D
-lrb-,-LRB-,O
200,CD,O
mg/day,NN,O
for,IN,O
14,CD,O
days,NNS,O
-rrb-,-RRB-,O
with,IN,O
a,DT,O
15-mg,JJ,O
single,JJ,O
dose,NN,O
of,IN,O
aripiprazole,NN,D
increased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
aripiprazole,NN,D
and,CC,O
its,PRP$,O
active,JJ,O
metabolite,NN,O
by,IN,O
63,CD,O
%,NN,O
and,CC,O
77,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
a,DT,O
higher,JJR,O
ketoconazole,NN,D
dose,NN,O
-lrb-,-LRB-,O
400,CD,O
mg/day,NN,O
-rrb-,-RRB-,O
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
when,WRB,O
concomitant,JJ,O
administration,NN,O
of,IN,O
ketoconazole,NN,D
with,IN,O
aripiprazole,NN,D
occurs,VBZ,O
",",",",O
aripiprazole,NN,D
dose,NN,O
should,MD,O
be,VB,O
reduced,VBN,O
to,TO,O
one-half,NN,O
of,IN,O
its,PRP$,O
normal,JJ,O
dose,NN,O
.,.,.
,,
other,JJ,O
strong,JJ,O
inhibitors,NNS,O
of,IN,O
cyp3a4,NN,D
-lrb-,-LRB-,O
itraconazole,NN,D
-rrb-,-RRB-,O
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
have,VB,O
similar,JJ,O
effects,NNS,O
and,CC,O
need,VBP,O
similar,JJ,O
dose,NN,O
reductions,NNS,O
.,.,.
,,
weaker,JJR,O
inhibitors,NNS,O
-lrb-,-LRB-,O
erythromycin,NN,D
",",",",O
grapefruit,NN,O
juice,NN,O
-rrb-,-RRB-,O
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
when,WRB,O
the,DT,O
cyp3a4,NN,D
inhibitor,NN,O
is,VBZ,O
withdrawn,VBN,O
from,IN,O
the,DT,O
combination,NN,O
therapy,NN,O
",",",",O
aripiprazole,NN,D
dose,NN,O
should,MD,O
then,RB,O
be,VB,O
increased,VBN,O
.,.,.
,,
quinidine,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
a,DT,O
10-mg,JJ,O
single,JJ,O
dose,NN,O
of,IN,O
aripiprazole,NN,D
with,IN,O
quinidine,NN,D
-lrb-,-LRB-,O
166,CD,O
mg/day,NN,O
for,IN,O
13,CD,O
days,NNS,O
-rrb-,-RRB-,O
",",",",O
a,DT,O
potent,JJ,O
inhibitor,NN,O
of,IN,O
cyp2d6,NN,D
",",",",O
increased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
aripiprazole,NN,D
by,IN,O
112,CD,O
%,NN,O
but,CC,O
decreased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
its,PRP$,O
active,JJ,O
metabolite,NN,O
",",",",O
dehydroaripiprazole,NN,D_n
",",",",O
by,IN,O
35,CD,O
%,NN,O
.,.,.
,,
aripiprazole,NNP,D
dose,NN,O
should,MD,O
be,VB,O
reduced,VBN,O
to,TO,O
one-half,NN,O
of,IN,O
its,PRP$,O
normal,JJ,O
dose,NN,O
when,WRB,O
concomitant,JJ,O
administration,NN,O
of,IN,O
quinidine,NN,D
with,IN,O
aripiprazole,NN,D
occurs,VBZ,O
.,.,.
,,
other,JJ,O
significant,JJ,O
inhibitors,NNS,O
of,IN,O
cyp2d6,NN,D
",",",",O
such,JJ,O
as,IN,O
fluoxetine,NN,D
or,CC,O
paroxetine,NN,D
",",",",O
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
have,VB,O
similar,JJ,O
effects,NNS,O
and,CC,O
",",",",O
therefore,RB,O
",",",",O
should,MD,O
be,VB,O
accompanied,VBN,O
by,IN,O
similar,JJ,O
dose,NN,O
reductions,NNS,O
.,.,.
,,
when,WRB,O
the,DT,O
cyp2d6,NN,D
inhibitor,NN,O
is,VBZ,O
withdrawn,VBN,O
from,IN,O
the,DT,O
combination,NN,O
therapy,NN,O
",",",",O
aripiprazole,NN,D
dose,NN,O
should,MD,O
then,RB,O
be,VB,O
increased,VBN,O
.,.,.
,,
carbamazepine,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
carbamazepine,NN,D
-lrb-,-LRB-,O
200,CD,O
mg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
",",",",O
a,DT,O
potent,JJ,O
cyp3a4,NN,D
inducer,NN,O
",",",",O
with,IN,O
aripiprazole,NN,D
-lrb-,-LRB-,O
30,CD,O
mg,NN,O
qd,NN,O
-rrb-,-RRB-,O
resulted,VBD,O
in,IN,O
an,DT,O
approximate,JJ,O
70,CD,O
%,NN,O
decrease,NN,O
in,IN,O
cmax,NN,O
and,CC,O
auc,NN,O
values,NNS,O
of,IN,O
both,DT,O
aripiprazole,NN,D
and,CC,O
its,PRP$,O
active,JJ,O
metabolite,NN,O
",",",",O
dehydro-aripiprazole,NN,D_n
.,.,.
,,
when,WRB,O
carbamazepine,NN,D
is,VBZ,O
added,VBN,O
to,TO,O
aripiprazole,NN,D
therapy,NN,O
",",",",O
aripiprazole,NN,D
dose,NN,O
should,MD,O
be,VB,O
doubled,VBN,O
.,.,.
,,
additional,JJ,O
dose,NN,O
increases,NNS,O
should,MD,O
be,VB,O
based,VBN,O
on,IN,O
clinical,JJ,O
evaluation,NN,O
.,.,.
,,
when,WRB,O
carbamazepine,NN,D
is,VBZ,O
withdrawn,VBN,O
from,IN,O
the,DT,O
combination,NN,O
therapy,NN,O
",",",",O
aripiprazole,NN,D
dose,NN,O
should,MD,O
then,RB,O
be,VB,O
reduced,VBN,O
.,.,.
,,
no,DT,O
clinically,RB,O
significant,JJ,O
effect,NN,O
of,IN,O
famotidine,NN,D
",",",",O
valproate,NN,D
",",",",O
or,CC,O
lithium,NN,D
was,VBD,O
seen,VBN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
aripiprazole,NN,D
-lrb-,-LRB-,O
see,VB,O
clinical,NNP,O
pharmacology,NNP,O
:,:,O
drug,NN,O
-,:,O
drug,NN,O
interactions,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
potential,JJ,O
for,IN,O
abilify,NNP,B
to,TO,O
affect,VB,O
other,JJ,O
drugs,NNS,O
aripiprazole,NN,D
is,VBZ,O
unlikely,JJ,O
to,TO,O
cause,VB,O
clinically,RB,O
important,JJ,O
pharmacokinetic,JJ,O
interactions,NNS,O
with,IN,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
.,.,.
,,
in,IN,O
in,FW,O
vivo,FW,O
studies,NNS,O
",",",",O
10,CD,O
-,:,O
to,TO,O
30-mg/day,JJ,O
doses,NNS,O
of,IN,O
aripiprazole,NN,D
had,VBD,O
no,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
metabolism,NN,O
by,IN,O
cyp2d6,NN,D
-lrb-,-LRB-,O
dextromethorphan,NN,D
-rrb-,-RRB-,O
",",",",O
cyp2c9,NN,D
-lrb-,-LRB-,O
warfarin,NN,D
-rrb-,-RRB-,O
",",",",O
cyp2c19,NN,O
-lrb-,-LRB-,O
omeprazole,NN,D
",",",",O
warfarin,NN,D
-rrb-,-RRB-,O
",",",",O
and,CC,O
cyp3a4,NN,D
-lrb-,-LRB-,O
dextromethorphan,NN,D
-rrb-,-RRB-,O
substrates,NNS,O
.,.,.
,,
additionally,RB,O
",",",",O
aripiprazole,NN,D
and,CC,O
dehydroaripiprazole,NN,D_n
did,VBD,O
not,RB,O
show,VB,O
potential,JJ,O
for,IN,O
altering,VBG,O
cyp1a2-mediated,JJ,O
metabolism,NN,O
in,FW,O
vitro,FW,O
.,.,.
,,
alcohol,NN,D
:,:,O
there,EX,O
was,VBD,O
no,DT,O
significant,JJ,O
difference,NN,O
between,IN,O
aripiprazole,NN,D
coadministered,VBN,O
with,IN,O
ethanol,NN,D
and,CC,O
placebo,NN,O
coadministered,VBN,O
with,IN,O
ethanol,NN,D
on,IN,O
performance,NN,O
of,IN,O
gross,JJ,O
motor,NN,O
skills,NNS,O
or,CC,O
stimulus,NN,O
response,NN,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
.,.,.
,,
as,IN,O
with,IN,O
most,JJS,O
psychoactive,JJ,O
medications,NNS,O
",",",",O
patients,NNS,O
should,MD,O
be,VB,O
advised,VBN,O
to,TO,O
avoid,VB,O
alcohol,NN,D
while,IN,O
taking,VBG,O
abilif,NNP,O
.,.,.
,,
no,DT,O
formal,JJ,O
assessments,NNS,O
of,IN,O
pharmacokinetic,JJ,O
drug-drug,NN,O
interactions,NNS,O
between,IN,O
trisenox,NN,B
and,CC,O
other,JJ,O
agents,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
caution,NN,O
is,VBZ,O
advised,VBN,O
when,WRB,O
trisenox,NN,B
is,VBZ,O
coadministered,VBN,O
with,IN,O
other,JJ,O
medications,NNS,O
that,WDT,O
can,MD,O
prolong,VB,O
the,DT,O
qt,NNP,O
interval,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
certain,JJ,O
antiarrhythmics,NNS,G
or,CC,O
thioridazine,NN,D
-rrb-,-RRB-,O
or,CC,O
lead,VB,O
to,TO,O
electrolyte,NN,O
abnormalities,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
diuretics,NNS,G
or,CC,O
amphotericin,NN,D
b,NN,O
-rrb-,-RRB-,O
.,.,.
,,
tissue,NN,O
culture,NN,O
and,CC,O
animal,NN,O
studies,NNS,O
indicate,VBP,O
that,IN,O
elspar,NN,B
can,MD,O
diminish,VB,O
or,CC,O
abolish,VB,O
the,DT,O
effect,NN,O
of,IN,O
methotrexate,NN,D
on,IN,O
malignant,JJ,O
cells,NNS,O
0.14,CD,O
this,DT,O
effect,NN,O
on,IN,O
methotrexate,NN,D
activity,NN,O
persists,VBZ,O
as,RB,O
long,JJ,O
as,IN,O
plasma,NN,O
asparagine,NN,O
levels,NNS,O
are,VBP,O
suppressed,VBN,O
.,.,.
,,
these,DT,O
results,NNS,O
would,MD,O
seem,VB,O
to,TO,O
dictate,VB,O
against,IN,O
the,DT,O
clinical,JJ,O
use,NN,O
of,IN,O
methotrexate,NN,D
with,IN,O
elspar,NN,B
",",",",O
or,CC,O
during,IN,O
the,DT,O
period,NN,O
following,VBG,O
elspar,NN,B
therapy,NN,O
when,WRB,O
plasma,NN,O
asparagine,NN,O
levels,NNS,O
are,VBP,O
below,IN,O
normal,JJ,O
.,.,.
,,
uricosuric,NNP,O
agents,NNPS,O
:,:,O
aspirin,NN,B
may,MD,O
decrease,VB,O
the,DT,O
effects,NNS,O
of,IN,O
probenecid,NN,D
",",",",O
sulfinpyrazone,NN,D
",",",",O
and,CC,O
phenylbutazone,NN,D
.,.,.
,,
alcohol,NN,D
:,:,O
has,VBZ,O
a,DT,O
synergistic,JJ,O
effect,NN,O
with,IN,O
aspirin,NN,B
in,IN,O
causing,VBG,O
gastrointestinal,JJ,O
bleeding,NN,O
.,.,.
,,
corticosteroids,NNS,G
:,:,O
concomitant,JJ,O
administration,NN,O
with,IN,O
aspirin,NN,B
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
gastrointestinal,JJ,O
ulceration,NN,O
and,CC,O
may,MD,O
reduce,VB,O
serum,NN,O
salicylate,NN,G
levels,NNS,O
.,.,.
,,
pyrazolone,NNP,O
derivatives,NNS,O
-lrb-,-LRB-,O
phenylbutazone,NN,D
",",",",O
oxyphenbutazone,NN,D
",",",",O
and,CC,O
possibly,RB,O
dipyrone,NN,D
-rrb-,-RRB-,O
:,:,O
concomitant,JJ,O
administration,NN,O
with,IN,O
aspirin,NN,B
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
gastrointestinal,JJ,O
ulceration,NN,O
.,.,.
,,
nonsteroidal,JJ,O
antiinflammatory,JJ,O
agents,NNS,O
:,:,O
aspirin,NN,B
is,VBZ,O
contraindicated,VBN,O
in,IN,O
patients,NNS,O
who,WP,O
are,VBP,O
hypersensitive,JJ,O
to,TO,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
.,.,.
,,
urinary,JJ,O
alkalinizers,NNS,O
:,:,O
decrease,NN,O
aspirin,NN,B
effectiveness,NN,O
by,IN,O
increasing,VBG,O
the,DT,O
rate,NN,O
of,IN,O
salicylate,NN,G
renal,JJ,O
excretion,NN,O
.,.,.
,,
phenobarbital,NNP,D
:,:,O
decreases,VBZ,O
aspirin,NN,B
effectiveness,NN,O
by,IN,O
enzyme,NN,O
induction,NN,O
.,.,.
,,
phenytoin,NNP,D
:,:,O
serum,NN,O
phenytoin,NN,D
levels,NNS,O
may,MD,O
be,VB,O
increased,VBN,O
by,IN,O
aspirin,NN,B
.,.,.
,,
propranolol,NN,D
:,:,O
may,NNP,O
decrease,VB,O
aspirins,NNS,B
anti-inflammatory,JJ,G
action,NN,O
by,IN,O
competing,VBG,O
for,IN,O
the,DT,O
same,JJ,O
receptors,NNS,O
.,.,.
,,
antacids,NNS,G
:,:,O
enteric,JJ,O
coated,JJ,O
aspirin,NN,B
should,MD,O
not,RB,O
be,VB,O
given,VBN,O
concurrently,RB,O
with,IN,O
antacids,NNS,G
",",",",O
since,IN,O
an,DT,O
increase,NN,O
in,IN,O
the,DT,O
ph,NN,O
of,IN,O
the,DT,O
stomach,NN,O
may,MD,O
effect,VB,O
the,DT,O
enteric,JJ,O
coating,NN,O
of,IN,O
the,DT,O
tablets,NNS,O
.,.,.
,,
ketoconazole/itraconazole,NNP,O
",",",",O
macrolides,NNP,G
",",",",O
including,VBG,O
erythromyci,NNP,O
.,.,.
,,
catecholamine-depleting,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
eg,FW,O
",",",",O
reserpine,NN,D
-rrb-,-RRB-,O
may,MD,O
have,VB,O
an,DT,O
additive,JJ,O
effect,NN,O
when,WRB,O
given,VBN,O
with,IN,O
beta-blocking,JJ,D
agents,NNS,O
.,.,.
,,
patients,NNS,O
treated,VBN,O
with,IN,O
tenormin,NN,B
plus,CC,O
a,DT,O
catecholamine,NN,O
depletor,NN,O
should,MD,O
therefore,RB,O
be,VB,O
closely,RB,O
observed,VBN,O
for,IN,O
evidence,NN,O
of,IN,O
hypotension,NN,O
and/or,CC,O
marked,JJ,O
bradycardia,NN,O
which,WDT,O
may,MD,O
produce,VB,O
vertigo,NN,O
",",",",O
syncope,NN,O
",",",",O
or,CC,O
postural,JJ,O
hypotension,NN,O
.,.,.
,,
calcium,NN,D
channel,NN,O
blockers,NNS,O
may,MD,O
also,RB,O
have,VB,O
an,DT,O
additive,JJ,O
effect,NN,O
when,WRB,O
given,VBN,O
with,IN,O
tenormin,NN,B
.,.,.
,,
beta,NN,O
blockers,NNS,O
may,MD,O
exacerbate,VB,O
the,DT,O
rebound,NN,O
hypertension,NN,O
which,WDT,O
can,MD,O
follow,VB,O
the,DT,O
withdrawal,NN,O
of,IN,O
clonidine,NN,D
.,.,.
,,
if,IN,O
the,DT,O
two,CD,O
drugs,NNS,D
are,VBP,O
coadministered,VBN,O
",",",",O
the,DT,O
beta,NN,O
blocker,NN,O
should,MD,O
be,VB,O
withdrawn,VBN,O
several,JJ,O
days,NNS,O
before,IN,O
the,DT,O
gradual,JJ,O
withdrawal,NN,O
of,IN,O
clonidine,NN,D
.,.,.
,,
if,IN,O
replacing,VBG,O
clonidine,NN,D
by,IN,O
beta-blocker,NN,G
therapy,NN,O
",",",",O
the,DT,O
introduction,NN,O
of,IN,O
beta,NN,O
blockers,NNS,O
should,MD,O
be,VB,O
delayed,VBN,O
for,IN,O
several,JJ,O
days,NNS,O
after,IN,O
clonidine,NN,D
administration,NN,O
has,VBZ,O
stopped,VBN,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
prostaglandin,NN,O
synthase,NN,O
inhibiting,VBG,O
drugs,NNS,D
",",",",O
eg,FW,O
",",",",O
indomethacin,NN,D
",",",",O
may,MD,O
decrease,VB,O
the,DT,O
hypotensive,JJ,O
effects,NNS,O
of,IN,O
beta,NN,O
blockers,NNS,O
.,.,.
,,
information,NN,O
on,IN,O
concurrent,JJ,O
usage,NN,O
of,IN,O
atenolol,NN,D
and,CC,O
aspirin,NN,B
is,VBZ,O
limited,VBN,O
.,.,.
,,
data,NNS,O
from,IN,O
several,JJ,O
studies,NNS,O
",",",",O
ie,FW,O
",",",",O
timi-ii,NN,O
",",",",O
isis-2,NN,O
",",",",O
currently,RB,O
do,VBP,O
not,RB,O
suggest,VB,O
any,DT,O
clinical,JJ,O
interaction,NN,O
between,IN,O
aspirin,NN,B
and,CC,O
beta,NN,O
blockers,NNS,O
in,IN,O
the,DT,O
acute,JJ,O
myocardial,JJ,O
infarction,NN,O
setting,NN,O
.,.,.
,,
while,IN,O
taking,VBG,O
beta,NN,O
blockers,NNS,O
",",",",O
patients,NNS,O
with,IN,O
a,DT,O
history,NN,O
of,IN,O
anaphylactic,JJ,O
reaction,NN,O
to,TO,O
a,DT,O
variety,NN,O
of,IN,O
allergens,NNS,O
may,MD,O
have,VB,O
a,DT,O
more,RBR,O
severe,JJ,O
reaction,NN,O
on,IN,O
repeated,VBN,O
challenge,NN,O
",",",",O
either,CC,O
accidental,JJ,O
",",",",O
diagnostic,JJ,O
or,CC,O
therapeutic,JJ,O
.,.,.
,,
such,JJ,O
patients,NNS,O
may,MD,O
be,VB,O
unresponsive,JJ,O
to,TO,O
the,DT,O
usual,JJ,O
doses,NNS,O
of,IN,O
epinephrine,NN,D
used,VBN,O
to,TO,O
treat,VB,O
the,DT,O
allergic,JJ,O
reaction,NN,O
.,.,.
,,
drug-drug,NNP,O
interactions,NNS,O
albuterol,NNP,D
-,:,O
strattera,NN,B
should,MD,O
be,VB,O
administered,VBN,O
with,IN,O
caution,NN,O
to,TO,O
patients,NNS,O
being,VBG,O
treated,VBN,O
with,IN,O
systemically-administered,JJ,O
-lrb-,-LRB-,O
oral,JJ,O
or,CC,O
intravenous,JJ,O
-rrb-,-RRB-,O
albuterol,NN,D
-lrb-,-LRB-,O
or,CC,O
other,JJ,O
beta2,NN,O
agonists,NNS,O
-rrb-,-RRB-,O
because,IN,O
the,DT,O
action,NN,O
of,IN,O
albuterol,NN,D
on,IN,O
the,DT,O
cardiovascular,JJ,O
system,NN,O
can,MD,O
be,VB,O
potentiated,JJ,O
resulting,VBG,O
in,IN,O
increases,NNS,O
in,IN,O
heart,NN,O
rate,NN,O
and,CC,O
blood,NN,O
pressure,NN,O
.,.,.
,,
cyp2d6,NN,D
inhibitors,NNS,O
-,:,O
atomoxetine,NN,D
is,VBZ,O
primarily,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
cyp2d6,NN,D
pathway,NN,O
to,TO,O
4-hydroxyatomoxetine,NN,D_n
.,.,.
,,
in,IN,O
ems,NNS,O
",",",",O
selective,JJ,O
inhibitors,NNS,O
of,IN,O
cyp2d6,NN,D
increase,NN,O
atomoxetine,NN,D
steady-state,JJ,O
plasma,NN,O
concentrations,NNS,O
to,TO,O
exposures,NNS,O
similar,JJ,O
to,TO,O
those,DT,O
observed,VBN,O
in,IN,O
pms,NNS,O
.,.,.
,,
dosage,NN,O
adjustment,NN,O
of,IN,O
strattera,NNP,B
may,MD,O
be,VB,O
necessary,JJ,O
when,WRB,O
coadministered,VBN,O
with,IN,O
cyp2d6,NN,D
inhibitors,NNS,O
",",",",O
e.g.,FW,O
",",",",O
paroxetine,NN,D
",",",",O
fluoxetine,NN,D
",",",",O
and,CC,O
quinidine,NN,D
.,.,.
,,
in,IN,O
em,NN,O
individuals,NNS,O
treated,VBN,O
with,IN,O
paroxetine,NN,D
or,CC,O
fluoxetine,NN,D
",",",",O
the,DT,O
auc,NN,O
of,IN,O
atomoxetine,NN,D
is,VBZ,O
approximately,RB,O
6,CD,O
-,:,O
to,TO,O
8-fold,JJ,O
and,CC,O
css,NN,O
",",",",O
max,NN,O
is,VBZ,O
about,IN,O
3,CD,O
-,:,O
to,TO,O
4-fold,RB,O
greater,JJR,O
than,IN,O
atomoxetine,NN,D
alone,RB,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
suggest,VBP,O
that,IN,O
coadministration,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
inhibitors,NNS,O
to,TO,O
pms,NNS,O
will,MD,O
not,RB,O
increase,VB,O
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
atomoxetine,NN,D
.,.,.
,,
pressor,NNP,O
agents,NNS,O
-,:,O
because,IN,O
of,IN,O
possible,JJ,O
effects,NNS,O
on,IN,O
blood,NN,O
pressure,NN,O
",",",",O
strattera,NN,B
should,MD,O
be,VB,O
used,VBN,O
cautiously,RB,O
with,IN,O
pressor,NN,O
agents,NNS,O
.,.,.
,,
the,DT,O
risk,NN,O
of,IN,O
myopathy,NN,O
during,IN,O
treatment,NN,O
with,IN,O
drugs,NNS,D
of,IN,O
this,DT,O
class,NN,O
is,VBZ,O
increased,VBN,O
with,IN,O
concurrent,JJ,O
administration,NN,O
of,IN,O
cyclosporine,NN,D
",",",",O
fibric,JJ,O
acid,NN,O
derivatives,NNS,O
",",",",O
niacin,NN,D
-lrb-,-LRB-,O
nicotinic,JJ,O
acid,NN,O
-rrb-,-RRB-,O
",",",",O
erythromycin,NN,D
",",",",O
azole,NN,O
antifungals,NNS,G
.,.,.
,,
antacid,NN,G
:,:,O
when,WRB,O
atorvastatin,NN,D
and,CC,O
maalox,NNP,B
tc,NNP,O
suspension,NN,O
were,VBD,O
coadministered,VBN,O
",",",",O
plasma,NN,O
concentrations,NNS,O
of,IN,O
atorvastatin,NN,D
decreased,VBD,O
approximately,RB,O
35,CD,O
%,NN,O
.,.,.
,,
however,RB,O
",",",",O
ldl-c,NN,O
reduction,NN,O
was,VBD,O
not,RB,O
altered,VBN,O
.,.,.
,,
antipyrine,NNP,D
:,:,O
because,IN,O
atorvastatin,NN,D
does,VBZ,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
antipyrine,NN,D
",",",",O
interactions,NNS,O
with,IN,O
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
via,IN,O
the,DT,O
same,JJ,O
cytochrome,NN,O
isozymes,NNS,O
are,VBP,O
not,RB,O
expected,VBN,O
.,.,.
,,
colestipol,NNP,D
:,:,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
atorvastatin,NN,D
decreased,VBD,O
approximately,RB,O
25,CD,O
%,NN,O
when,WRB,O
colestipol,NN,D
and,CC,O
atorvastatin,NN,D
were,VBD,O
coadministered,VBN,O
.,.,.
,,
however,RB,O
",",",",O
ldl-c,NN,O
reduction,NN,O
was,VBD,O
greater,JJR,O
when,WRB,O
atorvastatin,NN,D
and,CC,O
colestipol,NN,D
were,VBD,O
coadministered,VBN,O
than,IN,O
when,WRB,O
either,CC,O
drug,NN,D
was,VBD,O
given,VBN,O
alone,RB,O
.,.,.
,,
cimetidine,NNP,D
:,:,O
atorvastatin,NNP,D
plasma,NN,O
concentrations,NNS,O
and,CC,O
ldl-c,NN,O
reduction,NN,O
were,VBD,O
not,RB,O
altered,VBN,O
by,IN,O
coadministration,NN,O
of,IN,O
cimetidine,NN,D
.,.,.
,,
digoxin,NNP,D
:,:,O
when,WRB,O
multiple,JJ,O
doses,NNS,O
of,IN,O
atorvastatin,NN,D
and,CC,O
digoxin,NN,D
were,VBD,O
coadministered,VBN,O
",",",",O
steady-state,JJ,O
plasma,NN,O
digoxin,NN,D
concentrations,NNS,O
increased,VBN,O
by,IN,O
approximately,RB,O
20,CD,O
%,NN,O
.,.,.
,,
patients,NNS,O
taking,VBG,O
digoxin,NN,D
should,MD,O
be,VB,O
monitored,VBN,O
appropriately,RB,O
.,.,.
,,
erythromycin,NNP,D
:,:,O
in,IN,O
healthy,JJ,O
individuals,NNS,O
",",",",O
plasma,NN,O
concentrations,NNS,O
of,IN,O
atorvastatin,NN,D
increased,VBD,O
approximately,RB,O
40,CD,O
%,NN,O
with,IN,O
coadministration,NN,O
of,IN,O
atorvastatin,NN,D
and,CC,O
erythromycin,NN,D
",",",",O
a,DT,O
known,JJ,O
inhibitor,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
.,.,.
,,
oral,JJ,O
contraceptives,NNS,G
:,:,O
coadministration,NN,O
of,IN,O
atorvastatin,NN,D
and,CC,O
an,DT,O
oral,JJ,O
contraceptive,NN,G
increased,VBD,O
auc,NN,O
values,NNS,O
for,IN,O
norethindrone,NN,D
and,CC,O
ethinyl,NN,O
estradiol,NN,O
by,IN,O
approximately,RB,O
30,CD,O
%,NN,O
and,CC,O
20,CD,O
%,NN,O
.,.,.
,,
these,DT,O
increases,NNS,O
should,MD,O
be,VB,O
considered,VBN,O
when,WRB,O
selecting,VBG,O
an,DT,O
oral,JJ,O
contraceptive,NN,G
for,IN,O
a,DT,O
woman,NN,O
taking,VBG,O
atorvastatin,NN,D
.,.,.
,,
warfarin,NNP,D
:,:,O
atorvastatin,NNP,D
had,VBD,O
no,DT,O
clinically,RB,O
significant,JJ,O
effect,NN,O
on,IN,O
prothrombin,NN,O
time,NN,O
when,WRB,O
administered,VBN,O
to,TO,O
patients,NNS,O
receiving,VBG,O
chronic,JJ,O
warfarin,NN,D
treatment,NN,O
.,.,.
,,
endocrine,JJ,O
function,NN,O
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
interfere,VBP,O
with,IN,O
cholesterol,NN,O
synthesis,NN,O
and,CC,O
theoretically,RB,O
might,MD,O
blunt,VB,O
adrenal,JJ,O
and/or,CC,O
gonadal,JJ,O
steroid,NN,G
production,NN,O
.,.,.
,,
clinical,JJ,O
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
atorvastatin,NN,D
does,VBZ,O
not,RB,O
reduce,VB,O
basal,JJ,O
plasma,NN,O
cortisol,NN,O
concentration,NN,O
or,CC,O
impair,VB,O
adrenal,JJ,O
reserve,NN,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
on,IN,O
male,JJ,O
fertility,NN,O
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
in,IN,O
adequate,JJ,O
numbers,NNS,O
of,IN,O
patients,NNS,O
.,.,.
,,
the,DT,O
effects,NNS,O
",",",",O
if,IN,O
any,DT,O
",",",",O
on,IN,O
the,DT,O
pituitary-gonadal,JJ,O
axis,NN,O
in,IN,O
premenopausal,JJ,O
women,NNS,O
are,VBP,O
unknown,JJ,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
if,IN,O
an,DT,O
hmg-coa,NN,O
reductase,NN,O
inhibitor,NN,O
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
drugs,NNS,D
that,WDT,O
may,MD,O
decrease,VB,O
the,DT,O
levels,NNS,O
or,CC,O
activity,NN,O
of,IN,O
endogenous,JJ,O
steroid,NN,G
hormones,NNS,O
",",",",O
such,JJ,O
as,IN,O
ketoconazole,NN,D
",",",",O
spironolactone,NN,D
",",",",O
and,CC,O
cimetidine,NN,D
.,.,.
,,
cns,NN,O
toxicity,NN,O
brain,NN,O
hemorrhage,NN,O
was,VBD,O
seen,VBN,O
in,IN,O
a,DT,O
female,JJ,O
dog,NN,O
treated,VBN,O
for,IN,O
3,CD,O
months,NNS,O
at,IN,O
120,CD,O
mg/kg/day,NN,O
.,.,.
,,
brain,NN,O
hemorrhage,NN,O
and,CC,O
optic,JJ,O
nerve,NN,O
vacuolation,NN,O
were,VBD,O
seen,VBN,O
in,IN,O
another,DT,O
female,JJ,O
dog,NN,O
that,WDT,O
was,VBD,O
sacrificed,VBN,O
in,IN,O
moribund,JJ,O
condition,NN,O
after,IN,O
11,CD,O
weeks,NNS,O
of,IN,O
escalating,VBG,O
doses,NNS,O
up,RB,O
to,TO,O
280,CD,O
mg/kg/day,NN,O
.,.,.
,,
the,DT,O
120,CD,O
mg/kg,NN,O
dose,NN,O
resulted,VBD,O
in,IN,O
a,DT,O
systemic,JJ,O
exposure,NN,O
approximately,RB,O
16,CD,O
times,NNS,O
the,DT,O
human,JJ,O
plasma,NN,O
area-under-the-curve,NN,O
-lrb-,-LRB-,O
auc,NN,O
",",",",O
0-24,CD,O
hours,NNS,O
-rrb-,-RRB-,O
based,VBN,O
on,IN,O
the,DT,O
maximum,NN,O
human,JJ,O
dose,NN,O
of,IN,O
80,CD,O
mg/day,NN,O
.,.,.
,,
a,DT,O
single,JJ,O
tonic,JJ,O
convulsion,NN,O
was,VBD,O
seen,VBN,O
in,IN,O
each,DT,O
of,IN,O
2,CD,O
male,JJ,O
dogs,NNS,O
-lrb-,-LRB-,O
one,CD,O
treated,VBN,O
at,IN,O
10,CD,O
mg/kg/day,NN,O
and,CC,O
one,CD,O
at,IN,O
120,CD,O
mg/kg/day,NN,O
-rrb-,-RRB-,O
in,IN,O
a,DT,O
2-year,JJ,O
study,NN,O
.,.,.
,,
no,DT,O
cns,NN,O
lesions,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
in,IN,O
mice,NNS,O
after,IN,O
chronic,JJ,O
treatment,NN,O
for,IN,O
up,RB,O
to,TO,O
2,CD,O
years,NNS,O
at,IN,O
doses,NNS,O
up,RB,O
to,TO,O
400,CD,O
mg/kg/day,NN,O
or,CC,O
in,IN,O
rats,NNS,O
at,IN,O
doses,NNS,O
up,RB,O
to,TO,O
100,CD,O
mg/kg/day,NN,O
.,.,.
,,
these,DT,O
doses,NNS,O
were,VBD,O
6,CD,O
to,TO,O
11,CD,O
times,NNS,O
-lrb-,-LRB-,O
mouse,NN,O
-rrb-,-RRB-,O
and,CC,O
8,CD,O
to,TO,O
16,CD,O
times,NNS,O
-lrb-,-LRB-,O
rat,NN,O
-rrb-,-RRB-,O
the,DT,O
human,JJ,O
auc,NN,O
-lrb-,-LRB-,O
0-24,CD,O
-rrb-,-RRB-,O
based,VBN,O
on,IN,O
the,DT,O
maximum,NN,O
recommended,VBD,O
human,JJ,O
dose,NN,O
of,IN,O
80,CD,O
mg/day,NN,O
.,.,.
,,
cns,NN,O
vascular,JJ,O
lesions,NNS,O
",",",",O
characterized,VBN,O
by,IN,O
perivascular,JJ,O
hemorrhages,NNS,O
",",",",O
edema,NN,O
",",",",O
and,CC,O
mononuclear,JJ,O
cell,NN,O
infiltration,NN,O
of,IN,O
perivascular,JJ,O
spaces,NNS,O
",",",",O
have,VBP,O
been,VBN,O
observed,VBN,O
in,IN,O
dogs,NNS,O
treated,VBN,O
with,IN,O
other,JJ,O
members,NNS,O
of,IN,O
this,DT,O
class,NN,O
.,.,.
,,
a,DT,O
chemically,RB,O
similar,JJ,O
drug,NN,D
in,IN,O
this,DT,O
class,NN,O
produced,VBD,O
optic,JJ,O
nerve,NN,O
degeneration,NN,O
-lrb-,-LRB-,O
wallerian,JJ,O
degeneration,NN,O
of,IN,O
retinogeniculate,NN,O
fibers,NNS,O
-rrb-,-RRB-,O
in,IN,O
clinically,RB,O
normal,JJ,O
dogs,NNS,O
in,IN,O
a,DT,O
dose-dependent,JJ,O
fashion,NN,O
at,IN,O
a,DT,O
dose,NN,O
that,WDT,O
produced,VBD,O
plasma,NN,O
drug,NN,D
levels,NNS,O
about,IN,O
30,CD,O
times,NNS,O
higher,JJR,O
than,IN,O
the,DT,O
mean,NN,O
drug,NN,D
level,NN,O
in,IN,O
humans,NNS,O
taking,VBG,O
the,DT,O
highest,JJS,O
recommended,VBN,O
dose,NN,O
.,.,.
,,
atovaquone,NNP,D
is,VBZ,O
highly,RB,O
bound,VBN,O
to,TO,O
plasma,NN,O
protein,NN,O
-lrb-,-LRB-,O
99.9,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
therefore,RB,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
when,WRB,O
administering,VBG,O
mepron,NNP,B
concurrently,RB,O
with,IN,O
other,JJ,O
highly,RB,O
plasma,NN,O
protein,NN,O
-,:,O
bound,VBN,O
drugs,NNS,D
with,IN,O
narrow,JJ,O
therapeutic,JJ,O
indices,NNS,O
",",",",O
as,IN,O
competition,NN,O
for,IN,O
binding,VBG,O
sites,NNS,O
may,MD,O
occur,VB,O
.,.,.
,,
the,DT,O
extent,NN,O
of,IN,O
plasma,NN,O
protein,NN,O
binding,NN,O
of,IN,O
atovaquone,NN,D
in,IN,O
human,JJ,O
plasma,NN,O
is,VBZ,O
not,RB,O
affected,VBN,O
by,IN,O
the,DT,O
presence,NN,O
of,IN,O
therapeutic,JJ,O
concentrations,NNS,O
of,IN,O
phenytoin,NN,D
-lrb-,-LRB-,O
15,CD,O
mcg,NN,O
/,:,O
ml,NN,O
-rrb-,-RRB-,O
",",",",O
nor,CC,O
is,VBZ,O
the,DT,O
binding,NN,O
of,IN,O
phenytoin,NN,D
affected,VBN,O
by,IN,O
the,DT,O
presence,NN,O
of,IN,O
atovaquone,NN,D
.,.,.
,,
rifampin,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
rifampin,NN,D
and,CC,O
mepron,NNP,B
suspension,NNP,O
results,VBZ,O
in,IN,O
a,DT,O
significant,JJ,O
decrease,NN,O
in,IN,O
average,JJ,O
steady,JJ,O
-,:,O
state,NN,O
plasma,NN,O
atovaquone,NN,D
concentrations,NNS,O
.,.,.
,,
alternatives,NNP,O
to,TO,O
rifampin,NN,D
should,MD,O
be,VB,O
considered,VBN,O
during,IN,O
the,DT,O
course,NN,O
of,IN,O
pcp,NN,O
treatment,NN,O
with,IN,O
mepron,NN,B
.,.,.
,,
rifabutin,NNP,D
",",",",O
another,DT,O
rifamycin,NN,D
",",",",O
is,VBZ,O
structurally,RB,O
similar,JJ,O
to,TO,O
rifampin,NN,D
and,CC,O
may,MD,O
possibly,RB,O
have,VB,O
some,DT,O
of,IN,O
the,DT,O
same,JJ,O
drug,NN,D
interactions,NNS,O
as,IN,O
rifampin,NN,D
.,.,.
,,
no,DT,O
interaction,NN,O
trials,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
with,IN,O
mepron,NN,B
and,CC,O
rifabutin,NN,D
.,.,.
,,
drug,NN,O
/,:,O
laboratory,NNP,O
test,NNP,O
interactions,NNS,O
:,:,O
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
if,IN,O
mepron,NN,B
interferes,VBZ,O
with,IN,O
clinical,JJ,O
laboratory,NN,O
test,NN,O
or,CC,O
assay,NN,O
results,NNS,O
.,.,.
,,
drugs,NNS,O
which,WDT,O
may,MD,O
enhance,VB,O
the,DT,O
neuromuscular,JJ,O
blocking,VBG,O
action,NN,O
of,IN,O
tracrium,NN,B
include,VBP,O
:,:,O
enflurane,NN,D
.,.,.
,,
isoflurane,NN,D
.,.,.
,,
halothane,NN,D
.,.,.
,,
certain,JJ,O
antibiotics,NNS,G
",",",",O
especially,RB,O
the,DT,O
aminoglycosides,NNS,G
and,CC,O
polymyxins,NNS,G
.,.,.
,,
lithium,NN,D
.,.,.
,,
magnesium,NN,D
salts,NNS,O
.,.,.
,,
procainamide,NN,D
.,.,.
,,
drugs,NNS,O
which,WDT,O
may,MD,O
enhance,VB,O
the,DT,O
neuromuscular,JJ,O
blocking,VBG,O
action,NN,O
of,IN,O
tracrium,NN,B
include,VBP,O
:,:,O
enflurane,NN,D
;,:,O
isoflurane,NN,D
;,:,O
halothane,NN,D
;,:,O
certain,JJ,O
antibiotics,NNS,G
",",",",O
especially,RB,O
the,DT,O
aminoglycosides,NNS,G
and,CC,O
polymyxins,NNS,G
;,:,O
lithium,NN,D
;,:,O
magnesium,NN,D
salts,NNS,O
;,:,O
procainamide,NN,D
;,:,O
and,CC,O
quinidine,NN,D
.,.,.
,,
if,IN,O
other,JJ,O
muscle,NN,O
relaxants,NNS,O
are,VBP,O
used,VBN,O
during,IN,O
the,DT,O
same,JJ,O
procedure,NN,O
",",",",O
the,DT,O
possibility,NN,O
of,IN,O
a,DT,O
synergistic,JJ,O
or,CC,O
antagonist,NN,O
effect,NN,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
the,DT,O
prior,JJ,O
administration,NN,O
of,IN,O
succinylcholine,NN,D
does,VBZ,O
not,RB,O
enhance,VB,O
the,DT,O
duration,NN,O
",",",",O
but,CC,O
quickens,VBZ,O
the,DT,O
onset,NN,O
and,CC,O
may,MD,O
increase,VB,O
the,DT,O
depth,NN,O
",",",",O
of,IN,O
neuromuscular,JJ,O
block,NN,O
induced,VBN,O
by,IN,O
tracrium,NN,B
.,.,.
,,
tracrium,NN,B
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
until,IN,O
a,DT,O
patient,NN,O
has,VBZ,O
recovered,VBN,O
from,IN,O
succinylcholine-induced,JJ,O
neuromuscular,JJ,O
block,NN,O
.,.,.
,,
when,WRB,O
atropine,NN,D
and,CC,O
pralidoxime,NN,D
are,VBP,O
used,VBN,O
together,RB,O
",",",",O
the,DT,O
signs,NNS,O
of,IN,O
atropinization,NN,O
-lrb-,-LRB-,O
flushing,NN,O
",",",",O
mydriasis,NN,O
",",",",O
tachycardia,NN,O
",",",",O
dryness,NN,O
of,IN,O
the,DT,O
mouth,NN,O
and,CC,O
nose,NN,O
-rrb-,-RRB-,O
may,MD,O
occur,VB,O
earlier,JJR,O
than,IN,O
might,MD,O
be,VB,O
expected,VBN,O
than,IN,O
when,WRB,O
atropine,NN,D
is,VBZ,O
used,VBN,O
alone,RB,O
because,IN,O
pralidoxime,NN,D
may,MD,O
potentiate,VB,O
the,DT,O
effect,NN,O
of,IN,O
atropine,NN,D
.,.,.
,,
the,DT,O
following,VBG,O
precautions,NNS,O
should,MD,O
be,VB,O
kept,VBN,O
in,IN,O
mind,NN,O
in,IN,O
the,DT,O
treatment,NN,O
of,IN,O
anticholinesterase,JJ,G
poisoning,NN,O
although,IN,O
they,PRP,O
do,VBP,O
not,RB,O
bear,VB,O
directly,RB,O
on,IN,O
the,DT,O
use,NN,O
of,IN,O
atropine,NN,D
and,CC,O
pralidoxime,NN,D
.,.,.
,,
since,IN,O
barbiturates,NNS,G
are,VBP,O
potentiated,VBN,O
by,IN,O
the,DT,O
anticholinesterases,NNS,G
",",",",O
they,PRP,O
should,MD,O
be,VB,O
used,VBN,O
cautiously,RB,O
in,IN,O
the,DT,O
treatment,NN,O
of,IN,O
convulsions,NNS,O
.,.,.
,,
auranofin,NNP,D
should,MD,O
be,VB,O
avoided,VBN,O
by,IN,O
patients,NNS,O
with,IN,O
a,DT,O
history,NN,O
of,IN,O
serious,JJ,O
reaction,NN,O
to,TO,O
any,DT,O
gold,NN,D
medication,NN,O
",",",",O
including,VBG,O
solganal,NNP,B
and,CC,O
myochrysine,NNP,B
.,.,.
,,
auranofin,NNP,D
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
together,RP,O
with,IN,O
penicillamine,NN,D
-lrb-,-LRB-,O
depen,NN,B
",",",",O
cuprimine,NN,B
-rrb-,-RRB-,O
",",",",O
another,DT,O
arthritis,NN,O
medication,NN,O
.,.,.
,,
it,PRP,O
should,MD,O
also,RB,O
be,VB,O
avoided,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
blood,NN,O
",",",",O
liver,NN,O
or,CC,O
kidney,NN,O
diseases,NNS,O
",",",",O
recent,JJ,O
radiation,NN,O
treatment,NN,O
",",",",O
or,CC,O
uncontrolled,JJ,O
diabetes,NN,O
.,.,.
,,
patients,NNS,O
should,MD,O
report,VB,O
to,TO,O
their,PRP$,O
practitioners,NNS,O
any,DT,O
new,JJ,O
rashes,NNS,O
",",",",O
itching,VBG,O
",",",",O
mouth,NN,O
sores,NNS,O
",",",",O
or,CC,O
unusual,JJ,O
taste,NN,O
while,IN,O
taking,VBG,O
auranofin,NN,D
.,.,.
,,
gold,NN,D
is,VBZ,O
excreted,VBN,O
slowly,RB,O
from,IN,O
the,DT,O
body,NN,O
.,.,.
,,
safety,NN,O
and,CC,O
effectiveness,NN,O
in,IN,O
children,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
no,DT,O
formal,JJ,O
assessments,NNS,O
of,IN,O
drug-drug,JJ,O
interactions,NNS,O
between,IN,O
vidaza,NNP,B
and,CC,O
other,JJ,O
agents,NNS,O
have,VBP,O
been,VBN,O
conducte,NN,O
.,.,.
,,
mao,NN,O
inhibitors,NNS,O
prolong,VB,O
and,CC,O
intensify,VB,O
the,DT,O
effects,NNS,O
of,IN,O
antihistamines,NNS,G
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
antihistamines,NNS,G
with,IN,O
alcohol,NN,D
",",",",O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
barbiturates,NNS,G
",",",",O
or,CC,O
other,JJ,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressants,NNS,O
may,MD,O
have,VB,O
an,DT,O
additive,JJ,O
effect,NN,O
.,.,.
,,
when,WRB,O
sympathomimetic,JJ,G
drugs,NNS,D
are,VBP,O
given,VBN,O
to,TO,O
patients,NNS,O
receiving,VBG,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
",",",",O
hypertensive,JJ,O
reactions,NNS,O
",",",",O
including,VBG,O
hypertensive,JJ,O
crises,NNS,O
",",",",O
may,MD,O
occur,VB,O
.,.,.
,,
the,DT,O
antihypertensive,JJ,G
effects,NNS,O
of,IN,O
methyldopa,NN,D
",",",",O
mecamylamine,NN,D
",",",",O
reserpine,NN,D
",",",",O
and,CC,O
veratrum,NN,O
alkaloids,NNS,O
may,MD,O
be,VB,O
reduced,VBN,O
by,IN,O
sympathomimetics,NNS,G
.,.,.
,,
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
may,MD,O
also,RB,O
interact,VB,O
with,IN,O
sympathomimetics,NNS,G
.,.,.
,,
increased,VBN,O
ectopic,JJ,O
pacemaker,NN,O
activity,NN,O
can,MD,O
occur,VB,O
when,WRB,O
pseudoephedrine,NN,D
is,VBZ,O
used,VBN,O
concomitantly,RB,O
with,IN,O
digitalis,NN,G
.,.,.
,,
antacids,NNS,G
increase,VBP,O
the,DT,O
rate,NN,O
of,IN,O
absorption,NN,O
of,IN,O
pseudoephedrine,NN,D
",",",",O
while,IN,O
kaolin,NN,D
decreases,VBZ,O
it,PRP,O
.,.,.
,,
use,NN,O
with,IN,O
allopurinol,NNP,D
:,:,O
the,DT,O
principal,JJ,O
pathway,NN,O
for,IN,O
detoxification,NN,O
of,IN,O
azathioprine,NN,D
is,VBZ,O
inhibited,VBN,O
by,IN,O
allopurinol,NN,D
.,.,.
,,
patients,NNS,O
receiving,VBG,O
azathioprine,NN,D
and,CC,O
allopurinol,NN,D
concomitantly,RB,O
should,MD,O
have,VB,O
a,DT,O
dose,NN,O
reduction,NN,O
of,IN,O
azathioprine,NN,D
",",",",O
to,TO,O
approximately,RB,O
3-Jan,CD,O
to,TO,O
4-Jan,CD,O
the,DT,O
usual,JJ,O
dose,NN,O
.,.,.
,,
use,NN,O
with,IN,O
other,JJ,O
agents,NNS,O
affecting,VBG,O
myelopoesis,NNP,O
:,:,O
drugs,NNS,O
which,WDT,O
may,MD,O
affect,VB,O
leukocyte,NN,O
production,NN,O
",",",",O
including,VBG,O
co-trimoxazole,NN,B
",",",",O
may,MD,O
lead,VB,O
to,TO,O
exaggerated,JJ,O
leukopenia,NN,O
",",",",O
especially,RB,O
in,IN,O
renal,JJ,O
transplant,NN,O
recipients,NNS,O
.,.,.
,,
use,NN,O
with,IN,O
angiotensln,NNP,O
converting,NNP,O
enzyme,NNP,O
inhibitors,NNS,O
:,:,O
the,DT,O
use,NN,O
of,IN,O
angiotensin,NN,O
converting,VBG,O
enzyme,NN,O
inhibitors,NNS,O
to,TO,O
control,VB,O
hypertension,NN,O
in,IN,O
patients,NNS,O
on,IN,O
azathioprine,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
induce,VB,O
severe,JJ,O
leukopenia,NN,O
.,.,.
,,
no,DT,O
information,NN,O
provided,VBN,O
.,.,.
,,
co-administration,NN,O
of,IN,O
nelfinavir,NN,D
at,IN,O
steady-state,JJ,O
with,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
azithromycin,NN,D
.,.,.
,,
co-administration,NN,O
of,IN,O
nelfinavir,NN,D
at,IN,O
steady-state,JJ,O
with,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
azithromycin,NN,D
-lrb-,-LRB-,O
2,CD,O
x,CC,O
600,CD,O
mg,NN,O
tablets,NNS,O
-rrb-,-RRB-,O
results,VBZ,O
in,IN,O
increased,VBN,O
azithromycin,NN,D
serum,NN,O
concentrations,NNS,O
.,.,.
,,
although,IN,O
a,DT,O
dose,NN,O
adjustment,NN,O
of,IN,O
azithromycin,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
when,WRB,O
administered,VBN,O
in,IN,O
combination,NN,O
with,IN,O
nelfinavir,NN,D
",",",",O
close,JJ,O
monitoring,NN,O
for,IN,O
known,JJ,O
side,JJ,O
effects,NNS,O
of,IN,O
azithromycin,NN,D
",",",",O
such,JJ,O
as,IN,O
liver,NN,O
enzyme,NN,O
abnormalities,NNS,O
and,CC,O
hearing,VBG,O
impairment,NN,O
",",",",O
is,VBZ,O
warranted,VBN,O
.,.,.
,,
azithromycin,NNP,D
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
prothrombin,NN,O
time,NN,O
response,NN,O
to,TO,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
warfarin,NN,D
.,.,.
,,
however,RB,O
",",",",O
prudent,JJ,O
medical,JJ,O
practice,NN,O
dictates,VBZ,O
careful,JJ,O
monitoring,NN,O
of,IN,O
prothrombin,NN,O
time,NN,O
in,IN,O
all,DT,O
patients,NNS,O
treated,VBN,O
with,IN,O
azithromycin,NN,D
and,CC,O
warfarin,NN,D
concomitantly,RB,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
of,IN,O
macrolides,NNS,G
and,CC,O
warfarin,NN,D
in,IN,O
clinical,JJ,O
practice,NN,O
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
increased,VBN,O
anticoagulant,JJ,G
effects,NNS,O
.,.,.
,,
drug,NN,O
interaction,NN,O
studies,NNS,O
were,VBD,O
performed,VBN,O
with,IN,O
azithromycin,NN,D
and,CC,O
other,JJ,O
drugs,NNS,D
likely,JJ,O
to,TO,O
be,VB,O
co-administered,VBN,O
.,.,.
,,
when,WRB,O
used,VBN,O
in,IN,O
therapeutic,JJ,O
doses,NNS,O
",",",",O
azithromycin,NN,D
had,VBD,O
a,DT,O
modest,JJ,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
atorvastatin,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
cetirizine,NN,D
",",",",O
didanosine,NN,D
",",",",O
efavirenz,NN,D
",",",",O
fluconazole,NN,D
",",",",O
indinavir,NN,D
",",",",O
midazolam,NN,D
",",",",O
rifabutin,NN,D
",",",",O
sildenafil,NN,D
",",",",O
theophylline,NN,D
-lrb-,-LRB-,O
intravenous,JJ,O
and,CC,O
oral,JJ,O
-rrb-,-RRB-,O
",",",",O
triazolam,NN,D
",",",",O
trimethoprim/sulfamethoxazole,NN,O
or,CC,O
zidovudine,NN,D
.,.,.
,,
co-administration,NN,O
with,IN,O
efavirenz,NN,D
or,CC,O
fluconazole,NN,D
had,VBD,O
a,DT,O
modest,JJ,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
azithromycin,NN,D
.,.,.
,,
no,DT,O
dosage,NN,O
adjustment,NN,O
of,IN,O
either,CC,O
drug,NN,D
is,VBZ,O
recommended,VBN,O
when,WRB,O
azithromycin,NN,D
is,VBZ,O
co,NN,O
administered,VBN,O
with,IN,O
any,DT,O
of,IN,O
the,DT,O
above,JJ,O
agents,NNS,O
.,.,.
,,
interactions,NNS,O
with,IN,O
the,DT,O
drugs,NNS,D
listed,VBN,O
below,RB,O
have,VBP,O
not,RB,O
been,VBN,O
reported,VBN,O
in,IN,O
clinical,JJ,O
trials,NNS,O
with,IN,O
azithromycin,NN,D
.,.,.
,,
however,RB,O
",",",",O
no,DT,O
specific,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
to,TO,O
evaluate,VB,O
potential,JJ,O
drug-drug,JJ,O
interaction,NN,O
.,.,.
,,
nonetheless,RB,O
",",",",O
they,PRP,O
have,VBP,O
been,VBN,O
observed,VBN,O
with,IN,O
macrolide,NN,O
products,NNS,O
.,.,.
,,
until,IN,O
further,JJ,O
data,NNS,O
are,VBP,O
developed,VBN,O
regarding,VBG,O
drug,NN,D
interactions,NNS,O
when,WRB,O
azithromycin,NN,D
and,CC,O
these,DT,O
drugs,NNS,D
are,VBP,O
used,VBN,O
concomitantly,RB,O
",",",",O
careful,JJ,O
monitoring,NN,O
of,IN,O
patients,NNS,O
is,VBZ,O
advised,VBN,O
:,:,O
digoxin,NN,D
elevated,JJ,O
digoxin,NN,D
concentrations,NNS,O
.,.,.
,,
ergotamine,NN,D
or,CC,O
dihydroergotamine,NN,D
acute,JJ,O
ergot,NN,G
toxicity,NN,O
characterized,VBN,O
by,IN,O
severe,JJ,O
peripheral,JJ,O
vasospasm,NN,O
and,CC,O
dysesthesia,NN,O
.,.,.
,,
cyclosporine,NN,D
",",",",O
hexobarbital,NN,D
and,CC,O
phenytoin,NN,D
concentrations,NNS,O
.,.,.
,,
laboratory,NNP,O
test,NNP,O
interactions,NNS,O
there,EX,O
are,VBP,O
no,DT,O
reported,VBN,O
laboratory,NN,O
test,NN,O
interactions,NNS,O
.,.,.
,,
repeat,NN,O
treatment,NN,O
studies,NNS,O
evaluating,VBG,O
the,DT,O
use,NN,O
of,IN,O
repeated,VBN,O
courses,NNS,O
of,IN,O
zmax,NNP,B
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
azlocillin,NN,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
amikacin,NN,D
",",",",O
ciprofloxacin,NN,D
",",",",O
gentamicin,NN,D
",",",",O
netilmicin,NN,D
",",",",O
or,CC,O
tobramycin,NN,D
.,.,.
,,
injection,NN,O
there,EX,O
is,VBZ,O
inadequate,JJ,O
systematic,JJ,O
experience,NN,O
with,IN,O
the,DT,O
use,NN,O
of,IN,O
baclofen,NN,D
injection,NN,O
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
medications,NNS,O
to,TO,O
predict,VB,O
specific,JJ,O
drug-drug,JJ,O
interactions,NNS,O
.,.,.
,,
interactions,NNS,O
attributed,VBD,O
to,TO,O
the,DT,O
combined,VBN,O
use,NN,O
of,IN,O
baclofen,NN,D
injection,NN,O
and,CC,O
epidural,JJ,O
morphine,NN,D
include,VBP,O
hypotension,NN,O
and,CC,O
dyspnea,NN,O
.,.,.
,,
side,NNP,O
effects,NNP,O
-lrb-,-LRB-,O
kemstro,NNP,B
-rrb-,-RRB-,O
the,DT,O
most,RBS,O
common,JJ,O
adverse,JJ,O
reaction,NN,O
during,IN,O
treatment,NN,O
with,IN,O
baclofen,NN,D
is,VBZ,O
transient,JJ,O
drowsiness,NN,O
-lrb-,-LRB-,O
Oct-63,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
one,CD,O
controlled,JJ,O
study,NN,O
of,IN,O
175,CD,O
patients,NNS,O
",",",",O
transient,JJ,O
drowsiness,NN,O
was,VBD,O
observed,VBN,O
in,IN,O
63,CD,O
%,NN,O
of,IN,O
those,DT,O
receiving,VBG,O
baclofen,NN,D
tablets,NNS,O
compared,VBN,O
to,TO,O
36,CD,O
%,NN,O
of,IN,O
those,DT,O
in,IN,O
the,DT,O
placebo,NN,O
group,NN,O
.,.,.
,,
other,JJ,O
common,JJ,O
adverse,JJ,O
reactions,NNS,O
are,VBP,O
dizziness,NN,O
-lrb-,-LRB-,O
15-May,CD,O
%,NN,O
-rrb-,-RRB-,O
",",",",O
weakness,NN,O
-lrb-,-LRB-,O
15-May,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
fatigue,NN,O
-lrb-,-LRB-,O
4-Feb,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
others,NNS,O
reported,VBD,O
:,:,O
neuropsychiatric,NNP,O
:,:,O
confusion,NN,O
-lrb-,-LRB-,O
11-Jan,CD,O
%,NN,O
-rrb-,-RRB-,O
",",",",O
headache,NN,O
-lrb-,-LRB-,O
8-Apr,CD,O
%,NN,O
-rrb-,-RRB-,O
",",",",O
insomnia,NN,O
-lrb-,-LRB-,O
7-Feb,CD,O
%,NN,O
-rrb-,-RRB-,O
;,:,O
.,.,.
,,
and,CC,O
",",",",O
rarely,RB,O
",",",",O
euphoria,NN,O
",",",",O
excitement,NN,O
",",",",O
depression,NN,O
",",",",O
hallucinations,NNS,O
",",",",O
paresthesia,NN,O
",",",",O
muscle,NN,O
pain,NN,O
",",",",O
tinnitus,NN,O
",",",",O
slurred,VBD,O
speech,NN,O
",",",",O
coordination,NN,O
disorder,NN,O
",",",",O
tremor,NN,O
",",",",O
rigidity,NN,O
",",",",O
dystonia,NN,O
",",",",O
ataxia,NN,O
",",",",O
blurred,VBD,O
vision,NN,O
",",",",O
nystagmus,NN,O
",",",",O
strabismus,NN,O
",",",",O
miosis,NN,O
",",",",O
mydriasis,NN,O
",",",",O
diplopia,NN,O
",",",",O
dysarthria,NN,O
",",",",O
epileptic,JJ,O
seizure,NN,O
.,.,.
,,
cardiovascular,NNP,O
:,:,O
hypotension,NN,O
-lrb-,-LRB-,O
0-9,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
rare,JJ,O
instances,NNS,O
of,IN,O
dyspnea,NN,O
",",",",O
palpitation,NN,O
",",",",O
chest,NN,O
pain,NN,O
",",",",O
syncope,NN,O
.,.,.
,,
gastrointestinal,JJ,O
:,:,O
nausea,NN,O
-lrb-,-LRB-,O
12-Apr,CD,O
%,NN,O
-rrb-,-RRB-,O
",",",",O
constipation,NN,O
-lrb-,-LRB-,O
6-Feb,CD,O
%,NN,O
-rrb-,-RRB-,O
;,:,O
.,.,.
,,
and,CC,O
",",",",O
rarely,RB,O
",",",",O
dry,JJ,O
mouth,NN,O
",",",",O
anorexia,NN,O
",",",",O
taste,VBP,O
disorder,NN,O
",",",",O
abdominal,JJ,O
pain,NN,O
",",",",O
vomiting,VBG,O
",",",",O
diarrhea,NN,O
",",",",O
and,CC,O
positive,JJ,O
test,NN,O
for,IN,O
occult,VBN,O
blood,NN,O
in,IN,O
stool,NN,O
.,.,.
,,
genitourinary,NNP,O
:,:,O
urinary,JJ,O
frequency,NN,O
-lrb-,-LRB-,O
6-Feb,CD,O
%,NN,O
-rrb-,-RRB-,O
;,:,O
.,.,.
,,
and,CC,O
",",",",O
rarely,RB,O
",",",",O
enuresis,NN,O
",",",",O
urinary,JJ,O
retention,NN,O
",",",",O
dysuria,NN,O
",",",",O
impotence,NN,O
",",",",O
inability,NN,O
to,TO,O
ejaculate,VB,O
",",",",O
nocturia,NN,O
",",",",O
hematuria,NN,O
.,.,.
,,
other,JJ,O
:,:,O
instances,NNS,O
of,IN,O
rash,NN,O
",",",",O
pruritus,NN,O
",",",",O
ankle,NN,O
edema,NN,O
",",",",O
excessive,JJ,O
perspiration,NN,O
",",",",O
weight,NN,O
gain,NN,O
",",",",O
nasal,JJ,O
congestion,NN,O
.,.,.
,,
some,DT,O
of,IN,O
the,DT,O
cns,NN,O
and,CC,O
genitourinary,JJ,O
symptoms,NNS,O
may,MD,O
be,VB,O
related,VBN,O
to,TO,O
the,DT,O
underlying,VBG,O
disease,NN,O
rather,RB,O
than,IN,O
to,TO,O
drug,NN,D
therapy,NN,O
.,.,.
,,
the,DT,O
following,VBG,O
laboratory,NN,O
tests,NNS,O
have,VBP,O
been,VBN,O
found,VBN,O
to,TO,O
be,VB,O
abnormal,JJ,O
in,IN,O
a,DT,O
few,JJ,O
patients,NNS,O
receiving,VBG,O
baclofen,NN,D
:,:,O
increased,VBN,O
sgot,NNP,O
",",",",O
elevated,JJ,O
alkaline,NN,O
phosphatase,NN,O
",",",",O
and,CC,O
elevation,NN,O
of,IN,O
blood,NN,O
sugar,NN,O
.,.,.
,,
the,DT,O
adverse,JJ,O
experience,NN,O
profile,NN,O
seen,VBN,O
with,IN,O
kemstrotm,NN,B
was,VBD,O
similar,JJ,O
to,TO,O
that,DT,O
seen,VBN,O
with,IN,O
baclofen,NN,D
tablets,NNS,O
.,.,.
,,
no,DT,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
for,IN,O
colazal,NNP,B
",",",",O
however,RB,O
the,DT,O
use,NN,O
of,IN,O
orally,RB,O
administered,VBN,O
antibiotics,NNS,G
could,MD,O
",",",",O
theoretically,RB,O
",",",",O
interfere,VBP,O
with,IN,O
the,DT,O
release,NN,O
of,IN,O
mesalamine,NN,D
in,IN,O
the,DT,O
colon,NN,O
.,.,.
,,
no,DT,O
dose,NN,O
adjustment,NN,O
is,VBZ,O
necessary,JJ,O
when,WRB,O
simulect,NNP,B
is,VBZ,O
added,VBN,O
to,TO,O
triple-immunosuppression,JJ,O
regimens,NNS,O
including,VBG,O
cyclosporine,NN,D
",",",",O
corticosteroids,NNS,G
",",",",O
and,CC,O
either,CC,O
azathioprine,NN,D
or,CC,O
mycophenolate,JJ,D
mofetil,NN,O
.,.,.
,,
three,CD,O
clinical,JJ,O
trials,NNS,O
have,VBP,O
investigated,VBN,O
simulect,NNP,B
use,NN,O
in,IN,O
combination,NN,O
with,IN,O
triple-therapy,JJ,O
regimens,NNS,O
.,.,.
,,
pharmacokinetics,NNS,O
were,VBD,O
assessed,VBN,O
in,IN,O
two,CD,O
of,IN,O
these,DT,O
trials,NNS,O
.,.,.
,,
total,JJ,O
body,NN,O
clearance,NN,O
of,IN,O
simulect,NNP,B
was,VBD,O
reduced,VBN,O
by,IN,O
an,DT,O
average,JJ,O
22,CD,O
%,NN,O
and,CC,O
51,CD,O
%,NN,O
when,WRB,O
azathioprine,NN,D
and,CC,O
mycophenolate,JJ,D
mofetil,NN,O
",",",",O
respectively,RB,O
",",",",O
were,VBD,O
added,VBN,O
to,TO,O
a,DT,O
regimen,NN,O
consisting,VBG,O
of,IN,O
cyclosporine,NN,D
",",",",O
usp,NN,O
-lrb-,-LRB-,O
modified,VBN,O
-rrb-,-RRB-,O
and,CC,O
corticosteroids,NNS,G
.,.,.
,,
nonetheless,RB,O
",",",",O
the,DT,O
range,NN,O
of,IN,O
individual,JJ,O
simulect,JJ,B
clearance,NN,O
values,NNS,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
azathioprine,NN,D
-lrb-,-LRB-,O
Dec-57,CD,O
ml/h,NN,O
-rrb-,-RRB-,O
or,CC,O
mycophenolate,JJ,D
mofetil,NN,O
-lrb-,-LRB-,O
Jul-54,CD,O
ml/h,NN,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
extend,VB,O
outside,IN,O
the,DT,O
range,NN,O
observed,VBN,O
with,IN,O
dual,JJ,O
therapy,NN,O
-lrb-,-LRB-,O
Oct-78,CD,O
ml/h,NN,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
following,VBG,O
medications,NNS,O
have,VBP,O
been,VBN,O
administered,VBN,O
in,IN,O
clinical,JJ,O
trials,NNS,O
with,IN,O
simulect,NN,B
with,IN,O
no,DT,O
increase,NN,O
in,IN,O
adverse,JJ,O
reactions,NNS,O
:,:,O
atg/alg,NN,O
",",",",O
azathioprine,NN,D
",",",",O
corticosteroids,NNS,G
",",",",O
cyclosporine,NN,D
",",",",O
mycophenolate,JJ,D
mofetil,NN,O
",",",",O
and,CC,O
muromonab-cd3,NN,D
.,.,.
,,
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
if,IN,O
regranex,NNP,B
gel,NN,O
interacts,VBZ,O
with,IN,O
other,JJ,O
topical,JJ,O
medications,NNS,O
applied,VBD,O
to,TO,O
the,DT,O
ulcer,NN,O
site,NN,O
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
regranex,NNP,B
gel,NN,O
with,IN,O
other,JJ,O
topical,JJ,O
drugs,NNS,D
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
albuterol,NNP,D
",",",",O
antihistamines,NNP,D
",",",",O
antidiabetic,JJ,D
drugs,NNS,D
",",",",O
diuretics,NNS,G
",",",",O
digitalis,NN,G
.,.,.
,,
diuretics,NNS,G
:,:,O
patients,NNS,O
on,IN,O
diuretics,NNS,G
",",",",O
especially,RB,O
those,DT,O
in,IN,O
whom,WP,O
diuretic,JJ,G
therapy,NN,O
was,VBD,O
recently,RB,O
instituted,VBN,O
",",",",O
may,MD,O
occasionally,RB,O
experience,VB,O
an,DT,O
excessive,JJ,O
reduction,NN,O
of,IN,O
blood,NN,O
pressure,NN,O
after,IN,O
initiation,NN,O
of,IN,O
therapy,NN,O
with,IN,O
lotensin,NN,B
.,.,.
,,
the,DT,O
possibility,NN,O
of,IN,O
hypotensive,JJ,O
effects,NNS,O
with,IN,O
lotensin,NN,B
can,MD,O
be,VB,O
minimized,VBN,O
by,IN,O
either,CC,O
discontinuing,VBG,O
the,DT,O
diuretic,JJ,G
or,CC,O
increasing,VBG,O
the,DT,O
salt,NN,O
intake,NN,O
prior,RB,O
to,TO,O
initiation,NN,O
of,IN,O
treatment,NN,O
with,IN,O
lotensin,NN,B
.,.,.
,,
if,IN,O
this,DT,O
is,VBZ,O
not,RB,O
possible,JJ,O
",",",",O
the,DT,O
starting,VBG,O
dose,NN,O
should,MD,O
be,VB,O
reduced,VBN,O
.,.,.
,,
potassium,NN,D
supplements,NNS,O
and,CC,O
potassium-sparing,NNP,O
diuretics,NNP,G
lotensin,NNP,B
can,MD,O
attenuate,VB,O
potassium,NN,D
loss,NN,O
caused,VBN,O
by,IN,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
potassium-sparing,JJ,O
diuretics,NNS,G
-lrb-,-LRB-,O
spironolactone,NN,D
",",",",O
amiloride,NN,D
",",",",O
triamterene,NN,D
",",",",O
and,CC,O
others,NNS,O
-rrb-,-RRB-,O
or,CC,O
potassium,NN,D
supplements,NNS,O
can,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
hyperkalemia,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
if,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
such,JJ,O
agents,NNS,O
is,VBZ,O
indicated,VBN,O
",",",",O
they,PRP,O
should,MD,O
be,VB,O
given,VBN,O
with,IN,O
caution,NN,O
",",",",O
and,CC,O
the,DT,O
patient,NN,O
's,POS,O
serum,NN,O
potassium,NN,D
should,MD,O
be,VB,O
monitored,VBN,O
frequently,RB,O
.,.,.
,,
oral,JJ,O
anticoagulants,NNPS,G
interaction,NN,O
studies,NNS,O
with,IN,O
warfarin,NN,D
and,CC,O
acenocoumarol,NN,D
failed,VBD,O
to,TO,O
identify,VB,O
any,DT,O
clinically,RB,O
important,JJ,O
effects,NNS,O
on,IN,O
the,DT,O
serum,NN,O
concentrations,NNS,O
or,CC,O
clinical,JJ,O
effects,NNS,O
of,IN,O
these,DT,O
anticoagulants,NNS,G
.,.,.
,,
lithium,NN,D
:,:,O
increased,VBN,O
serum,NN,O
lithium,NN,D
levels,NNS,O
and,CC,O
symptoms,NNS,O
of,IN,O
lithium,NN,D
toxicity,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
ace,NN,O
inhibitors,NNS,O
during,IN,O
therapy,NN,O
with,IN,O
lithium,NN,D
.,.,.
,,
these,DT,O
drugs,NNS,D
should,MD,O
be,VB,O
coadministered,VBN,O
with,IN,O
caution,NN,O
",",",",O
and,CC,O
frequent,JJ,O
monitoring,NN,O
of,IN,O
serum,NN,O
lithium,NN,D
levels,NNS,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
if,IN,O
a,DT,O
diuretic,JJ,G
is,VBZ,O
also,RB,O
used,VBN,O
",",",",O
the,DT,O
risk,NN,O
of,IN,O
lithium,NN,D
toxicity,NN,O
may,MD,O
be,VB,O
increased,VBN,O
.,.,.
,,
other,JJ,O
no,DT,O
clinically,RB,O
important,JJ,O
pharmacokinetic,JJ,O
interactions,NNS,O
occurred,VBD,O
when,WRB,O
lotensin,NNP,B
was,VBD,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
hydrochlorothiazide,NN,D
",",",",O
chlorthalidone,NN,D
",",",",O
furosemide,NN,D
",",",",O
digoxin,NN,D
",",",",O
propranolol,NN,D
",",",",O
atenolol,NN,D
",",",",O
naproxen,NN,D
",",",",O
or,CC,O
cimetidine,NN,D
.,.,.
,,
lotensin,NNP,B
has,VBZ,O
been,VBN,O
used,VBN,O
concomitantly,RB,O
with,IN,O
beta-adrenergic-blocking,JJ,O
agents,NNS,O
",",",",O
calcium-channel-blocking,JJ,O
agents,NNS,O
",",",",O
diuretics,NNS,G
",",",",O
digoxin,NN,D
",",",",O
and,CC,O
hydralazine,NN,D
",",",",O
without,IN,O
evidence,NN,O
of,IN,O
clinically,RB,O
important,JJ,O
adverse,JJ,O
interactions,NNS,O
.,.,.
,,
benazepril,NNP,D
",",",",O
like,IN,O
other,JJ,O
ace,NN,O
inhibitors,NNS,O
",",",",O
has,VBZ,O
had,VBN,O
less,JJR,O
than,IN,O
additive,JJ,O
effects,NNS,O
with,IN,O
beta-adrenergic,JJ,O
blockers,NNS,O
",",",",O
presumably,RB,O
because,IN,O
both,DT,O
drugs,NNS,D
lower,JJR,O
blood,NN,O
pressure,NN,O
by,IN,O
inhibiting,VBG,O
parts,NNS,O
of,IN,O
the,DT,O
renin-angiotensin,JJ,O
syste,NN,O
.,.,.
,,
may,NNP,O
interact,VBP,O
with,IN,O
the,DT,O
following,NN,O
:,:,O
cholestyramine,NN,D
",",",",O
colestipol,NN,D
-lrb-,-LRB-,O
use,NN,O
with,IN,O
thiazide,JJ,G
diuretics,NNS,G
may,MD,O
prevent,VB,O
the,DT,O
diuretic,JJ,G
from,IN,O
working,VBG,O
properly,RB,O
.,.,.
,,
bentiromide,NNP,D
may,MD,O
interact,VB,O
with,IN,O
acetaminophen,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
tylenol,NNP,B
-rrb-,-RRB-,O
",",",",O
chloramphenicol,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
chloromycetin,NN,B
-rrb-,-RRB-,O
",",",",O
local,JJ,O
anesthetics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
benzocaine,NN,D
and,CC,O
lidocaine,NN,D
-rrb-,-RRB-,O
",",",",O
para-aminobenzoic,JJ,O
acid,NN,O
-lrb-,-LRB-,O
paba,NN,D_n
-rrb-,-RRB-,O
-,:,O
containing,VBG,O
preparations,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
sunscreens,NNS,O
and,CC,O
some,DT,O
multivitamins,NNS,G
-rrb-,-RRB-,O
",",",",O
procainamide,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
pronestyl,NNP,B
-rrb-,-RRB-,O
",",",",O
sulfonamides,NNS,G
-lrb-,-LRB-,O
sulfa,NN,O
medicines,NNS,O
-rrb-,-RRB-,O
",",",",O
thiazide,JJ,G
diuretics,NNS,G
-lrb-,-LRB-,O
use,NN,O
of,IN,O
these,DT,O
medicines,NNS,O
during,IN,O
the,DT,O
test,NN,O
period,NN,O
will,MD,O
affect,VB,O
the,DT,O
test,NN,O
results,VBZ,O
-rrb-,-RRB-,O
",",",",O
and,CC,O
pancreatic,JJ,O
supplements,NNS,O
-lrb-,-LRB-,O
use,NN,O
of,IN,O
pancreatic,JJ,O
supplements,NNS,O
may,MD,O
give,VB,O
FALSE,JJ,O
test,NN,O
results,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
may,NNP,O
interact,VBP,O
with,IN,O
other,JJ,O
creams,NNS,O
",",",",O
lotions,NNS,O
",",",",O
or,CC,O
skin,NN,O
medicines,NNS,O
when,WRB,O
placed,VBN,O
on,IN,O
the,DT,O
same,JJ,O
areas,NNS,O
of,IN,O
your,PRP$,O
skin,NN,O
that,IN,O
you,PRP,O
are,VBP,O
using,VBG,O
bentoquatam,NN,D_n
.,.,.
,,
no,DT,O
information,NN,O
is,VBZ,O
available,JJ,O
.,.,.
,,
hypertensive,JJ,O
crises,NNS,O
have,VBP,O
resulted,VBN,O
when,WRB,O
sympathomimetic,JJ,G
amines,NNS,O
have,VBP,O
been,VBN,O
used,VBN,O
concomitantly,RB,O
within14,CD,O
days,NNS,O
following,VBG,O
use,NN,O
of,IN,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
.,.,.
,,
didrex,NNP,B
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
concomitantly,RB,O
with,IN,O
other,JJ,O
cns,NN,O
stimulants,NNS,O
.,.,.
,,
amphetamines,NNS,G
may,MD,O
decrease,VB,O
the,DT,O
hypotensive,JJ,O
effect,NN,O
of,IN,O
antihypertensives,NNS,D
.,.,.
,,
amphetamines,NNS,G
may,MD,O
enhance,VB,O
the,DT,O
effects,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
.,.,.
,,
urinary,JJ,O
alkalinizing,JJ,O
agents,NNS,O
increase,VBP,O
blood,NN,O
levels,NNS,O
and,CC,O
decrease,VB,O
excretion,NN,O
of,IN,O
amphetamines,NNS,G
.,.,.
,,
urinary,JJ,O
acidifying,VBG,O
agents,NNS,O
decrease,VB,O
blood,NN,O
levels,NNS,O
and,CC,O
increase,VB,O
excretion,NN,O
of,IN,O
amphetamines,NNS,G
.,.,.
,,
benzthiazide,NNP,D
may,MD,O
interact,VB,O
with,IN,O
alcohol,NN,D
",",",",O
blood,NN,O
thinners,NNS,O
",",",",O
decongestant,NN,O
drugs,NNS,D
-lrb-,-LRB-,O
allergy,NN,O
",",",",O
cold,JJ,O
",",",",O
and,CC,O
sinus,NN,O
medicines,NNS,O
-rrb-,-RRB-,O
",",",",O
diabetic,JJ,O
drugs,NNS,D
",",",",O
lithium,NN,D
",",",",O
norepinephrine,NN,D
",",",",O
nsaids,NNS,G
like,IN,O
aleve,NNP,B
or,CC,O
ibuprofen,NNP,D
",",",",O
and,CC,O
high,JJ,O
blood,NN,O
pressure,NN,O
medications,NNS,O
.,.,.
,,
antipsychotic,JJ,O
drugs,NNS,D
such,JJ,O
as,IN,O
phenothiazines,NNS,G
or,CC,O
haloperidol,NN,D
.,.,.
,,
tricyclic,JJ,G
antidepressants,NNS,G
.,.,.
,,
nitrates,NNS,G
:,:,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
bepridil,NN,D
with,IN,O
long,JJ,O
-,:,O
and,CC,O
short-acting,JJ,O
nitrates,NNS,G
has,VBZ,O
been,VBN,O
safely,RB,O
tolerated,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
stable,JJ,O
angina,NN,O
pectoris,NN,O
.,.,.
,,
sublingual,JJ,O
nitroglycerin,NN,D
may,MD,O
be,VB,O
taken,VBN,O
if,IN,O
necessary,JJ,O
for,IN,O
the,DT,O
control,NN,O
of,IN,O
acute,JJ,O
angina,NN,O
attacks,NNS,O
during,IN,O
bepridil,NN,D
therapy,NN,O
.,.,.
,,
beta-blocking,JJ,O
agents,NNS,O
:,:,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
bepridil,NNP,D
and,CC,O
beta-blocking,JJ,D
agents,NNS,O
has,VBZ,O
been,VBN,O
well,RB,O
tolerated,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
stable,JJ,O
angina,NN,O
.,.,.
,,
available,JJ,O
data,NNS,O
are,VBP,O
not,RB,O
sufficient,JJ,O
",",",",O
however,RB,O
",",",",O
to,TO,O
predict,VB,O
the,DT,O
effects,NNS,O
of,IN,O
concomitant,JJ,O
medication,NN,O
on,IN,O
patients,NNS,O
with,IN,O
impaired,JJ,O
ventricular,JJ,O
function,NN,O
or,CC,O
cardiac,JJ,O
conduction,NN,O
abnormalities,NNS,O
.,.,.
,,
digoxin,NNP,D
:,:,O
in,IN,O
controlled,JJ,O
studies,NNS,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
bepridil,NN,D
hydrochloride,NN,O
either,CC,O
had,VBD,O
no,DT,O
effect,NN,O
-lrb-,-LRB-,O
one,CD,O
study,NN,O
-rrb-,-RRB-,O
or,CC,O
was,VBD,O
associated,VBN,O
with,IN,O
modest,JJ,O
increases,NNS,O
",",",",O
about,IN,O
30,CD,O
%,NN,O
-lrb-,-LRB-,O
two,CD,O
studies,NNS,O
-rrb-,-RRB-,O
in,IN,O
steady-state,JJ,O
serum,NN,O
digoxin,NN,D
concentrations,NNS,O
.,.,.
,,
limited,JJ,O
clinical,JJ,O
data,NNS,O
in,IN,O
angina,NN,O
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
bepridil,NN,D
hydrochloride,NN,O
and,CC,O
digoxin,NN,D
therapy,NN,O
indicate,VBP,O
no,DT,O
discernible,JJ,O
changes,NNS,O
in,IN,O
serum,NN,O
digoxin,NN,D
levels,NNS,O
.,.,.
,,
available,JJ,O
data,NNS,O
are,VBP,O
neither,DT,O
sufficient,JJ,O
to,TO,O
rule,VB,O
out,RP,O
possible,JJ,O
increases,NNS,O
in,IN,O
serum,NN,O
digoxin,NN,D
with,IN,O
concomitant,JJ,O
treatment,NN,O
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
nor,CC,O
other,JJ,O
possible,JJ,O
interactions,NNS,O
",",",",O
particularly,RB,O
in,IN,O
patients,NNS,O
with,IN,O
cardiac,JJ,O
conduction,NN,O
abnormalities,NNS,O
-lrb-,-LRB-,O
also,RB,O
see,VB,O
warnings,NNP,O
congestive,JJ,O
heart,NNP,O
failure,NN,O
-rrb-,-RRB-,O
.,.,.
,,
oral,JJ,O
hypoglycemics,NNS,G
:,:,O
bepridil,NNP,D
has,VBZ,O
been,VBN,O
safely,RB,O
used,VBN,O
in,IN,O
diabetic,JJ,O
patients,NNS,O
without,IN,O
significantly,RB,O
lowering,VBG,O
their,PRP$,O
blood,NN,O
glucose,NN,O
levels,NNS,O
or,CC,O
altering,VBG,O
their,PRP$,O
need,NN,O
for,IN,O
insulin,NN,D
or,CC,O
oral,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
.,.,.
,,
general,NNP,O
interactions,NNS,O
:,:,O
certain,JJ,O
drugs,NNS,D
could,MD,O
increase,VB,O
the,DT,O
likelihood,NN,O
of,IN,O
potentially,RB,O
serious,JJ,O
adverse,JJ,O
effects,NNS,O
with,IN,O
bepridil,NN,D
hydrochloride,NN,O
.,.,.
,,
in,IN,O
general,JJ,O
",",",",O
these,DT,O
are,VBP,O
drugs,NNS,D
that,WDT,O
have,VBP,O
one,CD,O
or,CC,O
more,JJR,O
pharmacologic,JJ,O
activities,NNS,O
similar,JJ,O
to,TO,O
bepridil,NN,D
hydrochloride,NN,O
",",",",O
including,VBG,O
anti-arrhythmic,JJ,D
agents,NNS,O
such,JJ,O
as,IN,O
quinidine,NN,D
and,CC,O
procainamide,NN,D
",",",",O
cardiac,JJ,O
glycosides,NNS,G
and,CC,O
tricyclic,JJ,G
anti-depressants,NNS,G
.,.,.
,,
anti-arrhythmics,NNS,G
and,CC,O
tricyclic,JJ,G
anti-depressants,NNS,G
could,MD,O
exaggerate,VB,O
the,DT,O
prolongation,NN,O
of,IN,O
the,DT,O
qt,NNP,O
interval,NN,O
observed,VBN,O
with,IN,O
bepridil,NN,D
hydrochloride,NN,O
.,.,.
,,
cardiac,JJ,O
glycosides,NNS,G
could,MD,O
exaggerate,VB,O
the,DT,O
depression,NN,O
of,IN,O
av,NN,O
nodal,JJ,O
conduction,NN,O
observed,VBN,O
with,IN,O
bepridil,NN,D
hydrochloride,NN,O
.,.,.
,,
the,DT,O
following,VBG,O
drugs,NNS,D
have,VBP,O
been,VBN,O
coadministered,VBN,O
with,IN,O
kerlone,NNP,B
and,CC,O
have,VBP,O
not,RB,O
altered,VBN,O
its,PRP$,O
pharmacokinetics,NNS,O
:,:,O
cimetidine,NN,D
",",",",O
nifedipine,NN,D
",",",",O
chlorthalidone,NN,D
",",",",O
and,CC,O
hydrochlorothiazide,NN,D
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
kerlone,NNP,B
with,IN,O
the,DT,O
oral,JJ,O
anticoagulant,JJ,G
warfarin,NN,D
has,VBZ,O
been,VBN,O
shown,VBN,O
not,RB,O
to,TO,O
potentiate,VB,O
the,DT,O
anticoagulant,JJ,G
effect,NN,O
of,IN,O
warfarin,NN,D
.,.,.
,,
catecholamine-depleting,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
reserpine,NN,D
-rrb-,-RRB-,O
may,MD,O
have,VB,O
an,DT,O
additive,JJ,O
effect,NN,O
when,WRB,O
given,VBN,O
with,IN,O
beta-blocking,JJ,D
agents,NNS,O
.,.,.
,,
patients,NNS,O
treated,VBN,O
with,IN,O
a,DT,O
beta-adrenergic,JJ,O
receptor,NN,D
blocking,VBG,O
agent,NN,O
plus,CC,O
a,DT,O
catecholamine,NN,O
depletor,NN,O
should,MD,O
therefore,RB,O
be,VB,O
closely,RB,O
observed,VBN,O
for,IN,O
evidence,NN,O
of,IN,O
hypotension,NN,O
or,CC,O
marked,JJ,O
bradycardia,NN,O
",",",",O
which,WDT,O
may,MD,O
produce,VB,O
vertigo,NN,O
",",",",O
syncope,NN,O
",",",",O
or,CC,O
postural,JJ,O
hypotension,NN,O
.,.,.
,,
should,MD,O
it,PRP,O
be,VB,O
decided,VBN,O
to,TO,O
discontinue,VB,O
therapy,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
beta-blockers,NNS,G
and,CC,O
clonidine,NN,D
concurrently,RB,O
",",",",O
the,DT,O
beta-blocker,NN,G
should,MD,O
be,VB,O
discontinued,VBN,O
slowly,RB,O
over,IN,O
several,JJ,O
days,NNS,O
before,IN,O
the,DT,O
gradual,JJ,O
withdrawal,NN,O
of,IN,O
clonidine,NN,D
.,.,.
,,
literature,NN,O
reports,NNS,O
suggest,VBP,O
that,IN,O
oral,JJ,O
calcium,NN,D
antagonists,NNS,O
may,MD,O
be,VB,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
when,WRB,O
heart,NN,O
function,NN,O
is,VBZ,O
normal,JJ,O
",",",",O
but,CC,O
should,MD,O
be,VB,O
avoided,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
impaired,JJ,O
cardiac,JJ,O
function,NN,O
.,.,.
,,
hypotension,NN,O
",",",",O
av,NN,O
conduction,NN,O
disturbances,NNS,O
",",",",O
and,CC,O
left,VBD,O
ventricular,JJ,O
failure,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
some,DT,O
patients,NNS,O
receiving,VBG,O
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
when,WRB,O
an,DT,O
oral,JJ,O
calcium,NN,D
antagonist,NN,O
was,VBD,O
added,VBN,O
to,TO,O
the,DT,O
treatment,NN,O
regimen,NN,O
.,.,.
,,
hypotension,NN,O
was,VBD,O
more,RBR,O
likely,JJ,O
to,TO,O
occur,VB,O
if,IN,O
the,DT,O
calcium,NN,D
antagonist,NN,O
were,VBD,O
a,DT,O
dihydropyridine,NN,O
derivative,NN,O
",",",",O
e.g.,FW,O
",",",",O
nifedipine,NN,D
",",",",O
while,IN,O
left,VBN,O
ventricular,JJ,O
failure,NN,O
and,CC,O
av,NN,O
conduction,NN,O
disturbances,NNS,O
",",",",O
including,VBG,O
complete,JJ,O
heart,NN,O
block,NN,O
",",",",O
were,VBD,O
more,RBR,O
likely,JJ,O
to,TO,O
occur,VB,O
with,IN,O
either,CC,O
verapamil,NN,D
or,CC,O
diltiazem,NN,D
.,.,.
,,
risk,NN,O
of,IN,O
anaphylactic,NNP,O
reaction,NNP,O
:,:,O
although,IN,O
it,PRP,O
is,VBZ,O
known,VBN,O
that,IN,O
patients,NNS,O
on,IN,O
beta-blockers,NNS,G
may,MD,O
be,VB,O
refractory,JJ,O
to,TO,O
epinephrine,NN,D
in,IN,O
the,DT,O
treatment,NN,O
of,IN,O
anaphylactic,JJ,O
shock,NN,O
",",",",O
beta-blockers,NNS,G
can,MD,O
",",",",O
in,IN,O
addition,NN,O
",",",",O
interfere,VBP,O
with,IN,O
the,DT,O
modulation,NN,O
of,IN,O
allergic,JJ,O
reaction,NN,O
and,CC,O
lead,VB,O
to,TO,O
an,DT,O
increased,VBN,O
severity,NN,O
and/or,CC,O
frequency,NN,O
of,IN,O
attacks,NNS,O
.,.,.
,,
severe,JJ,O
allergic,JJ,O
reactions,NNS,O
including,VBG,O
anaphylaxis,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
exposed,VBN,O
to,TO,O
a,DT,O
variety,NN,O
of,IN,O
allergens,NNS,O
either,CC,O
by,IN,O
repeated,VBN,O
challenge,NN,O
",",",",O
or,CC,O
accidental,JJ,O
contact,NN,O
",",",",O
and,CC,O
with,IN,O
diagnostic,JJ,O
or,CC,O
therapeutic,JJ,O
agents,NNS,O
while,IN,O
receiving,VBG,O
beta-blockers,NNS,G
.,.,.
,,
such,JJ,O
patients,NNS,O
may,MD,O
be,VB,O
unresponsive,JJ,O
to,TO,O
the,DT,O
usual,JJ,O
doses,NNS,O
of,IN,O
epinephrine,NN,D
used,VBN,O
to,TO,O
treat,VB,O
allergic,JJ,O
reaction,NN,O
.,.,.
,,
special,JJ,O
care,NN,O
is,VBZ,O
required,VBN,O
if,IN,O
this,DT,O
drug,NN,D
is,VBZ,O
given,VBN,O
to,TO,O
patients,NNS,O
receiving,VBG,O
ganglion,NN,O
blocking,VBG,O
compounds,NNS,O
because,IN,O
a,DT,O
critical,JJ,O
fall,NN,O
in,IN,O
blood,NN,O
pressure,NN,O
may,MD,O
occur,VB,O
.,.,.
,,
usually,RB,O
",",",",O
severe,JJ,O
abdominal,JJ,O
symptoms,NNS,O
appear,VBP,O
before,IN,O
there,EX,O
is,VBZ,O
such,JJ,O
a,DT,O
fall,NN,O
in,IN,O
the,DT,O
blood,NN,O
pressure,NN,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
with,IN,O
anti-neoplastic,JJ,O
agents,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
in,IN,O
study,NNP,O
1,CD,O
",",",",O
patients,NNS,O
with,IN,O
colorectal,JJ,O
cancer,NN,O
were,VBD,O
given,VBN,O
irinotecan/5-fu/leucovorin,NN,O
-lrb-,-LRB-,O
bolus-ifl,NN,O
-rrb-,-RRB-,O
with,IN,O
or,CC,O
without,IN,O
avastin,NNP,B
.,.,.
,,
irinotecan,JJ,D
concentrations,NNS,O
were,VBD,O
similar,JJ,O
in,IN,O
patients,NNS,O
receiving,VBG,O
bolus-ifl,NN,O
alone,RB,O
and,CC,O
in,IN,O
combination,NN,O
with,IN,O
avastin,NNP,B
.,.,.
,,
the,DT,O
concentrations,NNS,O
of,IN,O
sn38,NN,D_n
",",",",O
the,DT,O
active,JJ,O
metabolite,NN,O
of,IN,O
irinotecan,NN,D
",",",",O
were,VBD,O
on,IN,O
average,JJ,O
33,CD,O
%,NN,O
higher,JJR,O
in,IN,O
patients,NNS,O
receiving,VBG,O
bolus-ifl,NN,O
in,IN,O
combination,NN,O
with,IN,O
avastin,NN,B
when,WRB,O
compared,VBN,O
with,IN,O
bolus-ifl,NN,O
alone,RB,O
.,.,.
,,
in,IN,O
study,NNP,O
1,CD,O
",",",",O
patients,NNS,O
receiving,VBG,O
bolus-ifl,NN,O
plus,CC,O
avastin,NNP,B
had,VBD,O
a,DT,O
higher,JJR,O
incidence,NN,O
of,IN,O
grade,NNP,O
4-Mar,CD,O
diarrhea,NN,O
and,CC,O
neutropenia,NN,O
.,.,.
,,
due,JJ,O
to,TO,O
high,JJ,O
inter-patient,JJ,O
variability,NN,O
and,CC,O
limited,JJ,O
sampling,NN,O
",",",",O
the,DT,O
extent,NN,O
of,IN,O
the,DT,O
increase,NN,O
in,IN,O
sn38,NN,D_n
levels,NNS,O
in,IN,O
patients,NNS,O
receiving,VBG,O
concurrent,JJ,O
irinotecan,NN,D
and,CC,O
avastin,NN,B
is,VBZ,O
uncertain,JJ,O
.,.,.
,,
no,DT,O
formal,JJ,O
studies,NNS,O
to,TO,O
evaluate,VB,O
drug,NN,D
interactions,NNS,O
with,IN,O
bexarotene,NN,D
have,VBP,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
bexarotene,NNP,D
oxidative,JJ,O
metabolites,NNS,O
appear,VBP,O
to,TO,O
be,VB,O
formed,VBN,O
by,IN,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
.,.,.
,,
on,IN,O
the,DT,O
basis,NN,O
of,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
bexarotene,NN,D
by,IN,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
",",",",O
ketoconazole,NN,D
",",",",O
itraconazole,NN,D
",",",",O
erythromycin,NN,D
",",",",O
gemfibrozil,NN,D
",",",",O
grapefruit,NN,O
juice,NN,O
",",",",O
and,CC,O
other,JJ,O
inhibitors,NNS,O
of,IN,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
lead,VB,O
to,TO,O
an,DT,O
increase,NN,O
in,IN,O
plasma,NN,O
bexarotene,NN,D
concentrations,NNS,O
.,.,.
,,
furthermore,RB,O
",",",",O
rifampin,NN,D
",",",",O
phenytoin,NN,D
",",",",O
phenobarbital,NN,D
",",",",O
and,CC,O
other,JJ,O
inducers,NNS,O
of,IN,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
may,MD,O
cause,VB,O
a,DT,O
reduction,NN,O
in,IN,O
plasma,NN,O
bexarotene,NN,D
concentrations,NNS,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
targretin,NNP,B
capsules,NNS,O
and,CC,O
gemfibrozil,NN,D
resulted,VBD,O
in,IN,O
substantial,JJ,O
increases,NNS,O
in,IN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
bexarotene,NN,D
",",",",O
probably,RB,O
at,IN,O
least,JJS,O
partially,RB,O
related,JJ,O
to,TO,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
inhibition,NN,O
by,IN,O
gemfibrozil,NN,D
.,.,.
,,
under,IN,O
similar,JJ,O
conditions,NNS,O
",",",",O
bexarotene,NN,D
concentrations,NNS,O
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
concomitant,JJ,O
atorvastatin,NN,D
administration,NN,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
gemfibrozil,NN,D
with,IN,O
targretin,NNP,B
capsules,NNS,O
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
when,WRB,O
bezalip,NNP,B
or,CC,O
bezalip,NNP,B
retard,VBP,O
is,VBZ,O
used,VBN,O
at,IN,O
the,DT,O
same,JJ,O
time,NN,O
as,IN,O
other,JJ,O
medicines,NNS,O
or,CC,O
substances,NNS,O
the,DT,O
following,JJ,O
interactions,NNS,O
must,MD,O
be,VB,O
taken,VBN,O
into,IN,O
account,NN,O
:,:,O
-,:,O
bezalip,NN,B
and,CC,O
bezalip,NN,B
retard,VBP,O
may,MD,O
enhance,VB,O
the,DT,O
action,NN,O
of,IN,O
anticoagulants,NNS,G
of,IN,O
the,DT,O
coumarin,NN,G
type,NN,O
.,.,.
,,
for,IN,O
this,DT,O
reason,NN,O
",",",",O
the,DT,O
dose,NN,O
of,IN,O
the,DT,O
anticoagulant,NN,G
should,MD,O
be,VB,O
reduced,VBN,O
by,IN,O
30,CD,O
-,:,O
50,CD,O
%,NN,O
at,IN,O
the,DT,O
start,NN,O
of,IN,O
treatment,NN,O
with,IN,O
bezalip,NN,B
or,CC,O
bezalip,JJ,B
retard,VB,O
and,CC,O
then,RB,O
titrated,VBD,O
according,VBG,O
to,TO,O
the,DT,O
blood,NN,O
clotting,NN,O
parameter,NN,O
.,.,.
,,
-,:,O
the,DT,O
action,NN,O
of,IN,O
sulphonylureas,NNS,G
and,CC,O
insulin,NN,D
may,MD,O
be,VB,O
enhanced,VBN,O
by,IN,O
bezalip,NNP,B
or,CC,O
bezalip,NNP,B
retard,VBP,O
.,.,.
,,
this,DT,O
may,MD,O
be,VB,O
due,JJ,O
to,TO,O
an,DT,O
improved,VBN,O
glucose,NN,O
utilization,NN,O
with,IN,O
simultaneous,JJ,O
reduction,NN,O
in,IN,O
insulin,NN,D
requiremen,NN,O
.,.,.
,,
-,:,O
in,IN,O
isolated,VBN,O
cases,NNS,O
",",",",O
a,DT,O
pronounced,JJ,O
though,IN,O
reversible,JJ,O
",",",",O
impairment,NN,O
of,IN,O
renal,JJ,O
function,NN,O
-lrb-,-LRB-,O
accompanied,VBN,O
by,IN,O
a,DT,O
corresponding,JJ,O
increase,NN,O
in,IN,O
the,DT,O
serum,NN,O
creatinine,NN,O
level,NN,O
-rrb-,-RRB-,O
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
organ,NN,O
transplant,NN,O
patients,NNS,O
receiving,VBG,O
immuno-suppressant,JJ,G
therapy,NN,O
and,CC,O
concomitant,JJ,O
bezafibrate,NN,D
.,.,.
,,
accordingly,RB,O
",",",",O
renal,JJ,O
function,NN,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
in,IN,O
these,DT,O
patients,NNS,O
and,CC,O
",",",",O
in,IN,O
the,DT,O
event,NN,O
of,IN,O
relevant,JJ,O
significant,JJ,O
changes,NNS,O
in,IN,O
laboratory,NN,O
parameters,NNS,O
",",",",O
bezafibrate,NN,D
should,MD,O
",",",",O
if,IN,O
necessary,JJ,O
",",",",O
be,VB,O
discontinue,VB,O
.,.,.
,,
-,:,O
when,WRB,O
bezalip,NNP,B
or,CC,O
bezalip,NNP,B
retard,VBP,O
is,VBZ,O
used,VBN,O
concurrently,RB,O
with,IN,O
anion-exchange,JJ,O
resins,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
cholestryramine,FW,D
-rrb-,-RRB-,O
",",",",O
an,DT,O
interval,NN,O
of,IN,O
at,IN,O
least,JJS,O
2,CD,O
hours,NNS,O
should,MD,O
be,VB,O
maintained,VBN,O
between,IN,O
the,DT,O
two,CD,O
medicines,NNS,O
",",",",O
since,IN,O
the,DT,O
absorption,NN,O
of,IN,O
bezalip,NNP,B
or,CC,O
bezalip,NNP,B
retard,VBP,O
is,VBZ,O
impaire,NN,O
.,.,.
,,
-,:,O
perhexiline,NN,O
hydrogen,NN,O
maleate,NN,O
or,CC,O
mao-inhibitors,NNS,G
-lrb-,-LRB-,O
with,IN,O
hepatotoxic,JJ,O
potential,NN,O
-rrb-,-RRB-,O
must,MD,O
not,RB,O
be,VB,O
administered,VBN,O
together,RB,O
with,IN,O
bezalip,NN,B
or,CC,O
bezalip,NN,B
retard,VBP,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
have,VBP,O
shown,VBN,O
casodex,NNP,B
can,MD,O
displace,VB,O
coumarin,NN,G
anticoagulants,NNS,G
",",",",O
such,JJ,O
as,IN,O
warfarin,NN,D
",",",",O
from,IN,O
their,PRP$,O
protein-binding,JJ,O
sites,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
if,IN,O
casodex,NNP,B
is,VBZ,O
started,VBN,O
in,IN,O
patients,NNS,O
already,RB,O
receiving,VBG,O
coumarin,NN,G
anticoagulants,NNS,G
",",",",O
prothrombin,NN,O
times,NNS,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
and,CC,O
adjustment,NN,O
of,IN,O
the,DT,O
anticoagulant,JJ,G
dose,NN,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
no,DT,O
information,NN,O
provided,VBN,O
.,.,.
,,
drug,NN,O
interactions,NNS,O
:,:,O
the,DT,O
central,JJ,O
anticholinergic,JJ,G
syndrome,NN,O
can,MD,O
occur,VB,O
when,WRB,O
anticholinergic,JJ,G
agents,NNS,O
such,JJ,O
as,IN,O
akineton,NNP,B
are,VBP,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
drugs,NNS,D
that,WDT,O
have,VBP,O
secondary,JJ,O
anticholinergic,JJ,G
actions,NNS,O
",",",",O
e.g.,FW,O
",",",",O
certain,JJ,O
narcotic,JJ,G
analgesics,NNS,G
such,JJ,O
as,IN,O
meperidine,NN,D
",",",",O
the,DT,O
phenothiazines,NNS,G
and,CC,O
other,JJ,O
antipsychotics,NNS,G
",",",",O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
certain,JJ,O
antiarrhythmics,NNS,G
such,JJ,O
as,IN,O
the,DT,O
quinidine,NN,D
salts,NNS,O
",",",",O
and,CC,O
antihistamines,NNS,G
.,.,.
,,
zebeta,NN,B
should,MD,O
not,RB,O
be,VB,O
combined,VBN,O
with,IN,O
other,JJ,O
beta-blocking,JJ,D
agents,NNS,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
catecholamine-depleting,JJ,O
drugs,NNS,D
",",",",O
such,JJ,O
as,IN,O
reserpine,NN,D
or,CC,O
guanethidine,NN,D
",",",",O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
",",",",O
because,IN,O
the,DT,O
added,VBN,O
beta-adrenergic,JJ,O
blocking,VBG,O
action,NN,O
of,IN,O
zebeta,NNP,B
may,MD,O
produce,VB,O
excessive,JJ,O
reduction,NN,O
of,IN,O
sympathetic,JJ,O
activity,NN,O
.,.,.
,,
in,IN,O
patients,NNS,O
receiving,VBG,O
concurrent,JJ,O
therapy,NN,O
with,IN,O
clonidine,NN,D
",",",",O
if,IN,O
therapy,NN,O
is,VBZ,O
to,TO,O
be,VB,O
discontinued,VBN,O
",",",",O
it,PRP,O
is,VBZ,O
suggested,VBN,O
that,IN,O
zebeta,NNP,B
be,VB,O
discontinued,VBN,O
for,IN,O
several,JJ,O
days,NNS,O
before,IN,O
the,DT,O
withdrawal,NN,O
of,IN,O
clonidine,NN,D
.,.,.
,,
zebeta,NN,B
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
care,NN,O
when,WRB,O
myocardial,JJ,O
depressants,NNS,O
or,CC,O
inhibitors,NNS,O
of,IN,O
av,NN,O
conduction,NN,O
",",",",O
such,JJ,O
as,IN,O
certain,JJ,O
calcium,NN,D
antagonists,NNS,O
-lrb-,-LRB-,O
particularly,RB,O
of,IN,O
the,DT,O
phenylalkylamine,NN,G
-lsb-,-LRB-,O
verapamil,NN,D
-rsb-,-RRB-,O
and,CC,O
benzothiazepine,NN,G
-lsb-,-LRB-,O
diltiazem,NN,D
-rsb-,-RRB-,O
classes,NNS,O
-rrb-,-RRB-,O
",",",",O
or,CC,O
antiarrhythmic,JJ,D
agents,NNS,O
",",",",O
such,JJ,O
as,IN,O
disopyramide,NN,D
",",",",O
are,VBP,O
used,VBN,O
concurrently,RB,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
of,IN,O
rifampin,NN,D
increases,VBZ,O
the,DT,O
metabolic,JJ,O
clearance,NN,O
of,IN,O
zebeta,NNP,B
",",",",O
resulting,VBG,O
in,IN,O
a,DT,O
shortened,VBN,O
elimination,NN,O
half-life,NN,O
of,IN,O
zebeta,NN,B
.,.,.
,,
however,RB,O
",",",",O
initial,JJ,O
dose,NN,O
modification,NN,O
is,VBZ,O
generally,RB,O
not,RB,O
necessary,JJ,O
.,.,.
,,
pharmacokinetic,JJ,O
studies,NNS,O
document,VBP,O
no,DT,O
clinically,RB,O
relevant,JJ,O
interactions,NNS,O
with,IN,O
other,JJ,O
agents,NNS,O
given,VBN,O
concomitantly,RB,O
",",",",O
including,VBG,O
thiazide,JJ,G
diuretics,NNS,G
",",",",O
digoxin,NN,D
",",",",O
and,CC,O
cimetidine,NN,D
.,.,.
,,
there,EX,O
was,VBD,O
no,DT,O
effect,NN,O
of,IN,O
zebeta,NN,B
on,IN,O
prothrombin,NN,O
time,NN,O
in,IN,O
patients,NNS,O
on,IN,O
stable,JJ,O
doses,NNS,O
of,IN,O
warfarin,NN,D
.,.,.
,,
risk,NN,O
of,IN,O
anaphylactic,NNP,O
reaction,NNP,O
:,:,O
while,IN,O
taking,VBG,O
beta-blockers,NNS,G
",",",",O
patients,NNS,O
with,IN,O
a,DT,O
history,NN,O
of,IN,O
severe,JJ,O
anaphylactic,JJ,O
reaction,NN,O
to,TO,O
a,DT,O
variety,NN,O
of,IN,O
allergens,NNS,O
may,MD,O
be,VB,O
more,RBR,O
reactive,JJ,O
to,TO,O
repeated,VBN,O
challenge,NN,O
",",",",O
either,CC,O
accidental,JJ,O
",",",",O
diagnostic,JJ,O
",",",",O
or,CC,O
therapeutic,JJ,O
.,.,.
,,
such,JJ,O
patients,NNS,O
may,MD,O
be,VB,O
unresponsive,JJ,O
to,TO,O
the,DT,O
usual,JJ,O
doses,NNS,O
of,IN,O
epinephrine,NN,D
used,VBN,O
to,TO,O
treat,VB,O
allergic,JJ,O
reactions,NNS,O
.,.,.
,,
use,NN,O
of,IN,O
mao,NN,O
inhibitors,NNS,O
may,MD,O
cause,VB,O
an,DT,O
excessive,JJ,O
increase,NN,O
in,IN,O
blood,NN,O
pressure,NN,O
and,CC,O
heart,NN,O
stimulation,NN,O
.,.,.
,,
if,IN,O
you,PRP,O
are,VBP,O
also,RB,O
using,VBG,O
a,DT,O
steroid,NN,G
inhaler,NN,O
",",",",O
take,VB,O
bitolterol,NN,D
first,JJ,O
and,CC,O
then,RB,O
wait,VB,O
about,RB,O
15,CD,O
minutes,NNS,O
before,IN,O
using,VBG,O
the,DT,O
steroid,NN,G
inhaler,NN,O
.,.,.
,,
this,DT,O
allows,VBZ,O
bitolterol,NN,D
to,TO,O
open,VB,O
air,NN,O
passages,NNS,O
",",",",O
increasing,VBG,O
the,DT,O
effectiveness,NN,O
of,IN,O
the,DT,O
steroid,NN,G
.,.,.
,,
angiomax,NN,B
does,VBZ,O
not,RB,O
exhibit,VB,O
binding,VBG,O
to,TO,O
plasma,NN,O
proteins,NNS,O
-lrb-,-LRB-,O
other,JJ,O
than,IN,O
thrombin,NN,O
-rrb-,-RRB-,O
or,CC,O
red,JJ,O
blood,NN,O
cells,NNS,O
.,.,.
,,
in,IN,O
clinical,JJ,O
trials,NNS,O
in,IN,O
patients,NNS,O
undergoing,VBG,O
ptca/pci,NN,O
",",",",O
co-administration,NN,O
of,IN,O
angiomax,NN,B
with,IN,O
heparin,NN,D
",",",",O
warfarin,NN,D
",",",",O
thrombolytics,NNS,G
or,CC,O
glycoprotein,NN,O
iib/iiia,NN,O
inhibitors,NNS,O
was,VBD,O
associated,VBN,O
with,IN,O
increased,VBN,O
risks,NNS,O
of,IN,O
major,JJ,O
bleeding,JJ,O
events,NNS,O
compared,VBN,O
to,TO,O
patients,NNS,O
not,RB,O
receiving,VBG,O
these,DT,O
concomitant,JJ,O
medications,NNS,O
.,.,.
,,
there,EX,O
is,VBZ,O
no,DT,O
experience,NN,O
with,IN,O
co-administration,NN,O
of,IN,O
angiomax,NN,B
and,CC,O
plasma,NN,O
expanders,NNS,O
such,JJ,O
as,IN,O
dextran,NN,D
.,.,.
,,
angiomax,NN,B
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
with,IN,O
disease,NN,O
states,NNS,O
associated,VBN,O
with,IN,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
bleeding,NN,O
.,.,.
,,
immunogenicity/re-exposure,NN,O
:,:,O
in,IN,O
in,FW,O
vitro,FW,O
studies,NNS,O
",",",",O
angiomax,NN,B
exhibited,VBD,O
no,DT,O
platelet,NN,O
aggregation,NN,O
response,NN,O
against,IN,O
sera,NNS,O
from,IN,O
patients,NNS,O
with,IN,O
a,DT,O
history,NN,O
of,IN,O
hit/hitts,NN,O
.,.,.
,,
among,IN,O
494,CD,O
subjects,NNS,O
who,WP,O
received,VBD,O
angiomax,NNP,B
in,IN,O
clinical,JJ,O
trials,NNS,O
and,CC,O
were,VBD,O
tested,VBN,O
for,IN,O
antibodies,NNS,G
",",",",O
2,CD,O
subjects,NNS,O
had,VBD,O
treatment-emergent,JJ,O
positive,JJ,O
bivalirudin,NN,D
antibody,NN,O
tests,NNS,O
.,.,.
,,
neither,DT,O
subject,JJ,O
demonstrated,VBD,O
clinical,JJ,O
evidence,NN,O
of,IN,O
allergic,JJ,O
or,CC,O
anaphylactic,JJ,O
reactions,NNS,O
and,CC,O
repeat,NN,O
testing,NN,O
was,VBD,O
not,RB,O
performed,VBN,O
.,.,.
,,
nine,CD,O
additional,JJ,O
patients,NNS,O
who,WP,O
had,VBD,O
initial,JJ,O
positive,JJ,O
tests,NNS,O
were,VBD,O
negative,JJ,O
on,IN,O
repeat,NN,O
testing,NN,O
.,.,.
,,
certain,JJ,O
antibiotic,JJ,G
",",",",O
cisplatin,NN,D
",",",",O
cyclosporine,NN,D
",",",",O
diuretic,JJ,G
",",",",O
foscarnet,NN,D
",",",",O
and,CC,O
vaccines,NNS,G
.,.,.
,,
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
with,IN,O
velcade,NN,B
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
with,IN,O
human,JJ,O
liver,NN,O
microsomes,NNS,O
indicate,VBP,O
that,IN,O
bortezomib,NN,D
is,VBZ,O
primarily,RB,O
a,DT,O
substrate,NN,O
for,IN,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
",",",",O
2c19,NN,O
",",",",O
and,CC,O
1a2,NN,O
.,.,.
,,
patients,NNS,O
who,WP,O
are,VBP,O
concomitantly,RB,O
receiving,VBG,O
velcade,NNP,B
and,CC,O
drugs,NNS,D
that,WDT,O
are,VBP,O
inhibitors,NNS,O
or,CC,O
inducers,NNS,O
of,IN,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
for,IN,O
either,CC,O
toxicities,NNS,O
or,CC,O
reduced,VBN,O
efficacy,NN,O
.,.,.
,,
during,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
hypoglycemia,NN,O
and,CC,O
hyperglycemia,NN,O
were,VBD,O
reported,VBN,O
in,IN,O
diabetic,JJ,O
patients,NNS,O
receiving,VBG,O
oral,JJ,O
hypoglycemics,NNS,G
.,.,.
,,
patients,NNS,O
on,IN,O
oral,JJ,O
antidiabetic,JJ,D
agents,NNS,O
receiving,VBG,O
velcade,NNP,B
treatment,NN,O
may,MD,O
require,VB,O
close,JJ,O
monitoring,NN,O
of,IN,O
their,PRP$,O
blood,NN,O
glucose,NN,O
levels,NNS,O
and,CC,O
adjustment,NN,O
of,IN,O
the,DT,O
dose,NN,O
of,IN,O
their,PRP$,O
antidiabetic,JJ,D
medication,NN,O
.,.,.
,,
drug,NNP,O
laboratory,NNP,O
test,NNP,O
interactions,NNS,O
none,NN,O
known,VBN,O
.,.,.
,,
bosentan,NNP,D
is,VBZ,O
metabolized,VBN,O
by,IN,O
cyp2c9,NN,D
and,CC,O
cyp3a4,NN,D
.,.,.
,,
inhibition,NN,O
of,IN,O
these,DT,O
isoenzymes,NNS,O
may,MD,O
increase,VB,O
the,DT,O
plasma,NN,O
concentration,NN,O
of,IN,O
bosentan,NN,D
.,.,.
,,
bosentan,NNP,D
is,VBZ,O
an,DT,O
inducer,NN,O
of,IN,O
cyp3a4,NN,D
and,CC,O
cyp2c9,NN,D
.,.,.
,,
consequently,RB,O
",",",",O
plasma,NN,O
concentrations,NNS,O
of,IN,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
these,DT,O
two,CD,O
isoenzymes,NNS,O
will,MD,O
be,VB,O
decreased,VBN,O
when,WRB,O
tracleer,NN,B
is,VBZ,O
co-administered,JJ,O
.,.,.
,,
bosentan,NNP,D
had,VBD,O
no,DT,O
relevant,JJ,O
inhibitory,JJ,O
effect,NN,O
on,IN,O
any,DT,O
cyp,NN,O
isoenzymes,NNS,O
tested,VBN,O
-lrb-,-LRB-,O
cyp1a2,NN,D
",",",",O
cyp2c9,NN,D
",",",",O
cyp2c19,NN,O
",",",",O
cyp2d6,NN,D
",",",",O
cyp3a4,NN,D
-rrb-,-RRB-,O
.,.,.
,,
consequently,RB,O
",",",",O
tracleer,NN,B
is,VBZ,O
not,RB,O
expected,VBN,O
to,TO,O
increase,VB,O
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
these,DT,O
enzymes,NNS,O
.,.,.
,,
hormonal,JJ,O
contraceptives,NNS,G
",",",",O
including,VBG,O
oral,JJ,O
",",",",O
injectable,JJ,O
",",",",O
transdermal,JJ,O
",",",",O
and,CC,O
implantable,JJ,O
contraceptives,NNS,G
:,:,O
an,DT,O
interaction,NN,O
study,NN,O
demonstrated,VBD,O
that,IN,O
co-administration,NN,O
of,IN,O
bosentan,NN,D
and,CC,O
the,DT,O
oral,JJ,O
hormonal,JJ,O
contraceptive,JJ,G
ortho-novum,NNP,B
produced,VBN,O
average,JJ,O
decreases,NNS,O
of,IN,O
norethindrone,NN,D
and,CC,O
ethinyl,NN,O
estradiol,NN,O
levels,NNS,O
of,IN,O
14,CD,O
%,NN,O
and,CC,O
31,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
however,RB,O
",",",",O
decreases,VBZ,O
in,IN,O
exposure,NN,O
were,VBD,O
as,RB,O
much,JJ,O
as,IN,O
56,CD,O
%,NN,O
and,CC,O
66,CD,O
%,NN,O
",",",",O
respectively,RB,O
",",",",O
in,IN,O
individual,JJ,O
subjects,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
hormonal,JJ,O
contraceptives,NNS,G
",",",",O
including,VBG,O
oral,JJ,O
",",",",O
injectable,JJ,O
",",",",O
transdermal,JJ,O
",",",",O
and,CC,O
implantable,JJ,O
forms,NNS,O
",",",",O
may,MD,O
not,RB,O
be,VB,O
reliable,JJ,O
when,WRB,O
tracleer,NN,B
is,VBZ,O
co-administered,JJ,O
.,.,.
,,
women,NNS,O
should,MD,O
practice,VB,O
additional,JJ,O
methods,NNS,O
of,IN,O
contraception,NN,O
and,CC,O
not,RB,O
rely,VB,O
on,IN,O
hormonal,JJ,O
contraception,NN,O
alone,RB,O
when,WRB,O
taking,VBG,O
tracleer,NN,B
.,.,.
,,
specific,JJ,O
interaction,NN,O
studies,NNS,O
have,VBP,O
demonstrated,VBN,O
the,DT,O
following,NN,O
:,:,O
cyclosporine,NN,D
a,NN,O
:,:,O
during,IN,O
the,DT,O
first,JJ,O
day,NN,O
of,IN,O
concomitant,JJ,O
administration,NN,O
",",",",O
trough,NN,O
concentrations,NNS,O
of,IN,O
bosentan,NN,D
were,VBD,O
increased,VBN,O
by,IN,O
about,IN,O
30-fold,RB,O
.,.,.
,,
steady-state,JJ,O
bosentan,NN,D
plasma,NN,O
concentrations,NNS,O
were,VBD,O
3,LS,O
-,:,O
to,TO,O
4-fold,RB,O
higher,JJR,O
than,IN,O
in,IN,O
the,DT,O
absence,NN,O
of,IN,O
cyclosporine,NN,D
a,NN,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
bosentan,NN,D
and,CC,O
cyclosporine,NN,D
a,NN,O
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
co-administration,NN,O
of,IN,O
bosentan,NN,D
decreased,VBD,O
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
cyclosporine,NN,D
a,NN,O
-lrb-,-LRB-,O
a,DT,O
cyp3a4,NN,D
substrate,NN,O
-rrb-,-RRB-,O
by,IN,O
approximately,RB,O
50,CD,O
%,NN,O
.,.,.
,,
tacrolimus,NN,D
:,:,O
co-administration,NN,O
of,IN,O
tacrolimus,NN,D
and,CC,O
bosentan,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
in,IN,O
man,NN,O
.,.,.
,,
co-administration,NN,O
of,IN,O
tacrolimus,NN,D
and,CC,O
bosentan,NN,D
resulted,VBD,O
in,IN,O
markedly,RB,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
bosentan,NN,D
in,IN,O
animals,NNS,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
if,IN,O
tacrolimus,NN,D
and,CC,O
bosentan,NN,D
are,VBP,O
used,VBN,O
together,RB,O
.,.,.
,,
glyburide,NNP,D
:,:,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
elevated,JJ,O
liver,NN,O
aminotransferases,NNS,O
was,VBD,O
observed,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
therapy,NN,O
with,IN,O
glyburide,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
tracleer,NN,B
and,CC,O
glyburide,NN,D
is,VBZ,O
contraindicated,VBN,O
",",",",O
and,CC,O
alternative,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
co-administration,NN,O
of,IN,O
bosentan,NN,D
decreased,VBD,O
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
glyburide,NN,D
by,IN,O
approximately,RB,O
40,CD,O
%,NN,O
.,.,.
,,
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
bosentan,NN,D
were,VBD,O
also,RB,O
decreased,VBN,O
by,IN,O
approximately,RB,O
30,CD,O
%,NN,O
.,.,.
,,
bosentan,NNP,D
is,VBZ,O
also,RB,O
expected,VBN,O
to,TO,O
reduce,VB,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
other,JJ,O
oral,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
that,WDT,O
are,VBP,O
predominantly,RB,O
metabolized,VBN,O
by,IN,O
cyp2c9,NN,D
or,CC,O
cyp3a4,NN,D
.,.,.
,,
the,DT,O
possibility,NN,O
of,IN,O
worsened,VBN,O
glucose,NN,O
control,NN,O
in,IN,O
patients,NNS,O
using,VBG,O
these,DT,O
agents,NNS,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
co-administration,NN,O
of,IN,O
bosentan,NN,D
125,CD,O
mg,NN,O
b.i.d.,NN,O
and,CC,O
ketoconazole,NN,D
",",",",O
a,DT,O
potent,JJ,O
cyp3a4,NN,D
inhibitor,NN,O
",",",",O
increased,VBD,O
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
bosentan,NN,D
by,IN,O
approximately,RB,O
2-fold,RB,O
.,.,.
,,
no,DT,O
dose,NN,O
adjustment,NN,O
of,IN,O
bosentan,NN,D
is,VBZ,O
necessary,JJ,O
",",",",O
but,CC,O
increased,VBD,O
effects,NNS,O
of,IN,O
bosentan,NN,D
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
simvastatin,NNP,D
and,CC,O
other,JJ,O
statins,NNS,G
:,:,O
co-administration,NN,O
of,IN,O
bosentan,NN,D
decreased,VBD,O
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
simvastatin,NN,D
-lrb-,-LRB-,O
a,DT,O
cyp3a4,NN,D
substrate,NN,O
-rrb-,-RRB-,O
",",",",O
and,CC,O
its,PRP$,O
active,JJ,O
-,:,O
hydroxy,NN,O
acid,NN,O
metabolite,NN,O
",",",",O
by,IN,O
approximately,RB,O
50,CD,O
%,NN,O
.,.,.
,,
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
bosentan,NN,D
were,VBD,O
not,RB,O
affected,VBN,O
.,.,.
,,
bosentan,NNP,D
is,VBZ,O
also,RB,O
expected,VBN,O
to,TO,O
reduce,VB,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
other,JJ,O
statins,NNS,G
that,WDT,O
have,VBP,O
significant,JJ,O
metabolism,NN,O
by,IN,O
cyp3a4,NN,D
",",",",O
such,JJ,O
as,IN,O
lovastatin,NN,D
and,CC,O
atorvastatin,NN,D
.,.,.
,,
the,DT,O
possibility,NN,O
of,IN,O
reduced,VBN,O
statin,NN,G
efficacy,NN,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
patients,NNS,O
using,VBG,O
cyp3a4,NN,D
metabolized,VBN,O
statins,NNS,G
should,MD,O
have,VB,O
cholesterol,NN,O
levels,NNS,O
monitored,VBD,O
after,IN,O
tracleer,NN,B
is,VBZ,O
initiated,VBN,O
to,TO,O
see,VB,O
whether,IN,O
the,DT,O
statin,NN,G
dose,NN,O
needs,VBZ,O
adjustment,NN,O
.,.,.
,,
warfarin,NNP,D
:,:,O
co-administration,NN,O
of,IN,O
bosentan,NN,D
500,CD,O
mg,NN,O
b.i.d.,NN,O
for,IN,O
6,CD,O
days,NNS,O
decreased,VBD,O
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
both,DT,O
s-warfarin,NN,D
-lrb-,-LRB-,O
a,DT,O
cyp2c9,NN,D
substrate,NN,O
-rrb-,-RRB-,O
and,CC,O
r-warfarin,NN,D
-lrb-,-LRB-,O
a,DT,O
cyp3a4,NN,D
substrate,NN,O
-rrb-,-RRB-,O
by,IN,O
29,CD,O
and,CC,O
38,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
clinical,JJ,O
experience,NN,O
with,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
bosentan,NN,D
and,CC,O
warfarin,NN,D
in,IN,O
patients,NNS,O
with,IN,O
pulmonary,JJ,O
arterial,JJ,O
hypertension,NN,O
did,VBD,O
not,RB,O
show,VB,O
clinically,RB,O
relevant,JJ,O
changes,NNS,O
in,IN,O
inr,NN,O
or,CC,O
warfarin,NN,D
dose,NN,O
-lrb-,-LRB-,O
baseline,NN,O
vs.,CC,O
end,NN,O
of,IN,O
the,DT,O
clinical,JJ,O
studies,NNS,O
-rrb-,-RRB-,O
",",",",O
and,CC,O
the,DT,O
need,NN,O
to,TO,O
change,VB,O
the,DT,O
warfarin,NN,D
dose,NN,O
during,IN,O
the,DT,O
trials,NNS,O
due,JJ,O
to,TO,O
changes,NNS,O
in,IN,O
inr,NN,O
or,CC,O
due,JJ,O
to,TO,O
adverse,JJ,O
events,NNS,O
was,VBD,O
similar,JJ,O
among,IN,O
bosentan,NN,D
-,:,O
and,CC,O
placebo-treated,JJ,O
patients,NNS,O
.,.,.
,,
digoxin,NNP,D
",",",",O
nimodipine,NNP,D
and,CC,O
losartan,NNP,D
:,:,O
bosentan,NNP,D
has,VBZ,O
no,DT,O
significant,JJ,O
pharmacokinetic,JJ,O
interactions,NNS,O
with,IN,O
digoxin,NN,D
and,CC,O
nimodipine,NN,D
",",",",O
and,CC,O
losartan,NN,D
has,VBZ,O
no,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
plasma,NN,O
levels,NNS,O
of,IN,O
bosentan,NN,D
.,.,.
,,
co-administration,NN,O
of,IN,O
botox,NNP,B
and,CC,O
aminoglycosides,NNS,G
or,CC,O
other,JJ,O
agents,NNS,O
interfering,VBG,O
with,IN,O
neuromuscular,JJ,O
transmission,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
curare-like,JJ,O
compounds,NNS,O
-rrb-,-RRB-,O
should,MD,O
only,RB,O
be,VB,O
performed,VBN,O
with,IN,O
caution,NN,O
as,IN,O
the,DT,O
effect,NN,O
of,IN,O
the,DT,O
toxin,NN,D
may,MD,O
be,VB,O
potentiated,VBN,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
administering,VBG,O
different,JJ,O
botulinum,NN,O
neurotoxin,NN,O
serotypes,NNS,O
at,IN,O
the,DT,O
same,JJ,O
time,NN,O
or,CC,O
within,IN,O
several,JJ,O
months,NNS,O
of,IN,O
each,DT,O
other,JJ,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
excessive,JJ,O
neuromuscular,JJ,O
weakness,NN,O
may,MD,O
be,VB,O
exacerbated,VBN,O
by,IN,O
administration,NN,O
of,IN,O
another,DT,O
botulinum,NN,O
toxin,NN,D
prior,RB,O
to,TO,O
the,DT,O
resolution,NN,O
of,IN,O
the,DT,O
effects,NNS,O
of,IN,O
a,DT,O
previously,RB,O
administered,VBN,O
botulinum,NN,O
toxin,NN,D
.,.,.
,,
co-administration,NN,O
of,IN,O
myobloc,NNP,B
and,CC,O
aminoglycosides,NNS,G
or,CC,O
other,JJ,O
agents,NNS,O
interfering,VBG,O
with,IN,O
neuromuscular,JJ,O
transmission,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
curare-like,JJ,O
compounds,NNS,O
-rrb-,-RRB-,O
should,MD,O
only,RB,O
be,VB,O
performed,VBN,O
with,IN,O
caution,NN,O
as,IN,O
the,DT,O
effect,NN,O
of,IN,O
the,DT,O
toxin,NN,D
may,MD,O
be,VB,O
potentiated,VBN,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
administering,VBG,O
different,JJ,O
botulinum,NN,O
neurotoxin,NN,O
serotypes,NNS,O
at,IN,O
the,DT,O
same,JJ,O
time,NN,O
or,CC,O
within,IN,O
less,JJR,O
than,IN,O
4,CD,O
months,NNS,O
of,IN,O
each,DT,O
other,JJ,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
however,RB,O
",",",",O
neuromuscular,JJ,O
paralysis,NN,O
may,MD,O
be,VB,O
potentiated,VBN,O
by,IN,O
co-administration,NN,O
or,CC,O
overlapping,VBG,O
administration,NN,O
of,IN,O
different,JJ,O
botulinum,NN,O
toxin,NN,D
serotypes,NNS,O
.,.,.
,,
digitalis,NN,G
toxicity,NN,O
may,MD,O
be,VB,O
aggravated,VBN,O
by,IN,O
the,DT,O
initial,JJ,O
release,NN,O
of,IN,O
norepinephrine,NN,D
caused,VBN,O
by,IN,O
bretylium,NNP,O
tosylate,NNP,O
injection,NN,O
.,.,.
,,
the,DT,O
pressor,JJ,O
effects,NNS,O
of,IN,O
catecholamines,NNS,G
such,JJ,O
as,IN,O
dopamine,NN,D
or,CC,O
norepinephrine,NN,D
are,VBP,O
enhanced,VBN,O
by,IN,O
bretylium,NNP,O
tosylate,NNP,O
.,.,.
,,
when,WRB,O
catecholamines,NNS,G
are,VBP,O
administered,VBN,O
",",",",O
dilute,VB,O
solutions,NNS,O
should,MD,O
be,VB,O
used,VBN,O
and,CC,O
blood,NN,O
pressure,NN,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
although,IN,O
there,EX,O
is,VBZ,O
little,JJ,O
published,VBN,O
information,NN,O
on,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
lidocaine,NN,D
and,CC,O
bretylium,NNP,O
tosylate,NNP,O
",",",",O
these,DT,O
drugs,NNS,D
are,VBP,O
often,RB,O
administered,VBN,O
concurrently,RB,O
without,IN,O
any,DT,O
evidence,NN,O
of,IN,O
interactions,NNS,O
resulting,VBG,O
in,IN,O
adverse,JJ,O
effects,NNS,O
or,CC,O
diminished,VBN,O
efficacy,NN,O
.,.,.
,,
although,IN,O
specific,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
with,IN,O
alphagan,NN,O
p,NN,O
",",",",O
the,DT,O
possibility,NN,O
of,IN,O
an,DT,O
additive,JJ,O
or,CC,O
potentiating,NN,O
effect,NN,O
with,IN,O
cns,NN,O
depressants,NNS,O
-lrb-,-LRB-,O
alcohol,NN,D
",",",",O
barbiturates,NNS,G
",",",",O
opiates,NNS,G
",",",",O
sedatives,NNS,G
",",",",O
or,CC,O
anesthetics,NNS,G
-rrb-,-RRB-,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
alpha-agonists,NNS,G
",",",",O
as,IN,O
a,DT,O
class,NN,O
",",",",O
may,MD,O
reduce,VB,O
pulse,NN,O
and,CC,O
blood,NN,O
pressure,NN,O
.,.,.
,,
caution,NN,O
in,IN,O
using,VBG,O
concomitant,JJ,O
drugs,NNS,D
such,JJ,O
as,IN,O
beta-blockers,NNS,G
-lrb-,-LRB-,O
ophthalmic,JJ,O
and,CC,O
systemic,JJ,O
-rrb-,-RRB-,O
",",",",O
anti-hypertensives,JJ,G
and/or,CC,O
cardiac,JJ,O
glycosides,NNS,G
is,VBZ,O
advised,VBN,O
.,.,.
,,
tricyclic,JJ,O
antidepressants,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
blunt,VB,O
the,DT,O
hypotensive,JJ,O
effect,NN,O
of,IN,O
systemic,JJ,O
clonidine.it,NN,O
is,VBZ,O
not,RB,O
known,VBN,O
whether,IN,O
the,DT,O
concurrent,JJ,O
use,NN,O
of,IN,O
these,DT,O
agents,NNS,O
with,IN,O
alphagan,NN,O
p,NN,O
in,IN,O
humans,NNS,O
can,MD,O
lead,VB,O
to,TO,O
resulting,VBG,O
interference,NN,O
with,IN,O
the,DT,O
iop,NN,O
lowering,NN,O
effect,NN,O
.,.,.
,,
no,DT,O
data,NNS,O
on,IN,O
the,DT,O
level,NN,O
of,IN,O
circulating,VBG,O
catecholamines,NNS,G
after,IN,O
alphagan,NNP,O
p,NN,O
administration,NN,O
are,VBP,O
available,JJ,O
.,.,.
,,
caution,NN,O
",",",",O
however,RB,O
",",",",O
is,VBZ,O
advised,VBN,O
in,IN,O
patients,NNS,O
taking,VBG,O
tricyclic,JJ,G
antidepressants,NNS,G
which,WDT,O
can,MD,O
affect,VB,O
the,DT,O
metabolism,NN,O
and,CC,O
uptake,NN,O
of,IN,O
circulating,VBG,O
amines,NNS,O
.,.,.
,,
azopt,NN,B
-lrb-,-LRB-,O
brinzolamide,NN,D
ophthalmic,JJ,O
suspension,NN,O
-rrb-,-RRB-,O
1,CD,O
%,NN,O
contains,VBZ,O
a,DT,O
carbonic,JJ,O
anhydrase,NN,O
inhibitor,NN,O
.,.,.
,,
acid-base,NN,O
and,CC,O
electrolyte,NN,O
alterations,NNS,O
were,VBD,O
not,RB,O
reported,VBN,O
in,IN,O
the,DT,O
clinical,JJ,O
trials,NNS,O
with,IN,O
brinzolamide,NN,D
.,.,.
,,
however,RB,O
",",",",O
in,IN,O
patients,NNS,O
treated,VBN,O
with,IN,O
oral,JJ,O
carbonic,JJ,O
anhydrase,NN,O
inhibitors,NNS,O
",",",",O
rare,JJ,O
instances,NNS,O
of,IN,O
drug,NN,D
interactions,NNS,O
have,VBP,O
occurred,VBN,O
with,IN,O
high-dose,JJ,O
salicylate,NN,G
therapy,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
potential,NN,O
for,IN,O
such,JJ,O
drug,NN,D
interaction,NN,O
should,MD,O
be,VB,O
considered,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
azopt,NNP,B
-lrb-,-LRB-,O
brinzolamide,JJ,D
ophthalmic,JJ,O
suspension,NN,O
-rrb-,-RRB-,O
1,CD,O
%,NN,O
.,.,.
,,
the,DT,O
risk,NN,O
of,IN,O
using,VBG,O
bromocriptine,NN,D
mesylate,NN,O
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
has,VBZ,O
not,RB,O
been,VBN,O
systematically,RB,O
evaluated,VBN,O
",",",",O
but,CC,O
alcohol,NN,D
may,MD,O
potentiate,VB,O
the,DT,O
side,JJ,O
effects,NNS,O
of,IN,O
bromocriptine,NN,D
mesylate,NN,O
.,.,.
,,
bromocriptine,NN,O
mesylate,NN,O
may,MD,O
interact,VB,O
with,IN,O
dopamine,NN,D
antagonists,NNS,O
",",",",O
butyrophenones,NNS,G
",",",",O
and,CC,O
certain,JJ,O
other,JJ,O
agents,NNS,O
.,.,.
,,
compounds,NNS,O
in,IN,O
these,DT,O
categories,NNS,O
result,VBP,O
in,IN,O
a,DT,O
decreased,VBN,O
efficacy,NN,O
of,IN,O
bromocriptine,NN,D
mesylate,NN,O
:,:,O
phenothiazines,NNS,G
",",",",O
haloperidol,NN,D
",",",",O
metoclopramide,NN,D
",",",",O
pimozide,NN,D
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
bromocriptine,NN,D
mesylate,NN,O
with,IN,O
other,JJ,O
ergot,NN,G
alkaloids,NNS,O
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
dexbrompheniramine,NN,D
can,MD,O
interact,VB,O
with,IN,O
alcohol,NN,D
or,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
-lrb-,-LRB-,O
may,MD,O
potentiate,VB,O
the,DT,O
cns,NN,O
depressant,NN,O
effects,NNS,O
of,IN,O
either,CC,O
these,DT,O
medications,NNS,O
or,CC,O
antihistamines,NNS,G
-rrb-,-RRB-,O
",",",",O
anticholinergics,NNS,G
or,CC,O
other,JJ,O
medications,NNS,O
with,IN,O
anticholinergic,JJ,G
activity,NN,O
-lrb-,-LRB-,O
anticholinergic,JJ,G
effects,NNS,O
may,MD,O
be,VB,O
potentiated,VBN,O
when,WRB,O
these,DT,O
medications,NNS,O
are,VBP,O
used,VBN,O
concurrently,RB,O
with,IN,O
antihistamines,NNS,G
-rrb-,-RRB-,O
",",",",O
and,CC,O
monoamine,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
mao,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
-lrb-,-LRB-,O
concurrent,JJ,O
use,NN,O
with,IN,O
antihistamines,NNS,G
may,MD,O
prolong,VB,O
and,CC,O
intensify,VB,O
the,DT,O
anticholinergic,JJ,G
and,CC,O
cns,NN,O
depressant,NN,O
effects,NNS,O
of,IN,O
antihistamines,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
this,DT,O
drug,NN,D
may,MD,O
interact,VB,O
with,IN,O
alcohol,NN,D
or,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
-lrb-,-LRB-,O
may,MD,O
potentiate,VB,O
the,DT,O
cns,NN,O
depressant,NN,O
effects,NNS,O
of,IN,O
either,CC,O
these,DT,O
medications,NNS,O
or,CC,O
antihistamines,NNS,G
-rrb-,-RRB-,O
",",",",O
anticholinergics,NNS,G
or,CC,O
other,JJ,O
medications,NNS,O
with,IN,O
anticholinergic,JJ,G
activity,NN,O
-lrb-,-LRB-,O
anticholinergic,JJ,G
effects,NNS,O
may,MD,O
be,VB,O
potentiated,VBN,O
when,WRB,O
these,DT,O
medications,NNS,O
are,VBP,O
used,VBN,O
concurrently,RB,O
with,IN,O
antihistamines,NNS,G
-rrb-,-RRB-,O
",",",",O
and,CC,O
monoamine,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
mao,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
-lrb-,-LRB-,O
concurrent,JJ,O
use,NN,O
with,IN,O
antihistamines,NNS,G
may,MD,O
prolong,VB,O
and,CC,O
intensify,VB,O
the,DT,O
anticholinergic,JJ,G
and,CC,O
cns,NN,O
depressant,NN,O
effects,NNS,O
of,IN,O
antihistamines,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
concomitant,JJ,O
oral,JJ,O
administration,NN,O
of,IN,O
ketoconazole,NN,D
-lrb-,-LRB-,O
a,DT,O
known,JJ,O
inhibitor,NN,O
of,IN,O
cyp3a4,NN,D
activity,NN,O
in,IN,O
the,DT,O
liver,NN,O
and,CC,O
in,IN,O
the,DT,O
intestinal,JJ,O
mucosa,NN,O
-rrb-,-RRB-,O
caused,VBD,O
an,DT,O
eight-fold,JJ,O
increase,NN,O
of,IN,O
the,DT,O
systemic,JJ,O
exposure,NN,O
to,TO,O
oral,JJ,O
budesonide,NN,D
.,.,.
,,
if,IN,O
treatment,NN,O
with,IN,O
inhibitors,NNS,O
of,IN,O
cyp3a4,NN,D
activity,NN,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
ketoconazole,NN,D
",",",",O
intraconazole,NN,D
",",",",O
ritonavir,NN,D
",",",",O
indinavir,NN,D
",",",",O
saquinavir,NN,D
",",",",O
erythromycin,NN,D
",",",",O
etc.,FW,O
-rrb-,-RRB-,O
is,VBZ,O
indicated,VBN,O
",",",",O
reduction,NN,O
of,IN,O
the,DT,O
budesonide,NN,D
dose,NN,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
after,IN,O
extensive,JJ,O
intake,NN,O
of,IN,O
grapefruit,NN,O
juice,NN,O
-lrb-,-LRB-,O
which,WDT,O
inhibits,VBZ,O
cyp3a4,NN,D
activity,NN,O
predominantly,RB,O
in,IN,O
the,DT,O
intestinal,JJ,O
mucosa,NN,O
-rrb-,-RRB-,O
",",",",O
the,DT,O
systemic,JJ,O
exposure,NN,O
for,IN,O
oral,JJ,O
budesonide,NN,D
increased,VBD,O
about,IN,O
two,CD,O
times,NNS,O
.,.,.
,,
as,IN,O
with,IN,O
other,JJ,O
drugs,NNS,D
primarily,RB,O
being,VBG,O
metabolized,VBN,O
through,IN,O
cyp3a4,NN,D
",",",",O
ingestion,NN,O
of,IN,O
grapefruit,NN,O
or,CC,O
grapefruit,NN,O
juice,NN,O
should,MD,O
be,VB,O
avoided,VBN,O
in,IN,O
connection,NN,O
with,IN,O
budesonide,NN,D
administration,NN,O
.,.,.
,,
-,:,O
drugs,NNS,O
with,IN,O
ototoxic,JJ,O
potential,NN,O
:,:,O
especially,RB,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
impaired,JJ,O
renal,JJ,O
function,NN,O
",",",",O
the,DT,O
use,NN,O
of,IN,O
parenterally,RB,O
administered,VBN,O
bumetanide,NN,D
in,IN,O
patients,NNS,O
to,TO,O
whom,WP,O
aminoglycoside,RB,G
antibiotics,NNS,G
are,VBP,O
also,RB,O
being,VBG,O
given,VBN,O
should,MD,O
be,VB,O
avoided,VBN,O
",",",",O
except,IN,O
in,IN,O
life-threatening,JJ,O
conditions,NNS,O
.,.,.
,,
-,:,O
drugs,NNS,O
with,IN,O
nephrotoxic,JJ,O
potential,NN,O
:,:,O
there,EX,O
has,VBZ,O
been,VBN,O
no,DT,O
experience,NN,O
on,IN,O
the,DT,O
concurrent,JJ,O
use,NN,O
of,IN,O
bumetanide,NN,D
with,IN,O
drugs,NNS,D
known,VBN,O
to,TO,O
have,VB,O
a,DT,O
nephrotoxic,JJ,O
potential,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
simultaneous,JJ,O
administration,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
-,:,O
lithium,NN,D
:,:,O
lithium,NN,D
should,MD,O
generally,RB,O
not,RB,O
be,VB,O
given,VBN,O
with,IN,O
diuretics,NNS,G
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
bumetanide,NN,D
-rrb-,-RRB-,O
because,IN,O
they,PRP,O
reduce,VBP,O
its,PRP$,O
renal,JJ,O
clearance,NN,O
and,CC,O
add,VB,O
a,DT,O
high,JJ,O
risk,NN,O
of,IN,O
lithium,NN,D
toxicity,NN,O
.,.,.
,,
-,:,O
probenecid,NNP,D
:,:,O
pretreatment,NN,O
with,IN,O
probenecid,NN,D
reduces,VBZ,O
both,CC,O
the,DT,O
natriuresis,NN,O
and,CC,O
hyperreninemia,NN,O
produced,VBN,O
by,IN,O
bumetanide,NN,D
.,.,.
,,
this,DT,O
antagonistic,JJ,O
effect,NN,O
of,IN,O
probenecid,NN,D
on,IN,O
bumetanide,NN,D
natriuresis,NN,O
is,VBZ,O
not,RB,O
due,JJ,O
to,TO,O
a,DT,O
direct,JJ,O
action,NN,O
on,IN,O
sodium,NN,O
excretion,NN,O
but,CC,O
is,VBZ,O
probably,RB,O
secondary,JJ,O
to,TO,O
its,PRP$,O
inhibitory,JJ,O
effect,NN,O
on,IN,O
renal,JJ,O
tubular,JJ,O
secretion,NN,O
of,IN,O
bumetanide,NN,D
.,.,.
,,
thus,RB,O
",",",",O
probenecid,NN,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
concurrently,RB,O
with,IN,O
bumetanide,NN,D
.,.,.
,,
-,:,O
indomethacin,NN,D
:,:,O
indomethacin,NN,D
blunts,VBZ,O
the,DT,O
increases,NNS,O
in,IN,O
urine,NN,O
volume,NN,O
and,CC,O
sodium,NN,O
excretion,NN,O
seen,VBN,O
during,IN,O
bumetanide,NN,D
treatment,NN,O
and,CC,O
inhibits,VBZ,O
the,DT,O
bumetanide-induced,JJ,O
increase,NN,O
in,IN,O
plasma,NN,O
renin,NN,O
activity,NN,O
.,.,.
,,
concurrent,JJ,O
therapy,NN,O
with,IN,O
bumetanide,NN,D
is,VBZ,O
thus,RB,O
not,RB,O
recommended,VBN,O
.,.,.
,,
-,:,O
antihypertensives,NNS,G
:,:,O
bumetanide,NNP,D
may,MD,O
potentiate,VB,O
the,DT,O
effect,NN,O
of,IN,O
various,JJ,O
antihypertensive,JJ,G
drugs,NNS,D
",",",",O
necessitating,VBG,O
a,DT,O
reduction,NN,O
in,IN,O
the,DT,O
dosage,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
-,:,O
digoxin,NN,D
:,:,O
interaction,NN,O
studies,NNS,O
in,IN,O
humans,NNS,O
have,VBP,O
shown,VBN,O
no,DT,O
effect,NN,O
on,IN,O
digoxin,NN,D
blood,NN,O
levels,NNS,O
.,.,.
,,
-,:,O
anticoagulants,NNPS,G
:,:,O
interaction,NN,O
studies,NNS,O
in,IN,O
humans,NNS,O
have,VBP,O
shown,VBN,O
bumetanide,NN,D
to,TO,O
have,VB,O
no,DT,O
effect,NN,O
on,IN,O
warfarin,NN,D
metabolism,NN,O
or,CC,O
on,IN,O
plasma,NN,O
prothrombin,NN,O
activity,NN,O
.,.,.
,,
the,DT,O
administration,NN,O
of,IN,O
local,JJ,O
anesthetic,JJ,G
solutions,NNS,O
containing,VBG,O
epinephrine,NN,D
or,CC,O
norepinephrine,NN,D
to,TO,O
patients,NNS,O
receiving,VBG,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
or,CC,O
tricyclic,JJ,G
antidepressants,NNS,G
may,MD,O
produce,VB,O
severe,JJ,O
",",",",O
prolonged,JJ,O
hypertension,NN,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
of,IN,O
these,DT,O
agents,NNS,O
should,MD,O
generally,RB,O
be,VB,O
avoided,VBN,O
.,.,.
,,
in,IN,O
situations,NNS,O
in,IN,O
which,WDT,O
concurrent,JJ,O
therapy,NN,O
is,VBZ,O
necessary,JJ,O
",",",",O
careful,JJ,O
patient,NN,O
monitoring,NN,O
is,VBZ,O
essential,JJ,O
.,.,.
,,
concurrent,JJ,O
administration,NN,O
of,IN,O
vasopressor,NN,G
drugs,NNS,D
and,CC,O
of,IN,O
ergot-type,JJ,O
oxytocic,JJ,O
drugs,NNS,D
may,MD,O
cause,VB,O
severe,JJ,O
",",",",O
persistent,JJ,O
hypertension,NN,O
or,CC,O
cerebrovascular,JJ,O
accidents,NNS,O
.,.,.
,,
phenothiazines,NNS,G
and,CC,O
butyrophenones,NNS,G
may,MD,O
reduce,VB,O
or,CC,O
reverse,VB,O
the,DT,O
pressor,NN,O
effect,NN,O
of,IN,O
epinephrine,NN,D
.,.,.
,,
buprenorphine,NNP,D
is,VBZ,O
metabolized,VBN,O
to,TO,O
norbuprenorphine,NN,D_n
by,IN,O
cytochrome,NN,O
cyp,NN,O
3a4,NN,O
.,.,.
,,
because,IN,O
cyp,NN,O
3a4,NN,O
inhibitors,NNS,O
may,MD,O
increase,VB,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
buprenorphine,NN,D
",",",",O
patients,NNS,O
already,RB,O
on,IN,O
cyp,NN,O
3a4,NN,O
inhibitors,NNS,O
such,JJ,O
as,IN,O
azole,NN,O
antifungals,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
ketoconazole,NN,D
-rrb-,-RRB-,O
",",",",O
macrolide,NN,O
antibiotics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
erythromycin,NN,D
-rrb-,-RRB-,O
",",",",O
and,CC,O
hiv,NN,O
protease,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
ritonavir,FW,D
",",",",O
indinavir,NN,D
and,CC,O
saquinavir,NN,D
-rrb-,-RRB-,O
should,MD,O
have,VB,O
their,PRP$,O
dose,NN,O
of,IN,O
subutex,NNP,B
or,CC,O
suboxone,NNP,B
adjusted,VBN,O
.,.,.
,,
based,VBN,O
on,IN,O
anecdotal,JJ,O
reports,NNS,O
",",",",O
there,EX,O
may,MD,O
be,VB,O
an,DT,O
interaction,NN,O
between,IN,O
buprenorphine,NN,D
and,CC,O
benzodiazepines,NNS,G
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
a,DT,O
number,NN,O
of,IN,O
reports,NNS,O
in,IN,O
the,DT,O
post-marketing,JJ,O
experience,NN,O
of,IN,O
coma,NN,O
and,CC,O
death,NN,O
associated,VBN,O
with,IN,O
the,DT,O
concomitant,JJ,O
intravenous,JJ,O
misuse,NN,O
of,IN,O
buprenorphine,NN,D
and,CC,O
benzodiazepines,NNS,G
by,IN,O
addicts,NNS,O
.,.,.
,,
in,IN,O
many,JJ,O
of,IN,O
these,DT,O
cases,NNS,O
",",",",O
buprenorphine,NN,D
was,VBD,O
misused,VBN,O
by,IN,O
self-injection,NN,O
of,IN,O
crushed,JJ,O
subutex,NNP,B
tablets,NNS,O
.,.,.
,,
subutex,NNP,B
and,CC,O
suboxone,NNP,B
should,MD,O
be,VB,O
prescribed,VBN,O
with,IN,O
caution,NN,O
to,TO,O
patients,NNS,O
on,IN,O
benzodiazepines,NNS,G
or,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
act,VBP,O
on,IN,O
the,DT,O
central,JJ,O
nervous,JJ,O
system,NN,O
",",",",O
regardless,RB,O
of,IN,O
whether,IN,O
these,DT,O
drugs,NNS,D
are,VBP,O
taken,VBN,O
on,IN,O
the,DT,O
advice,NN,O
of,IN,O
a,DT,O
physician,NN,O
or,CC,O
are,VBP,O
taken,VBN,O
as,IN,O
drugs,NNS,D
of,IN,O
abuse,NN,O
.,.,.
,,
patients,NNS,O
should,MD,O
be,VB,O
warned,VBN,O
of,IN,O
the,DT,O
potential,JJ,O
danger,NN,O
of,IN,O
the,DT,O
intravenous,JJ,O
self-administration,NN,O
of,IN,O
benzodiazepines,NNS,G
while,IN,O
under,IN,O
treatment,NN,O
with,IN,O
suboxone,NN,B
or,CC,O
subutex,NN,B
.,.,.
,,
few,JJ,O
systemic,JJ,O
data,NNS,O
have,VBP,O
been,VBN,O
collected,VBN,O
on,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
wellbutrin,NNP,B
following,VBG,O
concomitant,JJ,O
administration,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
or,CC,O
",",",",O
alternatively,RB,O
",",",",O
the,DT,O
effect,NN,O
of,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
wellbutrin,NNP,B
on,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
.,.,.
,,
because,IN,O
bupropion,NN,D
is,VBZ,O
extensively,RB,O
metabolized,VBN,O
",",",",O
the,DT,O
coadministration,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
may,MD,O
affect,VB,O
its,PRP$,O
clinical,JJ,O
activity,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
indicate,VBP,O
that,IN,O
bupropion,NN,D
is,VBZ,O
primarily,RB,O
metabolized,VBN,O
to,TO,O
hydroxybupropion,NN,D_n
by,IN,O
the,DT,O
cyp2b6,NN,O
isoenzyme,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
potential,JJ,O
exists,VBZ,O
for,IN,O
a,DT,O
drug,NN,D
interaction,NN,O
between,IN,O
wellbutrin,NNP,B
and,CC,O
drugs,NNS,D
that,WDT,O
affect,VBP,O
the,DT,O
cyp2b6,NN,O
isoenzyme,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
orphenadrine,NN,D
and,CC,O
cyclophosphamide,NN,D
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
threohydrobupropion,NN,D_n
metabolite,NN,O
of,IN,O
bupropion,NN,D
does,VBZ,O
not,RB,O
appear,VB,O
to,TO,O
be,VB,O
produced,VBN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
isoenzymes,NNS,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
cimetidine,NN,D
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
bupropion,NN,D
and,CC,O
its,PRP$,O
active,JJ,O
metabolites,NNS,O
were,VBD,O
studied,VBN,O
in,IN,O
24,CD,O
healthy,JJ,O
young,JJ,O
male,JJ,O
volunteers,NNS,O
.,.,.
,,
following,VBG,O
oral,JJ,O
administration,NN,O
of,IN,O
two,CD,O
150-mg,JJ,O
sustained-release,JJ,O
tablets,NNS,O
with,IN,O
and,CC,O
without,IN,O
800,CD,O
mg,NN,O
of,IN,O
cimetidine,NN,D
",",",",O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
bupropion,NN,D
and,CC,O
hydroxybupropion,NN,D_n
were,VBD,O
unaffected,JJ,O
.,.,.
,,
however,RB,O
",",",",O
there,EX,O
were,VBD,O
16,CD,O
%,NN,O
and,CC,O
32,CD,O
%,NN,O
increases,NNS,O
in,IN,O
the,DT,O
auc,NN,O
and,CC,O
cmax,NN,O
",",",",O
respectively,RB,O
",",",",O
of,IN,O
the,DT,O
combined,JJ,O
moieties,NNS,O
of,IN,O
threohydrobupropion,NN,D_n
and,CC,O
erythrohydrobupropion,NN,D_n
.,.,.
,,
while,IN,O
not,RB,O
systematically,RB,O
studied,VBN,O
",",",",O
certain,JJ,O
drugs,NNS,D
may,MD,O
induce,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
bupropion,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
carbamazepine,NN,D
",",",",O
phenobarbital,NN,D
",",",",O
phenytoin,NN,D
-rrb-,-RRB-,O
.,.,.
,,
animal,NN,O
data,NNS,O
indicated,VBD,O
that,IN,O
bupropion,NN,D
may,MD,O
be,VB,O
an,DT,O
inducer,NN,O
of,IN,O
drug-metabolizing,JJ,O
enzymes,NNS,O
in,IN,O
humans,NNS,O
.,.,.
,,
in,IN,O
one,CD,O
study,NN,O
",",",",O
following,VBG,O
chronic,JJ,O
administration,NN,O
of,IN,O
bupropion,NN,D
",",",",O
100,CD,O
mg,NN,O
3,CD,O
times,NNS,O
daily,JJ,O
to,TO,O
8,CD,O
healthy,JJ,O
male,JJ,O
volunteers,NNS,O
for,IN,O
14,CD,O
days,NNS,O
",",",",O
there,EX,O
was,VBD,O
no,DT,O
evidence,NN,O
of,IN,O
induction,NN,O
of,IN,O
its,PRP$,O
own,JJ,O
metabolism,NN,O
.,.,.
,,
nevertheless,RB,O
",",",",O
there,EX,O
may,MD,O
be,VB,O
the,DT,O
potential,NN,O
for,IN,O
clinically,RB,O
important,JJ,O
alterations,NNS,O
of,IN,O
blood,NN,O
levels,NNS,O
of,IN,O
coadministered,JJ,O
drugs,NNS,D
.,.,.
,,
drugs,NNS,O
metabolized,VBN,O
by,IN,O
cytochrome,NN,O
p450iid6,NN,O
-lrb-,-LRB-,O
cyp2d6,NN,D
-rrb-,-RRB-,O
:,:,O
many,JJ,O
drugs,NNS,D
",",",",O
including,VBG,O
most,RBS,O
antidepressants,NNS,G
-lrb-,-LRB-,O
ssris,NNS,G
",",",",O
many,JJ,O
tricyclics,NNS,G
-rrb-,-RRB-,O
",",",",O
beta-blockers,NNS,G
",",",",O
antiarrhythmics,NNS,G
",",",",O
and,CC,O
antipsychotics,NNS,G
are,VBP,O
metabolized,VBN,O
by,IN,O
the,DT,O
cyp2d6,NN,D
isoenzyme,NN,O
.,.,.
,,
although,IN,O
bupropion,NN,D
is,VBZ,O
not,RB,O
metabolized,VBN,O
by,IN,O
this,DT,O
isoenzyme,NN,O
",",",",O
bupropion,NN,D
and,CC,O
hydroxybupropion,NN,D_n
are,VBP,O
inhibitors,NNS,O
of,IN,O
the,DT,O
cyp2d6,NN,D
isoenzyme,NN,O
in,FW,O
vitro,FW,O
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
of,IN,O
15,CD,O
male,JJ,O
subjects,NNS,O
-lrb-,-LRB-,O
ages,NNS,O
19,CD,O
to,TO,O
35,CD,O
years,NNS,O
-rrb-,-RRB-,O
who,WP,O
were,VBD,O
extensive,JJ,O
metabolizers,NNS,O
of,IN,O
the,DT,O
cyp2d6,NN,D
isoenzyme,NN,O
",",",",O
daily,JJ,O
doses,NNS,O
of,IN,O
bupropion,NN,D
given,VBN,O
as,IN,O
150,CD,O
mg,NN,O
twice,RB,O
daily,JJ,O
followed,VBN,O
by,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
50,CD,O
mg,NN,O
desipramine,NN,D
increased,VBD,O
the,DT,O
cmax,NNP,O
",",",",O
auc,NN,O
",",",",O
and,CC,O
t1/2,NN,O
of,IN,O
desipramine,NN,D
by,IN,O
an,DT,O
average,NN,O
of,IN,O
approximately,RB,O
2,LS,O
-,:,O
",",",",O
5,LS,O
-,:,O
and,CC,O
2-fold,RB,O
",",",",O
respectively,RB,O
.,.,.
,,
the,DT,O
effect,NN,O
was,VBD,O
present,JJ,O
for,IN,O
at,IN,O
least,JJS,O
7,CD,O
days,NNS,O
after,IN,O
the,DT,O
last,JJ,O
dose,NN,O
of,IN,O
bupropion,NN,D
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
bupropion,NN,D
with,IN,O
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
cyp2d6,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
formally,RB,O
studied,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
co-administration,NN,O
of,IN,O
bupropion,NN,D
with,IN,O
drugs,NNS,D
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
cyp2d6,NN,D
isoenzyme,NN,O
including,VBG,O
certain,JJ,O
antidepressants,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
nortriptyline,NN,D
",",",",O
imipramine,NN,D
",",",",O
desipramine,NN,D
",",",",O
paroxetine,NN,D
",",",",O
fluoxetine,NN,D
",",",",O
sertraline,NN,D
-rrb-,-RRB-,O
",",",",O
antipsychotics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
haloperidol,NN,D
",",",",O
risperidone,NN,D
",",",",O
thioridazine,NN,D
-rrb-,-RRB-,O
",",",",O
beta-blockers,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
metoprolol,NN,D
-rrb-,-RRB-,O
",",",",O
and,CC,O
type,NN,O
1c,NN,O
antiarrhythmics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
propafenone,NN,D
",",",",O
flecainide,NN,D
-rrb-,-RRB-,O
",",",",O
should,MD,O
be,VB,O
approached,VBN,O
with,IN,O
caution,NN,O
and,CC,O
should,MD,O
be,VB,O
initiated,VBN,O
at,IN,O
the,DT,O
lower,JJR,O
end,NN,O
of,IN,O
the,DT,O
dose,NN,O
range,NN,O
of,IN,O
the,DT,O
concomitant,JJ,O
medication,NN,O
.,.,.
,,
if,IN,O
bupropion,NN,D
is,VBZ,O
added,VBN,O
to,TO,O
the,DT,O
treatment,NN,O
regimen,NN,O
of,IN,O
a,DT,O
patient,NN,O
already,RB,O
receiving,VBG,O
a,DT,O
drug,NN,D
metabolized,VBN,O
by,IN,O
cyp2d6,NN,D
",",",",O
the,DT,O
need,NN,O
to,TO,O
decrease,VB,O
the,DT,O
dose,NN,O
of,IN,O
the,DT,O
original,JJ,O
medication,NN,O
should,MD,O
be,VB,O
considered,VBN,O
",",",",O
particularly,RB,O
for,IN,O
those,DT,O
concomitant,JJ,O
medications,NNS,O
with,IN,O
a,DT,O
narrow,JJ,O
therapeutic,JJ,O
index,NN,O
.,.,.
,,
mao,NNP,O
inhibitors,NNS,O
:,:,O
studies,NNS,O
in,IN,O
animals,NNS,O
demonstrate,VBP,O
that,IN,O
the,DT,O
acute,JJ,O
toxicity,NN,O
of,IN,O
bupropion,NN,D
is,VBZ,O
enhanced,VBN,O
by,IN,O
the,DT,O
mao,NNP,O
inhibitor,NN,O
phenelzine,NN,D
.,.,.
,,
levodopa,NN,D
and,CC,O
amantadine,NNP,D
:,:,O
limited,NNP,O
clinical,JJ,O
data,NNS,O
suggest,VBP,O
a,DT,O
higher,JJR,O
incidence,NN,O
of,IN,O
adverse,JJ,O
experiences,NNS,O
in,IN,O
patients,NNS,O
receiving,VBG,O
bupropion,NN,D
concurrently,RB,O
with,IN,O
either,CC,O
levodopa,NN,D
or,CC,O
amantadine,NN,D
.,.,.
,,
administration,NN,O
of,IN,O
wellbutrin,NNP,B
tablets,NNPS,O
to,TO,O
patients,NNS,O
receiving,VBG,O
either,CC,O
levodopa,NN,D
or,CC,O
amantadine,NN,D
concurrently,RB,O
should,MD,O
be,VB,O
undertaken,VBN,O
with,IN,O
caution,NN,O
",",",",O
using,VBG,O
small,JJ,O
initial,JJ,O
doses,NNS,O
and,CC,O
small,JJ,O
gradual,JJ,O
dose,NN,O
increases,NNS,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
lower,NNP,O
seizure,NNP,O
threshold,NNP,O
:,:,O
concurrent,JJ,O
administration,NN,O
of,IN,O
wellbutrin,NNP,B
and,CC,O
agents,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
antipsychotics,NNS,G
",",",",O
other,JJ,O
antidepressants,NNS,G
",",",",O
theophylline,NN,D
",",",",O
systemic,JJ,O
steroids,NNS,G
",",",",O
etc.,FW,O
-rrb-,-RRB-,O
that,WDT,O
lower,JJR,O
seizure,NN,O
threshold,NN,O
should,MD,O
be,VB,O
undertaken,VBN,O
only,RB,O
with,IN,O
extreme,JJ,O
caution,NN,O
.,.,.
,,
low,JJ,O
initial,JJ,O
dosing,NN,O
and,CC,O
small,JJ,O
gradual,JJ,O
dose,NN,O
increases,NNS,O
should,MD,O
be,VB,O
employed,VBN,O
.,.,.
,,
nicotine,NN,D
transdermal,NNP,O
system,NNP,O
:,:,O
.,.,.
,,
alcohol,NN,D
:,:,O
in,IN,O
post-marketing,JJ,O
experience,NN,O
",",",",O
there,EX,O
have,VBP,O
been,VBN,O
rare,JJ,O
reports,NNS,O
of,IN,O
adverse,JJ,O
neuropsychiatric,JJ,O
events,NNS,O
or,CC,O
reduced,VBN,O
alcohol,NN,D
tolerance,NN,O
in,IN,O
patients,NNS,O
who,WP,O
were,VBD,O
drinking,VBG,O
alcohol,NN,D
during,IN,O
treatment,NN,O
with,IN,O
wellbutrin,NNP,B
.,.,.
,,
the,DT,O
consumption,NN,O
of,IN,O
alcohol,NN,D
during,IN,O
treatment,NN,O
with,IN,O
wellbutrin,NN,B
should,MD,O
be,VB,O
minimized,VBN,O
or,CC,O
avoided,VBN,O
-lrb-,-LRB-,O
also,RB,O
see,VB,O
a,DT,O
href,NN,O
=,JJ,O
bupropz,NN,O
htm,NN,O
#ci,NN,O
contraindications,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
buspirone,NN,D
hydrochloride,NN,O
not,RB,O
be,VB,O
used,VBN,O
concomitantly,RB,O
with,IN,O
mao,NN,O
inhibitors,NNS,O
because,IN,O
the,DT,O
effects,NNS,O
of,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
buspirone,NN,D
hcl,NN,O
with,IN,O
most,JJS,O
other,JJ,O
psychotropic,JJ,O
drugs,NNS,D
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
",",",",O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
buspirone,NN,D
hcl,NN,O
with,IN,O
other,JJ,O
cns-active,JJ,O
drugs,NNS,D
should,MD,O
be,VB,O
approached,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
there,EX,O
is,VBZ,O
one,CD,O
report,NN,O
suggesting,VBG,O
that,IN,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
trazodone,NN,D
hydrochloride,NN,O
-lrb-,-LRB-,O
desyrel,NN,B
-rrb-,-RRB-,O
and,CC,O
buspirone,NN,D
hcl,NN,O
may,MD,O
have,VB,O
caused,VBN,O
3,LS,O
-,:,O
to,TO,O
6-fold,RB,O
elevations,NNS,O
on,IN,O
sgpt,NN,O
-lrb-,-LRB-,O
alt,NN,O
-rrb-,-RRB-,O
in,IN,O
a,DT,O
few,JJ,O
patients,NNS,O
.,.,.
,,
in,IN,O
a,DT,O
similar,JJ,O
study,NN,O
",",",",O
attempting,VBG,O
to,TO,O
replicate,VB,O
this,DT,O
finding,NN,O
",",",",O
no,DT,O
interactive,JJ,O
effect,NN,O
on,IN,O
hepatic,JJ,O
transaminases,NNS,O
was,VBD,O
identified,VBN,O
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
buspirone,NN,D
hcl,NN,O
and,CC,O
haloperidol,NN,D
resulted,VBD,O
in,IN,O
increased,VBN,O
serum,NN,O
haloperidol,NN,D
concentrations,NNS,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
finding,NN,O
is,VBZ,O
not,RB,O
clear,JJ,O
.,.,.
,,
in,FW,O
vitro,FW,O
",",",",O
buspirone,NN,D
does,VBZ,O
not,RB,O
displace,VB,O
tightly,RB,O
bound,VBN,O
drugs,NNS,D
like,IN,O
phenytoin,NN,D
",",",",O
propranolol,NN,D
",",",",O
and,CC,O
warfarin,NN,D
from,IN,O
serum,NN,O
proteins,NNS,O
.,.,.
,,
however,RB,O
",",",",O
there,EX,O
has,VBZ,O
been,VBN,O
one,CD,O
report,NN,O
of,IN,O
prolonged,JJ,O
prothrombin,NN,O
time,NN,O
when,WRB,O
buspirone,NN,D
was,VBD,O
added,VBN,O
to,TO,O
the,DT,O
regimen,NN,O
of,IN,O
a,DT,O
patient,NN,O
treated,VBN,O
with,IN,O
warfarin,NN,D
.,.,.
,,
the,DT,O
patient,NN,O
was,VBD,O
also,RB,O
chronically,RB,O
receiving,VBG,O
phenytoin,NN,D
",",",",O
phenobarbital,NN,D
",",",",O
digoxin,NN,D
",",",",O
and,CC,O
levothyroxine,NN,D
sodium,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
",",",",O
buspirone,NN,D
may,MD,O
displace,VB,O
less,JJR,O
firmly,RB,O
bound,VBN,O
drugs,NNS,D
like,IN,O
digoxin,NN,D
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
property,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
itraconazole,NN,D
decreases,VBZ,O
busulfan,JJ,D
clearance,NN,O
by,IN,O
up,RB,O
to,TO,O
25,CD,O
%,NN,O
",",",",O
and,CC,O
may,MD,O
produce,VB,O
aucs,NNS,O
1500,CD,O
m,NN,O
min,NN,O
in,IN,O
some,DT,O
patients,NNS,O
.,.,.
,,
fluconazole,NNP,D
",",",",O
and,CC,O
the,DT,O
5-ht3,NN,O
antiemetics,NNS,G
ondansetron,NN,D
-lrb-,-LRB-,O
zofran,NN,B
-rrb-,-RRB-,O
and,CC,O
granisetron,NN,D
-lrb-,-LRB-,O
kytril,NN,B
-rrb-,-RRB-,O
have,VBP,O
all,DT,O
been,VBN,O
used,VBN,O
with,IN,O
busulfex,NN,B
.,.,.
,,
phenytoin,NNP,D
increases,VBZ,O
the,DT,O
clearance,NN,O
of,IN,O
busulfan,NN,D
by,IN,O
15,CD,O
%,NN,O
or,CC,O
more,JJR,O
",",",",O
possibly,RB,O
due,JJ,O
to,TO,O
the,DT,O
induction,NN,O
of,IN,O
glutathione-s-transferase,NN,O
.,.,.
,,
since,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
busulfex,NNP,B
were,VBD,O
studied,VBN,O
in,IN,O
patients,NNS,O
treated,VBN,O
with,IN,O
phenytoin,NN,D
",",",",O
the,DT,O
clearance,NN,O
of,IN,O
busulfex,NNP,B
at,IN,O
the,DT,O
recommended,VBN,O
dose,NN,O
may,MD,O
be,VB,O
lower,JJR,O
and,CC,O
exposure,NN,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
higher,JJR,O
in,IN,O
patients,NNS,O
not,RB,O
treated,VBN,O
with,IN,O
phenytoin,NN,D
.,.,.
,,
because,IN,O
busulfan,NN,D
is,VBZ,O
eliminated,VBN,O
from,IN,O
the,DT,O
body,NN,O
via,IN,O
conjugation,NN,O
with,IN,O
glutathione,NN,O
",",",",O
use,NN,O
of,IN,O
acetaminophen,NN,D
prior,RB,O
to,TO,O
-lrb-,-LRB-,O
72,CD,O
hours,NNS,O
-rrb-,-RRB-,O
or,CC,O
concurrent,JJ,O
with,IN,O
busulfex,NN,B
may,MD,O
result,VB,O
in,IN,O
reduced,VBN,O
busulfan,JJ,D
clearance,NN,O
based,VBN,O
upon,IN,O
the,DT,O
known,JJ,O
property,NN,O
of,IN,O
acetaminophen,NN,D
to,TO,O
decrease,VB,O
glutathione,NN,O
levels,NNS,O
in,IN,O
the,DT,O
blood,NN,O
and,CC,O
tissues,NNS,O
.,.,.
,,
interactions,NNS,O
may,MD,O
occur,VB,O
with,IN,O
the,DT,O
following,NN,O
:,:,O
adrenocorticoids,NNS,O
-lrb-,-LRB-,O
cortisone-like,JJ,O
medicine,NN,O
-rrb-,-RRB-,O
",",",",O
anticoagulants,NNS,G
-lrb-,-LRB-,O
blood,NN,O
thinners,NNS,O
-rrb-,-RRB-,O
",",",",O
carbamazepine,NN,D
",",",",O
corticotropin,NN,D
-lrb-,-LRB-,O
barbiturates,NNS,G
may,MD,O
decrease,VB,O
the,DT,O
effects,NNS,O
of,IN,O
these,DT,O
medicines,NNS,O
-rrb-,-RRB-,O
",",",",O
central,JJ,O
nervous,JJ,O
system,NN,O
-lrb-,-LRB-,O
cns,NN,O
-rrb-,-RRB-,O
depressants,NNS,O
-lrb-,-LRB-,O
using,VBG,O
these,DT,O
medicines,NNS,O
with,IN,O
barbiturates,NNS,G
may,MD,O
result,VB,O
in,IN,O
increased,VBN,O
cns,NN,O
depressant,NN,O
effects,NNS,O
-rrb-,-RRB-,O
",",",",O
divalproex,NN,O
sodium,NN,O
",",",",O
valproic,JJ,O
acid,NN,O
-lrb-,-LRB-,O
using,VBG,O
these,DT,O
medicines,NNS,O
with,IN,O
barbiturates,NNS,G
may,MD,O
change,VB,O
the,DT,O
amount,NN,O
of,IN,O
either,CC,O
medicine,NN,O
that,IN,O
you,PRP,O
need,VBP,O
to,TO,O
take,VB,O
-rrb-,-RRB-,O
",",",",O
and,CC,O
oral,JJ,O
contraceptives,NNS,G
containing,VBG,O
estrogens,NNS,G
-lrb-,-LRB-,O
barbiturates,NNS,G
may,MD,O
decrease,VB,O
the,DT,O
effectiveness,NN,O
of,IN,O
these,DT,O
oral,JJ,O
contraceptives,NNS,G
",",",",O
and,CC,O
you,PRP,O
may,MD,O
need,VB,O
to,TO,O
change,VB,O
to,TO,O
a,DT,O
different,JJ,O
type,NN,O
of,IN,O
birth,NN,O
control,NN,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
cns,NN,O
effects,NNS,O
of,IN,O
butalbital,NN,D
may,MD,O
be,VB,O
enhanced,VBN,O
by,IN,O
monoamine,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
mao,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
.,.,.
,,
butalbital,NNP,D
",",",",O
acetaminophen,NN,D
and,CC,O
caffeine,NN,D
may,MD,O
enhance,VB,O
the,DT,O
effects,NNS,O
of,IN,O
:,:,O
other,JJ,O
narcotic,JJ,G
analgesics,NNS,G
",",",",O
alcohol,NN,D
",",",",O
general,JJ,O
anesthetics,NNS,G
",",",",O
tranquilizers,NNS,G
such,JJ,O
as,IN,O
chlordiazepoxide,NN,D
",",",",O
sedative-hypnotics,NNS,G
",",",",O
or,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
",",",",O
causing,VBG,O
increased,VBN,O
cns,NN,O
depression,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
acetaminophen,NN,D
may,MD,O
produce,VB,O
false-positive,JJ,O
test,NN,O
results,VBZ,O
for,IN,O
urinary,JJ,O
5-hydroxyindoleacetic,JJ,O
acid,NN,O
.,.,.
,,
potential,JJ,O
drug,NN,D
interactions,NNS,O
between,IN,O
mentax,NN,B
-lrb-,-LRB-,O
butenafine,NN,O
hcl,NN,O
cream,NN,O
-rrb-,-RRB-,O
cream,NN,O
",",",",O
1,CD,O
%,NN,O
",",",",O
and,CC,O
other,JJ,O
drugs,NNS,D
have,VBP,O
not,RB,O
been,VBN,O
systematically,RB,O
evaluated,VBN,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
of,IN,O
butorphanol,NN,D
with,IN,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressants,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
alcohol,NN,D
",",",",O
barbiturates,NNS,G
",",",",O
tranquilizers,NNS,G
",",",",O
and,CC,O
antihistamines,NNS,G
-rrb-,-RRB-,O
may,MD,O
result,VB,O
in,IN,O
increased,VBN,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressant,NN,O
effects,NNS,O
.,.,.
,,
when,WRB,O
used,VBN,O
concurrently,RB,O
with,IN,O
such,JJ,O
drugs,NNS,D
",",",",O
the,DT,O
dose,NN,O
of,IN,O
butorphanol,NN,D
should,MD,O
be,VB,O
the,DT,O
smallest,JJS,O
effective,JJ,O
dose,NN,O
and,CC,O
the,DT,O
frequency,NN,O
of,IN,O
dosing,NN,O
reduced,VBD,O
as,RB,O
much,JJ,O
as,IN,O
possible,JJ,O
when,WRB,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
drugs,NNS,D
that,WDT,O
potentiate,VBP,O
the,DT,O
action,NN,O
of,IN,O
opioids,NNS,G
.,.,.
,,
in,IN,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
a,DT,O
1-mg,JJ,O
dose,NN,O
of,IN,O
butorphanol,NN,D
administered,VBN,O
as,IN,O
stadol,NN,O
ns,NN,O
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
the,DT,O
coadministration,NN,O
of,IN,O
a,DT,O
single,JJ,O
6-mg,JJ,O
subcutaneous,JJ,O
dose,NN,O
of,IN,O
sumatriptan,NN,D
.,.,.
,,
however,RB,O
",",",",O
in,IN,O
another,DT,O
study,NN,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
butorphanol,NN,D
were,VBD,O
significantly,RB,O
altered,JJ,O
-lrb-,-LRB-,O
29,CD,O
%,NN,O
decrease,NN,O
in,IN,O
auc,NN,O
and,CC,O
38,CD,O
%,NN,O
decrease,NN,O
in,IN,O
cmax,NN,O
-rrb-,-RRB-,O
when,WRB,O
a,DT,O
1-mg,JJ,O
dose,NN,O
of,IN,O
stadol,NN,O
ns,NN,O
was,VBD,O
administered,VBN,O
1,CD,O
minute,NN,O
after,IN,O
a,DT,O
20-mg,JJ,O
dose,NN,O
of,IN,O
sumatriptan,NN,D
nasal,JJ,O
spray,NN,O
.,.,.
,,
-lrb-,-LRB-,O
the,DT,O
two,CD,O
drugs,NNS,D
were,VBD,O
administered,VBN,O
in,IN,O
opposite,JJ,O
nostrils,NNS,O
.,.,.
,,
-rrb-,-RRB-,O
.,.,.
,,
when,WRB,O
the,DT,O
stadol,NN,O
ns,NN,O
was,VBD,O
administered,VBN,O
30,CD,O
minutes,NNS,O
after,IN,O
the,DT,O
sumatriptan,NN,D
nasal,JJ,O
spray,NN,O
",",",",O
the,DT,O
auc,NN,O
of,IN,O
butorphanol,NN,D
increased,VBD,O
11,CD,O
%,NN,O
and,CC,O
cmax,NN,O
decreased,VBD,O
18,CD,O
%,NN,O
.,.,.
,,
in,IN,O
neither,DT,O
case,NN,O
were,VBD,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
sumatriptan,NN,D
affected,VBN,O
by,IN,O
coadministration,NN,O
with,IN,O
stadol,NN,O
ns,NN,O
.,.,.
,,
these,DT,O
results,NNS,O
suggest,VBP,O
that,IN,O
the,DT,O
analgesic,JJ,O
effect,NN,O
of,IN,O
stadol,NN,O
ns,NN,O
may,MD,O
be,VB,O
diminished,VBN,O
when,WRB,O
it,PRP,O
is,VBZ,O
administered,VBN,O
shortly,RB,O
after,IN,O
sumatriptan,NN,D
nasal,JJ,O
spray,NN,O
",",",",O
but,CC,O
by,IN,O
30,CD,O
minutes,NNS,O
any,DT,O
such,JJ,O
reduction,NN,O
in,IN,O
effect,NN,O
should,MD,O
be,VB,O
minimal,JJ,O
.,.,.
,,
the,DT,O
safety,NN,O
of,IN,O
using,VBG,O
stadol,NN,O
ns,NN,O
and,CC,O
imitrex,NN,B
-lrb-,-LRB-,O
sumatriptan,NN,D
-rrb-,-RRB-,O
nasal,JJ,O
spray,NN,O
during,IN,O
the,DT,O
same,JJ,O
episode,NN,O
of,IN,O
migraine,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
however,RB,O
",",",",O
it,PRP,O
should,MD,O
be,VB,O
noted,VBN,O
that,IN,O
both,CC,O
products,NNS,O
are,VBP,O
capable,JJ,O
of,IN,O
producing,VBG,O
transient,JJ,O
increases,NNS,O
in,IN,O
blood,NN,O
pressure,NN,O
.,.,.
,,
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
a,DT,O
1-mg,JJ,O
dose,NN,O
of,IN,O
butorphanol,NN,D
administered,VBN,O
as,IN,O
stadol,NN,O
ns,NN,O
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
the,DT,O
coadministration,NN,O
of,IN,O
cimetidine,NN,D
-lrb-,-LRB-,O
300,CD,O
mg,NN,O
qid,NN,O
-rrb-,-RRB-,O
.,.,.
,,
conversely,RB,O
",",",",O
the,DT,O
administration,NN,O
of,IN,O
stadol,NN,O
ns,NN,O
-lrb-,-LRB-,O
1,CD,O
mg,NN,O
butorphanol,NN,D
qid,NN,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
a,DT,O
300-mg,JJ,O
dose,NN,O
of,IN,O
cimetidine,NN,D
.,.,.
,,
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
if,IN,O
the,DT,O
effects,NNS,O
of,IN,O
butorphanol,NN,D
are,VBP,O
altered,VBN,O
by,IN,O
concomitant,JJ,O
medications,NNS,O
that,WDT,O
affect,VBP,O
hepatic,JJ,O
metabolism,NN,O
of,IN,O
drugs,NNS,D
-lrb-,-LRB-,O
erythromycin,NN,D
",",",",O
etc.,FW,O
-rrb-,-RRB-,O
",",",",O
but,CC,O
physicians,NNS,O
should,MD,O
be,VB,O
alert,JJ,O
to,TO,O
the,DT,O
possibility,NN,O
that,IN,O
a,DT,O
smaller,JJR,O
initial,JJ,O
dose,NN,O
and,CC,O
longer,JJR,O
intervals,NNS,O
between,IN,O
doses,NNS,O
may,MD,O
be,VB,O
needed,VBN,O
.,.,.
,,
the,DT,O
fraction,NN,O
of,IN,O
stadol,NN,O
ns,NN,O
absorbed,VBN,O
is,VBZ,O
unaffected,JJ,O
by,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
a,DT,O
nasal,JJ,O
vasoconstrictor,NN,O
-lrb-,-LRB-,O
oxymetazoline,NN,D
-rrb-,-RRB-,O
",",",",O
but,CC,O
the,DT,O
rate,NN,O
of,IN,O
absorption,NN,O
is,VBZ,O
decreased,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
a,DT,O
slower,JJR,O
onset,NN,O
can,MD,O
be,VB,O
anticipated,VBN,O
if,IN,O
stadol,NN,O
ns,NN,O
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
",",",",O
or,CC,O
immediately,RB,O
following,VBG,O
",",",",O
a,DT,O
nasal,JJ,O
vasoconstrictor,NN,O
.,.,.
,,
no,DT,O
information,NN,O
is,VBZ,O
available,JJ,O
about,IN,O
the,DT,O
use,NN,O
of,IN,O
butorphanol,NN,D
concurrently,RB,O
with,IN,O
mao,NN,O
inhibitors,NNS,O
.,.,.
,,
dostinex,NNP,B
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
concurrently,RB,O
with,IN,O
d2-antagonists,NNS,O
",",",",O
such,JJ,O
as,IN,O
phenothiazines,NNS,G
",",",",O
butyrophenones,NNS,G
",",",",O
thioxanthines,NNS,G
",",",",O
or,CC,O
metoclopramide,NN,D
.,.,.
,,
cytochrome,NN,O
p450,NN,O
1a2,NN,O
-lrb-,-LRB-,O
cyp1a2,NN,D
-rrb-,-RRB-,O
is,VBZ,O
known,VBN,O
to,TO,O
be,VB,O
the,DT,O
major,JJ,O
enzyme,NN,O
involved,VBN,O
in,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
caffeine,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
caffeine,NN,D
has,VBZ,O
the,DT,O
potential,JJ,O
to,TO,O
interact,VB,O
with,IN,O
drugs,NNS,D
that,WDT,O
are,VBP,O
substrates,NNS,O
for,IN,O
cyp1a2,NN,D
",",",",O
inhibit,VBP,O
cyp1a2,NN,D
",",",",O
or,CC,O
induce,VB,O
cyp1a2,NN,D
.,.,.
,,
few,JJ,O
data,NNS,O
exist,VBP,O
on,IN,O
drug,NN,D
interactions,NNS,O
with,IN,O
caffeine,NN,D
in,IN,O
preterm,JJ,O
neonates,NNS,O
.,.,.
,,
based,VBN,O
on,IN,O
adult,JJ,O
data,NNS,O
",",",",O
lower,JJR,O
doses,NNS,O
of,IN,O
caffeine,NN,D
may,MD,O
be,VB,O
needed,VBN,O
following,VBG,O
coadministration,NN,O
of,IN,O
drugs,NNS,D
which,WDT,O
are,VBP,O
reported,VBN,O
to,TO,O
decrease,VB,O
caffeine,NN,D
elimination,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
cimetidine,NN,D
and,CC,O
ketoconazole,NN,D
-rrb-,-RRB-,O
and,CC,O
higher,JJR,O
caffeine,NN,D
doses,NNS,O
may,MD,O
be,VB,O
needed,VBN,O
following,VBG,O
coadministration,NN,O
of,IN,O
drugs,NNS,D
that,WDT,O
increase,VBP,O
caffeine,NN,D
elimination,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
phenobarbital,JJ,D
and,CC,O
phenytoin,NN,D
-rrb-,-RRB-,O
.,.,.
,,
caffeine,NN,D
administered,VBN,O
concurrently,RB,O
with,IN,O
ketoprofen,NN,D
reduced,VBD,O
the,DT,O
urine,NN,O
volume,NN,O
in,IN,O
4,CD,O
healthy,JJ,O
volunteers,NNS,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
interaction,NN,O
in,IN,O
preterm,JJ,O
neonates,NNS,O
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
interconversion,NN,O
between,IN,O
caffeine,NN,D
and,CC,O
theophylline,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
preterm,JJ,O
neonates,NNS,O
.,.,.
,,
the,DT,O
concurrent,JJ,O
use,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
interactions,NNS,O
for,IN,O
vitamin,NN,G
d,NN,O
analogues,NNS,O
-lrb-,-LRB-,O
vitamin,NN,O
d2,NN,O
",",",",O
vitamin,NN,O
d3,NN,O
",",",",O
calcitriol,NN,D
",",",",O
and,CC,O
calcidiol,NN,D
-rrb-,-RRB-,O
:,:,O
cholestyramine,NNP,D
:,:,O
cholestyramine,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
reduce,VB,O
intestinal,JJ,O
absorption,NN,O
of,IN,O
fat,JJ,O
soluble,JJ,O
vitamins,NNS,G
.,.,.
,,
as,IN,O
such,JJ,O
it,PRP,O
may,MD,O
impair,VB,O
intestinal,JJ,O
absorption,NN,O
of,IN,O
any,DT,O
of,IN,O
vitamin,NN,G
d.,NNP,O
phenytoin/phenobarbital,NNP,O
:,:,O
the,DT,O
coadministration,NN,O
of,IN,O
phenytoin,NN,D
or,CC,O
phenobarbital,NN,D
will,MD,O
not,RB,O
affect,VB,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
vitamin,NN,G
d,NN,O
",",",",O
but,CC,O
may,MD,O
reduce,VB,O
endogenous,JJ,O
plasma,NN,O
levels,NNS,O
of,IN,O
calcitriol/ergocalcitriol,NN,O
by,IN,O
accelerating,VBG,O
metabolism,NN,O
.,.,.
,,
since,IN,O
blood,NN,O
level,NN,O
of,IN,O
calcitriol/ergocalcitriol,NN,O
will,MD,O
be,VB,O
reduced,VBN,O
",",",",O
higher,JJR,O
doses,NNS,O
of,IN,O
rocaltrol,NNP,B
may,MD,O
be,VB,O
necessary,JJ,O
if,IN,O
these,DT,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
simultaneously,RB,O
.,.,.
,,
thiazides,NNP,G
:,:,O
thiazides,NNS,G
are,VBP,O
known,VBN,O
to,TO,O
induce,VB,O
hypercalcemia,NN,O
by,IN,O
the,DT,O
reduction,NN,O
of,IN,O
calcium,NN,D
excretion,NN,O
in,IN,O
urine,NN,O
.,.,.
,,
some,DT,O
reports,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
thiazides,NNS,G
with,IN,O
vitamin,NN,G
d,NN,O
causes,VBZ,O
hypercalcemia,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
precaution,NN,O
should,MD,O
be,VB,O
taken,VBN,O
when,WRB,O
coadministration,NN,O
is,VBZ,O
necessary,JJ,O
.,.,.
,,
digitalis,NNP,G
:,:,O
vitamin,NN,O
d,NN,O
dosage,NN,O
must,MD,O
be,VB,O
determined,VBN,O
with,IN,O
care,NN,O
in,IN,O
patients,NNS,O
undergoing,VBG,O
treatment,NN,O
with,IN,O
digitalis,NN,G
",",",",O
as,IN,O
hypercalcemia,NN,O
in,IN,O
such,JJ,O
patients,NNS,O
may,MD,O
precipitate,VB,O
cardiac,JJ,O
arrhythmias,NNS,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
ketoconazole,NN,D
may,MD,O
inhibit,VB,O
both,DT,O
synthetic,JJ,O
and,CC,O
catabolic,JJ,O
enzymes,NNS,O
of,IN,O
vitamin,NN,G
d.,NNP,O
reductions,NNPS,O
in,IN,O
serum,NN,O
endogenous,JJ,O
vitamin,NN,G
d,NN,O
concentrations,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
following,VBG,O
the,DT,O
administration,NN,O
of,IN,O
300,CD,O
mg/day,NN,O
to,TO,O
1200,CD,O
mg/day,NN,O
ketoconazole,NN,D
for,IN,O
a,DT,O
week,NN,O
to,TO,O
healthy,JJ,O
men,NNS,O
.,.,.
,,
however,RB,O
",",",",O
in,FW,O
vivo,FW,O
drug,NN,D
interaction,NN,O
studies,NNS,O
of,IN,O
ketoconazole,NN,D
with,IN,O
vitamin,NN,G
d,NN,O
have,VBP,O
not,RB,O
been,VBN,O
investigated,VBN,O
.,.,.
,,
corticosteroids,NNS,G
:,:,O
a,DT,O
relationship,NN,O
of,IN,O
functional,JJ,O
antagonism,NN,O
exists,VBZ,O
between,IN,O
vitamin,NN,G
d,NN,O
analogues,NNS,O
",",",",O
which,WDT,O
promote,VBP,O
calcium,NN,D
absorption,NN,O
",",",",O
and,CC,O
corticosteroids,NNS,G
",",",",O
which,WDT,O
inhibit,VBP,O
calcium,NN,D
absorption,NN,O
.,.,.
,,
phosphate-binding,JJ,O
agents,NNS,O
:,:,O
since,IN,O
vitamin,NN,G
d,NN,O
also,RB,O
has,VBZ,O
an,DT,O
effect,NN,O
on,IN,O
phosphate,NN,D
transport,NN,O
in,IN,O
the,DT,O
intestine,NN,O
",",",",O
kidneys,NNS,O
and,CC,O
bones,NNS,O
",",",",O
the,DT,O
dosage,NN,O
of,IN,O
phosphate-binding,JJ,O
agents,NNS,O
must,MD,O
be,VB,O
adjusted,VBN,O
in,IN,O
accordance,NN,O
with,IN,O
the,DT,O
serum,NN,O
phosphate,NN,D
concentration,NN,O
.,.,.
,,
vitamin,NN,O
d,NN,O
:,:,O
the,DT,O
coadministration,NN,O
of,IN,O
any,DT,O
of,IN,O
the,DT,O
vitamin,NN,G
d,NN,O
analogues,NNS,O
should,MD,O
be,VB,O
avoided,VBN,O
as,IN,O
this,DT,O
could,MD,O
create,VB,O
possible,JJ,O
additive,JJ,O
effects,NNS,O
and,CC,O
hypercalcemia,NN,O
.,.,.
,,
calcium,NN,D
supplements,NNS,O
:,:,O
uncontrolled,JJ,O
intake,NN,O
of,IN,O
additional,JJ,O
calcium-containing,JJ,O
preparations,NNS,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
magnesium,NN,D
:,:,O
magnesium-containing,JJ,O
preparations,NNS,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
antacids,NNS,G
-rrb-,-RRB-,O
may,MD,O
cause,VB,O
hypermagnesemia,NN,O
and,CC,O
should,MD,O
therefore,RB,O
not,RB,O
be,VB,O
taken,VBN,O
during,IN,O
therapy,NN,O
with,IN,O
vitamin,NN,G
d,NN,O
by,IN,O
patients,NNS,O
on,IN,O
chronic,JJ,O
renal,JJ,O
dialysis,NN,O
.,.,.
,,
interactions,NNS,O
for,IN,O
vitamin,NN,G
d,NN,O
analogues,NNS,O
-lrb-,-LRB-,O
vitamin,NN,O
d2,NN,O
",",",",O
vitamin,NN,O
d3,NN,O
",",",",O
calcitriol,NN,D
",",",",O
and,CC,O
calcidiol,NN,D
-rrb-,-RRB-,O
:,:,O
cholestyramine,NNP,D
:,:,O
cholestyramine,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
reduce,VB,O
intestinal,JJ,O
absorption,NN,O
of,IN,O
fat,JJ,O
soluble,JJ,O
vitamins,NNS,G
.,.,.
,,
as,IN,O
such,JJ,O
it,PRP,O
may,MD,O
impair,VB,O
intestinal,JJ,O
absorption,NN,O
of,IN,O
any,DT,O
of,IN,O
vitamin,NN,G
d.,NNP,O
phenytoin/phenobarbital,NNP,O
:,:,O
the,DT,O
coadministration,NN,O
of,IN,O
phenytoin,NN,D
or,CC,O
phenobarbital,NN,D
will,MD,O
not,RB,O
affect,VB,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
vitamin,NN,G
d,NN,O
",",",",O
but,CC,O
may,MD,O
reduce,VB,O
endogenous,JJ,O
plasma,NN,O
levels,NNS,O
of,IN,O
calcitriol/ergocalcitriol,NN,O
by,IN,O
accelerating,VBG,O
metabolism,NN,O
.,.,.
,,
since,IN,O
blood,NN,O
level,NN,O
of,IN,O
calcitriol/ergocalcitriol,NN,O
will,MD,O
be,VB,O
reduced,VBN,O
",",",",O
higher,JJR,O
doses,NNS,O
of,IN,O
rocaltrol,NNP,B
may,MD,O
be,VB,O
necessary,JJ,O
if,IN,O
these,DT,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
simultaneously,RB,O
.,.,.
,,
thiazides,NNP,G
:,:,O
thiazides,NNS,G
are,VBP,O
known,VBN,O
to,TO,O
induce,VB,O
hypercalcemia,NN,O
by,IN,O
the,DT,O
reduction,NN,O
of,IN,O
calcium,NN,D
excretion,NN,O
in,IN,O
urine,NN,O
.,.,.
,,
some,DT,O
reports,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
thiazides,NNS,G
with,IN,O
vitamin,NN,G
d,NN,O
causes,VBZ,O
hypercalcemia,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
precaution,NN,O
should,MD,O
be,VB,O
taken,VBN,O
when,WRB,O
coadministration,NN,O
is,VBZ,O
necessary,JJ,O
.,.,.
,,
digitalis,NNP,G
:,:,O
vitamin,NN,O
d,NN,O
dosage,NN,O
must,MD,O
be,VB,O
determined,VBN,O
with,IN,O
care,NN,O
in,IN,O
patients,NNS,O
undergoing,VBG,O
treatment,NN,O
with,IN,O
digitalis,NN,G
",",",",O
as,IN,O
hypercalcemia,NN,O
in,IN,O
such,JJ,O
patients,NNS,O
may,MD,O
precipitate,VB,O
cardiac,JJ,O
arrhythmias,NNS,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
ketoconazole,NN,D
may,MD,O
inhibit,VB,O
both,DT,O
synthetic,JJ,O
and,CC,O
catabolic,JJ,O
enzymes,NNS,O
of,IN,O
vitamin,NN,G
d.,NNP,O
reductions,NNPS,O
in,IN,O
serum,NN,O
endogenous,JJ,O
vitamin,NN,G
d,NN,O
concentrations,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
following,VBG,O
the,DT,O
administration,NN,O
of,IN,O
300,CD,O
mg/day,NN,O
to,TO,O
1200,CD,O
mg/day,NN,O
ketoconazole,NN,D
for,IN,O
a,DT,O
week,NN,O
to,TO,O
healthy,JJ,O
men,NNS,O
.,.,.
,,
however,RB,O
",",",",O
in,FW,O
vivo,FW,O
drug,NN,D
interaction,NN,O
studies,NNS,O
of,IN,O
ketoconazole,NN,D
with,IN,O
vitamin,NN,G
d,NN,O
have,VBP,O
not,RB,O
been,VBN,O
investigated,VBN,O
.,.,.
,,
corticosteroids,NNS,G
:,:,O
a,DT,O
relationship,NN,O
of,IN,O
functional,JJ,O
antagonism,NN,O
exists,VBZ,O
between,IN,O
vitamin,NN,G
d,NN,O
analogues,NNS,O
",",",",O
which,WDT,O
promote,VBP,O
calcium,NN,D
absorption,NN,O
",",",",O
and,CC,O
corticosteroids,NNS,G
",",",",O
which,WDT,O
inhibit,VBP,O
calcium,NN,D
absorption,NN,O
.,.,.
,,
phosphate-binding,JJ,O
agents,NNS,O
:,:,O
since,IN,O
vitamin,NN,G
d,NN,O
also,RB,O
has,VBZ,O
an,DT,O
effect,NN,O
on,IN,O
phosphate,NN,D
transport,NN,O
in,IN,O
the,DT,O
intestine,NN,O
",",",",O
kidneys,NNS,O
and,CC,O
bones,NNS,O
",",",",O
the,DT,O
dosage,NN,O
of,IN,O
phosphate-binding,JJ,O
agents,NNS,O
must,MD,O
be,VB,O
adjusted,VBN,O
in,IN,O
accordance,NN,O
with,IN,O
the,DT,O
serum,NN,O
phosphate,NN,D
concentration,NN,O
.,.,.
,,
vitamin,NN,O
d,NN,O
:,:,O
the,DT,O
coadministration,NN,O
of,IN,O
any,DT,O
of,IN,O
the,DT,O
vitamin,NN,G
d,NN,O
analogues,NNS,O
should,MD,O
be,VB,O
avoided,VBN,O
as,IN,O
this,DT,O
could,MD,O
create,VB,O
possible,JJ,O
additive,JJ,O
effects,NNS,O
and,CC,O
hypercalcemia,NN,O
.,.,.
,,
calcium,NN,D
supplements,NNS,O
:,:,O
uncontrolled,JJ,O
intake,NN,O
of,IN,O
additional,JJ,O
calcium-containing,JJ,O
preparations,NNS,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
magnesium,NN,D
:,:,O
magnesium-containing,JJ,O
preparations,NNS,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
antacids,NNS,G
-rrb-,-RRB-,O
may,MD,O
cause,VB,O
hypermagnesemia,NN,O
and,CC,O
should,MD,O
therefore,RB,O
not,RB,O
be,VB,O
taken,VBN,O
during,IN,O
therapy,NN,O
with,IN,O
vitamin,NN,G
d,NN,O
by,IN,O
patients,NNS,O
on,IN,O
chronic,JJ,O
renal,JJ,O
dialysis,NN,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
with,IN,O
other,JJ,O
calcium-containing,JJ,O
medicines,NNS,O
-lrb-,-LRB-,O
including,VBG,O
antacids,NNS,G
-rrb-,-RRB-,O
may,MD,O
cause,VB,O
too,RB,O
much,JJ,O
calcium,NN,D
in,IN,O
the,DT,O
blood,NN,O
or,CC,O
urine,NN,O
",",",",O
which,WDT,O
may,MD,O
increase,VB,O
the,DT,O
chance,NN,O
of,IN,O
side,JJ,O
effects,NNS,O
.,.,.
,,
using,VBG,O
calcium,NN,D
acetate,NN,O
with,IN,O
digitalis,NN,G
glycosides,NNS,G
-lrb-,-LRB-,O
heart,NN,O
medicine,NN,O
-rrb-,-RRB-,O
may,MD,O
cause,VB,O
hypercalcemia,NN,O
-lrb-,-LRB-,O
too,RB,O
much,JJ,O
calcium,NN,D
in,IN,O
the,DT,O
blood,NN,O
-rrb-,-RRB-,O
",",",",O
which,WDT,O
could,MD,O
increase,VB,O
the,DT,O
chance,NN,O
of,IN,O
developing,VBG,O
an,DT,O
irregular,JJ,O
heartbeat,NN,O
.,.,.
,,
may,NNP,O
interact,VBP,O
with,IN,O
cefamandole,NN,D
naftate,NN,O
",",",",O
cephalothin,NN,D
sodium,NN,O
",",",",O
magnesium,NN,D
sulfate,NN,O
",",",",O
prednisolone,JJ,D
sodium,NN,O
succinate,NN,O
",",",",O
and,CC,O
prochlorperazine,NN,D
edisylate,NN,O
.,.,.
,,
no,DT,O
significant,JJ,O
drug,NN,D
interactions,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
studies,NNS,O
of,IN,O
candesartan,NN,D
cilexetil,NN,O
given,VBN,O
with,IN,O
other,JJ,O
drugs,NNS,D
such,JJ,O
as,IN,O
glyburide,NN,D
",",",",O
nifedipine,NN,D
",",",",O
digoxin,NN,D
",",",",O
warfarin,NN,D
",",",",O
hydrochlorothiazide,NN,D
",",",",O
and,CC,O
oral,JJ,O
contraceptives,NNS,G
in,IN,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
or,CC,O
given,VBN,O
with,IN,O
enalapril,NN,D
to,TO,O
patients,NNS,O
with,IN,O
heart,NN,O
failure,NN,O
-lrb-,-LRB-,O
nyha,NN,O
class,NN,O
ii,CD,O
and,CC,O
iii,CD,O
-rrb-,-RRB-,O
.,.,.
,,
because,IN,O
candesartan,NN,D
is,VBZ,O
not,RB,O
significantly,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
system,NN,O
and,CC,O
at,IN,O
therapeutic,JJ,O
concentrations,NNS,O
has,VBZ,O
no,DT,O
effects,NNS,O
on,IN,O
p450,NN,O
enzymes,NNS,O
",",",",O
interactions,NNS,O
with,IN,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
or,CC,O
are,VBP,O
metabolized,VBN,O
by,IN,O
those,DT,O
enzymes,NNS,O
would,MD,O
not,RB,O
be,VB,O
expected,VBN,O
.,.,.
,,
lithium,NN,D
reversible,JJ,O
increases,NNS,O
in,IN,O
serum,NN,O
lithium,NN,D
concentrations,NNS,O
and,CC,O
toxicity,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
during,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
lithium,NN,D
with,IN,O
ace,NN,O
inhibitors,NNS,O
",",",",O
and,CC,O
with,IN,O
some,DT,O
angiotensin,NN,O
ii,CD,O
receptor,NN,D
antagonists,NNS,O
.,.,.
,,
an,DT,O
increase,NN,O
in,IN,O
serum,NN,O
lithium,NN,D
concentration,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
during,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
lithium,NN,D
with,IN,O
atacand,NN,B
",",",",O
so,RB,O
careful,JJ,O
monitoring,NN,O
of,IN,O
serum,NN,O
lithium,NN,D
levels,NNS,O
is,VBZ,O
recommended,VBN,O
during,IN,O
concomitant,JJ,O
use,NN,O
.,.,.
,,
antacid,NN,G
:,:,O
the,DT,O
effect,NN,O
of,IN,O
an,DT,O
aluminum,NN,D
hydroxide,NN,O
-,:,O
and,CC,O
magnesium,NN,D
hydroxide-containing,JJ,O
antacid,NN,G
-lrb-,-LRB-,O
maalox,NNP,B
-rrb-,-RRB-,O
*,SYM,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
capecitabine,NN,D
was,VBD,O
investigated,VBN,O
in,IN,O
12,CD,O
cancer,NN,O
patients,NNS,O
.,.,.
,,
there,EX,O
was,VBD,O
a,DT,O
small,JJ,O
increase,NN,O
in,IN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
capecitabine,NN,D
and,CC,O
one,CD,O
metabolite,NN,O
-lrb-,-LRB-,O
5-dfcr,NN,D_n
-rrb-,-RRB-,O
.,.,.
,,
there,EX,O
was,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
3,CD,O
major,JJ,O
metabolites,NNS,O
-lrb-,-LRB-,O
5-dfur,NN,D_n
",",",",O
5-fu,NN,D_n
and,CC,O
fbal,NN,D_n
-rrb-,-RRB-,O
.,.,.
,,
coumarin,NNP,O
anticoagulants,NNPS,G
altered,JJ,O
coagulation,NN,O
parameters,NNS,O
and/or,CC,O
bleeding,VBG,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
taking,VBG,O
capecitabine,NN,D
concomitantly,RB,O
with,IN,O
coumarin-derivative,JJ,O
anticoagulants,NNS,G
such,JJ,O
as,IN,O
warfarin,NN,D
and,CC,O
phenprocoumon,NN,D
.,.,.
,,
patients,NNS,O
taking,VBG,O
coumarin-derivative,JJ,O
anticoagulants,NNS,G
concomitantly,RB,O
with,IN,O
capecitabine,NN,D
should,MD,O
be,VB,O
monitored,VBN,O
regularly,RB,O
for,IN,O
alterations,NNS,O
in,IN,O
their,PRP$,O
coagulation,NN,O
parameters,NNS,O
-lrb-,-LRB-,O
pt,NN,O
or,CC,O
inr,NN,O
-rrb-,-RRB-,O
.,.,.
,,
leucovorin,NNP,D
:,:,O
the,DT,O
concentration,NN,O
of,IN,O
5-fluorouracil,NN,D
is,VBZ,O
increased,VBN,O
and,CC,O
its,PRP$,O
toxicity,NN,O
may,MD,O
be,VB,O
enhanced,VBN,O
by,IN,O
leucovorin,NN,D
.,.,.
,,
deaths,NNS,O
from,IN,O
severe,JJ,O
enterocolitis,NN,O
",",",",O
diarrhea,NN,O
",",",",O
and,CC,O
dehydration,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
elderly,JJ,O
patients,NNS,O
receiving,VBG,O
weekly,JJ,O
leucovorin,NN,D
and,CC,O
fluorouracil,NN,D
.,.,.
,,
hypotension,NN,O
patients,NNS,O
on,IN,O
diuretic,JJ,G
therapy,NN,O
:,:,O
patients,NNS,O
on,IN,O
diuretics,NNS,G
and,CC,O
especially,RB,O
those,DT,O
in,IN,O
whom,WP,O
diuretic,JJ,G
therapy,NN,O
was,VBD,O
recently,RB,O
instituted,VBN,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
those,DT,O
on,IN,O
severe,JJ,O
dietary,JJ,O
salt,NN,O
restriction,NN,O
or,CC,O
dialysis,NN,O
",",",",O
may,MD,O
occasionally,RB,O
experience,VB,O
a,DT,O
precipitous,JJ,O
reduction,NN,O
of,IN,O
blood,NN,O
pressure,NN,O
usually,RB,O
within,IN,O
the,DT,O
first,JJ,O
hour,NN,O
after,IN,O
receiving,VBG,O
the,DT,O
initial,JJ,O
dose,NN,O
of,IN,O
captopril,NN,D
.,.,.
,,
the,DT,O
possibility,NN,O
of,IN,O
hypotensive,JJ,O
effects,NNS,O
with,IN,O
captopril,NN,D
can,MD,O
be,VB,O
minimized,VBN,O
by,IN,O
either,CC,O
discontinuing,VBG,O
the,DT,O
diuretic,JJ,G
or,CC,O
increasing,VBG,O
the,DT,O
salt,NN,O
intake,NN,O
approximately,RB,O
one,CD,O
week,NN,O
prior,RB,O
to,TO,O
initiation,NN,O
of,IN,O
treatment,NN,O
with,IN,O
captopril,NN,D
-lrb-,-LRB-,O
captopril,NN,D
tablets,NNS,O
",",",",O
usp,NN,O
-rrb-,-RRB-,O
or,CC,O
initiating,VBG,O
therapy,NN,O
with,IN,O
small,JJ,O
doses,NNS,O
-lrb-,-LRB-,O
6.25,CD,O
or,CC,O
12.5,CD,O
mg,NN,O
-rrb-,-RRB-,O
.,.,.
,,
alternatively,RB,O
",",",",O
provide,VBP,O
medical,JJ,O
supervision,NN,O
for,IN,O
at,IN,O
least,JJS,O
one,CD,O
hour,NN,O
after,IN,O
the,DT,O
initial,JJ,O
dose,NN,O
.,.,.
,,
if,IN,O
hypotension,NN,O
occurs,VBZ,O
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
placed,VBN,O
in,IN,O
a,DT,O
supine,NN,O
position,NN,O
and,CC,O
",",",",O
if,IN,O
necessary,JJ,O
",",",",O
receive,VBP,O
an,DT,O
intravenous,JJ,O
infusion,NN,O
of,IN,O
normal,JJ,O
saline,NN,O
.,.,.
,,
this,DT,O
transient,JJ,O
hypotensive,JJ,O
response,NN,O
is,VBZ,O
not,RB,O
a,DT,O
contraindication,NN,O
to,TO,O
further,JJ,O
doses,NNS,O
which,WDT,O
can,MD,O
be,VB,O
given,VBN,O
without,IN,O
difficulty,NN,O
once,IN,O
the,DT,O
blood,NN,O
pressure,NN,O
has,VBZ,O
increased,VBN,O
after,IN,O
volume,NN,O
expansion,NN,O
.,.,.
,,
agents,NNS,O
having,VBG,O
vasodilator,NN,O
activity,NN,O
:,:,O
data,NNS,O
on,IN,O
the,DT,O
effect,NN,O
of,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
other,JJ,O
vasodilators,NNS,G
in,IN,O
patients,NNS,O
receiving,VBG,O
captopril,NN,D
for,IN,O
heart,NN,O
failure,NN,O
are,VBP,O
not,RB,O
available,JJ,O
.,.,.
,,
therefore,RB,O
",",",",O
nitroglycerin,NN,D
or,CC,O
other,JJ,O
nitrates,NNS,G
-lrb-,-LRB-,O
as,IN,O
used,VBN,O
for,IN,O
management,NN,O
of,IN,O
angina,NN,O
-rrb-,-RRB-,O
or,CC,O
other,JJ,O
drugs,NNS,D
having,VBG,O
vasodilator,NN,O
activity,NN,O
should,MD,O
",",",",O
if,IN,O
possible,JJ,O
",",",",O
be,VB,O
discontinued,VBN,O
before,IN,O
starting,VBG,O
captopril,NN,D
.,.,.
,,
if,IN,O
resumed,VBN,O
during,IN,O
captopril,NN,D
therapy,NN,O
",",",",O
such,JJ,O
agents,NNS,O
should,MD,O
be,VB,O
administered,VBN,O
cautiously,RB,O
",",",",O
and,CC,O
perhaps,RB,O
at,IN,O
lower,JJR,O
dosage,NN,O
.,.,.
,,
agents,NNS,O
causing,VBG,O
renin,NNP,O
release,NNP,O
captopril,NNP,D
's,POS,O
effect,NN,O
will,MD,O
be,VB,O
augmented,VBN,O
by,IN,O
antihypertensive,JJ,G
agents,NNS,O
that,WDT,O
cause,VBP,O
renin,NN,O
release,NN,O
.,.,.
,,
for,IN,O
example,NN,O
",",",",O
diuretics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
thiazides,NNS,G
-rrb-,-RRB-,O
may,MD,O
activate,VB,O
the,DT,O
renin-angiotensin-aldosterone,NN,O
system,NN,O
.,.,.
,,
agents,NNS,O
affecting,VBG,O
sympathetic,JJ,O
activity,NN,O
the,DT,O
sympathetic,JJ,O
nervous,JJ,O
system,NN,O
may,MD,O
be,VB,O
especially,RB,O
important,JJ,O
in,IN,O
supporting,VBG,O
blood,NN,O
pressure,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
captopril,NN,D
alone,RB,O
or,CC,O
with,IN,O
diuretics,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
agents,NNS,O
affecting,VBG,O
sympathetic,JJ,O
activity,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
ganglionic,JJ,O
blocking,VBG,O
agents,NNS,O
or,CC,O
adrenergic,JJ,G
neuron,NN,O
blocking,VBG,O
agents,NNS,O
-rrb-,-RRB-,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
beta-adrenergic,JJ,O
blocking,NN,O
drugs,NNS,D
add,VBP,O
some,DT,O
further,JJ,O
antihypertensive,JJ,G
effect,NN,O
to,TO,O
captopril,NN,D
",",",",O
but,CC,O
the,DT,O
overall,JJ,O
response,NN,O
is,VBZ,O
less,JJR,O
than,IN,O
additive,JJ,O
.,.,.
,,
agents,NNS,O
increasing,VBG,O
serum,NN,O
potassium,NN,D
since,IN,O
captopril,NN,D
decreases,VBZ,O
aldosterone,NN,O
production,NN,O
",",",",O
elevation,NN,O
of,IN,O
serum,NN,O
potassium,NN,D
may,MD,O
occur,VB,O
.,.,.
,,
potassium-sparing,JJ,O
diuretics,NNS,G
such,JJ,O
as,IN,O
spironolactone,NN,D
",",",",O
triamterene,NN,D
",",",",O
or,CC,O
amiloride,NN,D
",",",",O
or,CC,O
potassium,NN,D
supplements,NNS,O
should,MD,O
be,VB,O
given,VBN,O
only,RB,O
for,IN,O
documented,VBN,O
hypokalemia,NN,O
",",",",O
and,CC,O
then,RB,O
with,IN,O
caution,NN,O
",",",",O
since,IN,O
they,PRP,O
may,MD,O
lead,VB,O
to,TO,O
a,DT,O
significant,JJ,O
increase,NN,O
of,IN,O
serum,NN,O
potassium,NN,D
.,.,.
,,
salt,NNP,O
substitutes,VBZ,O
containing,VBG,O
potassium,NN,D
should,MD,O
also,RB,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
inhibitors,NNS,O
of,IN,O
endogenous,JJ,O
prostaglandin,NN,O
synthesis,NN,O
it,PRP,O
has,VBZ,O
been,VBN,O
reported,VBN,O
that,IN,O
indomethacin,NN,D
may,MD,O
reduce,VB,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
captopril,NN,D
",",",",O
especially,RB,O
in,IN,O
cases,NNS,O
of,IN,O
low,JJ,O
renin,NN,O
hypertension,NN,O
.,.,.
,,
other,JJ,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
aspirin,NN,B
-rrb-,-RRB-,O
may,MD,O
also,RB,O
have,VB,O
this,DT,O
effect,NN,O
.,.,.
,,
lithium,NN,D
:,:,O
increased,VBN,O
serum,NN,O
lithium,NN,D
levels,NNS,O
and,CC,O
symptoms,NNS,O
of,IN,O
lithium,NN,D
toxicity,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
lithium,NN,D
and,CC,O
ace,NN,O
inhibitor,NN,O
therapy,NN,O
.,.,.
,,
these,DT,O
drugs,NNS,D
should,MD,O
be,VB,O
coad-ministered,JJ,O
with,IN,O
caution,NN,O
and,CC,O
frequent,JJ,O
monitoring,NN,O
of,IN,O
serum,NN,O
lithium,NN,D
levels,NNS,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
if,IN,O
a,DT,O
diuretic,JJ,G
is,VBZ,O
also,RB,O
used,VBN,O
",",",",O
it,PRP,O
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
lithium,NN,D
toxicity,NN,O
.,.,.
,,
cardiac,JJ,O
glycosides,NNS,O
:,:,O
in,IN,O
a,DT,O
study,NN,O
of,IN,O
young,JJ,O
healthy,JJ,O
male,JJ,O
subjects,NNS,O
no,DT,O
evidence,NN,O
of,IN,O
a,DT,O
direct,JJ,O
pharmacokinetic,JJ,O
captopril-digoxin,NN,O
interaction,NN,O
could,MD,O
be,VB,O
found,VBN,O
.,.,.
,,
loop,NNP,O
diuretics,NNPS,G
:,:,O
furosemide,NN,D
administered,VBN,O
concurrently,RB,O
with,IN,O
captopril,NN,D
does,VBZ,O
not,RB,O
alter,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
captopril,NN,D
in,IN,O
renally,RB,O
impaired,JJ,O
hypertensive,JJ,O
patients,NNS,O
.,.,.
,,
allopurinol,NNP,D
:,:,O
in,IN,O
a,DT,O
study,NN,O
of,IN,O
healthy,JJ,O
male,JJ,O
volunteers,NNS,O
no,DT,O
significant,JJ,O
pharmacokinetic,JJ,O
interaction,NN,O
occurred,VBD,O
when,WRB,O
captopril,NN,D
and,CC,O
allopurinol,NN,D
were,VBD,O
administered,VBN,O
concomitantly,RB,O
for,IN,O
6,CD,O
days,NNS,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interaction,NN,O
captopril,NN,D
may,MD,O
cause,VB,O
a,DT,O
false-positive,JJ,O
urine,NN,O
test,NN,O
for,IN,O
acetone,NN,O
.,.,.
,,
clinically,RB,O
meaningful,JJ,O
drug,NN,D
interactions,NNS,O
have,VBP,O
occurred,VBN,O
with,IN,O
concomitant,JJ,O
medications,NNS,O
and,CC,O
include,VBP,O
",",",",O
but,CC,O
are,VBP,O
not,RB,O
limited,VBN,O
to,TO,O
the,DT,O
following,NN,O
:,:,O
agents,NNS,O
highly,RB,O
bound,VBN,O
to,TO,O
plasma,NN,O
protein,NN,O
carbamazepine,NN,D
is,VBZ,O
not,RB,O
highly,RB,O
bound,VBN,O
to,TO,O
plasma,NN,O
proteins,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
administration,NN,O
of,IN,O
equetrotm,NNP,B
to,TO,O
a,DT,O
patient,NN,O
taking,VBG,O
another,DT,O
drug,NN,D
that,WDT,O
is,VBZ,O
highly,RB,O
protein,NN,O
bound,VBD,O
should,MD,O
not,RB,O
cause,VB,O
increased,VBN,O
free,JJ,O
concentrations,NNS,O
of,IN,O
the,DT,O
other,JJ,O
drug,NN,D
.,.,.
,,
agents,NNS,O
that,WDT,O
inhibit,VBP,O
cytochrome,NN,O
p450,NN,O
isoenzymes,NNS,O
and/or,CC,O
epoxide,NNP,O
hydrolase,NNP,O
carbamazepine,NNP,D
is,VBZ,O
metabolized,VBN,O
mainly,RB,O
by,IN,O
cytochrome,NN,O
p450,NN,O
-lrb-,-LRB-,O
cyp,NN,O
-rrb-,-RRB-,O
3a4,NN,O
to,TO,O
the,DT,O
active,JJ,O
carbamazepine,NN,D
"10,11-epoxide",NN,O
",",",",O
which,WDT,O
is,VBZ,O
further,JJ,O
metabolized,VBN,O
to,TO,O
the,DT,O
trans-diol,NN,O
by,IN,O
epoxide,NN,O
hydrolase,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
potential,JJ,O
exists,VBZ,O
for,IN,O
interaction,NN,O
between,IN,O
carbamazepine,NN,D
and,CC,O
any,DT,O
agent,NN,O
that,WDT,O
inhibits,VBZ,O
cyp3a4,NN,D
and/or,CC,O
epoxide,NN,O
hydrolase,NN,O
.,.,.
,,
agents,NNS,O
that,WDT,O
are,VBP,O
cyp3a4,NN,D
inhibitors,NNS,O
that,WDT,O
have,VBP,O
been,VBN,O
found,VBN,O
",",",",O
or,CC,O
are,VBP,O
expected,VBN,O
",",",",O
to,TO,O
increase,VB,O
plasma,NN,O
levels,NNS,O
of,IN,O
equetrotm,NNP,B
are,VBP,O
the,DT,O
following,NN,O
:,:,O
acetazolamide,NNP,D
",",",",O
azole,NN,O
antifungals,NNS,G
",",",",O
cimetidine,NN,D
",",",",O
clarithromycin,NN,D
-lrb-,-LRB-,O
1,CD,O
-rrb-,-RRB-,O
",",",",O
dalfopristin,NN,D
",",",",O
danazol,NN,D
",",",",O
delavirdine,NN,D
",",",",O
diltiazem,NN,D
",",",",O
erythromycin,NN,D
-lrb-,-LRB-,O
1,CD,O
-rrb-,-RRB-,O
",",",",O
fluoxetine,NN,D
",",",",O
fluvoxamine,NN,D
",",",",O
grapefruit,NN,O
juice,NN,O
",",",",O
isoniazid,NN,D
",",",",O
itraconazole,NN,D
",",",",O
ketoconazole,NN,D
",",",",O
loratadine,NN,D
",",",",O
nefazodone,NN,D
",",",",O
niacinamide,NN,D
",",",",O
nicotinamide,NN,D
",",",",O
protease,NN,O
inhibitors,NNS,O
",",",",O
propoxyphene,NN,D
",",",",O
quinine,NN,D
",",",",O
quinupristin,NN,D
",",",",O
troleandomycin,NN,D
",",",",O
valproate,NN,D
-lrb-,-LRB-,O
1,CD,O
-rrb-,-RRB-,O
",",",",O
verapamil,NN,D
",",",",O
zileuton,NN,D
.,.,.
,,
thus,RB,O
",",",",O
if,IN,O
a,DT,O
patient,NN,O
has,VBZ,O
been,VBN,O
titrated,VBN,O
to,TO,O
a,DT,O
stable,JJ,O
dosage,NN,O
of,IN,O
equetrotm,NNP,B
",",",",O
and,CC,O
then,RB,O
begins,VBZ,O
a,DT,O
course,NN,O
of,IN,O
treatment,NN,O
with,IN,O
one,CD,O
of,IN,O
these,DT,O
cyp3a4,NN,D
or,CC,O
epoxide,NN,O
hydrolase,NN,O
inhibitors,NNS,O
",",",",O
it,PRP,O
is,VBZ,O
reasonable,JJ,O
to,TO,O
expect,VB,O
that,IN,O
a,DT,O
dose,NN,O
reduction,NN,O
for,IN,O
equetrotm,NNP,B
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
agents,NNS,O
that,WDT,O
induce,VBP,O
cytochrome,NN,O
p450,NN,O
isoenzymes,NNS,O
carbamazepine,NN,D
is,VBZ,O
metabolized,VBN,O
by,IN,O
cyp3a4,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
potential,JJ,O
exists,VBZ,O
for,IN,O
interaction,NN,O
between,IN,O
carbamazepine,NN,D
and,CC,O
any,DT,O
agent,NN,O
that,WDT,O
induces,VBZ,O
cyp3a4,NN,D
.,.,.
,,
agents,NNS,O
that,WDT,O
are,VBP,O
cyp,NNP,O
inducers,NNS,O
that,WDT,O
have,VBP,O
been,VBN,O
found,VBN,O
",",",",O
or,CC,O
are,VBP,O
expected,VBN,O
",",",",O
to,TO,O
decrease,VB,O
plasma,NN,O
levels,NNS,O
of,IN,O
equetrotm,NNP,B
are,VBP,O
the,DT,O
following,NN,O
:,:,O
cisplatin,NNP,D
",",",",O
doxorubicin,NN,D
hcl,NNP,O
",",",",O
felbamate,NN,D
",",",",O
rifampin,NN,D
",",",",O
phenobarbital,NN,D
",",",",O
phenytoin,NN,D
-lrb-,-LRB-,O
2,CD,O
-rrb-,-RRB-,O
",",",",O
primidone,NN,D
",",",",O
methsuximide,NN,D
",",",",O
and,CC,O
theophylline,NN,D
thus,RB,O
",",",",O
if,IN,O
a,DT,O
patient,NN,O
has,VBZ,O
been,VBN,O
titrated,VBN,O
to,TO,O
a,DT,O
stable,JJ,O
dosage,NN,O
on,IN,O
equetrotm,NNP,B
",",",",O
and,CC,O
then,RB,O
begins,VBZ,O
a,DT,O
course,NN,O
of,IN,O
treatment,NN,O
with,IN,O
one,CD,O
of,IN,O
these,DT,O
cyp3a4,NN,D
inducers,NNS,O
",",",",O
it,PRP,O
is,VBZ,O
reasonable,JJ,O
to,TO,O
expect,VB,O
that,IN,O
a,DT,O
dose,NN,O
increase,NN,O
for,IN,O
equetrotm,NNP,B
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
agents,NNS,O
with,IN,O
decreased,VBN,O
levels,NNS,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
carbamazepine,NNP,D
due,JJ,O
to,TO,O
induction,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
carbamazepine,NN,D
is,VBZ,O
known,VBN,O
to,TO,O
induce,VB,O
cyp1a2,NN,D
and,CC,O
cyp3a4,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
potential,JJ,O
exists,VBZ,O
for,IN,O
interaction,NN,O
between,IN,O
carbamazepine,NN,D
and,CC,O
any,DT,O
agent,NN,O
metabolized,VBN,O
by,IN,O
one,CD,O
-lrb-,-LRB-,O
or,CC,O
more,JJR,O
-rrb-,-RRB-,O
of,IN,O
these,DT,O
enzymes,NNS,O
.,.,.
,,
agents,NNS,O
that,WDT,O
have,VBP,O
been,VBN,O
found,VBN,O
",",",",O
or,CC,O
are,VBP,O
expected,VBN,O
to,TO,O
have,VB,O
decreased,VBN,O
plasma,NN,O
levels,NNS,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
equetrotm,NNP,B
due,JJ,O
to,TO,O
induction,NN,O
of,IN,O
cyp,NN,O
enzymes,NNS,O
are,VBP,O
the,DT,O
following,NN,O
:,:,O
acetaminophen,NNP,D
",",",",O
alprazolam,NN,D
",",",",O
amitriptyline,NNP,D
",",",",O
bupropion,NN,D
",",",",O
buspirone,NN,D
",",",",O
citalopram,NN,D
",",",",O
clobazam,NN,D
",",",",O
clonazepam,NN,D
",",",",O
clozapine,NN,D
",",",",O
cyclosporin,NN,D
",",",",O
delavirdine,NN,D
",",",",O
desipramine,NN,D
",",",",O
diazepam,NN,D
",",",",O
dicumarol,NN,D
",",",",O
doxycycline,NN,D
",",",",O
ethosuximide,NN,D
",",",",O
felbamate,NN,D
",",",",O
felodipine,NN,D
",",",",O
glucocorticoids,NNS,G
",",",",O
haloperidol,NN,D
",",",",O
itraconazole,NN,D
",",",",O
lamotrigine,NN,D
",",",",O
levothyroxine,NN,D
",",",",O
lorazepam,NN,D
",",",",O
methadone,NN,D
",",",",O
midazolam,NN,D
",",",",O
mirtazapine,NN,D
",",",",O
nortriptyline,NN,D
",",",",O
olanzapine,NN,D
",",",",O
oral,JJ,O
contraceptives,NNS,G
-lrb-,-LRB-,O
3,CD,O
-rrb-,-RRB-,O
",",",",O
oxcarbazepine,NN,D
",",",",O
phenytoin,NN,D
-lrb-,-LRB-,O
4,CD,O
-rrb-,-RRB-,O
",",",",O
praziquantel,NN,D
",",",",O
protease,NN,O
inhibitors,NNS,O
",",",",O
quetiapine,NN,D
",",",",O
risperidone,NN,D
",",",",O
theophylline,NN,D
",",",",O
topiramate,NN,D
",",",",O
tiagabine,NN,D
",",",",O
tramadol,NN,D
",",",",O
triazolam,NN,D
",",",",O
valproate,NN,D
",",",",O
warfarin,NN,D
-lrb-,-LRB-,O
5,CD,O
-rrb-,-RRB-,O
",",",",O
ziprasidone,NN,D
",",",",O
and,CC,O
zonisamide,NN,D
.,.,.
,,
thus,RB,O
",",",",O
if,IN,O
a,DT,O
patient,NN,O
has,VBZ,O
been,VBN,O
titrated,VBN,O
to,TO,O
a,DT,O
stable,JJ,O
dosage,NN,O
on,IN,O
one,CD,O
of,IN,O
the,DT,O
agents,NNS,O
in,IN,O
this,DT,O
category,NN,O
",",",",O
and,CC,O
then,RB,O
begins,VBZ,O
a,DT,O
course,NN,O
of,IN,O
treatment,NN,O
with,IN,O
equetrotm,NN,B
",",",",O
it,PRP,O
is,VBZ,O
reasonable,JJ,O
to,TO,O
expect,VB,O
that,IN,O
a,DT,O
dose,NN,O
increase,NN,O
for,IN,O
the,DT,O
concomitant,JJ,O
agent,NN,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
agents,NNS,O
with,IN,O
increased,VBN,O
levels,NNS,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
carbamazepine,NNP,D
:,:,O
equetrotm,NNP,B
increases,VBZ,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
the,DT,O
following,VBG,O
agents,NNS,O
:,:,O
clomipramine,NNP,O
hcl,NN,O
",",",",O
phenytoin,NNP,D
-lrb-,-LRB-,O
6,CD,O
-rrb-,-RRB-,O
",",",",O
and,CC,O
primidone,NN,D
thus,RB,O
",",",",O
if,IN,O
a,DT,O
patient,NN,O
has,VBZ,O
been,VBN,O
titrated,VBN,O
to,TO,O
a,DT,O
stable,JJ,O
dosage,NN,O
on,IN,O
one,CD,O
of,IN,O
the,DT,O
agents,NNS,O
in,IN,O
this,DT,O
category,NN,O
",",",",O
and,CC,O
then,RB,O
begins,VBZ,O
a,DT,O
course,NN,O
of,IN,O
the,DT,O
treatment,NN,O
with,IN,O
equetrotm,NN,B
",",",",O
it,PRP,O
is,VBZ,O
reasonable,JJ,O
to,TO,O
expect,VB,O
that,IN,O
a,DT,O
dose,NN,O
decrease,NN,O
for,IN,O
the,DT,O
concomitant,JJ,O
agent,NN,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
pharmacological/pharmacodynamic,JJ,O
interactions,NNS,O
with,IN,O
carbamazepine,NNP,D
concomitant,JJ,O
administration,NN,O
of,IN,O
carbamazepine,NN,D
and,CC,O
lithium,NN,D
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
neurotoxic,JJ,O
side,JJ,O
effects,NNS,O
.,.,.
,,
given,VBN,O
the,DT,O
anticonvulsant,JJ,G
properties,NNS,O
of,IN,O
carbamazepine,NN,D
",",",",O
equetrotm,NN,B
may,MD,O
reduce,VB,O
the,DT,O
thyroid,NN,G
function,NN,O
as,IN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
with,IN,O
other,JJ,O
anticonvulsants,NNS,G
.,.,.
,,
additionally,RB,O
",",",",O
anti-malarial,JJ,O
drugs,NNS,D
",",",",O
such,JJ,O
as,IN,O
chloroquine,NN,D
and,CC,O
mefloquine,NN,D
",",",",O
may,MD,O
antagonize,VB,O
the,DT,O
activity,NN,O
of,IN,O
carbamazepine,NN,D
.,.,.
,,
thus,RB,O
if,IN,O
a,DT,O
patient,NN,O
has,VBZ,O
been,VBN,O
titrated,VBN,O
to,TO,O
a,DT,O
stable,JJ,O
dosage,NN,O
on,IN,O
one,CD,O
of,IN,O
the,DT,O
agents,NNS,O
in,IN,O
this,DT,O
category,NN,O
",",",",O
and,CC,O
then,RB,O
begins,VBZ,O
a,DT,O
course,NN,O
of,IN,O
treatment,NN,O
with,IN,O
equetrotm,NN,B
",",",",O
it,PRP,O
is,VBZ,O
reasonable,JJ,O
to,TO,O
expect,VB,O
that,IN,O
a,DT,O
dose,NN,O
adjustment,NN,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
because,IN,O
of,IN,O
its,PRP$,O
primary,JJ,O
cns,NN,O
effect,NN,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
when,WRB,O
equetrotm,NNP,B
is,VBZ,O
taken,VBN,O
with,IN,O
other,JJ,O
centrally,RB,O
acting,VBG,O
drugs,NNS,D
and,CC,O
alcohol,NN,D
.,.,.
,,
geocillin,NN,B
-lrb-,-LRB-,O
carbenicillin,NN,O
indanyl,NN,O
sodium,NN,O
-rrb-,-RRB-,O
blood,NN,O
levels,NNS,O
may,MD,O
be,VB,O
increased,VBN,O
and,CC,O
prolonged,VBN,O
by,IN,O
concurrent,JJ,O
administration,NN,O
of,IN,O
probenecid,NN,D
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
the,DT,O
following,VBG,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
lodosyn,NN,B
-lrb-,-LRB-,O
carbidopa,NN,D
-rrb-,-RRB-,O
given,VBN,O
with,IN,O
levodopa,NN,D
or,CC,O
carbidopa-levodopa,NN,O
combination,NN,O
products,NNS,O
.,.,.
,,
for,IN,O
patients,NNS,O
receiving,VBG,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
",",",",O
see,VBP,O
contraindications,NNS,O
.,.,.
,,
dopamine,NN,D
d2,NN,O
receptor,NN,D
antagonists,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
phenothiazines,NNS,G
",",",",O
butyrophenones,NNS,G
",",",",O
risperidone,NN,D
-rrb-,-RRB-,O
and,CC,O
isoniazid,NN,D
may,MD,O
reduce,VB,O
the,DT,O
therapeutic,JJ,O
effects,NNS,O
of,IN,O
levodopa,NN,D
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
the,DT,O
beneficial,JJ,O
effects,NNS,O
of,IN,O
levodopa,NN,D
in,IN,O
parkinsons,NNPS,O
disease,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
be,VB,O
reversed,VBN,O
by,IN,O
phenytoin,NN,D
and,CC,O
papaverine,NN,D
.,.,.
,,
patients,NNS,O
taking,VBG,O
these,DT,O
drugs,NNS,D
with,IN,O
lodosyn,NN,B
and,CC,O
levodopa,NN,D
or,CC,O
carbidopa-levodopa,NN,O
combination,NN,O
products,NNS,O
should,MD,O
be,VB,O
carefully,RB,O
observed,VBN,O
for,IN,O
loss,NN,O
of,IN,O
therapeutic,JJ,O
response,NN,O
.,.,.
,,
iron,NNP,D
salts,NNS,O
may,MD,O
reduce,VB,O
the,DT,O
bioavailability,NN,O
of,IN,O
carbidopa,NN,D
and,CC,O
levodopa,NN,D
.,.,.
,,
the,DT,O
clinical,JJ,O
relevance,NN,O
is,VBZ,O
unclear,JJ,O
.,.,.
,,
although,IN,O
metoclopramide,NN,D
may,MD,O
increase,VB,O
the,DT,O
bioavailability,NN,O
of,IN,O
levodopa,NN,D
by,IN,O
increasing,VBG,O
gastric,JJ,O
emptying,NN,O
",",",",O
metoclopramide,NN,D
may,MD,O
also,RB,O
adversely,RB,O
affect,VB,O
disease,NN,O
control,NN,O
by,IN,O
its,PRP$,O
dopamine,NN,D
receptor,NN,D
antagonistic,JJ,O
properties,NNS,O
.,.,.
,,
iodine,NN,D
or,CC,O
iodine,NN,G
excess,NN,O
may,MD,O
decrease,VB,O
the,DT,O
effect,NN,O
of,IN,O
carbimazole,NNP,D
",",",",O
and,CC,O
an,DT,O
iodine,NN,G
deficiency,NN,O
can,MD,O
increase,VB,O
the,DT,O
effect,NN,O
of,IN,O
carbimazole,NN,D
.,.,.
,,
serum,NN,O
concentration,NN,O
of,IN,O
digoxin,NN,D
and,CC,O
digitoxin,NN,D
may,MD,O
increase,VB,O
when,WRB,O
patients,NNS,O
take,VBP,O
antithyroid,JJ,O
agents,NNS,O
.,.,.
,,
a,DT,O
decrease,NN,O
of,IN,O
the,DT,O
dosage,NN,O
may,MD,O
be,VB,O
necessary,JJ,O
when,WRB,O
patient,NN,O
becomes,VBZ,O
euthyroid,JJ,O
.,.,.
,,
antithyroid,JJ,O
agents,NNS,O
may,MD,O
decrease,VB,O
thyroidal,JJ,O
uptake,NN,O
of,IN,O
sodium,NN,O
iodide,NN,O
i131,NN,O
",",",",O
a,DT,O
rebound,NN,O
in,IN,O
uptake,NN,O
may,MD,O
occur,VB,O
up,RP,O
to,TO,O
5,CD,O
days,NNS,O
after,IN,O
sudden,JJ,O
withdrawal,NN,O
of,IN,O
carbimazole,NN,D
.,.,.
,,
patients,NNS,O
response,NN,O
to,TO,O
oral,JJ,O
anticoagulants,NNS,G
may,MD,O
be,VB,O
affected,VBN,O
by,IN,O
his/her,NN,O
thyroid,NN,G
and,CC,O
metabolic,JJ,O
status,NN,O
.,.,.
,,
an,DT,O
evaluation,NN,O
of,IN,O
prothrombin,NN,O
time,NN,O
and,CC,O
an,DT,O
adjustment,NN,O
of,IN,O
anticoagulant,JJ,G
dosage,NN,O
are,VBP,O
recommende,NN,O
.,.,.
,,
antihistamines,NNS,D
may,MD,O
enhance,VB,O
the,DT,O
effects,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
barbiturates,NNS,G
",",",",O
alcohol,NN,D
",",",",O
and,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
.,.,.
,,
mao,NN,O
inhibitors,NNS,O
prolong,VB,O
and,CC,O
intensify,VB,O
the,DT,O
anticholinergic,JJ,G
effects,NNS,O
of,IN,O
antihistamines,NNS,G
.,.,.
,,
sympathomimetic,JJ,O
amines,NNS,O
may,MD,O
reduce,VB,O
the,DT,O
antihypertensive,JJ,G
effects,NNS,O
of,IN,O
reserpine,NN,D
",",",",O
veratrum,NN,O
alkaloids,NNS,O
",",",",O
methyldopa,NN,D
and,CC,O
mecamylamine,NN,D
.,.,.
,,
effects,NNS,O
of,IN,O
sympathomimetics,NNS,G
are,VBP,O
increased,VBN,O
with,IN,O
mao,NN,O
inhibitors,NNS,O
and,CC,O
beta,NN,O
adrenergic,JJ,G
blockers,NNS,O
.,.,.
,,
the,DT,O
renal,JJ,O
effects,NNS,O
of,IN,O
nephrotoxic,JJ,O
compounds,NNS,O
may,MD,O
be,VB,O
potentiated,VBN,O
by,IN,O
carboplatin,NNP,D
.,.,.
,,
hemabate,NN,B
may,MD,O
augment,VB,O
the,DT,O
activity,NN,O
of,IN,O
other,JJ,O
oxytocic,JJ,O
agents,NNS,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
with,IN,O
other,JJ,O
oxytocic,JJ,O
agents,NNS,O
is,VBZ,O
not,RB,O
recommende,NN,O
.,.,.
,,
ocupress,NN,B
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
who,WP,O
are,VBP,O
receiving,VBG,O
a,DT,O
beta-adrenergic,JJ,O
blocking,VBG,O
agent,NN,O
orally,RB,O
because,IN,O
of,IN,O
the,DT,O
potential,NN,O
for,IN,O
additive,JJ,O
effects,NNS,O
on,IN,O
systemic,JJ,O
beta-blockade,NN,O
.,.,.
,,
close,JJ,O
observation,NN,O
of,IN,O
the,DT,O
patient,NN,O
is,VBZ,O
recommended,VBN,O
when,WRB,O
a,DT,O
beta-blocker,NN,G
is,VBZ,O
administered,VBN,O
to,TO,O
patients,NNS,O
receiving,VBG,O
catecholamine-depleting,JJ,O
drugs,NNS,D
such,JJ,O
as,IN,O
reserpine,NN,D
",",",",O
because,IN,O
of,IN,O
possible,JJ,O
additive,JJ,O
effects,NNS,O
and,CC,O
the,DT,O
production,NN,O
of,IN,O
hypotension,NN,O
and/or,CC,O
marked,JJ,O
bradycardia,NN,O
",",",",O
which,WDT,O
may,MD,O
produce,VB,O
vertigo,NN,O
",",",",O
syncope,NN,O
",",",",O
or,CC,O
postural,JJ,O
hypotension,NN,O
.,.,.
,,
inhibitors,NNS,O
of,IN,O
cyp2d6,NN,D
;,:,O
.,.,.
,,
poor,JJ,O
metabolizers,NNS,O
of,IN,O
debrisoquin,NN,D
:,:,O
interactions,NNS,O
of,IN,O
carvedilol,NN,D
with,IN,O
strong,JJ,O
inhibitors,NNS,O
of,IN,O
cyp2d6,NN,D
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
quinidine,NN,D
",",",",O
fluoxetine,NN,D
",",",",O
paroxetine,NN,D
",",",",O
and,CC,O
propafenone,NN,D
-rrb-,-RRB-,O
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
",",",",O
but,CC,O
these,DT,O
drugs,NNS,D
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
increase,VB,O
blood,NN,O
levels,NNS,O
of,IN,O
the,DT,O
r,NN,O
-lrb-,-LRB-,O
+,CC,O
-rrb-,-RRB-,O
enantiomer,NN,O
of,IN,O
carvedilol,NN,D
.,.,.
,,
retrospective,JJ,O
analysis,NN,O
of,IN,O
side,JJ,O
effects,NNS,O
in,IN,O
clinical,JJ,O
trials,NNS,O
showed,VBD,O
that,IN,O
poor,JJ,O
2d6,NN,O
metabolizers,NNS,O
had,VBD,O
a,DT,O
higher,JJR,O
rate,NN,O
of,IN,O
dizziness,NN,O
during,IN,O
up-titration,NN,O
",",",",O
presumably,RB,O
resulting,VBG,O
from,IN,O
vasodilating,VBG,O
effects,NNS,O
of,IN,O
the,DT,O
higher,JJR,O
concentrations,NNS,O
of,IN,O
the,DT,O
a-blocking,NN,O
r,NN,O
-lrb-,-LRB-,O
+,CC,O
-rrb-,-RRB-,O
enantiomer,NN,O
.,.,.
,,
catecholamine-depleting,JJ,O
agents,NNS,O
:,:,O
patients,NNS,O
taking,VBG,O
both,CC,O
agents,NNS,O
with,IN,O
b-blocking,NN,O
properties,NNS,O
and,CC,O
a,DT,O
drug,NN,D
that,WDT,O
can,MD,O
deplete,VB,O
catecholamines,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
reserpine,NN,D
and,CC,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
-rrb-,-RRB-,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
signs,NNS,O
of,IN,O
hypotension,NN,O
and/or,CC,O
severe,JJ,O
bradycardia,NN,O
.,.,.
,,
clonidine,NNP,D
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
clonidine,NN,D
with,IN,O
agents,NNS,O
with,IN,O
b-blocking,NN,O
properties,NNS,O
may,MD,O
potentiate,VB,O
blood-pressure,NN,O
-,:,O
and,CC,O
heart-rate-lowering,JJ,O
effects,NNS,O
.,.,.
,,
when,WRB,O
concomitant,JJ,O
treatment,NN,O
with,IN,O
agents,NNS,O
with,IN,O
b-blocking,NN,O
properties,NNS,O
and,CC,O
clonidine,NN,D
is,VBZ,O
to,TO,O
be,VB,O
terminated,VBN,O
",",",",O
the,DT,O
b-blocking,JJ,O
agent,NN,O
should,MD,O
be,VB,O
discontinued,VBN,O
first,RB,O
.,.,.
,,
clonidine,NN,D
therapy,NN,O
can,MD,O
then,RB,O
be,VB,O
discontinued,VBN,O
several,JJ,O
days,NNS,O
later,RB,O
by,IN,O
gradually,RB,O
decreasing,VBG,O
the,DT,O
dosage,NN,O
.,.,.
,,
cyclosporine,NN,D
:,:,O
modest,JJ,O
increases,NNS,O
in,IN,O
mean,JJ,O
trough,NN,O
cyclosporine,NN,D
concentrations,NNS,O
were,VBD,O
observed,VBN,O
following,VBG,O
initiation,NN,O
of,IN,O
carvedilol,NN,D
treatment,NN,O
in,IN,O
21,CD,O
renal,JJ,O
transplant,NN,O
patients,NNS,O
suffering,VBG,O
from,IN,O
chronic,JJ,O
vascular,JJ,O
rejection,NN,O
.,.,.
,,
in,IN,O
about,RB,O
30,CD,O
%,NN,O
of,IN,O
patients,NNS,O
",",",",O
the,DT,O
dose,NN,O
of,IN,O
cyclosporine,NN,D
had,VBD,O
to,TO,O
be,VB,O
reduced,VBN,O
in,IN,O
order,NN,O
to,TO,O
maintain,VB,O
cyclosporine,NN,D
concentrations,NNS,O
within,IN,O
the,DT,O
therapeutic,JJ,O
range,NN,O
",",",",O
while,IN,O
in,IN,O
the,DT,O
remainder,NN,O
no,DT,O
adjustment,NN,O
was,VBD,O
needed,VBN,O
.,.,.
,,
on,IN,O
the,DT,O
average,NN,O
for,IN,O
the,DT,O
group,NN,O
",",",",O
the,DT,O
dose,NN,O
of,IN,O
cyclosporine,NN,D
was,VBD,O
reduced,VBN,O
about,IN,O
20,CD,O
%,NN,O
in,IN,O
these,DT,O
patients,NNS,O
.,.,.
,,
due,JJ,O
to,TO,O
wide,JJ,O
interindividual,JJ,O
variability,NN,O
in,IN,O
the,DT,O
dose,NN,O
adjustment,NN,O
required,VBN,O
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
cyclosporine,NN,D
concentrations,NNS,O
be,VB,O
monitored,VBN,O
closely,RB,O
after,IN,O
initiation,NN,O
of,IN,O
carvedilol,NN,D
therapy,NN,O
and,CC,O
that,IN,O
the,DT,O
dose,NN,O
of,IN,O
cyclosporine,NN,D
be,VB,O
adjusted,VBN,O
as,IN,O
appropriate,JJ,O
.,.,.
,,
digoxin,NNP,D
:,:,O
digoxin,NN,D
concentrations,NNS,O
are,VBP,O
increased,VBN,O
by,IN,O
about,RB,O
15,CD,O
%,NN,O
when,WRB,O
digoxin,NN,D
and,CC,O
carvedilol,NN,D
are,VBP,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
both,DT,O
digoxin,NN,D
and,CC,O
coreg,NNP,B
slow,JJ,O
av,NN,O
conduction,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
increased,VBD,O
monitoring,NN,O
of,IN,O
digoxin,NN,D
is,VBZ,O
recommended,VBN,O
when,WRB,O
initiating,VBG,O
",",",",O
adjusting,VBG,O
",",",",O
or,CC,O
discontinuing,VBG,O
coreg,NNP,B
.,.,.
,,
inducers,NNS,O
and,CC,O
inhibitors,NNS,O
of,IN,O
hepatic,JJ,O
metabolism,NN,O
:,:,O
rifampin,NNP,D
reduced,VBD,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
carvedilol,NN,D
by,IN,O
about,RB,O
70,CD,O
%,NN,O
.,.,.
,,
cimetidine,NN,D
increased,VBD,O
auc,NN,O
by,IN,O
about,IN,O
30,CD,O
%,NN,O
but,CC,O
caused,VBD,O
no,DT,O
change,NN,O
in,IN,O
cmax,NNP,O
.,.,.
,,
calcium,NN,D
channel,NNP,O
blockers,NNPS,O
:,:,O
isolated,VBN,O
cases,NNS,O
of,IN,O
conduction,NN,O
disturbance,NN,O
-lrb-,-LRB-,O
rarely,RB,O
with,IN,O
hemodynamic,JJ,O
compromise,NN,O
-rrb-,-RRB-,O
have,VBP,O
been,VBN,O
observed,VBN,O
when,WRB,O
coreg,NNP,B
is,VBZ,O
co-administered,VBN,O
with,IN,O
diltiazem,NN,D
.,.,.
,,
as,IN,O
with,IN,O
other,JJ,O
agents,NNS,O
with,IN,O
b-blocking,NN,O
properties,NNS,O
",",",",O
if,IN,O
coreg,NNP,B
is,VBZ,O
to,TO,O
be,VB,O
administered,VBN,O
orally,RB,O
with,IN,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
of,IN,O
the,DT,O
verapamil,NN,D
or,CC,O
diltiazem,NN,D
type,NN,O
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
ecg,NN,O
and,CC,O
blood,NN,O
pressure,NN,O
be,VB,O
monitored,VBN,O
.,.,.
,,
insulin,NN,D
or,CC,O
oral,JJ,O
hypoglycemics,NNS,G
:,:,O
agents,NNS,O
with,IN,O
b-blocking,NN,O
properties,NNS,O
may,MD,O
enhance,VB,O
the,DT,O
blood-sugar-reducing,JJ,O
effect,NN,O
of,IN,O
insulin,NN,D
and,CC,O
oral,JJ,O
hypoglycemics,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
in,IN,O
patients,NNS,O
taking,VBG,O
insulin,NN,D
or,CC,O
oral,JJ,O
hypoglycemics,NNS,G
",",",",O
regular,JJ,O
monitoring,NN,O
of,IN,O
blood,NN,O
glucose,NN,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
studies,NNS,O
in,FW,O
vitro,FW,O
show,VBP,O
that,IN,O
caspofungin,NN,D
acetate,NN,O
is,VBZ,O
not,RB,O
an,DT,O
inhibitor,NN,O
of,IN,O
any,DT,O
enzyme,NN,O
in,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
-lrb-,-LRB-,O
cyp,NN,O
-rrb-,-RRB-,O
system,NN,O
.,.,.
,,
in,IN,O
clinical,JJ,O
studies,NNS,O
",",",",O
caspofungin,NN,D
did,VBD,O
not,RB,O
induce,VB,O
the,DT,O
cyp3a4,NN,D
metabolism,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
.,.,.
,,
caspofungin,NNP,D
is,VBZ,O
not,RB,O
a,DT,O
substrate,NN,O
for,IN,O
p-glycoprotein,NN,O
and,CC,O
is,VBZ,O
a,DT,O
poor,JJ,O
substrate,NN,O
for,IN,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
.,.,.
,,
clinical,JJ,O
studies,NNS,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
show,VBP,O
that,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
cancidas,NNP,B
are,VBP,O
not,RB,O
altered,VBN,O
by,IN,O
itraconazole,NN,D
",",",",O
amphotericin,NN,D
b,NN,O
",",",",O
mycophenolate,NN,D
",",",",O
nelfinavir,NN,D
",",",",O
or,CC,O
tacrolimus,NN,D
.,.,.
,,
cancidas,NNP,B
has,VBZ,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
itraconazole,NN,D
",",",",O
amphotericin,NN,D
b,NN,O
",",",",O
or,CC,O
the,DT,O
active,JJ,O
metabolite,NN,O
of,IN,O
mycophenolate,NN,D
.,.,.
,,
cancidas,NNP,B
reduced,VBD,O
the,DT,O
blood,NN,O
auc0-12,NN,O
of,IN,O
tacrolimus,NN,D
by,IN,O
approximately,RB,O
20,CD,O
%,NN,O
",",",",O
peak,JJ,O
blood,NN,O
concentration,NN,O
-lrb-,-LRB-,O
cmax,NN,O
-rrb-,-RRB-,O
by,IN,O
16,CD,O
%,NN,O
",",",",O
and,CC,O
12-hour,JJ,O
blood,NN,O
concentration,NN,O
-lrb-,-LRB-,O
c12hr,NN,O
-rrb-,-RRB-,O
by,IN,O
26,CD,O
%,NN,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
when,WRB,O
tacrolimus,NN,D
-lrb-,-LRB-,O
2,CD,O
doses,NNS,O
of,IN,O
0.1,CD,O
mg/kg,NN,O
12,CD,O
hours,NNS,O
apart,RB,O
-rrb-,-RRB-,O
was,VBD,O
administered,VBN,O
on,IN,O
the,DT,O
10th,JJ,O
day,NN,O
of,IN,O
cancidas,NNP,B
70,CD,O
mg,NN,O
daily,RB,O
",",",",O
as,IN,O
compared,VBN,O
to,TO,O
results,NNS,O
from,IN,O
a,DT,O
control,NN,O
period,NN,O
in,IN,O
which,WDT,O
tacrolimus,NN,D
was,VBD,O
administered,VBN,O
alone,RB,O
.,.,.
,,
for,IN,O
patients,NNS,O
receiving,VBG,O
both,CC,O
therapies,NNS,O
",",",",O
standard,JJ,O
monitoring,NN,O
of,IN,O
tacrolimus,NN,D
blood,NN,O
concentrations,NNS,O
and,CC,O
appropriate,JJ,O
tacrolimus,NN,D
dosage,NN,O
adjustments,NNS,O
are,VBP,O
recommended,VBN,O
.,.,.
,,
in,IN,O
two,CD,O
clinical,JJ,O
studies,NNS,O
",",",",O
cyclosporine,NN,D
-lrb-,-LRB-,O
one,CD,O
4,CD,O
mg/kg,NN,O
dose,NN,O
or,CC,O
two,CD,O
3,CD,O
mg/kg,NN,O
doses,NNS,O
-rrb-,-RRB-,O
increased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
caspofungin,NN,D
by,IN,O
approximately,RB,O
35,CD,O
%,NN,O
.,.,.
,,
cancidas,NNP,B
did,VBD,O
not,RB,O
increase,VB,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
cyclosporine,NN,D
.,.,.
,,
there,EX,O
were,VBD,O
transient,JJ,O
increases,NNS,O
in,IN,O
liver,NN,O
alt,NN,O
and,CC,O
ast,NNP,O
when,WRB,O
cancidas,NNP,B
and,CC,O
cyclosporine,NN,D
were,VBD,O
co-administered,VBN,O
.,.,.
,,
a,DT,O
drug-drug,JJ,O
interaction,NN,O
study,NN,O
with,IN,O
rifampin,NN,D
in,IN,O
healthy,JJ,O
volunteers,NNS,O
has,VBZ,O
shown,VBN,O
a,DT,O
30,CD,O
%,NN,O
decrease,NN,O
in,IN,O
caspofungin,NN,D
trough,NN,O
concentrations,NNS,O
.,.,.
,,
patients,NNS,O
on,IN,O
rifampin,NN,D
should,MD,O
receive,VB,O
70,CD,O
mg,NN,O
of,IN,O
cancidas,NNP,B
daily,RB,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
results,VBZ,O
from,IN,O
regression,NN,O
analyses,NNS,O
of,IN,O
patient,NN,O
pharmacokinetic,JJ,O
data,NNS,O
suggest,VBP,O
that,IN,O
co-administration,NN,O
of,IN,O
other,JJ,O
inducers,NNS,O
of,IN,O
drug,NN,D
clearance,NN,O
-lrb-,-LRB-,O
efavirenz,NN,D
",",",",O
nevirapine,NN,D
",",",",O
phenytoin,NN,D
",",",",O
dexamethasone,NN,D
",",",",O
or,CC,O
carbamazepine,NN,D
-rrb-,-RRB-,O
with,IN,O
cancidas,NNS,B
may,MD,O
result,VB,O
in,IN,O
clinically,RB,O
meaningful,JJ,O
reductions,NNS,O
in,IN,O
caspofungin,NN,D
concentrations,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
which,WDT,O
drug,NN,D
clearance,NN,O
mechanism,NN,O
involved,VBN,O
in,IN,O
caspofungin,NN,D
disposition,NN,O
may,MD,O
be,VB,O
inducible,JJ,O
.,.,.
,,
when,WRB,O
cancidas,NNP,B
is,VBZ,O
co-administered,VBN,O
with,IN,O
inducers,NNS,O
of,IN,O
drug,NN,D
clearance,NN,O
",",",",O
such,JJ,O
as,IN,O
efavirenz,NN,D
",",",",O
nevirapine,NN,D
",",",",O
phenytoin,NN,D
",",",",O
dexamethasone,NN,D
",",",",O
or,CC,O
carbamazepine,NN,D
",",",",O
use,NN,O
of,IN,O
a,DT,O
daily,JJ,O
dose,NN,O
of,IN,O
70,CD,O
mg,NN,O
of,IN,O
cancidas,NNP,B
should,MD,O
be,VB,O
considere,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
positive,JJ,O
direct,JJ,O
coombs,NNP,O
tests,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
during,IN,O
treatment,NN,O
with,IN,O
the,DT,O
cephalosporin,NN,G
antibiotics,NNS,G
.,.,.
,,
in,IN,O
hematologic,JJ,O
studies,NNS,O
or,CC,O
in,IN,O
transfusion,NN,O
cross-matching,NN,O
procedures,NNS,O
when,WRB,O
anti-globulin,JJ,O
tests,NNS,O
are,VBP,O
performed,VBN,O
on,IN,O
the,DT,O
minor,JJ,O
side,NN,O
or,CC,O
in,IN,O
coombs,NNP,O
testing,NN,O
of,IN,O
newborns,NNS,O
whose,WP$,O
mothers,NNS,O
have,VBP,O
received,VBN,O
cephalosporin,NN,G
antibiotics,NNS,G
before,IN,O
parturition,NN,O
",",",",O
it,PRP,O
should,MD,O
be,VB,O
recognized,VBN,O
that,IN,O
a,DT,O
positive,JJ,O
coombs,NNP,O
test,NN,O
may,MD,O
be,VB,O
due,JJ,O
to,TO,O
the,DT,O
drug,NN,D
.,.,.
,,
probenecid,NNP,D
may,MD,O
decrease,VB,O
renal,JJ,O
tubular,JJ,O
secretion,NN,O
of,IN,O
cephalosporins,NNS,G
when,WRB,O
used,VBN,O
concurrently,RB,O
",",",",O
resulting,VBG,O
in,IN,O
increased,VBN,O
and,CC,O
more,RBR,O
prolonged,JJ,O
cephalosporin,NN,G
blood,NN,O
levels,NNS,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
a,DT,O
FALSE,JJ,O
positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
the,DT,O
urine,NN,O
may,MD,O
occur,VB,O
with,IN,O
benedicts,NNS,O
solution,NN,O
",",",",O
fehlings,NNP,O
solution,NN,O
or,CC,O
with,IN,O
clinitest,NN,O
tablets,NNS,O
",",",",O
but,CC,O
not,RB,O
with,IN,O
enzyme-based,JJ,O
tests,NNS,O
such,JJ,O
as,IN,O
clinistix,NN,O
.,.,.
,,
positive,JJ,O
direct,JJ,O
and,CC,O
indirect,JJ,O
antiglobulin,NN,O
-lrb-,-LRB-,O
coombs,NNS,O
-rrb-,-RRB-,O
tests,NNS,O
have,VBP,O
occurred,VBN,O
;,:,O
.,.,.
,,
these,DT,O
may,MD,O
also,RB,O
occur,VB,O
in,IN,O
neonates,NNS,O
whose,WP$,O
mothers,NNS,O
received,VBD,O
cephalosporins,NNS,G
before,IN,O
delivery,NN,O
.,.,.
,,
antacids,NNS,G
-lrb-,-LRB-,O
aluminum,NN,D
-,:,O
or,CC,O
magnesium-containing,JJ,O
-rrb-,-RRB-,O
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
300-mg,JJ,O
cefdinir,NN,D
capsules,NNS,O
with,IN,O
30,CD,O
ml,NN,O
maalox,NNP,B
tc,NNP,O
suspension,NN,O
reduces,VBZ,O
the,DT,O
rate,NN,O
-lrb-,-LRB-,O
cmax,NN,O
-rrb-,-RRB-,O
and,CC,O
extent,NN,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
of,IN,O
absorption,NN,O
by,IN,O
approximately,RB,O
40,CD,O
%,NN,O
.,.,.
,,
time,NNP,O
to,TO,O
reach,VB,O
cmax,NNP,O
is,VBZ,O
also,RB,O
prolonged,VBN,O
by,IN,O
1,CD,O
hour,NN,O
.,.,.
,,
there,EX,O
are,VBP,O
no,DT,O
significant,JJ,O
effects,NNS,O
on,IN,O
cefdinir,NN,D
pharmacokinetics,NNS,O
if,IN,O
the,DT,O
antacid,NN,G
is,VBZ,O
administered,VBN,O
2,CD,O
hours,NNS,O
before,IN,O
or,CC,O
2,CD,O
hours,NNS,O
after,IN,O
cefdinir,NN,D
.,.,.
,,
if,IN,O
antacids,NNS,G
are,VBP,O
required,VBN,O
during,IN,O
omnicef,NN,B
therapy,NN,O
",",",",O
omnicef,NN,B
should,MD,O
be,VB,O
taken,VBN,O
at,IN,O
least,JJS,O
2,CD,O
hours,NNS,O
before,IN,O
or,CC,O
after,IN,O
the,DT,O
antacid,NN,G
.,.,.
,,
probenecid,NNP,D
:,:,O
as,IN,O
with,IN,O
other,JJ,O
b-lactam,NN,O
antibiotics,NNS,G
",",",",O
probenecid,NN,D
inhibits,VBZ,O
the,DT,O
renal,JJ,O
excretion,NN,O
of,IN,O
cefdinir,NN,D
",",",",O
resulting,VBG,O
in,IN,O
an,DT,O
approximate,JJ,O
doubling,NN,O
in,IN,O
a.c.,NNP,O
a,DT,O
54,CD,O
%,NN,O
increase,NN,O
in,IN,O
peak,JJ,O
cefdinir,NN,D
plasma,NN,O
levels,NNS,O
",",",",O
and,CC,O
a,DT,O
50,CD,O
%,NN,O
prolongation,NN,O
in,IN,O
the,DT,O
apparent,JJ,O
elimination,NN,O
half-life,NN,O
.,.,.
,,
iron,NNP,D
supplements,NNP,O
and,CC,O
foods,NNP,O
fortified,VBD,O
with,IN,O
iron,NNP,D
concomitant,JJ,O
administration,NN,O
of,IN,O
cefdinir,NN,D
with,IN,O
a,DT,O
therapeutic,JJ,O
iron,NN,D
supplement,NN,O
containing,VBG,O
60,CD,O
mg,NN,O
of,IN,O
elemental,JJ,O
iron,NN,D
-lrb-,-LRB-,O
as,IN,O
feso4,NN,O
-rrb-,-RRB-,O
or,CC,O
vitamins,NNS,G
supplemented,VBN,O
with,IN,O
10,CD,O
mg,NN,O
of,IN,O
elemental,JJ,O
iron,NN,D
reduced,VBD,O
extent,NN,O
of,IN,O
absorption,NN,O
by,IN,O
80,CD,O
%,NN,O
and,CC,O
31,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
if,IN,O
iron,NN,D
supplements,NNS,O
are,VBP,O
required,VBN,O
during,IN,O
omnicef,NN,B
therapy,NN,O
",",",",O
omnicef,NN,B
should,MD,O
be,VB,O
taken,VBN,O
at,IN,O
least,JJS,O
2,CD,O
hours,NNS,O
before,IN,O
or,CC,O
after,IN,O
the,DT,O
supplement,NN,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
foods,NNS,O
highly,RB,O
fortified,VBD,O
with,IN,O
elemental,JJ,O
iron,NN,D
-lrb-,-LRB-,O
primarily,RB,O
iron-fortified,JJ,O
breakfast,NN,O
cereals,NNS,O
-rrb-,-RRB-,O
on,IN,O
cefdinir,NN,D
absorption,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
concomitantly,RB,O
administered,VBN,O
iron-fortified,JJ,O
infant,NN,O
formula,NN,O
-lrb-,-LRB-,O
2.2,CD,O
mg,NN,O
elemental,JJ,O
iron/6,NN,O
oz,NN,O
-rrb-,-RRB-,O
has,VBZ,O
no,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
cefdinir,NN,D
pharmacokinetics,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
omnicef,NN,B
for,IN,O
oral,NNP,O
suspension,NNP,O
can,MD,O
be,VB,O
administered,VBN,O
with,IN,O
iron-fortified,JJ,O
infant,NN,O
formula,NN,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
rare,JJ,O
reports,NNS,O
of,IN,O
reddish,JJ,O
stools,NNS,O
in,IN,O
patients,NNS,O
who,WP,O
have,VBP,O
received,VBN,O
cefdinir,NN,D
in,IN,O
japan,NNP,O
.,.,.
,,
the,DT,O
reddish,JJ,O
color,NN,O
is,VBZ,O
due,JJ,O
to,TO,O
the,DT,O
formation,NN,O
of,IN,O
a,DT,O
nonabsorbable,JJ,O
complex,NN,O
between,IN,O
cefdinir,NN,D
or,CC,O
its,PRP$,O
breakdown,NN,O
products,NNS,O
and,CC,O
iron,NN,D
in,IN,O
the,DT,O
gastrointestinal,JJ,O
tract,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
ketones,NNS,O
in,IN,O
the,DT,O
urine,NN,O
may,MD,O
occur,VB,O
with,IN,O
tests,NNS,O
using,VBG,O
nitroprusside,NN,D
",",",",O
but,CC,O
not,RB,O
with,IN,O
those,DT,O
using,VBG,O
nitroferricyanide,NN,D
.,.,.
,,
the,DT,O
administration,NN,O
of,IN,O
cefdinir,NN,D
may,MD,O
result,VB,O
in,IN,O
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
urine,NN,O
using,VBG,O
clinitest,NNP,O
",",",",O
benedict,NNP,O
s,VBZ,O
solution,NN,O
",",",",O
or,CC,O
fehlings,NNP,O
solution,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
glucose,NN,O
tests,NNS,O
based,VBN,O
on,IN,O
enzymatic,JJ,O
glucose,NN,O
oxidase,NN,O
reactions,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
clinistix,NNP,O
or,CC,O
tes-tape,NNP,O
-rrb-,-RRB-,O
be,VB,O
used,VBN,O
.,.,.
,,
cephalosporins,NNS,G
are,VBP,O
known,VBN,O
to,TO,O
occasionally,RB,O
induce,VB,O
a,DT,O
positive,JJ,O
direct,JJ,O
coombs,NNS,O
test,NN,O
.,.,.
,,
oral,JJ,O
contraceptives,NNS,G
multiple,JJ,O
doses,NNS,O
of,IN,O
cefditoren,NN,D
pivoxil,NN,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
ethinyl,NN,O
estradiol,NN,O
",",",",O
the,DT,O
estrogenic,JJ,O
component,NN,O
in,IN,O
most,JJS,O
oral,JJ,O
contraceptives,NNS,G
.,.,.
,,
although,IN,O
the,DT,O
clinical,JJ,O
significance,NN,O
is,VBZ,O
not,RB,O
known,VBN,O
",",",",O
it,PRP,O
is,VBZ,O
not,RB,O
recommended,VBN,O
that,IN,O
cefditoren,NN,D
pivoxil,NN,O
be,VB,O
taken,VBN,O
concomitantly,RB,O
with,IN,O
antacids,NNS,G
.,.,.
,,
h2-receptor,NN,O
antagonists,NNS,O
:,:,O
co-administration,NN,O
of,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
intravenously,RB,O
administered,VBN,O
famotidine,NN,D
-lrb-,-LRB-,O
20,CD,O
mg,NN,O
-rrb-,-RRB-,O
reduced,VBD,O
the,DT,O
oral,JJ,O
absorption,NN,O
of,IN,O
a,DT,O
single,JJ,O
400,CD,O
mg,NN,O
dose,NN,O
of,IN,O
cefditoren,NN,D
pivoxil,NN,O
administered,VBN,O
following,VBG,O
a,DT,O
meal,NN,O
",",",",O
as,IN,O
evidenced,VBN,O
by,IN,O
a,DT,O
27,CD,O
%,NN,O
decrease,NN,O
in,IN,O
mean,JJ,O
cmax,NN,O
and,CC,O
a,DT,O
22,CD,O
%,NN,O
decrease,NN,O
in,IN,O
mean,JJ,O
auc,NN,O
.,.,.
,,
although,IN,O
the,DT,O
clinical,JJ,O
significance,NN,O
is,VBZ,O
not,RB,O
known,VBN,O
",",",",O
it,PRP,O
is,VBZ,O
not,RB,O
recommended,VBN,O
that,IN,O
cefditoren,NN,D
pivoxil,NN,O
be,VB,O
taken,VBN,O
concomitantly,RB,O
with,IN,O
h2,NN,O
receptor,NN,D
antagonists,NNS,O
.,.,.
,,
probenecid,NNP,D
:,:,O
as,IN,O
with,IN,O
other,JJ,O
b-lactam,NN,O
antibiotics,NNS,G
",",",",O
co-administration,NN,O
of,IN,O
probenecid,NN,D
with,IN,O
cefditoren,NN,D
pivoxil,NN,O
resulted,VBD,O
in,IN,O
an,DT,O
increase,NN,O
in,IN,O
the,DT,O
plasma,NN,O
exposure,NN,O
of,IN,O
cefditoren,NNS,D
",",",",O
with,IN,O
a,DT,O
49,CD,O
%,NN,O
increase,NN,O
in,IN,O
mean,NN,O
cmax,NN,O
",",",",O
a,DT,O
122,CD,O
%,NN,O
increase,NN,O
in,IN,O
mean,JJ,O
auc,NN,O
",",",",O
and,CC,O
a,DT,O
53,CD,O
%,NN,O
increase,NN,O
in,IN,O
half-life,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
cephalosporins,NNS,G
are,VBP,O
known,VBN,O
to,TO,O
occasionally,RB,O
induce,VB,O
a,DT,O
positive,JJ,O
direct,JJ,O
coombs,NNS,O
test,NN,O
.,.,.
,,
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
the,DT,O
urine,NN,O
may,MD,O
occur,VB,O
with,IN,O
copper,NN,O
reduction,NN,O
tests,NNS,O
-lrb-,-LRB-,O
benedicts,NNS,O
or,CC,O
fehlings,NNS,O
solution,NN,O
or,CC,O
with,IN,O
clinitest,NN,O
tablets,NNS,O
-rrb-,-RRB-,O
",",",",O
but,CC,O
not,RB,O
with,IN,O
enzyme-based,JJ,O
tests,NNS,O
for,IN,O
glycosuria,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
clinistix,NN,O
",",",",O
tes-tape,NN,O
-rrb-,-RRB-,O
.,.,.
,,
as,IN,O
a,DT,O
false-negative,JJ,O
result,NN,O
may,MD,O
occur,VB,O
in,IN,O
the,DT,O
ferricyanide,JJ,O
test,NN,O
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
either,CC,O
the,DT,O
glucose,NN,O
oxidase,NN,O
or,CC,O
hexokinase,NN,O
method,NN,O
be,VB,O
used,VBN,O
to,TO,O
determine,VB,O
blood/plasma,NN,O
glucose,NN,O
levels,NNS,O
in,IN,O
patients,NNS,O
receiving,VBG,O
cefditoren,NN,D
pivoxil,NN,O
.,.,.
,,
renal,JJ,O
function,NN,O
should,MD,O
be,VB,O
monitored,VBN,O
carefully,RB,O
if,IN,O
high,JJ,O
doses,NNS,O
of,IN,O
aminoglycosides,NNS,G
are,VBP,O
to,TO,O
be,VB,O
administered,VBN,O
with,IN,O
maxipime,NN,B
because,IN,O
of,IN,O
the,DT,O
increased,VBN,O
potential,NN,O
of,IN,O
nephrotoxicity,NN,O
and,CC,O
ototoxicity,NN,O
of,IN,O
aminoglycoside,NN,G
antibiotics,NNS,G
.,.,.
,,
nephrotoxicity,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
following,VBG,O
concomitant,JJ,O
administration,NN,O
of,IN,O
other,JJ,O
cephalosporins,NNS,G
with,IN,O
potent,JJ,O
diuretics,NNS,G
such,JJ,O
as,IN,O
furosemide,NN,D
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
the,DT,O
administration,NN,O
of,IN,O
cefepime,NN,D
may,MD,O
result,VB,O
in,IN,O
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
the,DT,O
urine,NN,O
when,WRB,O
using,VBG,O
clinitest,NNP,O
tablets,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
glucose,NN,O
tests,NNS,O
based,VBN,O
on,IN,O
enzymatic,JJ,O
glucose,NN,O
oxidase,NN,O
reactions,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
clinistix,NNP,O
or,CC,O
tes-tape,NNP,O
-rrb-,-RRB-,O
be,VB,O
used,VBN,O
.,.,.
,,
carbamazepine,NNP,D
:,:,O
elevated,JJ,O
carbamazepine,NN,D
levels,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
postmarketing,VBG,O
experience,NN,O
when,WRB,O
suprax,NNP,B
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
drug,NN,O
monitoring,NN,O
may,MD,O
be,VB,O
of,IN,O
assistance,NN,O
in,IN,O
detecting,VBG,O
alterations,NNS,O
in,IN,O
carbamazepine,NN,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
warfarin,NNP,D
and,CC,O
anticoagulants,NNPS,G
:,:,O
increased,VBN,O
prothrombin,NN,O
time,NN,O
",",",",O
with,IN,O
or,CC,O
without,IN,O
clinical,JJ,O
bleeding,NN,O
",",",",O
has,VBZ,O
been,VBN,O
reported,VBN,O
when,WRB,O
cefixime,NN,D
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
ketones,NNS,O
in,IN,O
the,DT,O
urine,NN,O
may,MD,O
occur,VB,O
with,IN,O
tests,NNS,O
using,VBG,O
nitroprusside,NN,D
but,CC,O
not,RB,O
with,IN,O
those,DT,O
using,VBG,O
nitroferricyanide,NN,D
.,.,.
,,
the,DT,O
administration,NN,O
of,IN,O
suprax,NNP,B
may,MD,O
result,VB,O
in,IN,O
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
the,DT,O
urine,NN,O
using,VBG,O
clinitest,NNP,O
**,SYM,O
",",",",O
benedict,NNP,O
s,VBZ,O
solution,NN,O
",",",",O
or,CC,O
fehling,NN,O
s,NNS,O
solution,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
glucose,NN,O
tests,NNS,O
based,VBN,O
on,IN,O
enzymatic,JJ,O
glucose,NN,O
oxidase,NN,O
reactions,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
clinistix,NNP,O
**,SYM,O
or,CC,O
tes-tape,JJ,O
**,SYM,O
-rrb-,-RRB-,O
be,VB,O
used,VBN,O
.,.,.
,,
a,DT,O
false-positive,JJ,O
direct,JJ,O
coombs,NNS,O
test,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
during,IN,O
treatment,NN,O
with,IN,O
other,JJ,O
cephalosporin,NN,G
antibiotics,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
it,PRP,O
should,MD,O
be,VB,O
recognized,VBN,O
that,IN,O
a,DT,O
positive,JJ,O
coombs,NNP,O
test,NN,O
may,MD,O
be,VB,O
due,JJ,O
to,TO,O
the,DT,O
drug,NN,D
.,.,.
,,
increased,VBN,O
nephrotoxicity,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
following,VBG,O
concomitant,JJ,O
administration,NN,O
of,IN,O
cephalosporins,NNS,G
and,CC,O
aminoglycoside,NN,G
antibiotics,NNS,G
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
cephalosporins,NNS,G
",",",",O
including,VBG,O
cefotaxime,NN,O
sodium,NN,O
",",",",O
are,VBP,O
known,VBN,O
to,TO,O
occasionally,RB,O
induce,VB,O
a,DT,O
positive,JJ,O
direct,JJ,O
coombs,NNS,O
test,NN,O
.,.,.
,,
increases,NNS,O
in,IN,O
serum,NN,O
creatinine,NN,O
have,VBP,O
occurred,VBN,O
when,WRB,O
cefotan,NNP,B
was,VBD,O
given,VBN,O
alone,RB,O
.,.,.
,,
if,IN,O
cefotan,NNP,B
and,CC,O
an,DT,O
aminoglycoside,NN,G
are,VBP,O
used,VBN,O
concomitantly,RB,O
",",",",O
renal,JJ,O
function,NN,O
should,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
",",",",O
because,IN,O
nephrotoxicity,NN,O
may,MD,O
be,VB,O
potentiated,VBN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
:,:,O
the,DT,O
administration,NN,O
of,IN,O
cefotan,NNP,B
may,MD,O
result,VB,O
in,IN,O
a,DT,O
FALSE,JJ,O
positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
the,DT,O
urine,NN,O
using,VBG,O
clinitest,NNP,O
",",",",O
benedicts,NNP,O
solution,NN,O
",",",",O
or,CC,O
fehlings,NNP,O
solution,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
glucose,NN,O
tests,NNS,O
based,VBN,O
on,IN,O
enzymatic,JJ,O
glucose,NN,O
oxidase,NN,O
be,VB,O
used,VBN,O
.,.,.
,,
as,IN,O
with,IN,O
other,JJ,O
cephalosporins,NNS,G
",",",",O
high,JJ,O
concentrations,NNS,O
of,IN,O
cefotetan,NN,D
may,MD,O
interfere,VB,O
with,IN,O
measurement,NN,O
of,IN,O
serum,NN,O
and,CC,O
urine,NN,O
creatinine,NN,O
levels,NNS,O
by,IN,O
jaffe,NNP,O
reaction,NN,O
and,CC,O
produce,VBP,O
FALSE,JJ,O
increases,NNS,O
in,IN,O
the,DT,O
levels,NNS,O
of,IN,O
creatinine,NN,O
reported,VBD,O
.,.,.
,,
increased,VBN,O
nephrotoxicity,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
following,VBG,O
concomitant,JJ,O
administration,NN,O
of,IN,O
cephalosporins,NNS,G
and,CC,O
aminoglycoside,NN,G
antibiotics,NNS,G
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
as,IN,O
with,IN,O
cephalothin,NN,D
",",",",O
high,JJ,O
concentrations,NNS,O
of,IN,O
cefoxitin,NN,D
-lrb-,-LRB-,O
100,CD,O
micrograms/ml,NNS,O
-rrb-,-RRB-,O
may,MD,O
interfere,VB,O
with,IN,O
measurement,NN,O
of,IN,O
serum,NN,O
and,CC,O
urine,NN,O
creatinine,NN,O
levels,NNS,O
by,IN,O
the,DT,O
jaff,NNP,O
reaction,NN,O
",",",",O
and,CC,O
produce,VBP,O
FALSE,JJ,O
increases,NNS,O
of,IN,O
modest,JJ,O
degree,NN,O
in,IN,O
the,DT,O
levels,NNS,O
of,IN,O
creatinine,NN,O
reported,VBD,O
.,.,.
,,
serum,NN,O
samples,NNS,O
from,IN,O
patients,NNS,O
treated,VBN,O
with,IN,O
cefoxitin,NN,D
should,MD,O
not,RB,O
be,VB,O
analyzed,VBN,O
for,IN,O
creatinine,NN,O
if,IN,O
withdrawn,VBN,O
within,IN,O
2,CD,O
hours,NNS,O
of,IN,O
drug,NN,D
administration,NN,O
.,.,.
,,
high,JJ,O
concentrations,NNS,O
of,IN,O
cefoxitin,NN,D
in,IN,O
the,DT,O
urine,NN,O
may,MD,O
interfere,VB,O
with,IN,O
measurement,NN,O
of,IN,O
urinary,JJ,O
17-hydroxy-corticosteroids,NNS,O
by,IN,O
the,DT,O
porter-silber,NNP,O
reaction,NN,O
",",",",O
and,CC,O
produce,VBP,O
FALSE,JJ,O
increases,NNS,O
of,IN,O
modest,JJ,O
degree,NN,O
in,IN,O
the,DT,O
levels,NNS,O
reported,VBD,O
.,.,.
,,
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
the,DT,O
urine,NN,O
may,MD,O
occur,VB,O
.,.,.
,,
this,DT,O
has,VBZ,O
been,VBN,O
observed,VBN,O
with,IN,O
clinitest,NN,O
reagent,NN,O
tablets,NNS,O
.,.,.
,,
registered,NNP,O
trademark,NN,O
of,IN,O
ames,NNP,O
company,NNP,O
",",",",O
division,NNP,O
of,IN,O
miles,NNP,O
laboratories,NNPS,O
",",",",O
inc.,NNP,O
.,.,.
,,
nephrotoxicity,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
following,VBG,O
concomitant,JJ,O
administration,NN,O
of,IN,O
aminoglycoside,NN,G
antibiotics,NNS,G
and,CC,O
cephalosporin,NN,G
antibiotics,NNS,G
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
probenecid,NN,D
doubled,VBD,O
the,DT,O
auc,NN,O
for,IN,O
cefprozil,NN,D
.,.,.
,,
the,DT,O
bioavailability,NN,O
of,IN,O
the,DT,O
capsule,NN,O
formulation,NN,O
of,IN,O
cefprozil,NN,D
was,VBD,O
not,RB,O
affected,VBN,O
when,WRB,O
administered,VBN,O
5,CD,O
minutes,NNS,O
following,VBG,O
an,DT,O
antacid,NN,G
.,.,.
,,
nephrotoxicity,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
following,VBG,O
concomitant,JJ,O
administration,NN,O
of,IN,O
cephalosporins,NNS,G
with,IN,O
aminoglycoside,NN,G
antibiotics,NNS,G
or,CC,O
potent,JJ,O
diuretics,NNS,G
such,JJ,O
as,IN,O
furosemide,NN,D
.,.,.
,,
renal,JJ,O
function,NN,O
should,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
",",",",O
especially,RB,O
if,IN,O
higher,JJR,O
dosages,NNS,O
of,IN,O
the,DT,O
aminoglycosides,NNS,G
are,VBP,O
to,TO,O
be,VB,O
administered,VBN,O
or,CC,O
if,IN,O
therapy,NN,O
is,VBZ,O
prolonged,VBN,O
",",",",O
because,IN,O
of,IN,O
the,DT,O
potential,JJ,O
nephrotoxicity,NN,O
and,CC,O
ototoxicity,NN,O
of,IN,O
aminoglycosidic,JJ,O
antibiotics,NNS,G
.,.,.
,,
nephrotoxicity,NN,O
and,CC,O
ototoxicity,NN,O
were,VBD,O
not,RB,O
noted,VBN,O
when,WRB,O
ceftazidime,NN,D
was,VBD,O
given,VBN,O
alone,RB,O
in,IN,O
clinical,JJ,O
trials,NNS,O
.,.,.
,,
chloramphenicol,NN,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
be,VB,O
antagonistic,JJ,O
to,TO,O
beta-lactam,JJ,O
antibiotics,NNS,G
",",",",O
including,VBG,O
ceftazidime,NN,D
",",",",O
based,VBN,O
on,IN,O
in,FW,O
vitro,FW,O
studies,NNS,O
and,CC,O
time,NN,O
kill,VBP,O
curves,NNS,O
with,IN,O
enteric,JJ,O
gram-negative,JJ,O
bacilli,NNS,O
.,.,.
,,
due,JJ,O
to,TO,O
the,DT,O
possibility,NN,O
of,IN,O
antagonism,NN,O
in,FW,O
vivo,FW,O
",",",",O
particularly,RB,O
when,WRB,O
bactericidal,JJ,O
activity,NN,O
is,VBZ,O
desired,VBN,O
",",",",O
this,DT,O
drug,NN,D
combination,NN,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
the,DT,O
administration,NN,O
of,IN,O
ceftazidime,NN,D
may,MD,O
result,VB,O
in,IN,O
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
the,DT,O
urine,NN,O
when,WRB,O
using,VBG,O
clinitest,NN,O
tablets,NNS,O
",",",",O
benedicts,NNP,O
solution,NN,O
",",",",O
or,CC,O
fehlings,NNP,O
solution,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
glucose,NN,O
tests,NNS,O
based,VBN,O
on,IN,O
enzymatic,JJ,O
glucose,NN,O
oxidase,NN,O
reactions,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
clinistix,NN,O
or,CC,O
tes-tape,NN,O
-rrb-,-RRB-,O
be,VB,O
used,VBN,O
.,.,.
,,
theophylline,NNP,D
:,:,O
twelve,CD,O
healthy,JJ,O
male,JJ,O
volunteers,NNS,O
were,VBD,O
administered,VBN,O
one,CD,O
200-mg,JJ,O
ceftibuten,NN,D
capsule,NN,O
twice,RB,O
daily,RB,O
for,IN,O
6,CD,O
days,NNS,O
.,.,.
,,
with,IN,O
the,DT,O
morning,NN,O
dose,NN,O
of,IN,O
ceftibuten,NN,D
on,IN,O
day,NN,O
6,CD,O
",",",",O
each,DT,O
volunteer,NN,O
received,VBD,O
a,DT,O
single,JJ,O
intravenous,JJ,O
infusion,NN,O
of,IN,O
theophylline,NN,D
-lrb-,-LRB-,O
4,CD,O
mg/kg,NN,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
theophylline,NN,D
were,VBD,O
not,RB,O
altered,VBN,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
ceftibuten,NN,D
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
theophylline,NN,D
administered,VBN,O
orally,RB,O
has,VBZ,O
not,RB,O
been,VBN,O
investigated,VBN,O
.,.,.
,,
antacids,NNS,G
or,CC,O
h,NN,O
2,CD,O
-,:,O
receptor,NN,D
antagonists,NNS,O
:,:,O
the,DT,O
effect,NN,O
of,IN,O
increased,VBN,O
gastric,JJ,O
ph,NN,O
on,IN,O
the,DT,O
bioavailability,NN,O
of,IN,O
ceftibuten,NN,D
was,VBD,O
evaluated,VBN,O
in,IN,O
18,CD,O
healthy,JJ,O
adult,JJ,O
volunteers,NNS,O
.,.,.
,,
each,DT,O
volunteer,NN,O
was,VBD,O
administered,VBN,O
one,CD,O
400-mg,JJ,O
ceftibuten,NN,D
capsule,NN,O
.,.,.
,,
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
liquid,JJ,O
antacid,NN,G
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
c,NN,O
max,NN,O
or,CC,O
auc,NN,O
of,IN,O
ceftibuten,NN,D
.,.,.
,,
however,RB,O
",",",",O
150,CD,O
mg,NN,O
of,IN,O
ranitidine,NN,D
q12h,NN,O
for,IN,O
3,CD,O
days,NNS,O
increased,VBD,O
the,DT,O
ceftibuten,NN,D
c,NN,O
max,NN,O
by,IN,O
23,CD,O
%,NN,O
and,CC,O
ceftibuten,NN,D
auc,NN,O
by,IN,O
16,CD,O
%,NN,O
.,.,.
,,
the,DT,O
clinical,JJ,O
relevance,NN,O
of,IN,O
these,DT,O
increases,NNS,O
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
:,:,O
there,EX,O
have,VBP,O
been,VBN,O
no,DT,O
chemical,NN,O
or,CC,O
laboratory,NN,O
test,NN,O
interactions,NNS,O
with,IN,O
ceftibuten,NN,D
noted,VBD,O
to,TO,O
date,NN,O
.,.,.
,,
false-positive,JJ,O
direct,JJ,O
coombs,NNP,O
tests,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
during,IN,O
treatment,NN,O
with,IN,O
other,JJ,O
cephalosporins,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
it,PRP,O
should,MD,O
be,VB,O
recognized,VBN,O
that,IN,O
a,DT,O
positive,JJ,O
coombs,NNP,O
test,NN,O
could,MD,O
be,VB,O
due,JJ,O
to,TO,O
the,DT,O
drug,NN,D
.,.,.
,,
the,DT,O
results,NNS,O
of,IN,O
assays,NNS,O
using,VBG,O
red,JJ,O
cells,NNS,O
from,IN,O
healthy,JJ,O
subjects,NNS,O
to,TO,O
determine,VB,O
whether,IN,O
ceftibuten,NN,D
would,MD,O
cause,VB,O
direct,JJ,O
coombs,NNP,O
reactions,NNS,O
in,FW,O
vitro,FW,O
showed,VBD,O
no,DT,O
positive,JJ,O
reaction,NN,O
at,IN,O
ceftibuten,NN,D
concentrations,NNS,O
as,IN,O
high,JJ,O
as,IN,O
40,CD,O
g/ml,NN,O
.,.,.
,,
although,IN,O
the,DT,O
occurrence,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
reported,VBN,O
with,IN,O
cefizox,NN,B
",",",",O
nephrotoxicity,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
following,VBG,O
concomitant,JJ,O
administration,NN,O
of,IN,O
other,JJ,O
cephalosporins,NNS,G
and,CC,O
aminoglycosides,NNS,G
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
:,:,O
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
the,DT,O
urine,NN,O
may,MD,O
occur,VB,O
with,IN,O
copper,NN,O
reduction,NN,O
tests,NNS,O
-lrb-,-LRB-,O
benedict,NNP,O
s,NNS,O
or,CC,O
fehling,NN,O
s,NNS,O
solution,NN,O
or,CC,O
with,IN,O
clinitest,NNP,O
tablets,NNS,O
-rrb-,-RRB-,O
but,CC,O
not,RB,O
with,IN,O
enzyme-based,JJ,O
tests,NNS,O
for,IN,O
glycosuria,NN,O
.,.,.
,,
as,IN,O
a,DT,O
false-negative,JJ,O
result,NN,O
may,MD,O
occur,VB,O
in,IN,O
the,DT,O
ferricyanide,JJ,O
test,NN,O
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
either,CC,O
the,DT,O
glucose,NN,O
oxidase,NN,O
or,CC,O
hexokinase,NN,O
method,NN,O
be,VB,O
used,VBN,O
to,TO,O
determine,VB,O
blood,NN,O
plasma,NN,O
glucose,NN,O
levels,NNS,O
in,IN,O
patients,NNS,O
receiving,VBG,O
cefuroxime,NN,D
.,.,.
,,
cefuroxime,RB,D
does,VBZ,O
not,RB,O
interfere,VB,O
with,IN,O
the,DT,O
assay,NN,O
of,IN,O
serum,NN,O
and,CC,O
urine,NN,O
creatinine,NN,O
by,IN,O
the,DT,O
alkaline,NN,O
picrate,NN,O
method,NN,O
.,.,.
,,
general,NNP,O
:,:,O
significant,JJ,O
interactions,NNS,O
may,MD,O
occur,VB,O
when,WRB,O
celecoxib,NN,D
is,VBZ,O
administered,VBN,O
together,RB,O
with,IN,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
p450,NN,O
2c9,NN,O
.,.,.
,,
celecoxib,NNP,D
metabolism,NN,O
is,VBZ,O
predominantly,RB,O
mediated,VBN,O
via,IN,O
cytochrome,NN,O
p450,NN,O
2c9,NN,O
in,IN,O
the,DT,O
liver,NN,O
.,.,.
,,
co-administration,NN,O
of,IN,O
celecoxib,NN,D
with,IN,O
drugs,NNS,D
that,WDT,O
are,VBP,O
known,VBN,O
to,TO,O
inhibit,VB,O
2c9,NN,O
should,MD,O
be,VB,O
done,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
indicate,VBP,O
that,IN,O
celecoxib,NN,D
is,VBZ,O
not,RB,O
an,DT,O
inhibitor,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
2c9,NN,O
",",",",O
2c19,NN,O
or,CC,O
3a4,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
also,RB,O
indicate,VBP,O
that,IN,O
celecoxib,NN,D
",",",",O
although,IN,O
not,RB,O
a,DT,O
substrate,NN,O
",",",",O
is,VBZ,O
an,DT,O
inhibitor,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
there,EX,O
is,VBZ,O
a,DT,O
potential,NN,O
for,IN,O
an,DT,O
in,FW,O
vivo,FW,O
drug,NN,D
interaction,NN,O
with,IN,O
drugs,NNS,D
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
p450,NN,O
2d6,NN,O
.,.,.
,,
clinical,JJ,O
studies,NNS,O
with,IN,O
celecoxib,NNS,D
have,VBP,O
identified,VBN,O
potentially,RB,O
significant,JJ,O
interactions,NNS,O
with,IN,O
fluconazole,NN,D
and,CC,O
lithium,NN,D
.,.,.
,,
experience,NN,O
with,IN,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
-lrb-,-LRB-,O
nsaids,NNS,G
-rrb-,-RRB-,O
suggests,VBZ,O
the,DT,O
potential,NN,O
for,IN,O
interactions,NNS,O
with,IN,O
furosemide,NN,D
and,CC,O
ace,NN,O
inhibitors,NNS,O
.,.,.
,,
the,DT,O
effects,NNS,O
celecoxib,VBP,D
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
and/or,CC,O
pharmacodynamics,NNS,O
of,IN,O
glyburide,NN,D
",",",",O
ketoconazole,NN,D
",",",",O
methotrexate,NN,D
",",",",O
phenytoin,NN,D
",",",",O
tolbutamide,NN,D
",",",",O
and,CC,O
warfarin,NN,D
have,VBP,O
been,VBN,O
studied,VBN,O
in,FW,O
vivo,FW,O
and,CC,O
clinically,RB,O
important,JJ,O
interactions,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
found,VBN,O
.,.,.
,,
ace,NN,O
inhibitors,NNS,O
:,:,O
reports,NNS,O
suggest,VBP,O
that,IN,O
nsaids,NNS,G
may,MD,O
diminish,VB,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
angiotensin,NN,O
converting,VBG,O
enzyme,NN,O
-lrb-,-LRB-,O
ace,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
.,.,.
,,
this,DT,O
interaction,NN,O
should,MD,O
be,VB,O
given,VBN,O
consideration,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
celebrex,NNP,B
concomitantly,RB,O
with,IN,O
ace-inhibitors,NNS,G
.,.,.
,,
furosemide,NNP,D
:,:,O
clinical,JJ,O
studies,NNS,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
post,NN,O
marketing,NN,O
observations,NNS,O
",",",",O
have,VBP,O
shown,VBN,O
that,IN,O
nsaids,NNS,G
can,MD,O
reduce,VB,O
the,DT,O
natriuretic,JJ,O
effect,NN,O
of,IN,O
furosemide,NN,D
and,CC,O
thiazides,NNS,G
in,IN,O
some,DT,O
patients,NNS,O
.,.,.
,,
this,DT,O
response,NN,O
has,VBZ,O
been,VBN,O
attributed,VBN,O
to,TO,O
inhibition,NN,O
of,IN,O
renal,JJ,O
prostaglandin,NN,O
synthesis,NN,O
.,.,.
,,
aspirin,NN,B
:,:,O
celebrex,NNP,B
can,MD,O
be,VB,O
used,VBN,O
with,IN,O
low,JJ,O
dose,NN,O
aspirin,NN,B
.,.,.
,,
however,RB,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
aspirin,NN,B
with,IN,O
celebrex,NNP,B
may,MD,O
result,VB,O
in,IN,O
an,DT,O
increased,VBN,O
rate,NN,O
of,IN,O
gi,NN,O
ulceration,NN,O
or,CC,O
other,JJ,O
complications,NNS,O
",",",",O
compared,VBN,O
to,TO,O
use,VB,O
of,IN,O
celebrex,NNP,B
alone,RB,O
.,.,.
,,
because,IN,O
of,IN,O
its,PRP$,O
lack,NN,O
of,IN,O
platelet,NN,O
effects,NNS,O
",",",",O
celebrex,NNP,B
is,VBZ,O
not,RB,O
a,DT,O
substitute,NN,O
for,IN,O
aspirin,NN,B
for,IN,O
cardiovascular,JJ,O
prophylaxis,NN,O
.,.,.
,,
fluconazole,NNP,D
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
fluconazole,NN,D
at,IN,O
200,CD,O
mg,NN,O
qd,NN,O
resulted,VBD,O
in,IN,O
a,DT,O
two-fold,JJ,O
increase,NN,O
in,IN,O
celecoxib,NN,D
plasma,NN,O
concentration,NN,O
.,.,.
,,
this,DT,O
increase,NN,O
is,VBZ,O
due,JJ,O
to,TO,O
the,DT,O
inhibition,NN,O
of,IN,O
celecoxib,NN,D
metabolism,NN,O
via,IN,O
p450,NN,O
2c9,NN,O
by,IN,O
fluconazole,NN,D
-lrb-,-LRB-,O
see,VB,O
clinical,NNP,O
pharmacology,NNP,O
-,:,O
pharmacokinetics,NNS,O
:,:,O
metabolism,NN,O
-rrb-,-RRB-,O
.,.,.
,,
celebrex,NNP,B
should,MD,O
be,VB,O
introduced,VBN,O
at,IN,O
the,DT,O
lowest,JJS,O
recommended,VBN,O
dose,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
fluconazole,NN,D
.,.,.
,,
lithium,NN,D
:,:,O
in,IN,O
a,DT,O
study,NN,O
conducted,VBN,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
",",",",O
mean,VB,O
steady-state,JJ,O
lithium,NN,D
plasma,NN,O
levels,NNS,O
increased,VBD,O
approximately,RB,O
17,CD,O
%,NN,O
in,IN,O
subjects,NNS,O
receiving,VBG,O
lithium,NN,D
450,CD,O
mg,NN,O
bid,NNP,O
with,IN,O
celebrex,NNP,B
200,CD,O
mg,NN,O
bid,NNP,O
as,IN,O
compared,VBN,O
to,TO,O
subjects,NNS,O
receiving,VBG,O
lithium,NN,D
alone,RB,O
.,.,.
,,
patients,NNS,O
on,IN,O
lithium,NN,D
treatment,NN,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
when,WRB,O
celebrex,NNP,B
is,VBZ,O
introduced,VBN,O
or,CC,O
withdrawn,VBN,O
.,.,.
,,
methotrexate,NNP,D
:,:,O
in,IN,O
an,DT,O
interaction,NN,O
study,NN,O
of,IN,O
rheumatoid,JJ,O
arthritis,NN,O
patients,NNS,O
taking,VBG,O
methotrexate,NN,D
",",",",O
celebrex,NNP,B
did,VBD,O
not,RB,O
have,VB,O
a,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
methotrexate,NN,D
.,.,.
,,
warfarin,NNP,D
:,:,O
the,DT,O
effect,NN,O
of,IN,O
celecoxib,NN,D
on,IN,O
the,DT,O
anti-coagulant,JJ,O
effect,NN,O
of,IN,O
warfarin,NN,D
was,VBD,O
studied,VBN,O
in,IN,O
a,DT,O
group,NN,O
of,IN,O
healthy,JJ,O
subjects,NNS,O
receiving,VBG,O
daily,JJ,O
doses,NNS,O
of,IN,O
5-Feb,CD,O
mg,NN,O
of,IN,O
warfarin,NN,D
.,.,.
,,
in,IN,O
these,DT,O
subjects,NNS,O
",",",",O
celecoxib,NN,D
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
anticoagulant,JJ,G
effect,NN,O
of,IN,O
warfarin,NN,D
as,IN,O
determined,VBN,O
by,IN,O
prothrombin,NN,O
time,NN,O
.,.,.
,,
however,RB,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
when,WRB,O
administering,VBG,O
celebrex,NN,B
with,IN,O
warfarin,NN,D
since,IN,O
these,DT,O
patients,NNS,O
are,VBP,O
at,IN,O
increased,VBN,O
risk,NN,O
of,IN,O
bleeding,VBG,O
complications,NNS,O
.,.,.
,,
metformin,NNP,D
:,:,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
given,VBN,O
single,JJ,O
500,CD,O
mg,NN,O
doses,NNS,O
of,IN,O
cephalexin,NN,D
and,CC,O
metformin,NN,D
",",",",O
plasma,NN,O
metformin,NN,D
mean,VB,O
cmax,NN,O
and,CC,O
auc,NN,O
increased,VBN,O
by,IN,O
an,DT,O
average,NN,O
of,IN,O
34,CD,O
%,NN,O
and,CC,O
24,CD,O
%,NN,O
",",",",O
respectively,RB,O
",",",",O
and,CC,O
metformin,NN,D
mean,VBP,O
renal,JJ,O
clearance,NN,O
decreased,VBN,O
by,IN,O
14,CD,O
%,NN,O
.,.,.
,,
no,DT,O
information,NN,O
is,VBZ,O
available,JJ,O
about,IN,O
the,DT,O
interaction,NN,O
of,IN,O
cephalexin,NN,D
and,CC,O
metformin,NN,D
following,VBG,O
multiple,JJ,O
doses,NNS,O
of,IN,O
either,CC,O
drug,NN,D
.,.,.
,,
although,IN,O
not,RB,O
observed,VBN,O
in,IN,O
this,DT,O
study,NN,O
",",",",O
adverse,JJ,O
effects,NNS,O
could,MD,O
potentially,RB,O
arise,VB,O
from,IN,O
co-administration,NN,O
of,IN,O
cephalexin,NN,D
and,CC,O
metformin,NN,D
by,IN,O
inhibition,NN,O
of,IN,O
tubular,JJ,O
secretion,NN,O
via,IN,O
organic,JJ,O
cationic,JJ,O
transporter,NN,O
systems,NNS,O
.,.,.
,,
accordingly,RB,O
",",",",O
careful,JJ,O
patient,NN,O
monitoring,NN,O
and,CC,O
dose,NN,O
adjustment,NN,O
of,IN,O
metformin,NN,D
is,VBZ,O
recommended,VBN,O
in,IN,O
patients,NNS,O
concomitantly,RB,O
taking,VBG,O
cephalexin,NN,D
and,CC,O
metformin,NN,D
.,.,.
,,
probenecid,NNP,D
:,:,O
as,IN,O
with,IN,O
other,JJ,O
b-lactams,NNS,G
",",",",O
the,DT,O
renal,JJ,O
excretion,NN,O
of,IN,O
cephalexin,NN,D
is,VBZ,O
inhibited,VBN,O
by,IN,O
probenecid,NN,D
.,.,.
,,
drug,NN,O
/,:,O
laboratory,NNP,O
test,NNP,O
interactions,NNS,O
as,IN,O
a,DT,O
result,NN,O
of,IN,O
administration,NN,O
of,IN,O
keflex,NNP,B
",",",",O
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
the,DT,O
urine,NN,O
may,MD,O
occur,VB,O
.,.,.
,,
this,DT,O
has,VBZ,O
been,VBN,O
observed,VBN,O
with,IN,O
benedict,NNP,O
s,NNS,O
and,CC,O
fehling,NN,O
s,NNS,O
solutions,NNS,O
and,CC,O
also,RB,O
with,IN,O
clinitest,NNP,O
tablets,NNS,O
.,.,.
,,
immunosuppressive,JJ,D
drugs,NNS,O
",",",",O
fibric,JJ,O
acid,NN,O
derivatives,NNS,O
",",",",O
niacin,NN,D
-lrb-,-LRB-,O
nicotinic,JJ,O
acid,NN,O
",",",",O
erythromycin,NNP,D
",",",",O
azole,NNP,O
antifungals,NNPS,G
:,:,O
skeletal,JJ,O
muscle,NN,O
.,.,.
,,
antacid,NN,G
-lrb-,-LRB-,O
magnesium-aluminum,NNP,O
hydroxide,NNP,O
-rrb-,-RRB-,O
:,:,O
cerivastatin,NNP,D
plasma,NN,O
concentrations,NNS,O
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
co-administration,NN,O
of,IN,O
antacid,NN,G
.,.,.
,,
cimetldine,NNP,D
:,:,O
cerivastatin,NNP,D
plasma,NN,O
concentrations,NNS,O
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
co-administration,NN,O
of,IN,O
cimetidine,NN,D
.,.,.
,,
cholestyramine,NNP,D
:,:,O
the,DT,O
influence,NN,O
of,IN,O
the,DT,O
bile-acidsequestering,JJ,O
agent,NN,O
cholestyramine,NN,D
on,IN,O
the,DT,O
pharmacokinetits,NNS,O
of,IN,O
cerivastatin,NN,D
sodium,NN,O
was,VBD,O
evaluated,VBN,O
in,IN,O
12,CD,O
healthy,JJ,O
males,NNS,O
in,IN,O
2,CD,O
separate,JJ,O
randomized,JJ,O
crossover,NN,O
studies,NNS,O
.,.,.
,,
in,IN,O
the,DT,O
first,JJ,O
study,NN,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
0.2,CD,O
mg,NN,O
cerivastatin,NN,D
sodium,NN,O
and,CC,O
12,CD,O
g,NN,O
cholestyramine,NN,D
resulted,VBD,O
in,IN,O
decreases,NNS,O
of,IN,O
more,JJR,O
than,IN,O
22,CD,O
%,NN,O
for,IN,O
auc,NN,O
and,CC,O
40,CD,O
%,NN,O
for,IN,O
cmax,NNP,O
when,WRB,O
compared,VBN,O
to,TO,O
dosing,NN,O
cerivastatin,NN,D
sodium,NN,O
alone,RB,O
.,.,.
,,
however,RB,O
",",",",O
in,IN,O
the,DT,O
second,JJ,O
study,NN,O
",",",",O
administration,NN,O
of,IN,O
12,CD,O
g,NN,O
cholestyramine,NN,D
1,CD,O
hour,NN,O
before,IN,O
the,DT,O
evening,NN,O
meal,NN,O
and,CC,O
0.3,CD,O
mg,NN,O
cerivastatin,NN,D
sodium,NN,O
approximately,RB,O
4,CD,O
hours,NNS,O
after,IN,O
the,DT,O
same,JJ,O
evening,NN,O
meal,NN,O
resulted,VBD,O
in,IN,O
a,DT,O
decrease,NN,O
in,IN,O
the,DT,O
cerivastatin,NN,D
auc,NN,O
of,IN,O
less,JJR,O
than,IN,O
8,CD,O
%,NN,O
",",",",O
and,CC,O
a,DT,O
decrease,NN,O
in,IN,O
cmax,NN,O
of,IN,O
about,IN,O
30,CD,O
%,NN,O
when,WRB,O
compared,VBN,O
to,TO,O
dosing,NN,O
cerivastatin,NN,D
sodium,NN,O
alone,RB,O
.,.,.
,,
therefore,RB,O
",",",",O
it,PRP,O
would,MD,O
be,VB,O
expected,VBN,O
that,IN,O
a,DT,O
dosing,NN,O
schedule,NN,O
of,IN,O
cerivastatin,NN,D
sodium,NN,O
given,VBN,O
at,IN,O
bedtime,NN,O
and,CC,O
cholestyramine,NN,D
given,VBN,O
before,IN,O
the,DT,O
evening,NN,O
meal,NN,O
would,MD,O
not,RB,O
result,VB,O
in,IN,O
a,DT,O
significant,JJ,O
decrease,NN,O
in,IN,O
the,DT,O
clinical,JJ,O
effect,NN,O
of,IN,O
cerivastatin,NN,D
sodium,NN,O
.,.,.
,,
digoxin,NNP,D
:,:,O
plasma,NN,O
digoxin,NN,D
levels,NNS,O
and,CC,O
digoxin,NN,D
clearance,NN,O
at,IN,O
steady-state,JJ,O
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
co-administration,NN,O
of,IN,O
0.2,CD,O
mg,NN,O
cerivastatin,NN,D
sodium,NN,O
.,.,.
,,
cerivastatin,NNP,D
plasma,NN,O
concentrations,NNS,O
were,VBD,O
also,RB,O
not,RB,O
affected,VBN,O
by,IN,O
co-administration,NN,O
of,IN,O
digoxin,NN,D
.,.,.
,,
warfarin,NNP,D
:,:,O
co,NNP,O
-,:,O
administration,NN,O
of,IN,O
warfarin,NN,D
and,CC,O
cerivastatin,NN,D
to,TO,O
healthy,JJ,O
volunteers,NNS,O
did,VBD,O
not,RB,O
result,VB,O
in,IN,O
any,DT,O
changes,NNS,O
in,IN,O
prothrombin,NN,O
time,NN,O
or,CC,O
clotting,NN,O
factor,NN,O
vii,NN,O
when,WRB,O
compared,VBN,O
to,TO,O
co-administration,NN,O
of,IN,O
warfarin,NN,D
and,CC,O
placebo,NN,O
.,.,.
,,
the,DT,O
auc,NN,O
and,CC,O
cmax,NN,O
of,IN,O
both,CC,O
the,DT,O
-lrb-,-LRB-,O
r,NN,O
-rrb-,-RRB-,O
and,CC,O
-lrb-,-LRB-,O
s,NN,O
-rrb-,-RRB-,O
isomers,NNS,O
of,IN,O
warfarin,NN,D
were,VBD,O
unaffected,JJ,O
by,IN,O
concurrent,JJ,O
dosing,NN,O
of,IN,O
0.3,CD,O
mg,NN,O
cerivastatin,NN,D
sodium,NN,O
.,.,.
,,
co-administration,NN,O
of,IN,O
warfarin,NN,D
and,CC,O
cerivastatin,NN,D
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
cerivastatin,NN,D
sodium,NN,O
.,.,.
,,
erythromycin,NNP,D
:,:,O
in,IN,O
hypercholesterolemic,JJ,O
patients,NNS,O
",",",",O
steady-state,JJ,O
cerivastatin,NN,D
auc,NN,O
and,CC,O
cmax,NN,O
increased,VBD,O
approximately,RB,O
50,CD,O
%,NN,O
and,CC,O
24,CD,O
%,NN,O
respectively,RB,O
after,IN,O
10,CD,O
days,NNS,O
with,IN,O
co-administration,NN,O
of,IN,O
erythromycin,NN,D
",",",",O
a,DT,O
known,JJ,O
inhibitor,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
.,.,.
,,
other,JJ,O
concomitant,JJ,O
therapy,NN,O
:,:,O
although,IN,O
specific,JJ,O
interaction,NN,O
studies,NNS,O
were,VBD,O
not,RB,O
performed,VBN,O
",",",",O
in,IN,O
clinical,JJ,O
studies,NNS,O
",",",",O
cerivastatin,NN,D
sodium,NN,O
was,VBD,O
used,VBN,O
concomitantly,RB,O
with,IN,O
angiotensin,NN,O
-,:,O
converting,VBG,O
enzyme,NN,O
-lrb-,-LRB-,O
ace,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
",",",",O
betablockers,NNS,G
",",",",O
calcium-channel,JJ,O
blockers,NNS,O
",",",",O
diuretics,NNS,G
",",",",O
and,CC,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
-lrb-,-LRB-,O
nsaids,NNS,G
-rrb-,-RRB-,O
without,IN,O
evidence,NN,O
of,IN,O
clinically,RB,O
significant,JJ,O
adverse,JJ,O
interactions,NNS,O
.,.,.
,,
pharmacokinetic,JJ,O
interaction,NN,O
studies,NNS,O
with,IN,O
cetirizine,NN,D
in,IN,O
adults,NNS,O
were,VBD,O
conducted,VBN,O
with,IN,O
pseudoephedrine,NN,D
",",",",O
antipyrine,NN,D
",",",",O
ketoconazole,NN,D
",",",",O
erythromycin,NN,D
and,CC,O
azithromycin,NN,D
.,.,.
,,
no,DT,O
interactions,NNS,O
were,VBD,O
observed,VBN,O
.,.,.
,,
in,IN,O
a,DT,O
multiple,JJ,O
dose,NN,O
study,NN,O
of,IN,O
theophylline,NN,D
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
once,RB,O
daily,RB,O
for,IN,O
3,CD,O
days,NNS,O
-rrb-,-RRB-,O
and,CC,O
cetirizine,NN,D
-lrb-,-LRB-,O
20,CD,O
mg,NN,O
once,RB,O
daily,RB,O
for,IN,O
3,CD,O
days,NNS,O
-rrb-,-RRB-,O
",",",",O
a,DT,O
16,CD,O
%,NN,O
decrease,NN,O
in,IN,O
the,DT,O
clearance,NN,O
of,IN,O
cetirizine,NN,D
was,VBD,O
observed,VBN,O
.,.,.
,,
the,DT,O
disposition,NN,O
of,IN,O
theophylline,NN,D
was,VBD,O
not,RB,O
altered,VBN,O
by,IN,O
concomitant,JJ,O
cetirizine,NN,D
administration,NN,O
.,.,.
,,
drug-drug,NNP,O
interactions,NNS,O
:,:,O
no,DT,O
clinically,RB,O
significant,JJ,O
drug,NN,D
interactions,NNS,O
have,VBP,O
been,VBN,O
found,VBN,O
with,IN,O
theophylline,NN,D
at,IN,O
a,DT,O
low,JJ,O
dose,NN,O
",",",",O
azithromycin,NN,D
",",",",O
pseudoephedrine,NN,D
",",",",O
ketoconazole,NN,D
",",",",O
or,CC,O
erythromycin,NN,D
.,.,.
,,
there,EX,O
was,VBD,O
a,DT,O
small,JJ,O
decrease,NN,O
in,IN,O
the,DT,O
clearance,NN,O
of,IN,O
cetirizine,NN,D
caused,VBN,O
by,IN,O
a,DT,O
400-mg,JJ,O
dose,NN,O
of,IN,O
theophylline,NN,D
.,.,.
,,
it,PRP,O
is,VBZ,O
possible,JJ,O
that,IN,O
larger,JJR,O
theophylline,NN,D
doses,NNS,O
could,MD,O
have,VB,O
a,DT,O
greater,JJR,O
effect,NN,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
with,IN,O
cetrotide,NN,B
.,.,.
,,
a,DT,O
drug,NN,D
interaction,NN,O
study,NN,O
was,VBD,O
performed,VBN,O
in,IN,O
which,WDT,O
erbitux,NNP,B
was,VBD,O
administered,VBN,O
in,IN,O
combination,NN,O
with,IN,O
irinotecan,NN,D
.,.,.
,,
there,EX,O
was,VBD,O
no,DT,O
evidence,NN,O
of,IN,O
any,DT,O
pharmacokinetic,JJ,O
interactions,NNS,O
between,IN,O
erbitux,NNP,B
and,CC,O
irinotecan,NN,D
.,.,.
,,
cevimeline,NNP,D
should,MD,O
be,VB,O
administered,VBN,O
with,IN,O
caution,NN,O
to,TO,O
patients,NNS,O
taking,VBG,O
beta,NN,O
adrenergic,JJ,G
antagonists,NNS,O
",",",",O
because,IN,O
of,IN,O
the,DT,O
possibility,NN,O
of,IN,O
conduction,NN,O
disturbances,NNS,O
.,.,.
,,
drugs,NNS,O
with,IN,O
parasympathomimetic,JJ,O
effects,NNS,O
administered,VBN,O
concurrently,RB,O
with,IN,O
cevimeline,NN,D
can,MD,O
be,VB,O
expected,VBN,O
to,TO,O
have,VB,O
additive,JJ,O
effects,NNS,O
.,.,.
,,
cevimeline,NNP,D
might,MD,O
interfere,VB,O
with,IN,O
desirable,JJ,O
antimuscarinic,JJ,O
effects,NNS,O
of,IN,O
drugs,NNS,D
used,VBN,O
concomitantly,RB,O
.,.,.
,,
drugs,NNS,O
which,WDT,O
inhibit,VBP,O
cyp2d6,NN,D
and,CC,O
cyp3a3/4,NN,O
also,RB,O
inhibit,VBP,O
the,DT,O
metabolism,NN,O
of,IN,O
cevimeline,NN,D
.,.,.
,,
cevimeline,NNP,D
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
individuals,NNS,O
known,VBN,O
or,CC,O
suspected,VBN,O
to,TO,O
be,VB,O
deficient,JJ,O
in,IN,O
cyp2d6,NN,D
activity,NN,O
",",",",O
based,VBN,O
on,IN,O
previous,JJ,O
experience,NN,O
",",",",O
as,IN,O
they,PRP,O
may,MD,O
be,VB,O
at,IN,O
a,DT,O
higher,JJR,O
risk,NN,O
of,IN,O
adverse,JJ,O
events,NNS,O
.,.,.
,,
in,IN,O
an,DT,O
in,FW,O
vitro,FW,O
study,NN,O
",",",",O
cytochrome,NN,O
p450,NN,O
isozymes,NNS,O
1a2,NN,O
",",",",O
2a6,NN,O
",",",",O
2c9,NN,O
",",",",O
2c19,NN,O
",",",",O
2d6,NN,O
",",",",O
2.00E+01,NN,O
",",",",O
and,CC,O
3a4,NN,O
were,VBD,O
not,RB,O
inhibited,VBN,O
by,IN,O
exposure,NN,O
to,TO,O
cevimeline,NN,D
.,.,.
,,
there,EX,O
are,VBP,O
no,DT,O
known,JJ,O
drug/drug,NN,O
interactions,NNS,O
with,IN,O
chlorambucil,NN,D
.,.,.
,,
although,IN,O
clinical,JJ,O
studies,NNS,O
have,VBP,O
not,RB,O
established,VBN,O
a,DT,O
cause,NN,O
and,CC,O
effect,NN,O
relationship,NN,O
",",",",O
physicians,NNS,O
should,MD,O
be,VB,O
aware,JJ,O
that,IN,O
variable,JJ,O
effects,NNS,O
an,DT,O
blood,NN,O
coagulation,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
very,RB,O
rarely,RB,O
in,IN,O
patients,NNS,O
receiving,VBG,O
oral,JJ,O
anticoagulants,NNS,G
and,CC,O
chlordiazepoxide,NN,D
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
alcohol,NN,D
or,CC,O
other,JJ,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressants,NNS,O
may,MD,O
have,VB,O
an,DT,O
additive,JJ,O
effect,NN,O
.,.,.
,,
the,DT,O
administration,NN,O
of,IN,O
local,JJ,O
anesthetic,JJ,G
solutions,NNS,O
containing,VBG,O
epinephrine,NN,D
or,CC,O
norepinephrine,NN,D
to,TO,O
patients,NNS,O
receiving,VBG,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
",",",",O
tricyclic,JJ,G
antidepressants,NNS,G
or,CC,O
phenothiazines,NNS,G
may,MD,O
produce,VB,O
severe,JJ,O
",",",",O
prolonged,JJ,O
hypotension,NN,O
or,CC,O
hypertension,NN,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
of,IN,O
these,DT,O
agents,NNS,O
should,MD,O
generally,RB,O
be,VB,O
avoided,VBN,O
.,.,.
,,
in,IN,O
situations,NNS,O
when,WRB,O
concurrent,JJ,O
therapy,NN,O
is,VBZ,O
necessary,JJ,O
",",",",O
careful,JJ,O
patient,NN,O
monitoring,NN,O
is,VBZ,O
essential,JJ,O
.,.,.
,,
concurrent,JJ,O
administration,NN,O
of,IN,O
vasopressor,NN,G
drugs,NNS,D
-lrb-,-LRB-,O
for,IN,O
the,DT,O
treatment,NN,O
of,IN,O
hypotension,NN,O
related,JJ,O
to,TO,O
obstetric,JJ,O
blocks,NNS,O
-rrb-,-RRB-,O
and,CC,O
ergot-type,JJ,O
oxytocic,JJ,O
drugs,NNS,D
may,MD,O
cause,VB,O
severe,JJ,O
",",",",O
persistent,JJ,O
hypertension,NN,O
or,CC,O
cerebrovascular,JJ,O
accidents,NNS,O
.,.,.
,,
the,DT,O
para-aminobenzoic,JJ,O
acid,NN,O
metabolite,NN,O
of,IN,O
chloroprocaine,NN,D
inhibits,VBZ,O
the,DT,O
action,NN,O
of,IN,O
sulfonamides,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
chloroprocaine,NN,D
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
in,IN,O
any,DT,O
condition,NN,O
in,IN,O
which,WDT,O
a,DT,O
sulfonamide,NN,G
drug,NN,D
is,VBZ,O
being,VBG,O
employed,VBN,O
.,.,.
,,
antacids,NNS,G
and,CC,O
kaolin,NN,D
:,:,O
antacids,NNS,G
and,CC,O
kaolin,NN,D
can,MD,O
reduce,VB,O
absorption,NN,O
of,IN,O
chloroquine,NN,D
.,.,.
,,
an,DT,O
interval,NN,O
of,IN,O
at,IN,O
least,JJS,O
4,CD,O
hours,NNS,O
between,IN,O
intake,NN,O
of,IN,O
these,DT,O
agents,NNS,O
and,CC,O
chloroquine,NN,D
should,MD,O
be,VB,O
observed,VBN,O
.,.,.
,,
cimetidine,NNP,D
:,:,O
cimetidine,NNP,D
can,MD,O
inhibit,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
chloroquine,NN,D
",",",",O
increasing,VBG,O
its,PRP$,O
plasma,NN,O
level,NN,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
cimetidine,NN,D
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
ampicillin,NNP,D
:,:,O
in,IN,O
a,DT,O
study,NN,O
of,IN,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
chloroquine,NN,D
significantly,RB,O
reduced,VBD,O
the,DT,O
bioavailability,NN,O
of,IN,O
ampicillin,NN,D
.,.,.
,,
an,DT,O
interval,NN,O
of,IN,O
at,IN,O
least,JJS,O
two,CD,O
hours,NNS,O
between,IN,O
intake,NN,O
of,IN,O
this,DT,O
agent,NN,O
and,CC,O
chloroquine,NN,D
should,MD,O
be,VB,O
observed,VBN,O
.,.,.
,,
cyclosporin,NN,D
:,:,O
after,IN,O
introduction,NN,O
of,IN,O
chloroquine,NN,D
-lrb-,-LRB-,O
oral,JJ,O
form,NN,O
-rrb-,-RRB-,O
",",",",O
a,DT,O
sudden,JJ,O
increase,NN,O
in,IN,O
serum,NN,O
cyclosporin,NN,D
level,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
close,JJ,O
monitoring,NN,O
of,IN,O
serum,NN,O
cyclosporin,NN,D
level,NN,O
is,VBZ,O
recommended,VBN,O
and,CC,O
",",",",O
if,IN,O
necessary,JJ,O
",",",",O
chloroquine,NN,D
should,MD,O
be,VB,O
discontinued,VBN,O
.,.,.
,,
when,WRB,O
given,VBN,O
concurrently,RB,O
the,DT,O
following,VBG,O
drugs,NNS,D
may,MD,O
interact,VB,O
with,IN,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
-,:,O
alcohol,NN,D
",",",",O
barbiturates,NNS,G
",",",",O
or,CC,O
narcotics,NNS,G
:,:,O
potentiation,NN,O
of,IN,O
otthostatic,JJ,O
hypotension,NN,O
may,MD,O
occu,VB,O
.,.,.
,,
-,:,O
antidiabetic,JJ,O
drugs,NNS,D
:,:,O
-lrb-,-LRB-,O
oral,JJ,O
agents,NNS,O
and,CC,O
insulin,NN,D
-rrb-,-RRB-,O
dosage,NN,O
adjustment,NN,O
of,IN,O
the,DT,O
antidiabetic,JJ,D
drug,NN,D
may,MD,O
be,VB,O
require,VB,O
.,.,.
,,
-,:,O
other,JJ,O
antihypertensive,JJ,G
drugs,NNS,D
:,:,O
additive,JJ,O
effect,NN,O
or,CC,O
potentiatio,NN,O
.,.,.
,,
-,:,O
cholestyramine,NN,D
and,CC,O
colestipol,NN,D
resins,NNS,G
:,:,O
cholestytamine,NN,D
and,CC,O
colestipol,NN,D
resins,NNS,G
have,VBP,O
the,DT,O
potential,NN,O
of,IN,O
binding,VBG,O
thiazide,JJ,G
diuretics,NNS,G
and,CC,O
reducing,VBG,O
diuretic,JJ,G
absorption,NN,O
from,IN,O
the,DT,O
gastrointestinal,JJ,O
trac,NN,O
.,.,.
,,
-,:,O
corticosteroids,NNS,G
",",",",O
acth,NN,D
:,:,O
intensified,VBN,O
electrolyte,NN,O
depletion,NN,O
",",",",O
particularly,RB,O
hypokalemi,NN,O
.,.,.
,,
-,:,O
pressor,NN,O
amines,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
norepinephrine,NN,D
-rrb-,-RRB-,O
:,:,O
possible,JJ,O
decreased,VBN,O
response,NN,O
to,TO,O
pressor,NN,O
amines,NNS,O
but,CC,O
not,RB,O
sufficient,JJ,O
to,TO,O
preclude,VB,O
their,PRP$,O
us,PRP,O
.,.,.
,,
-,:,O
skeletal,JJ,O
muscle,NN,O
relaxants,NNS,O
",",",",O
nondepolarizing,JJ,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
tubocurarine,NN,D
-rrb-,-RRB-,O
:,:,O
possible,JJ,O
increased,VBN,O
responsiveness,NN,O
to,TO,O
the,DT,O
muscle,NN,O
relaxan,NN,O
.,.,.
,,
-,:,O
lithium,NN,D
:,:,O
generally,RB,O
should,MD,O
not,RB,O
be,VB,O
given,VBN,O
with,IN,O
diuretics,NNS,G
.,.,.
,,
diuretic,JJ,G
agents,NNS,O
reduce,VB,O
the,DT,O
renal,JJ,O
clearance,NN,O
of,IN,O
lithium,NN,D
and,CC,O
add,VB,O
a,DT,O
high,JJ,O
risk,NN,O
of,IN,O
lithium,NN,D
toxicity,NN,O
.,.,.
,,
refer,VB,O
to,TO,O
the,DT,O
package,NN,O
insert,NN,O
for,IN,O
lithium,NN,D
preparations,NNS,O
before,IN,O
use,NN,O
of,IN,O
such,JJ,O
preparations,NNS,O
with,IN,O
chlorothiazid,NN,O
.,.,.
,,
-,:,O
non-steroidal,JJ,O
anti-inflammatory,JJ,O
drugs,NNS,O
:,:,O
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
the,DT,O
administration,NN,O
of,IN,O
a,DT,O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
agent,NN,O
can,MD,O
reduce,VB,O
the,DT,O
diuretic,JJ,G
",",",",O
natriuretic,JJ,O
",",",",O
and,CC,O
antihypertensive,JJ,G
effects,NNS,O
of,IN,O
loop,NN,O
",",",",O
potassium-sparing,NN,O
and,CC,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
when,WRB,O
chlorothiazide,NN,D
and,CC,O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
are,VBP,O
used,VBN,O
concomitantly,RB,O
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
to,TO,O
determine,VB,O
if,IN,O
the,DT,O
desired,VBN,O
effect,NN,O
of,IN,O
the,DT,O
diuretic,JJ,G
is,VBZ,O
obtaine,NN,O
.,.,.
,,
-,:,O
drug/laboratory,NN,O
test,NN,O
interactions,NNS,O
:,:,O
thiazides,NNS,G
should,MD,O
be,VB,O
discontinued,VBN,O
before,IN,O
carrying,VBG,O
out,RP,O
tests,NNS,O
for,IN,O
parathyroid,JJ,O
function,NN,O
.,.,.
,,
chlorotrianisene,NN,D
may,MD,O
interact,VB,O
with,IN,O
antidepressants,NNS,G
",",",",O
aspirin,NN,B
",",",",O
barbiturates,NNS,G
",",",",O
bromocriptine,NN,D
",",",",O
calcium,NN,D
supplements,NNS,O
",",",",O
corticosteroids,NNS,G
",",",",O
corticotropin,NN,D
",",",",O
cyclosporine,NN,D
",",",",O
dantrolene,NN,D
",",",",O
nicotine,NN,D
",",",",O
somatropin,NN,D
",",",",O
tamoxifen,NN,D
",",",",O
and,CC,O
warfarin,NN,D
.,.,.
,,
may,NNP,O
interact,VBP,O
with,IN,O
skin,NN,O
products,NNS,O
or,CC,O
shampoos,NNS,O
for,IN,O
dandruff,NN,O
or,CC,O
psoriasis,NN,O
.,.,.
,,
substrate,NN,O
of,IN,O
cyp2d6,NN,D
-lrb-,-LRB-,O
minor,JJ,O
-rrb-,-RRB-,O
",",",",O
3a4,NN,O
-lrb-,-LRB-,O
major,JJ,O
-rrb-,-RRB-,O
;,:,O
.,.,.
,,
inhibits,VBZ,O
cyp2d6,NN,D
-lrb-,-LRB-,O
weak,JJ,O
-rrb-,-RRB-,O
.,.,.
,,
increased,VBN,O
toxicity,NN,O
-lrb-,-LRB-,O
cns,NN,O
depression,NN,O
-rrb-,-RRB-,O
:,:,O
cns,NN,O
depressants,NNS,O
",",",",O
mao,NN,O
inhibitors,NNS,O
",",",",O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
phenothiazines,NNS,G
.,.,.
,,
cyp3a4,NN,D
inhibitors,NNS,O
:,:,O
may,NNP,O
increase,VB,O
the,DT,O
levels/effects,NNS,O
of,IN,O
chlorpheniramine,NN,G
.,.,.
,,
example,NN,O
inhibitors,NNS,O
include,VBP,O
azole,NN,O
antifungals,NNS,G
",",",",O
ciprofloxacin,NN,D
",",",",O
clarithromycin,NN,D
",",",",O
diclofenac,NN,D
",",",",O
doxycycline,NN,D
",",",",O
erythromycin,NN,D
",",",",O
imatinib,NN,D
",",",",O
isoniazid,NN,D
",",",",O
nefazodone,NN,D
",",",",O
nicardipine,NN,D
",",",",O
propofol,NN,D
",",",",O
protease,NN,O
inhibitors,NNS,O
",",",",O
quinidine,NN,D
",",",",O
and,CC,O
verapamil,NN,D
.,.,.
,,
the,DT,O
concurrent,JJ,O
use,NN,O
of,IN,O
two,CD,O
or,CC,O
more,JJR,O
drugs,NNS,D
with,IN,O
anticholinergic,JJ,G
activity,NN,O
--,:,O
such,JJ,O
as,IN,O
an,DT,O
antipsychotic,JJ,O
drug,NN,D
-lrb-,-LRB-,O
eg,FW,O
",",",",O
chlorpromazine,NN,D
-rrb-,-RRB-,O
",",",",O
an,DT,O
antiparkinsonian,JJ,O
drug,NN,D
-lrb-,-LRB-,O
eg,FW,O
",",",",O
trihexyphenidyl,NN,D
-rrb-,-RRB-,O
",",",",O
and/or,CC,O
a,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
-lrb-,-LRB-,O
eg,FW,O
",",",",O
amitriptyline,NNP,D
-rrb-,-RRB-,O
--,:,O
commonly,RB,O
results,VBZ,O
in,IN,O
excessive,JJ,O
anticholinergic,JJ,G
effects,NNS,O
",",",",O
including,VBG,O
dry,JJ,O
mouth,NN,O
and,CC,O
associated,VBN,O
dental,JJ,O
complications,NNS,O
",",",",O
blurred,VBD,O
vision,NN,O
",",",",O
and,CC,O
",",",",O
in,IN,O
patients,NNS,O
exposed,VBN,O
to,TO,O
high,JJ,O
temperature,NN,O
and,CC,O
humidity,NN,O
",",",",O
hyperpyrexia,NN,O
.,.,.
,,
interactions,NNS,O
may,MD,O
also,RB,O
occur,VB,O
with,IN,O
the,DT,O
following,NN,O
:,:,O
anti-depressants/anti-anxiety,JJ,O
drugs,NNS,D
",",",",O
drugs,NNS,D
used,VBN,O
to,TO,O
treat,VB,O
an,DT,O
overactive,JJ,O
thyroid,NN,G
",",",",O
beta-blockers,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
propranolol,NN,D
-rrb-,-RRB-,O
",",",",O
sparfloxacin,NN,D
",",",",O
grepafloxacin,NN,D
",",",",O
guanethidine,NN,D
",",",",O
guanadrel,NN,D
",",",",O
metrizamide,NN,D
",",",",O
cabergoline,NN,D
",",",",O
lithium,NN,D
",",",",O
narcotic,JJ,G
pain,NN,O
medication,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
codeine,NN,D
-rrb-,-RRB-,O
",",",",O
drugs,NNS,D
used,VBN,O
to,TO,O
aid,VB,O
sleep,NN,O
",",",",O
drowsiness-causing,JJ,O
antihistamines,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
diphenhydramine,NN,D
-rrb-,-RRB-,O
",",",",O
any,DT,O
other,JJ,O
drugs,NNS,D
that,WDT,O
may,MD,O
make,VB,O
you,PRP,O
drowsy,JJ,O
.,.,.
,,
the,DT,O
hypoglycemic,JJ,G
action,NN,O
of,IN,O
sulfonylurea,NN,G
may,MD,O
be,VB,O
potentiated,VBN,O
by,IN,O
certain,JJ,O
drugs,NNS,D
including,VBG,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
and,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
highly,RB,O
protein,NN,O
bound,VBD,O
",",",",O
salicylates,NNS,G
",",",",O
sulfonamides,NNS,G
",",",",O
chloramphenicol,NN,D
",",",",O
probenecid,NN,D
",",",",O
coumarins,NNS,G
",",",",O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
",",",",O
and,CC,O
beta,NN,O
adrenergic,JJ,G
blocking,VBG,O
agents,NNS,O
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
to,TO,O
a,DT,O
patient,NN,O
receiving,VBG,O
diabinese,NNP,B
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
hypoglycemia,NN,O
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
withdrawn,VBN,O
from,IN,O
a,DT,O
patient,NN,O
receiving,VBG,O
diabinese,NNP,B
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
loss,NN,O
of,IN,O
control,NN,O
.,.,.
,,
certain,JJ,O
drugs,NNS,D
tend,VBP,O
to,TO,O
produce,VB,O
hyperglycemia,NN,O
and,CC,O
may,MD,O
lead,VB,O
to,TO,O
loss,NN,O
of,IN,O
control,NN,O
.,.,.
,,
these,DT,O
drugs,NNS,D
include,VBP,O
the,DT,O
thiazides,NNS,G
and,CC,O
other,JJ,O
diuretics,NNS,G
",",",",O
corticosteroids,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
thyroid,NN,G
products,NNS,O
",",",",O
estrogens,NNS,G
",",",",O
oral,JJ,O
contraceptives,NNS,G
",",",",O
phenytoin,NN,D
",",",",O
nicotinic,JJ,O
acid,NN,O
",",",",O
sympathomimetics,NNS,G
",",",",O
calcium,NN,D
channel,NN,O
blocking,VBG,O
drugs,NNS,D
",",",",O
and,CC,O
isoniazid,NN,D
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
to,TO,O
a,DT,O
patient,NN,O
receiving,VBG,O
diabinese,NNP,B
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
closely,RB,O
observed,VBN,O
for,IN,O
loss,NN,O
of,IN,O
control,NN,O
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
withdrawn,VBN,O
from,IN,O
a,DT,O
patient,NN,O
receiving,VBG,O
diabinese,NNP,B
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
hypoglycemia,NN,O
.,.,.
,,
since,IN,O
animal,NN,O
studies,NNS,O
suggest,VBP,O
that,IN,O
the,DT,O
action,NN,O
of,IN,O
barbiturates,NNS,G
may,MD,O
be,VB,O
prolonged,VBN,O
by,IN,O
therapy,NN,O
with,IN,O
chlorpropamide,NN,D
",",",",O
barbiturates,NNS,G
should,MD,O
be,VB,O
employed,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
a,DT,O
disulfiram-like,JJ,O
reaction,NN,O
may,MD,O
be,VB,O
produced,VBN,O
by,IN,O
the,DT,O
ingestion,NN,O
of,IN,O
alcohol,NN,D
.,.,.
,,
a,DT,O
potential,JJ,O
interaction,NN,O
between,IN,O
oral,JJ,O
miconazole,NN,D
and,CC,O
oral,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
leading,VBG,O
to,TO,O
severe,JJ,O
hypoglycemia,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
.,.,.
,,
whether,IN,O
this,DT,O
interaction,NN,O
also,RB,O
occurs,VBZ,O
with,IN,O
the,DT,O
intravenous,JJ,O
",",",",O
topical,JJ,O
",",",",O
or,CC,O
vaginal,JJ,O
preparations,NNS,O
of,IN,O
miconazole,NN,D
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
chlorprothixene,NN,D
may,MD,O
increase,VB,O
the,DT,O
plasma-level,NN,O
of,IN,O
concomitantly,RB,O
given,VBN,O
lithium,NN,D
.,.,.
,,
in,IN,O
order,NN,O
to,TO,O
avoid,VB,O
lithium,NN,D
intoxication,NN,O
",",",",O
lithium,NN,D
plasma,NN,O
levels,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
.,.,.
,,
if,IN,O
chlorprothixene,NN,D
is,VBZ,O
given,VBN,O
concomitantly,RB,O
with,IN,O
opioids,NNS,G
",",",",O
the,DT,O
opioid,JJ,G
dose,NN,O
should,MD,O
be,VB,O
reduced,VBN,O
-lrb-,-LRB-,O
by,IN,O
approx,RB,O
.,.,.
,,
50,CD,O
%,NN,O
-rrb-,-RRB-,O
",",",",O
because,IN,O
chlorprothixene,NN,D
amplifies,VBZ,O
the,DT,O
therapeutic,JJ,O
actions,NNS,O
and,CC,O
side-effects,NNS,O
of,IN,O
opioids,NNS,G
massively,RB,O
.,.,.
,,
avoid,VB,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
chlorprothixene,NN,D
and,CC,O
tramadol,NN,D
-lrb-,-LRB-,O
ultram,NN,B
-rrb-,-RRB-,O
.,.,.
,,
massive,JJ,O
seizures,NNS,O
may,MD,O
be,VB,O
encountered,VBN,O
with,IN,O
this,DT,O
combination,NN,O
.,.,.
,,
consider,VB,O
additive,JJ,O
sedative,JJ,G
effects,NNS,O
and,CC,O
confusional,JJ,O
states,NNS,O
to,TO,O
emerge,VB,O
",",",",O
if,IN,O
chlorprothixene,NN,D
is,VBZ,O
given,VBN,O
with,IN,O
benzodiazepines,NNS,G
or,CC,O
barbituates,NNS,G
.,.,.
,,
choose,VB,O
particular,JJ,O
low,JJ,O
doses,NNS,O
of,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
exert,VB,O
particular,JJ,O
caution,NN,O
in,IN,O
combining,VBG,O
chlorprothixene,NN,D
with,IN,O
other,JJ,O
anticholinergic,JJ,G
drugs,NNS,D
-lrb-,-LRB-,O
tricyclic,JJ,G
antidepressants,NNS,G
and,CC,O
antiparkinsonian,JJ,O
agents,NNS,O
-rrb-,-RRB-,O
:,:,O
particularly,RB,O
the,DT,O
elderly,JJ,O
may,MD,O
develop,VB,O
delirium,NN,O
",",",",O
high,JJ,O
fever,NN,O
",",",",O
severe,JJ,O
obstipation,NN,O
",",",",O
even,RB,O
ileus,NN,O
and,CC,O
glaucoma,NN,O
.,.,.
,,
chlorthalidone,NNP,D
may,MD,O
add,VB,O
to,TO,O
or,CC,O
potentiate,VB,O
the,DT,O
action,NN,O
of,IN,O
other,JJ,O
antihypertensive,JJ,G
drugs,NNS,D
.,.,.
,,
potentiation,NN,O
occurs,VBZ,O
with,IN,O
ganglionic,JJ,O
peripheral,JJ,O
adrenergic,JJ,G
blocking,NN,O
drugs,NNS,D
.,.,.
,,
medication,NN,O
such,JJ,O
as,IN,O
digitalis,NN,G
may,MD,O
also,RB,O
influence,VB,O
serum,NN,O
electrolytes,NNS,O
.,.,.
,,
warning,NN,O
signs,NNS,O
",",",",O
irrespective,RB,O
of,IN,O
cause,NN,O
",",",",O
are,VBP,O
:,:,O
dryness,NN,O
of,IN,O
mouth,NN,O
",",",",O
thirst,NN,O
",",",",O
weakness,NN,O
",",",",O
lethargy,NN,O
",",",",O
drowsiness,NN,O
",",",",O
restlessness,NN,O
",",",",O
muscle,NN,O
pains,NNS,O
or,CC,O
cramps,NNS,O
",",",",O
muscular,JJ,O
fatigue,NN,O
",",",",O
hypotension,NN,O
",",",",O
oliguria,NN,O
",",",",O
tachycardia,NN,O
",",",",O
and,CC,O
gastrointestinal,JJ,O
disturbances,NNS,O
such,JJ,O
as,IN,O
nausea,NN,O
and,CC,O
vomiting,NN,O
.,.,.
,,
insulin,NN,D
requirements,NNS,O
in,IN,O
diabetic,JJ,O
patients,NNS,O
may,MD,O
be,VB,O
increased,VBN,O
",",",",O
decreased,VBN,O
",",",",O
or,CC,O
unchanged,JJ,O
.,.,.
,,
higher,JJR,O
dosage,NN,O
of,IN,O
oral,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
latent,JJ,O
diabetes,NN,O
mellitus,NN,O
may,MD,O
become,VB,O
manifest,JJ,O
during,IN,O
chlorthalidone,NN,D
administration,NN,O
.,.,.
,,
chlorthalidone,NNP,D
and,CC,O
related,JJ,O
drugs,NNS,D
may,MD,O
increase,VB,O
the,DT,O
responsiveness,NN,O
to,TO,O
tubocurarine,NN,D
.,.,.
,,
chlorthalidone,NNP,D
and,CC,O
related,JJ,O
drugs,NNS,D
may,MD,O
decrease,VB,O
arterial,JJ,O
responsiveness,NN,O
to,TO,O
norepinephrine,NN,D
.,.,.
,,
this,DT,O
diminution,NN,O
is,VBZ,O
not,RB,O
sufficient,JJ,O
to,TO,O
preclude,VB,O
effectiveness,NN,O
of,IN,O
the,DT,O
pressor,NN,O
agent,NN,O
for,IN,O
therapeutic,JJ,O
use,NN,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
alcohol,NN,D
or,CC,O
other,JJ,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressants,NNS,O
may,MD,O
have,VB,O
an,DT,O
additive,JJ,O
effect,NN,O
.,.,.
,,
interactions,NNS,O
for,IN,O
vitamin,NN,G
d,NN,O
analogues,NNS,O
-lrb-,-LRB-,O
vitamin,NN,O
d2,NN,O
",",",",O
vitamin,NN,O
d3,NN,O
",",",",O
calcitriol,NN,D
",",",",O
and,CC,O
calcidiol,NN,D
-rrb-,-RRB-,O
:,:,O
cholestyramine,NNP,D
:,:,O
cholestyramine,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
reduce,VB,O
intestinal,JJ,O
absorption,NN,O
of,IN,O
fat,JJ,O
soluble,JJ,O
vitamins,NNS,G
.,.,.
,,
as,IN,O
such,JJ,O
it,PRP,O
may,MD,O
impair,VB,O
intestinal,JJ,O
absorption,NN,O
of,IN,O
any,DT,O
of,IN,O
vitamin,NN,G
d.,NNP,O
phenytoin/phenobarbital,NNP,O
:,:,O
the,DT,O
coadministration,NN,O
of,IN,O
phenytoin,NN,D
or,CC,O
phenobarbital,NN,D
will,MD,O
not,RB,O
affect,VB,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
vitamin,NN,G
d,NN,O
",",",",O
but,CC,O
may,MD,O
reduce,VB,O
endogenous,JJ,O
plasma,NN,O
levels,NNS,O
of,IN,O
calcitriol/ergocalcitriol,NN,O
by,IN,O
accelerating,VBG,O
metabolism,NN,O
.,.,.
,,
since,IN,O
blood,NN,O
level,NN,O
of,IN,O
calcitriol/ergocalcitriol,NN,O
will,MD,O
be,VB,O
reduced,VBN,O
",",",",O
higher,JJR,O
doses,NNS,O
of,IN,O
rocaltrol,NNP,B
may,MD,O
be,VB,O
necessary,JJ,O
if,IN,O
these,DT,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
simultaneously,RB,O
.,.,.
,,
thiazides,NNP,G
:,:,O
thiazides,NNS,G
are,VBP,O
known,VBN,O
to,TO,O
induce,VB,O
hypercalcemia,NN,O
by,IN,O
the,DT,O
reduction,NN,O
of,IN,O
calcium,NN,D
excretion,NN,O
in,IN,O
urine,NN,O
.,.,.
,,
some,DT,O
reports,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
thiazides,NNS,G
with,IN,O
vitamin,NN,G
d,NN,O
causes,VBZ,O
hypercalcemia,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
precaution,NN,O
should,MD,O
be,VB,O
taken,VBN,O
when,WRB,O
coadministration,NN,O
is,VBZ,O
necessary,JJ,O
.,.,.
,,
digitalis,NNP,G
:,:,O
vitamin,NN,O
d,NN,O
dosage,NN,O
must,MD,O
be,VB,O
determined,VBN,O
with,IN,O
care,NN,O
in,IN,O
patients,NNS,O
undergoing,VBG,O
treatment,NN,O
with,IN,O
digitalis,NN,G
",",",",O
as,IN,O
hypercalcemia,NN,O
in,IN,O
such,JJ,O
patients,NNS,O
may,MD,O
precipitate,VB,O
cardiac,JJ,O
arrhythmias,NNS,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
ketoconazole,NN,D
may,MD,O
inhibit,VB,O
both,DT,O
synthetic,JJ,O
and,CC,O
catabolic,JJ,O
enzymes,NNS,O
of,IN,O
vitamin,NN,G
d.,NNP,O
reductions,NNPS,O
in,IN,O
serum,NN,O
endogenous,JJ,O
vitamin,NN,G
d,NN,O
concentrations,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
following,VBG,O
the,DT,O
administration,NN,O
of,IN,O
300,CD,O
mg/day,NN,O
to,TO,O
1200,CD,O
mg/day,NN,O
ketoconazole,NN,D
for,IN,O
a,DT,O
week,NN,O
to,TO,O
healthy,JJ,O
men,NNS,O
.,.,.
,,
however,RB,O
",",",",O
in,FW,O
vivo,FW,O
drug,NN,D
interaction,NN,O
studies,NNS,O
of,IN,O
ketoconazole,NN,D
with,IN,O
vitamin,NN,G
d,NN,O
have,VBP,O
not,RB,O
been,VBN,O
investigated,VBN,O
.,.,.
,,
corticosteroids,NNS,G
:,:,O
a,DT,O
relationship,NN,O
of,IN,O
functional,JJ,O
antagonism,NN,O
exists,VBZ,O
between,IN,O
vitamin,NN,G
d,NN,O
analogues,NNS,O
",",",",O
which,WDT,O
promote,VBP,O
calcium,NN,D
absorption,NN,O
",",",",O
and,CC,O
corticosteroids,NNS,G
",",",",O
which,WDT,O
inhibit,VBP,O
calcium,NN,D
absorption,NN,O
.,.,.
,,
phosphate-binding,JJ,O
agents,NNS,O
:,:,O
since,IN,O
vitamin,NN,G
d,NN,O
also,RB,O
has,VBZ,O
an,DT,O
effect,NN,O
on,IN,O
phosphate,NN,D
transport,NN,O
in,IN,O
the,DT,O
intestine,NN,O
",",",",O
kidneys,NNS,O
and,CC,O
bones,NNS,O
",",",",O
the,DT,O
dosage,NN,O
of,IN,O
phosphate-binding,JJ,O
agents,NNS,O
must,MD,O
be,VB,O
adjusted,VBN,O
in,IN,O
accordance,NN,O
with,IN,O
the,DT,O
serum,NN,O
phosphate,NN,D
concentration,NN,O
.,.,.
,,
vitamin,NN,O
d,NN,O
:,:,O
the,DT,O
coadministration,NN,O
of,IN,O
any,DT,O
of,IN,O
the,DT,O
vitamin,NN,G
d,NN,O
analogues,NNS,O
should,MD,O
be,VB,O
avoided,VBN,O
as,IN,O
this,DT,O
could,MD,O
create,VB,O
possible,JJ,O
additive,JJ,O
effects,NNS,O
and,CC,O
hypercalcemia,NN,O
.,.,.
,,
calcium,NN,D
supplements,NNS,O
:,:,O
uncontrolled,JJ,O
intake,NN,O
of,IN,O
additional,JJ,O
calcium-containing,JJ,O
preparations,NNS,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
magnesium,NN,D
:,:,O
magnesium-containing,JJ,O
preparations,NNS,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
antacids,NNS,G
-rrb-,-RRB-,O
may,MD,O
cause,VB,O
hypermagnesemia,NN,O
and,CC,O
should,MD,O
therefore,RB,O
not,RB,O
be,VB,O
taken,VBN,O
during,IN,O
therapy,NN,O
with,IN,O
vitamin,NN,G
d,NN,O
by,IN,O
patients,NNS,O
on,IN,O
chronic,JJ,O
renal,JJ,O
dialysis,NN,O
.,.,.
,,
cholestyramine,NNP,D
resin,NN,G
may,MD,O
delay,VB,O
or,CC,O
reduce,VB,O
the,DT,O
absorption,NN,O
of,IN,O
concomitant,JJ,O
oral,JJ,O
medication,NN,O
such,JJ,O
as,IN,O
phenylbutazone,NN,D
",",",",O
warfarin,NN,D
",",",",O
thiazide,JJ,G
diuretics,NNS,G
-lrb-,-LRB-,O
acidic,JJ,O
-rrb-,-RRB-,O
or,CC,O
propranolol,NN,D
-lrb-,-LRB-,O
basic,JJ,O
-rrb-,-RRB-,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
tetracycline,NN,D
penicillin,NN,D
g,NN,O
",",",",O
phenobarbital,NN,D
",",",",O
thyroid,NN,G
and,CC,O
thyroxine,NN,D
preparations,NNS,O
",",",",O
estrogens,NNS,G
and,CC,O
progestins,NNS,G
",",",",O
and,CC,O
digitalis,NN,G
.,.,.
,,
interference,NN,O
with,IN,O
the,DT,O
absorption,NN,O
of,IN,O
oral,JJ,O
phosphate,NN,D
supplements,NNS,O
has,VBZ,O
been,VBN,O
observed,VBN,O
with,IN,O
another,DT,O
positively-charged,JJ,O
bile,NN,O
acid,NN,O
sequestrant,NN,O
.,.,.
,,
cholestyramine,NNP,D
resin,NN,G
may,MD,O
interfere,VB,O
with,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
drugs,NNS,D
that,WDT,O
undergo,VBP,O
enterohepatic,JJ,O
circulation,NN,O
",",",",O
the,DT,O
discontinuance,NN,O
of,IN,O
cholestyramine,NN,D
resin,NN,G
could,MD,O
pose,VB,O
a,DT,O
hazard,NN,O
to,TO,O
health,NN,O
if,IN,O
a,DT,O
potentially,RB,O
toxic,JJ,O
drug,NN,D
such,JJ,O
as,IN,O
digitalis,NN,G
has,VBZ,O
been,VBN,O
filtrated,VBN,O
to,TO,O
a,DT,O
maintenance,NN,O
level,NN,O
while,IN,O
the,DT,O
patient,NN,O
was,VBD,O
taking,VBG,O
cholestyramine,NN,D
resin,NN,G
.,.,.
,,
because,IN,O
cholestyramine,NN,D
binds,VBZ,O
bile,NN,O
acids,NNS,O
",",",",O
cholestyramine,NN,D
resin,NN,G
may,MD,O
interfere,VB,O
with,IN,O
normal,JJ,O
fat,JJ,O
digestion,NN,O
and,CC,O
absorption,NN,O
and,CC,O
thus,RB,O
may,MD,O
prevent,VB,O
absorption,NN,O
of,IN,O
fat,JJ,O
soluble,JJ,O
vitamins,NNS,G
such,JJ,O
as,IN,O
a,DT,O
",",",",O
d,NN,O
",",",",O
e,NN,O
",",",",O
and,CC,O
k,NN,O
.,.,.
,,
when,WRB,O
cholestyramine,NN,D
resin,NN,G
is,VBZ,O
given,VBN,O
for,IN,O
long,JJ,O
periods,NNS,O
of,IN,O
time,NN,O
",",",",O
concomitant,JJ,O
supplementation,NN,O
with,IN,O
water-miscible,JJ,O
-lrb-,-LRB-,O
or,CC,O
parenteral,JJ,O
-rrb-,-RRB-,O
forms,NNS,O
of,IN,O
fat-soluble,JJ,O
vitamins,NNS,G
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
since,IN,O
cholestyramine,NNP,D
resin,NNP,G
may,NNP,O
bind,VBP,O
other,JJ,O
drugs,NNS,O
given,VBP,O
concurrently,RB,O
",",",",O
it,PRP,O
is,VBZ,O
recommended,NNP,O
that,WDT,O
patients,NNS,O
take,VBP,O
other,JJ,O
drugs,NNS,O
at,IN,O
least,NN,O
1,CD,O
hour,NN,O
before,IN,O
or,NN,O
4,CD,O
to,TO,O
6,CD,O
hours,NNS,O
after,IN,O
cholestyramine,NNP,D
resin,NNP,G
-lrb-,-LRB-,O
or,NN,O
at,IN,O
as,JJ,O
great,JJ,O
an,DT,O
interval,NNP,O
as,NNP,O
possible,NN,O
-rrb-,-RRB-,O
to,TO,O
avoid,VB,O
impeding,NNP,O
their,NNP,O
absorption,NNP,O
.,.,.
,,
based,VBN,O
on,IN,O
in,FW,O
vitro,FW,O
studies,NNS,O
in,IN,O
human,JJ,O
liver,NN,O
microsomes,NNS,O
",",",",O
des-ciclesonide,NN,D
appears,VBZ,O
to,TO,O
have,VB,O
no,DT,O
inhibitory,JJ,O
or,CC,O
induction,NN,O
potential,NN,O
on,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
cyp,NN,O
450,CD,O
enzymes,NNS,O
.,.,.
,,
the,DT,O
inhibitory,JJ,O
potential,NN,O
of,IN,O
ciclesonide,NN,D
on,IN,O
cyp450,NN,O
isoenzymes,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
demonstrated,VBD,O
that,IN,O
the,DT,O
plasma,NN,O
protein,NN,O
binding,NN,O
of,IN,O
des-ciclesonide,NN,D
was,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
warfarin,NN,D
or,CC,O
salicylic,JJ,O
acid,NN,O
",",",",O
indicating,VBG,O
no,DT,O
potential,NN,O
for,IN,O
protein,NN,O
binding-based,JJ,O
drug,NN,D
interactions,NNS,O
.,.,.
,,
in,IN,O
a,DT,O
drug,NN,D
interaction,NN,O
study,NN,O
",",",",O
co-administration,NN,O
of,IN,O
orally,RB,O
inhaled,VBN,O
ciclesonide,NN,D
and,CC,O
oral,JJ,O
erythromycin,NN,D
",",",",O
an,DT,O
inhibitor,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
",",",",O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
des-ciclesonide,NN,D
or,CC,O
erythromycin,NN,D
.,.,.
,,
in,IN,O
another,DT,O
drug,NN,D
interaction,NN,O
study,NN,O
",",",",O
co-administration,NN,O
of,IN,O
orally,RB,O
inhaled,VBN,O
ciclesonide,NN,D
and,CC,O
oral,JJ,O
ketoconazole,NN,D
",",",",O
a,DT,O
potent,JJ,O
inhibitor,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
",",",",O
increased,VBD,O
the,DT,O
exposure,NN,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
of,IN,O
des-ciclesonide,NN,D
by,IN,O
approximately,RB,O
3.6-fold,RB,O
at,IN,O
steady,JJ,O
state,NN,O
",",",",O
while,IN,O
levels,NNS,O
of,IN,O
ciclesonide,NN,D
remained,VBD,O
unchanged,JJ,O
.,.,.
,,
therefore,RB,O
",",",",O
ketoconazole,NN,D
should,MD,O
be,VB,O
administered,VBN,O
with,IN,O
caution,NN,O
with,IN,O
intranasal,JJ,O
ciclesonide,NN,D
.,.,.
,,
probenecid,NNP,D
:,:,O
probenecid,NNP,D
is,VBZ,O
known,VBN,O
to,TO,O
interact,VB,O
with,IN,O
the,DT,O
metabolism,NN,O
or,CC,O
renal,JJ,O
tubular,JJ,O
excretion,NN,O
of,IN,O
many,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
acetaminophen,NN,D
",",",",O
acyclovir,NN,D
",",",",O
angiotensin-converting,JJ,O
enzyme,NN,O
inhibitors,NNS,O
",",",",O
aminosalicylic,JJ,O
acid,NN,O
",",",",O
barbiturates,NNS,G
",",",",O
benzodiazepines,NNS,G
",",",",O
bumetanide,NN,D
",",",",O
clofibrate,NN,D
",",",",O
methotrexate,NN,D
",",",",O
famotidine,NN,D
",",",",O
furosemide,NN,D
",",",",O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
",",",",O
theophylline,NN,D
",",",",O
and,CC,O
zidovudine,NN,D
-rrb-,-RRB-,O
.,.,.
,,
concomitant,JJ,O
medications,NNS,O
should,MD,O
be,VB,O
carefully,RB,O
assessed,VBN,O
.,.,.
,,
zidovudine,NN,D
should,MD,O
either,RB,O
be,VB,O
temporarily,RB,O
discontinued,VBN,O
or,CC,O
decreased,VBN,O
by,IN,O
50,CD,O
%,NN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
probenecid,NN,D
on,IN,O
the,DT,O
day,NN,O
of,IN,O
vistide,NNP,B
infusion,NN,O
.,.,.
,,
nephrotoxic,JJ,O
agents,NNS,O
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
vistide,NNP,B
and,CC,O
agents,NNS,O
with,IN,O
nephrotoxic,JJ,O
potential,JJ,O
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
intravenous,JJ,O
aminoglycosides,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
tobramycin,NN,D
",",",",O
gentamicin,NN,D
",",",",O
and,CC,O
amikacin,NN,D
-rrb-,-RRB-,O
",",",",O
amphotericin,NN,D
b,NN,O
",",",",O
foscarnet,NN,D
",",",",O
intravenous,JJ,O
pentamidine,NN,D
",",",",O
vancomycin,NN,D
",",",",O
and,CC,O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
-rsb-,-RRB-,O
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
such,JJ,O
agents,NNS,O
must,MD,O
be,VB,O
discontinued,VBN,O
at,IN,O
least,JJS,O
seven,CD,O
days,NNS,O
prior,RB,O
to,TO,O
starting,VBG,O
therapy,NN,O
with,IN,O
vistide,NN,B
.,.,.
,,
since,IN,O
pletal,NN,B
is,VBZ,O
extensively,RB,O
metabolized,VBN,O
by,IN,O
cytochrome,NN,O
p-450,NN,O
isoenzymes,NNS,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
pletal,NNP,B
is,VBZ,O
coadministered,VBN,O
with,IN,O
inhibitors,NNS,O
of,IN,O
c.p.a.,NNP,O
such,JJ,O
as,IN,O
ketoconazole,NN,D
and,CC,O
erythromycin,NN,D
or,CC,O
inhibitors,NNS,O
of,IN,O
cyp2c19,NN,O
such,JJ,O
as,IN,O
omeprazole,NN,D
.,.,.
,,
pharmacokinetic,JJ,O
studies,NNS,O
have,VBP,O
demonstrated,VBN,O
that,IN,O
omeprazole,NN,D
and,CC,O
erythromycin,NN,D
significantly,RB,O
increased,VBD,O
the,DT,O
systemic,JJ,O
exposure,NN,O
of,IN,O
cilostazol,NN,D
and/or,CC,O
its,PRP$,O
major,JJ,O
metabolites,NNS,O
.,.,.
,,
population,NNP,O
pharmacokinetic,JJ,O
studies,NNS,O
showed,VBD,O
higher,JJR,O
concentrations,NNS,O
of,IN,O
cilostazol,NN,D
among,IN,O
patients,NNS,O
concurrently,RB,O
treated,VBN,O
with,IN,O
diltiazem,NN,D
",",",",O
an,DT,O
inhibitor,NN,O
of,IN,O
c.p.a.,NNP,O
pletal,NNP,B
does,VBZ,O
not,RB,O
",",",",O
however,RB,O
",",",",O
appear,VBP,O
to,TO,O
cause,VB,O
increased,VBN,O
blood,NN,O
levels,NNS,O
of,IN,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
cyp3a4,NN,D
",",",",O
as,IN,O
it,PRP,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
lovastatin,NN,D
",",",",O
a,DT,O
drug,NN,D
with,IN,O
metabolism,NN,O
very,RB,O
sensitive,JJ,O
to,TO,O
c.p.a.,NNP,O
inhibition,NN,O
.,.,.
,,
tagamet,NNP,B
",",",",O
apparently,RB,O
through,IN,O
an,DT,O
effect,NN,O
on,IN,O
certain,JJ,O
microsomal,JJ,O
enzyme,NN,O
systems,NNS,O
",",",",O
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
reduce,VB,O
the,DT,O
hepatic,JJ,O
metabolism,NN,O
of,IN,O
warfarin-type,JJ,O
anticoagulants,NNS,G
",",",",O
phenytoin,NN,D
",",",",O
propranolol,NN,D
",",",",O
nifedipine,NN,D
",",",",O
chlordiazepoxide,NN,D
",",",",O
diazepam,NN,D
",",",",O
certain,JJ,O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
lidocaine,NN,D
",",",",O
theophylline,NN,D
and,CC,O
metronidazole,NN,D
",",",",O
thereby,RB,O
delaying,VBG,O
elimination,NN,O
and,CC,O
increasing,VBG,O
blood,NN,O
levels,NNS,O
of,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
clinically,RB,O
significant,JJ,O
effects,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
the,DT,O
warfarin,NN,D
anticoagulants,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
close,JJ,O
monitoring,NN,O
of,IN,O
prothrombin,NN,O
time,NN,O
is,VBZ,O
recommended,VBN,O
",",",",O
and,CC,O
adjustment,NN,O
of,IN,O
the,DT,O
anticoagulant,JJ,G
dose,NN,O
may,MD,O
be,VB,O
necessary,JJ,O
when,WRB,O
tagamet,NNP,B
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
interaction,NN,O
with,IN,O
phenytoin,NN,D
",",",",O
lidocaine,NN,D
and,CC,O
theophylline,NN,D
has,VBZ,O
also,RB,O
been,VBN,O
reported,VBN,O
to,TO,O
produce,VB,O
adverse,JJ,O
clinical,JJ,O
effects,NNS,O
.,.,.
,,
however,RB,O
",",",",O
a,DT,O
crossover,NN,O
study,NN,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
receiving,VBG,O
either,CC,O
tagamet,NNP,B
300,CD,O
mg,NN,O
q.i.d.,NN,O
or,CC,O
800,CD,O
mg,NN,O
h.s.,NN,O
concomitantly,RB,O
with,IN,O
a,DT,O
300,CD,O
mg,NN,O
b.i.d.,NN,O
dosage,NN,O
of,IN,O
theophylline,NN,D
-lrb-,-LRB-,O
theo-dur,NNP,B
",",",",O
key,NNP,O
pharmaceuticals,NNP,O
",",",",O
inc.,NNP,O
-rrb-,-RRB-,O
demonstrated,VBD,O
less,JJR,O
alteration,NN,O
in,IN,O
steady-state,JJ,O
theophylline,NN,D
peak,NN,O
serum,NN,O
levels,NNS,O
with,IN,O
the,DT,O
800,CD,O
mg,NN,O
h.s.,NN,O
regimen,NN,O
",",",",O
particularly,RB,O
in,IN,O
subjects,NNS,O
aged,JJ,O
54,CD,O
years,NNS,O
and,CC,O
older,JJR,O
.,.,.
,,
data,NNS,O
beyond,IN,O
10,CD,O
days,NNS,O
are,VBP,O
not,RB,O
available,JJ,O
.,.,.
,,
-lrb-,-LRB-,O
note,NN,O
:,:,O
all,DT,O
patients,NNS,O
receiving,VBG,O
theophylline,NN,D
should,MD,O
be,VB,O
monitored,VBN,O
appropriately,RB,O
",",",",O
regardless,RB,O
of,IN,O
concomitant,JJ,O
drug,NN,D
therapy,NN,O
.,.,.
,,
dosage,NN,O
of,IN,O
the,DT,O
drugs,NNS,D
mentioned,VBN,O
above,IN,O
and,CC,O
other,JJ,O
similarly,RB,O
metabolized,VBN,O
drugs,NNS,D
",",",",O
particularly,RB,O
those,DT,O
of,IN,O
low,JJ,O
therapeutic,JJ,O
ratio,NN,O
or,CC,O
in,IN,O
patients,NNS,O
with,IN,O
renal,JJ,O
and/or,CC,O
hepatic,JJ,O
impairment,NN,O
",",",",O
may,MD,O
require,VB,O
adjustment,NN,O
when,WRB,O
starting,VBG,O
or,CC,O
stopping,VBG,O
concomitantly,RB,O
administered,VBN,O
tagamet,NNP,B
to,TO,O
maintain,VB,O
optimum,JJ,O
therapeutic,JJ,O
blood,NN,O
levels,NNS,O
.,.,.
,,
alteration,NN,O
of,IN,O
ph,NN,O
may,MD,O
affect,VB,O
absorption,NN,O
of,IN,O
certain,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
ketoconazole,NN,D
-rrb-,-RRB-,O
.,.,.
,,
if,IN,O
these,DT,O
products,NNS,O
are,VBP,O
needed,VBN,O
",",",",O
they,PRP,O
should,MD,O
be,VB,O
given,VBN,O
at,IN,O
least,JJS,O
2,CD,O
hours,NNS,O
before,IN,O
cimetidine,NN,D
administration,NN,O
.,.,.
,,
additional,JJ,O
clinical,JJ,O
experience,NN,O
may,MD,O
reveal,VB,O
other,JJ,O
drugs,NNS,D
affected,VBN,O
by,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
tagamet,NNP,B
.,.,.
,,
and/or,CC,O
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
see,VB,O
clinical,NNP,O
pharmacology,NNP,O
",",",",O
pharmacokinetics,NNP,O
and,CC,O
drug,NNP,O
interactions,NNS,O
.,.,.
,,
effect,NN,O
of,IN,O
sensipar,NN,B
on,IN,O
other,JJ,O
drugs,NNS,D
:,:,O
drugs,NNS,O
metabolized,VBN,O
by,IN,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
-lrb-,-LRB-,O
cyp2d6,NN,D
-rrb-,-RRB-,O
:,:,O
sensipar,NN,B
is,VBZ,O
a,DT,O
strong,JJ,O
in,FW,O
vitro,FW,O
inhibitor,NN,O
of,IN,O
cyp2d6,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
dose,NN,O
adjustments,NNS,O
of,IN,O
concomitant,JJ,O
medications,NNS,O
that,WDT,O
are,VBP,O
predominantly,RB,O
metabolized,VBN,O
by,IN,O
cyp2d6,NN,D
and,CC,O
have,VBP,O
a,DT,O
narrow,JJ,O
therapeutic,JJ,O
index,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
flecainide,NN,D
",",",",O
vinblastine,NN,D
",",",",O
thioridazine,NN,D
and,CC,O
most,RBS,O
tricyclic,JJ,G
antidepressants,NNS,G
-rrb-,-RRB-,O
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
amitriptyline,NNP,D
:,:,O
concurrent,JJ,O
administration,NN,O
of,IN,O
25,CD,O
mg,NN,O
or,CC,O
100,CD,O
mg,NN,O
cinacalcet,NN,D
with,IN,O
50,CD,O
mg,NN,O
amitriptyline,NNP,D
increased,VBD,O
amitriptyline,NNP,D
exposure,NN,O
and,CC,O
nortriptyline,NN,D
-lrb-,-LRB-,O
active,JJ,O
metabolite,NN,O
-rrb-,-RRB-,O
exposure,NN,O
by,IN,O
approximately,RB,O
20,CD,O
%,NN,O
in,IN,O
cyp2d6,NN,D
extensive,JJ,O
metabolizers,NNS,O
.,.,.
,,
effect,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
on,IN,O
sensipar,NNP,B
:,:,O
sensipar,NNP,B
is,VBZ,O
metabolized,VBN,O
by,IN,O
multiple,JJ,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
",",",",O
primarily,RB,O
cyp3a4,NN,D
",",",",O
cyp2d6,NN,D
",",",",O
and,CC,O
cyp1a2,NN,D
.,.,.
,,
ketoconazole,NN,D
:,:,O
sensipar,NN,B
is,VBZ,O
metabolized,VBN,O
in,IN,O
part,NN,O
by,IN,O
cyp3a4,NN,D
.,.,.
,,
co-administration,NN,O
of,IN,O
ketoconazole,NN,D
",",",",O
a,DT,O
strong,JJ,O
inhibitor,NN,O
of,IN,O
cyp3a4,NN,D
",",",",O
increased,VBD,O
cinacalcet,NN,D
exposure,NN,O
following,VBG,O
a,DT,O
single,JJ,O
90,CD,O
mg,NN,O
dose,NN,O
of,IN,O
sensipar,NN,B
by,IN,O
2.3,CD,O
fold,NN,O
.,.,.
,,
dose,NN,O
adjustment,NN,O
of,IN,O
sensipar,NN,B
may,MD,O
be,VB,O
required,VBN,O
and,CC,O
pth,NN,O
and,CC,O
serum,NN,O
calcium,NN,D
concentrations,NNS,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
if,IN,O
a,DT,O
patient,NN,O
initiates,VBZ,O
or,CC,O
discontinues,VBZ,O
therapy,NN,O
with,IN,O
a,DT,O
strong,JJ,O
cyp3a4,NN,D
inhibitor,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
ketoconazole,NN,D
",",",",O
erythromycin,NN,D
",",",",O
itraconazole,NN,D
.,.,.
,,
see,VB,O
dosage,NNP,O
and,CC,O
administration,NNP,O
-rrb-,-RRB-,O
.,.,.
,,
elevated,JJ,O
plasma,NN,O
levels,NNS,O
of,IN,O
theophylline,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
some,DT,O
quinolones,NNS,G
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
theophylline-related,JJ,O
side-effects,NNS,O
in,IN,O
patients,NNS,O
on,IN,O
concomitant,JJ,O
theophylline-quinolone,JJ,O
therapy,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
monitoring,NN,O
of,IN,O
theophylline,NN,D
plasma,NN,O
levels,NNS,O
should,MD,O
be,VB,O
considered,VBN,O
and,CC,O
dosage,NN,O
of,IN,O
theophylline,NN,D
adjusted,VBN,O
as,IN,O
required,VBN,O
.,.,.
,,
quinolones,NNS,G
have,VBP,O
also,RB,O
been,VBN,O
shown,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
caffeine,NN,D
.,.,.
,,
this,DT,O
may,MD,O
lead,VB,O
to,TO,O
reduced,VBN,O
clearance,NN,O
of,IN,O
caffeine,NN,D
and,CC,O
a,DT,O
prolongation,NN,O
of,IN,O
its,PRP$,O
plasma,NN,O
half-life,NN,O
.,.,.
,,
although,IN,O
this,DT,O
interaction,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
reported,VBN,O
with,IN,O
cinoxacin,NN,D
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
cinoxacin,NN,D
is,VBZ,O
given,VBN,O
concomitantly,RB,O
with,IN,O
caffeine-containing,JJ,O
products,NNS,O
.,.,.
,,
antacids,NNS,G
or,CC,O
sucralfate,NN,D
substantially,RB,O
interfere,VBP,O
with,IN,O
the,DT,O
absorption,NN,O
of,IN,O
some,DT,O
quinolones,NNS,G
",",",",O
resulting,VBG,O
in,IN,O
low,JJ,O
urine,NN,O
levels,NNS,O
.,.,.
,,
also,RB,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
quinolones,NNS,G
with,IN,O
products,NNS,O
containing,VBG,O
iron,NN,D
",",",",O
multivitamins,NNS,G
containing,VBG,O
zinc,NN,D
",",",",O
or,CC,O
videx,NNP,B
-lrb-,-LRB-,O
didanosine,NN,D
-rrb-,-RRB-,O
chewable/buffered,VBD,O
tablets,NNS,O
or,CC,O
the,DT,O
pediatric,JJ,O
powder,NN,O
for,IN,O
oral,JJ,O
solution,NN,O
may,MD,O
result,VB,O
in,IN,O
low,JJ,O
urine,NN,O
levels,NNS,O
.,.,.
,,
quinolones,NNP,G
",",",",O
including,VBG,O
cinoxacin,NN,D
",",",",O
may,MD,O
enhance,VB,O
the,DT,O
effects,NNS,O
of,IN,O
oral,JJ,O
anticoagulants,NNS,G
",",",",O
such,JJ,O
as,IN,O
warfarin,NN,D
or,CC,O
its,PRP$,O
derivatives,NNS,O
.,.,.
,,
when,WRB,O
these,DT,O
products,NNS,O
are,VBP,O
administered,VBN,O
concomitantly,RB,O
",",",",O
prothrombin,NN,O
time,NN,O
or,CC,O
other,JJ,O
suitable,JJ,O
coagulation,NN,O
tests,NNS,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
.,.,.
,,
seizures,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
taking,VBG,O
another,DT,O
quinolone,NN,G
class,NN,O
antimicrobial,JJ,O
and,CC,O
the,DT,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drug,NN,D
fenbufen,NN,D
concurrently,RB,O
.,.,.
,,
animal,NN,O
studies,NNS,O
also,RB,O
suggest,VBP,O
an,DT,O
increased,VBN,O
potential,NN,O
for,IN,O
seizures,NNS,O
when,WRB,O
these,DT,O
2,CD,O
drugs,NNS,D
are,VBP,O
given,VBN,O
concomitantly,RB,O
.,.,.
,,
fenbufen,NNP,D
is,VBZ,O
not,RB,O
approved,VBN,O
in,IN,O
the,DT,O
united,NNP,O
states,NNPS,O
at,IN,O
this,DT,O
time,NN,O
.,.,.
,,
physicians,NNP,O
are,VBP,O
provided,VBN,O
this,DT,O
information,NN,O
to,TO,O
increase,VB,O
awareness,NN,O
of,IN,O
the,DT,O
potential,NN,O
for,IN,O
serious,JJ,O
interactions,NNS,O
when,WRB,O
cinoxacin,NN,D
and,CC,O
certain,JJ,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
are,VBP,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
elevated,JJ,O
cyclosporine,NN,D
serum,NN,O
levels,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
quinolones,NNS,G
and,CC,O
cyclosporine,NN,D
.,.,.
,,
some,DT,O
quinolones,NNS,G
",",",",O
including,VBG,O
ciprofloxacin,NN,D
",",",",O
have,VBP,O
also,RB,O
been,VBN,O
shown,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
caffeine,NN,D
.,.,.
,,
this,DT,O
may,MD,O
lead,VB,O
to,TO,O
reduced,VBN,O
clearance,NN,O
of,IN,O
caffeine,NN,D
and,CC,O
a,DT,O
prolongation,NN,O
of,IN,O
its,PRP$,O
serum,NN,O
half-life,NN,O
.,.,.
,,
some,DT,O
quinolones,NNS,G
",",",",O
including,VBG,O
ciprofloxacin,NN,D
",",",",O
have,VBP,O
been,VBN,O
associated,VBN,O
with,IN,O
transient,JJ,O
elevations,NNS,O
in,IN,O
serum,NN,O
creatinine,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
cyclosporine,NN,D
concomitantly,RB,O
.,.,.
,,
glyburide,NNP,D
:,:,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
ciprofloxacin,NN,D
with,IN,O
the,DT,O
sulfonylurea,NN,G
glyburide,NN,D
has,VBZ,O
",",",",O
on,IN,O
rare,JJ,O
occasions,NNS,O
",",",",O
resulted,VBD,O
in,IN,O
severe,JJ,O
hypoglycemia,NN,O
.,.,.
,,
histamine,NN,O
h2-receptor,NN,O
antagonists,NNS,O
:,:,O
histamine,NN,O
h2-receptor,NN,O
antagonists,NNS,O
appear,VBP,O
to,TO,O
have,VB,O
no,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
bioavailability,NN,O
of,IN,O
ciprofloxacin,NN,D
.,.,.
,,
methotrexate,NNP,D
renal,JJ,O
tubular,JJ,O
transport,NN,O
of,IN,O
methotrexate,NN,D
may,MD,O
be,VB,O
inhibited,VBN,O
by,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
ciprofloxacin,NN,D
",",",",O
potentially,RB,O
leading,VBG,O
to,TO,O
increased,VBN,O
plasma,NN,O
levels,NNS,O
of,IN,O
methotrexate,NN,D
.,.,.
,,
this,DT,O
might,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
methotrexate,NN,D
toxic,JJ,O
reactions,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
patients,NNS,O
under,IN,O
methotrexate,NN,D
therapy,NN,O
should,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
when,WRB,O
concomitant,JJ,O
ciprofloxacin,NN,D
therapy,NN,O
is,VBZ,O
indicated,VBN,O
.,.,.
,,
multivalent,JJ,O
cation-containing,NNP,O
products,NNPS,O
:,:,O
concurrent,JJ,O
administration,NN,O
of,IN,O
a,DT,O
quinolone,NN,G
",",",",O
including,VBG,O
ciprofloxacin,NN,D
",",",",O
with,IN,O
multivalent,JJ,O
cation-containing,JJ,O
products,NNS,O
such,JJ,O
as,IN,O
magnesium,NN,D
or,CC,O
aluminum,NN,D
antacids,NNS,G
",",",",O
sucralfate,NN,D
",",",",O
videx,NNP,B
chewable/buffered,VBD,O
tablets,NNS,O
or,CC,O
pediatric,JJ,O
powder,NN,O
",",",",O
or,CC,O
products,NNS,O
containing,VBG,O
calcium,NN,D
",",",",O
iron,NN,D
",",",",O
or,CC,O
zinc,NN,D
may,MD,O
substantially,RB,O
decrease,VB,O
the,DT,O
absorption,NN,O
of,IN,O
ciprofloxacin,NN,D
",",",",O
resulting,VBG,O
in,IN,O
serum,NN,O
and,CC,O
urine,NN,O
levels,NNS,O
considerably,RB,O
lower,JJR,O
than,IN,O
desired,VBN,O
.,.,.
,,
proquin,NNP,O
xr,NNP,O
should,MD,O
be,VB,O
administered,VBN,O
at,IN,O
least,JJS,O
4,CD,O
hours,NNS,O
before,IN,O
or,CC,O
2,CD,O
hours,NNS,O
after,IN,O
these,DT,O
products,NNS,O
.,.,.
,,
this,DT,O
time,NN,O
window,NN,O
is,VBZ,O
different,JJ,O
than,IN,O
for,IN,O
other,JJ,O
oral,JJ,O
formulations,NNS,O
of,IN,O
ciprofloxacin,NN,D
",",",",O
which,WDT,O
are,VBP,O
usually,RB,O
administered,VBN,O
2,CD,O
hours,NNS,O
before,IN,O
or,CC,O
6,CD,O
hours,NNS,O
after,IN,O
antacids,NNS,G
.,.,.
,,
non-steroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
-lrb-,-LRB-,O
but,CC,O
not,RB,O
aspirin,NN,B
-rrb-,-RRB-,O
:,:,O
these,DT,O
drugs,NNS,D
in,IN,O
combination,NN,O
with,IN,O
very,RB,O
high,JJ,O
doses,NNS,O
of,IN,O
quinolones,NNS,G
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
provoke,VB,O
convulsions,NNS,O
in,IN,O
pre-clinical,JJ,O
studies,NNS,O
.,.,.
,,
omeprazole,NNP,D
:,:,O
the,DT,O
rate,NN,O
and,CC,O
extent,NN,O
of,IN,O
absorption,NN,O
of,IN,O
ciprofloxacin,NN,D
was,VBD,O
bioequivalent,JJ,O
when,WRB,O
proquin,NNP,O
xr,NNP,O
was,VBD,O
given,VBN,O
alone,RB,O
or,CC,O
when,WRB,O
proquin,NNP,O
xr,NNP,O
was,VBD,O
given,VBN,O
2,CD,O
hours,NNS,O
after,IN,O
omeprazole,NN,D
at,IN,O
the,DT,O
dose,NN,O
that,WDT,O
maximally,RB,O
suppresses,VBZ,O
gastric,JJ,O
acid,NN,O
secretion,NN,O
.,.,.
,,
omeprazole,NNP,D
should,MD,O
be,VB,O
taken,VBN,O
as,IN,O
directed,VBN,O
and,CC,O
proquin,NNP,O
xr,NN,O
should,MD,O
be,VB,O
taken,VBN,O
with,IN,O
a,DT,O
main,JJ,O
meal,NN,O
of,IN,O
the,DT,O
day,NN,O
",",",",O
preferably,RB,O
the,DT,O
evening,NN,O
meal,NN,O
.,.,.
,,
phenytoin,NNP,D
:,:,O
altered,JJ,O
serum,NN,O
levels,NNS,O
of,IN,O
phenytoin,NN,D
-lrb-,-LRB-,O
increased,VBN,O
and,CC,O
decreased,VBN,O
-rrb-,-RRB-,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
ciprofloxacin,NN,D
.,.,.
,,
probenecid,NNP,D
:,:,O
probenecid,NNP,D
interferes,VBZ,O
with,IN,O
renal,JJ,O
tubular,JJ,O
secretion,NN,O
of,IN,O
ciprofloxacin,NN,D
and,CC,O
produces,VBZ,O
an,DT,O
increase,NN,O
in,IN,O
the,DT,O
level,NN,O
of,IN,O
ciprofloxacin,NN,D
in,IN,O
serum,NN,O
.,.,.
,,
theophylline,NNP,D
:,:,O
as,IN,O
with,IN,O
some,DT,O
other,JJ,O
quinolones,NNS,G
",",",",O
concurrent,JJ,O
administration,NN,O
of,IN,O
ciprofloxacin,NN,D
with,IN,O
theophylline,NN,D
may,MD,O
lead,VB,O
to,TO,O
elevated,JJ,O
serum,NN,O
concentrations,NNS,O
of,IN,O
theophylline,NN,D
and,CC,O
prolongation,NN,O
of,IN,O
its,PRP$,O
elimination,NN,O
half-life,NN,O
.,.,.
,,
this,DT,O
may,MD,O
result,VB,O
in,IN,O
increased,VBN,O
risk,NN,O
of,IN,O
theophylline-related,JJ,O
adverse,JJ,O
reactions,NNS,O
.,.,.
,,
if,IN,O
concomitant,JJ,O
use,NN,O
can,MD,O
not,RB,O
be,VB,O
avoided,VBN,O
",",",",O
serum,NN,O
levels,NNS,O
of,IN,O
theophylline,NN,D
should,MD,O
be,VB,O
monitored,VBN,O
and,CC,O
dosage,NN,O
adjustments,NNS,O
made,VBN,O
as,IN,O
appropriate,JJ,O
.,.,.
,,
warfarin,NNP,D
:,:,O
quinolones,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
enhance,VB,O
the,DT,O
effects,NNS,O
of,IN,O
the,DT,O
oral,JJ,O
anticoagulant,JJ,G
warfarin,NN,D
or,CC,O
its,PRP$,O
derivatives,NNS,O
.,.,.
,,
when,WRB,O
these,DT,O
products,NNS,O
are,VBP,O
administered,VBN,O
concomitantly,RB,O
",",",",O
prothrombin,NN,O
time,NN,O
or,CC,O
other,JJ,O
suitable,JJ,O
coagulation,NN,O
tests,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
.,.,.
,,
cisapride,NNP,D
is,VBZ,O
metabolized,VBN,O
mainly,RB,O
via,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
enzyme,NN,O
.,.,.
,,
in,IN,O
some,DT,O
cases,NNS,O
where,WRB,O
serious,JJ,O
ventricular,JJ,O
arrhythmias,NNS,O
",",",",O
qt,NN,O
prolongation,NN,O
",",",",O
and,CC,O
torsades,NNS,O
de,IN,O
pointes,NNS,O
have,VBP,O
occurred,VBN,O
when,WRB,O
cisapride,NN,D
was,VBD,O
taken,VBN,O
in,IN,O
conjunction,NN,O
with,IN,O
one,CD,O
of,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
inhibitors,NNS,O
",",",",O
elevated,JJ,O
blood,NN,O
cisapride,NN,D
levels,NNS,O
were,VBD,O
noted,VBN,O
at,IN,O
the,DT,O
time,NN,O
of,IN,O
the,DT,O
qt,NNP,O
prolongation,NN,O
.,.,.
,,
antibiotics,NNS,G
:,:,O
in,FW,O
vitro,FW,O
and/or,CC,O
in,FW,O
vivo,FW,O
data,NNS,O
show,VBP,O
that,IN,O
clarithromycin,NN,D
",",",",O
erythromycin,NN,D
",",",",O
and,CC,O
troleandomycin,NN,D
markedly,RB,O
inhibit,VBP,O
the,DT,O
metabolism,NN,O
of,IN,O
cisapride,NN,D
",",",",O
which,WDT,O
can,MD,O
result,VB,O
in,IN,O
an,DT,O
increase,NN,O
in,IN,O
plasma,NN,O
cisapride,NN,D
levels,NNS,O
and,CC,O
prolongation,NN,O
of,IN,O
the,DT,O
qt,NNP,O
interval,NN,O
on,IN,O
the,DT,O
ecg,NN,O
.,.,.
,,
anticholinergics,NNP,G
:,:,O
concurrent,JJ,O
administration,NN,O
of,IN,O
certain,JJ,O
anticholinergic,JJ,G
compounds,NNS,O
",",",",O
such,JJ,O
as,IN,O
belladonna,NN,O
alkaloids,NNS,O
and,CC,O
dicyclomine,NN,D
",",",",O
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
compromise,VB,O
the,DT,O
beneficial,JJ,O
effects,NNS,O
of,IN,O
cisapride,NN,D
.,.,.
,,
anticoagulants,NNS,G
-lrb-,-LRB-,O
oral,JJ,O
-rrb-,-RRB-,O
:,:,O
in,IN,O
patients,NNS,O
receiving,VBG,O
oral,JJ,O
anticoagulants,NNS,G
",",",",O
the,DT,O
coagulation,NN,O
times,NNS,O
were,VBD,O
increased,VBN,O
in,IN,O
some,DT,O
cases,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
advisable,JJ,O
to,TO,O
check,VB,O
coagulation,NN,O
time,NN,O
within,IN,O
the,DT,O
first,JJ,O
few,JJ,O
days,NNS,O
after,IN,O
the,DT,O
start,NN,O
and,CC,O
discontinuation,NN,O
of,IN,O
cisapride,NN,D
therapy,NN,O
",",",",O
with,IN,O
an,DT,O
appropriate,JJ,O
adjustment,NN,O
of,IN,O
the,DT,O
anticoagulant,JJ,G
dose,NN,O
",",",",O
if,IN,O
necessary,JJ,O
.,.,.
,,
antidepressants,NNS,G
:,:,O
in,FW,O
vitro,FW,O
data,NNS,O
indicate,VBP,O
that,IN,O
nefazodone,NN,D
inhibits,VBZ,O
the,DT,O
metabolism,NN,O
of,IN,O
cisapride,NN,D
",",",",O
which,WDT,O
can,MD,O
result,VB,O
in,IN,O
an,DT,O
increase,NN,O
in,IN,O
plasma,NN,O
cisapride,NN,D
levels,NNS,O
and,CC,O
prolongation,NN,O
of,IN,O
the,DT,O
qt,NNP,O
interval,NN,O
on,IN,O
the,DT,O
ecg,NN,O
.,.,.
,,
antifungals,NNS,G
:,:,O
in,FW,O
vitro,FW,O
and/or,CC,O
in,FW,O
vivo,FW,O
data,NNS,O
indicate,VBP,O
that,IN,O
fluconazole,NN,D
",",",",O
itraconazole,NN,D
",",",",O
and,CC,O
oral,JJ,O
ketoconazole,NN,D
markedly,RB,O
inhibit,VBP,O
the,DT,O
metabolism,NN,O
of,IN,O
cisapride,NN,D
",",",",O
which,WDT,O
can,MD,O
result,VB,O
in,IN,O
an,DT,O
increase,NN,O
in,IN,O
plasma,NN,O
cisapride,NN,D
levels,NNS,O
and,CC,O
prolongation,NN,O
of,IN,O
the,DT,O
qt,NNP,O
interval,NN,O
on,IN,O
the,DT,O
ecg,NN,O
.,.,.
,,
human,JJ,O
pharmacokinetic,JJ,O
data,NNS,O
indicate,VBP,O
that,IN,O
oral,JJ,O
ketoconazole,NN,D
markedly,RB,O
inhibits,VBZ,O
the,DT,O
metabolism,NN,O
of,IN,O
cisapride,NN,D
",",",",O
resulting,VBG,O
in,IN,O
a,DT,O
mean,NN,O
eight-fold,JJ,O
increase,NN,O
in,IN,O
auc,NN,O
of,IN,O
cisapride,NN,D
.,.,.
,,
a,DT,O
study,NN,O
in,IN,O
14,CD,O
normal,JJ,O
male,NN,O
and,CC,O
female,JJ,O
volunteers,NNS,O
suggests,VBZ,O
that,IN,O
coadministration,NN,O
of,IN,O
cisapride,NN,D
and,CC,O
ketoconazole,NN,D
can,MD,O
result,VB,O
in,IN,O
prolongation,NN,O
of,IN,O
the,DT,O
qt,NNP,O
interval,NN,O
on,IN,O
the,DT,O
ecg,NN,O
.,.,.
,,
h2,NN,O
receptor,NN,O
antagonists,NNS,O
:,:,O
cimetidine,NN,D
coadministration,NN,O
leads,VBZ,O
to,TO,O
an,DT,O
increased,VBN,O
peak,NN,O
plasma,NN,O
concentration,NN,O
and,CC,O
auc,NN,O
of,IN,O
cisapride,NN,D
",",",",O
there,EX,O
is,VBZ,O
no,DT,O
effect,NN,O
on,IN,O
cisapride,NN,D
absorption,NN,O
when,WRB,O
it,PRP,O
is,VBZ,O
coadministered,VBN,O
with,IN,O
ranitidine,NN,D
.,.,.
,,
the,DT,O
gastrointestinal,JJ,O
absorption,NN,O
of,IN,O
cimetidine,NN,D
and,CC,O
ranitidine,NN,D
is,VBZ,O
accelerated,VBN,O
when,WRB,O
they,PRP,O
are,VBP,O
coadministered,VBN,O
with,IN,O
cisapride,NN,D
.,.,.
,,
protease,NN,O
inhibitors,NNS,O
:,:,O
in,FW,O
vitro,FW,O
data,NNS,O
indicate,VBP,O
that,IN,O
indinavir,NN,D
and,CC,O
ritonavir,NN,D
markedly,RB,O
inhibit,VBP,O
the,DT,O
metabolism,NN,O
of,IN,O
cisapride,NN,D
which,WDT,O
can,MD,O
result,VB,O
in,IN,O
an,DT,O
increase,NN,O
in,IN,O
plasma,NN,O
cisapride,NN,D
levels,NNS,O
and,CC,O
prolongation,NN,O
of,IN,O
the,DT,O
qt,NNP,O
interval,NN,O
on,IN,O
the,DT,O
ecg,NN,O
.,.,.
,,
other,JJ,O
:,:,O
coadministration,NN,O
of,IN,O
grapefruit,NN,O
juice,NN,O
with,IN,O
cisapride,NN,D
increases,VBZ,O
the,DT,O
bioavailability,NN,O
of,IN,O
cisapride,NN,D
and,CC,O
concomitant,JJ,O
use,NN,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
cisapride,NNP,D
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
concomitantly,RB,O
with,IN,O
other,JJ,O
drugs,NNS,D
known,VBN,O
to,TO,O
prolong,VB,O
the,DT,O
qt,NNP,O
interval,NN,O
:,:,O
certain,JJ,O
antiarrhythmics,NNS,G
",",",",O
including,VBG,O
those,DT,O
of,IN,O
class,NNP,O
ia,NNP,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
quinidine,NN,D
and,CC,O
procainamide,NN,D
-rrb-,-RRB-,O
and,CC,O
class,NN,O
iii,CD,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
sotalol,NN,D
-rrb-,-RRB-,O
.,.,.
,,
tricyclic,JJ,G
antidepressants,NNS,G
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
amitriptyline,NNP,D
-rrb-,-RRB-,O
.,.,.
,,
certain,JJ,O
tetracyclic,JJ,O
antidepressants,NNS,G
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
maprotiline,NN,D
-rrb-,-RRB-,O
.,.,.
,,
certain,JJ,O
antipsychotic,JJ,O
medications,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
sertindole,NN,D
-rrb-,-RRB-,O
.,.,.
,,
astemizole,NN,D
",",",",O
bepridil,NN,D
",",",",O
sparfloxacin,NN,D
",",",",O
and,CC,O
terodiline,NN,D
.,.,.
,,
the,DT,O
preceding,VBG,O
lists,NNS,O
of,IN,O
drugs,NNS,D
are,VBP,O
not,RB,O
comprehensive,JJ,O
.,.,.
,,
the,DT,O
acceleration,NN,O
of,IN,O
gastric,JJ,O
emptying,NN,O
by,IN,O
cisapride,NN,D
could,MD,O
affect,VB,O
the,DT,O
rate,NN,O
of,IN,O
absorption,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
.,.,.
,,
patients,NNS,O
receiving,VBG,O
narrow,JJ,O
therapeutic,JJ,O
ratio,NN,O
drugs,NNS,D
or,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
require,VBP,O
careful,JJ,O
titration,NN,O
should,MD,O
be,VB,O
followed,VBN,O
closely,RB,O
;,:,O
.,.,.
,,
if,IN,O
plasma,NN,O
levels,NNS,O
are,VBP,O
being,VBG,O
monitored,VBN,O
",",",",O
they,PRP,O
should,MD,O
be,VB,O
reassessed,VBN,O
.,.,.
,,
administration,NN,O
of,IN,O
0.1-mg,JJ,O
/,:,O
kg,NN,O
-lrb-,-LRB-,O
2,CD,O
x,CC,O
ed95,NN,O
-rrb-,-RRB-,O
nimbex,NN,B
at,IN,O
10,CD,O
%,NN,O
or,CC,O
95,CD,O
%,NN,O
recovery,NN,O
following,VBG,O
an,DT,O
intubating,VBG,O
dose,NN,O
of,IN,O
succinylcholine,NN,D
-lrb-,-LRB-,O
1,CD,O
mg/kg,NN,O
-rrb-,-RRB-,O
produced,VBD,O
95,CD,O
%,NN,O
neuromuscular,JJ,O
block,NN,O
.,.,.
,,
the,DT,O
time,NN,O
to,TO,O
onset,NN,O
of,IN,O
maximum,NN,O
block,NN,O
following,VBG,O
nimbex,NNP,B
is,VBZ,O
approximately,RB,O
2,CD,O
minutes,NNS,O
faster,RBR,O
with,IN,O
prior,JJ,O
administration,NN,O
of,IN,O
succinylcholine,NN,D
.,.,.
,,
prior,RB,O
administration,NN,O
of,IN,O
succinylcholine,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
duration,NN,O
of,IN,O
neuromuscular,JJ,O
block,NN,O
following,VBG,O
initial,JJ,O
or,CC,O
maintenance,NN,O
bolus,NN,O
doses,NNS,O
of,IN,O
nimbex,NNP,B
.,.,.
,,
infusion,NN,O
requirements,NNS,O
of,IN,O
nimbex,NNP,B
in,IN,O
patients,NNS,O
administered,VBN,O
succinylcholine,NN,D
prior,RB,O
to,TO,O
infusions,NNS,O
of,IN,O
nimbex,NNP,B
were,VBD,O
comparable,JJ,O
to,TO,O
or,CC,O
slightly,RB,O
greater,JJR,O
than,IN,O
when,WRB,O
succinylcholine,NN,D
was,VBD,O
not,RB,O
administered,VBN,O
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
nimbex,NN,B
before,IN,O
succinylcholine,NN,D
to,TO,O
attenuate,VB,O
some,DT,O
of,IN,O
the,DT,O
side,JJ,O
effects,NNS,O
of,IN,O
succinylcholine,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
although,IN,O
not,RB,O
studied,VBN,O
systematically,RB,O
in,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
no,DT,O
drug,NN,D
interactions,NNS,O
were,VBD,O
observed,VBN,O
when,WRB,O
vecuronium,NN,D
",",",",O
pancuronium,NN,D
",",",",O
or,CC,O
atracurium,NN,D
were,VBD,O
administered,VBN,O
following,VBG,O
varying,VBG,O
degrees,NNS,O
of,IN,O
recovery,NN,O
from,IN,O
single,JJ,O
doses,NNS,O
or,CC,O
infusions,NNS,O
of,IN,O
nimbex,NNP,B
.,.,.
,,
isoflurane,NN,D
or,CC,O
enflurane,NN,D
administered,VBN,O
with,IN,O
nitrous,JJ,O
oxide/oxygen,NN,O
to,TO,O
achieve,VB,O
1.25,CD,O
mac,NNP,O
-lsb-,-LRB-,O
minimum,NNP,O
alveolar,JJ,O
concentration,NN,O
-rsb-,-RRB-,O
may,MD,O
prolong,VB,O
the,DT,O
clinically,RB,O
effective,JJ,O
duration,NN,O
of,IN,O
action,NN,O
of,IN,O
initial,JJ,O
and,CC,O
maintenance,NN,O
doses,NNS,O
of,IN,O
nimbex,NNP,B
and,CC,O
decrease,VB,O
the,DT,O
required,VBN,O
infusion,NN,O
rate,NN,O
of,IN,O
nimbex,NNP,B
.,.,.
,,
the,DT,O
magnitude,NN,O
of,IN,O
these,DT,O
effects,NNS,O
may,MD,O
depend,VB,O
on,IN,O
the,DT,O
duration,NN,O
of,IN,O
administration,NN,O
of,IN,O
the,DT,O
volatile,JJ,O
agents,NNS,O
.,.,.
,,
fifteen,CD,O
to,TO,O
30,CD,O
minutes,NNS,O
of,IN,O
exposure,NN,O
to,TO,O
1.25,CD,O
mac,NNP,O
isoflurane,NN,D
or,CC,O
enflurane,NN,D
had,VBD,O
minimal,JJ,O
effects,NNS,O
on,IN,O
the,DT,O
duration,NN,O
of,IN,O
action,NN,O
of,IN,O
initial,JJ,O
doses,NNS,O
of,IN,O
nimbex,NNP,B
and,CC,O
therefore,RB,O
",",",",O
no,DT,O
adjustment,NN,O
to,TO,O
the,DT,O
initial,JJ,O
dose,NN,O
should,MD,O
be,VB,O
necessary,JJ,O
when,WRB,O
nimbex,NNP,B
is,VBZ,O
administered,VBN,O
shortly,RB,O
after,IN,O
initiation,NN,O
of,IN,O
volatile,JJ,O
agents,NNS,O
.,.,.
,,
in,IN,O
long,JJ,O
surgical,JJ,O
procedures,NNS,O
during,IN,O
enflurane,NN,D
or,CC,O
isoflurane,NN,D
anesthesia,NN,D
",",",",O
less,JJR,O
frequent,JJ,O
maintenance,NN,O
dosing,NN,O
",",",",O
lower,JJR,O
maintenance,NN,O
doses,NNS,O
",",",",O
or,CC,O
reduced,VBN,O
infusion,NN,O
rates,NNS,O
of,IN,O
nimbex,NNP,B
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
the,DT,O
average,JJ,O
infusion,NN,O
rate,NN,O
requirement,NN,O
may,MD,O
be,VB,O
decreased,VBN,O
by,IN,O
as,RB,O
much,JJ,O
as,IN,O
30,CD,O
%,NN,O
to,TO,O
40,CD,O
%,NN,O
.,.,.
,,
in,IN,O
clinical,JJ,O
studies,NNS,O
propofol,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
duration,NN,O
of,IN,O
action,NN,O
or,CC,O
dosing,NN,O
requirements,NNS,O
for,IN,O
nimbex,NNP,B
.,.,.
,,
other,JJ,O
drugs,NNS,D
which,WDT,O
may,MD,O
enhance,VB,O
the,DT,O
neuromuscular,JJ,O
blocking,VBG,O
action,NN,O
of,IN,O
nondepolarizing,JJ,O
agents,NNS,O
such,JJ,O
as,IN,O
nimbex,NNP,B
include,VBP,O
certain,JJ,O
antibiotics,NNS,G
-lrb-,-LRB-,O
e.,FW,O
g.,FW,O
",",",",O
aminoglycosides,NNS,G
",",",",O
tetracyclines,NNS,G
",",",",O
bacitracin,NN,G
",",",",O
polymyxins,NNS,G
",",",",O
lincomycin,NN,D
",",",",O
clindamycin,NN,D
",",",",O
colistin,NN,D
",",",",O
and,CC,O
sodium,NN,O
colistemethate,NN,O
-rrb-,-RRB-,O
",",",",O
magnesium,NN,D
salts,NNS,O
",",",",O
lithium,NN,D
",",",",O
local,JJ,O
anesthetics,NNS,G
",",",",O
procainamide,NN,D
",",",",O
and,CC,O
quinidine,NN,D
.,.,.
,,
resistance,NN,O
to,TO,O
the,DT,O
neuromuscular,JJ,O
blocking,VBG,O
action,NN,O
of,IN,O
nondepolarizing,JJ,O
neuromuscular,JJ,O
blocking,VBG,O
agents,NNS,O
has,VBZ,O
been,VBN,O
demonstrated,VBN,O
in,IN,O
patients,NNS,O
chronically,RB,O
administered,VBN,O
phenytoin,NN,D
or,CC,O
carbamazepine,NN,D
.,.,.
,,
while,IN,O
the,DT,O
effects,NNS,O
of,IN,O
chronic,JJ,O
phenytoin,NN,D
or,CC,O
carbamazepine,NN,D
therapy,NN,O
on,IN,O
the,DT,O
action,NN,O
of,IN,O
nimbex,NNP,B
are,VBP,O
unknown,JJ,O
",",",",O
slightly,RB,O
shorter,JJR,O
durations,NNS,O
of,IN,O
neuromuscular,JJ,O
block,NN,O
may,MD,O
be,VB,O
anticipated,VBN,O
and,CC,O
infusion,NN,O
rate,NN,O
requirements,NNS,O
may,MD,O
be,VB,O
higher,JJR,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
none,NN,O
known,VBN,O
.,.,.
,,
plasma,NN,O
levels,NNS,O
of,IN,O
anticonvulsant,JJ,G
agents,NNS,O
may,MD,O
become,VB,O
subtherapeutic,JJ,O
during,IN,O
cisplatin,NN,D
therapy,NN,O
.,.,.
,,
central,NNP,O
nervous,JJ,O
system,NN,O
depressant,NN,O
-lrb-,-LRB-,O
cns,NN,O
-rrb-,-RRB-,O
drugs,NNS,D
including,VBG,O
alcohol,NN,D
",",",",O
antidepressants,NNS,G
",",",",O
antihistamines,NNS,G
",",",",O
antipsychotics,NNS,G
",",",",O
blood,NN,O
pressure,NN,O
medications,NNS,O
-lrb-,-LRB-,O
reserpine,NN,D
",",",",O
methyldopa,NN,D
",",",",O
beta-blockers,NNS,G
-rrb-,-RRB-,O
",",",",O
motion,NN,O
sickness,NN,O
medications,NNS,O
",",",",O
muscle,NN,O
relaxants,NNS,O
",",",",O
narcotics,NNS,G
",",",",O
sedatives,NNS,G
",",",",O
sleeping,VBG,O
pills,NNS,O
and,CC,O
tranquilizer,NN,O
.,.,.
,,
there,EX,O
are,VBP,O
no,RB,O
known,VBN,O
drug,NN,D
interactions,NNS,O
with,IN,O
leustatin,NNP,B
injection,NN,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
if,IN,O
leustatin,NNP,B
injection,NN,O
is,VBZ,O
administered,VBN,O
before,RB,O
",",",",O
after,IN,O
",",",",O
or,CC,O
in,IN,O
conjunction,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
known,VBN,O
to,TO,O
cause,VB,O
immunosuppression,NN,O
or,CC,O
myelosuppression,NN,O
.,.,.
,,
the,DT,O
concurrent,JJ,O
administration,NN,O
of,IN,O
allopurinol,NN,D
and,CC,O
ampicillin,NN,D
increases,NNS,O
substantially,RB,O
the,DT,O
incidence,NN,O
of,IN,O
rashes,NNS,O
in,IN,O
patients,NNS,O
receiving,VBG,O
both,CC,O
drugs,NNS,D
as,IN,O
compared,VBN,O
to,TO,O
patients,NNS,O
receiving,VBG,O
ampicillin,NN,D
alone,RB,O
.,.,.
,,
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
whether,IN,O
this,DT,O
potentiation,NN,O
of,IN,O
ampicillin,NN,D
rashes,NNS,O
is,VBZ,O
due,JJ,O
to,TO,O
allopurinol,NN,D
or,CC,O
the,DT,O
hyperuricemia,NN,O
present,JJ,O
in,IN,O
these,DT,O
patients,NNS,O
.,.,.
,,
in,IN,O
controlled,JJ,O
clinical,JJ,O
trials,NNS,O
of,IN,O
augmentin,NNP,O
xr,NNP,O
",",",",O
22,CD,O
patients,NNS,O
received,VBD,O
concomitant,JJ,O
allopurinol,NN,D
and,CC,O
augmentin,NNP,O
xr,NNP,O
.,.,.
,,
no,DT,O
rashes,NNS,O
were,VBD,O
reported,VBN,O
in,IN,O
these,DT,O
patients,NNS,O
.,.,.
,,
however,RB,O
",",",",O
this,DT,O
sample,NN,O
size,NN,O
is,VBZ,O
too,RB,O
small,JJ,O
to,TO,O
allow,VB,O
for,IN,O
any,DT,O
conclusions,NNS,O
to,TO,O
be,VB,O
drawn,VBN,O
regarding,VBG,O
the,DT,O
risk,NN,O
of,IN,O
rashes,NNS,O
with,IN,O
concomitant,JJ,O
augmentin,NNP,O
xr,NN,O
and,CC,O
allopurinol,NN,D
use,NN,O
.,.,.
,,
in,IN,O
common,JJ,O
with,IN,O
other,JJ,O
broad-spectrum,JJ,O
antibiotics,NNS,G
",",",",O
augmentin,NNP,O
xr,NNP,O
may,MD,O
reduce,VB,O
the,DT,O
efficacy,NN,O
of,IN,O
oral,JJ,O
contraceptive,NN,G
.,.,.
,,
additive,JJ,O
cns,NN,O
depression,NN,O
may,MD,O
occur,VB,O
when,WRB,O
antihistamines,NNS,G
are,VBP,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
other,JJ,O
cns,NN,O
depressants,NNS,O
including,VBG,O
barbiturates,NNS,G
",",",",O
tranquilizers,NNS,G
",",",",O
and,CC,O
alcohol,NN,D
.,.,.
,,
patients,NNS,O
receiving,VBG,O
antihistamines,NNS,G
should,MD,O
be,VB,O
advised,VBN,O
against,IN,O
the,DT,O
concurrent,JJ,O
use,NN,O
of,IN,O
other,JJ,O
cns,NNS,O
depressant,NN,O
drugs,NNS,D
.,.,.
,,
monoamine,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
mao,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
prolong,VB,O
and,CC,O
intensify,VB,O
the,DT,O
anticholinergic,JJ,G
effects,NNS,O
of,IN,O
antihistamines,NNS,G
.,.,.
,,
amantadine,NNP,D
",",",",O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
and,CC,O
maois,NNS,G
may,MD,O
increase,VB,O
anticholinergic,JJ,G
effect,NN,O
of,IN,O
clidinium,NN,D
.,.,.
,,
clidinium,NNP,D
may,MD,O
decrease,VB,O
the,DT,O
effect,NN,O
of,IN,O
phenothiazines,NNS,G
",",",",O
levodopa,NN,D
",",",",O
and,CC,O
ketoconazole,NN,D
.,.,.
,,
clindamycin,NNP,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
have,VB,O
neuromuscular,JJ,O
blocking,VBG,O
properties,NNS,O
that,WDT,O
may,MD,O
enhance,VB,O
the,DT,O
action,NN,O
of,IN,O
other,JJ,O
neuromuscular,JJ,O
blocking,VBG,O
agents,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
it,PRP,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
such,JJ,O
agents,NNS,O
.,.,.
,,
antagonism,NN,O
has,VBZ,O
been,VBN,O
demonstrated,VBN,O
between,IN,O
clindamycin,NN,D
and,CC,O
erythromycin,NN,D
in,FW,O
vitro,FW,O
.,.,.
,,
because,IN,O
of,IN,O
possible,JJ,O
clinical,JJ,O
significance,NN,O
",",",",O
these,DT,O
two,CD,O
drugs,NNS,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
concurrently,RB,O
.,.,.
,,
alcohol,NN,D
-lrb-,-LRB-,O
increases,NNS,O
bioavailability,NN,O
by,IN,O
50,CD,O
%,NN,O
-rrb-,-RRB-,O
",",",",O
cimetidine,NN,D
",",",",O
and,CC,O
valproates,NNS,O
.,.,.
,,
no,DT,O
separate,JJ,O
information,NN,O
available,JJ,O
.,.,.
,,
although,IN,O
no,DT,O
clinical,JJ,O
drug-drug,JJ,O
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
to,TO,O
date,NN,O
",",",",O
on,IN,O
the,DT,O
basis,NN,O
of,IN,O
the,DT,O
in,FW,O
vitro,FW,O
studies,NNS,O
",",",",O
cytochrome,NN,O
p450,NN,O
inhibitors,NNS,O
and,CC,O
inducers,NNS,O
are,VBP,O
unlikely,JJ,O
to,TO,O
affect,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
clofarabine,NN,D
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
clofarabine,NN,D
on,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
substrates,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
drug/laboratory,NNP,O
tests,NNP,O
interactions,NNS,O
there,EX,O
are,VBP,O
no,DT,O
known,JJ,O
clinically,RB,O
significant,JJ,O
interactions,NNS,O
of,IN,O
clolar,NN,B
with,IN,O
other,JJ,O
medications,NNS,O
or,CC,O
laboratory,NN,O
tests,NNS,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug/laboratory,JJ,O
test,NN,O
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
with,IN,O
clolar,NN,B
.,.,.
,,
preliminary,JJ,O
data,NNS,O
which,WDT,O
suggest,VBP,O
that,IN,O
dapsone,NN,D
may,MD,O
inhibit,VB,O
the,DT,O
anti-inflammatory,JJ,G
activity,NN,O
of,IN,O
lamprene,NNP,B
have,VBP,O
not,RB,O
been,VBN,O
confirmed,VBN,O
.,.,.
,,
if,IN,O
leprosy-associated,JJ,O
inflammatory,JJ,O
reactions,NNS,O
develop,VBP,O
in,IN,O
patients,NNS,O
being,VBG,O
treated,VBN,O
with,IN,O
dapsone,NN,D
and,CC,O
clofazimine,NN,D
",",",",O
it,PRP,O
is,VBZ,O
still,RB,O
advisable,JJ,O
to,TO,O
continue,VB,O
treatment,NN,O
with,IN,O
both,CC,O
drugs,NNS,D
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
anticoagulants,NNS,G
are,VBP,O
given,VBN,O
in,IN,O
conjunction,NN,O
with,IN,O
atromid-s,NN,B
.,.,.
,,
usually,RB,O
",",",",O
the,DT,O
dosage,NN,O
of,IN,O
the,DT,O
anticoagulant,NN,G
should,MD,O
be,VB,O
reduced,VBN,O
by,IN,O
one-half,NN,O
-lrb-,-LRB-,O
depending,VBG,O
on,IN,O
the,DT,O
individual,JJ,O
case,NN,O
-rrb-,-RRB-,O
to,TO,O
maintain,VB,O
the,DT,O
prothrombin,NN,O
time,NN,O
at,IN,O
the,DT,O
desired,VBN,O
level,NN,O
to,TO,O
prevent,VB,O
bleeding,JJ,O
complications,NNS,O
.,.,.
,,
frequent,JJ,O
prothrombin,NN,O
determinations,NNS,O
are,VBP,O
advisable,JJ,O
until,IN,O
it,PRP,O
has,VBZ,O
been,VBN,O
determined,VBN,O
definitely,RB,O
that,IN,O
the,DT,O
prothrombin,NN,O
level,NN,O
has,VBZ,O
been,VBN,O
stabilized,VBN,O
.,.,.
,,
atromid-s,NN,B
may,MD,O
displace,VB,O
acidic,JJ,O
drugs,NNS,D
such,JJ,O
as,IN,O
phenytoin,NN,D
or,CC,O
tolbutamide,NN,D
from,IN,O
their,PRP$,O
binding,NN,O
sites,NNS,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
treating,VBG,O
patients,NNS,O
with,IN,O
either,DT,O
of,IN,O
these,DT,O
drugs,NNS,D
or,CC,O
other,JJ,O
highly,RB,O
protein-bound,JJ,O
drugs,NNS,D
and,CC,O
atromid-s,NN,B
.,.,.
,,
the,DT,O
hypoglycemic,JJ,G
effect,NN,O
of,IN,O
tolbutamide,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
increase,VB,O
when,WRB,O
atromid-s,NN,B
is,VBZ,O
given,VBN,O
concurrently,RB,O
.,.,.
,,
fulminant,JJ,O
rhabdomyolysis,NN,O
has,VBZ,O
been,VBN,O
seen,VBN,O
as,IN,O
early,JJ,O
as,IN,O
three,CD,O
weeks,NNS,O
after,IN,O
initiation,NN,O
of,IN,O
combined,JJ,O
therapy,NN,O
with,IN,O
another,DT,O
fibrate,NN,G
and,CC,O
lovastatin,NN,D
but,CC,O
may,MD,O
be,VB,O
seen,VBN,O
after,IN,O
several,JJ,O
months,NNS,O
.,.,.
,,
for,IN,O
these,DT,O
reasons,NNS,O
",",",",O
it,PRP,O
is,VBZ,O
felt,VBN,O
that,IN,O
",",",",O
in,IN,O
most,JJS,O
subjects,NNS,O
who,WP,O
have,VBP,O
had,VBD,O
an,DT,O
unsatisfactory,JJ,O
lipid,NN,O
response,NN,O
to,TO,O
either,CC,O
drug,NN,D
alone,RB,O
",",",",O
the,DT,O
possible,JJ,O
benefits,NNS,O
of,IN,O
combined,JJ,O
therapy,NN,O
with,IN,O
lovastatin,NN,D
and,CC,O
a,DT,O
fibrate,NN,G
do,VBP,O
not,RB,O
outweigh,VB,O
the,DT,O
risks,NNS,O
of,IN,O
severe,JJ,O
myopathy,NN,O
",",",",O
rhabdomyolysis,NN,O
",",",",O
and,CC,O
acute,JJ,O
renal,JJ,O
failure,NN,O
.,.,.
,,
while,IN,O
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
whether,IN,O
this,DT,O
interaction,NN,O
occurs,VBZ,O
with,IN,O
fibrates,NNS,G
other,JJ,O
than,IN,O
gemfibrozil,NN,D
",",",",O
myopathy,NN,O
and,CC,O
rhabdomyolysis,NN,O
have,VBP,O
occasionally,RB,O
been,VBN,O
associated,VBN,O
with,IN,O
the,DT,O
use,NN,O
of,IN,O
fibrates,NNS,G
alone,RB,O
",",",",O
including,VBG,O
clofibrate,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
combined,VBN,O
use,NN,O
of,IN,O
lovastatin,NN,D
with,IN,O
fibrates,NNS,G
should,MD,O
generally,RB,O
be,VB,O
avoided,VBN,O
.,.,.
,,
drug,NN,O
interactions,NNS,O
with,IN,O
clomiphene,NN,O
citrate,NN,O
tablets,NNS,O
usp,NNP,O
have,VBP,O
not,RB,O
been,VBN,O
documented,VBN,O
.,.,.
,,
the,DT,O
risks,NNS,O
of,IN,O
using,VBG,O
anafranil,NNP,B
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
have,VBP,O
not,RB,O
been,VBN,O
systematically,RB,O
evaluated,VBN,O
.,.,.
,,
given,VBN,O
the,DT,O
primary,JJ,O
cns,NN,O
effects,NNS,O
of,IN,O
anafranil,NNP,B
",",",",O
caution,NN,O
is,VBZ,O
advised,VBN,O
in,IN,O
using,VBG,O
it,PRP,O
concomitantly,RB,O
with,IN,O
other,JJ,O
cns-active,JJ,O
drugs,NNS,D
.,.,.
,,
anafranil,NNP,B
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
with,IN,O
mao,NN,O
inhibitors,NNS,O
.,.,.
,,
close,JJ,O
supervision,NN,O
and,CC,O
careful,JJ,O
adjustment,NN,O
of,IN,O
dosage,NN,O
are,VBP,O
required,VBN,O
when,WRB,O
anafranil,NNP,B
is,VBZ,O
administered,VBN,O
with,IN,O
anticholinergic,JJ,G
or,CC,O
sympathomimetic,JJ,G
drugs,NNS,D
.,.,.
,,
several,JJ,O
tricyclic,JJ,G
antidepressants,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
block,VB,O
the,DT,O
pharmacologic,JJ,O
effects,NNS,O
of,IN,O
guanethidine,NN,D
",",",",O
clonidine,NN,D
",",",",O
or,CC,O
similar,JJ,O
agents,NNS,O
",",",",O
and,CC,O
such,PDT,O
an,DT,O
effect,NN,O
may,MD,O
be,VB,O
anticipated,VBN,O
with,IN,O
cmi,NN,D
because,IN,O
of,IN,O
its,PRP$,O
structural,JJ,O
similarity,NN,O
to,TO,O
other,JJ,O
tricyclic,JJ,G
antidepressants,NNS,G
.,.,.
,,
the,DT,O
plasma,NN,O
concentration,NN,O
of,IN,O
cmi,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
be,VB,O
increased,VBN,O
by,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
haloperidol,NN,D
.,.,.
,,
plasma,NN,O
levels,NNS,O
of,IN,O
several,JJ,O
closely,RB,O
related,JJ,O
tricyclic,JJ,G
antidepressants,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
be,VB,O
increased,VBN,O
by,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
methylphenidate,NN,D
or,CC,O
hepatic,JJ,O
enzyme,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
cimetidine,NN,D
",",",",O
fluoxetine,NN,D
-rrb-,-RRB-,O
and,CC,O
decreased,VBN,O
by,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
hepatic,JJ,O
enzyme,NN,O
inducers,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
barbiturates,NNS,G
",",",",O
phenytoin,NN,D
-rrb-,-RRB-,O
",",",",O
and,CC,O
such,PDT,O
an,DT,O
effect,NN,O
may,MD,O
be,VB,O
anticipated,VBN,O
with,IN,O
cmi,NNP,D
as,RB,O
well,RB,O
.,.,.
,,
administration,NN,O
of,IN,O
cmi,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
increase,VB,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
phenobarbital,NN,D
",",",",O
if,IN,O
given,VBN,O
concomitantly,RB,O
.,.,.
,,
drugs,NNS,O
metabolized,VBN,O
by,IN,O
p450,NN,O
2d6,NN,O
:,:,O
the,DT,O
biochemical,JJ,O
activity,NN,O
of,IN,O
the,DT,O
drug,NN,D
metabolizing,VBG,O
isozyme,NN,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
-lrb-,-LRB-,O
debrisoquin,NN,D
hydroxylase,NN,O
-rrb-,-RRB-,O
is,VBZ,O
reduced,VBN,O
in,IN,O
a,DT,O
subset,NN,O
of,IN,O
the,DT,O
aucasian,JJ,O
population,NN,O
-lrb-,-LRB-,O
about,IN,O
7,CD,O
%,NN,O
-10,CD,O
%,NN,O
of,IN,O
caucasians,NNPS,O
are,VBP,O
so-called,JJ,O
poor,JJ,O
metabolizers,NNS,O
-rrb-,-RRB-,O
;,:,O
.,.,.
,,
reliable,JJ,O
estimates,NNS,O
of,IN,O
the,DT,O
prevalence,NN,O
of,IN,O
reduced,VBN,O
p450,NN,O
2d6,NN,O
isozyme,NN,O
activity,NN,O
among,IN,O
asian,JJ,O
",",",",O
african,JJ,O
and,CC,O
other,JJ,O
populations,NNS,O
are,VBP,O
not,RB,O
yet,RB,O
available,JJ,O
.,.,.
,,
poor,NNP,O
metabolizers,NNS,O
have,VBP,O
higher,JJR,O
than,IN,O
expected,VBN,O
lasma,NN,O
concentrations,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
-lrb-,-LRB-,O
tcas,NNS,G
-rrb-,-RRB-,O
when,WRB,O
given,VBN,O
usual,JJ,O
doses,NNS,O
.,.,.
,,
depending,VBG,O
on,IN,O
the,DT,O
fraction,NN,O
of,IN,O
drug,NN,D
metabolized,VBN,O
by,IN,O
p450,NN,O
2d6,NN,O
",",",",O
the,DT,O
increase,NN,O
in,IN,O
plasma,NN,O
concentration,NN,O
may,MD,O
be,VB,O
small,JJ,O
",",",",O
or,CC,O
quite,RB,O
large,JJ,O
-lrb-,-LRB-,O
8,CD,O
fold,JJ,O
increase,NN,O
in,IN,O
plasma,NN,O
auc,NN,O
of,IN,O
the,DT,O
tca,NNP,G
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
certain,JJ,O
drugs,NNS,D
inhibit,VBP,O
the,DT,O
activity,NN,O
of,IN,O
this,DT,O
isozyme,NN,O
and,CC,O
make,VB,O
normal,JJ,O
metabolizers,NNS,O
resemble,VBP,O
poor,JJ,O
metabolizers,NNS,O
.,.,.
,,
an,DT,O
individual,NN,O
who,WP,O
is,VBZ,O
stable,JJ,O
on,IN,O
a,DT,O
given,VBN,O
dose,NN,O
of,IN,O
tcamay,NN,O
become,VBP,O
abruptly,RB,O
toxic,JJ,O
when,WRB,O
given,VBN,O
one,CD,O
of,IN,O
these,DT,O
inhibiting,VBG,O
drugs,NNS,D
as,IN,O
concomitant,JJ,O
therapy,NN,O
.,.,.
,,
the,DT,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
include,VBP,O
some,DT,O
that,WDT,O
are,VBP,O
not,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
enzyme,NN,O
-lrb-,-LRB-,O
quinidine,NN,D
.,.,.
,,
cimetidine,NN,D
-rrb-,-RRB-,O
and,CC,O
many,JJ,O
that,WDT,O
are,VBP,O
substrates,NNS,O
for,IN,O
p450,NN,O
2d6,NN,O
-lrb-,-LRB-,O
many,JJ,O
other,JJ,O
antidepressants,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
and,CC,O
the,DT,O
type,NN,O
1c,NN,O
antiarrhythmics,NNS,G
propafenone,NN,D
and,CC,O
flecainide,NN,D
-rrb-,-RRB-,O
.,.,.
,,
while,IN,O
all,PDT,O
the,DT,O
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
ssris,NNS,G
-rrb-,-RRB-,O
",",",",O
e.g.,FW,O
",",",",O
fluoxetine,NN,D
",",",",O
sertraline,NN,D
",",",",O
paroxetine,NN,D
",",",",O
and,CC,O
fluvoxamine,NN,D
",",",",O
inhibit,VBP,O
p450,NN,O
2d6,NN,O
",",",",O
they,PRP,O
may,MD,O
vary,VB,O
in,IN,O
the,DT,O
extent,NN,O
of,IN,O
inhibition,NN,O
.,.,.
,,
fluvoxamine,NNP,D
has,VBZ,O
also,RB,O
been,VBN,O
shown,VBN,O
to,TO,O
inhibit,VB,O
p450,NN,O
1a2,NN,O
",",",",O
an,DT,O
isoform,NN,O
also,RB,O
involved,VBN,O
in,IN,O
tcametabolism,NN,O
.,.,.
,,
the,DT,O
extent,NN,O
to,TO,O
which,WDT,O
ssri-tcainteractions,NNS,O
may,MD,O
pose,VB,O
clinical,JJ,O
problems,NNS,O
will,MD,O
depend,VB,O
on,IN,O
the,DT,O
degree,NN,O
of,IN,O
inhibition,NN,O
and,CC,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
the,DT,O
ssri,NNP,G
involved,VBN,O
.,.,.
,,
nevertheless,RB,O
",",",",O
caution,NN,O
is,VBZ,O
indicated,VBN,O
in,IN,O
the,DT,O
co-administration,NN,O
of,IN,O
tcas,NNS,G
with,IN,O
any,DT,O
of,IN,O
the,DT,O
ssris,NNS,G
and,CC,O
also,RB,O
in,IN,O
switching,NN,O
from,IN,O
one,CD,O
class,NN,O
to,TO,O
the,DT,O
other,JJ,O
.,.,.
,,
of,IN,O
particular,JJ,O
importance,NN,O
",",",",O
sufficient,JJ,O
time,NN,O
must,MD,O
elapse,VB,O
before,IN,O
initiating,VBG,O
tcatreatment,NN,O
in,IN,O
a,DT,O
patient,NN,O
being,VBG,O
withdrawn,VBN,O
from,IN,O
fluoxetine,NN,D
",",",",O
given,VBN,O
the,DT,O
long,JJ,O
half-life,NN,O
of,IN,O
the,DT,O
parent,NN,O
and,CC,O
active,JJ,O
metabolite,NN,O
-lrb-,-LRB-,O
at,IN,O
least,JJS,O
5,CD,O
weeks,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
-rrb-,-RRB-,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
agents,NNS,O
in,IN,O
the,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
class,NN,O
-lrb-,-LRB-,O
which,WDT,O
includes,VBZ,O
anafranil,NNP,B
-rrb-,-RRB-,O
with,IN,O
drugs,NNS,D
that,WDT,O
can,MD,O
inhibit,VB,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
may,MD,O
require,VB,O
lower,JJR,O
doses,NNS,O
than,IN,O
usually,RB,O
prescribed,VBN,O
for,IN,O
either,CC,O
the,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
agent,NN,O
or,CC,O
the,DT,O
other,JJ,O
drug,NN,D
.,.,.
,,
furthermore,RB,O
",",",",O
whenever,WRB,O
one,CD,O
of,IN,O
these,DT,O
drugs,NNS,D
is,VBZ,O
withdrawn,VBN,O
from,IN,O
co-therapy,JJ,O
",",",",O
an,DT,O
increased,VBN,O
dose,NN,O
of,IN,O
tricyclic,JJ,G
antidepressant,JJ,G
agent,NN,O
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
desirable,JJ,O
to,TO,O
monitor,VB,O
tcaplasma,NN,O
levels,NNS,O
whenever,WRB,O
an,DT,O
agent,NN,O
of,IN,O
the,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
class,NN,O
including,VBG,O
anafranil,NNP,B
is,VBZ,O
going,VBG,O
to,TO,O
be,VB,O
co-administered,VBN,O
with,IN,O
another,DT,O
drug,NN,D
known,VBN,O
to,TO,O
be,VB,O
an,DT,O
inhibitor,NN,O
of,IN,O
p450,NN,O
2d6,NN,O
-lrb-,-LRB-,O
and/or,CC,O
p450,NN,O
1a2,NN,O
-rrb-,-RRB-,O
.,.,.
,,
because,IN,O
anafranil,NNP,B
is,VBZ,O
highly,RB,O
bound,VBN,O
to,TO,O
serum,NN,O
protein,NN,O
",",",",O
the,DT,O
administration,NN,O
of,IN,O
anafranil,NNP,B
to,TO,O
patients,NNS,O
taking,VBG,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
highly,RB,O
bound,VBN,O
to,TO,O
protein,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
warfarin,NN,D
",",",",O
digoxin,NN,D
-rrb-,-RRB-,O
may,MD,O
cause,VB,O
an,DT,O
increase,NN,O
in,IN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
these,DT,O
drugs,NNS,D
",",",",O
potentially,RB,O
resulting,VBG,O
in,IN,O
adverse,JJ,O
effects,NNS,O
.,.,.
,,
conversely,RB,O
",",",",O
adverse,JJ,O
effects,NNS,O
may,MD,O
result,VB,O
from,IN,O
displacement,NN,O
of,IN,O
protein-bound,JJ,O
anafranil,NNP,B
by,IN,O
other,JJ,O
highly,RB,O
bound,VBN,O
drugs,NNS,D
.,.,.
,,
effect,NN,O
of,IN,O
clonazepam,NNP,D
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
other,JJ,O
drugs,NNS,O
:,:,O
clonazepam,NN,D
does,VBZ,O
not,RB,O
appear,VB,O
to,TO,O
alter,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
phenytoin,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
or,CC,O
phenobarbital,NN,D
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
clonazepam,NN,D
on,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
has,VBZ,O
not,RB,O
been,VBN,O
investigated,VBN,O
.,.,.
,,
effect,NN,O
of,IN,O
other,JJ,O
drugs,NNS,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
clonazepam,NNP,D
:,:,O
literature,NNP,O
reports,NNS,O
suggest,VBP,O
that,IN,O
ranitidine,NN,D
",",",",O
an,DT,O
agent,NN,O
that,WDT,O
decreases,VBZ,O
stomach,NN,O
acidity,NN,O
",",",",O
does,VBZ,O
not,RB,O
greatly,RB,O
alter,VB,O
clonazepam,NN,D
pharmacokinetics,NNS,O
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
in,IN,O
which,WDT,O
the,DT,O
2,CD,O
mg,NN,O
clonazepam,NN,D
orally,RB,O
disintegrating,VBG,O
tablet,NN,O
was,VBD,O
administered,VBN,O
with,IN,O
and,CC,O
without,IN,O
propantheline,NN,D
-lrb-,-LRB-,O
an,DT,O
anticholinergic,JJ,G
agent,NN,O
with,IN,O
multiple,JJ,O
effects,NNS,O
on,IN,O
the,DT,O
gi,NN,O
tract,NN,O
-rrb-,-RRB-,O
to,TO,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
the,DT,O
auc,NN,O
of,IN,O
clonazepam,NN,D
was,VBD,O
10,CD,O
%,NN,O
lower,JJR,O
and,CC,O
the,DT,O
cmax,NN,O
of,IN,O
clonazepam,NN,D
was,VBD,O
20,CD,O
%,NN,O
lower,JJR,O
when,WRB,O
the,DT,O
orally,RB,O
disintegrating,VBG,O
tablet,NN,O
was,VBD,O
given,VBN,O
with,IN,O
propantheline,NN,D
compared,VBN,O
to,TO,O
when,WRB,O
it,PRP,O
was,VBD,O
given,VBN,O
alone,RB,O
.,.,.
,,
fluoxetine,NN,D
does,VBZ,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
clonazepam,NN,D
.,.,.
,,
cytochrome,NN,O
p-450,NN,O
inducers,NNS,O
",",",",O
such,JJ,O
as,IN,O
phenytoin,NN,D
",",",",O
carbamazepine,NN,D
and,CC,O
phenobarbital,NN,D
",",",",O
induce,VBP,O
clonazepam,NN,D
metabolism,NN,O
",",",",O
causing,VBG,O
an,DT,O
approximately,RB,O
30,CD,O
%,NN,O
decrease,NN,O
in,IN,O
plasma,NN,O
clonazepam,NN,D
levels,NNS,O
.,.,.
,,
although,IN,O
clinical,JJ,O
studies,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
performed,VBN,O
",",",",O
based,VBN,O
on,IN,O
the,DT,O
involvement,NN,O
of,IN,O
the,DT,O
cytochrome,NN,O
p-450,NN,O
3a,NN,O
family,NN,O
in,IN,O
clonazepam,NN,D
metabolism,NN,O
",",",",O
inhibitors,NNS,O
of,IN,O
this,DT,O
enzyme,NN,O
system,NN,O
",",",",O
notably,RB,O
oral,JJ,O
antifungal,JJ,O
agents,NNS,O
",",",",O
should,MD,O
be,VB,O
used,VBN,O
cautiously,RB,O
in,IN,O
patients,NNS,O
receiving,VBG,O
clonazepam,NN,D
.,.,.
,,
pharmacodynamic,JJ,O
interactions,NNS,O
:,:,O
the,DT,O
cns-depressant,JJ,O
action,NN,O
of,IN,O
the,DT,O
benzodiazepine,NN,G
class,NN,O
of,IN,O
drugs,NNS,D
may,MD,O
be,VB,O
potentiated,VBN,O
by,IN,O
alcohol,NN,D
",",",",O
narcotics,NNS,G
",",",",O
barbiturates,NNS,G
",",",",O
nonbarbiturate,JJ,O
hypnotics,NNS,G
",",",",O
antianxiety,JJ,O
agents,NNS,O
",",",",O
the,DT,O
phenothiazines,NNS,G
",",",",O
thioxanthene,NN,O
and,CC,O
butyrophenone,NN,O
classes,NNS,O
of,IN,O
antipsychotic,JJ,O
agents,NNS,O
",",",",O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
and,CC,O
the,DT,O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
and,CC,O
by,IN,O
other,JJ,O
anticonvulsant,JJ,G
drugs,NNS,D
.,.,.
,,
tablet,NNP,O
if,IN,O
a,DT,O
patient,NN,O
receiving,VBG,O
clonidine,NN,D
hydrochloride,NN,O
is,VBZ,O
also,RB,O
taking,VBG,O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
the,DT,O
effect,NN,O
of,IN,O
clonidine,NN,D
may,MD,O
be,VB,O
reduced,VBN,O
",",",",O
thus,RB,O
necessitating,VBG,O
an,DT,O
increase,NN,O
in,IN,O
dosage,NN,O
.,.,.
,,
clonidine,NN,D
hydrochloride,NN,O
may,MD,O
enhance,VB,O
the,DT,O
cns-depressive,JJ,O
effects,NNS,O
of,IN,O
alcohol,NN,D
",",",",O
barbiturates,NNS,G
or,CC,O
other,JJ,O
sedatives,NNS,G
.,.,.
,,
amitriptyline,NNP,D
in,IN,O
combination,NN,O
with,IN,O
clonidine,NN,D
enhances,VBZ,O
the,DT,O
manifestation,NN,O
of,IN,O
corneal,NN,O
lesions,NNS,O
in,IN,O
rats,NNS,O
epidural,JJ,O
injection,NN,O
clonidine,NN,D
may,MD,O
potentiate,VB,O
the,DT,O
cns-depressive,JJ,O
effect,NN,O
of,IN,O
alcohol,NN,D
",",",",O
barbiturates,NNS,G
or,CC,O
other,JJ,O
sedating,VBG,O
drugs,NNS,D
.,.,.
,,
narcotic,JJ,O
analgesics,NNS,G
may,MD,O
potentiate,VB,O
the,DT,O
hypotensive,JJ,O
effects,NNS,O
of,IN,O
clonidine,NN,D
.,.,.
,,
tricyclic,JJ,O
antidepressants,NNS,G
may,MD,O
antagonize,VB,O
the,DT,O
hypotensive,JJ,O
effects,NNS,O
of,IN,O
clonidine,NN,D
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
on,IN,O
clonidines,NNS,O
analgesic,JJ,O
actions,NNS,O
are,VBP,O
not,RB,O
known,VBN,O
.,.,.
,,
beta,NN,O
blockers,NNS,O
may,MD,O
exacerbate,VB,O
the,DT,O
hypertensive,JJ,O
response,NN,O
seen,VBN,O
with,IN,O
clonidine,NN,D
withdrawl,NN,O
.,.,.
,,
also,RB,O
",",",",O
due,JJ,O
to,TO,O
the,DT,O
potential,NN,O
for,IN,O
additive,JJ,O
effects,NNS,O
such,JJ,O
as,IN,O
bradycardia,NN,O
and,CC,O
av,NN,O
block,NN,O
",",",",O
caution,NN,O
is,VBZ,O
warranted,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
clonidine,NN,D
with,IN,O
agents,NNS,O
known,VBN,O
to,TO,O
affect,VB,O
sinus,NN,O
node,NN,O
function,NN,O
or,CC,O
av,NN,O
nodal,JJ,O
conduction,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
digitalis,NN,G
",",",",O
calcium,NN,D
channel,NN,O
blockers,NNS,O
",",",",O
and,CC,O
beta-blockers,NNS,G
.,.,.
,,
there,EX,O
is,VBZ,O
one,CD,O
reported,VBD,O
case,NN,O
of,IN,O
a,DT,O
patient,NN,O
with,IN,O
acute,JJ,O
delirium,NN,O
associated,VBN,O
with,IN,O
the,DT,O
simultaneous,JJ,O
use,NN,O
of,IN,O
fluphenazine,NN,D
and,CC,O
oral,JJ,O
clonidine,NN,D
.,.,.
,,
symptoms,NNS,O
resolved,VBN,O
when,WRB,O
clonidine,NN,D
was,VBD,O
withdrawn,VBN,O
and,CC,O
recurred,VBN,O
when,WRB,O
the,DT,O
patient,NN,O
was,VBD,O
rechallenged,VBN,O
with,IN,O
clonidine,NN,D
.,.,.
,,
epidural,JJ,O
clonidine,NN,D
may,MD,O
prolong,VB,O
the,DT,O
duration,NN,O
of,IN,O
pharmacologic,JJ,O
effects,NNS,O
of,IN,O
epidural,JJ,O
local,JJ,O
anesthetics,NNS,G
",",",",O
including,VBG,O
both,DT,O
sensory,JJ,O
and,CC,O
motor,NN,O
blockade,NN,O
.,.,.
,,
aspirin,NN,B
",",",",O
warfarin,NN,D
",",",",O
heparin,NN,D
",",",",O
nsaid,NN,G
.,.,.
,,
if,IN,O
tranxene,NN,B
is,VBZ,O
to,TO,O
be,VB,O
combined,VBN,O
with,IN,O
other,JJ,O
drugs,NNS,D
acting,VBG,O
on,IN,O
the,DT,O
central,JJ,O
nervous,JJ,O
system,NN,O
",",",",O
careful,JJ,O
consideration,NN,O
should,MD,O
be,VB,O
given,VBN,O
to,TO,O
the,DT,O
pharmacology,NN,O
of,IN,O
the,DT,O
agents,NNS,O
to,TO,O
be,VB,O
employed,VBN,O
.,.,.
,,
animal,NN,O
experience,NN,O
indicates,VBZ,O
that,IN,O
clorazepate,NN,O
dipotassium,NN,O
prolongs,VBZ,O
the,DT,O
sleeping,VBG,O
time,NN,O
after,IN,O
hexobarbital,JJ,D
or,CC,O
after,IN,O
ethyl,NN,O
alcohol,NN,D
",",",",O
increases,VBZ,O
the,DT,O
inhibitory,JJ,O
effects,NNS,O
of,IN,O
chlorpromazine,NN,D
",",",",O
but,CC,O
does,VBZ,O
not,RB,O
exhibit,VB,O
monoamine,NN,O
oxidase,NN,O
inhibition,NN,O
.,.,.
,,
clinical,JJ,O
studies,NNS,O
have,VBP,O
shown,VBN,O
increased,VBN,O
sedation,NN,O
with,IN,O
concurrent,JJ,O
hypnotic,JJ,G
medications,NNS,O
.,.,.
,,
the,DT,O
actions,NNS,O
of,IN,O
the,DT,O
benzodiazepines,NNS,G
may,MD,O
be,VB,O
potentiated,VBN,O
by,IN,O
barbiturates,NNS,G
",",",",O
narcotics,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
or,CC,O
other,JJ,O
antidepressants,NNS,G
.,.,.
,,
if,IN,O
tranxene,NN,B
tablets,NNS,O
are,VBP,O
used,VBN,O
to,TO,O
treat,VB,O
anxiety,NN,O
associated,VBN,O
with,IN,O
somatic,JJ,O
disease,NN,O
states,NNS,O
",",",",O
careful,JJ,O
attention,NN,O
must,MD,O
be,VB,O
paid,VBN,O
to,TO,O
possible,JJ,O
drug,NN,D
interaction,NN,O
with,IN,O
concomitant,JJ,O
medication,NN,O
.,.,.
,,
in,IN,O
bioavailability,NN,O
studies,NNS,O
with,IN,O
normal,JJ,O
subjects,NNS,O
",",",",O
the,DT,O
concurrent,JJ,O
administration,NN,O
of,IN,O
antacids,NNS,G
at,IN,O
therapeutic,JJ,O
levels,NNS,O
did,VBD,O
not,RB,O
significantly,RB,O
influence,VB,O
the,DT,O
bioavailability,NN,O
of,IN,O
tranxene,NNP,B
tablets,NNS,O
.,.,.
,,
the,DT,O
risks,NNS,O
of,IN,O
using,VBG,O
clozapine,NNP,D
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
have,VBP,O
not,RB,O
been,VBN,O
systematically,RB,O
evaluated,VBN,O
.,.,.
,,
pharmacodynamic-related,JJ,O
interactions,NNS,O
:,:,O
the,DT,O
mechanism,NN,O
of,IN,O
clozapine,NN,D
induced,VBD,O
agranulocytosis,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
nonetheless,RB,O
",",",",O
the,DT,O
possibility,NN,O
that,IN,O
causative,JJ,O
factors,NNS,O
may,MD,O
interact,VB,O
synergistically,RB,O
to,TO,O
increase,VB,O
the,DT,O
risk,NN,O
and/or,CC,O
severity,NN,O
of,IN,O
bone,NN,O
marrow,NN,O
suppression,NN,O
warrants,NNS,O
consideration,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
clozapine,NNP,D
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
with,IN,O
other,JJ,O
agents,NNS,O
having,VBG,O
a,DT,O
well-known,JJ,O
potential,NN,O
to,TO,O
suppress,VB,O
bone,NN,O
marrow,NN,O
function,NN,O
.,.,.
,,
given,VBN,O
the,DT,O
primary,JJ,O
cns,NN,O
effects,NNS,O
of,IN,O
clozapine,NNP,D
",",",",O
caution,NN,O
is,VBZ,O
advised,VBN,O
in,IN,O
using,VBG,O
it,PRP,O
concomitantly,RB,O
with,IN,O
other,JJ,O
cns-active,JJ,O
drugs,NNS,D
or,CC,O
alcohol,NN,D
.,.,.
,,
orthostatic,JJ,O
hypotension,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
clozapine,NN,D
can,MD,O
",",",",O
in,IN,O
rare,JJ,O
cases,NNS,O
-lrb-,-LRB-,O
approximately,RB,O
1,CD,O
case,NN,O
per,IN,O
"3,000",CD,O
patients,NNS,O
-rrb-,-RRB-,O
",",",",O
be,VB,O
accompanied,VBN,O
by,IN,O
profound,JJ,O
collapse,NN,O
and,CC,O
respiratory,JJ,O
and/or,CC,O
cardiac,JJ,O
arrest,NN,O
.,.,.
,,
some,DT,O
of,IN,O
the,DT,O
cases,NNS,O
of,IN,O
collapse/respiratory,JJ,O
arrest/cardiac,JJ,O
arrest,NN,O
during,IN,O
initial,JJ,O
treatment,NN,O
occurred,VBD,O
in,IN,O
patients,NNS,O
who,WP,O
were,VBD,O
being,VBG,O
administered,VBN,O
benzodiazepines,NNS,G
.,.,.
,,
similar,JJ,O
events,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
taking,VBG,O
other,JJ,O
psychotropic,JJ,O
drugs,NNS,D
or,CC,O
even,RB,O
clozapine,NNP,D
by,IN,O
itself,PRP,O
.,.,.
,,
although,IN,O
it,PRP,O
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
that,IN,O
there,EX,O
is,VBZ,O
an,DT,O
interaction,NN,O
between,IN,O
clozapine,NNP,D
and,CC,O
benzodiazepines,NNS,G
or,CC,O
other,JJ,O
psychotropics,NNS,G
",",",",O
caution,NN,O
is,VBZ,O
advised,VBN,O
when,WRB,O
clozapine,NN,D
is,VBZ,O
initiated,VBN,O
in,IN,O
patients,NNS,O
taking,VBG,O
a,DT,O
benzodiazepine,NN,G
or,CC,O
any,DT,O
other,JJ,O
psychotropic,JJ,O
drug,NN,D
.,.,.
,,
clozapine,NNP,D
may,MD,O
potentiate,VB,O
the,DT,O
hypotensive,JJ,O
effects,NNS,O
of,IN,O
antihypertensive,JJ,G
drugs,NNS,D
and,CC,O
the,DT,O
anticholinergic,JJ,G
effects,NNS,O
of,IN,O
atropine-type,JJ,O
drugs,NNS,D
.,.,.
,,
the,DT,O
administration,NN,O
of,IN,O
epinephrine,NN,D
should,MD,O
be,VB,O
avoided,VBN,O
in,IN,O
the,DT,O
treatment,NN,O
of,IN,O
drug,NN,D
induced,VBD,O
hypotension,NN,O
because,IN,O
of,IN,O
a,DT,O
possible,JJ,O
reverse,JJ,O
epinephrine,NN,D
effect,NN,O
.,.,.
,,
pharmacokinetic-related,JJ,O
interactions,NNS,O
:,:,O
clozapine,NNP,D
is,VBZ,O
a,DT,O
substrate,NN,O
for,IN,O
many,JJ,O
cyp,NN,O
450,CD,O
isozymes,NNS,O
",",",",O
in,IN,O
particular,JJ,O
1a2,NN,O
",",",",O
2d6,NN,O
",",",",O
and,CC,O
3a4,NN,O
.,.,.
,,
the,DT,O
risk,NN,O
of,IN,O
metabolic,JJ,O
interactions,NNS,O
caused,VBN,O
by,IN,O
an,DT,O
effect,NN,O
on,IN,O
an,DT,O
individual,JJ,O
isoform,NN,O
is,VBZ,O
therefore,RB,O
minimized,VBN,O
.,.,.
,,
nevertheless,RB,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
treatment,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
either,DT,O
inhibitors,NNS,O
or,CC,O
inducers,NNS,O
of,IN,O
these,DT,O
enzymes,NNS,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
drugs,NNS,D
known,VBN,O
to,TO,O
induce,VB,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
may,MD,O
decrease,VB,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
clozapine,NN,D
.,.,.
,,
phenytoin,NNP,D
",",",",O
nicotine,NN,D
",",",",O
and,CC,O
rifampin,NN,D
may,MD,O
decrease,VB,O
clozapine,NNP,D
plasma,NN,O
levels,NNS,O
",",",",O
resulting,VBG,O
in,IN,O
a,DT,O
decrease,NN,O
in,IN,O
effectiveness,NN,O
of,IN,O
a,DT,O
previously,RB,O
effective,JJ,O
clozapine,NNP,D
dose,NN,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
drugs,NNS,D
known,VBN,O
to,TO,O
inhibit,VB,O
the,DT,O
activity,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
isozymes,NNS,O
may,MD,O
increase,VB,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
clozapine,NN,D
.,.,.
,,
cimetidine,NNP,D
",",",",O
caffeine,NN,D
",",",",O
and,CC,O
erythromycin,NN,D
may,MD,O
increase,VB,O
plasma,NN,O
levels,NNS,O
of,IN,O
clozapine,NNP,D
",",",",O
potentially,RB,O
resulting,VBG,O
in,IN,O
adverse,JJ,O
effects,NNS,O
.,.,.
,,
although,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
clozapine,NNP,D
and,CC,O
carbamazepine,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
",",",",O
it,PRP,O
should,MD,O
be,VB,O
noted,VBN,O
that,IN,O
discontinuation,NN,O
of,IN,O
concomitant,JJ,O
carbamazepine,NN,D
administration,NN,O
may,MD,O
result,VB,O
in,IN,O
an,DT,O
increase,NN,O
in,IN,O
clozapine,NNP,D
plasma,NN,O
levels,NNS,O
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
of,IN,O
schizophrenic,JJ,O
patients,NNS,O
who,WP,O
received,VBD,O
clozapine,NN,D
under,IN,O
steady,JJ,O
state,NN,O
conditions,NNS,O
",",",",O
fluvoxamine,NN,D
or,CC,O
paroxetine,NN,D
was,VBD,O
added,VBN,O
in,IN,O
16,CD,O
and,CC,O
14,CD,O
patients,NNS,O
",",",",O
respectively,RB,O
.,.,.
,,
after,IN,O
14,CD,O
days,NNS,O
of,IN,O
co-administration,NN,O
",",",",O
mean,VB,O
trough,NN,O
concentrations,NNS,O
of,IN,O
clozapine,NN,D
and,CC,O
its,PRP$,O
metabolites,NNS,O
",",",",O
n-desmethylclozapine,NN,D_n
and,CC,O
clozapine,NN,D
n-oxide,NN,O
",",",",O
were,VBD,O
elevated,JJ,O
with,IN,O
fluvoxamine,NN,D
by,IN,O
about,IN,O
three-fold,JJ,O
compared,VBN,O
to,TO,O
baseline,NN,O
concentrations,NNS,O
.,.,.
,,
paroxetine,NNP,D
produced,VBD,O
only,RB,O
minor,JJ,O
changes,NNS,O
in,IN,O
the,DT,O
levels,NNS,O
of,IN,O
clozapine,NN,D
and,CC,O
its,PRP$,O
metabolites,NNS,O
.,.,.
,,
however,RB,O
",",",",O
other,JJ,O
published,VBN,O
reports,NNS,O
describe,VBP,O
modest,JJ,O
elevations,NNS,O
-lrb-,-LRB-,O
less,JJR,O
than,IN,O
two-fold,JJ,O
-rrb-,-RRB-,O
of,IN,O
clozapine,NN,D
and,CC,O
metabolite,NN,O
concentrations,NNS,O
when,WRB,O
clozapine,NN,D
was,VBD,O
taken,VBN,O
with,IN,O
paroxetine,NN,D
",",",",O
fluoxetine,NN,D
",",",",O
and,CC,O
sertraline,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
such,JJ,O
combined,JJ,O
treatment,NN,O
should,MD,O
be,VB,O
approached,VBN,O
with,IN,O
caution,NN,O
and,CC,O
patients,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
when,WRB,O
clozapine,NNP,D
is,VBZ,O
combined,VBN,O
with,IN,O
these,DT,O
drugs,NNS,D
",",",",O
particularly,RB,O
with,IN,O
fluvoxamine,NN,D
.,.,.
,,
a,DT,O
reduced,VBN,O
clozapine,NNP,D
dose,NN,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
a,DT,O
subset,NN,O
-lrb-,-LRB-,O
3,CD,O
%,NN,O
-10,CD,O
%,NN,O
-rrb-,-RRB-,O
of,IN,O
the,DT,O
population,NN,O
has,VBZ,O
reduced,VBN,O
activity,NN,O
of,IN,O
certain,JJ,O
drug,NN,D
metabolizing,VBG,O
enzymes,NNS,O
such,JJ,O
as,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
isozyme,NN,O
p450,NN,O
2d6,NN,O
.,.,.
,,
such,JJ,O
individuals,NNS,O
are,VBP,O
referred,VBN,O
to,TO,O
as,IN,O
poor,JJ,O
metabolizers,NNS,O
of,IN,O
drugs,NNS,D
such,JJ,O
as,IN,O
debrisoquin,NN,D
",",",",O
dextromethorphan,NN,D
",",",",O
the,DT,O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
and,CC,O
clozapine,NN,D
.,.,.
,,
these,DT,O
individuals,NNS,O
may,MD,O
develop,VB,O
higher,JJR,O
than,IN,O
expected,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
clozapine,NN,D
when,WRB,O
given,VBN,O
usual,JJ,O
doses,NNS,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
certain,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
this,DT,O
isozyme,NN,O
",",",",O
including,VBG,O
many,JJ,O
antidepressants,NNS,G
-lrb-,-LRB-,O
clozapine,NN,D
",",",",O
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
",",",",O
and,CC,O
others,NNS,O
-rrb-,-RRB-,O
",",",",O
may,MD,O
inhibit,VB,O
the,DT,O
activity,NN,O
of,IN,O
this,DT,O
isozyme,NN,O
",",",",O
and,CC,O
thus,RB,O
may,MD,O
make,VB,O
normal,JJ,O
metabolizers,NNS,O
resemble,VBP,O
poor,JJ,O
metabolizers,NNS,O
with,IN,O
regard,NN,O
to,TO,O
concomitant,JJ,O
therapy,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
this,DT,O
enzyme,NN,O
system,NN,O
",",",",O
leading,VBG,O
to,TO,O
drug,NN,D
interaction,NN,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
clozapine,NN,D
with,IN,O
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
may,MD,O
require,VB,O
lower,JJR,O
doses,NNS,O
than,IN,O
usually,RB,O
prescribed,VBN,O
for,IN,O
either,CC,O
clozapine,NN,D
or,CC,O
the,DT,O
other,JJ,O
drug,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
co-administration,NN,O
of,IN,O
clozapine,NN,D
with,IN,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
this,DT,O
isozyme,NN,O
",",",",O
including,VBG,O
antidepressants,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
carbamazepine,NN,D
",",",",O
and,CC,O
type,NN,O
1c,NN,O
antiarrhythmics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
propafenone,NN,D
",",",",O
flecainide,NN,D
and,CC,O
encainide,NN,D
-rrb-,-RRB-,O
",",",",O
or,CC,O
that,IN,O
inhibit,VBP,O
this,DT,O
enzyme,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
quinidine,NN,D
-rrb-,-RRB-,O
",",",",O
should,MD,O
be,VB,O
approached,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
the,DT,O
risk,NN,O
of,IN,O
a,DT,O
potential,JJ,O
interaction,NN,O
between,IN,O
novoseven,NNP,B
and,CC,O
coagulation,NN,O
factor,NN,O
concentrates,VBZ,O
has,VBZ,O
not,RB,O
been,VBN,O
adequately,RB,O
evaluated,VBN,O
in,IN,O
preclinical,JJ,O
or,CC,O
clinical,JJ,O
studies,NNS,O
.,.,.
,,
simultaneous,JJ,O
use,NN,O
of,IN,O
activated,VBN,O
prothrombin,NN,O
complex,NN,O
concentrates,VBZ,O
or,CC,O
prothrombin,NN,O
complex,NN,O
concentrates,VBZ,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
although,IN,O
the,DT,O
specific,JJ,O
drug,NN,D
interaction,NN,O
was,VBD,O
not,RB,O
studied,VBN,O
in,IN,O
a,DT,O
clinical,JJ,O
trial,NN,O
",",",",O
there,EX,O
have,VBP,O
been,VBN,O
more,JJR,O
than,IN,O
50,CD,O
episodes,NNS,O
of,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
antifibrinolytic,JJ,O
therapies,NNS,O
-lrb-,-LRB-,O
i.e.,FW,O
",",",",O
tranexamic,JJ,O
acid,NN,O
",",",",O
aminocaproic,JJ,O
acid,NN,O
-rrb-,-RRB-,O
and,CC,O
novoseven,NNP,B
.,.,.
,,
novoseven,NNP,B
should,MD,O
not,RB,O
be,VB,O
mixed,VBN,O
with,IN,O
infusion,NN,O
solutions,NNS,O
until,IN,O
clinical,JJ,O
data,NNS,O
are,VBP,O
available,JJ,O
to,TO,O
direct,VB,O
this,DT,O
use,NN,O
.,.,.
,,
codeine,NNP,D
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
narcotic,JJ,G
analgesics,NNS,G
",",",",O
general,JJ,O
anesthetics,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
tranquilizers,NNS,G
",",",",O
sedative-hypnotics,NNS,G
",",",",O
or,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
-lrb-,-LRB-,O
including,VBG,O
alcohol,NN,D
-rrb-,-RRB-,O
has,VBZ,O
additive,JJ,O
depressant,NN,O
effects,NNS,O
.,.,.
,,
when,WRB,O
s.c.,NN,O
combination,NN,O
therapy,NN,O
is,VBZ,O
contemplated,VBN,O
",",",",O
the,DT,O
dosage,NN,O
of,IN,O
one,CD,O
or,CC,O
both,DT,O
agents,NNS,O
should,MD,O
be,VB,O
reduced,VBN,O
.,.,.
,,
colchicine,NNP,D
is,VBZ,O
inhibited,VBN,O
by,IN,O
acidifying,VBG,O
agents,NNS,O
.,.,.
,,
the,DT,O
action,NN,O
of,IN,O
colchicine,NN,D
is,VBZ,O
potentiated,VBN,O
by,IN,O
alkalinizing,VBG,O
agents,NNS,O
.,.,.
,,
colchicine,NNP,D
may,MD,O
increase,VB,O
sensitivity,NN,O
to,TO,O
the,DT,O
cns,NN,O
depressants,NNS,O
.,.,.
,,
response,NN,O
to,TO,O
sympathomimetic,JJ,G
agents,NNS,O
may,MD,O
be,VB,O
enhanced,VBN,O
by,IN,O
colchicine,NN,D
.,.,.
,,
welchol,NNP,B
has,VBZ,O
been,VBN,O
studied,VBN,O
in,IN,O
several,JJ,O
human,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
in,IN,O
which,WDT,O
it,PRP,O
was,VBD,O
administered,VBN,O
with,IN,O
a,DT,O
meal,NN,O
and,CC,O
the,DT,O
test,NN,O
drug,NN,D
.,.,.
,,
welchol,NNP,B
was,VBD,O
found,VBN,O
to,TO,O
have,VB,O
no,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
bioavailability,NN,O
of,IN,O
digoxin,NN,D
",",",",O
lovastatin,NN,D
",",",",O
metoprolol,NN,D
",",",",O
quinidine,NN,D
",",",",O
valproic,JJ,O
acid,NN,O
",",",",O
and,CC,O
warfarin,NN,D
.,.,.
,,
welchol,NNP,B
decreased,VBD,O
the,DT,O
cmax,NN,O
and,CC,O
auc,NN,O
of,IN,O
sustained-release,JJ,O
verapamil,NN,D
-lrb-,-LRB-,O
calan,JJ,O
sr,NN,O
-rrb-,-RRB-,O
by,IN,O
approximately,RB,O
31,CD,O
%,NN,O
and,CC,O
11,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
since,IN,O
there,EX,O
is,VBZ,O
a,DT,O
high,JJ,O
degree,NN,O
of,IN,O
variability,NN,O
in,IN,O
the,DT,O
bioavailability,NN,O
of,IN,O
verapamil,NN,D
",",",",O
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
finding,NN,O
is,VBZ,O
unclear,JJ,O
.,.,.
,,
in,IN,O
clinical,JJ,O
studies,NNS,O
",",",",O
coadministration,NN,O
of,IN,O
welchol,NN,B
with,IN,O
atorvastatin,NN,D
",",",",O
lovastatin,NN,D
",",",",O
or,CC,O
simvastatin,NN,D
did,VBD,O
not,RB,O
interfere,VB,O
with,IN,O
the,DT,O
lipid-lowering,JJ,O
activity,NN,O
of,IN,O
the,DT,O
hmg-coa,NN,O
reductase,NN,O
inhibitor,NN,O
.,.,.
,,
other,JJ,O
drugs,NNS,D
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
when,WRB,O
administering,VBG,O
other,JJ,O
drugs,NNS,D
for,IN,O
which,WDT,O
alterations,NNS,O
in,IN,O
blood,NN,O
levels,NNS,O
could,MD,O
have,VB,O
a,DT,O
clinically,RB,O
significant,JJ,O
effect,NN,O
on,IN,O
safety,NN,O
or,CC,O
efficacy,NN,O
",",",",O
physicians,NNS,O
should,MD,O
consider,VB,O
monitoring,VBG,O
drug,NN,D
levels,NNS,O
or,CC,O
effects,NNS,O
.,.,.
,,
since,IN,O
colestipol,NN,D
hydrochloride,NN,O
is,VBZ,O
an,DT,O
anion,NN,O
exchange,NN,O
resin,NN,G
",",",",O
it,PRP,O
may,MD,O
have,VB,O
a,DT,O
strong,JJ,O
affinity,NN,O
for,IN,O
anions,NNS,O
other,JJ,O
than,IN,O
the,DT,O
bile,NN,O
acids,NNS,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
have,VBP,O
indicated,VBN,O
that,IN,O
colestipol,NN,D
hydrochloride,NN,O
binds,VBZ,O
a,DT,O
number,NN,O
of,IN,O
drugs,NNS,D
.,.,.
,,
therefore,RB,O
",",",",O
colestld,NNP,B
tablets,NNPS,O
may,MD,O
delay,VB,O
or,CC,O
reduce,VB,O
the,DT,O
absorption,NN,O
of,IN,O
concomitant,JJ,O
oral,JJ,O
medication,NN,O
.,.,.
,,
the,DT,O
interval,NN,O
between,IN,O
the,DT,O
administration,NN,O
of,IN,O
colestid,NNP,B
tablets,NNPS,O
and,CC,O
any,DT,O
other,JJ,O
medication,NN,O
should,MD,O
be,VB,O
as,RB,O
long,RB,O
as,IN,O
possible,JJ,O
.,.,.
,,
patients,NNS,O
should,MD,O
take,VB,O
other,JJ,O
drugs,NNS,D
at,IN,O
least,JJS,O
one,CD,O
hour,NN,O
before,IN,O
or,CC,O
four,CD,O
hours,NNS,O
after,IN,O
colestid,NNP,B
tablets,NNPS,O
to,TO,O
avoid,VB,O
impeding,VBG,O
their,PRP$,O
absorption,NN,O
.,.,.
,,
repeated,JJ,O
doses,NNS,O
of,IN,O
colestipol,NN,D
hydrochloride,NN,O
given,VBN,O
prior,RB,O
to,TO,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
propranolol,NN,D
in,IN,O
human,JJ,O
trials,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
decrease,VB,O
propranolol,NN,D
absorption,NN,O
.,.,.
,,
however,RB,O
",",",",O
in,IN,O
a,DT,O
follow-up,JJ,O
study,NN,O
in,IN,O
normal,JJ,O
subjects,NNS,O
",",",",O
single-dose,JJ,O
administration,NN,O
of,IN,O
colestipol,NN,D
hydrochloride,NN,O
and,CC,O
propranolol,NN,D
and,CC,O
twice-a-day,JJ,O
administration,NN,O
for,IN,O
5,CD,O
days,NNS,O
of,IN,O
both,DT,O
agents,NNS,O
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
extent,NN,O
of,IN,O
propranolol,NN,D
absorption,NN,O
",",",",O
but,CC,O
had,VBD,O
a,DT,O
small,JJ,O
yet,RB,O
statistically,RB,O
significant,JJ,O
effect,NN,O
on,IN,O
its,PRP$,O
rate,NN,O
of,IN,O
absorption,NN,O
.,.,.
,,
the,DT,O
time,NN,O
to,TO,O
reach,VB,O
maximum,NN,O
concentration,NN,O
was,VBD,O
delayed,VBN,O
approximately,RB,O
30,CD,O
minutes,NNS,O
.,.,.
,,
effects,NNS,O
on,IN,O
the,DT,O
absorption,NN,O
of,IN,O
other,JJ,O
beta-blockers,NNS,G
have,VBP,O
not,RB,O
been,VBN,O
determined,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
patients,NNS,O
on,IN,O
propranolol,NN,D
should,MD,O
be,VB,O
observed,VBN,O
when,WRB,O
colestid,NNP,B
tablets,NNS,O
are,VBP,O
either,RB,O
added,VBN,O
or,CC,O
deleted,VBN,O
from,IN,O
a,DT,O
therapeutic,JJ,O
regimen,NN,O
.,.,.
,,
studies,NNS,O
in,IN,O
humans,NNS,O
show,VBP,O
that,IN,O
the,DT,O
absorption,NN,O
of,IN,O
chlorothiazide,NN,D
as,IN,O
reflected,VBN,O
in,IN,O
urinary,JJ,O
excretion,NN,O
is,VBZ,O
markedly,RB,O
decreased,VBN,O
even,RB,O
when,WRB,O
administered,VBN,O
one,CD,O
hour,NN,O
before,IN,O
colestipol,NN,D
hydrochloride,NN,O
.,.,.
,,
the,DT,O
absorption,NN,O
of,IN,O
tetracycline,NN,D
",",",",O
furosemide,NN,D
",",",",O
penicillin,NN,D
g,NN,O
",",",",O
hydrochlorothiazide,NN,D
",",",",O
and,CC,O
gemfibrozil,NN,D
was,VBD,O
significantly,RB,O
decreased,VBN,O
when,WRB,O
given,VBN,O
simultaneously,RB,O
with,IN,O
colestipol,NN,D
hydrochloride,NN,O
.,.,.
,,
these,DT,O
drugs,NNS,D
were,VBD,O
not,RB,O
tested,VBN,O
to,TO,O
determine,VB,O
the,DT,O
effect,NN,O
of,IN,O
administration,NN,O
one,CD,O
hour,NN,O
before,IN,O
colestipol,NN,D
hydrochloride,NN,O
.,.,.
,,
no,DT,O
depressant,NN,O
effect,NN,O
on,IN,O
blood,NN,O
levels,NNS,O
in,IN,O
humans,NNS,O
was,VBD,O
noted,VBN,O
when,WRB,O
colestipol,NN,D
hydrochloride,NN,O
was,VBD,O
administered,VBN,O
with,IN,O
any,DT,O
of,IN,O
the,DT,O
following,VBG,O
drugs,NNS,D
:,:,O
aspirin,NN,B
",",",",O
clindamycin,NN,D
",",",",O
clofibrate,NN,D
",",",",O
methyldopa,NN,D
",",",",O
nicotinic,JJ,O
acid,NN,O
-lrb-,-LRB-,O
niacin,NN,D
-rrb-,-RRB-,O
",",",",O
tolbutamide,NN,D
",",",",O
phenytoin,NN,D
or,CC,O
warfarin,NN,D
.,.,.
,,
particular,JJ,O
caution,NN,O
should,MD,O
be,VB,O
observed,VBN,O
with,IN,O
digitalis,NN,G
preparations,NNS,O
since,IN,O
there,EX,O
are,VBP,O
conflicting,VBG,O
results,NNS,O
for,IN,O
the,DT,O
effect,NN,O
of,IN,O
colestipol,NN,D
hydrochloride,NN,O
on,IN,O
the,DT,O
availability,NN,O
of,IN,O
digoxin,NN,D
and,CC,O
digitoxin,NN,D
.,.,.
,,
the,DT,O
potential,NN,O
for,IN,O
binding,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
if,IN,O
given,VBN,O
concomitantly,RB,O
is,VBZ,O
present,JJ,O
.,.,.
,,
discontinuing,VBG,O
colestipol,NN,D
hydrochloride,NN,O
could,MD,O
pose,VB,O
a,DT,O
hazard,NN,O
to,TO,O
health,NN,O
if,IN,O
a,DT,O
potentially,RB,O
toxic,JJ,O
drug,NN,D
that,WDT,O
is,VBZ,O
significantly,RB,O
bound,VBN,O
to,TO,O
the,DT,O
resin,NN,G
has,VBZ,O
been,VBN,O
titrated,VBN,O
to,TO,O
a,DT,O
maintenance,NN,O
level,NN,O
while,IN,O
the,DT,O
patient,NN,O
was,VBD,O
taking,VBG,O
colestipol,NN,D
hydrochloride,NN,O
.,.,.
,,
bile,NN,O
acid,NN,O
binding,NN,O
resins,NNS,G
may,MD,O
also,RB,O
interfere,VB,O
with,IN,O
the,DT,O
absorption,NN,O
of,IN,O
oral,JJ,O
phosphate,NN,D
supplements,NNS,O
and,CC,O
hydrocortisone,NN,D
.,.,.
,,
certain,JJ,O
other,JJ,O
antibiotics,NNS,G
-lrb-,-LRB-,O
aminoglycosides,NNS,G
and,CC,O
polymyxin,NN,G
-rrb-,-RRB-,O
have,VBP,O
also,RB,O
been,VBN,O
reported,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
the,DT,O
nerve,NN,O
transmission,NN,O
at,IN,O
the,DT,O
neuromuscular,JJ,O
junction,NN,O
.,.,.
,,
based,VBN,O
on,IN,O
this,DT,O
reported,VBN,O
activity,NN,O
",",",",O
they,PRP,O
should,MD,O
not,RB,O
be,VB,O
given,VBN,O
concomitantly,RB,O
with,IN,O
coly-mycin,NN,O
m,NN,O
parenteral,JJ,O
except,IN,O
with,IN,O
the,DT,O
greatest,JJS,O
caution,NN,O
.,.,.
,,
curariform,JJ,O
muscle,NN,O
relaxants,NNS,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
tubocurarine,NN,D
-rrb-,-RRB-,O
and,CC,O
other,JJ,O
drugs,NNS,D
",",",",O
including,VBG,O
ether,NN,O
",",",",O
succinylcholine,NN,D
",",",",O
gallamine,NN,D
",",",",O
decamethonium,NN,D
and,CC,O
sodium,NN,O
citrate,NN,O
",",",",O
potentiate,VB,O
the,DT,O
neuromuscular,JJ,O
blocking,NN,O
effect,NN,O
and,CC,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
extreme,JJ,O
caution,NN,O
in,IN,O
patients,NNS,O
being,VBG,O
treated,VBN,O
with,IN,O
coly-mycin,NN,O
m,NN,O
parenteral,NN,O
.,.,.
,,
sodium,NN,O
cephalothin,NN,D
may,MD,O
enhance,VB,O
the,DT,O
nephrotoxicity,NN,O
of,IN,O
coly-mycin,NNP,O
m,NN,O
parenteral,NN,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
sodium,NN,O
cephalothin,NN,D
and,CC,O
coly-mycin,NN,O
m,NN,O
parenteral,NN,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
digoxin,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
digoxin,NN,D
",",",",O
a,DT,O
p-glycoprotein,NN,O
substrate,NN,O
",",",",O
with,IN,O
oral,JJ,O
conivaptan,NN,D
resulted,VBD,O
in,IN,O
a,DT,O
reduction,NN,O
in,IN,O
clearance,NN,O
and,CC,O
an,DT,O
increase,NN,O
in,IN,O
digoxin,NN,D
cmax,NN,O
and,CC,O
auc,NN,O
values,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
if,IN,O
digoxin,NN,D
is,VBZ,O
administered,VBN,O
with,IN,O
vaprisol,NN,B
",",",",O
the,DT,O
clinician,NN,O
should,MD,O
be,VB,O
alert,JJ,O
to,TO,O
the,DT,O
possibility,NN,O
of,IN,O
increases,NNS,O
in,IN,O
digoxin,NN,D
levels,NNS,O
.,.,.
,,
drug/laboratory,NN,O
test,NN,O
interactions,NNS,O
1,CD,O
.,.,.
,,
accelerated,VBN,O
prothrombin,NN,O
time,NN,O
",",",",O
partial,JJ,O
thromboplastin,NN,O
time,NN,O
",",",",O
and,CC,O
platelet,NN,O
aggregation,NN,O
time,NN,O
;,:,O
.,.,.
,,
increased,VBN,O
platelet,NN,O
count,NN,O
;,:,O
.,.,.
,,
increased,VBN,O
factors,NNS,O
ii,CD,O
",",",",O
vii,NN,O
antigen,NN,O
",",",",O
viii,CD,O
antigen,NN,O
",",",",O
viii,CD,O
coagulant,NN,O
activity,NN,O
",",",",O
ix,CD,O
",",",",O
x,NN,O
",",",",O
xii,NNP,O
",",",",O
vii-x,NN,O
complex,NN,O
",",",",O
ii-vii-x,NN,O
complex,NN,O
",",",",O
and,CC,O
beta-thromboglobulin,NN,O
;,:,O
.,.,.
,,
decreased,VBN,O
levels,NNS,O
of,IN,O
anti-factor,JJ,O
xa,NN,O
and,CC,O
antithrombin,NN,O
iii,CD,O
",",",",O
decreased,VBD,O
antithrombin,NN,O
iii,CD,O
activity,NN,O
.,.,.
,,
increased,VBN,O
levels,NNS,O
of,IN,O
fibrinogen,NN,D
and,CC,O
fibrinogen,NN,D
activity,NN,O
.,.,.
,,
increased,VBN,O
plasminogen,NN,O
antigen,NN,O
and,CC,O
activity,NN,O
.,.,.
,,
2,LS,O
.,.,.
,,
increased,VBN,O
thyroid-binding,JJ,O
globulin,NN,O
-lrb-,-LRB-,O
tbg,NN,O
-rrb-,-RRB-,O
levels,NNS,O
leading,VBG,O
to,TO,O
increased,VBN,O
circulating,VBG,O
total,JJ,O
thyroid,NN,G
hormone,NN,O
levels,NNS,O
as,IN,O
measured,VBN,O
by,IN,O
protein-bound,JJ,O
iodine,NN,G
-lrb-,-LRB-,O
pbi,NN,O
-rrb-,-RRB-,O
",",",",O
t4,NN,D
levels,NNS,O
-lrb-,-LRB-,O
by,IN,O
column,NN,O
or,CC,O
by,IN,O
radioimmunoassay,NN,O
-rrb-,-RRB-,O
or,CC,O
t3,NN,D
levels,NNS,O
by,IN,O
radioimmunoassay,NN,O
.,.,.
,,
t3,NN,D
resin,NN,G
uptake,NN,O
is,VBZ,O
decreased,VBN,O
",",",",O
reflecting,VBG,O
the,DT,O
elevated,JJ,O
tbg,NN,O
.,.,.
,,
free,NNP,O
t4,NN,D
and,CC,O
free,JJ,O
t3,NN,D
concentrations,NNS,O
are,VBP,O
unaltered,JJ,O
.,.,.
,,
patients,NNS,O
on,IN,O
thyroid,NN,G
replacement,NN,O
therapy,NN,O
may,MD,O
require,VB,O
higher,JJR,O
doses,NNS,O
of,IN,O
thyroid,NN,G
hormone,NN,O
.,.,.
,,
3,LS,O
.,.,.
,,
other,JJ,O
binding,NN,O
proteins,NNS,O
may,MD,O
be,VB,O
elevated,JJ,O
in,IN,O
serum,NN,O
",",",",O
-lrb-,-LRB-,O
i.e.,FW,O
",",",",O
corticosteroid,NN,G
binding,NN,O
globulin,NN,O
-lrb-,-LRB-,O
cbg,NN,O
-rrb-,-RRB-,O
",",",",O
sex,NN,O
hormone,NN,O
binding,NN,O
globulin,NN,O
-lrb-,-LRB-,O
shbg,NN,O
-rrb-,-RRB-,O
-rrb-,-RRB-,O
leading,VBG,O
to,TO,O
increased,VBN,O
total,JJ,O
circulating,VBG,O
corticosteroids,NNS,G
and,CC,O
sex,NN,O
steroids,NNS,G
",",",",O
respectively,RB,O
.,.,.
,,
free,NNP,O
hormone,NN,O
concentrations,NNS,O
may,MD,O
be,VB,O
decreased,VBN,O
.,.,.
,,
other,JJ,O
plasma,NN,O
proteins,NNS,O
may,MD,O
be,VB,O
increased,VBN,O
-lrb-,-LRB-,O
angiotensinogen/renin,NN,O
substrate,NN,O
",",",",O
alpha-1-antitrypsin,NN,O
",",",",O
ceruloplasmin,NN,O
-rrb-,-RRB-,O
.,.,.
,,
4,LS,O
.,.,.
,,
increased,VBN,O
plasma,NN,O
hdl,NN,O
and,CC,O
hdl2,NN,O
cholesterol,NN,O
subfraction,NN,O
concentrations,NNS,O
",",",",O
reduced,VBD,O
ldl,NN,O
cholesterol,NN,O
concentration,NN,O
",",",",O
increased,VBD,O
triglyceride,NN,O
levels,NNS,O
.,.,.
,,
5,CD,O
.,.,.
,,
impaired,JJ,O
glucose,NN,O
tolerance,NN,O
.,.,.
,,
6,CD,O
.,.,.
,,
reduced,VBN,O
response,NN,O
to,TO,O
metyrapone,NN,O
test,NN,O
.,.,.
,,
corticotropin,NNP,D
may,MD,O
accentuate,VB,O
the,DT,O
electrolyte,NN,O
loss,NN,O
associated,VBN,O
with,IN,O
diuretic,JJ,G
therapy,NN,O
.,.,.
,,
the,DT,O
pharmacokinetic,JJ,O
interactions,NNS,O
listed,VBN,O
below,RB,O
are,VBP,O
potentially,RB,O
clinically,RB,O
important,JJ,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
induce,VBP,O
hepatic,JJ,O
enzymes,NNS,O
such,JJ,O
as,IN,O
phenobarbital,NN,D
",",",",O
phenytoin,NN,D
and,CC,O
rifampin,NN,D
may,MD,O
increase,VB,O
the,DT,O
clearance,NN,O
of,IN,O
corticosteroids,NNS,G
and,CC,O
may,MD,O
require,VB,O
increases,NNS,O
in,IN,O
corticosteroid,NN,G
dose,NN,O
to,TO,O
achieve,VB,O
the,DT,O
desired,VBN,O
response,NN,O
.,.,.
,,
drugs,NNS,O
such,JJ,O
as,IN,O
troleandomycin,NN,D
and,CC,O
ketoconazole,NN,D
may,MD,O
inhibit,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
corticosteroids,NNS,G
and,CC,O
thus,RB,O
decrease,VB,O
their,PRP$,O
clearance,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
dose,NN,O
of,IN,O
corticosteroid,NN,G
should,MD,O
be,VB,O
titrated,VBN,O
to,TO,O
avoid,VB,O
steroid,NN,G
toxicity,NN,O
.,.,.
,,
corticosteroids,NNS,G
may,MD,O
increase,VB,O
the,DT,O
clearance,NN,O
of,IN,O
chronic,JJ,O
high,JJ,O
dose,NN,O
aspirin,NN,B
.,.,.
,,
this,DT,O
could,MD,O
lead,VB,O
to,TO,O
decreased,VBN,O
salicylate,NN,G
serum,NN,O
levels,NNS,O
or,CC,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
salicylate,NN,G
toxicity,NN,O
when,WRB,O
corticosteroid,NN,G
is,VBZ,O
withdrawn,VBN,O
.,.,.
,,
aspirin,NN,B
should,MD,O
be,VB,O
used,VBN,O
cautiously,RB,O
in,IN,O
conjunction,NN,O
with,IN,O
cortico-steroids,NNS,G
in,IN,O
patients,NNS,O
suffering,VBG,O
from,IN,O
hypopro-thrombinemia,JJ,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
corticosteroids,NNS,G
on,IN,O
oral,JJ,O
anticoagulants,NNS,G
is,VBZ,O
variable,JJ,O
.,.,.
,,
there,EX,O
are,VBP,O
reports,NNS,O
of,IN,O
enhanced,VBN,O
as,RB,O
well,RB,O
as,IN,O
diminished,JJ,O
effects,NNS,O
of,IN,O
anticoagulants,NNS,G
when,WRB,O
given,VBN,O
concurrently,RB,O
with,IN,O
corticosteroids,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
coagulation,NN,O
indices,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
to,TO,O
maintain,VB,O
the,DT,O
desired,VBN,O
anticoagulant,JJ,G
effect,NN,O
.,.,.
,,
corticotropin,NNP,D
may,MD,O
accentuate,VB,O
the,DT,O
electrolyte,NN,O
loss,NN,O
associated,VBN,O
with,IN,O
diuretic,JJ,G
therapy,NN,O
.,.,.
,,
drug,NN,O
interaction,NN,O
during,IN,O
pregnancy,NNP,O
:,:,O
cromolyn,NNP,O
sodium,NN,O
and,CC,O
isoproterenol,NN,D
were,VBD,O
studied,VBN,O
following,VBG,O
subcutaneous,JJ,O
injections,NNS,O
in,IN,O
pregnant,JJ,O
mice,NNS,O
.,.,.
,,
cromolyn,NNP,O
sodium,NN,O
alone,RB,O
in,IN,O
doses,NNS,O
up,RB,O
to,TO,O
540,CD,O
mg/kg/day,NN,O
-lrb-,-LRB-,O
approximately,RB,O
340,CD,O
times,NNS,O
the,DT,O
maximum,NN,O
recommended,VBD,O
daily,JJ,O
inhalation,NN,O
dose,NN,O
in,IN,O
adults,NNS,O
on,IN,O
a,DT,O
mg/m2,NN,O
basis,NN,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
cause,VB,O
significant,JJ,O
increases,NNS,O
in,IN,O
resorptions,NNS,O
or,CC,O
major,JJ,O
malformations,NNS,O
.,.,.
,,
isoproterenol,NN,D
alone,RB,O
at,IN,O
a,DT,O
dose,NN,O
of,IN,O
2.7,CD,O
mg/kg/day,NN,O
-lrb-,-LRB-,O
approximately,RB,O
7,CD,O
times,NNS,O
the,DT,O
maximum,NN,O
recommended,VBD,O
daily,JJ,O
inhalation,NN,O
dose,NN,O
in,IN,O
adults,NNS,O
on,IN,O
a,DT,O
mg/m2,NN,O
basis,NN,O
-rrb-,-RRB-,O
increased,VBD,O
both,DT,O
resorptions,NNS,O
and,CC,O
malformations,NNS,O
.,.,.
,,
the,DT,O
addition,NN,O
of,IN,O
540,CD,O
mg/kg/day,NN,O
of,IN,O
cromolyn,NN,O
sodium,NN,O
-lrb-,-LRB-,O
approximately,RB,O
340,CD,O
times,NNS,O
the,DT,O
maximum,NN,O
recommended,VBD,O
daily,JJ,O
inhalation,NN,O
dose,NN,O
in,IN,O
adults,NNS,O
on,IN,O
a,DT,O
mg/m2,NN,O
basis,NN,O
-rrb-,-RRB-,O
to,TO,O
2.7,CD,O
mg/kg/day,NN,O
of,IN,O
isoproterenol,NN,D
-lrb-,-LRB-,O
approximately,RB,O
7,CD,O
times,NNS,O
the,DT,O
maximum,NN,O
recommended,VBD,O
daily,JJ,O
inhalation,NN,O
dose,NN,O
in,IN,O
adults,NNS,O
on,IN,O
a,DT,O
mg/m2,NN,O
basis,NN,O
-rrb-,-RRB-,O
appears,VBZ,O
to,TO,O
have,VB,O
increased,VBN,O
the,DT,O
incidence,NN,O
of,IN,O
both,DT,O
resorptions,NNS,O
and,CC,O
malformations,NNS,O
.,.,.
,,
none,NN,O
known,VBN,O
.,.,.
,,
persons,NNS,O
taking,VBG,O
most,RBS,O
antibiotics,NNS,G
",",",",O
methotrexate,NN,D
and,CC,O
pyrimethamine,NN,D
invalidate,VBP,O
folic,JJ,O
acid,NN,O
and,CC,O
vitamin,NN,G
b12,NN,O
diagnostic,JJ,O
blood,NN,O
assays,NNS,O
.,.,.
,,
colchicine,NNP,D
para-aminosalicylic,JJ,O
acid,NN,O
and,CC,O
heavy,JJ,O
alcohol,NN,D
intake,NN,O
for,IN,O
longer,JJR,O
than,IN,O
2,CD,O
weeks,NNS,O
may,MD,O
produce,VB,O
malabsorption,NN,O
of,IN,O
vitamin,NN,G
b12,NN,O
.,.,.
,,
flexeril,NNP,B
may,MD,O
have,VB,O
life-threatening,JJ,O
interactions,NNS,O
with,IN,O
mao,NN,O
inhibitors,NNS,O
.,.,.
,,
flexeril,NNP,B
may,MD,O
enhance,VB,O
the,DT,O
effects,NNS,O
of,IN,O
alcohol,NN,D
",",",",O
barbiturates,NNS,G
",",",",O
and,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
.,.,.
,,
tricyclic,JJ,O
antidepressants,NNS,G
may,MD,O
block,VB,O
the,DT,O
antihypertensive,JJ,G
action,NN,O
of,IN,O
guanethidine,NN,D
and,CC,O
similarly,RB,O
acting,VBG,O
compounds,NNS,O
.,.,.
,,
tricyclic,JJ,O
antidepressants,NNS,G
may,MD,O
enhance,VB,O
the,DT,O
seizure,NN,O
risk,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
tramado,NN,O
.,.,.
,,
cyclopentolate,NNP,D
may,MD,O
interfere,VB,O
with,IN,O
the,DT,O
anti-glaucoma,JJ,O
action,NN,O
of,IN,O
carbachol,NN,D
or,CC,O
pilocarpine,NN,D
.,.,.
,,
also,RB,O
",",",",O
concurrent,JJ,O
use,NN,O
of,IN,O
this,DT,O
medication,NN,O
may,MD,O
antagonise,VB,O
the,DT,O
anti-glaucoma,JJ,O
and,CC,O
miotic,JJ,O
actions,NNS,O
of,IN,O
ophthalmic,JJ,O
cholinesterase,NN,O
inhibitors,NNS,O
.,.,.
,,
the,DT,O
rate,NN,O
of,IN,O
metabolism,NN,O
and,CC,O
the,DT,O
leukopenic,JJ,O
activity,NN,O
of,IN,O
cyclophosphamide,NN,D
reportedly,RB,O
are,VBP,O
increased,VBN,O
by,IN,O
chronic,JJ,O
administration,NN,O
of,IN,O
high,JJ,O
doses,NNS,O
of,IN,O
phenobarbital,NN,D
.,.,.
,,
the,DT,O
physician,NN,O
should,MD,O
be,VB,O
alert,JJ,O
for,IN,O
possible,JJ,O
combined,VBN,O
drug,NN,D
actions,NNS,O
",",",",O
desirable,JJ,O
or,CC,O
undesirable,JJ,O
",",",",O
involving,VBG,O
cyclophosphamide,NN,D
even,RB,O
though,IN,O
cyclophosphamide,NN,D
has,VBZ,O
been,VBN,O
used,VBN,O
successfully,RB,O
concurrently,RB,O
with,IN,O
other,JJ,O
drugs,NNS,D
",",",",O
including,VBG,O
other,JJ,O
cytotoxic,JJ,G
drugs,NNS,D
.,.,.
,,
cyclophosphamide,NN,D
treatment,NN,O
",",",",O
which,WDT,O
causes,VBZ,O
a,DT,O
marked,JJ,O
and,CC,O
persistent,JJ,O
inhibition,NN,O
of,IN,O
cholinesterase,NN,O
activity,NN,O
",",",",O
potentiates,VBZ,O
the,DT,O
effect,NN,O
of,IN,O
succinylcholine,NN,D
chloride,NN,O
.,.,.
,,
if,IN,O
a,DT,O
patient,NN,O
has,VBZ,O
been,VBN,O
treated,VBN,O
with,IN,O
cyclophosphamide,NN,D
within,IN,O
10,CD,O
days,NNS,O
of,IN,O
general,JJ,O
anesthesia,NN,D
",",",",O
the,DT,O
anesthesiologist,NN,O
should,MD,O
be,VB,O
alerted,VBN,O
.,.,.
,,
may,NNP,O
interact,VBP,O
with,IN,O
wthionamide,NN,O
-lrb-,-LRB-,O
trecator-sc,NN,B
-rrb-,-RRB-,O
and,CC,O
isoniazid,NN,D
-lrb-,-LRB-,O
nydrazid,NN,B
-rrb-,-RRB-,O
.,.,.
,,
mao,NN,O
inhibitors,NNS,O
prolong,VB,O
and,CC,O
intensify,VB,O
the,DT,O
anticholinergic,JJ,G
effects,NNS,O
of,IN,O
antihistamines,NNS,G
.,.,.
,,
antihistamines,NNS,D
may,MD,O
have,VB,O
additive,JJ,O
effects,NNS,O
with,IN,O
alcohol,NN,D
and,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
",",",",O
e.g.,FW,O
",",",",O
hypnotics,NNS,G
",",",",O
sedatives,NNS,G
",",",",O
tranquilizers,NNS,G
",",",",O
antianxiety,JJ,O
agents,NNS,O
.,.,.
,,
no,DT,O
drug,NN,D
interactions,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
.,.,.
,,
steady,JJ,O
state,NN,O
plasma,NN,O
digitoxin,NN,D
concentrations,NNS,O
did,VBD,O
not,RB,O
appear,VB,O
to,TO,O
change,VB,O
.,.,.
,,
therefore,RB,O
",",",",O
monitoring,NN,O
of,IN,O
plasma,NN,O
digoxin,NN,D
levels,NNS,O
may,MD,O
be,VB,O
indicated,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
similar,JJ,O
combination,NN,O
chemotherapy,NN,O
regimens,NNS,O
.,.,.
,,
the,DT,O
utilization,NN,O
of,IN,O
digitoxin,NN,D
for,IN,O
such,JJ,O
patients,NNS,O
may,MD,O
be,VB,O
considered,VBN,O
as,IN,O
an,DT,O
alternative,NN,O
.,.,.
,,
also,RB,O
flucytosine,NN,D
.,.,.
,,
drug/laboratorytest,NNP,O
interactions,NNS,O
dactinomycin,NN,D
may,MD,O
interfere,VB,O
with,IN,O
bioassay,NN,O
procedures,NNS,O
for,IN,O
the,DT,O
determination,NN,O
of,IN,O
antibacterial,JJ,G
drug,NN,D
levels,NNS,O
.,.,.
,,
dantrium,NNP,B
is,VBZ,O
metabolized,VBN,O
by,IN,O
the,DT,O
liver,NN,O
",",",",O
and,CC,O
it,PRP,O
is,VBZ,O
theoretically,RB,O
possible,JJ,O
that,IN,O
its,PRP$,O
metabolism,NN,O
may,MD,O
be,VB,O
enhanced,VBN,O
by,IN,O
drugs,NNS,D
known,VBN,O
to,TO,O
induce,VB,O
hepatic,JJ,O
microsomal,JJ,O
enzymes,NNS,O
.,.,.
,,
however,RB,O
",",",",O
neither,DT,O
phenobarbital,JJ,D
nor,CC,O
diazepam,NN,D
appears,VBZ,O
to,TO,O
affect,VB,O
dantrium,NNP,B
metabolism,NN,O
.,.,.
,,
binding,NN,O
to,TO,O
plasma,NN,O
protein,NN,O
is,VBZ,O
not,RB,O
significantly,RB,O
altered,VBN,O
by,IN,O
diazepam,NN,D
",",",",O
diphenylhydantoin,NN,D
",",",",O
or,CC,O
phenylbutazone,NN,D
.,.,.
,,
binding,NN,O
to,TO,O
plasma,NN,O
proteins,NNS,O
is,VBZ,O
reduced,VBN,O
by,IN,O
warfarin,NN,D
and,CC,O
clotibrate,NN,O
and,CC,O
increased,VBN,O
by,IN,O
tolbutamide,NN,D
.,.,.
,,
cardiovascular,NNP,O
collapse,NN,O
in,IN,O
patients,NNS,O
treated,VBN,O
simultaneously,RB,O
with,IN,O
varapamil,NN,O
and,CC,O
dantrolene,JJ,D
sodium,NN,O
is,VBZ,O
rare,JJ,O
.,.,.
,,
the,DT,O
combination,NN,O
of,IN,O
therapeutic,JJ,O
doses,NNS,O
of,IN,O
intravenous,JJ,O
dantrolene,JJ,D
sodium,NN,O
and,CC,O
verapamil,NN,D
in,IN,O
halothane,NN,D
a-chloralose,NN,O
anesthetized,JJ,O
swine,NNS,O
has,VBZ,O
resulted,VBN,O
in,IN,O
ventricular,JJ,O
fibrillation,NN,O
and,CC,O
cardiovascular,JJ,O
collapse,NN,O
in,IN,O
association,NN,O
with,IN,O
marked,JJ,O
hyperkalemia,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
the,DT,O
combination,NN,O
of,IN,O
intravenous,JJ,O
dantrolene,JJ,D
sodium,NN,O
and,CC,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
",",",",O
such,JJ,O
as,IN,O
verapamil,NN,D
",",",",O
not,RB,O
be,VB,O
used,VBN,O
together,RB,O
during,IN,O
the,DT,O
management,NN,O
of,IN,O
malignant,JJ,O
hyperthermia,NN,O
crisis,NN,O
until,IN,O
the,DT,O
relevance,NN,O
of,IN,O
these,DT,O
findings,NNS,O
to,TO,O
humans,NNS,O
is,VBZ,O
established,VBN,O
.,.,.
,,
administration,NN,O
of,IN,O
dantrolene,NN,D
may,MD,O
potentiate,VB,O
vecuronium-induced,JJ,O
neuromuscular,JJ,O
block,NN,O
.,.,.
,,
a,DT,O
drug-drug,JJ,O
interaction,NN,O
study,NN,O
evaluated,VBD,O
the,DT,O
effect,NN,O
of,IN,O
the,DT,O
use,NN,O
of,IN,O
aczone,NNP,B
gel,NN,O
",",",",O
5,CD,O
%,NN,O
",",",",O
in,IN,O
combination,NN,O
with,IN,O
double,JJ,O
strength,NN,O
-lrb-,-LRB-,O
160,CD,O
mg/800,NN,O
mg,NN,O
-rrb-,-RRB-,O
trimethoprim/sulfamethoxazole,NN,O
-lrb-,-LRB-,O
tmp/smx,NN,O
-rrb-,-RRB-,O
.,.,.
,,
during,IN,O
co-administration,NN,O
",",",",O
systemic,JJ,O
levels,NNS,O
of,IN,O
tmp,NNP,D
and,CC,O
smx,NN,D
were,VBD,O
essentially,RB,O
unchanged,JJ,O
.,.,.
,,
notably,RB,O
",",",",O
systemic,JJ,O
exposure,NN,O
-lrb-,-LRB-,O
auc0-12,NN,O
-rrb-,-RRB-,O
of,IN,O
dapsone,NN,D
hydroxylamine,NN,O
-lrb-,-LRB-,O
dha,NN,D_n
-rrb-,-RRB-,O
was,VBD,O
more,JJR,O
than,IN,O
doubled,VBN,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
tmp/smx,NN,O
.,.,.
,,
exposure,NN,O
from,IN,O
the,DT,O
proposed,VBN,O
topical,JJ,O
dose,NN,O
is,VBZ,O
about,IN,O
1,CD,O
%,NN,O
of,IN,O
that,DT,O
from,IN,O
the,DT,O
100,CD,O
mg,NN,O
oral,JJ,O
dose,NN,O
",",",",O
even,RB,O
when,WRB,O
co-administered,VBN,O
with,IN,O
tmp/smx,NN,O
.,.,.
,,
certain,JJ,O
concomitant,JJ,O
medications,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
rifampin,NN,D
",",",",O
anticonvulsants,NNS,G
",",",",O
st.,NNP,O
john,NNP,O
s,VBZ,O
wort,NN,O
-rrb-,-RRB-,O
may,MD,O
increase,VB,O
the,DT,O
formation,NN,O
of,IN,O
dapsone,NN,D
hydroxylamine,NN,O
",",",",O
a,DT,O
metabolite,NN,O
of,IN,O
dapsone,NN,D
associated,VBN,O
with,IN,O
hemolysis,NN,O
.,.,.
,,
with,IN,O
oral,JJ,O
dapsone,NN,D
treatment,NN,O
",",",",O
folic,JJ,O
acid,NN,O
antagonists,NNS,O
such,JJ,O
as,IN,O
pyrimethamine,NN,D
have,VBP,O
been,VBN,O
noted,VBN,O
to,TO,O
possibly,RB,O
increase,VB,O
the,DT,O
likelihood,NN,O
of,IN,O
hematologic,JJ,O
reaction,NN,O
.,.,.
,,
warfarin,NNP,D
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
daptomycin,NN,D
-lrb-,-LRB-,O
6,CD,O
mg/kg,NN,O
once,RB,O
every,DT,O
24,CD,O
hours,NNS,O
for,IN,O
5,CD,O
days,NNS,O
-rrb-,-RRB-,O
and,CC,O
warfarin,NN,D
-lrb-,-LRB-,O
25,CD,O
mg,NN,O
single,JJ,O
oral,JJ,O
dose,NN,O
-rrb-,-RRB-,O
had,VBD,O
no,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
drug,NN,D
",",",",O
and,CC,O
the,DT,O
inr,NN,O
was,VBD,O
not,RB,O
significantly,RB,O
altered,VBN,O
.,.,.
,,
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
:,:,O
inhibitors,NNS,O
of,IN,O
hmg-coa,NN,O
reductase,NN,O
may,MD,O
cause,VB,O
myopathy,NN,O
",",",",O
which,WDT,O
is,VBZ,O
manifested,VBN,O
as,IN,O
muscle,NN,O
pain,NN,O
or,CC,O
weakness,NN,O
associated,VBN,O
with,IN,O
elevated,JJ,O
levels,NNS,O
of,IN,O
cpk,NNP,O
.,.,.
,,
there,EX,O
were,VBD,O
no,DT,O
reports,NNS,O
of,IN,O
skeletal,JJ,O
myopathy,NN,O
in,IN,O
a,DT,O
placebo-controlled,JJ,O
phase,NN,O
i,PRP,O
trial,NN,O
in,IN,O
which,WDT,O
10,CD,O
healthy,JJ,O
subjects,NNS,O
on,IN,O
stable,JJ,O
simvastatin,NN,D
therapy,NN,O
were,VBD,O
treated,VBN,O
concurrently,RB,O
with,IN,O
daptomycin,NN,D
-lrb-,-LRB-,O
4,CD,O
mg/kg,NN,O
once,RB,O
every,DT,O
24,CD,O
hours,NNS,O
-rrb-,-RRB-,O
for,IN,O
14,CD,O
days,NNS,O
.,.,.
,,
experience,NN,O
with,IN,O
co-administration,NN,O
of,IN,O
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
and,CC,O
fentanyl,NNP,D
in,IN,O
patients,NNS,O
is,VBZ,O
limited,VBN,O
",",",",O
therefore,RB,O
",",",",O
consideration,NN,O
should,MD,O
be,VB,O
given,VBN,O
to,TO,O
temporarily,RB,O
suspending,VBG,O
use,NN,O
of,IN,O
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
in,IN,O
patients,NNS,O
receiving,VBG,O
fentanyl,NNP,D
.,.,.
,,
drug-laboratory,JJ,O
test,NN,O
interactions,NNS,O
:,:,O
there,EX,O
are,VBP,O
no,DT,O
reported,VBN,O
drug-laboratory,JJ,O
test,NN,O
interactions,NNS,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
of,IN,O
aranesp,NNP,B
have,VBP,O
been,VBN,O
performed,VBN,O
.,.,.
,,
the,DT,O
daily,JJ,O
dose,NN,O
of,IN,O
enablex,NNP,B
should,MD,O
not,RB,O
exceed,VB,O
7.5,CD,O
mg,NN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
potent,JJ,O
cyp3a4,NN,D
inhibitors,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
ketoconazole,NN,D
",",",",O
itraconazole,NN,D
",",",",O
ritonavir,NN,D
",",",",O
nelfinavir,NN,D
",",",",O
clarithromycin,NN,D
and,CC,O
nefazadone,NN,D
-rrb-,-RRB-,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
taken,VBN,O
when,WRB,O
enablex,NNP,B
is,VBZ,O
used,VBN,O
concomitantly,RB,O
with,IN,O
medications,NNS,O
that,WDT,O
are,VBP,O
predominantly,RB,O
metabolized,VBN,O
by,IN,O
cyp2d6,NN,D
and,CC,O
which,WDT,O
have,VBP,O
a,DT,O
narrow,JJ,O
therapeutic,JJ,O
window,NN,O
",",",",O
such,JJ,O
as,IN,O
flecainide,NN,D
",",",",O
thioridazine,NN,D
and,CC,O
tricyclic,JJ,G
antidepressants,NNS,G
-lrb-,-LRB-,O
see,VB,O
clinical,NNP,O
pharmacology,NNP,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
enablex,NN,B
with,IN,O
other,JJ,O
anticholinergic,JJ,G
agents,NNS,O
may,MD,O
increase,VB,O
the,DT,O
frequency,NN,O
and/or,CC,O
severity,NN,O
of,IN,O
dry,JJ,O
mouth,NN,O
",",",",O
constipation,NN,O
",",",",O
blurred,VBD,O
vision,NN,O
and,CC,O
other,JJ,O
anticholinergic,JJ,G
pharmacological,JJ,O
effects,NNS,O
.,.,.
,,
anticholinergic,JJ,O
agents,NNS,O
may,MD,O
potentially,RB,O
alter,VB,O
the,DT,O
absorption,NN,O
of,IN,O
some,DT,O
concomitantly,RB,O
administered,VBN,O
drugs,NNS,D
due,JJ,O
to,TO,O
effects,NNS,O
on,IN,O
gastrointestinal,JJ,O
motility,NN,O
.,.,.
,,
drug,NNP,O
laboratory,NNP,O
test,NNP,O
interactions,NNS,O
interactions,NNS,O
between,IN,O
darifenacin,NN,D
and,CC,O
laboratory,NN,O
tests,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
may,MD,O
increase,VB,O
dasatinib,JJ,D
plasma,NN,O
concentrations,NNS,O
cyp3a4,NN,D
inhibitors,NNS,O
:,:,O
dasatinib,NN,D
is,VBZ,O
a,DT,O
cyp3a4,NN,D
substrate,NN,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
sprycel,NN,B
and,CC,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
cyp3a4,NN,D
-lrb-,-LRB-,O
eg,FW,O
",",",",O
ketoconazole,NN,D
",",",",O
itraconazole,NN,D
",",",",O
erythromycin,NN,D
",",",",O
clarithromycin,NN,D
",",",",O
ritonavir,NN,D
",",",",O
atazanavir,NN,D
",",",",O
indinavir,NN,D
",",",",O
nefazodone,NN,D
",",",",O
nelfinavir,NN,D
",",",",O
saquinavir,NN,D
",",",",O
telithromycin,NN,D
-rrb-,-RRB-,O
may,MD,O
increase,VB,O
exposure,NN,O
to,TO,O
dasatinib,NN,D
and,CC,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
in,IN,O
patients,NNS,O
receiving,VBG,O
treatment,NN,O
with,IN,O
sprycel,NN,B
",",",",O
close,JJ,O
monitoring,NN,O
for,IN,O
toxicity,NN,O
and,CC,O
a,DT,O
sprycel,NNP,B
dose,NN,O
reduction,NN,O
should,MD,O
be,VB,O
considered,VBN,O
if,IN,O
systemic,JJ,O
administration,NN,O
of,IN,O
a,DT,O
potent,JJ,O
cyp3a4,NN,D
inhibitor,NN,O
can,MD,O
not,RB,O
be,VB,O
avoided,VBN,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
may,MD,O
decrease,VB,O
dasatinib,JJ,D
plasma,NN,O
concentrations,NNS,O
cyp3a4,NN,D
inducers,NNS,O
:,:,O
drugs,NNS,O
that,WDT,O
induce,VBP,O
cyp3a4,NN,D
activity,NN,O
may,MD,O
decrease,VB,O
dasatinib,JJ,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
in,IN,O
patients,NNS,O
in,IN,O
whom,WP,O
cyp3a4,NN,D
inducers,NNS,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
dexamethasone,NN,D
",",",",O
phenytoin,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
rifampicin,NN,D
",",",",O
phenobarbital,NN,D
-rrb-,-RRB-,O
are,VBP,O
indicated,VBN,O
",",",",O
alternative,JJ,O
agents,NNS,O
with,IN,O
less,JJR,O
enzyme,NN,O
induction,NN,O
potential,NN,O
should,MD,O
be,VB,O
used,VBN,O
.,.,.
,,
if,IN,O
sprycel,NNP,B
must,MD,O
be,VB,O
administered,VBN,O
with,IN,O
a,DT,O
cyp3a4,NN,D
inducer,NN,O
",",",",O
a,DT,O
dose,NN,O
increase,NN,O
in,IN,O
sprycel,NN,B
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
st.,NNP,O
johns,NNP,O
wort,NN,O
-lrb-,-LRB-,O
hypericum,NN,O
perforatum,NN,O
-rrb-,-RRB-,O
may,MD,O
decrease,VB,O
sprycel,NNP,B
plasma,NN,O
concentrations,NNS,O
unpredictably,RB,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
sprycel,NN,B
should,MD,O
not,RB,O
take,VB,O
st.,NNP,O
johns,NNP,O
wort,NN,O
.,.,.
,,
antacids,NNS,G
:,:,O
nonclinical,JJ,O
data,NNS,O
demonstrate,VBP,O
that,IN,O
the,DT,O
solubility,NN,O
of,IN,O
dasatinib,NN,D
is,VBZ,O
ph,NN,O
dependent,JJ,O
.,.,.
,,
simultaneous,JJ,O
administration,NN,O
of,IN,O
sprycel,NN,B
with,IN,O
antacids,NNS,G
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
if,IN,O
antacid,NN,G
therapy,NN,O
is,VBZ,O
needed,VBN,O
",",",",O
the,DT,O
antacid,NN,G
dose,NN,O
should,MD,O
be,VB,O
administered,VBN,O
at,IN,O
least,JJS,O
2,CD,O
hours,NNS,O
prior,RB,O
to,TO,O
or,CC,O
2,CD,O
hours,NNS,O
after,IN,O
the,DT,O
dose,NN,O
of,IN,O
sprycel,NN,B
.,.,.
,,
h2,NN,O
blockers/proton,NN,O
pump,NN,O
inhibitors,NNS,O
:,:,O
long-term,JJ,O
suppression,NN,O
of,IN,O
gastric,JJ,O
acid,NN,O
secretion,NN,O
by,IN,O
h2,NN,O
blockers,NNS,O
or,CC,O
proton,NN,O
pump,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
famotidine,NN,D
and,CC,O
omeprazole,NN,D
-rrb-,-RRB-,O
is,VBZ,O
likely,JJ,O
to,TO,O
reduce,VB,O
dasatinib,NN,D
exposure,NN,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
h2,NN,O
blockers,NNS,O
or,CC,O
proton,NN,O
pump,NN,O
inhibitors,NNS,O
with,IN,O
sprycel,NN,B
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
antacids,NNS,G
should,MD,O
be,VB,O
considered,VBN,O
in,IN,O
place,NN,O
of,IN,O
h2,NN,O
blockers,NNS,O
or,CC,O
proton,NN,O
pump,NN,O
inhibitors,NNS,O
in,IN,O
patients,NNS,O
receiving,VBG,O
sprycel,NN,B
therapy,NN,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
may,MD,O
have,VB,O
their,PRP$,O
plasma,NN,O
concentration,NN,O
altered,VBN,O
by,IN,O
dasatinib,NN,D
cyp3a4,NN,D
substrates,NNS,O
:,:,O
dasatinib,NN,D
is,VBZ,O
a,DT,O
time-dependent,JJ,O
inhibitor,NN,O
of,IN,O
cyp3a4,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
cyp3a4,NN,D
substrates,NNS,O
known,VBN,O
to,TO,O
have,VB,O
a,DT,O
narrow,JJ,O
therapeutic,JJ,O
index,NN,O
such,JJ,O
as,IN,O
alfentanil,NN,D
",",",",O
astemizole,NN,D
",",",",O
terfenadine,NN,D
",",",",O
cisapride,NN,D
",",",",O
cyclosporine,NN,D
",",",",O
fentanyl,NN,D
",",",",O
pimozide,NN,D
",",",",O
quinidine,NN,D
",",",",O
sirolimus,NN,D
",",",",O
tacrolimus,NN,D
",",",",O
or,CC,O
ergot,NN,G
alkaloids,NNS,O
-lrb-,-LRB-,O
ergotamine,NN,D
",",",",O
dihydroergotamine,NN,D
-rrb-,-RRB-,O
should,MD,O
be,VB,O
administered,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
sprycel,NNP,B
.,.,.
,,
hepatic,JJ,O
impairment,NN,O
there,EX,O
are,VBP,O
currently,RB,O
no,DT,O
clinical,JJ,O
studies,NNS,O
with,IN,O
sprycel,NN,B
in,IN,O
patients,NNS,O
with,IN,O
impaired,JJ,O
liver,NN,O
function,NN,O
-lrb-,-LRB-,O
clinical,JJ,O
studies,NNS,O
have,VBP,O
excluded,VBN,O
patients,NNS,O
with,IN,O
alt,NN,O
and/or,CC,O
ast,NNP,O
2.5,CD,O
times,NNS,O
the,DT,O
upper,JJ,O
limit,NN,O
of,IN,O
the,DT,O
normal,JJ,O
range,NN,O
and/or,CC,O
total,JJ,O
bilirubin,NN,O
2,CD,O
times,NNS,O
the,DT,O
upper,JJ,O
limit,NN,O
of,IN,O
the,DT,O
normal,JJ,O
range,NN,O
-rrb-,-RRB-,O
.,.,.
,,
metabolism,NN,O
of,IN,O
dasatinib,NN,D
is,VBZ,O
mainly,RB,O
hepatic,JJ,O
.,.,.
,,
caution,NN,O
is,VBZ,O
recommended,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
hepatic,JJ,O
impairment,NN,O
.,.,.
,,
renal,JJ,O
impairment,NN,O
there,EX,O
are,VBP,O
currently,RB,O
no,DT,O
clinical,JJ,O
studies,NNS,O
with,IN,O
sprycel,NN,B
in,IN,O
patients,NNS,O
with,IN,O
impaired,JJ,O
renal,JJ,O
function,NN,O
-lrb-,-LRB-,O
clinical,JJ,O
studies,NNS,O
have,VBP,O
excluded,VBN,O
patients,NNS,O
with,IN,O
serum,NN,O
creatinine,NN,O
concentration,NN,O
1.5,CD,O
times,NNS,O
the,DT,O
upper,JJ,O
limit,NN,O
of,IN,O
the,DT,O
normal,JJ,O
range,NN,O
-rrb-,-RRB-,O
.,.,.
,,
dasatinib,NNP,D
and,CC,O
its,PRP$,O
metabolites,NNS,O
are,VBP,O
minimally,RB,O
excreted,VBN,O
via,IN,O
the,DT,O
kidney,NN,O
.,.,.
,,
since,IN,O
the,DT,O
renal,JJ,O
excretion,NN,O
of,IN,O
unchanged,JJ,O
dasatinib,NN,D
and,CC,O
its,PRP$,O
metabolites,NNS,O
is,VBZ,O
4,CD,O
%,NN,O
",",",",O
a,DT,O
decrease,NN,O
in,IN,O
total,JJ,O
body,NN,O
clearance,NN,O
is,VBZ,O
not,RB,O
expected,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
renal,JJ,O
insufficiency,NN,O
.,.,.
,,
use,NN,O
of,IN,O
cerubidine,NNP,B
in,IN,O
a,DT,O
patient,NN,O
who,WP,O
has,VBZ,O
previously,RB,O
received,VBN,O
doxorubicin,NN,D
increases,VBZ,O
the,DT,O
risk,NN,O
of,IN,O
cardiotoxicity,NN,O
.,.,.
,,
cerubidine,NN,B
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
in,IN,O
patients,NNS,O
who,WP,O
have,VBP,O
previously,RB,O
received,VBN,O
the,DT,O
recommended,VBN,O
maximum,NN,O
cumulative,JJ,O
doses,NNS,O
of,IN,O
doxorubicin,NN,D
or,CC,O
cerubidine,NN,B
.,.,.
,,
cyclophosphamide,NNP,D
used,VBD,O
concurrently,RB,O
with,IN,O
cerubidine,NN,B
may,MD,O
also,RB,O
result,VB,O
in,IN,O
increased,VBN,O
cardiotoxicity,NN,O
.,.,.
,,
dosage,NN,O
reduction,NN,O
of,IN,O
cerubidine,NN,B
may,MD,O
be,VB,O
required,VBN,O
when,WRB,O
used,VBN,O
concurrently,RB,O
with,IN,O
other,JJ,O
myelosuppressive,JJ,O
agents,NNS,O
.,.,.
,,
hepatotoxic,JJ,O
medications,NNS,O
",",",",O
such,JJ,O
as,IN,O
high-dose,JJ,O
methotrexate,NN,D
",",",",O
may,MD,O
impair,VB,O
liver,NN,O
function,NN,O
and,CC,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
toxicity,NN,O
.,.,.
,,
potentially,RB,O
fatal,JJ,O
drug,NN,D
interactions,NNS,O
may,MD,O
occur,VB,O
when,WRB,O
coadministered,VBN,O
with,IN,O
digoxin,NN,D
",",",",O
as,IN,O
this,DT,O
may,MD,O
enhance,VB,O
cardiovascular,JJ,O
depression,NN,O
and,CC,O
bradyarrhythmias,NNS,O
may,MD,O
occur,VB,O
.,.,.
,,
anticholinesterases,NNS,G
-lrb-,-LRB-,O
neostgmine,NN,O
",",",",O
physostigmine,NN,D
-rrb-,-RRB-,O
",",",",O
lignocaine,NN,D
",",",",O
quinine,NN,D
",",",",O
procainamide,NN,D
can,MD,O
enhance,VB,O
toxicity,NN,O
and,CC,O
cause,VB,O
cardio,NN,O
respiratory,JJ,O
depression,NN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
neuromuscular,JJ,O
blocking,VBG,O
action,NN,O
is,VBZ,O
enhanced,VBN,O
by,IN,O
general,JJ,O
anesthetics,NNS,G
",",",",O
local,JJ,O
anesthetics,NNS,G
like,IN,O
lidocaine,NN,D
",",",",O
procaine,NN,D
",",",",O
beta-blockers,NNS,G
",",",",O
metaclopramide,NN,D
",",",",O
lithium,NN,D
carbonate,NN,O
",",",",O
and,CC,O
terbutaline,NN,D
.,.,.
,,
drug,NN,O
interaction,NN,O
studies,NNS,O
with,IN,O
decitabine,NN,D
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
in,IN,O
human,JJ,O
liver,NN,O
microsomes,NNS,O
suggest,VBP,O
that,IN,O
decitabine,NN,D
is,VBZ,O
unlikely,JJ,O
to,TO,O
inhibit,VB,O
or,CC,O
induce,VB,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
.,.,.
,,
in,FW,O
vitro,FW,O
metabolism,NN,O
studies,NNS,O
have,VBP,O
suggested,VBN,O
that,IN,O
decitabine,NN,D
is,VBZ,O
not,RB,O
a,DT,O
substrate,NN,O
for,IN,O
the,DT,O
human,JJ,O
liver,NN,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
.,.,.
,,
as,IN,O
plasma,NN,O
protein,NN,O
binding,NN,O
of,IN,O
decitabine,NN,D
is,VBZ,O
negligible,JJ,O
-lrb-,-LRB-,O
1,CD,O
%,NN,O
-rrb-,-RRB-,O
",",",",O
interactions,NNS,O
due,JJ,O
to,TO,O
displacement,NN,O
of,IN,O
more,RBR,O
highly,RB,O
protein,NN,O
bound,VBD,O
drugs,NNS,D
from,IN,O
plasma,NN,O
proteins,NNS,O
are,VBP,O
not,RB,O
expected,VBN,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
exjade,NNP,B
and,CC,O
aluminum-containing,JJ,O
antacid,NN,G
preparations,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
formally,RB,O
studied,VBN,O
.,.,.
,,
although,IN,O
deferasirox,NN,D
has,VBZ,O
a,DT,O
lower,JJR,O
affinity,NN,O
for,IN,O
aluminum,NN,D
than,IN,O
for,IN,O
iron,NN,D
",",",",O
exjade,NN,B
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
with,IN,O
aluminum-containing,JJ,O
antacid,NN,G
preparations,NNS,O
.,.,.
,,
in,IN,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
exjade,NNP,B
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
digoxin,NN,D
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
digoxin,NN,D
on,IN,O
exjade,NNP,B
pharmacokinetics,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
exjade,NNP,B
and,CC,O
vitamin,NN,G
c,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
formally,RB,O
studied,VBN,O
.,.,.
,,
doses,NNS,O
of,IN,O
vitamin,NN,G
c,NN,O
up,IN,O
to,TO,O
200,CD,O
mg,NN,O
were,VBD,O
allowed,VBN,O
in,IN,O
clinical,JJ,O
studies,NNS,O
without,IN,O
negative,JJ,O
consequences,NNS,O
.,.,.
,,
the,DT,O
interaction,NN,O
of,IN,O
exjade,NN,B
with,IN,O
hydroxyurea,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
formally,RB,O
studied,VBN,O
.,.,.
,,
no,DT,O
inhibition,NN,O
of,IN,O
deferasirox,NN,D
metabolism,NN,O
by,IN,O
hydroxyurea,NN,D
is,VBZ,O
expected,VBN,O
based,VBN,O
on,IN,O
the,DT,O
results,NNS,O
of,IN,O
an,DT,O
in,FW,O
vitro,FW,O
study,NN,O
.,.,.
,,
exjade,NN,B
should,MD,O
not,RB,O
be,VB,O
combined,VBN,O
with,IN,O
other,JJ,O
iron,NN,D
chelator,NN,O
therapies,NNS,O
",",",",O
as,IN,O
safety,NN,O
of,IN,O
such,JJ,O
combinations,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
drug/food,NNP,O
interactions,NNS,O
the,DT,O
bioavailability,NN,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
of,IN,O
deferasirox,NN,D
was,VBD,O
variably,RB,O
increased,VBN,O
when,WRB,O
taken,VBN,O
with,IN,O
a,DT,O
meal,NN,O
.,.,.
,,
deferasirox,NN,D
should,MD,O
be,VB,O
taken,VBN,O
on,IN,O
an,DT,O
empty,JJ,O
stomach,NN,O
30,CD,O
minutes,NNS,O
before,IN,O
eating,VBG,O
.,.,.
,,
exjade,NNP,B
tablets,NNS,O
for,IN,O
oral,JJ,O
suspension,NN,O
can,MD,O
be,VB,O
dispersed,VBN,O
in,IN,O
water,NN,O
",",",",O
orange,JJ,O
juice,NN,O
",",",",O
or,CC,O
apple,NN,O
juice,NN,O
.,.,.
,,
antiacid,NNP,O
",",",",O
clarithromycin,NN,D
",",",",O
didanosine,NNP,D
",",",",O
fluconazole,NNP,D
",",",",O
fluoxetine,NNP,D
",",",",O
indanavir,NNP,O
",",",",O
ketoconazole,NNP,D
",",",",O
phenytoin,NNP,D
",",",",O
phenobarbitol,NNP,O
",",",",O
carbamazepine,NN,D
",",",",O
rifabutin,NN,D
",",",",O
rifampin,NNP,D
",",",",O
ritanovir,NNP,O
",",",",O
saquinavir,NNP,D
.,.,.
,,
possible,JJ,O
drug,NN,D
interactions,NNS,O
of,IN,O
humorsol,NN,B
with,IN,O
succinylcholine,NN,D
or,CC,O
with,IN,O
other,JJ,O
anticholinesterase,JJ,G
agents,NNS,O
.,.,.
,,
because,IN,O
the,DT,O
tetracyclines,NNS,G
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
depress,VB,O
plasma,NN,O
prothrombin,NN,O
activity,NN,O
",",",",O
patients,NNS,O
who,WP,O
are,VBP,O
on,IN,O
anticoagulant,JJ,G
therapy,NN,O
may,MD,O
require,VB,O
downward,JJ,O
adjustment,NN,O
of,IN,O
their,PRP$,O
anticoagulant,JJ,G
dosage,NN,O
.,.,.
,,
since,IN,O
bacteriostatic,JJ,O
drugs,NNS,D
",",",",O
such,JJ,O
as,IN,O
the,DT,O
tetracycline,NN,D
class,NN,O
of,IN,O
antibiotics,NNS,G
",",",",O
may,MD,O
interfere,VB,O
with,IN,O
the,DT,O
bactericidal,JJ,O
action,NN,O
of,IN,O
penicillins,NNS,D
",",",",O
it,PRP,O
is,VBZ,O
not,RB,O
advisable,JJ,O
to,TO,O
administer,VB,O
these,DT,O
drugs,NNS,D
concomitantly,RB,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
of,IN,O
tetracyclines,NNS,G
with,IN,O
oral,JJ,O
contraceptives,NNS,G
may,MD,O
render,VB,O
oral,JJ,O
contraceptives,NNS,G
less,RBR,O
effective,JJ,O
.,.,.
,,
breakthrough,NN,O
bleeding,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
.,.,.
,,
no,DT,O
clinical,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
however,RB,O
",",",",O
in,IN,O
a,DT,O
single,JJ,O
in,FW,O
vivo,FW,O
rodent,JJ,O
study,NN,O
denileukin,NN,O
diftitox,NN,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
p450,NN,O
levels,NNS,O
.,.,.
,,
taking,VBG,O
a,DT,O
rauwolfia,NN,O
alkaloid,NN,O
while,IN,O
you,PRP,O
are,VBP,O
taking,VBG,O
or,CC,O
within,IN,O
2,CD,O
weeks,NNS,O
of,IN,O
taking,VBG,O
mao,NNP,O
inhibitors,NNS,O
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
central,JJ,O
nervous,JJ,O
system,NN,O
depression,NN,O
or,CC,O
may,MD,O
cause,VB,O
a,DT,O
severe,JJ,O
high,JJ,O
blood,NN,O
pressure,NN,O
reaction,NN,O
.,.,.
,,
no,DT,O
clinically,RB,O
significant,JJ,O
adverse,JJ,O
interactions,NNS,O
with,IN,O
commonly,RB,O
used,VBN,O
preanesthetic,JJ,O
drugs,NNS,D
",",",",O
or,CC,O
drugs,NNS,D
used,VBN,O
during,IN,O
anesthesia,NN,D
-lrb-,-LRB-,O
muscle,NN,O
relaxants,NNS,O
",",",",O
intravenous,JJ,O
agents,NNS,O
",",",",O
and,CC,O
local,JJ,O
anesthetic,JJ,G
agents,NNS,O
-rrb-,-RRB-,O
were,VBD,O
reported,VBN,O
in,IN,O
clinical,JJ,O
trials,NNS,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
desflurane,NN,D
on,IN,O
the,DT,O
disposition,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
has,VBZ,O
not,RB,O
been,VBN,O
determined,VBN,O
.,.,.
,,
like,IN,O
isoflurane,NN,D
",",",",O
desflurane,NN,D
does,VBZ,O
not,RB,O
predispose,VB,O
to,TO,O
premature,JJ,O
ventricular,JJ,O
arrhythmias,NNS,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
exogenously,RB,O
infused,VBN,O
epinephrine,NN,D
in,IN,O
swine,NNS,O
.,.,.
,,
1,LS,O
.,.,.
,,
drugs,NNS,O
metabolized,VBN,O
by,IN,O
p450,NN,O
2d6,NN,O
:,:,O
the,DT,O
biochemical,JJ,O
activity,NN,O
of,IN,O
the,DT,O
drug,NN,D
metabolizing,VBG,O
isozyme,NN,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
-lrb-,-LRB-,O
debrisoquin,NN,D
hydroxylase,NN,O
-rrb-,-RRB-,O
is,VBZ,O
reduced,VBN,O
in,IN,O
a,DT,O
subset,NN,O
of,IN,O
the,DT,O
caucasian,JJ,O
population,NN,O
-lrb-,-LRB-,O
about,IN,O
7,CD,O
to,TO,O
10,CD,O
%,NN,O
of,IN,O
caucasians,NNS,O
are,VBP,O
so,RB,O
called,VBN,O
poor,JJ,O
metabolizers,NNS,O
-rrb-,-RRB-,O
;,:,O
.,.,.
,,
reliable,JJ,O
estimates,NNS,O
of,IN,O
the,DT,O
prevalence,NN,O
of,IN,O
reduced,VBN,O
p450,NN,O
2d6,NN,O
isozyme,NN,O
activity,NN,O
among,IN,O
asian,JJ,O
",",",",O
african,JJ,O
and,CC,O
other,JJ,O
populations,NNS,O
are,VBP,O
not,RB,O
yet,RB,O
available,JJ,O
.,.,.
,,
poor,NNP,O
metabolizers,NNS,O
have,VBP,O
higher,JJR,O
than,IN,O
expected,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
-lrb-,-LRB-,O
tcas,NNS,G
-rrb-,-RRB-,O
when,WRB,O
given,VBN,O
usual,JJ,O
doses,NNS,O
.,.,.
,,
depending,VBG,O
on,IN,O
the,DT,O
traction,NN,O
of,IN,O
drug,NN,D
metabolized,VBN,O
by,IN,O
p450,NN,O
2d6,NN,O
",",",",O
the,DT,O
increase,NN,O
in,IN,O
plasma,NN,O
concentration,NN,O
may,MD,O
be,VB,O
small,JJ,O
",",",",O
or,CC,O
quite,RB,O
large,JJ,O
-lrb-,-LRB-,O
8,CD,O
fold,JJ,O
increase,NN,O
in,IN,O
plasma,NN,O
auc,NN,O
of,IN,O
the,DT,O
tca,NNP,G
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
certain,JJ,O
drugs,NNS,D
inhibit,VBP,O
the,DT,O
activity,NN,O
of,IN,O
this,DT,O
isozyme,NN,O
and,CC,O
make,VB,O
normal,JJ,O
metabolizers,NNS,O
resemble,VBP,O
p.o.,NN,O
metabolizers,NNS,O
.,.,.
,,
an,DT,O
individual,NN,O
who,WP,O
is,VBZ,O
stable,JJ,O
on,IN,O
a,DT,O
given,VBN,O
dose,NN,O
of,IN,O
tca,NNP,G
may,MD,O
become,VB,O
abruptly,RB,O
toxic,JJ,O
when,WRB,O
given,VBN,O
one,CD,O
of,IN,O
these,DT,O
inhibiting,VBG,O
drugs,NNS,D
as,IN,O
concomitant,JJ,O
therapy,NN,O
.,.,.
,,
the,DT,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
include,VBP,O
some,DT,O
that,WDT,O
are,VBP,O
not,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
enzyme,NN,O
-lrb-,-LRB-,O
quinidine,NN,D
.,.,.
,,
cimetidine,NN,D
-rrb-,-RRB-,O
and,CC,O
many,JJ,O
that,WDT,O
are,VBP,O
substrates,NNS,O
for,IN,O
p450,NN,O
2d6,NN,O
-lrb-,-LRB-,O
many,JJ,O
other,JJ,O
antidepressants,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
and,CC,O
the,DT,O
type,NN,O
1c,NN,O
antiarrhythrnics,NNS,O
propatenone,NN,O
and,CC,O
flecainide,NN,D
-rrb-,-RRB-,O
.,.,.
,,
while,IN,O
all,PDT,O
the,DT,O
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
ssris,NNS,G
-rrb-,-RRB-,O
",",",",O
e.g.,FW,O
",",",",O
fluoxetine,NN,D
",",",",O
seriraline,NN,O
",",",",O
and,CC,O
paroxetine,NN,D
",",",",O
inhibit,VBP,O
p450,NN,O
2d6,NN,O
",",",",O
they,PRP,O
may,MD,O
vary,VB,O
in,IN,O
the,DT,O
extent,NN,O
of,IN,O
inhibition,NN,O
.,.,.
,,
the,DT,O
extent,NN,O
to,TO,O
which,WDT,O
ssri-tca,NNP,O
interactions,NNS,O
may,MD,O
pose,VB,O
clinical,JJ,O
problems,NNS,O
will,MD,O
depend,VB,O
on,IN,O
the,DT,O
degree,NN,O
of,IN,O
inhibition,NN,O
and,CC,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
the,DT,O
ssri,NNP,G
involved,VBN,O
.,.,.
,,
nevertheless,RB,O
",",",",O
caution,NN,O
is,VBZ,O
indicated,VBN,O
in,IN,O
the,DT,O
co-administration,NN,O
of,IN,O
t.a.,NN,G
with,IN,O
any,DT,O
of,IN,O
the,DT,O
ssris,NNS,G
and,CC,O
also,RB,O
in,IN,O
switching,NN,O
from,IN,O
one,CD,O
class,NN,O
to,TO,O
the,DT,O
other,JJ,O
.,.,.
,,
of,IN,O
particular,JJ,O
importance,NN,O
",",",",O
sufficient,JJ,O
time,NN,O
must,MD,O
elapse,VB,O
before,IN,O
initiating,VBG,O
tca,NNP,G
treatment,NN,O
in,IN,O
a,DT,O
patient,NN,O
being,VBG,O
withdrawn,VBN,O
from,IN,O
fluoxetine,NN,D
",",",",O
given,VBN,O
the,DT,O
long,JJ,O
half-life,NN,O
of,IN,O
the,DT,O
parent,NN,O
and,CC,O
active,JJ,O
metabolite,NN,O
-lrb-,-LRB-,O
at,IN,O
least,JJS,O
5,CD,O
weeks,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
-rrb-,-RRB-,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
with,IN,O
drugs,NNS,D
that,WDT,O
can,MD,O
inhibit,VB,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
may,MD,O
require,VB,O
lower,JJR,O
doses,NNS,O
than,IN,O
usually,RB,O
prescribed,VBN,O
for,IN,O
either,CC,O
the,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
or,CC,O
the,DT,O
other,JJ,O
drug,NN,D
.,.,.
,,
furthermore,RB,O
",",",",O
whenever,WRB,O
one,CD,O
of,IN,O
these,DT,O
other,JJ,O
drugs,NNS,D
is,VBZ,O
withdrawn,VBN,O
from,IN,O
co-therapy,JJ,O
",",",",O
an,DT,O
increased,VBN,O
dose,NN,O
of,IN,O
tricyclic,JJ,G
antidepressant,JJ,G
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
desirable,JJ,O
to,TO,O
monitor,VB,O
tca,NNP,G
plasma,NN,O
levels,NNS,O
whenever,WRB,O
a,DT,O
tca,NNP,G
is,VBZ,O
going,VBG,O
to,TO,O
be,VB,O
co-administered,VBN,O
with,IN,O
another,DT,O
drug,NN,D
known,VBN,O
to,TO,O
be,VB,O
an,DT,O
inhibitor,NN,O
of,IN,O
p450,NN,O
2d6,NN,O
.,.,.
,,
2,LS,O
.,.,.
,,
close,JJ,O
supervision,NN,O
and,CC,O
careful,JJ,O
adjustment,NN,O
of,IN,O
dosage,NN,O
are,VBP,O
required,VBN,O
when,WRB,O
this,DT,O
drug,NN,D
is,VBZ,O
given,VBN,O
concomitantly,RB,O
with,IN,O
anticholinergic,JJ,G
or,CC,O
sympathomimetic,JJ,G
drugs,NNS,D
.,.,.
,,
3,LS,O
.,.,.
,,
clinical,JJ,O
experience,NN,O
in,IN,O
the,DT,O
concurrent,JJ,O
administration,NN,O
of,IN,O
ect,NNP,O
and,CC,O
antidepressant,JJ,G
drugs,NNS,D
is,VBZ,O
limited,VBN,O
.,.,.
,,
thus,RB,O
",",",",O
if,IN,O
such,JJ,O
treatment,NN,O
is,VBZ,O
essential,JJ,O
",",",",O
the,DT,O
possibility,NN,O
of,IN,O
increased,VBN,O
risk,NN,O
relative,JJ,O
to,TO,O
benefits,NNS,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
4,LS,O
.,.,.
,,
if,IN,O
desipramine,NN,D
hydrochloride,NN,O
is,VBZ,O
to,TO,O
be,VB,O
combined,VBN,O
with,IN,O
other,JJ,O
psychotropic,JJ,O
agents,NNS,O
such,JJ,O
as,IN,O
tranquilizers,NNS,G
or,CC,O
sedative/hypnotics,NNS,O
",",",",O
careful,JJ,O
consideration,NN,O
should,MD,O
be,VB,O
given,VBN,O
to,TO,O
the,DT,O
pharmacology,NN,O
of,IN,O
the,DT,O
agents,NNS,O
employed,VBN,O
since,IN,O
the,DT,O
sedative,JJ,G
effects,NNS,O
of,IN,O
desipramine,NN,D
and,CC,O
benzodiazepines,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
chlordiazepoxide,NN,D
or,CC,O
diazepam,NN,D
-rrb-,-RRB-,O
are,VBP,O
additive,JJ,O
.,.,.
,,
both,CC,O
the,DT,O
sedative,NN,G
and,CC,O
anticholinergic,JJ,G
effects,NNS,O
of,IN,O
the,DT,O
major,JJ,O
tranquilizers,NNS,G
are,VBP,O
also,RB,O
additive,JJ,O
to,TO,O
those,DT,O
of,IN,O
desipramine,NN,D
.,.,.
,,
5,CD,O
.,.,.
,,
concurrent,JJ,O
administration,NN,O
of,IN,O
cimetidine,NN,D
and,CC,O
tricyclic,JJ,G
antidepressants,NNS,G
can,MD,O
produce,VB,O
clinically,RB,O
significant,JJ,O
increases,NNS,O
in,IN,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
the,DT,O
tricyclic,JJ,G
antidepressants,NNS,G
.,.,.
,,
conversely,RB,O
",",",",O
decreases,VBZ,O
in,IN,O
plasma,NN,O
levels,NNS,O
of,IN,O
the,DT,O
tricyclic,JJ,G
antidepressants,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
upon,IN,O
discontinuation,NN,O
of,IN,O
cimetidine,NN,D
which,WDT,O
may,MD,O
result,VB,O
in,IN,O
the,DT,O
loss,NN,O
of,IN,O
the,DT,O
therapeutic,JJ,O
efficacy,NN,O
of,IN,O
the,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
6,CD,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
greater,JJR,O
than,IN,O
two-fold,JJ,O
increases,NNS,O
of,IN,O
previously,RB,O
stable,JJ,O
plasma,NN,O
levels,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
when,WRB,O
fluoxetine,NN,D
has,VBZ,O
been,VBN,O
administered,VBN,O
in,IN,O
combination,NN,O
with,IN,O
these,DT,O
agents,NNS,O
.,.,.
,,
in,IN,O
two,CD,O
controlled,JJ,O
crossover,NN,O
clinical,JJ,O
pharmacology,NN,O
studies,NNS,O
in,IN,O
healthy,JJ,O
male,NN,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
12,CD,O
in,IN,O
each,DT,O
study,NN,O
-rrb-,-RRB-,O
a,DT,O
nd,NN,O
female,NN,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
12,CD,O
in,IN,O
each,DT,O
study,NN,O
-rrb-,-RRB-,O
volunteers,NNS,O
",",",",O
desloratadine,NN,D
7.5,CD,O
mg,NN,O
-lrb-,-LRB-,O
1.5,CD,O
times,NNS,O
the,DT,O
daily,JJ,O
dose,NN,O
-rrb-,-RRB-,O
once,RB,O
daily,RB,O
was,VBD,O
coadministered,VBN,O
with,IN,O
erythromycin,NN,D
500,CD,O
mg,NN,O
every,DT,O
8,CD,O
hours,NNS,O
or,CC,O
ketoconazole,NN,D
200,CD,O
mg,NN,O
every,DT,O
12,CD,O
hours,NNS,O
for,IN,O
10,CD,O
days,NNS,O
.,.,.
,,
in,IN,O
three,CD,O
separate,JJ,O
controlled,JJ,O
",",",",O
parallel,JJ,O
group,NN,O
clinical,JJ,O
pharmacology,NN,O
studies,NNS,O
",",",",O
desloratadine,NN,D
at,IN,O
the,DT,O
clinical,JJ,O
dose,NN,O
of,IN,O
5,CD,O
mg,NN,O
has,VBZ,O
been,VBN,O
coadministered,VBN,O
with,IN,O
azithromycin,NN,D
500,CD,O
mg,NN,O
followed,VBN,O
by,IN,O
250,CD,O
mg,NN,O
once,RB,O
daily,RB,O
for,IN,O
4,CD,O
days,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
18,CD,O
-rrb-,-RRB-,O
or,CC,O
with,IN,O
fluoxetine,NN,D
20,CD,O
mg,NN,O
once,RB,O
daily,RB,O
for,IN,O
7,CD,O
days,NNS,O
after,IN,O
a,DT,O
23,CD,O
day,NN,O
pretreatment,NN,O
period,NN,O
with,IN,O
fluoxetine,NN,D
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
18,CD,O
-rrb-,-RRB-,O
or,CC,O
with,IN,O
cimetidine,NN,D
600,CD,O
mg,NN,O
every,DT,O
12,CD,O
hours,NNS,O
for,IN,O
14,CD,O
days,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
18,CD,O
-rrb-,-RRB-,O
under,IN,O
steady,JJ,O
state,NN,O
conditions,NNS,O
to,TO,O
normal,JJ,O
healthy,JJ,O
male,NN,O
and,CC,O
female,JJ,O
volunteers,NNS,O
.,.,.
,,
although,IN,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
-lrb-,-LRB-,O
c,NN,O
max,NN,O
and,CC,O
auc,NN,O
0-24,CD,O
hrs,NNS,O
-rrb-,-RRB-,O
of,IN,O
desloratadine,NN,D
and,CC,O
3-hydroxydesloratadine,NN,D_n
were,VBD,O
observed,VBN,O
",",",",O
there,EX,O
were,VBD,O
no,DT,O
clinically,RB,O
relevant,JJ,O
changes,NNS,O
in,IN,O
the,DT,O
safety,NN,O
profile,NN,O
of,IN,O
desloratadine,NN,D
",",",",O
as,IN,O
assessed,VBN,O
by,IN,O
electrocardiographic,JJ,O
parameters,NNS,O
-lrb-,-LRB-,O
including,VBG,O
the,DT,O
corrected,VBN,O
qt,NN,O
interval,NN,O
-rrb-,-RRB-,O
",",",",O
clinical,JJ,O
laboratory,NN,O
tests,NNS,O
",",",",O
vital,JJ,O
signs,NNS,O
",",",",O
and,CC,O
adverse,JJ,O
events,NNS,O
.,.,.
,,
table,NNP,O
1,CD,O
changes,NNS,O
in,IN,O
desloratadine,NN,D
and,CC,O
3-hydroxydesloratadine,NN,D_n
pharmacokinetics,NNS,O
in,IN,O
healthy,JJ,O
male,NN,O
and,CC,O
female,JJ,O
volunteer,NN,O
.,.,.
,,
desloratadine,NN,D
3-hydroxydesloratadin,NN,O
.,.,.
,,
c,NN,O
max,NN,O
auc,NN,O
0-24,CD,O
hrs,NNS,O
c,NN,O
max,NN,O
auc,NN,O
0-24,CD,O
hrs,NNS,O
.,.,.
,,
erythromyci,NNP,O
.,.,.
,,
-lrb-,-LRB-,O
500,CD,O
mg,NN,O
q8h,NN,O
-rrb-,-RRB-,O
.,.,.
,,
24,CD,O
%,NN,O
14,CD,O
%,NN,O
43,CD,O
%,NN,O
40,CD,O
%,NN,O
.,.,.
,,
ketoconazol,NNP,O
.,.,.
,,
-lrb-,-LRB-,O
200,CD,O
mg,NN,O
q12h,NN,O
-rrb-,-RRB-,O
.,.,.
,,
45,CD,O
%,NN,O
39,CD,O
%,NN,O
43,CD,O
%,NN,O
72,CD,O
%,NN,O
.,.,.
,,
azithromyci,NNP,O
.,.,.
,,
-lrb-,-LRB-,O
500,CD,O
mg,NN,O
day,NN,O
1,CD,O
",",",",O
250,CD,O
mg,NN,O
qd,NN,O
4,CD,O
days,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
15,CD,O
%,NN,O
5,CD,O
%,NN,O
15,CD,O
%,NN,O
4,CD,O
%,NN,O
.,.,.
,,
fluoxetin,NNP,O
.,.,.
,,
-lrb-,-LRB-,O
20,CD,O
mg,NN,O
qd,NN,O
-rrb-,-RRB-,O
.,.,.
,,
15,CD,O
%,NN,O
0,CD,O
%,NN,O
17,CD,O
%,NN,O
13,CD,O
%,NN,O
.,.,.
,,
cimetidin,NNP,O
.,.,.
,,
-lrb-,-LRB-,O
600,CD,O
mg,NN,O
q12h,NN,O
-rrb-,-RRB-,O
.,.,.
,,
12,CD,O
%,NN,O
19,CD,O
%,NN,O
-11,CD,O
%,NN,O
-3,CD,O
%,NN,O
.,.,.
,,
although,IN,O
the,DT,O
pressor,NN,O
activity,NN,O
of,IN,O
desmopressin,NN,D
is,VBZ,O
very,RB,O
low,JJ,O
compared,VBN,O
to,TO,O
its,PRP$,O
antidiuretic,JJ,O
activity,NN,O
",",",",O
large,JJ,O
doses,NNS,O
of,IN,O
desmopressin,NNP,D
tablets,NNS,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
other,JJ,O
pressor,NN,O
agents,NNS,O
only,RB,O
with,IN,O
careful,JJ,O
patient,NN,O
monitoring,NN,O
.,.,.
,,
reduced,VBN,O
efficacy,NN,O
and,CC,O
increased,VBD,O
incidence,NN,O
of,IN,O
breakthrough,NN,O
bleeding,NN,O
and,CC,O
menstrual,JJ,O
irregularities,NNS,O
have,VBP,O
been,VBN,O
associated,VBN,O
with,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
rifampin,NN,D
.,.,.
,,
a,DT,O
similar,JJ,O
association,NN,O
",",",",O
though,IN,O
less,JJR,O
marked,JJ,O
",",",",O
has,VBZ,O
been,VBN,O
suggested,VBN,O
with,IN,O
barbiturates,NNS,G
",",",",O
phenyl-butazone,NN,O
",",",",O
phenytoin,NN,D
sodium,NN,O
",",",",O
carbamazepine,NN,D
and,CC,O
possibly,RB,O
with,IN,O
griseofulvin,NN,D
",",",",O
ampicillin,NN,D
",",",",O
and,CC,O
tetracyclines,NNS,G
-lrb-,-LRB-,O
72,CD,O
.,.,.
,,
no,DT,O
specific,JJ,O
information,NN,O
available,JJ,O
.,.,.
,,
aminoglutethimide,NNP,D
:,:,O
aminoglutethimide,NNP,D
may,MD,O
diminish,VB,O
adrenal,JJ,O
suppression,NN,O
by,IN,O
corticosteroids,NNS,G
.,.,.
,,
amphotericin,NN,D
b,NN,O
injection,NN,O
and,CC,O
potassium-depleting,JJ,O
agents,NNS,O
:,:,O
when,WRB,O
corticosteroids,NNS,G
are,VBP,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
potassium-depleting,JJ,O
agents,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
amphotericin,NN,D
b,NN,O
",",",",O
diuretics,NNS,G
-rrb-,-RRB-,O
",",",",O
patients,NNS,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
development,NN,O
of,IN,O
hypokalemia,NN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
there,EX,O
have,VBP,O
been,VBN,O
cases,NNS,O
reported,VBD,O
in,IN,O
which,WDT,O
concomitant,JJ,O
use,NN,O
of,IN,O
amphotericin,NN,D
b,NN,O
and,CC,O
hydrocortisone,NN,D
was,VBD,O
followed,VBN,O
by,IN,O
cardiac,JJ,O
enlargement,NN,O
and,CC,O
congestive,JJ,O
heart,NN,O
failure,NN,O
.,.,.
,,
antibiotics,NNS,G
:,:,O
macrolide,NNP,O
antibiotics,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
cause,VB,O
a,DT,O
significant,JJ,O
decrease,NN,O
in,IN,O
corticosteroid,NN,G
clearance,NN,O
.,.,.
,,
anticholinesterases,NNP,G
:,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
anticholinesterase,JJ,G
agents,NNS,O
and,CC,O
corticosteroids,NNS,G
may,MD,O
produce,VB,O
severe,JJ,O
weakness,NN,O
in,IN,O
patients,NNS,O
with,IN,O
myasthenia,NN,O
gravis,NN,O
.,.,.
,,
if,IN,O
possible,JJ,O
",",",",O
anticholinesterase,JJ,G
agents,NNS,O
should,MD,O
be,VB,O
withdrawn,VBN,O
at,IN,O
least,JJS,O
24,CD,O
hours,NNS,O
before,IN,O
initiating,VBG,O
corticosteroid,NN,G
therapy,NN,O
.,.,.
,,
anticoagulants,NNPS,G
",",",",O
oral,JJ,O
:,:,O
co-administration,NN,O
of,IN,O
corticosteroids,NNS,G
and,CC,O
warfarin,NN,D
usually,RB,O
results,VBZ,O
in,IN,O
inhibition,NN,O
of,IN,O
response,NN,O
to,TO,O
warfarin,NN,D
",",",",O
although,IN,O
there,EX,O
have,VBP,O
been,VBN,O
some,DT,O
conflicting,VBG,O
reports,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
coagulation,NN,O
indices,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
frequently,RB,O
to,TO,O
maintain,VB,O
the,DT,O
desired,VBN,O
anticoagulant,JJ,G
effect,NN,O
.,.,.
,,
antidiabetics,NNS,G
:,:,O
because,IN,O
corticosteroids,NNS,G
may,MD,O
increase,VB,O
blood,NN,O
glucose,NN,O
concentrations,NNS,O
",",",",O
dosage,NN,O
adjustments,NNS,O
of,IN,O
antidiabetic,JJ,D
agents,NNS,O
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
antitubercular,JJ,O
drugs,NNS,D
:,:,O
serum,NN,O
concentrations,NNS,O
of,IN,O
isoniazid,NN,D
may,MD,O
be,VB,O
decreased,VBN,O
.,.,.
,,
cholestyramine,NNP,D
:,:,O
cholestyramine,NNP,D
may,MD,O
increase,VB,O
the,DT,O
clearance,NN,O
of,IN,O
corticosteroids,NNS,G
.,.,.
,,
cyclosporine,NN,D
:,:,O
increased,VBN,O
activity,NN,O
of,IN,O
both,DT,O
cyclosporine,NN,D
and,CC,O
corticosteroids,NNS,G
may,MD,O
occur,VB,O
when,WRB,O
the,DT,O
two,CD,O
are,VBP,O
used,VBN,O
concurrently,RB,O
.,.,.
,,
convulsions,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
this,DT,O
concurrent,JJ,O
use,NN,O
.,.,.
,,
dexamethasone,NN,D
suppression,NN,O
test,NN,O
-lrb-,-LRB-,O
dst,NN,O
-rrb-,-RRB-,O
:,:,O
false-negative,JJ,O
results,NNS,O
in,IN,O
the,DT,O
dexamethasone,NN,D
suppression,NN,O
test,NN,O
-lrb-,-LRB-,O
dst,NN,O
-rrb-,-RRB-,O
in,IN,O
patients,NNS,O
being,VBG,O
treated,VBN,O
with,IN,O
indomethacin,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
.,.,.
,,
thus,RB,O
",",",",O
results,NNS,O
of,IN,O
the,DT,O
dst,NNP,O
should,MD,O
be,VB,O
interpreted,VBN,O
with,IN,O
caution,NN,O
in,IN,O
these,DT,O
patients,NNS,O
.,.,.
,,
digitalis,NN,G
glycosides,NNS,G
:,:,O
patients,NNS,O
on,IN,O
digitalis,NN,G
glycosides,NNS,G
may,MD,O
be,VB,O
at,IN,O
increased,VBN,O
risk,NN,O
of,IN,O
arrhythmias,NNS,O
due,JJ,O
to,TO,O
hypokalemia,NN,O
.,.,.
,,
ephedrine,NN,D
:,:,O
ephedrine,NN,D
may,MD,O
enhance,VB,O
the,DT,O
metabolic,JJ,O
clearance,NN,O
of,IN,O
corticosteroids,NNS,G
",",",",O
resulting,VBG,O
in,IN,O
decreased,VBN,O
blood,NN,O
levels,NNS,O
and,CC,O
lessened,VBD,O
physiologic,JJ,O
activity,NN,O
",",",",O
thus,RB,O
requiring,VBG,O
an,DT,O
increase,NN,O
in,IN,O
corticosteroid,NN,G
dosage,NN,O
.,.,.
,,
estrogens,NNS,G
",",",",O
including,VBG,O
oral,JJ,O
contraceptives,NNS,G
:,:,O
estrogens,NNS,G
may,MD,O
decrease,VB,O
the,DT,O
hepatic,JJ,O
metabolism,NN,O
of,IN,O
certain,JJ,O
corticosteroids,NNS,G
",",",",O
thereby,RB,O
increasing,VBG,O
their,PRP$,O
effect,NN,O
.,.,.
,,
hepatic,JJ,O
enzyme,NN,O
inducers,NNS,O
",",",",O
inhibitors,NNS,O
and,CC,O
substrates,NNS,O
:,:,O
drugs,NNS,O
which,WDT,O
induce,VBP,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
-lrb-,-LRB-,O
cyp,NN,O
3a4,NN,O
-rrb-,-RRB-,O
enzyme,NN,O
activity,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
barbiturates,NNS,G
",",",",O
phenytoin,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
rifampin,NN,D
-rrb-,-RRB-,O
may,MD,O
enhance,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
corticosteroids,NNS,G
and,CC,O
require,VBP,O
that,IN,O
the,DT,O
dosage,NN,O
of,IN,O
the,DT,O
corticosteroid,NN,G
be,VB,O
increased,VBN,O
.,.,.
,,
drugs,NNS,O
which,WDT,O
inhibit,VBP,O
cyp,NN,O
3a4,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
ketoconazole,NN,D
",",",",O
macrolide,NN,O
antibiotics,NNS,G
such,JJ,O
as,IN,O
erythromycin,NN,D
-rrb-,-RRB-,O
have,VBP,O
the,DT,O
potential,JJ,O
to,TO,O
result,VB,O
in,IN,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
corticosteroids,NNS,G
.,.,.
,,
dexamethasone,NN,D
is,VBZ,O
a,DT,O
moderate,JJ,O
inducer,NN,O
of,IN,O
cyp,NN,O
3a4,NN,O
.,.,.
,,
co-administration,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
cyp,NN,O
3a4,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
indinavir,NN,D
",",",",O
erythromycin,NN,D
-rrb-,-RRB-,O
may,MD,O
increase,VB,O
their,PRP$,O
clearance,NN,O
",",",",O
resulting,VBG,O
in,IN,O
decreased,VBN,O
plasma,NN,O
concentration,NN,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
ketoconazole,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
decrease,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
certain,JJ,O
corticosteroids,NNS,G
by,IN,O
up,RB,O
to,TO,O
60,CD,O
%,NN,O
",",",",O
leading,VBG,O
to,TO,O
increased,VBN,O
risk,NN,O
of,IN,O
corticosteroid,NN,G
side,NN,O
effects,NNS,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
ketoconazole,NN,D
alone,RB,O
can,MD,O
inhibit,VB,O
adrenal,JJ,O
corticosteroid,NN,G
synthesis,NN,O
and,CC,O
may,MD,O
cause,VB,O
adrenal,JJ,O
insufficiency,NN,O
during,IN,O
corticosteroid,NN,G
withdrawal,NN,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
-lrb-,-LRB-,O
nsaids,NNS,G
-rrb-,-RRB-,O
:,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
aspirin,NN,B
-lrb-,-LRB-,O
or,CC,O
other,JJ,O
nonsteroidal,JJ,O
antiinflammatory,JJ,O
agents,NNS,O
-rrb-,-RRB-,O
and,CC,O
corticosteroids,NNS,G
increases,VBZ,O
the,DT,O
risk,NN,O
of,IN,O
gastrointestinal,JJ,O
side,JJ,O
effects,NNS,O
.,.,.
,,
aspirin,NN,B
should,MD,O
be,VB,O
used,VBN,O
cautiously,RB,O
in,IN,O
conjunction,NN,O
with,IN,O
corticosteroids,NNS,G
in,IN,O
hypoprothrombinemia,NN,O
.,.,.
,,
the,DT,O
clearance,NN,O
of,IN,O
salicylates,NNS,G
may,MD,O
be,VB,O
increased,VBN,O
with,IN,O
concurrent,JJ,O
use,NN,O
of,IN,O
corticosteroids,NNS,G
.,.,.
,,
phenytoin,NNP,D
:,:,O
in,IN,O
post-marketing,JJ,O
experience,NN,O
",",",",O
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
both,DT,O
increases,NNS,O
and,CC,O
decreases,VBZ,O
in,IN,O
phenytoin,NN,D
levels,NNS,O
with,IN,O
dexamethasone,NN,D
co-administration,NN,O
",",",",O
leading,VBG,O
to,TO,O
alterations,NNS,O
in,IN,O
seizure,NN,O
control,NN,O
.,.,.
,,
skin,NN,O
tests,NNS,O
:,:,O
corticosteroids,NNS,G
may,MD,O
suppress,VB,O
reactions,NNS,O
to,TO,O
skin,NN,O
tests,NNS,O
.,.,.
,,
thalidomide,NNP,D
:,:,O
co-administration,NN,O
with,IN,O
thalidomide,NN,D
should,MD,O
be,VB,O
employed,VBN,O
cautiously,RB,O
",",",",O
as,IN,O
toxic,JJ,O
epidermal,JJ,O
necrolysis,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
with,IN,O
concomitant,JJ,O
use,NN,O
.,.,.
,,
vaccines,NNS,G
:,:,O
patients,NNS,O
on,IN,O
corticosteroid,NN,G
therapy,NN,O
may,MD,O
exhibit,VB,O
a,DT,O
diminished,JJ,O
response,NN,O
to,TO,O
toxoids,NNS,O
and,CC,O
live,VB,O
or,CC,O
inactivated,VBN,O
vaccines,NNS,G
due,JJ,O
to,TO,O
inhibition,NN,O
of,IN,O
antibody,NN,O
response,NN,O
.,.,.
,,
corticosteroids,NNS,G
may,MD,O
also,RB,O
potentiate,VB,O
the,DT,O
replication,NN,O
of,IN,O
some,DT,O
organisms,NNS,O
contained,VBD,O
in,IN,O
live,JJ,O
attenuated,VBN,O
vaccines,NNS,G
.,.,.
,,
routine,JJ,O
administration,NN,O
of,IN,O
vaccines,NNS,G
or,CC,O
toxoids,NNS,O
should,MD,O
be,VB,O
deferred,VBN,O
until,IN,O
corticosteroid,NN,G
therapy,NN,O
is,VBZ,O
discontinued,VBN,O
if,IN,O
possible,JJ,O
.,.,.
,,
dexbrompheniramine,NN,D
can,MD,O
interact,VB,O
with,IN,O
alcohol,NN,D
or,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
-lrb-,-LRB-,O
may,MD,O
potentiate,VB,O
the,DT,O
cns,NN,O
depressant,NN,O
effects,NNS,O
of,IN,O
either,CC,O
these,DT,O
medications,NNS,O
or,CC,O
antihistamines,NNS,G
-rrb-,-RRB-,O
",",",",O
anticholinergics,NNS,G
or,CC,O
other,JJ,O
medications,NNS,O
with,IN,O
anticholinergic,JJ,G
activity,NN,O
-lrb-,-LRB-,O
anticholinergic,JJ,G
effects,NNS,O
may,MD,O
be,VB,O
potentiated,VBN,O
when,WRB,O
these,DT,O
medications,NNS,O
are,VBP,O
used,VBN,O
concurrently,RB,O
with,IN,O
antihistamines,NNS,G
-rrb-,-RRB-,O
",",",",O
and,CC,O
monoamine,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
mao,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
-lrb-,-LRB-,O
concurrent,JJ,O
use,NN,O
with,IN,O
antihistamines,NNS,G
may,MD,O
prolong,VB,O
and,CC,O
intensify,VB,O
the,DT,O
anticholinergic,JJ,G
and,CC,O
cns,NN,O
depressant,NN,O
effects,NNS,O
of,IN,O
antihistamines,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
patients,NNS,O
receiving,VBG,O
nonselective,JJ,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
maois,NNS,G
-rrb-,-RRB-,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
selegiline,NN,D
hydrochloride,NN,O
-rrb-,-RRB-,O
in,IN,O
combination,NN,O
with,IN,O
serotoninergic,JJ,O
agents,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
fluoxetine,NN,D
",",",",O
fluvoxamine,NN,D
",",",",O
paroxetine,NN,D
",",",",O
sertraline,NN,D
",",",",O
venlafaxine,NN,D
-rrb-,-RRB-,O
",",",",O
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
serious,JJ,O
",",",",O
sometimes,RB,O
fatal,JJ,O
",",",",O
reactions,NNS,O
.,.,.
,,
because,IN,O
dexfenfluramine,NN,D
is,VBZ,O
a,DT,O
serotonin,NN,O
releaser,NN,O
and,CC,O
reuptake,NN,O
inhibitor,NN,O
",",",",O
dexfenfluramine,NN,D
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
concomitantly,RB,O
with,IN,O
a,DT,O
mao,NNP,O
inhibitor,NN,O
.,.,.
,,
at,IN,O
least,JJS,O
14,CD,O
days,NNS,O
should,MD,O
elapse,VB,O
between,IN,O
discontinuation,NN,O
of,IN,O
a,DT,O
mao,NNP,O
inhibitor,NN,O
and,CC,O
initiation,NN,O
of,IN,O
treatment,NN,O
with,IN,O
dexfenfluramine,NN,D
.,.,.
,,
at,IN,O
least,JJS,O
3,CD,O
weeks,NNS,O
should,MD,O
elapse,VB,O
between,IN,O
discontinuation,NN,O
of,IN,O
dexfenfluramine,NN,D
and,CC,O
initiation,NN,O
of,IN,O
treatment,NN,O
with,IN,O
a,DT,O
mao,NNP,O
inhibitor,NN,O
.,.,.
,,
a,DT,O
rare,JJ,O
",",",",O
but,CC,O
serious,JJ,O
",",",",O
constellation,NN,O
of,IN,O
symptoms,NNS,O
",",",",O
termed,VBN,O
serotonin,NN,O
syndrome,NN,O
",",",",O
has,VBZ,O
been,VBN,O
reported,VBN,O
with,IN,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
ssris,NNS,G
-rrb-,-RRB-,O
and,CC,O
agents,NNS,O
for,IN,O
migraine,NN,O
therapy,NN,O
",",",",O
such,JJ,O
as,IN,O
imitrex,NN,B
-lrb-,-LRB-,O
sumatriptan,NN,D
succinate,NN,O
-rrb-,-RRB-,O
and,CC,O
dihydroergotamine,NN,D
.,.,.
,,
the,DT,O
syndrome,NN,O
requires,VBZ,O
immediate,JJ,O
medical,JJ,O
attention,NN,O
and,CC,O
may,MD,O
include,VB,O
one,CD,O
or,CC,O
more,JJR,O
of,IN,O
the,DT,O
following,VBG,O
symptoms,NNS,O
:,:,O
excitement,NN,O
",",",",O
hypomania,NN,O
",",",",O
restlessness,NN,O
",",",",O
loss,NN,O
of,IN,O
consciousness,NN,O
",",",",O
confusion,NN,O
",",",",O
disorientation,NN,O
",",",",O
anxiety,NN,O
",",",",O
agitation,NN,O
",",",",O
motor,NN,O
weakness,NN,O
",",",",O
myoclonus,NN,O
",",",",O
tremor,NN,O
",",",",O
hemiballismus,NN,O
",",",",O
hyperreflexia,NN,O
",",",",O
ataxia,NN,O
",",",",O
dysarthria,NN,O
",",",",O
incoordination,NN,O
",",",",O
hyperthermia,NN,O
",",",",O
shivering,VBG,O
",",",",O
pupillary,JJ,O
dilation,NN,O
",",",",O
diaphoresis,NN,O
",",",",O
emesis,NN,O
",",",",O
and,CC,O
tachycardia,NN,O
.,.,.
,,
dexfenfluramine,NN,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
with,IN,O
other,JJ,O
serotoninergic,JJ,O
agents,NNS,O
.,.,.
,,
the,DT,O
appropriate,JJ,O
interval,NN,O
between,IN,O
administration,NN,O
of,IN,O
these,DT,O
agents,NNS,O
and,CC,O
dexfenfluramine,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
dexfenfluramine,NN,D
with,IN,O
other,JJ,O
cns-active,JJ,O
drugs,NNS,D
has,VBZ,O
not,RB,O
been,VBN,O
systematically,RB,O
evaluated,VBN,O
.,.,.
,,
consequently,RB,O
",",",",O
caution,NN,O
is,VBZ,O
advised,VBN,O
if,IN,O
dexfenfluramine,NN,D
and,CC,O
such,JJ,O
drugs,NNS,D
are,VBP,O
prescribed,VBN,O
concurrently,RB,O
.,.,.
,,
general,NNP,O
in,FW,O
vitro,FW,O
studies,NNS,O
in,IN,O
human,JJ,O
liver,NN,O
microsomes,NNS,O
demonstrated,VBD,O
no,DT,O
evidence,NN,O
of,IN,O
cytochrome,NN,O
p450-mediated,JJ,O
drug,NN,D
interactions,NNS,O
that,WDT,O
are,VBP,O
likely,JJ,O
to,TO,O
be,VB,O
of,IN,O
clinical,JJ,O
relevance,NN,O
.,.,.
,,
anesthetics/sedatives/hypnotics,NNS,O
/,:,O
opioids,NNS,G
:,:,O
co-administration,NN,O
of,IN,O
precedex,NN,B
with,IN,O
anesthetics,NNS,G
",",",",O
sedatives,NNS,G
",",",",O
hypnotics,NNS,G
",",",",O
and,CC,O
opioids,NNS,G
is,VBZ,O
likely,JJ,O
to,TO,O
lead,VB,O
to,TO,O
an,DT,O
enhancement,NN,O
of,IN,O
effects,NNS,O
.,.,.
,,
specific,JJ,O
studies,NNS,O
have,VBP,O
confirmed,VBN,O
these,DT,O
effects,NNS,O
with,IN,O
sevoflurane,NN,D
",",",",O
isoflurane,NN,D
",",",",O
propofol,NN,D
",",",",O
alfentanil,NN,D
",",",",O
and,CC,O
midazolam,NN,D
.,.,.
,,
no,DT,O
pharmacokinetic,JJ,O
interactions,NNS,O
between,IN,O
dexmedetomidine,NN,D
and,CC,O
isoflurane,NN,D
",",",",O
propofol,NN,D
",",",",O
alfentanil,NN,D
",",",",O
and,CC,O
midazolam,NN,D
have,VBP,O
been,VBN,O
demonstrated,VBN,O
.,.,.
,,
however,RB,O
",",",",O
due,JJ,O
to,TO,O
possible,JJ,O
pharmacodynamic,JJ,O
interactions,NNS,O
",",",",O
when,WRB,O
co-administered,VBN,O
with,IN,O
precedex,NN,B
",",",",O
a,DT,O
reduction,NN,O
in,IN,O
dosage,NN,O
of,IN,O
precedex,NNP,B
on,IN,O
the,DT,O
concomitant,JJ,O
anesthetic,NN,G
",",",",O
sedative,NN,G
",",",",O
hypnotic,JJ,G
or,CC,O
opioid,NN,G
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
neuromuscular,JJ,O
blockers,NNS,O
:,:,O
in,IN,O
one,CD,O
study,NN,O
of,IN,O
10,CD,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
administration,NN,O
of,IN,O
precedex,NNP,B
for,IN,O
45,CD,O
minutes,NNS,O
at,IN,O
a,DT,O
plasma,NN,O
concentration,NN,O
of,IN,O
1,CD,O
-lrb-,-LRB-,O
one,CD,O
-rrb-,-RRB-,O
ng/ml,NN,O
resulted,VBD,O
in,IN,O
no,DT,O
clinically,RB,O
meaningful,JJ,O
increases,NNS,O
in,IN,O
the,DT,O
magnitude,NN,O
or,CC,O
neuromuscular,JJ,O
blockade,NN,O
associated,VBN,O
with,IN,O
rocuronium,NN,D
administration,NN,O
.,.,.
,,
zinecard,NN,B
does,VBZ,O
not,RB,O
influence,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
doxorubicin,NN,D
.,.,.
,,
carcinogenesis,NN,O
",",",",O
mutagenesis,NN,O
",",",",O
impairment,NN,O
of,IN,O
fertility,NNP,O
no,NNP,O
long-term,JJ,O
carcinogenicity,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
carried,VBN,O
out,RP,O
with,IN,O
dexrazoxane,NN,D
in,IN,O
animals,NNS,O
.,.,.
,,
dexrazoxane,NN,D
was,VBD,O
not,RB,O
mutagenic,JJ,O
in,IN,O
the,DT,O
ames,NNP,O
test,NN,O
but,CC,O
was,VBD,O
found,VBN,O
to,TO,O
be,VB,O
clastogenic,JJ,O
to,TO,O
human,JJ,O
lymphocytes,NNS,O
in,FW,O
vitro,FW,O
and,CC,O
to,TO,O
mouse,NN,O
bone,NN,O
marrow,NN,O
erythrocytes,NNS,O
in,FW,O
vivo,FW,O
-lrb-,-LRB-,O
micronucleus,NN,O
test,NN,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
possible,JJ,O
adverse,JJ,O
effects,NNS,O
of,IN,O
zinecard,NN,B
on,IN,O
the,DT,O
fertility,NN,O
of,IN,O
humans,NNS,O
and,CC,O
experimental,JJ,O
animals,NNS,O
",",",",O
male,JJ,O
or,CC,O
female,JJ,O
",",",",O
have,VBP,O
not,RB,O
been,VBN,O
adequately,RB,O
studied,VBN,O
.,.,.
,,
testicular,JJ,O
atrophy,NN,O
was,VBD,O
seen,VBN,O
with,IN,O
dexrazoxane,NN,D
administration,NN,O
at,IN,O
doses,NNS,O
as,RB,O
low,JJ,O
as,IN,O
30,CD,O
mg/kg,NN,O
weekly,JJ,O
for,IN,O
6,CD,O
weeks,NNS,O
in,IN,O
rats,NNS,O
-lrb-,-LRB-,O
3-Jan,CD,O
the,DT,O
human,JJ,O
dose,NN,O
on,IN,O
a,DT,O
mg/m,NN,O
2,CD,O
basis,NN,O
-rrb-,-RRB-,O
and,CC,O
as,RB,O
low,JJ,O
as,IN,O
20,CD,O
mg/kg,NN,O
weekly,JJ,O
for,IN,O
13,CD,O
weeks,NNS,O
in,IN,O
dogs,NNS,O
-lrb-,-LRB-,O
approximately,RB,O
equal,JJ,O
to,TO,O
the,DT,O
human,JJ,O
dose,NN,O
on,IN,O
a,DT,O
mg/m,NN,O
2,CD,O
basis,NN,O
-rrb-,-RRB-,O
.,.,.
,,
acidifying,VBG,O
agents,NNS,O
:,:,O
gastrointestinal,JJ,O
acidifying,VBG,O
agents,NNS,O
-lrb-,-LRB-,O
guanethidine,NN,D
",",",",O
reserpine,NN,D
",",",",O
glutamic,JJ,O
acid,NN,O
hcl,NN,O
",",",",O
ascorbic,JJ,O
acid,NN,O
",",",",O
fruit,NN,O
juices,NNS,O
",",",",O
etc.,FW,O
-rrb-,-RRB-,O
lower,JJR,O
absorption,NN,O
of,IN,O
amphetamines,NNS,G
.,.,.
,,
urinary,JJ,O
acidifying,VBG,O
agents,NNS,O
-lrb-,-LRB-,O
ammonium,NN,O
chloride,NN,O
",",",",O
sodium,NN,O
acid,NN,O
phosphate,NN,D
",",",",O
etc.,FW,O
-rrb-,-RRB-,O
increase,VBP,O
the,DT,O
concentration,NN,O
of,IN,O
the,DT,O
ionized,VBN,O
species,NNS,O
of,IN,O
the,DT,O
amphetamine,NN,D
molecule,NN,O
",",",",O
thereby,RB,O
increasing,VBG,O
urinary,JJ,O
excretion,NN,O
.,.,.
,,
both,DT,O
groups,NNS,O
of,IN,O
agents,NNS,O
lower,JJR,O
blood,NN,O
levels,NNS,O
and,CC,O
efficacy,NN,O
of,IN,O
amphetamines,NNS,G
.,.,.
,,
adrenergic,JJ,O
blockers,NNS,O
:,:,O
adrenergic,JJ,O
blockers,NNS,O
are,VBP,O
inhibited,VBN,O
by,IN,O
amphetamines,NNS,G
.,.,.
,,
alkalinizing,JJ,O
agents,NNS,O
:,:,O
gastrointestinal,JJ,O
alkalinizing,JJ,O
agents,NNS,O
-lrb-,-LRB-,O
sodium,NN,O
bicarbonate,NN,O
",",",",O
etc.,FW,O
-rrb-,-RRB-,O
increase,NN,O
absorption,NN,O
of,IN,O
amphetamines,NNS,G
.,.,.
,,
urinary,JJ,O
alkalinizing,JJ,O
agents,NNS,O
-lrb-,-LRB-,O
acetazolamide,NN,D
",",",",O
some,DT,O
thiazides,NNS,G
-rrb-,-RRB-,O
increase,VBP,O
the,DT,O
concentration,NN,O
of,IN,O
the,DT,O
non-ionized,JJ,O
species,NNS,O
of,IN,O
the,DT,O
amphetamine,NN,D
molecule,NN,O
",",",",O
thereby,RB,O
decreasing,VBG,O
urinary,JJ,O
excretion,NN,O
.,.,.
,,
both,DT,O
groups,NNS,O
of,IN,O
agents,NNS,O
increase,VBP,O
blood,NN,O
levels,NNS,O
and,CC,O
therefore,RB,O
potentiate,VB,O
the,DT,O
actions,NNS,O
of,IN,O
amphetamines,NNS,G
.,.,.
,,
antidepressants,NNS,G
",",",",O
tricyclic,JJ,G
:,:,O
amphetamines,NNS,G
may,MD,O
enhance,VB,O
the,DT,O
activity,NN,O
of,IN,O
tricyclic,JJ,G
or,CC,O
sympathomimetic,JJ,G
agents,NNS,O
.,.,.
,,
d-amphetamine,NN,D
with,IN,O
desipramine,NN,D
or,CC,O
protriptyline,NN,D
and,CC,O
possibly,RB,O
other,JJ,O
tricyclics,NNS,G
cause,VBP,O
striking,JJ,O
and,CC,O
sustained,JJ,O
increases,NNS,O
in,IN,O
the,DT,O
concentration,NN,O
of,IN,O
d-amphetamine,NN,D
in,IN,O
the,DT,O
brain,NN,O
.,.,.
,,
cardiovascular,JJ,O
effects,NNS,O
can,MD,O
be,VB,O
potentiated,VBN,O
.,.,.
,,
mao,NN,O
inhibitors,NNS,O
:,:,O
maoi,NNP,G
antidepressants,NNS,G
",",",",O
as,RB,O
well,RB,O
as,IN,O
a,DT,O
metabolite,NN,O
of,IN,O
furazolidone,NN,D
",",",",O
slow,JJ,O
amphetamine,NN,D
metabolism,NN,O
.,.,.
,,
this,DT,O
slowing,VBG,O
potentiates,VBZ,O
amphetamines,NNS,G
",",",",O
increasing,VBG,O
their,PRP$,O
effect,NN,O
on,IN,O
the,DT,O
release,NN,O
of,IN,O
norepinephrine,NN,D
and,CC,O
other,JJ,O
monoamines,NNS,O
from,IN,O
adrenergic,JJ,G
nerve,NN,O
endings,NNS,O
.,.,.
,,
this,DT,O
can,MD,O
cause,VB,O
headaches,NNS,O
and,CC,O
other,JJ,O
signs,NNS,O
of,IN,O
hypertensive,JJ,O
crisis,NN,O
.,.,.
,,
a,DT,O
variety,NN,O
of,IN,O
neurological,JJ,O
toxic,JJ,O
effects,NNS,O
and,CC,O
malignant,JJ,O
hyperpyrexia,NN,O
can,MD,O
occur,VB,O
",",",",O
sometimes,RB,O
with,IN,O
fatal,JJ,O
results,NNS,O
.,.,.
,,
antihistamines,NNS,D
:,:,O
amphetamines,NNS,G
may,MD,O
counteract,VB,O
the,DT,O
sedative,JJ,G
effect,NN,O
of,IN,O
antihistamines,NNS,G
.,.,.
,,
antihypertensives,NNS,G
:,:,O
amphetamines,NNS,G
may,MD,O
antagonize,VB,O
the,DT,O
hypotensive,JJ,O
effects,NNS,O
of,IN,O
antihypertensives,NNS,D
.,.,.
,,
chlorpromazine,NNP,D
:,:,O
chlorpromazine,NNP,D
blocks,VBZ,O
dopamine,NN,D
and,CC,O
norepinephrine,NN,D
reuptake,NN,O
",",",",O
thus,RB,O
inhibiting,VBG,O
the,DT,O
central,JJ,O
stimulant,NN,O
effects,NNS,O
of,IN,O
amphetamines,NNS,G
",",",",O
and,CC,O
can,MD,O
be,VB,O
used,VBN,O
to,TO,O
treat,VB,O
amphetamine,NN,D
poisoning,NN,O
.,.,.
,,
ethosuximide,NNP,D
:,:,O
amphetamines,NNS,G
may,MD,O
delay,VB,O
intestinal,JJ,O
absorption,NN,O
of,IN,O
ethosuximide,NN,D
.,.,.
,,
haloperidol,NNP,D
:,:,O
haloperidol,NNP,D
blocks,VBZ,O
dopamine,NN,D
and,CC,O
norepinephrine,NN,D
reuptake,NN,O
",",",",O
thus,RB,O
inhibiting,VBG,O
the,DT,O
central,JJ,O
stimulant,NN,O
effects,NNS,O
of,IN,O
amphetamines,NNS,G
.,.,.
,,
lithium,NN,D
carbonate,NN,O
:,:,O
the,DT,O
stimulatory,JJ,O
effects,NNS,O
of,IN,O
amphetamines,NNS,G
may,MD,O
be,VB,O
inhibited,VBN,O
by,IN,O
lithium,NN,D
carbonate,NN,O
.,.,.
,,
meperidine,NNP,D
:,:,O
amphetamines,NNS,G
potentiate,VBP,O
the,DT,O
analgesic,JJ,O
effect,NN,O
of,IN,O
meperidine,NN,D
.,.,.
,,
methenamine,NN,D
therapy,NN,O
:,:,O
urinary,JJ,O
excretion,NN,O
of,IN,O
amphetamines,NNS,G
is,VBZ,O
increased,VBN,O
",",",",O
and,CC,O
efficacy,NN,O
is,VBZ,O
reduced,VBN,O
",",",",O
by,IN,O
acidifying,VBG,O
agents,NNS,O
used,VBN,O
in,IN,O
methenamine,NN,D
therapy,NN,O
.,.,.
,,
norepinephrine,NN,D
:,:,O
amphetamines,NNS,G
enhance,VBP,O
the,DT,O
adrenergic,JJ,G
effect,NN,O
of,IN,O
norepinephrine,NN,D
.,.,.
,,
phenobarbital,NNP,D
:,:,O
amphetamines,NNS,G
may,MD,O
delay,VB,O
intestinal,JJ,O
absorption,NN,O
of,IN,O
phenobarbital,NN,D
.,.,.
,,
co-administration,NN,O
of,IN,O
phenobarbital,NN,D
may,MD,O
produce,VB,O
a,DT,O
synergistic,JJ,O
anticonvulsant,JJ,G
action,NN,O
.,.,.
,,
phenytoin,NNP,D
:,:,O
amphetamines,NNS,G
may,MD,O
delay,VB,O
intestinal,JJ,O
absorption,NN,O
of,IN,O
phenytoin,NN,D
.,.,.
,,
co-administration,NN,O
of,IN,O
phenytoin,NN,D
may,MD,O
produce,VB,O
a,DT,O
synergistic,JJ,O
anticonvulsant,JJ,G
action,NN,O
.,.,.
,,
propoxyphene,NNP,D
:,:,O
in,IN,O
cases,NNS,O
of,IN,O
propoxyphene,NN,D
overdosage,NN,O
",",",",O
amphetamine,NN,D
cns,NN,O
stimulation,NN,O
is,VBZ,O
potentiated,JJ,O
and,CC,O
fatal,JJ,O
convulsions,NNS,O
can,MD,O
occur,VB,O
.,.,.
,,
veratrum,NNP,O
alkaloids,NNS,O
:,:,O
amphetamines,NNS,G
inhibit,VBP,O
the,DT,O
hypotensive,JJ,O
effect,NN,O
of,IN,O
veratrum,NN,O
alkaloids,NNS,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
:,:,O
amphetamines,NNS,G
can,MD,O
cause,VB,O
a,DT,O
significant,JJ,O
elevation,NN,O
in,IN,O
plasma,NN,O
corticosteroid,NN,G
levels,NNS,O
.,.,.
,,
this,DT,O
increase,NN,O
is,VBZ,O
greatest,JJS,O
in,IN,O
the,DT,O
evening,NN,O
.,.,.
,,
amphetamines,NNS,G
may,MD,O
interfere,VB,O
with,IN,O
urinary,JJ,O
steroid,NN,G
determinations,NNS,O
.,.,.
,,
additive,JJ,O
depressant,NN,O
effect,NN,O
when,WRB,O
used,VBN,O
with,IN,O
general,JJ,O
anesthetics,NNS,G
",",",",O
sedatives,NNS,G
",",",",O
antianxiety,JJ,O
drugs,NNS,D
",",",",O
hypnotics,NNS,G
",",",",O
alcohol,NN,D
",",",",O
and,CC,O
other,JJ,O
opiate,JJ,G
analgesics,NNS,G
.,.,.
,,
may,NNP,O
interact,VBP,O
with,IN,O
thyroid,NN,G
medication,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
levothyroxine,NN,D
-rrb-,-RRB-,O
",",",",O
iodine-containing,JJ,O
products,NNS,O
",",",",O
antacids,NNS,G
",",",",O
h2-antagonists,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
famotidine,NN,D
",",",",O
ranitidine,NN,D
-rrb-,-RRB-,O
",",",",O
and,CC,O
proton,NN,O
pump,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
lansoprazole,NN,D
",",",",O
omeprazole,NN,D
-rrb-,-RRB-,O
.,.,.
,,
this,DT,O
product,NN,O
can,MD,O
affect,VB,O
the,DT,O
results,NNS,O
of,IN,O
certain,JJ,O
lab,NN,O
tests,NNS,O
.,.,.
,,
caution,NN,O
is,VBZ,O
advised,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
high-dose,JJ,O
aspirin,NN,B
and,CC,O
carbonic,JJ,O
anhydrase,NN,O
inhibitors,NNS,O
",",",",O
as,IN,O
anorexia,NN,O
",",",",O
tachypnea,NN,O
",",",",O
lethargy,NN,O
and,CC,O
coma,NN,O
have,VBP,O
been,VBN,O
rarely,RB,O
reported,VBN,O
due,JJ,O
to,TO,O
a,DT,O
possible,JJ,O
drug,NN,D
interaction,NN,O
.,.,.
,,
aspirin,NN,B
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
diclofenac,NN,D
and,CC,O
aspirin,NN,B
is,VBZ,O
not,RB,O
recommended,VBN,O
because,IN,O
diclofenac,NN,D
is,VBZ,O
displaced,VBN,O
from,IN,O
its,PRP$,O
binding,NN,O
sites,NNS,O
during,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
aspirin,NN,B
",",",",O
resulting,VBG,O
in,IN,O
lower,JJR,O
plasma,NN,O
concentrations,NNS,O
",",",",O
peak,JJ,O
plasma,NN,O
levels,NNS,O
",",",",O
and,CC,O
auc,NN,O
values,NNS,O
.,.,.
,,
anticoagulants,NNPS,G
:,:,O
while,IN,O
studies,NNS,O
have,VBP,O
not,RB,O
shown,VBN,O
diclofenac,NN,D
to,TO,O
interact,VB,O
with,IN,O
anticoagulants,NNS,G
of,IN,O
the,DT,O
warfarin,NN,D
type,NN,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
",",",",O
nonetheless,RB,O
",",",",O
since,IN,O
interactions,NNS,O
have,VBP,O
been,VBN,O
seen,VBN,O
with,IN,O
other,JJ,O
nsaids,NNS,G
.,.,.
,,
because,IN,O
prostaglandins,NNS,O
play,VBP,O
an,DT,O
important,JJ,O
role,NN,O
in,IN,O
hemostasis,NN,O
",",",",O
and,CC,O
nsaids,NNS,G
affect,VBP,O
platelet,NN,O
function,NN,O
as,RB,O
well,RB,O
",",",",O
concurrent,JJ,O
therapy,NN,O
with,IN,O
all,DT,O
nsaids,NNS,G
",",",",O
including,VBG,O
diclofenac,NN,D
",",",",O
and,CC,O
warfarin,NN,D
requires,VBZ,O
close,JJ,O
monitoring,NN,O
of,IN,O
patients,NNS,O
to,TO,O
be,VB,O
certain,JJ,O
that,IN,O
no,DT,O
change,NN,O
in,IN,O
their,PRP$,O
anticoagulant,JJ,G
dosage,NN,O
is,VBZ,O
required,VBN,O
.,.,.
,,
digoxin,NNP,D
",",",",O
methotrexate,NNP,D
",",",",O
cyclosporine,NNP,D
:,:,O
diclofenac,NNP,D
",",",",O
like,IN,O
other,JJ,O
nsaids,NNS,G
",",",",O
may,MD,O
affect,VB,O
renal,JJ,O
prostaglandins,NNS,O
and,CC,O
increase,VB,O
the,DT,O
toxicity,NN,O
of,IN,O
certain,JJ,O
drugs,NNS,D
.,.,.
,,
ingestion,NN,O
of,IN,O
diclofenac,NN,D
may,MD,O
increase,VB,O
serum,NN,O
concentrations,NNS,O
of,IN,O
digoxin,NN,D
and,CC,O
methotrexate,NN,D
and,CC,O
increase,NN,O
cyclosporine,NN,D
s,VBZ,O
nephrotoxicity,NN,O
.,.,.
,,
patients,NNS,O
who,WP,O
begin,VBP,O
taking,VBG,O
diclofenac,NN,D
or,CC,O
who,WP,O
increase,VBP,O
their,PRP$,O
diclofenac,NN,D
dose,NN,O
or,CC,O
any,DT,O
other,JJ,O
nsaid,NN,G
while,IN,O
taking,VBG,O
digoxin,NN,D
",",",",O
methotrexate,NN,D
",",",",O
or,CC,O
cyclosporine,NN,D
may,MD,O
develop,VB,O
toxicity,NN,O
characteristics,NNS,O
for,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
they,PRP,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
",",",",O
particularly,RB,O
if,IN,O
renal,JJ,O
function,NN,O
is,VBZ,O
impaired,JJ,O
.,.,.
,,
in,IN,O
the,DT,O
case,NN,O
of,IN,O
digoxin,NN,D
",",",",O
serum,NN,O
levels,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
.,.,.
,,
lithium,NN,D
:,:,O
diclofenac,NNP,D
decreases,VBZ,O
lithium,NN,D
renal,JJ,O
clearance,NN,O
and,CC,O
increases,VBZ,O
lithium,NN,D
plasma,NN,O
levels,NNS,O
.,.,.
,,
in,IN,O
patients,NNS,O
taking,VBG,O
diclofenac,NN,D
and,CC,O
lithium,NN,D
concomitantly,RB,O
",",",",O
lithium,NN,D
toxicity,NN,O
may,MD,O
develop,VB,O
.,.,.
,,
oral,JJ,O
hypoglycemics,NNS,G
:,:,O
diclofenac,NNP,D
does,VBZ,O
not,RB,O
alter,VB,O
glucose,NN,O
metabolism,NN,O
in,IN,O
normal,JJ,O
subjects,NNS,O
nor,CC,O
does,VBZ,O
it,PRP,O
alter,VB,O
the,DT,O
effects,NNS,O
of,IN,O
oral,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
.,.,.
,,
there,EX,O
are,VBP,O
rare,JJ,O
reports,NNS,O
",",",",O
however,RB,O
",",",",O
from,IN,O
marketing,NN,O
experiences,NNS,O
",",",",O
of,IN,O
changes,NNS,O
in,IN,O
effects,NNS,O
of,IN,O
insulin,NN,D
or,CC,O
oral,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
diclofenac,NN,D
that,WDT,O
necessitated,VBD,O
changes,NNS,O
in,IN,O
the,DT,O
doses,NNS,O
of,IN,O
such,JJ,O
agents,NNS,O
.,.,.
,,
both,DT,O
hypo,NN,O
-,:,O
and,CC,O
hyperglycemic,JJ,O
effects,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
.,.,.
,,
a,DT,O
direct,JJ,O
causal,JJ,O
relationship,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
",",",",O
but,CC,O
physicians,NNS,O
should,MD,O
consider,VB,O
the,DT,O
possibility,NN,O
that,IN,O
diclofenac,NN,D
may,MD,O
alter,VB,O
a,DT,O
diabetic,JJ,O
patient,NN,O
s,NNS,O
response,NN,O
to,TO,O
insulin,NN,D
or,CC,O
oral,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
.,.,.
,,
diuretics,NNS,G
:,:,O
diclofenac,NNP,D
and,CC,O
other,JJ,O
nsaids,NNS,G
can,MD,O
inhibit,VB,O
the,DT,O
activity,NN,O
of,IN,O
diuretics,NNS,G
.,.,.
,,
concomitant,JJ,O
treatment,NN,O
with,IN,O
potassium-sparing,JJ,O
diuretics,NNS,G
may,MD,O
be,VB,O
associated,VBN,O
with,IN,O
increased,VBN,O
serum,NN,O
potassium,NN,D
levels,NNS,O
.,.,.
,,
other,JJ,O
drugs,NNS,O
:,:,O
in,IN,O
small,JJ,O
groups,NNS,O
of,IN,O
patients,NNS,O
-lrb-,-LRB-,O
10-Jul,CD,O
/,:,O
interaction,NN,O
study,NN,O
-rrb-,-RRB-,O
",",",",O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
azathioprine,NN,D
",",",",O
gold,NN,D
",",",",O
chloroquine,NN,D
",",",",O
d-penicillamine,NN,D
",",",",O
prednisolone,NN,D
",",",",O
doxycycline,NN,D
",",",",O
or,CC,O
digitoxin,NN,D
did,VBD,O
not,RB,O
significantly,RB,O
affect,VB,O
the,DT,O
peak,NN,O
levels,NNS,O
and,CC,O
auc,NN,O
values,NNS,O
of,IN,O
diclofenac,NN,D
.,.,.
,,
phenobarbital,JJ,D
toxicity,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
have,VB,O
occurred,VBN,O
in,IN,O
a,DT,O
patient,NN,O
on,IN,O
chronic,JJ,O
phenobarbital,JJ,D
treatment,NN,O
following,VBG,O
the,DT,O
initiation,NN,O
of,IN,O
diclofenac,NN,D
therapy,NN,O
.,.,.
,,
protein,NN,O
binding,NN,O
in,FW,O
vitro,FW,O
",",",",O
diclofenac,NN,D
interferes,VBZ,O
minimally,RB,O
or,CC,O
not,RB,O
at,IN,O
all,DT,O
with,IN,O
the,DT,O
protein,NN,O
binding,NN,O
of,IN,O
salicylic,JJ,O
acid,NN,O
-lrb-,-LRB-,O
20,CD,O
%,NN,O
decrease,NN,O
in,IN,O
binding,NN,O
-rrb-,-RRB-,O
",",",",O
tolbutamide,NN,D
",",",",O
prednisolone,NN,D
-lrb-,-LRB-,O
10,CD,O
%,NN,O
decrease,NN,O
in,IN,O
binding,NN,O
-rrb-,-RRB-,O
",",",",O
or,CC,O
warfarin,NN,D
.,.,.
,,
benzylpenicillin,NNP,D
",",",",O
ampicillin,NN,D
",",",",O
oxacillin,NN,D
",",",",O
chlortetracycline,NN,D
",",",",O
doxycycline,NN,D
",",",",O
cephalothin,NN,D
",",",",O
erythromycin,NN,D
",",",",O
and,CC,O
sulfamethoxazole,NN,D
have,VBP,O
no,DT,O
influence,NN,O
in,FW,O
vitro,FW,O
on,IN,O
the,DT,O
protein,NN,O
binding,NN,O
of,IN,O
diclofenac,NN,D
in,IN,O
human,JJ,O
serum,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
effect,NN,O
on,IN,O
blood,NN,O
coagulation,NN,O
:,:,O
diclofenac,NNP,D
increases,VBZ,O
platelet,NN,O
aggregation,NN,O
time,NN,O
but,CC,O
does,VBZ,O
not,RB,O
affect,VB,O
bleeding,JJ,O
time,NN,O
",",",",O
plasma,NN,O
thrombin,NN,O
clotting,NN,O
time,NN,O
",",",",O
plasma,NN,O
fibrinogen,NN,D
",",",",O
or,CC,O
factors,NNS,O
v,NN,O
and,CC,O
vii,NN,O
to,TO,O
xii,NNP,O
.,.,.
,,
statistically,RB,O
significant,JJ,O
changes,NNS,O
in,IN,O
prothrombin,NN,O
and,CC,O
partial,JJ,O
thromboplastin,NN,O
times,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
.,.,.
,,
the,DT,O
mean,JJ,O
changes,NNS,O
were,VBD,O
observed,VBN,O
to,TO,O
be,VB,O
less,JJR,O
than,IN,O
1,CD,O
second,JJ,O
in,IN,O
both,CC,O
instances,NNS,O
",",",",O
however,RB,O
",",",",O
and,CC,O
are,VBP,O
unlikely,JJ,O
to,TO,O
be,VB,O
clinically,RB,O
important,JJ,O
.,.,.
,,
diclofenac,NNP,D
is,VBZ,O
a,DT,O
prostaglandin,NN,O
synthetase,NN,O
inhibitor,NN,O
",",",",O
however,RB,O
",",",",O
and,CC,O
all,DT,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
prostaglandin,NN,O
synthesis,NN,O
interfere,VBP,O
with,IN,O
platelet,NN,O
function,NN,O
to,TO,O
some,DT,O
degree,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
patients,NNS,O
who,WP,O
may,MD,O
be,VB,O
adversely,RB,O
affected,VBN,O
by,IN,O
such,PDT,O
an,DT,O
action,NN,O
should,MD,O
be,VB,O
carefully,RB,O
observed,VBN,O
.,.,.
,,
tetracycline,NN,D
",",",",O
a,DT,O
bacteriostatic,JJ,O
antibiotic,JJ,G
",",",",O
may,MD,O
antagonize,VB,O
the,DT,O
bactercidal,JJ,O
effect,NN,O
of,IN,O
penicillin,NN,D
and,CC,O
concurrent,JJ,O
use,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
the,DT,O
following,VBG,O
agents,NNS,O
may,MD,O
increase,VB,O
certain,JJ,O
actions,NNS,O
or,CC,O
side,JJ,O
effects,NNS,O
of,IN,O
anticholinergic,JJ,G
drugs,NNS,D
.,.,.
,,
amantadine,NN,D
antiarrhythmic,JJ,D
agents,NNS,O
of,IN,O
class,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
quinidine,FW,D
-rrb-,-RRB-,O
",",",",O
antihistamines,NNS,G
antipsychotic,JJ,O
agents,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
phenothiazines,NNS,G
-rrb-,-RRB-,O
",",",",O
benzodiazepines,NNS,G
.,.,.
,,
mao,NN,O
inhibitors,NNS,O
",",",",O
narcotic,JJ,G
analgesics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
meperidine,NN,D
-rrb-,-RRB-,O
",",",",O
nitrates,NNS,G
and,CC,O
nitrites,NNS,G
",",",",O
sympathomimetic,JJ,G
agents,NNS,O
",",",",O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
and,CC,O
other,JJ,O
drugs,NNS,D
having,VBG,O
anticholinergic,JJ,G
activity,NN,O
.,.,.
,,
anticholinergics,NNS,G
antagonize,VBP,O
the,DT,O
effects,NNS,O
of,IN,O
antiglaucoma,NN,O
agents,NNS,O
.,.,.
,,
anticholinergic,JJ,O
drugs,NNS,D
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
increased,VBN,O
intraocular,JJ,O
pressure,NN,O
may,MD,O
be,VB,O
hazardous,JJ,O
when,WRB,O
taken,VBN,O
concurrently,RB,O
with,IN,O
agents,NNS,O
such,JJ,O
as,IN,O
corti,NN,O
costeroids,NNS,O
.,.,.
,,
anticholinergic,JJ,O
agents,NNS,O
may,MD,O
affect,VB,O
gastrointestinal,JJ,O
absorption,NN,O
of,IN,O
various,JJ,O
drugs,NNS,D
",",",",O
such,JJ,O
as,IN,O
slowly,RB,O
dissolving,VBG,O
dosage,JJ,O
forms,NNS,O
of,IN,O
digoxin,NN,D
.,.,.
,,
increased,VBN,O
serum,NN,O
digoxin,NN,D
concentrations,NNS,O
may,MD,O
result,VB,O
.,.,.
,,
anticholinergic,JJ,O
drugs,NNS,D
may,MD,O
antagonize,VB,O
the,DT,O
effects,NNS,O
of,IN,O
the,DT,O
drugs,NNS,D
that,WDT,O
alter,VBP,O
gastrointestinal,JJ,O
motility,NN,O
",",",",O
such,JJ,O
as,IN,O
metoclopramide,NN,D
.,.,.
,,
because,IN,O
antacids,NNS,G
may,MD,O
interfere,VB,O
with,IN,O
the,DT,O
absorption,NN,O
of,IN,O
anticholinergic,JJ,G
agents,NNS,O
",",",",O
simultaneous,JJ,O
use,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
the,DT,O
inhibiting,JJ,O
effects,NNS,O
of,IN,O
anticholinergic,JJ,G
drugs,NNS,D
on,IN,O
gastric,JJ,O
hydrochloric,JJ,O
acid,NN,O
secretion,NN,O
are,VBP,O
antagonized,VBN,O
by,IN,O
agents,NNS,O
used,VBN,O
to,TO,O
treat,VB,O
achlorhydria,NN,O
and,CC,O
those,DT,O
used,VBN,O
to,TO,O
test,VB,O
gastric,JJ,O
secretion,NN,O
.,.,.
,,
coadministration,NN,O
of,IN,O
videx,NN,B
with,IN,O
drugs,NNS,D
that,WDT,O
are,VBP,O
known,VBN,O
to,TO,O
cause,VB,O
pancreatitis,NN,O
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
this,DT,O
toxicity,NN,O
-lrb-,-LRB-,O
see,VB,O
warnings,NNS,O
-rrb-,-RRB-,O
and,CC,O
should,MD,O
be,VB,O
done,VBN,O
with,IN,O
extreme,JJ,O
caution,NN,O
",",",",O
only,RB,O
if,IN,O
other,JJ,O
alternatives,NNS,O
are,VBP,O
not,RB,O
available,JJ,O
",",",",O
and,CC,O
only,RB,O
if,IN,O
clearly,RB,O
indicated,VBN,O
.,.,.
,,
neuropathy,NN,O
has,VBZ,O
occurred,VBN,O
more,RBR,O
frequently,RB,O
in,IN,O
patients,NNS,O
with,IN,O
a,DT,O
history,NN,O
of,IN,O
neuropathy,NN,O
or,CC,O
neurotoxic,JJ,O
drug,NN,D
therapy,NN,O
",",",",O
including,VBG,O
stavudine,NN,D
",",",",O
and,CC,O
these,DT,O
patients,NNS,O
may,MD,O
be,VB,O
at,IN,O
increased,VBN,O
risk,NN,O
of,IN,O
neuropathy,NN,O
during,IN,O
videx,NN,B
therapy,NN,O
-lrb-,-LRB-,O
see,VB,O
adverse,JJ,O
reactions,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
allopurinol,NNP,D
:,:,O
the,DT,O
auc,NN,O
of,IN,O
didanosine,NN,D
was,VBD,O
increased,VBN,O
about,IN,O
4-fold,RB,O
when,WRB,O
allopurinol,NN,D
at,IN,O
300,CD,O
mg/day,NN,O
was,VBD,O
coadministered,VBN,O
with,IN,O
a,DT,O
single,JJ,O
200-mg,JJ,O
dose,NN,O
of,IN,O
videx,NNP,B
to,TO,O
two,CD,O
patients,NNS,O
with,IN,O
renal,JJ,O
impairment,NN,O
-lrb-,-LRB-,O
clcr,NN,O
=,JJ,O
15,CD,O
and,CC,O
18,CD,O
ml/min,NN,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
allopurinol,NN,D
on,IN,O
didanosine,NN,D
pharmacokinetics,NNS,O
in,IN,O
subjects,NNS,O
with,IN,O
normal,JJ,O
renal,JJ,O
function,NN,O
are,VBP,O
not,RB,O
known,VBN,O
.,.,.
,,
antacids,NNS,G
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
antacids,NNS,G
containing,VBG,O
magnesium,NN,D
or,CC,O
aluminum,NN,D
with,IN,O
videx,NNP,B
chewable/dispersible,NNP,O
buffered,NNP,O
tablets,NNPS,O
or,CC,O
pediatric,NNP,O
powder,NNP,O
for,IN,O
oral,NNP,O
solution,NN,O
may,MD,O
potentiate,VB,O
adverse,JJ,O
events,NNS,O
associated,VBN,O
with,IN,O
the,DT,O
antacid,NN,G
components,NNS,O
.,.,.
,,
drugs,NNS,O
whose,WP$,O
absorption,NN,O
can,MD,O
be,VB,O
affected,VBN,O
by,IN,O
the,DT,O
level,NN,O
of,IN,O
acidity,NN,O
in,IN,O
the,DT,O
stomach,NNP,O
:,:,O
drugs,NNS,O
such,JJ,O
as,IN,O
ketoconazole,NN,D
and,CC,O
itraconazole,NN,D
should,MD,O
be,VB,O
administered,VBN,O
at,IN,O
least,JJS,O
2,CD,O
hours,NNS,O
prior,RB,O
to,TO,O
dosing,NN,O
with,IN,O
videx,NN,B
.,.,.
,,
ganciclovir,NNP,D
:,:,O
administration,NNP,O
of,IN,O
videx,NNP,B
2,CD,O
hours,NNS,O
prior,RB,O
to,TO,O
or,CC,O
concurrent,JJ,O
with,IN,O
oral,JJ,O
ganciclovir,NN,D
was,VBD,O
associated,VBN,O
with,IN,O
a,DT,O
111,CD,O
-lrb-,-LRB-,O
114,CD,O
-rrb-,-RRB-,O
%,NN,O
increase,NN,O
in,IN,O
the,DT,O
steady-state,JJ,O
auc,NN,O
of,IN,O
didanosine,NN,D
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
12,CD,O
-rrb-,-RRB-,O
.,.,.
,,
a,DT,O
21,CD,O
-lrb-,-LRB-,O
17,CD,O
-rrb-,-RRB-,O
%,NN,O
decrease,NN,O
in,IN,O
the,DT,O
steady-state,JJ,O
auc,NN,O
of,IN,O
ganciclovir,NN,D
was,VBD,O
observed,VBN,O
when,WRB,O
videx,NNP,B
was,VBD,O
administered,VBN,O
2,CD,O
hours,NNS,O
prior,RB,O
to,TO,O
ganciclovir,NN,D
",",",",O
but,CC,O
not,RB,O
when,WRB,O
the,DT,O
two,CD,O
drugs,NNS,D
were,VBD,O
administered,VBN,O
simultaneously,RB,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
12,CD,O
-rrb-,-RRB-,O
.,.,.
,,
quinolone,NNP,O
antibiotics,NNPS,G
:,:,O
videx,NN,B
should,MD,O
be,VB,O
administered,VBN,O
at,IN,O
least,JJS,O
2,CD,O
hours,NNS,O
after,IN,O
or,CC,O
6,CD,O
hours,NNS,O
before,IN,O
dosing,NN,O
with,IN,O
ciprofloxacin,NN,D
because,IN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
ciprofloxacin,NN,D
are,VBP,O
decreased,VBN,O
when,WRB,O
administered,VBN,O
with,IN,O
antacids,NNS,G
containing,VBG,O
magnesium,NN,D
",",",",O
calcium,NN,D
",",",",O
or,CC,O
aluminum,NN,D
.,.,.
,,
in,IN,O
eight,CD,O
hiv-infected,JJ,O
patients,NNS,O
",",",",O
the,DT,O
steady-state,JJ,O
auc,NN,O
of,IN,O
ciprofloxacin,NN,D
was,VBD,O
decreased,VBN,O
an,DT,O
average,NN,O
of,IN,O
26,CD,O
%,NN,O
-lrb-,-LRB-,O
95,CD,O
%,NN,O
ci,NN,O
=,JJ,O
14,CD,O
%,NN,O
",",",",O
37,CD,O
%,NN,O
-rrb-,-RRB-,O
when,WRB,O
ciprofloxacin,NN,D
was,VBD,O
administered,VBN,O
2,CD,O
hours,NNS,O
prior,RB,O
to,TO,O
a,DT,O
marketed,VBN,O
chewable/dispersible,JJ,O
tablet,NN,O
formulation,NN,O
of,IN,O
videx,NNP,B
.,.,.
,,
the,DT,O
auc,NN,O
of,IN,O
ciprofloxacin,NN,D
was,VBD,O
decreased,VBN,O
an,DT,O
average,NN,O
of,IN,O
15-fold,JJ,O
in,IN,O
12,CD,O
healthy,JJ,O
subjects,NNS,O
given,VBN,O
ciprofloxacin,NN,D
and,CC,O
didanosine-placebo,JJ,O
tablets,NNS,O
concurrently,RB,O
.,.,.
,,
in,IN,O
a,DT,O
single,JJ,O
subject,JJ,O
given,VBN,O
one,CD,O
dose,NN,O
of,IN,O
ciprofloxacin,NN,D
2,CD,O
hours,NNS,O
after,IN,O
a,DT,O
dose,NN,O
of,IN,O
didanosine-placebo,JJ,O
tablets,NNS,O
",",",",O
a,DT,O
greater,JJR,O
than,IN,O
50,CD,O
%,NN,O
reduction,NN,O
in,IN,O
the,DT,O
auc,NN,O
of,IN,O
ciprofloxacin,NN,D
was,VBD,O
observed,VBN,O
.,.,.
,,
plasma,NN,O
concentrations,NNS,O
of,IN,O
quinolone,JJ,G
antibiotics,NNS,G
are,VBP,O
decreased,VBN,O
when,WRB,O
administered,VBN,O
with,IN,O
antacids,NNS,G
containing,VBG,O
magnesium,NN,D
",",",",O
calcium,NN,D
",",",",O
or,CC,O
aluminum,NN,D
.,.,.
,,
the,DT,O
optimal,JJ,O
dosing,NN,O
interval,NN,O
for,IN,O
coadministration,NN,O
with,IN,O
videx,NN,B
should,MD,O
be,VB,O
determined,VBN,O
by,IN,O
consulting,VBG,O
the,DT,O
appropriate,JJ,O
quinolone,NN,G
package,NN,O
insert,NN,O
.,.,.
,,
interactions,NNS,O
with,IN,O
other,JJ,O
antiretroviral,JJ,O
drugs,NNS,O
:,:,O
significant,JJ,O
decreases,NNS,O
in,IN,O
the,DT,O
auc,NN,O
of,IN,O
delavirdine,NN,D
-lrb-,-LRB-,O
20,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
indinavir,NN,D
-lrb-,-LRB-,O
84,CD,O
%,NN,O
-rrb-,-RRB-,O
occurred,VBD,O
following,VBG,O
simultaneous,JJ,O
administration,NN,O
of,IN,O
these,DT,O
agents,NNS,O
with,IN,O
videx,NN,B
.,.,.
,,
to,TO,O
avoid,VB,O
this,DT,O
interaction,NN,O
",",",",O
delavirdine,NN,D
or,CC,O
indinavir,NN,D
should,MD,O
be,VB,O
given,VBN,O
1,CD,O
hour,NN,O
prior,RB,O
to,TO,O
dosing,NN,O
with,IN,O
videx,NN,B
.,.,.
,,
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
nelfinavir,NN,D
are,VBP,O
not,RB,O
altered,VBN,O
to,TO,O
a,DT,O
clinically,RB,O
significant,JJ,O
degree,NN,O
when,WRB,O
it,PRP,O
is,VBZ,O
administered,VBN,O
with,IN,O
a,DT,O
light,JJ,O
meal,NN,O
1,CD,O
hour,NN,O
after,IN,O
videx,NNP,B
.,.,.
,,
drug,NN,O
/,:,O
laboratory,NNP,O
test,NNP,O
interactions,NNS,O
certain,JJ,O
endocrine,NN,O
and,CC,O
liver,NN,O
function,NN,O
tests,NNS,O
may,MD,O
be,VB,O
affected,VBN,O
by,IN,O
estrogen-containing,JJ,O
oral,JJ,O
contraceptives,NNS,G
.,.,.
,,
the,DT,O
following,VBG,O
similar,JJ,O
changes,NNS,O
may,MD,O
be,VB,O
expected,VBN,O
with,IN,O
larger,JJR,O
doses,NNS,O
of,IN,O
estrogen,NN,G
:,:,O
-,:,O
increased,VBN,O
sulfobromophthalein,NN,O
retentio,NN,O
.,.,.
,,
-,:,O
increased,VBN,O
prothrombin,NN,O
and,CC,O
factors,NNS,O
vii,NNP,O
",",",",O
viii,NNP,O
",",",",O
ix,CD,O
",",",",O
and,CC,O
x,NN,O
;,:,O
.,.,.
,,
decreased,VBN,O
antithrombin,NN,O
3,CD,O
.,.,.
,,
increased,VBN,O
norepinephrine-induced,JJ,O
platelet,NN,O
aggregability,NN,O
.,.,.
,,
-,:,O
increased,VBN,O
thyroid-binding,JJ,O
globulin,NN,O
-lrb-,-LRB-,O
tbg,NN,O
-rrb-,-RRB-,O
leading,VBG,O
to,TO,O
in-creased,JJ,O
circulating,VBG,O
total,JJ,O
thyroid,NN,G
hormone,NN,O
;,:,O
.,.,.
,,
as,IN,O
measured,VBN,O
by,IN,O
pbi,NN,O
",",",",O
t4,NN,D
by,IN,O
column,NN,O
",",",",O
or,CC,O
t4,NN,D
by,IN,O
radioimmunoassay,NN,O
.,.,.
,,
free,NNP,O
t3,NN,D
resin,NN,G
uptake,NN,O
is,VBZ,O
decreased,VBN,O
",",",",O
reflecting,VBG,O
the,DT,O
elevated,JJ,O
tbg,NN,O
;,:,O
.,.,.
,,
free,JJ,O
t4,NN,D
concentration,NN,O
is,VBZ,O
unaltered,JJ,O
.,.,.
,,
-,:,O
impaired,JJ,O
glucose,NN,O
tolerance,NN,O
.,.,.
,,
-,:,O
decreased,VBN,O
pregnanediol,NN,O
excretion,NN,O
.,.,.
,,
-,:,O
reduced,VBN,O
response,NN,O
to,TO,O
metyrapone,NN,O
test,NN,O
.,.,.
,,
-,:,O
reduced,VBN,O
serum,NN,O
folate,VBP,O
concentration,NN,O
.,.,.
,,
-,:,O
increased,VBN,O
serum,NN,O
triglyceride,NN,O
and,CC,O
phospholipid,JJ,O
concentration,NN,O
.,.,.
,,
antidiabetic,JJ,O
drug,NN,D
requirements,NNS,O
-lrb-,-LRB-,O
i.e.,FW,O
",",",",O
insulin,NN,D
-rrb-,-RRB-,O
may,MD,O
be,VB,O
altered,VBN,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
with,IN,O
general,JJ,O
anesthetics,NNS,G
may,MD,O
result,VB,O
in,IN,O
arrhythmias,NNS,O
.,.,.
,,
the,DT,O
pressor,JJ,O
effects,NNS,O
of,IN,O
diethylpropion,NN,D
and,CC,O
those,DT,O
of,IN,O
other,JJ,O
drugs,NNS,D
may,MD,O
be,VB,O
additive,JJ,O
when,WRB,O
the,DT,O
drugs,NNS,D
are,VBP,O
used,VBN,O
concomitantly,RB,O
.,.,.
,,
conversely,RB,O
",",",",O
diethylpropion,NN,D
may,MD,O
interfere,VB,O
with,IN,O
antihypertensive,JJ,G
drugs,NNS,D
-lrb-,-LRB-,O
i.e.,FW,O
",",",",O
guanethidine,NN,D
",",",",O
a-methyldopa,NN,D
-rrb-,-RRB-,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
of,IN,O
phenothiazines,NNS,G
may,MD,O
antagonize,VB,O
the,DT,O
anorectic,NN,O
effect,NN,O
of,IN,O
diethylpropion,NN,D
.,.,.
,,
may,NNP,O
interact,VBP,O
anticoagulants,NNS,G
-lrb-,-LRB-,O
altered,JJ,O
hypo-prothrombinemic,JJ,O
effect,NN,O
-rrb-,-RRB-,O
",",",",O
barbiturates,NNS,G
",",",",O
rifampin,NN,D
and,CC,O
other,JJ,O
inducers,NNS,O
of,IN,O
hepatic,JJ,O
microsomal,JJ,O
enzyme,NN,O
oxidation,NN,O
system,NN,O
-lrb-,-LRB-,O
decreased,VBN,O
effect,NN,O
of,IN,O
diethylstilbestrol,NN,D
-rrb-,-RRB-,O
",",",",O
corticosteroids,NNS,G
-lrb-,-LRB-,O
increased,VBN,O
effect,NN,O
of,IN,O
corticosteroids,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
oral,JJ,O
anticoagulants,NNPS,G
:,:,O
in,IN,O
some,DT,O
normal,JJ,O
volunteers,NNS,O
",",",",O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
diflunisal,NN,D
and,CC,O
warfarin,NN,D
",",",",O
acenocoumarol,NN,D
",",",",O
or,CC,O
phenprocoumon,NN,D
resulted,VBD,O
in,IN,O
prolongation,NN,O
of,IN,O
prothrombin,NN,O
time,NN,O
.,.,.
,,
this,DT,O
may,MD,O
occur,VB,O
because,IN,O
diflunisal,JJ,D
competitively,RB,O
displaces,VBZ,O
coumarins,NNS,G
from,IN,O
protein,NN,O
binding,NN,O
sites,NNS,O
.,.,.
,,
accordingly,RB,O
",",",",O
when,WRB,O
diflunisal,NN,D
is,VBZ,O
administered,VBN,O
with,IN,O
oral,JJ,O
anticoagulants,NNS,G
",",",",O
the,DT,O
prothrombin,NN,O
time,NN,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
during,IN,O
and,CC,O
for,IN,O
several,JJ,O
days,NNS,O
after,IN,O
concomitant,JJ,O
drug,NN,D
administration,NN,O
.,.,.
,,
adjustment,NNP,O
of,IN,O
dosage,NN,O
of,IN,O
oral,JJ,O
anticoagulants,NNS,G
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
tolbutamide,NNP,D
:,:,O
in,IN,O
diabetic,JJ,O
patients,NNS,O
receiving,VBG,O
diflunisal,JJ,D
and,CC,O
tolbutamide,NN,D
",",",",O
no,DT,O
significant,JJ,O
effects,NNS,O
were,VBD,O
seen,VBN,O
on,IN,O
tolbutamide,NN,D
plasma,NN,O
levels,NNS,O
or,CC,O
fasting,JJ,O
blood,NN,O
glucose,NN,O
.,.,.
,,
hydrochlorothiazide,NN,D
:,:,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
diflunisal,NN,D
and,CC,O
hydrochlorothiazide,NN,D
resulted,VBD,O
in,IN,O
significantly,RB,O
increased,VBN,O
plasma,NN,O
levels,NNS,O
of,IN,O
hydrochlorothiazide,NN,D
.,.,.
,,
diflunisal,NNP,D
decreased,VBD,O
the,DT,O
hyperuricemic,JJ,O
effect,NN,O
of,IN,O
hydrochlorothiazide,NN,D
.,.,.
,,
furosemide,NNP,D
:,:,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
",",",",O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
diflunisal,NN,D
and,CC,O
furosemide,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
diuretic,JJ,G
activity,NN,O
of,IN,O
furosemide,NN,D
.,.,.
,,
diflunisal,NNP,D
decreased,VBD,O
the,DT,O
hyperuricemic,JJ,O
effect,NN,O
of,IN,O
furosemide,NN,D
.,.,.
,,
antacids,NNS,G
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
antacids,NNS,G
may,MD,O
reduce,VB,O
plasma,NN,O
levels,NNS,O
of,IN,O
diflunisal,NN,D
.,.,.
,,
this,DT,O
effect,NN,O
is,VBZ,O
small,JJ,O
with,IN,O
occasional,JJ,O
doses,NNS,O
of,IN,O
antacids,NNS,G
",",",",O
but,CC,O
may,MD,O
be,VB,O
clinically,RB,O
significant,JJ,O
when,WRB,O
antacids,NNS,G
are,VBP,O
used,VBN,O
on,IN,O
a,DT,O
continuous,JJ,O
schedule,NN,O
.,.,.
,,
acetaminophen,NN,D
:,:,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
diflunisal,NN,D
and,CC,O
acetaminophen,NN,D
resulted,VBD,O
in,IN,O
an,DT,O
approximate,JJ,O
50,CD,O
%,NN,O
increase,NN,O
in,IN,O
plasma,NN,O
levels,NNS,O
of,IN,O
acetaminophen,NN,D
.,.,.
,,
acetaminophen,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
plasma,NN,O
levels,NNS,O
of,IN,O
diflunisal,NN,D
.,.,.
,,
since,IN,O
acetaminophen,NN,D
in,IN,O
high,JJ,O
doses,NNS,O
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
hepatotoxicity,NN,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
diflunisal,NN,D
and,CC,O
acetaminophen,NN,D
should,MD,O
be,VB,O
used,VBN,O
cautiously,RB,O
",",",",O
with,IN,O
careful,JJ,O
monitoring,NN,O
of,IN,O
patients,NNS,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
diflunisal,NN,D
and,CC,O
acetaminophen,NN,D
in,IN,O
dogs,NNS,O
",",",",O
but,CC,O
not,RB,O
in,IN,O
rats,NNS,O
",",",",O
at,IN,O
approximately,RB,O
2,CD,O
times,NNS,O
the,DT,O
recommended,VBN,O
maximum,NN,O
human,JJ,O
therapeutic,JJ,O
dose,NN,O
of,IN,O
each,DT,O
-lrb-,-LRB-,O
40,CD,O
to,TO,O
52,CD,O
mg/kg/day,NN,O
of,IN,O
diflunisal/acetaminophen,NN,O
-rrb-,-RRB-,O
resulted,VBD,O
in,IN,O
greater,JJR,O
gastrointestinal,JJ,O
toxicity,NN,O
than,IN,O
when,WRB,O
either,CC,O
drug,NN,D
was,VBD,O
administered,VBN,O
alone,RB,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
these,DT,O
findings,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
methotrexate,NNP,D
:,:,O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
if,IN,O
diflunisal,NN,D
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
methotrexate,NN,D
.,.,.
,,
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
decrease,VB,O
the,DT,O
tubular,JJ,O
secretion,NN,O
of,IN,O
methotrexate,NN,D
and,CC,O
to,TO,O
potentiate,VB,O
its,PRP$,O
toxicity,NN,O
.,.,.
,,
cyclosporine,NN,D
:,:,O
administration,NN,O
of,IN,O
nonsteroial,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
concomitantly,RB,O
with,IN,O
cyclosporine,NN,D
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
an,DT,O
increase,NN,O
in,IN,O
cyclosporine-induced,JJ,O
toxicity,NN,O
",",",",O
possibly,RB,O
due,JJ,O
to,TO,O
decreased,VBN,O
synthesis,NN,O
of,IN,O
renal,JJ,O
prostacyclin,NN,O
.,.,.
,,
nsaids,NNS,G
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
cyclosporine,NN,D
",",",",O
and,CC,O
renal,JJ,O
function,NN,O
should,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
.,.,.
,,
nonsteroidal,JJ,O
anti-inflammatory,JJ,O
drugs,NNS,O
:,:,O
the,DT,O
administration,NN,O
of,IN,O
diflunisal,NN,D
to,TO,O
normal,JJ,O
volunteers,NNS,O
receiving,VBG,O
indomethacin,NN,D
decreased,VBD,O
the,DT,O
renal,JJ,O
clearance,NN,O
and,CC,O
significantly,RB,O
increased,VBD,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
indomethacin,NN,D
.,.,.
,,
in,IN,O
some,DT,O
patients,NNS,O
the,DT,O
combined,JJ,O
use,NN,O
of,IN,O
indomethacin,NN,D
and,CC,O
diflunisal,NN,D
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
fatal,JJ,O
gastrointestinal,JJ,O
hemorrhage,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
indomethacin,NN,D
and,CC,O
diflunisal,NN,D
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
concomitantly,RB,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
diflunisal,JJ,D
tablets,NNS,O
and,CC,O
other,JJ,O
nsaids,NNS,G
is,VBZ,O
not,RB,O
recommended,VBN,O
due,JJ,O
to,TO,O
the,DT,O
increased,VBN,O
possibility,NN,O
of,IN,O
gastrointestinal,JJ,O
toxicity,NN,O
",",",",O
with,IN,O
little,JJ,O
or,CC,O
no,DT,O
increase,NN,O
in,IN,O
efficacy,NN,O
.,.,.
,,
the,DT,O
following,VBG,O
information,NN,O
was,VBD,O
obtained,VBN,O
from,IN,O
studies,NNS,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
.,.,.
,,
aspirin,NN,B
:,:,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
",",",",O
a,DT,O
small,JJ,O
decrease,NN,O
in,IN,O
diflunisal,JJ,D
levels,NNS,O
was,VBD,O
observed,VBN,O
when,WRB,O
multiple,JJ,O
doses,NNS,O
of,IN,O
diflunisal,NN,D
and,CC,O
aspirin,NN,B
were,VBD,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
sulindac,NN,D
:,:,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
diflunisal,NN,D
and,CC,O
sulindac,NN,D
in,IN,O
normal,JJ,O
volunteers,NNS,O
resulted,VBD,O
in,IN,O
lowering,NN,O
of,IN,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
the,DT,O
active,JJ,O
sulindac,NN,D
sulfide,NN,O
metabolite,NN,O
by,IN,O
approximately,RB,O
one-third,JJ,O
.,.,.
,,
naproxen,NN,D
:,:,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
diflunisal,NN,D
and,CC,O
naproxen,NN,D
in,IN,O
normal,JJ,O
volunteers,NNS,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
naproxen,NN,D
",",",",O
but,CC,O
significantly,RB,O
decreased,VBD,O
the,DT,O
urinary,JJ,O
excretion,NN,O
of,IN,O
naproxen,NN,D
and,CC,O
its,PRP$,O
glucuronide,NN,O
metabolite,NN,O
.,.,.
,,
naproxen,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
plasma,NN,O
levels,NNS,O
of,IN,O
diflunisal,NN,D
.,.,.
,,
drug,NN,O
laboratory,NN,O
test,NN,O
interactions,NNS,O
serum,NN,O
salicylate,NNP,G
assays,NNS,O
:,:,O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
in,IN,O
interpreting,VBG,O
the,DT,O
results,NNS,O
of,IN,O
serum,NN,O
salicylate,NN,G
assays,NNS,O
when,WRB,O
diflunisal,NN,D
is,VBZ,O
present,JJ,O
.,.,.
,,
salicylate,NN,G
levels,NNS,O
have,VBP,O
been,VBN,O
found,VBN,O
to,TO,O
be,VB,O
falsely,RB,O
elevated,JJ,O
with,IN,O
some,DT,O
assay,NN,O
methods,NNS,O
.,.,.
,,
potassium-depleting,JJ,O
diuretics,NNS,G
are,VBP,O
a,DT,O
major,JJ,O
contributing,JJ,O
factor,NN,O
to,TO,O
digitalis,NN,G
toxicity,NN,O
.,.,.
,,
calcium,NN,D
",",",",O
particularly,RB,O
if,IN,O
administered,VBN,O
rapidly,RB,O
by,IN,O
the,DT,O
intravenous,JJ,O
route,NN,O
",",",",O
may,MD,O
produce,VB,O
serious,JJ,O
arrhythmias,NNS,O
in,IN,O
digitalized,JJ,O
patients,NNS,O
.,.,.
,,
quinidine,NNP,D
",",",",O
verapamil,NN,D
",",",",O
amiodarone,NN,D
",",",",O
propafenone,NN,D
",",",",O
indomethacin,NN,D
",",",",O
itraconazole,NN,D
",",",",O
alprazolam,NN,D
",",",",O
and,CC,O
spironolactone,NN,D
raise,VBP,O
the,DT,O
serum,NN,O
digoxin,NN,D
concentration,NN,O
due,JJ,O
to,TO,O
a,DT,O
reduction,NN,O
in,IN,O
clearance,NN,O
and/or,CC,O
in,IN,O
volume,NN,O
of,IN,O
distribution,NN,O
of,IN,O
the,DT,O
drug,NN,D
",",",",O
with,IN,O
the,DT,O
implication,NN,O
that,WDT,O
digitalis,NN,G
intoxication,NN,O
may,MD,O
result,VB,O
.,.,.
,,
erythromycin,NN,D
and,CC,O
clarithromycin,NN,D
-lrb-,-LRB-,O
and,CC,O
possibly,RB,O
other,JJ,O
macrolide,NN,O
antibiotics,NNS,G
-rrb-,-RRB-,O
and,CC,O
tetracycline,NN,D
may,MD,O
increase,VB,O
digoxin,NN,D
absorption,NN,O
in,IN,O
patients,NNS,O
who,WP,O
inactivate,VBP,O
digoxin,NN,D
by,IN,O
bacterial,JJ,O
metabolism,NN,O
in,IN,O
the,DT,O
lower,JJR,O
intestine,NN,O
",",",",O
so,RB,O
that,IN,O
digitalis,NN,G
intoxication,NN,O
may,MD,O
result,VB,O
.,.,.
,,
the,DT,O
risk,NN,O
of,IN,O
this,DT,O
interaction,NN,O
may,MD,O
be,VB,O
reduced,VBN,O
if,IN,O
digoxin,NN,D
is,VBZ,O
given,VBN,O
as,IN,O
capsules,NNS,O
.,.,.
,,
propantheline,NNP,D
and,CC,O
diphenoxylate,NN,D
",",",",O
by,IN,O
decreasing,VBG,O
gut,NN,O
motility,NN,O
",",",",O
may,MD,O
increase,VB,O
digoxin,NN,D
absorption,NN,O
.,.,.
,,
antacids,NNS,G
",",",",O
kaolin-pectin,NN,O
",",",",O
sulfasalazine,NN,D
",",",",O
neomycin,NN,D
",",",",O
cholestyramine,NN,D
",",",",O
certain,JJ,O
anticancer,JJ,O
drugs,NNS,D
",",",",O
and,CC,O
metoclopramide,NN,D
may,MD,O
interfere,VB,O
with,IN,O
intestinal,JJ,O
digoxin,NN,D
absorption,NN,O
",",",",O
resulting,VBG,O
in,IN,O
unexpectedly,RB,O
low,JJ,O
serum,NN,O
concentrations,NNS,O
.,.,.
,,
rifampin,NNP,D
may,MD,O
decrease,VB,O
serum,NN,O
digoxin,NN,D
concentration,NN,O
",",",",O
especially,RB,O
in,IN,O
patients,NNS,O
with,IN,O
renal,JJ,O
dysfunction,NN,O
",",",",O
by,IN,O
increasing,VBG,O
the,DT,O
non-renal,JJ,O
clearance,NN,O
of,IN,O
digoxin,NN,D
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
inconsistent,JJ,O
reports,NNS,O
regarding,VBG,O
the,DT,O
effects,NNS,O
of,IN,O
other,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
quinine,NN,D
",",",",O
penicillamine,NN,D
-rrb-,-RRB-,O
on,IN,O
serum,NN,O
digoxin,NN,D
concentration,NN,O
.,.,.
,,
thyroid,NN,G
administration,NN,O
to,TO,O
a,DT,O
digitalized,JJ,O
",",",",O
hypothyroid,JJ,O
patient,NN,O
may,MD,O
increase,VB,O
the,DT,O
dose,NN,O
requirement,NN,O
of,IN,O
digoxin,NN,D
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
digoxin,NN,D
and,CC,O
sympathomimetics,NNS,G
increases,VBZ,O
the,DT,O
risk,NN,O
of,IN,O
cardiac,JJ,O
arrhythmias,NNS,O
.,.,.
,,
succinylcholine,NNP,D
may,MD,O
cause,VB,O
a,DT,O
sudden,JJ,O
extrusion,NN,O
of,IN,O
potassium,NN,D
from,IN,O
muscle,NN,O
cells,NNS,O
",",",",O
and,CC,O
may,MD,O
thereby,RB,O
cause,VB,O
arrhythmias,NNS,O
in,IN,O
digitalized,JJ,O
patients,NNS,O
.,.,.
,,
although,IN,O
beta-adrenergic,JJ,O
blockers,NNS,O
or,CC,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
and,CC,O
digoxin,NN,D
may,MD,O
be,VB,O
useful,JJ,O
in,IN,O
combination,NN,O
to,TO,O
control,VB,O
atrial,JJ,O
fibrillation,NN,O
",",",",O
their,PRP$,O
additive,JJ,O
effects,NNS,O
on,IN,O
av,NN,O
node,NN,O
conduction,NN,O
can,MD,O
result,VB,O
in,IN,O
advanced,JJ,O
or,CC,O
complete,JJ,O
heart,NN,O
block,NN,O
.,.,.
,,
due,JJ,O
to,TO,O
the,DT,O
considerable,JJ,O
variability,NN,O
of,IN,O
these,DT,O
interactions,NNS,O
",",",",O
the,DT,O
dosage,NN,O
of,IN,O
digoxin,NN,D
should,MD,O
be,VB,O
individualized,VBN,O
when,WRB,O
patients,NNS,O
receive,VBP,O
these,DT,O
medications,NNS,O
concurrently,RB,O
.,.,.
,,
furthermore,RB,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
combining,VBG,O
digoxin,NN,D
with,IN,O
any,DT,O
drug,NN,D
that,WDT,O
may,MD,O
cause,VB,O
a,DT,O
significant,JJ,O
deterioration,NN,O
in,IN,O
renal,JJ,O
function,NN,O
",",",",O
since,IN,O
a,DT,O
decline,NN,O
in,IN,O
glomerular,JJ,O
filtration,NN,O
or,CC,O
tubular,JJ,O
secretion,NN,O
may,MD,O
impair,VB,O
the,DT,O
excretion,NN,O
of,IN,O
digoxin,NN,D
.,.,.
,,
vasoconstrictors,NNP,G
:,:,O
d.h.e.,NNP,O
45,CD,O
-lrb-,-LRB-,O
dihydroergotamine,NN,D
mesylate,NN,O
-rrb-,-RRB-,O
injection,NN,O
",",",",O
usp,NN,O
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
with,IN,O
peripheral,JJ,O
vasoconstrictors,NNS,O
because,IN,O
the,DT,O
combination,NN,O
may,MD,O
cause,VB,O
synergistic,JJ,O
elevation,NN,O
of,IN,O
blood,NN,O
pressure,NN,O
.,.,.
,,
sumatriptan,NNP,D
:,:,O
sumatriptan,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
cause,VB,O
coronary,JJ,O
artery,NN,O
vasospasm,NN,O
",",",",O
and,CC,O
its,PRP$,O
effect,NN,O
could,MD,O
be,VB,O
additive,JJ,O
with,IN,O
d.h.e.,NNP,O
45,CD,O
-lrb-,-LRB-,O
dihydroergotamine,NN,D
mesylate,NN,O
-rrb-,-RRB-,O
injection,NN,O
",",",",O
usp,NN,O
.,.,.
,,
sumatriptan,NNP,D
and,CC,O
d.h.e.,NNP,O
45,CD,O
-lrb-,-LRB-,O
dihydroergotamine,NN,D
mesylate,NN,O
-rrb-,-RRB-,O
injection,NN,O
",",",",O
usp,NN,O
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
within,IN,O
24,CD,O
hours,NNS,O
of,IN,O
each,DT,O
other,JJ,O
.,.,.
,,
beta,NN,O
blockers,NNS,O
:,:,O
although,IN,O
the,DT,O
results,NNS,O
of,IN,O
a,DT,O
clinical,JJ,O
study,NN,O
did,VBD,O
not,RB,O
indicate,VB,O
a,DT,O
safe,JJ,O
problem,NN,O
associated,VBN,O
with,IN,O
the,DT,O
administration,NN,O
of,IN,O
d.h.e.,NNP,O
45,CD,O
-lrb-,-LRB-,O
dihydroergotamine,NN,D
mesylate,NN,O
-rrb-,-RRB-,O
injection,NN,O
",",",",O
usp,NN,O
to,TO,O
subjects,NNS,O
already,RB,O
receiving,VBG,O
propranolol,NN,D
",",",",O
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
that,IN,O
propranolol,NN,D
may,MD,O
potentiate,VB,O
the,DT,O
vasoconstrictive,JJ,O
action,NN,O
of,IN,O
ergotamine,NN,D
by,IN,O
blocking,VBG,O
the,DT,O
vasodilating,VBG,O
property,NN,O
of,IN,O
epinephrine,NN,D
.,.,.
,,
nicotine,NN,D
:,:,O
nicotine,NN,D
may,MD,O
provoke,VB,O
vasoconstriction,NN,O
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
predisposing,VBG,O
to,TO,O
a,DT,O
greater,JJR,O
ischemic,JJ,O
response,NN,O
to,TO,O
ergot,NN,G
therapy,NN,O
.,.,.
,,
macrolide,NNP,O
antibiotics,NNP,G
-lrb-,-LRB-,O
e.,FW,O
g.,FW,O
erythromycin,NN,D
and,CC,O
troleandomycin,NN,D
-rrb-,-RRB-,O
:,:,O
agents,NNS,O
of,IN,O
the,DT,O
ergot,NN,G
alkaloid,NN,O
class,NN,O
",",",",O
of,IN,O
which,WDT,O
d.h.e.,NNP,O
45,CD,O
-lrb-,-LRB-,O
dihydroergotamine,NN,D
mesylate,NN,O
-rrb-,-RRB-,O
injection,NN,O
",",",",O
usp,NN,O
is,VBZ,O
a,DT,O
member,NN,O
",",",",O
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
interact,VB,O
with,IN,O
antibiotics,NNS,G
of,IN,O
the,DT,O
macrolide,NN,O
class,NN,O
",",",",O
resulting,VBG,O
in,IN,O
increased,VBN,O
plasma,NN,O
levels,NNS,O
of,IN,O
unchanged,JJ,O
alkaloids,NNS,O
and,CC,O
peripheral,JJ,O
vasoconstriction,NN,O
.,.,.
,,
vasospastic,JJ,O
reactions,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
therapeutic,JJ,O
doses,NNS,O
of,IN,O
ergotamine-containing,JJ,O
drugs,NNS,D
when,WRB,O
co-administered,VBN,O
with,IN,O
these,DT,O
antibiotics,NNS,G
.,.,.
,,
ssris,NNS,G
:,:,O
weakness,NN,O
hyperreflexia,NN,O
",",",",O
and,CC,O
incoordination,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
rarely,RB,O
when,WRB,O
5-ht1,NN,O
agonists,NNS,O
have,VBP,O
been,VBN,O
co-administered,VBN,O
with,IN,O
ssris,NNS,G
-lrb-,-LRB-,O
e.,FW,O
g.,FW,O
fluoxetine,NN,D
",",",",O
fluvoxamine,NN,D
",",",",O
paroxetine,NN,D
",",",",O
sertraline,NN,D
-rrb-,-RRB-,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
no,DT,O
reported,VBN,O
cases,NNS,O
from,IN,O
spontaneous,JJ,O
reports,NNS,O
of,IN,O
drug,NN,D
interaction,NN,O
between,IN,O
ssris,NNS,G
and,CC,O
d.h.e.,NNP,O
45,CD,O
-lrb-,-LRB-,O
dihydroergotamine,NN,D
mesylate,NN,O
-rrb-,-RRB-,O
injection,NN,O
",",",",O
usp,NN,O
.,.,.
,,
oral,JJ,O
contraceptives,NNS,G
:,:,O
the,DT,O
effect,NN,O
of,IN,O
oral,JJ,O
contraceptives,NNS,G
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
d.h.e.,NNP,O
45,CD,O
-lrb-,-LRB-,O
dihydroergotamine,NN,D
mesylate,NN,O
-rrb-,-RRB-,O
injection,NN,O
",",",",O
usp,NNP,O
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
administration,NN,O
of,IN,O
thiazide,JJ,G
diuretics,NNS,G
to,TO,O
hypoparathyroid,JJ,O
patients,NNS,O
who,WP,O
are,VBP,O
concurrently,RB,O
being,VBG,O
treated,VBN,O
with,IN,O
dihydrotachysterol,NN,D
may,MD,O
cause,VB,O
hypercalcemia,NN,O
.,.,.
,,
due,JJ,O
to,TO,O
the,DT,O
potential,NN,O
for,IN,O
additive,JJ,O
effects,NNS,O
",",",",O
caution,NN,O
and,CC,O
careful,JJ,O
titration,NN,O
are,VBP,O
warranted,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
diltiazem,NN,D
hydrochloride,NN,O
concomitantly,RB,O
with,IN,O
other,JJ,O
agents,NNS,O
known,VBN,O
to,TO,O
affect,VB,O
cardiac,JJ,O
contractility,NN,O
and/or,CC,O
conduction,NN,O
.,.,.
,,
pharmacologic,JJ,O
studies,NNS,O
indicate,VBP,O
that,IN,O
there,EX,O
may,MD,O
be,VB,O
additive,JJ,O
effects,NNS,O
in,IN,O
prolonging,VBG,O
av,NN,O
conduction,NN,O
when,WRB,O
using,VBG,O
beta-blockers,NNS,G
or,CC,O
digitalis,NN,G
concomitantly,RB,O
with,IN,O
tiazac,NNP,B
.,.,.
,,
as,IN,O
with,IN,O
all,DT,O
drugs,NNS,D
",",",",O
care,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
treating,VBG,O
patients,NNS,O
with,IN,O
multiple,JJ,O
medications,NNS,O
.,.,.
,,
diltiazem,NNP,D
is,VBZ,O
both,CC,O
a,DT,O
substrate,NN,O
and,CC,O
an,DT,O
inhibitor,NN,O
of,IN,O
the,DT,O
cytochrome,NN,O
p-450,NN,O
3a4,NN,O
enzyme,NN,O
system,NN,O
.,.,.
,,
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
specific,JJ,O
substrates,NNS,O
",",",",O
inhibitors,NNS,O
",",",",O
or,CC,O
inducers,NNS,O
of,IN,O
the,DT,O
enzyme,NN,O
system,NN,O
may,MD,O
have,VB,O
a,DT,O
significant,JJ,O
impact,NN,O
on,IN,O
the,DT,O
efficacy,NN,O
and,CC,O
side,NN,O
effect,NN,O
profile,NN,O
of,IN,O
diltiazem,NN,D
.,.,.
,,
patients,NNS,O
taking,VBG,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
substrates,NNS,O
of,IN,O
cyp450,NN,O
3a4,NN,O
",",",",O
especially,RB,O
patients,NNS,O
with,IN,O
renal,JJ,O
and/or,CC,O
hepatic,JJ,O
impairment,NN,O
",",",",O
may,MD,O
require,VB,O
dosage,NN,O
adjustment,NN,O
when,WRB,O
starting,VBG,O
or,CC,O
stopping,VBG,O
concomitantly,RB,O
administered,VBN,O
diltiazem,NN,D
in,IN,O
order,NN,O
to,TO,O
maintain,VB,O
optimum,JJ,O
therapeutic,JJ,O
blood,NN,O
levels,NNS,O
.,.,.
,,
beta,NN,O
blocker,NN,O
.,.,.
,,
controlled,VBN,O
and,CC,O
uncontrolled,JJ,O
domestic,JJ,O
studies,NNS,O
suggest,VBP,O
that,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
diltiazem,NN,D
hydrochloride,NN,O
and,CC,O
beta-blockers,NNS,G
is,VBZ,O
usually,RB,O
well,RB,O
tolerated,VBD,O
",",",",O
but,CC,O
available,JJ,O
data,NNS,O
are,VBP,O
not,RB,O
sufficient,JJ,O
to,TO,O
predict,VB,O
the,DT,O
effects,NNS,O
of,IN,O
concomitant,JJ,O
treatment,NN,O
in,IN,O
patients,NNS,O
with,IN,O
left,JJ,O
ventricular,JJ,O
dysfunction,NN,O
or,CC,O
cardiac,JJ,O
conduction,NN,O
abnormalities,NNS,O
.,.,.
,,
administration,NN,O
of,IN,O
diltiazem,NN,D
hydrochloride,NN,O
concomitantly,RB,O
with,IN,O
propranolol,NN,D
in,IN,O
five,CD,O
normal,JJ,O
volunteers,NNS,O
resulted,VBD,O
in,IN,O
increased,VBN,O
propranolol,NN,D
levels,NNS,O
in,IN,O
all,DT,O
subjects,NNS,O
and,CC,O
bioavailability,NN,O
of,IN,O
propranolol,NN,D
was,VBD,O
increased,VBN,O
approximately,RB,O
50,CD,O
%,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
",",",",O
propranolol,NN,D
appears,VBZ,O
to,TO,O
be,VB,O
displaced,VBN,O
from,IN,O
its,PRP$,O
binding,NN,O
sites,NNS,O
by,IN,O
diltiazem,NN,D
.,.,.
,,
if,IN,O
combination,NN,O
therapy,NN,O
is,VBZ,O
initiated,VBN,O
or,CC,O
withdrawn,VBN,O
in,IN,O
conjunction,NN,O
with,IN,O
propranolol,NN,D
",",",",O
an,DT,O
adjustment,NN,O
in,IN,O
the,DT,O
propranolol,NN,D
dose,NN,O
may,MD,O
be,VB,O
warranted,VBN,O
.,.,.
,,
cimetidin,NNP,O
.,.,.
,,
a,DT,O
study,NN,O
in,IN,O
six,CD,O
healthy,JJ,O
volunteers,NNS,O
has,VBZ,O
shown,VBN,O
a,DT,O
significant,JJ,O
increase,NN,O
in,IN,O
peak,JJ,O
diltiazem,NN,D
plasma,NN,O
levels,NNS,O
-lrb-,-LRB-,O
58,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
auc,NN,O
-lrb-,-LRB-,O
53,CD,O
%,NN,O
-rrb-,-RRB-,O
after,IN,O
a,DT,O
1-week,JJ,O
course,NN,O
of,IN,O
cimetidine,NN,D
1200,CD,O
mg/day,NN,O
and,CC,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
diltiazem,NN,D
60mg,NN,O
.,.,.
,,
ranitidine,NN,D
produced,VBD,O
smaller,JJR,O
",",",",O
nonsignificant,JJ,O
increases,NNS,O
.,.,.
,,
the,DT,O
effect,NN,O
may,MD,O
be,VB,O
mediated,VBN,O
by,IN,O
cimetidines,NNS,O
known,VBN,O
inhibition,NN,O
of,IN,O
hepatic,JJ,O
cytochrome,NN,O
p-450,NN,O
",",",",O
the,DT,O
enzyme,NN,O
system,NN,O
responsible,JJ,O
for,IN,O
the,DT,O
first-pass,JJ,O
metabolism,NN,O
of,IN,O
diltiazem,NN,D
.,.,.
,,
patients,NNS,O
currently,RB,O
receiving,VBG,O
diltiazem,NN,D
therapy,NN,O
should,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
for,IN,O
a,DT,O
change,NN,O
in,IN,O
pharmacological,JJ,O
effect,NN,O
when,WRB,O
initiating,VBG,O
and,CC,O
discontinuing,VBG,O
therapy,NN,O
with,IN,O
cimetidine,NN,D
.,.,.
,,
an,DT,O
adjustment,NN,O
in,IN,O
the,DT,O
diltiazem,NN,D
dose,NN,O
may,MD,O
be,VB,O
warranted,VBN,O
.,.,.
,,
digitali,NNP,O
.,.,.
,,
administration,NN,O
of,IN,O
diltiazem,NN,D
hydrochloride,NN,O
with,IN,O
digoxin,NN,D
in,IN,O
24,CD,O
healthy,JJ,O
male,JJ,O
subjects,NNS,O
increased,VBN,O
plasma,NN,O
digoxin,NN,D
concentrations,NNS,O
approximately,RB,O
20,CD,O
%,NN,O
.,.,.
,,
another,DT,O
investigator,NN,O
found,VBD,O
no,DT,O
increase,NN,O
in,IN,O
digoxin,NN,D
levels,NNS,O
in,IN,O
12,CD,O
patients,NNS,O
with,IN,O
coronary,JJ,O
artery,NN,O
disease,NN,O
.,.,.
,,
since,IN,O
there,EX,O
have,VBP,O
been,VBN,O
conflicting,JJ,O
results,NNS,O
regarding,VBG,O
the,DT,O
effect,NN,O
of,IN,O
digoxin,NN,D
levels,NNS,O
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
digoxin,NN,D
levels,NNS,O
be,VB,O
monitored,VBN,O
when,WRB,O
initiating,VBG,O
",",",",O
adjusting,VBG,O
",",",",O
and,CC,O
discontinuing,VBG,O
diltiazem,NN,D
hydrochloride,NN,O
therapy,NN,O
to,TO,O
avoid,VB,O
possible,JJ,O
over,IN,O
-,:,O
or,CC,O
under-digitalization,NN,O
.,.,.
,,
anesthetic,NNP,D
.,.,.
,,
the,DT,O
depression,NN,O
of,IN,O
cardiac,JJ,O
contractility,NN,O
",",",",O
conductivity,NN,O
",",",",O
and,CC,O
automaticity,NN,O
as,RB,O
well,RB,O
as,IN,O
the,DT,O
vascular,JJ,O
dilation,NN,O
associated,VBN,O
with,IN,O
anesthetics,NNS,G
may,MD,O
be,VB,O
potentiated,VBN,O
by,IN,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
.,.,.
,,
when,WRB,O
used,VBN,O
concomitantly,RB,O
",",",",O
anesthetics,NNS,G
and,CC,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
should,MD,O
be,VB,O
titrated,VBN,O
carefully,RB,O
.,.,.
,,
cyclosporin,NN,D
.,.,.
,,
a,DT,O
pharmacokinetic,JJ,O
interaction,NN,O
between,IN,O
diltiazem,NN,D
and,CC,O
cyclosporine,NN,D
has,VBZ,O
been,VBN,O
observed,VBN,O
during,IN,O
studies,NNS,O
involving,VBG,O
renal,JJ,O
and,CC,O
cardiac,JJ,O
transplant,NN,O
patients,NNS,O
.,.,.
,,
in,IN,O
renal,JJ,O
and,CC,O
cardiac,JJ,O
transplant,NN,O
recipients,NNS,O
",",",",O
a,DT,O
reduction,NN,O
of,IN,O
cyclosporine,NN,D
dose,NN,O
ranging,VBG,O
from,IN,O
15,CD,O
%,NN,O
to,TO,O
48,CD,O
%,NN,O
was,VBD,O
necessary,JJ,O
to,TO,O
maintain,VB,O
cyclosporine,NN,D
trough,NN,O
concentrations,NNS,O
similar,JJ,O
to,TO,O
those,DT,O
seen,VBN,O
prior,JJ,O
to,TO,O
the,DT,O
addition,NN,O
of,IN,O
diltiazem,NN,D
.,.,.
,,
if,IN,O
these,DT,O
agents,NNS,O
are,VBP,O
to,TO,O
be,VB,O
administered,VBN,O
concurrently,RB,O
",",",",O
cyclosporine,NN,D
concentrations,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
",",",",O
especially,RB,O
when,WRB,O
diltiazem,NN,D
therapy,NN,O
is,VBZ,O
initiated,VBN,O
",",",",O
adjusted,VBN,O
",",",",O
or,CC,O
discontinued,VBN,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
cyclosporine,NN,D
on,IN,O
diltiazem,NN,D
plasma,NN,O
concentrations,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
evaluated,VBN,O
.,.,.
,,
carbamazepin,NNP,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
diltiazem,NN,D
with,IN,O
carbamazepine,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
result,VB,O
in,IN,O
elevated,JJ,O
serum,NN,O
levels,NNS,O
of,IN,O
carbamazepine,NN,D
-lrb-,-LRB-,O
40,CD,O
%,NN,O
to,TO,O
72,CD,O
%,NN,O
increase,NN,O
-rrb-,-RRB-,O
",",",",O
resulting,VBG,O
in,IN,O
toxicity,NN,O
in,IN,O
some,DT,O
cases,NNS,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
these,DT,O
drugs,NNS,D
concurrently,RB,O
should,MD,O
be,VB,O
monitored,VBN,O
for,IN,O
a,DT,O
potential,JJ,O
drug,NN,D
interaction,NN,O
.,.,.
,,
benzodiazepine,NN,O
.,.,.
,,
studies,NNS,O
showed,VBD,O
that,IN,O
diltiazem,NN,D
increased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
midazolam,NN,D
and,CC,O
triazolam,NN,D
by,IN,O
4-Mar,CD,O
fold,NN,O
and,CC,O
the,DT,O
cmax,NN,O
by,IN,O
2-fold,RB,O
",",",",O
compared,VBN,O
to,TO,O
placebo,NN,O
.,.,.
,,
the,DT,O
elimination,NN,O
half,NN,O
life,NN,O
of,IN,O
midazolam,NN,D
and,CC,O
triazolam,NN,D
also,RB,O
increased,VBD,O
-lrb-,-LRB-,O
1.5-2,CD,O
0.5,CD,O
fold,NN,O
-rrb-,-RRB-,O
during,IN,O
coadministration,NN,O
with,IN,O
diltiazem,NN,D
.,.,.
,,
these,DT,O
pharmacokinetic,JJ,O
effects,NNS,O
seen,VBN,O
during,IN,O
diltiazem,NN,D
coadministration,NN,O
can,MD,O
result,VB,O
in,IN,O
increased,VBN,O
clinical,JJ,O
effects,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
prolonged,JJ,O
sodation,NN,O
-rrb-,-RRB-,O
of,IN,O
both,DT,O
midazolam,NN,D
and,CC,O
triazolam,NN,D
.,.,.
,,
lovastati,NNP,O
.,.,.
,,
in,IN,O
a,DT,O
ten-subject,JJ,O
study,NN,O
",",",",O
coadministration,NN,O
of,IN,O
diltiazem,NN,D
-lrb-,-LRB-,O
120,CD,O
mg,NN,O
bid,NN,O
-rrb-,-RRB-,O
with,IN,O
lovastatin,NN,D
resulted,VBD,O
in,IN,O
a,DT,O
4-Mar,CD,O
times,NNS,O
increase,VBP,O
in,IN,O
mean,JJ,O
lovastatin,NN,D
auc,NN,O
and,CC,O
cmax,NN,O
vs.,CC,O
lovastatin,NN,D
alone,RB,O
.,.,.
,,
no,DT,O
change,NN,O
in,IN,O
pravastatin,NN,D
auc,NN,O
and,CC,O
cmax,NN,O
was,VBD,O
observed,VBN,O
during,IN,O
diltiazem,NN,D
coadministration,NN,O
.,.,.
,,
diltiazem,NNP,D
plasma,NN,O
levels,NNS,O
were,VBD,O
not,RB,O
significantly,RB,O
affected,VBN,O
by,IN,O
lovastatin,NN,D
or,CC,O
pravastatin,NN,D
.,.,.
,,
rifampi,NNP,O
.,.,.
,,
coadministration,NN,O
of,IN,O
rifampin,NN,D
with,IN,O
diltiazem,NN,D
lowered,VBD,O
the,DT,O
diltiazem,NN,D
plasma,NN,O
concentrations,NNS,O
to,TO,O
undetectable,JJ,O
levels,NNS,O
.,.,.
,,
coadministration,NN,O
of,IN,O
diltiazem,NN,D
with,IN,O
rifampin,NN,D
or,CC,O
any,DT,O
known,JJ,O
cyp3a4,NN,D
inducer,NN,O
should,MD,O
be,VB,O
avoided,VBN,O
when,WRB,O
possible,JJ,O
",",",",O
and,CC,O
alternative,JJ,O
therapy,NN,O
considered,VBN,O
.,.,.
,,
dimenhydrinate,NNP,D
may,MD,O
decrease,VB,O
emetic,JJ,G
response,NN,O
to,TO,O
apomorphine,NN,D
.,.,.
,,
oxytocin,NN,D
or,CC,O
other,JJ,O
oxytocics,NNS,G
-lrb-,-LRB-,O
concurrent,JJ,O
use,NN,O
with,IN,O
dinoprost,NN,D
may,MD,O
result,VB,O
in,IN,O
uterine,JJ,O
hypertonus,NN,O
",",",",O
possibly,RB,O
causing,VBG,O
uterine,JJ,O
rupture,NN,O
or,CC,O
cervical,JJ,O
laceration,NN,O
",",",",O
especially,RB,O
in,IN,O
the,DT,O
absence,NN,O
of,IN,O
adequate,JJ,O
cervical,JJ,O
dilatation,NN,O
.,.,.
,,
although,IN,O
combinations,NNS,O
are,VBP,O
sometimes,RB,O
used,VBN,O
for,IN,O
therapeutic,JJ,O
advantage,NN,O
",",",",O
when,WRB,O
used,VBN,O
concurrently,RB,O
",",",",O
patient,NN,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
.,.,.
,,
prostin,NNP,O
e2,NN,O
may,MD,O
augment,VB,O
the,DT,O
activity,NN,O
of,IN,O
other,JJ,O
oxytocic,JJ,O
drugs,NNS,D
.,.,.
,,
concomitant,JJ,O
use,NN,O
with,IN,O
other,JJ,O
oxytocic,JJ,O
agents,NNS,O
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
diphenhydramine,NN,D
hydrochloride,NN,O
has,VBZ,O
additive,JJ,O
effects,NNS,O
with,IN,O
alcohol,NN,D
and,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
-lrb-,-LRB-,O
hypnotics,NNS,G
",",",",O
sedatives,NNS,G
",",",",O
tranquilizers,NNS,G
",",",",O
etc,FW,O
-rrb-,-RRB-,O
.,.,.
,,
mao,NN,O
inhibitors,NNS,O
prolong,VB,O
and,CC,O
intensify,VB,O
the,DT,O
anticholinergic,JJ,G
-lrb-,-LRB-,O
drying,VBG,O
-rrb-,-RRB-,O
effects,NNS,O
of,IN,O
antihistamines,NNS,G
.,.,.
,,
cns,NN,O
depression,NN,O
producing,VBG,O
medications,NNS,O
-,:,O
concurrent,JJ,O
use,NN,O
may,MD,O
potentiate,VB,O
the,DT,O
effects,NNS,O
of,IN,O
either,CC,O
these,DT,O
medications,NNS,O
or,CC,O
diphenidol,NN,D
.,.,.
,,
anticholinergics,NNS,G
or,CC,O
other,JJ,O
medications,NNS,O
with,IN,O
anticholinergic,JJ,G
activity,NN,O
-,:,O
anticholinergic,JJ,G
effects,NNS,O
may,MD,O
be,VB,O
potentiated,VBN,O
when,WRB,O
these,DT,O
medications,NNS,O
are,VBP,O
used,VBN,O
concurrently,RB,O
with,IN,O
diphenidol,NN,D
.,.,.
,,
apomorphine,NN,D
-,:,O
prior,RB,O
ingestion,NN,O
of,IN,O
diphenidol,NN,D
may,MD,O
decrease,VB,O
the,DT,O
emetic,JJ,G
response,NN,O
to,TO,O
apomorphine,NN,D
in,IN,O
the,DT,O
treatment,NN,O
of,IN,O
poisoning,NN,O
.,.,.
,,
known,VBN,O
drug,NN,D
interactions,NNS,O
include,VBP,O
barbiturates,NNS,G
",",",",O
tranquilizers,NNS,G
",",",",O
and,CC,O
alcohol,NN,D
.,.,.
,,
diphenoxylate,NNP,O
hcl,NN,O
and,CC,O
atropine,NN,D
sulfate,NN,O
may,MD,O
interact,VB,O
with,IN,O
mao,NN,O
inhibitors,NNS,O
in,IN,O
studies,NNS,O
with,IN,O
male,JJ,O
rats,NNS,O
",",",",O
diphenoxylate,NN,D
hydrochloride,NN,O
was,VBD,O
found,VBN,O
to,TO,O
inhibit,VB,O
the,DT,O
hepatic,JJ,O
microsomal,JJ,O
enzyme,NN,O
system,NN,O
at,IN,O
a,DT,O
dose,NN,O
of,IN,O
2,CD,O
mg/kg/day,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
diphenoxylate,NN,D
has,VBZ,O
the,DT,O
potential,JJ,O
to,TO,O
prolong,VB,O
the,DT,O
biological,JJ,O
half-lives,NNS,O
of,IN,O
drugs,NNS,D
for,IN,O
which,WDT,O
the,DT,O
rate,NN,O
of,IN,O
elimination,NN,O
is,VBZ,O
dependent,JJ,O
on,IN,O
the,DT,O
microsomal,JJ,O
drug,NN,D
metabolizing,VBG,O
enzyme,NN,O
system,NN,O
.,.,.
,,
this,DT,O
drug,NN,D
may,MD,O
interact,VB,O
with,IN,O
alcohol,NN,D
or,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
-lrb-,-LRB-,O
may,MD,O
potentiate,VB,O
the,DT,O
cns,NN,O
depressant,NN,O
effects,NNS,O
of,IN,O
either,CC,O
these,DT,O
medications,NNS,O
or,CC,O
antihistamines,NNS,G
-rrb-,-RRB-,O
",",",",O
anticholinergics,NNS,G
or,CC,O
other,JJ,O
medications,NNS,O
with,IN,O
anticholinergic,JJ,G
activity,NN,O
-lrb-,-LRB-,O
anticholinergic,JJ,G
effects,NNS,O
may,MD,O
be,VB,O
potentiated,VBN,O
when,WRB,O
these,DT,O
medications,NNS,O
are,VBP,O
used,VBN,O
concurrently,RB,O
with,IN,O
antihistamines,NNS,G
-rrb-,-RRB-,O
",",",",O
and,CC,O
monoamine,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
mao,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
-lrb-,-LRB-,O
concurrent,JJ,O
use,NN,O
with,IN,O
antihistamines,NNS,G
may,MD,O
prolong,VB,O
and,CC,O
intensify,VB,O
the,DT,O
anticholinergic,JJ,G
and,CC,O
cns,NN,O
depressant,NN,O
effects,NNS,O
of,IN,O
antihistamines,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
no,DT,O
pharmacokinetic,JJ,O
drug-drug,NN,O
interaction,NN,O
studies,NNS,O
were,VBD,O
conducted,VBN,O
with,IN,O
persantine,NN,B
-lrb-,-LRB-,O
dipyridamole,NN,D
usp,NN,O
-rrb-,-RRB-,O
tablets,NNS,O
.,.,.
,,
the,DT,O
following,VBG,O
information,NN,O
was,VBD,O
obtained,VBN,O
from,IN,O
the,DT,O
literature,NN,O
.,.,.
,,
adenosine,NN,D
:,:,O
dipyridamole,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
increase,VB,O
the,DT,O
plasma,NN,O
levels,NNS,O
and,CC,O
cardiovascular,JJ,O
effects,NNS,O
of,IN,O
adenosine,NN,D
.,.,.
,,
adjustment,NNP,O
of,IN,O
adenosine,NN,D
dosage,NN,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
cholinesterase,NNP,O
inhibitors,NNS,O
:,:,O
dipyridamole,NNP,D
may,MD,O
counteract,VB,O
the,DT,O
anticholinesterase,NN,G
effect,NN,O
of,IN,O
cholinesterase,NN,O
inhibitors,NNS,O
",",",",O
thereby,RB,O
potentially,RB,O
aggravating,JJ,O
myasthenia,NN,O
gravis,NN,O
.,.,.
,,
terfenadine,NNP,D
:,:,O
in,IN,O
a,DT,O
prospective,JJ,O
study,NN,O
involving,VBG,O
six-healthy-male,JJ,O
volunteers,NNS,O
",",",",O
dirithromycin,NN,D
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
terfenadine,NN,D
.,.,.
,,
these,DT,O
six,CD,O
volunteers,NNS,O
received,VBD,O
terfenadine,NN,D
alone,RB,O
-lrb-,-LRB-,O
60,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
-rrb-,-RRB-,O
for,IN,O
8,CD,O
days,NNS,O
",",",",O
followed,VBN,O
by,IN,O
terfenadine,NN,D
in,IN,O
combination,NN,O
with,IN,O
dirithromycin,NN,D
-lrb-,-LRB-,O
500,CD,O
mg,NN,O
once,RB,O
daily,JJ,O
-rrb-,-RRB-,O
for,IN,O
10,CD,O
days,NNS,O
.,.,.
,,
-lrb-,-LRB-,O
both,CC,O
drugs,NNS,D
were,VBD,O
thus,RB,O
dosed,VBN,O
to,TO,O
steady,JJ,O
state,NN,O
.,.,.
,,
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
terfenadine,NN,D
and,CC,O
its,PRP$,O
acid,NN,O
metabolite,NN,O
and,CC,O
the,DT,O
electrocardiographic,JJ,O
qt,NN,O
c,NN,O
interval,NN,O
were,VBD,O
measured,VBN,O
during,IN,O
both,DT,O
periods,NNS,O
:,:,O
with,IN,O
terfenadine,NN,D
alone,RB,O
",",",",O
and,CC,O
with,IN,O
terfenadine,NN,D
plus,CC,O
dirithromycin,NN,D
.,.,.
,,
in,IN,O
five,CD,O
men,NNS,O
",",",",O
terfenadine,NN,D
levels,NNS,O
were,VBD,O
undetectable,JJ,O
-lrb-,-LRB-,O
5,CD,O
ng/ml,NN,O
-rrb-,-RRB-,O
throughout,IN,O
the,DT,O
study,NN,O
.,.,.
,,
in,IN,O
one,CD,O
man,NN,O
",",",",O
the,DT,O
c,NN,O
max,NN,O
of,IN,O
terfenadine,NN,D
was,VBD,O
8.1,CD,O
ng/ml,NN,O
with,IN,O
terfenadine,NN,D
alone,RB,O
and,CC,O
7.2,CD,O
ng/ml,NN,O
with,IN,O
terfenadine,NN,D
plus,CC,O
dirithromycin,NN,D
.,.,.
,,
the,DT,O
mean,NN,O
c,NN,O
max,NN,O
",",",",O
t,NN,O
max,NN,O
",",",",O
and,CC,O
auc,NN,O
of,IN,O
the,DT,O
acid,NN,O
metabolite,NN,O
of,IN,O
terfenadine,NN,D
were,VBD,O
not,RB,O
significantly,RB,O
changed,VBD,O
.,.,.
,,
the,DT,O
mean,NN,O
qt,NN,O
c,NN,O
interval,NN,O
-lrb-,-LRB-,O
msec,NN,O
-rrb-,-RRB-,O
was,VBD,O
369,CD,O
with,IN,O
terfenadine,NN,D
alone,RB,O
and,CC,O
367,CD,O
with,IN,O
terfenadine,NN,D
plus,CC,O
dirithromycin,NN,D
.,.,.
,,
also,RB,O
",",",",O
in,FW,O
vitro,FW,O
experiments,NNS,O
demonstrated,VBD,O
a,DT,O
lack,NN,O
of,IN,O
interaction,NN,O
between,IN,O
dirithromycin,NN,D
and,CC,O
terfenadine,NN,D
.,.,.
,,
thus,RB,O
",",",",O
the,DT,O
interaction,NN,O
observed,VBN,O
between,IN,O
erythromycin,NN,D
and,CC,O
terfenadine,NN,D
is,VBZ,O
not,RB,O
expected,VBN,O
for,IN,O
dirithromycin,NN,D
.,.,.
,,
serious,JJ,O
cardiac,JJ,O
dysrhythmias,NNS,O
",",",",O
some,DT,O
resulting,VBG,O
in,IN,O
death,NN,O
",",",",O
have,VBP,O
occurred,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
terfenadine,NN,D
concomitantly,RB,O
with,IN,O
other,JJ,O
macrolide,NN,O
antibiotics,NNS,G
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
most,JJS,O
macrolides,NNS,G
are,VBP,O
contraindicated,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
terfenadine,NN,D
therapy,NN,O
who,WP,O
have,VBP,O
pre-existing,JJ,O
cardiac,JJ,O
abnormalities,NNS,O
-lrb-,-LRB-,O
arrhythmia,NN,O
",",",",O
bradycardia,NN,O
",",",",O
qt,NN,O
c,NN,O
interval,NN,O
prolongation,NN,O
",",",",O
ischemic,JJ,O
heart,NN,O
disease,NN,O
",",",",O
congestive,JJ,O
heart,NN,O
failure,NN,O
",",",",O
etc.,FW,O
-rrb-,-RRB-,O
or,CC,O
electrolyte,NN,O
disturbances,NNS,O
.,.,.
,,
theophylline,NNP,D
:,:,O
following,VBG,O
co-administration,NN,O
of,IN,O
two,CD,O
250-mg,JJ,O
dirithromycin,NN,D
tablets,NNS,O
administered,VBN,O
once,RB,O
daily,RB,O
with,IN,O
200-mg,JJ,O
theophylline,NN,D
tablets,NNS,O
administered,VBN,O
twice,RB,O
daily,RB,O
for,IN,O
10,CD,O
days,NNS,O
to,TO,O
14,CD,O
healthy,JJ,O
subjects,NNS,O
",",",",O
the,DT,O
steady-state,JJ,O
plasma,NN,O
concentration,NN,O
of,IN,O
theophylline,NN,D
was,VBD,O
not,RB,O
significantly,RB,O
altered,VBN,O
.,.,.
,,
in,IN,O
general,JJ,O
",",",",O
most,JJS,O
patients,NNS,O
treated,VBN,O
with,IN,O
dirithromycin,NN,D
who,WP,O
are,VBP,O
receiving,VBG,O
concomitant,JJ,O
theophylline,NN,D
therapy,NN,O
may,MD,O
not,RB,O
require,VB,O
empiric,JJ,O
adjustment,NN,O
of,IN,O
theophylline,NN,D
dosage,NN,O
or,CC,O
monitoring,NN,O
of,IN,O
theophylline,NN,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
however,RB,O
",",",",O
theophylline,NN,D
plasma,NN,O
concentrations,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
",",",",O
with,IN,O
dosage,NN,O
adjustment,NN,O
as,IN,O
appropriate,JJ,O
",",",",O
in,IN,O
patients,NNS,O
whose,WP$,O
pulmonary,JJ,O
disease,NN,O
requires,VBZ,O
maintaining,VBG,O
a,DT,O
given,VBN,O
theophylline,NN,D
plasma,NN,O
concentration,NN,O
for,IN,O
optimal,JJ,O
pulmonary,JJ,O
function,NN,O
or,CC,O
in,IN,O
patients,NNS,O
with,IN,O
theophylline,NN,D
concentrations,NNS,O
at,IN,O
the,DT,O
higher,JJR,O
end,NN,O
of,IN,O
the,DT,O
therapeutic,JJ,O
range,NN,O
.,.,.
,,
antacids,NNS,G
or,CC,O
h,NN,O
2,CD,O
receptor,NN,D
antagonists,NNS,O
:,:,O
when,WRB,O
dirithromycin,NN,D
is,VBZ,O
administered,VBN,O
immediately,RB,O
following,VBG,O
antacids,NNS,G
or,CC,O
h,NN,O
2,CD,O
-,:,O
receptor,NN,D
antagonists,NNS,O
",",",",O
the,DT,O
absorption,NN,O
of,IN,O
dirithromycin,NN,D
is,VBZ,O
slightly,RB,O
enhanced,VBN,O
.,.,.
,,
the,DT,O
following,VBG,O
drug,NN,D
interactions,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
erythromycin,NN,D
products,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
presently,RB,O
not,RB,O
known,VBN,O
whether,IN,O
these,DT,O
same,JJ,O
drug,NN,D
interactions,NNS,O
occur,VBP,O
with,IN,O
dirithromycin,NN,D
.,.,.
,,
until,IN,O
further,JJ,O
data,NNS,O
are,VBP,O
available,JJ,O
regarding,VBG,O
the,DT,O
potential,JJ,O
interaction,NN,O
of,IN,O
dirithromycin,NN,D
with,IN,O
these,DT,O
compounds,NNS,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
during,IN,O
coadministration,NN,O
.,.,.
,,
triazolam,NNP,D
:,:,O
erythromycin,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
decrease,VB,O
the,DT,O
clearance,NN,O
of,IN,O
triazolam,NN,D
and,CC,O
",",",",O
thus,RB,O
",",",",O
may,MD,O
increase,VB,O
the,DT,O
pharmacologic,JJ,O
effect,NN,O
of,IN,O
triazolam,NN,D
.,.,.
,,
digoxin,NNP,D
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
erythromycin,NN,D
and,CC,O
digoxin,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
result,VB,O
in,IN,O
elevated,JJ,O
digoxin,NN,D
serum,NN,O
levels,NNS,O
.,.,.
,,
anticoagulants,NNPS,G
:,:,O
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
increased,VBN,O
anticoagulant,JJ,G
effects,NNS,O
when,WRB,O
erythromycin,NN,D
and,CC,O
oral,JJ,O
anticoagulants,NNS,G
were,VBD,O
used,VBN,O
concomitantly,RB,O
.,.,.
,,
increased,VBN,O
anticoagulation,JJ,O
effects,NNS,O
due,JJ,O
to,TO,O
a,DT,O
drug,NN,D
interaction,NN,O
with,IN,O
erythromycin,NN,D
may,MD,O
be,VB,O
more,RBR,O
pronounced,JJ,O
in,IN,O
the,DT,O
elderly,JJ,O
.,.,.
,,
ergotamine,NNP,D
:,:,O
concurrent,JJ,O
use,NN,O
of,IN,O
erythromycin,NN,D
and,CC,O
ergotamine,NN,D
or,CC,O
dihydroergotamine,NN,D
has,VBZ,O
been,VBN,O
associated,VBN,O
in,IN,O
some,DT,O
patients,NNS,O
with,IN,O
acute,JJ,O
ergot,NN,G
toxicity,NN,O
characterized,VBN,O
by,IN,O
severe,JJ,O
peripheral,JJ,O
vasospasm,NN,O
and,CC,O
dysesthesia,NN,O
.,.,.
,,
other,JJ,O
drugs,NNS,D
drug,NN,O
interactions,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
erythromycin,NN,D
and,CC,O
other,JJ,O
medications,NNS,O
",",",",O
including,VBG,O
cyclosporine,NN,D
",",",",O
hexobarbital,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
alfentanil,NN,D
",",",",O
disopyramide,NN,D
",",",",O
phenytoin,NN,D
",",",",O
bromocriptine,NN,D
",",",",O
valproate,NN,D
",",",",O
astemizole,NN,D
",",",",O
and,CC,O
lovastatin,NN,D
.,.,.
,,
if,IN,O
phenytoin,NN,D
or,CC,O
other,JJ,O
hepatic,JJ,O
enzyme,NN,O
inducers,NNS,O
are,VBP,O
taken,VBN,O
concurrently,RB,O
with,IN,O
norpace,NNP,B
or,CC,O
norpace,NNP,B
cr,NN,O
",",",",O
lower,JJR,O
plasma,NN,O
levels,NNS,O
of,IN,O
disopyramide,NN,D
may,MD,O
occur,VB,O
.,.,.
,,
monitoring,NN,O
of,IN,O
disopyramide,NN,D
plasma,NN,O
levels,NNS,O
is,VBZ,O
recommended,VBN,O
in,IN,O
such,JJ,O
concurrent,JJ,O
use,NN,O
to,TO,O
avoid,VB,O
ineffective,JJ,O
therapy,NN,O
.,.,.
,,
other,JJ,O
antiarrhythmic,JJ,D
drugs,NNS,D
-lrb-,-LRB-,O
eg,FW,O
",",",",O
quinidine,NN,D
",",",",O
procainamide,NN,D
",",",",O
lidocaine,NN,D
",",",",O
propranolol,NN,D
-rrb-,-RRB-,O
have,VBP,O
occasionally,RB,O
been,VBN,O
used,VBN,O
concurrently,RB,O
with,IN,O
norpace,NNP,B
.,.,.
,,
excessive,JJ,O
widening,NN,O
of,IN,O
the,DT,O
qrs,NNP,O
complex,NN,O
and/or,CC,O
prolongation,NN,O
of,IN,O
the,DT,O
q-t,JJ,O
interval,NN,O
may,MD,O
occur,VB,O
in,IN,O
these,DT,O
situations,NNS,O
.,.,.
,,
in,IN,O
healthy,JJ,O
subjects,NNS,O
",",",",O
no,DT,O
significant,JJ,O
drug-drug,JJ,O
interaction,NN,O
was,VBD,O
observed,VBN,O
when,WRB,O
norpace,NNP,B
was,VBD,O
coadministered,VBN,O
with,IN,O
either,CC,O
propranolol,NN,D
or,CC,O
diazepam,NN,D
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
norpace,NNP,B
and,CC,O
quinidine,NN,D
resulted,VBD,O
in,IN,O
slight,JJ,O
increases,NNS,O
in,IN,O
plasma,NN,O
disopyramide,NN,D
levels,NNS,O
and,CC,O
slight,JJ,O
decreases,NNS,O
in,IN,O
plasma,NN,O
quinidine,NN,D
levels,NNS,O
.,.,.
,,
norpace,NNP,B
does,VBZ,O
not,RB,O
increase,VB,O
serum,NN,O
digoxin,NN,D
levels,NNS,O
.,.,.
,,
patients,NNS,O
taking,VBG,O
disopyramide,JJ,D
phosphate,NN,D
and,CC,O
erythromycin,NN,D
concomitantly,RB,O
may,MD,O
develop,VB,O
increased,VBN,O
serum,NN,O
concentrations,NNS,O
of,IN,O
disopyramide,NN,D
resulting,VBG,O
in,IN,O
excessive,JJ,O
widening,NN,O
of,IN,O
the,DT,O
qrs,NNP,O
complex,NN,O
and/or,CC,O
prolongation,NN,O
of,IN,O
the,DT,O
q-t,JJ,O
interval,NN,O
.,.,.
,,
patients,NNS,O
taking,VBG,O
disopyramide,JJ,D
phosphate,NN,D
and,CC,O
hepatic,JJ,O
enzyme,NN,O
inhibitors,NNS,O
concomitantly,RB,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
.,.,.
,,
until,IN,O
data,NNS,O
on,IN,O
possible,JJ,O
interactions,NNS,O
between,IN,O
verapamil,NN,D
and,CC,O
disopyramide,NN,D
phosphate,NN,D
are,VBP,O
obtained,VBN,O
",",",",O
disopyramide,NN,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
within,IN,O
48,CD,O
hours,NNS,O
before,IN,O
or,CC,O
24,CD,O
hours,NNS,O
after,IN,O
verapamil,NN,D
administration,NN,O
.,.,.
,,
disulfiram,NNP,D
appears,VBZ,O
to,TO,O
decrease,VB,O
the,DT,O
rate,NN,O
at,IN,O
which,WDT,O
certain,JJ,O
drugs,NNS,D
are,VBP,O
metabolized,VBN,O
and,CC,O
therefore,RB,O
may,MD,O
increase,VB,O
the,DT,O
blood,NN,O
levels,NNS,O
and,CC,O
the,DT,O
possibility,NN,O
of,IN,O
clinical,JJ,O
toxicity,NN,O
of,IN,O
drugs,NNS,D
given,VBN,O
concomitantly,RB,O
.,.,.
,,
disulfiram,NNP,D
should,MD,O
be,VB,O
used,JJ,O
with,IN,O
caution,NN,O
in,IN,O
those,DT,O
patients,NNS,O
reveiving,VBG,O
phenytoin,NN,D
and,CC,O
its,NNS,O
congeners,NNS,O
.,.,.
,,
since,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
these,NN,O
two,CD,O
drugs,NNS,O
can,JJ,O
lead,NN,O
to,TO,O
phenytoin,NNP,D
intoxication,NNP,O
",",",",O
prior,NNP,O
to,TO,O
administering,NNP,O
disulfiram,NNP,D
to,TO,O
a,DT,O
patient,NN,O
on,IN,O
phenytoin,NNP,D
therapy,NNP,O
",",",",O
a,NNP,O
baseline,NNP,O
phenytoin,NNP,D
serum,NNP,O
level,NNP,O
should,MD,O
be,VB,O
obtained,NNP,O
.,.,.
,,
subsequent,JJ,O
to,TO,O
initiation,NNP,O
of,IN,O
disulfiram,NNP,D
therapy,NNP,O
.,.,.
,,
serum,NN,O
levels,NNS,O
of,IN,O
phenytoin,NNP,D
should,MD,O
be,VB,O
determined,VBN,O
on,IN,O
different,JJ,O
days,NNS,O
for,IN,O
evidence,NNS,O
of,IN,O
an,DT,O
increase,NN,O
or,NN,O
for,IN,O
a,DT,O
continuing,NNP,O
rise,NNP,O
in,IN,O
levels,NNP,O
.,.,.
,,
increased,VBN,O
phenytoin,NNP,D
levels,NNP,O
should,MD,O
be,VB,O
treated,VBN,O
with,IN,O
appropriate,JJ,O
dosage,NN,O
adjustment,NN,O
.,.,.
,,
it,PRP,O
may,MD,O
be,VB,O
necessary,JJ,O
to,TO,O
adjust,VB,O
the,DT,O
dosage,NN,O
of,IN,O
oral,JJ,O
anticoagulants,NNS,G
upon,IN,O
beginning,VBG,O
or,CC,O
stopping,VBG,O
disulfiram,NN,D
.,.,.
,,
since,IN,O
disulfiram,NN,D
may,MD,O
prolong,VB,O
prothrombin,NN,O
time,NN,O
.,.,.
,,
patients,NNS,O
taking,VBG,O
isoniazid,NN,D
when,WRB,O
disulfiram,NN,D
is,VBZ,O
given,VBN,O
should,MD,O
be,VB,O
observed,VBN,O
for,IN,O
the,DT,O
appearance,NN,O
of,IN,O
unsteady,JJ,O
gait,NN,O
or,CC,O
marked,JJ,O
changes,NNS,O
in,IN,O
mental,JJ,O
status,NN,O
.,.,.
,,
the,DT,O
disulfiram,NN,D
should,MD,O
be,VB,O
discontinued,VBN,O
if,IN,O
such,JJ,O
signs,NNS,O
appear,VBP,O
.,.,.
,,
in,IN,O
rats,NNS,O
",",",",O
simultaneous,JJ,O
ingestion,NN,O
of,IN,O
disulfiram,NN,D
and,CC,O
nitrite,NN,D
in,IN,O
the,DT,O
diet,NN,O
for,IN,O
78,CD,O
weeks,NNS,O
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
cause,VB,O
tumors,NNS,O
",",",",O
and,CC,O
it,PRP,O
has,VBZ,O
been,VBN,O
suggested,VBN,O
that,IN,O
disulfiram,NN,D
may,MD,O
react,VB,O
with,IN,O
nitrites,NNS,G
in,IN,O
the,DT,O
rat,NN,O
stomach,NN,O
to,TO,O
form,VB,O
a,DT,O
nitrosamine,NN,O
",",",",O
which,WDT,O
is,VBZ,O
tumorigenic,JJ,O
.,.,.
,,
disulfiram,NNP,D
alone,RB,O
in,IN,O
the,DT,O
rat,NN,O
s,VBZ,O
diet,NN,O
did,VBD,O
not,RB,O
lead,VB,O
to,TO,O
such,JJ,O
tumors,NNS,O
.,.,.
,,
the,DT,O
relevance,NN,O
of,IN,O
this,DT,O
finding,NN,O
to,TO,O
humans,NNS,O
is,VBZ,O
not,RB,O
known,VBN,O
at,IN,O
this,DT,O
time,NN,O
.,.,.
,,
animal,NN,O
studies,NNS,O
indicate,VBP,O
that,IN,O
dobutamine,NN,D
may,MD,O
be,VB,O
ineffective,JJ,O
if,IN,O
the,DT,O
patient,NN,O
has,VBZ,O
recently,RB,O
received,VBN,O
a,DT,O
b-blocking,NN,O
drug,NN,D
.,.,.
,,
in,IN,O
such,PDT,O
a,DT,O
case,NN,O
",",",",O
the,DT,O
peripheral,JJ,O
vascular,JJ,O
resistance,NN,O
may,MD,O
increase,VB,O
.,.,.
,,
preliminary,JJ,O
studies,NNS,O
indicate,VBP,O
that,IN,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
dobutamine,NN,D
and,CC,O
nitroprusside,JJ,D
results,NNS,O
in,IN,O
a,DT,O
higher,JJR,O
cardiac,JJ,O
output,NN,O
and,CC,O
",",",",O
usually,RB,O
",",",",O
a,DT,O
lower,JJR,O
pulmonary,JJ,O
wedge,NN,O
pressure,NN,O
than,IN,O
when,WRB,O
either,CC,O
drug,NN,D
is,VBZ,O
used,VBN,O
alone,RB,O
.,.,.
,,
there,EX,O
was,VBD,O
no,DT,O
evidence,NN,O
of,IN,O
drug,NN,D
interactions,NNS,O
in,IN,O
clinical,JJ,O
studies,NNS,O
in,IN,O
which,WDT,O
dobutamine,NN,D
was,VBD,O
administered,VBN,O
concurrently,RB,O
with,IN,O
other,JJ,O
drugs,NNS,D
",",",",O
including,VBG,O
digitalis,NN,G
preparations,NNS,O
",",",",O
furosemide,NN,D
",",",",O
spironolactone,NN,D
",",",",O
lidocaine,NN,D
",",",",O
glyceryl,NN,O
trinitrate,NN,O
",",",",O
isosorbide,NN,O
dinitrate,NN,O
",",",",O
morphine,NN,D
",",",",O
atropine,NN,D
",",",",O
heparin,NN,D
",",",",O
protamine,NN,D
",",",",O
potassium,NN,D
chloride,NN,O
",",",",O
folic,JJ,O
acid,NN,O
",",",",O
and,CC,O
acetaminophen,NN,D
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
no,DT,O
formal,JJ,O
clinical,JJ,O
studies,NNS,O
to,TO,O
evaluate,VB,O
the,DT,O
drug,NN,D
interactions,NNS,O
of,IN,O
taxotere,NN,B
with,IN,O
other,JJ,O
medications,NNS,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
docetaxel,NN,D
may,MD,O
be,VB,O
modified,VBN,O
by,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
compounds,NNS,O
that,WDT,O
induce,VBP,O
",",",",O
inhibit,VBP,O
",",",",O
or,CC,O
are,VBP,O
metabolized,VBN,O
by,IN,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
",",",",O
such,JJ,O
as,IN,O
cyclosporine,NN,D
",",",",O
terfenadine,NN,D
",",",",O
ketoconazole,NN,D
",",",",O
erythromycin,NN,D
",",",",O
and,CC,O
troleandomycin,NN,D
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
with,IN,O
these,DT,O
drugs,NNS,D
when,WRB,O
treating,VBG,O
patients,NNS,O
receiving,VBG,O
taxotere,NN,B
as,IN,O
there,EX,O
is,VBZ,O
a,DT,O
potential,NN,O
for,IN,O
a,DT,O
significant,JJ,O
interaction,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
none,NN,O
known,VBN,O
.,.,.
,,
drug-drug,NNP,O
interactions,NNS,O
cimetidine,NNP,D
:,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
cimetidine,NN,D
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
cimetidine,NN,D
at,IN,O
400,CD,O
mg,NN,O
bid,NNP,O
-lrb-,-LRB-,O
the,DT,O
usual,JJ,O
prescription,NN,O
dose,NN,O
-rrb-,-RRB-,O
co-administered,JJ,O
with,IN,O
tikosyn,NN,B
-lrb-,-LRB-,O
500,CD,O
mcg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
for,IN,O
7,CD,O
days,NNS,O
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
increase,VB,O
dofetilide,NN,D
plasma,NN,O
levels,NNS,O
by,IN,O
58,CD,O
%,NN,O
.,.,.
,,
cimetidine,NN,D
at,IN,O
doses,NNS,O
of,IN,O
100,CD,O
mg,NN,O
bid,NNP,O
-lrb-,-LRB-,O
otc,NNP,O
dose,NN,O
-rrb-,-RRB-,O
resulted,VBD,O
in,IN,O
a,DT,O
13,CD,O
%,NN,O
increase,NN,O
in,IN,O
dofetilide,NN,D
plasma,NN,O
levels,NNS,O
-lrb-,-LRB-,O
500,CD,O
mcg,NN,O
single,JJ,O
dose,NN,O
-rrb-,-RRB-,O
.,.,.
,,
no,DT,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
at,IN,O
intermediate,JJ,O
doses,NNS,O
of,IN,O
cimetidine,NN,D
.,.,.
,,
if,IN,O
a,DT,O
patient,NN,O
requires,VBZ,O
tikosyn,NNP,B
and,CC,O
anti-ulcer,JJ,G
therapy,NN,O
",",",",O
it,PRP,O
is,VBZ,O
suggested,VBN,O
that,IN,O
omeprazole,NN,D
",",",",O
ranitidine,NN,D
",",",",O
or,CC,O
antacids,NNS,G
-lrb-,-LRB-,O
aluminum,NN,D
and,CC,O
magnesium,NN,D
hydroxides,NNS,O
-rrb-,-RRB-,O
be,VB,O
used,VBN,O
as,IN,O
alternatives,NNS,O
to,TO,O
cimetidine,NN,D
",",",",O
as,IN,O
these,DT,O
agents,NNS,O
have,VBP,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetic,JJ,O
profile,NN,O
of,IN,O
tikosyn,NNP,B
.,.,.
,,
verapamil,NNP,D
:,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
verapamil,NN,D
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
co-administration,NN,O
of,IN,O
tikosyn,NN,B
with,IN,O
verapamil,NN,D
resulted,VBD,O
in,IN,O
increases,NNS,O
in,IN,O
dofetilide,NN,D
peak,NN,O
plasma,NN,O
levels,NNS,O
of,IN,O
42,CD,O
%,NN,O
",",",",O
although,IN,O
overall,JJ,O
exposure,NN,O
to,TO,O
dofetilide,NN,D
was,VBD,O
not,RB,O
significantly,RB,O
increased,VBN,O
.,.,.
,,
in,IN,O
an,DT,O
analysis,NN,O
of,IN,O
the,DT,O
supraventricular,JJ,O
arrhythmia,NN,O
and,CC,O
diamond,NN,O
patient,NN,O
populations,NNS,O
",",",",O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
verapamil,NN,D
with,IN,O
dofetilide,NN,D
was,VBD,O
associated,VBN,O
with,IN,O
a,DT,O
higher,JJR,O
occurrence,NN,O
of,IN,O
torsade,FW,O
de,FW,O
pointes,FW,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
ketoconazole,NN,D
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
ketoconazole,NN,D
at,IN,O
400,CD,O
mg,NN,O
daily,JJ,O
-lrb-,-LRB-,O
the,DT,O
maximum,NN,O
approved,VBD,O
prescription,NN,O
dose,NN,O
-rrb-,-RRB-,O
co-administered,JJ,O
with,IN,O
tikosyn,NN,B
-lrb-,-LRB-,O
500,CD,O
mcg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
for,IN,O
7,CD,O
days,NNS,O
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
increase,VB,O
dofetilide,NN,D
cmax,NN,O
by,IN,O
53,CD,O
%,NN,O
in,IN,O
males,NNS,O
and,CC,O
97,CD,O
%,NN,O
in,IN,O
females,NNS,O
",",",",O
and,CC,O
auc,NN,O
by,IN,O
41,CD,O
%,NN,O
in,IN,O
males,NNS,O
and,CC,O
69,CD,O
%,NN,O
in,IN,O
females,NNS,O
.,.,.
,,
trimethoprim,NNP,D
alone,RB,O
or,CC,O
in,IN,O
combination,NN,O
with,IN,O
sulfamethoxazole,NNP,D
:,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
trimethoprim,NN,D
alone,RB,O
or,CC,O
in,IN,O
combination,NN,O
with,IN,O
sulfamethoxazole,NN,D
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
hydrochlorothiazide,NN,D
-lrb-,-LRB-,O
hctz,NN,D
-rrb-,-RRB-,O
alone,RB,O
or,CC,O
in,IN,O
combination,NN,O
with,IN,O
triamterene,NN,D
:,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
hctz,NN,D
alone,RB,O
or,CC,O
in,IN,O
combination,NN,O
with,IN,O
triamterene,NN,D
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
hctz,NN,D
50,CD,O
mg,NN,O
qd,NN,O
or,CC,O
hctz/triamterene,NN,O
50/100,CD,O
mg,NN,O
qd,NN,O
was,VBD,O
co-administered,VBN,O
with,IN,O
tikosyn,NN,B
-lrb-,-LRB-,O
500,CD,O
mcg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
for,IN,O
5,CD,O
days,NNS,O
-lrb-,-LRB-,O
following,VBG,O
2,CD,O
days,NNS,O
of,IN,O
diuretic,JJ,G
use,NN,O
at,IN,O
half,NN,O
dose,NN,O
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
patients,NNS,O
receiving,VBG,O
hctz,NN,D
alone,RB,O
",",",",O
dofetilide,NN,D
auc,NN,O
increased,VBN,O
by,IN,O
27,CD,O
%,NN,O
and,CC,O
cmax,NN,O
by,IN,O
21,CD,O
%,NN,O
.,.,.
,,
however,RB,O
",",",",O
the,DT,O
pharmacodynamic,JJ,O
effect,NN,O
increased,VBN,O
by,IN,O
197,CD,O
%,NN,O
-lrb-,-LRB-,O
qtc,NN,O
increase,NN,O
over,IN,O
time,NN,O
-rrb-,-RRB-,O
and,CC,O
by,IN,O
95,CD,O
%,NN,O
-lrb-,-LRB-,O
maximum,NN,O
qtc,NN,O
increase,NN,O
-rrb-,-RRB-,O
.,.,.
,,
however,RB,O
",",",",O
the,DT,O
pharmacodynamic,JJ,O
effect,NN,O
increased,VBN,O
by,IN,O
190,CD,O
%,NN,O
-lrb-,-LRB-,O
qtc,NN,O
increase,NN,O
over,IN,O
time,NN,O
-rrb-,-RRB-,O
and,CC,O
by,IN,O
84,CD,O
%,NN,O
-lrb-,-LRB-,O
maximum,NNP,O
qtc,NNP,O
increase,NN,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
pharmacodynamic,JJ,O
effects,NNS,O
can,MD,O
be,VB,O
explained,VBN,O
by,IN,O
a,DT,O
combination,NN,O
of,IN,O
the,DT,O
increase,NN,O
in,IN,O
dofetilide,NN,D
exposure,NN,O
and,CC,O
the,DT,O
reductions,NNS,O
in,IN,O
serum,NN,O
potassium,NN,D
.,.,.
,,
in,IN,O
the,DT,O
diamond,NN,O
trials,NNS,O
",",",",O
1252,CD,O
patients,NNS,O
were,VBD,O
treated,VBN,O
with,IN,O
tikosyn,NN,B
and,CC,O
diuretics,NNS,G
concomitantly,RB,O
of,IN,O
whom,WP,O
493,CD,O
died,VBD,O
compared,VBN,O
to,TO,O
508,CD,O
deaths,NNS,O
among,IN,O
the,DT,O
1248,CD,O
patients,NNS,O
receiving,VBG,O
placebo,NN,O
and,CC,O
diuretics,NNS,G
.,.,.
,,
of,IN,O
the,DT,O
229,CD,O
patients,NNS,O
who,WP,O
had,VBD,O
potassium,NN,D
depleting,VBG,O
diuretics,NNS,G
added,VBD,O
to,TO,O
their,PRP$,O
concomitant,JJ,O
medications,NNS,O
in,IN,O
the,DT,O
diamond,NN,O
trials,NNS,O
",",",",O
the,DT,O
patients,NNS,O
on,IN,O
tikosyn,NNP,B
had,VBD,O
a,DT,O
non-significantly,JJ,O
reduced,VBN,O
relative,JJ,O
risk,NN,O
for,IN,O
death,NN,O
of,IN,O
0.68,CD,O
-lrb-,-LRB-,O
95,CD,O
%,NN,O
ci,NN,O
0.376,CD,O
",",",",O
1.23,CD,O
-rrb-,-RRB-,O
.,.,.
,,
potential,JJ,O
drug,NN,O
interactions,NNS,O
dofetilide,NNP,D
is,VBZ,O
eliminated,VBN,O
in,IN,O
the,DT,O
kidney,NN,O
by,IN,O
cationic,JJ,O
secretion,NN,O
.,.,.
,,
inhibitors,NNS,O
of,IN,O
renal,JJ,O
cationic,JJ,O
secretion,NN,O
are,VBP,O
contraindicated,VBN,O
with,IN,O
tikosyn,NN,B
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
drugs,NNS,D
that,WDT,O
are,VBP,O
actively,RB,O
secreted,VBN,O
via,IN,O
this,DT,O
route,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
triamterene,NN,D
",",",",O
metformin,NN,D
and,CC,O
amiloride,NN,D
-rrb-,-RRB-,O
should,MD,O
be,VB,O
co-administered,VBN,O
with,IN,O
care,NN,O
as,IN,O
they,PRP,O
might,MD,O
increase,VB,O
dofetilide,NN,D
levels,NNS,O
.,.,.
,,
dofetilide,NNP,D
is,VBZ,O
metabolized,VBN,O
to,TO,O
a,DT,O
small,JJ,O
extent,NN,O
by,IN,O
the,DT,O
cyp3a4,NN,D
isoenzyme,NN,O
of,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
system,NN,O
.,.,.
,,
inhibitors,NNS,O
of,IN,O
the,DT,O
cyp3a4,NN,D
isoenzyme,NN,O
could,MD,O
increase,VB,O
systemic,JJ,O
dofetilide,NN,D
exposure,NN,O
.,.,.
,,
inhibitors,NNS,O
of,IN,O
this,DT,O
isoenzyme,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
macrolide,NN,O
antibiotics,NNS,G
",",",",O
azole,JJ,O
antifungal,JJ,O
agents,NNS,O
",",",",O
protease,NN,O
inhibitors,NNS,O
",",",",O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
",",",",O
amiodarone,NN,D
",",",",O
cannabinoids,NNS,G
",",",",O
diltiazem,NN,D
",",",",O
grapefruit,NN,O
juice,NN,O
",",",",O
nefazadone,NN,D
",",",",O
norfloxacin,NN,D
",",",",O
quinine,NN,D
",",",",O
zafirlukast,NN,D
-rrb-,-RRB-,O
should,MD,O
be,VB,O
cautiously,RB,O
coadministered,VBN,O
with,IN,O
tikosyn,NN,B
as,IN,O
they,PRP,O
can,MD,O
potentially,RB,O
increase,VB,O
dofetilide,NN,D
levels,NNS,O
.,.,.
,,
dofetilide,NNP,D
is,VBZ,O
not,RB,O
an,DT,O
inhibitor,NN,O
of,IN,O
cyp3a4,NN,D
nor,CC,O
of,IN,O
other,JJ,O
cytochrome,NN,O
p450,NN,O
isoenzymes,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
cyp2c9,NN,D
",",",",O
cyp2d6,NN,D
-rrb-,-RRB-,O
and,CC,O
is,VBZ,O
not,RB,O
expected,VBN,O
to,TO,O
increase,VB,O
levels,NNS,O
of,IN,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
cyp3a4,NN,D
.,.,.
,,
other,JJ,O
drug,NN,O
interaction,NN,O
information,NN,O
digoxin,NNP,D
:,:,O
studies,NNS,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
tikosyn,NN,B
does,VBZ,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
digoxin,NN,D
.,.,.
,,
in,IN,O
patients,NNS,O
",",",",O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
digoxin,NN,D
with,IN,O
dofetilide,NN,D
was,VBD,O
associated,VBN,O
with,IN,O
a,DT,O
higher,JJR,O
occurrence,NN,O
of,IN,O
torsade,FW,O
de,FW,O
pointes,FW,O
.,.,.
,,
it,PRP,O
is,VBZ,O
not,RB,O
clear,JJ,O
whether,IN,O
this,DT,O
represents,VBZ,O
an,DT,O
interaction,NN,O
with,IN,O
tikosyn,NN,B
or,CC,O
the,DT,O
presence,NN,O
of,IN,O
more,RBR,O
severe,JJ,O
structural,JJ,O
heart,NN,O
disease,NN,O
in,IN,O
patients,NNS,O
on,IN,O
digoxin,NN,D
.,.,.
,,
structural,JJ,O
heart,NN,O
disease,NN,O
is,VBZ,O
a,DT,O
known,JJ,O
risk,NN,O
factor,NN,O
for,IN,O
arrhythmia,NN,O
.,.,.
,,
no,DT,O
increase,NN,O
in,IN,O
mortality,NN,O
was,VBD,O
observed,VBN,O
in,IN,O
patients,NNS,O
taking,VBG,O
digoxin,NN,D
as,IN,O
concomitant,JJ,O
medication,NN,O
.,.,.
,,
other,JJ,O
drugs,NNS,O
:,:,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
amlodipine,NN,D
",",",",O
phenytoin,NN,D
",",",",O
glyburide,NN,D
",",",",O
ranitidine,NN,D
",",",",O
omeprazole,NN,D
",",",",O
hormone,NN,O
replacement,NN,O
therapy,NN,O
-lrb-,-LRB-,O
a,DT,O
combination,NN,O
of,IN,O
conjugated,VBN,O
estrogens,NNS,G
and,CC,O
medroxyprogesterone,NN,D
-rrb-,-RRB-,O
",",",",O
antacid,NN,G
-lrb-,-LRB-,O
aluminum,NN,D
and,CC,O
magnesium,NN,D
hydroxides,NNS,O
-rrb-,-RRB-,O
and,CC,O
theophylline,NN,D
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
tikosyn,NN,B
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
studies,NNS,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
tikosyn,NN,B
does,VBZ,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
or,CC,O
pharmacodynamics,NNS,O
of,IN,O
warfarin,NN,D
",",",",O
or,CC,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
propranolol,NN,D
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
-rrb-,-RRB-,O
",",",",O
phenytoin,NN,D
",",",",O
theophylline,NN,D
",",",",O
or,CC,O
oral,JJ,O
contraceptives,NNS,G
.,.,.
,,
population,NNP,O
pharmacokinetic,JJ,O
analyses,NNS,O
were,VBD,O
conducted,VBN,O
on,IN,O
plasma,NN,O
concentration,NN,O
data,NNS,O
from,IN,O
1445,CD,O
patients,NNS,O
in,IN,O
clinical,JJ,O
trials,NNS,O
to,TO,O
examine,VB,O
the,DT,O
effects,NNS,O
of,IN,O
concomitant,JJ,O
medications,NNS,O
on,IN,O
clearance,NN,O
or,CC,O
volume,NN,O
of,IN,O
distribution,NN,O
of,IN,O
dofetilide,NN,D
.,.,.
,,
concomitant,JJ,O
medications,NNS,O
were,VBD,O
grouped,VBN,O
as,IN,O
ace,NN,O
inhibitors,NNS,O
",",",",O
oral,JJ,O
anticoagulants,NNS,G
",",",",O
calcium,NN,D
channel,NN,O
blockers,NNS,O
",",",",O
beta,NN,O
blockers,NNS,O
",",",",O
cardiac,JJ,O
glycosides,NNS,G
",",",",O
inducers,NNS,O
of,IN,O
cyp3a4,NN,D
",",",",O
substrates,NNS,O
and,CC,O
inhibitors,NNS,O
of,IN,O
cyp3a4,NN,D
",",",",O
substrates,NNS,O
and,CC,O
inhibitors,NNS,O
of,IN,O
p-glycoprotein,NN,O
",",",",O
nitrates,NNS,G
",",",",O
sulphonylureas,NNS,G
",",",",O
loop,NN,O
diuretics,NNS,G
",",",",O
potassium,NN,D
sparing,VBG,O
diuretics,NNS,G
",",",",O
thiazide,JJ,G
diuretics,NNS,G
",",",",O
substrates,NNS,O
and,CC,O
inhibitors,NNS,O
of,IN,O
tubular,JJ,O
organic,JJ,O
cation,NN,O
transport,NN,O
",",",",O
and,CC,O
qtc-prolonging,JJ,O
drugs,NNS,D
.,.,.
,,
differences,NNS,O
in,IN,O
clearance,NN,O
between,IN,O
patients,NNS,O
on,IN,O
these,DT,O
medications,NNS,O
-lrb-,-LRB-,O
at,IN,O
any,DT,O
occasion,NN,O
in,IN,O
the,DT,O
study,NN,O
-rrb-,-RRB-,O
and,CC,O
those,DT,O
off,IN,O
medications,NNS,O
varied,VBD,O
between,IN,O
-16,CD,O
%,NN,O
and,CC,O
3,CD,O
%,NN,O
.,.,.
,,
the,DT,O
mean,NN,O
clearances,NNS,O
of,IN,O
dofetilide,NN,D
were,VBD,O
16,CD,O
%,NN,O
and,CC,O
15,CD,O
%,NN,O
lower,JJR,O
in,IN,O
patients,NNS,O
on,IN,O
thiazide,JJ,G
diuretics,NNS,G
and,CC,O
inhibitors,NNS,O
of,IN,O
tubular,JJ,O
organic,JJ,O
cation,NN,O
transport,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
the,DT,O
potential,NN,O
for,IN,O
clinically,RB,O
significant,JJ,O
drug-drug,JJ,O
interactions,NNS,O
posed,VBN,O
by,IN,O
dolasetron,NN,D
and,CC,O
hydrodolasetron,NN,D_n
appears,VBZ,O
to,TO,O
be,VB,O
low,JJ,O
for,IN,O
drugs,NNS,D
commonly,RB,O
used,VBN,O
in,IN,O
chemotherapy,NN,O
or,CC,O
surgery,NN,O
",",",",O
because,IN,O
hydrodolasetron,NN,D_n
is,VBZ,O
eliminated,VBN,O
by,IN,O
multiple,JJ,O
routes,NNS,O
.,.,.
,,
blood,NN,O
levels,NNS,O
of,IN,O
hydrodolasetron,NN,D_n
increased,VBD,O
24,CD,O
%,NN,O
when,WRB,O
dolasetron,NN,D
was,VBD,O
coadministered,VBN,O
with,IN,O
cimetidine,NN,D
-lrb-,-LRB-,O
nonselective,JJ,O
inhibitor,NN,O
of,IN,O
cytochrome,NN,O
p-450,NN,O
-rrb-,-RRB-,O
for,IN,O
7,CD,O
days,NNS,O
",",",",O
and,CC,O
decreased,VBD,O
28,CD,O
%,NN,O
with,IN,O
coadministration,NN,O
of,IN,O
rifampin,NN,D
-lrb-,-LRB-,O
potent,JJ,O
inducer,NN,O
of,IN,O
cytochrome,NN,O
p-450,NN,O
-rrb-,-RRB-,O
for,IN,O
7,CD,O
days,NNS,O
.,.,.
,,
dolasetron,NNP,D
has,VBZ,O
been,VBN,O
safely,RB,O
coadministered,VBN,O
with,IN,O
drugs,NNS,D
used,VBN,O
in,IN,O
chemotherapy,NN,O
and,CC,O
surgery,NN,O
.,.,.
,,
as,IN,O
with,IN,O
other,JJ,O
agents,NNS,O
which,WDT,O
prolong,VBP,O
ecg,NN,O
intervals,NNS,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
in,IN,O
patients,NNS,O
taking,VBG,O
drugs,NNS,D
which,WDT,O
prolong,VBP,O
ecg,NN,O
intervals,NNS,O
",",",",O
particularly,RB,O
qtc,NN,O
.,.,.
,,
in,IN,O
patients,NNS,O
taking,VBG,O
furosemide,NN,D
",",",",O
nifedipine,NN,D
",",",",O
diltiazem,NN,D
",",",",O
ace,NN,O
inhibitors,NNS,O
",",",",O
verapamil,NN,D
",",",",O
glyburide,NN,D
",",",",O
propranolol,NN,D
",",",",O
and,CC,O
various,JJ,O
chemotherapy,NN,O
agents,NNS,O
",",",",O
no,DT,O
effect,NN,O
was,VBD,O
shown,VBN,O
on,IN,O
the,DT,O
clearance,NN,O
of,IN,O
hydrodolasetron,NN,D_n
.,.,.
,,
clearance,NN,O
of,IN,O
hydrodolasetron,NN,D_n
decreased,VBN,O
by,IN,O
about,IN,O
27,CD,O
%,NN,O
when,WRB,O
dolasetron,NN,D
mesylate,NN,O
was,VBD,O
administered,VBN,O
intravenously,RB,O
concomitantly,RB,O
with,IN,O
atenolol,NN,D
.,.,.
,,
dolasetron,NNP,D
does,VBZ,O
not,RB,O
influence,VB,O
anesthesia,NN,D
recovery,NN,O
time,NN,O
in,IN,O
patients,NNS,O
.,.,.
,,
dolasetron,NNP,D
mesylate,NN,O
did,VBD,O
not,RB,O
inhibit,VB,O
the,DT,O
antitumor,NN,O
activity,NN,O
of,IN,O
four,CD,O
chemotherapeutic,JJ,O
agents,NNS,O
-lrb-,-LRB-,O
cisplatin,NN,D
",",",",O
5-fluorouracil,NN,D
",",",",O
doxorubicin,NN,D
",",",",O
cyclophosphamide,NN,D
-rrb-,-RRB-,O
in,IN,O
four,CD,O
murine,JJ,O
models,NNS,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
inhibit,VBP,O
or,CC,O
induce,VBP,O
cyp,NN,O
2d6,NN,O
and,CC,O
cyp,NN,O
3a4,NN,O
may,MD,O
affect,VB,O
the,DT,O
concentration,NN,O
on,IN,O
aricept,NNP,B
.,.,.
,,
because,IN,O
dopamine,NN,D
is,VBZ,O
metabolized,VBN,O
by,IN,O
monoamine,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
mao,NN,O
-rrb-,-RRB-,O
",",",",O
inhibition,NN,O
of,IN,O
this,DT,O
enzyme,NN,O
prolongs,VBZ,O
and,CC,O
potentiates,VBZ,O
the,DT,O
effect,NN,O
of,IN,O
dopamine,NN,D
.,.,.
,,
patients,NNS,O
who,WP,O
have,VBP,O
been,VBN,O
treated,VBN,O
with,IN,O
mao,NN,O
inhibitors,NNS,O
within,IN,O
two,CD,O
to,TO,O
three,CD,O
weeks,NNS,O
prior,RB,O
to,TO,O
the,DT,O
administration,NN,O
of,IN,O
dopamine,NN,D
hcl,NN,O
should,MD,O
receive,VB,O
initial,JJ,O
doses,NNS,O
of,IN,O
dopamine,NN,D
hcl,NN,O
no,RB,O
greater,JJR,O
than,IN,O
one-tenth,JJ,O
-lrb-,-LRB-,O
10-Jan,CD,O
-rrb-,-RRB-,O
of,IN,O
the,DT,O
usual,JJ,O
dose,NN,O
.,.,.
,,
concurrent,JJ,O
administration,NN,O
of,IN,O
low-dose,JJ,O
dopamine,NN,D
hcl,NN,O
and,CC,O
diuretic,JJ,G
agents,NNS,O
may,MD,O
produce,VB,O
an,DT,O
additive,JJ,O
or,CC,O
potentiating,NN,O
effect,NN,O
on,IN,O
urine,NN,O
flow,NN,O
.,.,.
,,
tricyclic,JJ,O
antidepressants,NNS,G
may,MD,O
potentiate,VB,O
the,DT,O
cardiovascular,JJ,O
effects,NNS,O
of,IN,O
adreneric,JJ,O
agents,NNS,O
.,.,.
,,
cardiac,JJ,O
effects,NNS,O
of,IN,O
dopamine,NN,D
are,VBP,O
antagonized,VBN,O
by,IN,O
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
",",",",O
such,JJ,O
as,IN,O
propranolol,NN,D
and,CC,O
metoprolol,NN,D
.,.,.
,,
the,DT,O
peripheral,JJ,O
vasoconstriction,NN,O
caused,VBN,O
by,IN,O
high,JJ,O
doses,NNS,O
of,IN,O
dopamine,NN,D
hcl,NN,O
is,VBZ,O
antagonized,VBN,O
by,IN,O
alpha-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
.,.,.
,,
dopamine-induced,JJ,O
renal,JJ,O
and,CC,O
mesenteric,JJ,O
vasodilation,NN,O
is,VBZ,O
not,RB,O
antagonized,VBN,O
by,IN,O
either,CC,O
alpha,NN,O
-,:,O
or,CC,O
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
.,.,.
,,
butyrophenones,NNS,G
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
haloperidol,NN,D
-rrb-,-RRB-,O
and,CC,O
phenothiazines,NNS,G
can,MD,O
suppress,VB,O
the,DT,O
dopaminergic,JJ,O
renal,JJ,O
and,CC,O
mesenteric,JJ,O
vasodilation,NN,O
induced,VBN,O
with,IN,O
low,JJ,O
dose,NN,O
dopamine,NN,D
infusion,NN,O
.,.,.
,,
cyclopropane,NN,D
or,CC,O
halogenated,VBN,O
hydrocarbon,NN,O
anesthetics,NNS,G
increase,VBP,O
cardiac,JJ,O
autonomic,JJ,O
irritability,NN,O
and,CC,O
may,MD,O
sensitize,VB,O
the,DT,O
myocardium,NN,O
to,TO,O
the,DT,O
action,NN,O
of,IN,O
certain,JJ,O
intravenously,RB,O
administered,VBN,O
catecholamines,NNS,G
",",",",O
such,JJ,O
as,IN,O
dopamine,NN,D
.,.,.
,,
this,DT,O
interaction,NN,O
appears,VBZ,O
to,TO,O
be,VB,O
related,VBN,O
both,DT,O
to,TO,O
pressor,NN,O
activity,NN,O
and,CC,O
to,TO,O
beta-adrenergic,JJ,O
stimulating,NN,O
properties,NNS,O
of,IN,O
these,DT,O
catecholamines,NNS,G
and,CC,O
may,MD,O
produce,VB,O
ventricular,JJ,O
arrhythmias,NNS,O
and,CC,O
hypertension,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
extreme,JJ,O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
administering,VBG,O
dopamine,NN,D
hcl,NN,O
to,TO,O
patients,NNS,O
receiving,VBG,O
cyclopropane,NN,D
or,CC,O
halogenated,VBN,O
hydrocarbon,NN,O
anesthetics,NNS,G
.,.,.
,,
it,PRP,O
has,VBZ,O
been,VBN,O
reported,VBN,O
that,IN,O
results,NNS,O
of,IN,O
studies,NNS,O
in,IN,O
animals,NNS,O
indicate,VBP,O
that,IN,O
dopamine-induced,JJ,O
ventricular,JJ,O
arrhythmias,NNS,O
during,IN,O
anesthesia,NN,D
can,MD,O
be,VB,O
reversed,VBN,O
by,IN,O
propranolol,NN,D
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
vasopressors,NNS,G
",",",",O
vasoconstricting,VBG,O
agents,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
ergonovine,NN,D
-rrb-,-RRB-,O
and,CC,O
some,DT,O
oxytocic,JJ,O
drugs,NNS,D
may,MD,O
result,VB,O
in,IN,O
severe,JJ,O
hypertension,NN,O
.,.,.
,,
administration,NN,O
of,IN,O
phenytoin,NN,D
to,TO,O
patients,NNS,O
receiving,VBG,O
dopamine,NN,D
hcl,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
lead,VB,O
to,TO,O
hypotension,NN,O
and,CC,O
bradycardia,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
suggested,VBN,O
that,IN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
dopamine,NN,D
hcl,NN,O
",",",",O
alternatives,NNS,O
to,TO,O
phenytoin,NN,D
should,MD,O
be,VB,O
used,VBN,O
if,IN,O
anticonvulsant,JJ,G
therapy,NN,O
is,VBZ,O
needed,VBN,O
.,.,.
,,
clinical,JJ,O
trials,NNS,O
have,VBP,O
indicated,VBN,O
that,IN,O
pulmozyme,NNP,B
can,MD,O
be,VB,O
effectively,RB,O
and,CC,O
safely,RB,O
used,VBN,O
in,IN,O
conjunction,NN,O
with,IN,O
standard,JJ,O
cystic,JJ,O
fibrosis,NN,O
therapies,NNS,O
including,VBG,O
oral,JJ,O
",",",",O
inhaled,VBD,O
and/or,CC,O
parenteral,JJ,O
antibiotics,NNS,G
",",",",O
bronchodilators,NNS,G
",",",",O
enzyme,NN,O
supplements,NNS,O
",",",",O
vitamins,NNS,G
",",",",O
oral,JJ,O
or,CC,O
inhaled,VBN,O
corticosteroids,NNS,G
",",",",O
and,CC,O
analgesics,NNS,G
.,.,.
,,
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
.,.,.
,,
although,IN,O
acid-base,NN,O
and,CC,O
electrolyte,NN,O
disturbances,NNS,O
were,VBD,O
not,RB,O
reported,VBN,O
in,IN,O
the,DT,O
clinical,JJ,O
trials,NNS,O
with,IN,O
dorzolamide,NN,D
",",",",O
these,DT,O
disturbances,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
oral,JJ,O
carbonic,JJ,O
anhydrase,NN,O
inhibitors,NNS,O
and,CC,O
have,VBP,O
",",",",O
in,IN,O
some,DT,O
instances,NNS,O
",",",",O
resulted,VBD,O
in,IN,O
drug,NN,D
interactions,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
toxicity,NN,O
associated,VBN,O
with,IN,O
high-dose,JJ,O
salicylate,NN,G
therapy,NN,O
-rrb-,-RRB-,O
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
potential,NN,O
for,IN,O
such,JJ,O
drug,NN,D
interactions,NNS,O
should,MD,O
be,VB,O
considered,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
dorzolamide,NN,D
.,.,.
,,
prior,RB,O
administration,NN,O
of,IN,O
succinylcholine,NN,D
has,VBZ,O
no,DT,O
clinically,RB,O
important,JJ,O
effect,NN,O
on,IN,O
the,DT,O
neuromuscular,JJ,O
blocking,VBG,O
action,NN,O
of,IN,O
nuromax,NNP,B
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
nuromax,NN,B
before,IN,O
succinylcholine,NN,D
to,TO,O
attenuate,VB,O
some,DT,O
of,IN,O
the,DT,O
side,JJ,O
effects,NNS,O
of,IN,O
succinylcholine,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
there,EX,O
are,VBP,O
no,DT,O
clinical,JJ,O
data,NNS,O
on,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
nuromax,NNP,B
and,CC,O
other,JJ,O
nondepolarizing,JJ,O
neuromuscular,JJ,O
blocking,VBG,O
agents,NNS,O
.,.,.
,,
isoflurane,NNP,D
",",",",O
enflurane,NN,D
",",",",O
and,CC,O
halothane,NN,D
decrease,VBP,O
the,DT,O
ed50,NN,O
of,IN,O
nuromax,NN,B
by,IN,O
30,CD,O
%,NN,O
to,TO,O
45,CD,O
%,NN,O
.,.,.
,,
these,DT,O
agents,NNS,O
may,MD,O
also,RB,O
prolong,VB,O
the,DT,O
clinically,RB,O
effective,JJ,O
duration,NN,O
of,IN,O
action,NN,O
by,IN,O
up,RB,O
to,TO,O
25,CD,O
%,NN,O
.,.,.
,,
other,JJ,O
drugs,NNS,D
which,WDT,O
may,MD,O
enhance,VB,O
the,DT,O
neuromuscular,JJ,O
blocking,VBG,O
action,NN,O
of,IN,O
nondepolarizing,JJ,O
agents,NNS,O
such,JJ,O
as,IN,O
nuromax,NNP,B
include,VBP,O
certain,JJ,O
antibiotics,NNS,G
-lrb-,-LRB-,O
e.,FW,O
g.,FW,O
",",",",O
aminoglycosides,NNS,G
",",",",O
tetracyclines,NNS,G
",",",",O
bacitracin,NN,G
",",",",O
polymyxins,NNS,G
",",",",O
lincomycin,NN,D
",",",",O
clindamycin,NN,D
",",",",O
colistin,NN,D
",",",",O
and,CC,O
sodium,NN,O
colistimethate,NN,O
-rrb-,-RRB-,O
",",",",O
magnesium,NN,D
salts,NNS,O
",",",",O
lithium,NN,D
",",",",O
local,JJ,O
anesthetics,NNS,G
",",",",O
procainamide,NN,D
",",",",O
and,CC,O
quinidine,NN,D
.,.,.
,,
as,IN,O
with,IN,O
some,DT,O
other,JJ,O
nondepolarizing,JJ,O
neuromuscular,JJ,O
blocking,VBG,O
agents,NNS,O
",",",",O
the,DT,O
time,NN,O
of,IN,O
onset,NN,O
of,IN,O
neuromuscular,JJ,O
block,NN,O
induced,VBN,O
by,IN,O
nuromax,NNP,B
is,VBZ,O
lengthened,VBN,O
and,CC,O
the,DT,O
duration,NN,O
of,IN,O
block,NN,O
is,VBZ,O
shortened,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
phenytoin,NN,D
or,CC,O
carbamazepine,NN,D
.,.,.
,,
administration,NN,O
of,IN,O
doxapram,NN,D
to,TO,O
patients,NNS,O
who,WP,O
are,VBP,O
receiving,VBG,O
sympathomimetic,JJ,G
or,CC,O
monoamine,NN,O
oxidase,NN,O
inhibiting,VBG,O
drugs,NNS,D
may,MD,O
result,VB,O
in,IN,O
an,DT,O
additive,JJ,O
pressor,NN,O
effect,NN,O
.,.,.
,,
in,IN,O
patients,NNS,O
who,WP,O
have,VBP,O
received,VBN,O
muscle,NN,O
relaxants,NNS,O
",",",",O
doxapram,NN,D
may,MD,O
temporarily,RB,O
mask,NN,O
the,DT,O
residual,JJ,O
effects,NNS,O
of,IN,O
muscle,NN,O
relaxant,NN,O
drugs,NNS,D
.,.,.
,,
in,IN,O
patients,NNS,O
who,WP,O
have,VBP,O
received,VBN,O
general,JJ,O
anesthesia,NN,D
utilizing,VBG,O
a,DT,O
volatile,JJ,O
agent,NN,O
known,VBN,O
to,TO,O
sensitize,VB,O
the,DT,O
myocardium,NN,O
to,TO,O
catecholamines,NNS,G
",",",",O
administration,NN,O
of,IN,O
doxapram,NN,D
should,MD,O
be,VB,O
delayed,VBN,O
until,IN,O
the,DT,O
volatile,JJ,O
agent,NN,O
has,VBZ,O
been,VBN,O
excreted,VBN,O
in,IN,O
order,NN,O
to,TO,O
lessen,VB,O
the,DT,O
potential,NN,O
for,IN,O
arrhythmias,NNS,O
",",",",O
including,VBG,O
ventricular,JJ,O
tachycardia,NN,O
and,CC,O
ventricular,JJ,O
fibrillation,NN,O
.,.,.
,,
most,JJS,O
-lrb-,-LRB-,O
98,CD,O
%,NN,O
-rrb-,-RRB-,O
of,IN,O
plasma,NN,O
doxazosin,NN,D
is,VBZ,O
protein,NN,O
bound,VBN,O
.,.,.
,,
in,FW,O
vitro,FW,O
data,NNS,O
in,IN,O
human,JJ,O
plasma,NN,O
indicate,VBP,O
that,IN,O
doxazosin,NN,D
mesylate,NN,O
has,VBZ,O
no,DT,O
effect,NN,O
on,IN,O
protein,NN,O
binding,NN,O
of,IN,O
digoxin,NN,D
",",",",O
warfarin,NN,D
",",",",O
phenytoin,NN,D
or,CC,O
indomethacin,NN,D
.,.,.
,,
there,EX,O
is,VBZ,O
no,DT,O
information,NN,O
on,IN,O
the,DT,O
effect,NN,O
of,IN,O
other,JJ,O
highly,RB,O
plasma,NN,O
protein,NN,O
bound,VBD,O
drugs,NNS,D
on,IN,O
doxazosin,NN,D
binding,NN,O
.,.,.
,,
doxazosin,NN,O
mesylate,NN,O
has,VBZ,O
been,VBN,O
administered,VBN,O
without,IN,O
any,DT,O
evidence,NN,O
of,IN,O
an,DT,O
adverse,JJ,O
drug,NN,D
interaction,NN,O
to,TO,O
patients,NNS,O
receiving,VBG,O
thiazide,JJ,G
diuretics,NNS,G
",",",",O
beta-blocking,JJ,D
agents,NNS,O
",",",",O
and,CC,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
.,.,.
,,
in,IN,O
a,DT,O
placebo-controlled,JJ,O
trial,NN,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
",",",",O
the,DT,O
administration,NN,O
of,IN,O
a,DT,O
single,JJ,O
1,CD,O
mg,NN,O
dose,NN,O
of,IN,O
doxazosin,NN,D
on,IN,O
day,NN,O
1,CD,O
of,IN,O
a,DT,O
four-day,JJ,O
regimen,NN,O
of,IN,O
oral,JJ,O
cimetidine,NN,D
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
-rrb-,-RRB-,O
resulted,VBD,O
in,IN,O
a,DT,O
10,CD,O
%,NN,O
increase,NN,O
in,IN,O
mean,JJ,O
auc,NN,O
of,IN,O
doxazosin,NN,D
-lrb-,-LRB-,O
p,NN,O
=,JJ,O
0.006,CD,O
-rrb-,-RRB-,O
",",",",O
and,CC,O
a,DT,O
slight,JJ,O
but,CC,O
not,RB,O
statistically,RB,O
significant,JJ,O
increase,NN,O
in,IN,O
mean,JJ,O
cmax,NN,O
and,CC,O
mean,VB,O
half-life,NN,O
of,IN,O
doxazosin,NN,D
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
increase,NN,O
in,IN,O
doxazosin,NN,D
auc,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
in,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
doxazosin,NN,D
mesylate,NN,O
tablets,NNS,O
have,VBP,O
been,VBN,O
administered,VBN,O
to,TO,O
patients,NNS,O
on,IN,O
a,DT,O
variety,NN,O
of,IN,O
concomitant,JJ,O
medications,NNS,O
.,.,.
,,
while,IN,O
no,DT,O
formal,JJ,O
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
",",",",O
no,DT,O
interactions,NNS,O
were,VBD,O
observed,VBN,O
.,.,.
,,
doxazosin,NN,O
mesylate,NN,O
tablets,NNS,O
have,VBP,O
been,VBN,O
used,VBN,O
with,IN,O
the,DT,O
following,VBG,O
drugs,NNS,D
or,CC,O
drug,NN,D
classes,NNS,O
:,:,O
1,CD,O
.,.,.
,,
analgesic/anti-inflammatory,JJ,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
acetaminophen,NN,D
",",",",O
aspirin,NN,B
",",",",O
codeine,NN,D
and,CC,O
codeine,NN,D
combinations,NNS,O
",",",",O
ibuprofen,NN,D
",",",",O
indomethacin,NN,D
-rrb-,-RRB-,O
.,.,.
,,
2,LS,O
.,.,.
,,
antibiotics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
erythromycin,NN,D
",",",",O
trimethoprim,NN,D
and,CC,O
sulfamethoxazole,NN,D
",",",",O
amoxicillin,NNP,D
-rrb-,-RRB-,O
.,.,.
,,
3,LS,O
.,.,.
,,
antihistamines,NNS,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
chlorpheniramine,NN,G
-rrb-,-RRB-,O
.,.,.
,,
4,LS,O
.,.,.
,,
cardiovascular,NNP,O
agents,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
atenolol,NN,D
",",",",O
hydrochlorothiazide,NN,D
",",",",O
propranolol,NN,D
-rrb-,-RRB-,O
.,.,.
,,
5,CD,O
.,.,.
,,
corticosteroids,NNS,G
.,.,.
,,
6,CD,O
.,.,.
,,
gastrointestinal,JJ,O
agents,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
antacids,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
7,CD,O
.,.,.
,,
hypoglycemics,NNS,G
and,CC,O
endocrine,JJ,O
drugs,NNS,D
.,.,.
,,
8,CD,O
.,.,.
,,
sedatives,NNS,G
and,CC,O
tranquilizers,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
diazepam,NN,D
-rrb-,-RRB-,O
.,.,.
,,
9,CD,O
.,.,.
,,
cold,NNP,O
and,CC,O
flu,NN,O
remedies,NNS,O
.,.,.
,,
drugs,NNS,O
metabolized,VBN,O
by,IN,O
p450,NN,O
2d6,NN,O
:,:,O
the,DT,O
biochemical,JJ,O
activity,NN,O
of,IN,O
the,DT,O
drug,NN,D
metabolizing,VBG,O
isozyme,NN,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
-lrb-,-LRB-,O
debrisoquin,NN,D
hydroxylase,NN,O
-rrb-,-RRB-,O
is,VBZ,O
reduced,VBN,O
in,IN,O
a,DT,O
subset,NN,O
of,IN,O
the,DT,O
caucasian,JJ,O
population,NN,O
-lrb-,-LRB-,O
about,IN,O
10-Jul,CD,O
%,NN,O
of,IN,O
caucasians,NNPS,O
are,VBP,O
so-called,JJ,O
poor,JJ,O
metabolizers,NNS,O
-rrb-,-RRB-,O
;,:,O
.,.,.
,,
reliable,JJ,O
estimates,NNS,O
of,IN,O
the,DT,O
prevalence,NN,O
of,IN,O
reduced,VBN,O
p450,NN,O
2d6,NN,O
isozyme,NN,O
activity,NN,O
among,IN,O
asian,JJ,O
",",",",O
african,JJ,O
and,CC,O
other,JJ,O
populations,NNS,O
are,VBP,O
not,RB,O
yet,RB,O
available,JJ,O
.,.,.
,,
poor,NNP,O
metabolizers,NNS,O
have,VBP,O
higher,JJR,O
than,IN,O
expected,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
-lrb-,-LRB-,O
tcas,NNS,G
-rrb-,-RRB-,O
when,WRB,O
given,VBN,O
usual,JJ,O
doses,NNS,O
.,.,.
,,
depending,VBG,O
on,IN,O
the,DT,O
fraction,NN,O
of,IN,O
drug,NN,D
metabolized,VBN,O
by,IN,O
p450,NN,O
2d6,NN,O
",",",",O
the,DT,O
increase,NN,O
in,IN,O
plasma,NN,O
concentration,NN,O
may,MD,O
be,VB,O
small,JJ,O
",",",",O
or,CC,O
quite,RB,O
large,JJ,O
-lrb-,-LRB-,O
8-fold,JJ,O
increase,NN,O
in,IN,O
plasma,NN,O
auc,NN,O
of,IN,O
the,DT,O
tca,NNP,G
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
certain,JJ,O
drugs,NNS,D
inhibit,VBP,O
the,DT,O
activity,NN,O
of,IN,O
this,DT,O
isozyme,NN,O
and,CC,O
make,VB,O
normal,JJ,O
metabolizers,NNS,O
resemble,VBP,O
poor,JJ,O
metabolizers,NNS,O
.,.,.
,,
an,DT,O
individual,NN,O
who,WP,O
is,VBZ,O
stable,JJ,O
on,IN,O
a,DT,O
given,VBN,O
dose,NN,O
of,IN,O
tca,NNP,G
may,MD,O
become,VB,O
abruptly,RB,O
toxic,JJ,O
when,WRB,O
given,VBN,O
one,CD,O
of,IN,O
these,DT,O
inhibiting,VBG,O
drugs,NNS,D
as,IN,O
concomitant,JJ,O
therapy,NN,O
.,.,.
,,
the,DT,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
include,VBP,O
some,DT,O
that,WDT,O
are,VBP,O
not,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
enzyme,NN,O
-lrb-,-LRB-,O
quinidine,NN,D
.,.,.
,,
cimetidine,NN,D
-rrb-,-RRB-,O
and,CC,O
many,JJ,O
that,WDT,O
are,VBP,O
substrates,NNS,O
for,IN,O
p450,NN,O
2d6,NN,O
-lrb-,-LRB-,O
many,JJ,O
other,JJ,O
antidepressants,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
and,CC,O
the,DT,O
type,NN,O
1c,NN,O
antiarrhythmics,NNS,G
propafenone,NN,D
and,CC,O
flecainide,NN,D
-rrb-,-RRB-,O
.,.,.
,,
while,IN,O
all,PDT,O
the,DT,O
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
ssris,NNS,G
-rrb-,-RRB-,O
",",",",O
e.g.,FW,O
",",",",O
citalopram,NN,D
",",",",O
escitalopram,NN,D
",",",",O
fluoxetine,NN,D
",",",",O
sertraline,NN,D
",",",",O
and,CC,O
paroxetine,NN,D
",",",",O
inhibit,VBP,O
p450,NN,O
2d6,NN,O
",",",",O
they,PRP,O
may,MD,O
vary,VB,O
in,IN,O
the,DT,O
extent,NN,O
of,IN,O
inhibition,NN,O
.,.,.
,,
the,DT,O
extent,NN,O
to,TO,O
which,WDT,O
ssri-tca,NNP,O
interactions,NNS,O
may,MD,O
pose,VB,O
clinical,JJ,O
problems,NNS,O
will,MD,O
depend,VB,O
on,IN,O
the,DT,O
degree,NN,O
of,IN,O
inhibition,NN,O
and,CC,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
the,DT,O
ssri,NNP,G
involved,VBN,O
.,.,.
,,
nevertheless,RB,O
",",",",O
caution,NN,O
is,VBZ,O
indicated,VBN,O
in,IN,O
the,DT,O
co-administration,NN,O
of,IN,O
tcas,NNS,G
with,IN,O
any,DT,O
of,IN,O
the,DT,O
ssris,NNS,G
and,CC,O
also,RB,O
in,IN,O
switching,NN,O
from,IN,O
one,CD,O
class,NN,O
to,TO,O
the,DT,O
other,JJ,O
.,.,.
,,
of,IN,O
particular,JJ,O
importance,NN,O
",",",",O
sufficient,JJ,O
time,NN,O
must,MD,O
elapse,VB,O
before,IN,O
initiating,VBG,O
tca,NNP,G
treatment,NN,O
in,IN,O
a,DT,O
patient,NN,O
being,VBG,O
withdrawn,VBN,O
from,IN,O
fluoxetine,NN,D
",",",",O
given,VBN,O
the,DT,O
long,JJ,O
half-life,NN,O
of,IN,O
the,DT,O
parent,NN,O
and,CC,O
active,JJ,O
metabolite,NN,O
-lrb-,-LRB-,O
at,IN,O
least,JJS,O
5,CD,O
weeks,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
-rrb-,-RRB-,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
with,IN,O
drugs,NNS,D
that,WDT,O
can,MD,O
inhibit,VB,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
may,MD,O
require,VB,O
lower,JJR,O
doses,NNS,O
than,IN,O
usually,RB,O
prescribed,VBN,O
for,IN,O
either,CC,O
the,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
or,CC,O
the,DT,O
other,JJ,O
drug,NN,D
.,.,.
,,
furthermore,RB,O
",",",",O
whenever,WRB,O
one,CD,O
of,IN,O
these,DT,O
other,JJ,O
drugs,NNS,D
is,VBZ,O
withdrawn,VBN,O
from,IN,O
co-therapy,JJ,O
",",",",O
an,DT,O
increased,VBN,O
dose,NN,O
of,IN,O
tricyclic,JJ,G
antidepressant,JJ,G
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
desirable,JJ,O
to,TO,O
monitor,VB,O
tca,NNP,G
plasma,NN,O
levels,NNS,O
whenever,WRB,O
a,DT,O
tca,NNP,G
is,VBZ,O
going,VBG,O
to,TO,O
be,VB,O
co-administered,VBN,O
with,IN,O
another,DT,O
drug,NN,D
known,VBN,O
to,TO,O
be,VB,O
an,DT,O
inhibitor,NN,O
of,IN,O
p450,NN,O
2d6,NN,O
.,.,.
,,
doxepin,NN,D
is,VBZ,O
primarily,RB,O
metabolized,VBN,O
by,IN,O
cyp2d6,NN,D
-lrb-,-LRB-,O
with,IN,O
cyp1a2,NN,D
and,CC,O
cyp3a4,NN,D
as,IN,O
minor,JJ,O
pathways,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
inhibitors,NNS,O
or,CC,O
substrates,NNS,O
of,IN,O
cyp2d6,NN,D
-lrb-,-LRB-,O
i.e.,FW,O
",",",",O
quinidine,NN,D
",",",",O
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
-lsb-,-LRB-,O
ssris,NNS,G
-rsb-,-RRB-,O
-rrb-,-RRB-,O
may,MD,O
increase,VB,O
the,DT,O
plasma,NN,O
concentration,NN,O
of,IN,O
doxepin,NN,D
when,WRB,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
the,DT,O
extent,NN,O
of,IN,O
interaction,NN,O
depends,VBZ,O
on,IN,O
the,DT,O
variability,NN,O
of,IN,O
effect,NN,O
on,IN,O
cyp2d6,NN,D
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
interaction,NN,O
with,IN,O
doxepin,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
systematically,RB,O
evaluated,VBN,O
.,.,.
,,
mao,NNP,O
inhibitors,NNS,O
:,:,O
serious,JJ,O
side,JJ,O
effects,NNS,O
and,CC,O
even,RB,O
death,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
following,VBG,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
certain,JJ,O
drugs,NNS,D
with,IN,O
mao,NN,O
inhibitors,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
mao,NN,O
inhibitors,NNS,O
should,MD,O
be,VB,O
discontinued,VBN,O
at,IN,O
least,JJS,O
two,CD,O
weeks,NNS,O
prior,RB,O
to,TO,O
the,DT,O
cautious,JJ,O
initiation,NN,O
of,IN,O
therapy,NN,O
with,IN,O
sinequan,NNP,B
.,.,.
,,
the,DT,O
exact,JJ,O
length,NN,O
of,IN,O
time,NN,O
may,MD,O
vary,VB,O
and,CC,O
is,VBZ,O
dependent,JJ,O
upon,IN,O
the,DT,O
particular,JJ,O
mao,NNP,O
inhibitor,NN,O
being,VBG,O
used,VBN,O
",",",",O
the,DT,O
length,NN,O
of,IN,O
time,NN,O
it,PRP,O
has,VBZ,O
been,VBN,O
administered,VBN,O
",",",",O
and,CC,O
the,DT,O
dosage,NN,O
involved,VBN,O
.,.,.
,,
cimetidine,NNP,D
:,:,O
cimetidine,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
produce,VB,O
clinically,RB,O
significant,JJ,O
fluctuations,NNS,O
in,IN,O
steady-state,JJ,O
serum,NN,O
concentrations,NNS,O
of,IN,O
various,JJ,O
tricyclic,JJ,G
antidepressants,NNS,G
.,.,.
,,
serious,JJ,O
anticholinergic,JJ,G
symptoms,NNS,O
-lrb-,-LRB-,O
i.e.,FW,O
",",",",O
severe,JJ,O
dry,JJ,O
mouth,NN,O
",",",",O
urinary,JJ,O
retention,NN,O
and,CC,O
blurred,VBD,O
vision,NN,O
-rrb-,-RRB-,O
have,VBP,O
been,VBN,O
associated,VBN,O
with,IN,O
elevations,NNS,O
in,IN,O
the,DT,O
serum,NN,O
levels,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressant,JJ,G
when,WRB,O
cimetidine,NN,D
therapy,NN,O
is,VBZ,O
initiated,VBN,O
.,.,.
,,
additionally,RB,O
",",",",O
higher,JJR,O
than,IN,O
expected,VBN,O
tricyclic,JJ,G
antidepressant,JJ,G
levels,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
when,WRB,O
they,PRP,O
are,VBP,O
begun,VBN,O
in,IN,O
patients,NNS,O
already,RB,O
taking,VBG,O
cimetidine,NN,D
.,.,.
,,
in,IN,O
patients,NNS,O
who,WP,O
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
be,VB,O
well,RB,O
controlled,VBN,O
on,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
receiving,VBG,O
concurrent,JJ,O
cimetidine,NN,D
therapy,NN,O
",",",",O
discontinuation,NN,O
of,IN,O
cimetidine,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
decrease,VB,O
established,JJ,O
steady-state,JJ,O
serum,NN,O
tricyclic,JJ,G
antidepressant,JJ,G
levels,NNS,O
and,CC,O
compromise,VB,O
their,PRP$,O
therapeutic,JJ,O
effects,NNS,O
.,.,.
,,
alcohol,NN,D
:,:,O
it,PRP,O
should,MD,O
be,VB,O
borne,VBN,O
in,IN,O
mind,NN,O
that,WDT,O
alcohol,NN,D
ingestion,NN,O
may,MD,O
increase,VB,O
the,DT,O
danger,NN,O
inherent,JJ,O
in,IN,O
any,DT,O
intentional,JJ,O
or,CC,O
unintentional,JJ,O
sinequan,NN,B
overdosage,NN,O
.,.,.
,,
this,DT,O
is,VBZ,O
especially,RB,O
important,JJ,O
in,IN,O
patients,NNS,O
who,WP,O
may,MD,O
use,VB,O
alcohol,NN,D
excessively,RB,O
.,.,.
,,
tolazamide,NNP,D
:,:,O
a,DT,O
case,NN,O
of,IN,O
severe,JJ,O
hypoglycemia,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
a,DT,O
type,NN,O
ii,CD,O
diabetic,JJ,O
patient,NN,O
maintained,VBD,O
on,IN,O
tolazamide,NN,D
-lrb-,-LRB-,O
1,CD,O
gm/day,NN,O
-rrb-,-RRB-,O
11,CD,O
days,NNS,O
after,IN,O
the,DT,O
addition,NN,O
of,IN,O
doxepin,NN,D
-lrb-,-LRB-,O
75,CD,O
mg/day,NN,O
-rrb-,-RRB-,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
with,IN,O
doxil,NN,B
.,.,.
,,
until,IN,O
specific,JJ,O
compatibility,NN,O
data,NNS,O
are,VBP,O
available,JJ,O
",",",",O
it,PRP,O
is,VBZ,O
not,RB,O
recommended,VBN,O
that,IN,O
doxil,NNP,B
be,VB,O
mixed,VBN,O
with,IN,O
other,JJ,O
drugs,NNS,D
.,.,.
,,
doxil,NN,B
may,MD,O
interact,VB,O
with,IN,O
drugs,NNS,D
known,VBN,O
to,TO,O
interact,VB,O
with,IN,O
the,DT,O
conventional,JJ,O
formulation,NN,O
of,IN,O
doxorubicin,NN,D
hcl,NN,O
.,.,.
,,
because,IN,O
tetracyclines,NNS,G
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
depress,VB,O
plasma,NN,O
prothrombin,NN,O
activity,NN,O
",",",",O
patients,NNS,O
who,WP,O
are,VBP,O
on,IN,O
anticoagulant,JJ,G
therapy,NN,O
may,MD,O
require,VB,O
downward,JJ,O
adjustment,NN,O
of,IN,O
their,PRP$,O
anticoagulant,JJ,G
dosage,NN,O
.,.,.
,,
since,IN,O
bacteriostatic,JJ,O
drugs,NNS,D
may,MD,O
interfere,VB,O
with,IN,O
the,DT,O
bactericidal,JJ,O
action,NN,O
of,IN,O
penicillin,NN,D
",",",",O
it,PRP,O
is,VBZ,O
advisable,JJ,O
to,TO,O
avoid,VB,O
giving,VBG,O
tetracyclines,NNS,G
in,IN,O
conjunction,NN,O
with,IN,O
penicillin,NN,D
.,.,.
,,
absorption,NN,O
of,IN,O
tetracyclines,NNS,G
is,VBZ,O
impaired,VBN,O
by,IN,O
antacids,NNS,G
containing,VBG,O
aluminum,NN,D
",",",",O
calcium,NN,D
",",",",O
or,CC,O
magnesium,NN,D
",",",",O
and,CC,O
iron-containing,JJ,O
preparations,NNS,O
.,.,.
,,
absorption,NN,O
of,IN,O
tetracycline,NN,D
is,VBZ,O
impaired,VBN,O
by,IN,O
bismuth,NN,O
subsalicylate,NN,O
.,.,.
,,
barbiturates,NNP,G
",",",",O
carbamazepine,NN,D
",",",",O
and,CC,O
phenytoin,NN,D
decrease,VBP,O
the,DT,O
half-life,NN,O
of,IN,O
doxycycline,NN,D
.,.,.
,,
the,DT,O
concurrent,JJ,O
use,NN,O
of,IN,O
tetracycline,NN,D
and,CC,O
penthrane,NN,B
-lrb-,-LRB-,O
methoxyflurane,NN,D
-rrb-,-RRB-,O
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
result,VB,O
in,IN,O
fatal,JJ,O
renal,JJ,O
toxicity,NN,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
of,IN,O
tetracycline,NN,D
may,MD,O
render,VB,O
oral,JJ,O
contraceptives,NNS,G
less,RBR,O
effective,JJ,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
FALSE,JJ,O
elevations,NNS,O
of,IN,O
urinary,JJ,O
catecholamine,NN,O
levels,NNS,O
may,MD,O
occur,VB,O
due,JJ,O
to,TO,O
interference,NN,O
with,IN,O
the,DT,O
fluorescence,NN,O
test,NN,O
.,.,.
,,
potential,JJ,O
drug,NN,D
interactions,NNS,O
for,IN,O
doxylamine,NN,D
include,VBP,O
",",",",O
increased,VBD,O
sedation,NN,O
if,IN,O
doxylamine,NN,D
is,VBZ,O
combined,VBN,O
with,IN,O
other,JJ,O
cns,NNS,O
depressant,NN,O
drugs,NNS,D
.,.,.
,,
antihistamines,NNS,D
may,MD,O
partially,RB,O
counteract,VB,O
the,DT,O
anticoagulation,JJ,O
effects,NNS,O
of,IN,O
heparin,NN,D
or,CC,O
warfarin,NN,D
.,.,.
,,
doxylamine,NN,D
may,MD,O
enhance,VB,O
the,DT,O
effects,NNS,O
of,IN,O
epinephrine,NN,D
.,.,.
,,
androgens,NNS,G
may,MD,O
increase,VB,O
sensitivity,NN,O
to,TO,O
oral,JJ,O
anticoagulahts,NNS,O
.,.,.
,,
dosage,NN,O
of,IN,O
the,DT,O
anticoagulant,NN,G
may,MD,O
require,VB,O
reduction,NN,O
in,IN,O
order,NN,O
to,TO,O
maintain,VB,O
satisfactory,JJ,O
therapeutic,JJ,O
hypoprothrombinemia,NN,O
.,.,.
,,
concurrent,JJ,O
administration,NN,O
of,IN,O
oxyphenbutazone,NN,D
and,CC,O
androgens,NNS,G
may,MD,O
result,VB,O
in,IN,O
elevated,JJ,O
serum,NN,O
levels,NNS,O
of,IN,O
oxyphenbutazone,NN,D
.,.,.
,,
in,IN,O
diabetic,JJ,O
patients,NNS,O
",",",",O
the,DT,O
metabolic,JJ,O
effects,NNS,O
of,IN,O
androgens,NNS,G
may,MD,O
decrease,VB,O
blood,NN,O
glucose,NN,O
and,CC,O
therefore,RB,O
",",",",O
insulin,NN,D
requirements,NNS,O
.,.,.
,,
other,JJ,O
cns,NNS,O
depressant,NN,O
drugs,NNS,D
-lrb-,-LRB-,O
e.g.,FW,O
barbiturates,FW,G
",",",",O
tranquilizers,NNS,G
",",",",O
opioids,NNS,G
and,CC,O
general,JJ,O
anesthetics,NNS,G
-rrb-,-RRB-,O
have,VBP,O
additive,JJ,O
or,CC,O
potentiating,NN,O
effects,NNS,O
with,IN,O
inapsine,NN,B
.,.,.
,,
when,WRB,O
patients,NNS,O
have,VBP,O
received,VBN,O
such,JJ,O
drugs,NNS,D
",",",",O
the,DT,O
dose,NN,O
of,IN,O
inapsine,NN,B
required,VBN,O
will,MD,O
be,VB,O
less,JJR,O
than,IN,O
usual,JJ,O
.,.,.
,,
following,VBG,O
the,DT,O
administration,NN,O
of,IN,O
inapsine,NNP,B
",",",",O
the,DT,O
dose,NN,O
of,IN,O
other,JJ,O
cns,NNS,O
depressant,NN,O
drugs,NNS,D
should,MD,O
be,VB,O
reduced,VBN,O
.,.,.
,,
drug,NN,O
interaction,NN,O
studies,NNS,O
with,IN,O
xigris,NNP,B
have,VBP,O
not,RB,O
been,VBN,O
performed,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
severe,JJ,O
sepsis,NN,O
.,.,.
,,
however,RB,O
",",",",O
since,IN,O
there,EX,O
is,VBZ,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
bleeding,VBG,O
with,IN,O
xigris,NNP,B
",",",",O
caution,NN,O
should,MD,O
be,VB,O
employed,VBN,O
when,WRB,O
xigris,NNP,B
is,VBZ,O
used,VBN,O
with,IN,O
other,JJ,O
drugs,NNS,D
that,WDT,O
affect,VBP,O
hemostasis,NN,O
.,.,.
,,
approximately,RB,O
3-Feb,CD,O
of,IN,O
the,DT,O
patients,NNS,O
in,IN,O
the,DT,O
phase,NN,O
3,CD,O
study,NN,O
received,VBD,O
either,CC,O
prophylactic,NN,O
low,JJ,O
dose,NN,O
heparin,NN,D
-lrb-,-LRB-,O
unfractionated,JJ,O
heparin,NN,D
up,IN,O
to,TO,O
"15,000",CD,O
units/day,NNS,O
-rrb-,-RRB-,O
or,CC,O
prophylactic,NN,O
doses,NNS,O
of,IN,O
low,JJ,O
molecular,JJ,O
weight,NN,O
heparins,NNS,O
as,IN,O
indicated,VBN,O
in,IN,O
the,DT,O
prescribing,VBG,O
information,NN,O
for,IN,O
the,DT,O
specific,JJ,O
products,NNS,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
prophylactic,NN,O
low,JJ,O
dose,NN,O
heparin,NN,D
did,VBD,O
not,RB,O
appear,VB,O
to,TO,O
affect,VB,O
safety,NN,O
",",",",O
however,RB,O
",",",",O
its,PRP$,O
effects,NNS,O
on,IN,O
the,DT,O
efficacy,NN,O
of,IN,O
xigris,NNP,B
have,VBP,O
not,RB,O
been,VBN,O
evaluated,VBN,O
in,IN,O
an,DT,O
adequate,JJ,O
and,CC,O
well-controlled,JJ,O
clinical,JJ,O
trial,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interaction,NN,O
because,IN,O
xigris,NNP,B
may,MD,O
affect,VB,O
the,DT,O
aptt,NN,O
assay,NN,O
",",",",O
xigris,NNP,B
present,JJ,O
in,IN,O
plasma,NN,O
samples,NNS,O
may,MD,O
interfere,VB,O
with,IN,O
one-stage,JJ,O
coagulation,NN,O
assays,NNS,O
based,VBN,O
on,IN,O
the,DT,O
aptt,NNP,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
factor,NN,O
viii,CD,O
",",",",O
ix,CD,O
",",",",O
and,CC,O
xi,NN,O
assays,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
this,DT,O
interference,NN,O
may,MD,O
result,VB,O
in,IN,O
an,DT,O
apparent,JJ,O
factor,NN,O
concentration,NN,O
that,WDT,O
is,VBZ,O
lower,JJR,O
than,IN,O
the,DT,O
TRUE,JJ,O
concentration,NN,O
.,.,.
,,
xigris,NNP,B
present,JJ,O
in,IN,O
plasma,NN,O
samples,NNS,O
does,VBZ,O
not,RB,O
interfere,VB,O
with,IN,O
one-stage,JJ,O
factor,NN,O
assays,NNS,O
based,VBN,O
on,IN,O
the,DT,O
pt,NN,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
factor,NN,O
ii,CD,O
",",",",O
v,NN,O
",",",",O
vii,NN,O
",",",",O
and,CC,O
x,NN,O
assays,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
potential,JJ,O
for,IN,O
other,JJ,O
drugs,NNS,O
to,TO,O
affect,VB,O
duloxetine,NNP,D
:,:,O
both,CC,O
cyp1a2,NN,D
and,CC,O
cyp2d6,NN,D
are,VBP,O
responsible,JJ,O
for,IN,O
duloxetine,NN,D
metabolism,NN,O
.,.,.
,,
inhibitors,NNS,O
of,IN,O
cyp1a2,NN,D
:,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
duloxetine,NN,D
with,IN,O
fluvoxamine,NN,D
",",",",O
an,DT,O
inhibitor,NN,O
of,IN,O
cyp1a2,NN,D
",",",",O
results,VBZ,O
in,IN,O
approximately,RB,O
a,DT,O
6-fold,RB,O
increase,NN,O
in,IN,O
auc,NN,O
and,CC,O
about,IN,O
a,DT,O
2.5-fold,JJ,O
increase,NN,O
in,IN,O
cmax,NN,O
of,IN,O
duloxetine,NN,D
.,.,.
,,
some,DT,O
quinolone,JJ,G
antibiotics,NNS,G
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
have,VB,O
similar,JJ,O
effects,NNS,O
and,CC,O
these,DT,O
combinations,NNS,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
inhibitors,NNS,O
of,IN,O
cyp2d6,NN,D
:,:,O
because,IN,O
cyp2d6,NN,D
is,VBZ,O
involved,VBN,O
in,IN,O
duloxetine,NN,D
metabolism,NN,O
",",",",O
concomitant,JJ,O
use,NN,O
of,IN,O
duloxetine,NN,D
with,IN,O
potent,JJ,O
inhibitors,NNS,O
of,IN,O
cyp2d6,NN,D
may,MD,O
result,VB,O
in,IN,O
higher,JJR,O
concentrations,NNS,O
of,IN,O
duloxetine,NN,D
.,.,.
,,
paroxetine,NNP,D
-lrb-,-LRB-,O
20,CD,O
mg,NN,O
qd,NN,O
-rrb-,-RRB-,O
increased,VBD,O
the,DT,O
concentration,NN,O
of,IN,O
duloxetine,NN,D
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
qd,NN,O
-rrb-,-RRB-,O
by,IN,O
about,RB,O
60,CD,O
%,NN,O
",",",",O
and,CC,O
greater,JJR,O
degrees,NNS,O
of,IN,O
inhibition,NN,O
are,VBP,O
expected,VBN,O
with,IN,O
higher,JJR,O
doses,NNS,O
of,IN,O
paroxetine,NN,D
.,.,.
,,
similar,JJ,O
effects,NNS,O
would,MD,O
be,VB,O
expected,VBN,O
with,IN,O
other,JJ,O
potent,JJ,O
cyp2d6,NN,D
inhibitors,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
fluoxetine,NN,D
",",",",O
quinidine,NN,D
-rrb-,-RRB-,O
.,.,.
,,
potential,JJ,O
for,IN,O
duloxetine,NNP,D
to,TO,O
affect,VB,O
other,JJ,O
drugs,NNS,O
:,:,O
drugs,NNS,O
metabolized,VBN,O
by,IN,O
cyp1a2,NN,D
:,:,O
in,FW,O
vitro,FW,O
drug,NN,D
interaction,NN,O
studies,NNS,O
demonstrate,VBP,O
that,IN,O
duloxetine,NN,D
does,VBZ,O
not,RB,O
induce,VB,O
cyp1a2,NN,D
activity,NN,O
",",",",O
and,CC,O
it,PRP,O
is,VBZ,O
unlikely,JJ,O
to,TO,O
have,VB,O
a,DT,O
clinically,RB,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
cyp1a2,NN,D
substrates,NNS,O
.,.,.
,,
drugs,NNS,O
metabolized,VBN,O
by,IN,O
cyp2d6,NN,D
:,:,O
duloxetine,NNP,D
is,VBZ,O
a,DT,O
moderate,JJ,O
inhibitor,NN,O
of,IN,O
cyp2d6,NN,D
.,.,.
,,
when,WRB,O
duloxetine,NN,D
was,VBD,O
administered,VBN,O
-lrb-,-LRB-,O
at,IN,O
a,DT,O
dose,NN,O
of,IN,O
60,CD,O
mg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
in,IN,O
conjunction,NN,O
with,IN,O
a,DT,O
single,JJ,O
50-mg,JJ,O
dose,NN,O
of,IN,O
desipramine,NN,D
",",",",O
a,DT,O
cyp2d6,NN,D
substrate,NN,O
",",",",O
the,DT,O
auc,NN,O
of,IN,O
desipramine,NN,D
increased,VBD,O
3-fold,RB,O
.,.,.
,,
therefore,RB,O
",",",",O
co-administration,NN,O
of,IN,O
duloxetine,NN,D
with,IN,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
extensively,RB,O
metabolized,VBN,O
by,IN,O
this,DT,O
isozyme,NN,O
and,CC,O
which,WDT,O
have,VBP,O
a,DT,O
narrow,JJ,O
therapeutic,JJ,O
index,NN,O
",",",",O
including,VBG,O
certain,JJ,O
antidepressants,NNS,G
-lrb-,-LRB-,O
tricyclic,JJ,G
antidepressants,NNS,G
-lsb-,-LRB-,O
tcas,NNS,G
-rsb-,-RRB-,O
",",",",O
such,JJ,O
as,IN,O
nortriptyline,NN,D
",",",",O
amitriptyline,NNP,D
",",",",O
and,CC,O
imipramine,NN,D
-rrb-,-RRB-,O
",",",",O
phenothiazines,NNS,G
and,CC,O
type,NN,O
1c,NN,O
antiarrhythmics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
propafenone,NN,D
",",",",O
flecainide,NN,D
-rrb-,-RRB-,O
",",",",O
should,MD,O
be,VB,O
approached,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
plasma,NN,O
tca,NN,G
concentrations,NNS,O
may,MD,O
need,VB,O
to,TO,O
be,VB,O
monitored,VBN,O
and,CC,O
the,DT,O
dose,NN,O
of,IN,O
the,DT,O
tca,NNP,G
may,MD,O
need,VB,O
to,TO,O
be,VB,O
reduced,VBN,O
if,IN,O
a,DT,O
tca,NNP,G
is,VBZ,O
co-administered,VBN,O
with,IN,O
duloxetine,NN,D
.,.,.
,,
because,IN,O
of,IN,O
the,DT,O
risk,NN,O
of,IN,O
serious,JJ,O
ventricular,JJ,O
arrhythmias,NNS,O
and,CC,O
sudden,JJ,O
death,NN,O
potentially,RB,O
associated,VBN,O
with,IN,O
elevated,JJ,O
plasma,NN,O
levels,NNS,O
of,IN,O
thioridazine,NN,D
",",",",O
duloxetine,NNP,D
and,CC,O
thioridazine,NN,D
should,MD,O
not,RB,O
be,VB,O
co-administered,VBN,O
.,.,.
,,
drugs,NNS,O
metabolized,VBN,O
by,IN,O
cyp3a,NN,O
:,:,O
results,NNS,O
of,IN,O
in,FW,O
vitro,FW,O
studies,NNS,O
demonstrate,VBP,O
that,IN,O
duloxetine,NN,D
does,VBZ,O
not,RB,O
inhibit,VB,O
or,CC,O
induce,VB,O
cyp3a,NN,O
activity,NN,O
.,.,.
,,
duloxetine,NNP,D
may,NNP,O
have,VBP,O
a,DT,O
clinically,RB,O
important,JJ,O
interaction,NN,O
with,IN,O
the,DT,O
following,VBG,O
other,JJ,O
drugs,NNS,O
:,:,O
alcohol,NNP,D
:,:,O
when,WRB,O
duloxetine,NNP,D
and,CC,O
ethanol,NN,D
were,VBD,O
administered,VBN,O
several,JJ,O
hours,NNS,O
apart,RB,O
so,RB,O
that,IN,O
peak,JJ,O
concentrations,NNS,O
of,IN,O
each,DT,O
would,MD,O
coincide,VB,O
",",",",O
duloxetine,NNP,D
did,VBD,O
not,RB,O
increase,VB,O
the,DT,O
impairment,NN,O
of,IN,O
mental,JJ,O
and,CC,O
motor,NN,O
skills,NNS,O
caused,VBN,O
by,IN,O
alcohol,NN,D
.,.,.
,,
in,IN,O
the,DT,O
duloxetine,NNP,D
clinical,JJ,O
trials,NNS,O
database,NN,O
",",",",O
three,CD,O
duloxetine-treated,JJ,O
patients,NNS,O
had,VBD,O
liver,NN,O
injury,NN,O
as,IN,O
manifested,VBN,O
by,IN,O
alt,NNP,O
and,CC,O
total,JJ,O
bilirubin,NN,O
elevations,NNS,O
",",",",O
with,IN,O
evidence,NN,O
of,IN,O
obstruction,NN,O
.,.,.
,,
substantial,JJ,O
intercurrent,JJ,O
ethanol,NN,D
use,NN,O
was,VBD,O
present,JJ,O
in,IN,O
each,DT,O
of,IN,O
these,DT,O
cases,NNS,O
",",",",O
and,CC,O
this,DT,O
may,MD,O
have,VB,O
contributed,VBN,O
to,TO,O
the,DT,O
abnormalities,NNS,O
seen,VBN,O
.,.,.
,,
cns,NN,O
acting,NN,O
drugs,NNS,O
:,:,O
given,VBN,O
the,DT,O
primary,JJ,O
cns,NN,O
effects,NNS,O
of,IN,O
duloxetine,NNP,D
",",",",O
it,PRP,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
when,WRB,O
it,PRP,O
is,VBZ,O
taken,VBN,O
in,IN,O
combination,NN,O
with,IN,O
or,CC,O
substituted,VBN,O
for,IN,O
other,JJ,O
centrally,RB,O
acting,VBG,O
drugs,NNS,D
",",",",O
including,VBG,O
those,DT,O
with,IN,O
a,DT,O
similar,JJ,O
mechanism,NN,O
of,IN,O
action,NN,O
.,.,.
,,
potential,JJ,O
for,IN,O
interaction,NN,O
with,IN,O
drugs,NNS,O
that,WDT,O
affect,VBP,O
gastric,JJ,O
acidity,NN,O
:,:,O
duloxetine,NNP,D
has,VBZ,O
an,DT,O
enteric,JJ,O
coating,NN,O
that,WDT,O
resists,VBZ,O
dissolution,NN,O
until,IN,O
reaching,VBG,O
a,DT,O
segment,NN,O
of,IN,O
the,DT,O
gastrointestinal,JJ,O
tract,NN,O
where,WRB,O
the,DT,O
ph,NN,O
exceeds,VBZ,O
5.5,CD,O
.,.,.
,,
in,IN,O
extremely,RB,O
acidic,JJ,O
conditions,NNS,O
",",",",O
duloxetine,NNP,D
",",",",O
unprotected,JJ,O
by,IN,O
the,DT,O
enteric,JJ,O
coating,NN,O
",",",",O
may,MD,O
undergo,VB,O
hydrolysis,NN,O
to,TO,O
form,VB,O
naphthol,NN,O
.,.,.
,,
caution,NN,O
is,VBZ,O
advised,VBN,O
in,IN,O
using,VBG,O
duloxetine,NNP,D
in,IN,O
patients,NNS,O
with,IN,O
conditions,NNS,O
that,WDT,O
may,MD,O
slow,VB,O
gastric,JJ,O
emptying,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
some,DT,O
diabetics,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
raise,VBP,O
the,DT,O
gastrointestinal,JJ,O
ph,NN,O
may,MD,O
lead,VB,O
to,TO,O
an,DT,O
earlier,JJR,O
release,NN,O
of,IN,O
duloxetine,NN,D
.,.,.
,,
however,RB,O
",",",",O
co-administration,NN,O
of,IN,O
duloxetine,NN,D
with,IN,O
aluminum,NN,D
-,:,O
and,CC,O
magnesium-containing,JJ,O
antacids,NNS,G
-lrb-,-LRB-,O
51,CD,O
meq,NN,O
-rrb-,-RRB-,O
or,CC,O
duloxetine,NN,D
with,IN,O
famotidine,NN,D
",",",",O
had,VBD,O
no,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
rate,NN,O
or,CC,O
extent,NN,O
of,IN,O
duloxetine,NN,D
absorption,NN,O
after,IN,O
administration,NN,O
of,IN,O
a,DT,O
40-mg,JJ,O
oral,JJ,O
dose,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
unknown,JJ,O
whether,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
proton,NN,O
pump,NN,O
inhibitors,NNS,O
affects,VBZ,O
duloxetine,NN,D
absorption,NN,O
.,.,.
,,
synergism,NN,O
between,IN,O
xanthine,NN,O
bronchodilators,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
theophylline,NN,D
-rrb-,-RRB-,O
",",",",O
ephedrine,NN,D
",",",",O
and,CC,O
other,JJ,O
sympathomimetic,JJ,G
bronchodilators,NNS,G
has,VBZ,O
been,VBN,O
reported,VBN,O
.,.,.
,,
this,DT,O
should,MD,O
be,VB,O
considered,VBN,O
whenever,WRB,O
these,DT,O
agents,NNS,O
are,VBP,O
prescribed,VBN,O
concomitantly,RB,O
.,.,.
,,
concurrent,JJ,O
administration,NN,O
of,IN,O
dyphylline,NN,D
and,CC,O
probenecid,NN,D
",",",",O
which,WDT,O
competes,VBZ,O
for,IN,O
tubular,JJ,O
secretion,NN,O
",",",",O
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
increase,VB,O
the,DT,O
plasma,NN,O
half-life,NN,O
of,IN,O
dyphylline,NN,D
.,.,.
,,
phospholine,NN,O
iodide,NN,O
potentiates,VBZ,O
other,JJ,O
cholinesterase,NN,O
inhibitors,NNS,O
such,JJ,O
as,IN,O
succinylcholine,NN,D
or,CC,O
organophosphate,NN,O
and,CC,O
carbamate,NN,O
insecticides,NNS,O
.,.,.
,,
patients,NNS,O
undergoing,VBG,O
systemic,JJ,O
anticholinesterase,NN,G
treatment,NN,O
should,MD,O
be,VB,O
warned,VBN,O
of,IN,O
the,DT,O
possible,JJ,O
additive,JJ,O
effects,NNS,O
of,IN,O
phospholine,NNP,O
iodide,NNP,O
.,.,.
,,
drug,NN,O
interaction,NN,O
studies,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
performed,VBN,O
with,IN,O
soliris,NNP,B
.,.,.
,,
there,EX,O
is,VBZ,O
no,DT,O
known,JJ,O
drug,NN,D
interference,NN,O
with,IN,O
standard,JJ,O
clinical,JJ,O
laboratory,NN,O
tests,NNS,O
.,.,.
,,
steroids,NNS,G
enhance,VBP,O
the,DT,O
renal,JJ,O
toxicity,NN,O
of,IN,O
edetate,NN,O
calcium,NN,D
disodium,NN,O
in,IN,O
animals,NNS,O
.,.,.
,,
7,CD,O
edetate,NNP,O
calcium,NN,D
disodium,NN,O
interferes,VBZ,O
with,IN,O
the,DT,O
action,NN,O
of,IN,O
zinc,NN,D
insulin,NN,D
preparations,NNS,O
by,IN,O
chelating,VBG,O
the,DT,O
zinc,NN,D
.,.,.
,,
.,.,.
,,
care,NNP,O
should,MD,O
be,VB,O
given,VBN,O
when,WRB,O
administering,VBG,O
this,DT,O
drug,NN,D
to,TO,O
patients,NNS,O
with,IN,O
symptoms,NNS,O
of,IN,O
myasthenic,JJ,O
weakness,NN,O
who,WP,O
are,VBP,O
also,RB,O
on,IN,O
anticholinesterase,JJ,G
drugs,NNS,D
.,.,.
,,
since,IN,O
symptoms,NNS,O
of,IN,O
anticholinesterase,NN,G
overdose,NN,O
-lrb-,-LRB-,O
cholinergic,JJ,O
crisis,NN,O
-rrb-,-RRB-,O
may,MD,O
mimic,VB,O
underdosage,NN,O
-lrb-,-LRB-,O
myasthenic,JJ,O
weakness,NN,O
-rrb-,-RRB-,O
",",",",O
their,PRP$,O
condition,NN,O
may,MD,O
be,VB,O
worsened,VBN,O
by,IN,O
the,DT,O
use,NN,O
of,IN,O
this,DT,O
drug,NN,D
.,.,.
,,
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
with,IN,O
raptiva,NN,B
.,.,.
,,
raptiva,NN,B
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
with,IN,O
other,JJ,O
immunosuppressive,JJ,G
drugs,NNS,D
.,.,.
,,
acellular,JJ,O
",",",",O
live,JJ,O
and,CC,O
live-attenuated,JJ,O
vaccines,NNS,G
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
during,IN,O
raptiva,NN,B
treatment,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
increases,NNS,O
in,IN,O
lymphocyte,NN,O
counts,VBZ,O
related,JJ,O
to,TO,O
the,DT,O
pharmacologic,JJ,O
mechanism,NN,O
of,IN,O
action,NN,O
are,VBP,O
frequently,RB,O
observed,VBN,O
during,IN,O
raptiva,NN,B
treatment,NN,O
.,.,.
,,
efavirenz,NNP,D
has,VBZ,O
been,VBN,O
shown,VBN,O
in,FW,O
vivo,FW,O
to,TO,O
induce,VB,O
cyp3a4,NN,D
.,.,.
,,
other,JJ,O
compounds,NNS,O
that,WDT,O
are,VBP,O
substrates,NNS,O
of,IN,O
cyp3a4,NN,D
may,MD,O
have,VB,O
decreased,VBN,O
plasma,NN,O
concentrations,NNS,O
when,WRB,O
coadministered,VBN,O
with,IN,O
sustiva,NN,B
-lrb-,-LRB-,O
efavirenz,NN,D
-rrb-,-RRB-,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
have,VBP,O
demonstrated,VBN,O
that,IN,O
efavirenz,NN,D
inhibits,VBZ,O
2c9,NN,O
",",",",O
2c19,NN,O
",",",",O
and,CC,O
3a4,NN,O
isozymes,NNS,O
in,IN,O
the,DT,O
range,NN,O
of,IN,O
observed,VBN,O
efavirenz,NN,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
coadministration,NN,O
of,IN,O
efavirenz,NN,D
with,IN,O
drugs,NNS,D
primarily,RB,O
metabolized,VBN,O
by,IN,O
these,DT,O
isozymes,NNS,O
may,MD,O
result,VB,O
in,IN,O
altered,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
the,DT,O
coadministered,VBN,O
drug,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
appropriate,JJ,O
dose,NN,O
adjustments,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
for,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
drugs,NNS,O
which,WDT,O
induce,VBP,O
cyp3a4,NN,D
activity,NN,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
phenobarbital,JJ,D
",",",",O
rifampin,NN,D
",",",",O
rifabutin,NN,D
-rrb-,-RRB-,O
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
increase,VB,O
the,DT,O
clearance,NN,O
of,IN,O
efavirenz,NN,D
resulting,VBG,O
in,IN,O
lowered,JJ,O
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
drug,NN,O
interactions,NNS,O
with,IN,O
sustiva,NN,B
are,VBP,O
summarized,VBN,O
in,IN,O
table,NNP,O
5,CD,O
.,.,.
,,
table,NNP,O
5a,NN,O
:,:,O
drugs,NNS,O
that,WDT,O
should,MD,O
not,RB,O
be,VB,O
coadministered,JJ,O
with,IN,O
sustiv,NN,O
.,.,.
,,
drug,NN,O
class,NN,O
.,.,.
,,
drugs,NNS,O
within,IN,O
class,NNP,O
not,RB,O
to,TO,O
be,VB,O
coadministered,JJ,O
with,IN,O
sustiv,NN,O
.,.,.
,,
antihistamines,NNS,D
:,:,O
benzodiazepines,NNPS,G
gi,NNP,O
motility,NNP,O
agents,NNPS,O
anti-migraine,NNP,G
antifunga,NNP,O
.,.,.
,,
astemizole,NN,D
midazolam,NN,D
",",",",O
triazolam,NN,D
cisapride,NN,D
ergot,NN,G
derivatives,NNS,O
voriconazol,NN,O
.,.,.
,,
established,VBN,O
drug,NN,O
interactions,NNS,O
.,.,.
,,
drug,NN,O
name,VB,O
.,.,.
,,
effect,NN,O
.,.,.
,,
clinical,JJ,O
comment,NN,O
.,.,.
,,
atazanavi,NNP,O
.,.,.
,,
atazanavi,NN,O
.,.,.
,,
when,WRB,O
coadministered,VBN,O
with,IN,O
sustiva,NN,B
in,IN,O
treatment-naive,JJ,O
patients,NNS,O
",",",",O
the,DT,O
recommended,VBN,O
dose,NN,O
of,IN,O
atazanavir,NN,D
is,VBZ,O
300,CD,O
mg,NN,O
with,IN,O
ritonavir,NN,D
100,CD,O
mg,NN,O
and,CC,O
sustiva,NN,B
600,CD,O
mg,NN,O
-lrb-,-LRB-,O
all,DT,O
once,RB,O
daily,JJ,O
-rrb-,-RRB-,O
.,.,.
,,
dosing,NN,O
recommendations,NNS,O
for,IN,O
sustiva,NNP,B
and,CC,O
atazanavir,NN,D
in,IN,O
treatment-experienced,JJ,O
patients,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
established,VBN,O
drug,NN,O
interactions,NNS,O
-lrb-,-LRB-,O
continued,VBN,O
-rrb-,-RRB-,O
.,.,.
,,
drug,NN,O
name,VB,O
.,.,.
,,
effect,NN,O
.,.,.
,,
clinical,JJ,O
comment,NN,O
.,.,.
,,
clarithromyci,NNP,O
.,.,.
,,
clarithromycin,NN,D
concentratio,NN,O
.,.,.
,,
plasma,NN,O
concentrations,NNS,O
decreased,VBN,O
by,IN,O
sustiva,NNP,B
.,.,.
,,
clinical,JJ,O
significance,NN,O
unknown,NN,O
.,.,.
,,
in,IN,O
uninfected,JJ,O
volunteers,NNS,O
",",",",O
46,CD,O
%,NN,O
developed,VBD,O
rash,NN,O
while,IN,O
receiving,VBG,O
sustiva,NNP,B
and,CC,O
clarithromycin,NN,D
.,.,.
,,
no,DT,O
dose,NN,O
adjustment,NN,O
of,IN,O
sustiva,NNP,B
is,VBZ,O
recommended,VBN,O
when,WRB,O
given,VBN,O
with,IN,O
clarithromycin,NN,D
.,.,.
,,
alternatives,NNP,O
to,TO,O
clarithromycin,NN,D
",",",",O
such,JJ,O
as,IN,O
azithromycin,NN,D
",",",",O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
other,JJ,O
macrolide,NN,O
antibiotics,NNS,G
",",",",O
such,JJ,O
as,IN,O
erythromycin,NN,D
",",",",O
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
in,IN,O
combination,NN,O
with,IN,O
sustiva,NN,B
.,.,.
,,
14-oh,JJ,O
metabolite,NN,O
concentration,NN,O
.,.,.
,,
indinavi,NNP,O
.,.,.
,,
indinavir,NN,D
concentratio,NN,O
.,.,.
,,
the,DT,O
optimal,JJ,O
dose,NN,O
of,IN,O
indinavir,NN,D
",",",",O
when,WRB,O
given,VBN,O
in,IN,O
combination,NN,O
with,IN,O
sustiva,NNP,B
",",",",O
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
increasing,VBG,O
the,DT,O
indinavir,NN,D
dose,NN,O
to,TO,O
1000,CD,O
mg,NN,O
every,DT,O
8,CD,O
hours,NNS,O
does,VBZ,O
not,RB,O
compensate,VB,O
for,IN,O
the,DT,O
increased,VBN,O
indinavir,NN,D
metabolism,NN,O
due,JJ,O
to,TO,O
sustiva,NNP,B
.,.,.
,,
when,WRB,O
indinavir,NN,D
at,IN,O
an,DT,O
increased,VBN,O
dose,NN,O
-lrb-,-LRB-,O
1000,CD,O
mg,NN,O
every,DT,O
8,CD,O
hours,NNS,O
-rrb-,-RRB-,O
was,VBD,O
given,VBN,O
with,IN,O
sustiva,NN,B
-lrb-,-LRB-,O
600,CD,O
mg,NN,O
once,RB,O
daily,JJ,O
-rrb-,-RRB-,O
",",",",O
the,DT,O
indinavir,NN,D
auc,NN,O
and,CC,O
cmin,NN,O
were,VBD,O
decreased,VBN,O
on,IN,O
average,NN,O
by,IN,O
33-46,CD,O
%,NN,O
and,CC,O
39-57,CD,O
%,NN,O
",",",",O
respectively,RB,O
",",",",O
compared,VBN,O
to,TO,O
when,WRB,O
indinavir,NN,D
-lrb-,-LRB-,O
800,CD,O
mg,NN,O
every,DT,O
8,CD,O
hours,NNS,O
-rrb-,-RRB-,O
was,VBD,O
given,VBN,O
alone,RB,O
.,.,.
,,
lopinavir/ritonavi,NN,O
.,.,.
,,
lopinavir,NN,D
concentratio,NN,O
.,.,.
,,
a,DT,O
dose,NN,O
increase,NN,O
of,IN,O
lopinavir/ritonavir,NN,O
to,TO,O
533/133,CD,O
mg,NN,O
-lrb-,-LRB-,O
4,CD,O
capsules,NNS,O
or,CC,O
6.5,CD,O
ml,NN,O
-rrb-,-RRB-,O
twice,RB,O
daily,JJ,O
taken,VBN,O
with,IN,O
food,NN,O
is,VBZ,O
recommended,VBN,O
when,WRB,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
sustiva,NN,B
.,.,.
,,
methadon,NNP,O
.,.,.
,,
methadone,NN,D
concentratio,NN,O
.,.,.
,,
coadministration,NNP,O
in,IN,O
hiv-infected,JJ,O
individuals,NNS,O
with,IN,O
a,DT,O
history,NN,O
of,IN,O
injection,NN,O
drug,NN,D
use,NN,O
resulted,VBD,O
in,IN,O
decreased,VBN,O
plasma,NN,O
levels,NNS,O
of,IN,O
methadone,NN,D
and,CC,O
signs,NNS,O
of,IN,O
opiate,JJ,G
withdrawal,NN,O
.,.,.
,,
methadone,NNP,D
dose,NN,O
was,VBD,O
increased,VBN,O
by,IN,O
a,DT,O
mean,NN,O
of,IN,O
22,CD,O
%,NN,O
to,TO,O
alleviate,VB,O
withdrawal,NN,O
symptoms,NNS,O
.,.,.
,,
patients,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
for,IN,O
signs,NNS,O
of,IN,O
withdrawal,NN,O
and,CC,O
their,PRP$,O
methadone,NN,D
dose,NN,O
increased,VBD,O
as,IN,O
required,VBN,O
to,TO,O
alleviate,VB,O
withdrawal,NN,O
symptoms,NNS,O
.,.,.
,,
ethinyl,NN,O
estradio,NN,O
.,.,.
,,
ethinyl,NN,O
estradiol,NN,O
concentratio,NN,O
.,.,.
,,
plasma,NN,O
concentrations,NNS,O
increased,VBN,O
by,IN,O
sustiva,NN,B
-lrb-,-LRB-,O
efavirenz,NN,D
-rrb-,-RRB-,O
.,.,.
,,
clinical,JJ,O
significance,NN,O
unknown,NN,O
.,.,.
,,
because,IN,O
the,DT,O
potential,JJ,O
interaction,NN,O
of,IN,O
efavirenz,NN,D
with,IN,O
oral,JJ,O
contraceptives,NNS,G
has,VBZ,O
not,RB,O
been,VBN,O
fully,RB,O
characterized,VBN,O
",",",",O
a,DT,O
reliable,JJ,O
method,NN,O
of,IN,O
barrier,NN,O
contraception,NN,O
should,MD,O
be,VB,O
used,VBN,O
in,IN,O
addition,NN,O
to,TO,O
oral,JJ,O
contraceptives,NNS,G
.,.,.
,,
rifabuti,NNP,O
.,.,.
,,
rifabutin,NN,D
concentratio,NN,O
.,.,.
,,
increase,NN,O
daily,RB,O
dose,NN,O
of,IN,O
rifabutin,NN,D
by,IN,O
50,CD,O
%,NN,O
.,.,.
,,
consider,VB,O
doubling,VBG,O
the,DT,O
rifabutin,NN,D
dose,NN,O
in,IN,O
regimens,NNS,O
where,WRB,O
rifabutin,NN,D
is,VBZ,O
given,VBN,O
2,CD,O
or,CC,O
3,CD,O
times,NNS,O
a,DT,O
week,NN,O
.,.,.
,,
rifampi,NNP,O
.,.,.
,,
efavirenz,NN,D
concentratio,NN,O
.,.,.
,,
clinical,JJ,O
significance,NN,O
of,IN,O
reduced,VBN,O
efavirenz,NN,D
concentrations,NNS,O
unknown,JJ,O
.,.,.
,,
ritonavi,NNP,O
.,.,.
,,
ritonavir,NN,D
concentratio,NN,O
.,.,.
,,
combination,NN,O
was,VBD,O
associated,VBN,O
with,IN,O
a,DT,O
higher,JJR,O
frequency,NN,O
of,IN,O
adverse,JJ,O
clinical,JJ,O
experiences,NNS,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
dizziness,NN,O
",",",",O
nausea,NN,O
",",",",O
paresthesia,NN,O
-rrb-,-RRB-,O
and,CC,O
laboratory,NN,O
abnormalities,NNS,O
-lrb-,-LRB-,O
elevated,JJ,O
liver,NN,O
enzymes,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
monitoring,NN,O
of,IN,O
liver,NN,O
enzymes,NNS,O
is,VBZ,O
recommended,VBN,O
when,WRB,O
sustiva,NNP,B
is,VBZ,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
ritonavir,NN,D
.,.,.
,,
efavirenz,NN,D
concentratio,NN,O
.,.,.
,,
saquinavi,NNP,O
.,.,.
,,
saquinavir,NN,D
concentratio,NN,O
.,.,.
,,
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
as,IN,O
sole,JJ,O
protease,NN,O
inhibitor,NN,O
in,IN,O
combination,NN,O
with,IN,O
sustiva,NN,B
.,.,.
,,
sertralin,NN,O
.,.,.
,,
sertraline,NN,D
concentratio,NN,O
.,.,.
,,
increases,NNS,O
in,IN,O
sertraline,NN,D
dose,NN,O
should,MD,O
be,VB,O
guided,VBN,O
by,IN,O
clinical,JJ,O
response,NN,O
.,.,.
,,
other,JJ,O
potentially,RB,O
clinically,RB,O
significant,JJ,O
drug,NN,O
or,CC,O
herbal,NNP,O
product,NNP,O
interactions,NNS,O
with,IN,O
sustivab,NN,O
.,.,.
,,
anticoagulants,NNPS,G
:,:,O
warfari,NNS,O
.,.,.
,,
plasma,NN,O
concentrations,NNS,O
and,CC,O
effects,NNS,O
potentially,RB,O
increased,VBD,O
or,CC,O
decreased,VBN,O
by,IN,O
sustiva,NNP,B
.,.,.
,,
anticonvulsants,NNPS,G
:,:,O
phenytoin,NNP,D
phenobarbital,NNP,D
carbamazepin,NNP,O
.,.,.
,,
potential,JJ,O
for,IN,O
reduction,NN,O
in,IN,O
anticonvulsant,JJ,G
and/or,CC,O
efavirenz,JJ,D
plasma,NN,O
levels,NNS,O
.,.,.
,,
periodic,JJ,O
monitoring,NN,O
of,IN,O
anticonvulsant,JJ,G
plasma,NN,O
levels,NNS,O
should,MD,O
be,VB,O
conducted,VBN,O
.,.,.
,,
antifungals,NNS,G
:,:,O
itraconazole,NNP,D
ketoconazol,NNP,O
.,.,.
,,
drug,NN,O
interaction,NN,O
studies,NNS,O
with,IN,O
sustiva,NN,B
and,CC,O
these,DT,O
imidazole,NN,G
and,CC,O
triazole,NN,O
antifungals,NNS,G
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
sustiva,NNP,B
has,VBZ,O
the,DT,O
potential,JJ,O
to,TO,O
decrease,VB,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
itraconazole,NN,D
and,CC,O
ketoconazole,NN,D
.,.,.
,,
anti-hiv,JJ,O
protease,NN,O
inhibitors,NNS,O
:,:,O
saquinavir/ritonavir,NN,O
combinatio,NN,O
.,.,.
,,
no,DT,O
pharmacokinetic,JJ,O
data,NNS,O
are,VBP,O
available,JJ,O
.,.,.
,,
amprenavi,NNP,O
.,.,.
,,
sustivahas,NNS,O
the,DT,O
potential,JJ,O
to,TO,O
decrease,VB,O
serum,NN,O
concentrations,NNS,O
of,IN,O
amprenavir,NN,D
.,.,.
,,
non-nucleoside,JJ,O
reverse,JJ,O
transcriptase,NN,O
inhibitor,NN,O
.,.,.
,,
no,DT,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
with,IN,O
other,JJ,O
nnrtis,NNS,G
.,.,.
,,
st.,NNP,O
john,NNP,O
s,VBZ,O
wort,NN,O
-lrb-,-LRB-,O
hypericum,NN,O
perforatum,NN,O
-rrb-,-RRB-,O
.,.,.
,,
expected,VBN,O
to,TO,O
substantially,RB,O
decrease,VB,O
plasma,NN,O
levels,NNS,O
of,IN,O
efavirenz,NN,D
;,:,O
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
in,IN,O
combination,NN,O
with,IN,O
sustiva,NN,B
.,.,.
,,
a,DT,O
see,NNP,O
tables,NNP,O
1,CD,O
and,CC,O
2,CD,O
.,.,.
,,
b,NN,O
this,DT,O
table,NN,O
is,VBZ,O
not,RB,O
all-inclusive,JJ,O
.,.,.
,,
other,JJ,O
drugs,NNS,O
:,:,O
based,VBN,O
on,IN,O
the,DT,O
results,NNS,O
of,IN,O
drug,NN,D
interaction,NN,O
studies,NNS,O
",",",",O
no,DT,O
dosage,NN,O
adjustment,NN,O
is,VBZ,O
recommended,VBN,O
when,WRB,O
sustiva,NNP,B
-lrb-,-LRB-,O
efavirenz,NN,D
-rrb-,-RRB-,O
is,VBZ,O
given,VBN,O
with,IN,O
the,DT,O
following,NN,O
:,:,O
aluminum/magnesium,NN,O
hydroxide,NN,O
antacids,NNS,G
",",",",O
azithromycin,NN,D
",",",",O
cetirizine,NN,D
",",",",O
famotidine,NN,D
",",",",O
fluconazole,NN,D
",",",",O
lamivudine,NN,D
",",",",O
lorazepam,NN,D
",",",",O
nelfinavir,NN,D
",",",",O
paroxetine,NN,D
",",",",O
and,CC,O
zidovudine,NN,D
.,.,.
,,
specific,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
performed,VBN,O
with,IN,O
sustiva,NN,B
and,CC,O
nrtis,NNS,G
other,JJ,O
than,IN,O
lamivudine,NN,D
and,CC,O
zidovudine,NN,D
.,.,.
,,
clinically,RB,O
significant,JJ,O
interactions,NNS,O
would,MD,O
not,RB,O
be,VB,O
expected,VBN,O
since,IN,O
the,DT,O
nrtis,NNS,G
are,VBP,O
metabolized,VBN,O
via,IN,O
a,DT,O
different,JJ,O
route,NN,O
than,IN,O
efavirenz,NN,D
and,CC,O
would,MD,O
be,VB,O
unlikely,JJ,O
to,TO,O
compete,VB,O
for,IN,O
the,DT,O
same,JJ,O
metabolic,JJ,O
enzymes,NNS,O
and,CC,O
elimination,NN,O
pathways,NNS,O
.,.,.
,,
the,DT,O
potential,NN,O
for,IN,O
drug,NN,D
interactions,NNS,O
with,IN,O
emtriva,NNP,B
has,VBZ,O
been,VBN,O
studied,VBN,O
in,IN,O
combination,NN,O
with,IN,O
indinavir,NN,D
",",",",O
stavudine,NN,D
",",",",O
famciclovir,NN,D
",",",",O
and,CC,O
tenofovir,NN,O
disoproxil,NN,O
fumarate,NN,O
.,.,.
,,
there,EX,O
were,VBD,O
no,DT,O
clinically,RB,O
significant,JJ,O
drug,NN,D
interactions,NNS,O
for,IN,O
any,DT,O
of,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
hypotension,NN,O
:,:,O
patients,NNS,O
on,IN,O
diuretic,JJ,G
therapy,NN,O
:,:,O
patients,NNS,O
on,IN,O
diuretics,NNS,G
and,CC,O
especially,RB,O
those,DT,O
in,IN,O
whom,WP,O
diuretic,JJ,G
therapy,NN,O
was,VBD,O
recently,RB,O
instituted,VBN,O
",",",",O
may,MD,O
occasionally,RB,O
experience,VB,O
an,DT,O
excessive,JJ,O
reduction,NN,O
of,IN,O
blood,NN,O
pressure,NN,O
after,IN,O
initiation,NN,O
of,IN,O
therapy,NN,O
with,IN,O
enalapril,NN,D
or,CC,O
enalaprilat,NN,D
.,.,.
,,
the,DT,O
possibility,NN,O
of,IN,O
hypotensive,JJ,O
effects,NNS,O
with,IN,O
enalapril,NN,D
or,CC,O
enalaprilat,NN,D
can,MD,O
be,VB,O
minimized,VBN,O
by,IN,O
either,CC,O
discontinuing,VBG,O
the,DT,O
diuretic,JJ,G
or,CC,O
increasing,VBG,O
the,DT,O
salt,NN,O
intake,NN,O
prior,RB,O
to,TO,O
initiation,NN,O
of,IN,O
treatment,NN,O
with,IN,O
enalapril,NN,D
or,CC,O
enalaprilat,NN,D
.,.,.
,,
if,IN,O
it,PRP,O
is,VBZ,O
necessary,JJ,O
to,TO,O
continue,VB,O
the,DT,O
diuretic,JJ,G
",",",",O
provide,VBP,O
close,JJ,O
medical,JJ,O
supervision,NN,O
after,IN,O
the,DT,O
initial,JJ,O
dose,NN,O
for,IN,O
at,IN,O
least,JJS,O
two,CD,O
hours,NNS,O
and,CC,O
until,IN,O
blood,NN,O
pressure,NN,O
has,VBZ,O
stabilized,VBN,O
for,IN,O
at,IN,O
least,JJS,O
an,DT,O
additional,JJ,O
hour,NN,O
.,.,.
,,
agents,NNS,O
causing,VBG,O
renin,NNP,O
release,NNP,O
:,:,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
enalapril,NN,D
and,CC,O
enalapril,NN,D
iv,CD,O
is,VBZ,O
augmented,VBN,O
by,IN,O
antihypertensive,JJ,G
agents,NNS,O
that,WDT,O
cause,VBP,O
renin,NN,O
release,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
diuretics,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
non-steroidal,JJ,O
anti-inflammatory,JJ,O
agents,NNS,O
:,:,O
in,IN,O
some,DT,O
patients,NNS,O
with,IN,O
compromised,VBN,O
renal,JJ,O
function,NN,O
who,WP,O
are,VBP,O
being,VBG,O
treated,VBN,O
with,IN,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
",",",",O
the,DT,O
co-administration,NN,O
of,IN,O
enalapril,NN,D
may,MD,O
result,VB,O
in,IN,O
a,DT,O
further,JJ,O
deterioration,NN,O
of,IN,O
renal,JJ,O
function,NN,O
.,.,.
,,
these,DT,O
effects,NNS,O
are,VBP,O
usually,RB,O
reversible,JJ,O
.,.,.
,,
in,IN,O
a,DT,O
clinical,JJ,O
pharmacology,NN,O
study,NN,O
",",",",O
indomethacin,NN,D
or,CC,O
sulindac,NN,D
was,VBD,O
administered,VBN,O
to,TO,O
hypertensive,JJ,O
patients,NNS,O
receiving,VBG,O
vasotec,NNP,B
.,.,.
,,
in,IN,O
this,DT,O
study,NN,O
there,EX,O
was,VBD,O
no,DT,O
evidence,NN,O
of,IN,O
a,DT,O
blunting,NN,O
of,IN,O
the,DT,O
antihypertensive,JJ,G
action,NN,O
of,IN,O
vasotec,NNP,B
.,.,.
,,
however,RB,O
",",",",O
reports,NNS,O
suggest,VBP,O
that,IN,O
nsaids,NNS,G
may,MD,O
diminish,VB,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
ace,NN,O
inhibitors,NNS,O
.,.,.
,,
this,DT,O
interaction,NN,O
should,MD,O
be,VB,O
given,VBN,O
consideration,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
nsaids,NNS,G
concomitantly,RB,O
with,IN,O
ace,NN,O
inhibitors,NNS,O
.,.,.
,,
other,JJ,O
cardiovascular,NNP,O
agents,NNPS,O
:,:,O
enalapril,NN,D
and,CC,O
enalapril,NN,D
iv,CD,O
have,VBP,O
been,VBN,O
used,VBN,O
concomitantly,RB,O
with,IN,O
beta,NN,O
adrenergic-blocking,JJ,O
agents,NNS,O
",",",",O
methyldopa,NN,D
",",",",O
nitrates,NNS,G
",",",",O
calcium-blocking,JJ,O
agents,NNS,O
",",",",O
hydralazine,NN,D
",",",",O
prazosin,NN,D
and,CC,O
digoxin,NN,D
without,IN,O
evidence,NN,O
of,IN,O
clinically,RB,O
significant,JJ,O
adverse,JJ,O
interactions,NNS,O
.,.,.
,,
enalapril,NNP,D
iv,NNP,O
has,VBZ,O
been,VBN,O
used,VBN,O
concomitantly,RB,O
with,IN,O
digitalis,NN,G
without,IN,O
evidence,NN,O
of,IN,O
clinically,RB,O
significant,JJ,O
adverse,JJ,O
reactions,NNS,O
.,.,.
,,
agents,NNS,O
increasing,VBG,O
serum,NN,O
potassium,NN,D
:,:,O
enalapril,NNP,D
and,CC,O
enalapril,NN,D
iv,CD,O
attenuate,VBP,O
potassium,NN,D
loss,NN,O
caused,VBN,O
by,IN,O
thiazide-type,JJ,O
diuretics,NNS,G
.,.,.
,,
potassium-sparing,JJ,O
diuretics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
spironolactone,NN,D
",",",",O
triamterene,NN,D
",",",",O
or,CC,O
amiloride,NN,D
-rrb-,-RRB-,O
",",",",O
potassium,NN,D
supplements,NNS,O
",",",",O
or,CC,O
potassium-containing,JJ,O
salt,NN,O
substitutes,NNS,O
may,MD,O
lead,VB,O
to,TO,O
significant,JJ,O
increases,NNS,O
in,IN,O
serum,NN,O
potassium,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
if,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
these,DT,O
agents,NNS,O
is,VBZ,O
indicated,VBN,O
because,IN,O
of,IN,O
demonstrated,VBN,O
hypokalemia,NN,O
",",",",O
they,PRP,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
and,CC,O
with,IN,O
frequent,JJ,O
monitoring,NN,O
of,IN,O
serum,NN,O
potassium,NN,D
.,.,.
,,
potassium,NN,D
sparing,NN,O
agents,NNS,O
should,MD,O
generally,RB,O
not,RB,O
be,VB,O
used,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
heart,NN,O
failure,NN,O
receiving,VBG,O
enalapril,NN,D
.,.,.
,,
lithium,NN,D
:,:,O
lithium,NN,D
toxicity,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
lithium,NN,D
concomitantly,RB,O
with,IN,O
drugs,NNS,D
which,WDT,O
cause,VBP,O
elimination,NN,O
of,IN,O
sodium,NN,O
",",",",O
including,VBG,O
ace,NN,O
inhibitors,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
serum,NN,O
lithium,NN,D
levels,NNS,O
be,VB,O
monitored,VBN,O
frequently,RB,O
if,IN,O
enalapril,NN,D
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
lithium,NN,D
.,.,.
,,
the,DT,O
action,NN,O
of,IN,O
nondepolarizing,JJ,O
relaxants,NNS,O
is,VBZ,O
augmented,VBN,O
by,IN,O
enflurane,NN,D
.,.,.
,,
less,RBR,O
than,IN,O
the,DT,O
usual,JJ,O
amounts,NNS,O
of,IN,O
these,DT,O
medicines,NNS,O
should,MD,O
be,VB,O
used,VBN,O
.,.,.
,,
if,IN,O
the,DT,O
usual,JJ,O
amounts,NNS,O
of,IN,O
nondepolarizing,JJ,O
relaxants,NNS,O
are,VBP,O
given,VBN,O
",",",",O
the,DT,O
time,NN,O
for,IN,O
recovery,NN,O
from,IN,O
neuromuscular,JJ,O
blockade,NN,O
will,MD,O
be,VB,O
longer,RBR,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
enflurane,NN,D
than,IN,O
when,WRB,O
halothane,NN,D
or,CC,O
nitrous,JJ,O
oxide,NN,O
with,IN,O
a,DT,O
balanced,JJ,O
technique,NN,O
are,VBP,O
used,VBN,O
.,.,.
,,
cyp450,NN,O
metabolized,VBN,O
drugs,NNS,O
results,NNS,O
from,IN,O
in,FW,O
vitro,FW,O
and,CC,O
in,FW,O
vivo,FW,O
studies,NNS,O
suggest,VBP,O
that,IN,O
enfuvirtide,NN,D
is,VBZ,O
unlikely,JJ,O
to,TO,O
have,VB,O
significant,JJ,O
drug,NN,D
interactions,NNS,O
with,IN,O
concomitantly,RB,O
administered,VBN,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
cyp450,NN,O
enzymes,NNS,O
.,.,.
,,
antiretroviral,JJ,O
agents,NNS,O
:,:,O
no,DT,O
drug,NN,D
interactions,NNS,O
with,IN,O
other,JJ,O
antiretroviral,JJ,G
medications,NNS,O
have,VBP,O
been,VBN,O
identified,VBN,O
that,WDT,O
would,MD,O
warrant,VB,O
alteration,NN,O
of,IN,O
either,CC,O
the,DT,O
enfuvirtide,NN,D
dose,NN,O
or,CC,O
the,DT,O
dose,NN,O
of,IN,O
the,DT,O
other,JJ,O
antiretroviral,JJ,G
medication,NN,O
.,.,.
,,
bismuth,NNP,D
:,:,O
bismuth,NNP,D
subsalicylate,NNP,O
",",",",O
given,VBN,O
concomitantly,RB,O
with,IN,O
enoxacin,NN,D
or,CC,O
60,CD,O
minutes,NNS,O
following,VBG,O
enoxacin,NN,D
administration,NN,O
",",",",O
decreased,VBD,O
enoxacin,NN,D
bioavailability,NN,O
by,IN,O
approximately,RB,O
25,CD,O
%,NN,O
.,.,.
,,
thus,RB,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
enoxacin,NN,D
and,CC,O
bismuth,NN,O
subsalicylate,NN,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
caffeine,NN,D
:,:,O
enoxacin,NN,D
is,VBZ,O
a,DT,O
potent,JJ,O
inhibitor,NN,O
of,IN,O
the,DT,O
cytochrome,NN,O
p-450,NN,O
isozymes,NNS,O
responsible,JJ,O
for,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
methylxanthines,NNS,G
.,.,.
,,
in,IN,O
a,DT,O
multiple-dose,JJ,O
study,NN,O
",",",",O
enoxacin,NN,D
caused,VBD,O
a,DT,O
dose-related,JJ,O
increase,NN,O
in,IN,O
the,DT,O
mean,NN,O
elimination,NN,O
half-life,NN,O
of,IN,O
caffeine,NN,D
",",",",O
thereby,RB,O
decreasing,VBG,O
the,DT,O
clearance,NN,O
of,IN,O
caffeine,NN,D
by,IN,O
up,RB,O
to,TO,O
80,CD,O
%,NN,O
and,CC,O
leading,VBG,O
to,TO,O
a,DT,O
five-fold,JJ,O
increase,NN,O
in,IN,O
the,DT,O
auc,NN,O
and,CC,O
the,DT,O
half-life,NN,O
of,IN,O
caffeine,NN,D
.,.,.
,,
trough,NN,O
plasma,NN,O
enoxacin,NN,D
levels,NNS,O
were,VBD,O
also,RB,O
20,CD,O
%,NN,O
higher,JJR,O
when,WRB,O
caffeine,NN,D
and,CC,O
enoxacin,NN,D
were,VBD,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
caffeine-related,JJ,O
adverse,JJ,O
effects,NNS,O
have,VBP,O
occurred,VBN,O
in,IN,O
patients,NNS,O
consuming,VBG,O
caffeine,NN,D
while,IN,O
on,IN,O
therapy,NN,O
with,IN,O
enoxacin,NN,D
.,.,.
,,
cyclosporine,NN,D
:,:,O
elevated,JJ,O
serum,NN,O
levels,NNS,O
of,IN,O
cyclosporine,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
cyclosporine,NN,D
with,IN,O
other,JJ,O
members,NNS,O
of,IN,O
the,DT,O
quinolone,NN,G
class,NN,O
.,.,.
,,
digoxin,NNP,D
:,:,O
enoxacin,NN,D
may,MD,O
raise,VB,O
serum,NN,O
digoxin,NN,D
levels,NNS,O
in,IN,O
some,DT,O
individuals,NNS,O
.,.,.
,,
if,IN,O
signs,NNS,O
and,CC,O
symptoms,NNS,O
suggestive,JJ,O
of,IN,O
digoxin,NN,D
toxicity,NN,O
occur,VBP,O
when,WRB,O
enoxacin,NN,D
and,CC,O
digoxin,NN,D
are,VBP,O
given,VBN,O
concomitantly,RB,O
",",",",O
physicians,NNS,O
are,VBP,O
advised,VBN,O
to,TO,O
obtain,VB,O
serum,NN,O
digoxin,NN,D
levels,NNS,O
and,CC,O
adjust,VBP,O
digoxin,NN,D
doses,NNS,O
appropriately,RB,O
.,.,.
,,
non-steroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
:,:,O
seizures,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
taking,VBG,O
enoxacin,NN,D
concomitantly,RB,O
with,IN,O
the,DT,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drug,NN,D
fenbufen,NN,D
.,.,.
,,
animal,NN,O
studies,NNS,O
also,RB,O
suggest,VBP,O
an,DT,O
increased,VBN,O
potential,NN,O
for,IN,O
seizures,NNS,O
when,WRB,O
these,DT,O
two,CD,O
drugs,NNS,D
are,VBP,O
given,VBN,O
concomitantly,RB,O
.,.,.
,,
fenbufen,NNP,D
is,VBZ,O
not,RB,O
approved,VBN,O
in,IN,O
the,DT,O
united,NNP,O
states,NNPS,O
at,IN,O
this,DT,O
time,NN,O
.,.,.
,,
sucralfate,NNP,D
and,CC,O
antacids,NNS,G
:,:,O
quinolones,NNS,G
form,VBP,O
chelates,NNS,O
with,IN,O
metal,NN,O
cations,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
administration,NN,O
of,IN,O
quinolones,NNS,G
with,IN,O
antacids,NNS,G
containing,VBG,O
calcium,NN,D
",",",",O
magnesium,NN,D
",",",",O
or,CC,O
aluminum,NN,D
.,.,.
,,
with,IN,O
sucralfate,NN,D
.,.,.
,,
with,IN,O
divalent,JJ,O
or,CC,O
trivalent,JJ,O
cations,NNS,O
such,JJ,O
as,IN,O
iron,NN,D
.,.,.
,,
or,CC,O
with,IN,O
multivitamins,NNS,G
containing,VBG,O
zinc,NN,D
may,MD,O
substantially,RB,O
interfere,VB,O
with,IN,O
drug,NN,D
absorption,NN,O
and,CC,O
result,NN,O
in,IN,O
insufficient,JJ,O
plasma,NN,O
and,CC,O
tissue,NN,O
quinolone,NN,G
concentrations,NNS,O
.,.,.
,,
antacids,NNS,G
containing,VBG,O
aluminum,NN,D
hydroxide,NN,O
and,CC,O
magnesium,NN,D
hydroxide,NN,O
reduce,VB,O
the,DT,O
oral,JJ,O
absorption,NN,O
of,IN,O
enoxacin,NN,D
by,IN,O
75,CD,O
%,NN,O
.,.,.
,,
the,DT,O
oral,JJ,O
bioavailability,NN,O
of,IN,O
enoxacin,NN,D
is,VBZ,O
reduced,VBN,O
by,IN,O
60,CD,O
%,NN,O
with,IN,O
coadministration,NN,O
of,IN,O
ranitidine,NN,D
.,.,.
,,
these,DT,O
agents,NNS,O
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
for,IN,O
8,CD,O
hours,NNS,O
before,IN,O
or,CC,O
for,IN,O
2,CD,O
hours,NNS,O
after,IN,O
enoxacin,NN,D
administration,NN,O
.,.,.
,,
theophylline,NNP,D
:,:,O
enoxacin,NN,D
is,VBZ,O
a,DT,O
potent,JJ,O
inhibitor,NN,O
of,IN,O
the,DT,O
cytochrome,NN,O
p-450,NN,O
isozymes,NNS,O
responsible,JJ,O
for,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
methylxanthines,NNS,G
.,.,.
,,
enoxacin,NN,D
interferes,VBZ,O
with,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
theophylline,NN,D
resulting,VBG,O
in,IN,O
a,DT,O
42,CD,O
%,NN,O
to,TO,O
74,CD,O
%,NN,O
dose-related,JJ,O
decrease,NN,O
in,IN,O
theophylline,NN,D
clearance,NN,O
and,CC,O
a,DT,O
subsequent,JJ,O
260,CD,O
%,NN,O
to,TO,O
350,CD,O
%,NN,O
increase,NN,O
in,IN,O
serum,NN,O
theophylline,NN,D
levels,NNS,O
.,.,.
,,
theophylline-related,JJ,O
adverse,JJ,O
effects,NNS,O
have,VBP,O
occurred,VBN,O
in,IN,O
patients,NNS,O
when,WRB,O
theophylline,NN,D
and,CC,O
enoxacin,NN,D
were,VBD,O
coadministered,VBN,O
.,.,.
,,
warfarin,NNP,D
:,:,O
quinolones,NNS,G
",",",",O
including,VBG,O
enoxacin,NN,D
",",",",O
decrease,VB,O
the,DT,O
clearance,NN,O
of,IN,O
r-warfarin,NN,D
",",",",O
the,DT,O
less,RBR,O
active,JJ,O
isomer,NN,O
of,IN,O
racemic,JJ,O
warfarin,NN,D
.,.,.
,,
enoxacin,NN,D
does,VBZ,O
not,RB,O
affect,VB,O
the,DT,O
clearance,NN,O
of,IN,O
the,DT,O
active,JJ,O
s-isomer,NN,O
",",",",O
and,CC,O
changes,NNS,O
in,IN,O
clotting,VBG,O
time,NN,O
have,VBP,O
not,RB,O
been,VBN,O
observed,VBN,O
when,WRB,O
enoxacin,NN,D
and,CC,O
warfarin,NN,D
were,VBD,O
coadministered,VBN,O
.,.,.
,,
nevertheless,RB,O
",",",",O
the,DT,O
prothrombin,NN,O
time,NN,O
or,CC,O
other,JJ,O
suitable,JJ,O
coagulation,NN,O
test,NN,O
should,MD,O
be,VB,O
monitored,VBN,O
when,WRB,O
warfarin,NN,D
or,CC,O
its,PRP$,O
derivatives,NNS,O
and,CC,O
enoxacin,NN,D
are,VBP,O
given,VBN,O
concomitantly,RB,O
.,.,.
,,
unless,IN,O
really,RB,O
needed,VBN,O
",",",",O
agents,NNS,O
which,WDT,O
may,MD,O
enhance,VB,O
the,DT,O
risk,NN,O
of,IN,O
hemorrhage,NN,O
should,MD,O
be,VB,O
discontinued,VBN,O
prior,RB,O
to,TO,O
initiation,NN,O
of,IN,O
lovenox,NNP,B
injection,NN,O
therapy,NN,O
.,.,.
,,
these,DT,O
agents,NNS,O
include,VBP,O
medications,NNS,O
such,JJ,O
as,IN,O
:,:,O
anticoagulants,NNS,G
",",",",O
platelet,NN,O
inhibitors,NNS,O
including,VBG,O
acetylsalicylic,JJ,O
acid,NN,O
",",",",O
sali-cylates,NNS,O
",",",",O
nsaids,NNS,G
-lrb-,-LRB-,O
including,VBG,O
ketorolac,NN,D
tromethamine,NN,O
-rrb-,-RRB-,O
",",",",O
dipyridamole,NN,D
",",",",O
or,CC,O
sulfinpyrazone,NN,D
.,.,.
,,
if,IN,O
co-administration,NN,O
is,VBZ,O
essential,JJ,O
",",",",O
conduct,VB,O
close,JJ,O
clinical,JJ,O
and,CC,O
laboratory,JJ,O
monitoring,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
of,IN,O
human,JJ,O
cyp,NN,O
enzymes,NNS,O
showed,VBD,O
that,IN,O
entacapone,NN,D
inhibited,VBD,O
the,DT,O
cyp,NN,O
enzymes,NNS,O
1a2,NN,O
",",",",O
2a6,NN,O
",",",",O
2c9,NN,O
",",",",O
2c19,NN,O
",",",",O
2d6,NN,O
",",",",O
2.00E+01,NN,O
and,CC,O
3a,NN,O
only,RB,O
at,IN,O
very,RB,O
high,JJ,O
concentrations,NNS,O
-lrb-,-LRB-,O
ic50,NN,O
from,IN,O
200,CD,O
to,TO,O
over,IN,O
1000,CD,O
um,NN,O
.,.,.
,,
an,DT,O
oral,JJ,O
200,CD,O
mg,NN,O
dose,NN,O
achieves,VBZ,O
a,DT,O
highest,JJS,O
level,NN,O
of,IN,O
approximately,RB,O
5,CD,O
um,NN,O
in,IN,O
people,NNS,O
-rrb-,-RRB-,O
;,:,O
.,.,.
,,
these,DT,O
enzymes,NNS,O
would,MD,O
therefore,RB,O
not,RB,O
be,VB,O
expected,VBN,O
to,TO,O
be,VB,O
inhibited,VBN,O
in,IN,O
clinical,JJ,O
use,NN,O
.,.,.
,,
protein,NN,O
binding,NN,O
:,:,O
entacapone,NNP,D
is,VBZ,O
highly,RB,O
protein,NN,O
bound,VBD,O
-lrb-,-LRB-,O
98,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
have,VBP,O
shown,VBN,O
no,DT,O
binding,NN,O
displacement,NN,O
between,IN,O
entacapone,NN,D
and,CC,O
other,JJ,O
highly,RB,O
bound,VBN,O
drugs,NNS,D
",",",",O
such,JJ,O
as,IN,O
warfarin,NN,D
",",",",O
salicylic,JJ,O
acid,NN,O
",",",",O
phenylbutazone,NN,D
",",",",O
and,CC,O
diazepam,NN,D
.,.,.
,,
drugs,NNS,O
metabolized,VBN,O
by,IN,O
catechol-o-methyltransferase,NN,O
-lrb-,-LRB-,O
comt,NN,O
-rrb-,-RRB-,O
:,:,O
hormone,NN,O
levels,NNS,O
:,:,O
levodopa,NN,D
is,VBZ,O
known,VBN,O
to,TO,O
depress,VB,O
prolactin,NN,O
secretion,NN,O
and,CC,O
increase,NN,O
growth,NN,O
hormone,NN,O
levels,NNS,O
.,.,.
,,
treatment,NN,O
with,IN,O
entacapone,NN,D
coadministered,VBN,O
with,IN,O
levodopa/dopa,NN,O
decarboxylase,NN,O
inhibitor,NN,O
does,VBZ,O
not,RB,O
change,VB,O
these,DT,O
effects,NNS,O
.,.,.
,,
no,DT,O
interaction,NN,O
was,VBD,O
noted,VBN,O
with,IN,O
the,DT,O
mao-b,NN,O
inhibitor,NN,O
selegiline,NN,D
in,IN,O
two,CD,O
multiple-dose,JJ,O
interaction,NN,O
studies,NNS,O
when,WRB,O
entacapone,NN,D
was,VBD,O
coadministered,VBN,O
with,IN,O
a,DT,O
levodopa/dopa,NN,O
decarboxylase,NN,O
inhibitor,NN,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
29,CD,O
-rrb-,-RRB-,O
.,.,.
,,
more,JJR,O
than,IN,O
600,CD,O
parkinsons,NNPS,O
disease,NN,O
patients,NNS,O
in,IN,O
clinical,JJ,O
trials,NNS,O
have,VBP,O
used,VBN,O
selegiline,NN,D
in,IN,O
combination,NN,O
with,IN,O
entacapone,NN,D
and,CC,O
levodopa/dopa,NN,O
decarboxylase,NN,O
inhibitor,NN,O
.,.,.
,,
as,IN,O
most,JJS,O
entacapone,JJ,D
excretion,NN,O
is,VBZ,O
via,IN,O
the,DT,O
bile,NN,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
drugs,NNS,D
known,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
biliary,JJ,O
excretion,NN,O
",",",",O
glucuronidation,NN,O
",",",",O
and,CC,O
intestinal,JJ,O
beta-glucuronidase,NN,O
are,VBP,O
given,VBN,O
concurrently,RB,O
with,IN,O
entacapone,NN,D
.,.,.
,,
these,DT,O
include,VBP,O
probenecid,NN,D
",",",",O
cholestyramine,NN,D
",",",",O
and,CC,O
some,DT,O
antibiotics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
erythromycin,FW,D
",",",",O
rifamipicin,NN,O
",",",",O
ampicillin,NN,D
and,CC,O
chloramphenicol,NN,D
-rrb-,-RRB-,O
.,.,.
,,
no,DT,O
interaction,NN,O
with,IN,O
the,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
imipramine,NN,D
was,VBD,O
shown,VBN,O
in,IN,O
a,DT,O
single-dose,JJ,O
study,NN,O
with,IN,O
entacapone,NN,D
without,IN,O
coadministered,VBN,O
levodopa/dopa-decarboxylase,NN,O
inhibitor,NN,O
.,.,.
,,
since,IN,O
entecavir,NN,D
is,VBZ,O
primarily,RB,O
eliminated,VBN,O
by,IN,O
the,DT,O
kidneys,NNS,O
",",",",O
coadministration,NN,O
of,IN,O
baraclude,NN,B
with,IN,O
drugs,NNS,D
that,WDT,O
reduce,VBP,O
renal,JJ,O
function,NN,O
or,CC,O
compete,VB,O
for,IN,O
active,JJ,O
tubular,JJ,O
secretion,NN,O
may,MD,O
increase,VB,O
serum,NN,O
concentrations,NNS,O
of,IN,O
either,CC,O
entecavir,NN,D
or,CC,O
the,DT,O
coadministered,VBN,O
drug,NN,D
.,.,.
,,
coadministration,NN,O
of,IN,O
entecavir,NN,D
with,IN,O
lamivudine,NN,D
",",",",O
adefovir,NN,O
dipivoxil,NN,O
",",",",O
or,CC,O
tenofovir,NN,O
disoproxil,NN,O
fumarate,NN,O
did,VBD,O
not,RB,O
result,VB,O
in,IN,O
significant,JJ,O
drug,NN,D
interactions,NNS,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
coadministration,NN,O
of,IN,O
baraclude,NN,B
with,IN,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
renally,RB,O
eliminated,VBN,O
or,CC,O
are,VBP,O
known,VBN,O
to,TO,O
affect,VB,O
renal,JJ,O
function,NN,O
have,VBP,O
not,RB,O
been,VBN,O
evaluated,VBN,O
",",",",O
and,CC,O
patients,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
for,IN,O
adverse,JJ,O
events,NNS,O
when,WRB,O
baraclude,NNP,B
is,VBZ,O
coadministered,VBN,O
with,IN,O
such,JJ,O
drugs,NNS,D
.,.,.
,,
none,NN,O
reported,VBN,O
.,.,.
,,
epinephrine,NN,D
should,MD,O
be,VB,O
used,VBN,O
cautiously,RB,O
in,IN,O
patients,NNS,O
with,IN,O
hyperthyroidism,NN,O
",",",",O
hypertension,NN,O
and,CC,O
cardiac,JJ,O
arrhythmias,NNS,O
.,.,.
,,
all,DT,O
vasopressors,NNS,G
should,MD,O
be,VB,O
used,VBN,O
cautiously,RB,O
in,IN,O
patients,NNS,O
taking,VBG,O
monoamine,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
mao,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
.,.,.
,,
epinephrine,NN,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
other,JJ,O
sympathomimetic,JJ,G
drugs,NNS,D
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
isoproterenol,NN,D
-rrb-,-RRB-,O
because,IN,O
of,IN,O
possible,JJ,O
additive,JJ,O
effects,NNS,O
and,CC,O
increased,VBD,O
toxicity,NN,O
.,.,.
,,
combined,JJ,O
effects,NNS,O
may,MD,O
induce,VB,O
serious,JJ,O
cardiac,JJ,O
arrhythmias,NNS,O
.,.,.
,,
they,PRP,O
may,MD,O
be,VB,O
administered,VBN,O
alternately,RB,O
when,WRB,O
the,DT,O
preceding,JJ,O
effect,NN,O
of,IN,O
other,JJ,O
such,JJ,O
drug,NN,D
has,VBZ,O
subsided,VBN,O
.,.,.
,,
administration,NN,O
of,IN,O
epinephrine,NN,D
to,TO,O
patients,NNS,O
receiving,VBG,O
cyclopropane,NN,D
or,CC,O
halogenated,VBN,O
hydrocarbon,NN,O
general,JJ,O
anesthetics,NNS,G
such,JJ,O
as,IN,O
halothane,NN,D
which,WDT,O
sensitize,VBP,O
the,DT,O
myocardium,NN,O
",",",",O
may,MD,O
induce,VB,O
cardiac,JJ,O
arrhythmia,NN,O
.,.,.
,,
when,WRB,O
encountered,VBN,O
",",",",O
such,JJ,O
arrhythmias,NNS,O
may,MD,O
respond,VB,O
to,TO,O
administration,NN,O
of,IN,O
a,DT,O
beta-adrenergic,JJ,O
blocking,VBG,O
drug,NN,D
.,.,.
,,
epinephrine,NN,D
also,RB,O
should,MD,O
be,VB,O
used,VBN,O
cautiously,RB,O
with,IN,O
other,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
digitalis,NN,G
",",",",O
glycosides,NNS,G
-rrb-,-RRB-,O
that,WDT,O
sensitize,VBP,O
the,DT,O
myocardium,NN,O
to,TO,O
the,DT,O
actions,NNS,O
of,IN,O
sympathomimetic,JJ,G
drugs,NNS,D
.,.,.
,,
diuretic,JJ,G
agents,NNS,O
may,MD,O
decrease,VB,O
vascular,JJ,O
response,NN,O
to,TO,O
pressor,NN,O
drugs,NNS,D
such,JJ,O
as,IN,O
epinephrine,NN,D
.,.,.
,,
epinephrine,NN,D
may,MD,O
antagonize,VB,O
the,DT,O
neuron,NN,O
blockade,NN,O
produced,VBN,O
by,IN,O
guanethidine,NN,D
resulting,VBG,O
in,IN,O
decreased,VBN,O
antihypertensive,JJ,G
effect,NN,O
and,CC,O
requiring,VBG,O
increased,VBN,O
dosage,NN,O
of,IN,O
the,DT,O
latter,JJ,O
.,.,.
,,
ellence,NN,B
when,WRB,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
cytotoxic,JJ,G
drugs,NNS,D
may,MD,O
show,VB,O
on-treatment,JJ,O
additive,JJ,O
toxicity,NN,O
",",",",O
especially,RB,O
hematologic,JJ,O
and,CC,O
gastrointestinal,JJ,O
effects,NNS,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
ellence,NN,B
with,IN,O
other,JJ,O
cardioactive,JJ,O
compounds,NNS,O
that,WDT,O
could,MD,O
cause,VB,O
heart,NN,O
failure,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
calcium,NN,D
channel,NN,O
blockers,NNS,O
-rrb-,-RRB-,O
",",",",O
requires,VBZ,O
close,JJ,O
monitoring,NN,O
of,IN,O
cardiac,JJ,O
function,NN,O
throughout,IN,O
treatment,NN,O
.,.,.
,,
there,EX,O
are,VBP,O
few,JJ,O
data,NNS,O
regarding,VBG,O
the,DT,O
coadministration,NN,O
of,IN,O
radiation,NN,O
therapy,NN,O
and,CC,O
epirubicin,NN,D
.,.,.
,,
in,IN,O
adjuvant,JJ,O
trials,NNS,O
of,IN,O
epirubicin-containing,JJ,O
cef-120,NN,O
or,CC,O
fec-100,NN,O
chemotherapies,NNS,O
",",",",O
breast,NN,O
irradiation,NN,O
was,VBD,O
delayed,VBN,O
until,IN,O
after,IN,O
chemotherapy,NN,O
was,VBD,O
completed,VBN,O
.,.,.
,,
this,DT,O
practice,NN,O
resulted,VBD,O
in,IN,O
no,DT,O
apparent,JJ,O
increase,NN,O
in,IN,O
local,JJ,O
breast,NN,O
cancer,NN,O
recurrence,NN,O
relative,JJ,O
to,TO,O
published,VBN,O
accounts,NNS,O
in,IN,O
the,DT,O
literature,NN,O
.,.,.
,,
a,DT,O
small,JJ,O
number,NN,O
of,IN,O
patients,NNS,O
received,VBD,O
epirubicin-based,JJ,O
chemotherapy,NN,O
concomitantly,RB,O
with,IN,O
radiation,NN,O
therapy,NN,O
but,CC,O
had,VBD,O
chemotherapy,NN,O
interrupted,JJ,O
in,IN,O
order,NN,O
to,TO,O
avoid,VB,O
potential,JJ,O
overlapping,VBG,O
toxicities,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
likely,JJ,O
that,IN,O
use,NN,O
of,IN,O
epirubicin,NN,D
with,IN,O
radiotherapy,NN,O
may,MD,O
sensitize,VB,O
tissues,NNS,O
to,TO,O
the,DT,O
cytotoxic,JJ,G
actions,NNS,O
of,IN,O
irradiation,NN,O
.,.,.
,,
administration,NN,O
of,IN,O
ellence,NN,B
after,IN,O
previous,JJ,O
radiation,NN,O
therapy,NN,O
may,MD,O
induce,VB,O
an,DT,O
inflammatory,JJ,O
recall,NN,O
reaction,NN,O
at,IN,O
the,DT,O
site,NN,O
of,IN,O
the,DT,O
irradiation,NN,O
.,.,.
,,
epirubicin,NN,D
is,VBZ,O
extensively,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
liver,NN,O
.,.,.
,,
changes,NNS,O
in,IN,O
hepatic,JJ,O
function,NN,O
induced,VBN,O
by,IN,O
concomitant,JJ,O
therapies,NNS,O
may,MD,O
affect,VB,O
epirubicin,NN,D
metabolism,NN,O
",",",",O
pharmacokinetics,NNS,O
",",",",O
therapeutic,JJ,O
efficacy,NN,O
",",",",O
and/or,CC,O
toxicity,NN,O
.,.,.
,,
cimetidine,NN,D
increased,VBD,O
the,DT,O
auc,NN,O
of,IN,O
epirubicin,NN,D
by,IN,O
50,CD,O
%,NN,O
.,.,.
,,
cimetidine,NN,D
treatment,NN,O
should,MD,O
be,VB,O
stopped,VBN,O
during,IN,O
treatment,NN,O
with,IN,O
ellence,NN,B
.,.,.
,,
drug-laboratory,JJ,O
test,NN,O
interactions,NNS,O
there,EX,O
are,VBP,O
no,DT,O
known,JJ,O
interactions,NNS,O
between,IN,O
ellence,NNP,B
and,CC,O
laboratory,NN,O
tests,NNS,O
.,.,.
,,
inhibitors,NNS,O
of,IN,O
cyp3a4-eplerenone,NN,O
metabolism,NN,O
is,VBZ,O
predominantly,RB,O
mediated,VBN,O
via,IN,O
cyp3a4,NN,D
.,.,.
,,
a,DT,O
pharmacokinetic,JJ,O
study,NN,O
evaluating,VBG,O
the,DT,O
administration,NN,O
of,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
inspra,NN,B
100,CD,O
mg,NN,O
with,IN,O
ketoconazole,NN,D
200,CD,O
mg,NN,O
bid,NNP,O
",",",",O
a,DT,O
potent,JJ,O
inhibitor,NN,O
of,IN,O
the,DT,O
cyp3a4,NN,D
pathway,NN,O
",",",",O
showed,VBD,O
a,DT,O
1.7-fold,JJ,O
increase,NN,O
in,IN,O
cmax,NN,O
of,IN,O
eplerenone,NN,D
and,CC,O
a,DT,O
5.4-fold,JJ,O
increase,NN,O
in,IN,O
auc,NN,O
of,IN,O
eplerenone,NN,D
.,.,.
,,
inspra,NN,B
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
with,IN,O
drugs,NNS,D
described,VBN,O
as,IN,O
strong,JJ,O
inhibitors,NNS,O
of,IN,O
cyp3a4,NN,D
in,IN,O
their,PRP$,O
labeling,NN,O
.,.,.
,,
administration,NN,O
of,IN,O
eplerenone,NN,D
with,IN,O
other,JJ,O
cyp3a4,NN,D
inhibitors,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
erythromycin,NN,D
500,CD,O
mg,NN,O
bid,NNP,O
",",",",O
verapamil,NN,D
240,CD,O
mg,NN,O
qd,NN,O
",",",",O
saquinavir,NN,D
1200,CD,O
mg,NN,O
tid,NN,O
",",",",O
fluconazole,NN,D
200,CD,O
mg,NN,O
qd,NN,O
-rrb-,-RRB-,O
resulted,VBD,O
in,IN,O
increases,NNS,O
in,IN,O
cmax,NN,O
of,IN,O
eplerenone,NN,D
ranging,VBG,O
from,IN,O
1.4,CD,O
-,:,O
to,TO,O
1.6,CD,O
-,:,O
fold,JJ,O
and,CC,O
auc,NN,O
from,IN,O
2,CD,O
-,:,O
to,TO,O
2.9,CD,O
-,:,O
fold,NN,O
.,.,.
,,
ace,NN,O
inhibitors,NNS,O
and,CC,O
angiotensin,NN,O
ii,CD,O
receptor,NN,O
antagonists,NNS,O
-lrb-,-LRB-,O
congestive,JJ,O
heart,NNP,O
failure,NN,O
post-myocardial,JJ,O
infarction,NN,O
-rrb-,-RRB-,O
-,:,O
in,IN,O
ephesus,NNP,O
",",",",O
3020,CD,O
-lrb-,-LRB-,O
91,CD,O
%,NN,O
-rrb-,-RRB-,O
patients,NNS,O
receiving,VBG,O
inspra,NNP,B
25,CD,O
to,TO,O
50,CD,O
mg,NN,O
also,RB,O
received,VBD,O
ace,NN,O
inhibitors,NNS,O
or,CC,O
angiotensin,NN,O
ii,CD,O
receptor,NN,D
antagonists,NNS,O
-lrb-,-LRB-,O
acei/arb,NN,O
-rrb-,-RRB-,O
.,.,.
,,
rates,NNS,O
of,IN,O
patients,NNS,O
with,IN,O
maximum,NN,O
potassium,NN,D
levels,NNS,O
5.5,CD,O
meq/l,NN,O
were,VBD,O
similar,JJ,O
regardless,RB,O
of,IN,O
the,DT,O
use,NN,O
of,IN,O
acei/arb,NN,O
.,.,.
,,
ace,NN,O
inhibitors,NNS,O
and,CC,O
angiotensin,NN,O
ii,CD,O
receptor,NN,O
antagonists,NNS,O
-lrb-,-LRB-,O
hypertension,NN,O
-rrb-,-RRB-,O
-,:,O
in,IN,O
clinical,JJ,O
studies,NNS,O
of,IN,O
patients,NNS,O
with,IN,O
hypertension,NN,O
",",",",O
the,DT,O
addition,NN,O
of,IN,O
inspra,NNP,B
50,CD,O
to,TO,O
100,CD,O
mg,NN,O
to,TO,O
ace,NN,O
inhibitors,NNS,O
and,CC,O
angiotensin,NN,O
ii,CD,O
receptor,NN,D
antagonists,NNS,O
increased,VBD,O
mean,JJ,O
serum,NN,O
potassium,NN,D
slightly,RB,O
-lrb-,-LRB-,O
about,IN,O
0.09-0,CD,O
0.13,CD,O
meq/l,NN,O
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
in,IN,O
diabetics,NNS,O
with,IN,O
microalbuminuria,NN,O
inspra,NN,B
200,CD,O
mg,NN,O
combined,VBN,O
with,IN,O
the,DT,O
ace,NN,O
inhibitor,NN,O
enalapril,NN,D
10,CD,O
mg,NN,O
increased,VBD,O
the,DT,O
frequency,NN,O
of,IN,O
hyperkalemia,NN,O
-lrb-,-LRB-,O
serum,NN,O
potassium,NN,D
5.5,CD,O
meq/l,NN,O
-rrb-,-RRB-,O
from,IN,O
17,CD,O
%,NN,O
on,IN,O
enalapril,NN,D
alone,RB,O
to,TO,O
38,CD,O
%,NN,O
.,.,.
,,
lithium-a,NN,O
drug,NN,D
interaction,NN,O
study,NN,O
of,IN,O
eplerenone,NN,D
with,IN,O
lithium,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
serum,NN,O
lithium,NN,D
levels,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
frequently,RB,O
if,IN,O
inspra,NN,B
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
lithium,NN,D
.,.,.
,,
nonsteroidal,JJ,O
anti-inflammatory,JJ,O
drugs,NNS,O
-lrb-,-LRB-,O
nsaids,NNS,G
-rrb-,-RRB-,O
-,:,O
a,DT,O
drug,NN,D
interaction,NN,O
study,NN,O
of,IN,O
eplerenone,NN,D
with,IN,O
an,DT,O
nsaid,NN,G
has,VBZ,O
not,RB,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
the,DT,O
administration,NN,O
of,IN,O
other,JJ,O
potassium-sparing,JJ,O
antihypertensives,NNS,D
with,IN,O
nsaids,NNS,G
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
reduce,VB,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
in,IN,O
some,DT,O
patients,NNS,O
and,CC,O
result,VBP,O
in,IN,O
severe,JJ,O
hyperkalemia,NN,O
in,IN,O
patients,NNS,O
with,IN,O
impaired,JJ,O
renal,JJ,O
function,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
when,WRB,O
inspra,NNP,B
and,CC,O
nsaids,NNS,G
are,VBP,O
used,VBN,O
concomitantly,RB,O
",",",",O
patients,NNS,O
should,MD,O
be,VB,O
observed,VBN,O
to,TO,O
determine,VB,O
whether,IN,O
the,DT,O
desired,VBN,O
effect,NN,O
on,IN,O
blood,NN,O
pressure,NN,O
is,VBZ,O
obtained,VBN,O
.,.,.
,,
no,DT,O
evidence,NN,O
of,IN,O
interaction,NN,O
of,IN,O
procrit,NN,B
with,IN,O
other,JJ,O
drugs,NNS,D
was,VBD,O
observed,VBN,O
in,IN,O
the,DT,O
course,NN,O
of,IN,O
clinical,JJ,O
trials,NNS,O
.,.,.
,,
additional,JJ,O
reductions,NNS,O
in,IN,O
blood,NN,O
pressure,NN,O
may,MD,O
occur,VB,O
when,WRB,O
flolan,NNP,B
is,VBZ,O
administered,VBN,O
with,IN,O
diuretics,NNS,G
",",",",O
antihypertensive,JJ,G
agents,NNS,O
",",",",O
or,CC,O
other,JJ,O
vasodilators,NNS,G
.,.,.
,,
when,WRB,O
other,JJ,O
antiplatelet,JJ,O
agents,NNS,O
or,CC,O
anticoagulants,NNS,G
are,VBP,O
used,VBN,O
concomitantly,RB,O
",",",",O
there,EX,O
is,VBZ,O
the,DT,O
potential,NN,O
for,IN,O
flolan,NNP,B
to,TO,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
bleeding,NN,O
.,.,.
,,
however,RB,O
",",",",O
patients,NNS,O
receiving,VBG,O
infusions,NNS,O
of,IN,O
flolan,NNP,B
in,IN,O
clinical,JJ,O
trials,NNS,O
were,VBD,O
maintained,VBN,O
on,IN,O
anticoagulants,NNS,G
without,IN,O
evidence,NN,O
of,IN,O
increased,VBN,O
bleeding,NN,O
.,.,.
,,
in,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
flolan,NNP,B
was,VBD,O
used,VBN,O
with,IN,O
digoxin,NN,D
",",",",O
diuretics,NNS,G
",",",",O
anticoagulants,NNS,G
",",",",O
oral,JJ,O
vasodilators,NNS,G
",",",",O
and,CC,O
supplemental,JJ,O
oxygen.in,NN,O
a,DT,O
pharmacokinetic,JJ,O
substudy,NN,O
in,IN,O
patients,NNS,O
with,IN,O
congestive,JJ,O
heart,NN,O
failure,NN,O
receiving,VBG,O
furosemide,NN,D
or,CC,O
digoxin,NN,D
in,IN,O
whom,WP,O
therapy,NN,O
with,IN,O
flolan,NN,B
was,VBD,O
initiated,VBN,O
",",",",O
apparent,JJ,O
oral,JJ,O
clearance,NN,O
values,NNS,O
for,IN,O
furosemide,NN,D
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
23,CD,O
-rrb-,-RRB-,O
and,CC,O
digoxin,NN,D
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
30,CD,O
-rrb-,-RRB-,O
were,VBD,O
decreased,VBN,O
by,IN,O
13,CD,O
%,NN,O
and,CC,O
15,CD,O
%,NN,O
",",",",O
respectively,RB,O
",",",",O
on,IN,O
the,DT,O
second,JJ,O
day,NN,O
of,IN,O
therapy,NN,O
and,CC,O
had,VBD,O
returned,VBN,O
to,TO,O
baseline,NN,O
values,NNS,O
by,IN,O
day,NN,O
87,CD,O
.,.,.
,,
the,DT,O
change,NN,O
in,IN,O
furosemide,NN,D
clearance,NN,O
value,NN,O
is,VBZ,O
not,RB,O
likely,JJ,O
to,TO,O
be,VB,O
clinically,RB,O
significant,JJ,O
.,.,.
,,
however,RB,O
",",",",O
patients,NNS,O
on,IN,O
digoxin,NN,D
may,MD,O
show,VB,O
elevations,NNS,O
of,IN,O
digoxin,NN,D
concentrations,NNS,O
after,IN,O
initiation,NN,O
of,IN,O
therapy,NN,O
with,IN,O
flolan,NNP,B
",",",",O
which,WDT,O
may,MD,O
be,VB,O
clinically,RB,O
significant,JJ,O
in,IN,O
patients,NNS,O
prone,JJ,O
to,TO,O
digoxin,NN,D
toxicity,NN,O
.,.,.
,,
eprosartan,NNP,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
have,VB,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
digoxin,NN,D
and,CC,O
the,DT,O
pharmacodynamics,NNS,O
of,IN,O
warfarin,NN,D
and,CC,O
glyburide,NN,D
.,.,.
,,
thus,RB,O
no,DT,O
dosing,NN,O
adjustments,NNS,O
are,VBP,O
necessary,JJ,O
during,IN,O
concomitant,JJ,O
use,NN,O
with,IN,O
these,DT,O
agents,NNS,O
.,.,.
,,
because,IN,O
eprosartan,NN,D
is,VBZ,O
not,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
system,NN,O
",",",",O
inhibitors,NNS,O
of,IN,O
cyp450,NN,O
enzyme,NN,O
would,MD,O
not,RB,O
be,VB,O
expected,VBN,O
to,TO,O
affect,VB,O
its,PRP$,O
metabolism,NN,O
",",",",O
and,CC,O
ketoconazole,NN,D
and,CC,O
fluconazole,NN,D
",",",",O
potent,JJ,O
inhibitors,NNS,O
of,IN,O
cyp3a,NN,O
and,CC,O
2c9,NN,O
",",",",O
respectively,RB,O
",",",",O
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
have,VB,O
no,DT,O
effect,NN,O
on,IN,O
eprosartan,NN,D
pharmacokinetics,NNS,O
.,.,.
,,
ranitidine,NN,D
also,RB,O
has,VBZ,O
no,DT,O
effect,NN,O
on,IN,O
eprosartan,NN,D
pharmacokinetics,NNS,O
.,.,.
,,
eprosartan,NN,D
-lrb-,-LRB-,O
up,RB,O
to,TO,O
400,CD,O
mg,NN,O
b.i.d.,NN,O
or,CC,O
800,CD,O
mg,NN,O
q.d.,NN,O
-rrb-,-RRB-,O
doses,NNS,O
have,VBP,O
been,VBN,O
safely,RB,O
used,VBN,O
concomitantly,RB,O
with,IN,O
a,DT,O
thiazide,JJ,G
diuretic,JJ,G
-lrb-,-LRB-,O
hydrochlorothiazide,NN,D
-rrb-,-RRB-,O
.,.,.
,,
eprosartan,NN,D
doses,NNS,O
of,IN,O
up,RB,O
to,TO,O
300,CD,O
mg,NN,O
b.i.d.,NN,O
have,VBP,O
been,VBN,O
safely,RB,O
used,VBN,O
concomitantly,RB,O
with,IN,O
sustained-release,JJ,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
-lrb-,-LRB-,O
sustained-release,JJ,O
nifedipine,NN,D
-rrb-,-RRB-,O
with,IN,O
no,DT,O
clinically,RB,O
significant,JJ,O
adverse,JJ,O
interactions,NNS,O
.,.,.
,,
enoxaparin,NNP,D
dosed,VBD,O
as,IN,O
a,DT,O
1,CD,O
mg/kg,NN,O
subcutaneous,JJ,O
injection,NN,O
q12h,NN,O
for,IN,O
four,CD,O
doses,NNS,O
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
eptifibatide,NN,D
or,CC,O
the,DT,O
level,NN,O
of,IN,O
platelet,NN,O
aggregation,NN,O
in,IN,O
healthy,JJ,O
adults,NNS,O
.,.,.
,,
mineral,JJ,O
oil,NN,O
interferes,VBZ,O
with,IN,O
the,DT,O
absorption,NN,O
of,IN,O
fat-soluble,JJ,O
vitamins,NNS,G
",",",",O
including,VBG,O
vitamin,NN,G
d,NN,O
preparations,NNS,O
.,.,.
,,
administration,NN,O
of,IN,O
thiazide,JJ,G
diuretics,NNS,G
to,TO,O
hypoparathyroid,JJ,O
patients,NNS,O
who,WP,O
are,VBP,O
concurrently,RB,O
being,VBG,O
treated,VBN,O
with,IN,O
ergocalciferol,NN,D
may,MD,O
cause,VB,O
hypercalcemia,NN,O
.,.,.
,,
no,DT,O
reported,VBN,O
interactions,NNS,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
ergomar,NN,B
may,MD,O
be,VB,O
potentiated,VBN,O
by,IN,O
triacetyloleandomycin,NN,D
which,WDT,O
inhibits,VBZ,O
the,DT,O
metabolism,NN,O
of,IN,O
ergotamine,NN,D
.,.,.
,,
the,DT,O
pressor,JJ,O
effects,NNS,O
of,IN,O
ergomar,NN,B
and,CC,O
other,JJ,O
vasoconstrictor,NN,O
drugs,NNS,D
can,MD,O
combine,VB,O
to,TO,O
cause,VB,O
dangerous,JJ,O
hypertension,NN,O
.,.,.
,,
co-treatment,NN,O
with,IN,O
the,DT,O
potent,JJ,O
cyp3a4,NN,D
inhibitor,NN,O
ketoconazole,NN,D
increases,VBZ,O
erlotinib,JJ,D
auc,NN,O
by,IN,O
3-Feb,CD,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
when,WRB,O
administering,VBG,O
or,CC,O
taking,VBG,O
tarceva,NN,B
with,IN,O
ketoconazole,NN,D
and,CC,O
other,JJ,O
strong,JJ,O
cyp3a4,NN,D
inhibitors,NNS,O
such,JJ,O
as,IN,O
",",",",O
but,CC,O
not,RB,O
limited,VBN,O
to,TO,O
",",",",O
atazanavir,NN,D
",",",",O
clarithromycin,NN,D
",",",",O
indinavir,NN,D
",",",",O
itraconazole,NN,D
",",",",O
nefazodone,NN,D
",",",",O
nelfinavir,NN,D
",",",",O
ritonavir,NN,D
",",",",O
saquinavir,NN,D
",",",",O
telithromycin,NN,D
",",",",O
troleandomycin,NN,D
-lrb-,-LRB-,O
tao,NN,D
-rrb-,-RRB-,O
",",",",O
and,CC,O
voriconazole,NN,D
.,.,.
,,
pre-treatment,NN,O
with,IN,O
the,DT,O
cyp3a4,NN,D
inducer,NN,O
rifampicin,NN,D
decreased,VBD,O
erlotinib,NN,D
auc,NN,O
by,IN,O
about,IN,O
3-Feb,CD,O
.,.,.
,,
alternate,JJ,O
treatments,NNS,O
lacking,VBG,O
cyp3a4,NN,D
inducing,NN,O
activity,NN,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
if,IN,O
an,DT,O
alternative,JJ,O
treatment,NN,O
is,VBZ,O
unavailable,JJ,O
",",",",O
a,DT,O
tarceva,NNP,B
dose,NN,O
greater,JJR,O
than,IN,O
150,CD,O
mg,NN,O
should,MD,O
be,VB,O
considered,VBN,O
for,IN,O
nsclc,NN,O
patients,NNS,O
",",",",O
and,CC,O
greater,JJR,O
than,IN,O
100,CD,O
mg,NN,O
considered,VBN,O
for,IN,O
pancreatic,JJ,O
cancer,NN,O
patients,NNS,O
.,.,.
,,
if,IN,O
the,DT,O
tarceva,NNP,B
dose,NN,O
is,VBZ,O
adjusted,VBN,O
upward,RB,O
",",",",O
the,DT,O
dose,NN,O
will,MD,O
need,VB,O
to,TO,O
be,VB,O
reduced,VBN,O
upon,IN,O
discontinuation,NN,O
of,IN,O
rifampicin,NN,D
or,CC,O
other,JJ,O
inducers,NNS,O
.,.,.
,,
other,JJ,O
cyp3a4,NN,D
inducers,NNS,O
include,VBP,O
",",",",O
but,CC,O
are,VBP,O
not,RB,O
limited,VBN,O
to,TO,O
",",",",O
rifabutin,NN,D
",",",",O
rifapentine,NN,D
",",",",O
phenytoin,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
phenobarbital,NN,D
and,CC,O
st.,NNP,O
johns,NNP,O
wort,NNP,O
.,.,.
,,
hepatotoxicity,NN,O
asymptomatic,JJ,O
increases,NNS,O
in,IN,O
liver,NN,O
transaminases,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
in,IN,O
tarceva,NN,B
treated,JJ,O
patients,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
periodic,JJ,O
liver,NN,O
function,NN,O
testing,NN,O
-lrb-,-LRB-,O
transaminases,NNS,O
",",",",O
bilirubin,NN,O
",",",",O
and,CC,O
alkaline,NN,O
phosphatase,NN,O
-rrb-,-RRB-,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
dose,NN,O
reduction,NN,O
or,CC,O
interruption,NN,O
of,IN,O
tarceva,NN,B
should,MD,O
be,VB,O
considered,VBN,O
if,IN,O
changes,NNS,O
in,IN,O
liver,NN,O
function,NN,O
are,VBP,O
severe,JJ,O
.,.,.
,,
patients,NNS,O
with,IN,O
hepatic,JJ,O
impairment,NN,O
in,FW,O
vitro,FW,O
and,CC,O
in,FW,O
vivo,FW,O
evidence,NN,O
suggest,VBP,O
that,IN,O
erlotinib,NN,D
is,VBZ,O
cleared,VBN,O
primarily,RB,O
by,IN,O
the,DT,O
liver,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
erlotinib,JJ,D
exposure,NN,O
may,MD,O
be,VB,O
increased,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
hepatic,JJ,O
dysfunction,NN,O
.,.,.
,,
elevated,JJ,O
international,NNP,O
normalized,NNP,O
ratio,NNP,O
and,CC,O
potential,JJ,O
bleeding,NNP,O
international,NNP,O
normalized,NNP,O
ratio,NNP,O
-lrb-,-LRB-,O
inr,NNP,O
-rrb-,-RRB-,O
elevations,NNS,O
and,CC,O
infrequent,JJ,O
reports,NNS,O
of,IN,O
bleeding,VBG,O
events,NNS,O
including,VBG,O
gastrointestinal,JJ,O
and,CC,O
non-gastrointestinal,JJ,O
bleedings,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
clinical,JJ,O
studies,NNS,O
",",",",O
some,DT,O
associated,VBN,O
with,IN,O
concomitant,JJ,O
warfarin,NN,D
administration,NN,O
.,.,.
,,
patients,NNS,O
taking,VBG,O
warfarin,NN,D
or,CC,O
other,JJ,O
coumarin-derivative,JJ,O
anticoagulants,NNS,G
should,MD,O
be,VB,O
monitored,VBN,O
regularly,RB,O
for,IN,O
changes,NNS,O
in,IN,O
prothrombin,NN,O
time,NN,O
or,CC,O
in,IN,O
.,.,.
,,
when,WRB,O
ertapenem,NN,D
is,VBZ,O
co-administered,VBN,O
with,IN,O
probenecid,NN,D
-lrb-,-LRB-,O
500,CD,O
mg,NN,O
p.o.,NN,O
every,DT,O
6,CD,O
hours,NNS,O
-rrb-,-RRB-,O
",",",",O
probenecid,NN,D
competes,VBZ,O
for,IN,O
active,JJ,O
tubular,JJ,O
secretion,NN,O
and,CC,O
reduces,VBZ,O
the,DT,O
renal,JJ,O
clearance,NN,O
of,IN,O
ertapenem,NN,D
.,.,.
,,
based,VBN,O
on,IN,O
total,JJ,O
ertapenem,NN,D
concentrations,NNS,O
",",",",O
probenecid,NN,D
increased,VBD,O
the,DT,O
auc,NN,O
by,IN,O
25,CD,O
%,NN,O
and,CC,O
reduced,VBD,O
the,DT,O
plasma,NN,O
and,CC,O
renal,JJ,O
clearances,NNS,O
by,IN,O
20,CD,O
%,NN,O
and,CC,O
35,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
the,DT,O
half-life,NN,O
increased,VBN,O
from,IN,O
4,CD,O
to,TO,O
4.8,CD,O
hours,NNS,O
.,.,.
,,
because,IN,O
of,IN,O
the,DT,O
small,JJ,O
effect,NN,O
on,IN,O
half-life,NN,O
",",",",O
the,DT,O
coadministration,NN,O
with,IN,O
probenecid,NN,D
to,TO,O
extend,VB,O
the,DT,O
half-life,NN,O
of,IN,O
ertapenem,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
indicate,VBP,O
that,IN,O
ertapenem,NN,D
does,VBZ,O
not,RB,O
inhibit,VB,O
p-glycoprotein-mediated,JJ,O
transport,NN,O
of,IN,O
digoxin,NN,D
or,CC,O
vinblastine,NN,D
and,CC,O
that,IN,O
ertapenem,NN,D
is,VBZ,O
not,RB,O
a,DT,O
substrate,NN,O
for,IN,O
p-glycoprotein-mediated,JJ,O
transport,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
in,IN,O
human,JJ,O
liver,NN,O
microsomes,NNS,O
indicate,VBP,O
that,IN,O
ertapenem,NN,D
does,VBZ,O
not,RB,O
inhibit,VB,O
metabolism,NN,O
mediated,VBN,O
by,IN,O
any,DT,O
of,IN,O
the,DT,O
following,VBG,O
six,CD,O
cytochrome,NN,O
p450,NN,O
-lrb-,-LRB-,O
cyp,NN,O
-rrb-,-RRB-,O
isoforms,NNS,O
:,:,O
1a2,NN,O
",",",",O
2c9,NN,O
",",",",O
2c19,NN,O
",",",",O
2d6,NN,O
",",",",O
2.00E+01,NN,O
and,CC,O
3a4,NN,O
.,.,.
,,
drug,NN,O
interactions,NNS,O
caused,VBN,O
by,IN,O
inhibition,NN,O
of,IN,O
p-glycoprotein-mediated,JJ,O
drug,NN,D
clearance,NN,O
or,CC,O
cyp-mediated,JJ,O
drug,NN,D
clearance,NN,O
with,IN,O
the,DT,O
listed,VBN,O
isoforms,NNS,O
are,VBP,O
unlikely,JJ,O
.,.,.
,,
other,JJ,O
than,IN,O
with,IN,O
probenecid,NN,D
",",",",O
no,DT,O
specific,JJ,O
clinical,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducte,NN,O
.,.,.
,,
erythromycin,NNP,D
use,NN,O
in,IN,O
patients,NNS,O
who,WP,O
are,VBP,O
receiving,VBG,O
high,JJ,O
doses,NNS,O
of,IN,O
theophylline,NN,D
may,MD,O
be,VB,O
associated,VBN,O
with,IN,O
an,DT,O
increase,NN,O
in,IN,O
serum,NN,O
theophylline,NN,D
levels,NNS,O
and,CC,O
potential,JJ,O
theophylline,NN,D
toxicity,NN,O
.,.,.
,,
in,IN,O
case,NN,O
of,IN,O
theophylline,NN,D
toxicity,NN,O
and/or,CC,O
elevated,JJ,O
serum,NN,O
theophylline,NN,D
levels,NNS,O
",",",",O
the,DT,O
dose,NN,O
of,IN,O
theophylline,NN,D
should,MD,O
be,VB,O
reduced,VBN,O
while,IN,O
the,DT,O
patient,NN,O
is,VBZ,O
receiving,VBG,O
concomitant,JJ,O
erythromycin,NN,D
therapy,NN,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
erythromycin,NN,D
and,CC,O
digoxin,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
result,VB,O
in,IN,O
elevated,JJ,O
digoxin,NN,D
serum,NN,O
levels,NNS,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
increased,VBN,O
anticoagulant,JJ,G
effects,NNS,O
when,WRB,O
erythromycin,NN,D
and,CC,O
oral,JJ,O
anticoagulants,NNS,G
were,VBD,O
used,VBN,O
concomitantly,RB,O
.,.,.
,,
increased,VBN,O
anticoagulation,JJ,O
effects,NNS,O
due,JJ,O
to,TO,O
interactions,NNS,O
of,IN,O
erythromycin,NN,D
with,IN,O
various,JJ,O
oral,JJ,O
anticoagulents,NNS,O
may,MD,O
be,VB,O
more,RBR,O
pronounced,JJ,O
in,IN,O
the,DT,O
elderly,JJ,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
of,IN,O
erythromycin,NN,D
and,CC,O
ergotamine,NN,D
or,CC,O
dihydroergotamine,NN,D
has,VBZ,O
been,VBN,O
associated,VBN,O
in,IN,O
some,DT,O
patients,NNS,O
with,IN,O
acute,JJ,O
ergot,NN,G
toxicity,NN,O
characterized,VBN,O
by,IN,O
severe,JJ,O
peripheral,JJ,O
vasospasm,NN,O
and,CC,O
dysesthesia,NN,O
.,.,.
,,
erythromycin,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
decrease,VB,O
the,DT,O
clearance,NN,O
of,IN,O
triazolam,NN,D
and,CC,O
midazolam,NN,D
and,CC,O
thus,RB,O
may,MD,O
increase,VB,O
the,DT,O
pharmacologic,JJ,O
effect,NN,O
of,IN,O
these,DT,O
benzodiazepines,NNS,G
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
erythromycin,NN,D
in,IN,O
patients,NNS,O
concurrently,RB,O
taking,VBG,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
system,NN,O
may,MD,O
be,VB,O
associated,VBN,O
with,IN,O
elevations,NNS,O
in,IN,O
serum,NN,O
levels,NNS,O
of,IN,O
these,DT,O
other,JJ,O
drugs,NNS,D
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
interactions,NNS,O
of,IN,O
erythromycin,NN,D
with,IN,O
carbamazepine,NN,D
",",",",O
cyclosporine,NN,D
",",",",O
tacrolimus,NN,D
",",",",O
hexobarbital,NN,D
",",",",O
phenytoin,NN,D
",",",",O
alfentanil,NN,D
",",",",O
cisapride,NN,D
",",",",O
disopyramide,NN,D
",",",",O
lovastatin,NN,D
",",",",O
bromocriptine,NN,D
",",",",O
valproate,NN,D
",",",",O
terfenadine,NN,D
",",",",O
and,CC,O
astemizole,NN,D
.,.,.
,,
serum,NN,O
concentrations,NNS,O
of,IN,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
system,NN,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
in,IN,O
patients,NNS,O
concurrently,RB,O
receiving,VBG,O
erythromycin,NN,D
.,.,.
,,
erythromycin,NNP,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
significantly,RB,O
alter,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
nonsedating,JJ,O
antihistamines,NNS,G
terfenadine,NN,D
and,CC,O
astemizole,NN,D
when,WRB,O
taken,VBN,O
concomitantly,RB,O
.,.,.
,,
rare,JJ,O
cases,NNS,O
of,IN,O
serious,JJ,O
cardiovascular,JJ,O
adverse,JJ,O
events,NNS,O
",",",",O
including,VBG,O
electrocardiographic,JJ,O
qt/qtc,NN,O
interval,NN,O
prolongation,NN,O
",",",",O
cardiac,JJ,O
arrest,NN,O
",",",",O
torsades,NNS,O
de,IN,O
pointes,NNS,O
",",",",O
and,CC,O
other,JJ,O
ventricular,JJ,O
arrhythmias,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
deaths,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
rarely,RB,O
with,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
terfenadine,NN,D
and,CC,O
erythromycin,NN,D
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
postmarketing,VBG,O
reports,NNS,O
of,IN,O
drug,NN,D
interactions,NNS,O
when,WRB,O
erythromycin,NN,D
is,VBZ,O
coadministered,VBN,O
with,IN,O
cisapride,NN,D
",",",",O
resulting,VBG,O
in,IN,O
qt,NNP,O
prolongation,NN,O
",",",",O
cardiac,JJ,O
arrythmias,NNS,O
",",",",O
ventricular,JJ,O
tachycardia,NN,O
",",",",O
ventricular,JJ,O
fibrulation,NN,O
",",",",O
and,CC,O
torsades,NNS,O
de,IN,O
pointes,NNS,O
",",",",O
most,JJS,O
like,IN,O
due,JJ,O
to,TO,O
inhibition,NN,O
of,IN,O
hepatic,JJ,O
metabolism,NN,O
of,IN,O
cisapride,NN,D
by,IN,O
erythromycin,NN,D
.,.,.
,,
fatalities,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
lovastatin,NN,D
and,CC,O
erythromycin,NN,D
should,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
.,.,.
,,
cases,NNS,O
of,IN,O
rhabdomyolysis,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
seriously,RB,O
ill,JJ,O
patients,NNS,O
.,.,.
,,
cns,NN,O
drugs,NNS,O
-,:,O
given,VBN,O
the,DT,O
primary,JJ,O
cns,NN,O
effects,NNS,O
of,IN,O
escitalopram,NN,D
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
when,WRB,O
it,PRP,O
is,VBZ,O
taken,VBN,O
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
centrally,RB,O
acting,VBG,O
drugs,NNS,D
.,.,.
,,
alcohol,NN,D
-,:,O
although,IN,O
lexapro,NN,B
did,VBD,O
not,RB,O
potentiate,VB,O
the,DT,O
cognitive,JJ,O
and,CC,O
motor,NN,O
effects,NNS,O
of,IN,O
alcohol,NN,D
in,IN,O
a,DT,O
clinical,JJ,O
trial,NN,O
",",",",O
as,IN,O
with,IN,O
other,JJ,O
psychotropic,JJ,O
medications,NNS,O
",",",",O
the,DT,O
use,NN,O
of,IN,O
alcohol,NN,D
by,IN,O
patients,NNS,O
taking,VBG,O
lexapro,NNP,B
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
monoamine,NNP,O
oxidase,NNP,O
inhibitors,NNS,O
-lrb-,-LRB-,O
maois,NNS,G
.,.,.
,,
drugs,NNS,O
that,WDT,O
interfere,VBP,O
with,IN,O
hemostasis,NN,O
-lrb-,-LRB-,O
nsaids,NNS,G
",",",",O
aspirin,NNP,B
",",",",O
warfarin,NNP,D
",",",",O
etc.,FW,O
.,.,.
,,
serotonin,NN,O
release,NN,O
by,IN,O
platelets,NNS,O
plays,VBZ,O
an,DT,O
important,JJ,O
role,NN,O
in,IN,O
hemostasis,NN,O
.,.,.
,,
epidemiological,JJ,O
studies,NNS,O
of,IN,O
the,DT,O
case-control,JJ,O
and,CC,O
cohort,NN,O
design,NN,O
that,WDT,O
have,VBP,O
demonstrated,VBN,O
an,DT,O
association,NN,O
between,IN,O
use,NN,O
of,IN,O
psychotropic,JJ,O
drugs,NNS,D
that,WDT,O
interfere,VBP,O
with,IN,O
serotonin,NN,O
reuptake,NN,O
and,CC,O
the,DT,O
occurrence,NN,O
of,IN,O
upper,JJ,O
gastrointestinal,JJ,O
bleeding,NN,O
have,VBP,O
also,RB,O
shown,VBN,O
that,IN,O
concurrent,JJ,O
use,NN,O
of,IN,O
an,DT,O
nsaid,NN,G
or,CC,O
aspirin,NN,B
potentiated,VBD,O
the,DT,O
risk,NN,O
of,IN,O
bleeding,NN,O
.,.,.
,,
thus,RB,O
",",",",O
patients,NNS,O
should,MD,O
be,VB,O
cautioned,VBN,O
about,IN,O
the,DT,O
use,NN,O
of,IN,O
such,JJ,O
drugs,NNS,D
concurrently,RB,O
with,IN,O
lexapro,NN,B
.,.,.
,,
cimetidine,NN,D
-,:,O
in,IN,O
subjects,NNS,O
who,WP,O
had,VBD,O
received,VBN,O
21,CD,O
days,NNS,O
of,IN,O
40,CD,O
mg/day,NN,O
racemic,JJ,O
citalopram,NN,D
",",",",O
combined,VBN,O
administration,NN,O
of,IN,O
400,CD,O
mg/day,NN,O
cimetidine,NN,D
for,IN,O
8,CD,O
days,NNS,O
resulted,VBD,O
in,IN,O
an,DT,O
increase,NN,O
in,IN,O
citalopram,NN,D
auc,NN,O
and,CC,O
cmax,NN,O
of,IN,O
43,CD,O
%,NN,O
and,CC,O
39,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
these,DT,O
findings,NNS,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
digoxin,NN,D
-,:,O
in,IN,O
subjects,NNS,O
who,WP,O
had,VBD,O
received,VBN,O
21,CD,O
days,NNS,O
of,IN,O
40,CD,O
mg/day,NN,O
racemic,JJ,O
citalopram,NN,D
",",",",O
combined,VBN,O
administration,NN,O
of,IN,O
citalopram,NN,D
and,CC,O
digoxin,NN,D
-lrb-,-LRB-,O
single,JJ,O
dose,NN,O
of,IN,O
1,CD,O
mg,NN,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
significantly,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
citalopram,NN,D
or,CC,O
digoxin,NN,D
.,.,.
,,
lithium,NN,D
-,:,O
coadministration,NN,O
of,IN,O
racemic,JJ,O
citalopram,NN,D
-lrb-,-LRB-,O
40,CD,O
mg/day,NN,O
for,IN,O
10,CD,O
days,NNS,O
-rrb-,-RRB-,O
and,CC,O
lithium,NN,D
-lrb-,-LRB-,O
30,CD,O
mmol/day,NN,O
for,IN,O
5,CD,O
days,NNS,O
-rrb-,-RRB-,O
had,VBD,O
no,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
citalopram,NN,D
or,CC,O
lithium,NN,D
.,.,.
,,
nevertheless,RB,O
",",",",O
plasma,NN,O
lithium,NN,D
levels,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
with,IN,O
appropriate,JJ,O
adjustment,NN,O
to,TO,O
the,DT,O
lithium,NN,D
dose,NN,O
in,IN,O
accordance,NN,O
with,IN,O
standard,JJ,O
clinical,JJ,O
practice,NN,O
.,.,.
,,
because,IN,O
lithium,NN,D
may,MD,O
enhance,VB,O
the,DT,O
serotonergic,JJ,O
effects,NNS,O
of,IN,O
escitalopram,NN,D
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
lexapro,NNP,B
and,CC,O
lithium,NN,D
are,VBP,O
coadministered,VBN,O
.,.,.
,,
pimozide,NNP,D
and,CC,O
celexa,NNP,B
-,:,O
in,IN,O
a,DT,O
controlled,JJ,O
study,NN,O
",",",",O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
pimozide,NN,D
2,CD,O
mg,NN,O
co-administered,VBN,O
with,IN,O
racemic,JJ,O
citalopram,NN,D
40,CD,O
mg,NN,O
given,VBN,O
once,RB,O
daily,RB,O
for,IN,O
11,CD,O
days,NNS,O
was,VBD,O
associated,VBN,O
with,IN,O
a,DT,O
mean,JJ,O
increase,NN,O
in,IN,O
qtc,NN,O
values,NNS,O
of,IN,O
approximately,RB,O
10,CD,O
msec,NN,O
compared,VBN,O
to,TO,O
pimozide,VB,D
given,VBN,O
alone,RB,O
.,.,.
,,
racemic,JJ,O
citalopram,NN,D
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
mean,NN,O
auc,NN,O
or,CC,O
cmax,NN,O
of,IN,O
pimozide,NN,D
.,.,.
,,
the,DT,O
mechanism,NN,O
of,IN,O
this,DT,O
pharmacodynamic,JJ,O
interaction,NN,O
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
sumatriptan,NNP,D
-,:,O
there,EX,O
have,VBP,O
been,VBN,O
rare,JJ,O
postmarketing,VBG,O
reports,NNS,O
describing,VBG,O
patients,NNS,O
with,IN,O
weakness,NN,O
",",",",O
hyperreflexia,NN,O
",",",",O
and,CC,O
incoordination,NN,O
following,VBG,O
the,DT,O
use,NN,O
of,IN,O
a,DT,O
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitor,NN,O
-lrb-,-LRB-,O
ssri,NN,G
-rrb-,-RRB-,O
and,CC,O
sumatriptan,NN,D
.,.,.
,,
if,IN,O
concomitant,JJ,O
treatment,NN,O
with,IN,O
sumatriptan,NN,D
and,CC,O
an,DT,O
ssri,NN,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
fluoxetine,NN,D
",",",",O
fluvoxamine,NN,D
",",",",O
paroxetine,NN,D
",",",",O
sertraline,NN,D
",",",",O
citalopram,NN,D
",",",",O
escitalopram,NN,D
-rrb-,-RRB-,O
is,VBZ,O
clinically,RB,O
warranted,VBN,O
",",",",O
appropriate,JJ,O
observation,NN,O
of,IN,O
the,DT,O
patient,NN,O
is,VBZ,O
advised,VBN,O
.,.,.
,,
theophylline,NNP,D
-,:,O
combined,VBN,O
administration,NN,O
of,IN,O
racemic,JJ,O
citalopram,NN,D
-lrb-,-LRB-,O
40,CD,O
mg/day,NN,O
for,IN,O
21,CD,O
days,NNS,O
-rrb-,-RRB-,O
and,CC,O
the,DT,O
cyp1a2,NN,D
substrate,NN,O
theophylline,NN,D
-lrb-,-LRB-,O
single,JJ,O
dose,NN,O
of,IN,O
300,CD,O
mg,NN,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
theophylline,NN,D
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
theophylline,NN,D
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
citalopram,NN,D
was,VBD,O
not,RB,O
evaluated,VBN,O
.,.,.
,,
warfarin,NNP,D
-,:,O
administration,NN,O
of,IN,O
40,CD,O
mg/day,NN,O
racemic,JJ,O
citalopram,NN,D
for,IN,O
21,CD,O
days,NNS,O
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
warfarin,NN,D
",",",",O
a,DT,O
cyp3a4,NN,D
substrate,NN,O
.,.,.
,,
prothrombin,NNP,O
time,NN,O
was,VBD,O
increased,VBN,O
by,IN,O
5,CD,O
%,NN,O
",",",",O
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
which,WDT,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
carbamazepine,NNP,D
-,:,O
combined,VBN,O
administration,NN,O
of,IN,O
racemic,JJ,O
citalopram,NN,D
-lrb-,-LRB-,O
40,CD,O
mg/day,NN,O
for,IN,O
14,CD,O
days,NNS,O
-rrb-,-RRB-,O
and,CC,O
carbamazepine,NN,D
-lrb-,-LRB-,O
titrated,VBN,O
to,TO,O
400,CD,O
mg/day,NN,O
for,IN,O
35,CD,O
days,NNS,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
significantly,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
carbamazepine,NN,D
",",",",O
a,DT,O
cyp3a4,NN,D
substrate,NN,O
.,.,.
,,
although,IN,O
trough,NN,O
citalopram,NN,D
plasma,NN,O
levels,NNS,O
were,VBD,O
unaffected,JJ,O
",",",",O
given,VBN,O
the,DT,O
enzyme-inducing,JJ,O
properties,NNS,O
of,IN,O
carbamazepine,NN,D
",",",",O
the,DT,O
possibility,NN,O
that,IN,O
carbamazepine,NN,D
might,MD,O
increase,VB,O
the,DT,O
clearance,NN,O
of,IN,O
escitalopram,NN,D
should,MD,O
be,VB,O
considered,VBN,O
if,IN,O
the,DT,O
two,CD,O
drugs,NNS,D
are,VBP,O
coadministered,VBN,O
.,.,.
,,
triazolam,NN,D
-,:,O
combined,VBN,O
administration,NN,O
of,IN,O
racemic,JJ,O
citalopram,NN,D
-lrb-,-LRB-,O
titrated,VBN,O
to,TO,O
40,CD,O
mg/day,NN,O
for,IN,O
28,CD,O
days,NNS,O
-rrb-,-RRB-,O
and,CC,O
the,DT,O
cyp3a4,NN,D
substrate,NN,O
triazolam,NN,D
-lrb-,-LRB-,O
single,JJ,O
dose,NN,O
of,IN,O
0.25,CD,O
mg,NN,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
significantly,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
citalopram,NN,D
or,CC,O
triazolam,NN,D
.,.,.
,,
ketoconazole,NN,D
-,:,O
combined,VBN,O
administration,NN,O
of,IN,O
racemic,JJ,O
citalopram,NN,D
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
-rrb-,-RRB-,O
and,CC,O
ketoconazole,NN,D
-lrb-,-LRB-,O
200,CD,O
mg,NN,O
-rrb-,-RRB-,O
decreased,VBD,O
the,DT,O
cmax,NN,O
and,CC,O
auc,NN,O
of,IN,O
ketoconazole,NN,D
by,IN,O
21,CD,O
%,NN,O
and,CC,O
10,CD,O
%,NN,O
",",",",O
respectively,RB,O
",",",",O
and,CC,O
did,VBD,O
not,RB,O
significantly,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
citalopram,NN,D
.,.,.
,,
ritonavir,NNP,D
-,:,O
combined,VBN,O
administration,NN,O
of,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
ritonavir,NN,D
-lrb-,-LRB-,O
600,CD,O
mg,NN,O
-rrb-,-RRB-,O
",",",",O
both,CC,O
a,DT,O
cyp3a4,NN,D
substrate,NN,O
and,CC,O
a,DT,O
potent,JJ,O
inhibitor,NN,O
of,IN,O
cyp3a4,NN,D
",",",",O
and,CC,O
escitalopram,NN,D
-lrb-,-LRB-,O
20,CD,O
mg,NN,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
ritonavir,NN,D
or,CC,O
escitalopram,NN,D
.,.,.
,,
cyp3a4,NN,D
and,CC,O
-2,CD,O
c19,NN,O
inhibitors,NNS,O
-,:,O
in,FW,O
vitro,FW,O
studies,NNS,O
indicated,VBD,O
that,IN,O
cyp3a4,NN,D
and,CC,O
-2,CD,O
c19,NN,O
are,VBP,O
the,DT,O
primary,JJ,O
enzymes,NNS,O
involved,VBN,O
in,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
escitalopram,NN,D
.,.,.
,,
however,RB,O
",",",",O
coadministration,NN,O
of,IN,O
escitalopram,NN,D
-lrb-,-LRB-,O
20,CD,O
mg,NN,O
-rrb-,-RRB-,O
and,CC,O
ritonavir,NN,D
-lrb-,-LRB-,O
600,CD,O
mg,NN,O
-rrb-,-RRB-,O
",",",",O
a,DT,O
potent,JJ,O
inhibitor,NN,O
of,IN,O
cyp3a4,NN,D
",",",",O
did,VBD,O
not,RB,O
significantly,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
escitalopram,NN,D
.,.,.
,,
because,IN,O
escitalopram,NN,D
is,VBZ,O
metabolized,VBN,O
by,IN,O
multiple,JJ,O
enzyme,NN,O
systems,NNS,O
",",",",O
inhibition,NN,O
of,IN,O
a,DT,O
single,JJ,O
enzyme,NN,O
may,MD,O
not,RB,O
appreciably,RB,O
decrease,VB,O
escitalopram,JJ,D
clearance,NN,O
.,.,.
,,
drugs,NNS,O
metabolized,VBN,O
by,IN,O
cytochrome,NN,O
p4502d6,NN,O
-,:,O
in,FW,O
vitro,FW,O
studies,NNS,O
did,VBD,O
not,RB,O
reveal,VB,O
an,DT,O
inhibitory,JJ,O
effect,NN,O
of,IN,O
escitalopram,NN,D
on,IN,O
cyp2d6,NN,D
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
steady,JJ,O
state,NN,O
levels,NNS,O
of,IN,O
racemic,JJ,O
citalopram,NN,D
were,VBD,O
not,RB,O
significantly,RB,O
different,JJ,O
in,IN,O
poor,JJ,O
metabolizers,NNS,O
and,CC,O
extensive,JJ,O
cyp2d6,NN,D
metabolizers,NNS,O
after,IN,O
multiple-dose,JJ,O
administration,NN,O
of,IN,O
citalopram,NN,D
",",",",O
suggesting,VBG,O
that,IN,O
coadministration,NN,O
",",",",O
with,IN,O
escitalopram,NN,D
",",",",O
of,IN,O
a,DT,O
drug,NN,D
that,WDT,O
inhibits,VBZ,O
cyp2d6,NN,D
",",",",O
is,VBZ,O
unlikely,JJ,O
to,TO,O
have,VB,O
clinically,RB,O
significant,JJ,O
effects,NNS,O
on,IN,O
escitalopram,NN,D
metabolism,NN,O
.,.,.
,,
however,RB,O
",",",",O
there,EX,O
are,VBP,O
limited,JJ,O
in,FW,O
vivo,FW,O
data,NNS,O
suggesting,VBG,O
a,DT,O
modest,JJ,O
cyp2d6,NN,D
inhibitory,JJ,O
effect,NN,O
for,IN,O
escitalopram,NN,D
",",",",O
i.e.,FW,O
",",",",O
coadministration,NN,O
of,IN,O
escitalopram,NN,D
-lrb-,-LRB-,O
20,CD,O
mg/day,NN,O
for,IN,O
21,CD,O
days,NNS,O
-rrb-,-RRB-,O
with,IN,O
the,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
desipramine,NN,D
-lrb-,-LRB-,O
single,JJ,O
dose,NN,O
of,IN,O
50,CD,O
mg,NN,O
-rrb-,-RRB-,O
",",",",O
a,DT,O
substrate,NN,O
for,IN,O
cyp2d6,NN,D
",",",",O
resulted,VBD,O
in,IN,O
a,DT,O
40,CD,O
%,NN,O
increase,NN,O
in,IN,O
cmax,NNP,O
and,CC,O
a,DT,O
100,CD,O
%,NN,O
increase,NN,O
in,IN,O
auc,NN,O
of,IN,O
desipramine,NN,D
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
finding,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
nevertheless,RB,O
",",",",O
caution,NN,O
is,VBZ,O
indicated,VBN,O
in,IN,O
the,DT,O
coadministration,NN,O
of,IN,O
escitalopram,NN,D
and,CC,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
cyp2d6,NN,D
.,.,.
,,
metoprolol,NNP,D
-,:,O
administration,NN,O
of,IN,O
20,CD,O
mg/day,NN,O
lexapro,NN,B
for,IN,O
21,CD,O
days,NNS,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
resulted,VBD,O
in,IN,O
a,DT,O
50,CD,O
%,NN,O
increase,NN,O
in,IN,O
cmax,NNP,O
and,CC,O
82,CD,O
%,NN,O
increase,NN,O
in,IN,O
auc,NN,O
of,IN,O
the,DT,O
beta-adrenergic,JJ,O
blocker,NN,O
metoprolol,NN,D
-lrb-,-LRB-,O
given,VBN,O
in,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
100,CD,O
mg,NN,O
-rrb-,-RRB-,O
.,.,.
,,
increased,VBN,O
metoprolol,NN,D
plasma,NN,O
levels,NNS,O
have,VBP,O
been,VBN,O
associated,VBN,O
with,IN,O
decreased,VBN,O
cardioselectivity,NN,O
.,.,.
,,
coadministration,NNP,O
of,IN,O
lexapro,NNP,B
and,CC,O
metoprolol,NN,D
had,VBD,O
no,DT,O
clinically,RB,O
significant,JJ,O
effects,NNS,O
on,IN,O
blood,NN,O
pressure,NN,O
or,CC,O
heart,NN,O
rate,NN,O
.,.,.
,,
electroconvulsive,JJ,O
therapy,NN,O
-lrb-,-LRB-,O
ect,NN,O
-rrb-,-RRB-,O
-,:,O
there,EX,O
are,VBP,O
no,DT,O
clinical,JJ,O
studies,NNS,O
of,IN,O
the,DT,O
combined,VBN,O
use,NN,O
of,IN,O
ect,NNP,O
and,CC,O
escitalopram,NN,D
.,.,.
,,
concomitant,JJ,O
administration,NN,O
with,IN,O
racemic,JJ,O
citalopram,NNP,D
citalopram,NNP,D
-,:,O
since,IN,O
escitalopram,NN,D
is,VBZ,O
the,DT,O
active,JJ,O
isomer,NN,O
of,IN,O
racemic,JJ,O
citalopram,NN,D
-lrb-,-LRB-,O
celexa,NN,B
-rrb-,-RRB-,O
",",",",O
the,DT,O
two,CD,O
agents,NNS,O
should,MD,O
not,RB,O
be,VB,O
coadministered,VBN,O
.,.,.
,,
catecholamine-depleting,JJ,O
drugs,NNS,D
",",",",O
e.g.,FW,O
",",",",O
reserpine,NN,D
",",",",O
may,MD,O
have,VB,O
an,DT,O
additive,JJ,O
effect,NN,O
when,WRB,O
given,VBN,O
with,IN,O
beta,NN,O
blocking,VBG,O
agents,NNS,O
.,.,.
,,
patients,NNS,O
treated,VBN,O
concurrently,RB,O
with,IN,O
brevibloc,NN,B
-lrb-,-LRB-,O
esmolol,NN,O
hcl,NN,O
-rrb-,-RRB-,O
and,CC,O
a,DT,O
catecholamine,NN,O
depletor,NN,O
should,MD,O
therefore,RB,O
be,VB,O
closely,RB,O
observed,VBN,O
for,IN,O
evidence,NN,O
of,IN,O
hypotension,NN,O
or,CC,O
marked,JJ,O
bradycardia,NN,O
",",",",O
which,WDT,O
may,MD,O
result,VB,O
in,IN,O
vertigo,NN,O
",",",",O
syncope,NN,O
",",",",O
or,CC,O
postural,JJ,O
hypotension,NN,O
.,.,.
,,
a,DT,O
study,NN,O
of,IN,O
interaction,NN,O
between,IN,O
brevibloc,NNP,B
and,CC,O
warfarin,NN,D
showed,VBD,O
that,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
brevibloc,NNP,B
and,CC,O
warfarin,NN,D
does,VBZ,O
not,RB,O
alter,VB,O
warfarin,NN,D
plasma,NN,O
levels,NNS,O
.,.,.
,,
brevibloc,NN,B
concentrations,NNS,O
were,VBD,O
equivocally,RB,O
higher,JJR,O
when,WRB,O
given,VBN,O
with,IN,O
warfarin,NN,D
",",",",O
but,CC,O
this,DT,O
is,VBZ,O
not,RB,O
likely,JJ,O
to,TO,O
be,VB,O
clinically,RB,O
important,JJ,O
.,.,.
,,
when,WRB,O
digoxin,NN,D
and,CC,O
brevibloc,NN,B
were,VBD,O
concomitantly,RB,O
administered,VBN,O
intravenously,RB,O
to,TO,O
normal,JJ,O
volunteers,NNS,O
",",",",O
there,EX,O
was,VBD,O
a,DT,O
20-Oct,CD,O
%,NN,O
increase,NN,O
in,IN,O
digoxin,NN,D
blood,NN,O
levels,NNS,O
at,IN,O
some,DT,O
time,NN,O
points,NNS,O
.,.,.
,,
digoxin,NN,D
did,VBD,O
not,RB,O
affect,VB,O
brevibloc,NNP,B
pharmacokinetics,NNS,O
.,.,.
,,
when,WRB,O
intravenous,JJ,O
morphine,NN,D
and,CC,O
brevibloc,NN,B
were,VBD,O
concomitantly,RB,O
administered,VBN,O
in,IN,O
normal,JJ,O
subjects,NNS,O
",",",",O
no,DT,O
effect,NN,O
on,IN,O
morphine,NN,D
blood,NN,O
levels,NNS,O
was,VBD,O
seen,VBN,O
",",",",O
but,CC,O
brevibloc,NNP,B
steady-state,JJ,O
blood,NN,O
levels,NNS,O
were,VBD,O
increased,VBN,O
by,IN,O
46,CD,O
%,NN,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
morphine,NN,D
.,.,.
,,
no,DT,O
other,JJ,O
pharmacokinetic,JJ,O
parameters,NNS,O
were,VBD,O
changed,VBN,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
brevibloc,NN,B
on,IN,O
the,DT,O
duration,NN,O
of,IN,O
succinylcholine-induced,JJ,O
neuromuscular,JJ,O
blockade,NN,O
was,VBD,O
studied,VBN,O
in,IN,O
patients,NNS,O
undergoing,VBG,O
surgery,NN,O
.,.,.
,,
the,DT,O
onset,NN,O
of,IN,O
neuromuscular,JJ,O
blockade,NN,O
by,IN,O
succinylcholine,NN,D
was,VBD,O
unaffected,JJ,O
by,IN,O
brevibloc,NNP,B
",",",",O
but,CC,O
the,DT,O
duration,NN,O
of,IN,O
neuromuscular,JJ,O
blockade,NN,O
was,VBD,O
prolonged,VBN,O
from,IN,O
5,CD,O
minutes,NNS,O
to,TO,O
8,CD,O
minutes,NNS,O
.,.,.
,,
although,IN,O
the,DT,O
interactions,NNS,O
observed,VBN,O
in,IN,O
these,DT,O
studies,NNS,O
do,VBP,O
not,RB,O
appear,VB,O
to,TO,O
be,VB,O
of,IN,O
major,JJ,O
clinical,JJ,O
importance,NN,O
",",",",O
brevibloc,NN,B
should,MD,O
be,VB,O
titrated,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
being,VBG,O
treated,VBN,O
concurrently,RB,O
with,IN,O
digoxin,NN,D
",",",",O
morphine,NN,D
",",",",O
succinylcholine,NN,D
or,CC,O
warfarin,NN,D
.,.,.
,,
while,IN,O
taking,VBG,O
beta,NN,O
blockers,NNS,O
",",",",O
patients,NNS,O
with,IN,O
a,DT,O
history,NN,O
of,IN,O
severe,JJ,O
anaphylactic,JJ,O
reaction,NN,O
to,TO,O
a,DT,O
variety,NN,O
of,IN,O
allergens,NNS,O
may,MD,O
be,VB,O
more,RBR,O
reactive,JJ,O
to,TO,O
repeated,VBN,O
challenge,NN,O
",",",",O
either,CC,O
accidental,JJ,O
",",",",O
diagnostic,JJ,O
",",",",O
or,CC,O
therapeutic,JJ,O
.,.,.
,,
such,JJ,O
patients,NNS,O
may,MD,O
be,VB,O
unresponsive,JJ,O
to,TO,O
the,DT,O
usual,JJ,O
doses,NNS,O
of,IN,O
epinephrine,NN,D
used,VBN,O
to,TO,O
treat,VB,O
allergic,JJ,O
reaction,NN,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
considering,VBG,O
the,DT,O
use,NN,O
of,IN,O
brevibloc,NN,B
and,CC,O
verapamil,NN,D
in,IN,O
patients,NNS,O
with,IN,O
depressed,JJ,O
myocardial,JJ,O
function,NN,O
.,.,.
,,
fatal,JJ,O
cardiac,JJ,O
arrests,NNS,O
have,VBP,O
occurred,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
both,CC,O
drugs,NNS,D
.,.,.
,,
additionally,RB,O
",",",",O
brevibloc,NN,B
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
to,TO,O
control,VB,O
supraventricular,JJ,O
tachycardia,NN,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
agents,NNS,O
which,WDT,O
are,VBP,O
vasoconstrictive,JJ,O
and,CC,O
inotropic,JJ,O
such,JJ,O
as,IN,O
dopamine,NN,D
",",",",O
epinephrine,NN,D
",",",",O
and,CC,O
norepinephrine,NN,D
because,IN,O
of,IN,O
the,DT,O
danger,NN,O
of,IN,O
blocking,VBG,O
cardiac,JJ,O
contractility,NN,O
when,WRB,O
systemic,JJ,O
vascular,JJ,O
resistance,NN,O
is,VBZ,O
high,JJ,O
.,.,.
,,
esomeprazole,NNP,D
is,VBZ,O
extensively,RB,O
metabolized,VBN,O
in,IN,O
the,DT,O
liver,NN,O
by,IN,O
cyp2c19,NN,O
and,CC,O
cyp3a4,NN,D
.,.,.
,,
in,FW,O
vitro,FW,O
and,CC,O
in,FW,O
vivo,FW,O
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
esomeprazole,NN,D
is,VBZ,O
not,RB,O
likely,JJ,O
to,TO,O
inhibit,VB,O
cyps,NNS,O
1a2,NN,O
",",",",O
2a6,NN,O
",",",",O
2c9,NN,O
",",",",O
2d6,NN,O
",",",",O
2.00E+01,NN,O
and,CC,O
3a4,NN,O
.,.,.
,,
no,DT,O
clinically,RB,O
relevant,JJ,O
interactions,NNS,O
with,IN,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
these,DT,O
cyp,NN,O
enzymes,NNS,O
would,MD,O
be,VB,O
expected,VBN,O
.,.,.
,,
drug,NN,O
interaction,NN,O
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
esomeprazole,NN,D
does,VBZ,O
not,RB,O
have,VB,O
any,DT,O
clinically,RB,O
significant,JJ,O
interactions,NNS,O
with,IN,O
phenytoin,NN,D
",",",",O
warfarin,NN,D
",",",",O
quinidine,NN,D
",",",",O
clarithromycin,NN,D
or,CC,O
amoxicillin,NNP,D
.,.,.
,,
post-marketing,JJ,O
reports,NNS,O
of,IN,O
changes,NNS,O
in,IN,O
prothrombin,NN,O
measures,NNS,O
have,VBP,O
been,VBN,O
received,VBN,O
among,IN,O
patients,NNS,O
on,IN,O
concomitant,JJ,O
warfarin,NN,D
and,CC,O
esomeprazole,NN,D
therapy,NN,O
.,.,.
,,
increases,NNS,O
in,IN,O
inr,NN,O
and,CC,O
prothrombin,NN,O
time,NN,O
may,MD,O
lead,VB,O
to,TO,O
abnormal,JJ,O
bleeding,NN,O
and,CC,O
even,RB,O
death,NN,O
.,.,.
,,
patients,NNS,O
treated,VBN,O
with,IN,O
proton,NN,O
pump,NN,O
inhibitors,NNS,O
and,CC,O
warfarin,NN,D
concomitantly,RB,O
may,MD,O
need,VB,O
to,TO,O
be,VB,O
monitored,VBN,O
for,IN,O
increases,NNS,O
in,IN,O
inr,NN,O
and,CC,O
prothrombin,NN,O
time,NN,O
.,.,.
,,
esomeprazole,NNP,D
may,MD,O
potentially,RB,O
interfere,VB,O
with,IN,O
cyp2c19,NN,O
",",",",O
the,DT,O
major,JJ,O
esomeprazole,NN,D
metabolizing,VBG,O
enzyme,NN,O
.,.,.
,,
coadministration,NN,O
of,IN,O
esomeprazole,NN,D
30,CD,O
mg,NN,O
and,CC,O
diazepam,NN,D
",",",",O
a,DT,O
cyp2c19,NN,O
substrate,NN,O
",",",",O
resulted,VBD,O
in,IN,O
a,DT,O
45,CD,O
%,NN,O
decrease,NN,O
in,IN,O
clearance,NN,O
of,IN,O
diazepam,NN,D
.,.,.
,,
increased,VBN,O
plasma,NN,O
levels,NNS,O
of,IN,O
diazepam,NN,D
were,VBD,O
observed,VBN,O
12,CD,O
hours,NNS,O
after,IN,O
dosing,NN,O
and,CC,O
onwards,NNS,O
.,.,.
,,
however,RB,O
",",",",O
at,IN,O
that,DT,O
time,NN,O
",",",",O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
diazepam,NN,D
were,VBD,O
below,IN,O
the,DT,O
therapeutic,JJ,O
interval,NN,O
",",",",O
and,CC,O
thus,RB,O
this,DT,O
interaction,NN,O
is,VBZ,O
unlikely,JJ,O
to,TO,O
be,VB,O
of,IN,O
clinical,JJ,O
relevance,NN,O
.,.,.
,,
esomeprazole,NN,D
inhibits,VBZ,O
gastric,JJ,O
acid,NN,O
secretion,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
esomeprazole,NN,D
may,MD,O
interfere,VB,O
with,IN,O
the,DT,O
absorption,NN,O
of,IN,O
drugs,NNS,D
where,WRB,O
gastric,JJ,O
ph,NN,O
is,VBZ,O
an,DT,O
important,JJ,O
determinant,NN,O
of,IN,O
bioavailability,NN,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
ketoconazole,NN,D
",",",",O
iron,NN,D
salts,NNS,O
and,CC,O
digoxin,NN,D
-rrb-,-RRB-,O
.,.,.
,,
coadministration,NN,O
of,IN,O
oral,JJ,O
contraceptives,NNS,G
",",",",O
diazepam,NN,D
",",",",O
phenytoin,NN,D
",",",",O
or,CC,O
quinidine,NN,D
did,VBD,O
not,RB,O
seem,VB,O
to,TO,O
change,VB,O
the,DT,O
pharmacokinetic,JJ,O
profile,NN,O
of,IN,O
esomeprazole,NN,D
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
clarithromycin,NN,D
with,IN,O
pimozide,NN,D
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
if,IN,O
prosom,NNP,B
is,VBZ,O
given,VBN,O
concomitantly,RB,O
with,IN,O
other,JJ,O
drugs,NNS,D
acting,VBG,O
on,IN,O
the,DT,O
central,JJ,O
nervous,JJ,O
system,NN,O
",",",",O
careful,JJ,O
consideration,NN,O
should,MD,O
be,VB,O
given,VBN,O
to,TO,O
the,DT,O
pharmacology,NN,O
of,IN,O
all,DT,O
agents,NNS,O
.,.,.
,,
the,DT,O
action,NN,O
of,IN,O
the,DT,O
benzodiazepines,NNS,G
may,MD,O
be,VB,O
potentiated,VBN,O
by,IN,O
anticonvulsants,NNS,G
",",",",O
antihistamines,NNS,G
",",",",O
alcohol,NN,D
",",",",O
barbiturates,NNS,G
",",",",O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
",",",",O
narcotics,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
psychotropic,JJ,O
medications,NNS,O
",",",",O
or,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
produce,VBP,O
cns,NN,O
depression,NN,O
.,.,.
,,
smokers,NNS,O
have,VBP,O
an,DT,O
increased,VBN,O
clearance,NN,O
of,IN,O
benzodiazepines,NNS,G
as,IN,O
compared,VBN,O
to,TO,O
nonsmokers,NNS,O
.,.,.
,,
this,DT,O
was,VBD,O
seen,VBN,O
in,IN,O
studies,NNS,O
with,IN,O
estazolam,NN,D
.,.,.
,,
while,IN,O
no,DT,O
in,FW,O
vivo,FW,O
drug-drug,JJ,O
interaction,NN,O
studies,NNS,O
were,VBD,O
conducted,VBN,O
between,IN,O
estazolam,NN,D
and,CC,O
inducers,NNS,O
of,IN,O
cyp3a,NN,O
",",",",O
compounds,NNS,O
that,WDT,O
are,VBP,O
potent,JJ,O
cyp3a,NN,O
inducers,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
carbamazepine,NN,D
",",",",O
phenytoin,NN,D
",",",",O
rifampin,NN,D
",",",",O
and,CC,O
barbiturates,NNS,G
-rrb-,-RRB-,O
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
decrease,VB,O
estazolam,NN,D
concentrations,NNS,O
.,.,.
,,
estazolam,NNP,D
:,:,O
interaction,NN,O
with,IN,O
drugs,NNS,O
that,WDT,O
inhibit,VBP,O
metabolism,NN,O
via,IN,O
cytochrome,NNP,O
p450,NN,O
3a,NN,O
-lrb-,-LRB-,O
cyp3a,NN,O
-rrb-,-RRB-,O
:,:,O
the,DT,O
metabolism,NN,O
of,IN,O
estazolam,NN,D
to,TO,O
the,DT,O
major,JJ,O
circulating,VBG,O
metabolite,NN,O
4-hydroxy-estazolam,NN,D_n
and,CC,O
the,DT,O
metabolism,NN,O
of,IN,O
other,JJ,O
triazolobenzodiazepines,NNS,G
is,VBZ,O
catalyzed,VBN,O
by,IN,O
cyp3a,NN,O
.,.,.
,,
consequently,RB,O
",",",",O
estazolam,NN,D
should,MD,O
be,VB,O
avoided,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
ketoconazole,NN,D
and,CC,O
itraconazole,NN,D
",",",",O
which,WDT,O
are,VBP,O
very,RB,O
potent,JJ,O
inhibitors,NNS,O
of,IN,O
cyp3a,NN,O
.,.,.
,,
with,IN,O
drugs,NNS,D
inhibiting,VBG,O
cyp3a,NN,O
to,TO,O
a,DT,O
lesser,JJR,O
",",",",O
but,CC,O
still,RB,O
significant,JJ,O
degree,NN,O
",",",",O
estazolam,NN,D
should,MD,O
be,VB,O
used,VBN,O
only,RB,O
with,IN,O
caution,NN,O
and,CC,O
consideration,NN,O
of,IN,O
appropriate,JJ,O
dosage,NN,O
reduction,NN,O
.,.,.
,,
the,DT,O
following,VBG,O
are,VBP,O
examples,NNS,O
of,IN,O
drugs,NNS,D
known,VBN,O
to,TO,O
inhibit,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
other,JJ,O
related,JJ,O
benzodiazepines,NNS,G
",",",",O
presumably,RB,O
through,IN,O
inhibition,NN,O
of,IN,O
cyp3a,NN,O
:,:,O
nefazodone,NN,D
",",",",O
fluvoxamine,NN,D
",",",",O
cimetidine,NN,D
",",",",O
diltiazem,NN,D
",",",",O
isoniazide,NN,D
",",",",O
and,CC,O
some,DT,O
macrolide,NN,O
antibiotics,NNS,G
.,.,.
,,
drug,NN,O
interaction,NN,O
with,IN,O
fluoxetine,NN,D
:,:,O
a,DT,O
multiple-dose,JJ,O
study,NN,O
was,VBD,O
conducted,VBN,O
to,TO,O
assess,VB,O
the,DT,O
effect,NN,O
of,IN,O
fluoxetine,NN,D
20,CD,O
mg,NN,O
bid,NNP,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
estazolam,NN,D
2,CD,O
mg,NN,O
qhs,NN,O
after,IN,O
seven,CD,O
days,NNS,O
.,.,.
,,
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
estazolam,NN,D
-lrb-,-LRB-,O
cmax,NN,O
and,CC,O
auc,NN,O
-rrb-,-RRB-,O
were,VBD,O
not,RB,O
affected,VBN,O
during,IN,O
multiple-dose,JJ,O
fluoxetine,NN,D
",",",",O
suggesting,VBG,O
no,DT,O
clinically,RB,O
significant,JJ,O
pharmacokinetic,JJ,O
interaction,NN,O
.,.,.
,,
estazolam,NNP,D
:,:,O
interaction,NN,O
with,IN,O
other,JJ,O
drugs,NNS,O
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
cytochrome,NN,O
p450,NN,O
-lrb-,-LRB-,O
cyp,NN,O
-rrb-,-RRB-,O
:,:,O
at,IN,O
clinically,RB,O
relevant,JJ,O
concentrations,NNS,O
",",",",O
in,FW,O
vitro,FW,O
studies,NNS,O
indicate,VBP,O
that,IN,O
estazolam,NN,D
-lrb-,-LRB-,O
0.6,CD,O
m,NN,O
-rrb-,-RRB-,O
was,VBD,O
not,RB,O
inhibitory,JJ,O
towards,IN,O
the,DT,O
major,JJ,O
cytochrome,NN,O
p450,NN,O
isoforms,NNS,O
cyp1a2,NN,D
",",",",O
cyp2a6,NN,O
",",",",O
cyp2c9,NN,D
",",",",O
cyp2c19,NN,O
",",",",O
cyp2d6,NN,D
",",",",O
cyp2e1,NN,O
",",",",O
and,CC,O
cyp3a,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
based,VBN,O
on,IN,O
these,DT,O
in,FW,O
vitro,FW,O
data,NNS,O
",",",",O
estazolam,NN,D
is,VBZ,O
very,RB,O
unlikely,JJ,O
to,TO,O
inhibit,VB,O
the,DT,O
biotransformation,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
these,DT,O
cyp,NN,O
isoform,NN,O
.,.,.
,,
d.,NNP,O
drug,NNP,O
and,CC,O
laboratory,NNP,O
test,NNP,O
interactions,NNS,O
1,CD,O
.,.,.
,,
accelerated,VBN,O
prothrombin,NN,O
time,NN,O
",",",",O
partial,JJ,O
thromboplastin,NN,O
time,NN,O
",",",",O
and,CC,O
platelet,NN,O
aggregation,NN,O
time,NN,O
;,:,O
.,.,.
,,
increased,VBN,O
platelet,NN,O
count,NN,O
;,:,O
.,.,.
,,
increased,VBN,O
factors,NNS,O
ii,CD,O
",",",",O
vii,NN,O
antigen,NN,O
",",",",O
viii,CD,O
antigen,NN,O
",",",",O
viii,CD,O
coagulant,NN,O
activity,NN,O
",",",",O
ix,CD,O
",",",",O
x,NN,O
",",",",O
xii,NNP,O
",",",",O
vii-x,NN,O
complex,NN,O
",",",",O
ii-vii-x,NN,O
complex,NN,O
",",",",O
and,CC,O
beta-thromboglobulin,NN,O
;,:,O
.,.,.
,,
decreased,VBN,O
levels,NNS,O
of,IN,O
anti-factor,JJ,O
xa,NN,O
and,CC,O
antithrombin,NN,O
iii,CD,O
",",",",O
decreased,VBD,O
antithrombin,NN,O
iii,CD,O
activity,NN,O
;,:,O
.,.,.
,,
increased,VBN,O
levels,NNS,O
of,IN,O
fibrinogen,NN,D
and,CC,O
fibrinogen,NN,D
activity,NN,O
;,:,O
.,.,.
,,
increased,VBN,O
plasminogen,NN,O
antigen,NN,O
and,CC,O
activity,NN,O
.,.,.
,,
2,LS,O
.,.,.
,,
increased,VBN,O
thyroid-binding,JJ,O
globulin,NN,O
-lrb-,-LRB-,O
tbg,NN,O
-rrb-,-RRB-,O
leading,VBG,O
to,TO,O
increased,VBN,O
circulating,VBG,O
total,JJ,O
thyroid,NN,G
hormone,NN,O
levels,NNS,O
",",",",O
as,IN,O
measured,VBN,O
by,IN,O
protein-bound,JJ,O
iodine,NN,G
-lrb-,-LRB-,O
pbi,NN,O
-rrb-,-RRB-,O
",",",",O
t4,NN,D
levels,NNS,O
-lrb-,-LRB-,O
by,IN,O
column,NN,O
or,CC,O
by,IN,O
radioimmunoassay,NN,O
-rrb-,-RRB-,O
or,CC,O
t3,NN,D
levels,NNS,O
by,IN,O
radioimmunoassay,NN,O
.,.,.
,,
t3,NN,D
resin,NN,G
uptake,NN,O
is,VBZ,O
decreased,VBN,O
",",",",O
reflecting,VBG,O
the,DT,O
elevated,JJ,O
tbg,NN,O
.,.,.
,,
free,NNP,O
t4,NN,D
and,CC,O
t3,NN,D
concentrations,NNS,O
are,VBP,O
unaltered,JJ,O
.,.,.
,,
patients,NNS,O
on,IN,O
thyroid,NN,G
replacement,NN,O
therapy,NN,O
may,MD,O
require,VB,O
higher,JJR,O
doses,NNS,O
of,IN,O
thyroid,NN,G
hormone,NN,O
.,.,.
,,
3,LS,O
.,.,.
,,
other,JJ,O
binding,NN,O
proteins,NNS,O
may,MD,O
be,VB,O
elevated,JJ,O
in,IN,O
serum,NN,O
",",",",O
i.e.,FW,O
",",",",O
corticosteroid,NN,G
binding,NN,O
globulin,NN,O
-lrb-,-LRB-,O
cbg,NN,O
-rrb-,-RRB-,O
",",",",O
sex,NN,O
hormone-binding,JJ,O
globulin,NN,O
-lrb-,-LRB-,O
shbg,NN,O
-rrb-,-RRB-,O
",",",",O
leading,VBG,O
to,TO,O
increased,VBN,O
total,JJ,O
circulating,VBG,O
corticosteroids,NNS,G
and,CC,O
sex,NN,O
steroids,NNS,G
",",",",O
respectively,RB,O
.,.,.
,,
free,NNP,O
hormone,NN,O
concentrations,NNS,O
may,MD,O
be,VB,O
decreased,VBN,O
.,.,.
,,
other,JJ,O
plasma,NN,O
proteins,NNS,O
may,MD,O
be,VB,O
increased,VBN,O
-lrb-,-LRB-,O
angiotensinogen/renin,NN,O
substrate,NN,O
",",",",O
alpha-1-antitrypsin,NN,O
",",",",O
ceruloplasmin,NN,O
-rrb-,-RRB-,O
.,.,.
,,
4,LS,O
.,.,.
,,
increased,VBN,O
plasma,NN,O
hdl,NN,O
and,CC,O
hdl2,NN,O
cholesterol,NN,O
subfraction,NN,O
concentrations,NNS,O
",",",",O
reduced,VBD,O
ldl,NN,O
cholesterol,NN,O
concentration,NN,O
",",",",O
increased,VBD,O
triglyceride,NN,O
levels,NNS,O
.,.,.
,,
5,CD,O
.,.,.
,,
impaired,JJ,O
glucose,NN,O
tolerance,NN,O
.,.,.
,,
6,CD,O
.,.,.
,,
reduced,VBN,O
response,NN,O
to,TO,O
metyrapone,NN,O
test,NN,O
.,.,.
,,
milk,NN,O
",",",",O
milk,NN,O
products,NNS,O
",",",",O
and,CC,O
calcium-rich,JJ,O
foods,NNS,O
or,CC,O
drugs,NNS,D
may,MD,O
impair,VB,O
the,DT,O
absorption,NN,O
of,IN,O
emcyt,NNP,B
.,.,.
,,
cns-active,JJ,O
drugs,NNS,O
ethanol,NN,D
an,DT,O
additive,JJ,O
effect,NN,O
on,IN,O
psychomotor,NN,O
performance,NN,O
was,VBD,O
seen,VBN,O
with,IN,O
coadministration,NN,O
of,IN,O
eszopiclone,NN,D
and,CC,O
ethanol,NN,D
0.7,CD,O
g/kg,NN,O
for,IN,O
up,RB,O
to,TO,O
4,CD,O
hours,NNS,O
after,IN,O
ethanol,NN,D
administration,NN,O
.,.,.
,,
paroxetine,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
single,JJ,O
doses,NNS,O
of,IN,O
eszopiclone,NN,D
3,CD,O
mg,NN,O
and,CC,O
paroxetine,NN,D
20,CD,O
mg,NN,O
daily,RB,O
for,IN,O
7,CD,O
days,NNS,O
produced,VBD,O
no,DT,O
pharmacokinetic,JJ,O
or,CC,O
pharmacodynamic,JJ,O
interaction,NN,O
.,.,.
,,
lorazepam,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
single,JJ,O
doses,NNS,O
of,IN,O
eszopiclone,NN,D
3,CD,O
mg,NN,O
and,CC,O
lorazepam,NN,D
2,CD,O
mg,NN,O
did,VBD,O
not,RB,O
have,VB,O
clinically,RB,O
relevant,JJ,O
effects,NNS,O
on,IN,O
the,DT,O
pharmacodynamics,NNS,O
or,CC,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
drug,NN,D
.,.,.
,,
olanzapine,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
eszopiclone,NN,D
3,CD,O
mg,NN,O
and,CC,O
olanzapine,NN,D
10,CD,O
mg,NN,O
produced,VBD,O
a,DT,O
decrease,NN,O
in,IN,O
dsst,NN,O
scores,NNS,O
.,.,.
,,
the,DT,O
interaction,NN,O
was,VBD,O
pharmacodynamic,JJ,O
;,:,O
.,.,.
,,
there,EX,O
was,VBD,O
no,DT,O
alteration,NN,O
in,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
drug,NN,D
.,.,.
,,
drugs,NNS,O
that,WDT,O
inhibit,VBP,O
cyp3a4,NN,D
-lrb-,-LRB-,O
ketoconazole,NN,D
-rrb-,-RRB-,O
cyp3a4,NN,D
is,VBZ,O
a,DT,O
major,JJ,O
metabolic,JJ,O
pathway,NN,O
for,IN,O
elimination,NN,O
of,IN,O
eszopiclone,NN,D
.,.,.
,,
the,DT,O
auc,NN,O
of,IN,O
eszopiclone,NN,D
was,VBD,O
increased,VBN,O
2.2-fold,RB,O
by,IN,O
coadministration,NN,O
of,IN,O
ketoconazole,NN,D
",",",",O
a,DT,O
potent,JJ,O
inhibitor,NN,O
of,IN,O
cyp3a4,NN,D
",",",",O
400,CD,O
mg,NN,O
daily,RB,O
for,IN,O
5,CD,O
days,NNS,O
.,.,.
,,
cmax,NN,O
and,CC,O
t1/2,NN,O
were,VBD,O
increased,VBN,O
1.4-fold,RB,O
and,CC,O
1.3-fold,RB,O
",",",",O
respectively,RB,O
.,.,.
,,
other,JJ,O
strong,JJ,O
inhibitors,NNS,O
of,IN,O
cyp3a4,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
itraconazole,NN,D
",",",",O
clarithromycin,NN,D
",",",",O
nefazodone,NN,D
",",",",O
troleandomycin,NN,D
",",",",O
ritonavir,NN,D
",",",",O
nelfinavir,NN,D
-rrb-,-RRB-,O
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
behave,VB,O
similarly,RB,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
induce,VBP,O
cyp3a4,NN,D
-lrb-,-LRB-,O
rifampicin,NN,D
-rrb-,-RRB-,O
racemic,JJ,O
zopiclone,NN,D
exposure,NN,O
was,VBD,O
decreased,VBN,O
80,CD,O
%,NN,O
by,IN,O
concomitant,JJ,O
useof,JJ,O
rifampicin,NN,D
",",",",O
a,DT,O
potent,JJ,O
inducer,NN,O
of,IN,O
cyp3a4,NN,D
.,.,.
,,
a,DT,O
similar,JJ,O
effect,NN,O
would,MD,O
be,VB,O
expected,VBN,O
with,IN,O
eszopiclone,NN,D
.,.,.
,,
drugs,NNS,O
highly,RB,O
bound,VBN,O
to,TO,O
plasma,NN,O
protein,NN,O
eszopiclone,NN,D
is,VBZ,O
not,RB,O
highly,RB,O
bound,VBN,O
to,TO,O
plasma,NN,O
proteins,NNS,O
-lrb-,-LRB-,O
52-59,CD,O
%,NN,O
bound,VBN,O
-rrb-,-RRB-,O
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
disposition,NN,O
of,IN,O
eszopiclone,NN,D
is,VBZ,O
not,RB,O
expected,VBN,O
to,TO,O
be,VB,O
sensitive,JJ,O
to,TO,O
alterations,NNS,O
in,IN,O
protein,NN,O
binding,NN,O
.,.,.
,,
administration,NN,O
of,IN,O
eszopiclone,NN,D
3,CD,O
mg,NN,O
to,TO,O
a,DT,O
patient,NN,O
taking,VBG,O
another,DT,O
drug,NN,D
that,WDT,O
is,VBZ,O
highly,RB,O
protein-bound,JJ,O
would,MD,O
not,RB,O
be,VB,O
expected,VBN,O
to,TO,O
cause,VB,O
an,DT,O
alteration,NN,O
in,IN,O
the,DT,O
free,JJ,O
concentration,NN,O
of,IN,O
either,CC,O
drug,NN,D
.,.,.
,,
drugs,NNS,O
with,IN,O
a,DT,O
narrow,JJ,O
therapeutic,JJ,O
index,NN,O
digoxin,NN,D
a,NN,O
single,JJ,O
dose,NN,O
of,IN,O
eszopiclone,NN,D
3,CD,O
mg,NN,O
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
digoxin,NN,D
measured,VBN,O
at,IN,O
steady,JJ,O
state,NN,O
following,VBG,O
dosing,NN,O
of,IN,O
0.5,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
for,IN,O
one,CD,O
day,NN,O
and,CC,O
0.25,CD,O
mg,NN,O
daily,RB,O
for,IN,O
the,DT,O
next,JJ,O
6,CD,O
days,NNS,O
.,.,.
,,
warfarin,NNP,D
:,:,O
eszopiclone,NNP,D
3,CD,O
mg,NN,O
administered,VBN,O
daily,RB,O
for,IN,O
5,CD,O
days,NNS,O
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
-lrb-,-LRB-,O
r,NN,O
-rrb-,-RRB-,O
-,:,O
or,CC,O
-lrb-,-LRB-,O
s,NN,O
-rrb-,-RRB-,O
-,:,O
warfarin,NN,D
",",",",O
nor,CC,O
were,VBD,O
there,EX,O
any,DT,O
changes,NNS,O
in,IN,O
the,DT,O
pharmacodynamic,JJ,O
profile,NN,O
-lrb-,-LRB-,O
prothrombin,NN,O
time,NN,O
-rrb-,-RRB-,O
following,VBG,O
a,DT,O
single,JJ,O
25,CD,O
mg,NN,O
oral,JJ,O
dose,NN,O
of,IN,O
warfari,NN,O
.,.,.
,,
specific,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
with,IN,O
enbrel,NN,B
.,.,.
,,
however,RB,O
",",",",O
it,PRP,O
was,VBD,O
observed,VBN,O
that,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
enbrel,NNP,B
was,VBD,O
unaltered,JJ,O
by,IN,O
concomitant,JJ,O
methotrexate,NN,D
in,IN,O
rheumatoid,JJ,O
arthritis,NN,O
patients,NNS,O
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
in,IN,O
which,WDT,O
patients,NNS,O
with,IN,O
active,JJ,O
ra,NN,O
were,VBD,O
treated,VBN,O
for,IN,O
up,RB,O
to,TO,O
24,CD,O
weeks,NNS,O
with,IN,O
concurrent,JJ,O
enbrel,NN,B
and,CC,O
anakinra,NN,D
therapy,NN,O
",",",",O
a,DT,O
7,CD,O
%,NN,O
rate,NN,O
of,IN,O
serious,JJ,O
infections,NNS,O
was,VBD,O
observed,VBN,O
",",",",O
which,WDT,O
was,VBD,O
higher,JJR,O
than,IN,O
that,DT,O
observed,VBN,O
with,IN,O
enbrel,NN,B
alone,RB,O
-lrb-,-LRB-,O
0,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
two,CD,O
percent,NN,O
of,IN,O
patients,NNS,O
treated,VBN,O
concurrently,RB,O
with,IN,O
enbrel,NN,B
and,CC,O
anakinra,NN,D
developed,VBD,O
neutropenia,NN,O
-lrb-,-LRB-,O
anc,NNP,O
1,CD,O
x,CC,O
109/l,CD,O
-rrb-,-RRB-,O
.,.,.
,,
patients,NNS,O
in,IN,O
a,DT,O
clinical,JJ,O
study,NN,O
who,WP,O
were,VBD,O
on,IN,O
established,JJ,O
therapy,NN,O
with,IN,O
sulfasalazine,NN,D
",",",",O
to,TO,O
which,WDT,O
enbrel,NNP,B
was,VBD,O
added,VBN,O
",",",",O
were,VBD,O
noted,VBN,O
to,TO,O
develop,VB,O
a,DT,O
mild,JJ,O
decrease,NN,O
in,IN,O
mean,JJ,O
neutrophil,NN,O
counts,NNS,O
in,IN,O
comparison,NN,O
to,TO,O
groups,NNS,O
treated,VBN,O
with,IN,O
either,CC,O
enbrel,NN,B
ci,NN,O
or,CC,O
sulfasalazine,NN,D
alone,RB,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
observation,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
lithium,NN,D
generally,RB,O
should,MD,O
not,RB,O
be,VB,O
given,VBN,O
with,IN,O
diuretics,NNS,G
because,IN,O
they,PRP,O
reduce,VBP,O
its,PRP$,O
renal,JJ,O
clearance,NN,O
and,CC,O
add,VB,O
a,DT,O
high,JJ,O
risk,NN,O
of,IN,O
lithium,NN,D
toxicity,NN,O
.,.,.
,,
read,VB,O
circulars,NNS,O
for,IN,O
lithium,NN,D
preparations,NNS,O
before,IN,O
use,NN,O
of,IN,O
such,JJ,O
concomitant,JJ,O
therapy,NN,O
.,.,.
,,
edecrin,NN,B
may,MD,O
increase,VB,O
the,DT,O
ototoxic,JJ,O
potential,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
such,JJ,O
as,IN,O
aminoglycoside,NN,G
and,CC,O
some,DT,O
cephalosporin,NN,G
antibiotics,NNS,G
.,.,.
,,
their,PRP$,O
concurrent,JJ,O
use,NN,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
a,DT,O
number,NN,O
of,IN,O
drugs,NNS,D
",",",",O
including,VBG,O
ethacrynic,JJ,O
acid,NN,O
",",",",O
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
displace,VB,O
warfarin,NN,D
from,IN,O
plasma,NN,O
protein,NN,O
.,.,.
,,
a,DT,O
reduction,NN,O
in,IN,O
the,DT,O
usual,JJ,O
anticoagulant,JJ,G
dosage,NN,O
may,MD,O
be,VB,O
required,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
both,CC,O
drugs,NNS,D
.,.,.
,,
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
the,DT,O
administration,NN,O
of,IN,O
a,DT,O
non,JJ,O
-,:,O
steroidal,JJ,O
antiinflammatory,JJ,O
agent,NN,O
can,MD,O
reduce,VB,O
the,DT,O
diuretic,JJ,G
",",",",O
natriuretic,JJ,O
",",",",O
and,CC,O
antihypertensive,JJ,G
effects,NNS,O
of,IN,O
loop,NN,O
",",",",O
potassium,NN,D
-,:,O
sparing,NN,O
and,CC,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
when,WRB,O
edecrin,NNP,B
and,CC,O
non,JJ,O
-,:,O
steroidal,JJ,O
anti-,JJ,O
inflammatory,JJ,O
agents,NNS,O
are,VBP,O
used,VBN,O
concomitantly,RB,O
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
to,TO,O
determine,VB,O
if,IN,O
the,DT,O
desired,VBN,O
effect,NN,O
of,IN,O
the,DT,O
diuretic,JJ,G
is,VBZ,O
obtained,VBN,O
.,.,.
,,
the,DT,O
results,NNS,O
of,IN,O
a,DT,O
study,NN,O
of,IN,O
coadministration,NN,O
of,IN,O
ethambutol,NN,D
-lrb-,-LRB-,O
50,CD,O
mg/kg,NN,O
-rrb-,-RRB-,O
with,IN,O
an,DT,O
aluminum,NN,D
hydroxide,NN,O
containing,VBG,O
antacid,NN,G
to,TO,O
13,CD,O
patients,NNS,O
with,IN,O
tuberculosis,NN,O
showed,VBD,O
a,DT,O
reduction,NN,O
of,IN,O
mean,JJ,O
serum,NN,O
concentrations,NNS,O
and,CC,O
urinary,JJ,O
excretion,NN,O
of,IN,O
ethambutol,NN,D
of,IN,O
approximately,RB,O
20,CD,O
%,NN,O
and,CC,O
13,CD,O
%,NN,O
",",",",O
respectively,RB,O
",",",",O
suggesting,VBG,O
that,IN,O
the,DT,O
oral,JJ,O
absorption,NN,O
of,IN,O
ethambutol,NN,D
may,MD,O
be,VB,O
reduced,VBN,O
by,IN,O
these,DT,O
antacid,NN,G
products,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
to,TO,O
avoid,VB,O
concurrent,JJ,O
administration,NN,O
of,IN,O
ethambutol,NN,D
with,IN,O
aluminum,NN,D
hydroxide,NN,O
containing,VBG,O
antacids,NNS,G
for,IN,O
at,IN,O
least,JJS,O
4,CD,O
hours,NNS,O
following,VBG,O
ethambutol,NN,D
administration,NN,O
.,.,.
,,
dicumarol,NNP,D
and,CC,O
warfarin,NN,D
may,MD,O
decrease,VB,O
hypoprothrombinemic,JJ,O
effect,NN,O
.,.,.
,,
other,JJ,O
depressasnts,NNS,O
such,JJ,O
as,IN,O
alcohol,NN,D
",",",",O
barbiturates,NNS,G
",",",",O
and,CC,O
maois,NNS,G
may,MD,O
enhance,VB,O
cns,NN,O
depression,NN,O
when,WRB,O
administered,VBN,O
with,IN,O
ethchlorvynol,NN,D
.,.,.
,,
may,NNP,O
interact,VBP,O
with,IN,O
addictive,JJ,O
medications,NNS,O
",",",",O
especially,RB,O
central,JJ,O
nervous,JJ,O
system,NN,O
-lrb-,-LRB-,O
cns,NN,O
-rrb-,-RRB-,O
depressants,NNS,O
with,IN,O
habituating,VBG,O
potential,JJ,O
-lrb-,-LRB-,O
prolonged,JJ,O
concurrent,JJ,O
use,NN,O
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
habituation,NN,O
-rrb-,-RRB-,O
",",",",O
alcohol,NN,D
or,CC,O
cns,NN,O
depression,NN,O
producing,VBG,O
medications,NNS,O
-lrb-,-LRB-,O
concurrent,JJ,O
use,NN,O
may,MD,O
increase,VB,O
the,DT,O
cns,NN,O
depressant,NN,O
effects,NNS,O
of,IN,O
either,CC,O
these,DT,O
medications,NNS,O
or,CC,O
ethinamate,NN,D
-rrb-,-RRB-,O
.,.,.
,,
certain,JJ,O
endocrine,NN,O
and,CC,O
liver,NN,O
function,NN,O
tests,NNS,O
may,MD,O
be,VB,O
affected,VBN,O
by,IN,O
estrogen-containing,JJ,O
oral,JJ,O
contraceptives,NNS,G
.,.,.
,,
the,DT,O
following,VBG,O
similar,JJ,O
changes,NNS,O
may,MD,O
be,VB,O
expected,VBN,O
with,IN,O
larger,JJR,O
doses,NNS,O
of,IN,O
estrogen,NN,G
:,:,O
increased,VBN,O
sulfobromophthalein,NN,O
retention,NN,O
.,.,.
,,
increased,VBN,O
prothrombin,NN,O
and,CC,O
factors,NNS,O
vii,NNP,O
",",",",O
viii,NNP,O
",",",",O
ix,CD,O
",",",",O
and,CC,O
x,NN,O
;,:,O
.,.,.
,,
decreased,VBN,O
antithrombin,NN,O
3,CD,O
;,:,O
.,.,.
,,
increased,VBN,O
norepinephrine-induced,JJ,O
platel,NN,O
et,FW,O
aggregation,NN,O
;,:,O
.,.,.
,,
increased,VBN,O
thyroid,NN,G
binding,NN,O
globulin,NN,O
-lrb-,-LRB-,O
tbg,NN,O
-rrb-,-RRB-,O
leading,VBG,O
to,TO,O
increased,VBN,O
circulating,VBG,O
total,JJ,O
thyroid,NN,G
hormone,NN,O
",",",",O
as,IN,O
measured,VBN,O
by,IN,O
pbi,NN,O
",",",",O
t4,NN,D
by,IN,O
column,NN,O
",",",",O
or,CC,O
t4,NN,D
by,IN,O
radioimmunoassay,NN,O
.,.,.
,,
free,NNP,O
t3,NN,D
resin,NN,G
uptake,NN,O
is,VBZ,O
decreased,VBN,O
",",",",O
reflecting,VBG,O
the,DT,O
elevated,JJ,O
tbg,NN,O
;,:,O
.,.,.
,,
free,JJ,O
t4,NN,D
concentration,NN,O
is,VBZ,O
unaltered,JJ,O
:,:,O
impaired,JJ,O
glucose,NN,O
tolerance,NN,O
;,:,O
.,.,.
,,
decreased,VBN,O
pregnanediol,NN,O
excretion,NN,O
;,:,O
.,.,.
,,
reduced,VBN,O
response,NN,O
to,TO,O
metyrapone,NN,O
test,NN,O
;,:,O
.,.,.
,,
reduced,VBN,O
serum,NN,O
folate,VBP,O
concentration,NN,O
;,:,O
.,.,.
,,
increased,VBN,O
serum,NN,O
triglyceride,NN,O
and,CC,O
phospholipid,JJ,O
concentration,NN,O
.,.,.
,,
trecator,NNP,B
has,VBZ,O
been,VBN,O
found,VBN,O
to,TO,O
temporarily,RB,O
raise,VB,O
serum,NN,O
concentrations,NNS,O
of,IN,O
isoniazid,NN,D
.,.,.
,,
trecator,NNP,B
may,MD,O
potentiate,VB,O
the,DT,O
adverse,JJ,O
effects,NNS,O
of,IN,O
other,JJ,O
antituberculous,JJ,O
drugs,NNS,D
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
in,IN,O
particular,JJ,O
",",",",O
convulsions,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
when,WRB,O
ethionamide,NN,D
is,VBZ,O
administered,VBN,O
with,IN,O
cycloserine,NN,D
and,CC,O
special,JJ,O
care,NN,O
should,MD,O
be,VB,O
taken,VBN,O
when,WRB,O
the,DT,O
treatment,NN,O
regimen,NN,O
includes,VBZ,O
both,DT,O
of,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
excessive,JJ,O
ethanol,NN,D
ingestion,NN,O
should,MD,O
be,VB,O
avoided,VBN,O
because,IN,O
a,DT,O
psychotic,JJ,O
reaction,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
.,.,.
,,
ethopropazine,NN,D
may,MD,O
interact,VB,O
with,IN,O
alcohol,NN,D
or,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
",",",",O
causing,VBG,O
increased,VBN,O
sedative,JJ,G
effects,NNS,O
.,.,.
,,
it,PRP,O
may,MD,O
also,RB,O
interact,VB,O
with,IN,O
amantadine,NN,D
or,CC,O
other,JJ,O
anticholinergic,JJ,G
drugs,NNS,D
or,CC,O
maois,NNS,G
",",",",O
which,WDT,O
may,MD,O
intensify,VB,O
the,DT,O
anticholinergic,JJ,G
action,NN,O
.,.,.
,,
ethopropazine,NN,D
can,MD,O
interact,VB,O
with,IN,O
chlorpromazine,NN,D
",",",",O
increasing,VBG,O
the,DT,O
metabolism,NN,O
of,IN,O
chlorpromazine,NN,D
.,.,.
,,
since,IN,O
zarontin,NN,B
-lrb-,-LRB-,O
ethosuximide,NN,D
-rrb-,-RRB-,O
may,MD,O
interact,VB,O
with,IN,O
concurrently,RB,O
administered,VBN,O
antiepileptic,JJ,O
drugs,NNS,D
",",",",O
periodic,JJ,O
serum,NN,O
level,NN,O
determinations,NNS,O
of,IN,O
these,DT,O
drugs,NNS,D
may,MD,O
be,VB,O
necessary,JJ,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
ethosuximide,NN,D
may,MD,O
elevate,VB,O
phenytoin,NN,D
serum,NN,O
levels,NNS,O
and,CC,O
valproic,JJ,O
acid,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
both,DT,O
increase,NN,O
and,CC,O
decrease,VB,O
ethosuximide,NN,D
levels,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
peganone,NNP,B
used,VBD,O
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
known,VBN,O
to,TO,O
adversely,RB,O
affect,VB,O
the,DT,O
hematopoietic,JJ,O
system,NN,O
should,MD,O
be,VB,O
avoided,VBN,O
if,IN,O
possible,JJ,O
.,.,.
,,
considerable,JJ,O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
if,IN,O
peganone,NN,B
is,VBZ,O
administered,VBN,O
concurrently,RB,O
with,IN,O
phenurone,NN,B
-lrb-,-LRB-,O
phenacemide,NN,D
-rrb-,-RRB-,O
since,IN,O
paranoid,JJ,O
symptoms,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
during,IN,O
therapy,NN,O
with,IN,O
this,DT,O
combination,NN,O
.,.,.
,,
a,DT,O
two-way,JJ,O
interaction,NN,O
between,IN,O
the,DT,O
hydantoin,NN,G
antiepileptic,JJ,O
",",",",O
phenytoin,NN,D
",",",",O
and,CC,O
the,DT,O
coumarin,NN,G
anticoagulants,NNS,G
has,VBZ,O
been,VBN,O
suggested,VBN,O
.,.,.
,,
presumably,RB,O
",",",",O
phenytoin,NN,D
acts,VBZ,O
as,IN,O
a,DT,O
stimulator,NN,O
of,IN,O
coumarin,NN,G
metabolism,NN,O
and,CC,O
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
cause,VB,O
decreased,VBN,O
serum,NN,O
levels,NNS,O
of,IN,O
the,DT,O
coumarin,NN,G
anticoagulants,NNS,G
and,CC,O
increased,VBD,O
prothrombin-proconvertin,JJ,O
concentrations,NNS,O
.,.,.
,,
conversely,RB,O
",",",",O
the,DT,O
coumarin,NN,G
anticoagulants,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
increase,VB,O
the,DT,O
serum,NN,O
levels,NNS,O
and,CC,O
prolong,VB,O
the,DT,O
serum,NN,O
half-life,NN,O
of,IN,O
phenytoin,NN,D
by,IN,O
inhibiting,VBG,O
its,PRP$,O
metabolism,NN,O
.,.,.
,,
although,IN,O
there,EX,O
is,VBZ,O
no,DT,O
documentation,NN,O
of,IN,O
such,JJ,O
",",",",O
a,DT,O
similar,JJ,O
interaction,NN,O
between,IN,O
ethotoin,NN,D
and,CC,O
the,DT,O
coumarin,NN,G
anticoagulants,NNS,G
may,MD,O
occur,VB,O
.,.,.
,,
caution,NN,O
is,VBZ,O
therefore,RB,O
advised,VBN,O
when,WRB,O
administering,VBG,O
peganone,NN,B
to,TO,O
patients,NNS,O
receiving,VBG,O
coumarin,NN,G
anticoagulants,NNS,G
.,.,.
,,
ethoxzolamide,NN,D
may,MD,O
increase,VB,O
the,DT,O
action,NN,O
of,IN,O
tricyclics,NNS,G
",",",",O
amphetamines,NNS,G
",",",",O
procainamide,NN,D
",",",",O
and,CC,O
quinidine,NN,D
.,.,.
,,
it,PRP,O
may,MD,O
increase,VB,O
excretion,NN,O
of,IN,O
barbiturates,NNS,G
",",",",O
lithium,NN,D
",",",",O
and,CC,O
asa,NN,D
and,CC,O
may,MD,O
also,RB,O
increase,VB,O
the,DT,O
toxicity,NN,O
of,IN,O
salicylates,NNS,G
.,.,.
,,
coadministration,NN,O
of,IN,O
ethoxzolamide,NN,D
with,IN,O
other,JJ,O
diuretics,NNS,G
",",",",O
amphotericin,NN,D
b,NN,O
",",",",O
and,CC,O
corticosteroids,NNS,G
may,MD,O
cause,VB,O
hypokalemia,NN,O
.,.,.
,,
ethinyl,NN,O
estradiol,NN,O
:,:,O
substrate,NN,O
of,IN,O
cyp3a4,NN,D
-lrb-,-LRB-,O
major,JJ,O
-rrb-,-RRB-,O
",",",",O
3a5-7,NN,O
-lrb-,-LRB-,O
minor,JJ,O
-rrb-,-RRB-,O
.,.,.
,,
inhibits,VBZ,O
cyp1a2,NN,D
-lrb-,-LRB-,O
weak,JJ,O
-rrb-,-RRB-,O
",",",",O
2b6,NN,O
-lrb-,-LRB-,O
weak,JJ,O
-rrb-,-RRB-,O
",",",",O
2c19,NN,O
-lrb-,-LRB-,O
weak,JJ,O
-rrb-,-RRB-,O
",",",",O
3a4,NN,O
-lrb-,-LRB-,O
weak,JJ,O
-rrb-,-RRB-,O
.,.,.
,,
acetaminophen,NN,D
:,:,O
may,NNP,O
increase,NN,O
plasma,NN,O
concentration,NN,O
of,IN,O
synthetic,JJ,O
estrogens,NNS,G
",",",",O
possibly,RB,O
by,IN,O
inhibiting,VBG,O
conjugation,NN,O
.,.,.
,,
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
may,MD,O
also,RB,O
decrease,VB,O
the,DT,O
plasma,NN,O
concentration,NN,O
of,IN,O
acetaminophen,NN,D
.,.,.
,,
acitretin,NNP,D
:,:,O
interferes,NNS,O
with,IN,O
the,DT,O
contraceptive,JJ,G
effect,NN,O
of,IN,O
microdosed,JJ,O
progestin-containing,JJ,O
minipill,NN,O
preparations,NNS,O
.,.,.
,,
the,DT,O
effect,NN,O
on,IN,O
other,JJ,O
progestational,JJ,O
contraceptives,NNS,G
-lrb-,-LRB-,O
eg,FW,O
",",",",O
implants,NNS,O
",",",",O
injectables,NNS,O
-rrb-,-RRB-,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
aminoglutethimide,NNP,D
:,:,O
may,NNP,O
increase,NN,O
cyp,NN,O
metabolism,NN,O
of,IN,O
progestins,NNS,G
leading,VBG,O
to,TO,O
possible,JJ,O
decrease,NN,O
in,IN,O
contraceptive,JJ,G
effectiveness,NN,O
.,.,.
,,
use,NN,O
of,IN,O
a,DT,O
nonhormonal,JJ,O
contraceptive,JJ,G
product,NN,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
antibiotics,NNS,G
-lrb-,-LRB-,O
ampicillin,NN,D
",",",",O
tetracycline,NN,D
-rrb-,-RRB-,O
:,:,O
pregnancy,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
following,VBG,O
concomitant,JJ,O
use,NN,O
",",",",O
however,RB,O
",",",",O
pharmacokinetic,JJ,O
studies,NNS,O
have,VBP,O
not,RB,O
shown,VBN,O
consistent,JJ,O
effects,NNS,O
with,IN,O
these,DT,O
antibiotics,NNS,G
on,IN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
synthetic,JJ,O
steroids,NNS,G
.,.,.
,,
use,NN,O
of,IN,O
a,DT,O
nonhormonal,JJ,O
contraceptive,JJ,G
product,NN,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
anticoagulants,NNPS,G
:,:,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
may,MD,O
increase,VB,O
or,CC,O
decrease,VB,O
the,DT,O
effects,NNS,O
of,IN,O
coumarin,NN,G
derivatives,NNS,O
.,.,.
,,
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
may,MD,O
also,RB,O
increase,VB,O
risk,NN,O
of,IN,O
thromboembolic,JJ,O
disorders,NNS,O
.,.,.
,,
anticonvulsants,NNS,G
-lrb-,-LRB-,O
carbamazepine,NN,D
",",",",O
felbamate,NN,D
",",",",O
phenobarbital,NN,D
",",",",O
phenytoin,NN,D
",",",",O
topiramate,NN,D
-rrb-,-RRB-,O
:,:,O
increase,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
ethinyl,NN,O
estradiol,NN,O
and/or,CC,O
some,DT,O
progestins,NNS,G
",",",",O
leading,VBG,O
to,TO,O
possible,JJ,O
decrease,NN,O
in,IN,O
contraceptive,JJ,G
effectiveness,NN,O
.,.,.
,,
use,NN,O
of,IN,O
a,DT,O
nonhormonal,JJ,O
contraceptive,JJ,G
product,NN,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
ascorbic,JJ,O
acid,NN,O
:,:,O
doses,NNS,O
of,IN,O
ascorbic,JJ,O
acid,NN,O
-lrb-,-LRB-,O
vitamin,NN,G
c,NN,O
-rrb-,-RRB-,O
1,CD,O
g/day,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
increase,VB,O
plasma,NN,O
concentration,NN,O
of,IN,O
synthetic,JJ,O
estrogens,NNS,G
by,IN,O
~,NN,O
47,CD,O
%,NN,O
",",",",O
possibly,RB,O
by,IN,O
inhibiting,VBG,O
conjugation,NN,O
.,.,.
,,
clinical,JJ,O
implications,NNS,O
are,VBP,O
unclear,JJ,O
.,.,.
,,
atorvastatin,NNP,D
:,:,O
atorvastatin,NNP,D
increases,VBZ,O
the,DT,O
auc,NN,O
for,IN,O
norethindrone,NN,D
and,CC,O
ethinyl,NN,O
estradiol,NN,O
.,.,.
,,
benzodiazepines,NNS,G
:,:,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
may,MD,O
decrease,VB,O
the,DT,O
clearance,NN,O
of,IN,O
some,DT,O
benzodiazepines,NNS,G
-lrb-,-LRB-,O
alprazolam,NN,D
",",",",O
chlordiazepoxide,NN,D
",",",",O
diazepam,NN,D
-rrb-,-RRB-,O
and,CC,O
increase,VB,O
the,DT,O
clearance,NN,O
of,IN,O
others,NNS,O
-lrb-,-LRB-,O
lorazepam,NN,D
",",",",O
oxazepam,NN,D
",",",",O
temazepam,NN,D
-rrb-,-RRB-,O
.,.,.
,,
clofibric,JJ,O
acid,NN,O
:,:,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
may,MD,O
increase,VB,O
the,DT,O
clearance,NN,O
of,IN,O
clofibric,JJ,O
acid,NN,O
.,.,.
,,
cyclosporine,NN,D
:,:,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
may,MD,O
inhibit,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
cyclosporine,NN,D
",",",",O
leading,VBG,O
to,TO,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
monitor,NN,O
cyclosporine,NN,D
levels,NNS,O
.,.,.
,,
cyp3a4,NN,D
inducers,NNS,O
:,:,O
cyp3a4,NN,D
inducers,NNS,O
may,MD,O
decrease,VB,O
the,DT,O
levels/effects,NNS,O
of,IN,O
ethinyl,NN,O
estradiol,NN,O
.,.,.
,,
example,NN,O
inducers,NNS,O
include,VBP,O
aminoglutethimide,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
nafcillin,NN,D
",",",",O
nevirapine,NN,D
",",",",O
phenobarbital,NN,D
",",",",O
phenytoin,NN,D
",",",",O
and,CC,O
rifamycins,NNS,G
.,.,.
,,
griseofulvin,NNP,D
:,:,O
griseofulvin,NNP,D
may,MD,O
induce,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
causing,VBG,O
menstrual,JJ,O
changes,NNS,O
.,.,.
,,
pregnancies,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
.,.,.
,,
use,NN,O
of,IN,O
barrier,NN,O
form,NN,O
of,IN,O
contraception,NN,O
is,VBZ,O
suggested,VBN,O
while,IN,O
on,IN,O
griseofulvin,NN,D
therapy,NN,O
.,.,.
,,
morphine,NNP,D
:,:,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
may,MD,O
increase,VB,O
the,DT,O
clearance,NN,O
of,IN,O
morphine,NN,D
.,.,.
,,
non-nucleoside,JJ,O
reverse,JJ,O
transcriptase,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
nnrtis,NNS,G
-rrb-,-RRB-,O
:,:,O
nevirapine,NN,D
may,MD,O
decrease,VB,O
plasma,NN,O
levels,NNS,O
of,IN,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
.,.,.
,,
use,NN,O
of,IN,O
a,DT,O
nonhormonal,JJ,O
contraceptive,JJ,G
product,NN,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
no,DT,O
data,NNS,O
for,IN,O
delavirdine,NN,D
.,.,.
,,
incomplete,JJ,O
data,NNS,O
for,IN,O
efavirenz,NN,D
.,.,.
,,
prednisolone,NN,D
:,:,O
ethinyl,NN,O
estradiol,NN,O
may,MD,O
inhibit,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
prednisolone,NN,D
",",",",O
leading,VBG,O
to,TO,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
protease,NN,O
inhibitors,NNS,O
:,:,O
amprenavir,NNP,D
",",",",O
lopinavir,NN,D
",",",",O
nelfinavir,NN,D
",",",",O
and,CC,O
ritonavir,NN,D
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
decrease,VB,O
plasma,NN,O
levels,NNS,O
of,IN,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
.,.,.
,,
use,NN,O
of,IN,O
a,DT,O
nonhormonal,JJ,O
contraceptive,JJ,G
product,NN,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
indinavir,NNP,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
increase,VB,O
plasma,NN,O
levels,NNS,O
of,IN,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
.,.,.
,,
no,DT,O
data,NNS,O
for,IN,O
saquinavir,NN,D
.,.,.
,,
rifampin,NNP,D
:,:,O
rifampin,NNP,D
increases,VBZ,O
the,DT,O
metabolism,NN,O
of,IN,O
ethinyl,NN,O
estradiol,NN,O
and,CC,O
some,DT,O
progestins,NNS,G
-lrb-,-LRB-,O
norethindrone,NN,D
-rrb-,-RRB-,O
resulting,VBG,O
in,IN,O
decreased,VBN,O
contraceptive,JJ,G
effectiveness,NN,O
and,CC,O
increased,VBD,O
menstrual,JJ,O
irregularities,NNS,O
.,.,.
,,
use,NN,O
of,IN,O
a,DT,O
nonhormonal,JJ,O
contraceptive,JJ,G
product,NN,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
salicylic,JJ,O
acid,NN,O
:,:,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
may,MD,O
increase,VB,O
the,DT,O
clearance,NN,O
of,IN,O
salicylic,JJ,O
acid,NN,O
.,.,.
,,
selegiline,NNP,D
:,:,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
may,MD,O
increase,VB,O
the,DT,O
serum,NN,O
concentration,NN,O
of,IN,O
selegiline,NN,D
.,.,.
,,
theophylline,NNP,D
:,:,O
ethinyl,NNP,O
estradiol,NN,O
may,MD,O
inhibit,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
theophylline,NN,D
",",",",O
leading,VBG,O
to,TO,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
tricyclic,JJ,O
antidepressants,NNS,G
-lrb-,-LRB-,O
amitriptyline,NNP,D
",",",",O
imipramine,NN,D
",",",",O
nortriptyline,NN,D
-rrb-,-RRB-,O
:,:,O
metabolism,NN,O
may,MD,O
be,VB,O
inhibited,VBN,O
by,IN,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
",",",",O
increasing,VBG,O
plasma,NN,O
levels,NNS,O
of,IN,O
antidepressant,JJ,G
.,.,.
,,
use,NN,O
caution,NN,O
.,.,.
,,
ethanol,NN,D
/,:,O
nutrition,NNP,O
/,:,O
herb,NNP,O
interactions,NNPS,O
:,:,O
food,NNP,O
:,:,O
cns,NN,O
effects,NNS,O
of,IN,O
caffeine,NN,D
may,MD,O
be,VB,O
enhanced,VBN,O
if,IN,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
are,VBP,O
used,VBN,O
concurrently,RB,O
with,IN,O
caffeine,NN,D
.,.,.
,,
grapefruit,NN,O
juice,NN,O
increases,VBZ,O
ethinyl,NN,O
estradiol,NN,O
concentrations,NNS,O
and,CC,O
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
increase,VB,O
progesterone,NN,D
serum,NN,O
levels,NNS,O
as,RB,O
well,RB,O
.,.,.
,,
clinical,JJ,O
implications,NNS,O
are,VBP,O
unclear,JJ,O
.,.,.
,,
herb/nutraceutical,NNP,O
:,:,O
st,NNP,O
johns,NNP,O
wort,NN,O
may,MD,O
decrease,VB,O
the,DT,O
effectiveness,NN,O
of,IN,O
combination,NN,O
hormonal,JJ,O
contraceptives,NNS,G
by,IN,O
inducing,VBG,O
hepatic,JJ,O
enzymes,NNS,O
.,.,.
,,
avoid,VB,O
dong,FW,O
quai,FW,O
and,CC,O
black,JJ,O
cohosh,NN,O
-lrb-,-LRB-,O
have,VB,O
estrogen,NN,G
activity,NN,O
-rrb-,-RRB-,O
.,.,.
,,
avoid,VB,O
saw,NN,O
palmetto,NN,O
",",",",O
red,JJ,O
clover,NN,O
",",",",O
ginseng,NN,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
isolated,VBN,O
reports,NNS,O
of,IN,O
patients,NNS,O
experiencing,VBG,O
increases,NNS,O
in,IN,O
their,PRP$,O
prothrombin,NN,O
times,NNS,O
when,WRB,O
etidronate,NN,D
was,VBD,O
added,VBN,O
to,TO,O
warfarin,NN,D
therapy,NN,O
.,.,.
,,
the,DT,O
majority,NN,O
of,IN,O
these,DT,O
reports,NNS,O
concerned,VBN,O
variable,JJ,O
elevations,NNS,O
in,IN,O
prothrombin,NN,O
times,NNS,O
without,IN,O
clinically,RB,O
significant,JJ,O
sequelae,NN,O
.,.,.
,,
although,IN,O
the,DT,O
relevance,NN,O
of,IN,O
these,DT,O
reports,NNS,O
and,CC,O
any,DT,O
mechanism,NN,O
of,IN,O
coagulation,NN,O
alterations,NNS,O
is,VBZ,O
unclear,JJ,O
",",",",O
patients,NNS,O
on,IN,O
warfarin,NN,D
should,MD,O
have,VB,O
their,PRP$,O
prothrombin,NN,O
time,NN,O
monitored,VBD,O
.,.,.
,,
ace-inhibitors,NNS,G
reports,NNS,O
suggest,VBP,O
that,IN,O
nsaids,NNS,G
may,MD,O
diminish,VB,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
ace-inhibitors,NNS,G
.,.,.
,,
this,DT,O
interaction,NN,O
should,MD,O
be,VB,O
given,VBN,O
consideration,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
nsaids,NNS,G
concomitantly,RB,O
with,IN,O
ace-inhibitors,NNS,G
.,.,.
,,
antacids,NNS,G
:,:,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
antacids,NNS,G
has,VBZ,O
no,DT,O
apparent,JJ,O
effect,NN,O
on,IN,O
the,DT,O
extent,NN,O
of,IN,O
absorption,NN,O
of,IN,O
lodine,NNP,B
.,.,.
,,
however,RB,O
",",",",O
antacids,NNS,G
can,MD,O
decrease,VB,O
the,DT,O
peak,NN,O
concentration,NN,O
reached,VBN,O
by,IN,O
15,CD,O
%,NN,O
to,TO,O
20,CD,O
%,NN,O
but,CC,O
have,VBP,O
no,DT,O
detectable,JJ,O
effect,NN,O
on,IN,O
the,DT,O
time-to-peak,NN,O
.,.,.
,,
aspirin,NN,B
:,:,O
when,WRB,O
lodine,NNP,B
is,VBZ,O
administered,VBN,O
with,IN,O
aspirin,NN,B
",",",",O
its,PRP$,O
protein,NN,O
binding,NN,O
is,VBZ,O
reduced,VBN,O
",",",",O
although,IN,O
the,DT,O
clearance,NN,O
of,IN,O
free,JJ,O
etodolac,NN,D
is,VBZ,O
not,RB,O
altered,VBN,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
interaction,NN,O
is,VBZ,O
not,RB,O
known,VBN,O
;,:,O
.,.,.
,,
however,RB,O
",",",",O
as,IN,O
with,IN,O
other,JJ,O
nsaids,NNS,G
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
lodine,NNP,B
and,CC,O
aspirin,NN,B
is,VBZ,O
not,RB,O
generally,RB,O
recommended,VBN,O
because,IN,O
of,IN,O
the,DT,O
potential,NN,O
of,IN,O
increased,VBN,O
adverse,JJ,O
effects,NNS,O
.,.,.
,,
cyclosporine,NN,D
",",",",O
digoxin,NNP,D
",",",",O
methotrexate,NNP,D
lodine,NNP,B
",",",",O
like,IN,O
other,JJ,O
nsaids,NNS,G
",",",",O
through,IN,O
effects,NNS,O
on,IN,O
renal,JJ,O
prostaglandins,NNS,O
",",",",O
may,MD,O
cause,VB,O
changes,NNS,O
in,IN,O
the,DT,O
elimination,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
leading,VBG,O
to,TO,O
elevated,JJ,O
serum,NN,O
levels,NNS,O
of,IN,O
cyclosporine,NN,D
",",",",O
digoxin,NN,D
",",",",O
methotrexate,NN,D
",",",",O
and,CC,O
increased,VBD,O
toxicity,NN,O
.,.,.
,,
nephrotoxicity,NN,O
associated,VBN,O
with,IN,O
cyclosporine,NN,D
may,MD,O
also,RB,O
be,VB,O
enhanced,VBN,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
these,DT,O
drugs,NNS,D
who,WP,O
are,VBP,O
given,VBN,O
lodine,NNP,B
",",",",O
or,CC,O
any,DT,O
other,JJ,O
nsaid,NN,G
",",",",O
and,CC,O
particularly,RB,O
those,DT,O
patients,NNS,O
with,IN,O
altered,JJ,O
renal,JJ,O
function,NN,O
",",",",O
should,MD,O
be,VB,O
observed,VBN,O
for,IN,O
the,DT,O
development,NN,O
of,IN,O
the,DT,O
specific,JJ,O
toxicities,NNS,O
of,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
diuretics,NNS,G
:,:,O
etodolac,NNP,D
has,VBZ,O
no,DT,O
apparent,JJ,O
pharmacokinetic,JJ,O
interaction,NN,O
when,WRB,O
administered,VBN,O
with,IN,O
furosemide,NN,D
or,CC,O
hydrochlorothiazide,NN,D
.,.,.
,,
nevertheless,RB,O
",",",",O
clinical,JJ,O
studies,NNS,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
postmarketing,VBG,O
observations,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
lodine,NNP,B
can,MD,O
reduce,VB,O
the,DT,O
natriuretic,JJ,O
effect,NN,O
of,IN,O
furosemide,NN,D
and,CC,O
thiazides,NNS,G
in,IN,O
some,DT,O
patients,NNS,O
.,.,.
,,
this,DT,O
response,NN,O
has,VBZ,O
been,VBN,O
attributed,VBN,O
to,TO,O
inhibition,NN,O
of,IN,O
renal,JJ,O
prostaglandin,NN,O
synthesis,NN,O
.,.,.
,,
during,IN,O
concomitant,JJ,O
therapy,NN,O
with,IN,O
nsaids,NNS,G
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
signs,NNS,O
of,IN,O
renal,JJ,O
failure,NN,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
to,TO,O
assure,VB,O
diuretic,JJ,G
efficacy,NN,O
.,.,.
,,
glyburide,NNP,D
:,:,O
etodolac,NNP,D
has,VBZ,O
no,DT,O
apparent,JJ,O
pharmacokinetic,JJ,O
interaction,NN,O
when,WRB,O
administered,VBN,O
with,IN,O
glyburide,NN,D
.,.,.
,,
lithium,NN,D
:,:,O
nsaids,NNS,G
have,VBP,O
produced,VBN,O
an,DT,O
elevation,NN,O
of,IN,O
plasma,NN,O
lithium,NN,D
levels,NNS,O
and,CC,O
a,DT,O
reduction,NN,O
in,IN,O
renal,JJ,O
lithium,NN,D
clearance,NN,O
.,.,.
,,
the,DT,O
mean,NN,O
minimum,JJ,O
lithium,NN,D
concentration,NN,O
increased,VBD,O
15,CD,O
%,NN,O
and,CC,O
the,DT,O
renal,JJ,O
clearance,NN,O
was,VBD,O
decreased,VBN,O
by,IN,O
approximately,RB,O
20,CD,O
%,NN,O
.,.,.
,,
these,DT,O
effects,NNS,O
have,VBP,O
been,VBN,O
attributed,VBN,O
to,TO,O
inhibition,NN,O
of,IN,O
renal,JJ,O
prostaglandin,NN,O
synthesis,NN,O
by,IN,O
the,DT,O
nsaid,NN,G
.,.,.
,,
thus,RB,O
",",",",O
when,WRB,O
nsaids,NNS,G
and,CC,O
lithium,NN,D
are,VBP,O
administered,VBN,O
concurrently,RB,O
",",",",O
subjects,NNS,O
should,MD,O
be,VB,O
observed,VBN,O
carefully,RB,O
for,IN,O
signs,NNS,O
of,IN,O
lithium,NN,D
toxicity,NN,O
.,.,.
,,
phenylbutazone,NNP,D
:,:,O
phenylbutazone,NNP,D
causes,VBZ,O
increase,NN,O
-lrb-,-LRB-,O
by,IN,O
about,IN,O
80,CD,O
%,NN,O
-rrb-,-RRB-,O
in,IN,O
the,DT,O
free,JJ,O
fraction,NN,O
of,IN,O
etodolac,NN,D
.,.,.
,,
although,IN,O
in,FW,O
vivo,FW,O
studies,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
done,VBN,O
to,TO,O
see,VB,O
if,IN,O
etodolac,NN,D
clearance,NN,O
is,VBZ,O
changed,VBN,O
by,IN,O
coadministration,NN,O
of,IN,O
phenylbutazone,NN,D
",",",",O
it,PRP,O
is,VBZ,O
not,RB,O
recommended,VBN,O
that,IN,O
they,PRP,O
be,VB,O
coadministered,VBN,O
.,.,.
,,
phenytoin,NNP,D
:,:,O
etodolac,NNP,D
has,VBZ,O
no,DT,O
apparent,JJ,O
pharmacokinetic,JJ,O
interaction,NN,O
when,WRB,O
administered,VBN,O
with,IN,O
phenytoin,NN,D
.,.,.
,,
warfarin,NNP,D
:,:,O
the,DT,O
effects,NNS,O
of,IN,O
warfarin,NN,D
and,CC,O
nsaids,NNS,G
on,IN,O
gi,NN,O
bleeding,NN,O
are,VBP,O
synergistic,JJ,O
",",",",O
such,JJ,O
that,IN,O
users,NNS,O
of,IN,O
both,DT,O
drugs,NNS,D
together,RB,O
have,VBP,O
a,DT,O
risk,NN,O
of,IN,O
serious,JJ,O
gi,NN,O
bleeding,VBG,O
higher,JJR,O
than,IN,O
that,DT,O
of,IN,O
users,NNS,O
of,IN,O
either,CC,O
drug,NN,D
alone,RB,O
.,.,.
,,
short-term,JJ,O
pharmacokinetic,JJ,O
studies,NNS,O
have,VBP,O
demonstrated,VBN,O
that,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
warfarin,NN,D
and,CC,O
lodine,NN,B
-lrb-,-LRB-,O
etodolac,NN,D
capsules,NNS,O
and,CC,O
tablets,NNS,O
-rrb-,-RRB-,O
results,VBZ,O
in,IN,O
reduced,VBN,O
protein,NN,O
binding,NN,O
of,IN,O
warfarin,NN,D
",",",",O
but,CC,O
there,EX,O
was,VBD,O
no,DT,O
change,NN,O
in,IN,O
the,DT,O
clearance,NN,O
of,IN,O
free,JJ,O
warfarin,NN,D
.,.,.
,,
there,EX,O
was,VBD,O
no,DT,O
significant,JJ,O
difference,NN,O
in,IN,O
the,DT,O
pharmacodynamic,JJ,O
effect,NN,O
of,IN,O
warfarin,NN,D
administered,VBN,O
alone,RB,O
and,CC,O
warfarin,NN,D
administered,VBN,O
with,IN,O
lodine,NN,B
as,IN,O
measured,VBN,O
by,IN,O
prothrombin,NN,O
time,NN,O
.,.,.
,,
thus,RB,O
",",",",O
concomitant,JJ,O
therapy,NN,O
with,IN,O
warfarin,NN,D
and,CC,O
lodine,NN,B
should,MD,O
not,RB,O
require,VB,O
dosage,NN,O
adjustment,NN,O
of,IN,O
either,CC,O
drug,NN,D
.,.,.
,,
however,RB,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
because,IN,O
there,EX,O
have,VBP,O
been,VBN,O
a,DT,O
few,JJ,O
spontaneous,JJ,O
reports,NNS,O
of,IN,O
prolonged,JJ,O
prothrombin,NN,O
times,NNS,O
",",",",O
with,IN,O
or,CC,O
without,IN,O
bleeding,NN,O
",",",",O
in,IN,O
etodolac-treated,JJ,O
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
warfarin,NN,D
therapy,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
the,DT,O
urine,NN,O
of,IN,O
patients,NNS,O
who,WP,O
take,VBP,O
lodine,NN,B
can,MD,O
give,VB,O
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
urinary,JJ,O
bilirubin,NN,O
-lrb-,-LRB-,O
urobilin,NN,O
-rrb-,-RRB-,O
due,JJ,O
to,TO,O
the,DT,O
presence,NN,O
of,IN,O
phenolic,JJ,O
metabolites,NNS,O
of,IN,O
etodolac,NN,D
.,.,.
,,
diagnostic,JJ,O
dip-stick,NN,O
methodology,NN,O
",",",",O
used,VBN,O
to,TO,O
detect,VB,O
ketone,NN,O
bodies,NNS,O
in,IN,O
urine,NN,O
",",",",O
has,VBZ,O
resulted,VBN,O
in,IN,O
false-positive,JJ,O
findings,NNS,O
in,IN,O
some,DT,O
patients,NNS,O
treated,VBN,O
with,IN,O
lodine,NN,B
.,.,.
,,
generally,RB,O
",",",",O
this,DT,O
phenomenon,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
associated,VBN,O
with,IN,O
other,JJ,O
clinically,RB,O
significant,JJ,O
events,NNS,O
.,.,.
,,
no,DT,O
dose,NN,O
relationship,NN,O
has,VBZ,O
been,VBN,O
observed,VBN,O
.,.,.
,,
lodine,NN,B
treatment,NN,O
is,VBZ,O
associated,VBN,O
with,IN,O
a,DT,O
small,JJ,O
decrease,NN,O
in,IN,O
serum,NN,O
uric,JJ,O
acid,NN,O
levels,NNS,O
.,.,.
,,
in,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
mean,VB,O
decreases,NNS,O
of,IN,O
1,CD,O
to,TO,O
2,CD,O
mg/dl,NN,O
were,VBD,O
observed,VBN,O
in,IN,O
arthritic,JJ,O
patients,NNS,O
receiving,VBG,O
etodolac,NN,D
-lrb-,-LRB-,O
600,CD,O
mg,NN,O
to,TO,O
1000,CD,O
mg/day,NN,O
-rrb-,-RRB-,O
after,IN,O
4,CD,O
weeks,NNS,O
of,IN,O
therapy,NN,O
.,.,.
,,
these,DT,O
levels,NNS,O
then,RB,O
remained,VBD,O
stable,JJ,O
for,IN,O
up,RB,O
to,TO,O
1,CD,O
year,NN,O
of,IN,O
therapy,NN,O
.,.,.
,,
the,DT,O
following,VBG,O
drug,NN,D
interactions,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
etomidate,NN,D
.,.,.
,,
drug,NN,O
effect,NN,O
.,.,.
,,
probenecid,NNP,D
prolonged,JJ,O
action,NN,O
of,IN,O
etomidat,NN,O
.,.,.
,,
diazoxide,NNP,D
hypotensio,NNP,O
.,.,.
,,
zimelidine,NN,D_n
etomidate,NN,D
antagonis,NN,O
.,.,.
,,
opioid,JJ,O
analgesics,NNS,G
decreased,VBN,O
antinociceptive,JJ,O
actio,NN,O
.,.,.
,,
aminophylline,NNP,D
etomidate,NNP,D
antagonis,NN,O
.,.,.
,,
midazolam,NNP,D
synergis,NNP,O
.,.,.
,,
etonogestrel,NN,D
may,MD,O
interact,VB,O
with,IN,O
the,DT,O
following,VBG,O
medications,NNS,O
:,:,O
acetaminophen,NN,D
-lrb-,-LRB-,O
tylenol,NNP,B
-rrb-,-RRB-,O
",",",",O
antibiotics,NNS,G
such,JJ,O
as,IN,O
ampicillin,NN,D
and,CC,O
tetracycline,NN,D
",",",",O
anticonvulsants,NNS,G
-lrb-,-LRB-,O
dilantin,NNP,B
",",",",O
phenobarbital,NNP,D
",",",",O
tegretol,NNP,B
",",",",O
trileptal,NNP,B
",",",",O
topamax,NNP,B
",",",",O
felbatol,NNP,B
-rrb-,-RRB-,O
",",",",O
antifungals,NNS,G
-lrb-,-LRB-,O
gris-peg,NNP,B
",",",",O
nizoral,NNP,B
",",",",O
sporanox,NNP,B
-rrb-,-RRB-,O
",",",",O
atorvastatin,NN,D
-lrb-,-LRB-,O
lipitor,NN,B
-rrb-,-RRB-,O
",",",",O
clofibrate,NN,D
-lrb-,-LRB-,O
atromid-s,NN,B
-rrb-,-RRB-,O
",",",",O
cyclosporine,NN,D
-lrb-,-LRB-,O
neoral,NNP,B
",",",",O
sandimmune,NNP,B
-rrb-,-RRB-,O
",",",",O
hiv,NN,O
drugs,NNS,D
classified,VBN,O
as,IN,O
protease,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
agenerase,NN,B
",",",",O
crixivan,NNP,B
",",",",O
fortovase,NNP,B
",",",",O
invirase,NNP,B
",",",",O
kaletra,NNP,B
",",",",O
norvir,NNP,B
",",",",O
viracept,NNP,B
-rrb-,-RRB-,O
",",",",O
morphine,NN,D
-lrb-,-LRB-,O
astramorph,NNP,B
",",",",O
kadian,NNP,B
",",",",O
ms,NN,O
contin,NN,O
-rrb-,-RRB-,O
",",",",O
phenylbutazone,NN,D
",",",",O
prednisolone,NN,D
-lrb-,-LRB-,O
prelone,NN,B
-rrb-,-RRB-,O
",",",",O
rifadin,NN,B
-lrb-,-LRB-,O
rifampin,NN,D
-rrb-,-RRB-,O
",",",",O
st.,NNP,O
johns,NNP,O
wort,NN,O
",",",",O
temazepam,NN,D
",",",",O
theophylline,NN,D
-lrb-,-LRB-,O
theo-dur,NN,B
-rrb-,-RRB-,O
",",",",O
and,CC,O
vitamin,NN,G
c.,NN,O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
administering,VBG,O
etopophos,NNS,B
with,IN,O
drugs,NNS,D
that,WDT,O
are,VBP,O
known,VBN,O
to,TO,O
inhibit,VB,O
phosphatase,NN,O
activities,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
levamisole,NN,D
hydrochloride,NN,O
-rrb-,-RRB-,O
.,.,.
,,
high-dose,JJ,O
cyclosporin,NN,D
a,NN,O
resulting,VBG,O
in,IN,O
concentrations,NNS,O
above,IN,O
2000,CD,O
ng/ml,NN,O
administered,VBN,O
with,IN,O
oral,JJ,O
etoposide,NN,D
has,VBZ,O
led,VBN,O
to,TO,O
an,DT,O
80,CD,O
%,NN,O
increase,NN,O
in,IN,O
etoposide,NN,D
exposure,NN,O
with,IN,O
a,DT,O
38,CD,O
%,NN,O
decrease,NN,O
in,IN,O
total,JJ,O
body,NN,O
clearance,NN,O
of,IN,O
etoposide,NN,D
compared,VBN,O
to,TO,O
etoposide,NN,D
alone,RB,O
.,.,.
,,
exemestane,NN,D
is,VBZ,O
extensively,RB,O
metabolized,VBN,O
by,IN,O
cyp,NN,O
3a4,NN,O
",",",",O
but,CC,O
coadministration,NN,O
of,IN,O
ketoconazole,NN,D
",",",",O
a,DT,O
potent,JJ,O
inhibitor,NN,O
of,IN,O
cyp,NN,O
3a4,NN,O
",",",",O
has,VBZ,O
no,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
exemestane,NN,D
pharmacokinetics,NNS,O
.,.,.
,,
significant,JJ,O
pharmacokinetic,JJ,O
interactions,NNS,O
mediated,VBN,O
by,IN,O
inhibition,NN,O
of,IN,O
cyp,NN,O
isoenzymes,NNS,O
therefore,RB,O
appear,VBP,O
unlikely,JJ,O
.,.,.
,,
co-medications,NNS,O
that,WDT,O
induce,VBP,O
cyp,NN,O
3a4,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
rifampicin,NN,D
",",",",O
phenytoin,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
phenobarbital,NN,D
",",",",O
or,CC,O
st.,NNP,O
john,NNP,O
s,VBZ,O
wort,NN,O
-rrb-,-RRB-,O
may,MD,O
significantly,RB,O
decrease,VB,O
exposure,NN,O
to,TO,O
exemestane,NN,D
.,.,.
,,
dose,NN,O
modification,NN,O
is,VBZ,O
recommended,VBN,O
for,IN,O
patients,NNS,O
who,WP,O
are,VBP,O
also,RB,O
receiving,VBG,O
a,DT,O
potent,JJ,O
cyp,NN,O
3a4,NN,O
inducer,NN,O
.,.,.
,,
drug/laboratory,NNP,O
tests,NNP,O
interactions,NNS,O
no,DT,O
clinically,RB,O
relevant,JJ,O
changes,NNS,O
in,IN,O
the,DT,O
results,NNS,O
of,IN,O
clinical,JJ,O
laboratory,NN,O
tests,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
with,IN,O
probenecid,NN,D
or,CC,O
other,JJ,O
drugs,NNS,D
significantly,RB,O
eliminated,VBN,O
by,IN,O
active,JJ,O
renal,JJ,O
tubular,JJ,O
secretion,NN,O
may,MD,O
result,VB,O
in,IN,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
penciclovir,NN,D
.,.,.
,,
the,DT,O
conversion,NN,O
of,IN,O
6-deoxy,JJ,O
penciclovir,NN,D
to,TO,O
penciclovir,NN,D
is,VBZ,O
catalyzed,VBN,O
by,IN,O
aldehyde,NN,O
oxidase,NN,O
.,.,.
,,
interactions,NNS,O
with,IN,O
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
this,DT,O
enzyme,NN,O
could,MD,O
potentially,RB,O
occur,VB,O
.,.,.
,,
no,DT,O
drug,NN,D
interactions,NNS,O
have,VBP,O
been,VBN,O
identified,VBN,O
.,.,.
,,
studies,NNS,O
with,IN,O
famotidine,NN,D
in,IN,O
man,NN,O
",",",",O
in,IN,O
animal,NN,O
models,NNS,O
",",",",O
and,CC,O
in,FW,O
vitro,FW,O
have,VBP,O
shown,VBN,O
no,DT,O
significant,JJ,O
interference,NN,O
with,IN,O
the,DT,O
disposition,NN,O
of,IN,O
compounds,NNS,O
metabolized,VBN,O
by,IN,O
the,DT,O
hepatic,JJ,O
microsomal,JJ,O
enzymes,NNS,O
",",",",O
e.g.,FW,O
",",",",O
cytochrome,NN,O
p450,NN,O
system,NN,O
.,.,.
,,
compounds,NNS,O
tested,VBN,O
in,IN,O
man,NN,O
include,VBP,O
warfarin,NN,D
",",",",O
theophylline,NN,D
",",",",O
phenytoin,NN,D
",",",",O
diazepam,NN,D
",",",",O
aminopyrine,NN,D
and,CC,O
antipyrine,NN,D
.,.,.
,,
indocyanine,JJ,O
green,JJ,O
as,IN,O
an,DT,O
index,NN,O
of,IN,O
hepatic,JJ,O
drug,NN,D
extraction,NN,O
has,VBZ,O
been,VBN,O
tested,VBN,O
and,CC,O
no,DT,O
significant,JJ,O
effects,NNS,O
have,VBP,O
been,VBN,O
found,VBN,O
.,.,.
,,
the,DT,O
drug,NN,D
interaction,NN,O
data,NNS,O
described,VBN,O
in,IN,O
this,DT,O
section,NN,O
were,VBD,O
obtained,VBN,O
from,IN,O
controlled,JJ,O
clinical,JJ,O
trials,NNS,O
and,CC,O
studies,NNS,O
involving,VBG,O
otherwise,RB,O
healthy,JJ,O
adults,NNS,O
with,IN,O
epilepsy,NN,O
.,.,.
,,
use,NN,O
in,IN,O
conjunction,NN,O
with,IN,O
other,JJ,O
antiepileptic,JJ,O
drugs,NNS,O
:,:,O
the,DT,O
addition,NN,O
of,IN,O
felbatol,NNP,B
to,TO,O
antiepileptic,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
aeds,NNS,G
-rrb-,-RRB-,O
affects,VBZ,O
the,DT,O
steady-state,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
aeds,NNS,G
.,.,.
,,
the,DT,O
net,JJ,O
effect,NN,O
of,IN,O
these,DT,O
interactions,NNS,O
is,VBZ,O
summarized,VBN,O
in,IN,O
the,DT,O
following,VBG,O
table,NN,O
:,:,O
aed,NNP,G
aed,NNP,G
felbato,NNP,O
.,.,.
,,
coadministered,JJ,O
concentration,NN,O
concentration,NN,O
.,.,.
,,
phenytoi,NNP,O
.,.,.
,,
valproate,NNP,D
*,SYM,O
.,.,.
,,
carbamazepine,NNP,D
-lrb-,-LRB-,O
cbz,NNP,D
-rrb-,-RRB-,O
.,.,.
,,
*,SYM,O
cbz,NN,D
epoxide,NN,O
.,.,.
,,
phenobarbita,NNP,O
.,.,.
,,
*,SYM,O
not,RB,O
administered,VBN,O
",",",",O
but,CC,O
an,DT,O
active,JJ,O
metabolite,NN,O
of,IN,O
carbamazepine,NN,D
.,.,.
,,
**,SYM,O
no,DT,O
significant,JJ,O
effect,NN,O
.,.,.
,,
specific,JJ,O
effects,NNS,O
of,IN,O
felbatol,NN,B
on,IN,O
other,JJ,O
antiepileptic,JJ,O
drugs,NNS,O
phenytoin,NNP,D
:,:,O
felbatol,NNP,B
causes,VBZ,O
an,DT,O
increase,NN,O
in,IN,O
steady-state,JJ,O
phenytoin,NN,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
in,IN,O
10,CD,O
otherwise,RB,O
healthy,JJ,O
subjects,NNS,O
with,IN,O
epilepsy,NN,O
ingesting,VBG,O
phenytoin,NN,D
",",",",O
the,DT,O
steadystate,NN,O
trough,NN,O
-lrb-,-LRB-,O
cmin,NN,O
-rrb-,-RRB-,O
phenytoin,NN,D
plasma,NN,O
concentration,NN,O
was,VBD,O
17,CD,O
5,CD,O
micrograms/ml,NNS,O
.,.,.
,,
the,DT,O
steady-state,JJ,O
cmin,NN,O
increased,VBD,O
to,TO,O
21,CD,O
5,CD,O
micrograms/ml,NNS,O
when,WRB,O
1200,CD,O
mg/day,NN,O
of,IN,O
felbamate,NN,D
was,VBD,O
coadministered,VBN,O
.,.,.
,,
increasing,VBG,O
the,DT,O
felbamate,NN,D
dose,NN,O
to,TO,O
1800,CD,O
mg/day,NN,O
in,IN,O
six,CD,O
of,IN,O
these,DT,O
subjects,NNS,O
increased,VBD,O
the,DT,O
steady-state,JJ,O
phenytoin,NN,D
cmin,NN,O
to,TO,O
25,CD,O
7,CD,O
micrograms/ml,NNS,O
.,.,.
,,
in,IN,O
order,NN,O
to,TO,O
maintain,VB,O
phenytoin,NN,D
levels,NNS,O
",",",",O
limit,NN,O
adverse,JJ,O
experiences,NNS,O
",",",",O
and,CC,O
achieve,VB,O
the,DT,O
felbamate,NN,D
dose,NN,O
of,IN,O
3600,CD,O
mg/day,NN,O
",",",",O
a,DT,O
phenytoin,NN,D
dose,NN,O
reduction,NN,O
of,IN,O
approximately,RB,O
40,CD,O
%,NN,O
was,VBD,O
necessary,JJ,O
for,IN,O
eight,CD,O
of,IN,O
these,DT,O
10,CD,O
subjects,NNS,O
.,.,.
,,
in,IN,O
a,DT,O
controlled,JJ,O
clinical,JJ,O
trial,NN,O
",",",",O
a,DT,O
20,CD,O
%,NN,O
reduction,NN,O
of,IN,O
the,DT,O
phenytoin,NN,D
dose,NN,O
at,IN,O
the,DT,O
initiation,NN,O
of,IN,O
felbatol,NN,B
therapy,NN,O
resulted,VBD,O
in,IN,O
phenytoin,NN,D
levels,NNS,O
comparable,JJ,O
to,TO,O
those,DT,O
prior,JJ,O
to,TO,O
felbatol,NNP,B
administration,NN,O
.,.,.
,,
carbamazepine,NNP,D
:,:,O
felbatol,NNP,B
causes,VBZ,O
a,DT,O
decrease,NN,O
in,IN,O
the,DT,O
steady-state,JJ,O
carbamazepine,NN,D
plasma,NN,O
concentrations,NNS,O
and,CC,O
an,DT,O
increase,NN,O
in,IN,O
the,DT,O
steady-state,JJ,O
carbamazepine,NN,D
epoxide,NN,O
plasma,NN,O
concentration,NN,O
.,.,.
,,
in,IN,O
nine,CD,O
otherwise,RB,O
healthy,JJ,O
subjects,NNS,O
with,IN,O
epilepsy,NN,O
ingesting,VBG,O
carbamazepine,NN,D
",",",",O
the,DT,O
steady-state,JJ,O
trough,NN,O
-lrb-,-LRB-,O
cmin,NN,O
-rrb-,-RRB-,O
carbamazepine,NN,D
concentration,NN,O
was,VBD,O
8,CD,O
2,CD,O
micrograms/ml,NNS,O
.,.,.
,,
the,DT,O
carbamazepine,NN,D
steady-state,JJ,O
cmin,NN,O
decreased,VBD,O
31,CD,O
%,NN,O
to,TO,O
5,CD,O
1,CD,O
micrograms/ml,NNS,O
when,WRB,O
felbamate,NN,D
-lrb-,-LRB-,O
3000,CD,O
mg/day,NN,O
",",",",O
divided,VBN,O
into,IN,O
three,CD,O
doses,NNS,O
-rrb-,-RRB-,O
was,VBD,O
coadministered,VBN,O
.,.,.
,,
carbamazepine,NN,D
epoxide,NN,O
steady-state,JJ,O
cmin,JJ,O
concentrations,NNS,O
increased,VBD,O
57,CD,O
%,NN,O
from,IN,O
1,CD,O
0.3,CD,O
to,TO,O
1.6,CD,O
0.4,CD,O
micrograms/ml,NNS,O
with,IN,O
the,DT,O
addition,NN,O
of,IN,O
felbamate,NN,D
.,.,.
,,
in,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
similar,JJ,O
changes,NNS,O
in,IN,O
carbamazepine,NN,D
and,CC,O
carbamazepine,NN,D
epoxide,NN,O
were,VBD,O
seen,VBN,O
.,.,.
,,
valproate,NNP,D
:,:,O
felbatol,NNP,B
causes,VBZ,O
an,DT,O
increase,NN,O
in,IN,O
steady-state,JJ,O
valproate,NN,D
concentrations,NNS,O
.,.,.
,,
in,IN,O
four,CD,O
subjects,NNS,O
with,IN,O
epilepsy,NN,O
ingesting,VBG,O
valproate,NN,D
",",",",O
the,DT,O
steady-state,JJ,O
trough,NN,O
-lrb-,-LRB-,O
cmin,NN,O
-rrb-,-RRB-,O
valproate,NN,D
plasma,NN,O
concentration,NN,O
was,VBD,O
63,CD,O
16,CD,O
micrograms/ml,NNS,O
.,.,.
,,
the,DT,O
steady-state,JJ,O
cmin,NN,O
increased,VBD,O
to,TO,O
78,CD,O
14,CD,O
micrograms/ml,NNS,O
when,WRB,O
1200,CD,O
mg/day,NN,O
of,IN,O
felbamate,NN,D
was,VBD,O
coadministered,VBN,O
.,.,.
,,
increasing,VBG,O
the,DT,O
felbamate,NN,D
dose,NN,O
to,TO,O
2400,CD,O
mg/day,NN,O
increased,VBD,O
the,DT,O
steadystate,NN,O
valproate,NN,D
cmin,NN,O
to,TO,O
96,CD,O
25,CD,O
micrograms/ml,NNS,O
.,.,.
,,
corresponding,VBG,O
values,NNS,O
for,IN,O
free,JJ,O
valproate,NN,D
cmin,NN,O
concentrations,NNS,O
were,VBD,O
7,CD,O
3,CD,O
",",",",O
9,CD,O
4,CD,O
",",",",O
and,CC,O
11,CD,O
6,CD,O
micrograms/ml,NNS,O
for,IN,O
0,CD,O
",",",",O
1200,CD,O
",",",",O
and,CC,O
2400,CD,O
mg/day,NN,O
felbatol,NN,B
",",",",O
respectively,RB,O
.,.,.
,,
the,DT,O
ratios,NNS,O
of,IN,O
the,DT,O
aucs,NNS,O
of,IN,O
unbound,JJ,O
valproate,NN,D
to,TO,O
the,DT,O
aucs,NNS,O
of,IN,O
the,DT,O
total,JJ,O
valproate,NN,D
were,VBD,O
11.1,CD,O
%,NN,O
",",",",O
13,CD,O
%,NN,O
",",",",O
and,CC,O
11.5,CD,O
%,NN,O
",",",",O
with,IN,O
coadministration,NN,O
of,IN,O
0,CD,O
",",",",O
1200,CD,O
",",",",O
and,CC,O
2400,CD,O
mg/day,NN,O
of,IN,O
felbatol,NNP,B
",",",",O
respectively,RB,O
.,.,.
,,
phenobarbital,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
felbamate,NN,D
with,IN,O
phenobarbital,JJ,D
causes,NNS,O
an,DT,O
increase,NN,O
in,IN,O
phenobarbital,JJ,D
plasma,NN,O
concentrations,NNS,O
",",",",O
in,IN,O
12,CD,O
otherwise,RB,O
healthy,JJ,O
male,JJ,O
volunteers,NNS,O
ingesting,VBG,O
phenobarbital,JJ,D
",",",",O
the,DT,O
steady-state,JJ,O
trough,NN,O
-lrb-,-LRB-,O
cmin,NN,O
-rrb-,-RRB-,O
phenobarbital,JJ,D
concentration,NN,O
was,VBD,O
14.2,CD,O
micrograms/ml,NNS,O
.,.,.
,,
the,DT,O
steady-state,JJ,O
cmin,JJ,O
concentration,NN,O
increased,VBD,O
to,TO,O
17.8,CD,O
micrograms/ml,NNS,O
when,WRB,O
2400,CD,O
mg/day,NN,O
of,IN,O
felbamate,NN,D
was,VBD,O
coadministered,VBN,O
for,IN,O
one,CD,O
week,NN,O
.,.,.
,,
effects,NNS,O
of,IN,O
other,JJ,O
antiepileptic,JJ,O
drugs,NNS,O
on,IN,O
felbatol,NNP,B
phenytoin,NNP,D
:,:,O
phenytoin,NNP,D
causes,VBZ,O
an,DT,O
approximate,JJ,O
doubling,NN,O
of,IN,O
the,DT,O
clearance,NN,O
of,IN,O
felbatol,NN,B
-lrb-,-LRB-,O
felbamate,NN,D
-rrb-,-RRB-,O
at,IN,O
steady,JJ,O
state,NN,O
and,CC,O
",",",",O
therefore,RB,O
",",",",O
the,DT,O
addition,NN,O
of,IN,O
phenytoin,NN,D
causes,VBZ,O
an,DT,O
approximate,JJ,O
45,CD,O
%,NN,O
decrease,NN,O
in,IN,O
the,DT,O
steady-state,JJ,O
trough,NN,O
concentrations,NNS,O
of,IN,O
felbatol,NNP,B
as,IN,O
compared,VBN,O
to,TO,O
the,DT,O
same,JJ,O
dose,NN,O
of,IN,O
felbatol,NNP,B
given,VBN,O
as,IN,O
monotherapy,NN,O
.,.,.
,,
carbamazepine,NNP,D
:,:,O
carbamazepine,NNP,D
causes,VBZ,O
an,DT,O
approximate,JJ,O
50,CD,O
%,NN,O
increase,NN,O
in,IN,O
the,DT,O
clearance,NN,O
of,IN,O
felbatol,NNP,B
at,IN,O
steady,JJ,O
state,NN,O
and,CC,O
",",",",O
therefore,RB,O
",",",",O
the,DT,O
addition,NN,O
of,IN,O
carbamazepine,NN,D
results,VBZ,O
in,IN,O
an,DT,O
approximate,JJ,O
40,CD,O
%,NN,O
decrease,NN,O
in,IN,O
the,DT,O
steady-state,JJ,O
trough,NN,O
concentrations,NNS,O
of,IN,O
felbatol,NNP,B
as,IN,O
compared,VBN,O
to,TO,O
the,DT,O
same,JJ,O
dose,NN,O
of,IN,O
felbatol,NNP,B
given,VBN,O
as,IN,O
monotherapy,NN,O
.,.,.
,,
valproate,NNP,D
:,:,O
available,JJ,O
data,NNS,O
suggest,VBP,O
that,IN,O
there,EX,O
is,VBZ,O
no,DT,O
significant,JJ,O
effect,NN,O
of,IN,O
valproate,NN,D
on,IN,O
the,DT,O
clearance,NN,O
of,IN,O
felbatol,NNP,B
at,IN,O
steady,JJ,O
state,NN,O
",",",",O
therefore,RB,O
",",",",O
the,DT,O
addition,NN,O
of,IN,O
valproate,NN,D
is,VBZ,O
not,RB,O
expected,VBN,O
to,TO,O
cause,VB,O
a,DT,O
clinically,RB,O
important,JJ,O
effect,NN,O
on,IN,O
felbatol,NN,B
-lrb-,-LRB-,O
felbamate,NN,D
-rrb-,-RRB-,O
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
phenobarbital,NNP,D
:,:,O
it,PRP,O
appears,VBZ,O
that,IN,O
phenobarbital,NN,D
may,MD,O
reduce,VB,O
plasma,NN,O
felbamate,NN,D
concentrations,NNS,O
.,.,.
,,
steady-state,JJ,O
plasma,NN,O
felbamate,NN,D
concentrations,NNS,O
were,VBD,O
found,VBN,O
to,TO,O
be,VB,O
29,CD,O
%,NN,O
lower,JJR,O
than,IN,O
the,DT,O
mean,JJ,O
concentrations,NNS,O
of,IN,O
a,DT,O
group,NN,O
of,IN,O
newly,RB,O
diagnosed,VBN,O
subjects,NNS,O
with,IN,O
epilepsy,NN,O
also,RB,O
receiving,VBG,O
2400,CD,O
mg,NN,O
of,IN,O
felbamate,NN,D
a,DT,O
day,NN,O
.,.,.
,,
effects,NNS,O
of,IN,O
antacids,NNS,G
on,IN,O
felbatol,NNP,B
the,DT,O
rate,NN,O
and,CC,O
extent,NN,O
of,IN,O
absorption,NN,O
of,IN,O
a,DT,O
2400,CD,O
mg,NN,O
dose,NN,O
of,IN,O
felbatol,NNP,B
as,IN,O
monotherapy,JJ,O
given,VBN,O
as,IN,O
tablets,NNS,O
was,VBD,O
not,RB,O
affected,VBN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
antacids,NNS,G
.,.,.
,,
effects,NNS,O
of,IN,O
erythromycin,NN,D
on,IN,O
felbatol,NNP,B
the,DT,O
coadministration,NN,O
of,IN,O
erythromycin,NN,D
-lrb-,-LRB-,O
1000,CD,O
mg/day,NN,O
-rrb-,-RRB-,O
for,IN,O
10,CD,O
days,NNS,O
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
pharmacokinetic,JJ,O
parameters,NNS,O
of,IN,O
cmax,NNP,O
",",",",O
cmin,NNP,O
",",",",O
auc,NN,O
",",",",O
ci/kg,NN,O
or,CC,O
tmax,NN,O
at,IN,O
felbamate,NN,D
daily,JJ,O
doses,NNS,O
of,IN,O
3000,CD,O
or,CC,O
3600,CD,O
mg/day,NN,O
in,IN,O
10,CD,O
otherwise,RB,O
healthy,JJ,O
subjects,NNS,O
with,IN,O
epilepsy,NN,O
.,.,.
,,
effects,NNS,O
of,IN,O
felbatol,NNP,B
on,IN,O
low-dose,NNP,O
combination,NNP,O
oral,NNP,O
contraceptives,NNPS,G
a,DT,O
group,NN,O
of,IN,O
24,CD,O
nonsmoking,JJ,O
",",",",O
healthy,JJ,O
white,JJ,O
female,JJ,O
volunteers,NNS,O
established,VBN,O
on,IN,O
an,DT,O
oral,JJ,O
contraceptive,JJ,G
regimen,NN,O
containing,VBG,O
30,CD,O
mg,NN,O
ethinyl,NN,O
estradiol,NN,O
and,CC,O
75,CD,O
mg,NN,O
gestodene,NN,D
for,IN,O
at,IN,O
least,JJS,O
3,CD,O
months,NNS,O
received,VBD,O
2400,CD,O
mg/day,NN,O
of,IN,O
felbamate,NN,D
from,IN,O
midcycle,NN,O
-lrb-,-LRB-,O
day,NN,O
15,CD,O
-rrb-,-RRB-,O
to,TO,O
midcycle,NN,O
-lrb-,-LRB-,O
day,NN,O
14,CD,O
-rrb-,-RRB-,O
of,IN,O
two,CD,O
consecutive,JJ,O
oral,JJ,O
contraceptive,JJ,G
cycles,NNS,O
.,.,.
,,
felbamate,NN,D
treatment,NN,O
resulted,VBD,O
in,IN,O
a,DT,O
42,CD,O
%,NN,O
decrease,NN,O
in,IN,O
the,DT,O
gestodene,NN,D
auc,NN,O
0-24,CD,O
",",",",O
but,CC,O
no,DT,O
clinically,RB,O
relevant,JJ,O
effect,NN,O
was,VBD,O
observed,VBN,O
on,IN,O
the,DT,O
pharmacokinetic,JJ,O
parameters,NNS,O
of,IN,O
ethinyl,NN,O
estradiol,NN,O
.,.,.
,,
no,DT,O
volunteer,NN,O
showed,VBD,O
hormonal,JJ,O
evidence,NN,O
of,IN,O
ovulation,NN,O
",",",",O
but,CC,O
one,CD,O
volunteer,NN,O
reported,VBD,O
intermenstrual,JJ,O
bleeding,NN,O
during,IN,O
felbamate,NN,D
treatment,NN,O
.,.,.
,,
cyp3a4,NN,D
inhibitors,NNS,O
felodipine,NN,D
is,VBZ,O
metabolized,VBN,O
by,IN,O
cyp3a4,NN,D
.,.,.
,,
co-administration,NN,O
of,IN,O
cyp3a4,NN,D
inhibitors,NNS,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
ketoconazole,NN,D
",",",",O
itraconazole,NN,D
",",",",O
erythromycin,NN,D
",",",",O
grapefruit,NN,O
juice,NN,O
",",",",O
cimetidine,NN,D
-rrb-,-RRB-,O
with,IN,O
felodipine,NN,D
may,MD,O
lead,VB,O
to,TO,O
several,JJ,O
-,:,O
fold,JJ,O
increases,NNS,O
in,IN,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
felodipine,NN,D
",",",",O
either,CC,O
due,JJ,O
to,TO,O
an,DT,O
increase,NN,O
in,IN,O
bioavailability,NN,O
or,CC,O
due,JJ,O
to,TO,O
a,DT,O
decrease,NN,O
in,IN,O
metabolism,NN,O
.,.,.
,,
these,DT,O
increases,NNS,O
in,IN,O
concentration,NN,O
may,MD,O
lead,VB,O
to,TO,O
increased,VBN,O
effects,NNS,O
",",",",O
-lrb-,-LRB-,O
lower,JJR,O
blood,NN,O
pressure,NN,O
and,CC,O
increased,VBD,O
heart,NN,O
rate,NN,O
-rrb-,-RRB-,O
.,.,.
,,
these,DT,O
effects,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
with,IN,O
co-administration,NN,O
of,IN,O
itraconazole,NN,D
-lrb-,-LRB-,O
a,DT,O
potent,JJ,O
cyp3a4,NN,D
inhibitor,NN,O
-rrb-,-RRB-,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
when,WRB,O
cyp3a4,NN,D
inhibitors,NNS,O
are,VBP,O
co-administered,VBN,O
with,IN,O
felodipine,NN,D
.,.,.
,,
a,DT,O
conservative,JJ,O
approach,NN,O
to,TO,O
dosing,NN,O
felodipine,NN,D
should,MD,O
be,VB,O
taken,VBN,O
.,.,.
,,
the,DT,O
following,VBG,O
specific,JJ,O
interactions,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
:,:,O
itraconazole,NNP,D
co-administration,NN,O
of,IN,O
another,DT,O
extended,VBN,O
release,NN,O
formulation,NN,O
of,IN,O
felodipine,NN,D
with,IN,O
itraconazole,NN,D
resulted,VBD,O
in,IN,O
approximately,RB,O
8-fold,JJ,O
increase,NN,O
in,IN,O
the,DT,O
auc,NN,O
",",",",O
more,JJR,O
than,IN,O
6,CD,O
-,:,O
fold,JJ,O
increase,NN,O
in,IN,O
the,DT,O
cmax,NNP,O
",",",",O
and,CC,O
2-fold,JJ,O
prolongation,NN,O
in,IN,O
the,DT,O
half,NN,O
-,:,O
life,NN,O
of,IN,O
felodipine,NN,D
.,.,.
,,
erythromycin,NN,D
co-administration,NN,O
of,IN,O
felodipine,NN,D
-lrb-,-LRB-,O
plendil,NN,D
-rrb-,-RRB-,O
with,IN,O
erythromycin,NN,D
resulted,VBD,O
in,IN,O
approximately,RB,O
2.5,CD,O
-,:,O
fold,JJ,O
increase,NN,O
in,IN,O
the,DT,O
auc,NN,O
and,CC,O
cmax,NN,O
",",",",O
and,CC,O
about,IN,O
2,CD,O
-,:,O
fold,JJ,O
prolongation,NN,O
in,IN,O
the,DT,O
half,NN,O
-,:,O
life,NN,O
of,IN,O
felodipine,NN,D
.,.,.
,,
grapefruit,NN,O
juice,NN,O
co-administration,NN,O
of,IN,O
felodipine,NN,D
with,IN,O
grapefruit,NN,O
juice,NN,O
resulted,VBD,O
in,IN,O
more,JJR,O
than,IN,O
2-fold,JJ,O
increase,NN,O
in,IN,O
the,DT,O
auc,NN,O
and,CC,O
cmax,NN,O
",",",",O
but,CC,O
no,DT,O
prolongation,NN,O
in,IN,O
the,DT,O
half,NN,O
-,:,O
life,NN,O
of,IN,O
felodipine,NN,D
.,.,.
,,
cimetidine,NN,D
co-administration,NN,O
of,IN,O
felodipine,NN,D
with,IN,O
cimetidine,NN,D
-lrb-,-LRB-,O
a,DT,O
non-specific,JJ,O
cyp-450,NN,O
inhibitor,NN,O
-rrb-,-RRB-,O
resulted,VBD,O
in,IN,O
an,DT,O
increase,NN,O
of,IN,O
approximately,RB,O
50,CD,O
%,NN,O
in,IN,O
the,DT,O
auc,NN,O
and,CC,O
the,DT,O
cmax,NNP,O
",",",",O
of,IN,O
felodipine,NN,D
.,.,.
,,
beta-blocking,JJ,O
agents,NNPS,O
a,DT,O
pharmacokinetic,JJ,O
study,NN,O
of,IN,O
felodipine,NN,D
in,IN,O
conjunction,NN,O
with,IN,O
metoprolol,NN,D
demonstrated,VBD,O
no,DT,O
significant,JJ,O
effects,NNS,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
felodipine,NN,D
.,.,.
,,
the,DT,O
auc,NN,O
and,CC,O
cmax,NN,O
of,IN,O
metoprolol,NN,D
",",",",O
however,RB,O
",",",",O
were,VBD,O
increased,VBN,O
approximately,RB,O
31,CD,O
and,CC,O
38,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
in,IN,O
controlled,JJ,O
clinical,JJ,O
trials,NNS,O
",",",",O
however,RB,O
",",",",O
beta,NN,O
blockers,NNS,O
including,VBG,O
metoprolol,NN,D
were,VBD,O
concurrently,RB,O
administered,VBN,O
with,IN,O
felodipine,NN,D
and,CC,O
were,VBD,O
well,RB,O
tolerated,VBN,O
.,.,.
,,
digoxin,NNP,D
when,WRB,O
given,VBN,O
concomitantly,RB,O
with,IN,O
plendil,NN,D
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
digoxin,NN,D
in,IN,O
patients,NNS,O
with,IN,O
heart,NN,O
failure,NN,O
were,VBD,O
not,RB,O
significantly,RB,O
altered,VBN,O
.,.,.
,,
anticonvulsants,NNPS,G
:,:,O
in,IN,O
a,DT,O
pharmacokinetic,JJ,O
study,NN,O
",",",",O
maximum,NN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
felodipine,NN,D
were,VBD,O
considerably,RB,O
lower,JJR,O
in,IN,O
epileptic,JJ,O
patients,NNS,O
on,IN,O
long-term,JJ,O
anticonvulsant,JJ,G
therapy,NN,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
phenytoin,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
or,CC,O
phenobarbital,NN,D
-rrb-,-RRB-,O
than,IN,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
.,.,.
,,
in,IN,O
such,JJ,O
patients,NNS,O
",",",",O
the,DT,O
mean,JJ,O
area,NN,O
under,IN,O
the,DT,O
felodipine,NN,D
plasma,NN,O
concentration-time,NN,O
curve,NN,O
was,VBD,O
also,RB,O
reduced,VBN,O
to,TO,O
approximately,RB,O
6,CD,O
%,NN,O
of,IN,O
that,DT,O
observed,VBN,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
.,.,.
,,
since,IN,O
a,DT,O
clinically,RB,O
significant,JJ,O
interaction,NN,O
may,MD,O
be,VB,O
anticipated,VBN,O
",",",",O
alternative,JJ,O
antihypertensive,JJ,G
therapy,NN,O
should,MD,O
be,VB,O
considered,VBN,O
in,IN,O
these,DT,O
patients,NNS,O
.,.,.
,,
tacrolimus,NN,D
felodipine,NN,D
may,MD,O
increase,VB,O
the,DT,O
blood,NN,O
concentration,NN,O
of,IN,O
tacrolimus,NN,D
.,.,.
,,
when,WRB,O
given,VBN,O
concomitantly,RB,O
with,IN,O
felodipine,NN,D
",",",",O
the,DT,O
tacrolimus,NN,D
blood,NN,O
concentration,NN,O
should,MD,O
be,VB,O
followed,VBN,O
and,CC,O
the,DT,O
tacrolimus,NN,D
dose,NN,O
may,MD,O
need,VB,O
to,TO,O
be,VB,O
adjusted,VBN,O
.,.,.
,,
other,JJ,O
concomitant,JJ,O
therapy,NN,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
there,EX,O
were,VBD,O
no,DT,O
clinically,RB,O
significant,JJ,O
interactions,NNS,O
when,WRB,O
felodipine,NN,D
was,VBD,O
given,VBN,O
concomitantly,RB,O
with,IN,O
indomethacin,NN,D
or,CC,O
spironolactone,NN,D
.,.,.
,,
interaction,NN,O
with,IN,O
food,NNP,O
see,VB,O
clinical,NNP,O
pharmacology,NNP,O
",",",",O
pharmacokinetics,NNP,O
and,CC,O
metabolism,NNP,O
.,.,.
,,
fenfluramine,NN,D
may,MD,O
increase,VB,O
slightly,RB,O
the,DT,O
effect,NN,O
of,IN,O
antihypertensive,JJ,G
drugs,NNS,D
",",",",O
e.g.,FW,O
",",",",O
guanethidine,NN,D
",",",",O
methyldopa,NN,D
",",",",O
reserpine,NN,D
.,.,.
,,
other,JJ,O
cns,NNS,O
depressant,NN,O
drugs,NNS,D
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
fenfluramine,NN,D
",",",",O
since,IN,O
the,DT,O
effects,NNS,O
may,MD,O
be,VB,O
additive,JJ,O
.,.,.
,,
oral,JJ,O
anticoagulants,NNPS,G
caution,NNP,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
coumarin,NNP,O
anticoagulants,NNP,G
are,VBP,O
given,NNP,O
in,IN,O
conjunction,NNP,O
with,IN,O
tricor,NNP,B
.,.,.
,,
the,DT,O
dosage,NN,O
of,IN,O
the,DT,O
anticoagulants,NNS,G
should,MD,O
be,VB,O
reduced,NNP,O
to,TO,O
maintain,VB,O
the,DT,O
prothrombin,NN,O
time/inr,NN,O
at,IN,O
the,DT,O
desired,JJ,O
level,NN,O
to,TO,O
prevent,VB,O
bleeding,VBG,O
complications,NNS,O
.,.,.
,,
frequent,JJ,O
prothrombin,NN,O
time/inr,NN,O
determinations,NNS,O
are,VBP,O
advisable,JJ,O
until,IN,O
it,PRP,O
has,VBZ,O
been,NNP,O
definitely,NNP,O
determined,NNP,O
that,WDT,O
the,DT,O
prothrombin,NN,O
time/inr,NN,O
has,VBZ,O
stabilized,VBN,O
.,.,.
,,
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
:,:,O
the,DT,O
combined,VBN,O
use,NN,O
of,IN,O
tricor,NN,B
and,CC,O
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
should,MD,O
be,VB,O
avoided,VBN,O
unless,IN,O
the,DT,O
benefit,NN,O
of,IN,O
further,JJ,O
alterations,NNS,O
in,IN,O
lipid,NN,O
levels,NNS,O
is,VBZ,O
likely,JJ,O
to,TO,O
outweigh,VB,O
the,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
this,DT,O
drug,NN,D
combination,NN,O
.,.,.
,,
resins,NNS,G
:,:,O
since,IN,O
bile,NN,O
acid,NN,O
sequestrants,NNS,O
may,MD,O
bind,VB,O
other,JJ,O
drugs,NNS,D
given,VBN,O
concurrently,RB,O
",",",",O
patients,NNS,O
should,MD,O
take,VB,O
tricor,NNP,B
at,IN,O
least,JJS,O
1,CD,O
hour,NN,O
before,IN,O
or,CC,O
6-Apr,CD,O
hours,NNS,O
after,IN,O
a,DT,O
bile,NN,O
acid,NN,O
binding,NN,O
resin,NN,G
to,TO,O
avoid,VB,O
impeding,VBG,O
its,PRP$,O
absorption,NN,O
.,.,.
,,
cyclosporine,NN,D
:,:,O
because,IN,O
cyclosporine,NN,D
can,MD,O
produce,VB,O
nephrotoxicity,NN,O
with,IN,O
decreases,NNS,O
in,IN,O
creatinine,NN,O
clearance,NN,O
and,CC,O
rises,VBZ,O
in,IN,O
serum,NN,O
creatinine,NN,O
",",",",O
and,CC,O
because,IN,O
renal,JJ,O
excretion,NN,O
is,VBZ,O
the,DT,O
primary,JJ,O
elimination,NN,O
route,NN,O
of,IN,O
fibrate,JJ,G
drugs,NNS,D
including,VBG,O
tricor,NNP,B
",",",",O
there,EX,O
is,VBZ,O
a,DT,O
risk,NN,O
that,IN,O
an,DT,O
interaction,NN,O
will,MD,O
lead,VB,O
to,TO,O
deterioration,NN,O
.,.,.
,,
the,DT,O
benefits,NNS,O
and,CC,O
risks,NNS,O
of,IN,O
using,VBG,O
tricor,NN,B
with,IN,O
immunosuppressants,NNS,G
and,CC,O
other,JJ,O
potentially,RB,O
nephrotoxic,JJ,O
agents,NNS,O
should,MD,O
be,VB,O
carefully,RB,O
considered,VBN,O
",",",",O
and,CC,O
the,DT,O
lowest,JJS,O
effective,JJ,O
dose,NN,O
employe,NN,O
.,.,.
,,
drug-drug,JJ,O
interactions,NNS,O
in,FW,O
vitro,FW,O
studies,NNS,O
using,VBG,O
human,JJ,O
liver,NN,O
microsomes,NNS,O
indicate,VBP,O
that,IN,O
fenofibrate,NN,D
and,CC,O
fenofibric,JJ,O
acid,NN,O
are,VBP,O
not,RB,O
inhibitors,NNS,O
of,IN,O
cytochrome,NN,O
-lrb-,-LRB-,O
cyp,NN,O
-rrb-,-RRB-,O
p450,NN,O
isoforms,NNS,O
cyp3a4,NN,D
",",",",O
cyp2d6,NN,D
",",",",O
cyp2e1,NN,O
",",",",O
or,CC,O
cyp1a2,NN,D
.,.,.
,,
they,PRP,O
are,VBP,O
weak,JJ,O
inhibitors,NNS,O
of,IN,O
cyp2c19,NN,O
and,CC,O
cyp2a6,NN,O
",",",",O
and,CC,O
mild-to-moderate,JJ,O
inhibitors,NNS,O
of,IN,O
cyp2c9,NN,D
at,IN,O
therapeutic,JJ,O
concentrations,NNS,O
.,.,.
,,
potentiation,NN,O
of,IN,O
coumarin-type,JJ,O
anticoagulants,NNS,G
has,VBZ,O
been,VBN,O
observed,VBN,O
with,IN,O
prolongation,NN,O
of,IN,O
the,DT,O
prothrombin,NN,O
time/inr,NN,O
.,.,.
,,
bile,NN,O
acid,NN,O
sequestrants,NNS,O
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
bind,VB,O
other,JJ,O
drugs,NNS,D
given,VBN,O
concurrently,RB,O
.,.,.
,,
therefore,RB,O
",",",",O
fenofibrate,NN,D
should,MD,O
be,VB,O
taken,VBN,O
at,IN,O
least,JJS,O
1,CD,O
hour,NN,O
before,IN,O
or,CC,O
6-Apr,CD,O
hours,NNS,O
after,IN,O
a,DT,O
bile,NN,O
acid,NN,O
binding,NN,O
resin,NN,G
to,TO,O
avoid,VB,O
impeding,VBG,O
its,PRP$,O
absorption,NN,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
fenofibrate,NN,D
-lrb-,-LRB-,O
equivalent,JJ,O
to,TO,O
145mg,JJ,O
tricor,NN,B
-rrb-,-RRB-,O
with,IN,O
pravastatin,NN,D
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
-rrb-,-RRB-,O
once,RB,O
daily,RB,O
for,IN,O
10,CD,O
days,NNS,O
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
increase,VB,O
the,DT,O
mean,NN,O
cmax,NN,O
and,CC,O
auc,NN,O
values,NNS,O
for,IN,O
pravastatin,NN,D
by,IN,O
36,CD,O
%,NN,O
-lrb-,-LRB-,O
range,NN,O
from,IN,O
69,CD,O
%,NN,O
decrease,NN,O
to,TO,O
321,CD,O
%,NN,O
increase,NN,O
-rrb-,-RRB-,O
and,CC,O
28,CD,O
%,NN,O
-lrb-,-LRB-,O
range,NN,O
from,IN,O
54,CD,O
%,NN,O
decrease,NN,O
to,TO,O
128,CD,O
%,NN,O
increase,NN,O
-rrb-,-RRB-,O
",",",",O
respectively,RB,O
",",",",O
and,CC,O
for,IN,O
3,LS,O
-,:,O
hydroxy-iso-pravastatin,NN,O
by,IN,O
55,CD,O
%,NN,O
-lrb-,-LRB-,O
range,NN,O
from,IN,O
32,CD,O
%,NN,O
decrease,NN,O
to,TO,O
314,CD,O
%,NN,O
increase,NN,O
-rrb-,-RRB-,O
and,CC,O
39,CD,O
%,NN,O
-lrb-,-LRB-,O
range,NN,O
from,IN,O
24,CD,O
%,NN,O
decrease,NN,O
to,TO,O
261,CD,O
%,NN,O
increase,NN,O
-rrb-,-RRB-,O
",",",",O
respectively,RB,O
in,IN,O
23,CD,O
healthy,JJ,O
adults,NNS,O
.,.,.
,,
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
pravastatin,NN,D
had,VBD,O
no,DT,O
clinically,RB,O
important,JJ,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
fenofibric,JJ,O
acid,NN,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
fenofibrate,NN,D
-lrb-,-LRB-,O
equivalent,JJ,O
to,TO,O
145,CD,O
mg,NN,O
tricor,NN,B
-rrb-,-RRB-,O
with,IN,O
atorvastatin,NN,D
-lrb-,-LRB-,O
20,CD,O
mg,NN,O
-rrb-,-RRB-,O
once,RB,O
daily,RB,O
for,IN,O
10,CD,O
days,NNS,O
resulted,VBD,O
in,IN,O
approximately,RB,O
17,CD,O
%,NN,O
decrease,NN,O
-lrb-,-LRB-,O
range,NN,O
from,IN,O
67,CD,O
%,NN,O
decrease,NN,O
to,TO,O
44,CD,O
%,NN,O
increase,NN,O
-rrb-,-RRB-,O
in,IN,O
atorvastatin,NN,D
auc,NN,O
values,NNS,O
in,IN,O
22,CD,O
healthy,JJ,O
males,NNS,O
.,.,.
,,
the,DT,O
atorvastatin,NN,D
cmax,NN,O
values,NNS,O
were,VBD,O
not,RB,O
significantly,RB,O
affected,VBN,O
by,IN,O
fenofibrate,NN,D
.,.,.
,,
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
fenofibric,JJ,O
acid,NN,O
were,VBD,O
not,RB,O
significantly,RB,O
affected,VBN,O
by,IN,O
atorvastati,NN,O
.,.,.
,,
drug,NN,O
interactions,NNS,O
with,IN,O
beta-blockers,NNPS,G
:,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
fenoldopam,NN,D
with,IN,O
beta-blockers,NNS,G
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
if,IN,O
the,DT,O
drugs,NNS,D
are,VBP,O
used,VBN,O
together,RB,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
because,IN,O
unexpected,JJ,O
hypotension,NN,O
could,MD,O
result,VB,O
from,IN,O
beta-blocker,NN,G
inhibition,NN,O
of,IN,O
the,DT,O
sympathetic,JJ,O
reflex,JJ,O
response,NN,O
to,TO,O
fenoldopam,NN,D
.,.,.
,,
drug,NN,O
interactions,NNS,O
",",",",O
general,NNP,O
:,:,O
although,IN,O
there,EX,O
have,VBP,O
been,VBN,O
no,DT,O
formal,JJ,O
interaction,NN,O
studies,NNS,O
",",",",O
intravenous,JJ,O
fenoldopam,NN,D
has,VBZ,O
been,VBN,O
administered,VBN,O
safely,RB,O
with,IN,O
drugs,NNS,D
such,JJ,O
as,IN,O
digitalis,NN,G
and,CC,O
sublingual,JJ,O
nitroglycerin,NN,D
.,.,.
,,
there,EX,O
is,VBZ,O
limited,JJ,O
experience,NN,O
with,IN,O
concomitant,JJ,O
antihypertensive,JJ,G
agents,NNS,O
such,JJ,O
as,IN,O
alpha-blockers,NNS,G
",",",",O
calcium,NN,D
channel-blockers,NNS,O
",",",",O
ace,NN,O
inhibitors,NNS,O
",",",",O
and,CC,O
diuretics,NNS,G
-lrb-,-LRB-,O
both,CC,O
thiazide-like,JJ,O
and,CC,O
loop,NN,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
coadministration,NN,O
of,IN,O
aspirin,NN,B
decreases,VBZ,O
the,DT,O
biologic,JJ,O
half-life,NN,O
of,IN,O
fenoprofen,NN,D
because,IN,O
of,IN,O
an,DT,O
increase,NN,O
in,IN,O
metabolic,JJ,O
clearance,NN,O
that,WDT,O
results,VBZ,O
in,IN,O
a,DT,O
greater,JJR,O
amount,NN,O
of,IN,O
hydroxylated,VBN,O
fenoprofen,NN,D
in,IN,O
the,DT,O
urine,NN,O
.,.,.
,,
although,IN,O
the,DT,O
mechanism,NN,O
of,IN,O
interaction,NN,O
between,IN,O
fenoprofen,NN,D
and,CC,O
aspirin,NN,B
is,VBZ,O
not,RB,O
totally,RB,O
known,VBN,O
",",",",O
enzyme,NN,O
induction,NN,O
and,CC,O
displacement,NN,O
of,IN,O
fenoprofen,NN,D
from,IN,O
plasma,NN,O
albumin,NN,O
binding,VBG,O
sites,NNS,O
are,VBP,O
possibilities,NNS,O
.,.,.
,,
because,IN,O
nalfon,NNP,B
has,VBZ,O
not,RB,O
been,VBN,O
shown,VBN,O
to,TO,O
produce,VB,O
any,DT,O
additional,JJ,O
effect,NN,O
beyond,IN,O
that,DT,O
obtained,VBN,O
with,IN,O
aspirin,NN,B
alone,RB,O
and,CC,O
because,RB,O
aspirin,NN,B
increases,VBZ,O
the,DT,O
rate,NN,O
of,IN,O
excretion,NN,O
of,IN,O
nalfon,NNP,B
",",",",O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
nalfon,NNP,B
and,CC,O
salicylates,NNS,G
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
chronic,JJ,O
administration,NN,O
of,IN,O
phenobarbital,NN,D
",",",",O
a,DT,O
known,JJ,O
enzyme,NN,O
inducer,NN,O
",",",",O
may,MD,O
be,VB,O
associated,VBN,O
with,IN,O
a,DT,O
decrease,NN,O
in,IN,O
the,DT,O
plasma,NN,O
half-life,NN,O
of,IN,O
fenoprofen,NN,D
.,.,.
,,
when,WRB,O
phenobarbital,NN,D
is,VBZ,O
added,VBN,O
to,TO,O
or,CC,O
withdrawn,VBN,O
from,IN,O
treatment,NN,O
",",",",O
dosage,NN,O
adjustment,NN,O
of,IN,O
nalfon,NNP,B
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
fenoprofen,NN,D
",",",",O
because,IN,O
of,IN,O
its,PRP$,O
affinity,NN,O
for,IN,O
albumin,NN,O
",",",",O
may,MD,O
displace,VB,O
from,IN,O
their,PRP$,O
binding,NN,O
sites,NNS,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
also,RB,O
albumin,NN,O
bound,VBD,O
",",",",O
and,CC,O
this,DT,O
may,MD,O
lead,VB,O
to,TO,O
drug,NN,D
interaction,NN,O
.,.,.
,,
theoretically,RB,O
",",",",O
fenoprofen,NN,D
could,MD,O
likewise,RB,O
be,VB,O
displaced,VBN,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
hydantoins,NNS,G
",",",",O
sulfonamides,NNS,G
",",",",O
or,CC,O
sulfonylureas,NNS,G
should,MD,O
be,VB,O
observed,VBN,O
for,IN,O
increased,VBN,O
activity,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
and,CC,O
",",",",O
therefore,RB,O
",",",",O
signs,NNS,O
of,IN,O
toxicity,NN,O
from,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
in,IN,O
patients,NNS,O
receiving,VBG,O
coumarin-type,JJ,O
anticoagulants,NNS,G
",",",",O
the,DT,O
addition,NN,O
of,IN,O
nalfon,NNP,B
to,TO,O
therapy,NN,O
could,MD,O
prolong,VB,O
the,DT,O
prothrombin,NN,O
time,NN,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
both,CC,O
drugs,NNS,D
should,MD,O
be,VB,O
under,IN,O
careful,JJ,O
observation,NN,O
.,.,.
,,
patients,NNS,O
treated,VBN,O
with,IN,O
nalfon,NN,B
may,MD,O
be,VB,O
resistant,JJ,O
to,TO,O
the,DT,O
effects,NNS,O
of,IN,O
loop,NN,O
diuretics,NNS,G
.,.,.
,,
in,IN,O
patients,NNS,O
receiving,VBG,O
nalfon,NNP,B
and,CC,O
a,DT,O
steroid,NN,G
concomitantly,RB,O
",",",",O
any,DT,O
reduction,NN,O
in,IN,O
steroid,NN,G
dosage,NN,O
should,MD,O
be,VB,O
gradual,JJ,O
in,IN,O
order,NN,O
to,TO,O
avoid,VB,O
the,DT,O
possible,JJ,O
complications,NNS,O
of,IN,O
sudden,JJ,O
steroid,NN,G
withdrawal,NN,O
.,.,.
,,
agents,NNS,O
affecting,VBG,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
isoenzyme,NNP,O
system,NNP,O
fentanyl,NNP,D
is,VBZ,O
metabolized,VBN,O
mainly,RB,O
via,IN,O
the,DT,O
human,JJ,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
isoenzyme,NN,O
system,NN,O
-lrb-,-LRB-,O
cyp3a4,NN,D
-rrb-,-RRB-,O
",",",",O
therefore,RB,O
potential,JJ,O
interactions,NNS,O
may,MD,O
occur,VB,O
when,WRB,O
duragesic,NN,B
is,VBZ,O
given,VBN,O
concurrently,RB,O
with,IN,O
agents,NNS,O
that,WDT,O
affect,VBP,O
cyp3a4,NN,D
activity,NN,O
.,.,.
,,
coadminstration,NN,O
with,IN,O
agents,NNS,O
that,WDT,O
induce,VBP,O
3a4,NN,O
activity,NN,O
may,MD,O
reduce,VB,O
the,DT,O
efficacy,NN,O
of,IN,O
duragesic,NN,B
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
transdermal,JJ,O
fentanyl,NN,D
with,IN,O
ritonavir,NN,D
or,CC,O
other,JJ,O
potent,JJ,O
3a4,NN,O
inhibitors,NNS,O
such,JJ,O
as,IN,O
ketoconazole,NN,D
",",",",O
itraconazole,NN,D
",",",",O
troleandomycin,NN,D
",",",",O
clarithromycin,NN,D
",",",",O
nelfinavir,NN,D
",",",",O
and,CC,O
nefazadone,NN,D
may,MD,O
result,VB,O
in,IN,O
an,DT,O
increase,NN,O
in,IN,O
fentanyl,NN,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
other,JJ,O
cyp3a4,NN,D
inhibitors,NNS,O
such,JJ,O
as,IN,O
diltiazem,NN,D
and,CC,O
erythromycin,NN,D
with,IN,O
transdermal,JJ,O
fentanyl,NN,D
may,MD,O
also,RB,O
result,VB,O
in,IN,O
an,DT,O
increase,NN,O
in,IN,O
fentanyl,NN,D
plasma,NN,O
concentrations,NNS,O
",",",",O
which,WDT,O
could,MD,O
increase,VB,O
or,CC,O
prolong,VB,O
adverse,JJ,O
drug,NN,D
effects,NNS,O
and,CC,O
may,MD,O
cause,VB,O
serious,JJ,O
respiratory,JJ,O
depression,NN,O
.,.,.
,,
in,IN,O
this,DT,O
situation,NN,O
",",",",O
special,JJ,O
patient,NN,O
care,NN,O
and,CC,O
observation,NN,O
are,VBP,O
appropriate,JJ,O
.,.,.
,,
central,NNP,O
nervous,NNP,O
system,NNP,O
depressants,NNPS,O
:,:,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
duragesic,NN,B
-lrb-,-LRB-,O
fentanyl,NN,D
transdermal,JJ,O
system,NN,O
-rrb-,-RRB-,O
with,IN,O
other,JJ,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressants,NNS,O
",",",",O
including,VBG,O
but,CC,O
not,RB,O
limited,VBN,O
to,TO,O
other,JJ,O
opioids,NNS,G
",",",",O
sedatives,NNS,G
",",",",O
hypnotics,NNS,G
",",",",O
tranquilizers,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
benzodiazepines,NNS,G
-rrb-,-RRB-,O
",",",",O
general,JJ,O
anesthetics,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
skeletal,JJ,O
muscle,NN,O
relaxants,NNS,O
",",",",O
and,CC,O
alcohol,NN,D
",",",",O
may,MD,O
cause,VB,O
respiratory,JJ,O
depression,NN,O
",",",",O
hypotension,NN,O
",",",",O
and,CC,O
profound,JJ,O
sedation,NN,O
",",",",O
or,CC,O
potentially,RB,O
result,VBP,O
in,IN,O
coma,NN,O
or,CC,O
death,NN,O
.,.,.
,,
when,WRB,O
such,JJ,O
combined,JJ,O
therapy,NN,O
is,VBZ,O
contemplated,VBN,O
",",",",O
the,DT,O
dose,NN,O
of,IN,O
one,CD,O
or,CC,O
both,DT,O
agents,NNS,O
should,MD,O
be,VB,O
significantly,RB,O
reduced,VBN,O
.,.,.
,,
mao,NNP,O
inhibitors,NNS,O
:,:,O
duragesic,NN,B
is,VBZ,O
not,RB,O
recommended,VBN,O
for,IN,O
use,NN,O
in,IN,O
patients,NNS,O
who,WP,O
have,VBP,O
received,VBN,O
maoi,NNP,G
within,IN,O
14,CD,O
days,NNS,O
because,IN,O
severe,JJ,O
and,CC,O
unpredictable,JJ,O
potentiation,NN,O
by,IN,O
mao,NN,O
inhibitors,NNS,O
has,VBZ,O
been,VBN,O
reported,VBN,O
with,IN,O
opioid,JJ,G
analgesic,JJ,O
.,.,.
,,
drug,NN,O
interaction,NN,O
with,IN,O
erythromycin,NN,D
and,CC,O
ketoconazole,NNP,D
fexofenadine,NNP,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
exhibit,VB,O
minimal,JJ,O
-lrb-,-LRB-,O
ca.,FW,O
5,CD,O
%,NN,O
-rrb-,-RRB-,O
metabolism,NN,O
.,.,.
,,
however,RB,O
",",",",O
co,NN,O
administration,NN,O
of,IN,O
fexofenadine,NN,D
hydrochloride,NN,O
with,IN,O
either,CC,O
ketoconazole,NN,D
or,CC,O
erythromycin,NN,D
led,VBD,O
to,TO,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
fexofenadine,NN,D
.,.,.
,,
fexofenadine,NNP,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
erythromycin,NN,D
or,CC,O
ketoconazole,NN,D
.,.,.
,,
in,IN,O
2,CD,O
separate,JJ,O
studies,NNS,O
",",",",O
fexofenadine,NN,D
hydrochloride,NN,O
120,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
-lrb-,-LRB-,O
240,CD,O
mg,NN,O
total,JJ,O
daily,JJ,O
dose,NN,O
-rrb-,-RRB-,O
was,VBD,O
co-administered,VBN,O
with,IN,O
either,CC,O
erythromycin,NN,D
500,CD,O
mg,NN,O
every,DT,O
8,CD,O
hours,NNS,O
or,CC,O
ketoconazole,NN,D
400,CD,O
mg,NN,O
once,RB,O
daily,RB,O
under,IN,O
steady-state,JJ,O
conditions,NNS,O
to,TO,O
healthy,JJ,O
volunteers,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
24,CD,O
",",",",O
each,DT,O
study,NN,O
-rrb-,-RRB-,O
.,.,.
,,
no,DT,O
differences,NNS,O
in,IN,O
adverse,JJ,O
events,NNS,O
or,CC,O
qtc,NN,O
interval,NN,O
were,VBD,O
observed,VBN,O
when,WRB,O
subjects,NNS,O
were,VBD,O
administered,VBN,O
fexofenadine,NN,D
hydrochloride,NN,O
alone,RB,O
or,CC,O
in,IN,O
combination,NN,O
with,IN,O
either,CC,O
erythromycin,NN,D
or,CC,O
ketoconazole,NN,D
.,.,.
,,
the,DT,O
findings,NNS,O
of,IN,O
these,DT,O
studies,NNS,O
are,VBP,O
summarized,VBN,O
in,IN,O
the,DT,O
following,VBG,O
table,NN,O
:,:,O
effects,NNS,O
on,IN,O
steady-state,JJ,O
fexofenadine,NN,D
pharmacokinetics,NNS,O
after,IN,O
7,CD,O
days,NNS,O
of,IN,O
co-administration,NN,O
with,IN,O
fexofenadine,NN,D
hydrochloride,NN,O
120,CD,O
mg,NN,O
every,DT,O
12,CD,O
hours,NNS,O
-lrb-,-LRB-,O
two,CD,O
times,NNS,O
the,DT,O
recommended,VBN,O
twice,RB,O
daily,RB,O
dose,NN,O
-rrb-,-RRB-,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
24,CD,O
.,.,.
,,
concomitant,JJ,O
drug,NN,O
.,.,.
,,
cmaxss,NN,O
-lrb-,-LRB-,O
peak,JJ,O
plasma,NN,O
concentration,NN,O
-rrb-,-RRB-,O
.,.,.
,,
aucss,NN,O
-lrb-,-LRB-,O
0-12h,NN,O
-rrb-,-RRB-,O
-lrb-,-LRB-,O
extent,NN,O
of,IN,O
systemic,JJ,O
exposure,NN,O
-rrb-,-RRB-,O
.,.,.
,,
erythromycin,NN,D
-lrb-,-LRB-,O
500,CD,O
mg,NN,O
every,DT,O
8,CD,O
hrs,NNS,O
.,.,.
,,
82,CD,O
%,NN,O
.,.,.
,,
109,CD,O
%,NN,O
.,.,.
,,
ketoconazole,NN,D
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
once,RB,O
daily,RB,O
.,.,.
,,
135,CD,O
%,NN,O
.,.,.
,,
164,CD,O
%,NN,O
.,.,.
,,
the,DT,O
changes,NNS,O
in,IN,O
plasma,NN,O
levels,NNS,O
were,VBD,O
within,IN,O
the,DT,O
range,NN,O
of,IN,O
plasma,NN,O
levels,NNS,O
achieved,VBN,O
in,IN,O
adequate,JJ,O
and,CC,O
well-controlled,JJ,O
clinical,JJ,O
trials,NNS,O
.,.,.
,,
the,DT,O
mechanism,NN,O
of,IN,O
these,DT,O
interactions,NNS,O
has,VBZ,O
been,VBN,O
evaluated,VBN,O
in,IN,O
in,FW,O
vitro,FW,O
",",",",O
in,FW,O
situ,FW,O
",",",",O
and,CC,O
in,FW,O
vivo,FW,O
animal,NN,O
models,NNS,O
.,.,.
,,
these,DT,O
studies,NNS,O
indicate,VBP,O
that,IN,O
ketoconazole,NN,D
or,CC,O
erythromycin,NN,D
co-administration,NN,O
enhances,VBZ,O
fexofenadine,NN,D
gastrointestinal,JJ,O
absorption,NN,O
.,.,.
,,
this,DT,O
observed,VBN,O
increase,NN,O
in,IN,O
the,DT,O
bioavailability,NN,O
of,IN,O
fexofenadine,NN,D
may,MD,O
be,VB,O
due,JJ,O
to,TO,O
transport-related,JJ,O
effects,NNS,O
",",",",O
such,JJ,O
as,IN,O
p-glycoprotein,NN,O
.,.,.
,,
in,FW,O
vivo,FW,O
animal,NN,O
studies,NNS,O
also,RB,O
suggest,VBP,O
that,IN,O
in,IN,O
addition,NN,O
to,TO,O
enhancing,VBG,O
absorption,NN,O
",",",",O
ketoconazole,NN,D
decreases,VBZ,O
fexofenadine,NN,D
gastrointestinal,JJ,O
secretion,NN,O
",",",",O
while,IN,O
erythromycin,NN,D
may,MD,O
also,RB,O
decrease,VB,O
biliary,JJ,O
excretion,NN,O
.,.,.
,,
drug,NN,O
interactions,NNS,O
with,IN,O
antacids,NNPS,G
administration,NNP,O
of,IN,O
120,CD,O
mg,NN,O
of,IN,O
fexofenadine,NN,D
hydrochloride,NN,O
-lrb-,-LRB-,O
2,CD,O
x,CC,O
60,CD,O
mg,NN,O
capsule,NN,O
-rrb-,-RRB-,O
within,IN,O
15,CD,O
minutes,NNS,O
of,IN,O
an,DT,O
aluminum,NN,D
and,CC,O
magnesium,NN,D
containing,VBG,O
antacid,NN,G
-lrb-,-LRB-,O
maalox,NNP,B
-rrb-,-RRB-,O
decreased,VBD,O
fexofenadine,NN,D
auc,NN,O
by,IN,O
41,CD,O
%,NN,O
and,CC,O
cmax,NN,O
by,IN,O
43,CD,O
%,NN,O
.,.,.
,,
allegra,NNP,B
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
closely,RB,O
in,IN,O
time,NN,O
with,IN,O
aluminum,NN,D
and,CC,O
magnesium,NN,D
containing,VBG,O
antacids,NNS,G
.,.,.
,,
interactions,NNS,O
with,IN,O
fruit,NNP,O
juices,NNP,O
fruit,NNP,O
juices,NNS,O
such,JJ,O
as,IN,O
grapefruit,NN,O
",",",",O
orange,NN,O
and,CC,O
apple,NN,O
may,MD,O
reduce,VB,O
the,DT,O
bioavailability,NN,O
and,CC,O
exposure,NN,O
of,IN,O
fexofenadine,NN,D
.,.,.
,,
this,DT,O
is,VBZ,O
based,VBN,O
on,IN,O
the,DT,O
results,NNS,O
from,IN,O
3,CD,O
clinical,JJ,O
studies,NNS,O
using,VBG,O
histamine,NN,D
induced,VBD,O
skin,NN,O
wheals,NNS,O
and,CC,O
flares,NNS,O
coupled,VBN,O
with,IN,O
population,NN,O
pharmacokinetic,JJ,O
analysis,NN,O
.,.,.
,,
the,DT,O
size,NN,O
of,IN,O
wheal,NN,O
and,CC,O
flare,NN,O
were,VBD,O
significantly,RB,O
larger,JJR,O
when,WRB,O
fexofenadine,NN,D
hydrochloride,NN,O
was,VBD,O
administered,VBN,O
with,IN,O
either,CC,O
grapefruit,NN,O
or,CC,O
orange,JJ,O
juices,NNS,O
compared,VBN,O
to,TO,O
water,NN,O
.,.,.
,,
based,VBN,O
on,IN,O
the,DT,O
literature,NN,O
reports,NNS,O
",",",",O
the,DT,O
same,JJ,O
effects,NNS,O
may,MD,O
be,VB,O
extrapolated,VBN,O
to,TO,O
other,JJ,O
fruit,NN,O
juices,NNS,O
such,JJ,O
as,IN,O
apple,NN,O
juice,NN,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
these,DT,O
observations,NNS,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
based,VBN,O
on,IN,O
the,DT,O
population,NN,O
pharmacokinetics,NNS,O
analysis,NN,O
of,IN,O
the,DT,O
combined,JJ,O
data,NNS,O
from,IN,O
grapefruit,NN,O
and,CC,O
orange,JJ,O
juices,NNS,O
studies,NNS,O
with,IN,O
the,DT,O
data,NNS,O
from,IN,O
a,DT,O
bioequivalence,NN,O
study,NN,O
",",",",O
the,DT,O
bioavailability,NN,O
of,IN,O
fexofenadine,NN,D
was,VBD,O
reduced,VBN,O
by,IN,O
36,CD,O
%,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
to,TO,O
maximize,VB,O
the,DT,O
effects,NNS,O
of,IN,O
fexofenadine,NN,D
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
allegra,NNP,B
should,MD,O
be,VB,O
taken,VBN,O
with,IN,O
wate,NN,O
.,.,.
,,
drug,NN,O
interactions,NNS,O
between,IN,O
neupogen,NNP,B
and,CC,O
other,JJ,O
drugs,NNS,D
have,VBP,O
not,RB,O
been,VBN,O
fully,RB,O
evaluated,VBN,O
.,.,.
,,
drugs,NNS,O
which,WDT,O
may,MD,O
potentiate,VB,O
the,DT,O
release,NN,O
of,IN,O
neutrophils,NNS,O
",",",",O
such,JJ,O
as,IN,O
lithium,NN,D
",",",",O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
no,DT,O
drug,NN,D
interactions,NNS,O
of,IN,O
clinical,JJ,O
importance,NN,O
have,VBP,O
been,VBN,O
identified,VBN,O
.,.,.
,,
finasteride,NN,D
does,VBZ,O
not,RB,O
appear,VB,O
to,TO,O
affect,VB,O
the,DT,O
cytochrome,NN,O
p450-linked,JJ,O
drug-metabolizing,JJ,O
enzyme,NN,O
system,NN,O
.,.,.
,,
compounds,NNS,O
that,WDT,O
have,VBP,O
been,VBN,O
tested,VBN,O
in,IN,O
man,NN,O
include,VBP,O
antipyrine,NN,D
",",",",O
digoxin,NN,D
",",",",O
propranolol,NN,D
",",",",O
theophylline,NN,D
",",",",O
and,CC,O
warfarin,NN,D
and,CC,O
no,DT,O
clinically,RB,O
meaningful,JJ,O
interactions,NNS,O
were,VBD,O
found,VBN,O
.,.,.
,,
other,JJ,O
concomitant,JJ,O
therapy,NN,O
although,IN,O
specific,JJ,O
interaction,NN,O
studies,NNS,O
were,VBD,O
not,RB,O
performed,VBN,O
",",",",O
finasteride,NN,D
doses,NNS,O
of,IN,O
1,CD,O
mg,NN,O
or,CC,O
more,JJR,O
were,VBD,O
concomitantly,RB,O
used,VBN,O
in,IN,O
clinical,JJ,O
studies,NNS,O
with,IN,O
acetaminophen,NN,D
",",",",O
acetylsalicylic,JJ,O
acid,NN,O
",",",",O
a-blockers,NNS,O
",",",",O
analgesics,NNS,G
",",",",O
angiotensin-converting,JJ,O
enzyme,NN,O
-lrb-,-LRB-,O
ace,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
",",",",O
anticonvulsants,NNS,G
",",",",O
benzodiazepines,NNS,G
",",",",O
beta,NN,O
blockers,NNS,O
",",",",O
calcium-channel,JJ,O
blockers,NNS,O
",",",",O
cardiac,JJ,O
nitrates,NNS,G
",",",",O
diuretics,NNS,G
",",",",O
h2,NN,O
antagonists,NNS,O
",",",",O
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
",",",",O
prostaglandin,NN,O
synthetase,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
also,RB,O
referred,VBN,O
to,TO,O
as,IN,O
nsaids,NNS,G
-rrb-,-RRB-,O
",",",",O
and,CC,O
quinolone,NN,G
anti-infectives,NNS,G
without,IN,O
evidence,NN,O
of,IN,O
clinically,RB,O
significant,JJ,O
adverse,JJ,O
interactions,NNS,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
finasteride,NNP,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
circulating,VBG,O
levels,NNS,O
of,IN,O
cortisol,NN,O
",",",",O
thyroid-stimulating,JJ,O
hormone,NN,O
",",",",O
or,CC,O
thyroxine,NN,D
",",",",O
nor,CC,O
did,VBD,O
it,PRP,O
affect,VB,O
the,DT,O
plasma,NN,O
lipid,NN,O
profile,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
total,JJ,O
cholesterol,NN,O
",",",",O
low-density,JJ,O
lipoproteins,NNS,O
",",",",O
high-density,JJ,O
lipoproteins,NNS,O
and,CC,O
triglycerides,NNS,O
-rrb-,-RRB-,O
or,CC,O
bone,NN,O
mineral,NN,O
density,NN,O
.,.,.
,,
in,IN,O
studies,NNS,O
with,IN,O
finasteride,NN,D
",",",",O
no,DT,O
clinically,RB,O
meaningful,JJ,O
changes,NNS,O
in,IN,O
luteinizing,VBG,O
hormone,NN,O
-lrb-,-LRB-,O
lh,NN,O
-rrb-,-RRB-,O
",",",",O
follicle-stimulating,JJ,O
hormone,NN,O
-lrb-,-LRB-,O
fsh,NN,O
-rrb-,-RRB-,O
or,CC,O
prolactin,NN,O
were,VBD,O
detected,VBN,O
.,.,.
,,
in,IN,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
treatment,NN,O
with,IN,O
finasteride,NN,D
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
response,NN,O
of,IN,O
lh,NN,O
and,CC,O
fsh,NN,O
to,TO,O
gonadotropin-releasing,NN,O
hormone,NN,O
indicating,VBG,O
that,IN,O
the,DT,O
hypothalamic-pituitary-testicular,JJ,O
axis,NN,O
was,VBD,O
not,RB,O
affected,VBN,O
.,.,.
,,
in,IN,O
clinical,JJ,O
studies,NNS,O
with,IN,O
propecia,NN,B
-lrb-,-LRB-,O
finasteride,NN,D
",",",",O
1,CD,O
mg,NN,O
-rrb-,-RRB-,O
in,IN,O
men,NNS,O
18-41,CD,O
years,NNS,O
of,IN,O
age,NN,O
",",",",O
the,DT,O
mean,JJ,O
value,NN,O
of,IN,O
serum,NN,O
prostate-specific,JJ,O
antigen,NN,O
-lrb-,-LRB-,O
psa,NN,O
-rrb-,-RRB-,O
decreased,VBD,O
from,IN,O
0.7,CD,O
ng/ml,NN,O
at,IN,O
baseline,NN,O
to,TO,O
0.5,CD,O
ng/ml,NN,O
at,IN,O
month,NNP,O
12,CD,O
.,.,.
,,
further,RB,O
",",",",O
in,IN,O
clinical,JJ,O
studies,NNS,O
with,IN,O
proscar,NN,B
-lrb-,-LRB-,O
finasteride,NN,D
",",",",O
5,CD,O
mg,NN,O
-rrb-,-RRB-,O
when,WRB,O
used,VBN,O
in,IN,O
older,JJR,O
men,NNS,O
who,WP,O
have,VBP,O
benign,JJ,O
prostatic,JJ,O
hyperplasia,NN,O
-lrb-,-LRB-,O
bph,NNP,O
-rrb-,-RRB-,O
",",",",O
psa,NN,O
levels,NNS,O
are,VBP,O
decreased,VBN,O
by,IN,O
approximately,RB,O
50,CD,O
%,NN,O
.,.,.
,,
these,DT,O
findings,NNS,O
should,MD,O
be,VB,O
taken,VBN,O
into,IN,O
account,NN,O
for,IN,O
proper,JJ,O
interpretation,NN,O
of,IN,O
serum,NN,O
psa,NN,O
when,WRB,O
evaluating,VBG,O
men,NNS,O
treated,VBN,O
with,IN,O
finasteride,NN,D
.,.,.
,,
drug,NN,O
interactions,NNS,O
.,.,.
,,
tambocor,NN,B
has,VBZ,O
been,VBN,O
administered,VBN,O
to,TO,O
patients,NNS,O
receiving,VBG,O
digitalis,NN,G
preparations,NNS,O
or,CC,O
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
without,IN,O
adverse,JJ,O
effects,NNS,O
.,.,.
,,
during,IN,O
administration,NN,O
of,IN,O
multiple,JJ,O
oral,JJ,O
doses,NNS,O
of,IN,O
tambocor,NN,B
to,TO,O
healthy,JJ,O
subjects,NNS,O
stabilized,VBD,O
on,IN,O
a,DT,O
maintenance,NN,O
dose,NN,O
of,IN,O
digoxin,NN,D
",",",",O
a,DT,O
13,CD,O
%,NN,O
-19,CD,O
%,NN,O
increase,NN,O
in,IN,O
plasma,NN,O
digoxin,NN,D
levels,NNS,O
occurred,VBD,O
at,IN,O
six,CD,O
hours,NNS,O
postdose,NN,O
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
involving,VBG,O
healthy,JJ,O
subjects,NNS,O
receiving,VBG,O
tambocor,NN,B
and,CC,O
propranolol,NN,D
concurrently,RB,O
",",",",O
plasma,NN,O
flecainide,NN,D
levels,NNS,O
were,VBD,O
increased,VBN,O
about,RB,O
20,CD,O
%,NN,O
and,CC,O
propranolol,NN,D
levels,NNS,O
were,VBD,O
increased,VBN,O
about,IN,O
30,CD,O
%,NN,O
compared,VBN,O
to,TO,O
control,VB,O
values,NNS,O
.,.,.
,,
in,IN,O
this,DT,O
formal,JJ,O
interaction,NN,O
study,NN,O
",",",",O
tambocor,NN,B
and,CC,O
propranolol,NN,D
were,VBD,O
each,DT,O
found,VBN,O
to,TO,O
have,VB,O
negative,JJ,O
inotropic,JJ,O
effects,NNS,O
.,.,.
,,
when,WRB,O
the,DT,O
drugs,NNS,D
were,VBD,O
administered,VBN,O
together,RB,O
",",",",O
the,DT,O
effects,NNS,O
were,VBD,O
additive,JJ,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
tambocor,NN,B
and,CC,O
propranolol,NN,D
on,IN,O
the,DT,O
pr,NN,O
interval,NN,O
were,VBD,O
less,JJR,O
than,IN,O
additive,JJ,O
.,.,.
,,
in,IN,O
tambocor,NN,B
clinical,JJ,O
trials,NNS,O
",",",",O
patients,NNS,O
who,WP,O
were,VBD,O
receiving,VBG,O
beta,NN,O
blockers,NNS,O
concurrently,RB,O
did,VBD,O
not,RB,O
experience,VB,O
an,DT,O
increased,VBN,O
incidence,NN,O
of,IN,O
side,JJ,O
effects,NNS,O
.,.,.
,,
nevertheless,RB,O
",",",",O
the,DT,O
possibility,NN,O
of,IN,O
additive,JJ,O
negative,JJ,O
inotropic,JJ,O
effects,NNS,O
of,IN,O
beta,NN,O
blockers,NNS,O
and,CC,O
flecainide,NN,D
should,MD,O
be,VB,O
recognized,VBN,O
.,.,.
,,
flecainide,NNP,D
is,VBZ,O
not,RB,O
extensively,RB,O
bound,VBN,O
to,TO,O
plasma,NN,O
proteins,NNS,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
with,IN,O
several,JJ,O
drugs,NNS,D
which,WDT,O
may,MD,O
be,VB,O
administered,VBN,O
concomitantly,RB,O
showed,VBD,O
that,IN,O
the,DT,O
extent,NN,O
of,IN,O
flecainide,NN,D
binding,NN,O
to,TO,O
human,JJ,O
plasma,NN,O
proteins,NNS,O
is,VBZ,O
either,CC,O
unchanged,JJ,O
or,CC,O
only,RB,O
slightly,RB,O
less,RBR,O
.,.,.
,,
consequently,RB,O
",",",",O
interactions,NNS,O
with,IN,O
other,JJ,O
drugs,NNS,D
which,WDT,O
are,VBP,O
highly,RB,O
protein,NN,O
bound,VBD,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
anticoagulants,NNS,G
-rrb-,-RRB-,O
would,MD,O
not,RB,O
be,VB,O
expected,VBN,O
.,.,.
,,
tambocor,NN,B
has,VBZ,O
been,VBN,O
used,VBN,O
in,IN,O
a,DT,O
large,JJ,O
number,NN,O
of,IN,O
patients,NNS,O
receiving,VBG,O
diuretics,NNS,G
without,IN,O
apparent,JJ,O
interaction,NN,O
.,.,.
,,
limited,JJ,O
data,NNS,O
in,IN,O
patients,NNS,O
receiving,VBG,O
known,JJ,O
enzyme,NN,O
inducers,NNS,O
-lrb-,-LRB-,O
phenytoin,NN,D
",",",",O
phenobarbital,NN,D
",",",",O
carbamazepine,NN,D
-rrb-,-RRB-,O
indicate,VBP,O
only,RB,O
a,DT,O
30,CD,O
%,NN,O
increase,NN,O
in,IN,O
the,DT,O
rate,NN,O
of,IN,O
flecainide,NN,D
elimination,NN,O
.,.,.
,,
in,IN,O
healthy,JJ,O
subjects,NNS,O
receiving,VBG,O
cimetidine,NN,D
-lrb-,-LRB-,O
1,CD,O
gm,NN,O
daily,JJ,O
-rrb-,-RRB-,O
for,IN,O
one,CD,O
week,NN,O
",",",",O
plasma,NN,O
flecainide,NN,D
levels,NNS,O
increased,VBN,O
by,IN,O
about,IN,O
30,CD,O
%,NN,O
and,CC,O
half-life,NN,O
increased,VBN,O
by,IN,O
about,RB,O
10,CD,O
%,NN,O
.,.,.
,,
when,WRB,O
amiodarone,NN,D
is,VBZ,O
added,VBN,O
to,TO,O
flecainide,NN,D
therapy,NN,O
",",",",O
plasma,NN,O
flecainide,NN,D
levels,NNS,O
may,MD,O
increase,VB,O
two-fold,RB,O
or,CC,O
more,RBR,O
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
if,IN,O
flecainide,NN,D
dosage,NN,O
is,VBZ,O
not,RB,O
reduced,VBN,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
inhibit,VBP,O
cytochrome,NN,O
p450iid6,NN,O
",",",",O
such,JJ,O
as,IN,O
quinidine,NN,D
",",",",O
might,MD,O
increase,VB,O
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
flecainide,NN,D
in,IN,O
patients,NNS,O
that,WDT,O
are,VBP,O
on,IN,O
chronic,JJ,O
flecainide,NN,D
therapy,NN,O
.,.,.
,,
especially,RB,O
if,IN,O
these,DT,O
patients,NNS,O
are,VBP,O
extensive,JJ,O
metabolizers,NNS,O
.,.,.
,,
there,EX,O
has,VBZ,O
been,VBN,O
little,JJ,O
experience,NN,O
with,IN,O
the,DT,O
coadministration,NN,O
of,IN,O
tambocor,NN,B
and,CC,O
either,CC,O
disopyramide,NN,D
or,CC,O
verapamil,NN,D
.,.,.
,,
because,IN,O
both,DT,O
of,IN,O
these,DT,O
drugs,NNS,D
have,VBP,O
negative,JJ,O
inotropic,JJ,O
properties,NNS,O
and,CC,O
the,DT,O
effects,NNS,O
of,IN,O
coadministration,NN,O
with,IN,O
tambocor,NN,B
are,VBP,O
unknown,JJ,O
",",",",O
neither,CC,O
disopyramide,NN,D
nor,CC,O
verapamil,NN,D
should,MD,O
be,VB,O
administered,VBN,O
concurrently,RB,O
with,IN,O
tambocor,NN,B
unless,IN,O
",",",",O
in,IN,O
the,DT,O
judgment,NN,O
of,IN,O
the,DT,O
physician,NN,O
",",",",O
the,DT,O
benefits,NNS,O
of,IN,O
this,DT,O
combination,NN,O
outweigh,VBP,O
the,DT,O
risks,NNS,O
.,.,.
,,
there,EX,O
has,VBZ,O
been,VBN,O
too,RB,O
little,JJ,O
experience,NN,O
with,IN,O
the,DT,O
coadministration,NN,O
of,IN,O
tambocor,NN,B
with,IN,O
nifedipine,NN,D
or,CC,O
diltiazem,NN,D
to,TO,O
recommend,VB,O
concomitant,JJ,O
use,NN,O
.,.,.
,,
combination,NN,O
therapy,NN,O
:,:,O
any,DT,O
form,NN,O
of,IN,O
therapy,NN,O
which,WDT,O
adds,VBZ,O
to,TO,O
the,DT,O
stress,NN,O
of,IN,O
the,DT,O
patient,NN,O
",",",",O
interferes,VBZ,O
with,IN,O
nutrition,NN,O
or,CC,O
depresses,VBZ,O
bone,NN,O
marrow,NN,O
function,NN,O
will,MD,O
increase,VB,O
the,DT,O
toxicity,NN,O
of,IN,O
floxuridine,NN,D
.,.,.
,,
cytosine,NN,O
arabinoside,NN,O
",",",",O
a,DT,O
cytostatic,JJ,O
agent,NN,O
",",",",O
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
inactivate,VB,O
the,DT,O
antifungal,JJ,O
activity,NN,O
of,IN,O
flucytosine,NN,D
by,IN,O
competitive,JJ,O
inhibition,NN,O
.,.,.
,,
drugs,NNS,O
which,WDT,O
impair,VBP,O
glomerular,JJ,O
filtration,NN,O
may,MD,O
prolong,VB,O
the,DT,O
biological,JJ,O
half-life,NN,O
of,IN,O
flucytosine,NN,D
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
:,:,O
measurement,NN,O
of,IN,O
serum,NN,O
creatinine,NN,O
levels,NNS,O
should,MD,O
be,VB,O
determined,VBN,O
by,IN,O
the,DT,O
jaffe,NNP,O
reaction,NN,O
",",",",O
since,IN,O
ancobon,NNP,B
does,VBZ,O
not,RB,O
interfere,VB,O
with,IN,O
the,DT,O
determination,NN,O
of,IN,O
creatinine,NN,O
values,NNS,O
by,IN,O
this,DT,O
method,NN,O
.,.,.
,,
most,JJS,O
automated,JJ,O
equipment,NN,O
for,IN,O
measurement,NN,O
of,IN,O
creatinine,NN,O
makes,VBZ,O
use,NN,O
of,IN,O
the,DT,O
jaffe,NNP,O
reaction,NN,O
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
fludara,NNP,B
for,IN,O
injection,NNP,O
in,IN,O
combination,NN,O
with,IN,O
pentostatin,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
due,JJ,O
to,TO,O
the,DT,O
risk,NN,O
of,IN,O
severe,JJ,O
pulmonary,JJ,O
toxicity,NN,O
.,.,.
,,
when,WRB,O
administered,VBN,O
concurrently,RB,O
",",",",O
the,DT,O
following,VBG,O
drugs,NNS,D
may,MD,O
interact,VB,O
with,IN,O
adrenal,JJ,O
corticosteroids,NNS,G
.,.,.
,,
amphotericin,NN,D
b,NN,O
or,CC,O
potassium-depleting,JJ,O
diuretics,NNS,G
-lrb-,-LRB-,O
benzothiadiazines,NNS,G
and,CC,O
related,JJ,O
drugs,NNS,D
",",",",O
ethacrynic,JJ,O
acid,NN,O
and,CC,O
furosemide,NN,D
-rrb-,-RRB-,O
enhanced,VBD,O
hypokalemia,NN,O
.,.,.
,,
check,VB,O
serum,NN,O
potassium,NN,D
levels,NNS,O
at,IN,O
frequent,JJ,O
intervals,NNS,O
;,:,O
.,.,.
,,
use,NN,O
potassium,NN,D
supplements,NNS,O
if,IN,O
necessary,JJ,O
.,.,.
,,
digitalis,NN,G
glycosides,NNS,G
enhanced,VBD,O
possibility,NN,O
of,IN,O
arrhythmias,NNS,O
or,CC,O
digitalis,NN,G
toxicity,NN,O
associated,VBN,O
with,IN,O
hypokalemia,NN,O
.,.,.
,,
monitor,NNP,O
serum,NN,O
potassium,NN,D
levels,NNS,O
;,:,O
.,.,.
,,
use,NN,O
potassium,NN,D
supplements,NNS,O
if,IN,O
necessary,JJ,O
.,.,.
,,
oral,JJ,O
anticoagulants,NNS,G
decreased,VBD,O
prothrombin,NN,O
time,NN,O
response,NN,O
.,.,.
,,
monitor,NNP,O
prothrombin,NN,O
levels,NNS,O
and,CC,O
adjust,VBP,O
anticoagulant,JJ,G
dosage,NN,O
accordingly,RB,O
.,.,.
,,
antidiabetic,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
oral,JJ,O
agents,NNS,O
and,CC,O
insulin,NN,D
-rrb-,-RRB-,O
diminished,VBD,O
antidiabetic,JJ,D
effect,NN,O
.,.,.
,,
monitor,NNP,O
for,IN,O
symptoms,NNS,O
of,IN,O
hyperglycemia,NN,O
;,:,O
.,.,.
,,
adjust,VBP,O
dosage,NN,O
of,IN,O
antidiabetic,JJ,D
drug,NN,D
upward,RB,O
if,IN,O
necessary,JJ,O
.,.,.
,,
aspirin,NN,B
increased,VBD,O
ulcerogenic,JJ,O
effect,NN,O
.,.,.
,,
decreased,VBN,O
pharmacologic,JJ,O
effect,NN,O
of,IN,O
aspirin,NN,B
.,.,.
,,
rarely,RB,O
salicylate,NN,G
toxicity,NN,O
may,MD,O
occur,VB,O
in,IN,O
patients,NNS,O
who,WP,O
discontinue,VBP,O
steroids,NNS,G
after,IN,O
concurrent,JJ,O
high-dose,JJ,O
aspirin,NN,B
therapy,NN,O
.,.,.
,,
monitor,NNP,O
salicylate,NN,G
levels,NNS,O
or,CC,O
the,DT,O
therapeutic,JJ,O
effect,NN,O
for,IN,O
which,WDT,O
aspirin,NN,B
is,VBZ,O
given,VBN,O
.,.,.
,,
adjust,VBP,O
salicylate,NN,G
dosage,NN,O
accordingly,RB,O
if,IN,O
effect,NN,O
is,VBZ,O
altered,VBN,O
.,.,.
,,
barbiturates,NNP,G
",",",",O
phenytoin,NN,D
",",",",O
or,CC,O
rifampin,NN,D
increased,VBD,O
metabolic,JJ,O
clearance,NN,O
of,IN,O
fludrocortisone,NN,O
acetate,NN,O
because,IN,O
of,IN,O
the,DT,O
induction,NN,O
of,IN,O
hepatic,JJ,O
enzymes,NNS,O
.,.,.
,,
observe,VB,O
the,DT,O
patient,NN,O
for,IN,O
possible,JJ,O
diminished,JJ,O
effect,NN,O
of,IN,O
steroid,NN,G
and,CC,O
increase,VB,O
the,DT,O
steroid,NN,G
dosage,NN,O
accordingly,RB,O
.,.,.
,,
anabolic,JJ,O
steroids,NNS,G
-lrb-,-LRB-,O
particularly,RB,O
c-17,JJ,O
alkylated,VBN,O
androgens,NNS,G
such,JJ,O
as,IN,O
oxymetholone,NN,D
",",",",O
methandrostenolone,NN,D
",",",",O
norethandrolone,NN,D
",",",",O
and,CC,O
similar,JJ,O
compounds,NNS,O
-rrb-,-RRB-,O
enhanced,VBD,O
tendency,NN,O
toward,IN,O
edema,NN,O
.,.,.
,,
use,NNP,O
caution,NN,O
when,WRB,O
giving,VBG,O
these,DT,O
drugs,NNS,D
together,RB,O
",",",",O
especially,RB,O
in,IN,O
patients,NNS,O
with,IN,O
hepatic,JJ,O
or,CC,O
cardiac,JJ,O
disease,NN,O
.,.,.
,,
vaccines,NNS,G
neurological,JJ,O
complications,NNS,O
and,CC,O
lack,NN,O
of,IN,O
antibody,NN,O
response,NN,O
.,.,.
,,
estrogen,NN,G
increased,VBD,O
levels,NNS,O
of,IN,O
corticosteroid-binding,JJ,O
globulin,NN,O
",",",",O
thereby,RB,O
increasing,VBG,O
the,DT,O
bound,VBN,O
-lrb-,-LRB-,O
inactive,JJ,O
-rrb-,-RRB-,O
fraction,NN,O
.,.,.
,,
this,DT,O
effect,NN,O
is,VBZ,O
at,IN,O
least,JJS,O
balanced,VBN,O
by,IN,O
decreased,VBN,O
metabolism,NN,O
of,IN,O
corticosteroids,NNS,G
.,.,.
,,
when,WRB,O
estrogen,NN,G
therapy,NN,O
is,VBZ,O
initiated,VBN,O
",",",",O
a,DT,O
reduction,NN,O
in,IN,O
corticosteroid,NN,G
dosage,NN,O
may,MD,O
be,VB,O
required,VBN,O
",",",",O
and,CC,O
increased,VBD,O
amounts,NNS,O
may,MD,O
be,VB,O
required,VBN,O
when,WRB,O
estrogen,NN,G
is,VBZ,O
terminated,VBN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
corticosteroids,NNS,G
may,MD,O
affect,VB,O
the,DT,O
nitrobluetetrazolium,JJ,O
test,NN,O
for,IN,O
bacterial,JJ,O
infection,NN,O
and,CC,O
produce,VBP,O
false-negative,JJ,O
result,NN,O
.,.,.
,,
interaction,NN,O
with,IN,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressants,NNS,O
other,JJ,O
than,IN,O
benzodiazepines,NNS,G
has,VBZ,O
not,RB,O
been,VBN,O
specifically,RB,O
studied,VBN,O
.,.,.
,,
however,RB,O
",",",",O
no,DT,O
deleterious,JJ,O
interactions,NNS,O
were,VBD,O
seen,VBN,O
when,WRB,O
romazicon,NNP,B
was,VBD,O
administered,VBN,O
after,IN,O
narcotics,NNS,G
",",",",O
inhalational,JJ,O
anesthetics,NNS,G
",",",",O
muscle,NN,O
relaxants,NNS,O
and,CC,O
muscle,NN,O
relaxant,NN,O
antagonists,NNS,O
administered,VBN,O
in,IN,O
conjunction,NN,O
with,IN,O
sedation,NN,O
or,CC,O
anesthesia,NN,D
.,.,.
,,
particular,JJ,O
caution,NN,O
is,VBZ,O
necessary,JJ,O
when,WRB,O
using,VBG,O
romazicon,NNP,B
in,IN,O
cases,NNS,O
of,IN,O
mixed,JJ,O
drug,NN,D
overdosage,NN,O
since,IN,O
the,DT,O
toxic,JJ,O
effects,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
convulsions,NNS,O
and,CC,O
cardiac,JJ,O
dysrhythmias,NNS,O
-rrb-,-RRB-,O
of,IN,O
other,JJ,O
drugs,NNS,D
taken,VBN,O
in,IN,O
overdose,NN,O
-lrb-,-LRB-,O
especially,RB,O
cyclic,JJ,O
antidepressants,NNS,G
-rrb-,-RRB-,O
may,MD,O
emerge,VB,O
with,IN,O
the,DT,O
reversal,NN,O
of,IN,O
the,DT,O
benzodiazepine,NN,G
effect,NN,O
by,IN,O
flumazenil,NN,D
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
romazicon,NNP,B
is,VBZ,O
not,RB,O
recommended,VBN,O
in,IN,O
epileptic,JJ,O
patients,NNS,O
who,WP,O
have,VBP,O
been,VBN,O
receiving,VBG,O
benzodiazepine,NN,G
treatment,NN,O
for,IN,O
a,DT,O
prolonged,JJ,O
period,NN,O
.,.,.
,,
although,IN,O
romazicon,NN,B
exerts,VBZ,O
a,DT,O
slight,JJ,O
intrinsic,JJ,O
anticonvulsant,JJ,G
effect,NN,O
",",",",O
its,PRP$,O
abrupt,JJ,O
suppression,NN,O
of,IN,O
the,DT,O
protective,JJ,O
effect,NN,O
of,IN,O
a,DT,O
benzodiazepine,NN,G
agonist,NN,O
can,MD,O
give,VB,O
rise,VB,O
to,TO,O
convulsions,NNS,O
in,IN,O
epileptic,JJ,O
patients,NNS,O
.,.,.
,,
romazicon,NN,B
blocks,VBZ,O
the,DT,O
central,JJ,O
effects,NNS,O
of,IN,O
benzodiazepines,NNS,G
by,IN,O
competitive,JJ,O
interaction,NN,O
at,IN,O
the,DT,O
receptor,NN,D
level,NN,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
nonbenzodiazepine,JJ,O
agonists,NNS,O
at,IN,O
benzodiazepine,NN,G
receptors,NNS,O
",",",",O
such,JJ,O
as,IN,O
zopiclone,NN,D
",",",",O
triazolopyridazines,NNS,O
and,CC,O
others,NNS,O
",",",",O
are,VBP,O
also,RB,O
blocked,VBN,O
by,IN,O
romazicon,NN,B
.,.,.
,,
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
benzodiazepines,NNS,G
are,VBP,O
unaltered,JJ,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
flumazenil,NN,D
and,CC,O
vice,NN,O
versa,RB,O
.,.,.
,,
there,EX,O
is,VBZ,O
no,DT,O
pharmacokinetic,JJ,O
interaction,NN,O
between,IN,O
ethanol,NN,D
and,CC,O
flumazenil,NN,D
.,.,.
,,
use,NN,O
in,IN,O
ambulatory,JJ,O
patients,NNS,O
the,DT,O
effects,NNS,O
of,IN,O
romazicon,NN,B
may,MD,O
wear,VB,O
off,RP,O
before,IN,O
a,DT,O
long-acting,JJ,O
benzodiazepine,NN,G
is,VBZ,O
completely,RB,O
cleared,VBN,O
from,IN,O
the,DT,O
body,NN,O
.,.,.
,,
in,IN,O
general,JJ,O
",",",",O
if,IN,O
a,DT,O
patient,NN,O
shows,VBZ,O
no,DT,O
signs,NNS,O
of,IN,O
sedation,NN,O
within,IN,O
2,CD,O
hours,NNS,O
after,IN,O
a,DT,O
1-mg,JJ,O
dose,NN,O
of,IN,O
flumazenil,NN,D
",",",",O
serious,JJ,O
resedation,NN,O
at,IN,O
a,DT,O
later,JJ,O
time,NN,O
is,VBZ,O
unlikely,JJ,O
.,.,.
,,
an,DT,O
adequate,JJ,O
period,NN,O
of,IN,O
observation,NN,O
must,MD,O
be,VB,O
provided,VBN,O
for,IN,O
any,DT,O
patient,NN,O
in,IN,O
whom,WP,O
either,CC,O
long-acting,JJ,O
benzodiazepines,NNS,G
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
diazepam,NN,D
-rrb-,-RRB-,O
or,CC,O
large,JJ,O
doses,NNS,O
of,IN,O
short-acting,JJ,O
benzodiazepines,NNS,G
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
10,CD,O
mg,NN,O
of,IN,O
midazolam,NN,D
-rrb-,-RRB-,O
have,VBP,O
been,VBN,O
used,VBN,O
.,.,.
,,
because,IN,O
of,IN,O
the,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
adverse,JJ,O
reactions,NNS,O
in,IN,O
patients,NNS,O
who,WP,O
have,VBP,O
been,VBN,O
taking,VBG,O
benzodiazepines,NNS,G
on,IN,O
a,DT,O
regular,JJ,O
basis,NN,O
",",",",O
it,PRP,O
is,VBZ,O
particularly,RB,O
important,JJ,O
that,IN,O
physicians,NNS,O
query,NN,O
patients,NNS,O
or,CC,O
their,PRP$,O
guardians,NNS,O
carefully,RB,O
about,IN,O
benzodiazepine,NN,G
",",",",O
alcohol,NN,D
and,CC,O
sedative,NN,G
use,VBP,O
as,IN,O
part,NN,O
of,IN,O
the,DT,O
history,NN,O
prior,RB,O
to,TO,O
any,DT,O
procedure,NN,O
in,IN,O
which,WDT,O
the,DT,O
use,NN,O
of,IN,O
romazicon,NNP,B
is,VBZ,O
planned,VBN,O
.,.,.
,,
no,DT,O
information,NN,O
available,JJ,O
.,.,.
,,
do,VB,O
not,RB,O
take,VB,O
this,DT,O
medicine,NN,O
with,IN,O
thioridizine,NN,O
",",",",O
or,CC,O
within,IN,O
5,CD,O
weeks,NNS,O
of,IN,O
taking,VBG,O
fluoxetine,NN,D
.,.,.
,,
talk,NN,O
to,TO,O
your,PRP$,O
doctor,NN,O
if,IN,O
you,PRP,O
are,VBP,O
taking,VBG,O
certain,JJ,O
antibiotics,NNS,G
such,JJ,O
as,IN,O
erythromycin,NN,D
",",",",O
clarithromycin,NN,D
or,CC,O
azithromycin,NN,D
.,.,.
,,
this,DT,O
medicine,NN,O
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
with,IN,O
mao,NN,O
inhibitors,NNS,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
taking,VBG,O
this,DT,O
medicine,NN,O
certain,JJ,O
antibiotics,NNS,G
",",",",O
such,JJ,O
as,IN,O
erythromycin,NN,D
",",",",O
clarithromycin,NN,D
",",",",O
or,CC,O
azithromycin,NN,D
.,.,.
,,
this,DT,O
medicine,NN,O
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
with,IN,O
mao,NN,O
inhibitors,NNS,O
.,.,.
,,
if,IN,O
you,PRP,O
think,VBP,O
you,PRP,O
are,VBP,O
taking,VBG,O
an,DT,O
mao,NNP,O
inhibitor,NN,O
talk,NN,O
to,TO,O
your,PRP$,O
doctor,NN,O
or,CC,O
pharmacist,NN,O
.,.,.
,,
do,VB,O
not,RB,O
take,VB,O
this,DT,O
medicine,NN,O
with,IN,O
st.,NNP,O
johns,NNP,O
wort,NNP,O
because,IN,O
of,IN,O
the,DT,O
additive,JJ,O
effects,NNS,O
of,IN,O
sertonin,NN,O
.,.,.
,,
this,DT,O
medication,NN,O
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
with,IN,O
mao,NN,O
inhibitors,NNS,O
.,.,.
,,
your,PRP$,O
doctor,NN,O
or,CC,O
pharmacist,NN,O
can,MD,O
give,VB,O
you,PRP,O
more,JJR,O
information,NN,O
on,IN,O
mao,NN,O
inhibitors,NNS,O
.,.,.
,,
wait,VB,O
5,CD,O
weeks,NNS,O
after,IN,O
stopping,VBG,O
escitalopram,NN,D
before,IN,O
starting,VBG,O
a,DT,O
non-selective,JJ,O
mao,NNP,O
inhibitor,NN,O
.,.,.
,,
wait,VB,O
2,CD,O
weeks,NNS,O
after,IN,O
stopping,VBG,O
an,DT,O
mao,NNP,O
inhibitor,NN,O
before,IN,O
starting,VBG,O
escitalopram,NN,D
.,.,.
,,
if,IN,O
you,PRP,O
are,VBP,O
taking,VBG,O
medications,NNS,O
for,IN,O
migraines,NNS,O
such,JJ,O
as,IN,O
imitrex,NNP,B
",",",",O
talk,NN,O
to,TO,O
your,PRP$,O
doctor,NN,O
before,IN,O
starting,VBG,O
this,DT,O
medicine,NN,O
.,.,.
,,
if,IN,O
you,PRP,O
are,VBP,O
taking,VBG,O
a,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
",",",",O
talk,NN,O
to,TO,O
your,PRP$,O
doctor,NN,O
before,IN,O
taking,VBG,O
this,DT,O
medicine,NN,O
.,.,.
,,
st.,NNP,O
john,NNP,O
s,VBZ,O
wort,NNP,O
should,MD,O
be,VB,O
avoided,VBN,O
while,IN,O
taking,VBG,O
this,DT,O
medicine,NN,O
due,JJ,O
to,TO,O
the,DT,O
additive,JJ,O
effects,NNS,O
of,IN,O
serotonin,NN,O
.,.,.
,,
tell,VB,O
your,PRP$,O
doctor,NN,O
if,IN,O
you,PRP,O
are,VBP,O
taking,VBG,O
any,DT,O
of,IN,O
the,DT,O
following,VBG,O
drugs,NNS,D
:,:,O
blood,NN,O
thinners,NNS,O
-lrb-,-LRB-,O
coumadin,NN,B
-rrb-,-RRB-,O
other,JJ,O
antidepressants,NNS,G
metoprolol,NN,D
antihistamines,NNS,G
carbamazepine,NN,D
-lrb-,-LRB-,O
tegretol,NN,B
-rrb-,-RRB-,O
cimetidine,NN,D
-lrb-,-LRB-,O
tagamet,NN,B
-rrb-,-RRB-,O
estrogens,NNS,G
fluoxetine,NN,D
-lrb-,-LRB-,O
prozac,NNP,B
-rrb-,-RRB-,O
intraconazole,NN,D
-lrb-,-LRB-,O
sporanox,NN,B
-rrb-,-RRB-,O
ketoconazole,NN,D
-lrb-,-LRB-,O
nizoral,NN,B
-rrb-,-RRB-,O
levodopa,NN,D
lithium,NN,D
muscle,NN,O
relaxants,NNS,O
birth,NN,O
control,NN,O
pills,NNS,O
sleeping,VBG,O
pills,NNS,O
thyroid,NN,G
medication,NN,O
.,.,.
,,
androgens,NNS,G
may,MD,O
increase,VB,O
sensitivity,NN,O
to,TO,O
oral,JJ,O
anticoagulahts,NNS,O
.,.,.
,,
dosage,NN,O
of,IN,O
the,DT,O
anticoagulant,NN,G
may,MD,O
require,VB,O
reduction,NN,O
in,IN,O
order,NN,O
to,TO,O
maintain,VB,O
satisfactory,JJ,O
therapeutic,JJ,O
hypoprothrombinemia,NN,O
.,.,.
,,
concurrent,JJ,O
administration,NN,O
of,IN,O
oxyphenbutazone,NN,D
and,CC,O
androgens,NNS,G
may,MD,O
result,VB,O
in,IN,O
elevated,JJ,O
serum,NN,O
levels,NNS,O
of,IN,O
oxyphenbutazone,NN,D
.,.,.
,,
in,IN,O
diabetic,JJ,O
patients,NNS,O
",",",",O
the,DT,O
metabolic,JJ,O
effects,NNS,O
of,IN,O
androgens,NNS,G
may,MD,O
decrease,VB,O
blood,NN,O
glucose,NN,O
and,CC,O
therefore,RB,O
",",",",O
insulin,NN,D
requirements,NNS,O
.,.,.
,,
drug,NN,O
interactions,NNS,O
:,:,O
flupenthixol,NN,D
may,MD,O
interact,VB,O
with,IN,O
some,DT,O
drugs,NNS,D
",",",",O
like,IN,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
maoi,NN,G
-rrb-,-RRB-,O
:,:,O
maoi,NNP,G
could,MD,O
theoretically,RB,O
affect,VB,O
flupenthixol,NN,D
pharmacodynamics,NNS,O
-,:,O
arecoline,NN,D_n
-,:,O
eproxindine,NN,O
-,:,O
ethanol,NN,D
:,:,O
flupenthixol,NN,D
and,CC,O
ethanol,NN,D
cause,VBP,O
additive,JJ,O
cns,NN,O
depression,NN,O
-,:,O
tricyclic,JJ,O
antidepressants,NNS,G
:,:,O
flupenthixol,NN,D
increases,VBZ,O
the,DT,O
effect,NN,O
of,IN,O
tricyclic,JJ,O
antidepressant,JJ,G
.,.,.
,,
antacids,NNS,G
:,:,O
administration,NN,O
of,IN,O
flurbiprofen,NN,D
to,TO,O
volunteers,NNS,O
under,IN,O
fasting,NN,O
conditions,NNS,O
",",",",O
or,CC,O
with,IN,O
antacid,NN,G
suspension,NN,O
yielded,VBD,O
similar,JJ,O
serum,NN,O
flurbiprofen,NN,D
time,NN,O
profiles,NNS,O
in,IN,O
young,JJ,O
subjects,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
12,CD,O
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
geriatric,JJ,O
subjects,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
7,CD,O
-rrb-,-RRB-,O
there,EX,O
was,VBD,O
a,DT,O
reduction,NN,O
in,IN,O
the,DT,O
rate,NN,O
but,CC,O
not,RB,O
the,DT,O
extent,NN,O
of,IN,O
flurbiprofen,NN,D
absorption,NN,O
.,.,.
,,
anticoagulants,NNPS,G
:,:,O
flurbiprofen,NNP,D
like,IN,O
other,JJ,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
",",",",O
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
affect,VB,O
bleeding,VBG,O
parameters,NNS,O
in,IN,O
patients,NNS,O
receiving,VBG,O
anti-coagulants,NNS,G
",",",",O
and,CC,O
serious,JJ,O
clinical,JJ,O
bleeding,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
.,.,.
,,
the,DT,O
physician,NN,O
should,MD,O
be,VB,O
cautious,JJ,O
when,WRB,O
administering,VBG,O
flurbiprofen,NN,D
to,TO,O
patients,NNS,O
taking,VBG,O
anticoagulants,NNS,G
.,.,.
,,
aspirin,NN,B
:,:,O
concurrent,JJ,O
administration,NN,O
of,IN,O
aspirin,NN,B
and,CC,O
flurbiprofen,NN,D
resulted,VBD,O
in,IN,O
50,CD,O
%,NN,O
lower,JJR,O
serum,NN,O
flurbiprofen,NN,D
concentrations,NNS,O
.,.,.
,,
this,DT,O
effect,NN,O
of,IN,O
aspirin,NN,B
-lrb-,-LRB-,O
which,WDT,O
also,RB,O
lowers,VBZ,O
serum,NN,O
concentrations,NNS,O
of,IN,O
other,JJ,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
given,VBN,O
with,IN,O
it,PRP,O
-rrb-,-RRB-,O
has,VBZ,O
been,VBN,O
demonstrated,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
rheumatoid,JJ,O
arthritis,NN,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
15,CD,O
-rrb-,-RRB-,O
as,RB,O
well,RB,O
as,IN,O
normal,JJ,O
volunteers,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
16,CD,O
-rrb-,-RRB-,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
of,IN,O
flurbiprofen,NN,D
and,CC,O
aspirin,NN,B
is,VBZ,O
therefore,RB,O
not,RB,O
recommended,VBN,O
.,.,.
,,
beta-adrenergic,JJ,O
blocking,NN,O
agents,NNS,O
:,:,O
the,DT,O
effect,NN,O
of,IN,O
flurbiprofen,NN,D
on,IN,O
blood,NN,O
pressure,NN,O
response,NN,O
to,TO,O
propranolol,NN,D
and,CC,O
atenolol,NN,D
was,VBD,O
evaluated,VBN,O
in,IN,O
men,NNS,O
with,IN,O
mild,JJ,O
uncomplicated,JJ,O
hypertension,NN,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
10,CD,O
-rrb-,-RRB-,O
.,.,.
,,
flurbiprofen,NNP,D
pretreatment,NN,O
attenuated,VBD,O
the,DT,O
hypotensive,JJ,O
effect,NN,O
of,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
propranolol,NN,D
but,CC,O
not,RB,O
atenolol,NN,D
.,.,.
,,
flurbiprofen,NNP,D
did,VBD,O
not,RB,O
appear,VB,O
to,TO,O
affect,VB,O
the,DT,O
beta-blocker-mediated,JJ,O
reduction,NN,O
in,IN,O
heart,NN,O
rate,NN,O
.,.,.
,,
flurbiprofen,NNP,D
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetic,JJ,O
profile,NN,O
of,IN,O
either,CC,O
drug,NN,D
",",",",O
and,CC,O
the,DT,O
mechanism,NN,O
under,IN,O
lying,VBG,O
the,DT,O
interference,NN,O
with,IN,O
propranolols,NNS,O
hypotensive,JJ,O
effect,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
patients,NNS,O
taking,VBG,O
both,CC,O
flurbiprofen,NN,D
and,CC,O
a,DT,O
beta-blocker,NN,G
should,MD,O
be,VB,O
monitored,VBN,O
to,TO,O
ensure,VB,O
that,IN,O
a,DT,O
satisfactory,JJ,O
hypotensive,JJ,O
effect,NN,O
is,VBZ,O
achieved,VBN,O
.,.,.
,,
cimetidine,NNP,D
",",",",O
ranitidine,NNP,D
:,:,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
9,CD,O
-rrb-,-RRB-,O
",",",",O
pretreatment,NN,O
with,IN,O
cimetidine,NN,D
or,CC,O
ranitidine,NN,D
did,VBD,O
not,RB,O
affect,VB,O
flurbiprofen,JJ,D
pharmacokinetics,NNS,O
except,IN,O
that,IN,O
a,DT,O
small,JJ,O
-lrb-,-LRB-,O
13,CD,O
%,NN,O
-rrb-,-RRB-,O
but,CC,O
statistically,RB,O
significant,JJ,O
increase,NN,O
in,IN,O
the,DT,O
area,NN,O
under,IN,O
the,DT,O
serum,NN,O
concentration,NN,O
curve,NN,O
of,IN,O
flurbiprofen,NN,D
resulted,VBD,O
with,IN,O
cimetidine,NN,D
.,.,.
,,
digoxin,NNP,D
:,:,O
studies,NNS,O
of,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
flurbiprofen,NN,D
and,CC,O
digoxin,NN,D
to,TO,O
healthy,JJ,O
men,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
14,CD,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
show,VB,O
a,DT,O
change,NN,O
in,IN,O
the,DT,O
steady,JJ,O
state,NN,O
serum,NN,O
levels,NNS,O
of,IN,O
either,CC,O
drug,NN,D
.,.,.
,,
diuretics,NNS,G
:,:,O
studies,NNS,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
flurbiprofen,NN,D
like,IN,O
other,JJ,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
",",",",O
can,MD,O
interfere,VB,O
with,IN,O
the,DT,O
effects,NNS,O
of,IN,O
furosemide,NN,D
.,.,.
,,
although,IN,O
results,NNS,O
have,VBP,O
varied,VBN,O
from,IN,O
study,NN,O
to,TO,O
study,VB,O
",",",",O
effects,NNS,O
have,VBP,O
been,VBN,O
shown,VBN,O
on,IN,O
furosemide-stimulated,JJ,O
diuresis,NN,O
",",",",O
natriuresis,NN,O
",",",",O
and,CC,O
kaliuresis,NN,O
.,.,.
,,
other,JJ,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
prostaglandin,NN,O
synthesis,NN,O
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
thiazide,JJ,G
diuretics,NNS,G
in,IN,O
some,DT,O
studies,NNS,O
and,CC,O
with,IN,O
potassium-sparing,JJ,O
diuretics,NNS,G
.,.,.
,,
patients,NNS,O
receiving,VBG,O
flurbiprofen,NN,D
and,CC,O
furosemide,NN,D
or,CC,O
other,JJ,O
diuretics,NNS,G
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
to,TO,O
determine,VB,O
if,IN,O
the,DT,O
desired,VBN,O
effect,NN,O
is,VBZ,O
obtained,VBN,O
.,.,.
,,
oral,JJ,O
hypoglycemic,JJ,O
agents,NNS,O
:,:,O
in,IN,O
one,CD,O
study,NN,O
",",",",O
flurbiprofen,NN,D
was,VBD,O
given,VBN,O
to,TO,O
adult,JJ,O
diabetics,NNS,O
who,WP,O
were,VBD,O
already,RB,O
receiving,VBG,O
glyburide,NN,D
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
4,CD,O
-rrb-,-RRB-,O
",",",",O
metformin,NN,D
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
2,CD,O
-rrb-,-RRB-,O
chlorpropamide,NN,D
with,IN,O
phenformin,NN,D
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
3,CD,O
-rrb-,-RRB-,O
or,CC,O
glyburide,NN,D
with,IN,O
phenformin,NN,D
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
6,CD,O
-rrb-,-RRB-,O
.,.,.
,,
although,IN,O
there,EX,O
was,VBD,O
a,DT,O
slight,JJ,O
reduction,NN,O
in,IN,O
blood,NN,O
sugar,NN,O
concentrations,NNS,O
during,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
flurbiprofen,NN,D
and,CC,O
hypoglycemic,JJ,G
agents,NNS,O
",",",",O
there,EX,O
were,VBD,O
no,DT,O
signs,NNS,O
or,CC,O
symptoms,NNS,O
of,IN,O
hypoglycemia,NN,O
.,.,.
,,
increases,NNS,O
in,IN,O
prothrombin,NN,O
time,NN,O
have,VBP,O
been,VBN,O
noted,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
long,JJ,O
-,:,O
term,NN,O
warfarin,NN,D
therapy,NN,O
after,IN,O
flutamide,NN,D
was,VBD,O
initiated,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
close,JJ,O
monitoring,NN,O
of,IN,O
prothrombin,NN,O
time,NN,O
is,VBZ,O
recommended,VBN,O
and,CC,O
adjustment,NN,O
of,IN,O
the,DT,O
anticoagulant,JJ,G
dose,NN,O
may,MD,O
be,VB,O
necessary,JJ,O
when,WRB,O
eulexin,NNP,B
capsules,NNPS,O
are,VBP,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
warfarin,NN,D
.,.,.
,,
potential,JJ,O
for,IN,O
interaction,NN,O
with,IN,O
monoamine,NNP,O
oxidase,NNP,O
inhibitor,NNP,O
.,.,.
,,
in,IN,O
patients,NNS,O
receiving,VBG,O
another,DT,O
serotonin,NN,O
reuptake,NN,O
inhibitor,NN,O
drug,NN,D
in,IN,O
combination,NN,O
with,IN,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
maoi,NN,G
-rrb-,-RRB-,O
",",",",O
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
serious,JJ,O
",",",",O
sometimes,RB,O
fatal,JJ,O
",",",",O
reactions,NNS,O
including,VBG,O
hyperthermia,NN,O
",",",",O
rigidity,NN,O
",",",",O
myoclonus,NN,O
",",",",O
autonomic,JJ,O
instability,NN,O
with,IN,O
possible,JJ,O
rapid,JJ,O
fluctuations,NNS,O
of,IN,O
vital,JJ,O
signs,NNS,O
",",",",O
and,CC,O
mental,JJ,O
status,NN,O
changes,NNS,O
that,WDT,O
include,VBP,O
extreme,JJ,O
agitation,NN,O
progressing,VBG,O
to,TO,O
delirium,NN,O
and,CC,O
coma,NN,O
.,.,.
,,
these,DT,O
reactions,NNS,O
have,VBP,O
also,RB,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
who,WP,O
have,VBP,O
discontinued,VBN,O
that,IN,O
drug,NN,D
and,CC,O
have,VBP,O
been,VBN,O
started,VBN,O
on,IN,O
a,DT,O
maoi,NNP,G
.,.,.
,,
some,DT,O
cases,NNS,O
presented,VBN,O
with,IN,O
features,NNS,O
resembling,VBG,O
neuroleptic,JJ,G
malignant,JJ,O
syndrome,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
fluvoxamine,NNP,D
tablets,NNPS,O
not,RB,O
be,VB,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
maois,NNS,G
",",",",O
or,CC,O
within,IN,O
14,CD,O
days,NNS,O
of,IN,O
discontinuing,VBG,O
treatment,NN,O
with,IN,O
a,DT,O
maoi,NNP,G
.,.,.
,,
after,IN,O
stopping,VBG,O
fluvoxamine,NNP,D
tablets,NNPS,O
",",",",O
at,IN,O
least,JJS,O
2,CD,O
weeks,NNS,O
should,MD,O
be,VB,O
allowed,VBN,O
before,IN,O
starting,VBG,O
a,DT,O
maoi,NNP,G
.,.,.
,,
potential,JJ,O
terfenadine,NN,D
",",",",O
astemizole,NNP,D
",",",",O
and,CC,O
cisapride,NNP,D
interaction,NN,O
.,.,.
,,
terfenadine,NNP,D
",",",",O
astemizole,NN,D
and,CC,O
cisapride,NN,D
are,VBP,O
all,DT,O
metabolized,VBN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450iiia4,NN,O
isozyme,NN,O
",",",",O
and,CC,O
it,PRP,O
has,VBZ,O
been,VBN,O
demonstrated,VBN,O
that,IN,O
ketoconazole,NN,D
",",",",O
a,DT,O
potent,JJ,O
inhibitor,NN,O
of,IN,O
iiia4,NN,O
",",",",O
blocks,VBZ,O
the,DT,O
metabolism,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
",",",",O
resulting,VBG,O
in,IN,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
parent,NN,O
drug,NN,D
.,.,.
,,
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
terfenadine,NN,D
",",",",O
astemizole,NN,D
",",",",O
and,CC,O
cisapride,NN,D
cause,VBP,O
qt,NNP,O
prolongation,NN,O
and,CC,O
have,VBP,O
been,VBN,O
associated,VBN,O
with,IN,O
torsades,NNS,O
de,IN,O
pointes-type,JJ,O
ventricular,JJ,O
tachycardia,NN,O
",",",",O
sometimes,RB,O
fatal,JJ,O
.,.,.
,,
as,IN,O
noted,VBN,O
below,IN,O
",",",",O
a,DT,O
sub,NN,O
-,:,O
for,IN,O
fluvoxamine,NN,D
in,IN,O
combination,NN,O
with,IN,O
alprazolam,NN,D
",",",",O
a,DT,O
drug,NN,D
that,WDT,O
is,VBZ,O
known,VBN,O
to,TO,O
be,VB,O
metabolized,VBN,O
by,IN,O
the,DT,O
iiia4,NN,O
isozyme,NN,O
.,.,.
,,
although,IN,O
it,PRP,O
has,VBZ,O
not,RB,O
been,VBN,O
definitively,RB,O
demonstrated,VBN,O
that,IN,O
fluvoxamine,NN,D
is,VBZ,O
a,DT,O
potent,JJ,O
iiia4,NN,O
inhibitor,NN,O
",",",",O
it,PRP,O
is,VBZ,O
likely,JJ,O
to,TO,O
be,VB,O
",",",",O
given,VBN,O
the,DT,O
substantial,JJ,O
interaction,NN,O
of,IN,O
fluvoxamine,NN,D
with,IN,O
alprazolam,NN,D
.,.,.
,,
consequently,RB,O
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
fluvoxamine,NN,D
not,RB,O
be,VB,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
either,CC,O
terbinafine,NN,D
",",",",O
astemizole,NN,D
",",",",O
or,CC,O
cisapride,NN,D
.,.,.
,,
other,JJ,O
potentially,RB,O
important,JJ,O
drug,NN,O
interactions,NNS,O
:,:,O
benzodiazepines,NNS,G
:,:,O
benzodiazepines,NNS,G
metabolized,VBN,O
by,IN,O
hepatic,JJ,O
oxidation,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
alprazolam,NN,D
",",",",O
midazolam,NN,D
",",",",O
triazolam,NN,D
elc,NN,O
.,.,.
,,
-rrb-,-RRB-,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
because,IN,O
the,DT,O
clearance,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
is,VBZ,O
likely,JJ,O
to,TO,O
be,VB,O
reduced,VBN,O
by,IN,O
fluvoxamine,NN,D
.,.,.
,,
the,DT,O
clearance,NN,O
of,IN,O
benzodiazepines,NNS,G
metabolized,VBN,O
by,IN,O
glucuronidation,NN,O
-lrb-,-LRB-,O
e.,FW,O
g.,FW,O
",",",",O
lorazepam,NN,D
",",",",O
oxazepam,NN,D
",",",",O
temazepam,NN,D
-rrb-,-RRB-,O
is,VBZ,O
unlikely,JJ,O
to,TO,O
be,VB,O
affected,VBN,O
by,IN,O
fluvoxamine,NN,D
.,.,.
,,
alprazolam,NNP,D
:,:,O
when,WRB,O
fluvoxamine,NN,D
maleate,NN,O
-lrb-,-LRB-,O
100,CD,O
mg,NN,O
qd,NN,O
-rrb-,-RRB-,O
and,CC,O
alprazolam,NN,D
-lrb-,-LRB-,O
1,CD,O
mg,NN,O
q.d.,NN,O
were,VBD,O
co-administered,VBN,O
to,TO,O
steady,JJ,O
state,NN,O
",",",",O
plasma,NN,O
concentration,NN,O
and,CC,O
other,JJ,O
pharmacokinetics,NNS,O
parameters,NNS,O
-lrb-,-LRB-,O
auc,NN,O
",",",",O
cmax,NN,O
",",",",O
t1/2,NN,O
",",",",O
-rrb-,-RRB-,O
of,IN,O
alprazolam,NN,D
were,VBD,O
approximately,RB,O
twice,RB,O
those,DT,O
observed,VBN,O
when,WRB,O
alprazolam,NN,D
was,VBD,O
administered,VBN,O
alone,RB,O
.,.,.
,,
oral,JJ,O
clearance,NN,O
was,VBD,O
reduced,VBN,O
by,IN,O
about,IN,O
50,CD,O
%,NN,O
.,.,.
,,
the,DT,O
elevated,JJ,O
plasma,NN,O
alprazolam,NN,D
concentrations,NNS,O
resulted,VBD,O
in,IN,O
decreased,VBN,O
psychomotor,NN,O
performance,NN,O
and,CC,O
memory,NN,O
.,.,.
,,
this,DT,O
interaction,NN,O
",",",",O
which,WDT,O
has,VBZ,O
not,RB,O
been,VBN,O
investigated,VBN,O
using,VBG,O
higher,JJR,O
doses,NNS,O
of,IN,O
fluvoxamine,NN,D
",",",",O
may,MD,O
be,VB,O
more,RBR,O
pronounced,JJ,O
if,IN,O
a,DT,O
300,CD,O
mg,NN,O
daily,JJ,O
dose,NN,O
is,VBZ,O
co-administered,JJ,O
",",",",O
particularly,RB,O
since,IN,O
fluvoxamine,NN,D
exhibits,VBZ,O
non-linear,JJ,O
pharmacokinetics,NNS,O
over,IN,O
the,DT,O
dosage,NN,O
range,NN,O
100-300,CD,O
mg,NN,O
.,.,.
,,
if,IN,O
alprazolam,NN,D
is,VBZ,O
co-administered,VBN,O
with,IN,O
fluvoxamine,NNP,D
tablets,NNPS,O
",",",",O
the,DT,O
initial,JJ,O
alprazolam,NN,D
dosage,NN,O
should,MD,O
be,VB,O
at,IN,O
least,JJS,O
halved,JJ,O
and,CC,O
titration,NN,O
to,TO,O
the,DT,O
lowest,JJS,O
effective,JJ,O
dose,NN,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
no,DT,O
dosage,NN,O
adjustment,NN,O
is,VBZ,O
required,VBN,O
for,IN,O
fluvoxamine,NNP,D
tablets,NNPS,O
.,.,.
,,
diazepam,NN,D
:,:,O
the,DT,O
co-administration,NN,O
of,IN,O
fluvoxamine,NNP,D
tablets,NNPS,O
and,CC,O
diazepam,NN,D
is,VBZ,O
generally,RB,O
not,RB,O
advisable,JJ,O
.,.,.
,,
because,IN,O
fluvoxamine,NN,D
reduces,VBZ,O
the,DT,O
clearance,NN,O
of,IN,O
both,CC,O
diazepam,NN,D
and,CC,O
its,PRP$,O
active,JJ,O
metabolite,NN,O
",",",",O
n-desmethyldiazepam,NN,D_n
",",",",O
there,EX,O
is,VBZ,O
a,DT,O
strong,JJ,O
likelihood,NN,O
of,IN,O
substantial,JJ,O
accumulation,NN,O
of,IN,O
both,DT,O
species,NNS,O
during,IN,O
chronic,JJ,O
co-administration,NN,O
.,.,.
,,
evidence,NN,O
supporting,VBG,O
the,DT,O
conclusion,NN,O
that,IN,O
it,PRP,O
is,VBZ,O
inadvisable,JJ,O
to,TO,O
co-administer,NN,O
fluvoxamine,NN,D
and,CC,O
diazepam,NN,D
is,VBZ,O
derived,VBN,O
from,IN,O
a,DT,O
study,NN,O
in,IN,O
which,WDT,O
healthy,JJ,O
volunteers,NNS,O
taking,VBG,O
150,CD,O
mg/day,NN,O
of,IN,O
fluvoxamine,NN,D
were,VBD,O
administered,VBN,O
a,DT,O
single,JJ,O
oral,JJ,O
dose,NN,O
of,IN,O
10,CD,O
mg,NN,O
of,IN,O
diazepam,NN,D
.,.,.
,,
in,IN,O
these,DT,O
subjects,NNS,O
-lrb-,-LRB-,O
r,NN,O
=,JJ,O
b,NN,O
-rrb-,-RRB-,O
",",",",O
the,DT,O
clearance,NN,O
of,IN,O
diazepam,NN,D
was,VBD,O
reduced,VBN,O
by,IN,O
65,CD,O
%,NN,O
and,CC,O
that,IN,O
of,IN,O
n-desmethyldiazepam,NN,D_n
to,TO,O
a,DT,O
level,NN,O
that,WDT,O
was,VBD,O
too,RB,O
low,JJ,O
to,TO,O
measure,VB,O
over,IN,O
the,DT,O
course,NN,O
of,IN,O
the,DT,O
2,CD,O
week,NN,O
long,JJ,O
study,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
likely,JJ,O
that,IN,O
experience,NN,O
significantly,RB,O
underestimates,VBZ,O
the,DT,O
degree,NN,O
of,IN,O
accumulation,NN,O
that,WDT,O
might,MD,O
occur,VB,O
with,IN,O
repealed,VBN,O
diazepam,NN,D
administration,NN,O
.,.,.
,,
moreover,RB,O
",",",",O
as,IN,O
noted,VBN,O
with,IN,O
alprazolam,NN,D
",",",",O
the,DT,O
effect,NN,O
of,IN,O
fluvoxamine,NN,D
may,MD,O
even,RB,O
be,VB,O
more,RBR,O
pronounced,JJ,O
when,WRB,O
it,PRP,O
is,VBZ,O
administered,VBN,O
at,IN,O
higher,JJR,O
doses,NNS,O
.,.,.
,,
accordingly,RB,O
",",",",O
diazepam,NN,D
and,CC,O
fluvoxamine,NN,D
should,MD,O
not,RB,O
ordinarily,RB,O
be,VB,O
co-administered,VBN,O
.,.,.
,,
theophylline,NNP,D
:,:,O
the,DT,O
effect,NN,O
of,IN,O
steady-state,JJ,O
fluvoxamine,NN,D
l50,NN,O
mg,NN,O
bid,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
theophylline,NNP,D
-lrb-,-LRB-,O
375,CD,O
mg,NN,O
-rrb-,-RRB-,O
as,IN,O
442,CD,O
mg,NN,O
aminophylline,NN,D
was,VBD,O
evaluated,VBN,O
in,IN,O
12,CD,O
healthy,JJ,O
non-smoking,JJ,O
",",",",O
male,JJ,O
volunteers,NNS,O
.,.,.
,,
the,DT,O
clearance,NN,O
of,IN,O
theophylline,NN,D
was,VBD,O
decreased,VBN,O
approximately,RB,O
3-fold,RB,O
.,.,.
,,
therefore,RB,O
",",",",O
if,IN,O
theophylline,NN,D
is,VBZ,O
co-administered,VBN,O
with,IN,O
fluvoxamine,NN,D
maleate,NN,O
",",",",O
its,PRP$,O
dose,NN,O
should,MD,O
be,VB,O
reduced,VBN,O
to,TO,O
one,CD,O
third,NN,O
of,IN,O
the,DT,O
usual,JJ,O
daily,JJ,O
maintenance,NN,O
dose,NN,O
and,CC,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
theophylline,NN,D
should,MD,O
to,TO,O
monitored,VBN,O
.,.,.
,,
no,DT,O
dosage,NN,O
adjustment,NN,O
is,VBZ,O
required,VBN,O
for,IN,O
fluvoxamine,NNP,D
tablets,NNPS,O
.,.,.
,,
warfarin,NNP,D
:,:,O
when,WRB,O
fluvoxamine,NN,D
maleate,NN,O
-lrb-,-LRB-,O
50,CD,O
mg,NN,O
tid,NN,O
-rrb-,-RRB-,O
was,VBD,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
warfarin,NN,D
for,IN,O
two,CD,O
weeks,NNS,O
",",",",O
warfarin,NN,D
plasma,NN,O
concentrations,NNS,O
increased,VBN,O
by,IN,O
98,CD,O
%,NN,O
and,CC,O
prothrombin,NN,O
times,NNS,O
were,VBD,O
prolonged,VBN,O
.,.,.
,,
thus,RB,O
patients,NNS,O
receiving,VBG,O
oral,JJ,O
anticoagulants,NNS,G
and,CC,O
fluvoxamine,NNP,D
tablets,NNS,O
should,MD,O
have,VB,O
their,PRP$,O
prothrombin,NN,O
time,NN,O
monitored,VBD,O
and,CC,O
their,PRP$,O
anticoagulant,JJ,G
dose,NN,O
adjusted,VBN,O
accordingly,RB,O
.,.,.
,,
no,DT,O
dosage,NN,O
adjustment,NN,O
is,VBZ,O
required,VBN,O
for,IN,O
fluvoxamine,NNP,D
tablets,NNPS,O
.,.,.
,,
medications,NNS,O
that,WDT,O
interfere,VBP,O
with,IN,O
your,PRP$,O
bodys,NNS,O
ability,NN,O
to,TO,O
use,VB,O
folate,NN,O
may,MD,O
also,RB,O
increase,VB,O
the,DT,O
need,NN,O
for,IN,O
this,DT,O
vitamin,NN,G
.,.,.
,,
medications,NNS,O
can,MD,O
interfere,VB,O
with,IN,O
folate,NN,O
utilization,NN,O
",",",",O
including,VBG,O
:,:,O
anticonvulsant,JJ,G
medications,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
phenytoin,NN,D
",",",",O
and,CC,O
primidone,NN,D
-rrb-,-RRB-,O
metformin,NN,D
-lrb-,-LRB-,O
sometimes,RB,O
prescribed,VBN,O
to,TO,O
control,VB,O
blood,NN,O
sugar,NN,O
in,IN,O
type,NN,O
2,CD,O
diabetes,NN,O
-rrb-,-RRB-,O
sulfasalazine,NN,D
-lrb-,-LRB-,O
used,VBN,O
to,TO,O
control,VB,O
inflammation,NN,O
associated,VBN,O
with,IN,O
crohns,NN,O
disease,NN,O
and,CC,O
ulcerative,JJ,O
colitis,NN,O
-rrb-,-RRB-,O
triamterene,NN,D
-lrb-,-LRB-,O
a,DT,O
diuretic,JJ,G
-rrb-,-RRB-,O
methotrexate,NNP,D
there,EX,O
has,VBZ,O
been,VBN,O
concern,NN,O
about,IN,O
the,DT,O
interaction,NN,O
between,IN,O
vitamin,NN,G
b12,NN,O
and,CC,O
folic,JJ,O
acid,NN,O
.,.,.
,,
folic,JJ,O
acid,NN,O
supplements,NNS,O
can,MD,O
correct,VB,O
the,DT,O
anemia,NN,O
associated,VBN,O
with,IN,O
vitamin,NN,G
b12,NN,O
deficiency,NN,O
.,.,.
,,
unfortunately,RB,O
",",",",O
folic,JJ,O
acid,NN,O
will,MD,O
not,RB,O
correct,VB,O
changes,NNS,O
in,IN,O
the,DT,O
nervous,JJ,O
system,NN,O
that,WDT,O
result,VBP,O
from,IN,O
vitamin,NN,G
b12,NN,O
deficiency,NN,O
.,.,.
,,
permanent,JJ,O
nerve,NN,O
damage,NN,O
could,MD,O
theoretically,RB,O
occur,VB,O
if,IN,O
vitamin,NN,G
b12,NN,O
deficiency,NN,O
is,VBZ,O
not,RB,O
treated,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
intake,NN,O
of,IN,O
supplemental,JJ,O
folic,JJ,O
acid,NN,O
should,MD,O
not,RB,O
exceed,VB,O
1000,CD,O
micrograms,NNS,O
-lrb-,-LRB-,O
g,NN,O
",",",",O
sometimes,RB,O
mcg,NN,O
-rrb-,-RRB-,O
per,IN,O
day,NN,O
to,TO,O
prevent,VB,O
folic,JJ,O
acid,NN,O
from,IN,O
masking,VBG,O
symptoms,NNS,O
of,IN,O
vitamin,NN,G
b12,NN,O
deficiency,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
important,JJ,O
for,IN,O
older,JJR,O
adults,NNS,O
to,TO,O
be,VB,O
aware,JJ,O
of,IN,O
the,DT,O
relationship,NN,O
between,IN,O
folic,JJ,O
acid,NN,O
and,CC,O
vitamin,NN,G
b12,NN,O
because,IN,O
they,PRP,O
are,VBP,O
at,IN,O
greater,JJR,O
risk,NN,O
of,IN,O
having,VBG,O
a,DT,O
vitamin,NN,G
b12,NN,O
deficiency,NN,O
.,.,.
,,
if,IN,O
you,PRP,O
are,VBP,O
50,CD,O
years,NNS,O
of,IN,O
age,NN,O
or,CC,O
older,JJR,O
",",",",O
ask,VB,O
your,PRP$,O
physician,NN,O
to,TO,O
check,VB,O
your,PRP$,O
b12,NN,O
status,NN,O
before,IN,O
you,PRP,O
take,VBP,O
a,DT,O
supplement,NN,O
that,WDT,O
contains,VBZ,O
folic,JJ,O
acid,NN,O
.,.,.
,,
no,DT,O
drug/drug,NN,O
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
.,.,.
,,
oral,JJ,O
doses,NNS,O
of,IN,O
antizol,NNP,B
-lrb-,-LRB-,O
20-Oct,CD,O
mg/kg,NN,O
-rrb-,-RRB-,O
",",",",O
via,IN,O
alcohol,NN,D
dehydrogenase,NN,O
inhibition,NN,O
",",",",O
significantly,RB,O
reduced,VBD,O
the,DT,O
rate,NN,O
of,IN,O
elimination,NN,O
of,IN,O
ethanol,NN,D
-lrb-,-LRB-,O
by,IN,O
approximately,RB,O
40,CD,O
%,NN,O
-rrb-,-RRB-,O
given,VBN,O
to,TO,O
healthy,JJ,O
volunteers,NNS,O
in,IN,O
moderate,JJ,O
doses,NNS,O
.,.,.
,,
similarly,RB,O
",",",",O
ethanol,NN,D
decreased,VBD,O
the,DT,O
rate,NN,O
of,IN,O
elimination,NN,O
of,IN,O
antizol,NNP,B
-lrb-,-LRB-,O
by,IN,O
approximately,RB,O
50,CD,O
%,NN,O
-rrb-,-RRB-,O
by,IN,O
the,DT,O
same,JJ,O
mechanism,NN,O
.,.,.
,,
reciprocal,JJ,O
interactions,NNS,O
may,MD,O
occur,VB,O
with,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
antizol,NNP,B
and,CC,O
drugs,NNS,D
that,WDT,O
increase,VBP,O
or,CC,O
inhibit,VBP,O
the,DT,O
cytochrome,NN,O
p450,NN,O
system,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
phenytoin,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
cimetidine,NN,D
",",",",O
ketoconazole,NN,D
-rrb-,-RRB-,O
",",",",O
though,IN,O
this,DT,O
has,VBZ,O
not,RB,O
been,VBN,O
studie,NN,O
.,.,.
,,
in,IN,O
clinical,JJ,O
studies,NNS,O
performed,VBN,O
with,IN,O
fondaparinux,NN,D
",",",",O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
oral,JJ,O
anticoagulants,NNS,G
-lrb-,-LRB-,O
warfarin,NN,D
-rrb-,-RRB-,O
",",",",O
platelet,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
acetylsalicylic,JJ,O
acid,NN,O
-rrb-,-RRB-,O
",",",",O
nsaids,NNS,G
-lrb-,-LRB-,O
piroxicam,NN,D
-rrb-,-RRB-,O
",",",",O
and,CC,O
digoxin,NN,D
did,VBD,O
not,RB,O
significantly,RB,O
affect,VB,O
the,DT,O
pharmacokinetics/pharmacodynamics,NNS,O
of,IN,O
fondaparinux,NN,D
sodium,NN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
fondaparinux,NN,D
neither,CC,O
influenced,VBD,O
the,DT,O
pharmacodynamics,NNS,O
of,IN,O
warfarin,NN,D
",",",",O
acetylsalicylic,JJ,O
acid,NN,O
",",",",O
piroxicam,NN,D
",",",",O
and,CC,O
digoxin,NN,D
",",",",O
nor,CC,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
digoxin,NN,D
at,IN,O
steady,JJ,O
state,NN,O
.,.,.
,,
agents,NNS,O
that,WDT,O
may,MD,O
enhance,VB,O
the,DT,O
risk,NN,O
of,IN,O
hemorrhage,NN,O
should,MD,O
be,VB,O
discontinued,VBN,O
prior,RB,O
to,TO,O
initiation,NN,O
of,IN,O
fondaparinux,NN,D
therapy,NN,O
.,.,.
,,
if,IN,O
co-administration,NN,O
is,VBZ,O
essential,JJ,O
",",",",O
close,JJ,O
monitoring,NN,O
may,MD,O
be,VB,O
appropriate,JJ,O
.,.,.
,,
in,IN,O
an,DT,O
in,FW,O
vitro,FW,O
study,NN,O
in,IN,O
human,JJ,O
liver,NN,O
microsomes,NNS,O
",",",",O
inhibition,NN,O
of,IN,O
cyp2a6,NN,O
hydroxylation,NN,O
of,IN,O
coumarin,NN,G
by,IN,O
fondaparinux,NN,D
-lrb-,-LRB-,O
200,CD,O
m,NN,O
m,NN,O
m,NN,O
i.e.,FW,O
",",",",O
350,CD,O
mg/l,NN,O
-rrb-,-RRB-,O
was,VBD,O
17-28,CD,O
%,NN,O
.,.,.
,,
inhibition,NN,O
of,IN,O
the,DT,O
other,JJ,O
isozymes,NNS,O
evaluated,VBN,O
-lrb-,-LRB-,O
cyps,NNS,O
2a1,NN,O
",",",",O
2c9,NN,O
",",",",O
2c19,NN,O
",",",",O
2d6,NN,O
",",",",O
3a4,NN,O
",",",",O
and,CC,O
3.00E+01,NN,O
-rrb-,-RRB-,O
was,VBD,O
0-16,CD,O
%,NN,O
.,.,.
,,
since,IN,O
fondaparinux,NN,D
does,VBZ,O
not,RB,O
markedly,RB,O
inhibit,VB,O
cyp450s,NN,O
-lrb-,-LRB-,O
cyp1a2,NN,D
",",",",O
cyp2a6,NN,O
",",",",O
cyp2c9,NN,D
",",",",O
cyp2c19,NN,O
",",",",O
cyp2d6,NN,D
",",",",O
cyp2e1,NN,O
",",",",O
or,CC,O
cyp3a4,NN,D
-rrb-,-RRB-,O
in,FW,O
vitro,FW,O
",",",",O
fondaparinux,NN,D
sodium,NN,O
is,VBZ,O
not,RB,O
expected,VBN,O
to,TO,O
significantly,RB,O
interact,VB,O
with,IN,O
other,JJ,O
drugs,NNS,D
in,FW,O
vivo,FW,O
by,IN,O
inhibition,NN,O
of,IN,O
metabolism,NN,O
mediated,VBN,O
by,IN,O
these,DT,O
isozymes,NNS,O
.,.,.
,,
since,IN,O
fondaparinux,NN,D
sodium,NN,O
does,VBZ,O
not,RB,O
bind,VB,O
significantly,RB,O
to,TO,O
plasma,NN,O
proteins,NNS,O
other,JJ,O
than,IN,O
atiii,NN,O
",",",",O
no,DT,O
drug,NN,D
interactions,NNS,O
by,IN,O
protein-binding,JJ,O
displacement,NN,O
are,VBP,O
expected,VBN,O
.,.,.
,,
short-acting,JJ,O
beta2-agonists,NNS,G
:,:,O
aerosol,NN,O
bronchodilators,NNS,G
of,IN,O
the,DT,O
short-acting,JJ,O
adrenergic,JJ,G
stimulant,NN,O
type,NN,O
may,MD,O
be,VB,O
used,VBN,O
for,IN,O
relief,NN,O
of,IN,O
breakthrough,NN,O
symptoms,NNS,O
while,IN,O
using,VBG,O
formoterol,NN,D
.,.,.
,,
however,RB,O
",",",",O
increasing,VBG,O
use,NN,O
of,IN,O
such,JJ,O
preparations,NNS,O
to,TO,O
control,VB,O
symptoms,NNS,O
indicates,VBZ,O
deterioration,NN,O
of,IN,O
asthma,NN,O
control,NN,O
and,CC,O
the,DT,O
need,NN,O
to,TO,O
reassess,NN,O
the,DT,O
patient,NN,O
s,VBZ,O
therapy,NN,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
other,JJ,O
sympathomimetic,JJ,G
agents,NNS,O
may,MD,O
potentiate,VB,O
the,DT,O
undesirable,JJ,O
effects,NNS,O
of,IN,O
foradil,NNP,B
.,.,.
,,
monoamine,NNP,O
oxidase,NNP,O
inhibitors,NNS,O
and,CC,O
tricyclic,JJ,O
antidepressants,NNS,G
:,:,O
foradil,NN,B
should,MD,O
be,VB,O
administered,VBN,O
with,IN,O
extreme,JJ,O
caution,NN,O
in,IN,O
patients,NNS,O
being,VBG,O
treated,VBN,O
with,IN,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
or,CC,O
tricyclic,JJ,G
antidepressants,NNS,G
because,IN,O
the,DT,O
action,NN,O
of,IN,O
formoterol,NN,D
on,IN,O
the,DT,O
cardiovascular,JJ,O
system,NN,O
may,MD,O
be,VB,O
potentiated,VBN,O
by,IN,O
these,DT,O
agents,NNS,O
.,.,.
,,
corticosteroids,NNS,G
",",",",O
methylxanthines,NNS,G
and,CC,O
diuretics,NNS,G
:,:,O
concomitant,JJ,O
treatment,NN,O
with,IN,O
xanthine,NN,O
derivatives,NNS,O
",",",",O
steroids,NNS,G
",",",",O
or,CC,O
diuretics,NNS,G
may,MD,O
potentiate,VB,O
a,DT,O
possible,JJ,O
hypokalemic,JJ,O
effect,NN,O
of,IN,O
beta2-agonists,NNS,G
.,.,.
,,
hypokalemia,NN,O
may,MD,O
increase,VB,O
susceptibility,NN,O
to,TO,O
cardiac,JJ,O
arrhythmias,NNS,O
in,IN,O
patients,NNS,O
treated,VBN,O
with,IN,O
digitalis,NN,G
.,.,.
,,
-,:,O
adrenergic,JJ,G
blockers,NNS,O
:,:,O
-,:,O
adrenergic,JJ,G
blockers,NNS,O
may,MD,O
weaken,VB,O
or,CC,O
antagonise,VB,O
the,DT,O
effect,NN,O
of,IN,O
foradil,NNP,B
.,.,.
,,
therefore,RB,O
foradil,NNP,B
should,MD,O
not,RB,O
be,VB,O
given,VBN,O
together,RP,O
with,IN,O
-,:,O
adrenergic,JJ,G
blockers,NNS,O
-lrb-,-LRB-,O
including,VBG,O
eye,NN,O
drops,NNS,O
-rrb-,-RRB-,O
unless,IN,O
there,EX,O
are,VBP,O
compelling,JJ,O
reasons,NNS,O
for,IN,O
their,PRP$,O
use,NN,O
.,.,.
,,
other,JJ,O
drugs,NNS,O
:,:,O
drugs,NNS,O
such,JJ,O
as,IN,O
quinidine,NN,D
",",",",O
disopyramide,NN,D
",",",",O
procainamide,NN,D
",",",",O
phenothiazines,NNS,G
",",",",O
antihistamines,NNS,G
",",",",O
and,CC,O
tricyclic,JJ,G
antidepressants,NNS,G
may,MD,O
be,VB,O
associated,VBN,O
with,IN,O
qt-interval,JJ,O
prolongation,NN,O
and,CC,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
ventricular,JJ,O
arrhythmia,NN,O
.,.,.
,,
information,NN,O
to,TO,O
be,VB,O
provided,VBN,O
to,TO,O
the,DT,O
patient,NN,O
or,NN,O
guardian,NNP,O
see,NNP,O
illustrated,VBD,O
information,NN,O
for,IN,O
the,DT,O
patient,NN,O
or,CC,O
guardian,NNP,O
section,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
important,JJ,O
that,IN,O
patients,NNS,O
understand,VBP,O
how,WRB,O
to,TO,O
use,VB,O
foradil,NNP,B
-lrb-,-LRB-,O
formoterol,NN,D
fumarate,NN,O
-rrb-,-RRB-,O
capsules,NNS,O
with,IN,O
the,DT,O
supplied,VBN,O
aerolizertm,NN,O
inhalation,NN,O
device,NN,O
and,CC,O
how,WRB,O
it,PRP,O
should,MD,O
be,VB,O
used,VBN,O
in,IN,O
relation,NN,O
to,TO,O
other,JJ,O
asthma,NN,O
or,CC,O
copd,NN,O
medications,NNS,O
they,PRP,O
are,VBP,O
taking,VBG,O
.,.,.
,,
patients/guardians,NN,O
should,MD,O
be,VB,O
given,VBN,O
the,DT,O
following,VBG,O
information,NN,O
:,:,O
i,LS,O
.,.,.
,,
the,DT,O
recommended,VBN,O
dosage,NN,O
-lrb-,-LRB-,O
one,CD,O
or,CC,O
two,CD,O
capsules,NNS,O
twice,RB,O
daily,RB,O
",",",",O
morning,NN,O
and,CC,O
evening,NN,O
-rrb-,-RRB-,O
should,MD,O
not,RB,O
be,VB,O
exceeded,VBN,O
.,.,.
,,
ii,LS,O
.,.,.
,,
foradil,NNP,B
is,VBZ,O
not,RB,O
meant,VBN,O
to,TO,O
relieve,VB,O
acute,JJ,O
asthma,NN,O
or,CC,O
copd,NN,O
symptoms,NNS,O
and,CC,O
extra,JJ,O
doses,NNS,O
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
for,IN,O
that,DT,O
purpose,NN,O
.,.,.
,,
acute,JJ,O
symptoms,NNS,O
should,MD,O
be,VB,O
treated,VBN,O
with,IN,O
a,DT,O
short-acting,JJ,O
",",",",O
inhaled,VBN,O
beta2-agonist,NN,G
such,JJ,O
as,IN,O
salbutamol,NN,D
-lrb-,-LRB-,O
the,DT,O
physician,NN,O
should,MD,O
provide,VB,O
the,DT,O
patient,NN,O
with,IN,O
such,JJ,O
medication,NN,O
and,CC,O
instruct,VB,O
the,DT,O
patient,NN,O
in,IN,O
how,WRB,O
it,PRP,O
should,MD,O
be,VB,O
used,VBN,O
-rrb-,-RRB-,O
.,.,.
,,
iii,LS,O
.,.,.
,,
the,DT,O
physician,NN,O
should,MD,O
be,VB,O
notified,VBN,O
immediately,RB,O
if,IN,O
any,DT,O
of,IN,O
the,DT,O
following,VBG,O
situations,NNS,O
occur,VBP,O
",",",",O
which,WDT,O
may,MD,O
be,VB,O
a,DT,O
sign,NN,O
of,IN,O
seriously,RB,O
worsening,VBG,O
asthma,NN,O
:,:,O
decreased,VBN,O
effectiveness,NN,O
of,IN,O
short-acting,JJ,O
",",",",O
inhaled,VBD,O
beta2-agonists,NNS,G
.,.,.
,,
need,VBN,O
for,IN,O
more,JJR,O
inhalations,NNS,O
than,IN,O
usual,JJ,O
of,IN,O
short-acting,JJ,O
",",",",O
inhaled,VBD,O
beta2-agonists,NNS,G
.,.,.
,,
iv,NN,O
.,.,.
,,
foradil,NNP,B
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
as,IN,O
a,DT,O
substitute,NN,O
for,IN,O
oral,JJ,O
or,CC,O
inhaled,VBN,O
corticosteroids,NNS,G
.,.,.
,,
the,DT,O
dosage,NN,O
of,IN,O
these,DT,O
medications,NNS,O
should,MD,O
not,RB,O
be,VB,O
changed,VBN,O
and,CC,O
they,PRP,O
should,MD,O
not,RB,O
be,VB,O
stopped,VBN,O
without,IN,O
consulting,VBG,O
the,DT,O
physician,NN,O
",",",",O
even,RB,O
if,IN,O
the,DT,O
patient,NN,O
feels,VBZ,O
better,RB,O
after,IN,O
initiating,VBG,O
treatment,NN,O
with,IN,O
foradil,NN,B
.,.,.
,,
v.,CC,O
patients,NNS,O
should,MD,O
be,VB,O
cautioned,VBN,O
regarding,VBG,O
potential,JJ,O
adverse,JJ,O
cardiovascular,JJ,O
effects,NNS,O
",",",",O
such,JJ,O
as,IN,O
palpitations,NNS,O
or,CC,O
chest,NN,O
pain,NN,O
.,.,.
,,
vi,LS,O
.,.,.
,,
in,IN,O
patients,NNS,O
receiving,VBG,O
foradil,NNP,B
",",",",O
other,JJ,O
inhaled,VBN,O
medications,NNS,O
should,MD,O
be,VB,O
used,VBN,O
only,RB,O
as,IN,O
directed,VBN,O
by,IN,O
the,DT,O
physician,NN,O
.,.,.
,,
vii,LS,O
.,.,.
,,
guardians,NNS,O
of,IN,O
children,NNS,O
who,WP,O
have,VBP,O
been,VBN,O
prescribed,VBN,O
foradil,NNP,B
should,MD,O
be,VB,O
alerted,VBN,O
to,TO,O
the,DT,O
general,JJ,O
concern,NN,O
regarding,VBG,O
asthma,NN,O
therapy,NN,O
compliance,NN,O
",",",",O
especially,RB,O
neglect,NN,O
of,IN,O
anti-inflammatory,JJ,G
therapy,NN,O
and,CC,O
overuse,NN,O
of,IN,O
short-acting,JJ,O
beta2-agonists,NNS,G
.,.,.
,,
a,DT,O
possible,JJ,O
drug,NN,D
interaction,NN,O
of,IN,O
foscavir,NNP,B
and,CC,O
intravenous,JJ,O
pentamidine,NN,D
has,VBZ,O
been,VBN,O
described,VBN,O
.,.,.
,,
concomitant,JJ,O
treatment,NN,O
of,IN,O
four,CD,O
patients,NNS,O
in,IN,O
the,DT,O
united,NNP,O
kingdom,NNP,O
with,IN,O
foscavir,NNP,B
and,CC,O
intravenous,JJ,O
pentamidine,NN,D
may,MD,O
have,VB,O
caused,VBN,O
hypocalcemia,NN,O
.,.,.
,,
one,CD,O
patient,NN,O
died,VBD,O
with,IN,O
severe,JJ,O
hypocalcemia,NN,O
.,.,.
,,
toxicity,NN,O
associated,VBN,O
with,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
aerosolized,JJ,O
pentamidine,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
reported,VBN,O
.,.,.
,,
because,IN,O
of,IN,O
foscarnets,NNS,O
tendency,NN,O
to,TO,O
cause,VB,O
renal,JJ,O
impairment,NN,O
",",",",O
the,DT,O
use,NN,O
of,IN,O
foscavir,NNP,B
should,MD,O
be,VB,O
avoided,VBN,O
in,IN,O
combination,NN,O
with,IN,O
potentially,RB,O
nephrotoxic,JJ,O
drugs,NNS,D
such,JJ,O
as,IN,O
aminoglycosides,NNS,G
",",",",O
amphotericin,NN,D
b,NN,O
and,CC,O
intravenous,JJ,O
pentamidine,NN,D
unless,IN,O
the,DT,O
potential,JJ,O
benefits,NNS,O
outweigh,VBP,O
the,DT,O
risks,NNS,O
to,TO,O
the,DT,O
patient,NN,O
.,.,.
,,
since,IN,O
foscavir,NN,B
decreases,VBZ,O
serum,NN,O
concentrations,NNS,O
of,IN,O
ionized,VBN,O
calcium,NN,D
",",",",O
concurrent,JJ,O
treatment,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
known,VBN,O
to,TO,O
influence,VB,O
serum,NN,O
calcium,NN,D
concentrations,NNS,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
particular,JJ,O
caution,NN,O
.,.,.
,,
ganciclovir,NNP,D
:,:,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
foscarnet,NN,D
and,CC,O
ganciclovir,NN,D
were,VBD,O
not,RB,O
altered,VBN,O
in,IN,O
13,CD,O
patients,NNS,O
receiving,VBG,O
either,CC,O
concomitant,JJ,O
therapy,NN,O
or,CC,O
daily,JJ,O
alternating,VBG,O
therapy,NN,O
for,IN,O
maintenance,NN,O
of,IN,O
cmv,NN,O
disease,NN,O
.,.,.
,,
metoclopramide,NNP,D
:,:,O
when,WRB,O
coadministered,VBN,O
with,IN,O
monurol,NN,B
",",",",O
metoclopramide,NN,D
",",",",O
a,DT,O
drug,NN,D
which,WDT,O
increases,VBZ,O
gastrointestinal,JJ,O
motility,NN,O
",",",",O
lowers,VBZ,O
the,DT,O
serum,NN,O
concentration,NN,O
and,CC,O
urinary,JJ,O
excretion,NN,O
of,IN,O
fosfomycin,NN,D
.,.,.
,,
other,JJ,O
drugs,NNS,D
that,WDT,O
increase,VBP,O
gastrointestinal,JJ,O
motility,NN,O
may,MD,O
produce,VB,O
similar,JJ,O
effects,NNS,O
.,.,.
,,
cimetidine,NNP,D
:,:,O
cimetidine,NN,D
does,VBZ,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
fosfomycin,NN,D
when,WRB,O
coadministered,VBN,O
with,IN,O
monurol,NN,B
.,.,.
,,
diuretics,NNS,G
:,:,O
patients,NNS,O
on,IN,O
diuretics,NNS,G
",",",",O
especially,RB,O
those,DT,O
with,IN,O
intravascular,JJ,O
volume,NN,O
depletion,NN,O
",",",",O
may,MD,O
occasionally,RB,O
experience,VB,O
an,DT,O
excessive,JJ,O
reduction,NN,O
of,IN,O
blood,NN,O
pressure,NN,O
after,IN,O
initiation,NN,O
of,IN,O
therapy,NN,O
with,IN,O
fosinopril,NN,D
sodium,NN,O
.,.,.
,,
the,DT,O
possibility,NN,O
of,IN,O
hypotensive,JJ,O
effects,NNS,O
can,MD,O
be,VB,O
minimized,VBN,O
by,IN,O
either,CC,O
discontinuing,VBG,O
the,DT,O
diuretic,JJ,G
or,CC,O
increasing,VBG,O
salt,NN,O
intake,NN,O
prior,RB,O
to,TO,O
initiation,NN,O
of,IN,O
treatment,NN,O
with,IN,O
fosinopril,NN,D
sodium,NN,O
.,.,.
,,
if,IN,O
this,DT,O
is,VBZ,O
not,RB,O
possible,JJ,O
",",",",O
the,DT,O
starting,VBG,O
dose,NN,O
should,MD,O
be,VB,O
reduced,VBN,O
and,CC,O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
several,JJ,O
hours,NNS,O
following,VBG,O
an,DT,O
initial,JJ,O
dose,NN,O
and,CC,O
until,IN,O
blood,NN,O
pressure,NN,O
has,VBZ,O
stabilized,VBN,O
-lrb-,-LRB-,O
see,VB,O
dosage,NNP,O
and,CC,O
administration,NNP,O
.,.,.
,,
-rrb-,-RRB-,O
.,.,.
,,
potassium,NN,D
supplements,NNS,O
and,CC,O
potassium-sparing,NNP,O
diuretics,NNPS,G
:,:,O
fosinopril,NN,D
sodium,NN,O
can,MD,O
attenuate,VB,O
potassium,NN,D
loss,NN,O
caused,VBN,O
by,IN,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
potassium-sparing,JJ,O
diuretics,NNS,G
-lrb-,-LRB-,O
spironolactone,NN,D
",",",",O
amiloride,NN,D
",",",",O
triamterene,NN,D
",",",",O
and,CC,O
others,NNS,O
-rrb-,-RRB-,O
or,CC,O
potassium,NN,D
supplements,NNS,O
can,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
hyperkalemia,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
if,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
such,JJ,O
agents,NNS,O
is,VBZ,O
indicated,VBN,O
",",",",O
they,PRP,O
should,MD,O
be,VB,O
given,VBN,O
with,IN,O
caution,NN,O
",",",",O
and,CC,O
the,DT,O
patients,NNS,O
serum,NN,O
potassium,NN,D
should,MD,O
be,VB,O
monitored,VBN,O
frequently,RB,O
.,.,.
,,
lithium,NN,D
:,:,O
increased,VBN,O
serum,NN,O
lithium,NN,D
levels,NNS,O
and,CC,O
symptoms,NNS,O
of,IN,O
lithium,NN,D
toxicity,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
ace,NN,O
inhibitors,NNS,O
during,IN,O
therapy,NN,O
with,IN,O
lithium,NN,D
.,.,.
,,
these,DT,O
drugs,NNS,D
should,MD,O
be,VB,O
coadministered,VBN,O
with,IN,O
caution,NN,O
",",",",O
and,CC,O
frequent,JJ,O
monitoring,NN,O
of,IN,O
serum,NN,O
lithium,NN,D
levels,NNS,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
if,IN,O
a,DT,O
diuretic,JJ,G
is,VBZ,O
also,RB,O
used,VBN,O
",",",",O
the,DT,O
risk,NN,O
of,IN,O
lithium,NN,D
toxicity,NN,O
may,MD,O
be,VB,O
increased,VBN,O
.,.,.
,,
antacids,NNS,G
:,:,O
in,IN,O
a,DT,O
clinical,JJ,O
pharmacology,NN,O
study,NN,O
",",",",O
coadministration,NN,O
of,IN,O
an,DT,O
antacid,NN,G
-lrb-,-LRB-,O
aluminum,NN,D
hydroxide,NN,O
",",",",O
magnesium,NN,D
hydroxide,NN,O
",",",",O
and,CC,O
simethicone,NN,D
-rrb-,-RRB-,O
with,IN,O
fosinopril,NN,D
reduced,VBD,O
serum,NN,O
levels,NNS,O
and,CC,O
urinary,JJ,O
excretion,NN,O
of,IN,O
fosinoprilat,NN,D_n
as,IN,O
compared,VBN,O
with,IN,O
fosinopril,NN,D
administered,VBN,O
alone,RB,O
",",",",O
suggesting,VBG,O
that,IN,O
antacids,NNS,G
may,MD,O
impair,VB,O
absorption,NN,O
of,IN,O
fosinopril,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
if,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
these,DT,O
agents,NNS,O
is,VBZ,O
indicated,VBN,O
",",",",O
dosing,NN,O
should,MD,O
be,VB,O
separated,VBN,O
by,IN,O
2,CD,O
hours,NNS,O
.,.,.
,,
other,JJ,O
:,:,O
neither,DT,O
fosinopril,NN,D
sodium,NN,O
nor,CC,O
its,PRP$,O
metabolites,NNS,O
have,VBP,O
been,VBN,O
found,VBN,O
to,TO,O
interact,VB,O
with,IN,O
food,NN,O
.,.,.
,,
in,IN,O
separate,JJ,O
single,JJ,O
or,CC,O
multiple,JJ,O
dose,NN,O
pharmacokinetic,JJ,O
interaction,NN,O
studies,NNS,O
with,IN,O
chlorthalidone,NN,D
",",",",O
nifedipine,NN,D
",",",",O
propanolol,NN,D
",",",",O
hydrochlorothiazide,NN,D
",",",",O
cimetidine,NN,D
",",",",O
metoclopramide,NN,D
",",",",O
propantheline,NN,D
",",",",O
digoxin,NN,D
",",",",O
and,CC,O
warfarin,NN,D
",",",",O
the,DT,O
bioavailability,NN,O
of,IN,O
fosinoprilat,NN,D_n
was,VBD,O
not,RB,O
altered,VBN,O
by,IN,O
coadministration,NN,O
of,IN,O
fosinopril,NN,D
with,IN,O
any,DT,O
one,CD,O
of,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
with,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
aspirin,NN,B
and,CC,O
fosinopril,NN,D
sodium,NN,O
",",",",O
the,DT,O
bioavailability,NN,O
of,IN,O
unbound,JJ,O
fosinoprilat,NN,D_n
was,VBD,O
not,RB,O
altered,VBN,O
.,.,.
,,
in,IN,O
a,DT,O
pharmacokinetic,JJ,O
interaction,NN,O
study,NN,O
with,IN,O
warfarin,NN,D
",",",",O
bioavailability,NN,O
parameters,NNS,O
",",",",O
the,DT,O
degree,NN,O
of,IN,O
protein,NN,O
binding,NN,O
",",",",O
and,CC,O
the,DT,O
anticoagulant,JJ,G
effect,NN,O
-lrb-,-LRB-,O
measured,VBN,O
by,IN,O
prothrombin,NN,O
time,NN,O
-rrb-,-RRB-,O
of,IN,O
warfarin,NN,D
were,VBD,O
not,RB,O
significantly,RB,O
changed,VBD,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interaction,NN,O
fosinopril,NN,D
may,MD,O
cause,VB,O
a,DT,O
FALSE,JJ,O
low,JJ,O
measurement,NN,O
of,IN,O
serum,NN,O
digoxin,NN,D
levels,NNS,O
with,IN,O
the,DT,O
digi,NNP,O
-,:,O
tab,NNP,O
ria,NN,O
kit,NN,O
for,IN,O
digoxin,NNP,D
.,.,.
,,
other,JJ,O
kits,NNS,O
",",",",O
such,JJ,O
as,IN,O
the,DT,O
coat-a-count,NNP,O
ria,NN,O
kit,NN,O
",",",",O
may,MD,O
be,VB,O
used,VBN,O
.,.,.
,,
no,DT,O
drugs,NNS,D
are,VBP,O
known,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
the,DT,O
conversion,NN,O
of,IN,O
fosphenytoin,NN,D
to,TO,O
phenytoin,NN,D
.,.,.
,,
conversion,NN,O
could,MD,O
be,VB,O
affected,VBN,O
by,IN,O
alterations,NNS,O
in,IN,O
the,DT,O
level,NN,O
of,IN,O
phosphatase,NN,O
activity,NN,O
",",",",O
but,CC,O
given,VBN,O
the,DT,O
abundance,NN,O
and,CC,O
wide,JJ,O
distribution,NN,O
of,IN,O
phosphatases,NNS,O
in,IN,O
the,DT,O
body,NN,O
it,PRP,O
is,VBZ,O
unlikely,JJ,O
that,IN,O
drugs,NNS,D
would,MD,O
affect,VB,O
this,DT,O
activity,NN,O
enough,RB,O
to,TO,O
affect,VB,O
conversion,NN,O
of,IN,O
fosphenytoin,NN,D
to,TO,O
phenytoin,NN,D
.,.,.
,,
drugs,NNS,O
highly,RB,O
bound,VBD,O
to,TO,O
albumin,NN,O
could,MD,O
increase,VB,O
the,DT,O
unbound,JJ,O
fraction,NN,O
of,IN,O
fosphenytoin,NN,D
.,.,.
,,
although,IN,O
",",",",O
it,PRP,O
is,VBZ,O
unknown,JJ,O
whether,IN,O
this,DT,O
could,MD,O
result,VB,O
in,IN,O
clinically,RB,O
significant,JJ,O
effects,NNS,O
",",",",O
caution,NN,O
is,VBZ,O
advised,VBN,O
when,WRB,O
administering,VBG,O
cerebyx,NN,B
with,IN,O
other,JJ,O
drugs,NNS,D
that,WDT,O
significantly,RB,O
bind,VBP,O
to,TO,O
serum,NN,O
albumin,NN,O
.,.,.
,,
the,DT,O
pharmacokinetics,NNS,O
and,CC,O
protein,NN,O
binding,NN,O
of,IN,O
fosphenytoin,NN,D
",",",",O
phenytoin,NN,D
",",",",O
and,CC,O
diazepam,NN,D
were,VBD,O
not,RB,O
altered,VBN,O
when,WRB,O
diazepam,NN,D
and,CC,O
cerebyx,NN,B
were,VBD,O
concurrently,RB,O
administered,VBN,O
in,IN,O
single,JJ,O
submaximal,JJ,O
doses,NNS,O
.,.,.
,,
the,DT,O
most,RBS,O
significant,JJ,O
drug,NN,D
interactions,NNS,O
following,VBG,O
administration,NN,O
of,IN,O
cerebyx,NNP,B
are,VBP,O
expected,VBN,O
to,TO,O
occur,VB,O
with,IN,O
drugs,NNS,D
that,WDT,O
interact,VBP,O
with,IN,O
phenytoin,NN,D
.,.,.
,,
phenytoin,NNP,D
is,VBZ,O
extensively,RB,O
bound,VBN,O
to,TO,O
serum,NN,O
plasma,NN,O
proteins,NNS,O
and,CC,O
is,VBZ,O
prone,JJ,O
to,TO,O
competitive,JJ,O
displacement,NN,O
.,.,.
,,
phenytoin,NNP,D
is,VBZ,O
metabolized,VBN,O
by,IN,O
hepatic,JJ,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
and,CC,O
is,VBZ,O
particularly,RB,O
susceptible,JJ,O
to,TO,O
inhibitory,JJ,O
drug,NN,D
interactions,NNS,O
because,IN,O
it,PRP,O
is,VBZ,O
subject,JJ,O
to,TO,O
saturable,JJ,O
metabolism,NN,O
.,.,.
,,
inhibition,NN,O
of,IN,O
metabolism,NN,O
may,MD,O
produce,VB,O
significant,JJ,O
increases,NNS,O
in,IN,O
circulating,VBG,O
phenytoin,NN,D
concentrations,NNS,O
and,CC,O
enhance,VBP,O
the,DT,O
risk,NN,O
of,IN,O
drug,NN,D
toxicity,NN,O
.,.,.
,,
phenytoin,NNP,D
is,VBZ,O
a,DT,O
potent,JJ,O
inducer,NN,O
of,IN,O
hepatic,JJ,O
drug-metabolizing,JJ,O
enzymes,NNS,O
.,.,.
,,
the,DT,O
most,RBS,O
commonly,RB,O
occurring,VBG,O
drug,NN,D
interactions,NNS,O
are,VBP,O
listed,VBN,O
below,IN,O
:,:,O
-,:,O
drugs,NNS,O
that,WDT,O
may,MD,O
increase,VB,O
plasma,NN,O
phenytoin,NN,D
concentrations,NNS,O
include,VBP,O
:,:,O
acute,JJ,O
alcohol,NN,D
intake,NN,O
",",",",O
amiodarone,NN,D
",",",",O
chboramphenicol,NN,O
",",",",O
chlordiazepoxide,NN,D
",",",",O
cimetidine,NN,D
",",",",O
diazepam,NN,D
",",",",O
dicumarol,NN,D
",",",",O
disulfiram,NN,D
",",",",O
estrogens,NNS,G
",",",",O
ethosuximide,NN,D
",",",",O
fluoxetine,NN,D
",",",",O
h2-antagonists,NNS,G
",",",",O
halothane,NN,D
",",",",O
isoniazid,NN,D
",",",",O
methylphenidate,NN,D
",",",",O
phenothiazines,NNS,G
",",",",O
phenylbutazone,NN,D
",",",",O
salicylates,NNS,G
",",",",O
succinimides,NNS,G
",",",",O
sulfonamides,NNS,G
",",",",O
tolbutamide,NN,D
",",",",O
trazodon,NN,O
.,.,.
,,
-,:,O
drugs,NNS,O
that,WDT,O
may,MD,O
decrease,VB,O
plasma,NN,O
phenytoin,NN,D
concentrations,NNS,O
include,VBP,O
:,:,O
carbamazepine,NN,D
",",",",O
chronic,JJ,O
alcohol,NN,D
abuse,NN,O
",",",",O
reserpin,NN,O
.,.,.
,,
-,:,O
drugs,NNS,O
that,WDT,O
may,MD,O
either,RB,O
increase,VB,O
or,CC,O
decrease,VB,O
plasma,NN,O
phenytoin,NN,D
concentrations,NNS,O
include,VBP,O
:,:,O
phenobarbital,NN,D
",",",",O
vaiproic,JJ,O
acid,NN,O
",",",",O
and,CC,O
sodium,NN,O
valproate,NN,D
.,.,.
,,
similarly,RB,O
",",",",O
the,DT,O
effects,NNS,O
of,IN,O
phenytoin,NN,D
on,IN,O
phenobarbital,NN,D
",",",",O
valproic,JJ,O
acid,NN,O
and,CC,O
sodium,NN,O
plasma,NN,O
valproate,NN,D
concentrations,NNS,O
are,VBP,O
unpredictabl,NN,O
.,.,.
,,
-,:,O
although,IN,O
not,RB,O
a,DT,O
TRUE,JJ,O
drug,NN,D
interaction,NN,O
",",",",O
tricyclic,JJ,G
antidepressants,NNS,G
may,MD,O
precipitate,VB,O
seizures,NNS,O
in,IN,O
susceptible,JJ,O
patients,NNS,O
and,CC,O
cerebyx,NN,B
dosage,NN,O
may,MD,O
need,VB,O
to,TO,O
be,VB,O
adjuste,JJ,O
.,.,.
,,
-,:,O
drugs,NNS,O
whose,WP$,O
efficacy,NN,O
is,VBZ,O
impaired,VBN,O
by,IN,O
phenytoin,NN,D
include,VBP,O
:,:,O
anticoagulants,NNS,G
",",",",O
corticosteroids,NNS,G
",",",",O
coumarin,NN,G
",",",",O
digitoxin,NN,D
",",",",O
doxycycline,NN,D
",",",",O
estrogens,NNS,G
",",",",O
furosemide,NN,D
",",",",O
oral,JJ,O
contraceptives,NNS,G
",",",",O
rifampin,NN,D
",",",",O
quinidine,NN,D
",",",",O
theophylline,NN,D
",",",",O
vitamin,NN,G
d.,NNP,O
monitoring,NN,O
of,IN,O
plasma,NN,O
phenytoin,NN,D
concentrations,NNS,O
may,MD,O
be,VB,O
helpful,JJ,O
when,WRB,O
possible,JJ,O
drug,NN,D
interactions,NNS,O
are,VBP,O
suspected,VBN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
phenytoin,NNP,D
may,MD,O
decrease,VB,O
serum,NN,O
concentrations,NNS,O
of,IN,O
14,CD,O
.,.,.
,,
it,PRP,O
may,MD,O
also,RB,O
produce,VB,O
artifactually,RB,O
low,JJ,O
results,NNS,O
in,IN,O
dexamethasone,NN,D
or,CC,O
metyrapone,NN,O
tests,NNS,O
.,.,.
,,
phenytoin,NNP,D
may,MD,O
also,RB,O
cause,VB,O
increased,VBN,O
serum,NN,O
concentrations,NNS,O
of,IN,O
glucose,NN,O
",",",",O
alkaline,NN,O
phosphatase,NN,O
",",",",O
and,CC,O
gamma,NN,O
glutamyl,NN,O
transpeptidase,NN,O
-lrb-,-LRB-,O
ggt,NN,O
-rrb-,-RRB-,O
.,.,.
,,
care,NNP,O
should,MD,O
be,VB,O
taken,VBN,O
when,WRB,O
using,VBG,O
immunoanalytical,JJ,O
methods,NNS,O
to,TO,O
measure,VB,O
plasma,NN,O
phenytoin,NN,D
concentrations,NNS,O
following,VBG,O
cerebyx,NNP,B
administration,NN,O
.,.,.
,,
ergot-containing,JJ,O
drugs,NNS,D
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
cause,VB,O
prolonged,JJ,O
vasospastic,JJ,O
reactions,NNS,O
.,.,.
,,
due,JJ,O
to,TO,O
a,DT,O
theoretical,JJ,O
risk,NN,O
of,IN,O
a,DT,O
pharmacodynamic,JJ,O
interaction,NN,O
",",",",O
use,NN,O
of,IN,O
ergotamine-containing,JJ,O
or,CC,O
ergot-type,JJ,O
medications,NNS,O
-lrb-,-LRB-,O
like,IN,O
dihydroergotamine,NN,D
or,CC,O
methysergide,NN,D
-rrb-,-RRB-,O
and,CC,O
frova,NN,B
within,IN,O
24,CD,O
hours,NNS,O
of,IN,O
each,DT,O
other,JJ,O
should,MD,O
be,VB,O
avoided,VBN,O
-lrb-,-LRB-,O
see,VB,O
a,DT,O
href,NN,O
=,JJ,O
frova,NN,O
.,.,.
,,
htm,NN,O
#ci,NN,O
contraindications,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
other,JJ,O
5-ht1b,NN,O
/,:,O
1d,NN,O
agonists,NNS,O
within,IN,O
24,CD,O
hours,NNS,O
of,IN,O
frova,NN,B
treatment,NN,O
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
ssris,NNS,G
-rrb-,-RRB-,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
fluoxetine,NN,D
",",",",O
fluvoxamine,NN,D
",",",",O
paroxetine,NN,D
",",",",O
sertraline,NN,D
-rrb-,-RRB-,O
have,VBP,O
been,VBN,O
reported,VBN,O
",",",",O
rarely,RB,O
",",",",O
to,TO,O
cause,VB,O
weakness,NN,O
",",",",O
hyperreflexia,NN,O
",",",",O
and,CC,O
incoordination,NN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
5-ht1,NN,O
agonists,NNS,O
.,.,.
,,
if,IN,O
concomitant,JJ,O
treatment,NN,O
with,IN,O
frovatriptan,NN,D
and,CC,O
an,DT,O
ssri,NNP,G
is,VBZ,O
clinically,RB,O
warranted,VBN,O
",",",",O
appropriate,JJ,O
observation,NN,O
of,IN,O
the,DT,O
patient,NN,O
is,VBZ,O
advised,VBN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
frova,NN,B
is,VBZ,O
not,RB,O
known,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
commonly,RB,O
employed,VBN,O
clinical,JJ,O
laboratory,NN,O
tests,NNS,O
.,.,.
,,
fulvestrant,NNP,D
is,VBZ,O
metabolized,VBN,O
by,IN,O
cyp,NN,O
3a4,NN,O
in,FW,O
vitro,FW,O
.,.,.
,,
clinical,JJ,O
studies,NNS,O
of,IN,O
the,DT,O
effect,NN,O
of,IN,O
strong,JJ,O
cyp,NN,O
3a4,NN,O
inhibitors,NNS,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
fulvestrant,NN,D
have,VBP,O
not,RB,O
been,VBN,O
performed,VBN,O
.,.,.
,,
carcinogenesis,NN,O
",",",",O
mutagenesis,NN,O
and,CC,O
impairment,NN,O
of,IN,O
fertility,NN,O
a,NN,O
two-year,JJ,O
carcinogenesis,NN,O
study,NN,O
was,VBD,O
conducted,VBN,O
in,IN,O
female,JJ,O
and,CC,O
male,JJ,O
rats,NNS,O
",",",",O
at,IN,O
intramuscular,JJ,O
doses,NNS,O
of,IN,O
15,CD,O
mg/kg/30,CD,O
days,NNS,O
",",",",O
10,CD,O
mg/rat/30,CD,O
days,NNS,O
and,CC,O
10,CD,O
mg/rat/15,CD,O
days,NNS,O
.,.,.
,,
these,DT,O
doses,NNS,O
correspond,VBP,O
to,TO,O
approximately,RB,O
1,CD,O
-,:,O
",",",",O
3,LS,O
-,:,O
",",",",O
and,CC,O
5-fold,RB,O
-lrb-,-LRB-,O
in,IN,O
females,NNS,O
-rrb-,-RRB-,O
and,CC,O
1.3,CD,O
-,:,O
",",",",O
1.3,CD,O
-,:,O
",",",",O
and,CC,O
1.6-fold,RB,O
-lrb-,-LRB-,O
in,IN,O
males,NNS,O
-rrb-,-RRB-,O
the,DT,O
systemic,JJ,O
exposure,NN,O
-lsb-,-LRB-,O
auc0-30,CD,O
days,NNS,O
-rsb-,-RRB-,O
-rsb-,-RRB-,O
achieved,VBN,O
in,IN,O
women,NNS,O
receiving,VBG,O
the,DT,O
recommended,VBN,O
dose,NN,O
of,IN,O
250,CD,O
mg/month,NN,O
.,.,.
,,
an,DT,O
increased,VBN,O
incidence,NN,O
of,IN,O
benign,JJ,O
ovarian,JJ,O
granulosa,NN,O
cell,NN,O
tumors,NNS,O
and,CC,O
testicular,JJ,O
leydig,NN,O
cell,NN,O
tumors,NNS,O
was,VBD,O
evident,JJ,O
",",",",O
in,IN,O
females,NNS,O
dosed,VBN,O
at,IN,O
10,CD,O
mg/rat/15,CD,O
days,NNS,O
and,CC,O
males,NNS,O
dosed,VBN,O
at,IN,O
15,CD,O
mg/rat/30,CD,O
days,NNS,O
",",",",O
respectively,RB,O
.,.,.
,,
induction,NN,O
of,IN,O
such,JJ,O
tumors,NNS,O
is,VBZ,O
consistent,JJ,O
with,IN,O
the,DT,O
pharmacology-related,JJ,O
endocrine,JJ,O
feedback,NN,O
alterations,NNS,O
in,IN,O
gonadotropin,NN,O
levels,NNS,O
caused,VBN,O
by,IN,O
an,DT,O
antiestrogen,NN,G
.,.,.
,,
fulvestrant,NN,D
was,VBD,O
not,RB,O
mutagenic,JJ,O
or,CC,O
clastogenic,JJ,O
in,IN,O
multiple,JJ,O
in,FW,O
vitro,FW,O
tests,NNS,O
with,IN,O
and,CC,O
without,IN,O
the,DT,O
addition,NN,O
of,IN,O
a,DT,O
mammalian,JJ,O
liver,NN,O
metabolic,JJ,O
activation,NN,O
factor,NN,O
-lrb-,-LRB-,O
bacterial,JJ,O
mutation,NN,O
assay,NN,O
in,IN,O
strains,NNS,O
of,IN,O
salmonella,FW,O
typhimurium,FW,O
and,CC,O
escherichia,FW,O
coli,FW,O
",",",",O
in,FW,O
vitro,FW,O
cytogenetics,NNS,O
study,NN,O
in,IN,O
human,JJ,O
lymphocytes,NNS,O
",",",",O
mammalian,JJ,O
cell,NN,O
mutation,NN,O
assay,NN,O
in,IN,O
mouse,NN,O
lymphoma,NN,O
cells,NNS,O
and,CC,O
in,FW,O
vivo,FW,O
micronucleus,FW,O
test,NN,O
in,IN,O
rat,NN,O
.,.,.
,,
in,IN,O
female,JJ,O
rats,NNS,O
",",",",O
fulvestrant,JJ,D
administered,VBN,O
at,IN,O
doses,NNS,O
0.01,CD,O
mg/kg/day,NN,O
-lrb-,-LRB-,O
approximately,RB,O
one-hundredth,JJ,O
of,IN,O
the,DT,O
human,JJ,O
recommended,VBN,O
dose,NN,O
based,VBN,O
on,IN,O
body,NN,O
surface,NN,O
area,NN,O
-lsb-,-LRB-,O
bsa,NN,O
-rsb-,-RRB-,O
",",",",O
for,IN,O
2,CD,O
weeks,NNS,O
prior,RB,O
to,TO,O
and,CC,O
for,IN,O
1,CD,O
week,NN,O
following,VBG,O
mating,NN,O
",",",",O
caused,VBD,O
a,DT,O
reduction,NN,O
in,IN,O
fertility,NN,O
and,CC,O
embryonic,JJ,O
survival,NN,O
.,.,.
,,
no,DT,O
adverse,JJ,O
effects,NNS,O
on,IN,O
female,JJ,O
fertility,NN,O
and,CC,O
embryonic,JJ,O
survival,NN,O
were,VBD,O
evident,JJ,O
in,IN,O
female,JJ,O
animals,NNS,O
dosed,VBN,O
at,IN,O
0.001,CD,O
mg/kg/day,NN,O
-lrb-,-LRB-,O
approximately,RB,O
one-thousandth,JJ,O
of,IN,O
the,DT,O
human,JJ,O
dose,NN,O
based,VBN,O
on,IN,O
bsa,NN,O
-rrb-,-RRB-,O
.,.,.
,,
restoration,NN,O
of,IN,O
female,JJ,O
fertility,NN,O
to,TO,O
values,NNS,O
similar,JJ,O
to,TO,O
controls,NNS,O
was,VBD,O
evident,JJ,O
following,VBG,O
a,DT,O
29-day,JJ,O
withdrawal,NN,O
period,NN,O
after,IN,O
dosing,NN,O
at,IN,O
2,CD,O
mg/kg/day,NN,O
-lrb-,-LRB-,O
twice,RB,O
the,DT,O
human,JJ,O
dose,NN,O
based,VBN,O
on,IN,O
bsa,NN,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
fulvestrant,NN,D
on,IN,O
the,DT,O
fertility,NN,O
of,IN,O
female,JJ,O
rats,NNS,O
appear,VBP,O
to,TO,O
be,VB,O
consistent,JJ,O
with,IN,O
its,PRP$,O
anti-estrogenic,JJ,O
activity,NN,O
.,.,.
,,
the,DT,O
potential,JJ,O
effects,NNS,O
of,IN,O
fulvestrant,NN,D
on,IN,O
the,DT,O
fertility,NN,O
of,IN,O
male,JJ,O
animals,NNS,O
were,VBD,O
not,RB,O
studied,VBN,O
but,CC,O
in,IN,O
a,DT,O
6-month,JJ,O
toxicology,NN,O
study,NN,O
",",",",O
male,JJ,O
rats,NNS,O
treated,VBN,O
with,IN,O
intramuscular,JJ,O
doses,NNS,O
of,IN,O
15,CD,O
mg/kg/30,CD,O
days,NNS,O
",",",",O
10,CD,O
mg/rat/30,CD,O
days,NNS,O
",",",",O
or,CC,O
10,CD,O
mg/rat/15,CD,O
days,NNS,O
fulvestrant,JJ,D
showed,VBD,O
a,DT,O
loss,NN,O
of,IN,O
spermatozoa,NN,O
from,IN,O
the,DT,O
seminiferous,JJ,O
tubules,NNS,O
",",",",O
seminiferous,JJ,O
tubular,JJ,O
atrophy,NN,O
",",",",O
and,CC,O
degenerative,JJ,O
changes,NNS,O
in,IN,O
the,DT,O
epididymides,NNS,O
.,.,.
,,
changes,NNS,O
in,IN,O
the,DT,O
testes,NNS,O
and,CC,O
epididymides,NNS,O
had,VBD,O
not,RB,O
recovered,VBN,O
20,CD,O
weeks,NNS,O
after,IN,O
cessation,NN,O
of,IN,O
dosing,NN,O
.,.,.
,,
these,DT,O
fulvestrant,JJ,D
doses,NNS,O
correspond,VBP,O
to,TO,O
approximately,RB,O
2,CD,O
-,:,O
",",",",O
3,LS,O
-,:,O
",",",",O
and,CC,O
3-fold,RB,O
the,DT,O
systemic,JJ,O
exposure,NN,O
-lsb-,-LRB-,O
auc0-30,CD,O
days,NNS,O
-rsb-,-RRB-,O
achieved,VBN,O
in,IN,O
women,NNS,O
.,.,.
,,
pregnancy,NNP,O
pregnancy,NNP,O
category,NNP,O
d,NNP,O
:,:,O
.,.,.
,,
in,IN,O
studies,NNS,O
in,IN,O
female,JJ,O
rats,NNS,O
at,IN,O
doses,NNS,O
0.01,CD,O
mg/kg/day,NN,O
-lrb-,-LRB-,O
im,NN,O
;,:,O
.,.,.
,,
approximately,RB,O
one-hundredth,NN,O
of,IN,O
the,DT,O
human,JJ,O
recommended,VBN,O
dose,NN,O
based,VBN,O
on,IN,O
body,NN,O
surface,NN,O
area,NN,O
-lsb-,-LRB-,O
bsa,NN,O
-rsb-,-RRB-,O
-rrb-,-RRB-,O
",",",",O
fulvestrant,NN,D
caused,VBD,O
a,DT,O
reversible,JJ,O
reduction,NN,O
in,IN,O
female,JJ,O
fertility,NN,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
effects,NNS,O
on,IN,O
embryo/fetal,JJ,O
development,NN,O
consistent,JJ,O
with,IN,O
its,PRP$,O
anti-estrogenic,JJ,O
activity,NN,O
.,.,.
,,
fulvestrant,NN,D
caused,VBD,O
an,DT,O
increased,VBN,O
incidence,NN,O
of,IN,O
fetal,JJ,O
abnormalities,NNS,O
in,IN,O
rats,NNS,O
-lrb-,-LRB-,O
tarsal,JJ,O
flexure,NN,O
of,IN,O
the,DT,O
hind,JJ,O
paw,NN,O
at,IN,O
2,CD,O
mg/kg/day,NN,O
im,NN,O
.,.,.
,,
twice,RB,O
the,DT,O
human,JJ,O
dose,NN,O
on,IN,O
bsa,NN,O
-rrb-,-RRB-,O
and,CC,O
non-ossification,NN,O
of,IN,O
the,DT,O
odontoid,NN,O
and,CC,O
ventral,JJ,O
tubercle,NN,O
of,IN,O
the,DT,O
first,JJ,O
cervical,JJ,O
vertebra,NN,O
at,IN,O
doses,NNS,O
0.1,CD,O
mg/kg/day,NN,O
im,NN,O
-lrb-,-LRB-,O
approximately,RB,O
one-tenth,NN,O
of,IN,O
the,DT,O
human,JJ,O
dose,NN,O
on,IN,O
bsa,NN,O
-rrb-,-RRB-,O
when,WRB,O
administered,VBN,O
during,IN,O
the,DT,O
period,NN,O
of,IN,O
organogenesis,NN,O
.,.,.
,,
rabbits,NNS,O
failed,VBD,O
to,TO,O
maintain,VB,O
pregnancy,NN,O
when,WRB,O
dosed,VBN,O
with,IN,O
1,CD,O
mg/kg/day,NN,O
fulvestrant,JJ,D
im,NN,O
-lrb-,-LRB-,O
twice,RB,O
the,DT,O
human,JJ,O
dose,NN,O
on,IN,O
bsa,NN,O
-rrb-,-RRB-,O
during,IN,O
the,DT,O
period,NN,O
of,IN,O
organogenesis,NN,O
.,.,.
,,
further,RB,O
",",",",O
in,IN,O
rabbits,NNS,O
dosed,VBN,O
at,IN,O
0.25,CD,O
mg/kg/day,NN,O
-lrb-,-LRB-,O
about,IN,O
one-half,NN,O
the,DT,O
human,JJ,O
dose,NN,O
on,IN,O
bsa,NN,O
-rrb-,-RRB-,O
",",",",O
increases,VBZ,O
in,IN,O
placental,JJ,O
weight,NN,O
and,CC,O
post-implantation,JJ,O
loss,NN,O
were,VBD,O
observed,VBN,O
but,CC,O
",",",",O
there,EX,O
were,VBD,O
no,DT,O
observed,VBN,O
effects,NNS,O
on,IN,O
fetal,JJ,O
development,NN,O
.,.,.
,,
fulvestrant,NN,D
was,VBD,O
associated,VBN,O
with,IN,O
an,DT,O
increased,VBN,O
incidence,NN,O
of,IN,O
fetal,JJ,O
variations,NNS,O
in,IN,O
rabbits,NNS,O
-lrb-,-LRB-,O
backwards,RB,O
displacement,NN,O
of,IN,O
the,DT,O
pelvic,JJ,O
girdle,NN,O
",",",",O
and,CC,O
27,CD,O
pre-sacral,JJ,O
vertebrae,NNS,O
at,IN,O
0.25,CD,O
mg/kg/day,NN,O
im,NN,O
.,.,.
,,
one-half,NN,O
the,DT,O
human,JJ,O
dose,NN,O
on,IN,O
bsa,NN,O
-rrb-,-RRB-,O
when,WRB,O
administered,VBN,O
during,IN,O
the,DT,O
period,NN,O
of,IN,O
organogenesis,NN,O
.,.,.
,,
because,IN,O
pregnancy,NN,O
could,MD,O
not,RB,O
be,VB,O
maintained,VBN,O
in,IN,O
the,DT,O
rabbit,NN,O
following,VBG,O
doses,NNS,O
of,IN,O
fulvestrant,NN,D
of,IN,O
1,CD,O
mg/kg/day,NN,O
and,CC,O
above,RB,O
",",",",O
this,DT,O
study,NN,O
was,VBD,O
inadequate,JJ,O
to,TO,O
fully,RB,O
define,VB,O
the,DT,O
possible,JJ,O
adverse,JJ,O
effects,NNS,O
on,IN,O
fetal,JJ,O
development,NN,O
at,IN,O
clinically,RB,O
relevant,JJ,O
exposures,NNS,O
.,.,.
,,
nursing,NNP,O
mothers,NNP,O
fulvestrant,NNP,D
is,VBZ,O
found,VBN,O
in,IN,O
rat,NN,O
milk,NN,O
at,IN,O
levels,NNS,O
significantly,RB,O
higher,JJR,O
-lrb-,-LRB-,O
approximately,RB,O
12-fold,RB,O
-rrb-,-RRB-,O
than,IN,O
plasma,NN,O
after,IN,O
administration,NN,O
of,IN,O
2,CD,O
mg/kg,NN,O
.,.,.
,,
drug,NN,O
exposure,NN,O
in,IN,O
rodent,JJ,O
pups,NNS,O
from,IN,O
fulvestrant-treated,JJ,O
lactating,NN,O
dams,NNS,O
was,VBD,O
estimated,VBN,O
as,IN,O
10,CD,O
%,NN,O
of,IN,O
the,DT,O
administered,VBN,O
dose,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
if,IN,O
fulvestrant,NN,D
is,VBZ,O
excreted,VBN,O
in,IN,O
human,JJ,O
milk,NN,O
.,.,.
,,
because,IN,O
many,JJ,O
drugs,NNS,D
are,VBP,O
excreted,VBN,O
in,IN,O
human,JJ,O
milk,NN,O
",",",",O
and,CC,O
because,IN,O
of,IN,O
the,DT,O
potential,NN,O
for,IN,O
serious,JJ,O
adverse,JJ,O
reactions,NNS,O
from,IN,O
faslodex,NNP,B
in,IN,O
nursing,NN,O
infants,NNS,O
",",",",O
a,DT,O
decision,NN,O
should,MD,O
be,VB,O
made,VBN,O
whether,IN,O
to,TO,O
discontinue,VB,O
nursing,NN,O
or,CC,O
to,TO,O
discontinue,VB,O
the,DT,O
drug,NN,D
taking,VBG,O
into,IN,O
account,NN,O
the,DT,O
importance,NN,O
of,IN,O
the,DT,O
drug,NN,D
to,TO,O
the,DT,O
mother,NN,O
.,.,.
,,
pediatric,NNP,O
use,NNP,O
the,NNP,O
safety,NN,O
and,CC,O
efficacy,NN,O
of,IN,O
faslodex,NNP,B
in,IN,O
pediatric,JJ,O
patients,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
geriatric,NNP,O
use,NNP,O
when,WRB,O
tumor,NN,O
response,NN,O
was,VBD,O
considered,VBN,O
by,IN,O
age,NN,O
",",",",O
objective,JJ,O
responses,NNS,O
were,VBD,O
seen,VBN,O
in,IN,O
24,CD,O
%,NN,O
and,CC,O
22,CD,O
%,NN,O
of,IN,O
patients,NNS,O
under,IN,O
65,CD,O
years,NNS,O
of,IN,O
age,NN,O
and,CC,O
in,IN,O
16,CD,O
%,NN,O
and,CC,O
11,CD,O
%,NN,O
of,IN,O
patients,NNS,O
65,CD,O
years,NNS,O
of,IN,O
age,NN,O
and,CC,O
older,JJR,O
",",",",O
who,WP,O
were,VBD,O
treated,VBN,O
with,IN,O
faslodex,NNP,B
in,IN,O
the,DT,O
european,JJ,O
and,CC,O
north,JJ,O
american,JJ,O
trials,NNS,O
",",",",O
respectively,RB,O
.,.,.
,,
furosemide,NN,D
may,MD,O
increase,VB,O
the,DT,O
ototoxic,JJ,O
potential,NN,O
of,IN,O
aminoglycoside,NN,G
antibiotics,NNS,G
",",",",O
especially,RB,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
impaired,JJ,O
renal,JJ,O
function,NN,O
.,.,.
,,
except,IN,O
in,IN,O
life-threatening,JJ,O
situations,NNS,O
",",",",O
avoid,VB,O
this,DT,O
combination,NN,O
.,.,.
,,
furosemide,NN,D
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
concomitantly,RB,O
with,IN,O
ethacrynic,JJ,O
acid,NN,O
because,IN,O
of,IN,O
the,DT,O
possibility,NN,O
of,IN,O
ototoxicity,NN,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
high,JJ,O
doses,NNS,O
of,IN,O
salicylates,NNS,G
concomitantly,RB,O
with,IN,O
furosemide,NN,D
",",",",O
as,IN,O
in,IN,O
rheumatic,JJ,O
disease,NN,O
",",",",O
may,MD,O
experience,VB,O
salicylate,NN,G
toxicity,NN,O
at,IN,O
lower,JJR,O
doses,NNS,O
because,IN,O
of,IN,O
competitive,JJ,O
renal,JJ,O
excretory,NN,O
sites,NNS,O
.,.,.
,,
furosemide,NNP,D
has,VBZ,O
a,DT,O
tendency,NN,O
to,TO,O
antagonize,VB,O
the,DT,O
skeletal,JJ,O
muscle,NN,O
relaxing,NN,O
effect,NN,O
of,IN,O
tubocurarine,NN,D
and,CC,O
may,MD,O
potentiate,VB,O
the,DT,O
action,NN,O
of,IN,O
succinylcholine,NN,D
.,.,.
,,
lithium,NN,D
generally,RB,O
should,MD,O
not,RB,O
be,VB,O
given,VBN,O
with,IN,O
diuretics,NNS,G
because,IN,O
they,PRP,O
reduce,VBP,O
lithiums,NNS,O
renal,JJ,O
clearance,NN,O
and,CC,O
add,VB,O
a,DT,O
high,JJ,O
risk,NN,O
of,IN,O
lithium,NN,D
toxicity,NN,O
.,.,.
,,
furosemide,NN,D
may,MD,O
add,VB,O
to,TO,O
or,CC,O
potentiate,VB,O
the,DT,O
therapeutic,JJ,O
effect,NN,O
of,IN,O
other,JJ,O
antihypertensive,JJ,G
drugs,NNS,D
.,.,.
,,
potentiation,NN,O
occurs,VBZ,O
with,IN,O
ganglionic,JJ,O
or,CC,O
peripheral,JJ,O
adrenergic,JJ,G
blocking,NN,O
drugs,NNS,D
.,.,.
,,
furosemide,NN,D
may,MD,O
decrease,VB,O
arterial,JJ,O
responsiveness,NN,O
to,TO,O
norepinephrine,NN,D
.,.,.
,,
however,RB,O
",",",",O
norepinephrine,NN,D
may,MD,O
still,RB,O
be,VB,O
used,VBN,O
effectively,RB,O
.,.,.
,,
tablets,NNS,O
simultaneous,JJ,O
administration,NN,O
of,IN,O
sucralfate,NN,D
and,CC,O
furosemide,NN,D
tablets,NNS,O
may,MD,O
reduce,VB,O
the,DT,O
natriuretic,JJ,O
and,CC,O
antihypertensive,JJ,G
effects,NNS,O
of,IN,O
furosemide,NN,D
.,.,.
,,
patients,NNS,O
receiving,VBG,O
both,CC,O
drugs,NNS,D
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
to,TO,O
determine,VB,O
if,IN,O
the,DT,O
desired,VBN,O
diuretic,JJ,G
and/or,CC,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
furosemide,NN,D
is,VBZ,O
achieved,VBN,O
.,.,.
,,
the,DT,O
intake,NN,O
of,IN,O
furosemide,NN,D
and,CC,O
sucralfate,NN,D
should,MD,O
be,VB,O
separated,VBN,O
by,IN,O
at,IN,O
least,JJS,O
two,CD,O
hours,NNS,O
.,.,.
,,
tablets,NNS,O
",",",",O
injection,NN,O
",",",",O
and,CC,O
oral,NNP,O
solution,NN,O
one,CD,O
study,NN,O
in,IN,O
six,CD,O
subjects,NNS,O
demonstrated,VBD,O
that,IN,O
the,DT,O
combination,NN,O
of,IN,O
furosemide,NN,D
and,CC,O
acetylsalicylic,JJ,O
acid,NN,O
temporarily,RB,O
reduced,VBD,O
creatinine,NN,O
clearance,NN,O
in,IN,O
patients,NNS,O
with,IN,O
chronic,JJ,O
renal,JJ,O
insufficiency,NN,O
.,.,.
,,
there,EX,O
are,VBP,O
case,NN,O
reports,NNS,O
of,IN,O
patients,NNS,O
who,WP,O
developed,VBD,O
increased,VBN,O
bun,NN,O
",",",",O
serum,NN,O
creatinine,NN,O
and,CC,O
serum,NN,O
potassium,NN,D
levels,NNS,O
",",",",O
and,CC,O
weight,NN,O
gain,NN,O
when,WRB,O
furosemide,NN,D
was,VBD,O
used,VBN,O
in,IN,O
conjunction,NN,O
with,IN,O
nsaids,NNS,G
.,.,.
,,
literature,NN,O
reports,NNS,O
indicate,VBP,O
that,IN,O
coadministration,NN,O
of,IN,O
indomethacin,NN,D
may,MD,O
reduce,VB,O
the,DT,O
natriuretic,JJ,O
and,CC,O
antihypertensive,JJ,G
effects,NNS,O
of,IN,O
furosemide,NN,D
in,IN,O
some,DT,O
patients,NNS,O
by,IN,O
inhibiting,VBG,O
prostaglandin,NN,O
synthesis,NN,O
.,.,.
,,
indomethacin,NN,D
may,MD,O
also,RB,O
affect,VB,O
plasma,NN,O
renin,NN,O
levels,NNS,O
",",",",O
aldosterone,NN,O
excretion,NN,O
",",",",O
and,CC,O
renin,NN,O
profile,NN,O
evaluation,NN,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
both,CC,O
indomethacin,NN,D
and,CC,O
furosemide,NN,D
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
to,TO,O
determine,VB,O
if,IN,O
the,DT,O
desired,VBN,O
diuretic,JJ,G
and/or,CC,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
furosemide,NN,D
is,VBZ,O
achieved,VBN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
were,VBD,O
conducted,VBN,O
to,TO,O
investigate,VB,O
the,DT,O
potential,NN,O
of,IN,O
gabapentin,NN,D
to,TO,O
inhibit,VB,O
the,DT,O
major,JJ,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
-lrb-,-LRB-,O
cyp1a2,NN,D
",",",",O
cyp2a6,NN,O
",",",",O
cyp2c9,NN,D
",",",",O
cyp2c19,NN,O
",",",",O
cyp2d6,NN,D
",",",",O
cyp2e1,NN,O
",",",",O
and,CC,O
cyp3a4,NN,D
-rrb-,-RRB-,O
that,WDT,O
mediate,VBP,O
drug,NN,D
and,CC,O
xenobiotic,JJ,O
metabolism,NN,O
using,VBG,O
isoform,NN,O
selective,JJ,O
marker,NN,O
substrates,NNS,O
and,CC,O
human,JJ,O
liver,NN,O
microsomal,JJ,O
preparations,NNS,O
.,.,.
,,
only,RB,O
at,IN,O
the,DT,O
highest,JJS,O
concentration,NN,O
tested,VBN,O
-lrb-,-LRB-,O
171,CD,O
.,.,.
,,
g/ml,NN,O
;,:,O
.,.,.
,,
1,CD,O
mm,NN,O
-rrb-,-RRB-,O
was,VBD,O
a,DT,O
slight,JJ,O
degree,NN,O
of,IN,O
inhibition,NN,O
-lrb-,-LRB-,O
14,CD,O
%,NN,O
-30,CD,O
%,NN,O
-rrb-,-RRB-,O
of,IN,O
isoform,NN,O
cyp2a6,NN,O
observed,VBN,O
.,.,.
,,
no,DT,O
inhibition,NN,O
of,IN,O
any,DT,O
of,IN,O
the,DT,O
other,JJ,O
isoforms,NNS,O
tested,VBN,O
was,VBD,O
observed,VBN,O
at,IN,O
gabapentin,NN,D
concentrations,NNS,O
up,IN,O
to,TO,O
171,CD,O
mg/ml,NN,O
-lrb-,-LRB-,O
approximately,RB,O
15,CD,O
times,NNS,O
the,DT,O
cmax,NN,O
at,IN,O
3600,CD,O
mg/day,NN,O
-rrb-,-RRB-,O
.,.,.
,,
gabapentin,NNP,D
is,VBZ,O
not,RB,O
appreciably,RB,O
metabolized,VBN,O
nor,CC,O
does,VBZ,O
it,PRP,O
interfere,VB,O
with,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
commonly,RB,O
coadministered,VBN,O
antiepileptic,JJ,O
drugs,NNS,D
.,.,.
,,
the,DT,O
drug,NN,D
interaction,NN,O
data,NNS,O
described,VBN,O
in,IN,O
this,DT,O
section,NN,O
were,VBD,O
obtained,VBN,O
from,IN,O
studies,NNS,O
involving,VBG,O
healthy,JJ,O
adults,NNS,O
and,CC,O
adult,JJ,O
patients,NNS,O
with,IN,O
epilepsy,NN,O
.,.,.
,,
phenytoin,NNP,D
:,:,O
in,IN,O
a,DT,O
single,JJ,O
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
-rrb-,-RRB-,O
and,CC,O
multiple,JJ,O
dose,NN,O
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
tid,NN,O
-rrb-,-RRB-,O
study,NN,O
of,IN,O
neurontin,NNP,B
in,IN,O
epileptic,JJ,O
patients,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
8,CD,O
-rrb-,-RRB-,O
maintained,VBN,O
on,IN,O
phenytoin,NN,D
monotherapy,NN,O
for,IN,O
at,IN,O
least,JJS,O
2,CD,O
months,NNS,O
",",",",O
gabapentin,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
steady-state,JJ,O
trough,NN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
phenytoin,NN,D
and,CC,O
phenytoin,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
gabapentin,NN,D
pharmacokinetics,NNS,O
.,.,.
,,
carbamazepine,NNP,D
:,:,O
steady-state,JJ,O
trough,NN,O
plasma,NN,O
carbamazepine,NN,D
and,CC,O
carbamazepine,NN,D
10,CD,O
",",",",O
11,CD,O
epoxide,NN,O
concentrations,NNS,O
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
concomitant,JJ,O
gabapentin,NN,D
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
tid,NN,O
.,.,.
,,
n,NN,O
=,JJ,O
12,CD,O
-rrb-,-RRB-,O
administration,NN,O
.,.,.
,,
likewise,RB,O
",",",",O
gabapentin,NN,D
pharmacokinetics,NNS,O
were,VBD,O
unaltered,JJ,O
by,IN,O
carbamazepine,NN,D
administration,NN,O
.,.,.
,,
valproic,JJ,O
acid,NN,O
:,:,O
the,DT,O
mean,NN,O
steady-state,JJ,O
trough,NN,O
serum,NN,O
valproic,JJ,O
acid,NN,O
concentrations,NNS,O
prior,RB,O
to,TO,O
and,CC,O
during,IN,O
concomitant,JJ,O
gabapentin,NN,D
administration,NN,O
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
tid,NN,O
.,.,.
,,
n,NN,O
=,JJ,O
17,CD,O
-rrb-,-RRB-,O
were,VBD,O
not,RB,O
different,JJ,O
and,CC,O
neither,CC,O
were,VBD,O
gabapentin,NN,D
pharmacokinetic,JJ,O
parameters,NNS,O
affected,VBN,O
by,IN,O
valproic,JJ,O
acid,NN,O
.,.,.
,,
phenobarbital,NNP,D
:,:,O
estimates,NNS,O
of,IN,O
steady-state,JJ,O
pharmacokinetic,JJ,O
parameters,NNS,O
for,IN,O
phenobarbital,NN,D
or,CC,O
gabapentin,NN,D
-lrb-,-LRB-,O
300,CD,O
mg,NN,O
tid,NN,O
.,.,.
,,
n,NN,O
=,JJ,O
12,CD,O
-rrb-,-RRB-,O
are,VBP,O
identical,JJ,O
whether,IN,O
the,DT,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
alone,RB,O
or,CC,O
together,RB,O
.,.,.
,,
naproxen,NN,D
:,:,O
coadministration,NN,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
18,CD,O
-rrb-,-RRB-,O
of,IN,O
naproxen,NN,D
sodium,NN,O
capsules,NNS,O
-lrb-,-LRB-,O
250,CD,O
mg,NN,O
-rrb-,-RRB-,O
with,IN,O
neurontin,NN,B
-lrb-,-LRB-,O
125,CD,O
mg,NN,O
-rrb-,-RRB-,O
appears,VBZ,O
to,TO,O
increase,VB,O
the,DT,O
amount,NN,O
of,IN,O
gabapentin,NN,D
absorbed,VBN,O
by,IN,O
12,CD,O
%,NN,O
to,TO,O
15,CD,O
%,NN,O
.,.,.
,,
gabapentin,NNP,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
naproxen,NN,D
pharmacokinetic,JJ,O
parameters,NNS,O
.,.,.
,,
these,DT,O
doses,NNS,O
are,VBP,O
lower,JJR,O
than,IN,O
the,DT,O
therapeutic,JJ,O
doses,NNS,O
for,IN,O
both,DT,O
drugs,NNS,D
.,.,.
,,
the,DT,O
magnitude,NN,O
of,IN,O
interaction,NN,O
within,IN,O
the,DT,O
recommended,VBN,O
dose,NN,O
ranges,NNS,O
of,IN,O
either,CC,O
drug,NN,D
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
hydrocodone,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
neurontin,NNP,B
-lrb-,-LRB-,O
125,CD,O
to,TO,O
500,CD,O
mg,NN,O
.,.,.
,,
n,NN,O
=,JJ,O
48,CD,O
-rrb-,-RRB-,O
decreases,VBZ,O
hydrocodone,NN,D
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
.,.,.
,,
n,NN,O
=,JJ,O
50,CD,O
-rrb-,-RRB-,O
cmax,NN,O
and,CC,O
auc,NN,O
values,NNS,O
in,IN,O
a,DT,O
dose-dependent,JJ,O
manner,NN,O
relative,JJ,O
to,TO,O
administration,NN,O
of,IN,O
hydrocodone,NN,D
alone,RB,O
.,.,.
,,
cmax,NN,O
and,CC,O
auc,NN,O
values,NNS,O
are,VBP,O
3,CD,O
%,NN,O
to,TO,O
4,CD,O
%,NN,O
lower,JJR,O
",",",",O
respectively,RB,O
",",",",O
after,IN,O
administration,NN,O
of,IN,O
125,CD,O
mg,NN,O
neurontin,NN,B
and,CC,O
21,CD,O
%,NN,O
to,TO,O
22,CD,O
%,NN,O
lower,JJR,O
",",",",O
respectively,RB,O
",",",",O
after,IN,O
administration,NN,O
of,IN,O
500,CD,O
mg,NN,O
neurontin,NN,B
.,.,.
,,
the,DT,O
mechanism,NN,O
for,IN,O
this,DT,O
interaction,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
hydrocodone,NN,D
increases,VBZ,O
gabapentin,NN,D
auc,NN,O
values,NNS,O
by,IN,O
14,CD,O
%,NN,O
.,.,.
,,
the,DT,O
magnitude,NN,O
of,IN,O
interaction,NN,O
at,IN,O
other,JJ,O
doses,NNS,O
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
morphine,NNP,D
:,:,O
a,NNP,O
literature,NN,O
article,NN,O
reported,VBD,O
that,IN,O
when,WRB,O
a,DT,O
60-mg,JJ,O
controlled-release,NN,O
morphine,NN,D
capsule,NN,O
was,VBD,O
administered,VBN,O
2,CD,O
hours,NNS,O
prior,RB,O
to,TO,O
a,DT,O
600-mg,JJ,O
neurontin,NNP,B
capsule,NN,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
12,CD,O
-rrb-,-RRB-,O
",",",",O
mean,VB,O
gabapentin,NN,D
auc,NN,O
increased,VBN,O
by,IN,O
44,CD,O
%,NN,O
compared,VBN,O
to,TO,O
gabapentin,NN,D
administered,VBN,O
without,IN,O
morphine,NN,D
.,.,.
,,
morphine,NNP,D
pharmacokinetic,JJ,O
parameter,NN,O
values,NNS,O
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
administration,NN,O
of,IN,O
neurontin,NNP,B
2,CD,O
hours,NNS,O
after,IN,O
morphine,NN,D
.,.,.
,,
the,DT,O
magnitude,NN,O
of,IN,O
interaction,NN,O
at,IN,O
other,JJ,O
doses,NNS,O
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
cimetidine,NNP,D
:,:,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
cimetidine,NN,D
at,IN,O
300,CD,O
mg,NN,O
qid,NN,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
12,CD,O
-rrb-,-RRB-,O
the,DT,O
mean,NN,O
apparent,JJ,O
oral,JJ,O
clearance,NN,O
of,IN,O
gabapentin,NN,D
fell,VBD,O
by,IN,O
14,CD,O
%,NN,O
and,CC,O
creatinine,NN,O
clearance,NN,O
fell,VBD,O
by,IN,O
10,CD,O
%,NN,O
.,.,.
,,
thus,RB,O
cimetidine,NN,D
appeared,VBD,O
to,TO,O
alter,VB,O
the,DT,O
renal,JJ,O
excretion,NN,O
of,IN,O
both,CC,O
gabapentin,NN,D
and,CC,O
creatinine,NN,O
",",",",O
an,DT,O
endogenous,JJ,O
marker,NN,O
of,IN,O
renal,JJ,O
function,NN,O
.,.,.
,,
this,DT,O
small,JJ,O
decrease,NN,O
in,IN,O
excretion,NN,O
of,IN,O
gabapentin,NN,D
by,IN,O
cimetidine,NN,D
is,VBZ,O
not,RB,O
expected,VBN,O
to,TO,O
be,VB,O
of,IN,O
clinical,JJ,O
importance,NN,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
gabapentin,NN,D
on,IN,O
cimetidine,NN,D
was,VBD,O
not,RB,O
evaluated,VBN,O
.,.,.
,,
oral,JJ,O
contraceptive,NNP,G
:,:,O
based,VBN,O
on,IN,O
auc,NN,O
and,CC,O
half-life,NN,O
",",",",O
multiple-dose,JJ,O
pharmacokinetic,JJ,O
profiles,NNS,O
of,IN,O
norethindrone,NN,D
and,CC,O
ethinyl,NN,O
estradiol,NN,O
following,VBG,O
administration,NN,O
of,IN,O
tablets,NNS,O
containing,VBG,O
2.5,CD,O
mg,NN,O
of,IN,O
norethindrone,NN,D
acetate,NN,O
and,CC,O
50,CD,O
mcg,NN,O
of,IN,O
ethinyl,NN,O
estradiol,NN,O
were,VBD,O
similar,JJ,O
with,IN,O
and,CC,O
without,IN,O
coadministration,NN,O
of,IN,O
gabapentin,NN,D
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
tid,NN,O
.,.,.
,,
n,NN,O
=,JJ,O
13,CD,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
cmax,NN,O
of,IN,O
norethindrone,NN,D
was,VBD,O
13,CD,O
%,NN,O
higher,JJR,O
when,WRB,O
it,PRP,O
was,VBD,O
coadministered,VBN,O
with,IN,O
gabapentin,NN,D
.,.,.
,,
this,DT,O
interaction,NN,O
is,VBZ,O
not,RB,O
expected,VBN,O
to,TO,O
be,VB,O
of,IN,O
clinical,JJ,O
importance,NN,O
.,.,.
,,
antacid,NN,G
-lrb-,-LRB-,O
maalox,NNP,B
-rrb-,-RRB-,O
:,:,O
maalox,NNP,B
reduced,VBD,O
the,DT,O
bioavailability,NN,O
of,IN,O
gabapentin,NN,D
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
16,CD,O
-rrb-,-RRB-,O
by,IN,O
about,RB,O
20,CD,O
%,NN,O
.,.,.
,,
this,DT,O
decrease,NN,O
in,IN,O
bioavailability,NN,O
was,VBD,O
about,IN,O
5,CD,O
%,NN,O
when,WRB,O
gabapentin,NN,D
was,VBD,O
administered,VBN,O
2,CD,O
hours,NNS,O
after,IN,O
maalox,NNP,B
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
gabapentin,NN,D
be,VB,O
taken,VBN,O
at,IN,O
least,JJS,O
2,CD,O
hours,NNS,O
following,VBG,O
maalox,NNP,B
administration,NN,O
.,.,.
,,
effect,NN,O
of,IN,O
probenecid,NNP,D
:,:,O
probenecid,NNP,D
is,VBZ,O
a,DT,O
blocker,NN,O
of,IN,O
renal,JJ,O
tubular,JJ,O
secretion,NN,O
.,.,.
,,
gabapentin,NNP,D
pharmacokinetic,JJ,O
parameters,NNS,O
without,IN,O
and,CC,O
with,IN,O
probenecid,NN,D
were,VBD,O
comparable,JJ,O
.,.,.
,,
this,DT,O
indicates,VBZ,O
that,IN,O
gabapentin,NN,D
does,VBZ,O
not,RB,O
undergo,VB,O
renal,JJ,O
tubular,JJ,O
secretion,NN,O
by,IN,O
the,DT,O
pathway,NN,O
that,WDT,O
is,VBZ,O
blocked,VBN,O
by,IN,O
probenecid,NN,D
.,.,.
,,
drug/laboratory,NNP,O
tests,NNP,O
interactions,NNS,O
because,IN,O
FALSE,JJ,O
positive,JJ,O
readings,NNS,O
were,VBD,O
reported,VBN,O
with,IN,O
the,DT,O
ames,NNP,O
n-multistix,NNP,O
sg,NNP,O
dipstick,NN,O
test,NN,O
for,IN,O
urinary,JJ,O
protein,NN,O
when,WRB,O
gabapentin,NN,D
was,VBD,O
added,VBN,O
to,TO,O
other,JJ,O
antiepileptic,JJ,O
drugs,NNS,D
",",",",O
the,DT,O
more,RBR,O
specific,JJ,O
sulfosalicylic,JJ,O
acid,NN,O
precipitation,NN,O
procedure,NN,O
is,VBZ,O
recommended,VBN,O
to,TO,O
determine,VB,O
the,DT,O
presence,NN,O
of,IN,O
urine,NN,O
protei,NN,O
.,.,.
,,
laboratory,NN,O
test,NN,O
findings,VBZ,O
asymptomatic,JJ,O
",",",",O
transitory,JJ,O
changes,NNS,O
in,IN,O
serum,NN,O
iron,NN,D
have,VBP,O
been,VBN,O
observed,VBN,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
omniscan,NN,B
interferes,VBZ,O
with,IN,O
serum,NN,O
calcium,NN,D
measurements,NNS,O
with,IN,O
some,DT,O
colorimetric,JJ,O
-lrb-,-LRB-,O
complexometric,JJ,O
-rrb-,-RRB-,O
methods,NNS,O
commonly,RB,O
used,VBN,O
in,IN,O
hospitals,NNS,O
",",",",O
resulting,VBG,O
in,IN,O
serum,NN,O
calcium,NN,D
concentrations,NNS,O
lower,JJR,O
than,IN,O
the,DT,O
TRUE,JJ,O
values,NNS,O
.,.,.
,,
thus,RB,O
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
not,RB,O
to,TO,O
use,VB,O
such,JJ,O
methods,NNS,O
for,IN,O
24-Dec,CD,O
hours,NNS,O
after,IN,O
administration,NN,O
of,IN,O
omniscan,NNP,B
.,.,.
,,
if,IN,O
such,JJ,O
measurements,NNS,O
are,VBP,O
necessary,JJ,O
",",",",O
the,DT,O
use,NN,O
of,IN,O
other,JJ,O
methods,NNS,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
all,DT,O
patients,NNS,O
in,IN,O
whom,WP,O
this,DT,O
effect,NN,O
was,VBD,O
observed,VBN,O
remained,VBD,O
asymptomatic,JJ,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
no,DT,O
drug,NN,D
interactions,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
with,IN,O
the,DT,O
vitrasert,NN,B
implant,NN,O
.,.,.
,,
there,EX,O
is,VBZ,O
limited,JJ,O
experience,NN,O
with,IN,O
use,NN,O
of,IN,O
retinal,JJ,O
tamponades,NNS,O
in,IN,O
conjunction,NN,O
with,IN,O
the,DT,O
vitrasert,NN,B
implant,NN,O
.,.,.
,,
substances,NNS,O
that,WDT,O
are,VBP,O
inducers,NNS,O
of,IN,O
cyp3a4,NN,D
activity,NN,O
increase,VBP,O
the,DT,O
metabolism,NN,O
of,IN,O
gefitinib,NN,D
and,CC,O
decrease,VB,O
its,PRP$,O
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
in,IN,O
patients,NNS,O
receiving,VBG,O
a,DT,O
potent,JJ,O
cyp3a4,NN,D
inducer,NN,O
such,JJ,O
as,IN,O
rifampicin,NN,D
or,CC,O
phenytoin,NN,D
",",",",O
a,DT,O
dose,NN,O
increase,NN,O
to,TO,O
500,CD,O
mg,NN,O
daily,RB,O
should,MD,O
be,VB,O
considered,VBN,O
in,IN,O
the,DT,O
absence,NN,O
of,IN,O
severe,JJ,O
adverse,JJ,O
drug,NN,D
reaction,NN,O
",",",",O
and,CC,O
clinical,JJ,O
response,NN,O
and,CC,O
adverse,JJ,O
events,NNS,O
should,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
-lrb-,-LRB-,O
see,VB,O
clinical,NNP,O
pharmacology-pharmacokinetics-drug-drug,NNP,O
interactions,NNS,O
and,CC,O
dosage,NN,O
and,CC,O
administration-dosage,NN,O
adjustment,NNP,O
sections,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
international,NNP,O
normalized,NNP,O
ratio,NNP,O
-lrb-,-LRB-,O
inr,NNP,O
-rrb-,-RRB-,O
elevations,NNS,O
and/or,CC,O
bleeding,VBG,O
events,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
some,DT,O
patients,NNS,O
taking,VBG,O
warfarin,NN,D
while,IN,O
on,IN,O
iressa,NN,B
therapy,NN,O
.,.,.
,,
patients,NNS,O
taking,VBG,O
warfarin,NN,D
should,MD,O
be,VB,O
monitored,VBN,O
regularly,RB,O
for,IN,O
changes,NNS,O
in,IN,O
prothrombin,NN,O
time,NN,O
or,CC,O
inr,NN,O
.,.,.
,,
substances,NNS,O
that,WDT,O
are,VBP,O
potent,JJ,O
inhibitors,NNS,O
of,IN,O
cyp3a4,NN,D
activity,NN,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
ketoconazole,NN,D
and,CC,O
itraconazole,NN,D
-rrb-,-RRB-,O
decrease,NN,O
gefitinib,NN,D
metabolism,NN,O
and,CC,O
increase,NN,O
gefitinib,NN,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
this,DT,O
increase,NN,O
may,MD,O
be,VB,O
clinically,RB,O
relevant,JJ,O
as,IN,O
adverse,JJ,O
experiences,NNS,O
are,VBP,O
related,JJ,O
to,TO,O
dose,NN,O
and,CC,O
exposure,NN,O
;,:,O
.,.,.
,,
therefore,RB,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
when,WRB,O
administering,VBG,O
cyp3a4,NN,D
inhibitors,NNS,O
with,IN,O
iressa,NN,B
.,.,.
,,
drugs,NNS,O
that,WDT,O
cause,VBP,O
significant,JJ,O
sustained,JJ,O
elevation,NN,O
in,IN,O
gastric,JJ,O
ph,NN,O
-lrb-,-LRB-,O
histamine,NN,D
h2-receptor,NN,O
antagonists,NNS,O
such,JJ,O
as,IN,O
ranitidine,NN,D
or,CC,O
cimetidine,NN,D
-rrb-,-RRB-,O
may,MD,O
reduce,VB,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
iressa,NNP,B
and,CC,O
therefore,RB,O
potentially,RB,O
may,MD,O
reduce,VB,O
efficacy,NN,O
.,.,.
,,
phase,NN,O
ii,CD,O
clinical,JJ,O
trial,NN,O
data,NNS,O
",",",",O
where,WRB,O
iressa,NNP,B
and,CC,O
vinorelbine,NN,D
have,VBP,O
been,VBN,O
used,VBN,O
concomitantly,RB,O
",",",",O
indicate,VBP,O
that,IN,O
iressa,NNP,B
may,MD,O
exacerbate,VB,O
the,DT,O
neutropenic,JJ,O
effect,NN,O
of,IN,O
vinorelbine,NN,D
.,.,.
,,
no,DT,O
specific,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
for,IN,O
information,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
gemzar,NNP,B
and,CC,O
cisplatin,NN,D
in,IN,O
combination,NN,O
",",",",O
see,VBP,O
drug,NN,O
interactions,NNS,O
under,IN,O
clinical,NNP,O
pharmacology,NNP,O
section,NN,O
.,.,.
,,
-rrb-,-RRB-,O
.,.,.
,,
clinical,JJ,O
laboratory,NN,O
.,.,.
,,
increased,VBN,O
creatine,NN,O
.,.,.
,,
positive,JJ,O
antinuclear,JJ,O
.,.,.
,,
phosphokinase,NN,O
.,.,.
,,
antibody,NN,O
.,.,.
,,
increased,VBN,O
bilirubin,NN,O
.,.,.
,,
increased,VBN,O
liver,NN,O
.,.,.
,,
transaminases,NNS,O
-lrb-,-LRB-,O
ast,NNP,O
.,.,.
,,
-lrb-,-LRB-,O
sgot,NN,O
-rrb-,-RRB-,O
",",",",O
alt,NN,O
-lrb-,-LRB-,O
sgpt,NN,O
-rrb-,-RRB-,O
.,.,.
,,
increased,VBN,O
alkaline,NN,O
.,.,.
,,
phophatase,NN,O
.,.,.
,,
hematopoietic,JJ,O
.,.,.
,,
anemia,NN,O
.,.,.
,,
thrombocytopenia,NN,O
.,.,.
,,
leukopenia,NN,O
.,.,.
,,
bone,NN,O
marrow,NN,O
hypoplasia,NN,O
.,.,.
,,
eosinophilia,NN,O
.,.,.
,,
immunologic,JJ,O
.,.,.
,,
angioedema,NN,O
.,.,.
,,
anaphylaxis,NN,O
.,.,.
,,
laryngeal,JJ,O
edema,NN,O
.,.,.
,,
lupus-like,JJ,O
syndrome,NN,O
.,.,.
,,
urticaria,NN,O
.,.,.
,,
vasculitis,NN,O
.,.,.
,,
integumentary,NNP,O
.,.,.
,,
exfoliative,JJ,O
dermatitis,NN,O
.,.,.
,,
alopecia,NN,O
.,.,.
,,
rash,NN,O
.,.,.
,,
dermatitis,NN,O
.,.,.
,,
pruritus,NN,O
.,.,.
,,
administration,NN,O
of,IN,O
repeat,NN,O
doses,NNS,O
of,IN,O
factive,NNP,B
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
repeat,NN,O
dose,NN,O
pharmacokinetics,NNS,O
of,IN,O
theophylline,NN,D
",",",",O
digoxin,NN,D
or,CC,O
an,DT,O
ethinylestradiol/levonorgestrol,NN,O
oral,JJ,O
contraceptive,JJ,G
product,NN,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
factive,NN,B
and,CC,O
calcium,NN,D
carbonate,NN,O
",",",",O
cimetidine,NN,D
",",",",O
omeprazole,NN,D
",",",",O
or,CC,O
an,DT,O
estrogen/progesterone,JJ,O
oral,JJ,O
contraceptive,NN,G
produced,VBD,O
minor,JJ,O
changes,NNS,O
in,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
gemifloxacin,NN,D
",",",",O
which,WDT,O
were,VBD,O
considered,VBN,O
to,TO,O
be,VB,O
without,IN,O
clinical,JJ,O
significance,NN,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
factive,NN,B
with,IN,O
probenecid,NN,D
resulted,VBD,O
in,IN,O
a,DT,O
45,CD,O
%,NN,O
increase,NN,O
in,IN,O
systemic,JJ,O
exposure,NN,O
to,TO,O
gemifloxacin,NN,D
.,.,.
,,
factive,NNP,B
had,VBD,O
no,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
anticoagulant,JJ,G
effect,NN,O
of,IN,O
warfarin,NN,D
in,IN,O
healthy,JJ,O
subjects,NNS,O
on,IN,O
stable,JJ,O
warfarin,NN,D
therapy,NN,O
.,.,.
,,
however,RB,O
",",",",O
because,IN,O
some,DT,O
quinolones,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
enhance,VB,O
the,DT,O
anticoagulant,JJ,G
effects,NNS,O
of,IN,O
warfarin,NN,D
or,CC,O
its,PRP$,O
derivatives,NNS,O
in,IN,O
patients,NNS,O
",",",",O
the,DT,O
prothrombin,NN,O
time,NN,O
or,CC,O
other,JJ,O
suitable,JJ,O
coagulation,NN,O
test,NN,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
if,IN,O
a,DT,O
quinolone,JJ,G
antimicrobial,JJ,O
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
warfarin,NN,D
or,CC,O
its,PRP$,O
derivatives,NNS,O
.,.,.
,,
quinolones,NNS,G
form,VBP,O
chelates,NNS,O
with,IN,O
alkaline,NN,O
earth,NN,O
and,CC,O
transition,NN,O
metals,NNS,O
.,.,.
,,
the,DT,O
absorption,NN,O
of,IN,O
oral,JJ,O
gemifloxacin,NN,D
is,VBZ,O
significantly,RB,O
reduced,VBN,O
by,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
an,DT,O
antacid,NN,G
containing,VBG,O
aluminum,NN,D
and,CC,O
magnesium,NN,D
.,.,.
,,
magnesium,NN,D
-,:,O
and/or,CC,O
aluminum-containing,JJ,O
antacids,NNS,G
",",",",O
products,NNS,O
containing,VBG,O
ferrous,JJ,O
sulfate,NN,O
-lrb-,-LRB-,O
iron,NN,D
-rrb-,-RRB-,O
",",",",O
multivitamin,JJ,O
preparations,NNS,O
containing,VBG,O
zinc,NN,D
or,CC,O
other,JJ,O
metal,NN,O
cations,NNS,O
",",",",O
or,CC,O
videx,NNP,B
-lrb-,-LRB-,O
didanosine,NN,D
-rrb-,-RRB-,O
chewable/buffered,VBD,O
tablets,NNS,O
or,CC,O
the,DT,O
pediatric,JJ,O
powder,NN,O
for,IN,O
oral,JJ,O
solution,NN,O
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
within,IN,O
3,CD,O
hours,NNS,O
before,IN,O
or,CC,O
2,CD,O
hours,NNS,O
after,IN,O
factive,NNP,B
.,.,.
,,
sucralfate,NNP,D
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
within,IN,O
2,CD,O
hours,NNS,O
of,IN,O
factive,NN,B
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
no,DT,O
formal,JJ,O
drug-interaction,NN,O
studies,NNS,O
performed,VBN,O
with,IN,O
mylotarg,NN,B
.,.,.
,,
the,DT,O
potential,NN,O
for,IN,O
drug-drug,JJ,O
interaction,NN,O
with,IN,O
drugs,NNS,D
affected,VBN,O
by,IN,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
may,MD,O
not,RB,O
be,VB,O
ruled,VBN,O
out,RP,O
.,.,.
,,
laboratory,NNP,O
test,NNP,O
interactions,NNS,O
.,.,.
,,
mylotarg,NNP,B
is,VBZ,O
not,RB,O
known,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
any,DT,O
routine,JJ,O
diagnostic,JJ,O
tests,NNS,O
.,.,.
,,
interactions,NNS,O
between,IN,O
copaxone,NNP,B
and,CC,O
other,JJ,O
drugs,NNS,D
have,VBP,O
not,RB,O
been,VBN,O
fully,RB,O
evaluated,VBN,O
.,.,.
,,
results,NNS,O
from,IN,O
existing,VBG,O
clinical,JJ,O
trials,NNS,O
suggest,VBP,O
no,DT,O
significant,JJ,O
interactions,NNS,O
between,IN,O
copaxone,NNP,B
and,CC,O
other,JJ,O
therapies,NNS,O
commonly,RB,O
used,VBN,O
in,IN,O
ms,NN,O
patients,NNS,O
",",",",O
including,VBG,O
the,DT,O
concurrent,JJ,O
use,NN,O
of,IN,O
corticosteroids,NNS,G
for,IN,O
up,RB,O
to,TO,O
28,CD,O
days,NNS,O
.,.,.
,,
copaxone,NNP,B
has,VBZ,O
not,RB,O
been,VBN,O
formally,RB,O
evaluated,VBN,O
in,IN,O
combination,NN,O
with,IN,O
interferon,NN,O
beta,NN,O
.,.,.
,,
however,RB,O
",",",",O
10,CD,O
patients,NNS,O
who,WP,O
switched,VBD,O
from,IN,O
therapy,NN,O
with,IN,O
interferon,NN,O
beta,NN,O
to,TO,O
copaxone,NNP,B
did,VBD,O
not,RB,O
report,VB,O
any,DT,O
serious,JJ,O
and,CC,O
unexpected,JJ,O
adverse,JJ,O
reactions,NNS,O
thought,VBD,O
to,TO,O
be,VB,O
related,VBN,O
to,TO,O
treatment,NN,O
.,.,.
,,
the,DT,O
hypoglycemic,JJ,G
action,NN,O
of,IN,O
sulfonylureas,NNS,G
may,MD,O
be,VB,O
potentiated,VBN,O
by,IN,O
certain,JJ,O
drugs,NNS,D
including,VBG,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
and,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
highly,RB,O
protein,NN,O
bound,VBD,O
",",",",O
salicylates,NNS,G
",",",",O
sulfonamides,NNS,G
",",",",O
chloramphenicol,NN,D
",",",",O
probenecid,NN,D
",",",",O
coumarins,NNS,G
",",",",O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
",",",",O
and,CC,O
beta,NN,O
adrenergic,JJ,G
blocking,VBG,O
agents,NNS,O
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
to,TO,O
a,DT,O
patient,NN,O
receiving,VBG,O
micronase,NNP,B
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
hypoglycemia,NN,O
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
withdrawn,VBN,O
from,IN,O
a,DT,O
patient,NN,O
receiving,VBG,O
micronase,NNP,B
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
loss,NN,O
of,IN,O
control,NN,O
.,.,.
,,
certain,JJ,O
drugs,NNS,D
tend,VBP,O
to,TO,O
produce,VB,O
hyperglycemia,NN,O
and,CC,O
may,MD,O
lead,VB,O
to,TO,O
loss,NN,O
of,IN,O
control,NN,O
.,.,.
,,
these,DT,O
drugs,NNS,D
include,VBP,O
the,DT,O
thiazides,NNS,G
and,CC,O
other,JJ,O
diuretics,NNS,G
",",",",O
corticosteroids,NNS,G
",",",",O
phe-nothiazines,NNS,O
",",",",O
thyroid,NN,G
products,NNS,O
",",",",O
estrogens,NNS,G
",",",",O
oral,JJ,O
contraceptives,NNS,G
",",",",O
phenytoin,NN,D
",",",",O
nicotinic,JJ,O
acid,NN,O
",",",",O
sympathomimet-ics,NNS,O
",",",",O
calcium,NN,D
channel,NN,O
blocking,VBG,O
drugs,NNS,D
",",",",O
and,CC,O
isoniazid,NN,D
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
to,TO,O
a,DT,O
patient,NN,O
receiving,VBG,O
micronase,NNP,B
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
closely,RB,O
observed,VBN,O
for,IN,O
loss,NN,O
of,IN,O
control,NN,O
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
withdrawn,VBN,O
from,IN,O
a,DT,O
patient,NN,O
receiving,VBG,O
micronase,NNP,B
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
hypoglycemia,NN,O
.,.,.
,,
a,DT,O
possible,JJ,O
interaction,NN,O
between,IN,O
glyburide,NN,D
and,CC,O
ciprofloxacin,NN,D
",",",",O
a,DT,O
fluoroquinolone,JJ,O
antibiotic,JJ,G
",",",",O
has,VBZ,O
been,VBN,O
reported,VBN,O
",",",",O
resulting,VBG,O
in,IN,O
a,DT,O
potentiation,NN,O
of,IN,O
the,DT,O
hypoglycemic,JJ,G
action,NN,O
of,IN,O
glyburide,NN,D
.,.,.
,,
the,DT,O
mechanism,NN,O
for,IN,O
this,DT,O
interaction,NN,O
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
a,DT,O
potential,JJ,O
interaction,NN,O
between,IN,O
oral,JJ,O
miconazole,NN,D
and,CC,O
oral,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
leading,VBG,O
to,TO,O
severe,JJ,O
hypoglycemia,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
.,.,.
,,
whether,IN,O
this,DT,O
interaction,NN,O
also,RB,O
occurs,VBZ,O
with,IN,O
the,DT,O
intravenous,JJ,O
",",",",O
topical,JJ,O
or,CC,O
vaginal,JJ,O
preparations,NNS,O
of,IN,O
miconazole,NN,D
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
metformin,NNP,D
:,:,O
in,IN,O
a,DT,O
single-dose,JJ,O
interaction,NN,O
study,NN,O
in,IN,O
niddm,NNP,O
subjects,NNS,O
",",",",O
decreases,VBZ,O
in,IN,O
glyburide,NN,D
auc,NN,O
and,CC,O
cmax,NN,O
were,VBD,O
observed,VBN,O
",",",",O
but,CC,O
were,VBD,O
highly,RB,O
variable,JJ,O
.,.,.
,,
the,DT,O
single-dose,JJ,O
nature,NN,O
of,IN,O
this,DT,O
study,NN,O
and,CC,O
the,DT,O
lack,NN,O
of,IN,O
correlation,NN,O
between,IN,O
glyburide,NN,D
blood,NN,O
levels,NNS,O
and,CC,O
pharmaco-dynamic,JJ,O
effects,NNS,O
",",",",O
makes,VBZ,O
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
interaction,NN,O
uncertain,JJ,O
.,.,.
,,
coadministration,NN,O
of,IN,O
gly-buride,NN,O
and,CC,O
metformin,NN,D
did,VBD,O
not,RB,O
result,VB,O
in,IN,O
any,DT,O
changes,NNS,O
in,IN,O
either,CC,O
metformin,NN,D
pharmacokinetics,NNS,O
or,CC,O
pharmaco-dynamics,NNS,O
.,.,.
,,
many,JJ,O
other,JJ,O
medicines,NNS,O
may,MD,O
increase,VB,O
or,CC,O
decrease,VB,O
the,DT,O
effects,NNS,O
of,IN,O
glimepiride,NN,D
or,CC,O
affect,VB,O
your,PRP$,O
condition,NN,O
.,.,.
,,
before,IN,O
taking,VBG,O
glimepiride,NN,D
",",",",O
tell,VB,O
your,PRP$,O
doctor,NN,O
if,IN,O
you,PRP,O
are,VBP,O
taking,VBG,O
any,DT,O
of,IN,O
the,DT,O
following,VBG,O
medicines,NNS,O
:,:,O
-,:,O
aspirin,NN,B
or,CC,O
another,DT,O
salicylate,NN,G
such,JJ,O
as,IN,O
magnesium/choline,NN,O
salicylate,NN,G
-lrb-,-LRB-,O
trilisate,NN,B
-rrb-,-RRB-,O
",",",",O
salsalate,NN,D
-lrb-,-LRB-,O
disalcid,NNP,B
",",",",O
others,NNS,O
-rrb-,-RRB-,O
",",",",O
choline,NN,O
salicylate,NN,G
-lrb-,-LRB-,O
arthropan,NN,D
-rrb-,-RRB-,O
",",",",O
magnesium,NN,D
salicylate,NN,G
-lrb-,-LRB-,O
magan,NN,B
-rrb-,-RRB-,O
",",",",O
or,CC,O
bismuth,NN,O
subsalicylate,NN,O
-lrb-,-LRB-,O
pepto-bismol,NN,B
-rrb-,-RRB-,O
.,.,.
,,
-,:,O
a,DT,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drug,NN,D
-lrb-,-LRB-,O
nsaid,NN,G
-rrb-,-RRB-,O
such,JJ,O
as,IN,O
ibuprofen,NN,D
-lrb-,-LRB-,O
motrin,NN,B
",",",",O
advil,NNP,B
",",",",O
nuprin,NNP,B
",",",",O
others,NNS,O
-rrb-,-RRB-,O
",",",",O
ketoprofen,NN,D
-lrb-,-LRB-,O
orudis,NNP,B
",",",",O
orudis,NNP,B
kt,NNP,O
",",",",O
oruvail,NNP,B
-rrb-,-RRB-,O
",",",",O
diclofenac,NN,D
-lrb-,-LRB-,O
voltaren,NN,B
",",",",O
cataflam,NN,B
-rrb-,-RRB-,O
",",",",O
etodolac,NN,D
-lrb-,-LRB-,O
lodine,NN,B
-rrb-,-RRB-,O
",",",",O
indomethacin,NN,D
-lrb-,-LRB-,O
indocin,NN,B
-rrb-,-RRB-,O
",",",",O
nabumetone,NN,D
-lrb-,-LRB-,O
relafen,NN,B
-rrb-,-RRB-,O
",",",",O
oxaprozin,NN,D
-lrb-,-LRB-,O
daypro,NN,B
-rrb-,-RRB-,O
",",",",O
and,CC,O
naproxen,NN,D
-lrb-,-LRB-,O
anaprox,NNP,B
",",",",O
naprosyn,NNP,B
",",",",O
aleve,NNP,B
-rrb-,-RRB-,O
.,.,.
,,
-,:,O
a,DT,O
sulfa-based,JJ,O
drug,NN,D
such,JJ,O
as,IN,O
sulfamethoxazole-trimethoprim,NN,O
-lrb-,-LRB-,O
bactrim,NN,B
",",",",O
septra,NNP,B
-rrb-,-RRB-,O
",",",",O
sulfisoxazole,NN,D
-lrb-,-LRB-,O
gantrisin,NN,B
-rrb-,-RRB-,O
",",",",O
or,CC,O
sulfasalazine,NN,D
-lrb-,-LRB-,O
azulfidine,NN,B
-rrb-,-RRB-,O
.,.,.
,,
-,:,O
a,DT,O
monoamine,NN,O
oxidase,NN,O
inhibitor,NN,O
-lrb-,-LRB-,O
maoi,NN,G
-rrb-,-RRB-,O
such,JJ,O
as,IN,O
isocarboxazid,NN,D
-lrb-,-LRB-,O
marplan,NN,B
-rrb-,-RRB-,O
",",",",O
tranylcypromine,NN,D
-lrb-,-LRB-,O
parnate,NN,B
-rrb-,-RRB-,O
",",",",O
or,CC,O
phenelzine,NN,D
-lrb-,-LRB-,O
nardil,NN,B
-rrb-,-RRB-,O
.,.,.
,,
-,:,O
a,DT,O
beta-blocker,NN,G
such,JJ,O
as,IN,O
propranolol,NN,D
-lrb-,-LRB-,O
inderal,NN,B
-rrb-,-RRB-,O
",",",",O
atenolol,NN,D
-lrb-,-LRB-,O
tenormin,NN,B
-rrb-,-RRB-,O
",",",",O
acebutolol,NN,D
-lrb-,-LRB-,O
sectral,JJ,B
-rrb-,-RRB-,O
",",",",O
metoprolol,NN,D
-lrb-,-LRB-,O
lopressor,NN,B
-rrb-,-RRB-,O
",",",",O
and,CC,O
others,NNS,O
.,.,.
,,
-,:,O
a,DT,O
diuretic,JJ,G
-lrb-,-LRB-,O
water,NN,O
pill,NN,O
-rrb-,-RRB-,O
such,JJ,O
as,IN,O
hydrochlorothiazide,NN,D
-lrb-,-LRB-,O
hctz,NN,D
",",",",O
hydrodiuril,NN,B
-rrb-,-RRB-,O
",",",",O
chlorothiazide,NN,D
-lrb-,-LRB-,O
diuril,NN,B
-rrb-,-RRB-,O
",",",",O
and,CC,O
others,NNS,O
.,.,.
,,
-,:,O
a,DT,O
steroid,NN,G
medicine,NN,O
such,JJ,O
as,IN,O
prednisone,NN,D
-lrb-,-LRB-,O
deltasone,NNP,B
",",",",O
orasone,NNP,B
",",",",O
others,NNS,O
-rrb-,-RRB-,O
",",",",O
methylprednisolone,NN,D
-lrb-,-LRB-,O
medrol,NNP,B
",",",",O
others,NNS,O
-rrb-,-RRB-,O
",",",",O
prednisolone,NN,D
-lrb-,-LRB-,O
prelone,NNP,B
",",",",O
pediapred,NNP,B
",",",",O
others,NNS,O
-rrb-,-RRB-,O
",",",",O
and,CC,O
others,NNS,O
.,.,.
,,
-,:,O
a,DT,O
phenothiazine,NN,G
such,JJ,O
as,IN,O
chlorpromazine,NN,D
-lrb-,-LRB-,O
thorazine,NN,B
-rrb-,-RRB-,O
",",",",O
fluphenazine,NN,D
-lrb-,-LRB-,O
prolixin,NN,B
",",",",O
permitil,NN,B
-rrb-,-RRB-,O
",",",",O
prochlorperazine,NN,D
-lrb-,-LRB-,O
compazine,NN,B
-rrb-,-RRB-,O
",",",",O
promethazine,NN,D
-lrb-,-LRB-,O
phenergan,NN,B
-rrb-,-RRB-,O
",",",",O
and,CC,O
others,NNS,O
.,.,.
,,
-,:,O
phenytoin,NN,D
-lrb-,-LRB-,O
dilantin,NN,B
-rrb-,-RRB-,O
.,.,.
,,
-,:,O
isoniazid,NN,D
-lrb-,-LRB-,O
nydrazid,NN,B
-rrb-,-RRB-,O
.,.,.
,,
-,:,O
rifampin,NN,D
-lrb-,-LRB-,O
rifadin,NNP,B
",",",",O
rifamate,NNP,B
-rrb-,-RRB-,O
.,.,.
,,
or,CC,O
-,:,O
over-the-counter,JJ,O
cough,NN,O
",",",",O
cold,JJ,O
",",",",O
allergy,NN,O
",",",",O
or,CC,O
weight,NN,O
loss,NN,O
medications,NNS,O
.,.,.
,,
you,PRP,O
may,MD,O
require,VB,O
a,DT,O
dosage,NN,O
adjustment,NN,O
or,CC,O
special,JJ,O
monitoring,NN,O
if,IN,O
you,PRP,O
are,VBP,O
taking,VBG,O
any,DT,O
of,IN,O
the,DT,O
medicines,NNS,O
listed,VBN,O
above,RB,O
.,.,.
,,
drugs,NNS,O
other,JJ,O
than,IN,O
those,DT,O
listed,VBN,O
here,RB,O
may,MD,O
also,RB,O
interact,VB,O
with,IN,O
glimepiride,NN,D
or,CC,O
affect,VB,O
your,PRP$,O
condition,NN,O
.,.,.
,,
talk,NN,O
to,TO,O
your,PRP$,O
doctor,NN,O
and,CC,O
pharmacist,NN,O
before,IN,O
taking,VBG,O
any,DT,O
prescription,NN,O
or,CC,O
over-the-counter,JJ,O
medicines,NNS,O
",",",",O
including,VBG,O
herbal,JJ,O
products,NNS,O
.,.,.
,,
immediate,NNP,O
and,CC,O
extended,NNP,O
release,NNP,O
tablets,NNPS,O
the,DT,O
hypoglycemic,JJ,G
action,NN,O
of,IN,O
sulfonylureas,NNS,G
may,MD,O
be,VB,O
potentiated,VBN,O
by,IN,O
certain,JJ,O
drugs,NNS,D
including,VBG,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
",",",",O
some,DT,O
azoles,NNS,G
and,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
highly,RB,O
protein,NN,O
bound,VBD,O
",",",",O
salicylates,NNS,G
",",",",O
sulfonamides,NNS,G
",",",",O
chloramphenicol,NN,D
",",",",O
probenecid,NN,D
",",",",O
coumarins,NNS,G
",",",",O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
",",",",O
and,CC,O
beta,NN,O
adrenergic,JJ,G
blocking,VBG,O
agents,NNS,O
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
to,TO,O
a,DT,O
patient,NN,O
receiving,VBG,O
glipizide,NN,D
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
hypoglycemia,NN,O
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
withdrawn,VBN,O
from,IN,O
a,DT,O
patient,NN,O
receiving,VBG,O
glipizide,NN,D
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
loss,NN,O
of,IN,O
control,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
binding,NN,O
studies,NNS,O
with,IN,O
human,JJ,O
serum,NN,O
proteins,NNS,O
indicate,VBP,O
that,IN,O
glipizide,NN,D
binds,VBZ,O
differently,RB,O
than,IN,O
tolbutamide,NN,D
and,CC,O
does,VBZ,O
not,RB,O
interact,VB,O
with,IN,O
salicylate,NN,G
or,CC,O
dicumarol,NN,D
.,.,.
,,
however,RB,O
",",",",O
caution,NN,O
must,MD,O
be,VB,O
exercised,VBN,O
in,IN,O
extrapolating,VBG,O
these,DT,O
findings,NNS,O
to,TO,O
the,DT,O
clinical,JJ,O
situation,NN,O
and,CC,O
in,IN,O
the,DT,O
use,NN,O
of,IN,O
glipizide,NN,D
with,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
certain,JJ,O
drugs,NNS,D
tend,VBP,O
to,TO,O
produce,VB,O
hyperglycemia,NN,O
and,CC,O
may,MD,O
lead,VB,O
to,TO,O
loss,NN,O
of,IN,O
control,NN,O
.,.,.
,,
these,DT,O
drugs,NNS,D
include,VBP,O
the,DT,O
thiazides,NNS,G
and,CC,O
other,JJ,O
diuretics,NNS,G
",",",",O
corticosteroids,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
thyroid,NN,G
products,NNS,O
",",",",O
estrogens,NNS,G
",",",",O
oral,JJ,O
contraceptives,NNS,G
",",",",O
phenytoin,NN,D
",",",",O
nicotinic,JJ,O
acid,NN,O
",",",",O
sympathomimetics,NNS,G
",",",",O
calcium,NN,D
channel,NN,O
blocking,VBG,O
drugs,NNS,D
",",",",O
and,CC,O
isoniazid,NN,D
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
to,TO,O
a,DT,O
patient,NN,O
receiving,VBG,O
glipizide,NN,D
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
closely,RB,O
observed,VBN,O
for,IN,O
loss,NN,O
of,IN,O
control,NN,O
.,.,.
,,
when,WRB,O
such,JJ,O
drugs,NNS,D
are,VBP,O
withdrawn,VBN,O
from,IN,O
a,DT,O
patient,NN,O
receiving,VBG,O
glipizide,NN,D
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
hypoglycemia,NN,O
.,.,.
,,
a,DT,O
potential,JJ,O
interaction,NN,O
between,IN,O
oral,JJ,O
miconazole,NN,D
and,CC,O
oral,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
leading,VBG,O
to,TO,O
severe,JJ,O
hypoglycemia,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
.,.,.
,,
whether,IN,O
this,DT,O
interaction,NN,O
also,RB,O
occurs,VBZ,O
with,IN,O
the,DT,O
intravenous,JJ,O
",",",",O
topical,JJ,O
",",",",O
or,CC,O
vaginal,JJ,O
preparations,NNS,O
of,IN,O
miconazole,NN,D
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
fluconazole,NN,D
and,CC,O
glipizide,NN,D
has,VBZ,O
been,VBN,O
demonstrated,VBN,O
in,IN,O
a,DT,O
placebo-controlled,JJ,O
crossover,NN,O
study,NN,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
.,.,.
,,
all,DT,O
subjects,NNS,O
received,VBD,O
glipizide,NN,D
alone,RB,O
and,CC,O
following,VBG,O
treatment,NN,O
with,IN,O
100,CD,O
mg,NN,O
of,IN,O
fluconazole,NN,D
as,IN,O
a,DT,O
single,JJ,O
daily,JJ,O
oral,JJ,O
dose,NN,O
for,IN,O
seven,CD,O
days,NNS,O
.,.,.
,,
the,DT,O
mean,JJ,O
percentage,NN,O
increase,NN,O
in,IN,O
the,DT,O
glipizide,NN,D
auc,NN,O
after,IN,O
fluconazole,NN,D
administration,NN,O
was,VBD,O
56.9,CD,O
%,NN,O
-lrb-,-LRB-,O
range,NN,O
:,:,O
35,CD,O
to,TO,O
81,CD,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
concurrent,JJ,O
use,NN,O
of,IN,O
robinul,NNP,B
injection,NN,O
with,IN,O
other,JJ,O
anticholinergics,NNS,G
or,CC,O
medications,NNS,O
with,IN,O
anticholinergic,JJ,G
activity,NN,O
",",",",O
such,JJ,O
as,IN,O
phenothiazines,NNS,G
",",",",O
antiparkinson,JJ,O
drugs,NNS,D
",",",",O
or,CC,O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
may,MD,O
intensify,VB,O
the,DT,O
antimuscarinic,JJ,O
effects,NNS,O
and,CC,O
may,MD,O
result,VB,O
in,IN,O
an,DT,O
increase,NN,O
in,IN,O
anticholinergic,JJ,G
side,JJ,O
effects,NNS,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
robinul,NNP,B
injection,NN,O
and,CC,O
potassium,NN,D
chloride,NN,O
in,IN,O
a,DT,O
wax,NN,O
matrix,NN,O
may,MD,O
increase,VB,O
the,DT,O
severity,NN,O
of,IN,O
potassium,NN,D
chloride-induced,JJ,O
gastrointestinal,JJ,O
lesions,NNS,O
as,IN,O
a,DT,O
result,NN,O
of,IN,O
a,DT,O
slower,JJR,O
gastrointestinal,JJ,O
transit,NN,O
time,NN,O
.,.,.
,,
the,DT,O
factrel,NNP,B
test,NN,O
should,MD,O
be,VB,O
conducted,VBN,O
in,IN,O
the,DT,O
absence,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
which,WDT,O
directly,RB,O
affect,VBP,O
the,DT,O
pituitary,JJ,O
secretion,NN,O
of,IN,O
the,DT,O
gonadotropins,NNS,O
.,.,.
,,
these,DT,O
would,MD,O
include,VB,O
a,DT,O
variety,NN,O
of,IN,O
preparations,NNS,O
which,WDT,O
contain,VBP,O
androgens,NNS,G
",",",",O
estrogens,NNS,G
",",",",O
progestins,NNS,G
",",",",O
or,CC,O
glucocorticoids,NNS,G
.,.,.
,,
the,DT,O
gonadotropin,NN,O
levels,NNS,O
may,MD,O
be,VB,O
transiently,RB,O
elevated,JJ,O
by,IN,O
spironolactone,NN,D
",",",",O
minimally,RB,O
elevated,JJ,O
by,IN,O
levodopa,NN,D
",",",",O
and,CC,O
suppressed,VBN,O
by,IN,O
oral,JJ,O
contraceptives,NNS,G
and,CC,O
digoxin,NN,D
.,.,.
,,
the,DT,O
response,NN,O
to,TO,O
factrel,NNP,B
may,MD,O
be,VB,O
blunted,VBN,O
by,IN,O
phenothiazines,NNS,G
and,CC,O
dopamine,NN,D
antagonists,NNS,O
which,WDT,O
cause,VBP,O
a,DT,O
rise,NN,O
in,IN,O
prolactin,NN,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug-drug,JJ,O
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
.,.,.
,,
no,DT,O
confirmed,VBD,O
interactions,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
between,IN,O
zoladex,NNP,B
and,CC,O
other,JJ,O
drug,NN,D
.,.,.
,,
antacids,NNS,G
",",",",O
sucralfate,NNP,D
",",",",O
metal,NNP,O
cations,NNPS,O
",",",",O
multivitamins,NNPS,G
quinolones,NNPS,G
form,VBP,O
chelates,NNS,O
with,IN,O
alkaline,NN,O
earth,NN,O
and,CC,O
transition,NN,O
metal,NN,O
cations,NNS,O
.,.,.
,,
administration,NN,O
of,IN,O
quinolones,NNS,G
with,IN,O
antacids,NNS,G
containing,VBG,O
aluminum,NN,D
",",",",O
magnesium,NN,D
",",",",O
or,CC,O
calcium,NN,D
",",",",O
with,IN,O
sucralfate,NN,D
",",",",O
with,IN,O
metal,NN,O
cations,NNS,O
such,JJ,O
as,IN,O
iron,NN,D
",",",",O
or,CC,O
with,IN,O
multivitamins,NNS,G
containing,VBG,O
iron,NN,D
or,CC,O
zinc,NN,D
",",",",O
or,CC,O
with,IN,O
formulations,NNS,O
containing,VBG,O
divalent,JJ,O
and,CC,O
trivalent,JJ,O
cations,NNS,O
such,JJ,O
as,IN,O
videx,NN,B
-lrb-,-LRB-,O
didanosine,NN,D
-rrb-,-RRB-,O
chewable/buffered,VBD,O
tablets,NNS,O
or,CC,O
the,DT,O
pediatric,JJ,O
powder,NN,O
for,IN,O
oral,JJ,O
solution,NN,O
",",",",O
may,MD,O
substantially,RB,O
interfere,VB,O
with,IN,O
the,DT,O
absorption,NN,O
of,IN,O
quinolones,NNS,G
",",",",O
resulting,VBG,O
in,IN,O
systemic,JJ,O
concentrations,NNS,O
considerably,RB,O
lower,JJR,O
than,IN,O
desired,VBN,O
.,.,.
,,
these,DT,O
agents,NNS,O
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
within,IN,O
4,CD,O
hours,NNS,O
before,IN,O
or,CC,O
4,CD,O
hours,NNS,O
after,IN,O
grepafloxacin,NN,D
administration,NN,O
.,.,.
,,
caffeine,NNP,D
theobromine,NNP,D
grepafloxacin,NNP,D
",",",",O
like,IN,O
other,JJ,O
quinolones,NNS,G
",",",",O
may,MD,O
inhibit,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
caffeine,NN,D
and,CC,O
theobromine,NN,D
.,.,.
,,
these,DT,O
stimulants,NNS,O
are,VBP,O
commonly,RB,O
found,VBN,O
in,IN,O
coffee,NN,O
and,CC,O
tea,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
this,DT,O
may,MD,O
lead,VB,O
to,TO,O
reduced,VBN,O
clearance,NN,O
",",",",O
prolongation,NN,O
of,IN,O
plasma,NN,O
half-life,NN,O
",",",",O
and,CC,O
enhanced,VBD,O
effects,NNS,O
of,IN,O
caffeine,NN,D
and,CC,O
theobromine,NN,D
.,.,.
,,
theophylline,NNP,D
:,:,O
grepafloxacin,NNP,D
is,VBZ,O
a,DT,O
competitive,JJ,O
inhibitor,NN,O
of,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
theophylline,NN,D
.,.,.
,,
serum,NN,O
theophylline,NN,D
concentrations,NNS,O
increase,VBP,O
when,WRB,O
grepafloxacin,NN,D
is,VBZ,O
initiated,VBN,O
in,IN,O
a,DT,O
patient,NN,O
maintained,VBD,O
on,IN,O
theophylline,NN,D
.,.,.
,,
when,WRB,O
initiating,VBG,O
a,DT,O
multi-day,JJ,O
course,NN,O
of,IN,O
grepafloxacin,NN,D
in,IN,O
a,DT,O
patient,NN,O
maintained,VBD,O
on,IN,O
theophylline,NN,D
",",",",O
the,DT,O
theophylline,NN,D
maintenance,NN,O
dose,NN,O
should,MD,O
be,VB,O
halved,VBN,O
for,IN,O
the,DT,O
period,NN,O
of,IN,O
concurrent,JJ,O
use,NN,O
of,IN,O
grepafloxacin,NN,D
and,CC,O
monitoring,NN,O
of,IN,O
serum,NN,O
theophylline,NN,D
concentrations,NNS,O
should,MD,O
be,VB,O
initiated,VBN,O
as,IN,O
a,DT,O
guide,NN,O
to,TO,O
further,JJ,O
dosage,NN,O
adjustments,NNS,O
.,.,.
,,
warfarin,NNP,D
:,:,O
in,IN,O
subjects,NNS,O
receiving,VBG,O
warfarin,NN,D
",",",",O
no,DT,O
significant,JJ,O
change,NN,O
in,IN,O
clotting,VBG,O
time,NN,O
was,VBD,O
observed,VBN,O
when,WRB,O
grepafloxacin,NN,D
was,VBD,O
coadministered,VBN,O
.,.,.
,,
however,RB,O
",",",",O
because,IN,O
some,DT,O
quinolones,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
enhance,VB,O
the,DT,O
effects,NNS,O
of,IN,O
warfarin,NN,D
or,CC,O
its,PRP$,O
derivatives,NNS,O
",",",",O
prothrombin,NN,O
time,NN,O
or,CC,O
other,JJ,O
suitable,JJ,O
anticoagulation,JJ,O
test,NN,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
if,IN,O
a,DT,O
quinolone,JJ,G
antimicrobial,JJ,O
is,VBZ,O
administered,VBN,O
with,IN,O
warfarin,NN,D
or,CC,O
its,PRP$,O
derivatives,NNS,O
.,.,.
,,
drugs,NNS,O
metabolized,VBN,O
by,IN,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
the,DT,O
drug,NN,D
interaction,NN,O
study,NN,O
evaluating,VBG,O
the,DT,O
effect,NN,O
of,IN,O
grepafloxacin,NN,D
on,IN,O
theophylline,NN,D
indicates,VBZ,O
that,IN,O
grepafloxacin,NN,D
inhibits,VBZ,O
theophylline,NN,D
metabolism,NN,O
",",",",O
which,WDT,O
is,VBZ,O
mediated,VBN,O
by,IN,O
cyp1a2,NN,D
.,.,.
,,
while,IN,O
no,DT,O
clinical,JJ,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
to,TO,O
evaluate,VB,O
the,DT,O
effect,NN,O
of,IN,O
grepafloxacin,NN,D
on,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
c.p.a.,NNP,O
substrates,NNS,O
",",",",O
in,FW,O
vitro,FW,O
data,NNS,O
suggest,VBP,O
similar,JJ,O
effects,NNS,O
of,IN,O
grepafloxacin,NN,D
in,IN,O
cyp3a4,NN,D
mediated,VBD,O
metabolism,NN,O
and,CC,O
theophylline,NN,D
metabolism,NN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
other,JJ,O
quinolones,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
decrease,VB,O
the,DT,O
cyp3a4-mediated,JJ,O
metabolism,NN,O
of,IN,O
cyclosporine,NN,D
.,.,.
,,
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
c.p.a.,NNP,O
include,VBP,O
terfenadine,NN,D
",",",",O
astemizole,NN,D
",",",",O
cisapride,NN,D
",",",",O
midazolam,NN,D
",",",",O
and,CC,O
triazolam,NN,D
.,.,.
,,
the,DT,O
clinical,JJ,O
relevance,NN,O
of,IN,O
the,DT,O
potential,JJ,O
effect,NN,O
of,IN,O
grepafloxacin,NN,D
on,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
c.p.a.,NNP,O
substrates,NNS,O
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
concurrent,JJ,O
administration,NN,O
of,IN,O
substrates,NNS,O
of,IN,O
c.p.a.,NNP,O
were,VBD,O
not,RB,O
excluded,VBN,O
from,IN,O
clinical,JJ,O
trials,NNS,O
of,IN,O
grepafloxacin,NN,D
.,.,.
,,
nonsteroidal,JJ,O
anti-inflammatory,JJ,O
drugs,NNS,O
-lrb-,-LRB-,O
nsaids,NNS,G
-rrb-,-RRB-,O
:,:,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
a,DT,O
nonsteroidal,JJ,O
anti,JJ,O
inflammatory,JJ,O
drug,NN,D
with,IN,O
a,DT,O
quinolone,NN,G
may,MD,O
increase,VB,O
the,DT,O
risks,NNS,O
of,IN,O
cns,NN,O
stimulation,NN,O
and,CC,O
convulsions,NNS,O
.,.,.
,,
antidiabetic,JJ,O
agents,NNS,O
:,:,O
disturbances,NNS,O
of,IN,O
blood,NN,O
glucose,NN,O
",",",",O
including,VBG,O
hyperglycemia,NN,O
and,CC,O
hypoglycemia,NN,O
",",",",O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
treated,VBN,O
concomitantly,RB,O
with,IN,O
quinolones,NNS,G
and,CC,O
an,DT,O
antidiabetic,JJ,D
agent,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
careful,JJ,O
monitoring,NN,O
of,IN,O
blood,NN,O
glucose,NN,O
is,VBZ,O
recommended,VBN,O
when,WRB,O
these,DT,O
agents,NNS,O
are,VBP,O
coadministered,VBN,O
.,.,.
,,
patients,NNS,O
on,IN,O
warfarin-type,JJ,O
anticoagulant,JJ,G
therapy,NN,O
may,MD,O
require,VB,O
dosage,NN,O
adjustment,NN,O
of,IN,O
the,DT,O
anticoagulant,JJ,G
during,IN,O
and,CC,O
after,IN,O
griseofulvin,NN,D
therapy,NN,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
barbiturates,NNS,G
usually,RB,O
depresses,VBZ,O
griseofulvin,NN,D
activity,NN,O
and,CC,O
may,MD,O
necessitate,VB,O
raising,VBG,O
the,DT,O
dosage,NN,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
griseofulvin,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
reduce,VB,O
the,DT,O
efficacy,NN,O
of,IN,O
oral,JJ,O
contraceptives,NNS,G
and,CC,O
to,TO,O
increase,VB,O
the,DT,O
incidence,NN,O
of,IN,O
breakthrough,NN,O
bleeding,NN,O
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
codeine,NN,D
may,MD,O
result,VB,O
in,IN,O
additive,JJ,O
cns,NN,O
depressant,NN,O
effects,NNS,O
when,WRB,O
coadministered,VBN,O
with,IN,O
alcohol,NN,D
",",",",O
antihistamines,NNS,G
",",",",O
psychotropics,NNS,G
or,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
produce,VBP,O
cns,NN,O
depression,NN,O
.,.,.
,,
serious,JJ,O
toxicity,NN,O
may,MD,O
result,VB,O
if,IN,O
dextromethorphan,NN,D
is,VBZ,O
coadministered,VBN,O
with,IN,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
maois,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
dextromethorphan,NN,D
hydrobromide,NN,O
may,MD,O
result,VB,O
in,IN,O
additive,JJ,O
cns,NN,O
depressant,NN,O
effects,NNS,O
when,WRB,O
coadministered,VBN,O
with,IN,O
alcohol,NN,D
",",",",O
antihistamines,NNS,G
",",",",O
psychotropics,NNS,G
or,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
produce,VBP,O
cns,NN,O
depression,NN,O
.,.,.
,,
http://www.rxlist.com/cgi/generic3/guanethidine,NN,O
.,.,.
,,
the,DT,O
potential,NN,O
for,IN,O
increased,VBN,O
sedation,NN,O
when,WRB,O
guanfacine,NN,D
is,VBZ,O
given,VBN,O
with,IN,O
other,JJ,O
cns-depressant,JJ,O
drug,NN,D
should,MD,O
be,VB,O
appreciated,VBN,O
.,.,.
,,
the,DT,O
administration,NN,O
of,IN,O
guanfacine,NN,D
concomitantly,RB,O
with,IN,O
known,JJ,O
microsomal,JJ,O
enzyme,NN,O
inducer,NN,O
-lrb-,-LRB-,O
phenobarbital,NN,D
or,CC,O
phenytoin,NN,D
-rrb-,-RRB-,O
to,TO,O
two,CD,O
patients,NNS,O
with,IN,O
renal,JJ,O
impairment,NN,O
reportedly,RB,O
resulted,VBD,O
in,IN,O
significant,JJ,O
reductions,NNS,O
in,IN,O
elimination,NN,O
half-life,NN,O
and,CC,O
plasma,NN,O
concentration,NN,O
.,.,.
,,
in,IN,O
such,JJ,O
cases,NNS,O
",",",",O
therefore,RB,O
",",",",O
more,JJR,O
frequent,JJ,O
dosing,NN,O
may,MD,O
be,VB,O
required,VBN,O
to,TO,O
achieve,VB,O
or,CC,O
maintain,VB,O
the,DT,O
desired,VBN,O
hypotensive,NN,O
response,NN,O
.,.,.
,,
further,RB,O
",",",",O
if,IN,O
guanfacine,NN,D
is,VBZ,O
to,TO,O
be,VB,O
discontinued,VBN,O
in,IN,O
such,JJ,O
patients,NNS,O
",",",",O
careful,JJ,O
tapering,VBG,O
of,IN,O
the,DT,O
dosage,NN,O
may,MD,O
be,VB,O
necessary,JJ,O
in,IN,O
order,NN,O
to,TO,O
avoid,VB,O
rebound,NN,O
phenomena,NNS,O
.,.,.
,,
tcas,NNS,G
decrease,VBP,O
the,DT,O
hypotensive,JJ,O
effect,NN,O
of,IN,O
guanfacine,NN,D
.,.,.
,,
noncardioselective,JJ,O
beta-blockers,NNS,G
-lrb-,-LRB-,O
nadolol,NN,D
",",",",O
porpranolol,NN,O
",",",",O
timolol,NN,D
-rrb-,-RRB-,O
may,MD,O
exacerbate,VB,O
rebound,VB,O
hypertension,NN,O
when,WRB,O
guanfacine,NN,D
is,VBZ,O
withdrawn,VBN,O
.,.,.
,,
the,DT,O
beta-blocker,NN,G
should,MD,O
be,VB,O
withdrawn,VBN,O
first,RB,O
.,.,.
,,
the,DT,O
gradual,JJ,O
withdrawal,NN,O
of,IN,O
guafacine,NN,D
or,CC,O
a,DT,O
cardioselective,JJ,O
beta-blocker,NN,G
could,MD,O
be,VB,O
substituted,VBN,O
.,.,.
,,
anticoagulants,NNPS,G
:,:,O
ten,CD,O
patients,NNS,O
who,WP,O
were,VBD,O
stabilized,VBN,O
on,IN,O
oral,JJ,O
anticoagulants,NNS,G
were,VBD,O
given,VBN,O
guanfacine,NN,D
",",",",O
2-Jan,CD,O
mg/day,NN,O
",",",",O
for,IN,O
4,CD,O
weeks,NNS,O
.,.,.
,,
no,DT,O
changes,NNS,O
were,VBD,O
observed,VBN,O
in,IN,O
the,DT,O
degree,NN,O
of,IN,O
anticoagulation,NN,O
.,.,.
,,
in,IN,O
several,JJ,O
well-controlled,JJ,O
studies,NNS,O
",",",",O
guanfacine,NN,D
was,VBD,O
administered,VBN,O
together,RB,O
with,IN,O
diuretics,NNS,G
with,IN,O
no,DT,O
drug,NN,D
interactions,NNS,O
reported,VBD,O
.,.,.
,,
in,IN,O
the,DT,O
long-term,JJ,O
safety,NN,O
studies,NNS,O
",",",",O
guanfacine,NN,D
was,VBD,O
given,VBN,O
concomitantly,RB,O
with,IN,O
many,JJ,O
drugs,NNS,D
without,IN,O
evidence,NN,O
of,IN,O
any,DT,O
interactions,NNS,O
.,.,.
,,
the,DT,O
principal,JJ,O
drugs,NNS,D
given,VBN,O
-lrb-,-LRB-,O
number,NN,O
of,IN,O
patients,NNS,O
in,IN,O
parentheses,NNS,O
-rrb-,-RRB-,O
were,VBD,O
:,:,O
cardiac,JJ,O
glycosides,NNS,G
-lrb-,-LRB-,O
115,CD,O
-rrb-,-RRB-,O
",",",",O
sedatives,NNS,G
and,CC,O
hypnotics,NNS,G
-lrb-,-LRB-,O
103,CD,O
-rrb-,-RRB-,O
",",",",O
coronary,JJ,O
vasodilators,NNS,G
-lrb-,-LRB-,O
52,CD,O
-rrb-,-RRB-,O
",",",",O
oral,JJ,O
hypoglycemics,NNS,G
-lrb-,-LRB-,O
45,CD,O
-rrb-,-RRB-,O
",",",",O
cough,NN,O
and,CC,O
cold,JJ,O
preparations,NNS,O
-lrb-,-LRB-,O
45,CD,O
-rrb-,-RRB-,O
",",",",O
nsaids,NNS,G
-lrb-,-LRB-,O
38,CD,O
-rrb-,-RRB-,O
",",",",O
antihyperlipidemics,NNS,G
-lrb-,-LRB-,O
29,CD,O
-rrb-,-RRB-,O
",",",",O
antigout,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
24,CD,O
-rrb-,-RRB-,O
",",",",O
oral,JJ,O
contraceptives,NNS,G
-lrb-,-LRB-,O
18,CD,O
-rrb-,-RRB-,O
",",",",O
bronchodilators,NNS,G
-lrb-,-LRB-,O
13,CD,O
-rrb-,-RRB-,O
",",",",O
insulin,NN,D
-lrb-,-LRB-,O
10,CD,O
-rrb-,-RRB-,O
",",",",O
and,CC,O
beta,NN,O
blockers,NNS,O
-lrb-,-LRB-,O
10,CD,O
-rrb-,-RRB-,O
.,.,.
,,
laboratory,NNP,O
test,NNP,O
in,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
no,DT,O
clinically,RB,O
relevant,JJ,O
laboratory,NN,O
test,NN,O
abnormalities,NNS,O
were,VBD,O
identified,VBN,O
as,IN,O
causally,RB,O
related,JJ,O
to,TO,O
drug,NN,D
during,IN,O
short-term,JJ,O
treatment,NN,O
with,IN,O
guanfacine,NN,D
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
no,DT,O
laboratory,NN,O
test,NN,O
abnormalities,NNS,O
related,VBN,O
to,TO,O
the,DT,O
use,NN,O
of,IN,O
guanfacine,NN,D
have,VBP,O
been,VBN,O
identified,VBN,O
.,.,.
,,
an,DT,O
encephalopathic,JJ,O
syndrome,NN,O
-lrb-,-LRB-,O
characterized,VBN,O
by,IN,O
weakness,NN,O
",",",",O
lethargy,NN,O
",",",",O
fever,NN,O
",",",",O
tremulousness,NN,O
and,CC,O
confusion,NN,O
",",",",O
extrapyramidal,JJ,O
symptoms,NNS,O
",",",",O
leukocytosis,NN,O
",",",",O
elevated,JJ,O
serum,NN,O
enzymes,NNS,O
",",",",O
bun,NN,O
",",",",O
and,CC,O
fbs,NN,O
-rrb-,-RRB-,O
followed,VBN,O
by,IN,O
irreversible,JJ,O
brain,NN,O
damage,NN,O
has,VBZ,O
occurred,VBN,O
in,IN,O
a,DT,O
few,JJ,O
patients,NNS,O
treated,VBN,O
with,IN,O
lithium,NN,D
plus,CC,O
haldol,NN,B
.,.,.
,,
a,DT,O
causal,JJ,O
relationship,NN,O
between,IN,O
these,DT,O
events,NNS,O
and,CC,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
lithium,NN,D
and,CC,O
haldol,NN,B
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
however,RB,O
",",",",O
patients,NNS,O
receiving,VBG,O
such,JJ,O
combined,JJ,O
therapy,NN,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
for,IN,O
early,JJ,O
evidence,NN,O
of,IN,O
neurological,JJ,O
toxicity,NN,O
and,CC,O
treatment,NN,O
discontinued,VBN,O
promptly,RB,O
if,IN,O
such,JJ,O
signs,NNS,O
appear,VBP,O
.,.,.
,,
as,IN,O
with,IN,O
other,JJ,O
antipsychotic,JJ,O
agents,NNS,O
",",",",O
it,PRP,O
should,MD,O
be,VB,O
noted,VBN,O
that,IN,O
haldol,NNP,B
may,MD,O
be,VB,O
capable,JJ,O
of,IN,O
potentiating,VBG,O
cns,NN,O
depressants,NNS,O
such,JJ,O
as,IN,O
anesthetics,NNS,G
",",",",O
opiates,NNS,G
",",",",O
and,CC,O
alcohol,NN,D
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
of,IN,O
12,CD,O
schizophrenic,JJ,O
patients,NNS,O
coadministered,VBN,O
oral,JJ,O
haloperidol,NN,D
and,CC,O
rifampin,NN,D
",",",",O
plasma,NN,O
haloperidol,NN,D
levels,NNS,O
were,VBD,O
decreased,VBN,O
by,IN,O
a,DT,O
mean,NN,O
of,IN,O
70,CD,O
%,NN,O
and,CC,O
mean,VB,O
scores,NNS,O
on,IN,O
the,DT,O
brief,JJ,O
psychiatric,JJ,O
rating,NNP,O
scale,NNP,O
were,VBD,O
increased,VBN,O
from,IN,O
baseline,NN,O
.,.,.
,,
in,IN,O
5,CD,O
other,JJ,O
schizophrenic,JJ,O
patients,NNS,O
treated,VBN,O
with,IN,O
oral,JJ,O
haloperidol,NN,D
and,CC,O
rifampin,NN,D
",",",",O
discontinuation,NN,O
of,IN,O
rifampin,NN,D
produced,VBD,O
a,DT,O
mean,JJ,O
3.3-fold,RB,O
increase,VB,O
in,IN,O
haloperidol,NN,D
concentrations,NNS,O
.,.,.
,,
thus,RB,O
",",",",O
careful,JJ,O
monitoring,NN,O
of,IN,O
clinical,JJ,O
status,NN,O
is,VBZ,O
warranted,VBN,O
when,WRB,O
rifampin,NN,D
is,VBZ,O
administered,VBN,O
or,CC,O
discontinued,VBN,O
in,IN,O
haloperidol-treated,JJ,O
patients,NNS,O
.,.,.
,,
fluothane,NN,B
augments,VBZ,O
the,DT,O
action,NN,O
of,IN,O
non-depolarising,JJ,O
muscle,NN,O
relaxants,NNS,O
and,CC,O
the,DT,O
muscle,NN,O
relaxant,NN,O
effects,NNS,O
of,IN,O
aminoglycosides,NNS,G
.,.,.
,,
fluothane,NN,B
may,MD,O
augment,VB,O
the,DT,O
hypotension,NN,O
caused,VBN,O
by,IN,O
the,DT,O
ganglionic-blocking,NN,O
effect,NN,O
of,IN,O
tubocurarine,NN,D
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
during,IN,O
the,DT,O
administration,NN,O
of,IN,O
adrenaline,NN,D
to,TO,O
patients,NNS,O
anaesthetised,VBN,O
with,IN,O
fluothane,NN,B
as,IN,O
arrhythmias,NNS,O
may,MD,O
be,VB,O
precipitated,VBN,O
.,.,.
,,
for,IN,O
this,DT,O
reason,NN,O
the,DT,O
dose,NN,O
of,IN,O
adrenaline,NN,D
should,MD,O
be,VB,O
restricted,JJ,O
and,CC,O
an,DT,O
antiarrhythmic,JJ,D
agent,NN,O
administered,VBN,O
as,IN,O
appropriate,JJ,O
.,.,.
,,
caution,NN,O
should,MD,O
also,RB,O
be,VB,O
applied,VBN,O
for,IN,O
other,JJ,O
sympathomimetics,NNS,G
",",",",O
and,CC,O
for,IN,O
aminophylline,NN,D
and,CC,O
theophylline,NN,D
and,CC,O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
which,WDT,O
may,MD,O
also,RB,O
precipitate,VB,O
arrhythmias,NNS,O
.,.,.
,,
drug,NN,O
interactions,NNS,O
:,:,O
a.,VB,O
drugs,NNS,O
enhancing,NN,O
heparin,NN,D
effect,NN,O
:,:,O
oral,JJ,O
anticoagulants,NNS,G
:,:,O
heparin,NN,D
sodium,NN,O
may,MD,O
prolong,VB,O
the,DT,O
one-stage,JJ,O
prothrombin,NN,O
time,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
when,WRB,O
heparin,NN,D
sodium,NN,O
is,VBZ,O
given,VBN,O
with,IN,O
dicumarol,NN,D
or,CC,O
warfarin,NN,D
sodium,NN,O
",",",",O
a,DT,O
period,NN,O
of,IN,O
at,IN,O
least,JJS,O
5,CD,O
hours,NNS,O
after,IN,O
the,DT,O
last,JJ,O
intravenous,JJ,O
dose,NN,O
or,CC,O
24,CD,O
hours,NNS,O
after,IN,O
the,DT,O
last,JJ,O
subcutaneous,JJ,O
dose,NN,O
should,MD,O
elapse,VB,O
before,IN,O
blood,NN,O
is,VBZ,O
drawn,VBN,O
if,IN,O
a,DT,O
valid,JJ,O
prothrombin,NN,O
time,NN,O
is,VBZ,O
to,TO,O
be,VB,O
obtained,VBN,O
.,.,.
,,
platelet,NN,O
inhibitors,NNS,O
:,:,O
drugs,NNS,O
such,JJ,O
as,IN,O
acetylsalicylic,JJ,O
acid,NN,O
",",",",O
dextran,NN,D
",",",",O
phenylbutazone,NN,D
",",",",O
ibuprofen,NN,D
",",",",O
indomethacin,NN,D
",",",",O
dipyridamole,NN,D
",",",",O
hydroxychloroquine,NN,D
and,CC,O
others,NNS,O
that,WDT,O
interfere,VBP,O
with,IN,O
platelet-aggregation,JJ,O
reactions,NNS,O
-lrb-,-LRB-,O
the,DT,O
main,JJ,O
hemostatic,JJ,O
defense,NN,O
of,IN,O
heparinized,JJ,O
patients,NNS,O
-rrb-,-RRB-,O
may,MD,O
induce,VB,O
bleeding,NN,O
and,CC,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
heparin,NN,D
sodium,NN,O
.,.,.
,,
the,DT,O
anticoagulant,JJ,G
effect,NN,O
of,IN,O
heparin,NN,D
is,VBZ,O
enhanced,VBN,O
by,IN,O
concurrent,JJ,O
treatment,NN,O
with,IN,O
antithrombin,NN,O
iii,CD,O
-lrb-,-LRB-,O
human,JJ,O
-rrb-,-RRB-,O
in,IN,O
patients,NNS,O
with,IN,O
hereditary,JJ,O
antithrombin,NN,O
iii,CD,O
deficiency,NN,O
.,.,.
,,
thus,RB,O
in,IN,O
order,NN,O
to,TO,O
avoid,VB,O
bleeding,NN,O
",",",",O
reduced,VBD,O
dosage,NN,O
of,IN,O
heparin,NN,D
is,VBZ,O
recommended,VBN,O
during,IN,O
treatment,NN,O
with,IN,O
antithrombin,NN,O
iii,CD,O
-lrb-,-LRB-,O
human,JJ,O
-rrb-,-RRB-,O
.,.,.
,,
b.,NN,O
drugs,NNS,O
decreasing,VBG,O
heparin,NN,D
effect,NN,O
:,:,O
digitalis,NNP,G
",",",",O
tetracyclines,NNS,G
",",",",O
nicotine,NN,D
",",",",O
or,CC,O
antihistamines,NNS,G
may,MD,O
partially,RB,O
counteract,VB,O
the,DT,O
anticoagulant,JJ,G
action,NN,O
of,IN,O
heparin,NN,D
sodium,NN,O
.,.,.
,,
heparin,NN,D
sodium,NN,O
injection,NN,O
should,MD,O
not,RB,O
be,VB,O
mixed,VBN,O
with,IN,O
doxorubicin,NN,D
",",",",O
droperidol,NN,D
",",",",O
ciprofloxacin,NN,D
",",",",O
or,CC,O
mitoxantrone,NN,D
",",",",O
since,IN,O
it,PRP,O
has,VBZ,O
been,VBN,O
reported,VBN,O
that,IN,O
these,DT,O
drugs,NNS,D
are,VBP,O
incompatible,JJ,O
with,IN,O
heparin,NN,D
and,CC,O
a,DT,O
precipitate,NN,O
may,MD,O
form,VB,O
.,.,.
,,
drug,NN,O
/,:,O
laboratory,NNP,O
tests,NNP,O
interactions,NNS,O
hyperaminotransferasemia,NNP,O
:,:,O
significant,JJ,O
elevations,NNS,O
of,IN,O
aminotransferase,NN,O
-lrb-,-LRB-,O
sgot,NN,O
-lsb-,-LRB-,O
s-ast,NN,O
-rsb-,-RRB-,O
and,CC,O
sgpt,NN,O
-lsb-,-LRB-,O
s-alt,NN,O
-rsb-,-RRB-,O
-rrb-,-RRB-,O
levels,NNS,O
have,VBP,O
occurred,VBN,O
in,IN,O
a,DT,O
high,JJ,O
percentage,NN,O
of,IN,O
patients,NNS,O
-lrb-,-LRB-,O
and,CC,O
healthy,JJ,O
subjects,NNS,O
-rrb-,-RRB-,O
who,WP,O
have,VBP,O
received,VBN,O
heparin,NN,D
sodium,NN,O
.,.,.
,,
since,IN,O
aminotransferase,NN,O
determinations,NNS,O
are,VBP,O
important,JJ,O
in,IN,O
the,DT,O
differential,JJ,O
diagnosis,NN,O
of,IN,O
myocardial,JJ,O
infarction,NN,O
",",",",O
liver,NN,O
disease,NN,O
and,CC,O
pulmonary,JJ,O
emboli,NNS,O
",",",",O
rises,VBZ,O
that,IN,O
might,MD,O
be,VB,O
caused,VBN,O
by,IN,O
drugs,NNS,D
-lrb-,-LRB-,O
heparin,NN,D
sodium,NN,O
-rrb-,-RRB-,O
should,MD,O
be,VB,O
interpreted,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
opioids,NNS,G
are,VBP,O
strong,JJ,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressants,NNS,O
",",",",O
but,CC,O
regular,JJ,O
users,NNS,O
develop,VB,O
physiological,JJ,O
tolerance,NN,O
allowing,VBG,O
gradually,RB,O
increased,VBN,O
dosages,NNS,O
.,.,.
,,
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressants,NNS,O
",",",",O
heroin,NN,D_n
may,MD,O
still,RB,O
kill,VB,O
even,RB,O
experienced,JJ,O
users,NNS,O
",",",",O
particularly,RB,O
if,IN,O
their,PRP$,O
tolerance,NN,O
to,TO,O
the,DT,O
drug,NN,D
has,VBZ,O
reduced,VBN,O
or,CC,O
the,DT,O
strength,NN,O
of,IN,O
their,PRP$,O
usual,JJ,O
dose,NN,O
has,VBZ,O
increased,VBN,O
.,.,.
,,
toxicology,NN,O
studies,NNS,O
of,IN,O
heroin-related,JJ,O
deaths,NNS,O
reveal,VBP,O
frequent,JJ,O
involvement,NN,O
of,IN,O
other,JJ,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressants,NNS,O
",",",",O
including,VBG,O
alcohol,NN,D
",",",",O
benzodiazepines,NNS,G
such,JJ,O
as,IN,O
diazepam,NN,D
-lrb-,-LRB-,O
valium,NN,B
-rrb-,-RRB-,O
",",",",O
and,CC,O
",",",",O
to,TO,O
a,DT,O
rising,VBG,O
degree,NN,O
",",",",O
methadone,NN,D
.,.,.
,,
ironically,RB,O
",",",",O
benzodiazepines,NNS,G
are,VBP,O
often,RB,O
used,VBN,O
in,IN,O
the,DT,O
treatment,NN,O
of,IN,O
heroin,NN,D_n
addiction,NN,O
while,IN,O
they,PRP,O
cause,VBP,O
much,RB,O
more,RBR,O
severe,JJ,O
withdrawal,NN,O
symptoms,NNS,O
.,.,.
,,
cocaine,NN,D
sometimes,RB,O
proves,VBZ,O
to,TO,O
be,VB,O
fatal,JJ,O
when,WRB,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
heroin,NN,D_n
.,.,.
,,
no,DT,O
information,NN,O
available,JJ,O
.,.,.
,,
barbiturates,NNS,G
may,MD,O
decrease,VB,O
the,DT,O
effectiveness,NN,O
of,IN,O
oral,JJ,O
contraceptives,NNS,G
",",",",O
certain,JJ,O
antibiotics,NNS,G
",",",",O
quinidine,NN,D
",",",",O
theophylline,NN,D
",",",",O
corticosteroids,NNS,G
",",",",O
anticoagulants,NNS,G
",",",",O
and,CC,O
beta,NN,O
blockers,NNS,O
.,.,.
,,
mao,NN,O
inhibitors,NNS,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
hydralazine,NN,D
.,.,.
,,
when,WRB,O
other,JJ,O
potent,JJ,O
parental,JJ,O
antihypertensive,JJ,G
drugs,NNS,D
",",",",O
such,JJ,O
as,IN,O
diazoxide,NN,D
",",",",O
are,VBP,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
hydralazine,NN,D
",",",",O
patients,NNS,O
should,MD,O
be,VB,O
continuously,RB,O
observed,VBN,O
for,IN,O
several,JJ,O
hours,NNS,O
for,IN,O
any,DT,O
excessive,JJ,O
fall,NN,O
in,IN,O
blood,NN,O
pressure,NN,O
.,.,.
,,
profound,JJ,O
hypotensive,JJ,O
episodes,NNS,O
may,MD,O
occur,VB,O
when,WRB,O
diazoxide,NN,D
infection,NN,O
and,CC,O
hydralazine,NN,D
are,VBP,O
used,VBN,O
concomitantly,RB,O
.,.,.
,,
beta-blockers,NNS,G
-lrb-,-LRB-,O
metoprolol,NN,D
",",",",O
propranolol,NN,D
-rrb-,-RRB-,O
serum,NN,O
concentrations,NNS,O
and,CC,O
pharmacologic,JJ,O
effects,NNS,O
may,MD,O
be,VB,O
increased,VBN,O
.,.,.
,,
monitor,NNP,O
cardiovascular,JJ,O
status,NN,O
.,.,.
,,
propranolol,NN,D
increases,VBZ,O
hydralazines,NNS,O
serum,NN,O
concentrations,NNS,O
.,.,.
,,
acebutolol,NNP,D
",",",",O
atenolol,NN,D
",",",",O
and,CC,O
nadolol,NN,D
-lrb-,-LRB-,O
low,JJ,O
hepatic,JJ,O
clearance,NN,O
or,CC,O
no,DT,O
first-pass,JJ,O
metabolism,NN,O
-rrb-,-RRB-,O
are,VBP,O
unlikely,JJ,O
to,TO,O
be,VB,O
affected,VBN,O
.,.,.
,,
nsaids,NNS,G
may,MD,O
decrease,VB,O
the,DT,O
hemodynamic,JJ,O
effects,NNS,O
of,IN,O
hydralazine,NN,D
.,.,.
,,
avoid,VB,O
use,NN,O
if,IN,O
possible,JJ,O
or,CC,O
closely,RB,O
monitor,VB,O
cardiovascular,JJ,O
status,NN,O
at,IN,O
the,DT,O
end,NN,O
of,IN,O
drug,NN,D
interactions,NNS,O
.,.,.
,,
when,WRB,O
given,VBN,O
concurrently,RB,O
the,DT,O
following,VBG,O
drugs,NNS,D
may,MD,O
interact,VB,O
with,IN,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
alcohol,NN,D
",",",",O
barbiturates,NNS,G
",",",",O
or,CC,O
narcotics,NNS,G
:,:,O
potentiation,NN,O
of,IN,O
orthostatic,JJ,O
hypotension,NN,O
may,MD,O
occur,VB,O
.,.,.
,,
antidiabetic,JJ,O
drugs,NNS,D
:,:,O
-lrb-,-LRB-,O
oral,JJ,O
agents,NNS,O
and,CC,O
insulin,NN,D
-rrb-,-RRB-,O
-,:,O
dosage,NN,O
adjustment,NN,O
of,IN,O
the,DT,O
antidiabetic,JJ,D
drug,NN,D
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
other,JJ,O
antihypertensive,JJ,G
drugs,NNS,D
:,:,O
additive,JJ,O
effect,NN,O
or,CC,O
potentiation,NN,O
.,.,.
,,
cholestyramine,NN,D
and,CC,O
colestipol,NN,D
resins,NNS,G
:,:,O
absorption,NN,O
of,IN,O
hydrochlorothiazide,NN,D
is,VBZ,O
impaired,JJ,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
anionic,JJ,O
exchange,NN,O
resins,NNS,G
.,.,.
,,
single,JJ,O
doses,NNS,O
of,IN,O
either,CC,O
cholestyramine,NN,D
or,CC,O
colestipol,NN,D
resins,NNS,G
bind,VBP,O
the,DT,O
hydrochlorothiazide,NN,D
and,CC,O
reduce,VB,O
its,PRP$,O
absorption,NN,O
from,IN,O
the,DT,O
gastrointestinal,JJ,O
tract,NN,O
by,IN,O
up,RB,O
to,TO,O
85,CD,O
and,CC,O
43,CD,O
percent,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
corticosteroids,NNS,G
",",",",O
acth,NN,D
:,:,O
intensified,VBN,O
electrolyte,NN,O
depletion,NN,O
",",",",O
particularly,RB,O
hypokalemia,NN,O
.,.,.
,,
pressor,NNP,O
amines,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
norepinephrine,NN,D
-rrb-,-RRB-,O
:,:,O
possible,JJ,O
decreased,VBN,O
response,NN,O
to,TO,O
pressor,NN,O
amines,NNS,O
but,CC,O
not,RB,O
sufficient,JJ,O
to,TO,O
preclude,VB,O
their,PRP$,O
use,NN,O
.,.,.
,,
skeletal,JJ,O
muscle,NN,O
relaxants,NNS,O
",",",",O
nondepolarizing,JJ,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
tubocurarine,NN,D
-rrb-,-RRB-,O
:,:,O
possible,JJ,O
increased,VBN,O
responsiveness,NN,O
to,TO,O
the,DT,O
muscle,NN,O
relaxant,NN,O
.,.,.
,,
lithium,NN,D
:,:,O
generally,RB,O
should,MD,O
not,RB,O
be,VB,O
given,VBN,O
with,IN,O
diuretics,NNS,G
.,.,.
,,
diuretic,JJ,G
agents,NNS,O
reduce,VB,O
the,DT,O
renal,JJ,O
clearance,NN,O
of,IN,O
lithium,NN,D
and,CC,O
add,VB,O
a,DT,O
high,JJ,O
risk,NN,O
of,IN,O
lithium,NN,D
toxicity,NN,O
.,.,.
,,
refer,VB,O
to,TO,O
the,DT,O
package,NN,O
insert,NN,O
for,IN,O
lithium,NN,D
preparations,NNS,O
before,IN,O
use,NN,O
of,IN,O
such,JJ,O
preparations,NNS,O
with,IN,O
hydrochlorothiazide,NN,D
.,.,.
,,
non-steroidal,JJ,O
anti-inflammatory,JJ,O
drugs,NNS,O
:,:,O
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
the,DT,O
administration,NN,O
of,IN,O
a,DT,O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
agent,NN,O
can,MD,O
reduce,VB,O
the,DT,O
diuretic,JJ,G
",",",",O
natriuretic,JJ,O
",",",",O
and,CC,O
antihypertensive,JJ,G
effects,NNS,O
of,IN,O
loop,NN,O
",",",",O
potassium-sparing,NN,O
and,CC,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
when,WRB,O
hydrochlorothiazide,NN,D
and,CC,O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
are,VBP,O
used,VBN,O
concomitantly,RB,O
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
to,TO,O
determine,VB,O
if,IN,O
the,DT,O
desired,VBN,O
effect,NN,O
of,IN,O
the,DT,O
diuretic,JJ,G
is,VBZ,O
obtained,VBN,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
other,JJ,O
narcotic,JJ,G
analgesics,NNS,G
",",",",O
antipsychotics,NNS,G
",",",",O
antianxiety,JJ,O
agents,NNS,O
",",",",O
or,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
-lrb-,-LRB-,O
including,VBG,O
alcohol,NN,D
-rrb-,-RRB-,O
concomitantly,RB,O
with,IN,O
hydrocodone,NN,D
and,CC,O
acetaminophen,NN,D
tablets,NNS,O
may,MD,O
exhibit,VB,O
an,DT,O
additive,JJ,O
cns,NN,O
depression,NN,O
.,.,.
,,
when,WRB,O
combined,VBN,O
therapy,NN,O
is,VBZ,O
contemplated,VBN,O
",",",",O
the,DT,O
dose,NN,O
of,IN,O
one,CD,O
or,CC,O
both,DT,O
agents,NNS,O
should,MD,O
be,VB,O
reduced,VBN,O
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
mao,NN,O
inhibitors,NNS,O
or,CC,O
tricyclic,JJ,G
antidepressants,NNS,G
with,IN,O
hydrocodone,NN,D
preparations,NNS,O
may,MD,O
increase,VB,O
the,DT,O
effect,NN,O
of,IN,O
either,CC,O
the,DT,O
antidepressant,JJ,G
or,CC,O
hydrocodone,NN,D
.,.,.
,,
the,DT,O
concurrent,JJ,O
use,NN,O
of,IN,O
anticholinergics,NNS,G
with,IN,O
hydrocodone,NN,D
may,MD,O
produce,VB,O
paralytic,JJ,O
ileus,NN,O
.,.,.
,,
no,DT,O
information,NN,O
available,JJ,O
.,.,.
,,
anticoagulants,NNPS,G
",",",",O
ora,NN,O
.,.,.
,,
-lrb-,-LRB-,O
effects,NNS,O
may,MD,O
be,VB,O
decreased,VBN,O
when,WRB,O
used,VBN,O
concurrently,RB,O
with,IN,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
dosage,NN,O
adjustments,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
-rrb-,-RRB-,O
.,.,.
,,
antigout,JJ,O
medication,NN,O
.,.,.
,,
-lrb-,-LRB-,O
thiazide,NNP,O
diuretics,NNS,G
may,MD,O
raise,VB,O
the,DT,O
level,NN,O
of,IN,O
blood,NN,O
uric,JJ,O
acid,NN,O
.,.,.
,,
dosage,NN,O
adjustment,NN,O
of,IN,O
antigout,JJ,O
medications,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
to,TO,O
control,VB,O
hyperuricemia,NN,O
and,CC,O
gout,NN,O
.,.,.
,,
antihypertensive,JJ,G
medications,NNS,O
",",",",O
other,JJ,O
",",",",O
especially,RB,O
diazoxide,NN,D
",",",",O
or,CC,O
preanesthetic,JJ,O
and,CC,O
anesthetic,JJ,G
agents,NNS,O
used,VBN,O
in,IN,O
surgery,NN,O
or,CC,O
skeletal-muscle,JJ,O
relaxants,NNS,O
",",",",O
nondepolarizing,JJ,O
",",",",O
used,VBN,O
in,IN,O
surger,NN,O
.,.,.
,,
-lrb-,-LRB-,O
effects,NNS,O
may,MD,O
be,VB,O
potentiated,VBN,O
when,WRB,O
used,VBN,O
concurrently,RB,O
with,IN,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
dosage,NN,O
adjustments,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
-rrb-,-RRB-,O
.,.,.
,,
amphotericin,NN,D
b,NN,O
or,CC,O
corticosteroids,NNS,G
or,CC,O
corticotropin,NN,D
-lrb-,-LRB-,O
acth,NN,D
.,.,.
,,
-lrb-,-LRB-,O
concurrent,JJ,O
use,NN,O
with,IN,O
thiazide,JJ,G
diuretics,NNS,G
may,MD,O
intensify,VB,O
electrolyte,NN,O
imbalance,NN,O
",",",",O
particularly,RB,O
hypokalemia,NN,O
.,.,.
,,
cardiac,JJ,O
glycoside,NN,O
.,.,.
,,
-lrb-,-LRB-,O
concurrent,JJ,O
use,NN,O
with,IN,O
thiazide,JJ,G
diuretics,NNS,G
may,MD,O
enhance,VB,O
the,DT,O
possibility,NN,O
of,IN,O
digitalis,NN,G
toxicity,NN,O
associated,VBN,O
with,IN,O
hypokalemia,NN,O
.,.,.
,,
colestipo,NNP,O
.,.,.
,,
-lrb-,-LRB-,O
may,NNP,O
inhibit,VBP,O
gastrointestinal,JJ,O
absorption,NN,O
of,IN,O
the,DT,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
administration,NN,O
1,CD,O
hour,NN,O
before,IN,O
or,CC,O
4,CD,O
hours,NNS,O
after,IN,O
colestipol,NN,D
is,VBZ,O
recommended,VBN,O
.,.,.
,,
hypoglycemic,JJ,O
.,.,.
,,
-lrb-,-LRB-,O
thiazide,NNP,O
diuretics,NNS,G
may,MD,O
raise,VB,O
blood,NN,O
glucose,NN,O
levels,NNS,O
.,.,.
,,
for,IN,O
adult-onset,JJ,O
diabetics,NNS,O
",",",",O
dosage,NN,O
adjustment,NN,O
of,IN,O
hypoglycemic,JJ,G
medications,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
during,IN,O
and,CC,O
after,IN,O
thiazide,JJ,G
diuretic,JJ,G
therapy,NN,O
.,.,.
,,
insulin,NN,D
requirements,NNS,O
may,MD,O
be,VB,O
increased,VBN,O
",",",",O
decreased,VBN,O
",",",",O
or,CC,O
unchanged,JJ,O
.,.,.
,,
lithium,NN,D
salt,NN,O
.,.,.
,,
-lrb-,-LRB-,O
concurrent,JJ,O
use,NN,O
with,IN,O
thiazide,JJ,G
diuretics,NNS,G
is,VBZ,O
not,RB,O
recommended,VBN,O
",",",",O
as,IN,O
they,PRP,O
may,MD,O
provoke,VB,O
lithium,NN,D
toxicity,NN,O
because,IN,O
of,IN,O
reduced,VBN,O
renal,JJ,O
clearance,NN,O
.,.,.
,,
methenamin,NNP,O
.,.,.
,,
-lrb-,-LRB-,O
effectiveness,NN,O
may,MD,O
be,VB,O
decreased,VBN,O
when,WRB,O
used,VBN,O
concurrently,RB,O
with,IN,O
thiazide,JJ,G
diuretics,NNS,G
because,IN,O
of,IN,O
alkalinization,NN,O
of,IN,O
the,DT,O
urine,NN,O
.,.,.
,,
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agent,NN,O
.,.,.
,,
-lrb-,-LRB-,O
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
the,DT,O
steroidal,JJ,O
anti-inflammatory,JJ,G
agent,NN,O
can,MD,O
reduce,VB,O
the,DT,O
diuretic,JJ,G
",",",",O
natriuretic,JJ,O
",",",",O
and,CC,O
antihypertensive,JJ,G
effects,NNS,O
of,IN,O
loop,NN,O
",",",",O
potassium,NN,D
sparing,NN,O
",",",",O
and,CC,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
when,WRB,O
hydroflumethiazide,NN,D
and,CC,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
are,VBP,O
used,VBN,O
concomitantly,RB,O
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
to,TO,O
determine,VB,O
if,IN,O
the,DT,O
desired,VBN,O
effect,NN,O
of,IN,O
the,DT,O
diuretic,JJ,G
is,VBZ,O
obtained,VBN,O
.,.,.
,,
norepinephrin,NNP,O
.,.,.
,,
-lrb-,-LRB-,O
thiazides,NNS,G
may,MD,O
decrease,VB,O
arterial,JJ,O
responsiveness,NN,O
to,TO,O
norepinephrine,NN,D
.,.,.
,,
this,DT,O
diminution,NN,O
is,VBZ,O
not,RB,O
sufficient,JJ,O
to,TO,O
preclude,VB,O
effectiveness,NN,O
of,IN,O
the,DT,O
pressor,NN,O
agent,NN,O
for,IN,O
therapeutic,JJ,O
use,NN,O
.,.,.
,,
-rrb-,-RRB-,O
.,.,.
,,
tubocurarin,NN,O
.,.,.
,,
-lrb-,-LRB-,O
thiazide,NN,O
drugs,NNS,D
may,MD,O
increase,VB,O
the,DT,O
responsiveness,NN,O
to,TO,O
tubocurarine,NN,D
.,.,.
,,
diagnostic,JJ,O
interference,NN,O
with,IN,O
expected,VBN,O
physiologic,JJ,O
effects,NNS,O
:,:,O
blood,NN,O
and,CC,O
urine,NN,O
glucose,NN,O
levels,NNS,O
-lrb-,-LRB-,O
usually,RB,O
only,RB,O
in,IN,O
patients,NNS,O
with,IN,O
a,DT,O
predisposition,NN,O
for,IN,O
glucose,NN,O
intolerance,NN,O
-rrb-,-RRB-,O
and,CC,O
serum,NN,O
bilirubin,NN,O
levels,NNS,O
-lrb-,-LRB-,O
by,IN,O
displacement,NN,O
from,IN,O
albumin,NN,O
binding,NN,O
-rrb-,-RRB-,O
and,CC,O
serum,NN,O
calcium,NN,D
levels,NNS,O
-lrb-,-LRB-,O
thiazide,JJ,G
diuretics,NNS,G
should,MD,O
be,VB,O
discontinued,VBN,O
before,IN,O
parathyroid-function,NN,O
tests,NNS,O
are,VBP,O
carried,VBN,O
out,RP,O
-rrb-,-RRB-,O
and,CC,O
serum,NN,O
uric,JJ,O
acid,NN,O
levels,NNS,O
-lrb-,-LRB-,O
may,MD,O
be,VB,O
increased,VBN,O
-rrb-,-RRB-,O
serum,NN,O
magnesium,NN,D
",",",",O
potassium,NN,D
",",",",O
and,CC,O
sodium,NN,O
levels,NNS,O
-lrb-,-LRB-,O
may,MD,O
be,VB,O
decreased,VBN,O
.,.,.
,,
serum,NN,O
magnesium,NN,D
levels,NNS,O
may,MD,O
increase,VB,O
in,IN,O
uremic,JJ,O
patients,NNS,O
-rrb-,-RRB-,O
serum,NN,O
protein-bound,JJ,O
iodine,NN,G
-lrb-,-LRB-,O
pbi,NN,O
-rrb-,-RRB-,O
levels,NNS,O
-lrb-,-LRB-,O
may,MD,O
be,VB,O
decreased,VBN,O
-rrb-,-RRB-,O
thiazides,NNS,G
should,MD,O
be,VB,O
discontinued,VBN,O
before,IN,O
carrying,VBG,O
out,RP,O
tests,NNS,O
for,IN,O
parathyroid,JJ,O
function,NN,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
other,JJ,O
narcotic,JJ,G
analgesics,NNS,G
",",",",O
general,JJ,O
anesthetics,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
tranquilizers,NNS,G
",",",",O
sedative-hypnotics,NNS,G
",",",",O
tricyclic,JJ,G
antidepressants,NNS,G
or,CC,O
other,JJ,O
cns,NN,O
depressants,NNS,O
-lrb-,-LRB-,O
including,VBG,O
alcohol,NN,D
-rrb-,-RRB-,O
concomitantly,RB,O
with,IN,O
dilaudid,NN,B
may,MD,O
exhibit,VB,O
an,DT,O
additive,JJ,O
cns,NN,O
depression,NN,O
.,.,.
,,
when,WRB,O
such,JJ,O
combined,JJ,O
therapy,NN,O
is,VBZ,O
contemplated,VBN,O
",",",",O
the,DT,O
dose,NN,O
of,IN,O
one,CD,O
or,CC,O
both,DT,O
agents,NNS,O
should,MD,O
be,VB,O
reduced,VBN,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
with,IN,O
cyanokit,NN,B
.,.,.
,,
prospective,JJ,O
studies,NNS,O
on,IN,O
the,DT,O
potential,NN,O
for,IN,O
hydroxyurea,NN,D
to,TO,O
interact,VB,O
with,IN,O
other,JJ,O
drugs,NNS,D
have,VBP,O
not,RB,O
been,VBN,O
performed,VBN,O
.,.,.
,,
concurrent,JJ,O
use,NN,O
of,IN,O
hydroxyurea,NN,D
and,CC,O
other,JJ,O
myelosuppressive,JJ,O
agents,NNS,O
or,CC,O
radiation,NN,O
therapy,NN,O
may,MD,O
increase,VB,O
the,DT,O
likelihood,NN,O
of,IN,O
bone,NN,O
marrow,NN,O
depression,NN,O
or,CC,O
other,JJ,O
adverse,JJ,O
events,NNS,O
.,.,.
,,
since,IN,O
hydroxyurea,NN,D
may,MD,O
raise,VB,O
the,DT,O
serum,NN,O
uric,JJ,O
acid,NN,O
level,NN,O
",",",",O
dosage,NN,O
adjustment,NN,O
of,IN,O
uricosuric,JJ,O
medication,NN,O
may,MD,O
be,VB,O
necessar,JJ,O
.,.,.
,,
the,DT,O
potentiating,VBG,O
action,NN,O
of,IN,O
hydroxyzine,NNP,D
must,NNP,O
be,VB,O
considered,VBN,O
when,WRB,O
the,DT,O
drug,NN,O
is,VBZ,O
used,NNP,O
in,IN,O
conjunction,NNP,O
with,IN,O
central,NNP,O
nervous,NNP,O
system,NNP,O
depressants,NNP,O
such,NNP,O
as,NNP,O
narcotics,NNP,G
",",",",O
non-narcotic,NN,O
analgesics,NNS,O
and,CC,O
barbiturates,NNS,G
.,.,.
,,
therefore,RB,O
when,WRB,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressants,NNS,O
are,VBP,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
hydroxyzine,NN,D
their,PRP$,O
dosage,NN,O
should,MD,O
be,VB,O
reduced,VBN,O
.,.,.
,,
since,IN,O
drowsiness,NN,O
may,MD,O
occur,VB,O
with,IN,O
use,NN,O
of,IN,O
this,DT,O
drug,NN,D
",",",",O
patients,NNS,O
should,MD,O
be,VB,O
warned,VBN,O
of,IN,O
this,DT,O
possibility,NN,O
and,CC,O
cautioned,VBD,O
against,IN,O
driving,VBG,O
a,DT,O
car,NN,O
or,CC,O
operating,VBG,O
dangerous,JJ,O
machinery,NN,O
while,IN,O
taking,VBG,O
atarax,NNP,B
.,.,.
,,
patients,NNS,O
should,MD,O
be,VB,O
advised,VBN,O
against,IN,O
the,DT,O
simultaneous,JJ,O
use,NN,O
of,IN,O
other,JJ,O
cns,NNS,O
depressant,NN,O
drugs,NNS,D
",",",",O
and,CC,O
cautioned,VBD,O
that,IN,O
the,DT,O
effect,NN,O
of,IN,O
alcohol,NN,D
may,MD,O
be,VB,O
increased,VBN,O
.,.,.
,,
additive,JJ,O
adverse,JJ,O
effects,NNS,O
resulting,VBG,O
from,IN,O
cholinergic,JJ,O
blockade,NN,O
may,MD,O
occur,VB,O
when,WRB,O
levsin,NNP,B
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
other,JJ,O
antimuscarinics,NNS,G
",",",",O
amantadine,NN,D
",",",",O
haloperidol,NN,D
",",",",O
phenothiazines,NNS,G
",",",",O
monoamine,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
mao,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
",",",",O
tricyclic,JJ,G
antidepressants,NNS,G
or,CC,O
some,DT,O
antihistamines,NNS,G
.,.,.
,,
antacids,NNS,G
may,MD,O
interfere,VB,O
with,IN,O
the,DT,O
absorption,NN,O
of,IN,O
levsin,NNP,B
.,.,.
,,
administer,VB,O
levsin,NNP,B
before,IN,O
meals,NNS,O
.,.,.
,,
antacids,NNS,G
after,IN,O
meals,NNS,O
.,.,.
,,
calcium,NN,D
supplements/antacid,NN,O
.,.,.
,,
products,NNPS,O
containing,VBG,O
calcium,NN,D
and,CC,O
other,JJ,O
multivalent,JJ,O
cations,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
aluminum,NN,D
",",",",O
magnesium,NN,D
",",",",O
iron,NN,D
-rrb-,-RRB-,O
are,VBP,O
likely,JJ,O
to,TO,O
interfere,VB,O
with,IN,O
absorption,NN,O
of,IN,O
ibandronate,NN,D
.,.,.
,,
ibandronate,NN,D
should,MD,O
be,VB,O
taken,VBN,O
at,IN,O
least,JJS,O
60,CD,O
minutes,NNS,O
before,IN,O
any,DT,O
oral,JJ,O
medications,NNS,O
containing,VBG,O
multivalent,JJ,O
cations,NNS,O
-lrb-,-LRB-,O
including,VBG,O
antacids,NNS,G
",",",",O
supplements,NNS,O
or,CC,O
vitamins,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
h2,NN,O
blockers,NNS,O
and,CC,O
proton,NNP,O
pump,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
ppis,NNS,G
.,.,.
,,
of,IN,O
over,IN,O
3500,CD,O
patients,NNS,O
enrolled,VBN,O
in,IN,O
the,DT,O
ibandronate,NNP,D
osteoporosis,NN,O
treatment,NN,O
and,CC,O
prevention,NNP,O
studies,NNPS,O
",",",",O
15,CD,O
%,NN,O
used,VBN,O
anti-peptic,JJ,O
agents,NNS,O
-lrb-,-LRB-,O
primarily,RB,O
h2,NN,O
blockers,NNS,O
and,CC,O
ppis,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
among,IN,O
these,DT,O
patients,NNS,O
",",",",O
the,DT,O
incidence,NN,O
of,IN,O
upper,JJ,O
gastrointestinal,JJ,O
adverse,JJ,O
experiences,NNS,O
in,IN,O
the,DT,O
patients,NNS,O
treated,VBN,O
with,IN,O
ibandronate,NN,D
was,VBD,O
similar,JJ,O
to,TO,O
that,DT,O
in,IN,O
placebo-treated,JJ,O
patients,NNS,O
.,.,.
,,
similarly,RB,O
",",",",O
of,IN,O
over,IN,O
1600,CD,O
patients,NNS,O
enrolled,VBN,O
in,IN,O
a,DT,O
study,NN,O
comparing,VBG,O
once-monthly,JJ,O
with,IN,O
daily,JJ,O
dosing,NN,O
regimens,NNS,O
of,IN,O
ibandronate,NN,D
",",",",O
14,CD,O
%,NN,O
of,IN,O
patients,NNS,O
used,VBN,O
anti-peptic,JJ,O
agents,NNS,O
.,.,.
,,
among,IN,O
these,DT,O
patients,NNS,O
",",",",O
the,DT,O
incidence,NN,O
of,IN,O
upper,JJ,O
gastrointestinal,JJ,O
adverse,JJ,O
experiences,NNS,O
in,IN,O
the,DT,O
patients,NNS,O
treated,VBN,O
with,IN,O
ibandronate,NN,D
150,CD,O
mg,NN,O
once,RB,O
monthly,JJ,O
was,VBD,O
similar,JJ,O
to,TO,O
that,DT,O
in,IN,O
patients,NNS,O
treated,VBN,O
with,IN,O
ibandronate,JJ,D
2.5,CD,O
mg,NN,O
once,RB,O
daily,RB,O
.,.,.
,,
aspirin/nonsteroidal,JJ,O
antiinflammatory,JJ,O
drugs,NNS,O
-lrb-,-LRB-,O
nsaids,NNS,G
.,.,.
,,
in,IN,O
the,DT,O
large,JJ,O
",",",",O
placebo-controlled,JJ,O
osteoporosis,NN,O
treatment,NN,O
study,NN,O
",",",",O
aspirin,NN,B
and,CC,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
were,VBD,O
taken,VBN,O
by,IN,O
62,CD,O
%,NN,O
of,IN,O
the,DT,O
2946,CD,O
patients,NNS,O
.,.,.
,,
among,IN,O
aspirin,NN,B
or,CC,O
nsaid,NN,G
users,NNS,O
",",",",O
the,DT,O
incidence,NN,O
of,IN,O
upper,JJ,O
gastrointestinal,JJ,O
adverse,JJ,O
events,NNS,O
in,IN,O
patients,NNS,O
treated,VBN,O
with,IN,O
ibandronate,NN,D
2.5,CD,O
mg,NN,O
daily,JJ,O
-lrb-,-LRB-,O
28.9,CD,O
%,NN,O
-rrb-,-RRB-,O
was,VBD,O
similar,JJ,O
to,TO,O
that,DT,O
in,IN,O
placebo-treated,JJ,O
patients,NNS,O
-lrb-,-LRB-,O
30.7,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
similarly,RB,O
",",",",O
in,IN,O
the,DT,O
1-year,JJ,O
monthly,JJ,O
comparison,NN,O
study,NN,O
",",",",O
aspirin,NN,B
and,CC,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
were,VBD,O
taken,VBN,O
by,IN,O
39,CD,O
%,NN,O
of,IN,O
the,DT,O
1602,CD,O
patients,NNS,O
.,.,.
,,
the,DT,O
incidence,NN,O
of,IN,O
upper,JJ,O
gastrointestinal,JJ,O
events,NNS,O
in,IN,O
patients,NNS,O
concomitantly,RB,O
taking,VBG,O
aspirin,NN,B
or,CC,O
nsaids,NNS,G
was,VBD,O
similar,JJ,O
in,IN,O
patients,NNS,O
taking,VBG,O
ibandronate,JJ,D
2.5,CD,O
mg,NN,O
daily,JJ,O
-lrb-,-LRB-,O
21.7,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
150,CD,O
mg,NN,O
once,RB,O
monthly,JJ,O
-lrb-,-LRB-,O
22,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
however,RB,O
",",",",O
since,IN,O
aspirin,NN,B
",",",",O
nsaids,NNS,G
",",",",O
and,CC,O
bisphosphonates,NNS,G
are,VBP,O
all,DT,O
associated,VBN,O
with,IN,O
gastrointestinal,JJ,O
irritation,NN,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
in,IN,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
aspirin,NN,B
or,CC,O
nsaids,NNS,G
with,IN,O
ibandronate,NN,D
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
.,.,.
,,
bisphosphonates,NNS,G
are,VBP,O
known,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
the,DT,O
use,NN,O
of,IN,O
bone-imaging,JJ,O
agents,NNS,O
.,.,.
,,
specific,JJ,O
studies,NNS,O
with,IN,O
ibandronate,NN,D
have,VBP,O
not,RB,O
been,VBN,O
performed,VBN,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
with,IN,O
zevalin,NN,B
.,.,.
,,
due,JJ,O
to,TO,O
the,DT,O
frequent,JJ,O
occurrence,NN,O
of,IN,O
severe,JJ,O
and,CC,O
prolonged,JJ,O
thrombocytopenia,NN,O
",",",",O
the,DT,O
potential,JJ,O
benefits,NNS,O
of,IN,O
medications,NNS,O
which,WDT,O
interfere,VBP,O
with,IN,O
platelet,NN,O
function,NN,O
and/or,CC,O
anticoagulation,NN,O
should,MD,O
be,VB,O
weighed,VBN,O
against,IN,O
the,DT,O
potential,NN,O
increased,VBD,O
risks,NNS,O
of,IN,O
bleeding,NN,O
and,CC,O
hemorrhage,NN,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
medications,NNS,O
that,WDT,O
interfere,VBP,O
with,IN,O
platelet,NN,O
function,NN,O
or,CC,O
coagulation,NN,O
should,MD,O
have,VB,O
more,RBR,O
frequent,JJ,O
laboratory,NN,O
monitoring,NN,O
for,IN,O
thrombocytopenia,NN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
the,DT,O
transfusion,NN,O
practices,NNS,O
for,IN,O
such,JJ,O
patients,NNS,O
may,MD,O
need,VB,O
to,TO,O
be,VB,O
modified,VBN,O
given,VBN,O
the,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
bleeding,NN,O
.,.,.
,,
patients,NNS,O
in,IN,O
clinical,JJ,O
studies,NNS,O
were,VBD,O
prohibited,VBN,O
from,IN,O
receiving,VBG,O
growth,NN,O
factor,NN,O
treatment,NN,O
for,IN,O
2,CD,O
weeks,NNS,O
prior,RB,O
to,TO,O
the,DT,O
zevalin,NNP,B
therapeutic,JJ,O
regimen,NNS,O
as,RB,O
well,RB,O
as,IN,O
for,IN,O
2,CD,O
weeks,NNS,O
following,VBG,O
completion,NN,O
of,IN,O
the,DT,O
regimen,NN,O
.,.,.
,,
coumarin-type,JJ,O
anticoagulants,NNPS,G
:,:,O
several,JJ,O
short-term,JJ,O
controlled,JJ,O
studies,NNS,O
failed,VBD,O
to,TO,O
wshow,VB,O
that,IN,O
ibuprofen,NN,D
significantly,RB,O
affected,VBD,O
prothrombin,NN,O
times,NNS,O
or,CC,O
a,DT,O
variety,NN,O
of,IN,O
other,JJ,O
clotting,NN,O
factors,NNS,O
when,WRB,O
administered,VBN,O
to,TO,O
individuals,NNS,O
on,IN,O
coumarin-type,JJ,O
anticoagulants,NNS,G
.,.,.
,,
however,RB,O
",",",",O
because,IN,O
bleeding,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
when,WRB,O
ibuprofen,NN,D
and,CC,O
other,JJ,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
have,VBP,O
been,VBN,O
administered,VBN,O
to,TO,O
patients,NNS,O
on,IN,O
coumarin-type,JJ,O
anticoagulants,NNS,G
",",",",O
the,DT,O
physician,NN,O
should,MD,O
be,VB,O
cautious,JJ,O
when,WRB,O
administering,VBG,O
ibuprofen,NN,D
to,TO,O
patients,NNS,O
on,IN,O
anticoagulants,NNS,G
.,.,.
,,
aspirin,NN,B
:,:,O
animal,NN,O
studies,NNS,O
wshow,VBP,O
that,IN,O
aspirin,NN,B
given,VBN,O
with,IN,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
",",",",O
including,VBG,O
ibuprofen,NN,D
",",",",O
yields,VBZ,O
a,DT,O
net,JJ,O
decrease,NN,O
in,IN,O
anti-inflammatory,JJ,G
activity,NN,O
with,IN,O
lowered,JJ,O
blood,NN,O
levels,NNS,O
of,IN,O
the,DT,O
non-aspirin,JJ,O
drug,NN,D
.,.,.
,,
single,JJ,O
dose,NN,O
bioavailability,NN,O
studies,NNS,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
have,VBP,O
failed,VBN,O
to,TO,O
wshow,VB,O
an,DT,O
effect,NN,O
of,IN,O
aspirin,NN,B
on,IN,O
ibuprofen,NN,D
blood,NN,O
levels,NNS,O
.,.,.
,,
correlative,JJ,O
clinical,JJ,O
studies,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
performed,VBN,O
.,.,.
,,
methotrexate,NNP,D
:,:,O
ibuprofen,NNP,D
",",",",O
as,RB,O
well,RB,O
as,IN,O
other,JJ,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
",",",",O
probably,RB,O
reduces,VBZ,O
the,DT,O
tubular,JJ,O
secretion,NN,O
of,IN,O
methotrexate,NN,D
based,VBN,O
on,IN,O
in,FW,O
vitro,FW,O
studies,NNS,O
in,IN,O
rabbit,NN,O
kidney,NN,O
slices,NNS,O
.,.,.
,,
this,DT,O
may,MD,O
indicate,VB,O
that,IN,O
ibuprofen,NN,D
could,MD,O
enhance,VB,O
the,DT,O
toxicity,NN,O
of,IN,O
methotrexate,NN,D
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
if,IN,O
ibuprofen,NN,D
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
methotrexate,NN,D
.,.,.
,,
h-2,NN,O
antagonists,NNS,O
:,:,O
in,IN,O
studies,NNS,O
with,IN,O
human,JJ,O
volunteers,NNS,O
",",",",O
co-administration,NN,O
of,IN,O
cimetidine,NN,D
or,CC,O
ranitidine,NN,D
with,IN,O
ibuprofen,NN,D
had,VBD,O
no,DT,O
substantive,JJ,O
effect,NN,O
on,IN,O
ibuprofen,NN,D
serum,NN,O
concentrations,NNS,O
.,.,.
,,
furosemide,NNP,D
:,:,O
clinical,JJ,O
studies,NNS,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
random,JJ,O
observations,NNS,O
",",",",O
have,VBP,O
shown,VBN,O
that,IN,O
ibuprofen,NN,D
can,MD,O
reduce,VB,O
the,DT,O
natriuretic,JJ,O
effect,NN,O
of,IN,O
furosemide,NN,D
and,CC,O
thiazides,NNS,G
in,IN,O
some,DT,O
patients,NNS,O
.,.,.
,,
this,DT,O
response,NN,O
has,VBZ,O
been,VBN,O
attributed,VBN,O
to,TO,O
inhibition,NN,O
of,IN,O
renal,JJ,O
prostaglandin,NN,O
synthesis,NN,O
.,.,.
,,
during,IN,O
concomitant,JJ,O
therapy,NN,O
with,IN,O
ibuprofen,NN,D
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
signs,NNS,O
of,IN,O
renal,JJ,O
failure,NN,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
to,TO,O
assure,VB,O
diuretic,JJ,G
efficacy,NN,O
.,.,.
,,
lithium,NN,D
:,:,O
ibuprofen,NN,D
produced,VBD,O
an,DT,O
elevation,NN,O
of,IN,O
plasma,NN,O
lithium,NN,D
levels,NNS,O
and,CC,O
a,DT,O
reduction,NN,O
in,IN,O
renal,JJ,O
lithium,NN,D
clearance,NN,O
in,IN,O
a,DT,O
study,NN,O
of,IN,O
eleven,NNS,O
normal,JJ,O
volunteers,NNS,O
.,.,.
,,
the,DT,O
mean,NN,O
minimum,JJ,O
lithium,NN,D
concentration,NN,O
increased,VBD,O
15,CD,O
%,NN,O
and,CC,O
the,DT,O
renal,JJ,O
clearance,NN,O
of,IN,O
lithium,NN,D
was,VBD,O
decreased,VBN,O
by,IN,O
19,CD,O
%,NN,O
during,IN,O
this,DT,O
period,NN,O
of,IN,O
concomitant,JJ,O
drug,NN,D
administration,NN,O
.,.,.
,,
this,DT,O
effect,NN,O
has,VBZ,O
been,VBN,O
attributed,VBN,O
to,TO,O
inhibition,NN,O
of,IN,O
renal,JJ,O
prostaglandin,NN,O
synthesis,NN,O
by,IN,O
ibuprofen,NN,D
.,.,.
,,
thus,RB,O
",",",",O
when,WRB,O
ibuprofen,NN,D
and,CC,O
lithium,NN,D
are,VBP,O
administered,VBN,O
concurrently,RB,O
",",",",O
subjects,NNS,O
should,MD,O
be,VB,O
observed,VBN,O
carefully,RB,O
for,IN,O
signs,NNS,O
of,IN,O
lithium,NN,D
toxicity,NN,O
.,.,.
,,
-lrb-,-LRB-,O
read,VB,O
circulars,NNS,O
for,IN,O
lithium,NN,D
preparation,NN,O
before,IN,O
use,NN,O
of,IN,O
such,JJ,O
concurrent,JJ,O
therapy,NN,O
-rrb-,-RRB-,O
.,.,.
,,
no,DT,O
specific,JJ,O
pharmacokinetic,JJ,O
or,CC,O
other,JJ,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
were,VBD,O
conducted,VBN,O
.,.,.
,,
digoxin,NNP,D
:,:,O
supraventricular,JJ,O
arrhythmias,NNS,O
may,MD,O
mask,NN,O
the,DT,O
cardiotoxicity,NN,O
associated,VBN,O
with,IN,O
excessive,JJ,O
digoxin,NN,D
levels,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
it,PRP,O
is,VBZ,O
advisable,JJ,O
to,TO,O
be,VB,O
particularly,RB,O
cautious,JJ,O
in,IN,O
patients,NNS,O
whose,WP$,O
plasma,NN,O
digoxin,NN,D
levels,NNS,O
are,VBP,O
above,IN,O
or,CC,O
suspected,VBN,O
to,TO,O
be,VB,O
above,IN,O
the,DT,O
usual,JJ,O
therapeutic,JJ,O
range,NN,O
.,.,.
,,
coadministration,NN,O
of,IN,O
digoxin,NN,D
did,VBD,O
not,RB,O
have,VB,O
effects,NNS,O
on,IN,O
either,CC,O
the,DT,O
safety,NN,O
or,CC,O
efficacy,NN,O
of,IN,O
ibutilide,NN,D
in,IN,O
the,DT,O
clinical,JJ,O
trials,NNS,O
.,.,.
,,
calcium,NN,D
channel,NN,O
blocking,VBG,O
agents,NNS,O
:,:,O
coadministration,NN,O
of,IN,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
did,VBD,O
not,RB,O
have,VB,O
any,DT,O
effect,NN,O
on,IN,O
either,CC,O
the,DT,O
safety,NN,O
or,CC,O
efficacy,NN,O
of,IN,O
ibutilide,NN,D
in,IN,O
the,DT,O
clinical,JJ,O
trials,NNS,O
.,.,.
,,
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
:,:,O
coadministration,NN,O
of,IN,O
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
did,VBD,O
not,RB,O
have,VB,O
any,DT,O
effect,NN,O
on,IN,O
either,CC,O
the,DT,O
safety,NN,O
or,CC,O
efficacy,NN,O
of,IN,O
ibutilide,NN,D
in,IN,O
the,DT,O
clinical,JJ,O
trials,NNS,O
.,.,.
,,
general,NNP,O
no,NNP,O
clinical,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
were,VBD,O
performed,VBN,O
.,.,.
,,
no,DT,O
evaluation,NN,O
of,IN,O
extraneals,NNS,O
effects,NNS,O
on,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
system,NN,O
was,VBD,O
conducted,VBN,O
.,.,.
,,
as,IN,O
with,IN,O
other,JJ,O
dialysis,NN,O
solutions,NNS,O
",",",",O
blood,NN,O
concentrations,NNS,O
of,IN,O
dialyzable,JJ,O
drugs,NNS,D
may,MD,O
be,VB,O
reduced,VBN,O
by,IN,O
dialysis,NN,O
.,.,.
,,
dosage,NN,O
adjustment,NN,O
of,IN,O
concomitant,JJ,O
medications,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
in,IN,O
patients,NNS,O
using,VBG,O
cardiac,JJ,O
glycosides,NNS,G
-lrb-,-LRB-,O
digoxin,NN,D
and,CC,O
others,NNS,O
-rrb-,-RRB-,O
",",",",O
plasma,NN,O
levels,NNS,O
of,IN,O
calcium,NN,D
",",",",O
potassium,NN,D
and,CC,O
magnesium,NN,D
must,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
.,.,.
,,
insulin,NN,D
:,:,O
a,DT,O
clinical,JJ,O
study,NN,O
in,IN,O
6,CD,O
insulin-dependent,JJ,O
diabetic,JJ,O
patients,NNS,O
demonstrated,VBD,O
no,DT,O
effect,NN,O
of,IN,O
extraneal,NN,B
on,IN,O
insulin,NN,D
absorption,NN,O
from,IN,O
the,DT,O
peritoneal,JJ,O
cavity,NN,O
or,CC,O
on,IN,O
insulins,NNS,G
ability,NN,O
to,TO,O
control,VB,O
blood,NN,O
glucose,NN,O
when,WRB,O
insulin,NN,D
was,VBD,O
administered,VBN,O
intraperitoneally,RB,O
with,IN,O
extraneal,NN,B
.,.,.
,,
however,RB,O
",",",",O
appropriate,JJ,O
monitoring,NN,O
of,IN,O
blood,NN,O
glucose,NN,O
should,MD,O
be,VB,O
performed,VBN,O
when,WRB,O
initiating,VBG,O
extraneal,NNP,B
in,IN,O
diabetic,JJ,O
patients,NNS,O
and,CC,O
insulin,NN,D
dosage,NN,O
should,MD,O
be,VB,O
adjusted,VBN,O
if,IN,O
needed,VBN,O
.,.,.
,,
heparin,NN,D
:,:,O
no,DT,O
human,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
with,IN,O
heparin,NN,D
were,VBD,O
conducted,VBN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
demonstrated,VBD,O
no,DT,O
evidence,NN,O
of,IN,O
incompatibility,NN,O
of,IN,O
heparin,NN,D
with,IN,O
extraneal,NN,B
.,.,.
,,
antibiotics,NNS,G
:,:,O
no,DT,O
human,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
with,IN,O
antibiotics,NNS,G
were,VBD,O
conducted,VBN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
evaluating,VBG,O
the,DT,O
minimum,JJ,O
inhibitory,JJ,O
concentration,NN,O
-lrb-,-LRB-,O
mic,NN,O
-rrb-,-RRB-,O
of,IN,O
vancomycin,NN,D
",",",",O
cefazolin,NN,D
",",",",O
ampicillin,NN,D
",",",",O
ampicillin/flucoxacillin,NN,O
",",",",O
ceftazidime,NN,D
",",",",O
gentamicin,NN,D
",",",",O
and,CC,O
amphotericin,NN,D
demonstrated,VBD,O
no,DT,O
evidence,NN,O
of,IN,O
incompatibility,NN,O
of,IN,O
these,DT,O
antibiotics,NNS,G
with,IN,O
extraneal,NN,B
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
blood,NN,O
glucose,NN,O
blood,NN,O
glucose,NN,O
measurement,NN,O
must,MD,O
be,VB,O
done,VBN,O
with,IN,O
a,DT,O
glucose-specific,JJ,O
method,NN,O
to,TO,O
prevent,VB,O
maltose,NN,O
interference,NN,O
with,IN,O
test,NN,O
results,NNS,O
.,.,.
,,
since,IN,O
falsely,RB,O
elevated,JJ,O
glucose,NN,O
levels,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
with,IN,O
blood,NN,O
glucose,NN,O
monitoring,NN,O
devices,NNS,O
and,CC,O
test,NN,O
strips,NNS,O
that,WDT,O
use,VBP,O
glucose,NN,O
dehydrogenase,NN,O
pyrroloquinolinequinone,NN,O
-lrb-,-LRB-,O
gdh,NN,O
pqq,NN,O
-rrb-,-RRB-,O
-,:,O
based,VBN,O
methods,NNS,O
",",",",O
gdh,NN,O
pqq-based,JJ,O
methods,NNS,O
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
to,TO,O
measure,VB,O
glucose,NN,O
levels,NNS,O
in,IN,O
patients,NNS,O
administered,VBN,O
extraneal,NNP,B
.,.,.
,,
serum,NN,O
amylase,NN,O
an,DT,O
apparent,JJ,O
decrease,NN,O
in,IN,O
serum,NN,O
amylase,NN,D
activity,NN,O
has,VBZ,O
been,VBN,O
observed,VBN,O
in,IN,O
patients,NNS,O
administered,VBN,O
extraneal,NNP,B
.,.,.
,,
preliminary,JJ,O
investigations,NNS,O
indicate,VBP,O
that,IN,O
icodextrin,NN,D
and,CC,O
its,PRP$,O
metabolites,NNS,O
interfere,VBP,O
with,IN,O
enzymatic-based,JJ,O
amylase,NN,D
assays,NNS,O
",",",",O
resulting,VBG,O
in,IN,O
inaccurately,RB,O
low,JJ,O
values,NNS,O
.,.,.
,,
this,DT,O
should,MD,O
be,VB,O
taken,VBN,O
into,IN,O
account,NN,O
when,WRB,O
evaluating,VBG,O
serum,NN,O
amylase,NN,D
levels,NNS,O
for,IN,O
diagnosis,NN,O
or,CC,O
monitoring,NN,O
of,IN,O
pancreatitis,NN,O
in,IN,O
patients,NNS,O
using,VBG,O
extraneal,NNP,B
.,.,.
,,
interactions,NNS,O
may,MD,O
occur,VB,O
between,IN,O
epa,NNP,D
supplements,NNS,O
and,CC,O
aspirin,NN,B
and,CC,O
other,JJ,O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
and,CC,O
herbs,NNS,O
such,JJ,O
as,IN,O
garlic,NN,O
-lrb-,-LRB-,O
allium,NN,O
sativum,NN,O
-rrb-,-RRB-,O
and,CC,O
ginkgo,NN,D
-lrb-,-LRB-,O
ginkgo,NNP,O
biloba,NN,O
-rrb-,-RRB-,O
.,.,.
,,
such,JJ,O
interactions,NNS,O
might,MD,O
be,VB,O
manifested,VBN,O
by,IN,O
increased,VBN,O
susceptibility,NN,O
to,TO,O
bruising,VBG,O
",",",",O
nosebleeds,NNS,O
",",",",O
hemoptysis,NN,O
",",",",O
hematemesis,NN,O
",",",",O
hematuria,NN,O
and,CC,O
blood,NN,O
in,IN,O
the,DT,O
stool,NN,O
.,.,.
,,
most,JJS,O
who,WP,O
take,VBP,O
epa,NNP,D
supplements,NNS,O
and,CC,O
the,DT,O
above,JJ,O
drugs,NNS,D
or,CC,O
herbs,NNS,O
do,VBP,O
not,RB,O
suffer,VB,O
from,IN,O
these,DT,O
problems,NNS,O
and,CC,O
if,IN,O
they,PRP,O
occur,VBP,O
",",",",O
they,PRP,O
are,VBP,O
rare,JJ,O
.,.,.
,,
if,IN,O
they,PRP,O
do,VBP,O
occur,VB,O
",",",",O
the,DT,O
epa,NNP,D
dose,NN,O
should,MD,O
be,VB,O
lowered,VBN,O
or,CC,O
discontinued,VBN,O
.,.,.
,,
conflicting,JJ,O
results,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
regarding,VBG,O
the,DT,O
effects,NNS,O
of,IN,O
epa,NNP,D
supplements,NNS,O
on,IN,O
glycemic,JJ,O
control,NN,O
in,IN,O
non-diabetics,NNS,O
with,IN,O
glucose,NN,O
intolerance,NN,O
",",",",O
and,CC,O
those,DT,O
with,IN,O
type,NN,O
2,CD,O
diabetes,NN,O
.,.,.
,,
some,DT,O
early,JJ,O
studies,NNS,O
indicated,VBD,O
that,IN,O
epa,NNP,D
supplements,NNS,O
might,MD,O
have,VB,O
detrimental,JJ,O
effects,NNS,O
in,IN,O
those,DT,O
groups,NNS,O
.,.,.
,,
recent,JJ,O
",",",",O
better,RBR,O
designed,VBN,O
studies,NNS,O
have,VBP,O
not,RB,O
reported,VBN,O
these,DT,O
adverse,JJ,O
effects,NNS,O
.,.,.
,,
there,EX,O
is,VBZ,O
no,DT,O
evidence,NN,O
that,IN,O
epa,NNP,D
supplements,NNS,O
have,VBP,O
detrimental,JJ,O
effects,NNS,O
on,IN,O
glucose,NN,O
tolerance,NN,O
",",",",O
insulin,NN,D
secretion,NN,O
or,CC,O
insulin,NN,D
resistance,NN,O
in,IN,O
non-diabetic,JJ,O
subjects,NNS,O
.,.,.
,,
diabetics,NNS,O
should,MD,O
discuss,VB,O
the,DT,O
use,NN,O
of,IN,O
these,DT,O
supplements,NNS,O
with,IN,O
their,PRP$,O
physicians,NNS,O
and,CC,O
note,NN,O
if,IN,O
the,DT,O
supplements,NNS,O
affect,VBP,O
their,PRP$,O
glycemic,JJ,O
control,NN,O
.,.,.
,,
diabetics,NNS,O
who,WP,O
take,VBP,O
epa,NNP,D
supplements,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
by,IN,O
their,PRP$,O
physicians,NNS,O
.,.,.
,,
other,JJ,O
medicines,NNS,O
-,:,O
although,IN,O
certain,JJ,O
medicines,NNS,O
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
together,RB,O
at,IN,O
all,DT,O
",",",",O
in,IN,O
other,JJ,O
cases,NNS,O
two,CD,O
different,JJ,O
medicines,NNS,O
may,MD,O
be,VB,O
used,VBN,O
together,RB,O
even,RB,O
if,IN,O
an,DT,O
interaction,NN,O
might,MD,O
occur,VB,O
.,.,.
,,
in,IN,O
these,DT,O
cases,NNS,O
",",",",O
your,PRP$,O
doctor,NN,O
may,MD,O
want,VB,O
to,TO,O
change,VB,O
the,DT,O
dose,NN,O
",",",",O
or,CC,O
other,JJ,O
precautions,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
when,WRB,O
you,PRP,O
are,VBP,O
using,VBG,O
idoxuridine,NN,D
",",",",O
it,PRP,O
is,VBZ,O
especially,RB,O
important,JJ,O
that,IN,O
your,PRP$,O
health,NN,O
care,NN,O
professional,JJ,O
know,VBP,O
if,IN,O
you,PRP,O
are,VBP,O
using,VBG,O
the,DT,O
following,NN,O
:,:,O
eye,NNP,O
product,NN,O
containing,VBG,O
boric,JJ,O
acid,NN,O
.,.,.
,,
boric,JJ,O
acid,NN,O
may,MD,O
interact,VB,O
with,IN,O
the,DT,O
idoxuridine,NN,D
preparation,NN,O
causing,VBG,O
a,DT,O
gritty,JJ,O
substance,NN,O
to,TO,O
form,VB,O
or,CC,O
may,MD,O
interact,VB,O
with,IN,O
the,DT,O
preservative,NN,O
in,IN,O
the,DT,O
idoxuridine,NN,D
preparation,NN,O
causing,VBG,O
a,DT,O
toxic,JJ,O
effect,NN,O
in,IN,O
the,DT,O
eye,NN,O
.,.,.
,,
the,DT,O
physician,NN,O
should,MD,O
be,VB,O
alert,JJ,O
for,IN,O
possible,JJ,O
combined,VBN,O
drug,NN,D
actions,NNS,O
",",",",O
desirable,JJ,O
or,CC,O
undesirable,JJ,O
",",",",O
involving,VBG,O
ifosfamide,NN,D
even,RB,O
though,IN,O
ifosfamide,NN,D
has,VBZ,O
been,VBN,O
used,VBN,O
successfully,RB,O
concurrently,RB,O
with,IN,O
other,JJ,O
drugs,NNS,D
",",",",O
including,VBG,O
other,JJ,O
cytotoxic,JJ,G
drugs,NNS,D
.,.,.
,,
in,IN,O
studies,NNS,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
",",",",O
there,EX,O
was,VBD,O
no,DT,O
pharmacodynamic,JJ,O
interaction,NN,O
between,IN,O
intravenous,JJ,O
iloprost,NN,D
and,CC,O
either,CC,O
nifedipine,NN,D
",",",",O
diltiazem,NN,D
",",",",O
or,CC,O
captopril,NN,D
.,.,.
,,
however,RB,O
",",",",O
iloprost,NN,D
has,VBZ,O
the,DT,O
potential,JJ,O
to,TO,O
increase,VB,O
the,DT,O
hypotensive,JJ,O
effect,NN,O
of,IN,O
vasodilators,NNS,G
and,CC,O
antihypertensive,JJ,G
agents,NNS,O
.,.,.
,,
since,IN,O
iloprost,NN,D
inhibits,VBZ,O
platelet,NN,O
function,NN,O
",",",",O
there,EX,O
is,VBZ,O
a,DT,O
potential,NN,O
for,IN,O
increased,VBN,O
risk,NN,O
of,IN,O
bleeding,NN,O
",",",",O
particularly,RB,O
in,IN,O
patients,NNS,O
maintained,VBN,O
on,IN,O
anticoagulants,NNS,G
.,.,.
,,
during,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
iloprost,NN,D
was,VBD,O
used,VBN,O
concurrently,RB,O
with,IN,O
anticoagulants,NNS,G
",",",",O
diuretics,NNS,G
",",",",O
cardiac,JJ,O
glycosides,NNS,G
",",",",O
calcium,NN,D
channel,NN,O
blockers,NNS,O
",",",",O
analgesics,NNS,G
",",",",O
antipyretics,NNS,G
",",",",O
nonsteroidal,JJ,O
antiinflammatories,NNS,O
",",",",O
corticosteroids,NNS,G
",",",",O
and,CC,O
other,JJ,O
medications,NNS,O
.,.,.
,,
intravenous,JJ,O
infusion,NN,O
of,IN,O
iloprost,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
digoxin,NN,D
.,.,.
,,
acetylsalicylic,JJ,O
acid,NN,O
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
clearance,NN,O
-lrb-,-LRB-,O
pharmacokinetics,NNS,O
-rrb-,-RRB-,O
of,IN,O
iloprost,FW,D
.,.,.
,,
although,IN,O
clinical,JJ,O
studies,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
",",",",O
in,FW,O
vitro,FW,O
studies,NNS,O
of,IN,O
iloprost,JJ,D
indicate,VBP,O
that,IN,O
no,DT,O
relevant,JJ,O
inhibition,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
drug,NN,D
metabolism,NN,O
would,MD,O
be,VB,O
expected,VBN,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
may,MD,O
alter,VB,O
imatinib,JJ,D
plasma,NN,O
concentrations,NNS,O
drugs,NNS,O
that,WDT,O
may,MD,O
increase,VB,O
imatinib,JJ,D
plasma,NN,O
concentrations,NNS,O
:,:,O
caution,NN,O
is,VBZ,O
recommended,VBN,O
when,WRB,O
administering,VBG,O
gleevec,NN,B
with,IN,O
inhibitors,NNS,O
of,IN,O
the,DT,O
cyp3a4,NN,D
family,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
ketoconazole,NN,D
",",",",O
itraconazole,NN,D
",",",",O
erythromycin,NN,D
",",",",O
clarithromycin,NN,D
-rrb-,-RRB-,O
.,.,.
,,
substances,NNS,O
that,WDT,O
inhibit,VBP,O
the,DT,O
cytochrome,NN,O
p450,NN,O
isoenzyme,NN,O
-lrb-,-LRB-,O
cyp3a4,NN,D
-rrb-,-RRB-,O
activity,NN,O
may,MD,O
decrease,VB,O
metabolism,NN,O
and,CC,O
increase,NN,O
imatinib,NN,D
concentrations,NNS,O
.,.,.
,,
there,EX,O
is,VBZ,O
a,DT,O
significant,JJ,O
increase,NN,O
in,IN,O
exposure,NN,O
to,TO,O
imatinib,NN,D
when,WRB,O
gleevec,NNP,B
is,VBZ,O
coadministered,VBN,O
with,IN,O
ketoconazole,NN,D
-lrb-,-LRB-,O
cyp3a4,NN,D
inhibitor,NN,O
-rrb-,-RRB-,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
may,MD,O
decrease,VB,O
imatinib,JJ,D
plasma,NN,O
concentrations,NNS,O
:,:,O
substances,NNS,O
that,WDT,O
are,VBP,O
inducers,NNS,O
of,IN,O
cyp3a4,NN,D
activity,NN,O
may,MD,O
increase,VB,O
metabolism,NN,O
and,CC,O
decrease,VB,O
imatinib,JJ,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
co-medications,NNS,O
that,WDT,O
induce,VBP,O
cyp3a4,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
dexamethasone,NN,D
",",",",O
phenytoin,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
rifampin,NN,D
",",",",O
phenobarbital,NN,D
or,CC,O
st.,NNP,O
johns,NNP,O
wort,NNP,O
-rrb-,-RRB-,O
may,MD,O
significantly,RB,O
reduce,VB,O
exposure,NN,O
to,TO,O
gleevec,NNP,B
.,.,.
,,
pretreatment,NN,O
of,IN,O
healthy,JJ,O
volunteers,NNS,O
with,IN,O
multiple,JJ,O
doses,NNS,O
of,IN,O
rifampin,NN,D
followed,VBN,O
by,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
gleevec,NNP,B
",",",",O
increased,VBD,O
gleevec,NNP,B
oral-dose,JJ,O
clearance,NN,O
by,IN,O
3.8-fold,JJ,O
",",",",O
which,WDT,O
significantly,RB,O
-lrb-,-LRB-,O
p,NN,O
0.05,CD,O
-rrb-,-RRB-,O
decreased,VBD,O
mean,NN,O
cmax,NN,O
and,CC,O
auc,NN,O
-lrb-,-LRB-,O
0-8,CD,O
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
patients,NNS,O
where,WRB,O
rifampin,NN,D
or,CC,O
other,JJ,O
cyp3a4,NN,D
inducers,NNS,O
are,VBP,O
indicated,VBN,O
",",",",O
alternative,JJ,O
therapeutic,JJ,O
agents,NNS,O
with,IN,O
less,JJR,O
enzyme,NN,O
induction,NN,O
potential,NN,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
may,MD,O
have,VB,O
their,PRP$,O
plasma,NN,O
concentration,NN,O
altered,VBN,O
by,IN,O
gleevec,NNP,B
gleevec,NNP,B
increases,VBZ,O
the,DT,O
mean,NN,O
cmax,NN,O
and,CC,O
auc,NN,O
of,IN,O
simvastatin,NN,D
-lrb-,-LRB-,O
cyp3a4,NN,D
substrate,NN,O
-rrb-,-RRB-,O
2,LS,O
-,:,O
and,CC,O
3.5-fold,RB,O
",",",",O
respectively,RB,O
",",",",O
suggesting,VBG,O
an,DT,O
inhibition,NN,O
of,IN,O
the,DT,O
cyp3a4,NN,D
by,IN,O
gleevec,NNP,B
.,.,.
,,
particular,JJ,O
caution,NN,O
is,VBZ,O
recommended,VBN,O
when,WRB,O
administering,VBG,O
gleevec,NN,B
with,IN,O
cyp3a4,NN,D
substrates,NNS,O
that,WDT,O
have,VBP,O
a,DT,O
narrow,JJ,O
therapeutic,JJ,O
window,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
cyclosporine,NN,D
or,CC,O
pimozide,NN,D
-rrb-,-RRB-,O
.,.,.
,,
gleevec,NNP,B
will,MD,O
increase,VB,O
plasmaconcentration,NN,O
of,IN,O
other,JJ,O
cyp3a4,NN,D
metabolized,VBN,O
drugs,NNS,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
triazolo-benzodiazepines,NNS,O
",",",",O
dihydropyridine,NN,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
",",",",O
certain,JJ,O
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
",",",",O
etc.,FW,O
-rrb-,-RRB-,O
.,.,.
,,
because,IN,O
warfarin,NN,D
is,VBZ,O
metabolized,VBN,O
by,IN,O
cyp2c9,NN,D
and,CC,O
cyp3a4,NN,D
",",",",O
patients,NNS,O
who,WP,O
require,VBP,O
anticoagulation,NN,O
should,MD,O
receive,VB,O
low-molecular,JJ,O
weight,NN,O
or,CC,O
standard,JJ,O
heparin,NN,D
.,.,.
,,
in,FW,O
vitro,FW,O
",",",",O
gleevec,NN,B
inhibits,VBZ,O
the,DT,O
cytochrome,NN,O
p450,NN,O
isoenzyme,NN,O
cyp2d6,NN,D
activity,NN,O
at,IN,O
similar,JJ,O
concentrations,NNS,O
that,WDT,O
affect,VBP,O
cyp3a4,NN,D
activity,NN,O
.,.,.
,,
systemic,JJ,O
exposure,NN,O
to,TO,O
substrates,NNS,O
of,IN,O
cyp2d6,NN,D
is,VBZ,O
expected,VBN,O
to,TO,O
be,VB,O
increased,VBN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
gleevec,NN,B
.,.,.
,,
no,DT,O
specific,JJ,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
and,CC,O
caution,NN,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
in,FW,O
vitro,FW,O
",",",",O
gleevec,NN,B
inhibits,VBZ,O
acetaminophen,NN,D
o-glucuronidation,NN,O
-lrb-,-LRB-,O
ki,NN,O
value,NN,O
of,IN,O
58.5,CD,O
m,NN,O
-rrb-,-RRB-,O
at,IN,O
therapeutic,JJ,O
levels,NNS,O
.,.,.
,,
systemic,JJ,O
exposure,NN,O
to,TO,O
acetaminophen,NN,D
is,VBZ,O
expected,VBN,O
to,TO,O
be,VB,O
increased,VBN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
gleevec,NN,B
.,.,.
,,
no,DT,O
specific,JJ,O
studies,NNS,O
in,IN,O
humans,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
and,CC,O
caution,NN,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
in,IN,O
occasional,JJ,O
susceptible,JJ,O
patients,NNS,O
or,CC,O
in,IN,O
those,DT,O
receiving,VBG,O
anticholinergic,JJ,G
drugs,NNS,D
-lrb-,-LRB-,O
including,VBG,O
antiparkinsonism,JJ,O
agents,NNS,O
-rrb-,-RRB-,O
in,IN,O
addition,NN,O
",",",",O
the,DT,O
atropine-like,JJ,O
effects,NNS,O
may,MD,O
become,VB,O
more,RBR,O
pronounced,JJ,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
paralytic,JJ,O
ileus,NN,O
-rrb-,-RRB-,O
.,.,.
,,
close,JJ,O
supervision,NN,O
and,CC,O
careful,JJ,O
adjustment,NN,O
of,IN,O
dosage,NN,O
is,VBZ,O
required,VBN,O
when,WRB,O
this,DT,O
drug,NN,D
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
anticholinergic,JJ,G
drugs,NNS,D
.,.,.
,,
avoid,VB,O
the,DT,O
use,NN,O
of,IN,O
preparations,NNS,O
such,JJ,O
as,IN,O
decongestants,NNS,G
and,CC,O
local,JJ,O
anesthetics,NNS,G
which,WDT,O
contain,VBP,O
any,DT,O
sympathomimetic,JJ,G
amine,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
epinephrine,NN,D
",",",",O
norepinephrine,NN,D
-rrb-,-RRB-,O
",",",",O
since,IN,O
it,PRP,O
has,VBZ,O
been,VBN,O
reported,VBN,O
that,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
can,MD,O
potentiate,VB,O
the,DT,O
effects,NNS,O
of,IN,O
catecholamines,NNS,G
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
imipramine,NN,D
hydrochloride,NN,O
is,VBZ,O
used,VBN,O
with,IN,O
agents,NNS,O
that,WDT,O
lower,JJR,O
blood,NN,O
pressure,NN,O
.,.,.
,,
imipramine,NN,D
hydrochloride,NN,O
may,MD,O
potentiate,VB,O
the,DT,O
effects,NNS,O
of,IN,O
cns,NN,O
depressant,NN,O
drugs,NNS,D
.,.,.
,,
the,DT,O
plasma,NN,O
concentration,NN,O
of,IN,O
imipramine,NN,D
may,MD,O
increase,VB,O
when,WRB,O
the,DT,O
drug,NN,D
is,VBZ,O
given,VBN,O
concomitantly,RB,O
with,IN,O
hepatic,JJ,O
enzyme,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
cimetidine,NN,D
",",",",O
fluoxetine,NN,D
-rrb-,-RRB-,O
and,CC,O
decrease,NN,O
by,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
hepatic,JJ,O
enzyme,NN,O
inducers,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
barbiturates,NNS,G
",",",",O
phenytoin,NN,D
-rrb-,-RRB-,O
",",",",O
and,CC,O
adjustment,NN,O
of,IN,O
the,DT,O
dosage,NN,O
of,IN,O
imipramine,NN,D
may,MD,O
therefore,RB,O
be,VB,O
necessary,JJ,O
.,.,.
,,
drugs,NNS,O
metabolized,VBN,O
by,IN,O
p450,NN,O
2d6,NN,O
the,DT,O
biochemical,JJ,O
activity,NN,O
of,IN,O
the,DT,O
drug,NN,D
metabolizing,VBG,O
isozyme,NN,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
-lrb-,-LRB-,O
debrisoquin,NN,D
hydroxylase,NN,O
-rrb-,-RRB-,O
is,VBZ,O
reduced,VBN,O
in,IN,O
a,DT,O
subset,NN,O
of,IN,O
the,DT,O
caucasian,JJ,O
population,NN,O
-lrb-,-LRB-,O
about,IN,O
7,CD,O
to,TO,O
10,CD,O
%,NN,O
of,IN,O
caucasians,NNS,O
are,VBP,O
so,RB,O
called,VBN,O
poor,JJ,O
metabolizers,NNS,O
-rrb-,-RRB-,O
;,:,O
.,.,.
,,
reliable,JJ,O
estimates,NNS,O
of,IN,O
the,DT,O
prevalence,NN,O
of,IN,O
reduced,VBN,O
p450,NN,O
2d6,NN,O
isozyme,NN,O
activity,NN,O
among,IN,O
asian,JJ,O
",",",",O
african,JJ,O
and,CC,O
other,JJ,O
populations,NNS,O
are,VBP,O
not,RB,O
yet,RB,O
available,JJ,O
.,.,.
,,
poor,NNP,O
metabolizers,NNS,O
have,VBP,O
higher,JJR,O
than,IN,O
expected,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
-lrb-,-LRB-,O
tcas,NNS,G
-rrb-,-RRB-,O
when,WRB,O
given,VBN,O
usual,JJ,O
doses,NNS,O
.,.,.
,,
depending,VBG,O
on,IN,O
the,DT,O
fraction,NN,O
of,IN,O
drug,NN,D
metabolized,VBN,O
by,IN,O
p450,NN,O
2d6,NN,O
",",",",O
the,DT,O
increase,NN,O
in,IN,O
plasma,NN,O
concentration,NN,O
may,MD,O
be,VB,O
small,JJ,O
",",",",O
or,CC,O
quite,RB,O
large,JJ,O
-lrb-,-LRB-,O
8-fold,JJ,O
increase,NN,O
in,IN,O
plasma,NN,O
auc,NN,O
of,IN,O
the,DT,O
tca,NNP,G
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
certain,JJ,O
drugs,NNS,D
inhibit,VBP,O
the,DT,O
activity,NN,O
of,IN,O
this,DT,O
isozyme,NN,O
and,CC,O
make,VB,O
normal,JJ,O
metabolizers,NNS,O
resemble,VBP,O
p.o.,NN,O
metabolizers,NNS,O
.,.,.
,,
an,DT,O
individual,NN,O
who,WP,O
is,VBZ,O
stable,JJ,O
on,IN,O
a,DT,O
given,VBN,O
dose,NN,O
of,IN,O
tca,NNP,G
may,MD,O
become,VB,O
abruptly,RB,O
toxic,JJ,O
when,WRB,O
given,VBN,O
one,CD,O
of,IN,O
these,DT,O
inhibiting,VBG,O
drugs,NNS,D
as,IN,O
concomitant,JJ,O
therapy,NN,O
.,.,.
,,
the,DT,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
include,VBP,O
some,DT,O
that,WDT,O
are,VBP,O
not,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
enzyme,NN,O
-lrb-,-LRB-,O
quinidine,NN,D
.,.,.
,,
cimetidine,NN,D
-rrb-,-RRB-,O
and,CC,O
many,JJ,O
that,WDT,O
are,VBP,O
substrates,NNS,O
for,IN,O
p450,NN,O
2d6,NN,O
-lrb-,-LRB-,O
many,JJ,O
other,JJ,O
antidepressants,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
and,CC,O
the,DT,O
type,NN,O
1c,NN,O
antiarrhythmics,NNS,G
propafenone,NN,D
and,CC,O
flecainide,NN,D
-rrb-,-RRB-,O
.,.,.
,,
while,IN,O
all,PDT,O
the,DT,O
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
ssris,NNS,G
-rrb-,-RRB-,O
",",",",O
e.,FW,O
g.,FW,O
",",",",O
fluoxetine,NN,D
",",",",O
sertraline,NN,D
",",",",O
and,CC,O
paroxetine,NN,D
",",",",O
inhibit,VBP,O
p450,NN,O
2d6,NN,O
",",",",O
they,PRP,O
may,MD,O
vary,VB,O
in,IN,O
the,DT,O
extent,NN,O
of,IN,O
inhibition,NN,O
.,.,.
,,
the,DT,O
extent,NN,O
to,TO,O
which,WDT,O
ssri-tca,NNP,O
interactions,NNS,O
may,MD,O
pose,VB,O
clinical,JJ,O
problems,NNS,O
will,MD,O
depend,VB,O
on,IN,O
the,DT,O
degree,NN,O
of,IN,O
inhibition,NN,O
",",",",O
and,CC,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
the,DT,O
ssri,NNP,G
involved,VBN,O
.,.,.
,,
nevertheless,RB,O
",",",",O
caution,NN,O
is,VBZ,O
indicated,VBN,O
in,IN,O
the,DT,O
co-administration,NN,O
of,IN,O
tca5,NN,O
with,IN,O
any,DT,O
of,IN,O
the,DT,O
ssris,NNS,G
and,CC,O
also,RB,O
in,IN,O
switching,NN,O
from,IN,O
one,CD,O
class,NN,O
to,TO,O
the,DT,O
other,JJ,O
.,.,.
,,
of,IN,O
particular,JJ,O
importance,NN,O
",",",",O
sufficient,JJ,O
time,NN,O
must,MD,O
elapse,VB,O
before,IN,O
initiating,VBG,O
tca,NNP,G
treatment,NN,O
in,IN,O
a,DT,O
patient,NN,O
being,VBG,O
withdrawn,VBN,O
from,IN,O
fluoxetine,NN,D
",",",",O
given,VBN,O
the,DT,O
long,JJ,O
half-life,NN,O
of,IN,O
the,DT,O
parent,NN,O
and,CC,O
active,JJ,O
metabolite,NN,O
-lrb-,-LRB-,O
at,IN,O
least,JJS,O
5,CD,O
weeks,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
-rrb-,-RRB-,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
with,IN,O
drugs,NNS,D
that,WDT,O
can,MD,O
inhibit,VB,O
cytochrome,NN,O
p450,NN,O
2d6,NN,O
may,MD,O
require,VB,O
lower,JJR,O
doses,NNS,O
than,IN,O
usually,RB,O
prescribed,VBN,O
for,IN,O
either,CC,O
the,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
or,CC,O
the,DT,O
other,JJ,O
drug,NN,D
.,.,.
,,
furthermore,RB,O
",",",",O
whenever,WRB,O
one,CD,O
of,IN,O
these,DT,O
other,JJ,O
drugs,NNS,D
is,VBZ,O
withdrawn,VBN,O
from,IN,O
cotherapy,NN,O
",",",",O
an,DT,O
increased,VBN,O
dose,NN,O
of,IN,O
tricyclic,JJ,G
antidepressant,JJ,G
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
desirable,JJ,O
to,TO,O
monitor,VB,O
tca,NNP,G
plasma,NN,O
levels,NNS,O
whenever,WRB,O
a,DT,O
tca,NNP,G
is,VBZ,O
going,VBG,O
to,TO,O
be,VB,O
co-administered,VBN,O
with,IN,O
another,DT,O
drug,NN,D
known,VBN,O
to,TO,O
be,VB,O
an,DT,O
inhibitor,NN,O
of,IN,O
p450,NN,O
2d6,NN,O
.,.,.
,,
no,DT,O
information,NN,O
available,JJ,O
.,.,.
,,
indinavir,NNP,D
is,VBZ,O
an,DT,O
inhibitor,NN,O
of,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
isoform,NN,O
cyp3a4,NN,D
.,.,.
,,
coadministration,NNP,O
of,IN,O
crixivan,NNP,B
and,CC,O
drugs,NNS,D
primarily,RB,O
metabolized,VBN,O
by,IN,O
cyp3a4,NN,D
may,MD,O
result,VB,O
in,IN,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
the,DT,O
other,JJ,O
drug,NN,D
",",",",O
which,WDT,O
could,MD,O
increase,VB,O
or,CC,O
prolong,VB,O
its,PRP$,O
therapeutic,JJ,O
and,CC,O
adverse,JJ,O
effects,NNS,O
.,.,.
,,
indinavir,NNP,D
is,VBZ,O
metabolized,VBN,O
by,IN,O
cyp3a4,NN,D
.,.,.
,,
drugs,NNS,O
that,WDT,O
induce,VBP,O
cyp3a4,NN,D
activity,NN,O
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
increase,VB,O
the,DT,O
clearance,NN,O
of,IN,O
indinavir,NN,D
",",",",O
resulting,VBG,O
in,IN,O
lowered,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
indinavir,NN,D
.,.,.
,,
coadministration,NNP,O
of,IN,O
crixivan,NNP,B
and,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
cyp3a4,NN,D
may,MD,O
decrease,VB,O
the,DT,O
clearance,NN,O
of,IN,O
indinavir,NN,D
and,CC,O
may,MD,O
result,VB,O
in,IN,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
indinavir,NN,D
.,.,.
,,
table,NNP,O
8,CD,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
should,MD,O
not,RB,O
be,VB,O
coadministered,VBN,O
with,IN,O
crixiva,NN,O
.,.,.
,,
drug,NN,O
class,NN,O
:,:,O
drug,NNP,O
name,VB,O
clinical,JJ,O
comment,NN,O
.,.,.
,,
antiarrhythmics,NNS,G
:,:,O
amiodaron,NN,O
.,.,.
,,
contraindicated,VBN,O
due,JJ,O
to,TO,O
potential,JJ,O
for,IN,O
serious,JJ,O
and/or,CC,O
life-threatening,JJ,O
reactions,NNS,O
such,JJ,O
as,IN,O
cardiac,JJ,O
arrhythmias,NNS,O
.,.,.
,,
ergot,NNP,G
derivatives,NNS,O
:,:,O
dihydroergotamine,NN,D
",",",",O
ergonovine,NN,D
",",",",O
ergotamine,NN,D
",",",",O
methylergonovin,NN,O
.,.,.
,,
contraindicated,VBN,O
due,JJ,O
to,TO,O
potential,JJ,O
for,IN,O
serious,JJ,O
and/or,CC,O
life-threatening,JJ,O
reactions,NNS,O
such,JJ,O
as,IN,O
acute,JJ,O
ergot,NN,G
toxicity,NN,O
characterized,VBN,O
by,IN,O
peripheral,JJ,O
vasospasm,NN,O
and,CC,O
ischemia,NN,O
of,IN,O
the,DT,O
extremities,NNS,O
and,CC,O
other,JJ,O
tissues,NNS,O
.,.,.
,,
sedative/hypnotics,NNS,O
:,:,O
midazolam,NN,D
",",",",O
triazola,NN,O
.,.,.
,,
contraindicated,VBN,O
due,JJ,O
to,TO,O
potential,JJ,O
for,IN,O
serious,JJ,O
and/or,CC,O
life-threatening,JJ,O
reactions,NNS,O
such,JJ,O
as,IN,O
prolonged,JJ,O
or,CC,O
increased,VBN,O
sedation,NN,O
or,CC,O
respiratory,JJ,O
depression,NN,O
.,.,.
,,
gi,NN,O
motility,NN,O
agents,NNS,O
:,:,O
cisaprid,NN,O
.,.,.
,,
contraindicated,VBN,O
due,JJ,O
to,TO,O
potential,JJ,O
for,IN,O
serious,JJ,O
and/or,CC,O
life-threatening,JJ,O
reactions,NNS,O
such,JJ,O
as,IN,O
cardiac,JJ,O
arrhythmias,NNS,O
.,.,.
,,
neuroleptic,JJ,G
:,:,O
pimozid,NN,O
.,.,.
,,
contraindicated,VBN,O
due,JJ,O
to,TO,O
potential,JJ,O
for,IN,O
serious,JJ,O
and/or,CC,O
life-threatening,JJ,O
reactions,NNS,O
such,JJ,O
as,IN,O
cardiac,JJ,O
arrhythmias,NNS,O
.,.,.
,,
herbal,JJ,O
products,NNS,O
:,:,O
st.,NNP,O
john,NNP,O
s,VBZ,O
wort,NN,O
-lrb-,-LRB-,O
hypericum,NN,O
perforatum,NN,O
-rrb-,-RRB-,O
.,.,.
,,
may,MD,O
lead,VB,O
to,TO,O
loss,NN,O
of,IN,O
virologic,JJ,O
response,NN,O
and,CC,O
possible,JJ,O
resistance,NN,O
to,TO,O
crixivan,NNP,B
or,CC,O
to,TO,O
the,DT,O
class,NN,O
of,IN,O
protease,NN,O
inhibitors,NNS,O
.,.,.
,,
antimycobacterial,NNP,G
:,:,O
rifampi,NNS,O
.,.,.
,,
may,MD,O
lead,VB,O
to,TO,O
loss,NN,O
of,IN,O
virologic,JJ,O
response,NN,O
and,CC,O
possible,JJ,O
resistance,NN,O
to,TO,O
crixivan,NNP,B
or,CC,O
to,TO,O
the,DT,O
class,NN,O
of,IN,O
protease,NN,O
inhibitors,NNS,O
or,CC,O
other,JJ,O
coadministered,VBN,O
antiretroviral,JJ,G
agents,NNS,O
.,.,.
,,
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
:,:,O
lovastatin,NN,D
",",",",O
simvastati,NN,O
.,.,.
,,
potential,JJ,O
for,IN,O
serious,JJ,O
reactions,NNS,O
such,JJ,O
as,IN,O
risk,NN,O
of,IN,O
myopathy,NN,O
including,VBG,O
rhabdomyolysis,NN,O
.,.,.
,,
protease,NN,O
inhibitor,NN,O
:,:,O
atazanavi,NN,O
.,.,.
,,
both,DT,O
crixivan,NNP,B
and,CC,O
atazanavir,NN,D
are,VBP,O
associated,VBN,O
with,IN,O
indirect,JJ,O
-lrb-,-LRB-,O
unconjugated,JJ,O
-rrb-,-RRB-,O
hyperbilirubinemia,NN,O
.,.,.
,,
combinations,NNS,O
of,IN,O
these,DT,O
drugs,NNS,D
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
and,CC,O
coadministration,NN,O
of,IN,O
crixivan,NNP,B
and,CC,O
atazanavir,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
table,NNP,O
9,CD,O
.,.,.
,,
established,VBN,O
and,CC,O
other,JJ,O
potentially,RB,O
significant,JJ,O
drug,NN,O
interactions,NNS,O
:,:,O
alteration,NN,O
in,IN,O
dose,NN,O
or,CC,O
regimen,NNP,O
may,NNP,O
be,VB,O
recommended,VBN,O
based,VBN,O
on,IN,O
drug,NN,O
interaction,NN,O
studies,NNS,O
or,CC,O
predicted,VBN,O
interaction,NN,O
.,.,.
,,
drug,NN,O
name,VB,O
.,.,.
,,
effect,NN,O
.,.,.
,,
clinical,JJ,O
comment,NN,O
.,.,.
,,
hiv,NN,O
antiviral,JJ,O
agent,NNP,O
.,.,.
,,
delavirdin,NNP,O
.,.,.
,,
indinavir,NN,D
concentratio,NN,O
.,.,.
,,
dose,NN,O
reduction,NN,O
of,IN,O
crixivan,NNP,B
to,TO,O
600,CD,O
mg,NN,O
every,DT,O
8,CD,O
hours,NNS,O
should,MD,O
be,VB,O
considered,VBN,O
when,WRB,O
taking,VBG,O
delavirdine,NN,D
400,CD,O
mg,NN,O
three,CD,O
times,NNS,O
a,DT,O
day,NN,O
.,.,.
,,
didanosin,NNP,O
.,.,.
,,
indinavir,NNP,D
and,CC,O
didanosine,NN,D
formulations,NNS,O
containing,VBG,O
buffer,NN,O
should,MD,O
be,VB,O
administered,VBN,O
at,IN,O
least,JJS,O
one,CD,O
hour,NN,O
apart,RB,O
on,IN,O
an,DT,O
empty,JJ,O
stomach,NN,O
.,.,.
,,
efaviren,NNP,O
.,.,.
,,
indinavir,NN,D
concentratio,NN,O
.,.,.
,,
the,DT,O
optimal,JJ,O
dose,NN,O
of,IN,O
indinavir,NN,D
",",",",O
when,WRB,O
given,VBN,O
in,IN,O
combination,NN,O
with,IN,O
efavirenz,NN,D
",",",",O
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
increasing,VBG,O
the,DT,O
indinavir,NN,D
dose,NN,O
to,TO,O
1000,CD,O
mg,NN,O
every,DT,O
8,CD,O
hours,NNS,O
does,VBZ,O
not,RB,O
compensate,VB,O
for,IN,O
the,DT,O
increased,VBN,O
indinavir,NN,D
metabolism,NN,O
due,JJ,O
to,TO,O
efavirenz,NN,D
.,.,.
,,
nelfinavi,NNP,O
.,.,.
,,
indinavir,NN,D
concentratio,NN,O
.,.,.
,,
the,DT,O
appropriate,JJ,O
doses,NNS,O
for,IN,O
this,DT,O
combination,NN,O
",",",",O
with,IN,O
respect,NN,O
to,TO,O
efficacy,NN,O
and,CC,O
safety,NN,O
",",",",O
have,VBP,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
nevirapin,NNP,O
.,.,.
,,
indinavir,NN,D
concentratio,NN,O
.,.,.
,,
indinavir,NNP,D
concentrations,NNS,O
may,MD,O
be,VB,O
decreased,VBN,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
nevirapine,NN,D
.,.,.
,,
the,DT,O
appropriate,JJ,O
doses,NNS,O
for,IN,O
this,DT,O
combination,NN,O
",",",",O
with,IN,O
respect,NN,O
to,TO,O
efficacy,NN,O
and,CC,O
safety,NN,O
",",",",O
have,VBP,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
ritonavi,NNP,O
.,.,.
,,
indinavir,NN,D
concentration,NN,O
ritonavir,NN,D
concentratio,NN,O
.,.,.
,,
the,DT,O
appropriate,JJ,O
doses,NNS,O
for,IN,O
this,DT,O
combination,NN,O
",",",",O
with,IN,O
respect,NN,O
to,TO,O
efficacy,NN,O
and,CC,O
safety,NN,O
",",",",O
have,VBP,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
preliminary,JJ,O
clinical,JJ,O
data,NNS,O
suggest,VBP,O
that,IN,O
the,DT,O
incidence,NN,O
of,IN,O
nephrolithiasis,NN,O
is,VBZ,O
higher,JJR,O
in,IN,O
patients,NNS,O
receiving,VBG,O
indinavir,NN,D
in,IN,O
combination,NN,O
with,IN,O
ritonavir,NN,D
than,IN,O
those,DT,O
receiving,VBG,O
crixivan,NN,B
800,CD,O
mg,NN,O
q8h,NN,O
.,.,.
,,
saquinavi,NNP,O
.,.,.
,,
saquinavir,NN,D
concentratio,NN,O
.,.,.
,,
the,DT,O
appropriate,JJ,O
doses,NNS,O
for,IN,O
this,DT,O
combination,NN,O
",",",",O
with,IN,O
respect,NN,O
to,TO,O
efficacy,NN,O
and,CC,O
safety,NN,O
",",",",O
have,VBP,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
other,JJ,O
agents,NNS,O
.,.,.
,,
antiarrhythmics,NNS,G
:,:,O
bepridil,NN,D
",",",",O
lidocaine,NN,D
-lrb-,-LRB-,O
systemic,JJ,O
-rrb-,-RRB-,O
and,CC,O
quinidin,NN,O
.,.,.
,,
antiarrhythmic,JJ,D
agents,NNS,O
concentratio,NN,O
.,.,.
,,
caution,NN,O
is,VBZ,O
warranted,VBN,O
and,CC,O
therapeutic,JJ,O
concentration,NN,O
monitoring,NN,O
is,VBZ,O
recommended,VBN,O
for,IN,O
antiarrhythmics,NNS,G
when,WRB,O
coadministered,VBN,O
with,IN,O
crixivan,NNP,B
.,.,.
,,
anticonvulsants,NNPS,G
:,:,O
carbamazepine,NN,D
",",",",O
phenobarbital,NN,D
",",",",O
phenytoi,NN,O
.,.,.
,,
indinavir,NN,D
concentratio,NN,O
.,.,.
,,
use,NN,O
with,IN,O
caution,NN,O
.,.,.
,,
crixivan,NNP,B
may,MD,O
not,RB,O
be,VB,O
effective,JJ,O
due,JJ,O
to,TO,O
decreased,VBN,O
indinavir,NN,D
concentrations,NNS,O
in,IN,O
patients,NNS,O
taking,VBG,O
these,DT,O
agents,NNS,O
concomitantly,RB,O
.,.,.
,,
calcium,NN,D
channel,NNP,O
blockers,NNP,O
",",",",O
dihydropyridine,NNP,G
:,:,O
e.g.,FW,O
",",",",O
felodipine,NN,D
",",",",O
nifedipine,NN,D
",",",",O
nicardipin,NN,O
.,.,.
,,
dihydropyridine,NN,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
concentratio,NN,O
.,.,.
,,
caution,NN,O
is,VBZ,O
warranted,VBN,O
and,CC,O
clinical,JJ,O
monitoring,NN,O
of,IN,O
patients,NNS,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
clarithromyci,NNP,O
.,.,.
,,
clarithromycin,NN,D
concentration,NN,O
indinavir,NN,D
concentratio,NN,O
.,.,.
,,
the,DT,O
appropriate,JJ,O
doses,NNS,O
for,IN,O
this,DT,O
combination,NN,O
",",",",O
with,IN,O
respect,NN,O
to,TO,O
efficacy,NN,O
and,CC,O
safety,NN,O
",",",",O
have,VBP,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
hmg-coa,NN,O
reductase,NNP,O
inhibitor,NNP,O
:,:,O
atorvastati,NNS,O
.,.,.
,,
atorvastatin,NN,D
concentratio,NN,O
.,.,.
,,
use,NNP,O
lowest,JJS,O
possible,JJ,O
dose,NN,O
of,IN,O
atorvastatin,NN,D
with,IN,O
careful,JJ,O
monitoring,NN,O
",",",",O
or,CC,O
consider,VB,O
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
that,WDT,O
are,VBP,O
not,RB,O
primarily,RB,O
metabolized,VBN,O
by,IN,O
cyp3a4,NN,D
",",",",O
such,JJ,O
as,IN,O
pravastatin,NN,D
",",",",O
fluvastatin,NN,D
",",",",O
or,CC,O
rosuvastatin,NN,D
in,IN,O
combination,NN,O
with,IN,O
crixivan,NNP,B
.,.,.
,,
immunosuppressants,NNS,G
:,:,O
cyclosporine,NN,D
",",",",O
tacrolimus,NN,D
",",",",O
sirolimu,NN,O
.,.,.
,,
immunosuppressant,JJ,O
agents,NNS,O
concentratio,NN,O
.,.,.
,,
plasma,NN,O
concentrations,NNS,O
may,MD,O
be,VB,O
increased,VBN,O
by,IN,O
crixivan,NNP,B
.,.,.
,,
itraconazol,NNP,O
.,.,.
,,
indinavir,NN,D
concentratio,NN,O
.,.,.
,,
dose,NN,O
reduction,NN,O
of,IN,O
crixivan,NNP,B
to,TO,O
600,CD,O
mg,NN,O
every,DT,O
8,CD,O
hours,NNS,O
is,VBZ,O
recommended,VBN,O
when,WRB,O
administering,VBG,O
itraconazole,NN,D
concurrently,RB,O
.,.,.
,,
ketoconazol,NNP,O
.,.,.
,,
indinavir,NN,D
concentratio,NN,O
dose,NN,O
reduction,NN,O
of,IN,O
crixivan,NNP,B
to,TO,O
600,CD,O
mg,NN,O
every,DT,O
8,CD,O
hours,NNS,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
rifabuti,NNP,O
.,.,.
,,
indinavir,NN,D
concentration,NN,O
rifabutin,NN,D
concentratio,NN,O
.,.,.
,,
dose,NN,O
reduction,NN,O
of,IN,O
rifabutin,NN,D
to,TO,O
half,PDT,O
the,DT,O
standard,JJ,O
dose,NN,O
and,CC,O
a,DT,O
dose,NN,O
increase,NN,O
of,IN,O
crixivan,NNP,B
to,TO,O
1000,CD,O
mg,NN,O
-lrb-,-LRB-,O
three,CD,O
333-mg,JJ,O
capsules,NNS,O
-rrb-,-RRB-,O
every,DT,O
8,CD,O
hours,NNS,O
are,VBP,O
recommended,VBN,O
when,WRB,O
rifabutin,NN,D
and,CC,O
crixivan,NNP,B
are,VBP,O
coadministered,VBN,O
.,.,.
,,
sildenafi,NNP,O
.,.,.
,,
sildenafil,NN,D
concentratio,NN,O
.,.,.
,,
sildenafil,NNP,D
dose,NN,O
should,MD,O
not,RB,O
exceed,VB,O
a,DT,O
maximum,NN,O
of,IN,O
25,CD,O
mg,NN,O
in,IN,O
a,DT,O
48,CD,O
-,:,O
hour,NN,O
period,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
indinavir,NN,D
therapy,NN,O
.,.,.
,,
tadalafi,NNP,O
.,.,.
,,
tadalafil,NN,D
concentratio,NN,O
.,.,.
,,
tadalafil,NNP,D
dose,NN,O
should,MD,O
not,RB,O
exceed,VB,O
a,DT,O
maximum,NN,O
of,IN,O
10,CD,O
mg,NN,O
in,IN,O
a,DT,O
72,CD,O
-,:,O
hour,NN,O
period,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
indinavir,NN,D
therapy,NN,O
.,.,.
,,
vardenafi,NNP,O
.,.,.
,,
vardenafil,NN,D
concentratio,NN,O
.,.,.
,,
vardenafil,NNP,D
dose,NN,O
should,MD,O
not,RB,O
exceed,VB,O
a,DT,O
maximum,NN,O
of,IN,O
2.5,CD,O
mg,NN,O
in,IN,O
a,DT,O
24-hour,JJ,O
period,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
concomitant,JJ,O
indinavir,NN,D
therapy,NN,O
.,.,.
,,
note,VB,O
:,:,O
.,.,.
,,
=,JJ,O
increase,NN,O
;,:,O
.,.,.
,,
=,JJ,O
decrease,NN,O
.,.,.
,,
in,IN,O
normal,JJ,O
volunteers,NNS,O
receiving,VBG,O
indomethacin,NN,D
",",",",O
the,DT,O
administration,NN,O
of,IN,O
diflunisal,JJ,D
decreased,VBD,O
the,DT,O
renal,JJ,O
clearance,NN,O
and,CC,O
significantly,RB,O
increased,VBD,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
indomethacin,NN,D
.,.,.
,,
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
combined,VBN,O
use,NN,O
of,IN,O
indocin,NNP,B
and,CC,O
diflunisal,NN,D
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
fatal,JJ,O
gastrointestinal,JJ,O
hemorrhage,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
diflunisal,NN,D
and,CC,O
indocin,NN,B
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
concomitantly,RB,O
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
",",",",O
it,PRP,O
was,VBD,O
found,VBN,O
that,IN,O
chronic,JJ,O
concurrent,JJ,O
administration,NN,O
of,IN,O
3.6,CD,O
g,NN,O
of,IN,O
aspirin,NN,B
per,IN,O
day,NN,O
decreases,VBZ,O
indomethacin,NN,D
blood,NN,O
levels,NNS,O
approximately,RB,O
20,CD,O
%,NN,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
indocin,NN,B
with,IN,O
other,JJ,O
nsaids,NNS,G
is,VBZ,O
not,RB,O
recommended,VBN,O
due,JJ,O
to,TO,O
the,DT,O
increased,VBN,O
possibility,NN,O
of,IN,O
gastrointestinal,JJ,O
toxicity,NN,O
",",",",O
with,IN,O
little,JJ,O
or,CC,O
no,DT,O
increase,NN,O
in,IN,O
efficacy,NN,O
.,.,.
,,
clinical,JJ,O
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
indocin,NNP,B
does,VBZ,O
not,RB,O
influence,VB,O
the,DT,O
hypoprothrombinemia,NN,O
produced,VBN,O
by,IN,O
anticoagulants,NNS,G
.,.,.
,,
however,RB,O
",",",",O
when,WRB,O
any,DT,O
additional,JJ,O
drug,NN,D
",",",",O
including,VBG,O
indocin,NNP,B
",",",",O
is,VBZ,O
added,VBN,O
to,TO,O
the,DT,O
treatment,NN,O
of,IN,O
patients,NNS,O
on,IN,O
anticoagulant,JJ,G
therapy,NN,O
",",",",O
the,DT,O
patients,NNS,O
should,MD,O
be,VB,O
observed,VBN,O
for,IN,O
alterations,NNS,O
of,IN,O
the,DT,O
prothrombin,NN,O
time,NN,O
.,.,.
,,
in,IN,O
post-marketing,JJ,O
experience,NN,O
",",",",O
bleeding,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
on,IN,O
concomitant,JJ,O
treatment,NN,O
with,IN,O
anticoagulants,NNS,G
and,CC,O
indocin,NNP,B
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
indocin,NNP,B
and,CC,O
anticoagulants,NNS,G
are,VBP,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
when,WRB,O
indocin,NNP,B
is,VBZ,O
given,VBN,O
to,TO,O
patients,NNS,O
receiving,VBG,O
probenecid,NN,D
",",",",O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
indomethacin,NN,D
are,VBP,O
likely,JJ,O
to,TO,O
be,VB,O
increased,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
a,DT,O
lower,JJR,O
total,JJ,O
daily,RB,O
dosage,NN,O
of,IN,O
indocin,NNP,B
may,MD,O
produce,VB,O
a,DT,O
satisfactory,JJ,O
therapeutic,JJ,O
effect,NN,O
.,.,.
,,
when,WRB,O
increases,NNS,O
in,IN,O
the,DT,O
dose,NN,O
of,IN,O
indocin,NNP,B
are,VBP,O
made,VBN,O
",",",",O
they,PRP,O
should,MD,O
be,VB,O
made,VBN,O
carefully,RB,O
and,CC,O
in,IN,O
small,JJ,O
increments,NNS,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
if,IN,O
indocin,NNP,B
is,VBZ,O
administered,VBN,O
simultaneously,RB,O
with,IN,O
methotrexate,NN,D
.,.,.
,,
indocin,NNP,B
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
decrease,VB,O
the,DT,O
tubular,JJ,O
secretion,NN,O
of,IN,O
methotrexate,NN,D
and,CC,O
to,TO,O
potentiate,VB,O
its,PRP$,O
toxicity,NN,O
.,.,.
,,
administration,NN,O
of,IN,O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
concomitantly,RB,O
with,IN,O
cyclosporine,NN,D
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
an,DT,O
increase,NN,O
in,IN,O
cyclosporine-induced,JJ,O
toxicity,NN,O
",",",",O
possibly,RB,O
due,JJ,O
to,TO,O
decreased,VBN,O
synthesis,NN,O
of,IN,O
renal,JJ,O
prostacyclin,NN,O
.,.,.
,,
nsaids,NNS,G
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
cyclosporine,NN,D
",",",",O
and,CC,O
renal,JJ,O
function,NN,O
should,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
.,.,.
,,
capsules,NNS,O
indocin,NNP,B
50,CD,O
mg,NN,O
t.i.d.,NN,O
produced,VBD,O
a,DT,O
clinically,RB,O
relevant,JJ,O
elevation,NN,O
of,IN,O
plasma,NN,O
lithium,NN,D
and,CC,O
reduction,NN,O
in,IN,O
renal,JJ,O
lithium,NN,D
clearance,NN,O
in,IN,O
psychiatric,JJ,O
patients,NNS,O
and,CC,O
normal,JJ,O
subjects,NNS,O
with,IN,O
steady,JJ,O
state,NN,O
plasma,NN,O
lithium,NN,D
concentrations,NNS,O
.,.,.
,,
this,DT,O
effect,NN,O
has,VBZ,O
been,VBN,O
attributed,VBN,O
to,TO,O
inhibition,NN,O
of,IN,O
prostaglandin,NN,O
synthesis,NN,O
.,.,.
,,
as,IN,O
a,DT,O
consequence,NN,O
",",",",O
when,WRB,O
indocin,NNP,B
and,CC,O
lithium,NN,D
are,VBP,O
given,VBN,O
concomitantly,RB,O
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
carefully,RB,O
observed,VBN,O
for,IN,O
signs,NNS,O
of,IN,O
lithium,NN,D
toxicity,NN,O
.,.,.
,,
-lrb-,-LRB-,O
read,VB,O
circulars,NNS,O
for,IN,O
lithium,NN,D
preparations,NNS,O
before,IN,O
use,NN,O
of,IN,O
such,JJ,O
concomitant,JJ,O
therapy,NN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
the,DT,O
frequency,NN,O
of,IN,O
monitoring,VBG,O
serum,NN,O
lithium,NN,D
concentration,NN,O
should,MD,O
be,VB,O
increased,VBN,O
at,IN,O
the,DT,O
outset,NN,O
of,IN,O
such,JJ,O
combination,NN,O
drug,NN,D
treatment,NN,O
.,.,.
,,
indocin,NNP,B
given,VBN,O
concomitantly,RB,O
with,IN,O
digoxin,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
increase,VB,O
the,DT,O
serum,NN,O
concentration,NN,O
and,CC,O
prolong,VB,O
the,DT,O
half-life,NN,O
of,IN,O
digoxin,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
when,WRB,O
indocin,NNP,B
and,CC,O
digoxin,NN,D
are,VBP,O
used,VBN,O
concomitantly,RB,O
",",",",O
serum,NN,O
digoxin,NN,D
levels,NNS,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
.,.,.
,,
in,IN,O
some,DT,O
patients,NNS,O
",",",",O
the,DT,O
administration,NN,O
of,IN,O
indocin,NNP,B
can,MD,O
reduce,VB,O
the,DT,O
diuretic,JJ,G
",",",",O
natriuretic,JJ,O
",",",",O
and,CC,O
antihypertensive,JJ,G
effects,NNS,O
of,IN,O
loop,NN,O
",",",",O
potassium-sparing,NN,O
",",",",O
and,CC,O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
therefore,RB,O
",",",",O
when,WRB,O
indocin,NNP,B
and,CC,O
indocin,NNP,B
.,.,.
,,
-lrb-,-LRB-,O
indomethacin,NN,D
-rrb-,-RRB-,O
diuretics,NNS,G
are,VBP,O
used,VBN,O
concomitantly,RB,O
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
to,TO,O
determine,VB,O
if,IN,O
the,DT,O
desired,VBN,O
effect,NN,O
of,IN,O
the,DT,O
diuretic,JJ,G
is,VBZ,O
obtained,VBN,O
.,.,.
,,
indocin,NNP,B
reduces,VBZ,O
basal,JJ,O
plasma,NN,O
renin,NN,O
activity,NN,O
-lrb-,-LRB-,O
pra,NNP,O
-rrb-,-RRB-,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
those,DT,O
elevations,NNS,O
of,IN,O
pra,NNP,O
induced,VBN,O
by,IN,O
furosemide,NN,D
administration,NN,O
",",",",O
or,CC,O
salt,NN,O
or,CC,O
volume,NN,O
depletion,NN,O
.,.,.
,,
these,DT,O
facts,NNS,O
should,MD,O
be,VB,O
considered,VBN,O
when,WRB,O
evaluating,VBG,O
plasma,NN,O
renin,NN,O
activity,NN,O
in,IN,O
hypertensive,JJ,O
patients,NNS,O
.,.,.
,,
it,PRP,O
has,VBZ,O
been,VBN,O
reported,VBN,O
that,IN,O
the,DT,O
addition,NN,O
of,IN,O
triamterene,NN,D
to,TO,O
a,DT,O
maintenance,NN,O
schedule,NN,O
of,IN,O
indocin,NNP,B
resulted,VBD,O
in,IN,O
reversible,JJ,O
acute,JJ,O
renal,JJ,O
failure,NN,O
in,IN,O
two,CD,O
of,IN,O
four,CD,O
healthy,JJ,O
volunteers,NNS,O
.,.,.
,,
indocin,NNP,B
and,CC,O
triamterene,NN,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
together,RB,O
.,.,.
,,
indocin,NNP,B
and,CC,O
potassium-sparing,JJ,O
diuretics,NNS,G
each,DT,O
may,MD,O
be,VB,O
associated,VBN,O
with,IN,O
increased,VBN,O
serum,NN,O
potassium,NN,D
levels,NNS,O
.,.,.
,,
the,DT,O
potential,JJ,O
effects,NNS,O
of,IN,O
indocin,NNP,B
and,CC,O
potassium-sparing,JJ,O
diuretics,NNS,G
on,IN,O
potassium,NN,D
kinetics,NNS,O
and,CC,O
renal,JJ,O
function,NN,O
should,MD,O
be,VB,O
considered,VBN,O
when,WRB,O
these,DT,O
agents,NNS,O
are,VBP,O
administered,VBN,O
concurrently,RB,O
.,.,.
,,
most,JJS,O
of,IN,O
the,DT,O
above,JJ,O
effects,NNS,O
concerning,VBG,O
diuretics,NNS,G
have,VBP,O
been,VBN,O
attributed,VBN,O
",",",",O
at,IN,O
least,JJS,O
in,IN,O
part,NN,O
",",",",O
to,TO,O
mechanisms,NNS,O
involving,VBG,O
inhibition,NN,O
of,IN,O
prostaglandin,NN,O
synthesis,NN,O
by,IN,O
indocin,NNP,B
.,.,.
,,
blunting,VBG,O
of,IN,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
beta-adrenoceptor,NN,O
blocking,VBG,O
agents,NNS,O
by,IN,O
non-steroidal,JJ,O
antiinflammatory,JJ,O
drugs,NNS,D
including,VBG,O
indocin,NNP,B
has,VBZ,O
been,VBN,O
reported,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
when,WRB,O
using,VBG,O
these,DT,O
blocking,VBG,O
agents,NNS,O
to,TO,O
treat,VB,O
hypertension,NN,O
",",",",O
patients,NNS,O
should,MD,O
be,VB,O
observed,VBN,O
carefully,RB,O
in,IN,O
order,NN,O
to,TO,O
confirm,VB,O
that,IN,O
the,DT,O
desired,VBN,O
therapeutic,JJ,O
effect,NN,O
has,VBZ,O
been,VBN,O
obtained,VBN,O
.,.,.
,,
indocin,NNP,B
can,MD,O
reduce,VB,O
the,DT,O
antihypertensive,JJ,G
effects,NNS,O
of,IN,O
captopril,NN,D
and,CC,O
losartan,NN,D
.,.,.
,,
false-negative,JJ,O
results,NNS,O
in,IN,O
the,DT,O
dexamethasone,NN,D
suppression,NN,O
test,NN,O
-lrb-,-LRB-,O
dst,NN,O
-rrb-,-RRB-,O
in,IN,O
patients,NNS,O
being,VBG,O
treated,VBN,O
with,IN,O
indocin,NNP,B
have,VBP,O
been,VBN,O
reported,VBN,O
.,.,.
,,
thus,RB,O
",",",",O
results,NNS,O
of,IN,O
the,DT,O
dst,NNP,O
should,MD,O
be,VB,O
interpreted,VBN,O
with,IN,O
caution,NN,O
in,IN,O
these,DT,O
patients,NNS,O
.,.,.
,,
concurrent,JJ,O
administration,NN,O
of,IN,O
etanercept,NN,D
-lrb-,-LRB-,O
another,DT,O
tnf,NN,O
-,:,O
blocking,VBG,O
agent,NN,O
-rrb-,-RRB-,O
and,CC,O
anakinra,NN,D
-lrb-,-LRB-,O
an,DT,O
interleukin-1,NN,O
antagonist,NN,O
-rrb-,-RRB-,O
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
serious,JJ,O
infections,NNS,O
",",",",O
and,CC,O
increased,VBD,O
risk,NN,O
of,IN,O
neutropenia,NN,O
and,CC,O
no,DT,O
additional,JJ,O
benefit,NN,O
compared,VBN,O
to,TO,O
these,DT,O
medicinal,JJ,O
products,NNS,O
alone,RB,O
.,.,.
,,
other,JJ,O
tnfa-blocking,JJ,O
agents,NNS,O
-lrb-,-LRB-,O
including,VBG,O
remicade,NNP,B
-rrb-,-RRB-,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
anakinra,NN,D
may,MD,O
also,RB,O
result,VB,O
in,IN,O
similar,JJ,O
toxicities,NNS,O
.,.,.
,,
specific,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
",",",",O
including,VBG,O
interactions,NNS,O
with,IN,O
mtx,NN,D
",",",",O
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
the,DT,O
majority,NN,O
of,IN,O
patients,NNS,O
in,IN,O
rheumatoid,JJ,O
arthritis,NN,O
or,CC,O
crohn,NN,O
s,NNS,O
disease,NN,O
clinical,JJ,O
studies,NNS,O
received,VBD,O
one,CD,O
or,CC,O
more,JJR,O
concomitant,JJ,O
medications,NNS,O
.,.,.
,,
in,IN,O
rheumatoid,JJ,O
arthritis,NN,O
",",",",O
concomitant,JJ,O
medications,NNS,O
besides,IN,O
mtx,NN,D
were,VBD,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
",",",",O
folic,JJ,O
acid,NN,O
",",",",O
corticosteroids,NNS,G
and/or,CC,O
narcotics,NNS,G
.,.,.
,,
concomitant,JJ,O
crohn,NN,O
s,NNS,O
disease,NN,O
medications,NNS,O
were,VBD,O
antibiotics,NNS,G
",",",",O
antivirals,NNS,G
",",",",O
corticosteroids,NNS,G
",",",",O
6-mp/aza,NN,O
and,CC,O
aminosalicylates,NNS,O
.,.,.
,,
in,IN,O
psoriatic,JJ,O
arthritis,NN,O
clinical,JJ,O
trials,NNS,O
",",",",O
concomitant,JJ,O
medications,NNS,O
included,VBD,O
mtx,NNP,D
in,IN,O
approximately,RB,O
half,DT,O
of,IN,O
the,DT,O
patients,NNS,O
as,RB,O
well,RB,O
as,IN,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
",",",",O
folic,JJ,O
acid,NN,O
and,CC,O
corticosteroids,NNS,G
.,.,.
,,
patients,NNS,O
with,IN,O
crohn,NN,O
s,NNS,O
disease,NN,O
who,WP,O
received,VBD,O
immunosuppressants,NNS,G
tended,VBD,O
to,TO,O
experience,VB,O
fewer,JJR,O
infusion,NN,O
reactions,NNS,O
compared,VBN,O
to,TO,O
patients,NNS,O
on,IN,O
no,DT,O
immunosuppressants,NNS,G
.,.,.
,,
serum,NN,O
infliximab,NN,D
concentrations,NNS,O
appeared,VBD,O
to,TO,O
be,VB,O
unaffected,JJ,O
by,IN,O
baseline,NN,O
use,NN,O
of,IN,O
medications,NNS,O
for,IN,O
the,DT,O
treatment,NN,O
of,IN,O
crohn,NN,O
s,NNS,O
disease,NN,O
including,VBG,O
corticosteroids,NNS,G
",",",",O
antibiotics,NNS,G
-lrb-,-LRB-,O
metronidazole,NN,D
or,CC,O
ciprofloxacin,NN,D
-rrb-,-RRB-,O
and,CC,O
aminosalicylates,NNS,O
.,.,.
,,
a,DT,O
number,NN,O
of,IN,O
substances,NNS,O
affect,VBP,O
glucose,NN,O
metabolism,NN,O
and,CC,O
may,MD,O
require,VB,O
insulin,NN,D
dose,NN,O
adjustment,NN,O
and,CC,O
particularly,RB,O
close,JJ,O
monitoring,NN,O
.,.,.
,,
the,DT,O
following,VBG,O
are,VBP,O
examples,NNS,O
of,IN,O
substances,NNS,O
that,WDT,O
may,MD,O
increase,VB,O
the,DT,O
blood-glucose-lowering,NN,O
effect,NN,O
and,CC,O
susceptibility,NN,O
to,TO,O
hypoglycemia,NN,O
:,:,O
oral,JJ,O
antidiabetes,NNS,O
products,NNS,O
",",",",O
ace,NN,O
inhibitors,NNS,O
",",",",O
disopyramide,NN,D
",",",",O
fibrates,NNS,G
",",",",O
fluoxetine,NN,D
",",",",O
mao,NN,O
inhibitors,NNS,O
",",",",O
propoxyphene,NN,D
",",",",O
salicylates,NNS,G
",",",",O
somatostatin,NN,O
analog,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
octreotide,NN,D
-rrb-,-RRB-,O
",",",",O
sulfonamide,NN,G
antibiotics,NNS,G
.,.,.
,,
the,DT,O
following,VBG,O
are,VBP,O
examples,NNS,O
of,IN,O
substances,NNS,O
that,WDT,O
may,MD,O
reduce,VB,O
the,DT,O
blood-glucose-lowering,NN,O
effect,NN,O
of,IN,O
insulin,NN,D
:,:,O
corticosteroids,NNS,G
",",",",O
danazol,NN,D
",",",",O
diuretics,NNS,G
",",",",O
sympathomimetic,JJ,G
agents,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
epinephrine,NN,D
",",",",O
albuterol,NN,D
",",",",O
terbutaline,NN,D
-rrb-,-RRB-,O
",",",",O
isoniazid,NN,D
",",",",O
phenothiazine,NN,G
derivatives,NNS,O
",",",",O
somatropin,NN,D
",",",",O
thyroid,NN,G
hormones,NNS,O
",",",",O
estrogens,NNS,G
",",",",O
progestogens,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
in,IN,O
oral,JJ,O
contraceptives,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
beta-blockers,NNS,G
",",",",O
clonidine,NN,D
",",",",O
lithium,NN,D
salts,NNS,O
",",",",O
and,CC,O
alcohol,NN,D
may,MD,O
either,RB,O
potentiate,VB,O
or,CC,O
weaken,VB,O
the,DT,O
blood-glucose-lowering,NN,O
effect,NN,O
of,IN,O
insulin,NN,D
.,.,.
,,
pentamidine,NNP,D
may,MD,O
cause,VB,O
hypoglycemia,NN,O
",",",",O
which,WDT,O
may,MD,O
sometimes,RB,O
be,VB,O
followed,VBN,O
by,IN,O
hyperglycemia,NN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
under,IN,O
the,DT,O
influence,NN,O
of,IN,O
sympatholytic,JJ,O
medicinal,JJ,O
products,NNS,O
such,JJ,O
as,IN,O
beta-blockers,NNS,G
",",",",O
clonidine,NN,D
",",",",O
guanethidine,NN,D
",",",",O
and,CC,O
reserpine,NN,D
",",",",O
the,DT,O
signs,NNS,O
of,IN,O
hypoglycemia,NN,O
may,MD,O
be,VB,O
reduced,VBN,O
or,CC,O
absent,JJ,O
.,.,.
,,
a,DT,O
number,NN,O
of,IN,O
substances,NNS,O
affect,VBP,O
glucose,NN,O
metabolism,NN,O
and,CC,O
may,MD,O
require,VB,O
insulin,NN,D
dose,NN,O
adjustment,NN,O
and,CC,O
particularly,RB,O
close,JJ,O
monitoring,NN,O
.,.,.
,,
the,DT,O
following,VBG,O
are,VBP,O
examples,NNS,O
of,IN,O
substances,NNS,O
that,WDT,O
may,MD,O
increase,VB,O
the,DT,O
blood-glucose-lowering,NN,O
effect,NN,O
and,CC,O
susceptibility,NN,O
to,TO,O
hypoglycemia,NN,O
:,:,O
oral,JJ,O
antidiabetic,JJ,D
products,NNS,O
",",",",O
ace,NN,O
inhibitors,NNS,O
",",",",O
disopyramide,NN,D
",",",",O
fibrates,NNS,G
",",",",O
fluoxetine,NN,D
",",",",O
monoamine,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
mao,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
",",",",O
propoxyphene,NN,D
",",",",O
salicylates,NNS,G
",",",",O
somatostatin,NN,O
analog,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
octreotide,NN,D
-rrb-,-RRB-,O
",",",",O
sulfonamide,NN,G
antibiotics,NNS,G
.,.,.
,,
the,DT,O
following,VBG,O
are,VBP,O
examples,NNS,O
of,IN,O
substances,NNS,O
that,WDT,O
may,MD,O
reduce,VB,O
the,DT,O
blood-glucose-lowering,NN,O
effect,NN,O
:,:,O
corticosteroids,NNS,G
",",",",O
niacin,NN,D
",",",",O
danazol,NN,D
",",",",O
diuretics,NNS,G
",",",",O
sympathomimetic,JJ,G
agents,NNS,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
epinephrine,NN,D
",",",",O
salbutamol,NN,D
",",",",O
terbutaline,NN,D
-rrb-,-RRB-,O
",",",",O
isoniazid,NN,D
",",",",O
phenothiazine,NN,G
derivatives,NNS,O
",",",",O
somatropin,NN,D
",",",",O
thyroid,NN,G
hormones,NNS,O
",",",",O
estrogens,NNS,G
",",",",O
progestogens,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
in,IN,O
oral,JJ,O
contraceptives,NNS,G
-rrb-,-RRB-,O
.,.,.
,,
beta-blockers,NNS,G
",",",",O
clonidine,NN,D
",",",",O
lithium,NN,D
salts,NNS,O
",",",",O
and,CC,O
alcohol,NN,D
may,MD,O
either,RB,O
potentiate,VB,O
or,CC,O
weaken,VB,O
the,DT,O
blood-glucose-lowering,NN,O
effect,NN,O
of,IN,O
insulin,NN,D
.,.,.
,,
pentamidine,NNP,D
may,MD,O
cause,VB,O
hypoglycemia,NN,O
",",",",O
which,WDT,O
may,MD,O
sometimes,RB,O
be,VB,O
followed,VBN,O
by,IN,O
hyperglycemia,NN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
under,IN,O
the,DT,O
influence,NN,O
of,IN,O
sympatholytic,JJ,O
medicinal,JJ,O
products,NNS,O
such,JJ,O
as,IN,O
beta-blockers,NNS,G
",",",",O
clonidine,NN,D
",",",",O
guanethidine,NN,D
",",",",O
and,CC,O
reserpine,NN,D
",",",",O
the,DT,O
signs,NNS,O
of,IN,O
hypoglycemia,NN,O
may,MD,O
be,VB,O
reduced,VBN,O
or,CC,O
absent,JJ,O
.,.,.
,,
mixing,NN,O
of,IN,O
insulin,NN,D
.,.,.
,,
a,DT,O
clinical,JJ,O
study,NN,O
in,IN,O
healthy,JJ,O
male,JJ,O
volunteers,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
24,CD,O
-rrb-,-RRB-,O
demonstrated,VBD,O
that,IN,O
mixing,VBG,O
novolog,NN,B
with,IN,O
nph,NN,O
human,JJ,O
insulin,NN,D
immediately,RB,O
before,IN,O
injection,NN,O
produced,VBD,O
some,DT,O
attenuation,NN,O
in,IN,O
the,DT,O
peak,NN,O
concentration,NN,O
of,IN,O
novolog,NNP,B
",",",",O
but,CC,O
that,IN,O
the,DT,O
time,NN,O
to,TO,O
peak,NN,O
and,CC,O
the,DT,O
total,JJ,O
bioavailability,NN,O
of,IN,O
novolog,NNP,B
were,VBD,O
not,RB,O
significantly,RB,O
affected,VBN,O
.,.,.
,,
if,IN,O
novolog,NNP,B
is,VBZ,O
mixed,VBN,O
with,IN,O
nph,NN,O
human,JJ,O
insulin,NN,D
",",",",O
novolog,NNP,B
should,MD,O
be,VB,O
drawn,VBN,O
into,IN,O
the,DT,O
syringe,NN,O
first,RB,O
.,.,.
,,
the,DT,O
injection,NN,O
should,MD,O
be,VB,O
made,VBN,O
immediately,RB,O
after,IN,O
mixing,VBG,O
.,.,.
,,
because,IN,O
there,EX,O
are,VBP,O
no,DT,O
data,NNS,O
on,IN,O
the,DT,O
compatibility,NN,O
of,IN,O
novolog,NNP,B
and,CC,O
crystalline,JJ,O
zinc,NN,D
insulin,NN,D
preparations,NNS,O
",",",",O
novolog,NNP,B
should,MD,O
not,RB,O
be,VB,O
mixed,VBN,O
with,IN,O
these,DT,O
preparations,NNS,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
mixing,VBG,O
novolog,NN,B
with,IN,O
insulins,NNS,G
of,IN,O
animal,NN,O
source,NN,O
or,CC,O
insulin,NN,D
preparations,NNS,O
produced,VBN,O
by,IN,O
other,JJ,O
manufacturers,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
mixtures,NNS,O
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
intravenously,RB,O
.,.,.
,,
when,WRB,O
used,VBN,O
in,IN,O
external,JJ,O
subcutaneous,JJ,O
infusion,NN,O
pumps,NNS,O
for,IN,O
insulin,NN,D
",",",",O
novolog,NNP,B
should,MD,O
not,RB,O
be,VB,O
mixed,VBN,O
with,IN,O
any,DT,O
other,JJ,O
insulins,NNS,G
or,CC,O
diluent,NN,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
with,IN,O
rebif,NN,B
.,.,.
,,
due,JJ,O
to,TO,O
its,PRP$,O
potential,JJ,O
to,TO,O
cause,VB,O
neutropenia,NN,O
and,CC,O
lymphopenia,NN,O
",",",",O
proper,JJ,O
monitoring,NN,O
of,IN,O
patients,NNS,O
is,VBZ,O
required,VBN,O
if,IN,O
rebif,NN,B
is,VBZ,O
given,VBN,O
in,IN,O
combination,NN,O
with,IN,O
myelosuppressive,JJ,O
agents,NNS,O
.,.,.
,,
also,RB,O
",",",",O
the,DT,O
potential,NN,O
for,IN,O
hepatic,JJ,O
injury,NN,O
should,MD,O
be,VB,O
considered,VBN,O
when,WRB,O
rebif,NNP,B
is,VBZ,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
products,NNS,O
associated,VBN,O
with,IN,O
hepatic,JJ,O
injury,NN,O
",",",",O
or,CC,O
when,WRB,O
new,JJ,O
agents,NNS,O
are,VBP,O
added,VBN,O
to,TO,O
the,DT,O
regimen,NN,O
of,IN,O
patients,NNS,O
already,RB,O
on,IN,O
rebif,NNP,B
.,.,.
,,
interactions,NNS,O
between,IN,O
betaseron,NNP,B
and,CC,O
other,JJ,O
drugs,NNS,D
have,VBP,O
not,RB,O
been,VBN,O
fully,RB,O
evaluated,VBN,O
.,.,.
,,
although,IN,O
studies,NNS,O
designed,VBN,O
to,TO,O
examine,VB,O
drug,NN,D
interactions,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
done,VBN,O
",",",",O
it,PRP,O
was,VBD,O
noted,VBN,O
that,IN,O
corticosteroid,NN,G
or,CC,O
acth,NN,D
treatment,NN,O
of,IN,O
relapses,NNS,O
for,IN,O
periods,NNS,O
of,IN,O
up,RB,O
to,TO,O
28,CD,O
days,NNS,O
has,VBZ,O
been,VBN,O
administered,VBN,O
to,TO,O
patients,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
180,CD,O
-rrb-,-RRB-,O
receiving,VBG,O
betaseron,NNP,B
.,.,.
,,
betaseron,NNP,B
administration,NN,O
to,TO,O
three,CD,O
cancer,NN,O
patients,NNS,O
over,IN,O
a,DT,O
dose,NN,O
range,NN,O
of,IN,O
0.025,CD,O
mg,NN,O
to,TO,O
2.2,CD,O
mg,NN,O
led,VBD,O
to,TO,O
a,DT,O
dose-dependent,JJ,O
inhibition,NN,O
of,IN,O
antipyrine,JJ,D
elimination,NN,O
0.14,CD,O
the,DT,O
effect,NN,O
of,IN,O
alternate-day,JJ,O
administration,NN,O
of,IN,O
0.25,CD,O
mg,NN,O
of,IN,O
betaseron,NNP,B
on,IN,O
drug,NN,D
metabolism,NN,O
in,IN,O
ms,NN,O
patients,NNS,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
atrovent,NNP,B
inhalation,NNP,O
aerosol,NNP,O
has,VBZ,O
been,VBN,O
used,VBN,O
concomitantly,RB,O
with,IN,O
other,JJ,O
drugs,NNS,D
",",",",O
including,VBG,O
sympathomimetic,JJ,G
bronchodilators,NNS,G
",",",",O
methylxanthines,NNS,G
",",",",O
and,CC,O
steroids,NNS,G
",",",",O
commonly,RB,O
used,VBN,O
in,IN,O
the,DT,O
treatment,NN,O
of,IN,O
chronic,JJ,O
obstructive,JJ,O
pulmonary,JJ,O
disease,NN,O
.,.,.
,,
with,IN,O
the,DT,O
exception,NN,O
of,IN,O
albuterol,NN,D
",",",",O
there,EX,O
are,VBP,O
no,DT,O
formal,JJ,O
studies,NNS,O
fully,RB,O
evaluating,VBG,O
the,DT,O
interaction,NN,O
effects,NNS,O
of,IN,O
atrovent,NNP,B
inhalation,NNP,O
aerosol,NNP,O
and,CC,O
these,DT,O
drugs,NNS,D
with,IN,O
respect,NN,O
to,TO,O
effectiveness,NN,O
.,.,.
,,
anticholinergic,JJ,O
agents,NNS,O
:,:,O
although,IN,O
ipratropium,NN,O
bromide,NN,O
is,VBZ,O
minimally,RB,O
absorbed,VBN,O
into,IN,O
the,DT,O
systemic,JJ,O
circulation,NN,O
",",",",O
there,EX,O
is,VBZ,O
some,DT,O
potential,JJ,O
for,IN,O
an,DT,O
additive,JJ,O
interaction,NN,O
with,IN,O
concomitantly,RB,O
used,VBN,O
anticholinergic,JJ,G
medications,NNS,O
.,.,.
,,
caution,NN,O
is,VBZ,O
therefore,RB,O
advised,VBN,O
in,IN,O
the,DT,O
coadministration,NN,O
of,IN,O
atrovent,NNP,B
inhalation,NNP,O
aerosol,NNP,O
with,IN,O
other,JJ,O
anticholinergic-containing,JJ,O
drugs,NNS,D
.,.,.
,,
no,DT,O
significant,JJ,O
drug-drug,JJ,O
pharmacokinetic,JJ,O
-lrb-,-LRB-,O
or,CC,O
pharmacodynamic,JJ,O
-rrb-,-RRB-,O
interactions,NNS,O
have,VBP,O
been,VBN,O
found,VBN,O
in,IN,O
interaction,NN,O
studies,NNS,O
with,IN,O
hydrochlorothiazide,NN,D
",",",",O
digoxin,NN,D
",",",",O
warfarin,NN,D
",",",",O
and,CC,O
nifedipine,NN,D
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
show,VBP,O
significant,JJ,O
inhibition,NN,O
of,IN,O
the,DT,O
formation,NN,O
of,IN,O
oxidized,VBN,O
irbesartan,NN,D
metabolites,NNS,O
with,IN,O
the,DT,O
known,JJ,O
cytochrome,NN,O
cyp,NN,O
2c9,CD,O
substrates/inhibitors,NNS,O
sulphenazole,NN,D
",",",",O
tolbutamide,NN,D
and,CC,O
nifedipine,NN,D
.,.,.
,,
however,RB,O
",",",",O
in,IN,O
clinical,JJ,O
studies,NNS,O
the,DT,O
consequences,NNS,O
of,IN,O
concomitant,JJ,O
irbesartan,NN,D
on,IN,O
the,DT,O
pharmacodynamics,NNS,O
of,IN,O
warfarin,NN,D
were,VBD,O
negligible,JJ,O
.,.,.
,,
based,VBN,O
on,IN,O
in,FW,O
vitro,FW,O
data,NNS,O
",",",",O
no,DT,O
interaction,NN,O
would,MD,O
be,VB,O
expected,VBN,O
with,IN,O
drugs,NNS,D
whose,WP$,O
metabolism,NN,O
is,VBZ,O
dependent,JJ,O
upon,IN,O
cytochrome,NN,O
p450,NN,O
isozymes,NNS,O
1a1,NN,O
",",",",O
1a2,NN,O
",2",CD,O
a6,NN,O
",2",CD,O
b6,NN,O
",2",CD,O
d6,NN,O
",2",CD,O
e1,NN,O
",",",",O
or,CC,O
3a4,NN,O
.,.,.
,,
in,IN,O
separate,JJ,O
studies,NNS,O
of,IN,O
patients,NNS,O
receiving,VBG,O
maintenance,NN,O
doses,NNS,O
of,IN,O
warfarin,NN,D
",",",",O
hydrochlorothiazide,NN,D
",",",",O
or,CC,O
digoxin,NN,D
",",",",O
irbesartan,NN,D
administration,NN,O
for,IN,O
7,CD,O
days,NNS,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacodynamics,NNS,O
of,IN,O
warfarin,NN,D
-lrb-,-LRB-,O
prothrombin,NN,O
time,NN,O
-rrb-,-RRB-,O
or,CC,O
pharmacokinetics,NNS,O
of,IN,O
digoxin,NN,D
.,.,.
,,
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
irbesartan,NN,D
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
coadministration,NN,O
of,IN,O
nifedipine,NN,D
or,CC,O
hydrochlorothiazid,NN,O
.,.,.
,,
the,DT,O
adverse,JJ,O
effects,NNS,O
of,IN,O
camptosar,NNP,B
",",",",O
such,JJ,O
as,IN,O
myelosuppression,NN,O
and,CC,O
diarrhea,NN,O
",",",",O
would,MD,O
be,VB,O
expected,VBN,O
to,TO,O
be,VB,O
exacerbated,VBN,O
by,IN,O
other,JJ,O
antineoplastic,JJ,O
agents,NNS,O
having,VBG,O
similar,JJ,O
adverse,JJ,O
effects,NNS,O
.,.,.
,,
patients,NNS,O
who,WP,O
have,VBP,O
previously,RB,O
received,VBN,O
pelvic,JJ,O
/,:,O
abdominal,JJ,O
irradiation,NN,O
are,VBP,O
at,IN,O
increased,VBN,O
risk,NN,O
of,IN,O
severe,JJ,O
myelosuppression,NN,O
following,VBG,O
the,DT,O
administration,NN,O
of,IN,O
camptosar,NNP,B
.,.,.
,,
the,DT,O
concurrent,JJ,O
administration,NN,O
of,IN,O
camptosar,NN,B
with,IN,O
irradiation,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
adequately,RB,O
studied,VBN,O
and,CC,O
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
lymphocytopenia,NNP,O
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
camptosar,NNP,B
",",",",O
and,CC,O
it,PRP,O
is,VBZ,O
possible,JJ,O
that,IN,O
the,DT,O
administration,NN,O
of,IN,O
dexamethasone,NN,D
as,IN,O
antiemetic,JJ,O
prophylaxis,NN,O
may,MD,O
have,VB,O
enhanced,VBN,O
the,DT,O
likelihood,NN,O
of,IN,O
this,DT,O
effect,NN,O
.,.,.
,,
however,RB,O
",",",",O
serious,JJ,O
opportunistic,JJ,O
infections,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
observed,VBN,O
",",",",O
and,CC,O
no,DT,O
complications,NNS,O
have,VBP,O
specifically,RB,O
been,VBN,O
attributed,VBN,O
to,TO,O
lymphocytopenia,NN,O
.,.,.
,,
hyperglycemia,NN,O
has,VBZ,O
also,RB,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
camptosar,NNP,B
.,.,.
,,
usually,RB,O
",",",",O
this,DT,O
has,VBZ,O
been,VBN,O
observed,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
a,DT,O
history,NN,O
of,IN,O
diabetes,NN,O
mellitus,NN,O
or,CC,O
evidence,NN,O
of,IN,O
glucose,NN,O
intolerance,NN,O
prior,RB,O
to,TO,O
administration,NN,O
of,IN,O
camptosar,NNP,B
.,.,.
,,
it,PRP,O
is,VBZ,O
probable,JJ,O
that,IN,O
dexamethasone,NN,D
",",",",O
given,VBN,O
as,IN,O
antiemetic,JJ,O
prophylaxis,NN,O
",",",",O
contributed,VBD,O
to,TO,O
hyperglycemia,NN,O
in,IN,O
some,DT,O
patients,NNS,O
.,.,.
,,
the,DT,O
incidence,NN,O
of,IN,O
akathisia,NN,O
in,IN,O
clinical,JJ,O
trials,NNS,O
of,IN,O
the,DT,O
weekly,JJ,O
dosage,NN,O
schedule,NN,O
was,VBD,O
greater,JJR,O
-lrb-,-LRB-,O
8.5,CD,O
%,NN,O
",",",",O
Apr-47,CD,O
patients,NNS,O
-rrb-,-RRB-,O
when,WRB,O
prochlorperazine,NN,D
was,VBD,O
administered,VBN,O
on,IN,O
the,DT,O
same,JJ,O
day,NN,O
as,IN,O
camptosar,NN,B
than,IN,O
when,WRB,O
these,DT,O
drugs,NNS,D
were,VBD,O
given,VBN,O
on,IN,O
separate,JJ,O
days,NNS,O
-lrb-,-LRB-,O
1.3,CD,O
%,NN,O
",",",",O
Jan-80,CD,O
patients,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
8.5,CD,O
%,NN,O
incidence,NN,O
of,IN,O
akathisia,NN,O
",",",",O
however,RB,O
",",",",O
is,VBZ,O
within,IN,O
the,DT,O
range,NN,O
reported,VBD,O
for,IN,O
use,NN,O
of,IN,O
prochlorperazine,NN,D
when,WRB,O
given,VBN,O
as,IN,O
a,DT,O
premedication,NN,O
for,IN,O
other,JJ,O
chemotherapies,NNS,O
.,.,.
,,
it,PRP,O
would,MD,O
be,VB,O
expected,VBN,O
that,IN,O
laxative,NN,G
use,NN,O
during,IN,O
therapy,NN,O
with,IN,O
camptosar,NN,B
would,MD,O
worsen,VB,O
the,DT,O
incidence,NN,O
or,CC,O
severity,NN,O
of,IN,O
diarrhea,NN,O
",",",",O
but,CC,O
this,DT,O
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
in,IN,O
view,NN,O
of,IN,O
the,DT,O
potential,JJ,O
risk,NN,O
of,IN,O
dehydration,NN,O
secondary,JJ,O
to,TO,O
vomiting,VBG,O
and/or,CC,O
diarrhea,NN,O
induced,VBN,O
by,IN,O
camptosar,NNP,B
",",",",O
the,DT,O
physician,NN,O
may,MD,O
wish,VB,O
to,TO,O
withhold,VB,O
diuretics,NNS,G
during,IN,O
dosing,NN,O
with,IN,O
camptosar,NN,B
and,CC,O
",",",",O
certainly,RB,O
",",",",O
during,IN,O
periods,NNS,O
of,IN,O
active,JJ,O
vomiting,VBG,O
or,CC,O
diarrhea,NN,O
.,.,.
,,
drug-laboratory,JJ,O
test,NN,O
interactions,NNS,O
there,EX,O
are,VBP,O
no,DT,O
known,JJ,O
interactions,NNS,O
between,IN,O
camptosar,NN,B
and,CC,O
laboratory,NN,O
tests,NNS,O
.,.,.
,,
isocarboxazid,NN,D
should,MD,O
be,VB,O
administered,VBN,O
with,IN,O
caution,NN,O
to,TO,O
patients,NNS,O
receiving,VBG,O
antabuse,NN,B
-lrb-,-LRB-,O
disulfiram,NN,D
",",",",O
wyeth-ayerst,NNP,O
laboratories,NNP,O
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
a,DT,O
single,JJ,O
study,NN,O
",",",",O
rats,NNS,O
given,VBN,O
high,JJ,O
intraperitoneal,JJ,O
doses,NNS,O
of,IN,O
an,DT,O
mao,NNP,O
inhibitor,NN,O
plus,CC,O
disulfiram,NN,D
experienced,VBD,O
severe,JJ,O
toxicity,NN,O
",",",",O
including,VBG,O
convulsions,NNS,O
and,CC,O
death,NN,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
isocarboxazid,NN,D
and,CC,O
other,JJ,O
psychotropic,JJ,O
agents,NNS,O
is,VBZ,O
generally,RB,O
not,RB,O
recommended,VBN,O
because,IN,O
of,IN,O
possible,JJ,O
potentiating,NN,O
effects,NNS,O
.,.,.
,,
this,DT,O
is,VBZ,O
especially,RB,O
TRUE,JJ,O
in,IN,O
patients,NNS,O
who,WP,O
may,MD,O
subject,VB,O
themselves,PRP,O
to,TO,O
an,DT,O
overdosage,NN,O
of,IN,O
drugs,NNS,D
.,.,.
,,
if,IN,O
combination,NN,O
therapy,NN,O
is,VBZ,O
needed,VBN,O
",",",",O
careful,JJ,O
consideration,NN,O
should,MD,O
be,VB,O
given,VBN,O
to,TO,O
the,DT,O
pharmacology,NN,O
of,IN,O
all,DT,O
agents,NNS,O
to,TO,O
be,VB,O
used,VBN,O
.,.,.
,,
the,DT,O
monoamine,NN,O
oxidase,NN,O
inhibitory,JJ,O
effects,NNS,O
of,IN,O
isocarboxazid,NN,D
may,MD,O
persist,VB,O
for,IN,O
a,DT,O
substantial,JJ,O
period,NN,O
after,IN,O
discontinuation,NN,O
of,IN,O
the,DT,O
drug,NN,D
",",",",O
and,CC,O
this,DT,O
should,MD,O
be,VB,O
borne,VBN,O
in,IN,O
mind,NN,O
when,WRB,O
another,DT,O
drug,NN,D
is,VBZ,O
prescribed,VBN,O
following,VBG,O
isocarboxazid,NNP,D
.,.,.
,,
to,TO,O
avoid,VB,O
potentiation,NN,O
",",",",O
the,DT,O
physician,NN,O
wishing,VBG,O
to,TO,O
terminate,VB,O
treatment,NN,O
with,IN,O
isocarboxazid,NN,D
and,CC,O
begin,VB,O
therapy,NN,O
with,IN,O
another,DT,O
agent,NN,O
should,MD,O
allow,VB,O
for,IN,O
an,DT,O
interval,NN,O
of,IN,O
10,CD,O
days,NNS,O
.,.,.
,,
may,NNP,O
interact,VBP,O
with,IN,O
the,DT,O
following,NN,O
:,:,O
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
-lrb-,-LRB-,O
these,DT,O
medicines,NNS,O
may,MD,O
make,VB,O
your,PRP$,O
condition,NN,O
worse,JJR,O
and,CC,O
prevent,VB,O
the,DT,O
adrenergic,JJ,G
bronchodilators,NNS,G
from,IN,O
working,VBG,O
properly,RB,O
-rrb-,-RRB-,O
and,CC,O
disopyramide,NN,D
",",",",O
quinidine,NN,D
",",",",O
phenothiazines,NNS,G
",",",",O
and,CC,O
procainamide,NN,D
-lrb-,-LRB-,O
these,DT,O
medicines,NNS,O
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
heart,NN,O
problems,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
isoflurane,NN,D
potentiates,VBZ,O
the,DT,O
muscle,NN,O
relaxant,NN,O
effect,NN,O
of,IN,O
all,DT,O
muscle,NN,O
relaxants,NNS,O
",",",",O
most,RBS,O
notably,RB,O
nondepolarizing,JJ,O
muscle,NN,O
relaxants,NNS,O
",",",",O
and,CC,O
mac,NNP,O
-lrb-,-LRB-,O
minimum,JJ,O
alveolar,JJ,O
concentration,NN,O
-rrb-,-RRB-,O
is,VBZ,O
reduced,VBN,O
by,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
n,NN,O
2o,NN,O
.,.,.
,,
see,VB,O
clinical,NNP,O
pharmacology,NNP,O
.,.,.
,,
food,NNP,O
:,:,O
isoniazid,NNP,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
with,IN,O
food,NN,O
.,.,.
,,
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
the,DT,O
bioavailability,NN,O
of,IN,O
isoniazid,NN,D
is,VBZ,O
reduced,VBN,O
significantly,RB,O
when,WRB,O
administered,VBN,O
with,IN,O
food,NN,O
.,.,.
,,
acetaminophen,NN,D
:,:,O
a,DT,O
report,NN,O
of,IN,O
severe,JJ,O
acetaminophen,NN,D
toxicity,NN,O
was,VBD,O
reported,VBN,O
in,IN,O
a,DT,O
patient,NN,O
receiving,VBG,O
isoniazid,NNP,D
.,.,.
,,
it,PRP,O
is,VBZ,O
believed,VBN,O
that,IN,O
the,DT,O
toxicity,NN,O
may,MD,O
have,VB,O
resulted,VBN,O
from,IN,O
a,DT,O
previously,RB,O
unrecognized,JJ,O
interaction,NN,O
between,IN,O
isoniazid,NN,D
and,CC,O
acetaminophen,NN,D
and,CC,O
a,DT,O
molecular,JJ,O
basis,NN,O
for,IN,O
this,DT,O
interaction,NN,O
has,VBZ,O
been,VBN,O
proposed,VBN,O
.,.,.
,,
however,RB,O
",",",",O
current,JJ,O
evidence,NN,O
suggests,VBZ,O
that,IN,O
isoniazid,NN,D
does,VBZ,O
induce,VB,O
p-450iie1,NN,O
",",",",O
a,DT,O
mixed-function,NN,O
oxidase,NN,O
enzyme,NN,O
that,WDT,O
appears,VBZ,O
to,TO,O
generate,VB,O
the,DT,O
toxic,JJ,O
metabolites,NNS,O
",",",",O
in,IN,O
the,DT,O
liver,NN,O
.,.,.
,,
furthermore,RB,O
it,PRP,O
has,VBZ,O
been,VBN,O
proposed,VBN,O
that,IN,O
isoniazid,NN,D
resulted,VBD,O
in,IN,O
induction,NN,O
of,IN,O
p-450iie1,NN,O
in,IN,O
the,DT,O
patients,NNS,O
liver,NN,O
which,WDT,O
",",",",O
in,IN,O
turn,NN,O
",",",",O
resulted,VBD,O
in,IN,O
a,DT,O
greater,JJR,O
proportion,NN,O
of,IN,O
the,DT,O
ingested,VBN,O
acetaminophen,NN,D
being,VBG,O
converted,VBN,O
to,TO,O
the,DT,O
toxic,JJ,O
metabolites,NNS,O
.,.,.
,,
studies,NNS,O
have,VBP,O
demonstrated,VBN,O
that,IN,O
pretreatment,NN,O
with,IN,O
isoniazid,NN,D
potentiates,VBZ,O
a,DT,O
cetaminophen,NN,O
hepatoxicity,NN,O
in,IN,O
rats,NNS,O
.,.,.
,,
carbamazepine,NNP,D
:,:,O
isoniazid,NNP,D
is,VBZ,O
known,VBN,O
to,TO,O
slow,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
carbamazepine,NN,D
and,CC,O
increase,VB,O
its,PRP$,O
serum,NN,O
levels,NNS,O
carbamazepine,NN,D
levels,NNS,O
should,MD,O
be,VB,O
determined,VBN,O
prior,RB,O
to,TO,O
concurrent,JJ,O
administration,NN,O
with,IN,O
isoniazid,NN,D
",",",",O
signs,NNS,O
and,CC,O
symptoms,NNS,O
of,IN,O
carbamazepine,NN,D
toxicity,NN,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
",",",",O
and,CC,O
appropriate,JJ,O
dosage,NN,O
adjustment,NN,O
of,IN,O
the,DT,O
anticonvulsant,NN,G
should,MD,O
be,VB,O
made,VBN,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
potential,JJ,O
interaction,NN,O
of,IN,O
ketoconazole,NNP,D
and,CC,O
isoniazid,NNP,D
may,MD,O
exist,VB,O
.,.,.
,,
phenytoin,NNP,D
:,:,O
isoniazid,NNP,D
may,MD,O
increase,VB,O
serum,NN,O
levels,NNS,O
of,IN,O
phenytoin,NN,D
.,.,.
,,
to,TO,O
avoid,VB,O
phenytoin,NN,D
intoxication,NN,O
",",",",O
appropriate,JJ,O
adjustment,NN,O
of,IN,O
the,DT,O
anticonvulsant,NN,G
should,MD,O
be,VB,O
made,VBN,O
.,.,.
,,
therophylline,NNP,O
:,:,O
a,NNP,O
recent,JJ,O
study,NN,O
has,VBZ,O
shown,VBN,O
that,IN,O
concomitan,NN,O
administration,NN,O
of,IN,O
isoniazid,NN,D
and,CC,O
theophylline,NN,D
may,MD,O
cause,VB,O
elevated,JJ,O
plasma,NN,O
levels,NNS,O
of,IN,O
theophylline,NN,D
",",",",O
and,CC,O
in,IN,O
some,DT,O
instances,NNS,O
a,DT,O
slight,JJ,O
decrease,NN,O
in,IN,O
the,DT,O
elimination,NN,O
of,IN,O
isoniazid,NN,D
.,.,.
,,
since,IN,O
the,DT,O
therapeutic,JJ,O
range,NN,O
of,IN,O
theophylline,NN,D
is,VBZ,O
narrow,JJ,O
theophylline,NN,D
serum,NN,O
levels,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
",",",",O
and,CC,O
appropriate,JJ,O
dosage,NN,O
adjustments,NNS,O
of,IN,O
theophylline,NN,D
should,MD,O
be,VB,O
made,VBN,O
.,.,.
,,
valproate,NNP,D
:,:,O
a,NNP,O
recent,JJ,O
case,NN,O
study,NN,O
has,VBZ,O
shown,VBN,O
a,DT,O
possible,JJ,O
increase,NN,O
in,IN,O
the,DT,O
plasma,NN,O
level,NN,O
of,IN,O
valproate,NN,D
when,WRB,O
co,NN,O
administered,VBN,O
with,IN,O
isoniazid,NN,D
.,.,.
,,
plasma,NN,O
valproate,NN,D
concentration,NN,O
should,MD,O
be,VB,O
monitored,VBN,O
when,WRB,O
isoniazid,NN,D
and,CC,O
valproate,NN,D
are,VBP,O
co,NN,O
administered,VBN,O
",",",",O
and,CC,O
appropriate,JJ,O
dosage,NN,O
adjustments,NNS,O
of,IN,O
valproate,NN,D
should,MD,O
be,VB,O
made,VBN,O
.,.,.
,,
isoproterenol,NN,D
hydrochloride,NN,O
injection,NN,O
and,CC,O
epinephrine,NN,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
simultaneously,RB,O
because,IN,O
both,DT,O
drugs,NNS,D
are,VBP,O
direct,JJ,O
cardiac,JJ,O
stimulants,NNS,O
and,CC,O
their,PRP$,O
combined,JJ,O
effects,NNS,O
may,MD,O
induce,VB,O
serious,JJ,O
arrhythmias,NNS,O
.,.,.
,,
the,DT,O
drugs,NNS,D
may,MD,O
",",",",O
however,RB,O
",",",",O
be,VB,O
administered,VBN,O
alternately,RB,O
provided,VBN,O
a,DT,O
proper,JJ,O
interval,NN,O
has,VBZ,O
elapsed,VBN,O
between,IN,O
doses,NNS,O
.,.,.
,,
isuprel,NN,B
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
",",",",O
if,IN,O
at,IN,O
all,DT,O
",",",",O
when,WRB,O
potent,JJ,O
inhalational,JJ,O
anesthetics,NNS,G
such,JJ,O
as,IN,O
halothane,NN,D
are,VBP,O
employed,VBN,O
because,IN,O
of,IN,O
potential,JJ,O
to,TO,O
sensitize,VB,O
the,DT,O
myocardium,NN,O
to,TO,O
effects,NNS,O
of,IN,O
sympathomimetic,JJ,G
amines,NNS,O
.,.,.
,,
the,DT,O
vasodilating,JJ,O
effects,NNS,O
of,IN,O
isosorbide,NN,O
dinitrate,NN,O
may,MD,O
be,VB,O
additive,JJ,O
with,IN,O
those,DT,O
of,IN,O
other,JJ,O
vasodilators,NNS,G
.,.,.
,,
alcohol,NN,D
",",",",O
in,IN,O
particular,JJ,O
",",",",O
has,VBZ,O
been,VBN,O
found,VBN,O
to,TO,O
exhibit,VB,O
additive,JJ,O
effects,NNS,O
of,IN,O
this,DT,O
variety,NN,O
.,.,.
,,
the,DT,O
vasodilating,JJ,O
effects,NNS,O
of,IN,O
isosorbide,NN,O
mononitrate,NN,O
may,MD,O
be,VB,O
additive,JJ,O
with,IN,O
those,DT,O
of,IN,O
other,JJ,O
vasodilators,NNS,G
.,.,.
,,
alcohol,NN,D
",",",",O
in,IN,O
particular,JJ,O
",",",",O
has,VBZ,O
been,VBN,O
found,VBN,O
to,TO,O
exhibit,VB,O
additive,JJ,O
effects,NNS,O
of,IN,O
this,DT,O
variety,NN,O
.,.,.
,,
marked,JJ,O
symptomatic,JJ,O
orthostatic,JJ,O
hypotension,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
when,WRB,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
and,CC,O
organic,JJ,O
nitrates,NNS,G
were,VBD,O
used,VBN,O
in,IN,O
combination,NN,O
.,.,.
,,
dose,NN,O
adjustments,NNS,O
of,IN,O
either,CC,O
class,NN,O
of,IN,O
agents,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
vitamin,NN,O
a,NN,O
:,:,O
because,IN,O
of,IN,O
the,DT,O
relationship,NN,O
of,IN,O
accutane,NNP,B
to,TO,O
vitamin,NN,G
a,NN,O
",",",",O
patients,NNS,O
should,MD,O
be,VB,O
advised,VBN,O
against,IN,O
taking,VBG,O
vitamin,NN,G
supplements,NNS,O
containing,VBG,O
vitamin,NN,G
a,NN,O
to,TO,O
avoid,VB,O
additive,JJ,O
toxic,JJ,O
effect,NN,O
.,.,.
,,
tetracyclines,NNS,G
:,:,O
concomitant,JJ,O
treatment,NN,O
with,IN,O
accutane,NN,B
and,CC,O
tetracyclines,NNS,G
should,MD,O
be,VB,O
avoided,VBN,O
because,IN,O
accutane,NNP,B
use,NN,O
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
a,DT,O
number,NN,O
of,IN,O
cases,NNS,O
of,IN,O
pseudotumor,NN,O
cerebri,NN,O
-lrb-,-LRB-,O
benign,JJ,O
intracranial,JJ,O
hypertension,NN,O
-rrb-,-RRB-,O
",",",",O
some,DT,O
of,IN,O
which,WDT,O
involved,JJ,O
concomitant,JJ,O
use,NN,O
of,IN,O
tetracycline,NN,D
.,.,.
,,
micro-dosed,JJ,O
progesterone,NN,D
preparations,NNS,O
:,:,O
micro-dosed,JJ,O
progesterone,NN,D
preparations,NNS,O
-lrb-,-LRB-,O
minipills,NNS,O
that,WDT,O
do,VBP,O
not,RB,O
contain,VB,O
an,DT,O
estrogen,NN,G
-rrb-,-RRB-,O
may,MD,O
be,VB,O
an,DT,O
inadequate,JJ,O
method,NN,O
of,IN,O
contraception,NN,O
during,IN,O
accutane,NN,B
therapy,NN,O
.,.,.
,,
although,IN,O
other,JJ,O
hormonal,JJ,O
contraceptives,NNS,G
are,VBP,O
highly,RB,O
effective,JJ,O
",",",",O
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
pregnancy,NN,O
from,IN,O
women,NNS,O
who,WP,O
have,VBP,O
used,VBN,O
combined,JJ,O
oral,JJ,O
contraceptives,NNS,G
",",",",O
as,RB,O
well,RB,O
as,IN,O
topical/injectable/implantable,JJ,O
/,:,O
insertable,JJ,O
hormonal,JJ,O
birth,NN,O
control,NN,O
products,NNS,O
.,.,.
,,
these,DT,O
reports,NNS,O
are,VBP,O
more,RBR,O
frequent,JJ,O
for,IN,O
women,NNS,O
who,WP,O
use,VBP,O
only,RB,O
a,DT,O
single,JJ,O
method,NN,O
of,IN,O
contraception,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
if,IN,O
hormonal,JJ,O
contraceptives,NNS,G
differ,VBP,O
in,IN,O
their,PRP$,O
effectiveness,NN,O
when,WRB,O
used,VBN,O
with,IN,O
accutane,NN,B
.,.,.
,,
therefore,RB,O
",",",",O
it,PRP,O
is,VBZ,O
critically,RB,O
important,JJ,O
for,IN,O
women,NNS,O
of,IN,O
childbearing,JJ,O
potential,NN,O
to,TO,O
select,VB,O
and,CC,O
commit,VB,O
to,TO,O
use,VB,O
2,CD,O
forms,NNS,O
of,IN,O
effective,JJ,O
contraception,NN,O
simultaneously,RB,O
",",",",O
at,IN,O
least,JJS,O
1,CD,O
of,IN,O
which,WDT,O
must,MD,O
be,VB,O
a,DT,O
primary,JJ,O
form,NN,O
",",",",O
unless,IN,O
absolute,JJ,O
abstinence,NN,O
is,VBZ,O
the,DT,O
chosen,VBN,O
method,NN,O
",",",",O
or,CC,O
the,DT,O
patient,NN,O
has,VBZ,O
undergone,VBN,O
a,DT,O
hysterectomy,NN,O
.,.,.
,,
phenytoin,NNP,D
:,:,O
accutane,NNP,B
has,VBZ,O
not,RB,O
been,VBN,O
shown,VBN,O
to,TO,O
alter,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
phenytoin,NN,D
in,IN,O
a,DT,O
study,NN,O
in,IN,O
seven,CD,O
healthy,JJ,O
volunteers,NNS,O
.,.,.
,,
these,DT,O
results,NNS,O
are,VBP,O
consistent,JJ,O
with,IN,O
the,DT,O
in,FW,O
vitro,FW,O
finding,NN,O
that,IN,O
neither,CC,O
isotretinoin,NN,D
nor,CC,O
its,PRP$,O
metabolites,NNS,O
induce,VBP,O
or,CC,O
inhibit,VBP,O
the,DT,O
activity,NN,O
of,IN,O
the,DT,O
cyp,NN,O
2c9,NN,O
human,JJ,O
hepatic,JJ,O
p450,NN,O
enzyme,NN,O
.,.,.
,,
phenytoin,NNP,D
is,VBZ,O
known,VBN,O
to,TO,O
cause,VB,O
osteomalacia,NN,O
.,.,.
,,
no,DT,O
formal,JJ,O
clinical,JJ,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
to,TO,O
assess,VB,O
if,IN,O
there,EX,O
is,VBZ,O
an,DT,O
interactive,JJ,O
effect,NN,O
on,IN,O
bone,NN,O
loss,NN,O
between,IN,O
phenytoin,NN,D
and,CC,O
accutane,NN,B
.,.,.
,,
therefore,RB,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
using,VBG,O
these,DT,O
drugs,NNS,D
together,RB,O
.,.,.
,,
systemic,JJ,O
corticosteroids,NNS,G
:,:,O
systemic,JJ,O
corticosteroids,NNS,G
are,VBP,O
known,VBN,O
to,TO,O
cause,VB,O
osteoporosis,NN,O
.,.,.
,,
no,DT,O
formal,JJ,O
clinical,JJ,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
to,TO,O
assess,VB,O
if,IN,O
there,EX,O
is,VBZ,O
an,DT,O
interactive,JJ,O
effect,NN,O
on,IN,O
bone,NN,O
loss,NN,O
between,IN,O
systemic,JJ,O
corticosteroids,NNS,G
and,CC,O
accutane,NNP,B
.,.,.
,,
therefore,RB,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
using,VBG,O
these,DT,O
drugs,NNS,D
together,RB,O
.,.,.
,,
prescribers,NNS,O
are,VBP,O
advised,VBN,O
to,TO,O
consult,VB,O
the,DT,O
package,NN,O
insert,NN,O
of,IN,O
medication,NN,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
hormonal,JJ,O
contraceptives,NNS,G
",",",",O
since,IN,O
some,DT,O
medications,NNS,O
may,MD,O
decrease,VB,O
the,DT,O
effectiveness,NN,O
of,IN,O
these,DT,O
birth,NN,O
control,NN,O
products,NNS,O
.,.,.
,,
accutane,NNP,B
use,NN,O
is,VBZ,O
associated,VBN,O
with,IN,O
depression,NN,O
in,IN,O
some,DT,O
patients,NNS,O
.,.,.
,,
pregnancies,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
by,IN,O
users,NNS,O
of,IN,O
combined,JJ,O
hormonal,JJ,O
contraceptives,NNS,G
who,WP,O
also,RB,O
used,VBD,O
some,DT,O
form,NN,O
of,IN,O
st.,NNP,O
johns,NNP,O
wort,NNP,O
.,.,.
,,
laboratory,NNP,O
tests,NNP,O
pregnancy,NNP,O
test,NNP,O
female,JJ,O
patients,NNS,O
of,IN,O
childbearing,JJ,O
potential,NN,O
must,MD,O
have,VB,O
negative,JJ,O
results,NNS,O
from,IN,O
2,CD,O
urine,NN,O
or,CC,O
serum,NN,O
pregnancy,NN,O
tests,NNS,O
with,IN,O
a,DT,O
sensitivity,NN,O
of,IN,O
at,IN,O
least,JJS,O
25,CD,O
miu/ml,NN,O
before,IN,O
receiving,VBG,O
the,DT,O
initial,JJ,O
accutane,NN,B
prescription,NN,O
.,.,.
,,
the,DT,O
first,JJ,O
test,NN,O
is,VBZ,O
obtained,VBN,O
by,IN,O
the,DT,O
prescriber,NN,O
when,WRB,O
the,DT,O
decision,NN,O
is,VBZ,O
made,VBN,O
to,TO,O
pursue,VB,O
qualification,NN,O
of,IN,O
the,DT,O
patient,NN,O
for,IN,O
accutane,NNP,B
-lrb-,-LRB-,O
a,DT,O
screening,NN,O
test,NN,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
second,JJ,O
pregnancy,NN,O
test,NN,O
-lrb-,-LRB-,O
a,DT,O
confirmation,NN,O
test,NN,O
-rrb-,-RRB-,O
should,MD,O
be,VB,O
done,VBN,O
during,IN,O
the,DT,O
first,JJ,O
5,CD,O
days,NNS,O
of,IN,O
the,DT,O
menstrual,JJ,O
period,NN,O
immediately,RB,O
preceding,VBG,O
the,DT,O
beginning,NN,O
of,IN,O
accutane,NN,B
therapy,NN,O
.,.,.
,,
for,IN,O
patients,NNS,O
with,IN,O
amenorrhea,NN,O
",",",",O
the,DT,O
second,JJ,O
test,NN,O
should,MD,O
be,VB,O
done,VBN,O
at,IN,O
least,JJS,O
11,CD,O
days,NNS,O
after,IN,O
the,DT,O
last,JJ,O
act,NN,O
of,IN,O
unprotected,JJ,O
sexual,JJ,O
intercourse,NN,O
-lrb-,-LRB-,O
without,IN,O
using,VBG,O
2,CD,O
effective,JJ,O
forms,NNS,O
of,IN,O
contraception,NN,O
-rrb-,-RRB-,O
.,.,.
,,
each,DT,O
month,NN,O
of,IN,O
therapy,NN,O
",",",",O
the,DT,O
patient,NN,O
must,MD,O
have,VB,O
a,DT,O
negative,JJ,O
result,NN,O
from,IN,O
a,DT,O
urine,NN,O
or,CC,O
serum,NN,O
pregnancy,NN,O
test,NN,O
.,.,.
,,
a,DT,O
pregnancy,NN,O
test,NN,O
must,MD,O
be,VB,O
repeated,VBN,O
each,DT,O
month,NN,O
prior,RB,O
to,TO,O
the,DT,O
female,JJ,O
patient,NN,O
receiving,VBG,O
each,DT,O
prescription,NN,O
.,.,.
,,
lipids,NNS,O
:,:,O
pretreatment,NN,O
and,CC,O
follow-up,JJ,O
blood,NN,O
lipids,NNS,O
should,MD,O
be,VB,O
obtained,VBN,O
under,IN,O
fasting,NN,O
conditions,NNS,O
.,.,.
,,
after,IN,O
consumption,NN,O
of,IN,O
alcohol,NN,D
",",",",O
at,IN,O
least,JJS,O
36,CD,O
hours,NNS,O
should,MD,O
elapse,VB,O
before,IN,O
these,DT,O
determinations,NNS,O
are,VBP,O
made,VBN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
these,DT,O
tests,NNS,O
be,VB,O
performed,VBN,O
at,IN,O
weekly,JJ,O
or,CC,O
biweekly,JJ,O
intervals,NNS,O
until,IN,O
the,DT,O
lipid,NN,O
response,NN,O
to,TO,O
accutane,NNP,B
is,VBZ,O
established,VBN,O
.,.,.
,,
the,DT,O
incidence,NN,O
of,IN,O
hypertriglyceridemia,NN,O
is,VBZ,O
1,CD,O
patient,NN,O
in,IN,O
4,CD,O
on,IN,O
accutane,NNP,B
therap,NN,O
.,.,.
,,
liver,NN,O
function,NN,O
tests,NNS,O
:,:,O
since,IN,O
elevations,NNS,O
of,IN,O
liver,NN,O
enzymes,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
during,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
and,CC,O
hepatitis,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
",",",",O
pretreatment,NN,O
and,CC,O
follow-up,NN,O
liver,NN,O
function,NN,O
tests,NNS,O
should,MD,O
be,VB,O
performed,VBN,O
at,IN,O
weekly,JJ,O
or,CC,O
biweekly,JJ,O
intervals,NNS,O
until,IN,O
the,DT,O
response,NN,O
to,TO,O
accutane,NNP,B
has,VBZ,O
been,VBN,O
establishe,NN,O
.,.,.
,,
glucose,NN,O
:,:,O
some,DT,O
patients,NNS,O
receiving,VBG,O
accutane,NNP,B
have,VBP,O
experienced,VBN,O
problems,NNS,O
in,IN,O
the,DT,O
control,NN,O
of,IN,O
their,PRP$,O
blood,NN,O
sugar,NN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
new,JJ,O
cases,NNS,O
of,IN,O
diabetes,NNS,O
have,VBP,O
been,VBN,O
diagnosed,VBN,O
during,IN,O
accutane,NN,B
therapy,NN,O
",",",",O
although,IN,O
no,DT,O
causal,JJ,O
relationship,NN,O
has,VBZ,O
been,VBN,O
establishe,NN,O
.,.,.
,,
cpk,NNP,O
:,:,O
some,DT,O
patients,NNS,O
undergoing,VBG,O
vigorous,JJ,O
physical,JJ,O
activity,NN,O
while,IN,O
on,IN,O
accutane,NN,B
therapy,NN,O
have,VBP,O
experienced,VBN,O
elevated,JJ,O
cpk,NN,O
levels,NNS,O
.,.,.
,,
however,RB,O
",",",",O
the,DT,O
clinical,JJ,O
significance,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
rare,JJ,O
postmarketing,VBG,O
reports,NNS,O
of,IN,O
rhabdomyolysis,NN,O
",",",",O
some,DT,O
associated,VBN,O
with,IN,O
strenuous,JJ,O
physical,JJ,O
activity,NN,O
.,.,.
,,
in,IN,O
a,DT,O
clinical,JJ,O
trial,NN,O
of,IN,O
217,CD,O
pediatric,JJ,O
patients,NNS,O
-lrb-,-LRB-,O
12,CD,O
to,TO,O
17,CD,O
years,NNS,O
-rrb-,-RRB-,O
with,IN,O
severe,JJ,O
recalcitrant,JJ,O
nodular,JJ,O
acne,NN,O
",",",",O
transient,JJ,O
elevations,NNS,O
in,IN,O
cpk,NNP,O
were,VBD,O
observed,VBN,O
in,IN,O
12,CD,O
%,NN,O
of,IN,O
patients,NNS,O
",",",",O
including,VBG,O
those,DT,O
undergoing,VBG,O
strenuous,JJ,O
physical,JJ,O
activity,NN,O
in,IN,O
association,NN,O
with,IN,O
reported,VBN,O
musculoskeletal,JJ,O
adverse,JJ,O
events,NNS,O
such,JJ,O
as,IN,O
back,RB,O
pain,NN,O
",",",",O
arthralgia,NN,O
",",",",O
limb,NN,O
injury,NN,O
",",",",O
or,CC,O
muscle,NN,O
sprain,NN,O
.,.,.
,,
in,IN,O
these,DT,O
patients,NNS,O
",",",",O
approximately,RB,O
half,NN,O
of,IN,O
the,DT,O
cpk,NN,O
elevations,NNS,O
returned,VBD,O
to,TO,O
normal,JJ,O
within,IN,O
2,CD,O
weeks,NNS,O
and,CC,O
half,NN,O
returned,VBD,O
to,TO,O
normal,JJ,O
within,IN,O
4,CD,O
weeks,NNS,O
.,.,.
,,
no,DT,O
cases,NNS,O
of,IN,O
rhabdomyolysis,NN,O
were,VBD,O
reported,VBN,O
in,IN,O
this,DT,O
trial,NN,O
.,.,.
,,
nitroglycerin,NNP,D
:,:,O
dynacirc,NNP,B
-lrb-,-LRB-,O
isradipine,NN,D
-rrb-,-RRB-,O
has,VBZ,O
been,VBN,O
safely,RB,O
coadministered,VBN,O
with,IN,O
nitroglycerin,NN,D
.,.,.
,,
hydrochlorothiazide,NN,D
:,:,O
a,DT,O
study,NN,O
in,IN,O
normal,JJ,O
healthy,JJ,O
volunteers,NNS,O
has,VBZ,O
shown,VBN,O
that,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
dynacirc,NNP,B
-lrb-,-LRB-,O
isradipine,NN,D
-rrb-,-RRB-,O
and,CC,O
hydrochlorothiazide,NN,D
does,VBZ,O
not,RB,O
result,VB,O
in,IN,O
altered,JJ,O
pharmacoktnetics,NNS,O
of,IN,O
either,CC,O
drug,NN,D
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
in,IN,O
hypertensive,JJ,O
patients,NNS,O
",",",",O
addition,NN,O
of,IN,O
isradipine,NN,D
to,TO,O
existing,VBG,O
hydrochlorothiazide,NN,D
therapy,NN,O
did,VBD,O
not,RB,O
result,VB,O
in,IN,O
any,DT,O
unexpected,JJ,O
adverse,JJ,O
effects,NNS,O
",",",",O
and,CC,O
isradipine,NN,D
had,VBD,O
an,DT,O
additional,JJ,O
antihypertensive,JJ,G
effect,NN,O
.,.,.
,,
propranolol,NN,D
:,:,O
in,IN,O
a,DT,O
single,JJ,O
dose,NN,O
study,NN,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
",",",",O
coadministration,NN,O
of,IN,O
propranolol,NN,D
had,VBD,O
a,DT,O
small,JJ,O
effect,NN,O
on,IN,O
the,DT,O
rate,NN,O
but,CC,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
extent,NN,O
of,IN,O
isradipine,NN,D
bioavailability,NN,O
.,.,.
,,
significant,JJ,O
increases,NNS,O
in,IN,O
auc,NN,O
-lrb-,-LRB-,O
27,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
cmax,NN,O
-lrb-,-LRB-,O
58,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
decreases,VBZ,O
in,IN,O
tmax,NN,O
-lrb-,-LRB-,O
23,CD,O
%,NN,O
-rrb-,-RRB-,O
of,IN,O
propranolol,NN,D
were,VBD,O
noted,VBN,O
in,IN,O
this,DT,O
study,NN,O
.,.,.
,,
however,RB,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
5,CD,O
mg,NN,O
b.i.d.,NN,O
isradipine,NN,D
and,CC,O
40,CD,O
mg,NN,O
b.i.d.,NN,O
propranolol,NN,D
to,TO,O
healthy,JJ,O
volunteers,NNS,O
under,IN,O
steady-state,JJ,O
conditions,NNS,O
had,VBD,O
no,DT,O
relevant,JJ,O
effect,NN,O
on,IN,O
either,CC,O
drug,NN,D
s,NNS,O
bioavailability,NN,O
",",",",O
auc,NN,O
and,CC,O
cmax,NN,O
",",",",O
differences,NNS,O
were,VBD,O
20,CD,O
%,NN,O
between,IN,O
isradipine,NN,D
given,VBN,O
singly,RB,O
and,CC,O
in,IN,O
combination,NN,O
with,IN,O
propranolol,NN,D
",",",",O
and,CC,O
between,IN,O
propranolol,NN,D
given,VBN,O
singly,RB,O
and,CC,O
in,IN,O
combination,NN,O
with,IN,O
isradipine,NN,D
.,.,.
,,
cimetidine,NNP,D
:,:,O
in,IN,O
a,DT,O
study,NN,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
a,DT,O
one-week,JJ,O
course,NN,O
of,IN,O
cimetidine,NN,D
at,IN,O
400,CD,O
mg,NN,O
b.i.d.,NN,O
with,IN,O
a,DT,O
single,JJ,O
5,CD,O
mg,NN,O
dose,NN,O
of,IN,O
isradipine,NN,D
on,IN,O
the,DT,O
sixth,JJ,O
day,NN,O
showed,VBD,O
an,DT,O
increase,NN,O
in,IN,O
isradipine,NN,D
mean,NN,O
peak,JJ,O
plasma,NN,O
concentrations,NNS,O
-lrb-,-LRB-,O
36,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
significant,JJ,O
increase,NN,O
in,IN,O
area,NN,O
under,IN,O
the,DT,O
curve,NN,O
-lrb-,-LRB-,O
50,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
if,IN,O
isradipine,NN,D
therapy,NN,O
is,VBZ,O
initiated,VBN,O
in,IN,O
a,DT,O
patient,NN,O
currently,RB,O
receiving,VBG,O
cimetidine,NN,D
careful,JJ,O
monitoring,NN,O
for,IN,O
adverse,JJ,O
reactions,NNS,O
is,VBZ,O
advised,VBN,O
and,CC,O
downward,JJ,O
dose,NN,O
adjustment,NN,O
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
rifampicin,NNP,D
:,:,O
in,IN,O
a,DT,O
study,NN,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
a,DT,O
six-day,JJ,O
course,NN,O
of,IN,O
rifampicin,NN,D
at,IN,O
600,CD,O
mg/day,NN,O
followed,VBN,O
by,IN,O
a,DT,O
single,JJ,O
5,CD,O
mg,NN,O
dose,NN,O
of,IN,O
isradipine,NN,D
resulted,VBD,O
in,IN,O
a,DT,O
reduction,NN,O
in,IN,O
isradipine,NN,D
levels,NNS,O
to,TO,O
below,IN,O
detectable,JJ,O
limits,NNS,O
.,.,.
,,
if,IN,O
rifampicin,NN,D
therapy,NN,O
is,VBZ,O
required,VBN,O
",",",",O
isradipine,NN,D
concentrations,NNS,O
and,CC,O
therapeutic,JJ,O
effects,NNS,O
are,VBP,O
likely,JJ,O
to,TO,O
be,VB,O
markedly,RB,O
reduced,VBN,O
or,CC,O
abolished,VBN,O
as,IN,O
a,DT,O
consequence,NN,O
of,IN,O
increased,VBN,O
metabolism,NN,O
and,CC,O
higher,JJR,O
clearance,NN,O
of,IN,O
isradipine,NN,D
.,.,.
,,
warfarin,NNP,D
:,:,O
in,IN,O
a,DT,O
study,NN,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
no,DT,O
clinically,RB,O
relevant,JJ,O
pharmacokinetic,JJ,O
or,CC,O
pharmacodynamic,JJ,O
interaction,NN,O
between,IN,O
isradipine,NN,D
and,CC,O
racemic,JJ,O
warfarin,NN,D
was,VBD,O
seen,VBN,O
when,WRB,O
two,CD,O
single,JJ,O
oral,JJ,O
doses,NNS,O
of,IN,O
warfarin,NN,D
-lrb-,-LRB-,O
0.7,CD,O
mg/kg,NN,O
body,NN,O
weight,NN,O
-rrb-,-RRB-,O
were,VBD,O
administered,VBN,O
during,IN,O
11,CD,O
days,NNS,O
of,IN,O
multipledose,JJ,O
treatment,NN,O
with,IN,O
5,CD,O
mg,NN,O
b.i.d.,NN,O
isradipine,NN,D
.,.,.
,,
neither,DT,O
racemic,JJ,O
warfarin,NN,D
nor,CC,O
isradipine,NN,D
binding,NN,O
to,TO,O
plasma,NN,O
proteins,NNS,O
in,FW,O
vitro,FW,O
was,VBD,O
altered,VBN,O
by,IN,O
the,DT,O
addition,NN,O
of,IN,O
the,DT,O
other,JJ,O
drug,NN,D
.,.,.
,,
digoxin,NNP,D
:,:,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
dynacirc,NNP,B
-lrb-,-LRB-,O
isradipine,NN,D
-rrb-,-RRB-,O
and,CC,O
digoxin,NN,D
in,IN,O
a,DT,O
single-dose,JJ,O
pharmacokinetic,JJ,O
study,NN,O
did,VBD,O
not,RB,O
affect,VB,O
renal,JJ,O
",",",",O
nonrenal,JJ,O
and,CC,O
total,JJ,O
body,NN,O
clearance,NN,O
of,IN,O
digoxin,NN,D
.,.,.
,,
fentanyl,NNP,D
anesthesia,NNP,O
:,:,O
severe,JJ,O
hypotension,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
during,IN,O
fentanyl,NN,D
anesthesia,NN,D
with,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
a,DT,O
beta,NN,O
blocker,NN,O
and,CC,O
a,DT,O
calcium,NN,D
channel,NN,O
blocker,NN,O
.,.,.
,,
even,RB,O
though,IN,O
such,JJ,O
interactions,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
seen,VBN,O
in,IN,O
clinical,JJ,O
studies,NNS,O
with,IN,O
dynacirc,NN,B
-lrb-,-LRB-,O
isradipine,NN,D
-rrb-,-RRB-,O
",",",",O
an,DT,O
increased,VBN,O
volume,NN,O
of,IN,O
circulating,VBG,O
fluids,NNS,O
might,MD,O
be,VB,O
required,VBN,O
if,IN,O
such,PDT,O
an,DT,O
interaction,NN,O
were,VBD,O
to,TO,O
occur,VB,O
.,.,.
,,
both,DT,O
itraconazole,NN,D
and,CC,O
its,PRP$,O
major,JJ,O
metabolite,NN,O
",",",",O
hydroxyitraconazole,NN,D_n
",",",",O
are,VBP,O
inhibitors,NNS,O
of,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
enzyme,NN,O
system,NN,O
.,.,.
,,
coadministration,NNP,O
of,IN,O
itraconazole,NNP,D
and,CC,O
drugs,NNS,D
primarily,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
enzyme,NN,O
system,NN,O
may,MD,O
result,VB,O
in,IN,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
the,DT,O
drugs,NNS,D
that,WDT,O
could,MD,O
increase,VB,O
or,CC,O
prolong,VB,O
both,DT,O
therapeutic,JJ,O
and,CC,O
adverse,JJ,O
effects,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
unless,IN,O
otherwise,RB,O
specified,VBN,O
",",",",O
appropriate,JJ,O
dosage,NN,O
adjustments,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
coadministration,NN,O
of,IN,O
terfenadine,NN,D
with,IN,O
itraconazole,NNP,D
has,VBZ,O
led,VBN,O
to,TO,O
elevated,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
terfenadine,NN,D
",",",",O
resulting,VBG,O
in,IN,O
rare,JJ,O
instances,NNS,O
of,IN,O
life,NN,O
-,:,O
threatening,VBG,O
cardiac,JJ,O
dysrhythmias,NNS,O
and,CC,O
one,CD,O
death,NN,O
.,.,.
,,
another,DT,O
oral,JJ,O
azole,NN,O
antifungal,JJ,O
",",",",O
ketoconazole,NN,D
",",",",O
inhibits,VBZ,O
the,DT,O
metabolism,NN,O
of,IN,O
astemizole,NN,D
",",",",O
resulting,VBG,O
in,IN,O
elevated,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
astemizole,NN,D
and,CC,O
its,PRP$,O
active,JJ,O
metabolite,NN,O
desmethylastermizole,NN,D_n
which,WDT,O
may,MD,O
prolong,VB,O
qt,NNP,O
intervals,NNS,O
.,.,.
,,
in,FW,O
vitro,FW,O
data,NNS,O
suggest,VBP,O
that,IN,O
itraconazole,NN,D
",",",",O
when,WRB,O
compared,VBN,O
to,TO,O
ketoconazole,NN,D
",",",",O
has,VBZ,O
a,DT,O
less,RBR,O
pronounced,JJ,O
effect,NN,O
on,IN,O
the,DT,O
biotransformation,NN,O
system,NN,O
responsible,JJ,O
for,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
astemizole,NN,D
.,.,.
,,
based,VBN,O
on,IN,O
the,DT,O
chemical,NN,O
resemblance,NN,O
of,IN,O
itraconazole,NN,D
and,CC,O
ketoconazole,NN,D
",",",",O
coadministration,NN,O
of,IN,O
astemizole,NN,D
with,IN,O
itraconazole,NN,D
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
human,JJ,O
pharmacokinetics,NNS,O
data,NNS,O
indicate,VBP,O
that,IN,O
oral,JJ,O
ketoconazole,NN,D
potently,RB,O
inhibits,VBZ,O
the,DT,O
metabolism,NN,O
of,IN,O
cisapride,NN,D
resulting,VBG,O
in,IN,O
an,DT,O
eight-fold,JJ,O
increase,NN,O
in,IN,O
the,DT,O
mean,NN,O
auc,NN,O
of,IN,O
cisapride,NN,D
.,.,.
,,
data,NNS,O
suggest,VBP,O
that,IN,O
coadministration,NN,O
of,IN,O
oral,JJ,O
ketoconazole,NN,D
and,CC,O
cisapride,NN,D
can,MD,O
result,VB,O
in,IN,O
prolongation,NN,O
of,IN,O
the,DT,O
qt,NNP,O
interval,NN,O
on,IN,O
the,DT,O
ecg,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
data,NNS,O
suggest,VBP,O
that,IN,O
itraconazole,NN,D
also,RB,O
markedly,RB,O
inhibits,VBZ,O
the,DT,O
biotransformation,NN,O
system,NN,O
mainly,RB,O
responsible,JJ,O
for,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
cisapride,NN,D
.,.,.
,,
therefore,RB,O
concomitant,JJ,O
administration,NN,O
of,IN,O
itraconazole,NN,D
with,IN,O
cisapride,NN,D
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
coadministration,NNP,O
of,IN,O
itraconazole,NNP,D
with,IN,O
oral,JJ,O
midazolam,NN,D
or,CC,O
triazolam,NN,D
has,VBZ,O
resulted,VBN,O
in,IN,O
elevated,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
the,DT,O
latter,JJ,O
two,CD,O
drugs,NNS,D
.,.,.
,,
this,DT,O
may,MD,O
potentiate,VB,O
and,CC,O
prolong,VB,O
hypnotic,JJ,G
and,CC,O
sedative,JJ,G
effects,NNS,O
.,.,.
,,
these,DT,O
agents,NNS,O
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
in,IN,O
patients,NNS,O
treated,VBN,O
with,IN,O
itraconazole,NN,D
.,.,.
,,
if,IN,O
midazolam,NN,D
is,VBZ,O
administered,VBN,O
parenterally,RB,O
",",",",O
special,JJ,O
precaution,NN,O
is,VBZ,O
required,VBN,O
since,IN,O
the,DT,O
sedative,JJ,G
effect,NN,O
may,MD,O
be,VB,O
prolonged,VBN,O
.,.,.
,,
coadministration,NNP,O
of,IN,O
itraconazole,NNP,D
and,CC,O
cyclosporine,NN,D
",",",",O
tacrolimus,NN,D
or,CC,O
digoxin,NN,D
has,VBZ,O
led,VBN,O
to,TO,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
the,DT,O
latter,JJ,O
three,CD,O
drugs,NNS,D
.,.,.
,,
cyclosporine,NN,D
",",",",O
tacrolimus,NN,D
and,CC,O
digoxin,NN,D
concentrations,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
at,IN,O
the,DT,O
initiation,NN,O
of,IN,O
itraconazole,NN,D
therapy,NN,O
and,CC,O
frequently,RB,O
thereafter,RB,O
",",",",O
and,CC,O
the,DT,O
dose,NN,O
of,IN,O
these,DT,O
three,CD,O
drug,NN,D
products,NNS,O
adjusted,VBN,O
appropriately,RB,O
.,.,.
,,
rhabdomyolysis,NNP,O
has,VBZ,O
been,VBN,O
observed,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
administered,VBN,O
alone,RB,O
-lrb-,-LRB-,O
at,IN,O
recommended,VBN,O
dosages,NNS,O
-rrb-,-RRB-,O
or,CC,O
concomitantly,RB,O
with,IN,O
immunosuppressive,JJ,G
drugs,NNS,D
including,VBG,O
cyclosporine,NN,D
.,.,.
,,
when,WRB,O
itraconazole,NNP,D
was,VBD,O
coadministered,VBN,O
with,IN,O
phenytoin,NN,D
",",",",O
rifampin,NN,D
",",",",O
or,CC,O
h2antagonists,NNS,O
",",",",O
reduced,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
itraconazole,NN,D
were,VBD,O
reported,VBN,O
.,.,.
,,
the,DT,O
physician,NN,O
is,VBZ,O
advised,VBN,O
to,TO,O
monitor,VB,O
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
itraconazole,NN,D
when,WRB,O
any,DT,O
of,IN,O
these,DT,O
drugs,NNS,D
is,VBZ,O
taken,VBN,O
concurrently,RB,O
",",",",O
and,CC,O
to,TO,O
increase,VB,O
the,DT,O
dose,NN,O
of,IN,O
itraconazole,NNP,D
if,IN,O
necessary,JJ,O
.,.,.
,,
although,IN,O
no,DT,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
itraconazole,NNP,D
and,CC,O
phenytoin,NN,D
may,MD,O
alter,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
phenytoin,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
plasma,NN,O
concentrations,NNS,O
of,IN,O
phenytoin,NN,D
should,MD,O
also,RB,O
be,VB,O
monitored,VBN,O
when,WRB,O
it,PRP,O
is,VBZ,O
given,VBN,O
concurrently,RB,O
with,IN,O
itraconazole,NNP,D
.,.,.
,,
it,PRP,O
has,VBZ,O
been,VBN,O
reported,VBN,O
that,IN,O
itraconazole,NNP,D
enhances,VBZ,O
the,DT,O
anticoagulant,JJ,G
effect,NN,O
of,IN,O
coumarin-like,JJ,O
drugs,NNS,D
.,.,.
,,
therefore,RB,O
",",",",O
prothrombin,NN,O
time,NN,O
should,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
itraconazole,NNP,D
and,CC,O
coumarin-like,JJ,O
drugs,NNS,D
simultaneously,RB,O
.,.,.
,,
plasma,NN,O
concentrations,NNS,O
of,IN,O
azole,JJ,O
antifungal,JJ,O
agents,NNS,O
are,VBP,O
reduced,VBN,O
when,WRB,O
given,VBN,O
concurrently,RB,O
with,IN,O
isoniazid,NN,D
.,.,.
,,
itraconazole,NNP,D
plasma,NN,O
concentrations,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
when,WRB,O
itraconazole,NNP,D
and,CC,O
isoniazid,NN,D
are,VBP,O
coadministered,VBN,O
.,.,.
,,
severe,JJ,O
hypoglycemia,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
concomitantly,RB,O
receiving,VBG,O
azole,JJ,O
antifungal,JJ,O
agents,NNS,O
and,CC,O
oral,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
.,.,.
,,
blood,NN,O
glucose,NN,O
concentrations,NNS,O
should,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
when,WRB,O
itraconazole,NNP,D
and,CC,O
oral,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
are,VBP,O
coadministered,VBN,O
.,.,.
,,
tinnitus,NNP,O
and,CC,O
decreased,VBD,O
hearing,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
concomitantly,RB,O
receiving,VBG,O
itraconazole,NNP,D
and,CC,O
quinidine,NN,D
.,.,.
,,
edema,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
concomitantly,RB,O
receiving,VBG,O
itraconazole,NNP,D
and,CC,O
dihydropyridine,NN,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
.,.,.
,,
appropriate,JJ,O
dosage,NN,O
adjustments,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
the,DT,O
results,NNS,O
from,IN,O
a,DT,O
study,NN,O
in,IN,O
which,WDT,O
eight,CD,O
hiv-infected,JJ,O
individuals,NNS,O
were,VBD,O
treated,VBN,O
with,IN,O
zidovudine,NN,D
",",",",O
8,CD,O
+,CC,O
/,:,O
-,:,O
0.4,CD,O
mg/kg/day,NN,O
",",",",O
showed,VBD,O
that,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
zidovudine,NN,D
were,VBD,O
not,RB,O
affected,VBN,O
during,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
itraconazole,NNP,D
",",",",O
100,CD,O
mg,NN,O
b.i.d.,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
mixing,VBG,O
of,IN,O
an,DT,O
aminoglycoside,NN,G
with,IN,O
beta-lactamtype,JJ,O
antibiotics,NNS,G
-lrb-,-LRB-,O
penicillins,NNS,D
or,CC,O
cephalosporins,NNS,G
-rrb-,-RRB-,O
may,MD,O
result,VB,O
in,IN,O
a,DT,O
significant,JJ,O
mutual,JJ,O
inactivation,NN,O
.,.,.
,,
even,RB,O
when,WRB,O
an,DT,O
aminoglycoside,NN,G
and,CC,O
a,DT,O
penicillin-type,JJ,O
drug,NN,D
are,VBP,O
administered,VBN,O
separately,RB,O
by,IN,O
different,JJ,O
routes,NNS,O
",",",",O
a,DT,O
reduction,NN,O
in,IN,O
aminoglycoside,NN,G
serum,NN,O
half-life,NN,O
or,CC,O
serum,NN,O
levels,NNS,O
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
impaired,JJ,O
renal,JJ,O
function,NN,O
and,CC,O
in,IN,O
some,DT,O
patients,NNS,O
with,IN,O
normal,JJ,O
renal,JJ,O
function,NN,O
.,.,.
,,
usually,RB,O
",",",",O
such,JJ,O
inactivation,NN,O
of,IN,O
the,DT,O
aminoglycoside,NN,G
is,VBZ,O
clinically,RB,O
significant,JJ,O
only,RB,O
in,IN,O
patients,NNS,O
with,IN,O
severely,RB,O
impaired,JJ,O
renal,JJ,O
function,NN,O
.,.,.
,,
see,VB,O
.,.,.
,,
prolonged,JJ,O
recovery,NN,O
time,NN,O
may,MD,O
occur,VB,O
if,IN,O
barbiturates,NNS,G
and/or,CC,O
narcotics,NNS,G
are,VBP,O
used,VBN,O
concurrently,RB,O
with,IN,O
ketamine,NN,D
.,.,.
,,
ketamine,NNP,D
is,VBZ,O
clinically,RB,O
compatible,JJ,O
with,IN,O
the,DT,O
commonly,RB,O
used,VBN,O
general,JJ,O
and,CC,O
local,JJ,O
anesthetic,JJ,G
agents,NNS,O
when,WRB,O
an,DT,O
adequate,JJ,O
respiratory,JJ,O
exchange,NN,O
is,VBZ,O
maintained,VBN,O
.,.,.
,,
ketoconazole,NN,D
is,VBZ,O
a,DT,O
potent,JJ,O
inhibitor,NN,O
of,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
enzyme,NN,O
system,NN,O
.,.,.
,,
coadministration,NN,O
of,IN,O
nizoral,NNP,B
tablets,NNPS,O
and,CC,O
drugs,NNS,D
primarily,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
enzyme,NN,O
system,NN,O
may,MD,O
result,VB,O
in,IN,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
the,DT,O
drugs,NNS,D
that,WDT,O
could,MD,O
increase,VB,O
or,CC,O
prolong,VB,O
both,DT,O
therapeutic,JJ,O
and,CC,O
adverse,JJ,O
effects,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
unless,IN,O
otherwise,RB,O
specified,VBN,O
",",",",O
appropriate,JJ,O
dosage,NN,O
adjustments,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
the,DT,O
following,VBG,O
drug,NN,D
interactions,NNS,O
have,VBP,O
been,VBN,O
identified,VBN,O
involving,VBG,O
nizoral,NNP,B
tablets,NNPS,O
and,CC,O
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
enzyme,NN,O
system,NN,O
:,:,O
ketoconazole,NNP,D
tablets,NNS,O
inhibit,VBP,O
the,DT,O
metabolism,NN,O
of,IN,O
terfenadine,NN,D
",",",",O
resulting,VBG,O
in,IN,O
an,DT,O
increased,VBN,O
plasma,NN,O
concentration,NN,O
of,IN,O
terfenadine,NN,D
and,CC,O
a,DT,O
delay,NN,O
in,IN,O
the,DT,O
elimination,NN,O
of,IN,O
its,PRP$,O
acid,NN,O
metabolite,NN,O
.,.,.
,,
the,DT,O
increased,VBN,O
plasma,NN,O
concentration,NN,O
of,IN,O
terfenadine,NN,D
or,CC,O
its,PRP$,O
metabolite,NN,O
may,MD,O
result,VB,O
in,IN,O
prolonged,JJ,O
qt,NN,O
intervals,NNS,O
.,.,.
,,
pharmacokinetic,JJ,O
data,NNS,O
indicate,VBP,O
that,IN,O
oral,JJ,O
ketoconazole,NN,D
inhibits,VBZ,O
the,DT,O
metabolism,NN,O
of,IN,O
astemizole,NN,D
",",",",O
resulting,VBG,O
in,IN,O
elevated,JJ,O
plasma,NN,O
levels,NNS,O
of,IN,O
astemizole,NN,D
and,CC,O
its,PRP$,O
active,JJ,O
metabolite,NN,O
desmethylastemizole,NN,D_n
which,WDT,O
may,MD,O
prolong,VB,O
qt,NNP,O
intervals,NNS,O
.,.,.
,,
coadministration,NN,O
of,IN,O
astemizole,NN,D
with,IN,O
ketoconazole,NN,D
tablets,NNS,O
is,VBZ,O
therefore,RB,O
contraindicated,VBN,O
.,.,.
,,
human,JJ,O
pharmacokinetics,NNS,O
data,NNS,O
indicate,VBP,O
that,IN,O
oral,JJ,O
ketoconazole,NN,D
potently,RB,O
inhibits,VBZ,O
the,DT,O
metabolism,NN,O
of,IN,O
cisapride,NN,D
resulting,VBG,O
in,IN,O
a,DT,O
mean,NN,O
eight-fold,JJ,O
increase,NN,O
in,IN,O
auc,NN,O
of,IN,O
cisapride,NN,D
.,.,.
,,
data,NNS,O
suggest,VBP,O
that,IN,O
coadministration,NN,O
of,IN,O
oral,JJ,O
ketoconazole,NN,D
and,CC,O
cisapride,NN,D
can,MD,O
result,VB,O
in,IN,O
prolongation,NN,O
of,IN,O
the,DT,O
qt,NNP,O
interval,NN,O
on,IN,O
the,DT,O
ecg,NN,O
.,.,.
,,
therefore,RB,O
concomitant,JJ,O
administration,NN,O
of,IN,O
ketoconazole,NN,D
tablets,NNS,O
with,IN,O
cisapride,NN,D
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
ketoconazole,NN,D
tablets,NNS,O
may,MD,O
alter,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
cyclosporine,NN,D
",",",",O
tacrolimus,NN,D
",",",",O
and,CC,O
methylprednisolone,NN,D
",",",",O
resulting,VBG,O
in,IN,O
elevated,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
the,DT,O
latter,JJ,O
drugs,NNS,D
.,.,.
,,
dosage,NN,O
adjustment,NN,O
may,MD,O
be,VB,O
required,VBN,O
if,IN,O
cyclosporine,NN,D
",",",",O
tacrolimus,NN,D
",",",",O
or,CC,O
methylprednisolone,NN,D
are,VBP,O
given,VBN,O
concomitantly,RB,O
with,IN,O
nizoral,NNP,B
tablets,NNPS,O
.,.,.
,,
coadministration,NN,O
of,IN,O
nizoral,NNP,B
tablets,NNPS,O
with,IN,O
midazolam,NN,D
or,CC,O
triazolam,NN,D
has,VBZ,O
resulted,VBN,O
in,IN,O
elevated,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
the,DT,O
latter,JJ,O
two,CD,O
drugs,NNS,D
.,.,.
,,
this,DT,O
may,MD,O
potentiate,VB,O
and,CC,O
prolong,VB,O
hypnotic,JJ,G
and,CC,O
sedative,JJ,G
effects,NNS,O
",",",",O
especially,RB,O
with,IN,O
repeated,VBN,O
dosing,NN,O
or,CC,O
chronic,JJ,O
administration,NN,O
of,IN,O
these,DT,O
agents,NNS,O
.,.,.
,,
these,DT,O
agents,NNS,O
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
in,IN,O
patients,NNS,O
treated,VBN,O
with,IN,O
nizoral,NNP,B
tablets,NNPS,O
.,.,.
,,
if,IN,O
midazolam,NN,D
is,VBZ,O
administered,VBN,O
parenterally,RB,O
",",",",O
special,JJ,O
precaution,NN,O
is,VBZ,O
required,VBN,O
since,IN,O
the,DT,O
sedative,JJ,G
effect,NN,O
may,MD,O
be,VB,O
prolonged,VBN,O
.,.,.
,,
rare,JJ,O
cases,NNS,O
of,IN,O
elevated,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
digoxin,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
not,RB,O
clear,JJ,O
whether,IN,O
this,DT,O
was,VBD,O
due,JJ,O
to,TO,O
the,DT,O
combination,NN,O
of,IN,O
therapy,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
",",",",O
therefore,RB,O
",",",",O
advisable,JJ,O
to,TO,O
monitor,VB,O
digoxin,NN,D
concentrations,NNS,O
in,IN,O
patients,NNS,O
receiving,VBG,O
ketoconazole,NN,D
.,.,.
,,
when,WRB,O
taken,VBN,O
orally,RB,O
",",",",O
imidazole,NN,G
compounds,NNS,O
like,IN,O
ketoconazole,NN,D
may,MD,O
enhance,VB,O
the,DT,O
anticoagulant,JJ,G
effect,NN,O
of,IN,O
coumarin-like,JJ,O
drugs,NNS,D
.,.,.
,,
in,IN,O
simultaneous,JJ,O
treatment,NN,O
with,IN,O
imidazole,NN,G
drugs,NNS,D
and,CC,O
coumarin,NN,G
drugs,NNS,D
",",",",O
the,DT,O
anticoagulant,JJ,G
effect,NN,O
should,MD,O
be,VB,O
carefully,RB,O
titrated,VBN,O
and,CC,O
monitored,VBN,O
.,.,.
,,
because,IN,O
severe,JJ,O
hypoglycemia,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
concomitantly,RB,O
receiving,VBG,O
oral,JJ,O
miconazole,NN,D
-lrb-,-LRB-,O
an,DT,O
imidazole,NN,G
-rrb-,-RRB-,O
and,CC,O
oral,JJ,O
hypoglycemic,JJ,G
agents,NNS,O
",",",",O
such,PDT,O
a,DT,O
potential,JJ,O
interaction,NN,O
involving,VBG,O
the,DT,O
latter,JJ,O
agents,NNS,O
when,WRB,O
used,VBN,O
concomitantly,RB,O
with,IN,O
ketoconazole,NN,D
tablets,NNS,O
-lrb-,-LRB-,O
an,DT,O
imidazole,NN,G
-rrb-,-RRB-,O
can,MD,O
not,RB,O
be,VB,O
ruled,VBN,O
out,RP,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
ketoconazole,NN,D
tablets,NNS,O
with,IN,O
phenytoin,NN,D
may,MD,O
alter,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
one,CD,O
or,CC,O
both,DT,O
of,IN,O
the,DT,O
drugs,NNS,D
.,.,.
,,
it,PRP,O
is,VBZ,O
suggested,VBN,O
to,TO,O
monitor,VB,O
both,CC,O
ketoconazole,NN,D
and,CC,O
phenytoin,NN,D
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
rifampin,NN,D
with,IN,O
ketoconazole,NN,D
tablets,NNS,O
reduces,VBZ,O
the,DT,O
blood,NN,O
levels,NNS,O
of,IN,O
the,DT,O
latter,JJ,O
.,.,.
,,
inh,NN,D
-lrb-,-LRB-,O
isoniazid,NN,D
-rrb-,-RRB-,O
is,VBZ,O
also,RB,O
reported,VBN,O
to,TO,O
affect,VB,O
ketoconazole,NN,D
concentrations,NNS,O
adversely,RB,O
.,.,.
,,
these,DT,O
drugs,NNS,D
should,MD,O
not,RB,O
be,VB,O
given,VBN,O
concomitantly,RB,O
.,.,.
,,
after,IN,O
the,DT,O
coadministration,NN,O
of,IN,O
200,CD,O
mg,NN,O
oral,JJ,O
ketoconazole,NN,D
twice,RB,O
daily,RB,O
and,CC,O
one,CD,O
20,CD,O
mg,NN,O
dose,NN,O
of,IN,O
loratadine,NN,D
to,TO,O
11,CD,O
subjects,NNS,O
",",",",O
the,DT,O
auc,NN,O
and,CC,O
cmax,NN,O
of,IN,O
loratadine,NN,D
averaged,VBD,O
302,CD,O
%,NN,O
-lrb-,-LRB-,O
142,CD,O
s.d.,NN,O
-rrb-,-RRB-,O
and,CC,O
251,CD,O
%,NN,O
-lrb-,-LRB-,O
68,CD,O
s.d.,NN,O
-rrb-,-RRB-,O
",",",",O
respectively,RB,O
",",",",O
of,IN,O
those,DT,O
obtained,VBN,O
after,IN,O
co-treatment,NN,O
with,IN,O
placebo,NN,O
.,.,.
,,
the,DT,O
auc,NN,O
and,CC,O
cmax,NN,O
of,IN,O
descarboethoxyloratadine,NN,D
",",",",O
an,DT,O
active,JJ,O
metabolite,NN,O
",",",",O
averaged,VBD,O
155,CD,O
%,NN,O
-lrb-,-LRB-,O
27,CD,O
s.d.,NN,O
-rrb-,-RRB-,O
and,CC,O
141,CD,O
%,NN,O
-lrb-,-LRB-,O
35,CD,O
s.d.,NN,O
-rrb-,-RRB-,O
",",",",O
respectively,RB,O
.,.,.
,,
however,RB,O
",",",",O
no,DT,O
related,JJ,O
changes,NNS,O
were,VBD,O
noted,VBN,O
in,IN,O
the,DT,O
qt0,NN,O
on,IN,O
ecg,NN,O
taken,VBN,O
at,IN,O
2,CD,O
",",",",O
6,CD,O
",",",",O
and,CC,O
24,CD,O
hours,NNS,O
after,IN,O
the,DT,O
coadministration,NN,O
.,.,.
,,
also,RB,O
",",",",O
there,EX,O
were,VBD,O
no,DT,O
clinically,RB,O
significant,JJ,O
differences,NNS,O
in,IN,O
adverse,JJ,O
events,NNS,O
when,WRB,O
loratadine,NN,D
was,VBD,O
administered,VBN,O
with,IN,O
or,CC,O
without,IN,O
ketoconazole,NN,D
.,.,.
,,
rare,JJ,O
cases,NNS,O
of,IN,O
a,DT,O
disulfiram-like,JJ,O
reaction,NN,O
to,TO,O
alcohol,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
.,.,.
,,
these,DT,O
experiences,NNS,O
have,VBP,O
been,VBN,O
characterized,VBN,O
by,IN,O
flushing,NN,O
",",",",O
rash,NN,O
",",",",O
peripheral,JJ,O
edema,NN,O
",",",",O
nausea,NN,O
",",",",O
and,CC,O
headache,NN,O
.,.,.
,,
symptoms,NNS,O
resolved,VBN,O
within,IN,O
a,DT,O
few,JJ,O
hours,NNS,O
.,.,.
,,
the,DT,O
following,VBG,O
drug,NN,D
interactions,NNS,O
were,VBD,O
studied,VBN,O
with,IN,O
ketoprofen,NN,D
doses,NNS,O
of,IN,O
200,CD,O
mg/day,NN,O
.,.,.
,,
the,DT,O
possibility,NN,O
of,IN,O
increased,VBN,O
interaction,NN,O
should,MD,O
be,VB,O
kept,VBN,O
in,IN,O
mind,NN,O
when,WRB,O
orudis,NNP,B
doses,NNS,O
greater,JJR,O
than,IN,O
50,CD,O
mg,NN,O
as,IN,O
a,DT,O
single,JJ,O
dose,NN,O
or,CC,O
200,CD,O
mg,NN,O
of,IN,O
ketoprofen,NN,D
per,IN,O
day,NN,O
are,VBP,O
used,VBN,O
concomitantly,RB,O
with,IN,O
highly,RB,O
bound,VBN,O
drugs,NNS,D
.,.,.
,,
1,LS,O
.,.,.
,,
antacids,NNS,G
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
magnesium,NN,D
hydroxide,NN,O
and,CC,O
aluminum,NN,D
hydroxide,NN,O
does,VBZ,O
not,RB,O
interfere,VB,O
with,IN,O
the,DT,O
rate,NN,O
or,CC,O
extent,NN,O
of,IN,O
the,DT,O
absorption,NN,O
of,IN,O
ketoprofen,NN,D
administered,VBN,O
as,IN,O
orudis,NNP,B
.,.,.
,,
2,LS,O
.,.,.
,,
aspirin,NN,B
:,:,O
ketoprofen,NNP,D
does,VBZ,O
not,RB,O
alter,VB,O
aspirin,NN,B
absorption,NN,O
.,.,.
,,
however,RB,O
",",",",O
in,IN,O
a,DT,O
study,NN,O
of,IN,O
12,CD,O
normal,JJ,O
subjects,NNS,O
",",",",O
concurrent,JJ,O
administration,NN,O
of,IN,O
aspirin,NN,B
decreased,VBD,O
ketoprofen,NN,D
protein,NN,O
binding,NN,O
and,CC,O
increased,VBD,O
ketoprofen,NN,D
plasma,NN,O
clearance,NN,O
from,IN,O
0.07,CD,O
l/kg/h,NN,O
without,IN,O
aspirin,NN,B
to,TO,O
0.11,CD,O
l/kg/h,NN,O
with,IN,O
aspirin,NN,B
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
these,DT,O
changes,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
adequately,RB,O
studied,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
concurrent,JJ,O
use,NN,O
of,IN,O
aspirin,NN,B
and,CC,O
ketoprofen,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
3,LS,O
.,.,.
,,
diuretic,JJ,G
:,:,O
hydrochlorothiazide,NN,D
",",",",O
given,VBN,O
concomitantly,RB,O
with,IN,O
ketoprofen,NN,D
",",",",O
produces,VBZ,O
a,DT,O
reduction,NN,O
in,IN,O
urinary,JJ,O
potassium,NN,D
and,CC,O
chloride,NN,O
excretion,NN,O
compared,VBN,O
to,TO,O
hydrochlorothiazide,NN,D
alone,RB,O
.,.,.
,,
patients,NNS,O
taking,VBG,O
diuretics,NNS,G
are,VBP,O
at,IN,O
a,DT,O
greater,JJR,O
risk,NN,O
of,IN,O
developing,VBG,O
renal,JJ,O
failure,NN,O
secondary,JJ,O
to,TO,O
a,DT,O
decrease,NN,O
in,IN,O
renal,JJ,O
blood,NN,O
flow,NN,O
caused,VBN,O
by,IN,O
prostaglandin,NN,O
inhibition,NN,O
.,.,.
,,
4,LS,O
.,.,.
,,
digoxin,NNP,D
:,:,O
in,IN,O
a,DT,O
study,NN,O
in,IN,O
12,CD,O
patients,NNS,O
with,IN,O
congestive,JJ,O
heart,NN,O
failure,NN,O
where,WRB,O
ketoprofen,NN,D
and,CC,O
digoxin,NN,D
were,VBD,O
concomitantly,RB,O
administered,VBN,O
",",",",O
ketoprofen,NN,D
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
serum,NN,O
levels,NNS,O
of,IN,O
digoxin,NN,D
.,.,.
,,
5,CD,O
.,.,.
,,
warfarin,NNP,D
:,:,O
in,IN,O
a,DT,O
short-term,JJ,O
controlled,JJ,O
study,NN,O
in,IN,O
14,CD,O
normal,JJ,O
volunteers,NNS,O
",",",",O
ketoprofen,NN,D
did,VBD,O
not,RB,O
significantly,RB,O
interfere,VB,O
with,IN,O
the,DT,O
effect,NN,O
of,IN,O
warfarin,NN,D
on,IN,O
prothrombin,NN,O
time,NN,O
.,.,.
,,
bleeding,VBG,O
from,IN,O
a,DT,O
number,NN,O
of,IN,O
sites,NNS,O
may,MD,O
be,VB,O
a,DT,O
complication,NN,O
of,IN,O
warfarin,NN,D
treatment,NN,O
and,CC,O
gi,NN,O
bleeding,VBG,O
a,DT,O
complication,NN,O
of,IN,O
ketoprofen,NN,D
treatment,NN,O
.,.,.
,,
because,IN,O
prostaglandina,NNS,O
play,VBP,O
an,DT,O
important,JJ,O
role,NN,O
in,IN,O
hemostasis,NN,O
and,CC,O
ketoprofen,NN,D
has,VBZ,O
an,DT,O
effect,NN,O
on,IN,O
platelet,NN,O
function,NN,O
as,RB,O
well,RB,O
",",",",O
concurent,JJ,O
therapy,NN,O
with,IN,O
ketoprofen,NN,D
and,CC,O
warfarin,NN,D
requires,VBZ,O
close,JJ,O
monitoring,NN,O
of,IN,O
patients,NNS,O
on,IN,O
both,DT,O
drugs,NNS,D
.,.,.
,,
6,CD,O
.,.,.
,,
probenecid,NNP,D
:,:,O
probenecid,NNP,D
increases,VBZ,O
both,DT,O
free,JJ,O
and,CC,O
bound,VBD,O
ketoprofen,NN,D
by,IN,O
reducing,VBG,O
the,DT,O
plasma,NN,O
clearance,NN,O
of,IN,O
ketoprofen,NN,D
to,TO,O
about,IN,O
one-third,NN,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
decreasing,VBG,O
its,PRP$,O
protein,NN,O
binding,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
combination,NN,O
of,IN,O
ketoprofen,NN,D
and,CC,O
probenecid,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
7,CD,O
.,.,.
,,
methotrexate,NNP,D
:,:,O
ketoprofen,NNP,D
",",",",O
like,IN,O
other,JJ,O
nsaids,NNS,G
",",",",O
may,MD,O
cause,VB,O
changes,NNS,O
in,IN,O
the,DT,O
elimination,NN,O
of,IN,O
methotrexate,NN,D
leading,VBG,O
to,TO,O
elevated,JJ,O
serum,NN,O
levels,NNS,O
of,IN,O
the,DT,O
drug,NN,D
and,CC,O
increased,VBD,O
toxicity,NN,O
.,.,.
,,
8,CD,O
.,.,.
,,
lithium,NN,D
:,:,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
increase,VB,O
steadystate,JJ,O
plasma,NN,O
lithium,NN,D
levels,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
plasma,NN,O
lithium,NN,D
levels,NNS,O
be,VB,O
monitored,VBN,O
when,WRB,O
ketoprofen,NN,D
is,VBZ,O
coadministered,VBN,O
with,IN,O
lithium,NN,D
.,.,.
,,
drug/laboratory,NN,O
test,NN,O
interactions,NNS,O
:,:,O
effect,NN,O
on,IN,O
blood,NN,O
coagulation,NN,O
ketoprofen,NN,D
decreases,VBZ,O
platelet,NN,O
adhesion,NN,O
and,CC,O
aggregation,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
it,PRP,O
can,MD,O
prolong,VB,O
bleeding,JJ,O
time,NN,O
by,IN,O
approximately,RB,O
3,CD,O
to,TO,O
4,CD,O
minutes,NNS,O
from,IN,O
baseline,NN,O
values,NNS,O
.,.,.
,,
there,EX,O
is,VBZ,O
no,DT,O
significant,JJ,O
change,NN,O
in,IN,O
platelet,NN,O
count,NN,O
",",",",O
prothrombin,NN,O
time,NN,O
",",",",O
partial,JJ,O
thromboplastin,NN,O
time,NN,O
",",",",O
or,CC,O
thrombin,NN,O
time,NN,O
.,.,.
,,
ketorolac,NNP,D
is,VBZ,O
highly,RB,O
bound,VBN,O
to,TO,O
human,JJ,O
plasma,NN,O
protein,NN,O
-lrb-,-LRB-,O
mean,NN,O
99.2,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
warfarin,NNP,D
",",",",O
digoxin,NNP,D
",",",",O
salicylate,NNP,G
",",",",O
and,CC,O
heparin,NN,D
the,DT,O
in,FW,O
vitro,FW,O
binding,NN,O
of,IN,O
warfarin,NN,D
to,TO,O
plasma,NN,O
proteins,NNS,O
is,VBZ,O
only,RB,O
slightly,RB,O
reduced,VBN,O
by,IN,O
ketorolac,NN,D
tromethamine,NN,O
-lrb-,-LRB-,O
99.5,CD,O
%,NN,O
control,NN,O
vs,CC,O
99.3,CD,O
%,NN,O
-rrb-,-RRB-,O
when,WRB,O
ketorolac,JJ,D
plasma,NN,O
concentrations,NNS,O
reach,VBP,O
5,CD,O
to10,NN,O
m,NN,O
g/ml,NN,O
.,.,.
,,
ketorolac,NNP,D
does,VBZ,O
not,RB,O
alter,VB,O
digoxin,NN,D
protein,NN,O
binding,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
indicate,VBP,O
that,IN,O
",",",",O
at,IN,O
therapeutic,JJ,O
concentrations,NNS,O
of,IN,O
salicylate,NN,G
-lrb-,-LRB-,O
300,CD,O
m,NN,O
g/ml,NN,O
-rrb-,-RRB-,O
",",",",O
the,DT,O
binding,NN,O
of,IN,O
ketorolac,NN,D
was,VBD,O
reduced,VBN,O
from,IN,O
approximately,RB,O
99.2,CD,O
%,NN,O
to,TO,O
97.5,CD,O
%,NN,O
",",",",O
representing,VBG,O
a,DT,O
potential,JJ,O
twofold,JJ,O
increase,NN,O
in,IN,O
unbound,JJ,O
ketorolac,NN,D
plasma,NN,O
levels,NNS,O
.,.,.
,,
therapeutic,JJ,O
concentrations,NNS,O
of,IN,O
digoxin,NN,D
",",",",O
warfarin,NN,D
",",",",O
ibuprofen,NN,D
",",",",O
naproxen,NN,D
",",",",O
piroxicam,NN,D
",",",",O
acetaminophen,NN,D
",",",",O
phenytoin,NN,D
andtolbutamide,NN,O
did,VBD,O
not,RB,O
alter,VB,O
ketorolac,NN,D
tromethamine,NN,O
protein,NN,O
binding,NN,O
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
involving,VBG,O
12,CD,O
adult,JJ,O
volunteers,NNS,O
",",",",O
toradoloral,NN,O
was,VBD,O
coadministered,VBN,O
with,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
25,CD,O
mg,NN,O
warfarin,NN,D
",",",",O
causing,VBG,O
no,DT,O
significant,JJ,O
changes,NNS,O
in,IN,O
pharmacokinetics,NNS,O
or,CC,O
pharmacodynamics,NNS,O
of,IN,O
warfarin,NN,D
.,.,.
,,
in,IN,O
another,DT,O
study,NN,O
",",",",O
toradoliv/im,NN,O
was,VBD,O
given,VBN,O
with,IN,O
two,CD,O
doses,NNS,O
of,IN,O
5000,CD,O
u,NN,O
of,IN,O
heparin,NN,D
to,TO,O
11,CD,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
resulting,VBG,O
in,IN,O
a,DT,O
mean,JJ,O
template,NN,O
bleeding,NN,O
time,NN,O
of,IN,O
6.4,CD,O
minutes,NNS,O
-lrb-,-LRB-,O
3.2,CD,O
to,TO,O
11.4,CD,O
min,NN,O
-rrb-,-RRB-,O
compared,VBN,O
to,TO,O
a,DT,O
mean,NN,O
of,IN,O
6,CD,O
minutes,NNS,O
-lrb-,-LRB-,O
3.4,CD,O
to,TO,O
7.5,CD,O
min,NN,O
-rrb-,-RRB-,O
for,IN,O
heparin,NN,D
alone,RB,O
and,CC,O
5.1,CD,O
minutes,NNS,O
-lrb-,-LRB-,O
3.5,CD,O
to,TO,O
8.5,CD,O
min,NN,O
-rrb-,-RRB-,O
for,IN,O
placebo,NN,O
.,.,.
,,
although,IN,O
these,DT,O
results,NNS,O
do,VBP,O
not,RB,O
indicate,VB,O
a,DT,O
significant,JJ,O
interaction,NN,O
between,IN,O
toradol,NNP,B
and,CC,O
warfarin,NN,D
or,CC,O
heparin,NN,D
",",",",O
the,DT,O
administration,NN,O
of,IN,O
toradol,NN,B
to,TO,O
patients,NNS,O
taking,VBG,O
anticoagulants,NNS,G
should,MD,O
be,VB,O
done,VBN,O
extremely,RB,O
cautiously,RB,O
",",",",O
and,CC,O
patients,NNS,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
.,.,.
,,
furosemide,NNP,D
:,:,O
toradol,NNP,B
iv/im,NNP,O
reduced,VBD,O
the,DT,O
diuretic,JJ,G
response,NN,O
to,TO,O
furosemide,NN,D
in,IN,O
normovolemic,JJ,O
healthy,JJ,O
subjects,NNS,O
by,IN,O
approximately,RB,O
20,CD,O
%,NN,O
-lrb-,-LRB-,O
mean,NN,O
sodium,NN,O
and,CC,O
urinary,JJ,O
output,NN,O
decreased,VBD,O
17,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
probenecid,NNP,D
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
toradol,NNP,B
oral,NNP,O
and,CC,O
probenecid,NN,D
resulted,VBD,O
in,IN,O
decreased,VBN,O
clearance,NN,O
of,IN,O
ketorolac,NN,D
and,CC,O
significant,JJ,O
increases,NNS,O
in,IN,O
ketorolac,JJ,D
plasma,NN,O
levels,NNS,O
-lrb-,-LRB-,O
total,JJ,O
auc,NN,O
increased,VBD,O
approximately,RB,O
threefold,RB,O
from,IN,O
5.4,CD,O
to,TO,O
17.8,CD,O
m,NN,O
g/h/ml,NN,O
-rrb-,-RRB-,O
and,CC,O
terminal,JJ,O
half-life,NN,O
increased,VBD,O
approximately,RB,O
twofold,RB,O
from,IN,O
6.6,CD,O
to,TO,O
15.1,CD,O
hours,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
concomitant,JJ,O
use,NN,O
of,IN,O
toradol,NNP,B
and,CC,O
probenecid,NN,D
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
lithium,NN,D
:,:,O
inhibition,NN,O
of,IN,O
renal,JJ,O
lithium,NN,D
clearance,NN,O
",",",",O
leading,VBG,O
to,TO,O
an,DT,O
increase,NN,O
in,IN,O
plasma,NN,O
lithium,NN,D
concentration,NN,O
",",",",O
has,VBZ,O
been,VBN,O
reported,VBN,O
with,IN,O
some,DT,O
prostaglandin,NN,O
synthesis-inhibiting,JJ,O
drugs,NNS,D
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
toradol,NN,B
on,IN,O
plasma,NN,O
lithium,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
",",",",O
but,CC,O
cases,NNS,O
of,IN,O
increased,VBN,O
lithium,NN,D
plasma,NN,O
levels,NNS,O
during,IN,O
toradol,NN,B
therapy,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
.,.,.
,,
methotrexate,NNP,D
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
methotrexate,NN,D
and,CC,O
some,DT,O
nsaids,NNS,G
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
reduce,VB,O
the,DT,O
clearance,NN,O
of,IN,O
methotrexate,NN,D
",",",",O
enhancing,VBG,O
the,DT,O
toxicity,NN,O
of,IN,O
methotrexate,NN,D
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
toradol,NN,B
on,IN,O
methotrexate,NN,D
clearance,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
nondepolarizing,VBG,O
muscle,NN,O
relaxants,NNS,O
:,:,O
in,IN,O
postmarketing,VBG,O
experience,NN,O
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
a,DT,O
possible,JJ,O
interaction,NN,O
between,IN,O
toradoliv/im,NN,O
and,CC,O
nondepolarizing,JJ,O
muscle,NN,O
relaxants,NNS,O
that,WDT,O
resulted,VBD,O
in,IN,O
apnea,NN,O
.,.,.
,,
the,DT,O
concurrent,JJ,O
use,NN,O
of,IN,O
toradol,NN,B
with,IN,O
muscle,NN,O
relaxants,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
formally,RB,O
studied,VBN,O
.,.,.
,,
ace,NN,O
inhibitors,NNS,O
:,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
ace,NN,O
inhibitors,NNS,O
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
renal,JJ,O
impairment,NN,O
",",",",O
particularly,RB,O
in,IN,O
volume-depleted,JJ,O
patients,NNS,O
.,.,.
,,
antiepileptic,JJ,O
drugs,NNS,O
:,:,O
sporadic,JJ,O
cases,NNS,O
of,IN,O
seizures,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
during,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
toradol,NNP,B
and,CC,O
antiepileptic,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
phenytoin,NN,D
",",",",O
carbamazepine,NN,D
-rrb-,-RRB-,O
.,.,.
,,
psychoactive,JJ,O
drugs,NNS,O
:,:,O
hallucinations,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
when,WRB,O
toradol,NNP,B
was,VBD,O
used,VBN,O
in,IN,O
patients,NNS,O
taking,VBG,O
psychoactive,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
fluoxetine,NN,D
",",",",O
thiothixene,NN,D
",",",",O
alprazolam,NN,D
-rrb-,-RRB-,O
.,.,.
,,
morphine,NNP,D
:,:,O
toradoliv/im,NN,O
has,VBZ,O
been,VBN,O
administered,VBN,O
concurrently,RB,O
with,IN,O
morphine,NN,D
in,IN,O
several,JJ,O
clinical,JJ,O
trials,NNS,O
of,IN,O
postoperative,JJ,O
pain,NN,O
without,IN,O
evidence,NN,O
of,IN,O
adverse,JJ,O
interactions,NNS,O
.,.,.
,,
do,VB,O
not,RB,O
mix,VB,O
toradol,NN,B
and,CC,O
morphine,NN,D
in,IN,O
the,DT,O
same,JJ,O
syringe,NN,O
.,.,.
,,
there,EX,O
is,VBZ,O
no,DT,O
evidence,NN,O
in,IN,O
animal,NN,O
or,CC,O
human,JJ,O
studies,NNS,O
that,WDT,O
toradol,NN,B
induces,VBZ,O
or,CC,O
inhibits,VBZ,O
hepatic,JJ,O
enzymes,NNS,O
capable,JJ,O
of,IN,O
metabolizing,VBG,O
itself,PRP,O
or,CC,O
other,JJ,O
drug,NN,D
.,.,.
,,
cyclosporine,NN,D
-,:,O
l-arginine,NN,D
may,MD,O
counteract,VB,O
the,DT,O
antinaturetic,JJ,O
effect,NN,O
of,IN,O
cyclosporin,NN,D
.,.,.
,,
ibuprofen,NN,D
-,:,O
l-arginine,NN,D
may,MD,O
increase,VB,O
the,DT,O
absorption,NN,O
of,IN,O
ibuprofen,NN,D
if,IN,O
taken,VBN,O
concomitantly,RB,O
.,.,.
,,
organic,NNP,O
nitrates,NNS,G
-,:,O
l-arginine,NN,D
supplements,NNS,O
theoretically,RB,O
may,MD,O
potentiate,VB,O
the,DT,O
effects,NNS,O
of,IN,O
organic,JJ,O
nitrates,NNS,G
if,IN,O
taken,VBN,O
concomitantly,RB,O
.,.,.
,,
sildenafil,NN,D
citrate,NN,O
-,:,O
theoretically,RB,O
",",",",O
l-arginine,JJ,D
supplements,NNS,O
taken,VBN,O
concomitantly,RB,O
with,IN,O
sildenafil,NN,D
citrate,NN,O
",",",",O
may,MD,O
potentiate,VB,O
the,DT,O
effects,NNS,O
of,IN,O
the,DT,O
drug,NN,D
.,.,.
,,
no,DT,O
drug,NN,D
",",",",O
nutritional,JJ,O
supplement,NN,O
",",",",O
food,NN,O
or,CC,O
herb,NN,O
interactions,NNS,O
are,VBP,O
known,VBN,O
.,.,.
,,
interacts,NNS,O
with,IN,O
valproic,JJ,O
aci,NN,O
.,.,.
,,
no,DT,O
well-known,JJ,O
drug,NN,D
interactions,NNS,O
with,IN,O
glutamic,JJ,O
aci,NN,O
.,.,.
,,
human,JJ,O
growth,NN,O
hormone,NN,O
-,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
l-glutamine,NN,D
and,CC,O
human,JJ,O
growth,NN,O
hormone,NN,O
may,MD,O
enhance,VB,O
nutrient,JJ,O
absorption,NN,O
in,IN,O
those,DT,O
with,IN,O
severe,JJ,O
short,JJ,O
bowel,NN,O
syndrome,NN,O
.,.,.
,,
l-glutamine,NN,D
has,VBZ,O
orphan,JJ,O
drug,NN,D
status,NN,O
for,IN,O
this,DT,O
indication,NN,O
.,.,.
,,
indomethacin,NN,D
-,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
l-glutamine,NN,D
and,CC,O
indomethacin,NN,D
may,MD,O
ameliorate,VB,O
increased,VBN,O
intestinal,JJ,O
permeability,NN,O
caused,VBN,O
by,IN,O
indomethacin,NN,D
.,.,.
,,
the,DT,O
reported,VBN,O
dose,NN,O
used,VBN,O
for,IN,O
l-glutamine,NN,D
was,VBD,O
21,CD,O
grams,NNS,O
daily,JJ,O
taken,VBN,O
in,IN,O
divided,VBN,O
doses,NNS,O
three,CD,O
times,NNS,O
a,DT,O
day,NN,O
.,.,.
,,
further,RB,O
",",",",O
misoprostol,NN,D
is,VBZ,O
reported,VBN,O
to,TO,O
have,VB,O
a,DT,O
synergistic,JJ,O
effect,NN,O
with,IN,O
this,DT,O
combination,NN,O
in,IN,O
ameliorating,VBG,O
intestinal,JJ,O
permeability,NN,O
.,.,.
,,
methotrexate,NNP,D
-,:,O
there,EX,O
is,VBZ,O
one,CD,O
report,NN,O
that,IN,O
methotrexate,NN,D
may,MD,O
decrease,VB,O
the,DT,O
possible,JJ,O
effectiveness,NN,O
of,IN,O
supplemental,JJ,O
l-glutamine,NN,D
for,IN,O
chemotherapy-induced,JJ,O
mucositis,NN,O
.,.,.
,,
in,IN,O
another,DT,O
report,NN,O
",",",",O
nine,CD,O
patients,NNS,O
with,IN,O
breast,NN,O
cancer,NN,O
were,VBD,O
reported,VBN,O
to,TO,O
have,VB,O
decreased,VBN,O
symptoms,NNS,O
of,IN,O
methotrexate-related,JJ,O
toxicity,NN,O
when,WRB,O
given,VBN,O
supplemental,JJ,O
l-glutamine,NN,D
at,IN,O
a,DT,O
dose,NN,O
of,IN,O
0.5,CD,O
gram/kilogram/day,NN,O
.,.,.
,,
paclitaxel,NN,D
-,:,O
in,IN,O
one,CD,O
report,NN,O
",",",",O
l-glutamine,NN,D
at,IN,O
a,DT,O
dose,NN,O
of,IN,O
10,CD,O
grams,NNS,O
three,CD,O
times,NNS,O
daily,RB,O
",",",",O
given,VBN,O
24,CD,O
hours,NNS,O
after,IN,O
receiving,VBG,O
paclitaxel,NN,D
",",",",O
appeared,VBD,O
to,TO,O
prevent,VB,O
the,DT,O
development,NN,O
of,IN,O
myalgia,NN,O
and,CC,O
arthralgia,NN,O
",",",",O
adverse,JJ,O
reactions,NNS,O
of,IN,O
paclitaxel,NN,D
.,.,.
,,
medroxyprogesterone,NNP,O
acetate,NNP,O
-,:,O
l-histidine,NN,D
was,VBD,O
observed,VBN,O
to,TO,O
enhance,VB,O
-lrb-,-LRB-,O
in,IN,O
tissue,NN,O
culture,NN,O
-rrb-,-RRB-,O
the,DT,O
effect,NN,O
of,IN,O
medroxyprogesterone,NN,D
acetate,NN,O
in,IN,O
reducing,VBG,O
the,DT,O
number,NN,O
of,IN,O
human,JJ,O
breast,NN,O
cancer,NN,O
cells,NNS,O
that,WDT,O
were,VBD,O
in,IN,O
the,DT,O
s,NN,O
phase,NN,O
.,.,.
,,
h1,NN,O
and,CC,O
h2,NN,O
blockers,NNS,O
-,:,O
although,IN,O
not,RB,O
reported,VBN,O
",",",",O
l-histidine,NN,D
",",",",O
via,IN,O
its,PRP$,O
metabolism,NN,O
to,TO,O
histamine,NN,D
",",",",O
might,MD,O
decrease,VB,O
the,DT,O
efficacy,NN,O
of,IN,O
h1,NN,O
and,CC,O
h2,NN,O
blockers,NNS,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
calcium,NN,D
supplements,NNS,O
and,CC,O
l-lysine,NN,D
may,MD,O
increase,VB,O
calcium,NN,D
absorptio,NN,O
.,.,.
,,
acetaminophen,NN,D
and,CC,O
methotrexate,NN,D
-,:,O
l-methionine,NN,D
may,MD,O
decrease,VB,O
hepatic,JJ,O
toxicity,NN,O
in,IN,O
those,DT,O
with,IN,O
acetaminophen,NN,D
overdosage,NN,O
or,CC,O
in,IN,O
those,DT,O
taking,VBG,O
methotrexate,NN,D
.,.,.
,,
theoretically,RB,O
",",",",O
it,PRP,O
may,MD,O
decrease,VB,O
hepatic,JJ,O
toxicity,NN,O
in,IN,O
the,DT,O
case,NN,O
of,IN,O
other,JJ,O
potential,JJ,O
hepatotoxic,JJ,O
drugs,NNS,D
",",",",O
as,RB,O
well,RB,O
.,.,.
,,
gentamicin,NN,D
-,:,O
methionine,NN,D
may,MD,O
protect,VB,O
against,IN,O
the,DT,O
ototoxic,JJ,O
effects,NNS,O
of,IN,O
gentamicin,NN,D
.,.,.
,,
non-selective,JJ,O
monoamine,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
mao,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
-,:,O
including,VBG,O
phenelzine,NN,D
sulfate,NN,O
",",",",O
tranylcypromine,NN,D
sulfate,NN,O
and,CC,O
pargyline,NN,D
hc1,NN,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
l-phenylalanine,NN,D
and,CC,O
non-selective,JJ,O
mao,NN,O
inhibitors,NNS,O
may,MD,O
cause,VB,O
hypertension,NN,O
.,.,.
,,
selegiline,NNP,D
-,:,O
l-phenylalanine,NN,D
and,CC,O
the,DT,O
selective,JJ,O
mao,NNP,O
inhibitor,NN,O
selegiline,NN,D
may,MD,O
have,VB,O
synergistic,JJ,O
antidepressant,JJ,G
activity,NN,O
if,IN,O
used,VBN,O
concomitantly,RB,O
.,.,.
,,
neuroleptic,JJ,G
drugs,NNS,O
-,:,O
l-phenylalanine,NN,D
may,MD,O
potentiate,VB,O
the,DT,O
tardive,JJ,O
dyskinesia,NN,O
side,NN,O
reactions,NNS,O
of,IN,O
neuroleptic,JJ,G
drugs,NNS,D
if,IN,O
used,VBN,O
concomitantly,RB,O
with,IN,O
them,PRP,O
.,.,.
,,
monoamine,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
mao,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
such,JJ,O
as,IN,O
isocarboxazid,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
marplan,NNP,B
-rrb-,-RRB-,O
",",",",O
phenelzine,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
nardil,NNP,B
-rrb-,-RRB-,O
",",",",O
procarbazine,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
matulane,NN,B
-rrb-,-RRB-,O
",",",",O
selegiline,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
eldepryl,NN,B
-rrb-,-RRB-,O
",",",",O
and,CC,O
tranylcypromine,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
parnate,NNP,B
-rrb-,-RRB-,O
:,:,O
using,VBG,O
these,DT,O
medicines,NNS,O
with,IN,O
l-tryptophan,NN,D
may,MD,O
increase,VB,O
the,DT,O
chance,NN,O
of,IN,O
side,JJ,O
effects,NNS,O
.,.,.
,,
non-selective,JJ,O
mao,NN,O
inhibitors,NNS,O
including,VBG,O
tranylcypromine,NN,D
sulfate,NN,O
",",",",O
phenelzine,NN,D
sulfate,NN,O
",",",",O
and,CC,O
pargyline,NN,D
hc1,NN,O
:,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
l-tyrosine,NN,D
and,CC,O
non-selective,JJ,O
mao,NN,O
inhibitors,NNS,O
may,MD,O
cause,VB,O
hypertension,NN,O
.,.,.
,,
in,IN,O
one,CD,O
survey,NN,O
",",",",O
2.3,CD,O
%,NN,O
of,IN,O
patients,NNS,O
taking,VBG,O
labetalol,JJ,D
hcl,NN,O
in,IN,O
combination,NN,O
with,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
experienced,VBD,O
tremor,NN,O
",",",",O
as,IN,O
compared,VBN,O
to,TO,O
0.7,CD,O
%,NN,O
reported,VBD,O
to,TO,O
occur,VB,O
with,IN,O
labetalol,NN,D
hcl,NN,O
alone,RB,O
.,.,.
,,
the,DT,O
contribution,NN,O
of,IN,O
each,DT,O
of,IN,O
the,DT,O
treatments,NNS,O
to,TO,O
this,DT,O
adverse,JJ,O
reaction,NN,O
is,VBZ,O
unknown,JJ,O
but,CC,O
the,DT,O
possibility,NN,O
of,IN,O
a,DT,O
drug,NN,D
interaction,NN,O
can,MD,O
not,RB,O
be,VB,O
excluded,VBN,O
.,.,.
,,
drugs,NNS,O
possessing,VBG,O
beta-blocking,JJ,D
properties,NNS,O
can,MD,O
blunt,VB,O
the,DT,O
bronchodilator,NN,O
effect,NN,O
of,IN,O
beta-receptor,NN,O
agonist,NN,O
drugs,NNS,D
in,IN,O
patients,NNS,O
with,IN,O
bronchospasm,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
doses,NNS,O
greater,JJR,O
than,IN,O
the,DT,O
normal,JJ,O
antiasthmatic,JJ,O
dose,NN,O
of,IN,O
beta-agonist,JJ,G
bronchodilator,NN,O
drugs,NNS,D
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
cimetidine,NNP,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
increase,VB,O
the,DT,O
bioavailability,NN,O
of,IN,O
labetalol,NN,D
hcl,NN,O
.,.,.
,,
since,IN,O
this,DT,O
could,MD,O
be,VB,O
explained,VBN,O
either,CC,O
by,IN,O
enhanced,VBN,O
absorption,NN,O
or,CC,O
by,IN,O
an,DT,O
alteration,NN,O
of,IN,O
hepatic,JJ,O
metabolism,NN,O
of,IN,O
labetalol,NN,D
hcl,NN,O
",",",",O
special,JJ,O
care,NN,O
should,MD,O
be,VB,O
used,VBN,O
in,IN,O
establishing,VBG,O
the,DT,O
dose,NN,O
required,VBN,O
for,IN,O
blood,NN,O
pressure,NN,O
control,NN,O
in,IN,O
such,JJ,O
patients,NNS,O
.,.,.
,,
synergism,NN,O
has,VBZ,O
been,VBN,O
shown,VBN,O
between,IN,O
halothane,NN,D
anesthesia,NN,D
and,CC,O
intravenously,RB,O
administered,VBN,O
labetalol,NN,D
hcl,NN,O
.,.,.
,,
during,IN,O
controlled,JJ,O
hypotensive,JJ,O
anesthesia,NN,D
using,VBG,O
labetalol,NN,D
hcl,NN,O
in,IN,O
association,NN,O
with,IN,O
halothane,NN,D
",",",",O
high,JJ,O
concentrations,NNS,O
-lrb-,-LRB-,O
3,CD,O
%,NN,O
or,CC,O
above,IN,O
-rrb-,-RRB-,O
of,IN,O
halothane,NN,D
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
because,IN,O
the,DT,O
degree,NN,O
of,IN,O
hypotension,NN,O
will,MD,O
be,VB,O
increased,VBN,O
and,CC,O
because,IN,O
of,IN,O
the,DT,O
possibility,NN,O
of,IN,O
a,DT,O
large,JJ,O
reduction,NN,O
in,IN,O
cardiac,JJ,O
output,NN,O
and,CC,O
an,DT,O
increase,NN,O
in,IN,O
central,JJ,O
venous,JJ,O
pressure,NN,O
.,.,.
,,
the,DT,O
anesthesiologist,NN,O
should,MD,O
be,VB,O
informed,VBN,O
when,WRB,O
a,DT,O
patient,NN,O
is,VBZ,O
receiving,VBG,O
labetalol,NN,D
hcl,NN,O
.,.,.
,,
labetalol,NNP,O
hcl,NN,O
blunts,VBZ,O
the,DT,O
reflex,JJ,O
tachycardia,NN,O
produced,VBN,O
by,IN,O
nitroglycerin,NN,D
without,IN,O
preventing,VBG,O
its,PRP$,O
hypotensive,JJ,O
effect,NN,O
.,.,.
,,
if,IN,O
labetalol,JJ,D
hcl,NN,O
is,VBZ,O
used,VBN,O
with,IN,O
nitroglycerin,NN,D
in,IN,O
patients,NNS,O
with,IN,O
angina,NN,O
pectoris,NN,O
",",",",O
additional,JJ,O
antihypertensive,JJ,G
effects,NNS,O
may,MD,O
occur,VB,O
.,.,.
,,
care,NNP,O
should,MD,O
be,VB,O
taken,VBN,O
if,IN,O
labetalol,NN,D
is,VBZ,O
used,VBN,O
concomitantly,RB,O
with,IN,O
calcium,NN,D
antagonists,NNS,O
of,IN,O
the,DT,O
verapamil,NN,D
type,NN,O
.,.,.
,,
risk,NN,O
of,IN,O
anaphylactic,NNP,O
reaction,NNP,O
while,IN,O
taking,VBG,O
beta-blockers,NNS,G
",",",",O
patients,NNS,O
with,IN,O
a,DT,O
history,NN,O
of,IN,O
severe,JJ,O
anaphylactic,JJ,O
reaction,NN,O
to,TO,O
a,DT,O
variety,NN,O
of,IN,O
allergens,NNS,O
may,MD,O
be,VB,O
more,RBR,O
reactive,JJ,O
to,TO,O
repeated,VBN,O
challenge,NN,O
",",",",O
either,CC,O
accidental,JJ,O
",",",",O
diagnostic,JJ,O
",",",",O
or,CC,O
therapeutic,JJ,O
.,.,.
,,
such,JJ,O
patients,NNS,O
may,MD,O
be,VB,O
unresponsive,JJ,O
to,TO,O
the,DT,O
usual,JJ,O
doses,NNS,O
of,IN,O
epinephrine,NN,D
used,VBN,O
to,TO,O
treat,VB,O
allergic,JJ,O
reaction,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
the,DT,O
presence,NN,O
of,IN,O
labetalol,NN,D
metabolites,NNS,O
in,IN,O
the,DT,O
urine,NN,O
may,MD,O
result,VB,O
in,IN,O
falsely,RB,O
elevated,JJ,O
levels,NNS,O
of,IN,O
urinary,JJ,O
catecholamines,NNS,G
",",",",O
metanephrine,NN,O
",",",",O
normetanephrine,NN,O
and,CC,O
vanillylmandelic,JJ,O
acid,NN,O
when,WRB,O
measured,VBN,O
by,IN,O
fluorimetric,JJ,O
or,CC,O
photometric,JJ,O
methods,NNS,O
.,.,.
,,
in,IN,O
screening,NN,O
patients,NNS,O
suspected,VBN,O
of,IN,O
having,VBG,O
a,DT,O
pheochromocytoma,NN,O
and,CC,O
being,VBG,O
treated,VBN,O
with,IN,O
labetalol,NN,D
hcl,NN,O
",",",",O
a,DT,O
specific,JJ,O
method,NN,O
",",",",O
such,JJ,O
as,IN,O
a,DT,O
high,JJ,O
performance,NN,O
liquid,NN,O
chromatographic,JJ,O
assay,NN,O
with,IN,O
solid,JJ,O
phase,NN,O
extraction,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
j,NNP,O
chromatogr,NNP,O
"385:241,1987",CD,O
-rrb-,-RRB-,O
should,MD,O
be,VB,O
employed,VBN,O
in,IN,O
determining,VBG,O
levels,NNS,O
of,IN,O
catecholamines,NNS,G
.,.,.
,,
labetalol,NNP,O
hcl,NN,O
has,VBZ,O
also,RB,O
been,VBN,O
reported,VBN,O
to,TO,O
produce,VB,O
a,DT,O
FALSE,JJ,O
positive,JJ,O
test,NN,O
for,IN,O
amphetamine,NN,D
when,WRB,O
screening,VBG,O
urine,NN,O
for,IN,O
the,DT,O
presence,NN,O
of,IN,O
drugs,NNS,D
using,VBG,O
the,DT,O
commercially,RB,O
available,JJ,O
assay,NN,O
methods,NNS,O
toxi-lab,NNP,O
a,NNP,O
-lrb-,-LRB-,O
thin-layer,JJ,O
chromatographic,JJ,O
assay,NN,O
-rrb-,-RRB-,O
and,CC,O
emit-d.a.u.,NN,O
-lrb-,-LRB-,O
radioenzymatic,JJ,O
assay,NN,O
-rrb-,-RRB-,O
.,.,.
,,
when,WRB,O
patients,NNS,O
being,VBG,O
treated,VBN,O
with,IN,O
labetalol,NN,D
have,VBP,O
a,DT,O
positive,JJ,O
urine,NN,O
test,NN,O
for,IN,O
amphetamine,NN,D
using,VBG,O
these,DT,O
techniques,NNS,O
confirmation,NN,O
should,MD,O
be,VB,O
made,VBN,O
by,IN,O
using,VBG,O
more,RBR,O
specific,JJ,O
methods,NNS,O
such,JJ,O
as,IN,O
a,DT,O
gas,NN,O
chromatographic-mass,NN,O
spectrometer,NN,O
technique,NN,O
.,.,.
,,
results,NNS,O
of,IN,O
preliminary,JJ,O
studies,NNS,O
in,IN,O
humans,NNS,O
and,CC,O
rats,NNS,O
suggest,VBP,O
that,IN,O
nonabsorbable,JJ,O
antacids,NNS,G
given,VBN,O
concurrently,RB,O
with,IN,O
lactulose,NN,D
may,MD,O
inhibit,VB,O
the,DT,O
desired,VBN,O
lactulose-induced,JJ,O
drop,NN,O
in,IN,O
colonic,JJ,O
ph.,NN,O
therefore,RB,O
",",",",O
a,DT,O
possible,JJ,O
lack,NN,O
of,IN,O
desired,VBN,O
effect,NN,O
of,IN,O
treatment,NN,O
should,MD,O
be,VB,O
taken,VBN,O
into,IN,O
consideration,NN,O
before,IN,O
such,JJ,O
drugs,NNS,D
are,VBP,O
given,VBN,O
concomitantly,RB,O
with,IN,O
lactulose,NN,D
.,.,.
,,
lamivudine,NN,D
is,VBZ,O
predominantly,RB,O
eliminated,VBN,O
in,IN,O
the,DT,O
urine,NN,O
by,IN,O
active,JJ,O
organic,JJ,O
cationic,JJ,O
secretion,NN,O
.,.,.
,,
the,DT,O
possibility,NN,O
of,IN,O
interactions,NNS,O
with,IN,O
other,JJ,O
drugs,NNS,D
administered,VBN,O
concurrently,RB,O
should,MD,O
be,VB,O
considered,VBN,O
",",",",O
particularly,RB,O
when,WRB,O
their,PRP$,O
main,JJ,O
route,NN,O
of,IN,O
elimination,NN,O
is,VBZ,O
active,JJ,O
renal,JJ,O
secretion,NN,O
via,IN,O
the,DT,O
organic,JJ,O
cationic,NN,O
transport,NN,O
system,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
trimethoprim,NN,D
-rrb-,-RRB-,O
.,.,.
,,
no,DT,O
change,NN,O
in,IN,O
dose,NN,O
of,IN,O
either,CC,O
drug,NN,D
is,VBZ,O
recommended,VBN,O
.,.,.
,,
there,EX,O
is,VBZ,O
no,DT,O
information,NN,O
regarding,VBG,O
the,DT,O
effect,NN,O
on,IN,O
lamivudine,NN,D
pharmacokinetics,NNS,O
of,IN,O
higher,JJR,O
doses,NNS,O
of,IN,O
tmp/smx,NN,O
such,JJ,O
as,IN,O
those,DT,O
used,VBN,O
to,TO,O
treat,VB,O
pneumocystis,NN,O
carinii,NN,O
pneumonia,NN,O
.,.,.
,,
no,DT,O
data,NNS,O
are,VBP,O
available,JJ,O
regarding,VBG,O
interactions,NNS,O
with,IN,O
other,JJ,O
drugs,NNS,D
that,WDT,O
have,VBP,O
renal,JJ,O
clearance,NN,O
mechanisms,NNS,O
similar,JJ,O
to,TO,O
that,DT,O
of,IN,O
lamivudine,NN,D
.,.,.
,,
lamivudine,NN,D
and,CC,O
zalcitabine,NN,D
may,MD,O
inhibit,VB,O
the,DT,O
intracellular,JJ,O
phosphorylation,NN,O
of,IN,O
one,CD,O
another,DT,O
.,.,.
,,
therefore,RB,O
",",",",O
use,NN,O
of,IN,O
lamivudine,NN,D
in,IN,O
combination,NN,O
with,IN,O
zalcitabine,NN,D
is,VBZ,O
not,RB,O
recommende,NN,O
.,.,.
,,
lansoprazole,NNP,D
is,VBZ,O
metabolized,VBN,O
through,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
system,NN,O
",",",",O
specifically,RB,O
through,IN,O
the,DT,O
cyp3a,NN,O
and,CC,O
cyp2c19,NN,O
isozymes,NNS,O
.,.,.
,,
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
lansoprazole,NN,D
does,VBZ,O
not,RB,O
have,VB,O
clinically,RB,O
significant,JJ,O
interactions,NNS,O
with,IN,O
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
system,NN,O
",",",",O
such,JJ,O
as,IN,O
warfarin,NN,D
",",",",O
antipyrine,NN,D
",",",",O
indomethacin,NN,D
",",",",O
ibuprofen,NN,D
",",",",O
phenytoin,NN,D
",",",",O
propranolol,NN,D
",",",",O
prednisone,NN,D
",",",",O
diazepam,NN,D
",",",",O
clarithromycin,NN,D
",",",",O
or,CC,O
terfenadine,NN,D
in,IN,O
healthy,JJ,O
subjects,NNS,O
.,.,.
,,
these,DT,O
compounds,NNS,O
are,VBP,O
metabolized,VBN,O
through,IN,O
various,JJ,O
cytochrome,NN,O
p450,NN,O
isozymes,NNS,O
including,VBG,O
cyp1a2,NN,D
",",",",O
cyp2c9,NN,D
",",",",O
cyp2c19,NN,O
",",",",O
cyp2d6,NN,D
",",",",O
and,CC,O
cyp3a,NN,O
.,.,.
,,
when,WRB,O
lansoprazole,NN,D
was,VBD,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
theophylline,NN,D
-lrb-,-LRB-,O
cyp1a2,NN,D
",",",",O
cyp3a,NN,O
-rrb-,-RRB-,O
",",",",O
a,DT,O
minor,JJ,O
increase,NN,O
-lrb-,-LRB-,O
10,CD,O
%,NN,O
-rrb-,-RRB-,O
in,IN,O
the,DT,O
clearance,NN,O
of,IN,O
theophylline,NN,D
was,VBD,O
seen,VBN,O
.,.,.
,,
because,IN,O
the,DT,O
small,JJ,O
magnitude,NN,O
and,CC,O
the,DT,O
direction,NN,O
of,IN,O
the,DT,O
effect,NN,O
on,IN,O
theophylline,NN,D
clearance,NN,O
",",",",O
this,DT,O
interaction,NN,O
is,VBZ,O
unlikely,JJ,O
to,TO,O
be,VB,O
clinical,JJ,O
concern,NN,O
.,.,.
,,
nonetheless,RB,O
",",",",O
individual,JJ,O
patients,NNS,O
may,MD,O
require,VB,O
additional,JJ,O
titration,NN,O
of,IN,O
their,PRP$,O
theophylline,NN,D
dosage,NN,O
when,WRB,O
lansoprazole,NN,D
is,VBZ,O
started,VBN,O
or,CC,O
stopped,VBN,O
to,TO,O
ensure,VB,O
clinically,RB,O
effective,JJ,O
blood,NN,O
levels,NNS,O
.,.,.
,,
lansoprazole,NNP,D
has,VBZ,O
also,RB,O
been,VBN,O
shown,VBN,O
to,TO,O
have,VB,O
no,DT,O
clinically,RB,O
significant,JJ,O
interaction,NN,O
with,IN,O
amoxicillin,NNP,D
.,.,.
,,
in,IN,O
a,DT,O
single-dose,JJ,O
crossover,NN,O
study,NN,O
examining,VBG,O
lansoprazole,NN,D
30,CD,O
mg,NN,O
and,CC,O
omeprazole,NN,D
20,CD,O
mg,NN,O
each,DT,O
administered,VBN,O
alone,RB,O
and,CC,O
concomitantly,RB,O
with,IN,O
sucralfate,NN,D
1,CD,O
gram,NN,O
",",",",O
absorption,NN,O
of,IN,O
the,DT,O
proton,NN,O
pump,NN,O
inhibitors,NNS,O
was,VBD,O
delayed,VBN,O
and,CC,O
their,PRP$,O
bioavailability,NN,O
was,VBD,O
reduced,VBN,O
by,IN,O
17,CD,O
%,NN,O
and,CC,O
16,CD,O
%,NN,O
",",",",O
respectively,RB,O
",",",",O
when,WRB,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
sucralfate,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
proton,NN,O
pump,NN,O
inhibitors,NNS,O
should,MD,O
be,VB,O
taken,VBN,O
at,IN,O
least,JJS,O
30,CD,O
minutes,NNS,O
prior,RB,O
to,TO,O
sucralfate,NN,D
.,.,.
,,
in,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
antacids,NNS,G
were,VBD,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
lansoprazole,NN,D
delayed-release,NN,O
capsules,NNS,O
.,.,.
,,
this,DT,O
did,VBD,O
not,RB,O
interfere,VB,O
with,IN,O
its,PRP$,O
effect,NN,O
.,.,.
,,
lansoprazole,NN,D
causes,VBZ,O
a,DT,O
profound,JJ,O
and,CC,O
long,JJ,O
lasting,JJ,O
inhibition,NN,O
of,IN,O
gastric,JJ,O
acid,NN,O
secretion,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
it,PRP,O
is,VBZ,O
theoretically,RB,O
possible,JJ,O
that,IN,O
lansoprazole,NN,D
may,MD,O
interfere,VB,O
with,IN,O
the,DT,O
absorption,NN,O
of,IN,O
drugs,NNS,D
where,WRB,O
gastric,JJ,O
ph,NN,O
is,VBZ,O
an,DT,O
important,JJ,O
determinant,NN,O
of,IN,O
bioavailability,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
ketoconazole,NN,D
",",",",O
ampicillin,NN,D
esters,NNS,O
",",",",O
iron,NN,D
salts,NNS,O
",",",",O
digoxin,NN,D
-rrb-,-RRB-,O
.,.,.
,,
effects,NNS,O
of,IN,O
lapatinib,NN,D
on,IN,O
drug,NN,O
metabolizing,VBG,O
enzymes,NNS,O
and,CC,O
drug,NN,O
transport,NNP,O
systems,NNP,O
lapatinib,NNP,D
inhibits,VBZ,O
cyp3a4,NN,D
and,CC,O
cyp2c8,NN,O
in,FW,O
vitro,FW,O
at,IN,O
clinically,RB,O
relevant,JJ,O
concentrations,NNS,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
and,CC,O
dose,NN,O
reduction,NN,O
of,IN,O
the,DT,O
concomitant,JJ,O
substrate,NN,O
drug,NN,D
should,MD,O
be,VB,O
considered,VBN,O
when,WRB,O
dosing,NN,O
lapatinib,NN,D
concurrently,RB,O
with,IN,O
medications,NNS,O
with,IN,O
narrow,JJ,O
therapeutic,JJ,O
windows,NNS,O
that,WDT,O
are,VBP,O
substrates,NNS,O
of,IN,O
cyp3a4,NN,D
or,CC,O
cyp2c8,NN,O
.,.,.
,,
lapatinib,NNP,D
did,VBD,O
not,RB,O
significantly,RB,O
inhibit,VB,O
the,DT,O
following,VBG,O
enzymes,NNS,O
in,IN,O
human,JJ,O
liver,NN,O
microsomes,NNS,O
:,:,O
cyp1a2,NN,D
",",",",O
cyp2c9,NN,D
",",",",O
cyp2c19,NN,O
",",",",O
and,CC,O
cyp2d6,NN,D
or,CC,O
ugt,NN,O
enzymes,NNS,O
in,FW,O
vitro,FW,O
",",",",O
however,RB,O
",",",",O
the,DT,O
clinical,JJ,O
significance,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
lapatinib,NN,D
inhibits,VBZ,O
human,JJ,O
p-glycoprotein,NN,O
.,.,.
,,
if,IN,O
tykerb,NNP,B
is,VBZ,O
administered,VBN,O
with,IN,O
drugs,NNS,D
that,WDT,O
are,VBP,O
substrates,NNS,O
of,IN,O
pgp,NNP,O
",",",",O
increased,VBD,O
concentrations,NNS,O
of,IN,O
the,DT,O
substrate,NN,O
drug,NN,D
are,VBP,O
likely,JJ,O
",",",",O
and,CC,O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
inhibit,VBP,O
or,CC,O
induce,VBP,O
cytochrome,NN,O
p450,NN,O
3a4,NN,O
enzymes,NNS,O
lapatinib,NN,D
undergoes,VBZ,O
extensive,JJ,O
metabolism,NN,O
by,IN,O
cyp3a4,NN,D
",",",",O
and,CC,O
concomitant,JJ,O
administration,NN,O
of,IN,O
strong,JJ,O
inhibitors,NNS,O
or,CC,O
inducers,NNS,O
of,IN,O
cyp3a4,NN,D
alter,VBP,O
lapatinib,NN,D
concentrations,NNS,O
significantly,RB,O
.,.,.
,,
dose,NN,O
adjustment,NN,O
of,IN,O
lapatinib,NN,D
should,MD,O
be,VB,O
considered,VBN,O
for,IN,O
patients,NNS,O
who,WP,O
must,MD,O
receive,VB,O
concomitant,JJ,O
strong,JJ,O
inhibitors,NNS,O
or,CC,O
concomitant,JJ,O
strong,JJ,O
inducers,NNS,O
of,IN,O
cyp3a4,NN,D
enzymes,NNS,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
receiving,VBG,O
ketoconazole,NN,D
",",",",O
a,DT,O
cyp3a4,NN,D
inhibitor,NN,O
",",",",O
at,IN,O
200,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
for,IN,O
7,CD,O
days,NNS,O
",",",",O
systemic,JJ,O
exposure,NN,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
to,TO,O
lapatinib,NN,D
was,VBD,O
increased,VBN,O
to,TO,O
approximately,RB,O
3.6-fold,RB,O
of,IN,O
control,NN,O
and,CC,O
half-life,NN,O
increased,VBD,O
to,TO,O
1.7-fold,RB,O
of,IN,O
control,NN,O
.,.,.
,,
carbamazepine,NNP,D
:,:,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
receiving,VBG,O
the,DT,O
cyp3a4,NN,D
inducer,NN,O
",",",",O
carbamazepine,NN,D
",",",",O
at,IN,O
100,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
for,IN,O
3,CD,O
days,NNS,O
and,CC,O
200,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
for,IN,O
17,CD,O
days,NNS,O
",",",",O
systemic,JJ,O
exposure,NN,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
to,TO,O
lapatinib,NN,D
was,VBD,O
decreased,VBN,O
approximately,RB,O
72,CD,O
%,NN,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
inhibit,VBP,O
drug,NN,O
transport,NNP,O
systems,NNP,O
lapatinib,NNP,D
is,VBZ,O
a,DT,O
substrate,NN,O
of,IN,O
the,DT,O
efflux,NN,O
transporter,NN,O
p-glycoprotein,NN,O
-lrb-,-LRB-,O
pgp,NN,O
",",",",O
abcb1,NN,O
-rrb-,-RRB-,O
.,.,.
,,
if,IN,O
tykerb,NNP,B
is,VBZ,O
administered,VBN,O
with,IN,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
pgp,NNP,O
",",",",O
increased,VBD,O
concentrations,NNS,O
of,IN,O
lapatinib,NN,D
are,VBP,O
likely,JJ,O
",",",",O
and,CC,O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
.,.,.
,,
other,JJ,O
chemotherapy,NNP,O
agents,NNPS,O
in,IN,O
a,DT,O
separate,JJ,O
study,NN,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
lapatinib,NN,D
with,IN,O
capecitabine,NN,D
did,VBD,O
not,RB,O
meaningfully,RB,O
alter,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
agent,NN,O
-lrb-,-LRB-,O
or,CC,O
the,DT,O
metabolites,NNS,O
of,IN,O
capecitabine,NN,D
-rrb-,-RRB-,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
precipitation,NN,O
occurs,VBZ,O
when,WRB,O
eye,NN,O
drops,VBZ,O
containing,VBG,O
thimerosal,NN,D_n
are,VBP,O
mixed,VBN,O
with,IN,O
latanoprost,NN,D
.,.,.
,,
if,IN,O
such,JJ,O
drugs,NNS,D
are,VBP,O
used,VBN,O
they,PRP,O
should,MD,O
be,VB,O
administered,VBN,O
with,IN,O
an,DT,O
interval,NN,O
of,IN,O
at,IN,O
least,JJS,O
5,CD,O
minutes,NNS,O
between,IN,O
applications,NNS,O
.,.,.
,,
cholestyramine,NNP,D
and,CC,O
charcoal,NNP,D
administration,NNP,O
of,IN,O
cholestyramine,NN,D
or,CC,O
activated,VBN,O
charcoal,NN,D
in,IN,O
patients,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
13,CD,O
-rrb-,-RRB-,O
and,CC,O
volunteers,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
96,CD,O
-rrb-,-RRB-,O
resulted,VBD,O
in,IN,O
a,DT,O
rapid,JJ,O
and,CC,O
significant,JJ,O
decrease,NN,O
in,IN,O
plasma,NN,O
m1,NN,O
-lrb-,-LRB-,O
the,DT,O
active,JJ,O
metabolite,NN,O
of,IN,O
leflunomide,NN,D
-rrb-,-RRB-,O
concentration,NN,O
.,.,.
,,
hepatotoxic,JJ,O
drugs,NNS,O
increased,VBN,O
side,JJ,O
effects,NNS,O
may,MD,O
occur,VB,O
when,WRB,O
leflunomide,NN,D
is,VBZ,O
given,VBN,O
concomitantly,RB,O
with,IN,O
hepatotoxic,JJ,O
substances,NNS,O
.,.,.
,,
this,DT,O
is,VBZ,O
also,RB,O
to,TO,O
be,VB,O
considered,VBN,O
when,WRB,O
leflunomide,NN,D
treatment,NN,O
is,VBZ,O
followed,VBN,O
by,IN,O
such,JJ,O
drugs,NNS,D
without,IN,O
a,DT,O
drug,NN,D
elimination,NN,O
procedure,NN,O
.,.,.
,,
in,IN,O
a,DT,O
small,JJ,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
30,CD,O
-rrb-,-RRB-,O
combination,NN,O
study,NN,O
of,IN,O
arava,NN,B
with,IN,O
methotrexate,NN,D
",",",",O
a,DT,O
2,LS,O
-,:,O
to,TO,O
3-fold,JJ,O
elevation,NN,O
in,IN,O
liver,NN,O
enzymes,NNS,O
was,VBD,O
seen,VBN,O
in,IN,O
5,CD,O
of,IN,O
30,CD,O
patients,NNS,O
.,.,.
,,
all,DT,O
elevations,NNS,O
resolved,VBN,O
",",",",O
2,CD,O
with,IN,O
continuation,NN,O
of,IN,O
both,CC,O
drugs,NNS,D
and,CC,O
3,CD,O
after,IN,O
discontinuation,NN,O
of,IN,O
leflunomide,NN,D
.,.,.
,,
a,DT,O
3-fold,JJ,O
increase,NN,O
was,VBD,O
seen,VBN,O
in,IN,O
another,DT,O
5,CD,O
patients,NNS,O
.,.,.
,,
all,DT,O
of,IN,O
these,DT,O
also,RB,O
resolved,VBN,O
",",",",O
2,CD,O
with,IN,O
continuation,NN,O
of,IN,O
both,CC,O
drugs,NNS,D
and,CC,O
3,CD,O
after,IN,O
discontinuation,NN,O
of,IN,O
leflunomide,NN,D
.,.,.
,,
three,CD,O
patients,NNS,O
met,VBD,O
acr,NN,O
criteria,NNS,O
for,IN,O
liver,NN,O
biopsy,NN,O
-lrb-,-LRB-,O
1,CD,O
:,:,O
roegnik,NNP,O
grade,NNP,O
i,PRP,O
",",",",O
2,CD,O
:,:,O
roegnik,NNP,O
grade,NNP,O
iiia,NN,O
-rrb-,-RRB-,O
.,.,.
,,
no,DT,O
pharmacokinetic,JJ,O
interaction,NN,O
was,VBD,O
identified,VBN,O
.,.,.
,,
nsaids,NNS,G
:,:,O
in,IN,O
in,FW,O
vitro,FW,O
studies,NNS,O
",",",",O
m1,NN,O
was,VBD,O
shown,VBN,O
to,TO,O
cause,VB,O
increases,NNS,O
ranging,VBG,O
from,IN,O
13,CD,O
-,:,O
50,CD,O
%,NN,O
in,IN,O
the,DT,O
free,JJ,O
fraction,NN,O
of,IN,O
diclofenac,NN,D
and,CC,O
ibuprofen,NN,D
at,IN,O
concentrations,NNS,O
in,IN,O
the,DT,O
clinical,JJ,O
range,NN,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
finding,NN,O
is,VBZ,O
unknown,JJ,O
;,:,O
.,.,.
,,
however,RB,O
",",",",O
there,EX,O
was,VBD,O
extensive,JJ,O
concomitant,JJ,O
use,NN,O
of,IN,O
nsaids,NNS,G
in,IN,O
clinical,JJ,O
studies,NNS,O
and,CC,O
no,DT,O
differential,JJ,O
effect,NN,O
was,VBD,O
observed,VBN,O
.,.,.
,,
tolbutamide,NNP,D
:,:,O
in,IN,O
in,FW,O
vitro,FW,O
studies,NNS,O
",",",",O
m1,NN,O
was,VBD,O
shown,VBN,O
to,TO,O
cause,VB,O
increases,NNS,O
ranging,VBG,O
from,IN,O
13,CD,O
-,:,O
50,CD,O
%,NN,O
in,IN,O
the,DT,O
free,JJ,O
fraction,NN,O
of,IN,O
tolbutamide,NN,D
at,IN,O
concentrations,NNS,O
in,IN,O
the,DT,O
clinical,JJ,O
range,NN,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
finding,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
rifampin,NNP,D
:,:,O
following,VBG,O
concomitant,JJ,O
administration,NN,O
of,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
arava,NNP,B
to,TO,O
subjects,NNS,O
receiving,VBG,O
multiple,JJ,O
doses,NNS,O
of,IN,O
rifampin,NN,D
",",",",O
m1,NN,O
peak,NN,O
levels,NNS,O
were,VBD,O
increased,VBN,O
-lrb-,-LRB-,O
~,CD,O
40,CD,O
%,NN,O
-rrb-,-RRB-,O
over,IN,O
those,DT,O
seen,VBN,O
when,WRB,O
arava,NNP,B
was,VBD,O
given,VBN,O
alone,RB,O
.,.,.
,,
because,IN,O
of,IN,O
the,DT,O
potential,NN,O
for,IN,O
arava,NN,B
levels,NNS,O
to,TO,O
continue,VB,O
to,TO,O
increase,VB,O
with,IN,O
multiple,JJ,O
dosing,NN,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
if,IN,O
patients,NNS,O
are,VBP,O
to,TO,O
be,VB,O
receiving,VBG,O
both,DT,O
arava,NN,B
and,CC,O
rifampin,NN,D
.,.,.
,,
warfarin,NNP,D
:,:,O
increased,VBN,O
inr,NN,O
-lrb-,-LRB-,O
international,NNP,O
normalized,NNP,O
ratio,NNP,O
-rrb-,-RRB-,O
when,WRB,O
arava,NNP,B
and,CC,O
warfarin,NN,D
were,VBD,O
co-administered,VBN,O
has,VBZ,O
been,VBN,O
rarely,RB,O
reported,VBN,O
.,.,.
,,
results,NNS,O
from,IN,O
human,JJ,O
in,FW,O
vitro,FW,O
metabolism,NN,O
studies,NNS,O
and,CC,O
nonclinical,JJ,O
studies,NNS,O
show,VBP,O
that,IN,O
revlimid,NN,B
-lrb-,-LRB-,O
lenalidomide,NN,D
-rrb-,-RRB-,O
is,VBZ,O
neither,DT,O
metabolized,VBN,O
by,IN,O
nor,CC,O
inhibits,VBZ,O
or,CC,O
induces,VBZ,O
the,DT,O
cytochrome,NN,O
p450,NN,O
pathway,NN,O
suggesting,VBG,O
that,IN,O
lenalidomide,NN,D
is,VBZ,O
not,RB,O
likely,JJ,O
to,TO,O
cause,VB,O
or,CC,O
be,VB,O
subject,JJ,O
to,TO,O
p450-based,JJ,O
metabolic,JJ,O
drug,NN,D
interactions,NNS,O
in,IN,O
man,NN,O
.,.,.
,,
co-administration,NN,O
of,IN,O
multiple,JJ,O
doses,NNS,O
of,IN,O
10,CD,O
mg,NN,O
of,IN,O
lenalidomide,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
single,JJ,O
dose,NN,O
pharmacokinetics,NNS,O
of,IN,O
r,NN,O
-,:,O
and,CC,O
s,NN,O
-,:,O
warfarin,NN,D
.,.,.
,,
co-administration,NN,O
of,IN,O
single,JJ,O
25-mg,JJ,O
dose,NN,O
warfarin,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
total,JJ,O
lenalidomide,NN,D
.,.,.
,,
expected,VBN,O
changes,NNS,O
in,IN,O
laboratory,NN,O
assessments,NNS,O
of,IN,O
pt,NN,O
and,CC,O
inr,NN,O
were,VBD,O
observed,VBN,O
after,IN,O
warfarin,NN,D
administration,NN,O
",",",",O
but,CC,O
these,DT,O
changes,NNS,O
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
concomitant,JJ,O
lenalidomide,NN,D
administration,NN,O
.,.,.
,,
concomitant,JJ,O
treatment,NN,O
with,IN,O
thrombolytics,NNS,G
-lrb-,-LRB-,O
eg,FW,O
",",",",O
rt-pa,NN,O
or,CC,O
streptokinase,NNP,D
-rrb-,-RRB-,O
may,MD,O
:,:,O
-,:,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
bleeding,VBG,O
complications,NNS,O
-,:,O
considerably,RB,O
enhance,VBP,O
the,DT,O
effect,NN,O
of,IN,O
refludan,NN,B
on,IN,O
aptt,NN,O
prolongatio,NN,O
.,.,.
,,
concomitant,JJ,O
treatment,NN,O
with,IN,O
coumarin,NN,G
derivatives,NNS,O
-lrb-,-LRB-,O
vitamin,NN,G
k,NN,O
antagonists,NNS,O
-rrb-,-RRB-,O
and,CC,O
drugs,NNS,D
that,WDT,O
affect,VBP,O
platelet,NN,O
function,NN,O
may,MD,O
also,RB,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
bleeding,NN,O
.,.,.
,,
clinical,JJ,O
interaction,NN,O
studies,NNS,O
with,IN,O
cimetidine,NN,D
and,CC,O
warfarin,NN,D
indicated,VBD,O
that,IN,O
the,DT,O
coadministration,NN,O
of,IN,O
femara,NN,B
with,IN,O
these,DT,O
drugs,NNS,D
does,VBZ,O
not,RB,O
result,VB,O
in,IN,O
clinically,RB,O
-,:,O
significant,JJ,O
drug,NN,D
interactions,NNS,O
.,.,.
,,
-lrb-,-LRB-,O
see,VB,O
clinical,NNP,O
pharmacology,NNP,O
-rrb-,-RRB-,O
coadministration,NNP,O
of,IN,O
femara,NNP,B
and,CC,O
tamoxifen,NN,D
20,CD,O
mg,NN,O
daily,JJ,O
resulted,VBD,O
in,IN,O
a,DT,O
reduction,NN,O
of,IN,O
letrozole,NN,D
plasma,NN,O
levels,NNS,O
by,IN,O
38,CD,O
%,NN,O
on,IN,O
average,NN,O
.,.,.
,,
there,EX,O
is,VBZ,O
no,DT,O
clinical,JJ,O
experience,NN,O
to,TO,O
date,NN,O
on,IN,O
the,DT,O
use,NN,O
of,IN,O
femara,NNP,B
in,IN,O
combination,NN,O
with,IN,O
other,JJ,O
anticancer,JJ,O
agents,NNS,O
.,.,.
,,
drug/laboratory,JJ,O
test-interactions,NNS,O
none,NN,O
observed,VBN,O
.,.,.
,,
folic,JJ,O
acid,NN,O
in,IN,O
large,JJ,O
amounts,NNS,O
may,MD,O
counteract,VB,O
the,DT,O
antiepileptic,JJ,O
effect,NN,O
of,IN,O
phenobarbital,NN,D
",",",",O
phenytoin,NN,D
and,CC,O
primidone,NN,D
",",",",O
and,CC,O
increase,VB,O
the,DT,O
frequency,NN,O
of,IN,O
seizures,NNS,O
in,IN,O
susceptible,JJ,O
pediatric,JJ,O
patients,NNS,O
.,.,.
,,
preliminary,JJ,O
animal,NN,O
and,CC,O
human,JJ,O
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
small,JJ,O
quantities,NNS,O
of,IN,O
systemically,RB,O
administered,VBN,O
leucovorin,NN,D
enter,VBP,O
the,DT,O
csf,NN,O
primarily,RB,O
as,IN,O
5-methyltetrahydro-folate,JJ,O
and,CC,O
",",",",O
in,IN,O
humans,NNS,O
",",",",O
remain,VBP,O
1,CD,O
to,TO,O
3,CD,O
orders,NNS,O
of,IN,O
magnitude,NN,O
lower,JJR,O
than,IN,O
the,DT,O
usual,JJ,O
methotrexate,NN,D
concentrations,NNS,O
following,VBG,O
intrathecal,JJ,O
administration,NN,O
.,.,.
,,
however,RB,O
",",",",O
high,JJ,O
doses,NNS,O
of,IN,O
leucovorin,NN,D
may,MD,O
reduce,VB,O
the,DT,O
efficacy,NN,O
of,IN,O
intrathecally,RB,O
administered,VBN,O
methotrexate,NN,D
.,.,.
,,
leucovorin,NNP,D
may,MD,O
enhance,VB,O
the,DT,O
toxicity,NN,O
of,IN,O
5-fluorouracil,NN,D
.,.,.
,,
ergamisol,NN,B
-lrb-,-LRB-,O
levamisole,NN,D
hydrochloride,NN,O
-rrb-,-RRB-,O
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
produce,VB,O
antabuse-like,JJ,O
side,JJ,O
effects,NNS,O
when,WRB,O
given,VBN,O
concomitantly,RB,O
with,IN,O
alcohol,NN,D
.,.,.
,,
the,DT,O
physician,NN,O
is,VBZ,O
advised,VBN,O
to,TO,O
monitor,VB,O
plasma,NN,O
levels,NNS,O
of,IN,O
phenytoin,NN,D
and,CC,O
to,TO,O
decrease,VB,O
the,DT,O
dose,NN,O
if,IN,O
necessary,JJ,O
.,.,.
,,
because,IN,O
of,IN,O
reports,NNS,O
of,IN,O
prolongation,NN,O
of,IN,O
the,DT,O
prothrombin,NN,O
time,NN,O
beyond,IN,O
the,DT,O
therapeutic,JJ,O
range,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
concurrent,JJ,O
levamisole,NN,D
and,CC,O
warfarin,NN,D
sodium,NN,O
",",",",O
it,PRP,O
is,VBZ,O
suggested,VBN,O
that,IN,O
the,DT,O
prothrombin,NN,O
time,NN,O
be,VB,O
monitored,VBN,O
carefully,RB,O
",",",",O
and,CC,O
the,DT,O
dose,NN,O
of,IN,O
warfarin,NN,D
sodium,NN,O
or,CC,O
other,JJ,O
coumarin-like,JJ,O
drugs,NNS,D
should,MD,O
be,VB,O
adjusted,VBN,O
accordingly,RB,O
",",",",O
in,IN,O
patients,NNS,O
taking,VBG,O
both,CC,O
drugs,NNS,D
.,.,.
,,
in,FW,O
vitro,FW,O
data,NNS,O
on,IN,O
metabolic,JJ,O
interactions,NNS,O
indicate,VBP,O
that,IN,O
keppra,NNP,B
is,VBZ,O
unlikely,JJ,O
to,TO,O
produce,VB,O
",",",",O
or,CC,O
be,VB,O
subject,JJ,O
to,TO,O
",",",",O
pharmacokinetic,JJ,O
interactions,NNS,O
.,.,.
,,
levetiracetam,NNP,D
and,CC,O
its,PRP$,O
major,JJ,O
metabolite,NN,O
",",",",O
at,IN,O
concentrations,NNS,O
well,RB,O
above,IN,O
cmax,NN,O
levels,NNS,O
achieved,VBD,O
within,IN,O
the,DT,O
therapeutic,JJ,O
dose,NN,O
range,NN,O
",",",",O
are,VBP,O
neither,DT,O
inhibitors,NNS,O
of,IN,O
nor,CC,O
high,JJ,O
affinity,NN,O
substrates,NNS,O
for,IN,O
human,JJ,O
liver,NN,O
cytochrome,NN,O
p450,NN,O
isoforms,NNS,O
",",",",O
epoxide,NN,O
hydrolase,NN,O
or,CC,O
udp-glucuronidation,NN,O
enzymes,NNS,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
levetiracetam,NN,D
does,VBZ,O
not,RB,O
affect,VB,O
the,DT,O
in,FW,O
vitro,FW,O
glucuronidation,NN,O
of,IN,O
valproic,JJ,O
acid,NN,O
.,.,.
,,
levetiracetam,NN,D
circulates,VBZ,O
largely,RB,O
unbound,JJ,O
-lrb-,-LRB-,O
10,CD,O
%,NN,O
bound,VBN,O
-rrb-,-RRB-,O
to,TO,O
plasma,NN,O
proteins,NNS,O
.,.,.
,,
clinically,RB,O
significant,JJ,O
interactions,NNS,O
with,IN,O
other,JJ,O
drugs,NNS,D
through,IN,O
competition,NN,O
for,IN,O
protein,NN,O
binding,NN,O
sites,NNS,O
are,VBP,O
therefore,RB,O
unlikely,JJ,O
.,.,.
,,
potential,JJ,O
pharmacokinetic,JJ,O
interactions,NNS,O
were,VBD,O
assessed,VBN,O
in,IN,O
clinical,JJ,O
pharmacokinetic,JJ,O
studies,NNS,O
-lrb-,-LRB-,O
phenytoin,NN,D
",",",",O
valproate,NN,D
",",",",O
oral,JJ,O
contraceptive,NN,G
",",",",O
digoxin,NN,D
",",",",O
warfarin,NN,D
",",",",O
probenecid,NN,D
-rrb-,-RRB-,O
and,CC,O
through,IN,O
pharmacokinetic,JJ,O
screening,NN,O
in,IN,O
the,DT,O
placebo-controlled,JJ,O
clinical,JJ,O
studies,NNS,O
in,IN,O
epilepsy,NN,O
patients,NNS,O
.,.,.
,,
drug-drug,NNP,O
interactions,NNS,O
between,IN,O
keppra,NNP,B
and,CC,O
other,JJ,O
antiepileptic,JJ,O
drugs,NNS,O
-lrb-,-LRB-,O
aeds,NNS,G
-rrb-,-RRB-,O
phenytoin,NNP,D
keppra,NNP,B
-lrb-,-LRB-,O
3000,CD,O
mg,NN,O
daily,JJ,O
-rrb-,-RRB-,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetic,JJ,O
disposition,NN,O
of,IN,O
phenytoin,NN,D
in,IN,O
patients,NNS,O
with,IN,O
refractory,JJ,O
epilepsy,NN,O
.,.,.
,,
pharmacokinetics,NNS,O
of,IN,O
levetiracetam,NN,D
were,VBD,O
also,RB,O
not,RB,O
affected,VBN,O
by,IN,O
phenytoin,NN,D
.,.,.
,,
valproate,NNP,D
keppra,NNP,B
-lrb-,-LRB-,O
1500,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
valproate,NN,D
in,IN,O
healthy,JJ,O
volunteers,NNS,O
.,.,.
,,
valproate,NNP,D
500,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
did,VBD,O
not,RB,O
modify,VB,O
the,DT,O
rate,NN,O
or,CC,O
extent,NN,O
of,IN,O
levetiracetam,NN,D
absorption,NN,O
or,CC,O
its,PRP$,O
plasma,NN,O
clearance,NN,O
or,CC,O
urinary,JJ,O
excretion,NN,O
.,.,.
,,
there,EX,O
also,RB,O
was,VBD,O
no,DT,O
effect,NN,O
on,IN,O
exposure,NN,O
to,TO,O
and,CC,O
the,DT,O
excretion,NN,O
of,IN,O
the,DT,O
primary,JJ,O
metabolite,NN,O
",",",",O
ucb,NN,O
l057,NN,O
.,.,.
,,
potential,JJ,O
drug,NN,D
interactions,NNS,O
between,IN,O
keppra,NNP,B
and,CC,O
other,JJ,O
aeds,NNS,G
-lrb-,-LRB-,O
carbamazepine,NN,D
",",",",O
gabapentin,NN,D
",",",",O
lamotrigine,NN,D
",",",",O
phenobarbital,NN,D
",",",",O
phenytoin,NN,D
",",",",O
primidone,NN,D
and,CC,O
valproate,NN,D
-rrb-,-RRB-,O
were,VBD,O
also,RB,O
assessed,VBN,O
by,IN,O
evaluating,VBG,O
the,DT,O
serum,NN,O
concentrations,NNS,O
of,IN,O
levetiracetam,NN,D
and,CC,O
these,DT,O
aeds,NNS,G
during,IN,O
placebo-controlled,JJ,O
clinical,JJ,O
studies,NNS,O
.,.,.
,,
these,DT,O
data,NNS,O
indicate,VBP,O
that,IN,O
levetiracetam,NN,D
does,VBZ,O
not,RB,O
influence,VB,O
the,DT,O
plasma,NN,O
concentration,NN,O
of,IN,O
other,JJ,O
aeds,NNS,G
and,CC,O
that,IN,O
these,DT,O
aeds,NNS,G
do,VBP,O
not,RB,O
influence,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
levetiracetam,NN,D
.,.,.
,,
effect,NN,O
of,IN,O
aeds,NNS,G
in,IN,O
pediatric,NNP,O
patients,NNPS,O
there,EX,O
was,VBD,O
about,IN,O
a,DT,O
22,CD,O
%,NN,O
increase,NN,O
of,IN,O
apparent,JJ,O
total,JJ,O
body,NN,O
clearance,NN,O
of,IN,O
levetiracetam,NN,D
when,WRB,O
it,PRP,O
was,VBD,O
co-administered,VBN,O
with,IN,O
enzyme-inducing,JJ,O
aeds,NNS,G
.,.,.
,,
dose,NN,O
adjustment,NN,O
is,VBZ,O
not,RB,O
recommended.levetiracetam,NN,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
carbamazepine,NN,D
",",",",O
valproate,NN,D
",",",",O
topiramate,NN,D
",",",",O
or,CC,O
lamotrigine,NN,D
.,.,.
,,
other,JJ,O
drug,NN,O
interactions,NNS,O
oral,JJ,O
contraceptives,NNS,G
keppra,NN,B
-lrb-,-LRB-,O
500,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
influence,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
an,DT,O
oral,JJ,O
contraceptive,NN,G
containing,VBG,O
0.03,CD,O
mg,NN,O
ethinyl,NN,O
estradiol,NN,O
and,CC,O
0.15,CD,O
mg,NN,O
levonorgestrel,NN,D
",",",",O
or,CC,O
of,IN,O
the,DT,O
luteinizing,VBG,O
hormone,NN,O
and,CC,O
progesterone,NN,D
levels,NNS,O
",",",",O
indicating,VBG,O
that,IN,O
impairment,NN,O
of,IN,O
contraceptive,JJ,G
efficacy,NN,O
is,VBZ,O
unlikely,JJ,O
.,.,.
,,
coadministration,NN,O
of,IN,O
this,DT,O
oral,JJ,O
contraceptive,NN,G
did,VBD,O
not,RB,O
influence,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
levetiracetam,NN,D
.,.,.
,,
digoxin,NNP,D
keppra,NNP,B
-lrb-,-LRB-,O
1000,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
influence,VB,O
the,DT,O
pharmacokinetics,NNS,O
and,CC,O
pharmacodynamics,NNS,O
-lrb-,-LRB-,O
ecg,NN,O
-rrb-,-RRB-,O
of,IN,O
digoxin,NN,D
given,VBN,O
as,IN,O
a,DT,O
0.25,CD,O
mg,NN,O
dose,NN,O
every,DT,O
day,NN,O
.,.,.
,,
coadministration,NN,O
of,IN,O
digoxin,NN,D
did,VBD,O
not,RB,O
influence,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
levetiracetam,NN,D
.,.,.
,,
warfarin,NNP,D
keppra,NNP,B
-lrb-,-LRB-,O
1000,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
influence,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
r,NN,O
and,CC,O
s,NN,O
warfarin,NN,D
.,.,.
,,
prothrombin,NNP,O
time,NN,O
was,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
levetiracetam,NN,D
.,.,.
,,
coadministration,NN,O
of,IN,O
warfarin,NN,D
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
levetiracetam,NN,D
.,.,.
,,
probenecid,NNP,D
:,:,O
probenecid,NNP,D
",",",",O
a,DT,O
renal,JJ,O
tubular,JJ,O
secretion,NN,O
blocking,VBG,O
agent,NN,O
",",",",O
administered,VBN,O
at,IN,O
a,DT,O
dose,NN,O
of,IN,O
500,CD,O
mg,NN,O
four,CD,O
times,NNS,O
a,DT,O
day,NN,O
",",",",O
did,VBD,O
not,RB,O
change,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
levetiracetam,NN,D
1000,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
.,.,.
,,
cssmax,NN,O
of,IN,O
the,DT,O
metabolite,NN,O
",",",",O
ucb,NN,O
l057,NN,O
",",",",O
was,VBD,O
approximately,RB,O
doubled,VBN,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
probenecid,NN,D
while,IN,O
the,DT,O
fraction,NN,O
of,IN,O
drug,NN,D
excreted,VBD,O
unchanged,JJ,O
in,IN,O
the,DT,O
urine,NN,O
remained,VBD,O
the,DT,O
same,JJ,O
.,.,.
,,
renal,JJ,O
clearance,NN,O
of,IN,O
ucb,NN,O
l057,NN,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
probenecid,NN,D
decreased,VBD,O
60,CD,O
%,NN,O
",",",",O
probably,RB,O
related,VBN,O
to,TO,O
competitive,JJ,O
inhibition,NN,O
of,IN,O
tubular,JJ,O
secretion,NN,O
of,IN,O
ucb,NN,O
l057,NN,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
keppra,NNP,B
on,IN,O
probenecid,NN,D
was,VBD,O
not,RB,O
studied,VBN,O
.,.,.
,,
although,IN,O
betagan,NNP,B
used,VBD,O
alone,RB,O
has,VBZ,O
little,JJ,O
or,CC,O
no,DT,O
effect,NN,O
on,IN,O
pupil,NN,O
size,NN,O
",",",",O
mydriasis,NN,O
resulting,VBG,O
from,IN,O
concomitant,JJ,O
therapy,NN,O
with,IN,O
betagan,NN,B
and,CC,O
epinephrine,NN,D
may,MD,O
occur,VB,O
.,.,.
,,
close,JJ,O
observation,NN,O
of,IN,O
the,DT,O
patient,NN,O
is,VBZ,O
recommended,VBN,O
when,WRB,O
a,DT,O
beta-blocker,NN,G
is,VBZ,O
administered,VBN,O
to,TO,O
patients,NNS,O
receiving,VBG,O
catecholamine-depleting,JJ,O
drugs,NNS,D
such,JJ,O
as,IN,O
reserpine,NN,D
",",",",O
because,IN,O
of,IN,O
possible,JJ,O
additive,JJ,O
effects,NNS,O
and,CC,O
the,DT,O
production,NN,O
of,IN,O
hypotension,NN,O
and/or,CC,O
marked,JJ,O
bradycardia,NN,O
",",",",O
which,WDT,O
may,MD,O
produce,VB,O
vertigo,NN,O
",",",",O
syncope,NN,O
or,CC,O
postural,JJ,O
hypotension,NN,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
along,IN,O
with,IN,O
either,CC,O
oral,JJ,O
or,CC,O
intravenous,JJ,O
calcium,NN,D
antagonists,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
for,IN,O
possible,JJ,O
atrioventricular,JJ,O
conduction,NN,O
disturbances,NNS,O
",",",",O
left,VBD,O
ventricular,JJ,O
failure,NN,O
and,CC,O
hypotension,NN,O
.,.,.
,,
in,IN,O
patients,NNS,O
with,IN,O
impaired,JJ,O
cardiac,JJ,O
function,NN,O
",",",",O
simultaneous,JJ,O
use,NN,O
should,MD,O
be,VB,O
avoided,VBN,O
altogether,RB,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
with,IN,O
digitalis,NN,G
and,CC,O
calcium,NN,D
antagonists,NNS,O
may,MD,O
have,VB,O
additive,JJ,O
effects,NNS,O
on,IN,O
prolonging,VBG,O
atrioventricular,JJ,O
conduction,NN,O
time,NN,O
.,.,.
,,
phenothiazine-related,JJ,O
compounds,NNS,O
and,CC,O
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
may,MD,O
have,VB,O
additive,JJ,O
hypotensite,JJ,O
effects,NNS,O
due,JJ,O
to,TO,O
the,DT,O
inhibition,NN,O
of,IN,O
each,DT,O
other,JJ,O
s,NNS,O
metabolism,NN,O
.,.,.
,,
chirocaine,NNP,B
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
other,JJ,O
local,JJ,O
anesthetics,NNS,G
or,CC,O
agents,NNS,O
structurally,RB,O
related,JJ,O
to,TO,O
amide-type,JJ,O
local,JJ,O
anesthetics,NNS,G
since,IN,O
the,DT,O
toxic,JJ,O
effects,NNS,O
of,IN,O
these,DT,O
drugs,NNS,D
could,MD,O
be,VB,O
additive,JJ,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
indicate,VBP,O
cyp3a4,NN,D
isoform,NN,O
and,CC,O
cyp1a2,NN,D
isoform,NN,O
mediate,VBP,O
the,DT,O
metabolism,NN,O
of,IN,O
levobupivacaine,NN,D
to,TO,O
desbutyl,NN,O
levobupivacaine,NN,D
and,CC,O
3-hydroxy,JJ,O
levobupivacaine,NN,D
",",",",O
respectively,RB,O
.,.,.
,,
thus,RB,O
agents,NNS,O
likely,JJ,O
to,TO,O
be,VB,O
concomitantly,RB,O
administered,VBN,O
with,IN,O
chirocaine,NN,B
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
this,DT,O
isoenzyme,NN,O
family,NN,O
may,MD,O
potentially,RB,O
interact,VB,O
with,IN,O
chirocaine,NNP,B
.,.,.
,,
although,IN,O
no,DT,O
clinical,JJ,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
",",",",O
it,PRP,O
is,VBZ,O
likely,JJ,O
that,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
levobupivacaine,NN,D
may,MD,O
be,VB,O
affected,VBN,O
by,IN,O
the,DT,O
known,JJ,O
cyp3a4,NN,D
inducers,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
phenytoin,NN,D
",",",",O
phenobarbital,NN,D
",",",",O
rifampin,NN,D
-rrb-,-RRB-,O
",",",",O
cyp3a4,NN,D
inhibitors,NNS,O
-lrb-,-LRB-,O
azole,NN,O
antimycotics,NNS,O
e.g.,FW,O
",",",",O
ketoconazole,NN,D
.,.,.
,,
certain,JJ,O
protease,NN,O
inhibitors,NNS,O
e.g.,FW,O
",",",",O
ritanovir,NN,O
.,.,.
,,
macrolide,NN,O
antibiotics,NNS,G
e.g.,FW,O
",",",",O
erythromycin,NN,D
.,.,.
,,
and,CC,O
calcium,NN,D
channel,NN,O
antagonists,NNS,O
e.g.,FW,O
",",",",O
verapamil,NN,D
-rrb-,-RRB-,O
",",",",O
cyp1a2,NN,D
inducers,NNS,O
-lrb-,-LRB-,O
omeprazole,NN,D
-rrb-,-RRB-,O
and,CC,O
cyp1a2,NN,D
inhibitors,NNS,O
-lrb-,-LRB-,O
furafylline,NN,D
and,CC,O
clarithromycin,NN,D
-rrb-,-RRB-,O
.,.,.
,,
dosage,NN,O
adjustment,NN,O
may,MD,O
be,VB,O
warranted,VBN,O
when,WRB,O
levobupivacaine,NN,D
is,VBZ,O
concurrently,RB,O
administered,VBN,O
with,IN,O
cyp3a4,NN,D
inhibitors,NNS,O
and,CC,O
cyp1a2,NN,D
inhibitors,NNS,O
as,IN,O
systemic,JJ,O
levobupivacaine,NN,D
levels,NNS,O
may,MD,O
rise,VB,O
resulting,VBG,O
in,IN,O
toxicity,NN,O
.,.,.
,,
specific,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
with,IN,O
levofloxacin,NN,D
.,.,.
,,
however,RB,O
",",",",O
the,DT,O
systemic,JJ,O
administration,NN,O
of,IN,O
some,DT,O
quinolones,NNS,G
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
elevate,VB,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
theophylline,NN,D
",",",",O
interfere,VBP,O
with,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
caffeine,NN,D
",",",",O
and,CC,O
enhance,VBP,O
the,DT,O
effects,NNS,O
of,IN,O
the,DT,O
oral,JJ,O
anticoagulant,JJ,G
warfarin,NN,D
and,CC,O
its,PRP$,O
derivatives,NNS,O
",",",",O
and,CC,O
has,VBZ,O
been,VBN,O
associated,VBN,O
with,IN,O
transient,JJ,O
elevations,NNS,O
in,IN,O
serum,NN,O
creatinine,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
systemic,JJ,O
cyclosporine,NN,D
concomitantly,RB,O
.,.,.
,,
interactions,NNS,O
with,IN,O
other,JJ,O
cns,NNS,O
agents,NNS,O
:,:,O
concurrent,JJ,O
use,NN,O
of,IN,O
levo-dromoran,JJ,B
with,IN,O
all,DT,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressants,NNS,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
alcohol,NN,D
",",",",O
sedatives,NNS,G
",",",",O
hypnotics,NNS,G
",",",",O
other,JJ,O
opioids,NNS,G
",",",",O
general,JJ,O
anesthetics,NNS,G
",",",",O
barbiturates,NNS,G
",",",",O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
tranquilizers,NNS,G
",",",",O
skeletal,JJ,O
muscle,NN,O
relaxants,NNS,O
and,CC,O
antihistamines,NNS,G
-rrb-,-RRB-,O
may,MD,O
result,VB,O
in,IN,O
additive,JJ,O
central,JJ,O
nervous,JJ,O
system,NN,O
depressant,NN,O
effects,NNS,O
.,.,.
,,
respiratory,JJ,O
depression,NN,O
",",",",O
hypotension,NN,O
",",",",O
and,CC,O
profound,JJ,O
sedation,NN,O
or,CC,O
coma,NN,O
may,MD,O
occur,VB,O
.,.,.
,,
when,WRB,O
such,JJ,O
combined,JJ,O
therapy,NN,O
is,VBZ,O
contemplated,VBN,O
",",",",O
the,DT,O
dose,NN,O
of,IN,O
one,CD,O
or,CC,O
both,DT,O
agents,NNS,O
should,MD,O
be,VB,O
reduced,VBN,O
.,.,.
,,
although,IN,O
no,DT,O
interaction,NN,O
between,IN,O
mao,NNP,O
inhibitors,NNS,O
and,CC,O
levo-dromoran,NNP,B
has,VBZ,O
been,VBN,O
observed,VBN,O
",",",",O
it,PRP,O
is,VBZ,O
not,RB,O
recommended,VBN,O
for,IN,O
use,NN,O
with,IN,O
mao,NN,O
inhibitors,NNS,O
.,.,.
,,
most,JJS,O
cases,NNS,O
of,IN,O
serious,JJ,O
or,CC,O
fatal,JJ,O
adverse,JJ,O
events,NNS,O
involving,VBG,O
levo-dromoran,NNP,B
reported,VBD,O
to,TO,O
the,DT,O
manufacturer,NN,O
or,CC,O
the,DT,O
fda,NNP,O
have,VBP,O
involved,VBN,O
either,CC,O
the,DT,O
administration,NN,O
of,IN,O
large,JJ,O
initial,JJ,O
doses,NNS,O
or,CC,O
too,RB,O
frequent,JJ,O
doses,NNS,O
of,IN,O
the,DT,O
drug,NN,D
to,TO,O
nonopioid,JJ,O
tolerant,JJ,O
patients,NNS,O
",",",",O
or,CC,O
the,DT,O
simultaneous,JJ,O
administration,NN,O
of,IN,O
levorphanol,NN,D
with,IN,O
other,JJ,O
drugs,NNS,D
affecting,VBG,O
respiration,NN,O
.,.,.
,,
the,DT,O
initial,JJ,O
dose,NN,O
of,IN,O
levorphanol,NN,D
should,MD,O
be,VB,O
reduced,VBN,O
by,IN,O
approximately,RB,O
50,CD,O
%,NN,O
or,CC,O
more,JJR,O
when,WRB,O
it,PRP,O
is,VBZ,O
given,VBN,O
to,TO,O
patients,NNS,O
along,IN,O
with,IN,O
another,DT,O
drug,NN,D
affecting,VBG,O
respiration,NN,O
.,.,.
,,
interactions,NNS,O
with,IN,O
mixed,JJ,O
agonist/antagonist,NN,O
opioid,NN,O
analgesics,NNS,O
:,:,O
agonist/antagonist,NN,O
analgesics,NNS,G
-lrb-,-LRB-,O
eg,FW,O
",",",",O
pentazocine,NN,D
",",",",O
nalbuphine,NN,D
",",",",O
butorphanol,NN,D
",",",",O
dezocine,NN,D
and,CC,O
buprenorphine,NN,D
-rrb-,-RRB-,O
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
to,TO,O
a,DT,O
patient,NN,O
who,WP,O
has,VBZ,O
received,VBN,O
or,CC,O
is,VBZ,O
receiving,VBG,O
a,DT,O
course,NN,O
of,IN,O
therapy,NN,O
with,IN,O
a,DT,O
pure,JJ,O
agonist,NN,O
opioid,JJ,G
analgesic,JJ,O
such,JJ,O
as,IN,O
levo-dromoran,NNP,B
.,.,.
,,
in,IN,O
opioid-dependent,JJ,O
patients,NNS,O
",",",",O
mixed,JJ,O
agonist/antagonist,JJ,O
analgesics,NNS,G
may,MD,O
precipitate,VB,O
withdrawal,NN,O
symptoms,NNS,O
.,.,.
,,
no,DT,O
important,JJ,O
interactions,NNS,O
to,TO,O
date,VB,O
levosimendan,NNP,D
does,VBZ,O
not,RB,O
have,VB,O
clinically,RB,O
important,JJ,O
pharmacokinetic,JJ,O
interactions,NNS,O
with,IN,O
captopril,NN,D
",",",",O
beta-blockers,NNS,G
",",",",O
felodipine,NN,D
",",",",O
digoxin,NN,D
",",",",O
warfarin,NN,D
",",",",O
isosorbide,NN,O
mononitrate,NN,O
",",",",O
carvedilol,NN,D
",",",",O
ethanol,NN,D
or,CC,O
itraconazole,NN,D
.,.,.
,,
the,DT,O
magnitude,NN,O
and,CC,O
relative,JJ,O
importance,NN,O
of,IN,O
the,DT,O
effects,NNS,O
noted,VBD,O
below,RB,O
are,VBP,O
likely,JJ,O
to,TO,O
be,VB,O
patient,NN,O
specific,JJ,O
and,CC,O
may,MD,O
vary,VB,O
by,IN,O
such,JJ,O
factors,NNS,O
as,IN,O
age,NN,O
",",",",O
gender,NN,O
",",",",O
race,NN,O
",",",",O
intercurrent,JJ,O
illnesses,NNS,O
",",",",O
dose,NN,O
of,IN,O
either,CC,O
agent,NN,O
",",",",O
additional,JJ,O
concomitant,JJ,O
medications,NNS,O
",",",",O
and,CC,O
timing,NN,O
of,IN,O
drug,NN,D
administration,NN,O
.,.,.
,,
any,DT,O
agent,NN,O
that,WDT,O
alters,VBZ,O
thyroid,NN,G
hormone,NN,O
synthesis,NN,O
",",",",O
secretion,NN,O
",",",",O
distribution,NN,O
",",",",O
effect,NN,O
on,IN,O
target,NN,O
tissues,NNS,O
",",",",O
metabolism,NN,O
",",",",O
or,CC,O
elimination,NN,O
may,MD,O
alter,VB,O
the,DT,O
optimal,JJ,O
therapeutic,JJ,O
dose,NN,O
of,IN,O
levothyroxine,NN,D
sodium,NN,O
.,.,.
,,
levothyroxine,NNP,O
sodium,NN,O
absorption,NN,O
:,:,O
the,DT,O
following,VBG,O
agents,NNS,O
may,MD,O
bind,VB,O
and,CC,O
decrease,VB,O
absorption,NN,O
of,IN,O
levothyroxine,NN,D
sodium,NN,O
from,IN,O
the,DT,O
gastrointestinal,JJ,O
tract,NN,O
:,:,O
aluminum,NN,D
hydoxide,NN,O
",",",",O
cholestyramine,NN,D
resin,NN,G
",",",",O
colestipol,NN,D
hydrochloride,NN,O
",",",",O
ferrous,JJ,O
sulfate,NN,O
",",",",O
sodium,NN,O
polystyrene,NN,O
sulfonate,NN,O
",",",",O
soybean,NN,O
flour,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
infant,JJ,O
formula,NN,O
-rrb-,-RRB-,O
",",",",O
sucralfate,NN,D
.,.,.
,,
binding,NN,O
to,TO,O
serum,NN,O
proteins,NNS,O
:,:,O
the,DT,O
following,VBG,O
agents,NNS,O
may,MD,O
either,RB,O
inhibit,VB,O
levothyroxine,NN,D
sodium,NN,O
binding,NN,O
to,TO,O
serum,NN,O
proteins,NNS,O
or,CC,O
alter,VB,O
the,DT,O
concentrations,NNS,O
of,IN,O
serum,NN,O
binding,NN,O
proteins,NNS,O
:,:,O
androgens,NNS,G
and,CC,O
related,JJ,O
anabolic,JJ,O
hormones,NNS,O
",",",",O
asparaginase,NN,D
",",",",O
clofibrate,NN,D
",",",",O
estrogens,NNS,G
and,CC,O
estrogen-containing,JJ,O
compounds,NNS,O
",",",",O
5-fluorouracil,NN,D
",",",",O
furosemide,NN,D
",",",",O
glucocorticoids,NNS,G
",",",",O
meclofenamic,JJ,O
acid,NN,O
",",",",O
mefenamic,JJ,O
acid,NN,O
",",",",O
methadone,NN,D
",",",",O
perphenazine,NN,D
",",",",O
phenylbutazone,NN,D
",",",",O
phenytoin,NN,D
",",",",O
salicylates,NNS,G
",",",",O
tamoxifen,NN,D
.,.,.
,,
thyroid,NN,G
physiology,NNP,O
:,:,O
the,DT,O
following,VBG,O
agents,NNS,O
may,MD,O
alter,VB,O
thyroid,NN,G
hormone,NN,O
or,CC,O
tsh,NN,O
levels,NNS,O
",",",",O
generally,RB,O
by,IN,O
effects,NNS,O
on,IN,O
thyroid,NN,G
hormone,NN,O
synthesis,NN,O
",",",",O
secretion,NN,O
",",",",O
distribution,NN,O
",",",",O
metabolism,NN,O
",",",",O
hormone,NN,O
action,NN,O
",",",",O
or,CC,O
elimination,NN,O
",",",",O
or,CC,O
altered,JJ,O
tsh,NN,O
secretion,NN,O
:,:,O
aminoglutethimide,NN,D
",",",",O
p-aminosalicylic,JJ,O
acid,NN,O
",",",",O
amiodarone,NN,D
",",",",O
androgens,NNS,G
and,CC,O
related,JJ,O
anabolic,JJ,O
hormones,NNS,O
",",",",O
complex,JJ,O
anions,NNS,O
-lrb-,-LRB-,O
thiocyanate,NN,D
",",",",O
perchlorate,NN,D
",",",",O
pertechnetate,NN,D
-rrb-,-RRB-,O
",",",",O
antithyroid,JJ,O
drugs,NNS,D
",",",",O
b-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
",",",",O
carbamazepine,NN,D
",",",",O
chloral,JJ,O
hydrate,NN,O
",",",",O
diazepam,NN,D
",",",",O
dopamine,NN,D
and,CC,O
dopamine,NN,D
agonists,NNS,O
",",",",O
ethionamide,NN,D
",",",",O
glucocorticoids,NNS,G
",",",",O
heparin,NN,D
",",",",O
hepatic,JJ,O
enzyme,NN,O
inducers,NNS,O
",",",",O
insulin,NN,D
",",",",O
iodinated,VBN,O
cholestographic,JJ,O
agents,NNS,O
",",",",O
iodine-containing,JJ,O
compounds,NNS,O
",",",",O
levodopa,NN,D
",",",",O
lovastatin,NN,D
",",",",O
lithium,NN,D
",",",",O
6-mercaptopurine,NN,D
",",",",O
metoclopramide,NN,D
",",",",O
mitotane,NN,D
",",",",O
nitroprusside,NN,D
",",",",O
phenobarbital,NN,D
",",",",O
phenytoin,NN,D
",",",",O
resorcinol,NN,D
",",",",O
rifampin,NN,D
",",",",O
somatostatin,NN,O
analogs,NNS,O
",",",",O
sulfonamides,NNS,G
",",",",O
sulfonylureas,NNS,G
",",",",O
thiazide,JJ,G
diuretics,NNS,G
.,.,.
,,
adrenocorticoids,NNP,O
:,:,O
metabolic,JJ,O
clearance,NN,O
of,IN,O
adrenocorticoids,NNS,O
is,VBZ,O
decreased,VBN,O
in,IN,O
hypothyroid,JJ,O
patients,NNS,O
and,CC,O
increased,VBN,O
in,IN,O
hyperthyroid,JJ,O
patients,NNS,O
",",",",O
and,CC,O
may,MD,O
therefore,RB,O
change,VB,O
with,IN,O
changing,VBG,O
thyroid,NN,G
status,NN,O
.,.,.
,,
amiodarone,NNP,D
:,:,O
amiodarone,NN,D
therapy,NN,O
alone,RB,O
can,MD,O
cause,VB,O
hypothyroidism,NN,O
or,CC,O
hyperthyroidism,NN,O
.,.,.
,,
anticoagulants,NNS,G
-lrb-,-LRB-,O
oral,JJ,O
-rrb-,-RRB-,O
:,:,O
the,DT,O
hypoprothrombinemic,JJ,O
effect,NN,O
of,IN,O
anticoagulants,NNS,G
may,MD,O
be,VB,O
potentiated,JJ,O
",",",",O
apparently,RB,O
by,IN,O
increased,VBN,O
catabloism,NN,O
of,IN,O
vitamin,NN,G
k-dependent,JJ,O
clotting,NN,O
factors,NNS,O
.,.,.
,,
antidiabetic,JJ,O
agents,NNS,O
-lrb-,-LRB-,O
insulin,NN,D
",",",",O
sulfonylureas,NNP,G
-rrb-,-RRB-,O
:,:,O
requirements,NNS,O
for,IN,O
insulin,NN,D
or,CC,O
oral,JJ,O
antidiabetic,JJ,D
agents,NNS,O
may,MD,O
be,VB,O
reduced,VBN,O
in,IN,O
hypothyroid,JJ,O
patients,NNS,O
with,IN,O
diabetes,NN,O
mellitus,NN,O
and,CC,O
may,MD,O
subsequently,RB,O
increase,VB,O
with,IN,O
the,DT,O
initiation,NN,O
of,IN,O
thyroid,NN,G
hormone,NN,O
replacement,NN,O
therapy,NN,O
.,.,.
,,
b-adrenergic,JJ,O
blocking,NN,O
agents,NNS,O
:,:,O
actions,NNS,O
of,IN,O
some,DT,O
of,IN,O
beta-blocking,JJ,D
agents,NNS,O
may,MD,O
be,VB,O
impaired,JJ,O
when,WRB,O
hypothyroid,JJ,O
patients,NNS,O
become,VBP,O
euthyroid,JJ,O
.,.,.
,,
cytokines,NNS,G
-lrb-,-LRB-,O
interferon,NN,G
",",",",O
interleukin,NN,G
-rrb-,-RRB-,O
:,:,O
cytokines,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
induce,VB,O
both,CC,O
hyperthyroidism,NN,O
and,CC,O
hypothyroidism,NN,O
.,.,.
,,
digitalis,NNP,G
glycosides,NNPS,O
:,:,O
therapeutic,JJ,O
effects,NNS,O
of,IN,O
digitalis,NN,G
glycosides,NNS,G
may,MD,O
be,VB,O
reduced,VBN,O
.,.,.
,,
serum,NN,O
digitalis,NN,G
levels,NNS,O
may,MD,O
be,VB,O
decreased,VBN,O
in,IN,O
hyperthyroidism,NN,O
or,CC,O
when,WRB,O
a,DT,O
hypothyroid,JJ,O
patient,NN,O
becomes,VBZ,O
euthyroid,JJ,O
.,.,.
,,
ketamine,NNP,D
:,:,O
marked,JJ,O
hypertension,NN,O
and,CC,O
tachycardia,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
association,NN,O
with,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
levothyroxine,NN,D
sodium,NN,O
and,CC,O
ketamine,NN,D
.,.,.
,,
maprotiline,NNP,D
:,:,O
risk,NN,O
of,IN,O
cardiac,JJ,O
arrhythmias,NNS,O
may,MD,O
increase,VB,O
.,.,.
,,
sodium,NN,O
iodide,NN,O
-lrb-,-LRB-,O
123i,NN,O
and,CC,O
131i,NN,O
-rrb-,-RRB-,O
",",",",O
sodium,NN,O
pertechnetate,NN,O
tc99m,NN,O
:,:,O
uptake,NNP,O
of,IN,O
radiolabeled,VBN,O
ions,NNS,O
may,MD,O
be,VB,O
decreased,VBN,O
.,.,.
,,
somatrem/somatropin,NNP,O
:,:,O
excessive,JJ,O
concurrent,JJ,O
use,NN,O
of,IN,O
thyroid,NN,G
hormone,NN,O
may,MD,O
accelerate,VB,O
epiphyseal,NN,O
closure,NN,O
.,.,.
,,
untreated,JJ,O
hypothyroidism,NN,O
may,MD,O
interfere,VB,O
with,IN,O
the,DT,O
growth,NN,O
response,NN,O
to,TO,O
somatrem,NN,D
or,CC,O
somatropin,NN,D
.,.,.
,,
theophylline,NNP,D
:,:,O
theophylline,NN,D
clearance,NN,O
may,MD,O
decrease,VB,O
in,IN,O
hypothyroid,JJ,O
patients,NNS,O
and,CC,O
return,NN,O
toward,IN,O
normal,JJ,O
when,WRB,O
a,DT,O
euthyroid,JJ,O
state,NN,O
is,VBZ,O
achieved,VBN,O
.,.,.
,,
tricyclic,JJ,O
antidepressants,NNS,G
:,:,O
concurrent,JJ,O
use,NN,O
may,MD,O
increase,VB,O
the,DT,O
therapeutic,JJ,O
and,CC,O
toxic,JJ,O
effects,NNS,O
of,IN,O
both,DT,O
drugs,NNS,D
",",",",O
possibly,RB,O
due,JJ,O
to,TO,O
increased,VBN,O
catecholamine,NN,O
sensitivity,NN,O
.,.,.
,,
onset,NN,O
of,IN,O
action,NN,O
of,IN,O
tricyclics,NNS,G
may,MD,O
be,VB,O
accelerated,VBN,O
.,.,.
,,
sympathomimetic,JJ,O
agents,NNS,O
:,:,O
possible,JJ,O
increased,VBN,O
risk,NN,O
of,IN,O
coronary,JJ,O
insufficiency,NN,O
in,IN,O
patients,NNS,O
with,IN,O
coronary,JJ,O
artery,NN,O
disease,NN,O
.,.,.
,,
the,DT,O
administration,NN,O
of,IN,O
local,JJ,O
anesthetic,JJ,G
solutions,NNS,O
containing,VBG,O
epinephrine,NN,D
or,CC,O
norepinephrine,NN,D
to,TO,O
patients,NNS,O
receiving,VBG,O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
or,CC,O
tricyclic,JJ,G
antidepressants,NNS,G
may,MD,O
produce,VB,O
severe,JJ,O
",",",",O
prolonged,JJ,O
hypertension,NN,O
.,.,.
,,
phenothiazines,NNS,G
and,CC,O
butyrophenones,NNS,G
may,MD,O
reduce,VB,O
or,CC,O
reverse,VB,O
the,DT,O
pressor,NN,O
effect,NN,O
of,IN,O
epinephrine,NN,D
.,.,.
,,
concurrent,JJ,O
use,NN,O
of,IN,O
these,DT,O
agents,NNS,O
should,MD,O
generally,RB,O
be,VB,O
avoided,VBN,O
.,.,.
,,
in,IN,O
situations,NNS,O
when,WRB,O
concurrent,JJ,O
therapy,NN,O
is,VBZ,O
necessary,JJ,O
",",",",O
careful,JJ,O
patient,NN,O
monitoring,NN,O
is,VBZ,O
essential,JJ,O
.,.,.
,,
concurrent,JJ,O
administration,NN,O
of,IN,O
vasopressor,NN,G
drugs,NNS,D
-lrb-,-LRB-,O
for,IN,O
the,DT,O
treatment,NN,O
of,IN,O
hypotension,NN,O
related,JJ,O
to,TO,O
obstetric,JJ,O
blocks,NNS,O
-rrb-,-RRB-,O
and,CC,O
ergot-type,JJ,O
oxytocic,JJ,O
drugs,NNS,D
may,MD,O
cause,VB,O
severe,JJ,O
",",",",O
persistent,JJ,O
hypertension,NN,O
or,CC,O
cerebrovascular,JJ,O
accidents,NNS,O
.,.,.
,,
lincomycin,NNP,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
have,VB,O
neuromuscular,JJ,O
blocking,VBG,O
properties,NNS,O
that,WDT,O
may,MD,O
enhance,VB,O
the,DT,O
action,NN,O
of,IN,O
other,JJ,O
neuromuscular,JJ,O
blocking,VBG,O
agents,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
it,PRP,O
should,MD,O
be,VB,O
used,VBN,O
in,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
such,JJ,O
agents,NNS,O
.,.,.
,,
antagonism,NN,O
between,IN,O
lincomycin,NN,D
and,CC,O
erythromycin,NN,D
in,FW,O
vitro,FW,O
has,VBZ,O
been,VBN,O
demonstrated,VBN,O
.,.,.
,,
because,IN,O
of,IN,O
possible,JJ,O
clinical,JJ,O
significance,NN,O
",",",",O
the,DT,O
two,CD,O
drugs,NNS,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
concurrently,RB,O
.,.,.
,,
oils,NNS,O
may,MD,O
enhance,VB,O
absorption,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
simultaneous,JJ,O
use,NN,O
of,IN,O
creams,NNS,O
",",",",O
ointments,NNS,O
or,CC,O
oils,NNS,O
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
monoamine,NNP,O
oxidase,NNP,O
inhibition,NN,O
:,:,O
linezolid,NN,D
is,VBZ,O
a,DT,O
reversible,JJ,O
",",",",O
nonselective,JJ,O
inhibitor,NN,O
of,IN,O
monoamine,NN,O
oxidase,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
linezolid,NN,D
has,VBZ,O
the,DT,O
potential,NN,O
for,IN,O
interaction,NN,O
with,IN,O
adrenergic,JJ,G
and,CC,O
serotonergic,JJ,O
agents,NNS,O
.,.,.
,,
adrenergic,JJ,O
agents,NNS,O
:,:,O
some,DT,O
individuals,NNS,O
receiving,VBG,O
zyvox,NNP,B
may,MD,O
experience,VB,O
a,DT,O
reversible,JJ,O
enhancement,NN,O
of,IN,O
the,DT,O
pressor,NN,O
response,NN,O
to,TO,O
indirect-acting,JJ,O
sympathomimetic,JJ,G
agents,NNS,O
",",",",O
vasopressor,NN,G
or,CC,O
dopaminergic,JJ,O
agents,NNS,O
.,.,.
,,
commonly,RB,O
used,VBN,O
drugs,NNS,D
such,JJ,O
as,IN,O
phenylpropanolamine,NN,D
and,CC,O
pseudoephedrine,NN,D
have,VBP,O
been,VBN,O
specifically,RB,O
studied,VBN,O
.,.,.
,,
initial,JJ,O
doses,NNS,O
of,IN,O
adrenergic,JJ,G
agents,NNS,O
",",",",O
such,JJ,O
as,IN,O
dopamine,NN,D
or,CC,O
epinephrine,NN,D
",",",",O
should,MD,O
be,VB,O
reduced,VBN,O
and,CC,O
titrated,VBN,O
to,TO,O
achieve,VB,O
the,DT,O
desired,VBN,O
response,NN,O
.,.,.
,,
serotonergic,NNP,O
agents,NNPS,O
:,:,O
co-administration,NN,O
of,IN,O
linezolid,NN,D
and,CC,O
serotonergic,JJ,O
agents,NNS,O
was,VBD,O
not,RB,O
associated,VBN,O
with,IN,O
serotonin,NN,O
syndrome,NN,O
in,IN,O
phase,NN,O
1,CD,O
",",",",O
2,CD,O
or,CC,O
3,CD,O
studies,NNS,O
.,.,.
,,
spontaneous,JJ,O
reports,NNS,O
of,IN,O
serotonin,NN,O
syndrome,NN,O
associated,VBN,O
with,IN,O
co-administration,NN,O
of,IN,O
zyvox,NNP,B
and,CC,O
serotonergic,JJ,O
agents,NNS,O
",",",",O
including,VBG,O
antidepressants,NNS,G
such,JJ,O
as,IN,O
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
ssris,NNS,G
-rrb-,-RRB-,O
",",",",O
have,VBP,O
been,VBN,O
reported,VBN,O
.,.,.
,,
patients,NNS,O
who,WP,O
are,VBP,O
treated,VBN,O
with,IN,O
zyvox,NN,B
and,CC,O
concomitant,JJ,O
serotonergic,JJ,O
agents,NNS,O
should,MD,O
be,VB,O
closely,RB,O
observed,VBN,O
for,IN,O
signs,NNS,O
and,CC,O
symptoms,NNS,O
of,IN,O
serotonin,NN,O
syndrome,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
cognitive,JJ,O
dysfunction,NN,O
",",",",O
hyperpyrexia,NN,O
",",",",O
hyperreflexia,NN,O
",",",",O
incoordination,NN,O
-rrb-,-RRB-,O
.,.,.
,,
if,IN,O
any,DT,O
signs,NNS,O
or,CC,O
symptoms,NNS,O
occur,VBP,O
physicians,NNS,O
should,MD,O
consider,VB,O
discontinuation,NN,O
of,IN,O
either,DT,O
one,CD,O
or,CC,O
both,DT,O
agents,NNS,O
-lrb-,-LRB-,O
zyvox,NN,B
or,CC,O
concomitant,JJ,O
serotonergic,JJ,O
agents,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
drug-laboratory,JJ,O
test,NN,O
interactions,NNS,O
there,EX,O
are,VBP,O
no,DT,O
reported,VBN,O
drug-laboratory,JJ,O
test,NN,O
interactions,NNS,O
.,.,.
,,
oral,JJ,O
anticoagulants,NNPS,G
:,:,O
thyroid,NN,G
hormones,NNS,O
appear,VBP,O
to,TO,O
increase,VB,O
catabolism,NN,O
of,IN,O
vitamin,NN,G
k-dependent,JJ,O
clotting,NN,O
factors,NNS,O
.,.,.
,,
if,IN,O
oral,JJ,O
anticoagulants,NNS,G
are,VBP,O
also,RB,O
being,VBG,O
given,VBN,O
",",",",O
compensatory,JJ,O
increases,NNS,O
in,IN,O
clotting,NN,O
factor,NN,O
synthesis,NN,O
are,VBP,O
impaired,JJ,O
.,.,.
,,
patients,NNS,O
stabilized,VBD,O
on,IN,O
oral,JJ,O
anticoagulants,NNS,G
who,WP,O
are,VBP,O
found,VBN,O
to,TO,O
require,VB,O
thyroid,NN,G
replacement,NN,O
therapy,NN,O
should,MD,O
be,VB,O
watched,VBN,O
very,RB,O
closely,RB,O
when,WRB,O
thyroid,NN,G
is,VBZ,O
started,VBN,O
.,.,.
,,
if,IN,O
a,DT,O
patient,NN,O
is,VBZ,O
truly,RB,O
hypothyroid,JJ,O
",",",",O
it,PRP,O
is,VBZ,O
likely,JJ,O
that,IN,O
a,DT,O
reduction,NN,O
in,IN,O
anticoagulant,JJ,G
dosage,NN,O
will,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
no,DT,O
special,JJ,O
precautions,NNS,O
appear,VBP,O
to,TO,O
be,VB,O
necessary,JJ,O
when,WRB,O
oral,JJ,O
anticoagulant,JJ,G
therapy,NN,O
is,VBZ,O
begun,VBN,O
in,IN,O
a,DT,O
patient,NN,O
already,RB,O
stabilized,VBD,O
on,IN,O
maintenance,NN,O
thyroid,NN,G
replacement,NN,O
therapy,NN,O
.,.,.
,,
insulin,NN,D
or,CC,O
oral,JJ,O
hypoglycemics,NNS,G
:,:,O
initiating,VBG,O
thyroid,NN,G
replacement,NN,O
therapy,NN,O
may,MD,O
cause,VB,O
increases,NNS,O
in,IN,O
insulin,NN,D
or,CC,O
oral,JJ,O
hypoglycemic,JJ,G
requirements,NNS,O
.,.,.
,,
the,DT,O
effects,NNS,O
seen,VBN,O
are,VBP,O
poorly,RB,O
understood,VBN,O
and,CC,O
depend,VB,O
upon,IN,O
a,DT,O
variety,NN,O
of,IN,O
factors,NNS,O
such,JJ,O
as,IN,O
dose,NN,O
and,CC,O
type,NN,O
of,IN,O
thyroid,NN,G
preparations,NNS,O
and,CC,O
endocrine,JJ,O
status,NN,O
of,IN,O
the,DT,O
patient,NN,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
insulin,NN,D
or,CC,O
oral,JJ,O
hypoglycemics,NNS,G
should,MD,O
be,VB,O
closely,RB,O
watched,VBN,O
during,IN,O
initiation,NN,O
of,IN,O
thyroid,NN,G
replacement,NN,O
therapy,NN,O
.,.,.
,,
cholestyramine,NNP,D
:,:,O
cholestyramine,NN,D
binds,VBZ,O
both,CC,O
t4,NN,D
and,CC,O
t3,NN,D
in,IN,O
the,DT,O
intestine,NN,O
",",",",O
thus,RB,O
impairing,VBG,O
absorption,NN,O
of,IN,O
these,DT,O
thyroid,NN,G
hormones,NNS,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
indicate,VBP,O
that,IN,O
the,DT,O
binding,NN,O
is,VBZ,O
not,RB,O
easily,RB,O
removed,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
4,CD,O
to,TO,O
5,CD,O
hours,NNS,O
should,MD,O
elapse,VB,O
between,IN,O
administration,NN,O
of,IN,O
cholestyramine,NN,D
and,CC,O
thyroid,NN,G
hormones,NNS,O
.,.,.
,,
estrogen,NN,G
",",",",O
oral,JJ,O
contraceptives,NNS,G
:,:,O
estrogens,NNS,G
tend,VBP,O
to,TO,O
increase,VB,O
serum,NN,O
thyroxine-binding,JJ,O
globulin,NN,O
-lrb-,-LRB-,O
tbg,NN,O
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
a,DT,O
patient,NN,O
with,IN,O
a,DT,O
nonfunctioning,JJ,O
thyroid,NN,G
gland,NN,O
who,WP,O
is,VBZ,O
receiving,VBG,O
thyroid,NN,G
replacement,NN,O
therapy,NN,O
",",",",O
free,JJ,O
levothyroxine,NN,D
may,MD,O
be,VB,O
decreased,VBN,O
when,WRB,O
estrogens,NNS,G
are,VBP,O
started,VBN,O
thus,RB,O
increasing,VBG,O
thyroid,NN,G
requirements,NNS,O
.,.,.
,,
however,RB,O
",",",",O
if,IN,O
the,DT,O
patients,NNS,O
thyroid,NN,G
gland,NN,O
has,VBZ,O
sufficient,JJ,O
function,NN,O
",",",",O
the,DT,O
decreased,VBN,O
free,JJ,O
thyroxine,NN,D
will,MD,O
result,VB,O
in,IN,O
a,DT,O
compensatory,JJ,O
increase,NN,O
in,IN,O
thyroxine,JJ,D
output,NN,O
by,IN,O
the,DT,O
thyroid,NN,G
.,.,.
,,
therefore,RB,O
",",",",O
patients,NNS,O
without,IN,O
a,DT,O
functioning,VBG,O
thyroid,NN,G
gland,NN,O
who,WP,O
are,VBP,O
on,IN,O
thyroid,NN,G
replacement,NN,O
therapy,NN,O
may,MD,O
need,VB,O
to,TO,O
increase,VB,O
their,PRP$,O
thyroid,NN,G
dose,NN,O
if,IN,O
estrogens,NNS,G
or,CC,O
estrogen-containing,JJ,O
oral,JJ,O
contraceptives,NNS,G
are,VBP,O
given,VBN,O
.,.,.
,,
tricyclic,JJ,O
antidepressants,NNS,G
:,:,O
use,NN,O
of,IN,O
thyroid,NN,G
products,NNS,O
with,IN,O
imipramine,NN,D
and,CC,O
other,JJ,O
tricyclic,JJ,G
antidepressants,NNS,G
may,MD,O
increase,VB,O
receptor,NN,D
sensitivity,NN,O
and,CC,O
enhance,VBP,O
antidepressant,JJ,G
activity,NN,O
transient,JJ,O
cardiac,JJ,O
arrhythmias,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
.,.,.
,,
thyroid,NN,G
hormone,NN,O
activity,NN,O
may,MD,O
also,RB,O
be,VB,O
enhanced,VBN,O
.,.,.
,,
digitalis,NNP,G
:,:,O
thyroid,NN,G
preparations,NNS,O
may,MD,O
potentiate,VB,O
the,DT,O
toxic,JJ,O
effects,NNS,O
of,IN,O
digitalis,NN,G
.,.,.
,,
thyroid,NN,G
hormonal,JJ,O
replacement,NN,O
increases,VBZ,O
metabolic,JJ,O
rate,NN,O
",",",",O
which,WDT,O
requires,VBZ,O
an,DT,O
increase,NN,O
in,IN,O
digitalis,NN,G
dosage,NN,O
.,.,.
,,
ketamine,NNP,D
:,:,O
when,WRB,O
administered,VBN,O
to,TO,O
patients,NNS,O
on,IN,O
a,DT,O
thyroid,NN,G
preparation,NN,O
",",",",O
this,DT,O
parenteral,JJ,O
anesthetic,NN,G
may,MD,O
cause,VB,O
hypertension,NN,O
and,CC,O
tachycardia,NN,O
.,.,.
,,
use,NN,O
with,IN,O
caution,NN,O
and,CC,O
be,VB,O
prepared,VBN,O
to,TO,O
treat,VB,O
hypertension,NN,O
",",",",O
if,IN,O
necessary,JJ,O
.,.,.
,,
vasopressors,NNP,O
:,:,O
thyroxine,NN,D
increases,VBZ,O
the,DT,O
adrenergic,JJ,G
effect,NN,O
of,IN,O
catecholamines,NNS,G
such,JJ,O
as,IN,O
epinephrine,NN,D
and,CC,O
norepinephrine,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
injection,NN,O
of,IN,O
these,DT,O
agents,NNS,O
into,IN,O
patients,NNS,O
receiving,VBG,O
thyroid,NN,G
preparations,NNS,O
increases,VBZ,O
the,DT,O
risk,NN,O
of,IN,O
precipitating,VBG,O
coronary,JJ,O
insufficiency,NN,O
especially,RB,O
in,IN,O
patients,NNS,O
with,IN,O
coronary,JJ,O
artery,NN,O
disease,NN,O
.,.,.
,,
careful,JJ,O
observation,NN,O
is,VBZ,O
required,VBN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
the,DT,O
following,JJ,O
drugs,NNS,D
or,CC,O
moieties,NNS,O
are,VBP,O
known,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
laboratory,NN,O
tests,NNS,O
performed,VBN,O
in,IN,O
patients,NNS,O
on,IN,O
thyroid,NN,G
hormone,NN,O
therapy,NN,O
:,:,O
androgens,NNS,G
",",",",O
corticosteroids,NNS,G
",",",",O
estrogens,NNS,G
",",",",O
oral,JJ,O
contraceptives,NNS,G
containing,VBG,O
estrogens,NNS,G
",",",",O
iodine-containing,JJ,O
preparations,NNS,O
and,CC,O
the,DT,O
numerous,JJ,O
preparations,NNS,O
containing,VBG,O
salicylates,NNS,G
.,.,.
,,
-,:,O
changes,NNS,O
in,IN,O
tbg,NN,O
concentration,NN,O
should,MD,O
be,VB,O
taken,VBN,O
into,IN,O
consideration,NN,O
in,IN,O
the,DT,O
interpretation,NN,O
of,IN,O
t4,NN,D
and,CC,O
t3,NN,D
values,NNS,O
.,.,.
,,
in,IN,O
such,JJ,O
cases,NNS,O
",",",",O
the,DT,O
unbound,JJ,O
-lrb-,-LRB-,O
free,JJ,O
-rrb-,-RRB-,O
hormone,NN,O
should,MD,O
be,VB,O
measured,VBN,O
.,.,.
,,
pregnancy,NN,O
estrogens,NNS,G
and,CC,O
estrogen-containing,JJ,O
oral,JJ,O
contraceptives,NNS,G
increase,VBP,O
tbg,NN,O
concentrations,NNS,O
.,.,.
,,
tbg,NN,O
may,MD,O
also,RB,O
be,VB,O
increased,VBN,O
during,IN,O
infectious,JJ,O
hepatitis,NN,O
.,.,.
,,
decreases,VBZ,O
in,IN,O
tbg,NN,O
concentrations,NNS,O
are,VBP,O
observed,VBN,O
in,IN,O
nephrosis,NN,O
",",",",O
acromegaly,NN,O
and,CC,O
after,IN,O
androgen,NN,G
or,CC,O
corticosteroid,NN,G
therapy,NN,O
.,.,.
,,
familial,JJ,O
hyper,NN,O
-,:,O
or,CC,O
hypo-thyroxine-binding-globulinemias,NNS,O
have,VBP,O
been,VBN,O
described,VBN,O
.,.,.
,,
the,DT,O
incidence,NN,O
of,IN,O
tbg,NN,O
deficiency,NN,O
approximates,VBZ,O
1,CD,O
in,IN,O
9000,CD,O
.,.,.
,,
the,DT,O
binding,NN,O
of,IN,O
thyroxine,NN,D
by,IN,O
thyroxine-binding,JJ,O
prealbumin,NN,O
-lrb-,-LRB-,O
tbpa,NN,O
-rrb-,-RRB-,O
is,VBZ,O
inhibited,VBN,O
by,IN,O
salicylate,NN,G
.,.,.
,,
-,:,O
medicinal,JJ,O
or,CC,O
dietary,JJ,O
iodine,NN,G
interferes,VBZ,O
with,IN,O
all,DT,O
in,FW,O
vivo,FW,O
tests,NNS,O
of,IN,O
radio-iodine,NN,O
uptake,NN,O
producing,VBG,O
low,JJ,O
uptakes,NNS,O
which,WDT,O
may,MD,O
not,RB,O
be,VB,O
reflective,JJ,O
of,IN,O
a,DT,O
TRUE,JJ,O
decrease,NN,O
in,IN,O
hormone,NN,O
synthesi,NNS,O
.,.,.
,,
-,:,O
the,DT,O
persistence,NN,O
of,IN,O
clinical,JJ,O
and,CC,O
laboratory,JJ,O
evidence,NN,O
of,IN,O
hypothyroidism,NN,O
in,IN,O
spite,NN,O
of,IN,O
adequate,JJ,O
dosage,NN,O
replacement,NN,O
indicates,VBZ,O
either,CC,O
poor,JJ,O
patient,NN,O
compliance,NN,O
",",",",O
poor,JJ,O
absorption,NN,O
",",",",O
excessive,JJ,O
fecal,JJ,O
loss,NN,O
",",",",O
or,CC,O
inactivity,NN,O
of,IN,O
the,DT,O
preparation,NN,O
.,.,.
,,
intracellular,JJ,O
resistance,NN,O
to,TO,O
thyroid,NN,G
hormone,NN,O
is,VBZ,O
quite,RB,O
rare,JJ,O
.,.,.
,,
urinary,JJ,O
acidifying,VBG,O
agents,NNS,O
these,DT,O
agents,NNS,O
-lrb-,-LRB-,O
ammonium,NN,O
chloride,NN,O
",",",",O
sodium,NN,O
acid,NN,O
phosphate,NN,D
",",",",O
etc.,FW,O
-rrb-,-RRB-,O
increase,VBP,O
the,DT,O
concentration,NN,O
of,IN,O
the,DT,O
ionized,VBN,O
species,NNS,O
of,IN,O
the,DT,O
amphetamine,NN,D
molecule,NN,O
",",",",O
thereby,RB,O
increasing,VBG,O
urinary,JJ,O
excretion,NN,O
.,.,.
,,
both,DT,O
groups,NNS,O
of,IN,O
agents,NNS,O
lower,JJR,O
blood,NN,O
levels,NNS,O
and,CC,O
efficacy,NN,O
of,IN,O
amphetamines,NNS,G
.,.,.
,,
adrenergic,JJ,O
blockers,NNS,O
adrenergic,JJ,O
blockers,NNS,O
are,VBP,O
inhibited,VBN,O
by,IN,O
amphetamines,NNS,G
.,.,.
,,
antidepressants,NNS,G
",",",",O
tricyclic,JJ,G
amphetamines,NNS,G
may,MD,O
enhance,VB,O
the,DT,O
activity,NN,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
or,CC,O
sympathomimetic,JJ,G
agents,NNS,O
.,.,.
,,
d-amphetamine,NN,D
with,IN,O
desipramine,NN,D
or,CC,O
protriptyline,NN,D
and,CC,O
possibly,RB,O
other,JJ,O
tricyclics,NNS,G
cause,VBP,O
striking,JJ,O
and,CC,O
sustained,JJ,O
increases,NNS,O
in,IN,O
the,DT,O
concentration,NN,O
of,IN,O
d-amphetamine,NN,D
in,IN,O
the,DT,O
brain,NN,O
.,.,.
,,
cardiovascular,JJ,O
effects,NNS,O
can,MD,O
be,VB,O
potentiated,VBN,O
.,.,.
,,
mao,NN,O
inhibitors,NNS,O
maoi,NNP,G
antidepressants,NNS,G
",",",",O
as,RB,O
well,RB,O
as,IN,O
a,DT,O
metabolite,NN,O
of,IN,O
furazolidone,NN,D
",",",",O
slow,JJ,O
amphetamine,NN,D
metabolism,NN,O
.,.,.
,,
this,DT,O
slowing,VBG,O
potentiates,VBZ,O
amphetamines,NNS,G
",",",",O
increasing,VBG,O
their,PRP$,O
effect,NN,O
on,IN,O
the,DT,O
release,NN,O
of,IN,O
norepinephrine,NN,D
and,CC,O
other,JJ,O
monoamines,NNS,O
from,IN,O
adrenergic,JJ,G
nerve,NN,O
endings,NNS,O
.,.,.
,,
this,DT,O
can,MD,O
cause,VB,O
headaches,NNS,O
and,CC,O
other,JJ,O
signs,NNS,O
of,IN,O
hypertensive,JJ,O
crisis,NN,O
.,.,.
,,
a,DT,O
variety,NN,O
of,IN,O
toxic,JJ,O
neurological,JJ,O
effects,NNS,O
and,CC,O
malignant,JJ,O
hyperpyrexia,NN,O
can,MD,O
occur,VB,O
",",",",O
sometimes,RB,O
with,IN,O
fatal,JJ,O
results,NNS,O
.,.,.
,,
antihistamines,NNS,D
:,:,O
amphetamines,NNS,G
may,MD,O
counteract,VB,O
the,DT,O
sedative,JJ,G
effect,NN,O
of,IN,O
antihistamines,NNS,G
.,.,.
,,
antihypertensives,NNS,G
:,:,O
amphetamines,NNS,G
may,MD,O
antagonize,VB,O
the,DT,O
hypotensive,JJ,O
effects,NNS,O
of,IN,O
antihypertensives,NNS,D
.,.,.
,,
chlorpromazine,NNP,D
:,:,O
chlorpromazine,NNP,D
blocks,VBZ,O
dopamine,NN,D
and,CC,O
norepinephrine,NN,D
receptors,NNS,O
",",",",O
thus,RB,O
inhibiting,VBG,O
the,DT,O
central,JJ,O
stimulant,NN,O
effects,NNS,O
of,IN,O
amphetamines,NNS,G
and,CC,O
can,MD,O
be,VB,O
used,VBN,O
to,TO,O
treat,VB,O
amphetamine,NN,D
poisoning,NN,O
.,.,.
,,
ethosuximide,NNP,D
:,:,O
amphetamines,NNS,G
may,MD,O
delay,VB,O
intestinal,JJ,O
absorption,NN,O
of,IN,O
ethosuximide,NN,D
.,.,.
,,
haloperidol,NNP,D
:,:,O
haloperidol,NNP,D
blocks,VBZ,O
dopamine,NN,D
receptors,NNS,O
",",",",O
thus,RB,O
inhibiting,VBG,O
the,DT,O
central,JJ,O
stimulant,NN,O
effects,NNS,O
of,IN,O
amphetamines,NNS,G
.,.,.
,,
lithium,NN,D
carbonate,NN,O
:,:,O
the,DT,O
anorectic,NN,O
and,CC,O
stimulatory,JJ,O
effects,NNS,O
of,IN,O
amphetamines,NNS,G
may,MD,O
be,VB,O
inhibited,VBN,O
by,IN,O
lithium,NN,D
carbonate,NN,O
.,.,.
,,
meperidine,NNP,D
:,:,O
amphetamines,NNS,G
potentiate,VBP,O
the,DT,O
analgesic,JJ,O
effect,NN,O
of,IN,O
meperidine,NN,D
.,.,.
,,
methenamine,NN,D
therapy,NN,O
urinary,JJ,O
excretion,NN,O
of,IN,O
amphetamines,NNS,G
is,VBZ,O
increased,VBN,O
",",",",O
and,CC,O
efficacy,NN,O
is,VBZ,O
reduced,VBN,O
by,IN,O
acidifying,VBG,O
agents,NNS,O
used,VBN,O
in,IN,O
methenamine,NN,D
therapy,NN,O
.,.,.
,,
norepinephrine,NN,D
:,:,O
amphetamines,NNS,G
enhance,VBP,O
the,DT,O
adrenergic,JJ,G
effect,NN,O
of,IN,O
norepinephrine,NN,D
.,.,.
,,
phenobarbital,NNP,D
:,:,O
amphetamines,NNS,G
may,MD,O
delay,VB,O
intestinal,JJ,O
absorption,NN,O
of,IN,O
phenobarbital,NN,D
.,.,.
,,
co-administration,NN,O
of,IN,O
phenobarbital,NN,D
may,MD,O
produce,VB,O
a,DT,O
synergistic,JJ,O
anticonvulsant,JJ,G
action,NN,O
.,.,.
,,
phenytoin,NNP,D
:,:,O
amphetamines,NNS,G
may,MD,O
delay,VB,O
intestinal,JJ,O
absorption,NN,O
of,IN,O
phenytoin,NN,D
.,.,.
,,
co-administration,NN,O
of,IN,O
phenytoin,NN,D
may,MD,O
produce,VB,O
a,DT,O
synergistic,JJ,O
anticonvulsant,JJ,G
action,NN,O
.,.,.
,,
propoxyphene,NNP,D
:,:,O
in,IN,O
cases,NNS,O
of,IN,O
propoxyphene,NN,D
overdosage,NN,O
",",",",O
amphetamine,NN,D
cns,NN,O
stimulation,NN,O
is,VBZ,O
potentiated,JJ,O
and,CC,O
fatal,JJ,O
convulsions,NNS,O
can,MD,O
occur,VB,O
.,.,.
,,
veratrum,NNP,O
alkaloids,NNS,O
:,:,O
amphetamines,NNS,G
inhibit,VBP,O
the,DT,O
hypotensive,JJ,O
effect,NN,O
of,IN,O
veratrum,NN,O
alkaloids,NNS,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
:,:,O
amphetamines,NNS,G
can,MD,O
cause,VB,O
a,DT,O
significant,JJ,O
elevation,NN,O
in,IN,O
plasma,NN,O
corticosteroid,NN,G
levels,NNS,O
.,.,.
,,
this,DT,O
increase,NN,O
is,VBZ,O
greatest,JJS,O
in,IN,O
the,DT,O
evening,NN,O
.,.,.
,,
amphetamines,NNS,G
may,MD,O
interfere,VB,O
with,IN,O
urinary,JJ,O
steroid,NN,G
determinations,NNS,O
.,.,.
,,
hypotension,NN,O
-,:,O
patients,NNS,O
on,IN,O
diuretic,JJ,G
therapy,NN,O
:,:,O
patients,NNS,O
on,IN,O
diuretics,NNS,G
",",",",O
and,CC,O
especially,RB,O
those,DT,O
in,IN,O
whom,WP,O
diuretic,JJ,G
therapy,NN,O
was,VBD,O
recently,RB,O
instituted,VBN,O
",",",",O
may,MD,O
occasionally,RB,O
experience,VB,O
an,DT,O
excessive,JJ,O
reduction,NN,O
of,IN,O
blood,NN,O
pressure,NN,O
after,IN,O
initiation,NN,O
of,IN,O
therapy,NN,O
with,IN,O
prinivil,NN,B
.,.,.
,,
the,DT,O
possibility,NN,O
of,IN,O
hypotensive,JJ,O
effects,NNS,O
with,IN,O
prinivil,NN,B
can,MD,O
be,VB,O
minimized,VBN,O
by,IN,O
either,CC,O
discontinuing,VBG,O
the,DT,O
diuretic,JJ,G
or,CC,O
increasing,VBG,O
the,DT,O
salt,NN,O
intake,NN,O
prior,RB,O
to,TO,O
initiation,NN,O
of,IN,O
treatment,NN,O
with,IN,O
prinivil,NN,B
.,.,.
,,
if,IN,O
it,PRP,O
is,VBZ,O
necessary,JJ,O
to,TO,O
continue,VB,O
the,DT,O
diuretic,JJ,G
",",",",O
initiate,VB,O
therapy,NN,O
with,IN,O
prinivil,NN,B
at,IN,O
a,DT,O
dose,NN,O
of,IN,O
5,CD,O
mg,NN,O
daily,RB,O
",",",",O
and,CC,O
provide,VBP,O
close,JJ,O
medical,JJ,O
supervision,NN,O
after,IN,O
the,DT,O
initial,JJ,O
dose,NN,O
until,IN,O
blood,NN,O
pressure,NN,O
has,VBZ,O
stabilized,VBN,O
.,.,.
,,
when,WRB,O
a,DT,O
diuretic,JJ,G
is,VBZ,O
added,VBN,O
to,TO,O
the,DT,O
therapy,NN,O
of,IN,O
a,DT,O
patient,NN,O
receiving,VBG,O
prinivil,NNP,B
",",",",O
an,DT,O
additional,JJ,O
antihypertensive,JJ,G
effect,NN,O
is,VBZ,O
usually,RB,O
observed,VBN,O
.,.,.
,,
studies,NNS,O
with,IN,O
ace,NN,O
inhibitors,NNS,O
in,IN,O
combination,NN,O
with,IN,O
diuretics,NNS,G
indicate,VBP,O
that,IN,O
the,DT,O
dose,NN,O
of,IN,O
the,DT,O
ace,NN,O
inhibitor,NN,O
can,MD,O
be,VB,O
reduced,VBN,O
when,WRB,O
it,PRP,O
is,VBZ,O
given,VBN,O
with,IN,O
a,DT,O
diuretic,JJ,G
.,.,.
,,
non-steroidal,JJ,O
anti-inflammatory,JJ,O
agents,NNS,O
:,:,O
in,IN,O
some,DT,O
patients,NNS,O
with,IN,O
compromised,VBN,O
renal,JJ,O
function,NN,O
who,WP,O
are,VBP,O
being,VBG,O
treated,VBN,O
with,IN,O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
drugs,NNS,D
",",",",O
the,DT,O
co-administration,NN,O
of,IN,O
lisinopril,NN,D
may,MD,O
result,VB,O
in,IN,O
a,DT,O
further,JJ,O
deterioration,NN,O
of,IN,O
renal,JJ,O
function,NN,O
.,.,.
,,
these,DT,O
effects,NNS,O
are,VBP,O
usually,RB,O
reversible,JJ,O
.,.,.
,,
reports,NNS,O
suggest,VBP,O
that,IN,O
nsaids,NNS,G
may,MD,O
diminish,VB,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
ace,NN,O
inhibitors,NNS,O
",",",",O
including,VBG,O
lisinopril,NN,D
.,.,.
,,
this,DT,O
interaction,NN,O
should,MD,O
be,VB,O
given,VBN,O
consideration,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
nsaids,NNS,G
concomitantly,RB,O
with,IN,O
ace,NN,O
inhibitors,NNS,O
.,.,.
,,
in,IN,O
a,DT,O
study,NN,O
in,IN,O
36,CD,O
patients,NNS,O
with,IN,O
mild,JJ,O
to,TO,O
moderate,JJ,O
hypertension,NN,O
where,WRB,O
the,DT,O
antihypertensive,JJ,G
effects,NNS,O
of,IN,O
prinivil,NN,B
alone,RB,O
were,VBD,O
compared,VBN,O
to,TO,O
prinivil,NNP,B
given,VBN,O
concomitantly,RB,O
with,IN,O
indomethacin,NN,D
",",",",O
the,DT,O
use,NN,O
of,IN,O
indomethacin,NN,D
was,VBD,O
associated,VBN,O
with,IN,O
a,DT,O
reduced,VBN,O
antihypertensive,JJ,G
effect,NN,O
",",",",O
although,IN,O
the,DT,O
difference,NN,O
between,IN,O
the,DT,O
two,CD,O
regimens,NNS,O
was,VBD,O
not,RB,O
significant,JJ,O
.,.,.
,,
other,JJ,O
agents,NNS,O
:,:,O
prinivil,NNP,B
has,VBZ,O
been,VBN,O
used,VBN,O
concomitantly,RB,O
with,IN,O
nitrates,NNS,G
and/or,CC,O
digoxin,NN,D
without,IN,O
evidence,NN,O
of,IN,O
clinically,RB,O
significant,JJ,O
adverse,JJ,O
interactions,NNS,O
.,.,.
,,
this,DT,O
included,VBD,O
post,NN,O
myocardial,JJ,O
infarction,NN,O
patients,NNS,O
who,WP,O
were,VBD,O
receiving,VBG,O
intravenous,JJ,O
or,CC,O
transdermal,JJ,O
nitroglycerin,NN,D
.,.,.
,,
no,DT,O
clinically,RB,O
important,JJ,O
pharmacokinetic,JJ,O
interactions,NNS,O
occurred,VBD,O
when,WRB,O
prinivil,NNP,B
was,VBD,O
used,VBN,O
concomitantly,RB,O
with,IN,O
propranolol,NN,D
or,CC,O
hydrochlorothiazide,NN,D
.,.,.
,,
the,DT,O
presence,NN,O
of,IN,O
food,NN,O
in,IN,O
the,DT,O
stomach,NN,O
does,VBZ,O
not,RB,O
alter,VB,O
the,DT,O
bioavailability,NN,O
of,IN,O
prinivil,NNP,B
.,.,.
,,
agents,NNS,O
increasing,VBG,O
serum,NN,O
potassium,NN,D
:,:,O
prinivil,NNP,B
attenuates,VBZ,O
potassium,NN,D
loss,NN,O
caused,VBN,O
by,IN,O
thiazide-type,JJ,O
diuretics,NNS,G
.,.,.
,,
use,NN,O
of,IN,O
prinivil,NN,B
with,IN,O
potassium-sparing,JJ,O
diuretics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
spironolactone,NN,D
",",",",O
triamterene,NN,D
",",",",O
or,CC,O
amiloride,NN,D
-rrb-,-RRB-,O
",",",",O
potassium,NN,D
supplements,NNS,O
",",",",O
or,CC,O
potassium-containing,JJ,O
salt,NN,O
substitutes,NNS,O
may,MD,O
lead,VB,O
to,TO,O
significant,JJ,O
increases,NNS,O
in,IN,O
serum,NN,O
potassium,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
if,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
these,DT,O
agents,NNS,O
is,VBZ,O
indicated,VBN,O
because,IN,O
of,IN,O
demonstrated,VBN,O
hypokalemia,NN,O
",",",",O
they,PRP,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
and,CC,O
with,IN,O
frequent,JJ,O
monitoring,NN,O
of,IN,O
serum,NN,O
potassium,NN,D
.,.,.
,,
potassium,NN,D
sparing,NN,O
agents,NNS,O
should,MD,O
generally,RB,O
not,RB,O
be,VB,O
used,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
heart,NN,O
failure,NN,O
who,WP,O
are,VBP,O
receiving,VBG,O
prinivil,NNP,B
.,.,.
,,
lithium,NN,D
:,:,O
lithium,NN,D
toxicity,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
lithium,NN,D
concomitantly,RB,O
with,IN,O
drugs,NNS,D
which,WDT,O
cause,VBP,O
elimination,NN,O
of,IN,O
sodium,NN,O
",",",",O
including,VBG,O
ace,NN,O
inhibitors,NNS,O
.,.,.
,,
lithium,NN,D
toxicity,NN,O
was,VBD,O
usually,RB,O
reversible,JJ,O
upon,IN,O
discontinuation,NN,O
of,IN,O
lithium,NN,D
and,CC,O
the,DT,O
ace,NN,O
inhibitor,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
serum,NN,O
lithium,NN,D
levels,NNS,O
be,VB,O
monitored,VBN,O
frequently,RB,O
if,IN,O
prinivil,NN,B
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
lithium,NN,D
.,.,.
,,
-,:,O
lofexidine,NN,D
may,MD,O
enhance,VB,O
the,DT,O
cns,NN,O
depressive,JJ,O
effects,NNS,O
of,IN,O
alcohol,NN,D
",",",",O
barbiturates,NNS,G
and,CC,O
other,JJ,O
sedative,NN,G
.,.,.
,,
-,:,O
lofexidine,NN,D
may,MD,O
enhance,VB,O
the,DT,O
effects,NNS,O
of,IN,O
anti-hypertensive,JJ,O
drug,NN,D
therap,NN,O
.,.,.
,,
-,:,O
concomitant,JJ,O
use,NN,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
may,MD,O
reduce,VB,O
the,DT,O
efficacy,NN,O
of,IN,O
lofexidine,NN,D
.,.,.
,,
theophylline,NNP,D
:,:,O
in,IN,O
three,CD,O
pharmacokinetic,JJ,O
studies,NNS,O
including,VBG,O
46,CD,O
normal,JJ,O
",",",",O
healthy,JJ,O
subjects,NNS,O
",",",",O
theophylline,NN,D
clearance,NN,O
and,CC,O
concentration,NN,O
were,VBD,O
not,RB,O
significantly,RB,O
altered,VBN,O
by,IN,O
the,DT,O
addition,NN,O
of,IN,O
lomefloxacin,NN,D
.,.,.
,,
in,IN,O
clinical,JJ,O
studies,NNS,O
where,WRB,O
patients,NNS,O
were,VBD,O
on,IN,O
chronic,JJ,O
theophylline,NN,D
therapy,NN,O
",",",",O
lomefloxacin,NN,D
had,VBD,O
no,DT,O
measurable,JJ,O
effect,NN,O
on,IN,O
the,DT,O
mean,JJ,O
distribution,NN,O
of,IN,O
theophylline,NN,D
concentrations,NNS,O
or,CC,O
the,DT,O
mean,NN,O
estimates,NNS,O
of,IN,O
theophylline,NN,D
clearance,NN,O
.,.,.
,,
though,IN,O
individual,JJ,O
theophylline,NN,D
levels,NNS,O
fluctuated,VBD,O
",",",",O
there,EX,O
were,VBD,O
no,DT,O
clinically,RB,O
significant,JJ,O
symptoms,NNS,O
of,IN,O
drug,NN,D
inter-action,NN,O
.,.,.
,,
antacids,NNS,G
and,CC,O
sucralfate,NN,D
:,:,O
sucralfate,NNP,D
and,CC,O
antacids,NNS,G
containing,VBG,O
magnesium,NN,D
or,CC,O
aluminum,NN,D
",",",",O
as,RB,O
well,RB,O
as,IN,O
formulations,NNS,O
containing,VBG,O
divalent,JJ,O
and,CC,O
trivalent,JJ,O
cations,NNS,O
such,JJ,O
as,IN,O
videx,NNP,B
-lrb-,-LRB-,O
didanosine,NN,D
-rrb-,-RRB-,O
",",",",O
chewable/buffered,JJ,O
tablets,NNS,O
or,CC,O
the,DT,O
pediatric,JJ,O
powder,NN,O
for,IN,O
oral,JJ,O
solution,NN,O
can,MD,O
form,VB,O
chelation,NN,O
complexes,NNS,O
with,IN,O
lomefloxacin,NN,D
and,CC,O
interfere,VB,O
with,IN,O
its,PRP$,O
bioavailability,NN,O
.,.,.
,,
sucralfate,NNP,D
administered,VBN,O
2,CD,O
hours,NNS,O
before,IN,O
lomefloxacin,NN,D
resulted,VBD,O
in,IN,O
a,DT,O
slower,JJR,O
absorption,NN,O
-lrb-,-LRB-,O
mean,NN,O
c,NN,O
max,NN,O
decreased,VBN,O
by,IN,O
30,CD,O
%,NN,O
and,CC,O
mean,VB,O
t,NN,O
max,NN,O
increased,VBN,O
by,IN,O
1,CD,O
hour,NN,O
-rrb-,-RRB-,O
and,CC,O
a,DT,O
lesser,JJR,O
extent,NN,O
of,IN,O
absorption,NN,O
-lrb-,-LRB-,O
mean,NN,O
auc,NN,O
decreased,VBN,O
by,IN,O
approximately,RB,O
25,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
magnesium,NN,D
-,:,O
and,CC,O
aluminum-containing,JJ,O
antacids,NNS,G
",",",",O
administered,VBN,O
concomitantly,RB,O
with,IN,O
lomefloxacin,NN,D
",",",",O
significantly,RB,O
decreased,VBD,O
the,DT,O
bioavailability,NN,O
-lrb-,-LRB-,O
48,CD,O
%,NN,O
-rrb-,-RRB-,O
of,IN,O
lomefloxacin,NN,D
.,.,.
,,
separating,VBG,O
the,DT,O
doses,NNS,O
of,IN,O
antacid,NN,G
and,CC,O
lomefloxacin,NN,D
minimizes,VBZ,O
this,DT,O
decrease,NN,O
in,IN,O
bioavailability,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
administration,NN,O
of,IN,O
these,DT,O
agents,NNS,O
should,MD,O
precede,VB,O
lomefloxacin,NN,D
dosing,NN,O
by,IN,O
4,CD,O
hours,NNS,O
or,CC,O
follow,VB,O
lomefloxacin,NN,D
dosing,NN,O
by,IN,O
at,IN,O
least,JJS,O
2,CD,O
hours,NNS,O
.,.,.
,,
caffeine,NN,D
:,:,O
two,CD,O
hundred,CD,O
mg,NN,O
of,IN,O
caffeine,NN,D
-lrb-,-LRB-,O
equivalent,JJ,O
to,TO,O
1,CD,O
to,TO,O
3,CD,O
cups,NNS,O
of,IN,O
american,JJ,O
coffee,NN,O
-rrb-,-RRB-,O
was,VBD,O
administered,VBN,O
to,TO,O
16,CD,O
normal,JJ,O
",",",",O
healthy,JJ,O
volunteers,NNS,O
who,WP,O
had,VBD,O
achieved,VBN,O
steady-state,JJ,O
blood,NN,O
concentrations,NNS,O
of,IN,O
lomefloxacin,NN,D
after,IN,O
being,VBG,O
dosed,VBN,O
at,IN,O
400,CD,O
mg,NN,O
qd,NN,O
.,.,.
,,
this,DT,O
did,VBD,O
not,RB,O
result,VB,O
in,IN,O
any,DT,O
statistically,RB,O
or,CC,O
clinically,RB,O
relevant,JJ,O
changes,NNS,O
in,IN,O
the,DT,O
pharmacokinetic,JJ,O
parameters,NNS,O
of,IN,O
either,CC,O
caffeine,NN,D
or,CC,O
its,PRP$,O
major,JJ,O
metabolite,NN,O
",",",",O
paraxanthine,NN,D_n
.,.,.
,,
no,DT,O
data,NNS,O
are,VBP,O
available,JJ,O
on,IN,O
potential,JJ,O
interactions,NNS,O
in,IN,O
individuals,NNS,O
who,WP,O
consume,VBP,O
greater,JJR,O
than,IN,O
200,CD,O
mg,NN,O
of,IN,O
caffeine,NN,D
per,IN,O
day,NN,O
or,CC,O
in,IN,O
those,DT,O
",",",",O
such,JJ,O
as,IN,O
the,DT,O
geriatric,JJ,O
population,NN,O
",",",",O
who,WP,O
are,VBP,O
generally,RB,O
believed,VBN,O
to,TO,O
be,VB,O
more,RBR,O
susceptible,JJ,O
to,TO,O
the,DT,O
development,NN,O
of,IN,O
drug-induced,JJ,O
cns-related,JJ,O
adverse,JJ,O
effects,NNS,O
.,.,.
,,
other,JJ,O
quinolones,NNS,G
have,VBP,O
demonstrated,VBN,O
moderate,JJ,O
to,TO,O
marked,JJ,O
interference,NN,O
with,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
caffeine,NN,D
",",",",O
resulting,VBG,O
in,IN,O
a,DT,O
reduced,VBN,O
clearance,NN,O
",",",",O
a,DT,O
prolongation,NN,O
of,IN,O
plasma,NN,O
half-life,NN,O
",",",",O
and,CC,O
an,DT,O
increase,NN,O
in,IN,O
symptoms,NNS,O
that,WDT,O
accompany,VBP,O
high,JJ,O
levels,NNS,O
of,IN,O
caffeine,NN,D
.,.,.
,,
cimetidine,NNP,D
:,:,O
cimetidine,NNP,D
has,VBZ,O
been,VBN,O
demonstrated,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
the,DT,O
elimination,NN,O
of,IN,O
other,JJ,O
quinolones,NNS,G
.,.,.
,,
this,DT,O
interference,NN,O
has,VBZ,O
resulted,VBN,O
in,IN,O
significant,JJ,O
increases,NNS,O
in,IN,O
half-life,NN,O
and,CC,O
auc,NN,O
.,.,.
,,
the,DT,O
interaction,NN,O
between,IN,O
lomefloxacin,NN,D
and,CC,O
cimetidine,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
cyclosporine,NN,D
:,:,O
elevated,JJ,O
serum,NN,O
levels,NNS,O
of,IN,O
cyclosporine,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
cyclosporine,NN,D
with,IN,O
other,JJ,O
members,NNS,O
of,IN,O
the,DT,O
quinolone,NN,G
class,NN,O
.,.,.
,,
interaction,NN,O
between,IN,O
lomefloxacin,NN,D
and,CC,O
cyclosporine,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
omeprazole,NNP,D
:,:,O
no,NNP,O
clinically,RB,O
significant,JJ,O
changes,NNS,O
in,IN,O
lomefloxacin,NN,D
pharmacokinetics,NNS,O
-lrb-,-LRB-,O
auc,NN,O
",",",",O
c,NN,O
max,NN,O
",",",",O
or,CC,O
t,NN,O
max,NN,O
-rrb-,-RRB-,O
were,VBD,O
observed,VBN,O
when,WRB,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
lomefloxacin,NN,D
400,CD,O
mg,NN,O
was,VBD,O
given,VBN,O
after,IN,O
multiple,JJ,O
doses,NNS,O
of,IN,O
omeprazole,NN,D
-lrb-,-LRB-,O
20,CD,O
mg,NN,O
qd,NN,O
-rrb-,-RRB-,O
in,IN,O
13,CD,O
healthy,JJ,O
volunteers,NNS,O
.,.,.
,,
changes,NNS,O
in,IN,O
omeprazole,NN,D
pharmacokinetics,NNS,O
were,VBD,O
not,RB,O
studied,VBN,O
.,.,.
,,
phenytoin,NNP,D
:,:,O
no,NNP,O
significant,JJ,O
differences,NNS,O
were,VBD,O
observed,VBN,O
in,IN,O
mean,JJ,O
phenytoin,NN,D
auc,NN,O
",",",",O
c,NN,O
max,NN,O
",",",",O
c,NN,O
min,NN,O
or,CC,O
t,NN,O
max,NN,O
-lrb-,-LRB-,O
although,IN,O
c,NN,O
max,NN,O
increased,VBN,O
by,IN,O
11,CD,O
%,NN,O
-rrb-,-RRB-,O
when,WRB,O
extended,VBN,O
phenytoin,NN,D
sodium,NN,O
capsules,NNS,O
-lrb-,-LRB-,O
100,CD,O
mg,NN,O
tid,NN,O
-rrb-,-RRB-,O
were,VBD,O
coadministered,VBN,O
with,IN,O
lomefloxacin,NN,D
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
qd,NN,O
-rrb-,-RRB-,O
for,IN,O
five,CD,O
days,NNS,O
in,IN,O
15,CD,O
healthy,JJ,O
males,NNS,O
.,.,.
,,
lomefloxacin,NNP,D
is,VBZ,O
unlikely,JJ,O
to,TO,O
have,VB,O
a,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
phenytoin,NN,D
metabolism,NN,O
.,.,.
,,
probenecid,NNP,D
:,:,O
probenecid,NNP,D
slows,VBZ,O
the,DT,O
renal,JJ,O
elimination,NN,O
of,IN,O
lome-floxacin,NN,O
.,.,.
,,
an,DT,O
increase,NN,O
of,IN,O
63,CD,O
%,NN,O
in,IN,O
the,DT,O
mean,NN,O
auc,NN,O
and,CC,O
increases,NNS,O
of,IN,O
50,CD,O
%,NN,O
and,CC,O
4,CD,O
%,NN,O
",",",",O
respectively,RB,O
",",",",O
in,IN,O
the,DT,O
mean,JJ,O
t,NN,O
max,NN,O
and,CC,O
mean,VB,O
c,NN,O
max,NN,O
were,VBD,O
noted,VBN,O
in,IN,O
1,CD,O
study,NN,O
of,IN,O
6,CD,O
individuals,NNS,O
.,.,.
,,
terfenadine,NNP,D
:,:,O
no,NNP,O
clinically,RB,O
significant,JJ,O
changes,NNS,O
occurred,VBD,O
in,IN,O
heart,NN,O
rate,NN,O
or,CC,O
corrected,VBN,O
qt,NN,O
intervals,NNS,O
",",",",O
or,CC,O
in,IN,O
terfenadine,NN,D
metabolite,NN,O
or,CC,O
lomefloxacin,NN,D
pharmacokinetics,NNS,O
",",",",O
during,IN,O
concurrent,JJ,O
administration,NN,O
of,IN,O
lomefloxacin,NN,D
and,CC,O
terfenadine,NN,D
at,IN,O
steady-state,JJ,O
in,IN,O
28,CD,O
healthy,JJ,O
males,NNS,O
.,.,.
,,
warfarin,NNP,D
:,:,O
quinolones,NNS,G
may,MD,O
enhance,VB,O
the,DT,O
effects,NNS,O
of,IN,O
the,DT,O
oral,JJ,O
anticoagulant,NN,G
",",",",O
warfarin,NN,D
",",",",O
or,CC,O
its,PRP$,O
derivatives,NNS,O
.,.,.
,,
when,WRB,O
these,DT,O
products,NNS,O
are,VBP,O
administered,VBN,O
concomitantly,RB,O
",",",",O
prothrombin,NN,O
or,CC,O
other,JJ,O
suitable,JJ,O
coagulation,NN,O
tests,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
.,.,.
,,
however,RB,O
",",",",O
no,DT,O
clinically,RB,O
or,CC,O
statistically,RB,O
significant,JJ,O
differences,NNS,O
in,IN,O
prothrombin,NN,O
time,NN,O
ratio,NN,O
or,CC,O
warfarin,NN,D
enantiomer,NN,O
pharmacokinetics,NNS,O
were,VBD,O
observed,VBN,O
in,IN,O
a,DT,O
small,JJ,O
study,NN,O
of,IN,O
7,CD,O
healthy,JJ,O
males,NNS,O
who,WP,O
received,VBD,O
both,DT,O
warfarin,NN,D
and,CC,O
lomefloxacin,NN,D
under,IN,O
steady-state,JJ,O
conditions,NNS,O
.,.,.
,,
there,EX,O
was,VBD,O
no,DT,O
evidence,NN,O
in,IN,O
clinical,JJ,O
trials,NNS,O
of,IN,O
drug,NN,D
interactions,NNS,O
with,IN,O
concurrent,JJ,O
medications,NNS,O
.,.,.
,,
probenecid,NNP,D
:,:,O
as,IN,O
with,IN,O
other,JJ,O
b-lactam,NN,O
antibiotics,NNS,G
",",",",O
renal,JJ,O
excretion,NN,O
of,IN,O
loracarbef,NN,D
is,VBZ,O
inhibited,VBN,O
by,IN,O
probenecid,NN,D
and,CC,O
resulted,VBD,O
in,IN,O
an,DT,O
approximate,JJ,O
80,CD,O
%,NN,O
increase,NN,O
in,IN,O
the,DT,O
auc,NN,O
for,IN,O
loracarbef,NN,D
.,.,.
,,
loratadine,NN,D
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
once,RB,O
daily,JJ,O
-rrb-,-RRB-,O
has,VBZ,O
been,VBN,O
coadministered,VBN,O
with,IN,O
therapeutic,JJ,O
doses,NNS,O
of,IN,O
erythromycin,NN,D
",",",",O
cimetidine,NN,D
",",",",O
and,CC,O
ketoconazole,NN,D
in,IN,O
controlled,JJ,O
clinical,JJ,O
pharmacology,NN,O
studies,NNS,O
in,IN,O
adult,JJ,O
volunteers,NNS,O
.,.,.
,,
although,IN,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
-lrb-,-LRB-,O
auc,NN,O
0-24,CD,O
hrs,NNS,O
-rrb-,-RRB-,O
of,IN,O
loratadine,NN,D
and/or,CC,O
descarboethoxyloratadine,NN,D
were,VBD,O
observed,VBN,O
following,VBG,O
coadministration,NN,O
of,IN,O
loratadine,NN,D
with,IN,O
each,DT,O
of,IN,O
these,DT,O
drugs,NNS,D
in,IN,O
normal,JJ,O
volunteers,NNS,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
24,CD,O
in,IN,O
each,DT,O
study,NN,O
-rrb-,-RRB-,O
",",",",O
there,EX,O
were,VBD,O
no,DT,O
clinically,RB,O
relevant,JJ,O
changes,NNS,O
in,IN,O
the,DT,O
safety,NN,O
profile,NN,O
of,IN,O
loratadine,NN,D
",",",",O
as,IN,O
assessed,VBN,O
by,IN,O
electrocardiographic,JJ,O
parameters,NNS,O
",",",",O
clinical,JJ,O
laboratory,NN,O
tests,NNS,O
",",",",O
vital,JJ,O
signs,NNS,O
",",",",O
and,CC,O
adverse,JJ,O
events,NNS,O
.,.,.
,,
there,EX,O
were,VBD,O
no,DT,O
significant,JJ,O
effects,NNS,O
on,IN,O
qtc,NN,O
intervals,NNS,O
",",",",O
and,CC,O
no,DT,O
reports,NNS,O
of,IN,O
sedation,NN,O
or,CC,O
syncope,NN,O
.,.,.
,,
no,DT,O
effects,NNS,O
on,IN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
cimetidine,NN,D
or,CC,O
ketoconazole,NN,D
were,VBD,O
observed,VBN,O
.,.,.
,,
plasma,NN,O
concentrations,NNS,O
-lrb-,-LRB-,O
auc,NN,O
0-24,CD,O
hrs,NNS,O
-rrb-,-RRB-,O
of,IN,O
erythromycin,NN,D
decreased,VBD,O
15,CD,O
%,NN,O
with,IN,O
coadministration,NN,O
of,IN,O
loratadine,NN,D
relative,JJ,O
to,TO,O
that,DT,O
observed,VBN,O
with,IN,O
erythromycin,NN,D
alone,RB,O
.,.,.
,,
the,DT,O
clinical,JJ,O
relevance,NN,O
of,IN,O
this,DT,O
difference,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
these,DT,O
above,IN,O
findings,NNS,O
are,VBP,O
summarized,VBN,O
in,IN,O
table,NN,O
1,CD,O
.,.,.
,,
table,NN,O
1,CD,O
effects,NNS,O
on,IN,O
plasma,NN,O
concentrations,NNS,O
-lrb-,-LRB-,O
auc,NN,O
0-24,CD,O
hrs,NNS,O
-rrb-,-RRB-,O
of,IN,O
loratadine,NN,D
and,CC,O
descarboethoxyloratadine,NN,D
after,IN,O
10,CD,O
days,NNS,O
of,IN,O
coadministration,NNP,O
-lrb-,-LRB-,O
loratadine,NNP,D
10,CD,O
mg,NN,O
-rrb-,-RRB-,O
in,IN,O
normal,JJ,O
volunteer,NN,O
.,.,.
,,
loratadine,NNP,D
descarboethoxyloratadin,NNP,O
.,.,.
,,
erythromycin,NN,D
-lrb-,-LRB-,O
500,CD,O
mg,NN,O
q8h,NN,O
-rrb-,-RRB-,O
+,CC,O
40,CD,O
%,NN,O
46,CD,O
.,.,.
,,
cimetidine,NN,D
-lrb-,-LRB-,O
300,CD,O
mg,NN,O
qid,NN,O
-rrb-,-RRB-,O
103,CD,O
%,NN,O
+,CC,O
6,CD,O
.,.,.
,,
ketoconazole,NN,D
-lrb-,-LRB-,O
200,CD,O
mg,NN,O
q12h,NN,O
-rrb-,-RRB-,O
307,CD,O
%,NN,O
73,CD,O
.,.,.
,,
there,EX,O
does,VBZ,O
not,RB,O
appear,VB,O
to,TO,O
be,VB,O
an,DT,O
increase,NN,O
in,IN,O
adverse,JJ,O
events,NNS,O
in,IN,O
subjects,NNS,O
who,WP,O
received,VBD,O
oral,JJ,O
contraceptives,NNS,G
and,CC,O
loratadine,NN,D
.,.,.
,,
tablets,NNS,O
:,:,O
the,DT,O
benzodiazepines,NNS,G
",",",",O
including,VBG,O
lorazepam,NN,D
",",",",O
produce,VBP,O
cns-depressant,JJ,O
effects,NNS,O
when,WRB,O
administered,VBN,O
with,IN,O
such,JJ,O
medications,NNS,O
as,IN,O
barbiturates,NNS,G
or,CC,O
alcohol,NN,D
.,.,.
,,
injection,NN,O
:,:,O
lorazepam,NNP,D
injection,NN,O
",",",",O
like,IN,O
other,JJ,O
injectable,JJ,O
benzodiazepines,NNS,G
",",",",O
produces,VBZ,O
depression,NN,O
of,IN,O
the,DT,O
central,JJ,O
nervous,JJ,O
system,NN,O
when,WRB,O
administered,VBN,O
with,IN,O
ethyl,NN,O
alcohol,NN,D
",",",",O
phenothiazines,NNS,G
",",",",O
barbiturates,NNS,G
",",",",O
mao,NN,O
inhibitors,NNS,O
",",",",O
and,CC,O
other,JJ,O
antidepressants.when,JJ,O
scopolamine,NN,D
is,VBZ,O
used,VBN,O
concomitantly,RB,O
with,IN,O
injectable,JJ,O
lorazepam,NN,D
",",",",O
an,DT,O
increased,VBN,O
incidence,NN,O
of,IN,O
sedation,NN,O
",",",",O
hallucinations,NNS,O
",",",",O
and,CC,O
irrational,JJ,O
behavior,NN,O
has,VBZ,O
been,VBN,O
observed,VBN,O
.,.,.
,,
no,DT,O
significant,JJ,O
drug-drug,JJ,O
pharmacokinetic,JJ,O
interactions,NNS,O
have,VBP,O
been,VBN,O
found,VBN,O
in,IN,O
interaction,NN,O
studies,NNS,O
with,IN,O
hydrochlorothiazide,NN,D
",",",",O
digoxin,NN,D
",",",",O
warfarin,NN,D
",",",",O
cimetidine,NN,D
and,CC,O
phenobarbital,NN,D
.,.,.
,,
rifampin,NNP,D
",",",",O
an,DT,O
inducer,NN,O
of,IN,O
drug,NN,D
metabolism,NN,O
",",",",O
decreased,VBD,O
the,DT,O
concentrations,NNS,O
of,IN,O
losartan,NN,D
and,CC,O
its,PRP$,O
active,JJ,O
metabolite,NN,O
.,.,.
,,
in,IN,O
humans,NNS,O
",",",",O
two,CD,O
inhibitors,NNS,O
of,IN,O
p450,NN,O
3a4,NN,O
have,VBP,O
been,VBN,O
studied,VBN,O
.,.,.
,,
ketoconazole,NN,D
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
conversion,NN,O
of,IN,O
losartan,NN,D
to,TO,O
the,DT,O
active,JJ,O
metabolite,NN,O
after,IN,O
intravenous,JJ,O
administration,NN,O
of,IN,O
losartan,NN,D
",",",",O
and,CC,O
erythromycin,NN,D
had,VBD,O
no,DT,O
clinically,RB,O
significant,JJ,O
effect,NN,O
after,IN,O
oral,JJ,O
administration,NN,O
.,.,.
,,
fluconazole,NNP,D
",",",",O
an,DT,O
inhibitor,NN,O
of,IN,O
p450,NN,O
2c9,NN,O
",",",",O
decreased,VBD,O
active,JJ,O
metabolite,NN,O
concentration,NN,O
and,CC,O
increased,VBD,O
losartan,NN,D
concentration,NN,O
.,.,.
,,
the,DT,O
pharmacodynamic,JJ,O
consequences,NNS,O
of,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
losartan,NN,D
and,CC,O
inhibitors,NNS,O
of,IN,O
p450,NN,O
2c9,NN,O
have,VBP,O
not,RB,O
been,VBN,O
examined,VBN,O
.,.,.
,,
subjects,NNS,O
who,WP,O
do,VBP,O
not,RB,O
metabolize,VB,O
losartan,NN,D
to,TO,O
active,JJ,O
metabolite,NN,O
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
have,VB,O
a,DT,O
specific,JJ,O
",",",",O
rare,JJ,O
defect,NN,O
in,IN,O
cytochrome,NN,O
p450,NN,O
2c9,NN,O
.,.,.
,,
these,DT,O
data,NNS,O
suggest,VBP,O
that,IN,O
the,DT,O
conversion,NN,O
of,IN,O
losartan,NN,D
to,TO,O
its,PRP$,O
active,JJ,O
metabolite,NN,O
is,VBZ,O
mediated,VBN,O
primarily,RB,O
by,IN,O
p450,NN,O
2c9,NN,O
and,CC,O
not,RB,O
p450,NN,O
3a4,NN,O
.,.,.
,,
as,IN,O
with,IN,O
other,JJ,O
drugs,NNS,D
that,WDT,O
block,VBP,O
angiotensin,NN,O
ii,CD,O
or,CC,O
its,PRP$,O
effects,NNS,O
",",",",O
concomitant,JJ,O
use,NN,O
of,IN,O
potassium-sparing,JJ,O
diuretics,NNS,G
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
spironolactone,NN,D
",",",",O
triamterene,NN,D
",",",",O
amiloride,NN,D
-rrb-,-RRB-,O
",",",",O
potassium,NN,D
supplements,NNS,O
",",",",O
or,CC,O
salt,NN,O
substitutes,NNS,O
containing,VBG,O
potassium,NN,D
may,MD,O
lead,VB,O
to,TO,O
increases,NNS,O
in,IN,O
serum,NN,O
potassium,NN,D
.,.,.
,,
as,IN,O
with,IN,O
other,JJ,O
antihypertensive,JJ,G
agents,NNS,O
",",",",O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
losartan,NN,D
may,MD,O
be,VB,O
blunted,VBN,O
by,IN,O
the,DT,O
non-steroidal,JJ,O
anti-inflammatory,JJ,G
drug,NN,D
indomethaci,NNS,O
.,.,.
,,
cyp3a4,NN,D
interactions,NNS,O
.,.,.
,,
lovastatin,NNP,D
is,VBZ,O
metabolized,VBN,O
by,IN,O
cyp3a4,NN,D
but,CC,O
has,VBZ,O
no,DT,O
cyp3a4,NN,D
inhibitory,JJ,O
activity,NN,O
.,.,.
,,
therefore,RB,O
it,PRP,O
is,VBZ,O
not,RB,O
expected,VBN,O
to,TO,O
affect,VB,O
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
cyp3a4,NN,D
.,.,.
,,
potent,JJ,O
inhibitors,NNS,O
of,IN,O
cyp3a4,NN,D
-lrb-,-LRB-,O
below,IN,O
-rrb-,-RRB-,O
increase,VBP,O
the,DT,O
risk,NN,O
of,IN,O
myopathy,NN,O
by,IN,O
reducing,VBG,O
the,DT,O
elimination,NN,O
of,IN,O
lovastatin,NN,D
.,.,.
,,
pharmacokinetics,NNS,O
.,.,.
,,
itraconazole,NNP,D
ketoconazole,NNP,D
erythromycin,NNP,D
clarithromycin,NNP,D
telithromycin,NNP,D
hiv,NN,O
protease,NN,O
inhibitors,NNS,O
nefazodone,NNP,D
cyclosporine,NNP,D
large,JJ,O
quantities,NNS,O
of,IN,O
grapefruit,NN,O
juice,NN,O
-lrb-,-LRB-,O
1,CD,O
quart,NN,O
daily,RB,O
.,.,.
,,
interactions,NNS,O
with,IN,O
lipid-lowering,JJ,O
drugs,NNS,D
that,WDT,O
can,MD,O
cause,VB,O
myopathy,NN,O
when,WRB,O
given,VBN,O
alone,RB,O
.,.,.
,,
the,DT,O
risk,NN,O
of,IN,O
myopathy,NN,O
is,VBZ,O
also,RB,O
increased,VBN,O
by,IN,O
the,DT,O
following,VBG,O
lipid-lowering,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
not,RB,O
potent,JJ,O
cyp3a4,NN,D
inhibitors,NNS,O
",",",",O
but,CC,O
which,WDT,O
can,MD,O
cause,VB,O
myopathy,NN,O
when,WRB,O
given,VBN,O
alone,RB,O
.,.,.
,,
see,VB,O
warnings,NNP,O
",",",",O
myopathy/rhabdomyolysis,NNP,O
.,.,.
,,
gemfibrozil,NNP,D
other,JJ,O
fibrates,NNS,G
niacin,NNP,D
-lrb-,-LRB-,O
nicotinic,JJ,O
acid,NN,O
-rrb-,-RRB-,O
-lrb-,-LRB-,O
=,JJ,O
1,CD,O
g/day,NN,O
.,.,.
,,
other,JJ,O
drug,NN,D
interactions,NNS,O
.,.,.
,,
danazol,NN,D
:,:,O
the,DT,O
risk,NN,O
of,IN,O
myopathy/rhabdomyolysis,NN,O
is,VBZ,O
increased,VBN,O
by,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
danazol,NN,D
particularly,RB,O
with,IN,O
higher,JJR,O
doses,NNS,O
of,IN,O
lovastatin,NN,D
-lrb-,-LRB-,O
see,VB,O
warnings,NNS,O
",",",",O
myopathy/rhabdomyolysis,NN,O
-rrb-,-RRB-,O
.,.,.
,,
amiodarone,NNP,D
or,CC,O
verapamil,NNP,D
:,:,O
the,DT,O
risk,NN,O
of,IN,O
myopathy/rhabdomyolysis,NN,O
is,VBZ,O
increased,VBN,O
when,WRB,O
either,CC,O
amiodarone,NN,D
or,CC,O
verapamil,NN,D
is,VBZ,O
used,VBN,O
concomitantly,RB,O
with,IN,O
a,DT,O
closely,RB,O
related,JJ,O
member,NN,O
of,IN,O
the,DT,O
hmg-coa,NN,O
reductase,NN,O
inhibitor,NN,O
class,NN,O
-lrb-,-LRB-,O
see,VB,O
warnings,NNS,O
",",",",O
myopathy/rhabdomyolysis,NN,O
-rrb-,-RRB-,O
.,.,.
,,
coumarin,NNP,O
anticoagulants,NNPS,G
:,:,O
in,IN,O
a,DT,O
small,JJ,O
clinical,JJ,O
trial,NN,O
in,IN,O
which,WDT,O
lovastatin,NN,D
was,VBD,O
administered,VBN,O
to,TO,O
warfarin,NN,D
treated,JJ,O
patients,NNS,O
",",",",O
no,DT,O
effect,NN,O
on,IN,O
prothrombin,NN,O
time,NN,O
was,VBD,O
detected,VBN,O
.,.,.
,,
however,RB,O
",",",",O
another,DT,O
hmg-coa,NN,O
reductase,NN,O
inhibitor,NN,O
has,VBZ,O
been,VBN,O
found,VBN,O
to,TO,O
produce,VB,O
a,DT,O
less,JJR,O
than,IN,O
two-second,JJ,O
increase,NN,O
in,IN,O
prothrombin,NN,O
time,NN,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
receiving,VBG,O
low,JJ,O
doses,NNS,O
of,IN,O
warfarin,NN,D
.,.,.
,,
also,RB,O
",",",",O
bleeding,VBG,O
and/or,CC,O
increased,VBN,O
prothrombin,NN,O
time,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
a,DT,O
few,JJ,O
patients,NNS,O
taking,VBG,O
coumarin,NN,G
anticoagulants,NNS,G
concomitantly,RB,O
with,IN,O
lovastatin,NN,D
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
in,IN,O
patients,NNS,O
taking,VBG,O
anticoagulants,NNS,G
",",",",O
prothrombin,NN,O
time,NN,O
be,VB,O
determined,VBN,O
before,IN,O
starting,VBG,O
lovastatin,NN,D
and,CC,O
frequently,RB,O
enough,RB,O
during,IN,O
early,JJ,O
therapy,NN,O
to,TO,O
insure,VB,O
that,IN,O
no,DT,O
significant,JJ,O
alteration,NN,O
of,IN,O
prothrombin,NN,O
time,NN,O
occurs,VBZ,O
.,.,.
,,
once,RB,O
a,DT,O
stable,JJ,O
prothrombin,NN,O
time,NN,O
has,VBZ,O
been,VBN,O
documented,VBN,O
",",",",O
prothrombin,NN,O
times,NNS,O
can,MD,O
be,VB,O
monitored,VBN,O
at,IN,O
the,DT,O
intervals,NNS,O
usually,RB,O
recommended,VBN,O
for,IN,O
patients,NNS,O
on,IN,O
coumarin,NN,G
anticoagulants,NNS,G
.,.,.
,,
if,IN,O
the,DT,O
dose,NN,O
of,IN,O
lovastatin,NN,D
is,VBZ,O
changed,VBN,O
",",",",O
the,DT,O
same,JJ,O
procedure,NN,O
should,MD,O
be,VB,O
repeated,VBN,O
.,.,.
,,
lovastatin,NN,D
therapy,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
associated,VBN,O
with,IN,O
bleeding,NN,O
or,CC,O
with,IN,O
changes,NNS,O
in,IN,O
prothrombin,NN,O
time,NN,O
in,IN,O
patients,NNS,O
not,RB,O
taking,VBG,O
anticoagulants,NNS,G
.,.,.
,,
propranolol,NN,D
:,:,O
in,IN,O
normal,JJ,O
volunteers,NNS,O
",",",",O
there,EX,O
was,VBD,O
no,DT,O
clinically,RB,O
significant,JJ,O
pharmacokinetic,JJ,O
or,CC,O
pharmacodynamic,JJ,O
interaction,NN,O
with,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
single,JJ,O
doses,NNS,O
of,IN,O
lovastatin,NN,D
and,CC,O
propranolol,NN,D
.,.,.
,,
digoxin,NNP,D
:,:,O
in,IN,O
patients,NNS,O
with,IN,O
hypercholesterolemia,NN,O
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
lovastatin,NN,D
and,CC,O
digoxin,NN,D
resulted,VBD,O
in,IN,O
no,DT,O
effect,NN,O
on,IN,O
digoxin,NN,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
oral,JJ,O
hypoglycemic,JJ,O
agents,NNS,O
:,:,O
in,IN,O
pharmacokinetic,JJ,O
studies,NNS,O
of,IN,O
mevacor,NN,B
in,IN,O
hypercholesterolemic,JJ,O
noninsulin,NN,O
dependent,JJ,O
diabetic,JJ,O
patients,NNS,O
",",",",O
there,EX,O
was,VBD,O
no,DT,O
drug,NN,D
interaction,NN,O
with,IN,O
glipizide,NN,D
or,CC,O
with,IN,O
chlorpropamid,NN,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
rare,JJ,O
reports,NNS,O
of,IN,O
significant,JJ,O
respiratory,JJ,O
depression,NN,O
",",",",O
stupor,NN,O
and/or,CC,O
hypotension,NN,O
with,IN,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
loxapine,NN,D
and,CC,O
lorazepam,NN,D
.,.,.
,,
the,DT,O
risk,NN,O
of,IN,O
using,VBG,O
loxapine,NN,D
in,IN,O
combination,NN,O
with,IN,O
cns-active,JJ,O
drugs,NNS,D
has,VBZ,O
not,RB,O
been,VBN,O
systematically,RB,O
evaluated,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
caution,NN,O
is,VBZ,O
advised,VBN,O
if,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
loxapine,NN,D
and,CC,O
cns-active,JJ,O
drugs,NNS,D
is,VBZ,O
required,VBN,O
.,.,.
,,
the,DT,O
absorption,NN,O
of,IN,O
lymecycline,NN,D
may,MD,O
be,VB,O
affected,VBN,O
by,IN,O
the,DT,O
simultaneous,JJ,O
administration,NN,O
of,IN,O
indigestion,NN,O
remedies,NNS,O
",",",",O
iron,NN,D
or,CC,O
zinc,NN,D
supplements,NNS,O
.,.,.
,,
oral,JJ,O
contraceptives,NNS,G
may,MD,O
be,VB,O
less,RBR,O
effective,JJ,O
while,IN,O
you,PRP,O
are,VBP,O
taking,VBG,O
lymecycline,NN,D
.,.,.
,,
warfarin,NNP,D
:,:,O
meclofenamate,NNP,O
sodium,NN,O
enhances,VBZ,O
the,DT,O
effect,NN,O
of,IN,O
warfarin,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
when,WRB,O
meclofenamate,NN,O
sodium,NN,O
is,VBZ,O
given,VBN,O
to,TO,O
a,DT,O
patient,NN,O
receiving,VBG,O
warfarin,NN,D
",",",",O
the,DT,O
dosage,NN,O
of,IN,O
warfarin,NN,D
should,MD,O
be,VB,O
reduced,VBN,O
to,TO,O
prevent,VB,O
excessive,JJ,O
prolongation,NN,O
of,IN,O
the,DT,O
prothrombin,NN,O
time,NN,O
.,.,.
,,
aspirin,NN,B
:,:,O
concurrent,JJ,O
administration,NN,O
of,IN,O
aspirin,NN,B
may,MD,O
lower,VB,O
meclofenamate,NN,O
sodium,NN,O
plasma,NN,O
levels,NNS,O
",",",",O
possibly,RB,O
by,IN,O
competing,VBG,O
for,IN,O
protein-binding,JJ,O
sites,NNS,O
.,.,.
,,
the,DT,O
urinary,JJ,O
excretion,NN,O
of,IN,O
meclofenamate,NN,O
sodium,NN,O
is,VBZ,O
unaffected,JJ,O
by,IN,O
aspirin,NN,B
",",",",O
indicating,VBG,O
no,DT,O
change,NN,O
in,IN,O
meclofenamate,NN,O
sodium,NN,O
absorption,NN,O
.,.,.
,,
meclofenamate,NN,O
sodium,NN,O
does,VBZ,O
not,RB,O
affect,VB,O
serum,NN,O
salicylate,NN,G
levels,NNS,O
.,.,.
,,
greater,NNP,O
fecal,JJ,O
blood,NN,O
loss,NN,O
results,VBZ,O
from,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
both,CC,O
drugs,NNS,D
than,IN,O
from,IN,O
either,CC,O
drug,NN,D
alone,RB,O
.,.,.
,,
propoxyphene,NNP,D
:,:,O
the,DT,O
concurrent,JJ,O
administration,NN,O
of,IN,O
propoxyphene,NN,D
hydrochloride,NN,O
does,VBZ,O
not,RB,O
affect,VB,O
the,DT,O
bioavailability,NN,O
of,IN,O
meclofenamate,NN,O
sodium,NN,O
.,.,.
,,
antacids,NNS,G
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
aluminum,NN,D
and,CC,O
magnesium,NN,D
hydroxides,NNS,O
does,VBZ,O
not,RB,O
interfere,VB,O
with,IN,O
absorption,NN,O
of,IN,O
meclofenamate,NN,O
sodium,NN,O
.,.,.
,,
aspirin,NN,B
:,:,O
as,IN,O
with,IN,O
other,JJ,O
nsaids,NNS,G
",",",",O
concomitant,JJ,O
administration,NN,O
of,IN,O
ponstel,NNP,B
and,CC,O
aspirin,NN,B
is,VBZ,O
not,RB,O
generally,RB,O
recommended,VBN,O
because,IN,O
of,IN,O
the,DT,O
potential,NN,O
of,IN,O
increased,VBN,O
adverse,JJ,O
effects,NNS,O
.,.,.
,,
methotrexate,NNP,D
:,:,O
nsaids,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
competitively,RB,O
inhibit,VB,O
methotrexate,NN,D
accumulation,NN,O
in,IN,O
rabbit,NN,O
kidney,NN,O
slices,NNS,O
.,.,.
,,
this,DT,O
may,MD,O
indicate,VB,O
that,IN,O
they,PRP,O
could,MD,O
enhance,VB,O
the,DT,O
toxicity,NN,O
of,IN,O
methotrexate,NN,D
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
when,WRB,O
nsaids,NNS,G
are,VBP,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
methotrexate,NN,D
.,.,.
,,
ace,NN,O
inhibitors,NNS,O
:,:,O
reports,NNS,O
suggest,VBP,O
that,IN,O
nsaids,NNS,G
may,MD,O
diminish,VB,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
ace,NN,O
inhibitors,NNS,O
.,.,.
,,
this,DT,O
interaction,NN,O
should,MD,O
be,VB,O
given,VBN,O
consideration,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
nsaids,NNS,G
concomitantly,RB,O
with,IN,O
ace,NN,O
inhibitors,NNS,O
.,.,.
,,
furosemide,NNP,D
:,:,O
clinical,JJ,O
studies,NNS,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
post-marketing,JJ,O
observations,NNS,O
",",",",O
have,VBP,O
shown,VBN,O
that,IN,O
nsaids,NNS,G
can,MD,O
reduce,VB,O
the,DT,O
natriuretic,JJ,O
effect,NN,O
of,IN,O
furosemide,NN,D
and,CC,O
thiazides,NNS,G
in,IN,O
some,DT,O
patients,NNS,O
.,.,.
,,
this,DT,O
response,NN,O
has,VBZ,O
been,VBN,O
attributed,VBN,O
to,TO,O
inhibition,NN,O
of,IN,O
renal,JJ,O
prostaglandin,NN,O
synthesis,NN,O
.,.,.
,,
during,IN,O
concomitant,JJ,O
therapy,NN,O
of,IN,O
ponstel,NN,B
with,IN,O
furosemide,NN,D
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
signs,NNS,O
of,IN,O
renal,JJ,O
failure,NN,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
to,TO,O
assure,VB,O
diuretic,JJ,G
efficacy,NN,O
.,.,.
,,
lithium,NN,D
:,:,O
nsaids,NNS,G
have,VBP,O
produced,VBN,O
an,DT,O
elevation,NN,O
of,IN,O
plasma,NN,O
lithium,NN,D
levels,NNS,O
and,CC,O
a,DT,O
reduction,NN,O
in,IN,O
renal,JJ,O
lithium,NN,D
clearance,NN,O
.,.,.
,,
the,DT,O
mean,NN,O
minimum,JJ,O
lithium,NN,D
concentration,NN,O
increased,VBD,O
15,CD,O
%,NN,O
and,CC,O
the,DT,O
renal,JJ,O
clearance,NN,O
was,VBD,O
decreased,VBN,O
by,IN,O
approximately,RB,O
20,CD,O
%,NN,O
.,.,.
,,
these,DT,O
effects,NNS,O
have,VBP,O
been,VBN,O
attributed,VBN,O
to,TO,O
inhibition,NN,O
of,IN,O
renal,JJ,O
prostaglandin,NN,O
synthesis,NN,O
by,IN,O
the,DT,O
nsaid,NN,G
.,.,.
,,
thus,RB,O
",",",",O
when,WRB,O
nsaids,NNS,G
and,CC,O
lithium,NN,D
are,VBP,O
administered,VBN,O
concurrently,RB,O
",",",",O
subjects,NNS,O
should,MD,O
be,VB,O
observed,VBN,O
carefully,RB,O
for,IN,O
signs,NNS,O
of,IN,O
lithium,NN,D
toxicity,NN,O
.,.,.
,,
warfarin,NNP,D
:,:,O
the,DT,O
effects,NNS,O
of,IN,O
warfarin,NN,D
and,CC,O
nsaids,NNS,G
on,IN,O
gi,NN,O
bleeding,NN,O
are,VBP,O
synergistic,JJ,O
",",",",O
such,JJ,O
that,IN,O
users,NNS,O
of,IN,O
both,DT,O
drugs,NNS,D
together,RB,O
have,VBP,O
a,DT,O
risk,NN,O
of,IN,O
serious,JJ,O
gi,NN,O
bleeding,VBG,O
higher,JJR,O
than,IN,O
users,NNS,O
of,IN,O
either,CC,O
drug,NN,D
alone,RB,O
.,.,.
,,
antacids,NNS,G
:,:,O
in,IN,O
a,DT,O
single,JJ,O
dose,NN,O
study,NN,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
6,CD,O
-rrb-,-RRB-,O
",",",",O
ingestion,NN,O
of,IN,O
an,DT,O
antacid,NN,G
containing,VBG,O
1.7-gram,NN,O
of,IN,O
magnesium,NN,D
hydroxide,NN,O
with,IN,O
500-mg,NN,O
of,IN,O
mefenamic,JJ,O
acid,NN,O
increased,VBD,O
the,DT,O
cmax,NN,O
and,CC,O
auc,NN,O
of,IN,O
mefenamic,JJ,O
acid,NN,O
by,IN,O
125,CD,O
%,NN,O
and,CC,O
36,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
a,DT,O
number,NN,O
of,IN,O
compounds,NNS,O
are,VBP,O
inhibitors,NNS,O
of,IN,O
cyp2c9,NN,D
including,VBG,O
fluconazole,NN,D
",",",",O
lovastatin,NN,D
and,CC,O
trimethoprim,NN,D
.,.,.
,,
drug,NN,O
interaction,NN,O
studies,NNS,O
of,IN,O
mefenamic,JJ,O
acid,NN,O
and,CC,O
these,DT,O
compounds,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
the,DT,O
possibility,NN,O
of,IN,O
altered,JJ,O
safety,NN,O
and,CC,O
efficacy,NN,O
should,MD,O
be,VB,O
considered,VBN,O
when,WRB,O
ponstel,NNP,B
is,VBZ,O
used,VBN,O
concomitantly,RB,O
with,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
drug-drug,JJ,O
interactions,NNS,O
with,IN,O
mefloquine,NN,D
have,VBP,O
not,RB,O
been,VBN,O
explored,VBN,O
in,IN,O
detail,NN,O
.,.,.
,,
there,EX,O
is,VBZ,O
one,CD,O
report,NN,O
of,IN,O
cardiopulmonary,JJ,O
arrest,NN,O
",",",",O
with,IN,O
full,JJ,O
recovery,NN,O
",",",",O
in,IN,O
a,DT,O
patient,NN,O
who,WP,O
was,VBD,O
taking,VBG,O
a,DT,O
beta,NN,O
blocker,NN,O
-lrb-,-LRB-,O
propranolol,NN,D
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
mefloquineuine,NN,O
on,IN,O
the,DT,O
compromised,VBN,O
cardiovascular,JJ,O
system,NN,O
have,VBP,O
not,RB,O
been,VBN,O
evaluated,VBN,O
.,.,.
,,
the,DT,O
benefits,NNS,O
of,IN,O
mefloquine,NN,D
therapy,NN,O
should,MD,O
be,VB,O
weighed,VBN,O
against,IN,O
the,DT,O
possibility,NN,O
of,IN,O
adverse,JJ,O
effects,NNS,O
in,IN,O
patients,NNS,O
with,IN,O
cardiac,JJ,O
disease,NN,O
.,.,.
,,
because,IN,O
of,IN,O
the,DT,O
danger,NN,O
of,IN,O
a,DT,O
potentially,RB,O
fatal,JJ,O
prolongation,NN,O
of,IN,O
the,DT,O
qtc,NN,O
interval,NN,O
",",",",O
halofantrine,NN,D
must,MD,O
not,RB,O
be,VB,O
given,VBN,O
simultaneously,RB,O
with,IN,O
or,CC,O
subsequent,JJ,O
to,TO,O
mefloquine,NNP,D
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
mefloquine,NNP,D
and,CC,O
other,JJ,O
related,JJ,O
compounds,NNS,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
quinine,NN,D
",",",",O
quinidine,NN,D
and,CC,O
chloroquine,NN,D
-rrb-,-RRB-,O
may,MD,O
produce,VB,O
electrocardiographic,JJ,O
abnormalities,NNS,O
and,CC,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
convulsions,NNS,O
.,.,.
,,
if,IN,O
these,DT,O
drugs,NNS,D
are,VBP,O
to,TO,O
be,VB,O
used,VBN,O
in,IN,O
the,DT,O
initial,JJ,O
treatment,NN,O
of,IN,O
severe,JJ,O
malaria,NN,O
",",",",O
mefloquine,NNP,D
administration,NN,O
should,MD,O
be,VB,O
delayed,VBN,O
at,IN,O
least,JJS,O
12,CD,O
hours,NNS,O
after,IN,O
the,DT,O
last,JJ,O
dose,NN,O
.,.,.
,,
there,EX,O
is,VBZ,O
evidence,NN,O
that,IN,O
the,DT,O
use,NN,O
of,IN,O
halofantrine,NN,D
after,IN,O
mefloquineuine,NNP,O
causes,VBZ,O
a,DT,O
significant,JJ,O
lengthening,NN,O
of,IN,O
the,DT,O
qtc,NN,O
interval,NN,O
.,.,.
,,
clinically,RB,O
significant,JJ,O
qtc,NN,O
prolongation,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
found,VBN,O
with,IN,O
mefloquineuine,NN,O
alone,RB,O
.,.,.
,,
this,DT,O
appears,VBZ,O
to,TO,O
be,VB,O
the,DT,O
only,JJ,O
clinically,RB,O
relevant,JJ,O
interaction,NN,O
of,IN,O
this,DT,O
kind,NN,O
with,IN,O
mefloquine,NNP,D
",",",",O
although,IN,O
theoretically,RB,O
",",",",O
coadministration,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
known,VBN,O
to,TO,O
alter,VB,O
cardiac,JJ,O
conduction,NN,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
anti-arrhythmic,JJ,D
or,CC,O
beta-adrenergic,JJ,O
blocking,VBG,O
agents,NNS,O
",",",",O
calcium,NN,D
channel,NN,O
blockers,NNS,O
",",",",O
antihistamines,NNS,G
or,CC,O
h1-blocking,JJ,O
agents,NNS,O
",",",",O
tricyclic,JJ,G
antidepressants,NNS,G
and,CC,O
phenothiazines,NNS,G
-rrb-,-RRB-,O
might,MD,O
also,RB,O
contribute,VB,O
to,TO,O
a,DT,O
prolongation,NN,O
of,IN,O
the,DT,O
qtc,NN,O
interval,NN,O
.,.,.
,,
there,EX,O
are,VBP,O
no,DT,O
data,NNS,O
that,WDT,O
conclusively,RB,O
establish,VBP,O
whether,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
mefloquineuine,NN,O
and,CC,O
the,DT,O
above,JJ,O
listed,VBN,O
agents,NNS,O
has,VBZ,O
an,DT,O
effect,NN,O
on,IN,O
cardiac,JJ,O
function,NN,O
.,.,.
,,
in,IN,O
patients,NNS,O
taking,VBG,O
an,DT,O
anticonvulsant,JJ,G
-lrb-,-LRB-,O
eg,FW,O
",",",",O
valproic,JJ,O
acid,NN,O
",",",",O
carbamazepine,NN,D
",",",",O
phenobarbital,NN,D
or,CC,O
phenytoin,NN,D
-rrb-,-RRB-,O
",",",",O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
mefloquine,NNP,D
may,MD,O
reduce,VB,O
seizure,NN,O
control,NN,O
by,IN,O
lowering,VBG,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
the,DT,O
anticonvulsant,NN,G
.,.,.
,,
therefore,RB,O
",",",",O
patients,NNS,O
concurrently,RB,O
taking,VBG,O
antiseizure,JJ,O
medication,NN,O
and,CC,O
mefloquine,NN,D
should,MD,O
have,VB,O
the,DT,O
blood,NN,O
level,NN,O
of,IN,O
their,PRP$,O
antiseizure,JJ,O
medication,NN,O
monitored,VBD,O
and,CC,O
the,DT,O
dosage,NN,O
adjusted,VBN,O
appropriately,RB,O
.,.,.
,,
when,WRB,O
mefloquine,NNP,D
is,VBZ,O
taken,VBN,O
concurrently,RB,O
with,IN,O
oral,JJ,O
live,JJ,O
typhoid,NN,O
vaccines,NNS,G
",",",",O
attenuation,NN,O
of,IN,O
immunization,NN,O
can,MD,O
not,RB,O
be,VB,O
excluded,VBN,O
.,.,.
,,
vaccinations,NNS,O
with,IN,O
attenuated,VBN,O
live,JJ,O
bacteria,NNS,O
should,MD,O
therefore,RB,O
be,VB,O
completed,VBN,O
at,IN,O
least,JJS,O
3,CD,O
days,NNS,O
before,IN,O
the,DT,O
first,JJ,O
dose,NN,O
of,IN,O
mefloquine,NNP,D
.,.,.
,,
no,DT,O
other,JJ,O
drug,NN,D
interactions,NNS,O
are,VBP,O
known,VBN,O
.,.,.
,,
nevertheless,RB,O
",",",",O
the,DT,O
effects,NNS,O
of,IN,O
mefloquine,NN,D
on,IN,O
travelers,NNS,O
receiving,VBG,O
comedication,NN,O
",",",",O
particularly,RB,O
diabetics,NNS,O
or,CC,O
patients,NNS,O
using,VBG,O
anticoagulants,NNS,G
",",",",O
should,MD,O
be,VB,O
checked,VBN,O
before,IN,O
departure,NN,O
.,.,.
,,
in,IN,O
clinical,JJ,O
trials,NNS,O
",",",",O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
sulfadoxine,NN,D
and,CC,O
pyrimethamine,NN,D
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
adverse,JJ,O
reaction,NN,O
profile,NN,O
.,.,.
,,
broad-spectrum,NNP,O
antibiotics-broad-spectrum,NNP,O
antibiotics,NNS,G
may,MD,O
sterilize,VB,O
the,DT,O
bowel,NN,O
and,CC,O
decrease,VB,O
the,DT,O
vitamin,NN,G
k,NN,O
contribution,NN,O
to,TO,O
the,DT,O
body,NN,O
by,IN,O
the,DT,O
intestinal,JJ,O
microflora,NN,O
.,.,.
,,
cephalosporins-cephalosporins,NNS,O
containing,VBG,O
side,NN,O
chains,NNS,O
of,IN,O
n-methylthiotetrazole,NN,O
-lrb-,-LRB-,O
cefmenoxime,NN,D
",",",",O
cefoperazone,NN,D
",",",",O
cefotetan,NN,D
",",",",O
cefamandole,NN,D
",",",",O
latamoxef,NN,D
-rrb-,-RRB-,O
or,CC,O
methylthiadiazole,NN,O
-lrb-,-LRB-,O
cefazolin,NN,D
-rrb-,-RRB-,O
can,MD,O
cause,VB,O
vitamin,NN,G
k,NN,O
deficiency,NN,O
and,CC,O
hypoprothrombinemia,NN,O
.,.,.
,,
these,DT,O
cephalosporins,NNS,G
are,VBP,O
inhibitors,NNS,O
of,IN,O
hepatic,JJ,O
vitamin,NN,G
k,NN,O
epoxide,NN,O
reductase,NN,O
.,.,.
,,
cholestyramine-concomitant,JJ,O
intake,NN,O
of,IN,O
cholestyramine,NN,D
and,CC,O
vitamin,NN,G
k,NN,O
may,MD,O
reduce,VB,O
the,DT,O
absorption,NN,O
of,IN,O
vitamin,NN,G
k.,NNP,O
colestipol-concomitant,NNP,O
intake,NN,O
of,IN,O
colestipol,NN,D
and,CC,O
vitamin,NN,G
k,NN,O
may,MD,O
reduce,VB,O
the,DT,O
absorption,NN,O
of,IN,O
vitamin,NN,G
k.,NNP,O
mineral,NNP,O
oil-concomitant,JJ,O
intake,NN,O
of,IN,O
mineral,NN,O
oil,NN,O
and,CC,O
vitamin,NN,G
k,NN,O
may,MD,O
reduce,VB,O
the,DT,O
absorption,NN,O
of,IN,O
vitamin,NN,G
k.,NNP,O
orlistat-orlistat,NNP,O
may,MD,O
decrease,VB,O
the,DT,O
absorption,NN,O
of,IN,O
vitamin,NN,G
k.,NNP,O
salicylates-salicylates,NNP,O
in,IN,O
large,JJ,O
doses,NNS,O
may,MD,O
inhibit,VB,O
vitamin,NN,G
k,NN,O
epoxide,NN,O
reductase,NN,O
resulting,VBG,O
in,IN,O
vitamin,NN,G
k,NN,O
deficiency,NN,O
.,.,.
,,
warfarin-vitamin,JJ,O
k,NN,O
can,MD,O
antagonize,VB,O
the,DT,O
effect,NN,O
of,IN,O
warfari,NN,O
.,.,.
,,
nabilone,NN,D
should,MD,O
be,VB,O
administered,VBN,O
with,IN,O
caution,NN,O
to,TO,O
patients,NNS,O
who,WP,O
are,VBP,O
taking,VBG,O
other,JJ,O
psychoactive,JJ,O
drugs,NNS,D
or,CC,O
cns,NN,O
depressants,NNS,O
",",",",O
including,VBG,O
alcohol,NN,D
",",",",O
barbiturates,NNS,G
and,CC,O
narcotic,JJ,G
analgesics,NNS,G
",",",",O
or,CC,O
to,TO,O
those,DT,O
with,IN,O
a,DT,O
history,NN,O
of,IN,O
psychiatric,JJ,O
disorder,NN,O
-lrb-,-LRB-,O
including,VBG,O
manic-depressive,NN,O
illness,NN,O
and,CC,O
schizophrenia,NN,O
-rrb-,-RRB-,O
.,.,.
,,
nabilone,NNP,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
have,VB,O
an,DT,O
additive,JJ,O
cns,NN,O
depressant,NN,O
effect,NN,O
when,WRB,O
given,VBN,O
with,IN,O
either,CC,O
diazepam,NN,D
",",",",O
secobarbitone,NN,O
sodium,NN,O
",",",",O
alcohol,NN,D
or,CC,O
codeine,NN,D
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
",",",",O
because,IN,O
of,IN,O
its,PRP$,O
affinity,NN,O
for,IN,O
protein,NN,O
",",",",O
6mna,NN,D_n
may,MD,O
displace,VB,O
other,JJ,O
protein-bound,JJ,O
drugs,NNS,D
from,IN,O
their,PRP$,O
binding,NN,O
site,NN,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
administering,VBG,O
nabumetone,NN,D
with,IN,O
warfarin,NN,D
since,IN,O
interactions,NNS,O
have,VBP,O
been,VBN,O
seen,VBN,O
with,IN,O
other,JJ,O
nsaids,NNS,G
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
an,DT,O
aluminum-containing,JJ,O
antacid,NN,G
had,VBD,O
no,DT,O
significant,JJ,O
effect,NN,O
in,IN,O
the,DT,O
bioavailability,NN,O
of,IN,O
6mna,NN,D_n
.,.,.
,,
when,WRB,O
administered,VBN,O
with,IN,O
food,NN,O
or,CC,O
milk,NN,O
",",",",O
there,EX,O
is,VBZ,O
more,RBR,O
rapid,JJ,O
absorption,NN,O
;,:,O
.,.,.
,,
however,RB,O
",",",",O
the,DT,O
total,JJ,O
amount,NN,O
of,IN,O
6mna,NN,D_n
in,IN,O
the,DT,O
plasma,NN,O
is,VBZ,O
unchanged,JJ,O
.,.,.
,,
when,WRB,O
administered,VBN,O
concurrently,RB,O
",",",",O
the,DT,O
following,VBG,O
drugs,NNS,D
may,MD,O
interact,VB,O
with,IN,O
beta-adrenergic,JJ,O
receptor,NN,D
blocking,VBG,O
agents,NNS,O
:,:,O
anesthetics,NNS,G
",",",",O
general,JJ,O
:,:,O
exaggeration,NN,O
of,IN,O
the,DT,O
hypotension,NN,O
induced,VBN,O
by,IN,O
general,JJ,O
anesthetics,NNS,G
.,.,.
,,
antidiabetic,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
oral,JJ,O
agents,NNS,O
and,CC,O
insulin,NN,D
-rrb-,-RRB-,O
:,:,O
hypoglycemia,NN,O
or,CC,O
hyperglycemia,NN,O
.,.,.
,,
adjust,VBP,O
dosage,NN,O
of,IN,O
antidiabetic,JJ,D
drug,NN,D
accordingly,RB,O
.,.,.
,,
catecholamine-depleting,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
reserpine,NN,D
-rrb-,-RRB-,O
:,:,O
additive,JJ,O
effect,NN,O
.,.,.
,,
monitor,NN,O
closely,RB,O
for,IN,O
evidence,NN,O
of,IN,O
hypotension,NN,O
and/or,CC,O
excessive,JJ,O
bradycardia,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
vertigo,NN,O
",",",",O
syncope,NN,O
",",",",O
postural,JJ,O
hypotension,NN,O
-rrb-,-RRB-,O
.,.,.
,,
response,NN,O
to,TO,O
treatment,NN,O
for,IN,O
anaphylactic,NNP,O
reaction,NNP,O
:,:,O
while,IN,O
taking,VBG,O
beta-blockers,NNS,G
",",",",O
patients,NNS,O
with,IN,O
a,DT,O
history,NN,O
of,IN,O
severe,JJ,O
anaphylactic,JJ,O
reaction,NN,O
to,TO,O
a,DT,O
variety,NN,O
of,IN,O
allergens,NNS,O
may,MD,O
be,VB,O
more,RBR,O
reactive,JJ,O
to,TO,O
repeated,VBN,O
challenge,NN,O
",",",",O
either,CC,O
accidental,JJ,O
",",",",O
diagnostic,JJ,O
",",",",O
or,CC,O
therapeutic,JJ,O
.,.,.
,,
such,JJ,O
patients,NNS,O
may,MD,O
be,VB,O
unresponsive,JJ,O
to,TO,O
the,DT,O
usual,JJ,O
doses,NNS,O
of,IN,O
epinephrine,NN,D
used,VBN,O
to,TO,O
treat,VB,O
allergic,JJ,O
reaction,NN,O
.,.,.
,,
no,DT,O
pharmacokinetic-based,JJ,O
drug-drug,NN,O
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
with,IN,O
synarel,NNP,B
.,.,.
,,
however,RB,O
",",",",O
because,IN,O
nafarelin,NN,O
acetate,NN,O
is,VBZ,O
a,DT,O
peptide,NN,O
that,WDT,O
is,VBZ,O
primarily,RB,O
degraded,VBN,O
by,IN,O
peptidase,NN,O
and,CC,O
not,RB,O
by,IN,O
cytochrome,NN,O
p-450,NN,O
enzymes,NNS,O
",",",",O
and,CC,O
the,DT,O
drug,NN,D
is,VBZ,O
only,RB,O
about,RB,O
80,CD,O
%,NN,O
bound,VBD,O
to,TO,O
plasma,NN,O
proteins,NNS,O
at,IN,O
4,CD,O
c,NN,O
",",",",O
drug,NN,D
interactions,NNS,O
would,MD,O
not,RB,O
be,VB,O
expected,VBN,O
to,TO,O
occur,VB,O
.,.,.
,,
tetracycline,NN,D
",",",",O
a,DT,O
bacteriostatic,JJ,O
antibiotic,JJ,G
",",",",O
may,MD,O
antagonize,VB,O
the,DT,O
bactericidal,JJ,O
effect,NN,O
of,IN,O
penicillin,NN,D
and,CC,O
concurrent,JJ,O
use,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
no,DT,O
specific,JJ,O
information,NN,O
available,JJ,O
.,.,.
,,
elevated,JJ,O
plasma,NN,O
levels,NNS,O
of,IN,O
theophylline,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
concomitant,JJ,O
quinolone,NN,G
use,NN,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
theophylline-related,JJ,O
side,JJ,O
effects,NNS,O
in,IN,O
patients,NNS,O
on,IN,O
concomitant,JJ,O
therapy,NN,O
with,IN,O
quinolones,NNS,G
and,CC,O
theophylline,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
monitoring,NN,O
of,IN,O
theophylline,NN,D
plasma,NN,O
levels,NNS,O
should,MD,O
be,VB,O
considered,VBN,O
and,CC,O
dosage,NN,O
of,IN,O
theophylline,NN,D
adjusted,VBN,O
",",",",O
as,IN,O
required,VBN,O
.,.,.
,,
quinolones,NNS,G
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
caffeine,NN,D
.,.,.
,,
this,DT,O
may,MD,O
lead,VB,O
to,TO,O
reduced,VBN,O
clearance,NN,O
of,IN,O
caffeine,NN,D
and,CC,O
the,DT,O
prolongation,NN,O
of,IN,O
its,PRP$,O
plasma,NN,O
half-life,NN,O
.,.,.
,,
quinolones,NNP,G
",",",",O
including,VBG,O
nalidixic,JJ,O
acid,NN,O
",",",",O
may,MD,O
enhance,VB,O
the,DT,O
effects,NNS,O
of,IN,O
the,DT,O
oral,JJ,O
anticoagulant,JJ,G
warfarin,NN,D
or,CC,O
its,PRP$,O
derivatives,NNS,O
.,.,.
,,
when,WRB,O
these,DT,O
products,NNS,O
are,VBP,O
administered,VBN,O
concomitantly,RB,O
",",",",O
prothrombin,NN,O
time,NN,O
or,CC,O
other,JJ,O
suitable,JJ,O
coagulation,NN,O
test,NN,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
.,.,.
,,
nitrofurantoin,NN,D
interferes,VBZ,O
with,IN,O
the,DT,O
therapeutic,JJ,O
action,NN,O
of,IN,O
nalidixic,JJ,O
acid,NN,O
.,.,.
,,
antacids,NNS,G
containing,VBG,O
magnesium,NN,D
",",",",O
aluminum,NN,D
",",",",O
or,CC,O
calcium,NN,D
.,.,.
,,
sucralfate,NN,D
or,CC,O
divalent,JJ,O
or,CC,O
trivalent,JJ,O
cations,NNS,O
such,JJ,O
as,IN,O
iron,NN,D
.,.,.
,,
multivitamins,NNS,G
containing,VBG,O
zinc,NN,D
.,.,.
,,
and,CC,O
videx,NNP,B
",",",",O
-lrb-,-LRB-,O
didanosine,NNP,D
-rrb-,-RRB-,O
",",",",O
chewable/buffered,JJ,O
tablets,NNS,O
or,CC,O
the,DT,O
pediatric,JJ,O
powder,NN,O
for,IN,O
oral,JJ,O
solution,NN,O
may,MD,O
substantially,RB,O
interfere,VB,O
with,IN,O
the,DT,O
absorption,NN,O
of,IN,O
quinolones,NNS,G
",",",",O
resulting,VBG,O
in,IN,O
systemic,JJ,O
levels,NNS,O
considerably,RB,O
lower,JJR,O
than,IN,O
desired,VBN,O
.,.,.
,,
these,DT,O
agents,NNS,O
should,MD,O
not,RB,O
be,VB,O
taken,VBN,O
within,IN,O
the,DT,O
two,CD,O
hour,NN,O
period,NN,O
before,IN,O
or,CC,O
within,IN,O
the,DT,O
two-hour,JJ,O
period,NN,O
after,IN,O
nalidixic,JJ,O
acid,NN,O
administration,NN,O
.,.,.
,,
elevated,JJ,O
serum,NN,O
levels,NNS,O
of,IN,O
cyclosporine,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
some,DT,O
quinolones,NNS,G
and,CC,O
cyclosporine,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
cyclosporine,NN,D
serum,NN,O
levels,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
and,CC,O
appropriate,JJ,O
cyclosporine,NN,D
dosage,NN,O
adjustments,NNS,O
made,VBN,O
when,WRB,O
these,DT,O
drugs,NNS,D
are,VBP,O
used,VBN,O
concomitantly,RB,O
.,.,.
,,
studies,NNS,O
to,TO,O
evaluate,VB,O
possible,JJ,O
interactions,NNS,O
between,IN,O
revia,NNP,B
and,CC,O
drugs,NNS,D
other,JJ,O
than,IN,O
opiates,NNS,G
have,VBP,O
not,RB,O
been,VBN,O
performed,VBN,O
.,.,.
,,
consequently,RB,O
",",",",O
caution,NN,O
is,VBZ,O
advised,VBN,O
if,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
revia,NNP,B
and,CC,O
other,JJ,O
drugs,NNS,D
is,VBZ,O
required,VBN,O
.,.,.
,,
the,DT,O
safety,NN,O
and,CC,O
efficacy,NN,O
of,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
revia,NNP,B
and,CC,O
disulfiram,NN,D
is,VBZ,O
unknown,JJ,O
",",",",O
and,CC,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
two,CD,O
potentially,RB,O
hepatotoxic,JJ,O
medications,NNS,O
is,VBZ,O
not,RB,O
ordinarily,RB,O
recommended,VBN,O
unless,IN,O
the,DT,O
probable,JJ,O
benefits,NNS,O
outweigh,VBP,O
the,DT,O
known,JJ,O
risks,NNS,O
.,.,.
,,
lethargy,NN,O
and,CC,O
somnolence,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
following,VBG,O
doses,NNS,O
of,IN,O
revia,NNP,B
and,CC,O
thioridazine,NN,D
.,.,.
,,
patients,NNS,O
taking,VBG,O
revia,NNP,B
may,MD,O
not,RB,O
benefit,VB,O
from,IN,O
opioid,JJ,G
containing,VBG,O
medicines,NNS,O
",",",",O
such,JJ,O
as,IN,O
cough,NN,O
and,CC,O
cold,JJ,O
preparations,NNS,O
",",",",O
antidiarrheal,JJ,O
preparations,NNS,O
",",",",O
and,CC,O
opioid,JJ,G
analgesics,NNS,G
.,.,.
,,
in,IN,O
an,DT,O
emergency,NN,O
situation,NN,O
when,WRB,O
opioid,JJ,G
analgesia,NN,O
must,MD,O
be,VB,O
administered,VBN,O
to,TO,O
a,DT,O
patient,NN,O
receiving,VBG,O
revia,NNP,B
",",",",O
the,DT,O
amount,NN,O
of,IN,O
opioid,NN,G
required,VBN,O
may,MD,O
be,VB,O
greater,JJR,O
than,IN,O
usual,JJ,O
",",",",O
and,CC,O
the,DT,O
resulting,VBG,O
respiratory,JJ,O
depression,NN,O
may,MD,O
be,VB,O
deeper,JJR,O
and,CC,O
more,RBR,O
prolonged,JJ,O
.,.,.
,,
the,DT,O
use,NN,O
of,IN,O
nsaids,NNS,G
in,IN,O
patients,NNS,O
who,WP,O
are,VBP,O
receiving,VBG,O
ace,NN,O
inhibitors,NNS,O
may,MD,O
potentiate,VB,O
renal,JJ,O
disease,NN,O
states,NNS,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
have,VBP,O
shown,VBN,O
that,IN,O
naproxen,NN,D
anion,NN,O
",",",",O
because,IN,O
of,IN,O
its,PRP$,O
affinity,NN,O
for,IN,O
protein,NN,O
",",",",O
may,MD,O
displace,VB,O
from,IN,O
their,PRP$,O
binding,NN,O
sites,NNS,O
other,JJ,O
drugs,NNS,D
which,WDT,O
are,VBP,O
also,RB,O
albumin-bound,JJ,O
.,.,.
,,
theoretically,RB,O
",",",",O
the,DT,O
naproxen,NN,D
anion,NN,O
itself,PRP,O
could,MD,O
likewise,RB,O
be,VB,O
displaced,VBN,O
.,.,.
,,
short-term,JJ,O
controlled,JJ,O
studies,NNS,O
failed,VBD,O
to,TO,O
show,VB,O
that,IN,O
taking,VBG,O
the,DT,O
drug,NN,D
significantly,RB,O
affects,VBZ,O
prothrombin,NN,O
times,NNS,O
when,WRB,O
administered,VBN,O
to,TO,O
individuals,NNS,O
on,IN,O
coumarin-type,JJ,O
anticoagulants,NNS,G
.,.,.
,,
caution,NN,O
is,VBZ,O
advised,VBN,O
nonetheless,RB,O
",",",",O
since,IN,O
interactions,NNS,O
have,VBP,O
been,VBN,O
seen,VBN,O
with,IN,O
other,JJ,O
nonsteroidal,JJ,O
agents,NNS,O
of,IN,O
this,DT,O
class,NN,O
.,.,.
,,
similarly,RB,O
",",",",O
patients,NNS,O
receiving,VBG,O
the,DT,O
drug,NN,D
and,CC,O
a,DT,O
hydantoin,NN,G
",",",",O
sulfonamide,NN,G
or,CC,O
sulfonylurea,NN,G
should,MD,O
be,VB,O
observed,VBN,O
for,IN,O
signs,NNS,O
of,IN,O
toxicity,NN,O
to,TO,O
these,DT,O
drugs,NNS,D
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
naproxen,NN,D
and,CC,O
aspirin,NN,B
is,VBZ,O
not,RB,O
recommended,VBN,O
because,IN,O
naproxen,NN,D
is,VBZ,O
displaced,VBN,O
from,IN,O
its,PRP$,O
binding,NN,O
sites,NNS,O
during,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
aspirin,NN,B
",",",",O
resulting,VBG,O
in,IN,O
lower,JJR,O
plasma,NN,O
concentrations,NNS,O
and,CC,O
peak,JJ,O
plasma,NN,O
levels,NNS,O
.,.,.
,,
the,DT,O
natriuretic,JJ,O
effect,NN,O
of,IN,O
furosemide,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
be,VB,O
inhibited,VBN,O
by,IN,O
some,DT,O
drugs,NNS,D
of,IN,O
this,DT,O
class,NN,O
.,.,.
,,
inhibition,NN,O
of,IN,O
renal,JJ,O
lithium,NN,D
clearance,NN,O
leading,VBG,O
to,TO,O
increases,NNS,O
in,IN,O
plasma,NN,O
lithium,NN,D
concentrations,NNS,O
has,VBZ,O
also,RB,O
been,VBN,O
reported,VBN,O
.,.,.
,,
naproxen,NN,D
and,CC,O
other,JJ,O
nsaids,NNS,G
can,MD,O
reduce,VB,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
propranolol,NN,D
and,CC,O
other,JJ,O
beta-blockers,NNS,G
.,.,.
,,
probenecid,NNP,D
given,VBN,O
concurrently,RB,O
increases,VBZ,O
naproxen,NN,D
anion,NN,O
plasma,NN,O
levels,NNS,O
and,CC,O
extends,VBZ,O
its,PRP$,O
plasma,NN,O
half-life,NN,O
significantly,RB,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
if,IN,O
naproxen,NN,D
is,VBZ,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
methotrexate,NN,D
.,.,.
,,
naproxen,NN,D
",",",",O
naproxen,NN,D
sodium,NN,O
and,CC,O
other,JJ,O
nsaids,NNS,G
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
reduce,VB,O
the,DT,O
tubular,JJ,O
secretion,NN,O
of,IN,O
methotrexate,NN,D
in,IN,O
an,DT,O
animal,NN,O
model,NN,O
",",",",O
possibly,RB,O
increasing,VBG,O
the,DT,O
toxicity,NN,O
of,IN,O
methotrexate,NN,D
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
naproxen,NN,D
may,MD,O
decrease,VB,O
platelet,NN,O
aggregation,NN,O
and,CC,O
prolong,VB,O
bleeding,JJ,O
time,NN,O
.,.,.
,,
this,DT,O
effect,NN,O
should,MD,O
be,VB,O
kept,VBN,O
in,IN,O
mind,NN,O
when,WRB,O
bleeding,VBG,O
times,NNS,O
are,VBP,O
determined,VBN,O
.,.,.
,,
the,DT,O
administration,NN,O
of,IN,O
naproxen,NN,D
may,MD,O
result,VB,O
in,IN,O
increased,VBN,O
urinary,JJ,O
values,NNS,O
for,IN,O
17-ketogenic,JJ,O
steroids,NNS,G
because,IN,O
of,IN,O
an,DT,O
interaction,NN,O
between,IN,O
the,DT,O
drug,NN,D
and/or,CC,O
its,PRP$,O
metabolites,NNS,O
with,IN,O
m-dinitrobenzene,NN,O
used,VBN,O
in,IN,O
this,DT,O
assay,NN,O
.,.,.
,,
although,IN,O
17-hydroxy-corticosteroid,JJ,O
measurements,NNS,O
-lrb-,-LRB-,O
porter-silber,NNP,O
test,NN,O
-rrb-,-RRB-,O
do,VBP,O
not,RB,O
appear,VB,O
to,TO,O
be,VB,O
artifactually,RB,O
altered,VBN,O
",",",",O
it,PRP,O
is,VBZ,O
suggested,VBN,O
that,IN,O
therapy,NN,O
with,IN,O
naproxen,NN,D
be,VB,O
temporarily,RB,O
discontinued,VBN,O
72,CD,O
hours,NNS,O
before,IN,O
adrenal,JJ,O
function,NN,O
tests,NNS,O
are,VBP,O
performed,VBN,O
if,IN,O
the,DT,O
porter-silber,NNP,O
test,NN,O
is,VBZ,O
to,TO,O
be,VB,O
used,VBN,O
.,.,.
,,
naproxen,NN,D
may,MD,O
interfere,VB,O
with,IN,O
some,DT,O
urinary,JJ,O
assays,NNS,O
of,IN,O
5-hydroxy,JJ,O
indoleacetic,JJ,O
acid,NN,O
-lrb-,-LRB-,O
5hiaa,NN,O
-rrb-,-RRB-,O
.,.,.
,,
ergot-containing,JJ,O
drugs,NNS,D
have,VBP,O
been,VBN,O
reported,VBN,O
to,TO,O
cause,VB,O
prolonged,JJ,O
vasospastic,JJ,O
reactions,NNS,O
.,.,.
,,
because,IN,O
there,EX,O
is,VBZ,O
a,DT,O
theoretical,JJ,O
basis,NN,O
that,IN,O
these,DT,O
effects,NNS,O
may,MD,O
be,VB,O
additive,JJ,O
",",",",O
use,NN,O
of,IN,O
ergotamine-containing,JJ,O
or,CC,O
ergot-type,JJ,O
medications,NNS,O
-lrb-,-LRB-,O
like,IN,O
dihydroergotamine,NN,D
or,CC,O
methysergide,NN,D
-rrb-,-RRB-,O
and,CC,O
naratriptan,NN,D
within,IN,O
24,CD,O
hours,NNS,O
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
the,DT,O
administration,NN,O
of,IN,O
naratriptan,NN,D
with,IN,O
other,JJ,O
5-ht1,NN,O
agonists,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
evaluated,VBN,O
in,IN,O
migraine,NN,O
patients,NNS,O
.,.,.
,,
because,IN,O
their,PRP$,O
vasospastic,JJ,O
effects,NNS,O
may,MD,O
be,VB,O
additive,JJ,O
",",",",O
coadministration,NN,O
of,IN,O
naratriptan,NN,D
and,CC,O
other,JJ,O
5-ht1,NN,O
agonists,NNS,O
within,IN,O
24,CD,O
hours,NNS,O
of,IN,O
each,DT,O
other,JJ,O
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
ssris,NNS,G
-rrb-,-RRB-,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
fluoxetine,NN,D
",",",",O
fluvoxamine,NN,D
",",",",O
paroxetine,NN,D
",",",",O
sertraline,NN,D
-rrb-,-RRB-,O
have,VBP,O
been,VBN,O
reported,VBN,O
",",",",O
rarely,RB,O
",",",",O
to,TO,O
cause,VB,O
weakness,NN,O
",",",",O
hyperreflexia,NN,O
",",",",O
and,CC,O
incoordination,NN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
5-htv,NN,O
agonists,NNS,O
.,.,.
,,
if,IN,O
concomitant,JJ,O
treatment,NN,O
with,IN,O
naratriptan,NN,D
and,CC,O
an,DT,O
ssri,NNP,G
is,VBZ,O
clinically,RB,O
warranted,VBN,O
",",",",O
appropriate,JJ,O
observation,NN,O
of,IN,O
the,DT,O
patient,NN,O
is,VBZ,O
advised,VBN,O
.,.,.
,,
drug,NN,O
/,:,O
laboratory,NNP,O
test,NNP,O
interactions,NNS,O
amerge,NNP,B
tablets,NNS,O
are,VBP,O
not,RB,O
known,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
commonly,RB,O
employed,VBN,O
clinical,JJ,O
laboratory,NN,O
tests,NNS,O
.,.,.
,,
after,IN,O
multiple,JJ,O
dosing,NN,O
",",",",O
interferon,NN,G
beta-1a,NN,O
-lrb-,-LRB-,O
avonex,NN,B
30,CD,O
mcg,NN,O
im,NN,O
once,RB,O
weekly,JJ,O
-rrb-,-RRB-,O
reduced,VBD,O
tysabri,NN,B
clearance,NN,O
by,IN,O
approximately,RB,O
30,CD,O
%,NN,O
.,.,.
,,
the,DT,O
similarity,NN,O
of,IN,O
the,DT,O
tysabri,NNP,B
-,:,O
associated,VBN,O
adverse,JJ,O
event,NN,O
profile,NN,O
between,IN,O
study,NNP,O
1,CD,O
-lrb-,-LRB-,O
without,IN,O
co-administered,JJ,O
avonex,NNP,B
-rrb-,-RRB-,O
and,CC,O
study,NN,O
2,CD,O
-lrb-,-LRB-,O
with,IN,O
co-administered,JJ,O
avonex,NNP,B
-rrb-,-RRB-,O
indicates,VBZ,O
that,IN,O
this,DT,O
alteration,NN,O
in,IN,O
clearance,NN,O
does,VBZ,O
not,RB,O
necessitate,VB,O
reduction,NN,O
of,IN,O
the,DT,O
tysabri,NNP,B
dose,NN,O
to,TO,O
maintain,VB,O
safety,NN,O
",",",",O
general,NNP,O
-rrb-,-RRB-,O
.,.,.
,,
results,NNS,O
of,IN,O
studies,NNS,O
in,IN,O
multiple,JJ,O
sclerosis,NN,O
patients,NNS,O
taking,VBG,O
tysabri,NNP,B
and,CC,O
concomitant,JJ,O
interferon,NN,G
beta-1a,NN,O
-lrb-,-LRB-,O
avonex,NN,B
30,CD,O
mcg,NN,O
im,NN,O
once,RB,O
weekly,JJ,O
-rrb-,-RRB-,O
or,CC,O
glatiramer,NN,O
acetate,NN,O
were,VBD,O
inconclusive,JJ,O
with,IN,O
regard,NN,O
to,TO,O
the,DT,O
need,NN,O
for,IN,O
dose,NN,O
adjustment,NN,O
of,IN,O
the,DT,O
beta-interferon,NN,D
or,CC,O
glatiramer,NN,O
acetate,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
drug,NN,D
metabolism,NN,O
studies,NNS,O
indicate,VBP,O
that,IN,O
starlix,NNP,B
is,VBZ,O
predominantly,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
isozyme,NN,O
cyp2c9,NN,D
-lrb-,-LRB-,O
70,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
to,TO,O
a,DT,O
lesser,JJR,O
extent,NN,O
cyp3a4,NN,D
-lrb-,-LRB-,O
30,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
starlix,NNP,B
is,VBZ,O
a,DT,O
potential,JJ,O
inhibitor,NN,O
of,IN,O
the,DT,O
cyp2c9,NN,D
isoenzyme,NN,O
in,FW,O
vivo,FW,O
as,IN,O
indicated,VBN,O
by,IN,O
its,PRP$,O
ability,NN,O
to,TO,O
inhibit,VB,O
the,DT,O
in,FW,O
vitro,FW,O
metabolism,NN,O
of,IN,O
tolbutamide,NN,D
.,.,.
,,
inhibition,NN,O
of,IN,O
cyp3a4,NN,D
metabolic,JJ,O
reactions,NNS,O
was,VBD,O
not,RB,O
detected,VBN,O
in,IN,O
in,FW,O
vitro,FW,O
experiments,NNS,O
.,.,.
,,
glyburide,NNP,D
:,:,O
in,IN,O
a,DT,O
randomized,VBN,O
",",",",O
multiple-dose,JJ,O
crossover,NN,O
study,NN,O
",",",",O
patients,NNS,O
with,IN,O
type,NN,O
2,CD,O
diabetes,NNS,O
were,VBD,O
administered,VBN,O
120,CD,O
mg,NN,O
starlix,NN,B
three,CD,O
times,NNS,O
a,DT,O
day,NN,O
before,IN,O
meals,NNS,O
for,IN,O
1,CD,O
day,NN,O
in,IN,O
combination,NN,O
with,IN,O
glyburide,NN,D
10,CD,O
mg,NN,O
daily,RB,O
.,.,.
,,
there,EX,O
were,VBD,O
no,DT,O
clinically,RB,O
relevant,JJ,O
alterations,NNS,O
in,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
agent,NN,O
.,.,.
,,
metformin,NNP,D
:,:,O
when,WRB,O
starlix,NNP,B
120,CD,O
mg,NN,O
three,CD,O
times,NNS,O
daily,RB,O
before,IN,O
meals,NNS,O
was,VBD,O
administered,VBN,O
in,IN,O
combination,NN,O
with,IN,O
metformin,NN,D
500,CD,O
mg,NN,O
three,CD,O
times,NNS,O
daily,JJ,O
to,TO,O
patients,NNS,O
with,IN,O
type,NN,O
2,CD,O
diabetes,NN,O
",",",",O
there,EX,O
were,VBD,O
no,DT,O
clinically,RB,O
relevant,JJ,O
changes,NNS,O
in,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
agent,NN,O
.,.,.
,,
digoxin,NNP,D
:,:,O
when,WRB,O
starlix,NNP,B
120,CD,O
mg,NN,O
before,IN,O
meals,NNS,O
was,VBD,O
administered,VBN,O
in,IN,O
combination,NN,O
with,IN,O
a,DT,O
single,JJ,O
1-mg,JJ,O
dose,NN,O
of,IN,O
digoxin,NN,D
to,TO,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
there,EX,O
were,VBD,O
no,DT,O
clinically,RB,O
relevant,JJ,O
changes,NNS,O
in,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
agent,NN,O
.,.,.
,,
warfarin,NNP,D
:,:,O
when,WRB,O
healthy,JJ,O
subjects,NNS,O
were,VBD,O
administered,VBN,O
starlix,NNP,B
120,CD,O
mg,NN,O
three,CD,O
times,NNS,O
daily,RB,O
before,IN,O
meals,NNS,O
for,IN,O
four,CD,O
days,NNS,O
in,IN,O
combination,NN,O
with,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
warfarin,NN,D
30,CD,O
mg,NN,O
on,IN,O
day,NN,O
2,CD,O
",",",",O
there,EX,O
were,VBD,O
no,DT,O
alterations,NNS,O
in,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
agent,NN,O
.,.,.
,,
prothrombin,NNP,O
time,NN,O
was,VBD,O
not,RB,O
affected,VBN,O
.,.,.
,,
diclofenac,NNP,D
:,:,O
administration,NNP,O
of,IN,O
morning,NN,O
and,CC,O
lunch,NN,O
doses,NNS,O
of,IN,O
starlix,NNP,B
120,CD,O
mg,NN,O
in,IN,O
combination,NN,O
with,IN,O
a,DT,O
single,JJ,O
75-mg,JJ,O
dose,NN,O
of,IN,O
diclofenac,NN,D
in,IN,O
healthy,JJ,O
volunteers,NNS,O
resulted,VBD,O
in,IN,O
no,DT,O
significant,JJ,O
changes,NNS,O
to,TO,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
agent,NN,O
.,.,.
,,
nateglinide,NNP,D
is,VBZ,O
highly,RB,O
bound,VBN,O
to,TO,O
plasma,NN,O
proteins,NNS,O
-lrb-,-LRB-,O
98,CD,O
%,NN,O
-rrb-,-RRB-,O
",",",",O
mainly,RB,O
albumin,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
displacement,NN,O
studies,NNS,O
with,IN,O
highly,RB,O
protein-bound,JJ,O
drugs,NNS,D
such,JJ,O
as,IN,O
furosemide,NN,D
",",",",O
propranolol,NN,D
",",",",O
captopril,NN,D
",",",",O
nicardipine,NN,D
",",",",O
pravastatin,NN,D
",",",",O
glyburide,NN,D
",",",",O
warfarin,NN,D
",",",",O
phenytoin,NN,D
",",",",O
acetylsalicylic,JJ,O
acid,NN,O
",",",",O
tolbutamide,NN,D
",",",",O
and,CC,O
metformin,NN,D
showed,VBD,O
no,DT,O
influence,NN,O
on,IN,O
the,DT,O
extent,NN,O
of,IN,O
nateglinide,NN,D
protein,NN,O
binding,NN,O
.,.,.
,,
similarly,RB,O
",",",",O
nateglinide,NN,D
had,VBD,O
no,DT,O
influence,NN,O
on,IN,O
the,DT,O
serum,NN,O
protein,NN,O
binding,NN,O
of,IN,O
propranolol,NN,D
",",",",O
glyburide,NN,D
",",",",O
nicardipine,NN,D
",",",",O
warfarin,NN,D
",",",",O
phenytoin,NN,D
",",",",O
acetylsalicylic,JJ,O
acid,NN,O
",",",",O
and,CC,O
tolbutamide,NN,D
in,FW,O
vitro,FW,O
.,.,.
,,
however,RB,O
",",",",O
prudent,JJ,O
evaluation,NN,O
of,IN,O
individual,JJ,O
cases,NNS,O
is,VBZ,O
warranted,VBN,O
in,IN,O
the,DT,O
clinical,JJ,O
setting,NN,O
.,.,.
,,
certain,JJ,O
drugs,NNS,D
",",",",O
including,VBG,O
nonsteroidal,JJ,O
anti-inflammatory,JJ,G
agents,NNS,O
-lrb-,-LRB-,O
nsaids,NNS,G
-rrb-,-RRB-,O
",",",",O
salicylates,NNS,G
",",",",O
monoamine,NN,O
oxidase,NN,O
inhibitors,NNS,O
",",",",O
and,CC,O
non-selective,JJ,O
beta-adrenergic-blocking,JJ,O
agents,NNS,O
may,MD,O
potentiate,VB,O
the,DT,O
hypoglycemic,JJ,G
action,NN,O
of,IN,O
starlix,NNP,B
and,CC,O
other,JJ,O
oral,JJ,O
antidiabetic,JJ,D
drugs,NNS,D
.,.,.
,,
certain,JJ,O
drugs,NNS,D
including,VBG,O
thiazides,NNS,G
",",",",O
corticosteroids,NNS,G
",",",",O
thyroid,NN,G
products,NNS,O
",",",",O
and,CC,O
sympathomimetics,NNS,G
may,MD,O
reduce,VB,O
the,DT,O
hypoglycemic,JJ,G
action,NN,O
of,IN,O
starlix,NNP,B
and,CC,O
other,JJ,O
oral,JJ,O
antidiabetic,JJ,D
drugs,NNS,D
.,.,.
,,
when,WRB,O
these,DT,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
to,TO,O
or,CC,O
withdrawn,VBN,O
from,IN,O
patients,NNS,O
receiving,VBG,O
starlix,NNP,B
",",",",O
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
observed,VBN,O
closely,RB,O
for,IN,O
changes,NNS,O
in,IN,O
glycemic,JJ,O
control,NN,O
.,.,.
,,
in,IN,O
clinical,JJ,O
studies,NNS,O
",",",",O
tilade,NNP,B
has,VBZ,O
been,VBN,O
co-administered,VBN,O
with,IN,O
other,JJ,O
anti-asthma,JJ,O
medications,NNS,O
",",",",O
including,VBG,O
inhaled,VBN,O
and,CC,O
oral,JJ,O
bronchodilators,NNS,G
",",",",O
and,CC,O
inhaled,VBD,O
corticosteroids,NNS,G
",",",",O
with,IN,O
no,DT,O
evidence,NN,O
of,IN,O
increased,VBN,O
frequency,NN,O
of,IN,O
adverse,JJ,O
events,NNS,O
or,CC,O
laboratory,NN,O
abnormalities,NNS,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug-drug,JJ,O
interaction,NN,O
studies,NNS,O
",",",",O
however,RB,O
",",",",O
have,VBP,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
nelfinavir,NNP,D
is,VBZ,O
an,DT,O
inhibitor,NN,O
of,IN,O
cyp3a,NN,O
-lrb-,-LRB-,O
cytochrome,NN,O
p450,NN,O
3a,NN,O
-rrb-,-RRB-,O
.,.,.
,,
coadministration,NNP,O
of,IN,O
viracept,NNP,B
and,CC,O
drugs,NNS,D
primarily,RB,O
metabolized,VBN,O
by,IN,O
cyp3a,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
dihydropyridine,NN,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
-rrb-,-RRB-,O
may,MD,O
result,VB,O
in,IN,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
the,DT,O
other,JJ,O
drug,NN,D
that,WDT,O
could,MD,O
increase,VB,O
or,CC,O
prolong,VB,O
both,DT,O
its,PRP$,O
therapeutic,JJ,O
and,CC,O
adverse,JJ,O
effects,NNS,O
.,.,.
,,
nelfinavir,NNP,D
is,VBZ,O
metabolized,VBN,O
in,IN,O
proof,NN,O
by,IN,O
c.p.a.,NNP,O
coadministration,NNP,O
of,IN,O
viracept,NNP,B
and,CC,O
drugs,NNS,D
that,WDT,O
induce,VBP,O
cyp3a,NN,O
may,MD,O
decrease,VB,O
nelfinavir,NN,D
plasma,NN,O
concentrations,NNS,O
and,CC,O
reduce,VB,O
its,PRP$,O
therapeutic,JJ,O
effect,NN,O
.,.,.
,,
coadministration,NNP,O
of,IN,O
viracept,NNP,B
and,CC,O
drugs,NNS,D
that,WDT,O
inhibit,VBP,O
cyp3a,NN,O
may,MD,O
increase,VB,O
nelfinavir,NN,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
based,VBN,O
on,IN,O
known,JJ,O
metabolic,JJ,O
profiles,NNS,O
",",",",O
clinically,RB,O
significant,JJ,O
drug,NN,D
interactions,NNS,O
are,VBP,O
not,RB,O
expected,VBN,O
between,IN,O
viracept,NNP,B
and,CC,O
dapsone,NN,D
",",",",O
trimethoprim/sulfamethoxazole,NN,O
",",",",O
clarithromycin,NN,D
",",",",O
erythromycin,NN,D
",",",",O
itraconazole,NN,D
or,CC,O
fluconazole,NN,D
.,.,.
,,
drugs,NNS,O
that,WDT,O
should,MD,O
not,RB,O
be,VB,O
coadministered,JJ,O
with,IN,O
viracept,NNP,B
antiarrhythmics,NNPS,G
:,:,O
amiodarone,NN,D
",",",",O
quinidine,NN,D
antihistamines,NNS,D
:,:,O
astemizole,NN,D
",",",",O
terfenadine,NN,D
antimigraine,NNP,O
:,:,O
ergot,NN,G
derivatives,NNS,O
antimycobacterial,JJ,G
agents,NNS,O
:,:,O
rifampin,NN,D
benzodiazepines,NNS,G
midazolam,NN,D
",",",",O
triazolam,NN,D
gi,NN,O
motility,NN,O
agents,NNS,O
:,:,O
cisaprid,NN,O
.,.,.
,,
drugs,NNS,O
which,WDT,O
require,VBP,O
a,DT,O
dose,NN,O
reduction,NN,O
when,WRB,O
coadminstered,NNP,O
with,IN,O
viracept,NNP,B
antimycobacterial,JJ,G
agents,NNS,O
:,:,O
rifabuti,NNS,O
.,.,.
,,
*,SYM,O
this,DT,O
table,NN,O
is,VBZ,O
not,RB,O
all,DT,O
inclusive,JJ,O
**,SYM,O
viracept,NNP,B
may,MD,O
not,RB,O
be,VB,O
effective,JJ,O
due,JJ,O
to,TO,O
decreased,VBN,O
nelfinavir,NN,D
plasma,NN,O
concentrations,NNS,O
in,IN,O
patients,NNS,O
taking,VBG,O
these,DT,O
agents,NNS,O
concomitantl,NN,O
.,.,.
,,
antihistamine,NN,O
.,.,.
,,
terfenadine,NNP,D
:,:,O
administration,NNP,O
of,IN,O
terfenadine,NN,D
with,IN,O
viracept,NN,B
resulted,VBD,O
in,IN,O
the,DT,O
appearance,NN,O
of,IN,O
unchanged,JJ,O
terfenadine,NN,D
in,IN,O
plasma,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
viracept,NNP,B
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
concurrently,RB,O
with,IN,O
terfenadine,NN,D
because,IN,O
of,IN,O
the,DT,O
potential,NN,O
for,IN,O
serious,JJ,O
and/or,CC,O
life-threatening,JJ,O
cardiac,JJ,O
arrhythmias,NNS,O
.,.,.
,,
because,IN,O
a,DT,O
similar,JJ,O
interaction,NN,O
is,VBZ,O
likely,JJ,O
",",",",O
viracept,NNP,B
should,MD,O
also,RB,O
not,RB,O
be,VB,O
administered,VBN,O
concurrently,RB,O
with,IN,O
astemizole,NN,D
.,.,.
,,
anti-hiv,JJ,O
protease,NN,O
inhibitor,NN,O
.,.,.
,,
indinavir,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
indinavir,NN,D
with,IN,O
viracept,NN,B
resulted,VBD,O
in,IN,O
an,DT,O
83,CD,O
%,NN,O
increase,NN,O
in,IN,O
nelfinavir,NN,D
plasma,NN,O
auc,NN,O
and,CC,O
a,DT,O
51,CD,O
%,NN,O
increase,NN,O
in,IN,O
indinavir,NN,D
plasma,NN,O
a.c.,NNP,O
currently,NNP,O
",",",",O
there,EX,O
are,VBP,O
no,DT,O
safety,NN,O
and,CC,O
efficacy,NN,O
data,NNS,O
available,JJ,O
from,IN,O
the,DT,O
use,NN,O
of,IN,O
this,DT,O
combination,NN,O
.,.,.
,,
ritonavir,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
ritonavir,NN,D
with,IN,O
viracept,NN,B
resulted,VBD,O
in,IN,O
a,DT,O
152,CD,O
%,NN,O
increase,NN,O
in,IN,O
nelfinavir,NN,D
plasma,NN,O
auc,NN,O
and,CC,O
very,RB,O
little,JJ,O
change,NN,O
in,IN,O
ritonavir,NN,D
plasma,NN,O
a.c.,NNP,O
currently,NNP,O
",",",",O
there,EX,O
are,VBP,O
no,DT,O
safety,NN,O
and,CC,O
efficacy,NN,O
data,NNS,O
available,JJ,O
from,IN,O
the,DT,O
use,NN,O
of,IN,O
this,DT,O
combination,NN,O
.,.,.
,,
saquinavir,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
saquinavir,NN,D
-lrb-,-LRB-,O
using,VBG,O
an,DT,O
experimental,JJ,O
soft-gelatin,JJ,O
capsule,NN,O
formulation,NN,O
of,IN,O
saquinavir,NN,D
1200mg,NN,O
-rrb-,-RRB-,O
with,IN,O
viracept,NN,B
resulted,VBD,O
in,IN,O
an,DT,O
18,CD,O
%,NN,O
increase,NN,O
in,IN,O
nelfinavir,NN,D
plasma,NN,O
auc,NN,O
and,CC,O
a,DT,O
4-fold,JJ,O
increase,NN,O
in,IN,O
saquinavir,NN,D
plasma,NN,O
a.c.,NNP,O
.,.,.
,,
if,IN,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
saquinavir,NN,D
hard,JJ,O
gelatin,NN,O
capsules,NNS,O
at,IN,O
the,DT,O
recommended,VBN,O
dose,NN,O
of,IN,O
600,CD,O
mg,NN,O
tid,NN,O
",",",",O
no,DT,O
dose,NN,O
adjustments,NNS,O
are,VBP,O
needed,VBN,O
.,.,.
,,
currently,RB,O
",",",",O
there,EX,O
are,VBP,O
no,DT,O
safety,NN,O
and,CC,O
efficacy,NN,O
data,NNS,O
available,JJ,O
from,IN,O
the,DT,O
use,NN,O
of,IN,O
this,DT,O
combination,NN,O
.,.,.
,,
antifungal,JJ,G
agent,NNP,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
coadministration,NN,O
of,IN,O
ketoconazole,NN,D
with,IN,O
viracept,NN,B
resulted,VBD,O
in,IN,O
a,DT,O
35,CD,O
%,NN,O
increase,NN,O
in,IN,O
nelfinavir,NN,D
plasma,NN,O
a.c.,NNP,O
.,.,.
,,
this,DT,O
change,NN,O
was,VBD,O
not,RB,O
considered,VBN,O
clinically,RB,O
significant,JJ,O
and,CC,O
no,DT,O
dose,NN,O
adjustment,NN,O
is,VBZ,O
needed,VBN,O
when,WRB,O
ketoconazole,NN,D
and,CC,O
viracept,NN,B
are,VBP,O
coadministered,VBN,O
.,.,.
,,
anti-hiv,JJ,O
reverse,NN,O
transcriptase,NNP,O
inhibitor,NNP,O
.,.,.
,,
didanosine,NNP,D
:,:,O
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
didanosine,NN,D
be,VB,O
administered,VBN,O
on,IN,O
an,DT,O
empty,JJ,O
stomach,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
nelfinavir,NN,D
should,MD,O
be,VB,O
administered,VBN,O
-lrb-,-LRB-,O
with,IN,O
food,NN,O
-rrb-,-RRB-,O
one,CD,O
hour,NN,O
after,IN,O
or,CC,O
more,JJR,O
than,IN,O
two,CD,O
hours,NNS,O
before,IN,O
didanosine,NN,D
.,.,.
,,
a,DT,O
dose,NN,O
adjustment,NN,O
is,VBZ,O
not,RB,O
needed,VBN,O
when,WRB,O
zidovudine,NN,D
is,VBZ,O
administered,VBN,O
with,IN,O
viracept,NN,B
.,.,.
,,
little,JJ,O
or,CC,O
no,DT,O
change,NN,O
in,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
drug,NN,D
was,VBD,O
observed,VBN,O
when,WRB,O
viracept,NNP,B
was,VBD,O
coadministered,VBN,O
with,IN,O
lamivudine,NN,D
or,CC,O
stavudine,NN,D
.,.,.
,,
antimycobacterial,JJ,G
agent,NNP,O
.,.,.
,,
rifabutin,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
rifabutin,NN,D
and,CC,O
viracept,NN,B
resulted,VBD,O
in,IN,O
a,DT,O
32,CD,O
%,NN,O
decrease,NN,O
in,IN,O
nelfinavir,NN,D
plasma,NN,O
auc,NN,O
and,CC,O
a,DT,O
207,CD,O
%,NN,O
increase,NN,O
in,IN,O
rifabutin,NN,D
plasma,NN,O
a.c.,NNP,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
the,DT,O
dose,NN,O
of,IN,O
rifabutin,NN,D
be,VB,O
reduced,VBN,O
to,TO,O
one-half,NN,O
the,DT,O
usual,JJ,O
dose,NN,O
when,WRB,O
administered,VBN,O
with,IN,O
viracept,NN,B
.,.,.
,,
rifampin,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
rifampin,NN,D
and,CC,O
viracept,NN,B
resulted,VBD,O
in,IN,O
an,DT,O
82,CD,O
%,NN,O
decrease,NN,O
in,IN,O
nelfinavir,NN,D
plasma,NN,O
a.c.,NNP,O
viracept,NNP,B
and,CC,O
rifampin,NN,D
should,MD,O
not,RB,O
be,VB,O
coadministered,VBN,O
.,.,.
,,
oral,JJ,O
contraceptive,NN,G
.,.,.
,,
ethinyl,NNP,O
estradiol,NNP,O
and,CC,O
norethindrone,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
viracept,NNP,B
with,IN,O
ovcon-35,NN,B
resulted,VBD,O
in,IN,O
a,DT,O
47,CD,O
%,NN,O
decrease,NN,O
in,IN,O
ethinyl,NN,O
estradiol,NN,O
and,CC,O
an,DT,O
18,CD,O
%,NN,O
decrease,NN,O
in,IN,O
norethindrone,NN,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
alternate,JJ,O
or,CC,O
additional,JJ,O
contraceptive,JJ,G
measures,NNS,O
should,MD,O
be,VB,O
used,VBN,O
during,IN,O
therapy,NN,O
with,IN,O
viracep,NN,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
taken,VBN,O
in,IN,O
concurrent,JJ,O
or,CC,O
serial,JJ,O
use,NN,O
of,IN,O
other,JJ,O
neurotoxic,JJ,O
and,CC,O
/,:,O
or,CC,O
nephrotoxic,JJ,O
drugs,NNS,D
because,IN,O
of,IN,O
possible,JJ,O
enhancement,NN,O
of,IN,O
the,DT,O
nephrotoxicity,NN,O
and/or,CC,O
ototoxicity,NN,O
of,IN,O
neomycin,NN,D
.,.,.
,,
caution,NN,O
should,MD,O
also,RB,O
be,VB,O
taken,VBN,O
in,IN,O
concurrent,JJ,O
or,CC,O
serial,JJ,O
use,NN,O
of,IN,O
other,JJ,O
aminoglycosides,NNS,G
and,CC,O
polymyxins,NNS,G
because,IN,O
they,PRP,O
may,MD,O
enhance,VB,O
neomycin,NN,D
s,NNS,O
nephrotoxicity,NN,O
and/or,CC,O
ototoxicity,NN,O
and,CC,O
potentiate,VB,O
neomycin,NN,D
sulfate,NN,O
neuromuscular,JJ,O
blocking,NN,O
effects,NNS,O
.,.,.
,,
oral,JJ,O
neomycin,NN,D
inhibits,VBZ,O
the,DT,O
gastrointestinal,JJ,O
absorption,NN,O
of,IN,O
penicillin,NN,D
v,NN,O
",",",",O
oral,JJ,O
vitamin,NN,G
b-12,NN,O
",",",",O
methotrexate,NN,D
and,CC,O
5-fluorouracil,NN,D
.,.,.
,,
the,DT,O
gastrointestinal,JJ,O
absorption,NN,O
of,IN,O
digoxin,NN,D
also,RB,O
appears,VBZ,O
to,TO,O
be,VB,O
inhibited,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
digoxin,NN,D
serum,NN,O
levels,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
.,.,.
,,
oral,JJ,O
neomycin,NN,D
sulfate,NN,O
may,MD,O
enhance,VB,O
the,DT,O
effect,NN,O
of,IN,O
coumarin,NN,G
in,IN,O
anticoagulants,NNS,G
by,IN,O
decreasing,VBG,O
vitamin,NN,G
k,NN,O
availability,NN,O
.,.,.
,,
certain,JJ,O
antibiotics,NNS,G
",",",",O
especially,RB,O
neomycin,NN,D
",",",",O
streptomycin,NN,D
and,CC,O
kanamycin,NN,D
",",",",O
have,VBP,O
a,DT,O
mild,JJ,O
but,CC,O
definite,JJ,O
nondepolarizing,JJ,O
blocking,VBG,O
action,NN,O
which,WDT,O
may,MD,O
accentuate,VB,O
neuromuscular,JJ,O
block,NN,O
.,.,.
,,
these,DT,O
antibiotics,NNS,G
should,MD,O
be,VB,O
used,VBN,O
in,IN,O
the,DT,O
myasthenic,JJ,O
patient,NN,O
only,RB,O
where,WRB,O
definitely,RB,O
indicated,VBN,O
",",",",O
and,CC,O
then,RB,O
careful,JJ,O
adjustment,NN,O
should,MD,O
be,VB,O
made,VBN,O
of,IN,O
adjunctive,JJ,O
anticholinesterase,JJ,G
dosage,NN,O
.,.,.
,,
local,JJ,O
and,CC,O
some,DT,O
general,JJ,O
anesthetics,NNS,G
",",",",O
antiarrhythmic,JJ,D
agents,NNS,O
and,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
interfere,VBP,O
with,IN,O
neuromuscular,JJ,O
transmission,NN,O
should,MD,O
be,VB,O
used,VBN,O
cautiously,RB,O
",",",",O
if,IN,O
at,IN,O
all,DT,O
",",",",O
in,IN,O
patients,NNS,O
with,IN,O
myasthenia,NN,O
gravis,NN,O
.,.,.
,,
the,DT,O
dose,NN,O
of,IN,O
prostigmin,NNP,B
may,MD,O
have,VB,O
to,TO,O
be,VB,O
increased,VBN,O
accordingly,RB,O
.,.,.
,,
no,DT,O
trials,NNS,O
specifically,RB,O
examining,VBG,O
potential,JJ,O
drug,NN,D
interactions,NNS,O
with,IN,O
natrecor,NN,B
were,VBD,O
conducted,VBN,O
",",",",O
although,IN,O
many,JJ,O
concomitant,JJ,O
drugs,NNS,D
were,VBD,O
used,VBN,O
in,IN,O
clinical,JJ,O
trials,NNS,O
.,.,.
,,
no,DT,O
drug,NN,D
interactions,NNS,O
were,VBD,O
detected,VBN,O
except,IN,O
for,IN,O
an,DT,O
increase,NN,O
in,IN,O
symptomatic,JJ,O
hypotension,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
oral,JJ,O
ace,NN,O
inhibitors,NNS,O
.,.,.
,,
the,DT,O
co-administration,NN,O
of,IN,O
natrecor,NN,B
with,IN,O
iv,CD,O
vasodilators,NNS,G
such,JJ,O
as,IN,O
nitroglycerin,NN,D
",",",",O
nitroprusside,NN,D
",",",",O
milrinone,NN,D
",",",",O
or,CC,O
iv,CD,O
ace,NN,O
inhibitors,NNS,O
has,VBZ,O
not,RB,O
been,VBN,O
evaluated,VBN,O
-lrb-,-LRB-,O
these,DT,O
drugs,NNS,D
were,VBD,O
not,RB,O
co-administered,VBN,O
with,IN,O
natrecor,NNP,B
in,IN,O
clinical,JJ,O
trials,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
netilmicin,NN,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
potent,JJ,O
loop,NN,O
diuretics,NNS,G
such,JJ,O
as,IN,O
furosemide,NN,D
and,CC,O
ethacrynic,JJ,O
acid,NN,O
as,IN,O
the,DT,O
potential,NN,O
for,IN,O
ototoxicity,NN,O
is,VBZ,O
enhanced,VBN,O
by,IN,O
the,DT,O
combination,NN,O
.,.,.
,,
nevirapine,NNP,D
is,VBZ,O
principally,RB,O
metabolized,VBN,O
by,IN,O
the,DT,O
liver,NN,O
via,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
isoenzymes,NNS,O
",",",",O
3a4,NN,O
and,CC,O
2b6,NN,O
.,.,.
,,
nevirapine,NNP,D
is,VBZ,O
known,VBN,O
to,TO,O
be,VB,O
an,DT,O
inducer,NN,O
of,IN,O
these,DT,O
enzymes,NNS,O
.,.,.
,,
as,IN,O
a,DT,O
result,NN,O
",",",",O
drugs,NNS,D
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
these,DT,O
enzyme,NN,O
systems,NNS,O
may,MD,O
have,VB,O
lower,JJR,O
than,IN,O
expected,VBN,O
plasma,NN,O
levels,NNS,O
when,WRB,O
coadministered,VBN,O
with,IN,O
nevirapine,NN,D
.,.,.
,,
the,DT,O
specific,JJ,O
pharmacokinetic,JJ,O
changes,NNS,O
that,WDT,O
occur,VBP,O
with,IN,O
co-administration,NN,O
of,IN,O
nevirapine,NN,D
and,CC,O
other,JJ,O
drugs,NNS,D
are,VBP,O
listed,VBN,O
in,IN,O
clinical,NNP,O
pharmacology,NNP,O
",",",",O
table,NNP,O
1,CD,O
.,.,.
,,
clinical,JJ,O
comments,NNS,O
about,IN,O
possible,JJ,O
dosage,NN,O
modifications,NNS,O
based,VBN,O
on,IN,O
these,DT,O
pharmacokinetic,JJ,O
changes,NNS,O
are,VBP,O
listed,VBN,O
in,IN,O
table,NNP,O
3,CD,O
.,.,.
,,
the,DT,O
data,NNS,O
intables,NNS,O
1,CD,O
and,CC,O
3,CD,O
are,VBP,O
based,VBN,O
on,IN,O
the,DT,O
results,NNS,O
of,IN,O
drug,NN,D
interaction,NN,O
studies,NNS,O
conducted,VBN,O
in,IN,O
hiv-1,NN,O
seropositive,JJ,O
subjects,NNS,O
unless,IN,O
otherwise,RB,O
indicated,VBN,O
.,.,.
,,
in,IN,O
addition,NN,O
to,TO,O
established,VBN,O
drug,NN,D
interactions,NNS,O
",",",",O
there,EX,O
may,MD,O
be,VB,O
potential,JJ,O
pharmacokinetic,JJ,O
interactions,NNS,O
between,IN,O
nevirapine,NN,D
and,CC,O
other,JJ,O
drug,NN,D
classes,NNS,O
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
system,NN,O
.,.,.
,,
these,DT,O
potential,JJ,O
drug,NN,D
interactions,NNS,O
are,VBP,O
listed,VBN,O
in,IN,O
table,NNP,O
4,CD,O
.,.,.
,,
although,IN,O
specific,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
in,IN,O
hiv-1,NN,O
seropositive,JJ,O
subjects,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
for,IN,O
the,DT,O
classes,NNS,O
of,IN,O
drugs,NNS,D
listed,VBN,O
in,IN,O
table,NNP,O
4,CD,O
",",",",O
additional,JJ,O
clinical,JJ,O
monitoring,NN,O
may,MD,O
be,VB,O
warranted,VBN,O
when,WRB,O
co-administering,VBG,O
these,DT,O
drugs,NNS,D
.,.,.
,,
the,DT,O
in,FW,O
vitro,FW,O
interaction,NN,O
between,IN,O
nevirapine,NN,D
and,CC,O
the,DT,O
antithrombotic,JJ,O
agent,NN,O
warfarin,NN,D
is,VBZ,O
complex,NN,O
.,.,.
,,
as,IN,O
a,DT,O
result,NN,O
",",",",O
when,WRB,O
giving,VBG,O
these,DT,O
drugs,NNS,D
concomitantly,RB,O
",",",",O
plasma,NN,O
warfarin,NN,D
levels,NNS,O
may,MD,O
change,VB,O
with,IN,O
the,DT,O
potential,NN,O
for,IN,O
increases,NNS,O
in,IN,O
coagulation,NN,O
time,NN,O
.,.,.
,,
when,WRB,O
warfarin,NN,D
is,VBZ,O
co-administered,VBN,O
with,IN,O
nevirapine,NN,D
",",",",O
anticoagulation,NN,O
levels,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
frequently,RB,O
.,.,.
,,
table,NNP,O
3,CD,O
established,NNP,O
drug,NNP,O
interactions,NNS,O
:,:,O
alteration,NN,O
in,IN,O
dose,NN,O
or,CC,O
regimen,NNP,O
may,NNP,O
be,VB,O
recommended,VBN,O
based,VBN,O
on,IN,O
drug,NN,O
interaction,NN,O
studies,NNS,O
.,.,.
,,
drug,NN,O
name,VB,O
.,.,.
,,
effect,NN,O
on,IN,O
concentration,NN,O
of,IN,O
nevirapine,NNP,D
or,CC,O
concomitant,JJ,O
dru,NN,O
.,.,.
,,
clinical,JJ,O
comment,NN,O
.,.,.
,,
clarithromyci,NNP,O
.,.,.
,,
clarithromycin,NNP,D
14oh,NN,O
-,:,O
clarithromyci,NNS,O
.,.,.
,,
clarithromycin,NNP,D
exposure,NN,O
was,VBD,O
significantly,RB,O
decreased,VBN,O
by,IN,O
nevirapine,NN,D
.,.,.
,,
however,RB,O
",",",",O
14-oh,NN,O
metabolite,NN,O
concentrations,NNS,O
were,VBD,O
increased.because,JJ,O
clarithromycin,NN,D
active,JJ,O
metabolite,NN,O
has,VBZ,O
reduced,VBN,O
activity,NN,O
against,IN,O
mycobacteriumavium-intracellulare,JJ,O
complex,NN,O
",",",",O
overallactivity,NN,O
against,IN,O
this,DT,O
pathogen,NN,O
may,MD,O
bealtered,VB,O
.,.,.
,,
alternatives,NNP,O
to,TO,O
clarithromycin,NN,D
",",",",O
such,JJ,O
as,IN,O
azithromycin,NN,D
",",",",O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
efaviren,NNP,O
.,.,.
,,
efaviren,NNP,O
.,.,.
,,
appropriate,JJ,O
doses,NNS,O
for,IN,O
this,DT,O
combination,NN,O
are,VBP,O
not,RB,O
established,VBN,O
.,.,.
,,
ethinyl,NN,O
estradiol,NN,O
and,CC,O
norethindron,NN,O
.,.,.
,,
ethinyl,NN,O
estradiol,NN,O
norethindron,NNP,O
.,.,.
,,
oral,JJ,O
contraceptives,NNS,G
and,CC,O
other,JJ,O
hormonalmethods,NNS,O
of,IN,O
birth,NN,O
control,NN,O
should,MD,O
not,RB,O
be,VB,O
usedas,JJ,O
the,DT,O
sole,JJ,O
method,NN,O
of,IN,O
contraception,NN,O
inwomen,NN,O
taking,VBG,O
nevirapine,NN,D
",",",",O
since,IN,O
nevirapinemay,NN,O
lower,JJR,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
thesemedications,NNS,O
.,.,.
,,
an,DT,O
alternative,JJ,O
or,CC,O
additional,JJ,O
method,NN,O
of,IN,O
contraception,NN,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
fluconazol,NNP,O
.,.,.
,,
nevirapin,NNP,O
.,.,.
,,
because,IN,O
of,IN,O
the,DT,O
risk,NN,O
of,IN,O
increased,VBN,O
exposure,NN,O
tonevirapine,NN,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
inconcomitant,JJ,O
administration,NN,O
",",",",O
and,CC,O
patients,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
for,IN,O
nevirapine-associated,JJ,O
adverse,JJ,O
events,NNS,O
.,.,.
,,
indinavi,NNP,O
.,.,.
,,
indinavi,NNP,O
.,.,.
,,
appropriate,JJ,O
doses,NNS,O
for,IN,O
this,DT,O
combination,NN,O
arenot,NN,O
established,VBN,O
",",",",O
but,CC,O
an,DT,O
increase,NN,O
in,IN,O
thedosage,NN,O
of,IN,O
indinavir,NN,D
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
ketoconazol,NNP,O
.,.,.
,,
ketoconazol,NNP,O
.,.,.
,,
nevirapine,NNP,D
and,CC,O
ketoconazole,NN,D
should,MD,O
not,RB,O
beadministered,VBN,O
concomitantly,RB,O
becausedecreases,NNS,O
in,IN,O
ketoconazole,NN,D
plasmaconcentrations,NNS,O
may,MD,O
reduce,VB,O
the,DT,O
efficacy,NN,O
of,IN,O
the,DT,O
drug,NN,D
.,.,.
,,
lopinavir/ritonavi,NNP,O
.,.,.
,,
lopinavi,NNP,O
.,.,.
,,
a,DT,O
dose,NN,O
increase,NN,O
of,IN,O
lopinavir/ritonavir,NN,O
to,TO,O
533/133,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
with,IN,O
food,NN,O
isrecommended,VBN,O
in,IN,O
combination,NN,O
with,IN,O
nevirapine,NN,D
.,.,.
,,
methadon,NNP,O
.,.,.
,,
methadonea,NNP,O
.,.,.
,,
methadone,NN,D
levels,NNS,O
may,MD,O
be,VB,O
decreased,VBN,O
;,:,O
increased,VBN,O
dosages,NNS,O
may,MD,O
be,VB,O
required,VBN,O
to,TO,O
prevent,VB,O
symptoms,NNS,O
of,IN,O
opiate,JJ,G
withdrawal,NN,O
.,.,.
,,
methadone,NNP,D
maintained,VBD,O
patients,NNS,O
beginning,VBG,O
nevirapine,NN,D
therapy,NN,O
should,MD,O
be,VB,O
monitored,VBN,O
forevidence,NN,O
of,IN,O
withdrawal,NN,O
and,CC,O
methadone,NN,D
dose,NN,O
should,MD,O
be,VB,O
adjusted,VBN,O
accordingly,RB,O
.,.,.
,,
nelfinavi,NNP,O
.,.,.
,,
nelfinavir,NNP,D
m,NN,O
.,.,.
,,
the,DT,O
appropriate,JJ,O
dose,NN,O
for,IN,O
nelfinavir,NN,D
incombination,NN,O
with,IN,O
nevirapine,NN,D
",",",",O
with,IN,O
respectto,NN,O
safety,NN,O
and,CC,O
efficacy,NN,O
",",",",O
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
rifabuti,NNP,O
.,.,.
,,
rifabuti,NNP,O
.,.,.
,,
rifabutin,NN,D
and,CC,O
its,PRP$,O
metabolite,NN,O
concentrationswere,NN,O
moderately,RB,O
increased,VBD,O
.,.,.
,,
due,JJ,O
to,TO,O
highintersubject,JJ,O
variability,NN,O
",",",",O
however,RB,O
",",",",O
somepatients,NNS,O
may,MD,O
experience,VB,O
large,JJ,O
increases,NNS,O
inrifabutin,NN,O
exposure,NN,O
and,CC,O
may,MD,O
be,VB,O
at,IN,O
higher,JJR,O
riskfor,NN,O
rifabutin,NN,D
toxicity,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
in,IN,O
concomitant,JJ,O
administration,NN,O
.,.,.
,,
rifampi,NNP,O
.,.,.
,,
nevirapin,NNP,O
.,.,.
,,
nevirapine,NNP,D
and,CC,O
rifampin,NN,D
should,MD,O
not,RB,O
beadministered,VBN,O
concomitantly,RB,O
becausedecreases,NNS,O
in,IN,O
nevirapine,NN,D
plasmaconcentrations,NNS,O
may,MD,O
reduce,VB,O
the,DT,O
efficacy,NN,O
ofthe,NN,O
drug,NN,D
.,.,.
,,
physicians,NNP,O
needing,VBG,O
to,TO,O
treatpatients,NNS,O
co-infected,VBN,O
with,IN,O
tuberculosis,NN,O
andusing,NN,O
a,DT,O
nevirapine,NN,D
containing,VBG,O
regimen,NN,O
mayuse,NN,O
rifabutin,NN,D
instead,RB,O
.,.,.
,,
saquinavi,NNP,O
.,.,.
,,
saquinavi,NNP,O
.,.,.
,,
appropriate,JJ,O
doses,NNS,O
for,IN,O
this,DT,O
combination,NN,O
arenot,NN,O
established,VBN,O
",",",",O
but,CC,O
an,DT,O
increase,NN,O
in,IN,O
thedosage,NN,O
of,IN,O
saquinavir,NN,D
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
abased,VBN,O
on,IN,O
reports,NNS,O
of,IN,O
narcotic,JJ,G
withdrawal,NN,O
syndrome,NN,O
in,IN,O
patients,NNS,O
treated,VBN,O
with,IN,O
nevirapine,NN,D
and,CC,O
methadone,NN,D
concurrently,RB,O
",",",",O
and,CC,O
evidence,NN,O
of,IN,O
decreased,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
methadone,NN,D
.,.,.
,,
table,NNP,O
4,CD,O
potential,JJ,O
drug,NN,O
interactions,NNS,O
:,:,O
use,NNP,O
with,IN,O
caution,NN,O
",",",",O
dose,NNP,O
adjustment,NNP,O
of,IN,O
co-administered,NNP,O
drug,NNP,O
may,NNP,O
be,VB,O
needed,VBN,O
due,JJ,O
to,TO,O
possible,JJ,O
decrease,NN,O
in,IN,O
clinical,JJ,O
effect,NN,O
.,.,.
,,
examples,NNS,O
of,IN,O
drugs,NNS,O
in,IN,O
which,WDT,O
plasma,NN,O
concentrations,NNS,O
may,MD,O
be,VB,O
decreased,VBN,O
by,IN,O
co-administration,NN,O
with,IN,O
nevirapin,NN,O
.,.,.
,,
drug,NNP,O
class,NNP,O
examples,NNS,O
of,IN,O
drugs,NNS,O
.,.,.
,,
antiarrhythmic,JJ,O
.,.,.
,,
amiodarone,NNP,D
",",",",O
disopyramide,NN,D
",",",",O
lidocain,NN,O
.,.,.
,,
anticonvulsant,NN,O
.,.,.
,,
carbamazepine,NNP,D
",",",",O
clonazepam,NN,D
",",",",O
ethosuximid,NN,O
.,.,.
,,
antifungal,JJ,G
.,.,.
,,
itraconazol,NNP,O
.,.,.
,,
calcium,NN,D
channel,NN,O
blocker,NN,O
.,.,.
,,
diltiazem,NNP,D
",",",",O
nifedipine,NN,D
",",",",O
verapami,NN,O
.,.,.
,,
cancer,NN,O
chemotherapy,NN,O
.,.,.
,,
cyclophosphamid,NN,O
.,.,.
,,
ergot,NNP,G
alkaloid,NN,O
.,.,.
,,
ergotamin,NNP,O
.,.,.
,,
immunosuppressant,JJ,O
.,.,.
,,
cyclosporin,NN,D
",",",",O
tacrolimus,NN,D
",",",",O
sirolimu,NN,O
.,.,.
,,
motility,NN,O
agents,NNS,O
.,.,.
,,
cisaprid,NNP,O
.,.,.
,,
opiate,JJ,O
agonist,NN,O
.,.,.
,,
fentany,NNP,O
.,.,.
,,
examples,NNS,O
of,IN,O
drugs,NNS,O
in,IN,O
which,WDT,O
plasma,NN,O
concentrations,NNS,O
may,MD,O
be,VB,O
increased,VBN,O
by,IN,O
co-administration,NN,O
with,IN,O
nevirapin,NN,O
.,.,.
,,
antithrombotic,JJ,O
.,.,.
,,
warfari,NNP,O
.,.,.
,,
potential,JJ,O
effect,NN,O
on,IN,O
anticoagulation,NN,O
.,.,.
,,
monitoring,NN,O
of,IN,O
anticoagulation,NN,O
levels,NNS,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
fat,NNP,O
redistribution,NN,O
:,:,O
redistribution/accumulation,NN,O
of,IN,O
body,NN,O
fat,JJ,O
including,VBG,O
central,JJ,O
obesity,NN,O
",",",",O
dorsocervical,JJ,O
fat,JJ,O
enlargement,NN,O
-lrb-,-LRB-,O
buffalo,NN,O
hump,NN,O
-rrb-,-RRB-,O
",",",",O
peripheral,JJ,O
wasting,NN,O
",",",",O
facial,JJ,O
wasting,NN,O
",",",",O
breast,NN,O
enlargement,NN,O
",",",",O
and,CC,O
cushingoid,JJ,O
appearance,NN,O
have,VBP,O
been,VBN,O
observed,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
antiretroviral,JJ,G
therapy,NN,O
.,.,.
,,
the,DT,O
mechanism,NN,O
and,CC,O
long-term,JJ,O
consequences,NNS,O
of,IN,O
these,DT,O
events,NNS,O
are,VBP,O
currently,RB,O
unknown,JJ,O
.,.,.
,,
a,DT,O
causal,JJ,O
relationship,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
interactions,NNS,O
for,IN,O
vitamin,NN,O
b3,NN,O
-lrb-,-LRB-,O
niacin,NN,D
-rrb-,-RRB-,O
:,:,O
antihypertensive,JJ,G
therapy,NN,O
:,:,O
nicotinic,JJ,O
acid,NN,O
may,MD,O
potentiate,VB,O
the,DT,O
effects,NNS,O
of,IN,O
ganglionic,JJ,O
blocking,VBG,O
agents,NNS,O
and,CC,O
vasoactive,JJ,O
drugs,NNS,D
resulting,VBG,O
in,IN,O
postural,JJ,O
hypotension,NN,O
.,.,.
,,
aspirin,NN,B
:,:,O
concomitant,JJ,O
aspirin,NN,B
may,MD,O
decrease,VB,O
the,DT,O
metabolic,JJ,O
clearance,NN,O
of,IN,O
nicotinic,JJ,O
acid,NN,O
.,.,.
,,
the,DT,O
clinical,JJ,O
relevance,NN,O
of,IN,O
this,DT,O
finding,NN,O
is,VBZ,O
unclear,JJ,O
.,.,.
,,
other,JJ,O
:,:,O
concomitant,JJ,O
alcohol,NN,D
or,CC,O
hot,JJ,O
drinks,NNS,O
may,MD,O
increase,VB,O
the,DT,O
side,JJ,O
effects,NNS,O
of,IN,O
flushing,NN,O
and,CC,O
pruritus,NN,O
and,CC,O
should,MD,O
be,VB,O
avoided,VBN,O
at,IN,O
the,DT,O
time,NN,O
of,IN,O
drug,NN,D
ingestion,NN,O
.,.,.
,,
beta-blockers,NNPS,G
:,:,O
in,IN,O
controlled,JJ,O
clinical,JJ,O
studies,NNS,O
",",",",O
adrenergic,JJ,G
beta-receptor,NN,O
blockers,NNS,O
have,VBP,O
been,VBN,O
frequently,RB,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
nicardipine,JJ,D
hcl,NN,O
.,.,.
,,
the,DT,O
combination,NN,O
is,VBZ,O
well,RB,O
tolerated,VBN,O
.,.,.
,,
cimetidine,NNP,D
:,:,O
cimetidine,NNP,D
increases,VBZ,O
nicardipine,JJ,D
hcl,NN,O
plasma,NN,O
levels,NNS,O
.,.,.
,,
patients,NNS,O
receiving,VBG,O
the,DT,O
two,CD,O
drugs,NNS,D
concomitantly,RB,O
should,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
.,.,.
,,
digoxin,NNP,D
:,:,O
some,DT,O
calcium,NN,D
blockers,NNS,O
may,MD,O
increase,VB,O
the,DT,O
concentration,NN,O
of,IN,O
digitalis,NN,G
preparations,NNS,O
in,IN,O
the,DT,O
blood,NN,O
.,.,.
,,
nicardipine,NNP,O
hcl,NN,O
usually,RB,O
does,VBZ,O
not,RB,O
alter,VB,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
digoxin,NN,D
",",",",O
however,RB,O
",",",",O
serum,NN,O
digoxin,NN,D
levels,NNS,O
should,MD,O
be,VB,O
evaluated,VBN,O
after,IN,O
concomitant,JJ,O
therapy,NN,O
with,IN,O
nicardipine,JJ,D
hcl,NN,O
is,VBZ,O
initiated,VBN,O
.,.,.
,,
maalox,NNP,B
*,SYM,O
coadministration,NNP,O
of,IN,O
maalox,NNP,B
tc,NNP,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
nicardipine,JJ,D
hcl,NN,O
absorption,NN,O
.,.,.
,,
even,RB,O
though,IN,O
such,JJ,O
interactions,NNS,O
were,VBD,O
not,RB,O
seen,VBN,O
during,IN,O
clinical,JJ,O
studies,NNS,O
with,IN,O
nicardipine,JJ,D
hcl,NN,O
",",",",O
an,DT,O
increased,VBN,O
volume,NN,O
of,IN,O
circulating,VBG,O
fluids,NNS,O
might,MD,O
be,VB,O
required,VBN,O
if,IN,O
such,PDT,O
an,DT,O
interaction,NN,O
were,VBD,O
to,TO,O
occur,VB,O
.,.,.
,,
cyclosporine,NN,D
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
nicardipine,NN,D
and,CC,O
cyclosporine,NN,D
levels,NNS,O
.,.,.
,,
plasma,NN,O
concentrations,NNS,O
of,IN,O
cyclosporine,NN,D
should,MD,O
therefore,RB,O
be,VB,O
closely,RB,O
monitored,VBN,O
",",",",O
and,CC,O
its,PRP$,O
dosage,NN,O
reduced,VBD,O
accordingly,RB,O
",",",",O
in,IN,O
patients,NNS,O
treated,VBN,O
with,IN,O
nicardipine,NN,D
.,.,.
,,
when,WRB,O
therapeutic,JJ,O
concentrations,NNS,O
of,IN,O
furosemide,NN,D
",",",",O
propranolol,NN,D
",",",",O
dipyridamole,NN,D
",",",",O
warfarin,NN,D
",",",",O
quinidine,NN,D
",",",",O
or,CC,O
naproxen,NN,D
were,VBD,O
added,VBN,O
to,TO,O
human,JJ,O
plasma,NN,O
-lrb-,-LRB-,O
in,FW,O
vitro,FW,O
-rrb-,-RRB-,O
",",",",O
the,DT,O
plasma,NN,O
protein,NN,O
binding,NN,O
of,IN,O
nicardipine,JJ,D
hcl,NN,O
was,VBD,O
not,RB,O
altered,VBN,O
.,.,.
,,
physiological,JJ,O
changes,NNS,O
resulting,VBG,O
from,IN,O
smoking,NN,O
cessation,NN,O
",",",",O
with,IN,O
or,CC,O
without,IN,O
nicotine,NN,D
replacement,NN,O
",",",",O
may,MD,O
alter,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
certain,JJ,O
concomitant,JJ,O
medications,NNS,O
",",",",O
such,JJ,O
as,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
and,CC,O
theophylline,NN,D
.,.,.
,,
doses,NNS,O
of,IN,O
these,DT,O
and,CC,O
perhaps,RB,O
other,JJ,O
medications,NNS,O
may,MD,O
need,VB,O
to,TO,O
be,VB,O
adjusted,VBN,O
in,IN,O
patients,NNS,O
who,WP,O
successfully,RB,O
quit,VBD,O
smoking,NN,O
.,.,.
,,
beta-adrenergic,JJ,O
blocking,NN,O
agents,NNS,O
:,:,O
experience,NN,O
in,IN,O
over,IN,O
1400,CD,O
patients,NNS,O
in,IN,O
a,DT,O
non-comparative,JJ,O
clinical,JJ,O
trial,NN,O
has,VBZ,O
shown,VBN,O
that,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
nifedipine,NN,D
and,CC,O
beta-blocking,NN,D
agents,NNS,O
is,VBZ,O
usually,RB,O
well,RB,O
tolerated,VBD,O
",",",",O
but,CC,O
there,EX,O
have,VBP,O
been,VBN,O
occasional,JJ,O
literature,NN,O
reports,NNS,O
suggesting,VBG,O
that,IN,O
the,DT,O
combination,NN,O
may,MD,O
increase,VB,O
the,DT,O
likelihood,NN,O
of,IN,O
congestive,JJ,O
heart,NN,O
failure,NN,O
",",",",O
severe,JJ,O
hypotension,NN,O
or,CC,O
exacerbation,NN,O
of,IN,O
angina,NN,O
.,.,.
,,
long,NNP,O
acting,NNP,O
nitrates,NNPS,G
:,:,O
nifedipine,NN,D
may,MD,O
be,VB,O
safely,RB,O
co-administered,VBN,O
with,IN,O
nitrates,NNS,G
",",",",O
but,CC,O
there,EX,O
have,VBP,O
been,VBN,O
no,DT,O
controlled,JJ,O
studies,NNS,O
to,TO,O
evaluate,VB,O
the,DT,O
antianginal,JJ,O
effectiveness,NN,O
of,IN,O
this,DT,O
combination,NN,O
.,.,.
,,
digitalis,NNP,G
:,:,O
immediate,NNP,O
release,NNP,O
capsules,NNPS,O
:,:,O
since,IN,O
there,EX,O
have,VBP,O
been,VBN,O
isolated,VBN,O
reports,NNS,O
of,IN,O
patients,NNS,O
with,IN,O
elevated,JJ,O
digoxin,NN,D
levels,NNS,O
",",",",O
and,CC,O
there,EX,O
is,VBZ,O
a,DT,O
possible,JJ,O
interaction,NN,O
between,IN,O
digoxin,NN,D
and,CC,O
nifedipine,NN,D
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
digoxin,NN,D
levels,NNS,O
be,VB,O
monitored,VBN,O
when,WRB,O
initiating,VBG,O
",",",",O
adjusting,VBG,O
",",",",O
and,CC,O
discontinuing,VBG,O
nifedipine,NN,D
to,TO,O
avoid,VB,O
possible,JJ,O
over,IN,O
-,:,O
or,CC,O
under-digitalization,NN,O
.,.,.
,,
extended,NNP,O
release,NNP,O
tablets,NNPS,O
:,:,O
administration,NN,O
of,IN,O
nifedipine,NN,D
with,IN,O
digoxin,NN,D
increased,VBD,O
digoxin,NN,D
levels,NNS,O
in,IN,O
9,CD,O
of,IN,O
12,CD,O
normal,JJ,O
volunteers,NNS,O
.,.,.
,,
the,DT,O
average,JJ,O
increase,NN,O
was,VBD,O
45,CD,O
%,NN,O
.,.,.
,,
another,DT,O
investigator,NN,O
found,VBD,O
no,DT,O
increase,NN,O
in,IN,O
digoxin,NN,D
levels,NNS,O
in,IN,O
13,CD,O
patients,NNS,O
with,IN,O
coronary,JJ,O
artery,NN,O
disease,NN,O
.,.,.
,,
in,IN,O
an,DT,O
uncontrolled,JJ,O
study,NN,O
of,IN,O
over,IN,O
200,CD,O
patients,NNS,O
with,IN,O
congestive,JJ,O
heart,NN,O
failure,NN,O
during,IN,O
which,WDT,O
digoxin,NN,D
blood,NN,O
levels,NNS,O
were,VBD,O
not,RB,O
measured,VBN,O
",",",",O
digitalis,NN,G
toxicity,NN,O
was,VBD,O
not,RB,O
observed,VBN,O
.,.,.
,,
since,IN,O
there,EX,O
have,VBP,O
been,VBN,O
isolated,VBN,O
reports,NNS,O
of,IN,O
patients,NNS,O
with,IN,O
elevated,JJ,O
digoxin,NN,D
levels,NNS,O
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
digoxin,NN,D
levels,NNS,O
be,VB,O
monitored,VBN,O
when,WRB,O
initiating,VBG,O
",",",",O
adjusting,VBG,O
",",",",O
and,CC,O
discontinuing,VBG,O
nifedipine,NN,D
to,TO,O
avoid,VB,O
possible,JJ,O
over,IN,O
-,:,O
or,CC,O
under-digitalization,NN,O
.,.,.
,,
quinidine,NNP,D
:,:,O
immediate,NNP,O
release,NNP,O
capsules,NNPS,O
:,:,O
there,EX,O
have,VBP,O
been,VBN,O
rare,JJ,O
reports,NNS,O
of,IN,O
an,DT,O
interaction,NN,O
between,IN,O
quinidine,NN,D
and,CC,O
nifedipine,NN,D
-lrb-,-LRB-,O
with,IN,O
a,DT,O
decreased,VBN,O
plasma,NN,O
level,NN,O
of,IN,O
quinidine,NN,D
-rrb-,-RRB-,O
.,.,.
,,
coumarin,NNP,O
anticoagulants,NNPS,G
:,:,O
there,EX,O
have,VBP,O
been,VBN,O
rare,JJ,O
reports,NNS,O
of,IN,O
increased,VBN,O
prothrombin,NN,O
time,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
coumarin,NN,G
anticoagulants,NNS,G
to,TO,O
whom,WP,O
nifedipine,NN,D
was,VBD,O
administered,VBN,O
.,.,.
,,
however,RB,O
",",",",O
the,DT,O
relationship,NN,O
to,TO,O
nifedipine,NN,D
therapy,NN,O
is,VBZ,O
uncertain,JJ,O
.,.,.
,,
cimetidine,NNP,D
:,:,O
a,NNP,O
study,NN,O
in,IN,O
6,CD,O
healthy,JJ,O
volunteers,NNS,O
has,VBZ,O
shown,VBN,O
a,DT,O
significant,JJ,O
increase,NN,O
in,IN,O
peak,JJ,O
nifedipine,NN,D
plasma,NN,O
levels,NNS,O
-lrb-,-LRB-,O
80,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
area-under-the-curve,NN,O
-lrb-,-LRB-,O
74,CD,O
%,NN,O
-rrb-,-RRB-,O
after,IN,O
a,DT,O
1,CD,O
week,NN,O
course,NN,O
of,IN,O
cimetidine,NN,D
at,IN,O
1000,CD,O
mg,NN,O
per,IN,O
day,NN,O
and,CC,O
nifedipine,NN,D
at,IN,O
40,CD,O
mg,NN,O
per,IN,O
day,NN,O
.,.,.
,,
ranitidine,NN,D
produced,VBD,O
smaller,JJR,O
",",",",O
non-significant,JJ,O
increases,NNS,O
.,.,.
,,
the,DT,O
effect,NN,O
may,MD,O
be,VB,O
mediated,VBN,O
by,IN,O
the,DT,O
known,JJ,O
inhibition,NN,O
of,IN,O
cimetidine,NN,D
on,IN,O
hepatic,JJ,O
cytochrome,NN,O
p-450,NN,O
",",",",O
the,DT,O
enzyme,NN,O
system,NN,O
probably,RB,O
responsible,JJ,O
for,IN,O
the,DT,O
first-pass,JJ,O
metabolism,NN,O
of,IN,O
nifedipine,NN,D
.,.,.
,,
if,IN,O
nifedipine,NN,D
therapy,NN,O
is,VBZ,O
initiated,VBN,O
in,IN,O
a,DT,O
patient,NN,O
currently,RB,O
receiving,VBG,O
cimetidine,NN,D
",",",",O
cautious,JJ,O
titration,NN,O
is,VBZ,O
advised,VBN,O
.,.,.
,,
in,FW,O
vitro,FW,O
",",",",O
nilutamide,NN,D
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
inhibit,VB,O
the,DT,O
activity,NN,O
of,IN,O
liver,NN,O
cytochrome,NN,O
p-450,NN,O
isoenzymes,NNS,O
and,CC,O
therefore,RB,O
",",",",O
may,MD,O
reduce,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
compounds,NNS,O
requiring,VBG,O
these,DT,O
systems,NNS,O
.,.,.
,,
consequently,RB,O
",",",",O
drugs,NNS,D
with,IN,O
a,DT,O
low,JJ,O
therapeutic,JJ,O
margin,NN,O
",",",",O
such,JJ,O
as,IN,O
vitamin,NN,G
k,NN,O
antagonists,NNS,O
",",",",O
phenytoin,NN,D
",",",",O
and,CC,O
theophylline,NN,D
",",",",O
could,MD,O
have,VB,O
a,DT,O
delayed,VBN,O
elimination,NN,O
and,CC,O
increases,VBZ,O
in,IN,O
their,PRP$,O
serum,NN,O
half-life,NN,O
leading,VBG,O
to,TO,O
a,DT,O
toxic,JJ,O
level,NN,O
.,.,.
,,
the,DT,O
dosage,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
or,CC,O
others,NNS,O
with,IN,O
a,DT,O
similar,JJ,O
metabolism,NN,O
may,MD,O
need,VB,O
to,TO,O
be,VB,O
modified,VBN,O
if,IN,O
they,PRP,O
are,VBP,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
nilutamide,NN,D
.,.,.
,,
for,IN,O
example,NN,O
",",",",O
when,WRB,O
vitamin,NN,G
k,NN,O
antagonists,NNS,O
are,VBP,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
nilutamide,NN,D
",",",",O
prothrombin,NN,O
time,NN,O
should,MD,O
be,VB,O
carefully,RB,O
monitored,VBN,O
and,CC,O
if,IN,O
necessary,JJ,O
",",",",O
the,DT,O
dosage,NN,O
of,IN,O
vitamin,NN,G
k,NN,O
antagonists,NNS,O
should,MD,O
be,VB,O
reduced,VBN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
possible,JJ,O
that,IN,O
the,DT,O
cardiovascular,JJ,O
action,NN,O
of,IN,O
other,JJ,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
could,MD,O
be,VB,O
enhanced,VBN,O
by,IN,O
the,DT,O
addition,NN,O
of,IN,O
nimotop,NNP,B
.,.,.
,,
in,IN,O
europe,NNP,O
",",",",O
nimotop,NNP,B
was,VBD,O
observed,VBN,O
to,TO,O
occasionally,RB,O
intensify,VB,O
the,DT,O
effect,NN,O
of,IN,O
antihypertensive,JJ,G
compounds,NNS,O
taken,VBN,O
concomitantly,RB,O
by,IN,O
patients,NNS,O
suffering,VBG,O
from,IN,O
hypertension,NN,O
.,.,.
,,
this,DT,O
phenomenon,NN,O
was,VBD,O
not,RB,O
observed,VBN,O
in,IN,O
north,JJ,O
american,JJ,O
clinical,JJ,O
trials,NNS,O
.,.,.
,,
a,DT,O
study,NN,O
in,IN,O
eight,CD,O
healthy,JJ,O
volunteers,NNS,O
has,VBZ,O
shown,VBN,O
a,DT,O
50,CD,O
%,NN,O
increase,NN,O
in,IN,O
mean,JJ,O
peak,JJ,O
nimodipine,NN,D
plasma,NN,O
concentrations,NNS,O
and,CC,O
a,DT,O
90,CD,O
%,NN,O
increase,NN,O
in,IN,O
mean,JJ,O
area,NN,O
under,IN,O
the,DT,O
curve,NN,O
",",",",O
after,IN,O
a,DT,O
one,CD,O
week,NN,O
course,NN,O
of,IN,O
cimetidine,NN,D
at,IN,O
"1,000",CD,O
mg/day,NN,O
and,CC,O
nimodipine,NN,D
at,IN,O
90,CD,O
mg/day,NN,O
.,.,.
,,
this,DT,O
effect,NN,O
may,MD,O
be,VB,O
mediated,VBN,O
by,IN,O
the,DT,O
known,JJ,O
inhibition,NN,O
of,IN,O
hepatic,JJ,O
cytochrome,NN,O
p,NN,O
-,:,O
450,CD,O
by,IN,O
cimetidine,NN,D
",",",",O
which,WDT,O
could,MD,O
decrease,VB,O
first,JJ,O
pass,NN,O
metabolism,NN,O
of,IN,O
nimodipine,NN,D
.,.,.
,,
a,DT,O
30,CD,O
to,TO,O
45,CD,O
%,NN,O
increase,NN,O
in,IN,O
auc,NN,O
and,CC,O
cmax,NN,O
of,IN,O
nisoldipine,NN,D
was,VBD,O
observed,VBN,O
with,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
cimetidine,NN,D
400,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
.,.,.
,,
ranitidine,NN,D
150,CD,O
mg,NN,O
twice,RB,O
daily,RB,O
did,VBD,O
not,RB,O
interact,VB,O
significantly,RB,O
with,IN,O
nisoldipine,NN,D
-lrb-,-LRB-,O
auc,NN,O
was,VBD,O
decreased,VBN,O
by,IN,O
15-20,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
no,DT,O
pharmacodynamic,JJ,O
effects,NNS,O
of,IN,O
either,CC,O
histamine,NN,D
h2,NN,O
receptor,NN,D
antagonist,NN,O
were,VBD,O
observed,VBN,O
.,.,.
,,
coadministration,NN,O
of,IN,O
phenytoin,NN,D
with,IN,O
40,CD,O
mg,NN,O
sular,NN,B
tablets,NNS,O
in,IN,O
epileptic,JJ,O
patients,NNS,O
lowered,VBD,O
the,DT,O
nisoldipine,NN,D
plasma,NN,O
concentrations,NNS,O
to,TO,O
undetectable,JJ,O
levels,NNS,O
.,.,.
,,
coadministration,NN,O
of,IN,O
sular,NN,B
with,IN,O
phenytoin,NN,D
or,CC,O
any,DT,O
known,JJ,O
cyp3a4,NN,D
inducer,NN,O
should,MD,O
be,VB,O
avoided,VBN,O
and,CC,O
alternative,JJ,O
antihypertensive,JJ,G
therapy,NN,O
should,MD,O
be,VB,O
considered,VBN,O
.,.,.
,,
pharmacokinetic,JJ,O
interactions,NNS,O
between,IN,O
nisoldipine,NN,D
and,CC,O
beta-blockers,NNS,G
-lrb-,-LRB-,O
atenolol,NN,D
",",",",O
propranolol,NN,D
-rrb-,-RRB-,O
were,VBD,O
variable,JJ,O
and,CC,O
not,RB,O
significant,JJ,O
.,.,.
,,
propranolol,NN,D
attenuated,VBD,O
the,DT,O
heart,NN,O
rate,NN,O
increase,NN,O
following,VBG,O
administration,NN,O
of,IN,O
immediate,JJ,O
release,NN,O
nisoldipine,NN,D
.,.,.
,,
the,DT,O
blood,NN,O
pressure,NN,O
effect,NN,O
of,IN,O
sular,NN,B
tended,VBD,O
to,TO,O
be,VB,O
greater,JJR,O
in,IN,O
patients,NNS,O
on,IN,O
atenolol,NN,D
than,IN,O
in,IN,O
patients,NNS,O
on,IN,O
no,DT,O
other,JJ,O
antihypertensive,JJ,G
therapy,NN,O
.,.,.
,,
quinidine,NN,D
at,IN,O
648,CD,O
mg,NN,O
bid,NN,O
decreased,VBD,O
the,DT,O
bioavailability,NN,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
of,IN,O
nisoldipine,NN,D
by,IN,O
26,CD,O
%,NN,O
",",",",O
but,CC,O
not,RB,O
the,DT,O
peak,NN,O
concentration,NN,O
.,.,.
,,
the,DT,O
immediate,JJ,O
release,NN,O
",",",",O
but,CC,O
not,RB,O
the,DT,O
coat-core,JJ,O
formulation,NN,O
of,IN,O
nisoldipine,NN,D
increased,VBN,O
plasma,NN,O
quinidine,NN,D
concentrations,NNS,O
by,IN,O
about,RB,O
20,CD,O
%,NN,O
.,.,.
,,
this,DT,O
interaction,NN,O
was,VBD,O
not,RB,O
accompanied,VBN,O
by,IN,O
ecg,NN,O
changes,NNS,O
and,CC,O
its,PRP$,O
clinical,JJ,O
significance,NN,O
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
no,DT,O
significant,JJ,O
interactions,NNS,O
were,VBD,O
found,VBN,O
between,IN,O
nisoldipine,NN,D
and,CC,O
warfarin,NN,D
or,CC,O
digoxin,NN,D
.,.,.
,,
tizoxanide,NNP,D
is,VBZ,O
highly,RB,O
bound,VBN,O
to,TO,O
plasma,NN,O
protein,NN,O
-lrb-,-LRB-,O
99.9,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
therefore,RB,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
used,VBN,O
when,WRB,O
administering,VBG,O
nitazoxanide,NN,D
concurrently,RB,O
with,IN,O
other,JJ,O
highly,RB,O
plasma,NN,O
protein-bound,JJ,O
drugs,NNS,D
with,IN,O
narrow,JJ,O
therapeutic,JJ,O
indices,NNS,O
",",",",O
as,IN,O
competition,NN,O
for,IN,O
binding,VBG,O
sites,NNS,O
may,MD,O
occur,VB,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
warfarin,NN,D
-rrb-,-RRB-,O
.,.,.
,,
in,FW,O
vitro,FW,O
metabolism,NN,O
studies,NNS,O
have,VBP,O
demonstrated,VBN,O
that,IN,O
tizoxanide,NN,D
has,VBZ,O
no,DT,O
significant,JJ,O
inhibitory,JJ,O
effect,NN,O
on,IN,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
.,.,.
,,
although,IN,O
no,DT,O
drug-drug,JJ,O
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
conducted,VBN,O
in,FW,O
vivo,FW,O
",",",",O
it,PRP,O
is,VBZ,O
expected,VBN,O
that,IN,O
no,DT,O
significant,JJ,O
interaction,NN,O
would,MD,O
occur,VB,O
when,WRB,O
nitazoxanide,NN,D
is,VBZ,O
co-administered,VBN,O
with,IN,O
drugs,NNS,D
that,WDT,O
either,RB,O
are,VBP,O
metabolized,VBN,O
by,IN,O
or,CC,O
inhibit,VB,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
.,.,.
,,
no,DT,O
formal,JJ,O
drug-interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
",",",",O
and,CC,O
a,DT,O
clinically,RB,O
significant,JJ,O
interaction,NN,O
with,IN,O
other,JJ,O
medications,NNS,O
used,VBN,O
in,IN,O
the,DT,O
treatment,NN,O
of,IN,O
hypoxic,JJ,O
respiratory,JJ,O
failure,NN,O
can,MD,O
not,RB,O
be,VB,O
excluded,VBN,O
based,VBN,O
on,IN,O
the,DT,O
available,JJ,O
data,NNS,O
.,.,.
,,
inomax,NN,B
has,VBZ,O
been,VBN,O
administered,VBN,O
with,IN,O
tolazoline,NN,D
",",",",O
dopamine,NN,D
",",",",O
dobutamine,NN,D
",",",",O
steroids,NNS,G
",",",",O
surfactant,NN,D
",",",",O
and,CC,O
high-frequency,VB,O
ventilation,NN,O
.,.,.
,,
although,IN,O
there,EX,O
are,VBP,O
no,DT,O
study,NN,O
data,NNS,O
to,TO,O
evaluate,VB,O
the,DT,O
possibility,NN,O
",",",",O
nitric,JJ,O
oxide,NN,O
donor,NN,O
compounds,NNS,O
",",",",O
including,VBG,O
sodium,NN,O
nitroprusside,NN,D
and,CC,O
nitroglycerin,NN,D
",",",",O
may,MD,O
have,VB,O
an,DT,O
additive,JJ,O
effect,NN,O
with,IN,O
inomax,NN,B
on,IN,O
the,DT,O
risk,NN,O
of,IN,O
developing,VBG,O
methemoglobinemia,NN,O
.,.,.
,,
an,DT,O
association,NN,O
between,IN,O
prilocaine,NN,D
and,CC,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
methaemoglobinaemia,NN,O
",",",",O
particularly,RB,O
in,IN,O
infants,NNS,O
",",",",O
has,VBZ,O
specifically,RB,O
been,VBN,O
described,VBN,O
in,IN,O
a,DT,O
literature,NN,O
case,NN,O
report,NN,O
.,.,.
,,
this,DT,O
risk,NN,O
is,VBZ,O
present,JJ,O
whether,IN,O
the,DT,O
drugs,NNS,D
are,VBP,O
administered,VBN,O
as,IN,O
oral,JJ,O
",",",",O
parenteral,JJ,O
",",",",O
or,CC,O
topical,JJ,O
formulations,NNS,O
.,.,.
,,
antacids,NNS,G
containing,VBG,O
magnesium,NN,D
trisilicate,NN,O
",",",",O
when,WRB,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
nitrofurantoin,NN,D
",",",",O
reduce,VB,O
both,CC,O
the,DT,O
rate,NN,O
and,CC,O
extent,NN,O
of,IN,O
absorption,NN,O
.,.,.
,,
the,DT,O
mechanism,NN,O
for,IN,O
this,DT,O
interaction,NN,O
probably,RB,O
is,VBZ,O
adsorption,NN,O
of,IN,O
nitrofurantoin,NN,D
onto,IN,O
the,DT,O
surface,NN,O
of,IN,O
magnesium,NN,D
trisilicate,NN,O
.,.,.
,,
uricosuric,JJ,O
drugs,NNS,D
",",",",O
such,JJ,O
as,IN,O
probenecid,NN,D
and,CC,O
sulfinpyrazone,NN,D
",",",",O
can,MD,O
inhibit,VB,O
renal,JJ,O
tubular,JJ,O
secretion,NN,O
of,IN,O
nitrofurantoin,NN,D
.,.,.
,,
the,DT,O
resulting,VBG,O
increase,NN,O
in,IN,O
nitrofurantoin,NN,D
serum,NN,O
levels,NNS,O
may,MD,O
increase,VB,O
toxicity,NN,O
",",",",O
and,CC,O
the,DT,O
decreased,VBN,O
urinary,JJ,O
levels,NNS,O
could,MD,O
lessen,VB,O
its,PRP$,O
efficacy,NN,O
as,IN,O
a,DT,O
urinary,JJ,O
tract,NN,O
antibacterial,JJ,G
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
as,IN,O
a,DT,O
result,NN,O
of,IN,O
the,DT,O
presence,NN,O
of,IN,O
nitrofurantoin,NN,D
",",",",O
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
the,DT,O
urine,NN,O
may,MD,O
occur,VB,O
.,.,.
,,
this,DT,O
has,VBZ,O
been,VBN,O
observed,VBN,O
with,IN,O
benedict,NNP,O
s,NNS,O
and,CC,O
fehling,NN,O
s,NNS,O
solutions,NNS,O
but,CC,O
not,RB,O
with,IN,O
the,DT,O
glucose,NN,O
enzymatic,JJ,O
test,NN,O
.,.,.
,,
the,DT,O
vasodilating,JJ,O
effects,NNS,O
of,IN,O
nitroglycerin,NN,D
may,MD,O
be,VB,O
additive,JJ,O
with,IN,O
those,DT,O
of,IN,O
other,JJ,O
vasodilators,NNS,G
.,.,.
,,
alcohol,NN,D
",",",",O
in,IN,O
particular,JJ,O
",",",",O
has,VBZ,O
been,VBN,O
found,VBN,O
to,TO,O
exhibit,VB,O
additive,JJ,O
effects,NNS,O
of,IN,O
this,DT,O
variety,NN,O
.,.,.
,,
marked,JJ,O
symptomatic,JJ,O
orthostatic,JJ,O
hypotension,NN,O
has,VBZ,O
been,VBN,O
reported,VBN,O
when,WRB,O
calcium,NN,D
channel,NN,O
blockers,NNS,O
and,CC,O
organic,JJ,O
nitrates,NNS,G
were,VBD,O
used,VBN,O
in,IN,O
combination,NN,O
.,.,.
,,
dose,NN,O
adjustments,NNS,O
of,IN,O
either,CC,O
class,NN,O
of,IN,O
agents,NNS,O
may,MD,O
be,VB,O
necessary,JJ,O
.,.,.
,,
the,DT,O
hypotensive,JJ,O
effect,NN,O
of,IN,O
sodium,NN,O
nitroprusside,NN,D
is,VBZ,O
augmented,VBN,O
by,IN,O
that,DT,O
of,IN,O
most,RBS,O
other,JJ,O
hypotensive,JJ,O
drugs,NNS,D
",",",",O
including,VBG,O
ganglionic,JJ,O
blocking,VBG,O
agents,NNS,O
",",",",O
negative,JJ,O
inotropic,JJ,O
agents,NNS,O
",",",",O
and,CC,O
inhaled,VBD,O
anesthetics,NNS,G
.,.,.
,,
no,DT,O
interactions,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
between,IN,O
nizatidine,NN,D
and,CC,O
theophylline,NN,D
",",",",O
chlordiazepoxide,NN,D
",",",",O
lorazepam,NN,D
",",",",O
lidocaine,NN,D
",",",",O
phenytoin,NN,D
",",",",O
and,CC,O
warfarin,NN,D
.,.,.
,,
nizatidine,NN,D
does,VBZ,O
not,RB,O
inhibit,VB,O
the,DT,O
cytochrome,NN,O
p-450-linked,JJ,O
drug-metabolizing,JJ,O
enzyme,NN,O
system,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
drug,NN,D
interactions,NNS,O
mediated,VBN,O
by,IN,O
inhibition,NN,O
of,IN,O
hepatic,JJ,O
metabolism,NN,O
are,VBP,O
not,RB,O
expected,VBN,O
to,TO,O
occur,VB,O
.,.,.
,,
in,IN,O
patients,NNS,O
given,VBN,O
very,RB,O
high,JJ,O
doses,NNS,O
-lrb-,-LRB-,O
3900,CD,O
mg,NN,O
-rrb-,-RRB-,O
of,IN,O
aspirin,NN,B
daily,RB,O
",",",",O
increases,VBZ,O
in,IN,O
serum,NN,O
salicylate,NN,G
levels,NNS,O
were,VBD,O
seen,VBN,O
when,WRB,O
nizatidine,NN,D
",",",",O
150,CD,O
mg,NN,O
b.i.d.,NN,O
",",",",O
was,VBD,O
administered,VBN,O
concurrently,RB,O
.,.,.
,,
the,DT,O
effectiveness,NN,O
of,IN,O
progestin-only,JJ,O
pills,NNS,O
is,VBZ,O
reduced,VBN,O
by,IN,O
hepatic,JJ,O
enzyme-inducing,JJ,O
drugs,NNS,D
such,JJ,O
as,IN,O
the,DT,O
anticonvulsants,NNS,G
phenytoin,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
and,CC,O
barbiturates,NNS,G
",",",",O
and,CC,O
the,DT,O
antituberculosis,NN,O
drug,NN,D
rifampin,NN,D
.,.,.
,,
no,DT,O
significant,JJ,O
interaction,NN,O
has,VBZ,O
been,VBN,O
found,VBN,O
with,IN,O
broad-spectrum,JJ,O
antibiotics,NNS,G
.,.,.
,,
elevated,JJ,O
plasma,NN,O
levels,NNS,O
of,IN,O
theophylline,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
concomitant,JJ,O
quinolone,NN,G
use,NN,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
theophylline-related,JJ,O
side,JJ,O
effects,NNS,O
in,IN,O
patients,NNS,O
on,IN,O
concomitant,JJ,O
therapy,NN,O
with,IN,O
norfloxacin,NN,D
and,CC,O
theophylline,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
monitoring,NN,O
of,IN,O
theophylline,NN,D
plasma,NN,O
levels,NNS,O
should,MD,O
be,VB,O
considered,VBN,O
and,CC,O
dosage,NN,O
of,IN,O
theophylline,NN,D
adjusted,VBN,O
as,IN,O
required,VBN,O
.,.,.
,,
elevated,JJ,O
serum,NN,O
levels,NNS,O
of,IN,O
cyclosporine,NN,D
have,VBP,O
been,VBN,O
reported,VBN,O
with,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
cyclosporine,NN,D
with,IN,O
norfloxacin,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
cyclosporine,NN,D
serum,NN,O
levels,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
and,CC,O
appropriate,JJ,O
cyclosporine,NN,D
dosage,NN,O
adjustments,NNS,O
made,VBN,O
when,WRB,O
these,DT,O
drugs,NNS,D
are,VBP,O
used,VBN,O
concomitantly,RB,O
.,.,.
,,
quinolones,NNP,G
",",",",O
including,VBG,O
norfloxacin,NN,D
",",",",O
may,MD,O
enhance,VB,O
the,DT,O
effects,NNS,O
of,IN,O
oral,JJ,O
anticoagulants,NNS,G
",",",",O
including,VBG,O
warfarin,NN,D
or,CC,O
its,PRP$,O
derivatives,NNS,O
or,CC,O
similar,JJ,O
agents,NNS,O
.,.,.
,,
when,WRB,O
these,DT,O
products,NNS,O
are,VBP,O
administered,VBN,O
concomitantly,RB,O
",",",",O
prothrombin,NN,O
time,NN,O
or,CC,O
other,JJ,O
suitable,JJ,O
coagulation,NN,O
tests,NNS,O
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
.,.,.
,,
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
quinolones,NNS,G
including,VBG,O
norfloxacin,NN,D
with,IN,O
glyburide,NN,D
-lrb-,-LRB-,O
a,DT,O
sulfonylurea,NN,G
agent,NN,O
-rrb-,-RRB-,O
has,VBZ,O
",",",",O
on,IN,O
rare,JJ,O
occasions,NNS,O
",",",",O
resulted,VBD,O
in,IN,O
severe,JJ,O
hypoglycemia,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
monitoring,NN,O
of,IN,O
blood,NN,O
glucose,NN,O
is,VBZ,O
recommended,VBN,O
when,WRB,O
these,DT,O
agents,NNS,O
are,VBP,O
co-administered,JJ,O
.,.,.
,,
diminished,VBN,O
urinary,JJ,O
excretion,NN,O
of,IN,O
norfloxacin,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
during,IN,O
the,DT,O
concomitant,JJ,O
administration,NN,O
of,IN,O
probenecid,NN,D
and,CC,O
norfloxacin,NN,D
.,.,.
,,
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
nitrofurantoin,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
since,IN,O
nitrofurantoin,NN,D
may,MD,O
antagonize,VB,O
the,DT,O
antibacterial,JJ,G
effect,NN,O
of,IN,O
norfloxacin,NNP,D
in,IN,O
the,DT,O
urinary,JJ,O
tract,NN,O
.,.,.
,,
multivitamins,NNS,G
",",",",O
or,CC,O
other,JJ,O
products,NNS,O
containing,VBG,O
iron,NN,D
or,CC,O
zinc,NN,D
",",",",O
antacids,NNS,G
or,CC,O
sucralfate,NN,D
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
",",",",O
or,CC,O
within,IN,O
2,CD,O
hours,NNS,O
of,IN,O
",",",",O
the,DT,O
administration,NN,O
of,IN,O
norfloxacin,NN,D
",",",",O
because,IN,O
they,PRP,O
may,MD,O
interfere,VB,O
with,IN,O
absorption,NN,O
resulting,VBG,O
in,IN,O
lower,JJR,O
serum,NN,O
and,CC,O
urine,NN,O
levels,NNS,O
of,IN,O
norfloxacin,NN,D
.,.,.
,,
videx,NNP,B
-lrb-,-LRB-,O
didanosine,NNP,D
-rrb-,-RRB-,O
chewable/buffered,VBD,O
tablets,NNS,O
or,CC,O
the,DT,O
pediatric,JJ,O
powder,NN,O
for,IN,O
oral,JJ,O
solution,NN,O
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
",",",",O
or,CC,O
within,IN,O
2,CD,O
hours,NNS,O
of,IN,O
",",",",O
the,DT,O
administration,NN,O
of,IN,O
norfloxacin,NN,D
",",",",O
because,IN,O
these,DT,O
products,NNS,O
may,MD,O
interfere,VB,O
with,IN,O
absorption,NN,O
resulting,VBG,O
in,IN,O
lower,JJR,O
serum,NN,O
and,CC,O
urine,NN,O
levels,NNS,O
of,IN,O
norfloxacin,NN,D
.,.,.
,,
some,DT,O
quinolones,NNS,G
have,VBP,O
also,RB,O
been,VBN,O
shown,VBN,O
to,TO,O
interfere,VB,O
with,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
caffeine,NN,D
.,.,.
,,
this,DT,O
may,MD,O
lead,VB,O
to,TO,O
reduced,VBN,O
clearance,NN,O
of,IN,O
caffeine,NN,D
and,CC,O
a,DT,O
prolongation,NN,O
of,IN,O
its,PRP$,O
plasma,NN,O
half-life,NN,O
.,.,.
,,
reduced,VBN,O
efficacy,NN,O
and,CC,O
increased,VBD,O
incidence,NN,O
of,IN,O
breakthrough,NN,O
bleeding,NN,O
and,CC,O
menstrual,JJ,O
irregularities,NNS,O
have,VBP,O
been,VBN,O
associated,VBN,O
with,IN,O
concomitant,JJ,O
use,NN,O
of,IN,O
rifampin,NN,D
.,.,.
,,
a,DT,O
similar,JJ,O
association,NN,O
",",",",O
though,IN,O
less,JJR,O
marked,JJ,O
",",",",O
has,VBZ,O
been,VBN,O
suggested,VBN,O
with,IN,O
barbiturates,NNS,G
",",",",O
phenylbutazone,NN,D
",",",",O
phenytoin,NN,D
sodium,NN,O
",",",",O
carbamazepine,NN,D
",",",",O
griseofulvin,NN,D
",",",",O
topiramate,NN,D
",",",",O
and,CC,O
possibly,RB,O
with,IN,O
ampicillin,NN,D
and,CC,O
tetracyclines,NNS,G
72,CD,O
.,.,.
,,
a,DT,O
possible,JJ,O
interaction,NN,O
has,VBZ,O
been,VBN,O
suggested,VBN,O
with,IN,O
hormonal,JJ,O
contraceptives,NNS,G
and,CC,O
the,DT,O
herbal,JJ,O
supplement,NN,O
st.,NNP,O
johns,NNP,O
wort,NNP,O
based,VBN,O
on,IN,O
some,DT,O
reports,NNS,O
of,IN,O
oral,JJ,O
contraceptive,JJ,G
users,NNS,O
experiencing,VBG,O
breakthrough,NN,O
bleeding,NN,O
shortly,RB,O
after,IN,O
starting,VBG,O
st.,NNP,O
johns,NNP,O
wort,NNP,O
.,.,.
,,
pregnancies,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
by,IN,O
users,NNS,O
of,IN,O
combined,JJ,O
hormonal,JJ,O
contraceptives,NNS,G
who,WP,O
also,RB,O
used,VBD,O
some,DT,O
form,NN,O
of,IN,O
st.,NNP,O
johns,NNP,O
wort,NNP,O
.,.,.
,,
healthcare,NNP,O
prescribers,NNS,O
are,VBP,O
advised,VBN,O
to,TO,O
consult,VB,O
the,DT,O
package,NN,O
inserts,NNS,O
of,IN,O
medication,NN,O
administered,VBN,O
concomitantly,RB,O
with,IN,O
oral,JJ,O
contraceptives,NNS,G
.,.,.
,,
steady-state,JJ,O
serum,NN,O
concentrations,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
are,VBP,O
reported,VBN,O
to,TO,O
fluctuate,VB,O
significantly,RB,O
when,WRB,O
cimetidine,NN,D
is,VBZ,O
either,CC,O
added,VBN,O
or,CC,O
deleted,VBN,O
from,IN,O
the,DT,O
drug,NN,D
regimen,NN,O
.,.,.
,,
serious,JJ,O
anticholinergic,JJ,G
symptoms,NNS,O
-lrb-,-LRB-,O
severe,JJ,O
dry,JJ,O
mouth,NN,O
",",",",O
urinary,JJ,O
retention,NN,O
",",",",O
blurred,VBD,O
vision,NN,O
-rrb-,-RRB-,O
have,VBP,O
been,VBN,O
associated,VBN,O
with,IN,O
elevations,NNS,O
in,IN,O
the,DT,O
serum,NN,O
levels,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
when,WRB,O
cimetidine,NN,D
is,VBZ,O
added,VBN,O
to,TO,O
the,DT,O
drug,NN,D
regimen,NN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
higher-than,NN,O
expected,VBD,O
steady-state,JJ,O
serum,NN,O
concentrations,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
have,VBP,O
been,VBN,O
observed,VBN,O
when,WRB,O
therapy,NN,O
is,VBZ,O
initiated,VBN,O
in,IN,O
patients,NNS,O
already,RB,O
taking,VBG,O
cimetidine,NN,D
.,.,.
,,
in,IN,O
well-controlled,JJ,O
patients,NNS,O
undergoing,VBG,O
concurrent,JJ,O
therapy,NN,O
with,IN,O
cimetidine,NN,D
",",",",O
a,DT,O
decrease,NN,O
in,IN,O
the,DT,O
steady-state,JJ,O
serum,NN,O
concentrations,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
may,MD,O
occur,VB,O
when,WRB,O
cime-tidine,NN,O
therapy,NN,O
is,VBZ,O
discontinued,VBN,O
.,.,.
,,
the,DT,O
therapeutic,JJ,O
efficacy,NN,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
may,MD,O
be,VB,O
compromised,VBN,O
in,IN,O
these,DT,O
patients,NNS,O
when,WRB,O
cimetidine,NN,D
is,VBZ,O
discontinued,VBN,O
.,.,.
,,
several,JJ,O
of,IN,O
the,DT,O
tricyclic,JJ,G
antidepressants,NNS,G
have,VBP,O
been,VBN,O
cited,VBN,O
in,IN,O
these,DT,O
reports,NNS,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
greater,JJR,O
than,IN,O
2-fold,JJ,O
increases,NNS,O
in,IN,O
previously,RB,O
stable,JJ,O
plasma,NN,O
levels,NNS,O
of,IN,O
other,JJ,O
antidepressants,NNS,G
",",",",O
including,VBG,O
nortriptyline,NN,D
",",",",O
when,WRB,O
fluoxetine,NN,D
hydrochloride,NN,O
has,VBZ,O
been,VBN,O
administered,VBN,O
in,IN,O
combination,NN,O
with,IN,O
these,DT,O
agents,NNS,O
.,.,.
,,
fluoxetine,NNP,D
and,CC,O
its,PRP$,O
active,JJ,O
metabolite,NN,O
",",",",O
norfluoxe-tine,NN,O
",",",",O
have,VBP,O
long,JJ,O
half-lives,NNS,O
-lrb-,-LRB-,O
4,CD,O
to,TO,O
16,CD,O
days,NNS,O
for,IN,O
norfluoxetine,NN,D_n
-rrb-,-RRB-,O
",",",",O
that,WDT,O
may,MD,O
affect,VB,O
strategies,NNS,O
during,IN,O
conversion,NN,O
from,IN,O
one,CD,O
drug,NN,D
to,TO,O
the,DT,O
other,JJ,O
.,.,.
,,
administration,NN,O
of,IN,O
reserpine,NN,D
during,IN,O
therapy,NN,O
with,IN,O
a,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
produce,VB,O
a,DT,O
stimulating,JJ,O
effect,NN,O
in,IN,O
some,DT,O
depressed,JJ,O
patients,NNS,O
.,.,.
,,
close,JJ,O
supervision,NN,O
and,CC,O
careful,JJ,O
adjustment,NN,O
of,IN,O
the,DT,O
dosage,NN,O
are,VBP,O
required,VBN,O
when,WRB,O
nortriptyline,NN,D
hydrochloride,NN,O
is,VBZ,O
used,VBN,O
with,IN,O
other,JJ,O
anticholinergic,JJ,G
drugs,NNS,D
or,CC,O
sympathomimetic,JJ,G
drugs,NNS,D
.,.,.
,,
the,DT,O
patient,NN,O
should,MD,O
be,VB,O
informed,VBN,O
that,IN,O
the,DT,O
response,NN,O
to,TO,O
alcohol,NN,D
may,MD,O
be,VB,O
exaggerated,VBN,O
.,.,.
,,
drugs,NNS,O
metabolized,VBN,O
by,IN,O
p450iid6,NN,O
a,NN,O
subset,NN,O
-lrb-,-LRB-,O
3,CD,O
%,NN,O
to,TO,O
10,CD,O
%,NN,O
-rrb-,-RRB-,O
of,IN,O
the,DT,O
population,NN,O
has,VBZ,O
reduced,VBN,O
activity,NN,O
of,IN,O
certain,JJ,O
drug,NN,D
metabolizing,VBG,O
enzymes,NNS,O
such,JJ,O
as,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
isoenzyme,NN,O
p450iid6,NN,O
.,.,.
,,
such,JJ,O
individuals,NNS,O
are,VBP,O
referred,VBN,O
to,TO,O
as,IN,O
poor,JJ,O
metabolizers,NNS,O
of,IN,O
drugs,NNS,D
such,JJ,O
as,IN,O
debrisoquin,NN,D
",",",",O
dextromethorphan,NN,D
",",",",O
and,CC,O
the,DT,O
tricyclic,JJ,G
antidepressants,NNS,G
.,.,.
,,
these,DT,O
individuals,NNS,O
may,MD,O
have,VB,O
higher,JJR,O
than,IN,O
expected,VBN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
when,WRB,O
given,VBN,O
usual,JJ,O
doses,NNS,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
certain,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
this,DT,O
isoenzyme,NN,O
",",",",O
including,VBG,O
many,JJ,O
antidepressants,NNS,G
-lrb-,-LRB-,O
tricyclic,JJ,G
antidepressants,NNS,G
",",",",O
selective,JJ,O
serotonin,NN,O
reuptake,NN,O
inhibitors,NNS,O
",",",",O
and,CC,O
others,NNS,O
-rrb-,-RRB-,O
",",",",O
may,MD,O
inhibit,VB,O
the,DT,O
activity,NN,O
of,IN,O
this,DT,O
isoenzyme,NN,O
",",",",O
and,CC,O
thus,RB,O
may,MD,O
make,VB,O
normal,JJ,O
metab-olizers,NNS,O
resemble,VBP,O
poor,JJ,O
metabolizers,NNS,O
with,IN,O
regard,NN,O
to,TO,O
concomitant,JJ,O
therapy,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
this,DT,O
enzyme,NN,O
system,NN,O
",",",",O
leading,VBG,O
to,TO,O
drug,NN,D
interactions,NNS,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
with,IN,O
other,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
cytochrome,NN,O
p450iid6,NN,O
may,MD,O
require,VB,O
lower,JJR,O
doses,NNS,O
than,IN,O
usually,RB,O
prescribed,VBN,O
for,IN,O
either,CC,O
the,DT,O
tricyclic,JJ,G
antidepressant,JJ,G
or,CC,O
the,DT,O
other,JJ,O
drug,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
co-administration,NN,O
of,IN,O
tricyclic,JJ,G
antidepressants,NNS,G
with,IN,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
this,DT,O
isoenzyme,NN,O
",",",",O
including,VBG,O
other,JJ,O
antidepressants,NNS,G
",",",",O
phenothiazines,NNS,G
",",",",O
carbamazepine,NN,D
",",",",O
and,CC,O
type,NN,O
1c,NN,O
antiarrhythmics,NNS,G
-lrb-,-LRB-,O
eg,FW,O
",",",",O
propafenone,NN,D
",",",",O
flecainide,NN,D
",",",",O
and,CC,O
encainide,NN,D
-rrb-,-RRB-,O
",",",",O
or,CC,O
that,IN,O
inhibit,VBP,O
this,DT,O
enzyme,NN,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
quinidine,NN,D
-rrb-,-RRB-,O
",",",",O
should,MD,O
be,VB,O
approached,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
oxcarbazepine,NNP,D
can,MD,O
inhibit,VB,O
cyp2c19,NN,O
and,CC,O
induce,VB,O
cyp3a4/5,NN,O
with,IN,O
potentially,RB,O
important,JJ,O
effects,NNS,O
on,IN,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
other,JJ,O
drugs,NNS,D
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
several,JJ,O
aed,NN,G
s,NNS,O
that,WDT,O
are,VBP,O
cytochrome,NN,O
p450,NN,O
inducers,NNS,O
can,MD,O
decrease,VB,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
oxcarbazepine,NN,D
and,CC,O
mhd,NN,D_n
.,.,.
,,
oxcarbazepine,NN,D
was,VBD,O
evaluated,VBN,O
in,IN,O
human,JJ,O
liver,NN,O
microsomes,NNS,O
to,TO,O
determine,VB,O
its,PRP$,O
capacity,NN,O
to,TO,O
inhibit,VB,O
the,DT,O
major,JJ,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
responsible,JJ,O
for,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
.,.,.
,,
results,NNS,O
demonstrate,VBP,O
that,IN,O
oxcarbazepine,NN,D
and,CC,O
its,PRP$,O
pharmacologically,RB,O
active,JJ,O
10-monohydroxy,JJ,O
metabolite,NN,O
-lrb-,-LRB-,O
mhd,NN,D_n
-rrb-,-RRB-,O
have,VBP,O
little,JJ,O
or,CC,O
no,DT,O
capacity,NN,O
to,TO,O
function,VB,O
as,IN,O
inhibitors,NNS,O
for,IN,O
most,JJS,O
of,IN,O
the,DT,O
human,JJ,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
evaluated,VBN,O
-lrb-,-LRB-,O
cyp1a2,NN,D
",",",",O
cyp2a6,NN,O
",",",",O
cyp2c9,NN,D
",",",",O
cyp2d6,NN,D
",",",",O
cyp2e1,NN,O
",",",",O
cyp4a9,NN,O
and,CC,O
cyp4a11,NN,O
-rrb-,-RRB-,O
with,IN,O
the,DT,O
exception,NN,O
of,IN,O
cyp2c19,NN,O
and,CC,O
cyp3a4/5,NN,O
.,.,.
,,
although,IN,O
inhibition,NN,O
of,IN,O
cyp,NN,O
3a4/5,NN,O
by,IN,O
oxc,NN,D
and,CC,O
mhd,NN,D_n
did,VBD,O
occur,VB,O
at,IN,O
high,JJ,O
concentrations,NNS,O
",",",",O
it,PRP,O
is,VBZ,O
not,RB,O
likely,JJ,O
to,TO,O
be,VB,O
of,IN,O
clinical,JJ,O
significance,NN,O
.,.,.
,,
the,DT,O
inhibition,NN,O
of,IN,O
cyp-2c19,NN,O
by,IN,O
oxc,NN,D
and,CC,O
mhd,NN,D_n
",",",",O
however,RB,O
",",",",O
is,VBZ,O
clinically,RB,O
relevant,JJ,O
.,.,.
,,
in,FW,O
vitro,FW,O
",",",",O
the,DT,O
udp-glucuronyl,JJ,O
transferase,NN,O
level,NN,O
was,VBD,O
increased,VBN,O
",",",",O
indicating,VBG,O
induction,NN,O
of,IN,O
this,DT,O
enzyme,NN,O
.,.,.
,,
increases,NNS,O
of,IN,O
22,CD,O
%,NN,O
with,IN,O
mhd,NN,D_n
and,CC,O
47,CD,O
%,NN,O
with,IN,O
oxcarbazepine,NN,D
were,VBD,O
observed,VBN,O
.,.,.
,,
as,IN,O
mhd,NN,D_n
",",",",O
the,DT,O
predominant,JJ,O
plasma,NN,O
substrate,NN,O
",",",",O
is,VBZ,O
only,RB,O
a,DT,O
weak,JJ,O
inducer,NN,O
of,IN,O
udp-glucuronyl,JJ,O
transferase,NN,O
",",",",O
it,PRP,O
is,VBZ,O
unlikely,JJ,O
to,TO,O
have,VB,O
an,DT,O
effect,NN,O
on,IN,O
drugs,NNS,D
that,WDT,O
are,VBP,O
mainly,RB,O
eliminated,VBN,O
by,IN,O
conjugation,NN,O
through,IN,O
udp-glucuronyl,JJ,O
transferase,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
valproic,JJ,O
acid,NN,O
",",",",O
lamotrigine,NN,D
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
oxcarbazepine,NN,D
and,CC,O
mhd,NN,D_n
induce,VBP,O
a,DT,O
subgroup,NN,O
of,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
3a,NN,O
family,NN,O
-lrb-,-LRB-,O
cyp3a4,NN,D
and,CC,O
cyp3a5,NN,O
-rrb-,-RRB-,O
responsible,JJ,O
for,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
dihydropyridine,NN,O
calcium,NN,D
antagonists,NNS,O
and,CC,O
oral,JJ,O
contraceptives,NNS,G
",",",",O
resulting,VBG,O
in,IN,O
a,DT,O
lower,JJR,O
plasma,NN,O
concentration,NN,O
of,IN,O
these,DT,O
drugs,NNS,D
.,.,.
,,
as,IN,O
binding,NN,O
of,IN,O
mhd,NN,D_n
to,TO,O
plasma,NN,O
proteins,NNS,O
is,VBZ,O
low,JJ,O
-lrb-,-LRB-,O
40,CD,O
%,NN,O
-rrb-,-RRB-,O
",",",",O
clinically,RB,O
significant,JJ,O
interactions,NNS,O
with,IN,O
other,JJ,O
drugs,NNS,D
through,IN,O
competition,NN,O
for,IN,O
protein,NN,O
binding,NN,O
sites,NNS,O
are,VBP,O
unlikely,JJ,O
.,.,.
,,
antiepileptic,JJ,O
drugs,NNS,D
:,:,O
potential,JJ,O
interactions,NNS,O
between,IN,O
trileptal,JJ,B
and,CC,O
other,JJ,O
aeds,NNS,G
were,VBD,O
assessed,VBN,O
in,IN,O
clinical,JJ,O
studies,NNS,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
these,DT,O
interactions,NNS,O
on,IN,O
mean,NN,O
aucs,NNS,O
and,CC,O
cmin,NN,O
are,VBP,O
summarized,VBN,O
in,IN,O
table,NNP,O
2,CD,O
:,:,O
table,NNP,O
2,CD,O
:,:,O
summary,NNP,O
of,IN,O
aed,NNP,G
interactions,NNS,O
with,IN,O
trilepta,NN,O
.,.,.
,,
aed,NN,G
co-administere,NN,O
.,.,.
,,
dose,NN,O
of,IN,O
aed,NN,G
-lrb-,-LRB-,O
mg/day,NN,O
.,.,.
,,
trileptal,JJ,B
dose,NN,O
-lrb-,-LRB-,O
mg/day,NN,O
.,.,.
,,
influence,NN,O
of,IN,O
trileptal,JJ,B
on,IN,O
aed,NNP,G
concentration,NN,O
-lrb-,-LRB-,O
mean,NN,O
change,NN,O
",",",",O
90,CD,O
%,NN,O
confidence,NN,O
interval,NN,O
.,.,.
,,
influence,NN,O
of,IN,O
aed,NNP,G
on,IN,O
mhd,NNP,D_n
concentration,NN,O
-lrb-,-LRB-,O
mean,NN,O
change,NN,O
",",",",O
90,CD,O
%,NN,O
confidence,NN,O
interval,NN,O
.,.,.
,,
carbamazepin,NNP,O
.,.,.
,,
400-2000,CD,O
.,.,.
,,
900,CD,O
.,.,.
,,
nc1,NN,O
40,CD,O
%,NN,O
decrease,NN,O
-lsb-,-LRB-,O
ci,NN,O
:,:,O
17,CD,O
%,NN,O
decrease,NN,O
",",",",O
57,CD,O
%,NN,O
decrease,NN,O
-rsb-,-RRB-,O
.,.,.
,,
phenobarbita,NNP,O
.,.,.
,,
100-150,CD,O
.,.,.
,,
600-1800,CD,O
.,.,.
,,
14,CD,O
%,NN,O
increase,NN,O
-lsb-,-LRB-,O
ci,NN,O
:,:,O
2,CD,O
%,NN,O
increase,NN,O
",",",",O
24,CD,O
%,NN,O
increase,NN,O
-rsb-,-RRB-,O
25,CD,O
%,NN,O
decrease,NN,O
-lsb-,-LRB-,O
ci,NN,O
:,:,O
12,CD,O
%,NN,O
decrease,NN,O
",",",",O
51,CD,O
%,NN,O
decrease,NN,O
-rsb-,-RRB-,O
.,.,.
,,
phenytoi,NNP,O
.,.,.
,,
250-500,CD,O
.,.,.
,,
600-1800,CD,O
.,.,.
,,
nc1,NN,O
",2",CD,O
30,CD,O
%,NN,O
decrease,NN,O
-lsb-,-LRB-,O
ci,NN,O
:,:,O
3,CD,O
%,NN,O
decrease,NN,O
",",",",O
48,CD,O
%,NN,O
decrease,NN,O
-rsb-,-RRB-,O
.,.,.
,,
1200-2400,CD,O
up,IN,O
to,TO,O
40,CD,O
%,NN,O
increase3,NN,O
-lsb-,-LRB-,O
ci,NN,O
:,:,O
12,CD,O
%,NN,O
increase,NN,O
",",",",O
60,CD,O
%,NN,O
increase,NN,O
-rsb-,-RRB-,O
.,.,.
,,
valproic,JJ,O
aci,NN,O
.,.,.
,,
400-2800,CD,O
.,.,.
,,
600-1800,CD,O
.,.,.
,,
nc1,NN,O
18,CD,O
%,NN,O
decrease,NN,O
-lsb-,-LRB-,O
ci,NN,O
:,:,O
13,CD,O
%,NN,O
decrease,NN,O
",",",",O
40,CD,O
%,NN,O
decrease,NN,O
-rsb-,-RRB-,O
.,.,.
,,
1,LS,O
-,:,O
nc,NN,O
denotes,VBZ,O
a,DT,O
mean,JJ,O
change,NN,O
of,IN,O
less,JJR,O
than,IN,O
10,CD,O
%,NN,O
2,CD,O
-,:,O
pediatrics,NNS,O
3,LS,O
-,:,O
mean,NN,O
increase,NN,O
in,IN,O
adults,NNS,O
at,IN,O
high,JJ,O
trileptal,JJ,B
doses,NNS,O
in,FW,O
vivo,FW,O
",",",",O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
phenytoin,NN,D
increased,VBN,O
by,IN,O
up,RB,O
to,TO,O
40,CD,O
%,NN,O
",",",",O
when,WRB,O
trileptal,NNP,B
was,VBD,O
given,VBN,O
at,IN,O
doses,NNS,O
above,IN,O
1200,CD,O
mg/day,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
when,WRB,O
using,VBG,O
doses,NNS,O
of,IN,O
trileptal,JJ,B
greater,JJR,O
than,IN,O
1200,CD,O
mg/day,NN,O
during,IN,O
adjunctive,JJ,O
therapy,NN,O
",",",",O
a,DT,O
decrease,NN,O
in,IN,O
the,DT,O
dose,NN,O
of,IN,O
phenytoin,NN,D
may,MD,O
be,VB,O
required,VBN,O
.,.,.
,,
the,DT,O
increase,NN,O
of,IN,O
phenobarbital,JJ,D
level,NN,O
",",",",O
however,RB,O
",",",",O
is,VBZ,O
small,JJ,O
-lrb-,-LRB-,O
15,CD,O
%,NN,O
-rrb-,-RRB-,O
when,WRB,O
given,VBN,O
with,IN,O
trileptal,JJ,B
.,.,.
,,
strong,JJ,O
inducers,NNS,O
of,IN,O
cytochrome,NN,O
p450,NN,O
enzymes,NNS,O
-lrb-,-LRB-,O
i.e.,FW,O
carbamazepine,FW,D
",",",",O
phenytoin,NN,D
and,CC,O
phenobarbital,NN,D
-rrb-,-RRB-,O
have,VBP,O
been,VBN,O
shown,VBN,O
to,TO,O
decrease,VB,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
mhd,NN,D_n
-lrb-,-LRB-,O
29-40,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
no,DT,O
autoinduction,NN,O
has,VBZ,O
been,VBN,O
observed,VBN,O
with,IN,O
trileptal,JJ,B
.,.,.
,,
hormonal,JJ,O
contraceptives,NNS,G
co-administration,NN,O
of,IN,O
trileptal,JJ,B
with,IN,O
an,DT,O
oral,JJ,O
contraceptive,NN,G
has,VBZ,O
been,VBN,O
shown,VBN,O
to,TO,O
influence,VB,O
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
the,DT,O
two,CD,O
hormonal,JJ,O
components,NNS,O
",",",",O
ethinylestradiol,NN,D
-lrb-,-LRB-,O
ee,NN,O
-rrb-,-RRB-,O
and,CC,O
levonorgestrel,NN,D
-lrb-,-LRB-,O
lng,NN,O
-rrb-,-RRB-,O
.,.,.
,,
the,DT,O
mean,NN,O
auc,NN,O
values,NNS,O
of,IN,O
ee,NN,O
were,VBD,O
decreased,VBN,O
by,IN,O
48,CD,O
%,NN,O
-lsb-,-LRB-,O
90,CD,O
%,NN,O
ci,NN,O
:,:,O
22-65,CD,O
-rsb-,-RRB-,O
in,IN,O
one,CD,O
study,NN,O
and,CC,O
52,CD,O
%,NN,O
-lsb-,-LRB-,O
90,CD,O
%,NN,O
ci,NN,O
:,:,O
38-52,CD,O
-rsb-,-RRB-,O
in,IN,O
another,DT,O
study,NN,O
-lsb-,-LRB-,O
"1,2",CD,O
-rsb-,-RRB-,O
.,.,.
,,
the,DT,O
mean,NN,O
auc,NN,O
values,NNS,O
of,IN,O
lng,NN,O
were,VBD,O
decreased,VBN,O
by,IN,O
32,CD,O
%,NN,O
-lsb-,-LRB-,O
90,CD,O
%,NN,O
ci,NN,O
:,:,O
20-45,CD,O
-rsb-,-RRB-,O
in,IN,O
one,CD,O
study,NN,O
and,CC,O
52,CD,O
%,NN,O
-lsb-,-LRB-,O
90,CD,O
%,NN,O
ci,NN,O
:,:,O
42-52,CD,O
-rsb-,-RRB-,O
in,IN,O
another,DT,O
study,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
concurrent,JJ,O
use,NN,O
of,IN,O
trileptal,JJ,B
with,IN,O
hormonal,JJ,O
contraceptives,NNS,G
may,MD,O
render,VB,O
these,DT,O
contraceptives,NNS,G
less,RBR,O
effective,JJ,O
.,.,.
,,
studies,NNS,O
with,IN,O
other,JJ,O
oral,JJ,O
or,CC,O
implant,VB,O
contraceptives,NNS,G
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
calcium,NN,D
antagonists,NNS,O
:,:,O
after,IN,O
repeated,VBN,O
co-administration,NN,O
of,IN,O
trileptal,NNP,B
",",",",O
the,DT,O
auc,NN,O
of,IN,O
felodipine,NN,D
was,VBD,O
lowered,VBN,O
by,IN,O
28,CD,O
%,NN,O
-lsb-,-LRB-,O
90,CD,O
%,NN,O
ci,NN,O
:,:,O
20-33,CD,O
-rsb-,-RRB-,O
.,.,.
,,
verapamil,NNP,D
produced,VBD,O
a,DT,O
decrease,NN,O
of,IN,O
20,CD,O
%,NN,O
-lsb-,-LRB-,O
90,CD,O
%,NN,O
ci,NN,O
:,:,O
18-27,CD,O
-rsb-,-RRB-,O
of,IN,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
mhd,NNP,D_n
.,.,.
,,
other,JJ,O
drug,NN,D
interactions,NNS,O
cimetidine,NNP,D
",",",",O
erythromycin,NN,D
and,CC,O
dextropropoxyphene,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
mhd,NNP,D_n
.,.,.
,,
results,NNS,O
with,IN,O
warfarin,NN,D
wshow,NN,O
no,DT,O
evidence,NN,O
of,IN,O
interaction,NN,O
with,IN,O
either,CC,O
single,JJ,O
or,CC,O
repeated,JJ,O
doses,NNS,O
of,IN,O
trileptal,JJ,B
.,.,.
,,
in,IN,O
a,DT,O
phase,NN,O
i,PRP,O
trial,NN,O
using,VBG,O
escalating,VBG,O
doses,NNS,O
of,IN,O
taxol,NN,B
-lrb-,-LRB-,O
110-200,CD,O
mg/m2,NN,O
-rrb-,-RRB-,O
and,CC,O
cisplatin,NN,D
-lrb-,-LRB-,O
50,CD,O
or,CC,O
75,CD,O
mg/m2,NN,O
-rrb-,-RRB-,O
given,VBN,O
as,IN,O
sequential,JJ,O
infusions,NNS,O
",",",",O
myelosuppression,NN,O
was,VBD,O
more,RBR,O
profound,JJ,O
when,WRB,O
taxol,NNP,B
was,VBD,O
given,VBN,O
after,IN,O
cisplatin,NN,D
than,IN,O
with,IN,O
the,DT,O
alternate,JJ,O
sequence,NN,O
-lrb-,-LRB-,O
ie,FW,O
",",",",O
taxol,NN,B
before,IN,O
cisplatin,NN,D
-rrb-,-RRB-,O
.,.,.
,,
pharmacokinetic,JJ,O
data,NNS,O
from,IN,O
these,DT,O
patients,NNS,O
demonstrated,VBD,O
a,DT,O
decrease,NN,O
in,IN,O
paclitaxel,NN,D
clearance,NN,O
of,IN,O
approximately,RB,O
33,CD,O
%,NN,O
when,WRB,O
taxol,NNP,B
was,VBD,O
administered,VBN,O
following,VBG,O
cisplatin,NN,D
.,.,.
,,
the,DT,O
metabolism,NN,O
of,IN,O
taxol,NN,B
is,VBZ,O
catalyzed,VBN,O
by,IN,O
cytochrome,NN,O
p450,NN,O
isoen-zymes,NNS,O
cyp2c8,NN,O
and,CC,O
cyp3a4,NN,D
.,.,.
,,
in,IN,O
the,DT,O
absence,NN,O
of,IN,O
formal,JJ,O
clinical,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
",",",",O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
administering,VBG,O
taxol,NNP,B
concomitantly,RB,O
with,IN,O
known,JJ,O
substrates,NNS,O
or,CC,O
inhibitors,NNS,O
of,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
isoenzymes,NNS,O
cyp2c8,NN,O
and,CC,O
cyp3a4,NN,D
.,.,.
,,
potential,JJ,O
interactions,NNS,O
between,IN,O
taxol,NNP,B
",",",",O
a,DT,O
substrate,NN,O
of,IN,O
cyp3a4,NN,D
",",",",O
and,CC,O
protease,NN,O
inhibitors,NNS,O
-lrb-,-LRB-,O
ritonavir,NN,D
",",",",O
saquinavir,NN,D
",",",",O
indinavir,NN,D
",",",",O
and,CC,O
nelfinavir,NN,D
-rrb-,-RRB-,O
",",",",O
which,WDT,O
are,VBP,O
substrates,NNS,O
and/or,CC,O
inhibitors,NNS,O
of,IN,O
cyp3a4,NN,D
",",",",O
have,VBP,O
not,RB,O
been,VBN,O
evaluated,VBN,O
in,IN,O
clinical,JJ,O
trials,NNS,O
.,.,.
,,
reports,NNS,O
in,IN,O
the,DT,O
literature,NN,O
suggest,VBP,O
that,IN,O
plasma,NN,O
levels,NNS,O
of,IN,O
doxorubicin,NN,D
-lrb-,-LRB-,O
and,CC,O
its,PRP$,O
active,JJ,O
metabolite,NN,O
doxorubicinol,NN,D_n
-rrb-,-RRB-,O
may,MD,O
be,VB,O
increased,VBN,O
when,WRB,O
paclitaxel,NN,D
and,CC,O
doxorubicin,NN,D
are,VBP,O
used,VBN,O
in,IN,O
combination,NN,O
.,.,.
,,
hematology,NNP,O
:,:,O
taxol,NN,B
therapy,NN,O
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
to,TO,O
patients,NNS,O
with,IN,O
baseline,NN,O
neutrophil,NN,O
counts,NNS,O
of,IN,O
less,JJR,O
than,IN,O
"1,500",CD,O
cells/mm3,NNS,O
.,.,.
,,
in,IN,O
order,NN,O
to,TO,O
monitor,VB,O
the,DT,O
occurrence,NN,O
of,IN,O
myelotoxicity,NN,O
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
frequent,JJ,O
peripheral,JJ,O
blood,NN,O
cell,NN,O
counts,NNS,O
be,VB,O
performed,VBN,O
on,IN,O
all,DT,O
patients,NNS,O
receiving,VBG,O
taxol,NNP,B
.,.,.
,,
patients,NNS,O
should,MD,O
not,RB,O
be,VB,O
re-treated,JJ,O
with,IN,O
subsequent,JJ,O
cycles,NNS,O
of,IN,O
taxol,NN,B
until,IN,O
neutrophils,NNS,O
recover,VBP,O
to,TO,O
a,DT,O
level,NN,O
1500,CD,O
cells/mm3,NNS,O
and,CC,O
platelets,NNS,O
recover,VBP,O
to,TO,O
a,DT,O
level,NN,O
"100,000",CD,O
cells/mm3,NNS,O
.,.,.
,,
in,IN,O
the,DT,O
case,NN,O
of,IN,O
severe,JJ,O
neutropenia,NN,O
-lrb-,-LRB-,O
500,CD,O
cells/mm3,NN,O
for,IN,O
seven,CD,O
days,NNS,O
or,CC,O
more,JJR,O
-rrb-,-RRB-,O
during,IN,O
a,DT,O
course,NN,O
of,IN,O
taxol,NN,B
therapy,NN,O
",",",",O
a,DT,O
20,CD,O
%,NN,O
reduction,NN,O
in,IN,O
dose,NN,O
for,IN,O
subsequent,JJ,O
courses,NNS,O
of,IN,O
therapy,NN,O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
for,IN,O
patients,NNS,O
with,IN,O
advanced,JJ,O
hiv,NN,O
disease,NN,O
and,CC,O
poor-risk,JJ,O
aids-related,JJ,O
kaposi,NN,O
s,NNS,O
sarcoma,NN,O
",",",",O
taxol,NN,B
",",",",O
at,IN,O
the,DT,O
recommended,VBN,O
dose,NN,O
for,IN,O
this,DT,O
disease,NN,O
",",",",O
can,MD,O
be,VB,O
initiated,VBN,O
and,CC,O
repeated,VBN,O
if,IN,O
the,DT,O
neutrophil,NN,O
count,NN,O
is,VBZ,O
at,IN,O
least,JJS,O
1000,CD,O
cells/mm3,NNS,O
.,.,.
,,
hypersensitivity,NN,O
reactions,NNS,O
:,:,O
patients,NNS,O
with,IN,O
a,DT,O
history,NN,O
of,IN,O
severe,JJ,O
hypersensitivity,NN,O
reactions,NNS,O
to,TO,O
products,NNS,O
containing,VBG,O
cremophor,NNP,O
el,NNP,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
cyclosporin,NN,D
for,IN,O
injection,NN,O
concentrate,NN,O
and,CC,O
teniposide,NN,D
for,IN,O
injection,NN,O
concentrate,NN,O
-rrb-,-RRB-,O
should,MD,O
not,RB,O
be,VB,O
treated,VBN,O
with,IN,O
taxol,NN,B
.,.,.
,,
in,IN,O
order,NN,O
to,TO,O
avoid,VB,O
the,DT,O
occurrence,NN,O
of,IN,O
severe,JJ,O
hypersensitivity,NN,O
reactions,NNS,O
",",",",O
all,DT,O
patients,NNS,O
treated,VBN,O
with,IN,O
taxol,NN,B
should,MD,O
be,VB,O
premedicated,VBN,O
with,IN,O
corticosteroids,NNS,G
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
dexamethasone,NN,D
-rrb-,-RRB-,O
",",",",O
diphen-hydramine,NN,O
and,CC,O
h2,NN,O
antagonists,NNS,O
-lrb-,-LRB-,O
such,JJ,O
as,IN,O
cimetidine,NN,D
or,CC,O
ranitidine,NN,D
-rrb-,-RRB-,O
.,.,.
,,
minor,JJ,O
symptoms,NNS,O
such,JJ,O
as,IN,O
flushing,NN,O
",",",",O
skin,NN,O
reactions,NNS,O
",",",",O
dyspnea,NN,O
",",",",O
hypotension,NN,O
",",",",O
or,CC,O
tachycardia,NN,O
do,VBP,O
not,RB,O
require,VB,O
interruption,NN,O
of,IN,O
therapy,NN,O
.,.,.
,,
however,RB,O
",",",",O
severe,JJ,O
reactions,NNS,O
",",",",O
such,JJ,O
as,IN,O
hypotension,NN,O
requiring,VBG,O
treatment,NN,O
",",",",O
dyspnea,NN,O
requiring,VBG,O
bronchodilators,NNS,G
",",",",O
angioedema,NN,O
",",",",O
or,CC,O
generalized,VBN,O
urticaria,NN,O
require,VBP,O
immediate,JJ,O
discontinuation,NN,O
of,IN,O
taxol,NN,B
and,CC,O
aggressive,JJ,O
symptomatic,JJ,O
therapy,NN,O
.,.,.
,,
patients,NNS,O
who,WP,O
have,VBP,O
developed,VBN,O
severe,JJ,O
hypersensitivity,NN,O
reactions,NNS,O
should,MD,O
not,RB,O
be,VB,O
rechallenged,VBN,O
with,IN,O
taxol,NN,B
.,.,.
,,
cardiovascular,NNP,O
:,:,O
hypotension,NN,O
",",",",O
bradycardia,NN,O
",",",",O
and,CC,O
hypertension,NN,O
have,VBP,O
been,VBN,O
observed,VBN,O
during,IN,O
administration,NN,O
of,IN,O
taxol,NNP,B
",",",",O
but,CC,O
generally,RB,O
do,VBP,O
not,RB,O
require,VB,O
treatment,NN,O
.,.,.
,,
occasionally,RB,O
taxol,NN,B
infusions,NNS,O
must,MD,O
be,VB,O
interrupted,JJ,O
or,CC,O
discontinued,VBN,O
because,IN,O
of,IN,O
initial,JJ,O
or,CC,O
recurrent,JJ,O
hypertension,NN,O
.,.,.
,,
frequent,JJ,O
vital,JJ,O
sign,NN,O
monitoring,NN,O
",",",",O
particularly,RB,O
during,IN,O
the,DT,O
first,JJ,O
hour,NN,O
of,IN,O
taxol,NNP,B
infusion,NN,O
",",",",O
is,VBZ,O
recommended,VBN,O
.,.,.
,,
continuous,JJ,O
cardiac,JJ,O
monitoring,NN,O
is,VBZ,O
not,RB,O
required,VBN,O
except,IN,O
for,IN,O
patients,NNS,O
with,IN,O
serious,JJ,O
conduction,NN,O
abnormalities,NNS,O
.,.,.
,,
nervous,JJ,O
system,NN,O
:,:,O
although,IN,O
the,DT,O
occurrence,NN,O
of,IN,O
peripheral,JJ,O
neuropathy,NN,O
is,VBZ,O
frequent,JJ,O
",",",",O
the,DT,O
development,NN,O
of,IN,O
severe,JJ,O
symptomatology,NN,O
is,VBZ,O
unusual,JJ,O
and,CC,O
requires,VBZ,O
a,DT,O
dose,NN,O
reduction,NN,O
of,IN,O
20,CD,O
%,NN,O
for,IN,O
all,DT,O
subsequentcourses,NNS,O
of,IN,O
taxol,NN,B
.,.,.
,,
taxol,NN,B
contains,VBZ,O
dehydrated,JJ,O
alcohol,NN,D
usp,NN,O
",",",",O
396,CD,O
mg/ml,NN,O
.,.,.
,,
consideration,NN,O
should,MD,O
be,VB,O
given,VBN,O
to,TO,O
possible,JJ,O
cns,NN,O
and,CC,O
other,JJ,O
effects,NNS,O
of,IN,O
alcohol,NN,D
.,.,.
,,
hepatic,JJ,O
:,:,O
there,EX,O
is,VBZ,O
limited,JJ,O
evidence,NN,O
that,IN,O
the,DT,O
myelotoxicity,NN,O
of,IN,O
taxol,NN,B
may,MD,O
be,VB,O
exacerbated,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
serum,NN,O
total,JJ,O
bilirubin,NN,O
2,CD,O
times,NNS,O
uln,NNP,O
.,.,.
,,
extreme,JJ,O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
administering,VBG,O
taxol,NN,B
to,TO,O
such,JJ,O
patients,NNS,O
",",",",O
with,IN,O
dose,NN,O
reduction,NN,O
as,IN,O
recommended,VBN,O
in,IN,O
dosage,NNP,O
and,CC,O
administration,NNP,O
",",",",O
table,NNP,O
17,CD,O
.,.,.
,,
injectionsite,NNP,O
reaction,NNP,O
:,:,O
injection,NN,O
site,NN,O
reactions,NNS,O
",",",",O
including,VBG,O
reactions,NNS,O
secondary,JJ,O
to,TO,O
extravasation,NN,O
",",",",O
were,VBD,O
usually,RB,O
mild,JJ,O
and,CC,O
consisted,VBD,O
of,IN,O
erythema,NN,O
",",",",O
tenderness,NN,O
",",",",O
skin,NN,O
discoloration,NN,O
",",",",O
or,CC,O
swelling,VBG,O
at,IN,O
the,DT,O
injection,NN,O
site,NN,O
.,.,.
,,
these,DT,O
reactions,NNS,O
have,VBP,O
been,VBN,O
observed,VBN,O
more,RBR,O
frequently,RB,O
with,IN,O
the,DT,O
24-hour,JJ,O
infusion,NN,O
than,IN,O
with,IN,O
the,DT,O
3-hour,JJ,O
infusion,NN,O
.,.,.
,,
recurrence,NN,O
of,IN,O
skin,NN,O
reactions,NNS,O
at,IN,O
a,DT,O
site,NN,O
of,IN,O
previous,JJ,O
extravasation,NN,O
following,VBG,O
administration,NN,O
of,IN,O
taxol,NN,B
at,IN,O
a,DT,O
different,JJ,O
site,NN,O
",",",",O
ie,FW,O
",",",",O
recall,NN,O
",",",",O
has,VBZ,O
been,VBN,O
reported,VBN,O
rarely,RB,O
.,.,.
,,
rare,JJ,O
reports,NNS,O
of,IN,O
more,RBR,O
severe,JJ,O
events,NNS,O
such,JJ,O
as,IN,O
phlebitis,NN,O
",",",",O
cellulitis,NN,O
",",",",O
induration,NN,O
",",",",O
skin,NN,O
exfoliation,NN,O
",",",",O
necrosis,NN,O
",",",",O
and,CC,O
fibrosis,NN,O
have,VBP,O
been,VBN,O
received,VBN,O
as,IN,O
part,NN,O
of,IN,O
the,DT,O
continuing,VBG,O
surveillance,NN,O
of,IN,O
taxol,NN,B
safety,NN,O
.,.,.
,,
in,IN,O
some,DT,O
cases,NNS,O
the,DT,O
onset,NN,O
of,IN,O
the,DT,O
injection,NN,O
site,NN,O
reaction,NN,O
either,CC,O
occurred,VBD,O
during,IN,O
a,DT,O
prolonged,JJ,O
infusion,NN,O
or,CC,O
was,VBD,O
delayed,VBN,O
by,IN,O
a,DT,O
week,NN,O
to,TO,O
ten,CD,O
days,NNS,O
.,.,.
,,
a,DT,O
specific,JJ,O
treatment,NN,O
for,IN,O
extravasation,NN,O
reactions,NNS,O
is,VBZ,O
unknown,JJ,O
at,IN,O
this,DT,O
time,NN,O
.,.,.
,,
given,VBN,O
the,DT,O
possibility,NN,O
of,IN,O
extravasation,NN,O
",",",",O
it,PRP,O
is,VBZ,O
advisable,JJ,O
to,TO,O
closely,RB,O
monitor,VB,O
the,DT,O
infusion,NN,O
site,NN,O
for,IN,O
possible,JJ,O
infiltration,NN,O
during,IN,O
drug,NN,D
administration,NN,O
.,.,.
,,
treatment,NN,O
with,IN,O
pegasys,NN,B
once,RB,O
weekly,JJ,O
for,IN,O
4,CD,O
weeks,NNS,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
was,VBD,O
associated,VBN,O
with,IN,O
an,DT,O
inhibition,NN,O
of,IN,O
p450,NN,O
1a2,NN,O
and,CC,O
a,DT,O
25,CD,O
%,NN,O
increase,NN,O
in,IN,O
theophylline,NN,D
auc,NN,O
.,.,.
,,
theophylline,NN,D
serum,NN,O
levels,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
and,CC,O
appropriate,JJ,O
dose,NN,O
adjustments,NNS,O
considered,VBN,O
for,IN,O
patients,NNS,O
given,VBN,O
both,CC,O
theophylline,NN,D
and,CC,O
pegasys,NN,B
.,.,.
,,
there,EX,O
was,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
representative,JJ,O
drugs,NNS,D
metabolized,VBN,O
by,IN,O
cyp,NN,O
2c9,NN,O
",",",",O
cyp,NN,O
2c19,NN,O
",",",",O
cyp,NN,O
2d6,NN,O
or,CC,O
cyp,NN,O
3a4,NN,O
.,.,.
,,
in,IN,O
patients,NNS,O
with,IN,O
chronic,JJ,O
hepatitis,NN,O
c,NN,O
treated,VBN,O
with,IN,O
pegasys,NN,B
in,IN,O
combination,NN,O
with,IN,O
copegus,NNS,B
",",",",O
pegasys,NN,B
treatment,NN,O
did,VBD,O
not,RB,O
affect,VB,O
ribavirin,NNP,D
distribution,NN,O
or,CC,O
clearance,NN,O
.,.,.
,,
nucleoside,NN,O
analogues,NNP,O
didanosine,NNP,D
co-administration,NN,O
of,IN,O
copegus,NNP,B
and,CC,O
didanosine,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
reports,NNS,O
of,IN,O
fatal,JJ,O
hepatic,JJ,O
failure,NN,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
peripheral,JJ,O
neuropathy,NN,O
",",",",O
pancreatitis,NN,O
",",",",O
and,CC,O
symptomatic,JJ,O
hyperlactatemia/lactic,JJ,O
acidosis,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
in,IN,O
clinical,JJ,O
trials,NNS,O
.,.,.
,,
stavudine,NNP,D
and,CC,O
zidovudine,NNP,D
ribavirin,NNP,D
can,MD,O
antagonize,VB,O
the,DT,O
in,FW,O
vitro,FW,O
antiviral,JJ,O
activity,NN,O
of,IN,O
stavudine,NN,D
and,CC,O
zidovudine,NN,D
against,IN,O
hiv,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
concomitant,JJ,O
use,NN,O
of,IN,O
ribavirin,NNP,D
with,IN,O
either,DT,O
of,IN,O
these,DT,O
drugs,NNS,D
should,MD,O
be,VB,O
avoided,VBN,O
.,.,.
,,
carcinogenesis,NN,O
",",",",O
mutagenesis,NN,O
",",",",O
impairment,NN,O
of,IN,O
fertility,NN,O
carcinogenesis,NN,O
pegasys,NN,B
has,VBZ,O
not,RB,O
been,VBN,O
tested,VBN,O
for,IN,O
its,PRP$,O
carcinogenic,JJ,O
potential,NN,O
.,.,.
,,
mutagenesis,NN,O
pegasys,NN,B
did,VBD,O
not,RB,O
cause,VB,O
dna,NN,O
damage,NN,O
when,WRB,O
tested,VBN,O
in,IN,O
the,DT,O
ames,NNP,O
bacterial,JJ,O
mutagenicity,NN,O
assay,NN,O
and,CC,O
in,IN,O
the,DT,O
in,FW,O
vitro,FW,O
chromosomal,JJ,O
aberration,NN,O
assay,NN,O
in,IN,O
human,JJ,O
lymphocytes,NNS,O
",",",",O
either,CC,O
in,IN,O
the,DT,O
presence,NN,O
or,CC,O
absence,NN,O
of,IN,O
metabolic,JJ,O
activation,NN,O
.,.,.
,,
use,NNP,O
with,IN,O
ribavirin,NNP,D
ribavirin,NNP,D
is,VBZ,O
genotoxic,JJ,O
and,CC,O
mutagenic,JJ,O
.,.,.
,,
the,DT,O
carcinogenic,JJ,O
potential,NN,O
of,IN,O
ribavirin,NNP,D
has,VBZ,O
not,RB,O
been,VBN,O
fully,RB,O
determined,VBN,O
.,.,.
,,
in,IN,O
a,DT,O
p53,NN,O
-lrb-,-LRB-,O
+,CC,O
/,:,O
-,:,O
-rrb-,-RRB-,O
mouse,NN,O
carcinogenicity,NN,O
study,NN,O
at,IN,O
doses,NNS,O
up,RB,O
to,TO,O
the,DT,O
maximum,NN,O
tolerated,VBD,O
dose,NN,O
of,IN,O
100,CD,O
mg/kg/day,JJ,O
ribavirin,NNP,D
was,VBD,O
not,RB,O
oncogenic,JJ,O
.,.,.
,,
however,RB,O
",",",",O
on,IN,O
a,DT,O
body,NN,O
surface,NN,O
area,NN,O
basis,NN,O
",",",",O
this,DT,O
dose,NN,O
was,VBD,O
0.5,CD,O
times,NNS,O
maximum,JJ,O
recommended,VBN,O
human,JJ,O
24-hour,JJ,O
dose,NN,O
of,IN,O
ribavirin,NNP,D
.,.,.
,,
a,DT,O
study,NN,O
in,IN,O
rats,NNS,O
to,TO,O
assess,VB,O
the,DT,O
carcinogenic,JJ,O
potential,NN,O
of,IN,O
ribavirin,NNP,D
is,VBZ,O
ongoing,JJ,O
.,.,.
,,
mutagenesis,NN,O
impairment,NN,O
of,IN,O
fertility,NNP,O
pegasys,NNP,B
may,MD,O
impair,VB,O
fertility,NN,O
in,IN,O
women,NNS,O
.,.,.
,,
prolonged,JJ,O
menstrual,JJ,O
cycles,NNS,O
and/or,CC,O
amenorrhea,NN,O
were,VBD,O
observed,VBN,O
in,IN,O
female,JJ,O
cynomolgus,NN,O
monkeys,NNS,O
given,VBN,O
sc,NN,O
injections,NNS,O
of,IN,O
600,CD,O
m,NN,O
g/kg/dose,NN,O
-lrb-,-LRB-,O
7200,CD,O
m,NN,O
g/m2/dose,NN,O
-rrb-,-RRB-,O
of,IN,O
pegasys,NN,B
every,DT,O
other,JJ,O
day,NN,O
for,IN,O
one,CD,O
month,NN,O
",",",",O
at,IN,O
approximately,RB,O
180,CD,O
times,NNS,O
the,DT,O
recommended,VBN,O
weekly,JJ,O
human,JJ,O
dose,NN,O
for,IN,O
a,DT,O
60,CD,O
kg,NN,O
person,NN,O
-lrb-,-LRB-,O
based,VBN,O
on,IN,O
body,NN,O
surface,NN,O
area,NN,O
-rrb-,-RRB-,O
.,.,.
,,
menstrual,JJ,O
cycle,NN,O
irregularities,NNS,O
were,VBD,O
accompanied,VBN,O
by,IN,O
both,CC,O
a,DT,O
decrease,NN,O
and,CC,O
delay,NN,O
in,IN,O
the,DT,O
peak,JJ,O
17b,NN,O
-,:,O
estradiol,NN,O
and,CC,O
progesterone,NN,D
levels,NNS,O
following,VBG,O
administration,NN,O
of,IN,O
pegasys,NNP,B
to,TO,O
female,JJ,O
monkeys,NNS,O
.,.,.
,,
a,DT,O
return,NN,O
to,TO,O
normal,JJ,O
menstrual,JJ,O
rhythm,NN,O
followed,VBD,O
cessation,NN,O
of,IN,O
treatment,NN,O
.,.,.
,,
every,DT,O
other,JJ,O
day,NN,O
dosing,NN,O
with,IN,O
100m,NN,O
g/kg,NN,O
-lrb-,-LRB-,O
1200m,CD,O
g/m2,NN,O
-rrb-,-RRB-,O
pegasys,NN,B
-lrb-,-LRB-,O
equivalent,JJ,O
to,TO,O
approximately,RB,O
30,CD,O
times,NNS,O
the,DT,O
recommended,VBN,O
human,JJ,O
dose,NN,O
-rrb-,-RRB-,O
had,VBD,O
no,DT,O
effects,NNS,O
on,IN,O
cycle,NN,O
duration,NN,O
or,CC,O
reproductive,JJ,O
hormone,NN,O
status,NN,O
.,.,.
,,
the,DT,O
effects,NNS,O
of,IN,O
pegasys,NN,B
on,IN,O
male,JJ,O
fertility,NN,O
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
however,RB,O
",",",",O
no,DT,O
adverse,JJ,O
effects,NNS,O
on,IN,O
fertility,NN,O
were,VBD,O
observed,VBN,O
in,IN,O
male,JJ,O
rhesus,NNP,O
monkeys,NNS,O
treated,VBN,O
with,IN,O
non-pegylated,JJ,O
interferon,NN,G
alfa-2a,NN,O
for,IN,O
5,CD,O
months,NNS,O
at,IN,O
doses,NNS,O
up,RB,O
to,TO,O
25,CD,O
x,CC,O
106,CD,O
iu/kg/day,NN,O
.,.,.
,,
pregnancy,NNP,O
pregnancy,NNP,O
:,:,O
category,NN,O
c,NN,O
pegasys,NN,B
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
for,IN,O
its,PRP$,O
teratogenic,JJ,O
effect,NN,O
.,.,.
,,
non-pegylated,JJ,O
interferon,NN,G
alfa-2a,NN,O
treatment,NN,O
of,IN,O
pregnant,JJ,O
rhesus,NNP,O
monkeys,NNS,O
at,IN,O
approximately,RB,O
20,CD,O
to,TO,O
500,CD,O
times,NNS,O
the,DT,O
human,JJ,O
weekly,JJ,O
dose,NN,O
resulted,VBD,O
in,IN,O
a,DT,O
statistically,RB,O
significant,JJ,O
increase,NN,O
in,IN,O
abortions,NNS,O
.,.,.
,,
no,DT,O
teratogenic,JJ,O
effects,NNS,O
were,VBD,O
seen,VBN,O
in,IN,O
the,DT,O
offspring,NN,O
delivered,VBN,O
at,IN,O
term,NN,O
.,.,.
,,
pegasys,NN,B
should,MD,O
be,VB,O
assumed,VBN,O
to,TO,O
have,VB,O
abortifacient,JJ,O
potential,NN,O
.,.,.
,,
there,EX,O
are,VBP,O
no,DT,O
adequate,JJ,O
and,CC,O
well-controlled,JJ,O
studies,NNS,O
of,IN,O
pegasys,NNP,B
in,IN,O
pregnant,JJ,O
women,NNS,O
.,.,.
,,
pegasys,NNP,B
is,VBZ,O
to,TO,O
be,VB,O
used,VBN,O
during,IN,O
pregnancy,NN,O
only,RB,O
if,IN,O
the,DT,O
potential,JJ,O
benefit,NN,O
justifies,VBZ,O
the,DT,O
potential,JJ,O
risk,NN,O
to,TO,O
the,DT,O
fetus,NN,O
.,.,.
,,
pegasys,NNP,B
is,VBZ,O
recommended,VBN,O
for,IN,O
use,NN,O
in,IN,O
women,NNS,O
of,IN,O
childbearing,JJ,O
potential,NN,O
only,RB,O
when,WRB,O
they,PRP,O
are,VBP,O
using,VBG,O
effective,JJ,O
contraception,NN,O
during,IN,O
therapy,NN,O
.,.,.
,,
pregnancy,NN,O
:,:,O
category,NN,O
x,NN,O
:,:,O
use,NNP,O
with,IN,O
ribavirin,NNP,D
-lrb-,-LRB-,O
see,VB,O
contraindications,NNS,O
-rrb-,-RRB-,O
significant,JJ,O
teratogenic,JJ,O
and/or,CC,O
embryocidal,JJ,O
effects,NNS,O
have,VBP,O
been,VBN,O
demonstrated,VBN,O
in,IN,O
all,DT,O
animal,JJ,O
species,NNS,O
exposed,VBN,O
to,TO,O
ribavirin,NNP,D
.,.,.
,,
copegus,NN,B
therapy,NN,O
is,VBZ,O
contraindicated,VBN,O
in,IN,O
women,NNS,O
who,WP,O
are,VBP,O
pregnant,JJ,O
and,CC,O
in,IN,O
the,DT,O
male,JJ,O
partners,NNS,O
of,IN,O
women,NNS,O
who,WP,O
are,VBP,O
pregnant,JJ,O
.,.,.
,,
if,IN,O
pregnancy,NN,O
occurs,VBZ,O
in,IN,O
a,DT,O
patient,NN,O
or,CC,O
partner,NN,O
of,IN,O
a,DT,O
patient,NN,O
during,IN,O
treatment,NN,O
or,CC,O
during,IN,O
the,DT,O
6,CD,O
months,NNS,O
after,IN,O
treatment,NN,O
cessation,NN,O
",",",",O
such,JJ,O
cases,NNS,O
should,MD,O
be,VB,O
reported,VBN,O
to,TO,O
the,DT,O
copegus,NNP,B
pregnancy,NNP,O
registry,NNP,O
at,IN,O
1-800-526-6367,CD,O
.,.,.
,,
nursing,NNP,O
mothers,NNP,O
it,PRP,O
is,VBZ,O
not,RB,O
known,VBN,O
whether,IN,O
peginterferon,NN,D
or,CC,O
ribavirin,NNP,D
or,CC,O
its,PRP$,O
components,NNS,O
are,VBP,O
excreted,VBN,O
in,IN,O
human,JJ,O
milk,NN,O
.,.,.
,,
the,DT,O
effect,NN,O
of,IN,O
orally,RB,O
ingested,VBN,O
peginterferon,NN,D
or,CC,O
ribavirin,NNP,D
from,IN,O
breast,NN,O
milk,NN,O
on,IN,O
the,DT,O
nursing,NN,O
infant,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
evaluated,VBN,O
.,.,.
,,
because,IN,O
of,IN,O
the,DT,O
potential,NN,O
for,IN,O
adverse,JJ,O
reactions,NNS,O
from,IN,O
the,DT,O
drugs,NNS,D
in,IN,O
nursing,NN,O
infants,NNS,O
",",",",O
a,DT,O
decision,NN,O
must,MD,O
be,VB,O
made,VBN,O
whether,IN,O
to,TO,O
discontinue,VB,O
nursing,NN,O
or,CC,O
discontinue,VB,O
pegasys,NN,B
and,CC,O
copegus,NN,B
treatment,NN,O
.,.,.
,,
pediatric,NNP,O
use,NNP,O
the,NNP,O
safety,NN,O
and,CC,O
effectiveness,NN,O
of,IN,O
pegasys,NNP,B
",",",",O
alone,RB,O
or,CC,O
in,IN,O
combination,NN,O
with,IN,O
copegus,NNS,B
in,IN,O
patients,NNS,O
below,IN,O
the,DT,O
age,NN,O
of,IN,O
18,CD,O
years,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
established,VBN,O
.,.,.
,,
pegasys,NN,B
contains,VBZ,O
benzyl,NN,O
alcohol,NN,D
.,.,.
,,
benzyl,NNP,O
alcohol,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
to,TO,O
be,VB,O
associated,VBN,O
with,IN,O
an,DT,O
increased,VBN,O
incidence,NN,O
of,IN,O
neurological,JJ,O
and,CC,O
other,JJ,O
complications,NNS,O
in,IN,O
neonates,NNS,O
and,CC,O
infants,NNS,O
",",",",O
which,WDT,O
are,VBP,O
sometimes,RB,O
fatal,JJ,O
.,.,.
,,
geriatric,NNP,O
use,NNP,O
younger,NNP,O
patients,NNS,O
have,VBP,O
higher,JJR,O
virologic,JJ,O
response,NN,O
rates,NNS,O
than,IN,O
older,JJR,O
patients,NNS,O
.,.,.
,,
clinical,JJ,O
studies,NNS,O
of,IN,O
pegasys,NN,B
alone,RB,O
or,CC,O
in,IN,O
combination,NN,O
with,IN,O
copegus,NNS,B
did,VBD,O
not,RB,O
include,VB,O
sufficient,JJ,O
numbers,NNS,O
of,IN,O
subjects,NNS,O
aged,JJ,O
65,CD,O
or,CC,O
over,IN,O
to,TO,O
determine,VB,O
whether,IN,O
they,PRP,O
respond,VBP,O
differently,RB,O
from,IN,O
younger,JJR,O
subjects,NNS,O
.,.,.
,,
adverse,JJ,O
reactions,NNS,O
related,VBN,O
to,TO,O
alpha,NN,O
interferons,NNS,O
",",",",O
such,JJ,O
as,IN,O
cns,NN,O
",",",",O
cardiac,JJ,O
",",",",O
and,CC,O
systemic,JJ,O
-lrb-,-LRB-,O
eg,FW,O
",",",",O
flu-like,JJ,O
-rrb-,-RRB-,O
effects,NNS,O
may,MD,O
be,VB,O
more,RBR,O
severe,JJ,O
in,IN,O
the,DT,O
elderly,JJ,O
and,CC,O
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
in,IN,O
the,DT,O
use,NN,O
of,IN,O
pegasys,NNP,B
in,IN,O
this,DT,O
population,NN,O
.,.,.
,,
pegasys,NNP,B
and,CC,O
copegus,NNP,B
are,VBP,O
excreted,VBN,O
by,IN,O
the,DT,O
kidney,NN,O
",",",",O
and,CC,O
the,DT,O
risk,NN,O
of,IN,O
toxic,JJ,O
reactions,NNS,O
to,TO,O
this,DT,O
therapy,NN,O
may,MD,O
be,VB,O
greater,JJR,O
in,IN,O
patients,NNS,O
with,IN,O
impaired,JJ,O
renal,JJ,O
function,NN,O
.,.,.
,,
because,IN,O
elderly,JJ,O
patients,NNS,O
are,VBP,O
more,RBR,O
likely,JJ,O
to,TO,O
have,VB,O
decreased,VBN,O
renal,JJ,O
function,NN,O
",",",",O
care,NN,O
should,MD,O
be,VB,O
taken,VBN,O
in,IN,O
dose,NN,O
selection,NN,O
and,CC,O
it,PRP,O
may,MD,O
be,VB,O
useful,JJ,O
to,TO,O
monitor,VB,O
renal,JJ,O
function,NN,O
.,.,.
,,
pegasys,NN,B
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
in,IN,O
patients,NNS,O
with,IN,O
creatinine,NN,O
clearance,NN,O
50,CD,O
ml/min,NN,O
and,CC,O
copegus,NN,B
should,MD,O
not,RB,O
be,VB,O
administered,VBN,O
to,TO,O
patients,NNS,O
with,IN,O
creatinine,NN,O
clearance,NN,O
50,CD,O
ml/mi,NN,O
.,.,.
,,
aminoglycosides,NNS,G
:,:,O
the,DT,O
mixing,VBG,O
of,IN,O
piperacillin,NN,D
with,IN,O
an,DT,O
aminoglycoside,NN,G
in,FW,O
vitro,FW,O
can,MD,O
result,VB,O
in,IN,O
substantial,JJ,O
inactivation,NN,O
of,IN,O
the,DT,O
aminoglycoside,NN,G
.,.,.
,,
vecuronium,NNP,D
:,:,O
when,WRB,O
used,VBN,O
in,IN,O
the,DT,O
perioperative,JJ,O
period,NN,O
",",",",O
piperacillin,NN,D
has,VBZ,O
been,VBN,O
implicated,VBN,O
in,IN,O
the,DT,O
prolongation,NN,O
of,IN,O
the,DT,O
neuromuscular,JJ,O
blockade,NN,O
of,IN,O
vecuronium,NN,D
.,.,.
,,
caution,NN,O
is,VBZ,O
indicated,VBN,O
when,WRB,O
piperacillin,NN,D
is,VBZ,O
used,VBN,O
perioperatively,RB,O
.,.,.
,,
in,IN,O
one,CD,O
controlled,JJ,O
clinical,JJ,O
study,NN,O
",",",",O
the,DT,O
ureidopenicillins,NNS,O
",",",",O
including,VBG,O
piperacillin,NN,D
",",",",O
were,VBD,O
reported,VBN,O
to,TO,O
prolong,VB,O
the,DT,O
action,NN,O
of,IN,O
vecuronium,NN,D
.,.,.
,,
due,JJ,O
to,TO,O
their,PRP$,O
similar,JJ,O
mechanism,NN,O
of,IN,O
action,NN,O
",",",",O
it,PRP,O
is,VBZ,O
expected,VBN,O
that,IN,O
the,DT,O
neuromuscular,JJ,O
blockade,NN,O
produced,VBN,O
by,IN,O
any,DT,O
of,IN,O
the,DT,O
non-depolarizing,JJ,O
muscle,NN,O
relaxants,NNS,O
could,MD,O
be,VB,O
prolonged,VBN,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
piperacillin,NN,D
.,.,.
,,
probenecid,NNP,D
:,:,O
the,DT,O
oral,JJ,O
combination,NN,O
of,IN,O
probenecid,NN,D
before,IN,O
intramuscular,JJ,O
injection,NN,O
of,IN,O
pipracil,NN,B
produces,VBZ,O
an,DT,O
increase,NN,O
in,IN,O
piperacillin,NN,D
peak,JJ,O
serum,NN,O
level,NN,O
of,IN,O
about,IN,O
30,CD,O
%,NN,O
.,.,.
,,
anticoagulants,NNPS,G
:,:,O
coagulation,NN,O
parameters,NNS,O
should,MD,O
be,VB,O
tested,VBN,O
more,RBR,O
frequently,RB,O
and,CC,O
monitored,VBD,O
regularly,RB,O
during,IN,O
simultaneous,JJ,O
administration,NN,O
of,IN,O
high,JJ,O
doses,NNS,O
of,IN,O
heparin,NN,D
",",",",O
oral,JJ,O
anticoagulants,NNS,G
",",",",O
or,CC,O
other,JJ,O
drugs,NNS,D
that,WDT,O
may,MD,O
affect,VB,O
the,DT,O
blood,NN,O
coagulation,NN,O
system,NN,O
or,CC,O
the,DT,O
thrombocyte,NN,O
function,NN,O
.,.,.
,,
methotrexate,NNP,D
:,:,O
piperacillin,NNP,O
sodium,NN,O
may,MD,O
reduce,VB,O
the,DT,O
excretion,NN,O
of,IN,O
methotrexate,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
serum,NN,O
levels,NNS,O
of,IN,O
methotrexate,NN,D
should,MD,O
be,VB,O
monitored,VBN,O
in,IN,O
patients,NNS,O
to,TO,O
avoid,VB,O
drug,NN,D
toxicity,NN,O
.,.,.
,,
drug/laboratory,JJ,O
test,NN,O
interactions,NNS,O
as,IN,O
with,IN,O
other,JJ,O
penicillins,NNS,D
",",",",O
the,DT,O
administration,NN,O
of,IN,O
pipracil,NN,B
may,MD,O
result,VB,O
in,IN,O
a,DT,O
false-positive,JJ,O
reaction,NN,O
for,IN,O
glucose,NN,O
in,IN,O
the,DT,O
urine,NN,O
using,VBG,O
a,DT,O
copper-reduction,NN,O
method,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
that,IN,O
glucose,NN,O
tests,NNS,O
based,VBN,O
on,IN,O
enzymatic,JJ,O
glucose,NN,O
oxidase,NN,O
reactions,NNS,O
be,VB,O
used,VBN,O
.,.,.
,,
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
positive,JJ,O
test,NN,O
results,NNS,O
using,VBG,O
the,DT,O
bio-rad,NNP,O
laboratories,NNPS,O
platelia,NNP,O
aspergillus,NNPS,O
eia,NN,O
test,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
piperacillin/tazobactam,NN,O
injection,NN,O
who,WP,O
were,VBD,O
subsequently,RB,O
found,VBN,O
to,TO,O
be,VB,O
free,JJ,O
of,IN,O
aspergillus,JJ,O
infection,NN,O
.,.,.
,,
cross-reactions,NNS,O
with,IN,O
non-aspergillus,JJ,O
polysaccharides,NNS,O
and,CC,O
polyfuranoses,NNS,O
with,IN,O
the,DT,O
bio-rad,NNP,O
laboratories,NNPS,O
platelia,NNP,O
aspergillus,NNPS,O
eia,NN,O
test,NN,O
have,VBP,O
been,VBN,O
reported,VBN,O
.,.,.
,,
therefore,RB,O
",",",",O
positive,JJ,O
test,NN,O
results,VBZ,O
in,IN,O
patients,NNS,O
receiving,VBG,O
piperacillin,NN,D
should,MD,O
be,VB,O
interpreted,VBN,O
cautiously,RB,O
and,CC,O
confirmed,VBN,O
by,IN,O
other,JJ,O
diagnostic,JJ,O
methods,NNS,O
.,.,.
,,
phenothiazines,NNS,G
-,:,O
taking,VBG,O
piperazine,NN,D
and,CC,O
a,DT,O
phenothiazine,NN,G
together,RB,O
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
convulsions,NNS,O
-lrb-,-LRB-,O
seizures,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
pyrantel,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
antiminth,NNP,D
-rrb-,-RRB-,O
-,:,O
taking,VBG,O
piperazine,NN,D
and,CC,O
pyrantel,NN,D
together,RB,O
may,MD,O
decrease,VB,O
the,DT,O
effects,NNS,O
of,IN,O
piperazine,NN,D
.,.,.
,,
ace,NN,O
inhibitors,NNS,O
:,:,O
reports,NNS,O
suggest,VBP,O
that,IN,O
nsaids,NNS,G
may,MD,O
diminish,VB,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
angiotensin,NN,O
converting,VBG,O
enzyme,NN,O
-lrb-,-LRB-,O
ace,NN,O
-rrb-,-RRB-,O
inhibitors,NNS,O
.,.,.
,,
in,IN,O
patients,NNS,O
with,IN,O
mild,JJ,O
to,TO,O
moderate,JJ,O
hypertension,NN,O
",",",",O
administration,NN,O
of,IN,O
25,CD,O
mg,NN,O
daily,NN,O
of,IN,O
vioxx,NN,B
with,IN,O
the,DT,O
ace,NN,O
inhibitor,NN,O
benazepril,NN,D
",",",",O
10,CD,O
to,TO,O
40,CD,O
mg,NN,O
for,IN,O
4,CD,O
weeks,NNS,O
",",",",O
was,VBD,O
associated,VBN,O
with,IN,O
an,DT,O
average,JJ,O
increase,NN,O
in,IN,O
mean,JJ,O
arterial,JJ,O
pressure,NN,O
of,IN,O
about,IN,O
3,CD,O
mm,NN,O
hg,NN,O
compared,VBN,O
to,TO,O
ace,NN,O
inhibitor,NN,O
alone,RB,O
.,.,.
,,
this,DT,O
interaction,NN,O
should,MD,O
be,VB,O
given,VBN,O
consideration,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
vioxx,NNP,B
concomitantly,RB,O
with,IN,O
ace,NN,O
inhibitors,NNS,O
.,.,.
,,
aspirin,NN,B
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
low-dose,JJ,O
aspirin,NN,B
with,IN,O
vioxx,NN,B
may,MD,O
result,VB,O
in,IN,O
an,DT,O
increased,VBN,O
rate,NN,O
of,IN,O
gi,NN,O
ulceration,NN,O
or,CC,O
other,JJ,O
complications,NNS,O
",",",",O
compared,VBN,O
to,TO,O
use,VB,O
of,IN,O
vioxx,NN,B
alone,RB,O
.,.,.
,,
in,IN,O
a,DT,O
12-week,JJ,O
endoscopy,NN,O
study,NN,O
conducted,VBN,O
in,IN,O
oa,NN,O
patients,NNS,O
there,EX,O
was,VBD,O
no,DT,O
difference,NN,O
in,IN,O
the,DT,O
cumulative,JJ,O
incidence,NN,O
of,IN,O
endoscopic,JJ,O
gastroduodenal,JJ,O
ulcers,NNS,O
in,IN,O
patients,NNS,O
taking,VBG,O
low-dose,JJ,O
-lrb-,-LRB-,O
81,CD,O
mg,NN,O
-rrb-,-RRB-,O
enteric,JJ,O
coated,JJ,O
aspirin,NN,B
plus,CC,O
vioxx,NN,B
25,CD,O
mg,NN,O
daily,RB,O
",",",",O
as,IN,O
compared,VBN,O
to,TO,O
those,DT,O
taking,VBG,O
ibuprofen,NN,D
2400,CD,O
mg,NN,O
daily,JJ,O
alone,RB,O
.,.,.
,,
patients,NNS,O
taking,VBG,O
low-dose,JJ,O
aspirin,NN,B
plus,CC,O
ibuprofen,NN,D
were,VBD,O
not,RB,O
studied,VBN,O
.,.,.
,,
at,IN,O
steady,JJ,O
state,NN,O
",",",",O
vioxx,NNP,B
50,CD,O
mg,NN,O
once,RB,O
daily,RB,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
anti-platelet,JJ,O
activity,NN,O
of,IN,O
low-dose,JJ,O
-lrb-,-LRB-,O
81,CD,O
mg,NN,O
once,RB,O
daily,JJ,O
-rrb-,-RRB-,O
aspirin,NN,B
",",",",O
as,IN,O
assessed,VBN,O
by,IN,O
ex,FW,O
vivo,FW,O
platelet,NN,O
aggregation,NN,O
and,CC,O
serum,NN,O
txb2,NN,O
generation,NN,O
in,IN,O
clotting,VBG,O
blood,NN,O
.,.,.
,,
because,IN,O
of,IN,O
its,PRP$,O
lack,NN,O
of,IN,O
platelet,NN,O
effects,NNS,O
",",",",O
vioxx,NNP,B
is,VBZ,O
not,RB,O
a,DT,O
substitute,NN,O
for,IN,O
aspirin,NN,B
for,IN,O
cardiovascular,JJ,O
prophylaxis,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
in,IN,O
patients,NNS,O
taking,VBG,O
vioxx,NNP,B
",",",",O
antiplatelet,JJ,O
therapies,NNS,O
should,MD,O
not,RB,O
be,VB,O
discontinued,VBN,O
and,CC,O
should,MD,O
be,VB,O
considered,VBN,O
in,IN,O
patients,NNS,O
with,IN,O
an,DT,O
indication,NN,O
for,IN,O
cardiovascular,JJ,O
prophylaxis,NN,O
.,.,.
,,
prospective,JJ,O
",",",",O
long-term,JJ,O
studies,NNS,O
on,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
vioxx,NNP,B
and,CC,O
aspirin,NN,B
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
cimetidine,NNP,D
:,:,O
co-administration,NN,O
with,IN,O
high,JJ,O
doses,NNS,O
of,IN,O
cimetidine,NN,D
-lsb-,-LRB-,O
800,CD,O
mg,NN,O
twice,RB,O
daily,JJ,O
-rsb-,-RRB-,O
increased,VBD,O
the,DT,O
cmax,NN,O
of,IN,O
rofecoxib,NN,D
by,IN,O
21,CD,O
%,NN,O
",",",",O
the,DT,O
auc0-120hr,NN,O
by,IN,O
23,CD,O
%,NN,O
and,CC,O
the,DT,O
t1/2,NN,O
by,IN,O
15,CD,O
%,NN,O
.,.,.
,,
these,DT,O
small,JJ,O
changes,NNS,O
are,VBP,O
not,RB,O
clinically,RB,O
significant,JJ,O
and,CC,O
no,DT,O
dose,NN,O
adjustment,NN,O
is,VBZ,O
necessary,JJ,O
.,.,.
,,
digoxin,NNP,D
:,:,O
rofecoxib,NNP,D
75,CD,O
mg,NN,O
once,RB,O
daily,RB,O
for,IN,O
11,CD,O
days,NNS,O
does,VBZ,O
not,RB,O
alter,VB,O
the,DT,O
plasma,NN,O
concentration,NN,O
profile,NN,O
or,CC,O
renal,JJ,O
elimination,NN,O
of,IN,O
digoxin,NN,D
after,IN,O
a,DT,O
single,JJ,O
0.5,CD,O
mg,NN,O
oral,JJ,O
dose,NN,O
.,.,.
,,
furosemide,NNP,D
:,:,O
clinical,JJ,O
studies,NNS,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
post-marketing,JJ,O
observations,NNS,O
",",",",O
have,VBP,O
shown,VBN,O
that,IN,O
nsaids,NNS,G
can,MD,O
reduce,VB,O
the,DT,O
natriuretic,JJ,O
effect,NN,O
of,IN,O
furosemide,NN,D
and,CC,O
thiazides,NNS,G
in,IN,O
some,DT,O
patients,NNS,O
.,.,.
,,
this,DT,O
response,NN,O
has,VBZ,O
been,VBN,O
attributed,VBN,O
to,TO,O
inhibition,NN,O
of,IN,O
renal,JJ,O
prostaglandin,NN,O
synthesis,NN,O
.,.,.
,,
ketoconazole,NN,D
:,:,O
ketoconazole,NN,D
400,CD,O
mg,NN,O
daily,RB,O
did,VBD,O
not,RB,O
have,VB,O
any,DT,O
clinically,RB,O
important,JJ,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
rofecoxib,NN,D
.,.,.
,,
lithium,NN,D
:,:,O
nsaids,NNS,G
have,VBP,O
produced,VBN,O
an,DT,O
elevation,NN,O
of,IN,O
plasma,NN,O
lithium,NN,D
levels,NNS,O
and,CC,O
a,DT,O
reduction,NN,O
in,IN,O
renal,JJ,O
lithium,NN,D
clearance,NN,O
.,.,.
,,
in,IN,O
post-marketing,JJ,O
experience,NN,O
there,EX,O
have,VBP,O
been,VBN,O
reports,NNS,O
of,IN,O
increases,NNS,O
in,IN,O
plasma,NN,O
lithium,NN,D
levels,NNS,O
.,.,.
,,
thus,RB,O
",",",",O
when,WRB,O
vioxx,NNP,B
and,CC,O
lithium,NN,D
are,VBP,O
administered,VBN,O
concurrently,RB,O
",",",",O
subjects,NNS,O
should,MD,O
be,VB,O
observed,VBN,O
carefully,RB,O
for,IN,O
signs,NNS,O
of,IN,O
lithium,NN,D
toxicity,NN,O
.,.,.
,,
methotrexate,NNP,D
vioxx,NNP,B
12.5,CD,O
",",",",O
25,CD,O
",",",",O
and,CC,O
50,CD,O
mg,NN,O
",",",",O
each,DT,O
dose,NN,O
administered,VBN,O
once,RB,O
daily,RB,O
for,IN,O
7,CD,O
days,NNS,O
",",",",O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
plasma,NN,O
concentration,NN,O
of,IN,O
methotrexate,NN,D
as,IN,O
measured,VBN,O
by,IN,O
auc0-24hr,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
single,JJ,O
weekly,JJ,O
methotrexate,NN,D
doses,NNS,O
of,IN,O
7.5,CD,O
to,TO,O
20,CD,O
mg,NN,O
for,IN,O
rheumatoid,JJ,O
arthritis,NN,O
.,.,.
,,
at,IN,O
higher,JJR,O
than,IN,O
recommended,VBN,O
doses,NNS,O
",",",",O
vioxx,NNP,B
75,CD,O
mg,NN,O
administered,VBN,O
once,RB,O
daily,RB,O
for,IN,O
10,CD,O
days,NNS,O
increased,VBN,O
plasma,NN,O
concentrations,NNS,O
by,IN,O
23,CD,O
%,NN,O
as,IN,O
measured,VBN,O
by,IN,O
auc0-24hr,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
methotrexate,NN,D
7.5,CD,O
to,TO,O
15,CD,O
mg/week,NN,O
for,IN,O
rheumatoid,JJ,O
arthritis,NN,O
.,.,.
,,
at,IN,O
24,CD,O
hours,NNS,O
postdose,NN,O
",",",",O
a,DT,O
similar,JJ,O
proportion,NN,O
of,IN,O
patients,NNS,O
treated,VBN,O
with,IN,O
methotrexate,NN,D
alone,RB,O
-lrb-,-LRB-,O
94,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
subsequently,RB,O
treated,VBN,O
with,IN,O
methotrexate,NN,D
co-administered,JJ,O
with,IN,O
75,CD,O
mg,NN,O
of,IN,O
rofecoxib,NN,D
-lrb-,-LRB-,O
88,CD,O
%,NN,O
-rrb-,-RRB-,O
had,VBD,O
methotrexate,NN,D
plasma,NN,O
concentrations,NNS,O
below,IN,O
the,DT,O
measurable,JJ,O
limit,NN,O
-lrb-,-LRB-,O
5,CD,O
ng/ml,NN,O
-rrb-,-RRB-,O
.,.,.
,,
standard,NNP,O
monitoring,NN,O
of,IN,O
methotrexate-related,JJ,O
toxicity,NN,O
should,MD,O
be,VB,O
continued,VBN,O
if,IN,O
vioxx,NNP,B
and,CC,O
methotrexate,NN,D
are,VBP,O
administered,VBN,O
concomitantly,RB,O
.,.,.
,,
oral,JJ,O
contraceptives,NNS,G
rofecoxib,NNP,D
did,VBD,O
not,RB,O
have,VB,O
any,DT,O
clinically,RB,O
important,JJ,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
ethinyl,NN,O
estradiol,NN,O
and,CC,O
norethindrone,NN,D
.,.,.
,,
prednisone/prednisolone,NNP,O
:,:,O
rofecoxib,NNP,D
did,VBD,O
not,RB,O
have,VB,O
any,DT,O
clinically,RB,O
important,JJ,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
prednisolone,NN,D
or,CC,O
prednisone,NN,D
.,.,.
,,
rifampin,NNP,D
:,:,O
co-administration,NN,O
of,IN,O
vioxx,NN,B
with,IN,O
rifampin,NN,D
600,CD,O
mg,NN,O
daily,RB,O
",",",",O
a,DT,O
potent,JJ,O
inducer,NN,O
of,IN,O
hepatic,JJ,O
metabolism,NN,O
",",",",O
produced,VBD,O
an,DT,O
approximate,JJ,O
50,CD,O
%,NN,O
decrease,NN,O
in,IN,O
rofecoxib,NN,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
therefore,RB,O
",",",",O
a,DT,O
starting,VBG,O
daily,JJ,O
dose,NN,O
of,IN,O
25,CD,O
mg,NN,O
of,IN,O
vioxx,NNP,B
should,MD,O
be,VB,O
considered,VBN,O
for,IN,O
the,DT,O
treatment,NN,O
of,IN,O
osteoarthritis,NN,O
when,WRB,O
vioxx,NNP,B
is,VBZ,O
co-administered,VBN,O
with,IN,O
potent,JJ,O
inducers,NNS,O
of,IN,O
hepatic,JJ,O
metabolism,NN,O
.,.,.
,,
theophylline,NNP,D
vioxx,NNP,B
12.5,CD,O
",",",",O
25,CD,O
",",",",O
and,CC,O
50,CD,O
mg,NN,O
administered,VBN,O
once,RB,O
daily,RB,O
for,IN,O
7,CD,O
days,NNS,O
increased,VBN,O
plasma,NN,O
theophylline,NN,D
concentrations,NNS,O
-lrb-,-LRB-,O
auc,NN,O
-lrb-,-LRB-,O
0,CD,O
-,:,O
-rrb-,-RRB-,O
-rrb-,-RRB-,O
by,IN,O
38,CD,O
to,TO,O
60,CD,O
%,NN,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
administered,VBN,O
a,DT,O
single,JJ,O
300-mg,JJ,O
dose,NN,O
of,IN,O
theophylline,NN,D
.,.,.
,,
adequate,JJ,O
monitoring,NN,O
of,IN,O
theophylline,NN,D
plasma,NN,O
concentrations,NNS,O
should,MD,O
be,VB,O
considered,VBN,O
when,WRB,O
therapy,NN,O
with,IN,O
vioxx,NN,B
is,VBZ,O
initiated,VBN,O
or,CC,O
changed,VBN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
theophylline,NN,D
.,.,.
,,
these,DT,O
data,NNS,O
suggest,VBP,O
that,IN,O
rofecoxib,NN,D
may,MD,O
produce,VB,O
a,DT,O
modest,JJ,O
inhibition,NN,O
of,IN,O
cytochrome,NN,O
p450,NN,O
-lrb-,-LRB-,O
cyp,NN,O
-rrb-,-RRB-,O
1a2,NN,O
.,.,.
,,
therefore,RB,O
",",",",O
there,EX,O
is,VBZ,O
a,DT,O
potential,NN,O
for,IN,O
an,DT,O
interaction,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
metabolized,VBN,O
by,IN,O
cyp,NN,O
1a2,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
amitriptyline,NNP,D
",",",",O
tacrine,NN,D
",",",",O
and,CC,O
zileuton,NN,D
-rrb-,-RRB-,O
.,.,.
,,
warfarin,NNP,D
:,:,O
anticoagulant,JJ,B
activity,NN,O
should,MD,O
be,VB,O
monitored,VBN,O
",",",",O
particularly,RB,O
in,IN,O
the,DT,O
first,JJ,O
few,JJ,O
days,NNS,O
after,IN,O
initiating,VBG,O
or,CC,O
changing,VBG,O
vioxx,NN,B
therapy,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
warfarin,NN,D
or,CC,O
similar,JJ,O
agents,NNS,O
",",",",O
since,IN,O
these,DT,O
patients,NNS,O
are,VBP,O
at,IN,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
bleeding,VBG,O
complications,NNS,O
.,.,.
,,
in,IN,O
single,JJ,O
and,CC,O
multiple,JJ,O
dose,NN,O
studies,NNS,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
receiving,VBG,O
both,CC,O
warfarin,NN,D
and,CC,O
rofecoxib,NN,D
",",",",O
prothrombin,NN,O
time,NN,O
-lrb-,-LRB-,O
measured,VBN,O
as,IN,O
inr,NN,O
-rrb-,-RRB-,O
was,VBD,O
increased,VBN,O
by,IN,O
approximately,RB,O
8,CD,O
%,NN,O
to,TO,O
11,CD,O
%,NN,O
.,.,.
,,
in,IN,O
post-marketing,JJ,O
experience,NN,O
",",",",O
bleeding,VBG,O
events,NNS,O
have,VBP,O
been,VBN,O
reported,VBN,O
",",",",O
predominantly,RB,O
in,IN,O
the,DT,O
elderly,JJ,O
",",",",O
in,IN,O
association,NN,O
with,IN,O
increases,NNS,O
in,IN,O
prothrombin,NN,O
time,NN,O
in,IN,O
patients,NNS,O
receiving,VBG,O
vioxx,NNP,B
concurrently,RB,O
with,IN,O
warfarin,NN,D
.,.,.
,,
drug,NN,O
interactions,NNS,O
.,.,.
,,
several,JJ,O
drug,NN,D
interaction,NN,O
studies,NNS,O
have,VBP,O
been,VBN,O
completed,VBN,O
with,IN,O
both,CC,O
invirase,NN,B
and,CC,O
fortovase,NN,B
.,.,.
,,
observations,NNS,O
from,IN,O
drug,NN,D
interaction,NN,O
studies,NNS,O
with,IN,O
fortovase,NN,B
may,MD,O
not,RB,O
be,VB,O
predictive,JJ,O
for,IN,O
invirase,NNP,B
.,.,.
,,
because,IN,O
ritonavir,NN,D
is,VBZ,O
coadministered,VBN,O
",",",",O
prescribers,NNS,O
should,MD,O
also,RB,O
refer,VB,O
to,TO,O
the,DT,O
prescribing,VBG,O
information,NN,O
for,IN,O
ritonavir,NN,D
regarding,VBG,O
drug,NN,D
interactions,NNS,O
associated,VBN,O
with,IN,O
this,DT,O
agent,NN,O
.,.,.
,,
the,DT,O
metabolism,NN,O
of,IN,O
saquinavir,NN,D
is,VBZ,O
mediated,VBN,O
by,IN,O
cytochrome,NN,O
p450,NN,O
",",",",O
with,IN,O
the,DT,O
specific,JJ,O
isoenzyme,NN,O
cyp3a4,NN,D
responsible,JJ,O
for,IN,O
90,CD,O
%,NN,O
of,IN,O
the,DT,O
hepatic,JJ,O
metabolism,NN,O
.,.,.
,,
additionally,RB,O
",",",",O
saquinavir,NN,D
is,VBZ,O
a,DT,O
substrate,NN,O
for,IN,O
p-glycoprotein,NN,O
-lrb-,-LRB-,O
pgp,NN,O
-rrb-,-RRB-,O
.,.,.
,,
therefore,RB,O
",",",",O
drugs,NNS,D
that,WDT,O
affect,VBP,O
cyp3a4,NN,D
and/or,CC,O
pgp,NN,O
",",",",O
may,MD,O
modify,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
saquinavir,NN,D
.,.,.
,,
similarly,RB,O
",",",",O
saquinavir,NN,D
might,MD,O
also,RB,O
modify,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
other,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
substrates,NNS,O
for,IN,O
cyp3a4,NN,D
or,CC,O
pgp,NN,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
are,VBP,O
contraindicated,VBN,O
specifically,RB,O
due,JJ,O
to,TO,O
the,DT,O
expected,VBN,O
magnitude,NN,O
of,IN,O
interaction,NN,O
and,CC,O
potential,NN,O
for,IN,O
serious,JJ,O
adverse,JJ,O
events,NNS,O
are,VBP,O
listed,VBN,O
contraindications,NNS,O
.,.,.
,,
additional,JJ,O
drugs,NNS,D
that,WDT,O
are,VBP,O
not,RB,O
recommended,VBN,O
for,IN,O
coadministration,NN,O
with,IN,O
invirase,NN,B
and,CC,O
ritonavir,NN,D
are,VBP,O
included,VBN,O
below,IN,O
.,.,.
,,
these,DT,O
recommendations,NNS,O
are,VBP,O
based,VBN,O
on,IN,O
either,CC,O
drug,NN,D
interaction,NN,O
studies,NNS,O
or,CC,O
predicted,VBN,O
interactions,NNS,O
due,JJ,O
to,TO,O
the,DT,O
expected,VBN,O
magnitude,NN,O
of,IN,O
interaction,NN,O
and,CC,O
potential,NN,O
for,IN,O
serious,JJ,O
events,NNS,O
or,CC,O
loss,NN,O
of,IN,O
efficacy,NN,O
.,.,.
,,
with,IN,O
some,DT,O
agents,NNS,O
",",",",O
the,DT,O
metabolism,NN,O
may,MD,O
be,VB,O
induced,VBN,O
",",",",O
resulting,VBG,O
in,IN,O
decreased,VBN,O
concentrations,NNS,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
should,MD,O
not,RB,O
be,VB,O
coadministered,JJ,O
with,IN,O
invirase/ritonavi,NN,O
.,.,.
,,
drug,NN,O
class,NN,O
:,:,O
drug,NNP,O
name,VB,O
clinical,JJ,O
comment,NN,O
.,.,.
,,
antiarrhythmics,NNS,G
:,:,O
amiodarone,NNP,D
",",",",O
bepridil,NN,D
",",",",O
flecainide,NN,D
",",",",O
propafenone,NN,D
",",",",O
quinidine,NN,D
contraindicated,NNP,O
due,JJ,O
to,TO,O
potential,JJ,O
for,IN,O
serious,JJ,O
and/or,CC,O
life-threatening,JJ,O
reactions,NNS,O
.,.,.
,,
antihistamines,NNS,D
:,:,O
astemizole,NN,D
*,NN,O
",",",",O
terfenadine,NN,D
*,SYM,O
contraindicated,NNP,O
due,JJ,O
to,TO,O
potential,JJ,O
for,IN,O
serious,JJ,O
and/or,CC,O
life-threatening,JJ,O
cardiac,JJ,O
arrhythmias,NNS,O
.,.,.
,,
ergot,NNP,G
derivatives,NNPS,O
:,:,O
dihydroergotamine,NN,D
",",",",O
ergonovine,NN,D
",",",",O
ergotamine,NN,D
",",",",O
methylergonovine,NN,D
contraindicated,NNP,O
due,JJ,O
to,TO,O
potential,JJ,O
for,IN,O
serious,JJ,O
and,CC,O
life-threatening,JJ,O
reactions,NNS,O
such,JJ,O
as,IN,O
acute,JJ,O
ergot,NN,G
toxicity,NN,O
characterized,VBN,O
by,IN,O
peripheral,JJ,O
vasospasm,NN,O
and,CC,O
ischemia,NN,O
of,IN,O
the,DT,O
extremities,NNS,O
and,CC,O
other,JJ,O
tissues,NNS,O
.,.,.
,,
antimycobacterial,JJ,G
agents,NNS,O
:,:,O
rifampin,NN,D
contraindicated,NNP,O
since,IN,O
the,DT,O
coadministration,NN,O
of,IN,O
this,DT,O
product,NN,O
with,IN,O
saquinavir,NN,D
in,IN,O
an,DT,O
antiretroviral,JJ,G
regimen,NN,O
reduces,VBZ,O
the,DT,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
saquinavir,NN,D
.,.,.
,,
garlic,NNP,O
capsules,NNPS,O
garlic,NNP,O
capsules,NNS,O
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
while,IN,O
taking,VBG,O
saquinavir,NN,D
-lrb-,-LRB-,O
fortovase,NN,B
-rrb-,-RRB-,O
as,IN,O
the,DT,O
sole,JJ,O
protease,NN,O
inhibitor,NN,O
due,JJ,O
to,TO,O
the,DT,O
risk,NN,O
of,IN,O
decreased,VBN,O
saquinavir,NN,D
plasma,NN,O
concentrations,NNS,O
.,.,.
,,
no,DT,O
data,NNS,O
are,VBP,O
available,JJ,O
for,IN,O
the,DT,O
coadministration,NN,O
of,IN,O
invirase/ritonavir,NN,O
or,CC,O
fortovase/ritonavir,NN,O
and,CC,O
garlic,JJ,O
capsules,NNS,O
.,.,.
,,
gi,NN,O
motility,NN,O
agent,NNP,O
:,:,O
cisapride,NN,D
*,SYM,O
contraindicated,NNP,O
due,JJ,O
to,TO,O
potential,JJ,O
for,IN,O
serious,JJ,O
and/or,CC,O
life-threatening,JJ,O
reactions,NNS,O
such,JJ,O
as,IN,O
cardiac,JJ,O
arrhythmias,NNS,O
.,.,.
,,
herbal,NNP,O
products,NNPS,O
:,:,O
st.,NNP,O
john,NNP,O
s,VBZ,O
wort,NN,O
-lrb-,-LRB-,O
hypericum,NN,O
perforatum,NN,O
-rrb-,-RRB-,O
warning,NN,O
coadministration,NN,O
may,MD,O
lead,VB,O
to,TO,O
loss,NN,O
of,IN,O
virologic,JJ,O
response,NN,O
and,CC,O
possible,JJ,O
resistance,NN,O
to,TO,O
invirase,NNP,B
or,CC,O
to,TO,O
the,DT,O
class,NN,O
of,IN,O
protease,NN,O
inhibitors,NNS,O
.,.,.
,,
hmg-coa,NN,O
reductase,NN,O
inhibitors,NNS,O
:,:,O
lovastatin,NN,D
",",",",O
simvastatin,NN,D
warning,NNP,O
potential,NN,O
for,IN,O
serious,JJ,O
reactions,NNS,O
such,JJ,O
as,IN,O
risk,NN,O
of,IN,O
myopathy,NN,O
including,VBG,O
rhabdomyolysis,NN,O
.,.,.
,,
sedatives/hypnotics,NNS,O
:,:,O
triazolam,NN,D
",",",",O
midazolam,NN,D
contraindicated,NNP,O
due,JJ,O
to,TO,O
potential,JJ,O
for,IN,O
serious,JJ,O
and/or,CC,O
life-threatening,JJ,O
reactions,NNS,O
such,JJ,O
as,IN,O
prolonged,JJ,O
or,CC,O
increased,VBN,O
sedation,NN,O
or,CC,O
respiratory,JJ,O
depression,NN,O
.,.,.
,,
*,SYM,O
no,DT,O
longer,RBR,O
marketed,VBN,O
in,IN,O
the,DT,O
us,NNP,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
are,VBP,O
mainly,RB,O
metabolized,VBN,O
by,IN,O
cyp3a4,NN,D
.,.,.
,,
although,IN,O
specific,JJ,O
studies,NNS,O
have,VBP,O
not,RB,O
been,VBN,O
performed,VBN,O
",",",",O
coadministration,NN,O
with,IN,O
drugs,NNS,D
that,WDT,O
are,VBP,O
mainly,RB,O
metabolized,VBN,O
by,IN,O
cyp3a4,NN,D
-lrb-,-LRB-,O
eg,FW,O
",",",",O
calcium,NN,D
channel,NN,O
blockers,NNS,O
",",",",O
dapsone,NN,D
",",",",O
disopyramide,NN,D
",",",",O
quinine,NN,D
",",",",O
amiodarone,NN,D
",",",",O
quinidine,NN,D
",",",",O
warfarin,NN,D
",",",",O
tacrolimus,NN,D
",",",",O
cyclosporine,NN,D
",",",",O
ergot,NN,G
derivatives,NNS,O
",",",",O
pimozide,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
fentanyl,NN,D
",",",",O
alfentanyl,NN,D
",",",",O
alprazolam,NN,D
",",",",O
and,CC,O
triazolam,NN,D
-rrb-,-RRB-,O
may,MD,O
have,VB,O
elevated,JJ,O
plasma,NN,O
concentrations,NNS,O
when,WRB,O
coadministered,VBN,O
with,IN,O
saquinavir,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
these,DT,O
combinations,NNS,O
should,MD,O
be,VB,O
used,VBN,O
with,IN,O
caution,NN,O
.,.,.
,,
since,IN,O
invirase,NNP,B
is,VBZ,O
coadministered,VBN,O
with,IN,O
ritonavir,NN,D
",",",",O
the,DT,O
ritonavir,NN,D
label,NN,O
should,MD,O
be,VB,O
reviewed,VBN,O
for,IN,O
additional,JJ,O
drugs,NNS,D
that,WDT,O
should,MD,O
not,RB,O
be,VB,O
coadministered,VBN,O
.,.,.
,,
inducers,NNS,O
of,IN,O
cyp3a4,NN,D
.,.,.
,,
coadministration,NN,O
with,IN,O
compounds,NNS,O
that,WDT,O
are,VBP,O
potent,JJ,O
inducers,NNS,O
of,IN,O
cyp3a4,NN,D
-lrb-,-LRB-,O
eg,FW,O
",",",",O
phenobarbital,JJ,D
",",",",O
phenytoin,NN,D
",",",",O
dexamethasone,NN,D
",",",",O
carbamazepine,NN,D
-rrb-,-RRB-,O
may,MD,O
result,VB,O
in,IN,O
decreased,VBN,O
plasma,NN,O
levels,NNS,O
of,IN,O
saquinavir,NN,D
.,.,.
,,
sulfacetamide,NN,D
preparations,NNS,O
are,VBP,O
incompatible,JJ,O
with,IN,O
silver,NN,D
preparations,NNS,O
.,.,.
,,
interations,NNS,O
.,.,.
,,
sulfapyridine,NN,D
may,MD,O
interact,VB,O
with,IN,O
any,DT,O
of,IN,O
the,DT,O
following,NN,O
:,:,O
-,:,O
acetaminophen,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
tylenol,NNP,B
-rrb-,-RRB-,O
-lrb-,-LRB-,O
with,IN,O
long-term,JJ,O
",",",",O
high-dose,JJ,O
use,NN,O
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
amiodarone,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
cordarone,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
anabolic,JJ,O
steroids,NNS,G
-lrb-,-LRB-,O
nandrolone,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
anabolin,NNP,B
-rsb-,-RRB-,O
",",",",O
oxandrolone,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
anavar,JJ,B
-rsb-,-RRB-,O
",",",",O
oxymetholone,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
anadrol,NNP,B
-rsb-,-RRB-,O
",",",",O
stanozolol,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
winstrol,NNP,B
-rsb-,-RRB-,O
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
androgens,NNS,G
-lrb-,-LRB-,O
male,JJ,O
hormones,NNS,O
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
antithyroid,JJ,O
agents,NNS,O
-lrb-,-LRB-,O
medicine,NN,O
for,IN,O
overactive,JJ,O
thyroid,NN,G
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
carbamazepine,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
tegretol,NNP,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
carmustine,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
bicnu,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
chloroquine,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
aralen,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
dantrolene,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
dantrium,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
daunorubicin,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
cerubidine,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
disulfiram,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
antabuse,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
divalproex,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
depakote,NNP,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
estrogens,NNS,G
-lrb-,-LRB-,O
female,JJ,O
hormones,NNS,O
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
etretinate,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
tegison,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
gold,NN,D
salts,NNS,O
-lrb-,-LRB-,O
medicine,NN,O
for,IN,O
arthritis,NN,O
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
hydroxychloroquine,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
plaquenil,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
mercaptopurine,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
purinethol,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
naltrexone,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
trexan,NN,B
-rrb-,-RRB-,O
-lrb-,-LRB-,O
with,IN,O
long-term,JJ,O
",",",",O
high-dose,JJ,O
use,NN,O
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
oral,JJ,O
contraceptives,NNS,G
-lrb-,-LRB-,O
birth,NN,O
control,NN,O
pills,NNS,O
-rrb-,-RRB-,O
containing,VBG,O
estrogen,NN,G
o.,SYM,O
-,:,O
other,JJ,O
anti-infectives,NNS,G
by,IN,O
mouth,NN,O
or,CC,O
by,IN,O
injection,NN,O
-lrb-,-LRB-,O
medicine,NN,O
for,IN,O
infection,NN,O
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
phenothiazines,NNS,G
-lrb-,-LRB-,O
acetophenazine,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
tindal,JJ,B
-rsb-,-RRB-,O
",",",",O
chlorpromazine,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
thorazine,NN,B
-rsb-,-RRB-,O
",",",",O
fluphenazine,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
prolixin,NN,B
-rsb-,-RRB-,O
",",",",O
mesoridazine,NN,B
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
serentil,NN,B
-rsb-,-RRB-,O
",",",",O
perphenazine,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
trilafon,NNP,B
-rsb-,-RRB-,O
",",",",O
prochlorperazine,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
compazine,NN,B
-rsb-,-RRB-,O
",",",",O
promazine,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
sparine,JJ,B
-rsb-,-RRB-,O
",",",",O
promethazine,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
phenergan,NN,B
-rsb-,-RRB-,O
",",",",O
thioridazine,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
mellaril,NN,B
-rsb-,-RRB-,O
",",",",O
trifluoperazine,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
stelazine,NN,B
-rsb-,-RRB-,O
",",",",O
triflupromazine,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
vesprin,NN,B
-rsb-,-RRB-,O
",",",",O
trimeprazine,NN,D
-lsb-,-LRB-,O
e.g.,FW,O
",",",",O
temaril,NN,B
-rsb-,-RRB-,O
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
plicamycin,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
mithracin,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
valproic,JJ,O
acid,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
depakene,NN,B
-rrb-,-RRB-,O
use,NN,O
of,IN,O
sulfapyridine,NN,D
with,IN,O
these,DT,O
medicines,NNS,O
may,MD,O
increase,VB,O
the,DT,O
chance,NN,O
of,IN,O
side,JJ,O
effects,NNS,O
affecting,VBG,O
the,DT,O
live,JJ,O
.,.,.
,,
-,:,O
acetohydroxamic,JJ,O
acid,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
lithostat,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
dapsone,NN,D
o.,SYM,O
-,:,O
furazolidone,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
furoxone,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
nitrofurantoin,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
furadantin,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
primaquine,NN,D
o.,SYM,O
-,:,O
procainamide,NNP,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
pronestyl,NNP,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
quinidine,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
quinidex,NNP,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
quinine,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
quinamm,NNP,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
sulfoxone,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
diasone,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
vitamin,NN,O
k,NN,O
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
aquamephyton,NN,B
",",",",O
synkayvite,NN,B
-rrb-,-RRB-,O
use,NN,O
of,IN,O
sulfapyridine,NN,D
with,IN,O
these,DT,O
medicines,NNS,O
may,MD,O
increase,VB,O
the,DT,O
chance,NN,O
of,IN,O
side,JJ,O
effects,NNS,O
affecting,VBG,O
the,DT,O
bloo,NN,O
.,.,.
,,
-,:,O
anticoagulants,NNS,G
-lrb-,-LRB-,O
blood,NN,O
thinners,NNS,O
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
ethotoin,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
peganone,NN,B
-rrb-,-RRB-,O
o.,SYM,O
-,:,O
mephenytoin,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
mesantoin,NN,B
-rrb-,-RRB-,O
use,NN,O
of,IN,O
sulfapyridine,NN,D
with,IN,O
these,DT,O
medicines,NNS,O
may,MD,O
increase,VB,O
the,DT,O
chance,NN,O
of,IN,O
side,JJ,O
effects,NNS,O
of,IN,O
these,DT,O
medicine,NN,O
.,.,.
,,
-,:,O
antidiabetics,NNS,G
",",",",O
oral,JJ,O
-lrb-,-LRB-,O
diabetes,NN,O
medicine,NN,O
you,PRP,O
take,VBP,O
by,IN,O
mouth,NN,O
-rrb-,-RRB-,O
use,NN,O
of,IN,O
oral,JJ,O
antidiabetics,NNS,G
with,IN,O
sulfapyridine,NN,D
may,MD,O
increase,VB,O
the,DT,O
chance,NN,O
of,IN,O
side,JJ,O
effects,NNS,O
affecting,VBG,O
the,DT,O
blood,NN,O
and/or,CC,O
the,DT,O
side,JJ,O
effects,NNS,O
or,CC,O
oral,JJ,O
antidiabetic,JJ,D
.,.,.
,,
-,:,O
methotrexate,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
mexate,NN,B
-rrb-,-RRB-,O
use,NN,O
of,IN,O
methotrexate,NN,D
with,IN,O
sulfapyridine,NN,D
may,MD,O
increase,VB,O
the,DT,O
chance,NN,O
of,IN,O
side,JJ,O
effects,NNS,O
affecting,VBG,O
the,DT,O
liver,NN,O
and/or,CC,O
the,DT,O
side,JJ,O
effects,NNS,O
of,IN,O
methotrexat,NN,O
.,.,.
,,
-,:,O
methyldopa,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
aldomet,NNP,B
-rrb-,-RRB-,O
use,NN,O
of,IN,O
methyldopa,NN,D
with,IN,O
sulfapyridine,NN,D
may,MD,O
increase,VB,O
the,DT,O
chance,NN,O
of,IN,O
side,JJ,O
effects,NNS,O
affecting,VBG,O
the,DT,O
liver,NN,O
and/or,CC,O
the,DT,O
bloo,NN,O
.,.,.
,,
-,:,O
phenytoin,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
dilantin,NNP,B
-rrb-,-RRB-,O
use,NN,O
of,IN,O
phenytoin,NN,D
with,IN,O
sulfapyridine,NN,D
may,MD,O
increase,VB,O
the,DT,O
chance,NN,O
of,IN,O
side,JJ,O
effects,NNS,O
affecting,VBG,O
the,DT,O
liver,NN,O
and/or,CC,O
the,DT,O
side,JJ,O
effects,NNS,O
of,IN,O
phenytoi,NN,O
.,.,.
,,
in,IN,O
evaluating,VBG,O
the,DT,O
potential,NN,O
for,IN,O
interactions,NNS,O
among,IN,O
co-administered,JJ,O
antiepilepsy,JJ,O
drugs,NNS,D
-lrb-,-LRB-,O
aeds,NNS,G
-rrb-,-RRB-,O
",",",",O
whether,IN,O
or,CC,O
not,RB,O
an,DT,O
aed,NN,G
induces,VBZ,O
or,CC,O
does,VBZ,O
not,RB,O
induce,VB,O
metabolic,JJ,O
enzymes,NNS,O
is,VBZ,O
an,DT,O
important,JJ,O
consideration,NN,O
.,.,.
,,
phenytoin,NNP,D
",",",",O
phenobarbital,JJ,D
and,CC,O
carbamazepine,NN,D
are,VBP,O
ge,NN,O
nerally,RB,O
classified,VBN,O
as,IN,O
enzyme,NN,O
inducers,NNS,O
.,.,.
,,
valproate,NN,D
and,CC,O
gabapentin,NN,D
are,VBP,O
not,RB,O
.,.,.
,,
gabitril,NNP,B
is,VBZ,O
considered,VBN,O
to,TO,O
be,VB,O
a,DT,O
non-enzyme,JJ,O
inducing,VBG,O
aed,NN,G
.,.,.
,,
the,DT,O
drug,NN,D
interaction,NN,O
data,NNS,O
described,VBN,O
in,IN,O
this,DT,O
section,NN,O
were,VBD,O
obtained,VBN,O
from,IN,O
studies,NNS,O
involving,VBG,O
either,CC,O
healthy,JJ,O
subjects,NNS,O
or,CC,O
patients,NNS,O
with,IN,O
epilepsy,NN,O
.,.,.
,,
effects,NNS,O
of,IN,O
gabitril,NN,B
on,IN,O
other,JJ,O
antiepilepsy,NNP,O
drugs,NNS,O
-lrb-,-LRB-,O
aeds,NNS,G
-rrb-,-RRB-,O
:,:,O
phenytoin,NNP,D
:,:,O
tiagabine,NNP,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
steady-state,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
phenytoin,NN,D
in,IN,O
patients,NNS,O
with,IN,O
epilepsy,NN,O
.,.,.
,,
carbamazepine,NNP,D
:,:,O
tiagabine,NNP,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
steady-state,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
carbamazepine,NN,D
or,CC,O
its,PRP$,O
epoxide,NN,O
metabolite,NN,O
in,IN,O
patients,NNS,O
with,IN,O
epilepsy,NN,O
.,.,.
,,
valproate,NNP,D
:,:,O
tiagabine,NNP,D
causes,VBZ,O
a,DT,O
slight,JJ,O
decrease,NN,O
-lrb-,-LRB-,O
about,IN,O
10,CD,O
%,NN,O
-rrb-,-RRB-,O
in,IN,O
steady-state,JJ,O
valproate,NN,D
concentrations,NNS,O
.,.,.
,,
phenobarbital,NNP,D
or,CC,O
primidone,NNP,D
:,:,O
no,NNP,O
formal,JJ,O
pharmacokinetic,JJ,O
studies,NNS,O
have,VBP,O
been,VBN,O
performed,VBN,O
examining,VBG,O
the,DT,O
addition,NN,O
of,IN,O
tiagabine,NN,D
to,TO,O
regimens,NNS,O
containing,VBG,O
phenobarbital,NN,D
or,CC,O
primidone,NN,D
.,.,.
,,
the,DT,O
addition,NN,O
of,IN,O
tiagabine,NN,D
in,IN,O
a,DT,O
limited,JJ,O
number,NN,O
of,IN,O
patients,NNS,O
in,IN,O
three,CD,O
well-controlled,JJ,O
studies,NNS,O
caused,VBD,O
no,DT,O
systematic,JJ,O
changes,NNS,O
in,IN,O
phenobarbital,NN,D
or,CC,O
primidone,NN,D
concentrations,NNS,O
when,WRB,O
compared,VBN,O
to,TO,O
placebo,NN,O
.,.,.
,,
effects,NNS,O
of,IN,O
other,JJ,O
antiepilepsy,NNP,O
drugs,NNS,O
-lrb-,-LRB-,O
aeds,NNS,G
-rrb-,-RRB-,O
on,IN,O
gabitril,NNP,B
:,:,O
carbamazepine,NNP,D
:,:,O
population,NNP,O
pharmacokinetic,JJ,O
analyses,NNS,O
indicate,VBP,O
that,IN,O
tiagabine,NN,D
clearance,NN,O
is,VBZ,O
60,CD,O
%,NN,O
greater,JJR,O
in,IN,O
patients,NNS,O
taking,VBG,O
carbamazepine,NN,D
with,IN,O
or,CC,O
without,IN,O
other,JJ,O
enzyme,NN,O
-,:,O
inducing,VBG,O
aeds,NNS,G
.,.,.
,,
phenytoin,NNP,D
:,:,O
population,NNP,O
pharmacokinetic,JJ,O
analyses,NNS,O
indicate,VBP,O
that,IN,O
tiagabine,NN,D
clearance,NN,O
is,VBZ,O
60,CD,O
%,NN,O
greater,JJR,O
in,IN,O
patients,NNS,O
taking,VBG,O
phenytoin,NN,D
with,IN,O
or,CC,O
without,IN,O
other,JJ,O
enzyme,NN,O
-,:,O
inducing,VBG,O
aeds,NNS,G
.,.,.
,,
phenobarbital,NNP,D
-lrb-,-LRB-,O
primidone,NNP,D
-rrb-,-RRB-,O
:,:,O
population,NNP,O
pharmacokinetic,JJ,O
analyses,NNS,O
indicate,VBP,O
that,IN,O
tiagabine,NN,D
clearance,NN,O
is,VBZ,O
60,CD,O
%,NN,O
greater,JJR,O
in,IN,O
patients,NNS,O
taking,VBG,O
phenobarbital,JJ,D
-lrb-,-LRB-,O
primidone,NN,D
-rrb-,-RRB-,O
with,IN,O
or,CC,O
without,IN,O
other,JJ,O
enzyme-inducing,JJ,O
aeds,NNS,G
.,.,.
,,
valproate,NNP,D
:,:,O
the,DT,O
addition,NN,O
of,IN,O
tiagabine,NN,D
to,TO,O
patients,NNS,O
taking,VBG,O
valproate,NN,D
chronically,RB,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
tiagabine,NN,D
pharmacokinetics,NNS,O
",",",",O
but,CC,O
valproate,NN,D
significantly,RB,O
decreased,VBD,O
tiagabine,NN,D
binding,NN,O
in,FW,O
vitro,FW,O
from,IN,O
96.3,CD,O
to,TO,O
94.8,CD,O
%,NN,O
",",",",O
which,WDT,O
resulted,VBD,O
in,IN,O
an,DT,O
increase,NN,O
of,IN,O
approximately,RB,O
40,CD,O
%,NN,O
in,IN,O
the,DT,O
free,JJ,O
tiagabine,NN,D
concentration,NN,O
.,.,.
,,
the,DT,O
clinical,JJ,O
relevance,NN,O
of,IN,O
this,DT,O
in,FW,O
vitro,FW,O
finding,NN,O
is,VBZ,O
unknown,JJ,O
.,.,.
,,
interaction,NN,O
of,IN,O
gabitril,NN,B
with,IN,O
other,JJ,O
drugs,NNS,O
:,:,O
cimetidine,NNP,D
:,:,O
co-administration,NN,O
of,IN,O
cimetidine,NN,D
-lrb-,-LRB-,O
800,CD,O
mg/day,NN,O
-rrb-,-RRB-,O
to,TO,O
patients,NNS,O
taking,VBG,O
tiagabine,JJ,D
chronically,RB,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
tiagabine,NN,D
pharmacokinetics,NNS,O
.,.,.
,,
theophylline,NNP,D
:,:,O
a,NNP,O
single,JJ,O
10,CD,O
mg,NN,O
dose,NN,O
of,IN,O
tiagabine,NN,D
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
theophylline,NN,D
at,IN,O
steady,JJ,O
state,NN,O
.,.,.
,,
warfarin,NNP,D
:,:,O
no,NNP,O
significant,JJ,O
differences,NNS,O
were,VBD,O
observed,VBN,O
in,IN,O
the,DT,O
steady-state,JJ,O
pharmacokinetics,NNS,O
of,IN,O
r-warfarin,NN,D
or,CC,O
s-warfarin,NN,D
with,IN,O
the,DT,O
addition,NN,O
of,IN,O
tiagabine,NN,D
given,VBN,O
as,IN,O
a,DT,O
single,JJ,O
dose,NN,O
.,.,.
,,
prothrombin,NNP,O
times,NNS,O
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
tiagabine,NN,D
.,.,.
,,
digoxin,NNP,D
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
tiagabine,NN,D
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
steady-state,JJ,O
pharmacokinetics,NNS,O
of,IN,O
digoxin,NN,D
or,CC,O
the,DT,O
mean,JJ,O
daily,JJ,O
trough,NN,O
serum,NN,O
level,NN,O
of,IN,O
digoxin,NN,D
.,.,.
,,
ethanol,NN,D
or,CC,O
triazolam,NN,D
:,:,O
no,DT,O
significant,JJ,O
differences,NNS,O
were,VBD,O
observed,VBN,O
in,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
triazolam,NN,D
-lrb-,-LRB-,O
0.125,CD,O
mg,NN,O
-rrb-,-RRB-,O
and,CC,O
tiagabine,NN,D
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
-rrb-,-RRB-,O
when,WRB,O
given,VBN,O
together,RB,O
as,IN,O
a,DT,O
single,JJ,O
dose,NN,O
.,.,.
,,
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
ethanol,NN,D
were,VBD,O
not,RB,O
affected,VBN,O
by,IN,O
multiple-dose,JJ,O
administration,NN,O
of,IN,O
tiagabine,NN,D
.,.,.
,,
tiagabine,NNP,D
has,VBZ,O
shown,VBN,O
no,DT,O
clinically,RB,O
important,JJ,O
potentiation,NN,O
of,IN,O
the,DT,O
pharmacodynamic,JJ,O
effects,NNS,O
of,IN,O
triazo,NN,O
lam,NN,O
or,CC,O
alcohol,NN,D
.,.,.
,,
because,IN,O
of,IN,O
the,DT,O
possible,JJ,O
additive,JJ,O
effects,NNS,O
of,IN,O
drugs,NNS,D
that,WDT,O
may,MD,O
depress,VB,O
the,DT,O
nervous,JJ,O
system,NN,O
",",",",O
ethanol,NN,D
or,CC,O
triazolam,NN,D
should,MD,O
be,VB,O
used,VBN,O
cautiously,RB,O
in,IN,O
combination,NN,O
with,IN,O
tiagabine,NN,D
.,.,.
,,
oral,JJ,O
contraceptives,NNS,G
:,:,O
multiple,JJ,O
dose,NN,O
administration,NN,O
of,IN,O
tiagabine,NN,D
-lrb-,-LRB-,O
8,CD,O
mg/day,NN,O
monotherapy,NN,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
oral,JJ,O
contraceptives,NNS,G
in,IN,O
healthy,JJ,O
women,NNS,O
of,IN,O
childbearing,JJ,O
age,NN,O
.,.,.
,,
antipyrine,NNP,D
:,:,O
antipyrine,NNP,D
pharmacokinetics,NNS,O
were,VBD,O
not,RB,O
significantly,RB,O
different,JJ,O
before,IN,O
and,CC,O
after,IN,O
tiagabine,NN,D
multiple-dose,JJ,O
regimens,NNS,O
.,.,.
,,
this,DT,O
indicates,VBZ,O
that,IN,O
tiagabine,NN,D
does,VBZ,O
not,RB,O
cause,VB,O
induction,NN,O
or,CC,O
inhibition,NN,O
of,IN,O
the,DT,O
hepatic,JJ,O
microsomal,JJ,O
enzyme,NN,O
systems,NNS,O
responsible,JJ,O
for,IN,O
the,DT,O
metabolism,NN,O
of,IN,O
antipyrine,NN,D
.,.,.
,,
interaction,NN,O
of,IN,O
gabitril,NN,B
with,IN,O
highly,RB,O
protein,NN,O
bound,VBN,O
drugs,NNS,O
:,:,O
in,FW,O
vitro,FW,O
data,NNS,O
showed,VBD,O
that,IN,O
tiagabine,NN,D
is,VBZ,O
96,CD,O
%,NN,O
bound,VBD,O
to,TO,O
human,JJ,O
plasma,NN,O
protein,NN,O
and,CC,O
therefore,RB,O
has,VBZ,O
the,DT,O
potential,JJ,O
to,TO,O
interact,VB,O
with,IN,O
other,JJ,O
highly,RB,O
protein,NN,O
bound,VBD,O
compounds,NNS,O
.,.,.
,,
such,PDT,O
an,DT,O
interaction,NN,O
can,MD,O
potentially,RB,O
lead,VB,O
to,TO,O
higher,JJR,O
free,JJ,O
fractions,NNS,O
of,IN,O
either,CC,O
tiagabine,NN,D
or,CC,O
the,DT,O
competing,VBG,O
drug,NN,D
.,.,.
,,
the,DT,O
drug,NN,D
interaction,NN,O
studies,NNS,O
with,IN,O
valdecoxib,NN,D
were,VBD,O
performed,VBN,O
both,CC,O
with,IN,O
valdecoxib,NN,D
and,CC,O
a,DT,O
rapidly,RB,O
hydrolyzed,VBN,O
intravenous,JJ,O
prodrug,NN,O
form,NN,O
.,.,.
,,
the,DT,O
results,NNS,O
from,IN,O
trials,NNS,O
using,VBG,O
the,DT,O
intravenous,JJ,O
prodrug,NN,O
are,VBP,O
reported,VBN,O
in,IN,O
this,DT,O
section,NN,O
as,IN,O
they,PRP,O
relate,VBP,O
to,TO,O
the,DT,O
role,NN,O
of,IN,O
valdecoxib,NN,D
in,IN,O
drug,NN,D
interactions,NNS,O
.,.,.
,,
general,NNP,O
:,:,O
in,IN,O
humans,NNS,O
",",",",O
valdecoxib,NN,D
metabolism,NN,O
is,VBZ,O
predominantly,RB,O
mediated,VBN,O
via,IN,O
cyp,NN,O
3a4,NN,O
and,CC,O
2c9,NN,O
with,IN,O
glucuronidation,NN,O
being,VBG,O
a,DT,O
further,JJ,O
-lrb-,-LRB-,O
20,CD,O
%,NN,O
-rrb-,-RRB-,O
route,NN,O
of,IN,O
metabolism,NN,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
indicate,VBP,O
that,IN,O
valdecoxib,NN,D
is,VBZ,O
a,DT,O
moderate,JJ,O
inhibitor,NN,O
of,IN,O
cyp,NN,O
2c19,NN,O
-lrb-,-LRB-,O
ic50,NN,O
=,JJ,O
6,CD,O
g/ml,NN,O
or,CC,O
19,CD,O
m,NN,O
-rrb-,-RRB-,O
and,CC,O
2c9,NN,O
-lrb-,-LRB-,O
ic50,NN,O
=,JJ,O
13,CD,O
g/ml,NN,O
or,CC,O
41,CD,O
m,NN,O
-rrb-,-RRB-,O
",",",",O
and,CC,O
a,DT,O
weak,JJ,O
inhibitor,NN,O
of,IN,O
cyp,NN,O
2d6,NN,O
-lrb-,-LRB-,O
ic50,NN,O
=,JJ,O
31,CD,O
g/ml,NN,O
or,CC,O
100,CD,O
m,NN,O
-rrb-,-RRB-,O
and,CC,O
3a4,NN,O
-lrb-,-LRB-,O
ic50,NN,O
=,JJ,O
44,CD,O
g/ml,NN,O
or,CC,O
141,CD,O
m,NN,O
-rrb-,-RRB-,O
.,.,.
,,
aspirin,NN,B
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
aspirin,NN,B
with,IN,O
valdecoxib,NN,D
may,MD,O
result,VB,O
in,IN,O
an,DT,O
increased,VBN,O
risk,NN,O
of,IN,O
gi,NN,O
ulceration,NN,O
and,CC,O
complications,NNS,O
compared,VBN,O
to,TO,O
valdecoxib,NN,D
alone,RB,O
.,.,.
,,
because,IN,O
of,IN,O
its,PRP$,O
lack,NN,O
of,IN,O
anti-platelet,JJ,O
effect,NN,O
valdecoxib,NN,D
is,VBZ,O
not,RB,O
a,DT,O
substitute,NN,O
for,IN,O
aspirin,NN,B
for,IN,O
cardiovascular,JJ,O
prophylaxis,NN,O
.,.,.
,,
in,IN,O
a,DT,O
parallel,JJ,O
group,NN,O
drug,NN,D
interaction,NN,O
study,NN,O
comparing,VBG,O
the,DT,O
intravenous,JJ,O
prodrug,NN,O
form,NN,O
of,IN,O
valdecoxib,NN,D
at,IN,O
40,CD,O
mg,NN,O
bid,NNP,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
10,CD,O
-rrb-,-RRB-,O
vs,CC,O
placebo,NN,O
-lrb-,-LRB-,O
n,NN,O
=,JJ,O
9,CD,O
-rrb-,-RRB-,O
",",",",O
valdecoxib,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
in,FW,O
vitro,FW,O
aspirin-mediated,JJ,O
inhibition,NN,O
of,IN,O
arachidonate,NN,O
-,:,O
or,CC,O
collagen-stimulated,JJ,O
platelet,NN,O
aggregation,NN,O
.,.,.
,,
methotrexate,NNP,D
:,:,O
valdecoxib,NNP,D
10,CD,O
mg,NN,O
bid,NNP,O
did,VBD,O
not,RB,O
show,VB,O
a,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
plasma,NN,O
exposure,NN,O
or,CC,O
renal,JJ,O
clearance,NN,O
of,IN,O
methotrexate,NN,D
.,.,.
,,
ace-inhibitors,NNS,G
:,:,O
reports,NNS,O
suggest,VBP,O
that,IN,O
nsaids,NNS,G
may,MD,O
diminish,VB,O
the,DT,O
antihypertensive,JJ,G
effect,NN,O
of,IN,O
ace-inhibitors,NNS,G
.,.,.
,,
this,DT,O
interaction,NN,O
should,MD,O
be,VB,O
given,VBN,O
consideration,NN,O
in,IN,O
patients,NNS,O
taking,VBG,O
bextra,NNP,B
concomitantly,RB,O
with,IN,O
ace-inhibitors,NNS,G
.,.,.
,,
furosemide,NNP,D
:,:,O
clinical,JJ,O
studies,NNS,O
",",",",O
as,RB,O
well,RB,O
as,IN,O
post-marketing,JJ,O
observations,NNS,O
",",",",O
have,VBP,O
shown,VBN,O
that,IN,O
nsaids,NNS,G
can,MD,O
reduce,VB,O
the,DT,O
natriuretic,JJ,O
effect,NN,O
of,IN,O
furosemide,NN,D
and,CC,O
thiazides,NNS,G
in,IN,O
some,DT,O
patients,NNS,O
.,.,.
,,
this,DT,O
response,NN,O
has,VBZ,O
been,VBN,O
attributed,VBN,O
to,TO,O
inhibition,NN,O
of,IN,O
renal,JJ,O
prostaglandin,NN,O
synthesis,NN,O
.,.,.
,,
anticonvulsants,NNS,G
-lrb-,-LRB-,O
phenytoin,NN,D
-rrb-,-RRB-,O
:,:,O
steady,JJ,O
state,NN,O
plasma,NN,O
exposure,NN,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
of,IN,O
valdecoxib,NN,D
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
bid,NNP,O
for,IN,O
12,CD,O
days,NNS,O
-rrb-,-RRB-,O
was,VBD,O
decreased,VBN,O
by,IN,O
27,CD,O
%,NN,O
when,WRB,O
co-administered,VBN,O
with,IN,O
multiple,JJ,O
doses,NNS,O
-lrb-,-LRB-,O
300,CD,O
mg,NN,O
qd,NN,O
for,IN,O
12,CD,O
days,NNS,O
-rrb-,-RRB-,O
of,IN,O
phenytoin,NN,D
-lrb-,-LRB-,O
a,DT,O
cyp,NN,O
3a4,NN,O
inducer,NN,O
-rrb-,-RRB-,O
.,.,.
,,
patients,NNS,O
already,RB,O
stabilized,VBD,O
on,IN,O
valdecoxib,NN,D
should,MD,O
be,VB,O
closely,RB,O
monitored,VBN,O
for,IN,O
loss,NN,O
of,IN,O
symptom,NN,O
control,NN,O
with,IN,O
phenytoin,NN,D
coadministration,NN,O
.,.,.
,,
valdecoxib,NNP,D
did,VBD,O
not,RB,O
have,VB,O
a,DT,O
statistically,RB,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
phenytoin,NN,D
-lrb-,-LRB-,O
a,DT,O
cyp,NN,O
2c9,NN,O
and,CC,O
cyp,NN,O
2c19,NN,O
substrate,NN,O
-rrb-,-RRB-,O
.,.,.
,,
drug,NN,O
interaction,NN,O
studies,NNS,O
with,IN,O
other,JJ,O
anticonvulsants,NNS,G
have,VBP,O
not,RB,O
been,VBN,O
conducted,VBN,O
.,.,.
,,
routine,JJ,O
monitoring,NN,O
should,MD,O
be,VB,O
performed,VBN,O
when,WRB,O
therapy,NN,O
with,IN,O
bextra,NN,B
is,VBZ,O
either,CC,O
initiated,VBN,O
or,CC,O
discontinued,VBN,O
in,IN,O
patients,NNS,O
on,IN,O
anticonvulsant,JJ,G
therapy,NN,O
.,.,.
,,
dextromethorphan,NNP,D
:,:,O
dextromethorphan,NNP,D
is,VBZ,O
primarily,RB,O
metabolized,VBN,O
by,IN,O
cyp,NN,O
2d6,NN,O
and,CC,O
to,TO,O
a,DT,O
lesser,JJR,O
extent,NN,O
by,IN,O
3a4,NN,O
.,.,.
,,
coadministration,NN,O
with,IN,O
valdecoxib,NN,D
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
bid,NNP,O
for,IN,O
7,CD,O
days,NNS,O
-rrb-,-RRB-,O
resulted,VBD,O
in,IN,O
a,DT,O
significant,JJ,O
increase,NN,O
in,IN,O
dextromethorphan,NN,D
plasma,NN,O
levels,NNS,O
suggesting,VBG,O
that,IN,O
",",",",O
at,IN,O
these,DT,O
doses,NNS,O
",",",",O
valdecoxib,NN,D
is,VBZ,O
a,DT,O
weak,JJ,O
inhibitor,NN,O
of,IN,O
2d6,NN,O
.,.,.
,,
even,RB,O
so,RB,O
dextromethorphan,JJ,D
plasma,NN,O
concentrations,NNS,O
in,IN,O
the,DT,O
presence,NN,O
of,IN,O
high,JJ,O
doses,NNS,O
of,IN,O
valdecoxib,NN,D
were,VBD,O
almost,RB,O
5-fold,RB,O
lower,JJR,O
than,IN,O
those,DT,O
seen,VBN,O
in,IN,O
cyp,NN,O
2d6,NN,O
poor,JJ,O
metabolizers,NNS,O
suggesting,VBG,O
that,IN,O
dose,NN,O
adjustment,NN,O
is,VBZ,O
not,RB,O
necessary,JJ,O
.,.,.
,,
lithium,NN,D
:,:,O
valdecoxib,NNP,D
40,CD,O
mg,NN,O
bid,NNP,O
for,IN,O
7,CD,O
days,NNS,O
produced,VBD,O
significant,JJ,O
decreases,NNS,O
in,IN,O
lithium,NN,D
serum,NN,O
clearance,NN,O
-lrb-,-LRB-,O
25,CD,O
%,NN,O
-rrb-,-RRB-,O
and,CC,O
renal,JJ,O
clearance,NN,O
-lrb-,-LRB-,O
30,CD,O
%,NN,O
-rrb-,-RRB-,O
with,IN,O
a,DT,O
34,CD,O
%,NN,O
higher,JJR,O
serum,NN,O
exposure,NN,O
compared,VBN,O
to,TO,O
lithium,NN,D
alone,RB,O
.,.,.
,,
lithium,NN,D
serum,NN,O
concentrations,NNS,O
should,MD,O
be,VB,O
monitored,VBN,O
closely,RB,O
when,WRB,O
initiating,VBG,O
or,CC,O
changing,VBG,O
therapy,NN,O
with,IN,O
bextra,NNP,B
in,IN,O
patients,NNS,O
receiving,VBG,O
lithium,NN,D
.,.,.
,,
lithium,NN,D
carbonate,NN,O
-lrb-,-LRB-,O
450,CD,O
mg,NN,O
bid,NNP,O
for,IN,O
7,CD,O
days,NNS,O
-rrb-,-RRB-,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
valdecoxib,NN,D
pharmacokinetics,NNS,O
.,.,.
,,
warfarin,NNP,D
:,:,O
the,DT,O
effect,NN,O
of,IN,O
valdecoxib,NN,D
on,IN,O
the,DT,O
anticoagulant,JJ,G
effect,NN,O
of,IN,O
warfarin,NN,D
-lrb-,-LRB-,O
1,CD,O
-,:,O
8,CD,O
mg/day,NN,O
-rrb-,-RRB-,O
was,VBD,O
studied,VBN,O
in,IN,O
healthy,JJ,O
subjects,NNS,O
by,IN,O
coadministration,NN,O
of,IN,O
bextra,NNP,B
40,CD,O
mg,NN,O
bid,NNP,O
for,IN,O
7,CD,O
days,NNS,O
.,.,.
,,
valdecoxib,NN,D
caused,VBD,O
a,DT,O
statistically,RB,O
significant,JJ,O
increase,NN,O
in,IN,O
plasma,NN,O
exposures,NNS,O
of,IN,O
r-warfarin,NN,D
and,CC,O
s-warfarin,NN,D
-lrb-,-LRB-,O
12,CD,O
%,NN,O
and,CC,O
15,CD,O
%,NN,O
",",",",O
respectively,RB,O
-rrb-,-RRB-,O
",",",",O
and,CC,O
in,IN,O
the,DT,O
pharmacodynamic,JJ,O
effects,NNS,O
-lrb-,-LRB-,O
prothrombin,NN,O
time,NN,O
",",",",O
measured,VBN,O
as,IN,O
inr,NN,O
-rrb-,-RRB-,O
of,IN,O
warfarin,NN,D
.,.,.
,,
while,IN,O
mean,NN,O
inr,NN,O
values,NNS,O
were,VBD,O
only,RB,O
slightly,RB,O
increased,VBN,O
with,IN,O
coadministration,NN,O
of,IN,O
valdecoxib,NN,D
",",",",O
the,DT,O
day-to-day,JJ,O
variability,NN,O
in,IN,O
individual,JJ,O
inr,NN,O
values,NNS,O
was,VBD,O
increased,VBN,O
.,.,.
,,
anticoagulant,JJ,B
therapy,NN,O
should,MD,O
be,VB,O
monitored,VBN,O
",",",",O
particularly,RB,O
during,IN,O
the,DT,O
first,JJ,O
few,JJ,O
weeks,NNS,O
",",",",O
after,IN,O
initiating,VBG,O
therapy,NN,O
with,IN,O
bextra,NNP,B
in,IN,O
patients,NNS,O
receiving,VBG,O
warfarin,NN,D
or,CC,O
similar,JJ,O
agents,NNS,O
.,.,.
,,
fluconazole,NNP,D
and,CC,O
ketoconazole,NNP,D
:,:,O
ketoconazole,NNP,D
and,CC,O
fluconazole,NN,D
are,VBP,O
predominantly,RB,O
cyp,NNP,O
3a4,NN,O
and,CC,O
2c9,NN,O
inhibitors,NNS,O
",",",",O
respectively,RB,O
.,.,.
,,
concomitant,JJ,O
single,JJ,O
dose,NN,O
administration,NN,O
of,IN,O
valdecoxib,NN,D
20,CD,O
mg,NN,O
with,IN,O
multiple,JJ,O
doses,NNS,O
of,IN,O
ketoconazole,NN,D
and,CC,O
fluconazole,NN,D
produced,VBD,O
a,DT,O
significant,JJ,O
increase,NN,O
in,IN,O
exposure,NN,O
of,IN,O
valdecoxib,NN,D
.,.,.
,,
plasma,NN,O
exposure,NN,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
to,TO,O
valdecoxib,NN,D
was,VBD,O
increased,VBN,O
62,CD,O
%,NN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
fluconazole,NN,D
and,CC,O
38,CD,O
%,NN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
ketoconazole,NN,D
.,.,.
,,
glyburide,NNP,D
:,:,O
glyburide,NNP,D
is,VBZ,O
a,DT,O
cyp,NN,O
2c9,NN,O
substrate,NN,O
.,.,.
,,
coadministration,NN,O
of,IN,O
valdecoxib,NN,D
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
bid,NNP,O
for,IN,O
7,CD,O
days,NNS,O
-rrb-,-RRB-,O
with,IN,O
glyburide,NN,D
-lrb-,-LRB-,O
5,CD,O
mg,NN,O
qd,NN,O
or,CC,O
10,CD,O
mg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
-lrb-,-LRB-,O
exposure,NN,O
-rrb-,-RRB-,O
of,IN,O
glyburide,NN,D
.,.,.
,,
coadministration,NN,O
of,IN,O
valdecoxib,NN,D
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
bid,NNP,O
-lrb-,-LRB-,O
day,NN,O
1,CD,O
-rrb-,-RRB-,O
and,CC,O
40,CD,O
mg,NN,O
qd,NN,O
-lrb-,-LRB-,O
days,NNS,O
7-Feb,CD,O
-rrb-,-RRB-,O
-rrb-,-RRB-,O
with,IN,O
glyburide,NN,D
-lrb-,-LRB-,O
5,CD,O
mg,NN,O
qd,NN,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
affect,VB,O
either,CC,O
the,DT,O
pharmacokinetics,NNS,O
-lrb-,-LRB-,O
exposure,NN,O
-rrb-,-RRB-,O
or,CC,O
the,DT,O
pharmacodynamics,NNS,O
-lrb-,-LRB-,O
blood,NN,O
glucose,NN,O
and,CC,O
insulin,NN,D
levels,NNS,O
-rrb-,-RRB-,O
of,IN,O
glyburide,NN,D
.,.,.
,,
coadministration,NN,O
of,IN,O
valdecoxib,NN,D
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
bid,NNP,O
-lrb-,-LRB-,O
day,NN,O
1,CD,O
-rrb-,-RRB-,O
and,CC,O
40,CD,O
mg,NN,O
qd,NN,O
-lrb-,-LRB-,O
days,NNS,O
7-Feb,CD,O
-rrb-,-RRB-,O
-rrb-,-RRB-,O
with,IN,O
glyburide,NN,D
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
glyburide,NN,D
bid,NNP,O
-rrb-,-RRB-,O
resulted,VBD,O
in,IN,O
21,CD,O
%,NN,O
increase,NN,O
in,IN,O
glyburide,NN,D
auc0-12,NN,O
and,CC,O
a,DT,O
16,CD,O
%,NN,O
increase,NN,O
in,IN,O
glyburide,NN,D
cmax,NN,O
leading,VBG,O
to,TO,O
a,DT,O
16,CD,O
%,NN,O
decrease,NN,O
in,IN,O
glucose,NN,O
auc0-24,NN,O
.,.,.
,,
insulin,NN,D
parameters,NNS,O
were,VBD,O
not,RB,O
affected,VBN,O
.,.,.
,,
because,IN,O
changes,NNS,O
in,IN,O
glucose,NN,O
concentrations,NNS,O
with,IN,O
valdecoxib,NN,D
coadministration,NN,O
were,VBD,O
within,IN,O
the,DT,O
normal,JJ,O
variability,NN,O
and,CC,O
individual,JJ,O
glucose,NN,O
concentrations,NNS,O
were,VBD,O
above,IN,O
or,CC,O
near,IN,O
70,CD,O
mg/dl,NN,O
",",",",O
dose,NN,O
adjustment,NN,O
for,IN,O
glyburide,NN,D
-lrb-,-LRB-,O
5,CD,O
mg,NN,O
qd,NN,O
and,CC,O
10,CD,O
mg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
with,IN,O
valdecoxib,NN,D
coadministration,NN,O
-lrb-,-LRB-,O
up,RB,O
to,TO,O
40,CD,O
mg,NN,O
qd,NN,O
-rrb-,-RRB-,O
is,VBZ,O
not,RB,O
indicated,VBN,O
.,.,.
,,
coadministration,NN,O
of,IN,O
glyburide,NN,D
with,IN,O
doses,NNS,O
higher,JJR,O
than,IN,O
40,CD,O
mg,NN,O
valdecoxib,NN,D
-lrb-,-LRB-,O
e.g.,FW,O
",",",",O
40,CD,O
mg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
have,VBP,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
omeprazole,NNP,D
:,:,O
omeprazole,NNP,D
is,VBZ,O
a,DT,O
cyp,NN,O
3a4,NN,O
substrate,NN,O
and,CC,O
cyp,NN,O
2c19,NN,O
substrate,NN,O
and,CC,O
inhibitor,NN,O
.,.,.
,,
valdecoxib,NNP,D
steady,JJ,O
state,NN,O
plasma,NN,O
concentrations,NNS,O
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
were,VBD,O
not,RB,O
affected,VBN,O
significantly,RB,O
with,IN,O
multiple,JJ,O
doses,NNS,O
of,IN,O
omeprazole,NN,D
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
qd,NN,O
-rrb-,-RRB-,O
.,.,.
,,
coadministration,NN,O
with,IN,O
valdecoxib,NN,D
increased,VBD,O
exposure,NN,O
of,IN,O
omeprazole,NN,D
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
by,IN,O
46,CD,O
%,NN,O
.,.,.
,,
drugs,NNS,O
whose,WP$,O
absorption,NN,O
is,VBZ,O
sensitive,JJ,O
to,TO,O
ph,NN,O
may,MD,O
be,VB,O
negatively,RB,O
impacted,VBN,O
by,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
omeprazole,NN,D
and,CC,O
valdecoxib,NN,D
.,.,.
,,
however,RB,O
",",",",O
because,IN,O
higher,JJR,O
doses,NNS,O
-lrb-,-LRB-,O
up,RB,O
to,TO,O
360,CD,O
mg,NN,O
qd,NN,O
-rrb-,-RRB-,O
of,IN,O
omeprazole,NN,D
are,VBP,O
tolerated,VBN,O
in,IN,O
zollinger-ellison,NN,O
-lrb-,-LRB-,O
ze,NN,O
-rrb-,-RRB-,O
patients,NNS,O
",",",",O
no,DT,O
dose,NN,O
adjustment,NN,O
for,IN,O
omeprazole,NN,D
is,VBZ,O
recommended,VBN,O
at,IN,O
current,JJ,O
doses,NNS,O
.,.,.
,,
coadministration,NN,O
of,IN,O
valdecoxib,NN,D
with,IN,O
doses,NNS,O
higher,JJR,O
than,IN,O
40,CD,O
mg,NN,O
qd,NN,O
omeprazole,NN,D
has,VBZ,O
not,RB,O
been,VBN,O
studied,VBN,O
.,.,.
,,
oral,JJ,O
contraceptives,NNS,G
:,:,O
valdecoxib,NN,D
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
induce,VB,O
the,DT,O
metabolism,NN,O
of,IN,O
the,DT,O
combination,NN,O
oral,JJ,O
contraceptive,JJ,G
norethindrone/ethinyl,JJ,O
estradiol,NN,O
-lrb-,-LRB-,O
1,CD,O
mg,NN,O
/,:,O
35,CD,O
mcg,NN,O
combination,NN,O
",",",",O
ortho-novum,NNP,B
Jan-35,CD,O
-rrb-,-RRB-,O
.,.,.
,,
coadministration,NN,O
of,IN,O
valdecoxib,NN,D
and,CC,O
ortho-novum,NNP,B
Jan-35,CD,O
increased,VBD,O
the,DT,O
exposure,NN,O
of,IN,O
norethindrone,NN,D
and,CC,O
ethinyl,NN,O
estradiol,NN,O
by,IN,O
20,CD,O
%,NN,O
and,CC,O
34,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
although,IN,O
there,EX,O
is,VBZ,O
little,JJ,O
risk,NN,O
for,IN,O
loss,NN,O
of,IN,O
contraceptive,JJ,G
efficacy,NN,O
",",",",O
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
these,DT,O
increased,VBN,O
exposures,NNS,O
in,IN,O
terms,NNS,O
of,IN,O
safety,NN,O
is,VBZ,O
not,RB,O
known,VBN,O
.,.,.
,,
these,DT,O
increased,VBD,O
exposures,NNS,O
of,IN,O
norethindrone,NN,D
and,CC,O
ethinyl,NN,O
estradiol,NN,O
should,MD,O
be,VB,O
taken,VBN,O
into,IN,O
consideration,NN,O
when,WRB,O
selecting,VBG,O
an,DT,O
oral,JJ,O
contraceptive,NN,G
for,IN,O
women,NNS,O
taking,VBG,O
valdecoxib,NN,D
.,.,.
,,
diazepam,NN,D
:,:,O
diazepam,NN,D
-lrb-,-LRB-,O
valium,NN,B
-rrb-,-RRB-,O
is,VBZ,O
a,DT,O
cyp,NN,O
3a4,NN,O
and,CC,O
cyp,NN,O
2c19,NN,O
substrate,NN,O
.,.,.
,,
plasma,NN,O
exposure,NN,O
of,IN,O
diazepam,NN,D
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
was,VBD,O
increased,VBN,O
by,IN,O
28,CD,O
%,NN,O
following,VBG,O
administration,NN,O
of,IN,O
valdecoxib,NN,D
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
for,IN,O
12,CD,O
days,NNS,O
",",",",O
while,IN,O
plasma,NN,O
exposure,NN,O
of,IN,O
valdecoxib,NN,D
-lrb-,-LRB-,O
40,CD,O
mg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
was,VBD,O
not,RB,O
substantially,RB,O
increased,VBN,O
following,VBG,O
administration,NN,O
of,IN,O
diazepam,NN,D
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
bid,NNP,O
-rrb-,-RRB-,O
for,IN,O
12,CD,O
days,NNS,O
.,.,.
,,
although,IN,O
the,DT,O
magnitude,NN,O
of,IN,O
changes,NNS,O
in,IN,O
diazepam,NN,D
plasma,NN,O
exposure,NN,O
when,WRB,O
coadministered,VBN,O
with,IN,O
valdecoxib,NN,D
were,VBD,O
not,RB,O
sufficient,JJ,O
to,TO,O
warrant,VB,O
dosage,NN,O
adjustments,NNS,O
",",",",O
patients,NNS,O
may,MD,O
experience,VB,O
enhanced,VBN,O
sedative,JJ,G
side,JJ,O
effects,NNS,O
caused,VBN,O
by,IN,O
increased,VBN,O
exposure,NN,O
of,IN,O
diazepam,NN,D
under,IN,O
this,DT,O
circumstance,NN,O
.,.,.
,,
patients,NNS,O
should,MD,O
be,VB,O
cautioned,VBN,O
against,IN,O
engaging,VBG,O
in,IN,O
hazardous,JJ,O
activities,NNS,O
requiring,VBG,O
complete,JJ,O
mental,JJ,O
alertness,NN,O
such,JJ,O
as,IN,O
operating,VBG,O
machinery,NN,O
or,CC,O
driving,VBG,O
a,DT,O
motor,NN,O
vehicle,NN,O
.,.,.
,,
effect,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
on,IN,O
vardenafi,NNP,O
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
:,:,O
studies,NNS,O
in,IN,O
human,JJ,O
liver,NN,O
microsomes,NNS,O
showed,VBD,O
that,IN,O
vardenafil,NN,D
is,VBZ,O
metabolized,VBN,O
primarily,RB,O
by,IN,O
cytochrome,NN,O
p450,NN,O
-lrb-,-LRB-,O
cyp,NN,O
-rrb-,-RRB-,O
isoforms,NNS,O
3a4/5,NN,O
",",",",O
and,CC,O
to,TO,O
a,DT,O
lesser,JJR,O
degree,NN,O
by,IN,O
cyp2c9,NN,D
.,.,.
,,
therefore,RB,O
",",",",O
inhibitors,NNS,O
of,IN,O
these,DT,O
enzymes,NNS,O
are,VBP,O
expected,VBN,O
to,TO,O
reduce,VB,O
vardenafil,NN,D
clearance,NN,O
.,.,.
,,
in,FW,O
vivo,FW,O
studies,NNS,O
:,:,O
cytochrome,NN,O
p450,NN,O
inhibitors,NNS,O
.,.,.
,,
cimetidine,NN,D
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
b.i.d.,NN,O
-rrb-,-RRB-,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
vardenafil,NN,D
bioavailability,NN,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
and,CC,O
maximum,NN,O
concentration,NN,O
-lrb-,-LRB-,O
cmax,NN,O
-rrb-,-RRB-,O
of,IN,O
vardenafil,NN,D
when,WRB,O
co-administered,VBN,O
with,IN,O
20,CD,O
mg,NN,O
vardenafil,NNP,D
in,IN,O
healthy,JJ,O
volunteers,NNS,O
.,.,.
,,
erythromycin,NN,D
-lrb-,-LRB-,O
500,CD,O
mg,NN,O
t.i.d,NN,O
-rrb-,-RRB-,O
produced,VBD,O
a,DT,O
4-fold,JJ,O
increase,NN,O
in,IN,O
vardenafil,NN,D
auc,NN,O
and,CC,O
a,DT,O
3-fold,JJ,O
increase,NN,O
in,IN,O
cmax,NNP,O
when,WRB,O
co-administered,VBN,O
with,IN,O
vardenafil,NNP,D
5,CD,O
mg,NN,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
not,RB,O
to,TO,O
exceed,VB,O
a,DT,O
single,JJ,O
5,CD,O
mg,NN,O
dose,NN,O
of,IN,O
vardenafil,NNP,D
in,IN,O
a,DT,O
24-hour,JJ,O
period,NN,O
when,WRB,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
erythromycin,NN,D
.,.,.
,,
ketoconazole,NN,D
-lrb-,-LRB-,O
200,CD,O
mg,NN,O
once,RB,O
daily,JJ,O
-rrb-,-RRB-,O
produced,VBD,O
a,DT,O
10-fold,JJ,O
increase,NN,O
in,IN,O
vardenafil,NN,D
auc,NN,O
and,CC,O
a,DT,O
4-fold,JJ,O
increase,NN,O
in,IN,O
cmax,NNP,O
when,WRB,O
co-administered,VBN,O
with,IN,O
vardenafil,NNP,D
-lrb-,-LRB-,O
5,CD,O
mg,NN,O
-rrb-,-RRB-,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
.,.,.
,,
a,DT,O
5-mg,JJ,O
vardenafil,NNP,D
dose,NN,O
should,MD,O
not,RB,O
be,VB,O
exceeded,VBN,O
when,WRB,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
200,CD,O
mg,NN,O
once,RB,O
daily,JJ,O
ketoconazole,NN,D
.,.,.
,,
since,IN,O
higher,JJR,O
doses,NNS,O
of,IN,O
ketoconazole,NN,D
-lrb-,-LRB-,O
400,CD,O
mg,NN,O
daily,JJ,O
-rrb-,-RRB-,O
may,MD,O
result,VB,O
in,IN,O
higher,JJR,O
increases,NNS,O
in,IN,O
cmax,NN,O
and,CC,O
auc,NN,O
",",",",O
a,DT,O
single,JJ,O
2.5,CD,O
mg,NN,O
dose,NN,O
of,IN,O
vardenafil,NNP,D
should,MD,O
not,RB,O
be,VB,O
exceeded,VBN,O
in,IN,O
a,DT,O
24-hour,JJ,O
period,NN,O
when,WRB,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
ketoconazole,NN,D
400,CD,O
mg,NN,O
daily,RB,O
.,.,.
,,
hiv,NN,O
protease,NN,O
inhibitors,NNS,O
:,:,O
indinavir,NNP,D
-lrb-,-LRB-,O
800,CD,O
mg,NN,O
t.i.d.,NN,O
-rrb-,-RRB-,O
co-administered,JJ,O
with,IN,O
vardenafil,NNP,D
10,CD,O
mg,NN,O
resulted,VBD,O
in,IN,O
a,DT,O
16-fold,JJ,O
increase,NN,O
in,IN,O
vardenafil,NN,D
auc,NN,O
",",",",O
a,DT,O
7-fold,JJ,O
increase,NN,O
in,IN,O
vardenafil,NN,D
cmax,NN,O
and,CC,O
a,DT,O
2-fold,JJ,O
increase,NN,O
in,IN,O
vardenafil,NN,D
half-life,NN,O
.,.,.
,,
it,PRP,O
is,VBZ,O
recommended,VBN,O
not,RB,O
to,TO,O
exceed,VB,O
a,DT,O
single,JJ,O
2.5,CD,O
mg,NN,O
vardenafil,NNP,D
dose,NN,O
in,IN,O
a,DT,O
24-hour,JJ,O
period,NN,O
when,WRB,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
indinavir,NN,D
.,.,.
,,
ritonavir,NNP,D
-lrb-,-LRB-,O
600,CD,O
mg,NN,O
b.i.d.,NN,O
-rrb-,-RRB-,O
co-administered,JJ,O
with,IN,O
vardenafil,NNP,D
5,CD,O
mg,NN,O
resulted,VBD,O
in,IN,O
a,DT,O
49-fold,JJ,O
increase,NN,O
in,IN,O
vardenafil,NN,D
auc,NN,O
and,CC,O
a,DT,O
13-fold,RB,O
increase,NN,O
in,IN,O
vardenafil,NN,D
cmax,NN,O
.,.,.
,,
the,DT,O
interaction,NN,O
is,VBZ,O
a,DT,O
consequence,NN,O
of,IN,O
blocking,VBG,O
hepatic,JJ,O
metabolism,NN,O
of,IN,O
vardenafil,NN,D
by,IN,O
ritonavir,NN,D
",",",",O
a,DT,O
highly,RB,O
potent,JJ,O
cyp3a4,NN,D
inhibitor,NN,O
",",",",O
which,WDT,O
also,RB,O
inhibits,VBZ,O
cyp2c9,NN,D
.,.,.
,,
ritonavir,NNP,D
significantly,RB,O
prolonged,VBD,O
the,DT,O
half-life,NN,O
of,IN,O
vardenafil,NN,D
to,TO,O
26,CD,O
hours,NNS,O
.,.,.
,,
consequently,RB,O
",",",",O
it,PRP,O
is,VBZ,O
recommended,VBN,O
not,RB,O
to,TO,O
exceed,VB,O
a,DT,O
single,JJ,O
2.5,CD,O
mg,NN,O
vardenafil,NNP,D
dose,NN,O
in,IN,O
a,DT,O
72-hour,JJ,O
period,NN,O
when,WRB,O
used,VBN,O
in,IN,O
combination,NN,O
with,IN,O
ritonavir,NN,D
.,.,.
,,
other,JJ,O
drug,NN,O
interactions,NNS,O
:,:,O
no,DT,O
pharmacokinetic,JJ,O
interactions,NNS,O
were,VBD,O
observed,VBN,O
between,IN,O
vardenafil,NN,D
and,CC,O
the,DT,O
following,VBG,O
drugs,NNS,D
:,:,O
glyburide,NN,D
",",",",O
warfarin,NN,D
",",",",O
digoxin,NN,D
",",",",O
maalox,NNP,B
",",",",O
and,CC,O
ranitidine,NN,D
.,.,.
,,
in,IN,O
the,DT,O
warfarin,NN,D
study,NN,O
",",",",O
vardenafil,NN,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
prothrombin,NN,O
time,NN,O
or,CC,O
other,JJ,O
pharmacodynamic,JJ,O
parameters,NNS,O
.,.,.
,,
effects,NNS,O
of,IN,O
vardenafil,NNP,D
on,IN,O
other,JJ,O
drug,NN,D
.,.,.
,,
in,FW,O
vitro,FW,O
studies,NNS,O
:,:,O
vardenafil,NNP,D
and,CC,O
its,PRP$,O
metabolites,NNS,O
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
cyp1a2,NN,D
",",",",O
2a6,NN,O
",",",",O
and,CC,O
2.00E+01,NN,O
-lrb-,-LRB-,O
ki,NN,O
100um,NN,O
-rrb-,-RRB-,O
.,.,.
,,
weak,JJ,O
inhibitory,JJ,O
effects,NNS,O
toward,IN,O
other,JJ,O
isoforms,NNS,O
-lrb-,-LRB-,O
cyp2c8,NN,O
",",",",O
2c9,NN,O
",",",",O
2c19,NN,O
",",",",O
2d6,NN,O
",",",",O
3a4,NN,O
-rrb-,-RRB-,O
were,VBD,O
found,VBN,O
",",",",O
but,CC,O
ki,NN,O
values,NNS,O
were,VBD,O
in,IN,O
excess,NN,O
of,IN,O
plasma,NN,O
concentrations,NNS,O
achieved,VBN,O
following,VBG,O
dosing,NN,O
.,.,.
,,
the,DT,O
most,RBS,O
potent,JJ,O
inhibitory,JJ,O
activity,NN,O
was,VBD,O
observed,VBN,O
for,IN,O
vardenafil,NN,D
metabolite,NN,O
m1,NN,O
",",",",O
which,WDT,O
had,VBD,O
a,DT,O
ki,NN,O
of,IN,O
1.4,CD,O
um,NN,O
toward,IN,O
cyp3a4,NN,D
",",",",O
which,WDT,O
is,VBZ,O
about,IN,O
20,CD,O
times,NNS,O
higher,JJR,O
than,IN,O
the,DT,O
m1,NN,O
cmax,NN,O
values,NNS,O
after,IN,O
an,DT,O
80,CD,O
mg,NN,O
vardenafil,NNP,D
dose,NN,O
.,.,.
,,
in,FW,O
vivo,FW,O
studies,NNS,O
:,:,O
nitrates,NNS,G
:,:,O
the,DT,O
blood,NN,O
pressure,NN,O
lowering,VBG,O
effects,NNS,O
of,IN,O
sublingual,JJ,O
nitrates,NNS,G
-lrb-,-LRB-,O
0.4,CD,O
mg,NN,O
-rrb-,-RRB-,O
taken,VBN,O
1,CD,O
and,CC,O
4,CD,O
hours,NNS,O
after,IN,O
vardenafil,NN,D
and,CC,O
increases,VBZ,O
in,IN,O
heart,NN,O
rate,NN,O
when,WRB,O
taken,VBN,O
at,IN,O
1,CD,O
",",",",O
4,CD,O
and,CC,O
8,CD,O
hours,NNS,O
were,VBD,O
potentiated,VBN,O
by,IN,O
a,DT,O
20,CD,O
mg,NN,O
dose,NN,O
of,IN,O
vardenafil,NNP,D
in,IN,O
healthy,JJ,O
middle-aged,JJ,O
subjects,NNS,O
.,.,.
,,
these,DT,O
effects,NNS,O
were,VBD,O
not,RB,O
observed,VBN,O
when,WRB,O
vardenafil,NNP,D
20,CD,O
mg,NN,O
was,VBD,O
taken,VBN,O
24,CD,O
hours,NNS,O
before,IN,O
the,DT,O
ntg,NNP,D
.,.,.
,,
potentiation,NN,O
of,IN,O
the,DT,O
hypotensive,JJ,O
effects,NNS,O
of,IN,O
nitrates,NNS,G
for,IN,O
patients,NNS,O
with,IN,O
ischemic,JJ,O
heart,NN,O
disease,NN,O
has,VBZ,O
not,RB,O
been,VBN,O
evaluated,VBN,O
",",",",O
and,CC,O
concomitant,JJ,O
use,NN,O
of,IN,O
vardenafil,NNP,D
and,CC,O
nitrates,NNS,G
is,VBZ,O
contraindicated,VBN,O
.,.,.
,,
nifedipine,NNP,D
:,:,O
vardenafil,NNP,D
20,CD,O
mg,NN,O
",",",",O
when,WRB,O
co-administered,VBN,O
with,IN,O
slow-release,JJ,O
nifedipine,NN,D
30,CD,O
mg,NN,O
or,CC,O
60,CD,O
mg,NN,O
once,RB,O
daily,RB,O
",",",",O
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
relative,JJ,O
bioavailability,NN,O
-lrb-,-LRB-,O
auc,NN,O
-rrb-,-RRB-,O
or,CC,O
maximum,NN,O
concentration,NN,O
-lrb-,-LRB-,O
cmax,NN,O
-rrb-,-RRB-,O
of,IN,O
nifedipine,NN,D
",",",",O
a,DT,O
drug,NN,D
that,WDT,O
is,VBZ,O
metabolized,VBN,O
via,IN,O
cyp3a4,NN,D
.,.,.
,,
nifedipine,NN,D
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
plasma,NN,O
levels,NNS,O
of,IN,O
vardenafil,NNP,D
when,WRB,O
taken,VBN,O
in,IN,O
combination,NN,O
.,.,.
,,
in,IN,O
these,DT,O
patients,NNS,O
whose,WP$,O
hypertension,NN,O
was,VBD,O
controlled,VBN,O
with,IN,O
nifedipine,NN,D
",",",",O
vardenafil,NNP,D
20,CD,O
mg,NN,O
produced,VBD,O
mean,JJ,O
additional,JJ,O
supine,NN,O
systolic/diastolic,JJ,O
blood,NN,O
pressure,NN,O
reductions,NNS,O
of,IN,O
5-Jun,CD,O
mm,NN,O
hg,NN,O
compared,VBN,O
to,TO,O
placebo,NN,O
.,.,.
,,
alpha-blockers,NNS,G
:,:,O
when,WRB,O
vardenafil,NNP,D
10,CD,O
or,CC,O
20,CD,O
mg,NN,O
was,VBD,O
given,VBN,O
to,TO,O
healthy,JJ,O
volunteers,NNS,O
either,CC,O
simultaneously,RB,O
or,CC,O
6,CD,O
hours,NNS,O
after,IN,O
a,DT,O
10,CD,O
mg,NN,O
dose,NN,O
of,IN,O
terazosin,NN,D
",",",",O
significant,JJ,O
hypotension,NN,O
developed,VBN,O
in,IN,O
a,DT,O
substantial,JJ,O
number,NN,O
of,IN,O
subjects,NNS,O
.,.,.
,,
with,IN,O
simultaneous,JJ,O
dosing,NN,O
of,IN,O
vardenafil,NNP,D
10,CD,O
mg,NN,O
and,CC,O
terazosin,NN,D
10,CD,O
mg,NN,O
",",",",O
6,CD,O
of,IN,O
8,CD,O
subjects,NNS,O
experienced,VBD,O
a,DT,O
standing,NN,O
systolic,JJ,O
blood,NN,O
pressure,NN,O
of,IN,O
less,JJR,O
than,IN,O
85,CD,O
mm,NN,O
hg,NN,O
.,.,.
,,
with,IN,O
simultaneous,JJ,O
dosing,NN,O
of,IN,O
vardenafil,NNP,D
20,CD,O
mg,NN,O
and,CC,O
terazosin,NN,D
10,CD,O
mg,NN,O
",",",",O
2,CD,O
of,IN,O
9,CD,O
subjects,NNS,O
experienced,VBD,O
a,DT,O
standing,NN,O
systolic,JJ,O
blood,NN,O
pressure,NN,O
of,IN,O
less,JJR,O
than,IN,O
85,CD,O
mm,NN,O
hg,NN,O
.,.,.
,,
when,WRB,O
vardenafil,NNP,D
dosing,NN,O
was,VBD,O
separated,VBN,O
from,IN,O
terazosin,NN,D
10,CD,O
mg,NN,O
by,IN,O
6,CD,O
hours,NNS,O
",",",",O
7,CD,O
of,IN,O
28,CD,O
subjects,NNS,O
who,WP,O
received,VBD,O
20,CD,O
mg,NN,O
of,IN,O
vardenafil,NNP,D
experienced,VBD,O
a,DT,O
decrease,NN,O
in,IN,O
standing,VBG,O
systolic,JJ,O
blood,NN,O
pressure,NN,O
below,IN,O
85,CD,O
mm,NN,O
hg,NN,O
.,.,.
,,
in,IN,O
a,DT,O
similar,JJ,O
study,NN,O
with,IN,O
tamsulosin,NN,D
in,IN,O
healthy,JJ,O
volunteers,NNS,O
",",",",O
1,CD,O
of,IN,O
24,CD,O
subjects,NNS,O
dosed,JJ,O
with,IN,O
vardenafil,NNP,D
20,CD,O
mg,NN,O
and,CC,O
tamsulosin,NN,D
0.4,CD,O
mg,NN,O
separated,VBN,O
by,IN,O
6,CD,O
hours,NNS,O
experienced,VBD,O
a,DT,O
standing,NN,O
systolic,JJ,O
blood,NN,O
pressure,NN,O
below,IN,O
85,CD,O
mm,NN,O
hg,NN,O
.,.,.
,,
two,CD,O
of,IN,O
16,CD,O
subjects,NNS,O
dosed,JJ,O
simultaneously,RB,O
with,IN,O
vardenafil,NNP,D
10,CD,O
mg,NN,O
and,CC,O
tamsulosin,NN,D
0.4,CD,O
mg,NN,O
experienced,VBD,O
a,DT,O
standing,NN,O
systolic,JJ,O
blood,NN,O
pressure,NN,O
below,IN,O
85,CD,O
mm,NN,O
hg,NN,O
.,.,.
,,
the,DT,O
administration,NN,O
of,IN,O
lower,JJR,O
doses,NNS,O
of,IN,O
vardenafil,NN,D
with,IN,O
alpha-blockers,NNS,G
has,VBZ,O
not,RB,O
been,VBN,O
completely,RB,O
evaluated,VBN,O
to,TO,O
determine,VB,O
if,IN,O
they,PRP,O
can,MD,O
be,VB,O
safely,RB,O
administered,VBN,O
together,RB,O
.,.,.
,,
based,VBN,O
on,IN,O
these,DT,O
data,NNS,O
",",",",O
vardenafil,NNP,D
should,MD,O
not,RB,O
be,VB,O
used,VBN,O
in,IN,O
patients,NNS,O
on,IN,O
alpha-blocker,NN,G
therapy,NN,O
.,.,.
,,
ritonavir,NNP,D
and,CC,O
indinavir,NNP,D
:,:,O
upon,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
5,CD,O
mg,NN,O
of,IN,O
vardenafil,NNP,D
with,IN,O
600,CD,O
mg,NN,O
bid,NNP,O
ritonavir,NN,D
",",",",O
the,DT,O
cmax,NNP,O
and,CC,O
auc,NN,O
of,IN,O
ritonavir,NN,D
were,VBD,O
reduced,VBN,O
by,IN,O
approximately,RB,O
20,CD,O
%,NN,O
.,.,.
,,
upon,IN,O
administration,NN,O
of,IN,O
10,CD,O
mg,NN,O
of,IN,O
vardenafil,NNP,D
with,IN,O
800,CD,O
mg,NN,O
tid,NN,O
indinavir,NN,D
",",",",O
the,DT,O
cmax,NNP,O
and,CC,O
auc,NN,O
of,IN,O
indinavir,NN,D
were,VBD,O
reduced,VBN,O
by,IN,O
40,CD,O
%,NN,O
and,CC,O
30,CD,O
%,NN,O
",",",",O
respectively,RB,O
.,.,.
,,
alcohol,NN,D
:,:,O
alcohol,NN,D
-lrb-,-LRB-,O
0.5,CD,O
g/kg,NN,O
body,NN,O
weight,NN,O
:,:,O
approximately,RB,O
40,CD,O
ml,NN,O
of,IN,O
absolute,JJ,O
alcohol,NN,D
in,IN,O
a,DT,O
70,CD,O
kg,NN,O
person,NN,O
-rrb-,-RRB-,O
and,CC,O
vardenafil,NN,D
plasma,NN,O
levels,NNS,O
were,VBD,O
not,RB,O
altered,VBN,O
when,WRB,O
dosed,VBN,O
simultaneously,RB,O
.,.,.
,,
vardenafil,NNP,D
-lrb-,-LRB-,O
20,CD,O
mg,NN,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
potentiate,VB,O
the,DT,O
hypotensive,JJ,O
effects,NNS,O
of,IN,O
alcohol,NN,D
during,IN,O
the,DT,O
4-hour,JJ,O
observation,NN,O
period,NN,O
in,IN,O
healthy,JJ,O
volunteers,NNS,O
when,WRB,O
administered,VBN,O
with,IN,O
alcohol,NN,D
-lrb-,-LRB-,O
0.5,CD,O
g/kg,NN,O
body,NN,O
weight,NN,O
-rrb-,-RRB-,O
.,.,.
,,
aspirin,NN,B
:,:,O
vardenafil,NNP,D
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
and,CC,O
20,CD,O
mg,NN,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
potentiate,VB,O
the,DT,O
increase,NN,O
in,IN,O
bleeding,JJ,O
time,NN,O
caused,VBN,O
by,IN,O
aspirin,NN,B
-lrb-,-LRB-,O
two,CD,O
81,CD,O
mg,NN,O
tablets,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
other,JJ,O
interactions,NNS,O
:,:,O
vardenafil,NNP,D
had,VBD,O
no,DT,O
effect,NN,O
on,IN,O
the,DT,O
pharmacodynamics,NNS,O
of,IN,O
glyburide,NN,D
-lrb-,-LRB-,O
glucose,NN,O
and,CC,O
insulin,NN,D
concentrations,NNS,O
-rrb-,-RRB-,O
and,CC,O
warfarin,NN,D
-lrb-,-LRB-,O
prothrombin,NN,O
time,NN,O
or,CC,O
other,JJ,O
pharmacodynamic,JJ,O
parameters,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
zidovudine,NNP,D
:,:,O
there,EX,O
is,VBZ,O
no,DT,O
significant,JJ,O
pharmacokinetic,JJ,O
interaction,NN,O
between,IN,O
zdv,NN,D
and,CC,O
zalcitabine,NN,D
which,WDT,O
has,VBZ,O
been,VBN,O
confirmed,VBN,O
clinically,RB,O
.,.,.
,,
zalcitabine,NNP,D
also,RB,O
has,VBZ,O
no,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
intracellular,JJ,O
phosphorylation,NN,O
of,IN,O
zdv,NN,D
",",",",O
as,IN,O
shown,VBN,O
in,FW,O
vitro,FW,O
in,IN,O
peripheral,JJ,O
blood,NN,O
mononuclear,JJ,O
cells,NNS,O
or,CC,O
in,IN,O
two,CD,O
other,JJ,O
cell,NN,O
lines,NNS,O
-lrb-,-LRB-,O
u937,NN,O
and,CC,O
molt-4,NN,O
-rrb-,-RRB-,O
.,.,.
,,
in,IN,O
the,DT,O
same,JJ,O
study,NN,O
it,PRP,O
was,VBD,O
shown,VBN,O
that,IN,O
didanosine,NN,D
and,CC,O
stavudine,NN,D
had,VBD,O
no,DT,O
significant,JJ,O
effect,NN,O
on,IN,O
the,DT,O
intracellular,JJ,O
phosphorylation,NN,O
of,IN,O
zalcitabine,NN,D
in,IN,O
peripheral,JJ,O
blood,NN,O
mononuclear,JJ,O
cells,NNS,O
.,.,.
,,
lamivudine,NNP,D
:,:,O
in,FW,O
vitro,FW,O
studies,NNS,O
in,IN,O
peripheral,JJ,O
blood,NN,O
mononuclear,JJ,O
cells,NNS,O
",",",",O
u937,NN,O
and,CC,O
molt-4,NN,O
cells,NNS,O
revealed,VBD,O
that,IN,O
lamivudine,NN,D
significantly,RB,O
inhibited,VBD,O
zalcitabine,NN,D
phosphorylation,NN,O
in,IN,O
a,DT,O
dose,NN,O
dependent,JJ,O
manner,NN,O
.,.,.
,,
effects,NNS,O
were,VBD,O
already,RB,O
seen,VBN,O
with,IN,O
doses,NNS,O
corresponding,VBG,O
to,TO,O
relevant,JJ,O
plasma,NN,O
levels,NNS,O
in,IN,O
humans,NNS,O
",",",",O
and,CC,O
the,DT,O
intracellular,JJ,O
phosphorylation,NN,O
of,IN,O
zalcitabine,NN,D
to,TO,O
its,PRP$,O
three,CD,O
metabolites,NNS,O
-lrb-,-LRB-,O
including,VBG,O
the,DT,O
active,JJ,O
zalcitabine,NN,D
triphosphate,NN,O
metabolite,NN,O
-rrb-,-RRB-,O
was,VBD,O
significantly,RB,O
inhibited,VBN,O
.,.,.
,,
zalcitabine,NNP,D
inhibited,VBD,O
lamivudine,NN,D
phosphorylation,NN,O
at,IN,O
high,JJ,O
concentration,NN,O
ratios,NNS,O
-lrb-,-LRB-,O
10,CD,O
and,CC,O
100,CD,O
-rrb-,-RRB-,O
.,.,.
,,
however,RB,O
",",",",O
it,PRP,O
is,VBZ,O
considered,VBN,O
to,TO,O
be,VB,O
unlikely,JJ,O
that,IN,O
this,DT,O
decrease,NN,O
of,IN,O
phosphorylated,VBN,O
lamivudine,NN,D
concentration,NN,O
is,VBZ,O
of,IN,O
clinical,JJ,O
significance,NN,O
",",",",O
as,IN,O
lamivudine,NN,D
is,VBZ,O
a,DT,O
more,RBR,O
efficient,JJ,O
substrate,NN,O
for,IN,O
deoxycytidine,NN,O
kinase,NN,O
than,IN,O
zalcitabine,NN,D
.,.,.
,,
these,DT,O
in,FW,O
vitro,FW,O
studies,NNS,O
suggest,VBP,O
that,IN,O
concomitant,JJ,O
administration,NN,O
of,IN,O
zalcitabine,NN,D
and,CC,O
lamivudine,NN,D
in,IN,O
humans,NNS,O
may,MD,O
result,VB,O
in,IN,O
sub-therapeutic,JJ,O
concentrations,NNS,O
of,IN,O
active,JJ,O
phosphorylated,VBN,O
zalcitabine,NN,D
",",",",O
which,WDT,O
may,MD,O
lead,VB,O
to,TO,O
a,DT,O
decreased,VBN,O
antiretroviral,JJ,G
effect,NN,O
of,IN,O
zalcitabine,NN,D
.,.,.
,,
it,PRP,O
is,VBZ,O
unknown,JJ,O
how,WRB,O
the,DT,O
effect,NN,O
seen,VBN,O
in,IN,O
these,DT,O
in,FW,O
vitro,FW,O
studies,NNS,O
translates,VBZ,O
into,IN,O
clinical,JJ,O
consequences,NNS,O
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
zalcitabine,NN,D
and,CC,O
lamivudine,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
saquinavir,NNP,D
:,:,O
the,DT,O
combination,NN,O
of,IN,O
hivid,NNP,D
",",",",O
saquinavir,NN,D
",",",",O
and,CC,O
zdv,NN,D
has,VBZ,O
been,VBN,O
studied,VBN,O
-lrb-,-LRB-,O
as,IN,O
triple,JJ,O
combination,NN,O
-rrb-,-RRB-,O
in,IN,O
adults,NNS,O
.,.,.
,,
pharmacokinetic,JJ,O
data,NNS,O
suggest,VBP,O
that,IN,O
absorption,NN,O
",",",",O
metabolism,NN,O
",",",",O
and,CC,O
elimination,NN,O
of,IN,O
each,DT,O
of,IN,O
these,DT,O
drugs,NNS,D
are,VBP,O
unchanged,JJ,O
when,WRB,O
they,PRP,O
are,VBP,O
used,VBN,O
together,RB,O
.,.,.
,,
drugs,NNS,O
associated,VBD,O
with,IN,O
peripheral,JJ,O
neuropathy,NN,O
:,:,O
the,DT,O
concomitant,JJ,O
use,NN,O
of,IN,O
hivid,NN,D
with,IN,O
drugs,NNS,D
that,WDT,O
have,VBP,O
the,DT,O
potential,JJ,O
to,TO,O
cause,VB,O
peripheral,JJ,O
neuropathy,NN,O
should,MD,O
be,VB,O
avoided,VBN,O
where,WRB,O
possible,JJ,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
have,VBP,O
been,VBN,O
associated,VBN,O
with,IN,O
peripheral,JJ,O
neuropathy,NN,O
include,VBP,O
antiretroviral,JJ,G
nucleoside,NN,O
analogues,NNS,O
",",",",O
chloramphenicol,NN,D
",",",",O
cisplatin,NN,D
",",",",O
dapsone,NN,D
",",",",O
disulfiram,NN,D
",",",",O
ethionamide,NN,D
",",",",O
glutethimide,NN,D
",",",",O
gold,NN,D
",",",",O
hydralazine,NN,D
",",",",O
iodoquinol,NN,D
",",",",O
isoniazid,NN,D
",",",",O
metronidazole,NN,D
",",",",O
nitrofurantoin,NN,D
",",",",O
phenytoin,NN,D
",",",",O
ribavirin,NNP,D
",",",",O
and,CC,O
vincristine,NN,D
.,.,.
,,
concomitant,JJ,O
use,NN,O
of,IN,O
hivid,NN,D
with,IN,O
didanosine,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
.,.,.
,,
intravenous,JJ,O
pentamidine,NN,D
:,:,O
treatment,NN,O
with,IN,O
hivid,NN,D
should,MD,O
be,VB,O
interrupted,VBN,O
when,WRB,O
the,DT,O
use,NN,O
of,IN,O
a,DT,O
drug,NN,D
that,WDT,O
has,VBZ,O
the,DT,O
potential,JJ,O
to,TO,O
cause,VB,O
pancreatitis,NN,O
is,VBZ,O
required,VBN,O
.,.,.
,,
death,NN,O
due,JJ,O
to,TO,O
fulminant,JJ,O
pancreatitis,NN,O
possibly,RB,O
related,JJ,O
to,TO,O
intravenous,JJ,O
pentamidine,NN,D
and,CC,O
hivid,NN,D
has,VBZ,O
been,VBN,O
reported,VBN,O
.,.,.
,,
if,IN,O
intravenous,JJ,O
pentamidine,NN,D
is,VBZ,O
required,VBN,O
to,TO,O
treat,VB,O
pneumocystis,NN,O
carinii,NN,O
pneumonia,NN,O
",",",",O
treatment,NN,O
with,IN,O
hivid,NN,D
should,MD,O
be,VB,O
interrupted,VBN,O
.,.,.
,,
amphotericin,NNP,D
",",",",O
foscarnet,NNP,D
",",",",O
and,CC,O
aminoglycosides,NNS,G
:,:,O
drugs,NNS,O
such,JJ,O
as,IN,O
amphotericin,NN,D
",",",",O
foscarnet,NN,D
",",",",O
and,CC,O
aminoglycosides,NNS,G
may,MD,O
increase,VB,O
the,DT,O
risk,NN,O
of,IN,O
developing,VBG,O
peripheral,JJ,O
neuropathy,NN,O
or,CC,O
other,JJ,O
hivid-associated,JJ,O
adverse,JJ,O
events,NNS,O
by,IN,O
interfering,VBG,O
with,IN,O
the,DT,O
renal,JJ,O
clearance,NN,O
of,IN,O
zalcitabine,NN,D
-lrb-,-LRB-,O
thereby,RB,O
raising,VBG,O
systemic,JJ,O
exposure,NN,O
-rrb-,-RRB-,O
.,.,.
,,
patients,NNS,O
who,WP,O
require,VBP,O
the,DT,O
use,NN,O
of,IN,O
one,CD,O
of,IN,O
these,DT,O
drugs,NNS,D
with,IN,O
hivid,NN,D
should,MD,O
have,VB,O
frequent,JJ,O
clinical,JJ,O
and,CC,O
laboratory,JJ,O
monitoring,NN,O
with,IN,O
dosage,NN,O
adjustment,NN,O
for,IN,O
any,DT,O
significant,JJ,O
change,NN,O
in,IN,O
renal,JJ,O
function,NN,O
.,.,.
,,
probenecid,NNP,D
or,CC,O
cimetidine,NNP,D
:,:,O
concomitant,JJ,O
administration,NN,O
of,IN,O
probenecid,NN,D
or,CC,O
cimetidine,NN,D
decreases,VBZ,O
the,DT,O
elimination,NN,O
of,IN,O
zalcitabine,NN,D
",",",",O
most,RBS,O
likely,RB,O
by,IN,O
inhibition,NN,O
of,IN,O
renal,JJ,O
tubular,JJ,O
secretion,NN,O
of,IN,O
zalcitabine,NN,D
.,.,.
,,
patients,NNS,O
receiving,VBG,O
these,DT,O
drugs,NNS,D
in,IN,O
combination,NN,O
with,IN,O
zalcitabine,NN,D
should,MD,O
be,VB,O
monitored,VBN,O
for,IN,O
signs,NNS,O
of,IN,O
toxicity,NN,O
and,CC,O
the,DT,O
dose,NN,O
of,IN,O
zalcitabine,NN,D
reduced,VBN,O
if,IN,O
warranted,VBN,O
.,.,.
,,
magnesium/aluminum-containing,JJ,O
antacid,NNP,G
products,NNPS,O
:,:,O
absorption,NN,O
of,IN,O
zalcitabine,NN,D
is,VBZ,O
moderately,RB,O
reduced,VBN,O
-lrb-,-LRB-,O
approximately,RB,O
25,CD,O
%,NN,O
-rrb-,-RRB-,O
when,WRB,O
coadministered,VBN,O
with,IN,O
magnesium/aluminum-containing,JJ,O
antacid,NN,G
products,NNS,O
.,.,.
,,
the,DT,O
clinical,JJ,O
significance,NN,O
of,IN,O
this,DT,O
reduction,NN,O
is,VBZ,O
not,RB,O
known,VBN,O
",",",",O
hence,RB,O
zalcitabine,NN,D
is,VBZ,O
not,RB,O
recommended,VBN,O
to,TO,O
be,VB,O
ingested,VBN,O
simultaneously,RB,O
with,IN,O
magnesium/aluminum-containing,JJ,O
antacids,NNS,G
.,.,.
,,
metoclopramide,NNP,D
:,:,O
bioavailability,NN,O
is,VBZ,O
mildly,RB,O
reduced,VBN,O
-lrb-,-LRB-,O
approximately,RB,O
10,CD,O
%,NN,O
-rrb-,-RRB-,O
when,WRB,O
zalcitabine,NN,D
and,CC,O
metoclopramide,NN,D
are,VBP,O
coadministered,VBN,O
.,.,.
,,
doxorubicin,NN,D
:,:,O
doxorubicin,NN,D
caused,VBD,O
a,DT,O
decrease,NN,O
in,IN,O
zalcitabine,NN,D
phosphorylation,NN,O
-lrb-,-LRB-,O
50,CD,O
%,NN,O
inhibition,NN,O
of,IN,O
total,JJ,O
phosphate,NN,D
formation,NN,O
-rrb-,-RRB-,O
in,IN,O
u937/molt,NN,O
4,CD,O
cells,NNS,O
.,.,.
,,
although,IN,O
there,EX,O
may,MD,O
be,VB,O
decreased,VBN,O
zalcitabine,NN,D
activity,NN,O
because,IN,O
of,IN,O
lessened,VBN,O
active,JJ,O
metabolite,NN,O
formation,NN,O
",",",",O
the,DT,O
clinical,JJ,O
relevance,NN,O
of,IN,O
these,DT,O
in,FW,O
vitro,FW,O
results,NNS,O
are,VBP,O
not,RB,O
known,VBN,O
.,.,.
,,
as,IN,O
with,IN,O
all,DT,O
drugs,NNS,D
",",",",O
the,DT,O
potential,JJ,O
exists,VBZ,O
for,IN,O
interaction,NN,O
with,IN,O
other,JJ,O
drugs,NNS,D
by,IN,O
a,DT,O
variety,NN,O
of,IN,O
mechanisms,NNS,O
.,.,.
,,
cns-active,JJ,O
drugs,NNS,O
ethanol,NN,D
:,:,O
sonata,NNP,B
10,CD,O
mg,NN,O
potentiated,VBD,O
the,DT,O
cns-impairing,JJ,O
effects,NNS,O
of,IN,O
ethanol,NN,D
0.75,CD,O
g/kg,NN,O
on,IN,O
balance,NN,O
testing,NN,O
and,CC,O
reaction,NN,O
time,NN,O
for,IN,O
1,CD,O
hour,NN,O
after,IN,O
ethanol,NN,D
administration,NN,O
and,CC,O
on,IN,O
the,DT,O
digit,NN,O
symbol,NN,O
substitution,NN,O
test,NN,O
-lrb-,-LRB-,O
dsst,NN,O
-rrb-,-RRB-,O
",",",",O
symbol,NN,O
copying,NN,O
test,NN,O
",",",",O
and,CC,O
the,DT,O
variability,NN,O
component,NN,O
of,IN,O
the,DT,O
divided,VBN,O
attention,NN,O
test,NN,O
for,IN,O
2.5,CD,O
hours,NNS,O
after,IN,O
ethanol,NN,D
administration,NN,O
.,.,.
,,
the,DT,O
potentiation,NN,O
resulted,VBD,O
from,IN,O
a,DT,O
cns,NN,O
pharmacodynamic,JJ,O
interaction,NN,O
;,:,O
.,.,.
,,
zaleplon,NN,D
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
ethanol,NN,D
.,.,.
,,
imipramine,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
single,JJ,O
doses,NNS,O
of,IN,O
sonata,NNP,B
20,CD,O
mg,NN,O
and,CC,O
imipramine,NN,D
75,CD,O
mg,NN,O
produced,VBD,O
additive,JJ,O
effects,NNS,O
on,IN,O
decreased,VBN,O
alertness,NN,O
and,CC,O
impaired,JJ,O
psychomotor,NN,O
performance,NN,O
for,IN,O
2,CD,O
to,TO,O
4,CD,O
hours,NNS,O
after,IN,O
administration,NN,O
.,.,.
,,
the,DT,O
interaction,NN,O
was,VBD,O
pharmacodynamic,JJ,O
with,IN,O
no,DT,O
alteration,NN,O
of,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
drug,NN,D
.,.,.
,,
paroxetine,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
sonata,NNP,B
20,CD,O
mg,NN,O
and,CC,O
paroxetine,NN,D
20,CD,O
mg,NN,O
daily,RB,O
for,IN,O
7,CD,O
days,NNS,O
did,VBD,O
not,RB,O
produce,VB,O
any,DT,O
interaction,NN,O
on,IN,O
psychomotor,NN,O
performance,NN,O
.,.,.
,,
additionally,RB,O
",",",",O
paroxetine,NN,D
did,VBD,O
not,RB,O
alter,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
sonata,NNP,B
",",",",O
reflecting,VBG,O
the,DT,O
absence,NN,O
of,IN,O
a,DT,O
role,NN,O
of,IN,O
cyp2d6,NN,D
in,IN,O
zaleplon,NN,D
s,NNS,O
metabolism,NN,O
.,.,.
,,
thioridazine,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
single,JJ,O
doses,NNS,O
of,IN,O
sonata,NNP,B
20,CD,O
mg,NN,O
and,CC,O
thioridazine,NN,D
50,CD,O
mg,NN,O
produced,VBD,O
additive,JJ,O
effects,NNS,O
on,IN,O
decreased,VBN,O
alertness,NN,O
and,CC,O
impaired,JJ,O
psychomotor,NN,O
performance,NN,O
for,IN,O
2,CD,O
to,TO,O
4,CD,O
hours,NNS,O
after,IN,O
administration,NN,O
.,.,.
,,
the,DT,O
interaction,NN,O
was,VBD,O
pharmacodynamic,JJ,O
with,IN,O
no,DT,O
alteration,NN,O
of,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
drug,NN,D
.,.,.
,,
venlafaxine,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
zaleplon,NN,D
10,CD,O
mg,NN,O
and,CC,O
multiple,JJ,O
doses,NNS,O
of,IN,O
venlafaxine,NN,D
er,NN,O
-lrb-,-LRB-,O
extended,JJ,O
release,NN,O
-rrb-,-RRB-,O
150,CD,O
mg,NN,O
did,VBD,O
not,RB,O
result,VB,O
in,IN,O
any,DT,O
significant,JJ,O
changes,NNS,O
in,IN,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
either,CC,O
zaleplon,NN,D
or,CC,O
venlafaxine,NN,D
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
there,EX,O
was,VBD,O
no,DT,O
pharmacodynamic,JJ,O
interaction,NN,O
as,IN,O
a,DT,O
result,NN,O
of,IN,O
coadministration,NN,O
of,IN,O
zaleplon,NN,D
and,CC,O
venlafaxine,NN,D
er,NN,O
.,.,.
,,
promethazine,NNP,D
:,:,O
coadministration,NNP,O
of,IN,O
a,DT,O
single,JJ,O
dose,NN,O
of,IN,O
zaleplon,NN,D
and,CC,O
promethazine,NN,D
-lrb-,-LRB-,O
10,CD,O
and,CC,O
25,CD,O
mg,NN,O
",",",",O
respectively,RB,O
-rrb-,-RRB-,O
resulted,VBD,O
in,IN,O
a,DT,O
15,CD,O
%,NN,O
decrease,NN,O
in,IN,O
maximal,JJ,O
plasma,NN,O
concentrations,NNS,O
of,IN,O
zaleplon,NN,D
",",",",O
but,CC,O
no,DT,O
change,NN,O
in,IN,O
the,DT,O
area,NN,O
under,IN,O
the,DT,O
plasma,NN,O
concentration-time,NN,O
curve,NN,O
.,.,.
,,
however,RB,O
",",",",O
the,DT,O
pharmacodynamics,NNS,O
of,IN,O
coadministration,NN,O
of,IN,O
zaleplon,NN,D
and,CC,O
promethazine,NN,D
have,VBP,O
not,RB,O
been,VBN,O
evaluated,VBN,O
.,.,.
,,
caution,NN,O
should,MD,O
be,VB,O
exercised,VBN,O
when,WRB,O
these,DT,O
2,CD,O
agents,NNS,O
are,VBP,O
coadministered,VBN,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
induce,VBP,O
cyp3a4,NN,D
rifampin,NNP,D
:,:,O
cyp3a4,NN,D
is,VBZ,O
ordinarily,RB,O
a,DT,O
minor,JJ,O
metabolizing,VBG,O
enzyme,NN,O
of,IN,O
zaleplon,NN,D
.,.,.
,,
multiple-dose,JJ,O
administration,NN,O
of,IN,O
the,DT,O
potent,JJ,O
cyp3a4,NN,D
inducer,NN,O
rifampin,NN,D
-lrb-,-LRB-,O
600,CD,O
mg,NN,O
every,DT,O
24,CD,O
hours,NNS,O
",",",",O
q24h,NN,O
",",",",O
for,IN,O
14,CD,O
days,NNS,O
-rrb-,-RRB-,O
",",",",O
however,RB,O
",",",",O
reduced,VBD,O
zaleplon,NN,D
cmax,NN,O
and,CC,O
auc,NN,O
by,IN,O
approximately,RB,O
80,CD,O
%,NN,O
.,.,.
,,
the,DT,O
coadministration,NN,O
of,IN,O
a,DT,O
potent,JJ,O
cyp3a4,NN,D
enzyme,NN,O
inducer,NN,O
",",",",O
although,IN,O
not,RB,O
posing,VBG,O
a,DT,O
safety,NN,O
concern,NN,O
",",",",O
thus,RB,O
could,MD,O
lead,VB,O
to,TO,O
ineffectiveness,NN,O
of,IN,O
zaleplon,NN,D
.,.,.
,,
an,DT,O
alternative,JJ,O
non-cyp3a4,NN,O
substrate,NN,O
hypnotic,JJ,G
agent,NN,O
may,MD,O
be,VB,O
considered,VBN,O
in,IN,O
patients,NNS,O
taking,VBG,O
cyp3a4,NN,D
inducers,NNS,O
such,JJ,O
as,IN,O
rifampin,NN,D
",",",",O
phenytoin,NN,D
",",",",O
carbamazepine,NN,D
",",",",O
and,CC,O
phenobarbital,NN,D
.,.,.
,,
drugs,NNS,O
that,WDT,O
inhibit,VBP,O
cyp3a4,NN,D
cyp3a4,NN,D
is,VBZ,O
a,DT,O
minor,JJ,O
metabolic,JJ,O
pathway,NN,O
for,IN,O
the,DT,O
elimination,NN,O
of,IN,O
zaleplon,NN,D
because,IN,O
the,DT,O
sum,NN,O
of,IN,O
desethylzaleplon,NN,O
-lrb-,-LRB-,O
formed,VBN,O
via,IN,O
cyp3a4,NN,D
in,FW,O
vitro,FW,O
-rrb-,-RRB-,O
and,CC,O
its,PRP$,O
metabolites,NNS,O
",",",",O
5-oxo-desethylzaleplon,NN,D_n
and,CC,O
5-oxo-desethylzaleplon,JJ,D_n
glucuronide,NN,O
",",",",O
account,NN,O
for,IN,O
only,RB,O
9,CD,O
%,NN,O
of,IN,O
the,DT,O
urinary,JJ,O
recovery,NN,O
of,IN,O
a,DT,O
zaleplon,NN,D
dose,NN,O
.,.,.
,,
coadministration,NN,O
of,IN,O
single,JJ,O
",",",",O
oral,JJ,O
doses,NNS,O
of,IN,O
zaleplon,NN,D
with,IN,O
erythromycin,NN,D
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
and,CC,O
800,CD,O
mg,NN,O
",",",",O
respectively,RB,O
-rrb-,-RRB-,O
",",",",O
a,DT,O
strong,JJ,O
",",",",O
selective,JJ,O
cyp3a4,NN,D
inhibitor,NN,O
produced,VBD,O
a,DT,O
34,CD,O
%,NN,O
increase,NN,O
in,IN,O
zaleplons,NNS,O
maximal,JJ,O
plasma,NN,O
concentrations,NNS,O
and,CC,O
a,DT,O
20,CD,O
%,NN,O
increase,NN,O
in,IN,O
the,DT,O
area,NN,O
under,IN,O
the,DT,O
plasma,NN,O
concentration-time,NN,O
curve,NN,O
.,.,.
,,
the,DT,O
magnitude,NN,O
of,IN,O
interaction,NN,O
with,IN,O
multiple,JJ,O
doses,NNS,O
of,IN,O
erythromycin,NN,D
is,VBZ,O
unknown,JJ,O
.,.,.
,,
other,JJ,O
strong,JJ,O
selective,JJ,O
cyp3a4,NN,D
inhibitors,NNS,O
such,JJ,O
as,IN,O
ketoconazole,NN,D
can,MD,O
also,RB,O
be,VB,O
expected,VBN,O
to,TO,O
increase,VB,O
the,DT,O
exposure,NN,O
of,IN,O
zaleplon,NN,D
.,.,.
,,
a,DT,O
routine,JJ,O
dosage,NN,O
adjustment,NN,O
of,IN,O
zaleplon,NN,D
is,VBZ,O
not,RB,O
considered,VBN,O
necessary,JJ,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
inhibit,VBP,O
aldehyde,NNP,O
oxidase,NNP,O
the,NNP,O
aldehyde,NN,O
oxidase,NN,O
enzyme,NN,O
system,NN,O
is,VBZ,O
less,RBR,O
well,RB,O
studied,VBN,O
than,IN,O
the,DT,O
cytochrome,NN,O
p450,NN,O
enzyme,NN,O
system,NN,O
.,.,.
,,
diphenhydramine,NNP,D
:,:,O
diphenhydramine,NNP,D
is,VBZ,O
reported,VBN,O
to,TO,O
be,VB,O
a,DT,O
weak,JJ,O
inhibitor,NN,O
of,IN,O
aldehyde,NN,O
oxidase,NN,O
in,IN,O
rat,NN,O
liver,NN,O
",",",",O
but,CC,O
its,PRP$,O
inhibitory,JJ,O
effects,NNS,O
in,IN,O
human,JJ,O
liver,NN,O
are,VBP,O
not,RB,O
known,VBN,O
.,.,.
,,
there,EX,O
is,VBZ,O
no,DT,O
pharmacokinetic,JJ,O
interaction,NN,O
between,IN,O
zaleplon,NN,D
and,CC,O
diphenhydramine,NN,D
following,VBG,O
the,DT,O
administration,NN,O
of,IN,O
a,DT,O
single,JJ,O
dose,NN,O
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
and,CC,O
50,CD,O
mg,NN,O
",",",",O
respectively,RB,O
-rrb-,-RRB-,O
of,IN,O
each,DT,O
drug,NN,D
.,.,.
,,
however,RB,O
",",",",O
because,IN,O
both,DT,O
of,IN,O
these,DT,O
compounds,NNS,O
have,VBP,O
cns,NN,O
effects,NNS,O
",",",",O
an,DT,O
additive,JJ,O
pharmacodynamic,JJ,O
effect,NN,O
is,VBZ,O
possible,JJ,O
.,.,.
,,
drugs,NNS,O
that,WDT,O
inhibit,VBP,O
both,CC,O
aldehyde,VBP,O
oxidase,NN,O
and,CC,O
cyp3a4,NN,D
cimetidine,NN,D
:,:,O
cimetidine,NN,D
inhibits,VBZ,O
both,CC,O
aldehyde,NN,O
oxidase,NN,O
-lrb-,-LRB-,O
in,FW,O
vitro,FW,O
-rrb-,-RRB-,O
and,CC,O
cyp3a4,NN,D
-lrb-,-LRB-,O
in,FW,O
vitro,FW,O
and,CC,O
in,FW,O
vivo,FW,O
-rrb-,-RRB-,O
",",",",O
the,DT,O
primary,JJ,O
and,CC,O
secondary,JJ,O
enzymes,NNS,O
",",",",O
respectively,RB,O
",",",",O
responsible,JJ,O
for,IN,O
zaleplon,NN,D
metabolism,NN,O
.,.,.
,,
concomitant,JJ,O
administration,NN,O
of,IN,O
sonata,NNP,B
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
-rrb-,-RRB-,O
and,CC,O
cimetidine,NN,D
-lrb-,-LRB-,O
800,CD,O
mg,NN,O
-rrb-,-RRB-,O
produced,VBD,O
an,DT,O
85,CD,O
%,NN,O
increase,NN,O
in,IN,O
the,DT,O
mean,NN,O
cmax,NN,O
and,CC,O
auc,NN,O
of,IN,O
zaleplon,NN,D
.,.,.
,,
an,DT,O
initial,JJ,O
dose,NN,O
of,IN,O
5,CD,O
mg,NN,O
should,MD,O
be,VB,O
given,VBN,O
to,TO,O
patients,NNS,O
who,WP,O
are,VBP,O
concomitantly,RB,O
being,VBG,O
treated,VBN,O
with,IN,O
cimetidine,NN,D
.,.,.
,,
drugs,NNS,O
highly,RB,O
bound,VBN,O
to,TO,O
plasma,NN,O
protein,NN,O
zaleplon,NN,D
is,VBZ,O
not,RB,O
highly,RB,O
bound,VBN,O
to,TO,O
plasma,NN,O
proteins,NNS,O
-lrb-,-LRB-,O
fraction,NN,O
bound,VBN,O
60,CD,O
%,NN,O
15,CD,O
%,NN,O
-rrb-,-RRB-,O
.,.,.
,,
therefore,RB,O
",",",",O
the,DT,O
disposition,NN,O
of,IN,O
zaleplon,NN,D
is,VBZ,O
not,RB,O
expected,VBN,O
to,TO,O
be,VB,O
sensitive,JJ,O
to,TO,O
alterations,NNS,O
in,IN,O
protein,NN,O
binding,NN,O
.,.,.
,,
in,IN,O
addition,NN,O
",",",",O
administration,NN,O
of,IN,O
sonata,NNP,B
to,TO,O
a,DT,O
patient,NN,O
taking,VBG,O
another,DT,O
drug,NN,D
that,WDT,O
is,VBZ,O
highly,RB,O
protein,NN,O
bound,VBD,O
should,MD,O
not,RB,O
cause,VB,O
transient,JJ,O
increase,NN,O
in,IN,O
free,JJ,O
concentrations,NNS,O
of,IN,O
the,DT,O
other,JJ,O
drug,NN,D
.,.,.
,,
drugs,NNS,O
with,IN,O
a,DT,O
narrow,NNP,O
therapeutic,JJ,O
index,NN,O
digoxin,NN,D
:,:,O
sonata,NN,B
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetic,JJ,O
or,CC,O
pharmacodynamic,JJ,O
profile,NN,O
of,IN,O
digoxin,NN,D
-lrb-,-LRB-,O
0.375,CD,O
mg,NN,O
q24h,NN,O
for,IN,O
8,CD,O
days,NNS,O
-rrb-,-RRB-,O
.,.,.
,,
warfarin,NNP,D
:,:,O
multiple,JJ,O
oral,JJ,O
doses,NNS,O
of,IN,O
sonata,NN,B
-lrb-,-LRB-,O
20,CD,O
mg,NN,O
q24h,NN,O
for,IN,O
13,CD,O
days,NNS,O
-rrb-,-RRB-,O
did,VBD,O
not,RB,O
affect,VB,O
the,DT,O
pharmacokinetics,NNS,O
of,IN,O
warfarin,NN,D
-lrb-,-LRB-,O
r,NN,O
+,CC,O
-rrb-,-RRB-,O
-,:,O
or,CC,O
-lrb-,-LRB-,O
s,NN,O
-,:,O
-rrb-,-RRB-,O
-,:,O
enantiomers,NNS,O
or,CC,O
the,DT,O
pharmacodynamics,NNS,O
-lrb-,-LRB-,O
prothrombin,NN,O
time,NN,O
-rrb-,-RRB-,O
following,VBG,O
a,DT,O
single,JJ,O
25-mg,JJ,O
oral,JJ,O
dose,NN,O
of,IN,O
warfarin,NN,D
.,.,.
,,
drugs,NNS,O
that,WDT,O
alter,VBP,O
renal,JJ,O
excretion,NN,O
ibuprofen,NN,D
:,:,O
ibuprofen,NN,D
is,VBZ,O
known,VBN,O
to,TO,O
affect,VB,O
renal,JJ,O
function,NN,O
and,CC,O
",",",",O
consequently,RB,O
",",",",O
alter,VBP,O
the,DT,O
renal,JJ,O
excretion,NN,O
of,IN,O
other,JJ,O
drugs,NNS,D
.,.,.
,,
there,EX,O
was,VBD,O
no,DT,O
apparent,JJ,O
pharmacokinetic,JJ,O
interaction,NN,O
between,IN,O
zaleplon,NN,D
and,CC,O
ibuprofen,NN,D
following,VBG,O
single,JJ,O
dose,NN,O
administration,NN,O
-lrb-,-LRB-,O
10,CD,O
mg,NN,O
and,CC,O
600,CD,O
mg,NN,O
",",",",O
respectively,RB,O
-rrb-,-RRB-,O
of,IN,O
each,DT,O
drug,NN,D
.,.,.
,,
this,DT,O
was,VBD,O
expected,VBN,O
because,IN,O
zaleplon,NN,D
is,VBZ,O
primarily,RB,O
metabolized,VBN,O
and,CC,O
renal,JJ,O
excretion,NN,O
of,IN,O
unchanged,JJ,O
zaleplon,NN,D
accounts,NNS,O
for,IN,O
less,JJR,O
than,IN,O
1,CD,O
%,NN,O
of,IN,O
the,DT,O
administered,VBN,O
dose,NN,O
